cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
BRCA	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	42.76	1.57e-231	2.73e-225	0.9	0.8	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	37.94	1.57e-198	5.45e-193	0.87	0.76	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	36.68	8.82e-190	1.77e-184	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	36.38	9.53e-188	1.4e-182	1.06	0.75	Shingles;	chr7:38346957	chr7:38343894~38350022:-
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	36.24	1.01e-186	1.39e-181	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	36.06	1.67e-185	2.01e-180	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-35.74	3.16e-183	3.11e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-35.74	3.16e-183	3.11e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	35.73	3.75e-183	3.67e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	35.72	3.88e-183	3.78e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	35.72	4.34e-183	4.19e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-35.67	8.82e-183	8.44e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-35.66	1.03e-182	9.51e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	35.64	1.59e-182	1.46e-177	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-35.62	2.01e-182	1.84e-177	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	35.62	2.18e-182	1.98e-177	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-35.55	6.51e-182	5.85e-177	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-35.53	8.67e-182	7.73e-177	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	35.5	1.39e-181	1.23e-176	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-35.48	2.09e-181	1.83e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-35.48	2.09e-181	1.83e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-35.47	2.14e-181	1.86e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-35.47	2.16e-181	1.87e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-35.46	2.64e-181	2.27e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-35.45	3.37e-181	2.88e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	35.44	3.81e-181	3.22e-176	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-35.41	6.32e-181	5.32e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-35.41	6.38e-181	5.34e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-35.38	1.03e-180	8.62e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-35.36	1.41e-180	1.17e-175	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	35.29	3.93e-180	3.19e-175	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-35.24	8.65e-180	6.89e-175	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	35.18	2.44e-179	1.93e-174	0.98	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	35.17	2.86e-179	2.23e-174	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-35.17	2.88e-179	2.24e-174	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	35.17	2.9e-179	2.25e-174	0.98	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-35.16	3.49e-179	2.7e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-35.15	3.66e-179	2.81e-174	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-35.14	4.98e-179	3.79e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-35.13	5.36e-179	4.07e-174	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-35.09	1.01e-178	7.6e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-35.07	1.51e-178	1.13e-173	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	35.07	1.51e-178	1.13e-173	0.99	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-35.07	1.54e-178	1.15e-173	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	35.04	2.43e-178	1.8e-173	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	35.03	2.92e-178	2.16e-173	0.99	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	34.96	7.89e-178	5.78e-173	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	34.96	7.9e-178	5.78e-173	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-34.95	1.03e-177	7.5e-173	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	34.93	1.45e-177	1.02e-172	0.83	0.73	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-34.92	1.59e-177	1.11e-172	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	34.9	2.28e-177	1.59e-172	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	34.8	1.07e-176	7.29e-172	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	34.8	1.1e-176	7.46e-172	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-34.76	2.27e-176	1.51e-171	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-34.73	3.58e-176	2.37e-171	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-34.7	5.75e-176	3.79e-171	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-34.67	8.33e-176	5.48e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-34.67	9.54e-176	6.26e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-34.66	1.09e-175	7.15e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-34.62	1.92e-175	1.25e-170	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	34.59	3.26e-175	2.11e-170	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	34.57	4.8e-175	3.1e-170	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	34.54	6.9e-175	4.44e-170	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-34.53	9e-175	5.77e-170	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-34.43	4.4e-174	2.82e-169	-0.94	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	34.43	4.61e-174	2.94e-169	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	34.42	5.44e-174	3.46e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	34.4	7.09e-174	4.5e-169	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-34.4	7.14e-174	4.51e-169	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-34.39	8.13e-174	5.12e-169	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	34.39	8.4e-174	5.28e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	34.39	8.44e-174	5.29e-169	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	34.38	9e-174	5.6e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	34.38	9e-174	5.6e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-34.33	2.31e-173	1.42e-168	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-34.27	5.26e-173	3.19e-168	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-34.27	5.5e-173	3.32e-168	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	34.26	6.15e-173	3.71e-168	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	34.25	8.31e-173	4.99e-168	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-34.24	8.7e-173	5.21e-168	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	34.2	1.71e-172	1.02e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-34.19	2.17e-172	1.29e-167	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	34.18	2.53e-172	1.49e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	34.16	3.55e-172	2.08e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-34.11	7.23e-172	4.15e-167	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-34.11	7.23e-172	4.15e-167	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	34.11	7.23e-172	4.15e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-34.04	2.31e-171	1.3e-166	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	34.03	2.67e-171	1.5e-166	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	33.97	7.75e-171	4.22e-166	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	33.97	7.75e-171	4.22e-166	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	33.93	1.36e-170	7.36e-166	0.99	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	33.93	1.37e-170	7.38e-166	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	33.93	1.41e-170	7.6e-166	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	33.89	2.79e-170	1.5e-165	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	33.83	6.68e-170	3.56e-165	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	33.71	4.84e-169	2.54e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-33.7	5.85e-169	3.06e-164	-0.93	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	33.69	6.79e-169	3.54e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	33.68	7.71e-169	4.01e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-33.63	1.78e-168	9.1e-164	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	33.62	2.19e-168	1.11e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	33.61	2.36e-168	1.2e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	33.58	4.08e-168	2.05e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	33.53	8.89e-168	4.41e-163	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-33.51	1.26e-167	6.24e-163	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	33.46	2.81e-167	1.38e-162	0.96	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	33.45	3.28e-167	1.6e-162	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-33.43	4.57e-167	2.23e-162	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-33.4	6.65e-167	3.22e-162	-0.96	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	33.22	1.29e-165	6.12e-161	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	33.2	1.89e-165	8.94e-161	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	33.16	3.17e-165	1.48e-160	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	33.1	9.17e-165	4.26e-160	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	33.01	3.58e-164	1.65e-159	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	32.98	6.54e-164	3e-159	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	32.98	6.58e-164	3.02e-159	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	32.94	1.18e-163	5.38e-159	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	32.93	1.32e-163	6.04e-159	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-32.91	1.91e-163	8.69e-159	-0.96	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	32.84	6.38e-163	2.89e-158	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-32.84	6.49e-163	2.94e-158	-0.96	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	32.79	1.26e-162	5.67e-158	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	32.77	1.8e-162	8.08e-158	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	32.74	2.82e-162	1.26e-157	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-32.72	4.09e-162	1.83e-157	-0.97	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	32.69	6.29e-162	2.8e-157	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	32.66	1.1e-161	4.85e-157	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	32.54	7.71e-161	3.36e-156	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-32.47	2.34e-160	1.01e-155	-0.97	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-32.46	2.69e-160	1.16e-155	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	32.45	3.24e-160	1.39e-155	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	32.44	4.07e-160	1.74e-155	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	32.43	4.67e-160	1.99e-155	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-32.42	5.36e-160	2.27e-155	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	32.4	7.57e-160	3.19e-155	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	32.37	1.11e-159	4.67e-155	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-32.36	1.47e-159	6.15e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-32.36	1.47e-159	6.15e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-32.34	1.85e-159	7.73e-155	-0.92	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-32.33	2.18e-159	9.1e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-32.29	4.01e-159	1.67e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	32.29	4.09e-159	1.7e-154	0.95	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-32.27	6.16e-159	2.53e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-32.27	6.16e-159	2.53e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-32.26	7.57e-159	3.09e-154	-0.92	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	32.24	9.27e-159	3.78e-154	0.95	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	32.23	1.17e-158	4.75e-154	0.8	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	32.22	1.33e-158	5.41e-154	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-32.22	1.37e-158	5.56e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	32.19	2.04e-158	8.23e-154	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	32.11	7.71e-158	3.09e-153	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	32.06	1.91e-157	7.62e-153	0.81	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	32.04	2.43e-157	9.59e-153	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	32.04	2.43e-157	9.59e-153	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	32.04	2.55e-157	1e-152	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	32.04	2.55e-157	1e-152	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	32.02	3.44e-157	1.35e-152	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	31.99	5.61e-157	2.19e-152	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	31.98	6.33e-157	2.45e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	31.97	7.72e-157	2.98e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	31.94	1.2e-156	4.61e-152	0.82	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	31.86	4.27e-156	1.63e-151	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	31.84	6.65e-156	2.54e-151	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-31.74	3.1e-155	1.17e-150	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	31.64	1.7e-154	6.34e-150	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	31.54	8.42e-154	3.11e-149	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	31.53	8.67e-154	3.2e-149	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-31.52	1.16e-153	4.27e-149	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-31.47	2.66e-153	9.73e-149	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	31.46	2.93e-153	1.07e-148	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	31.4	8e-153	2.9e-148	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	31.39	9.46e-153	3.43e-148	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	31.37	1.32e-152	4.76e-148	0.92	0.7	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	31.37	1.32e-152	4.76e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-31.35	1.57e-152	5.64e-148	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	31.35	1.75e-152	6.24e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	31.35	1.79e-152	6.37e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	31.34	2.13e-152	7.56e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-31.29	4.26e-152	1.5e-147	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	31.29	4.43e-152	1.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	31.29	4.43e-152	1.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	31.29	4.83e-152	1.69e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	31.26	7.1e-152	2.48e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	31.26	7.1e-152	2.48e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	31.24	1.01e-151	3.52e-147	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-31.23	1.13e-151	3.91e-147	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	31.21	1.61e-151	5.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	31.19	2.35e-151	7.98e-147	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	31.18	2.67e-151	9.09e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	31.15	4.08e-151	1.38e-146	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	31.15	4.34e-151	1.47e-146	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	31.11	7.6e-151	2.56e-146	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	31.1	9.08e-151	3.05e-146	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	31.07	1.53e-150	5.12e-146	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	31.05	2.05e-150	6.85e-146	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	30.99	5.73e-150	1.89e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	30.99	5.73e-150	1.89e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	30.98	6.94e-150	2.29e-145	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	30.97	7.32e-150	2.41e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	30.94	1.19e-149	3.89e-145	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	30.91	2.08e-149	6.78e-145	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	30.91	2.11e-149	6.86e-145	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-30.86	4.42e-149	1.43e-144	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-30.85	5.48e-149	1.77e-144	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	30.85	5.56e-149	1.79e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	30.85	5.56e-149	1.79e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	30.82	9.06e-149	2.89e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	30.82	9.19e-149	2.93e-144	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	30.81	1.12e-148	3.57e-144	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	30.8	1.22e-148	3.87e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	30.76	2.23e-148	7.03e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	30.76	2.37e-148	7.47e-144	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	30.76	2.39e-148	7.51e-144	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	30.72	4.38e-148	1.37e-143	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-30.7	6.28e-148	1.96e-143	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	30.68	8.83e-148	2.75e-143	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	30.68	9.15e-148	2.84e-143	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	30.58	4.05e-147	1.25e-142	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	30.5	1.66e-146	5.09e-142	0.9	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	30.46	3.07e-146	9.41e-142	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	30.45	3.72e-146	1.14e-141	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-30.44	4.3e-146	1.31e-141	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	30.26	7.49e-145	2.26e-140	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-30.21	1.55e-144	4.67e-140	-0.96	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	30.2	2.08e-144	6.27e-140	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-30.12	7.08e-144	2.12e-139	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-30.07	1.57e-143	4.69e-139	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-30.05	2.2e-143	6.54e-139	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-30.04	2.46e-143	7.33e-139	-0.8	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	30.03	3.23e-143	9.59e-139	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	30.01	4.24e-143	1.25e-138	0.81	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-30.01	4.38e-143	1.29e-138	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-30	4.64e-143	1.37e-138	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-30	4.64e-143	1.37e-138	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-29.99	5.54e-143	1.63e-138	-0.96	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	29.99	6.07e-143	1.78e-138	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-29.96	9.84e-143	2.88e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-29.94	1.28e-142	3.74e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-29.94	1.28e-142	3.74e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-29.92	1.77e-142	5.14e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-29.92	1.77e-142	5.14e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	29.86	4.41e-142	1.27e-137	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	29.84	5.98e-142	1.72e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	29.83	7.33e-142	2.1e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	29.83	7.33e-142	2.1e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	29.83	7.85e-142	2.25e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	29.79	1.42e-141	4.04e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	29.79	1.42e-141	4.04e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	29.79	1.54e-141	4.37e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	29.76	2.23e-141	6.33e-137	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	29.76	2.47e-141	6.99e-137	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	29.71	5.46e-141	1.54e-136	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	29.68	7.88e-141	2.22e-136	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-29.67	9.77e-141	2.74e-136	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-29.67	9.77e-141	2.74e-136	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-29.65	1.45e-140	4.06e-136	-0.93	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	29.62	2.32e-140	6.5e-136	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	29.58	4.53e-140	1.25e-135	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-29.56	5.73e-140	1.58e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	29.51	1.42e-139	3.88e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	29.51	1.42e-139	3.88e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	29.47	2.32e-139	6.32e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	29.47	2.34e-139	6.39e-135	0.92	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	29.47	2.49e-139	6.78e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	29.47	2.49e-139	6.78e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	29.45	3.52e-139	9.52e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-29.45	3.69e-139	9.96e-135	-0.94	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	29.45	3.69e-139	9.96e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	29.44	4.38e-139	1.18e-134	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	29.42	5.85e-139	1.57e-134	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	29.4	7.56e-139	2.03e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	29.39	9.4e-139	2.51e-134	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	29.37	1.26e-138	3.38e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	29.34	2.14e-138	5.71e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-29.32	2.61e-138	6.93e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-29.31	3.18e-138	8.42e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-29.31	3.31e-138	8.76e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	29.26	7.68e-138	2.02e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	29.26	7.68e-138	2.02e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	29.17	3.02e-137	7.9e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	29.14	4.65e-137	1.22e-132	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-29.12	7.48e-137	1.95e-132	-0.84	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	29.11	8.3e-137	2.16e-132	0.82	0.67	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
BRCA	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-29.07	1.55e-136	3.95e-132	-0.95	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	29.02	3.42e-136	8.65e-132	0.83	0.67	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	29.01	3.94e-136	9.96e-132	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-28.96	9.54e-136	2.35e-131	-0.88	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	28.96	9.7e-136	2.39e-131	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	28.92	1.72e-135	4.2e-131	0.83	0.67	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	28.9	2.31e-135	5.64e-131	0.75	0.67	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
BRCA	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	28.9	2.46e-135	5.99e-131	0.83	0.67	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	28.88	3.55e-135	8.56e-131	0.83	0.67	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	28.88	3.55e-135	8.56e-131	0.83	0.67	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	28.87	3.84e-135	9.22e-131	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	28.86	4.64e-135	1.11e-130	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	28.85	5.06e-135	1.21e-130	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	28.85	5.58e-135	1.34e-130	0.83	0.67	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	28.79	1.41e-134	3.31e-130	0.83	0.67	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	28.78	1.63e-134	3.82e-130	0.83	0.67	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	28.78	1.72e-134	4.02e-130	0.83	0.67	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	28.75	2.51e-134	5.87e-130	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
BRCA	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	28.74	2.88e-134	6.71e-130	0.83	0.67	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	28.72	4.05e-134	9.39e-130	0.83	0.66	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	28.71	5.15e-134	1.19e-129	0.75	0.66	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	28.71	5.45e-134	1.26e-129	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	28.69	6.51e-134	1.5e-129	0.89	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-28.69	6.68e-134	1.54e-129	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	28.68	8.34e-134	1.92e-129	0.92	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	28.62	2.01e-133	4.62e-129	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	28.61	2.54e-133	5.84e-129	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	28.52	9.81e-133	2.24e-128	0.82	0.66	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-28.42	5.11e-132	1.16e-127	-0.82	-0.66	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	28.41	5.75e-132	1.31e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	28.41	5.75e-132	1.31e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	28.41	6.1e-132	1.38e-127	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	28.37	1.2e-131	2.71e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-28.37	1.24e-131	2.8e-127	-0.91	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	28.33	2.32e-131	5.21e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	28.31	3.27e-131	7.34e-127	0.8	0.66	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	28.31	3.3e-131	7.39e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	28.3	3.37e-131	7.54e-127	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	28.3	3.4e-131	7.6e-127	0.8	0.66	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	28.27	5.94e-131	1.31e-126	0.79	0.66	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	28.26	6.89e-131	1.52e-126	0.8	0.66	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	28.22	1.23e-130	2.7e-126	0.8	0.66	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	28.22	1.23e-130	2.7e-126	0.8	0.66	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	28.22	1.3e-130	2.83e-126	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	28.2	1.88e-130	4.1e-126	0.8	0.66	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	28.16	3.41e-130	7.43e-126	0.8	0.66	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	28.16	3.42e-130	7.43e-126	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	28.15	3.75e-130	8.14e-126	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-28.13	5.53e-130	1.2e-125	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-28.05	2e-129	4.33e-125	-0.93	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	27.94	1.19e-128	2.56e-124	0.94	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	27.72	3.65e-127	7.79e-123	0.74	0.65	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-27.69	6.38e-127	1.36e-122	-0.77	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	27.66	1.03e-126	2.19e-122	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	27.53	7.53e-126	1.57e-121	0.73	0.65	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-27.49	1.44e-125	3.01e-121	-0.73	-0.65	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-27.47	2.02e-125	4.2e-121	-0.86	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-27.28	4.5e-124	9.23e-120	-0.77	-0.65	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	27.25	7.18e-124	1.47e-119	0.77	0.65	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	27.2	1.6e-123	3.26e-119	0.73	0.64	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	27.14	4.2e-123	8.3e-119	0.77	0.64	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-27.14	4.27e-123	8.44e-119	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	27.13	4.82e-123	9.5e-119	0.73	0.64	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	27.12	5.2e-123	1.03e-118	0.72	0.64	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	27.09	9.35e-123	1.82e-118	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
BRCA	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	27.08	1.03e-122	1.99e-118	0.56	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-27.02	2.73e-122	5.26e-118	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	26.98	4.84e-122	9.22e-118	0.79	0.64	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
BRCA	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	26.89	1.99e-121	3.77e-117	0.72	0.64	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	26.84	5.02e-121	9.46e-117	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	26.82	7.06e-121	1.32e-116	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	26.79	1.02e-120	1.92e-116	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-26.67	6.96e-120	1.28e-115	-0.77	-0.64	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	26.63	1.34e-119	2.46e-115	0.74	0.64	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-26.57	3.33e-119	6.03e-115	-0.77	-0.64	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	26.57	3.61e-119	6.53e-115	0.72	0.64	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-26.56	4.16e-119	7.52e-115	-0.77	-0.64	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	26.47	1.76e-118	3.14e-114	0.85	0.63	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-26.45	2.15e-118	3.82e-114	-0.77	-0.63	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-26.43	3.21e-118	5.67e-114	-0.76	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
BRCA	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	26.41	4.69e-118	8.26e-114	0.71	0.63	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
BRCA	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-26.39	6.11e-118	1.07e-113	-0.82	-0.63	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
BRCA	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-26.34	1.3e-117	2.27e-113	-0.54	-0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	26.3	2.31e-117	3.97e-113	0.74	0.63	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-26.27	4.01e-117	6.89e-113	-0.76	-0.63	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-26.27	4.01e-117	6.89e-113	-0.76	-0.63	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-26.24	6.87e-117	1.17e-112	-0.76	-0.63	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-26.21	1.12e-116	1.9e-112	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-26.21	1.12e-116	1.9e-112	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-26.19	1.42e-116	2.4e-112	-0.76	-0.63	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-26.13	3.94e-116	6.52e-112	-0.74	-0.63	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-26.11	4.66e-116	7.68e-112	-0.76	-0.63	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	26.06	1.03e-115	1.69e-111	0.76	0.63	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	26.06	1.04e-115	1.7e-111	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	26.04	1.46e-115	2.38e-111	0.76	0.63	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-26.03	1.73e-115	2.81e-111	-0.76	-0.63	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-26.03	1.73e-115	2.81e-111	-0.76	-0.63	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	26.02	2.07e-115	3.36e-111	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-25.98	3.91e-115	6.27e-111	-0.75	-0.63	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	25.96	5.42e-115	8.61e-111	0.54	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-25.96	5.65e-115	8.98e-111	-0.76	-0.63	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	25.95	6.07e-115	9.63e-111	0.76	0.63	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-25.94	7.46e-115	1.18e-110	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-25.94	7.8e-115	1.23e-110	-0.75	-0.63	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-25.94	7.81e-115	1.23e-110	-0.76	-0.63	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-25.91	1.22e-114	1.91e-110	-0.76	-0.63	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	25.88	1.99e-114	3.07e-110	1.03	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	25.87	2.17e-114	3.35e-110	0.76	0.63	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	25.86	2.72e-114	4.19e-110	0.76	0.63	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	25.85	3.26e-114	5.02e-110	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	25.84	3.86e-114	5.92e-110	0.76	0.62	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-25.83	3.97e-114	6.08e-110	-0.75	-0.62	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-25.82	4.93e-114	7.52e-110	-0.76	-0.62	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	25.81	5.56e-114	8.48e-110	0.54	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-25.81	5.98e-114	9.12e-110	-0.76	-0.62	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-25.8	6.42e-114	9.78e-110	-0.76	-0.62	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	25.79	7.58e-114	1.15e-109	0.76	0.62	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-25.77	1.13e-113	1.7e-109	-0.76	-0.62	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	25.76	1.17e-113	1.77e-109	0.84	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-25.75	1.38e-113	2.09e-109	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	25.74	1.76e-113	2.65e-109	0.76	0.62	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	25.74	1.87e-113	2.8e-109	0.76	0.62	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-25.71	2.91e-113	4.33e-109	-0.75	-0.62	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-25.66	6.49e-113	9.56e-109	-0.76	-0.62	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-25.64	8.26e-113	1.21e-108	-0.74	-0.62	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-25.61	1.3e-112	1.91e-108	-0.75	-0.62	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-25.61	1.3e-112	1.91e-108	-0.75	-0.62	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	25.61	1.4e-112	2.05e-108	0.76	0.62	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	25.57	2.67e-112	3.9e-108	0.76	0.62	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	25.55	3.34e-112	4.85e-108	0.76	0.62	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	25.53	5.08e-112	7.32e-108	0.76	0.62	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	25.48	1.01e-111	1.45e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	25.47	1.14e-111	1.62e-107	0.75	0.62	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	25.47	1.2e-111	1.71e-107	0.76	0.62	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	25.46	1.49e-111	2.11e-107	0.76	0.62	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-25.45	1.73e-111	2.44e-107	-0.75	-0.62	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-25.45	1.73e-111	2.44e-107	-0.75	-0.62	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	25.45	1.73e-111	2.44e-107	0.75	0.62	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	25.45	1.73e-111	2.44e-107	0.75	0.62	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-25.44	1.95e-111	2.73e-107	-0.75	-0.62	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	25.43	2.36e-111	3.3e-107	0.74	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-25.42	2.7e-111	3.77e-107	-0.75	-0.62	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-25.39	4.44e-111	6.19e-107	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	25.38	5.04e-111	7.01e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	25.38	5.33e-111	7.41e-107	0.76	0.62	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	25.36	7.18e-111	9.95e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	25.29	2.2e-110	3.01e-106	0.75	0.62	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	25.28	2.47e-110	3.37e-106	0.75	0.62	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
BRCA	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	25.16	1.59e-109	2.13e-105	0.78	0.61	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
BRCA	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-25.15	1.71e-109	2.29e-105	-0.75	-0.61	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	25.09	4.39e-109	5.86e-105	0.81	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	25.08	5.69e-109	7.58e-105	0.75	0.61	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	25.04	9.81e-109	1.3e-104	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-25.04	1.01e-108	1.35e-104	-0.75	-0.61	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	25.02	1.42e-108	1.88e-104	0.82	0.61	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	25	1.79e-108	2.37e-104	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	24.94	4.74e-108	6.19e-104	0.75	0.61	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-24.93	5.6e-108	7.3e-104	-0.73	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	24.89	1.08e-107	1.4e-103	0.82	0.61	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	24.87	1.55e-107	1.99e-103	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	24.86	1.7e-107	2.18e-103	0.75	0.61	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-24.85	1.92e-107	2.46e-103	-0.74	-0.61	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	24.84	2.25e-107	2.87e-103	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-24.76	8.04e-107	1.02e-102	-0.79	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	24.75	9.35e-107	1.18e-102	0.74	0.61	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-24.75	9.62e-107	1.22e-102	-0.75	-0.61	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-24.73	1.37e-106	1.72e-102	-0.8	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	24.72	1.58e-106	1.98e-102	0.74	0.61	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	24.72	1.63e-106	2.04e-102	0.74	0.61	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	24.71	1.66e-106	2.09e-102	0.93	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
BRCA	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	24.65	4.28e-106	5.31e-102	0.52	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	24.62	7.16e-106	8.83e-102	0.68	0.61	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	24.62	7.31e-106	9.01e-102	0.74	0.61	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	24.58	1.27e-105	1.56e-101	0.81	0.61	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	24.48	6.63e-105	8.06e-101	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	24.46	8.56e-105	1.04e-100	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
BRCA	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	24.43	1.32e-104	1.6e-100	0.52	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-24.42	1.53e-104	1.85e-100	-0.72	-0.6	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	24.41	1.89e-104	2.28e-100	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
BRCA	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-24.36	4.04e-104	4.86e-100	-0.66	-0.6	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
BRCA	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	24.34	5.63e-104	6.76e-100	0.52	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	24.3	1.04e-103	1.23e-99	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
BRCA	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-24.25	2.47e-103	2.92e-99	-0.7	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-24.23	3.4e-103	4.01e-99	-0.74	-0.6	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	24.19	5.77e-103	6.79e-99	0.64	0.6	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
BRCA	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	24.17	8.01e-103	9.38e-99	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	24.17	8.07e-103	9.45e-99	1	0.6	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	24.16	9.17e-103	1.07e-98	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	24.14	1.24e-102	1.45e-98	0.81	0.6	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
BRCA	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-24.13	1.51e-102	1.76e-98	-0.64	-0.6	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-24.13	1.51e-102	1.76e-98	-0.64	-0.6	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-24.13	1.6e-102	1.86e-98	-0.64	-0.6	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	24.12	1.84e-102	2.14e-98	0.73	0.6	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
BRCA	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	24.1	2.46e-102	2.83e-98	0.73	0.6	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-24.08	3.1e-102	3.55e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-24.08	3.1e-102	3.55e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-24.05	5.46e-102	6.23e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
BRCA	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	24.05	5.55e-102	6.33e-98	0.51	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
BRCA	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-24.04	6.09e-102	6.94e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-23.98	1.6e-101	1.81e-97	-0.73	-0.6	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	23.97	1.85e-101	2.1e-97	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
BRCA	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	23.96	2.02e-101	2.29e-97	0.51	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	23.93	3.49e-101	3.91e-97	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-23.92	3.79e-101	4.25e-97	-0.72	-0.6	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-23.92	4.1e-101	4.6e-97	-0.64	-0.6	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
BRCA	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	23.9	5.48e-101	6.09e-97	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	23.9	5.56e-101	6.18e-97	0.72	0.59	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	23.87	8.86e-101	9.79e-97	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	23.84	1.33e-100	1.47e-96	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-23.84	1.42e-100	1.56e-96	-0.79	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	23.77	4.12e-100	4.51e-96	0.79	0.59	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
BRCA	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	23.67	1.79e-99	1.94e-95	0.51	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
BRCA	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	23.66	2.16e-99	2.33e-95	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	23.66	2.27e-99	2.44e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	23.63	3.42e-99	3.67e-95	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	23.6	5.51e-99	5.87e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	23.59	6.01e-99	6.37e-95	0.72	0.59	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	23.58	7.07e-99	7.48e-95	0.79	0.59	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	23.58	7.09e-99	7.5e-95	0.66	0.59	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
BRCA	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	23.57	8.88e-99	9.27e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	23.5	2.51e-98	2.58e-94	0.71	0.59	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	23.48	3.24e-98	3.32e-94	0.73	0.59	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	23.34	3.02e-97	3.04e-93	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
BRCA	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	23.33	3.46e-97	3.48e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	23.33	3.46e-97	3.48e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	23.31	4.39e-97	4.4e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
BRCA	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	23.31	4.92e-97	4.93e-93	0.5	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
BRCA	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	23.29	5.9e-97	5.9e-93	0.97	0.59	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-23.28	7.17e-97	7.17e-93	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	23.28	7.52e-97	7.51e-93	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
BRCA	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	23.22	1.74e-96	1.72e-92	0.98	0.58	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	23.21	2.2e-96	2.18e-92	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	23.2	2.37e-96	2.34e-92	0.72	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
BRCA	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	23.15	5.04e-96	4.92e-92	0.97	0.58	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	23.14	6.32e-96	6.16e-92	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
BRCA	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	23.14	6.71e-96	6.52e-92	0.65	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	23.07	1.99e-95	1.91e-91	0.66	0.58	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
BRCA	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-22.99	6.55e-95	6.16e-91	-0.72	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	22.98	7.35e-95	6.91e-91	0.65	0.58	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
BRCA	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	22.95	1.17e-94	1.1e-90	0.78	0.58	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
BRCA	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	22.93	1.48e-94	1.38e-90	0.68	0.58	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
BRCA	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	22.88	3.52e-94	3.25e-90	0.68	0.58	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-22.86	4.49e-94	4.12e-90	-0.72	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	22.75	2.48e-93	2.25e-89	0.76	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-22.7	5.19e-93	4.69e-89	-0.71	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	22.69	6.31e-93	5.66e-89	0.78	0.58	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	22.69	6.33e-93	5.69e-89	0.93	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
BRCA	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-22.67	8.49e-93	7.6e-89	-0.6	-0.57	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
BRCA	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	22.66	9.55e-93	8.51e-89	0.49	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	22.64	1.28e-92	1.14e-88	0.66	0.57	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	22.61	2.06e-92	1.83e-88	0.7	0.57	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	22.59	2.63e-92	2.33e-88	0.7	0.57	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	22.58	3.35e-92	2.97e-88	0.71	0.57	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-22.57	3.9e-92	3.45e-88	-0.7	-0.57	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	22.57	4.05e-92	3.58e-88	0.71	0.57	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-22.56	4.38e-92	3.87e-88	-0.71	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-22.56	4.41e-92	3.89e-88	-0.74	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	22.55	5.48e-92	4.83e-88	0.7	0.57	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	22.54	5.84e-92	5.14e-88	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	22.54	6.34e-92	5.57e-88	0.7	0.57	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	22.5	1.15e-91	1.01e-87	0.69	0.57	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	22.49	1.35e-91	1.18e-87	0.77	0.57	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-22.46	1.98e-91	1.73e-87	-0.7	-0.57	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-22.46	2.04e-91	1.77e-87	-0.71	-0.57	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-22.45	2.28e-91	1.98e-87	-0.68	-0.57	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-22.44	2.55e-91	2.21e-87	-0.7	-0.57	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-22.43	3.04e-91	2.64e-87	-0.71	-0.57	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-22.42	3.42e-91	2.95e-87	-0.68	-0.57	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-22.39	5.63e-91	4.82e-87	-0.68	-0.57	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-22.38	6.36e-91	5.44e-87	-0.7	-0.57	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	22.38	6.6e-91	5.63e-87	0.7	0.57	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	22.37	7.33e-91	6.24e-87	0.69	0.57	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-22.37	7.58e-91	6.45e-87	-0.69	-0.57	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	22.37	7.9e-91	6.72e-87	0.47	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-22.35	1e-90	8.49e-87	-0.48	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	22.34	1.18e-90	9.98e-87	0.69	0.57	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	22.34	1.2e-90	1.01e-86	0.69	0.57	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	22.34	1.2e-90	1.01e-86	0.69	0.57	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-22.34	1.24e-90	1.04e-86	-0.7	-0.57	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-22.34	1.25e-90	1.05e-86	-0.7	-0.57	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-22.34	1.29e-90	1.08e-86	-0.7	-0.57	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-22.33	1.35e-90	1.13e-86	-0.7	-0.57	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-22.33	1.35e-90	1.13e-86	-0.7	-0.57	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-22.33	1.38e-90	1.16e-86	-0.69	-0.57	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	22.33	1.38e-90	1.16e-86	0.48	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-22.32	1.54e-90	1.29e-86	-0.69	-0.57	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	22.3	2.17e-90	1.79e-86	0.68	0.57	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-22.3	2.26e-90	1.85e-86	-0.7	-0.57	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-22.29	2.54e-90	2.09e-86	-0.69	-0.57	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-22.29	2.72e-90	2.23e-86	-0.7	-0.57	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-22.28	2.89e-90	2.36e-86	-0.7	-0.57	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-22.28	2.89e-90	2.36e-86	-0.7	-0.57	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-22.28	3e-90	2.46e-86	-0.7	-0.57	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-22.25	4.48e-90	3.63e-86	-0.69	-0.57	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-22.25	4.77e-90	3.86e-86	-0.71	-0.57	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-22.21	8.72e-90	6.96e-86	-0.69	-0.57	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-22.2	9.56e-90	7.62e-86	-0.73	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-22.2	1.02e-89	8.14e-86	-0.69	-0.57	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-22.2	1.04e-89	8.31e-86	-0.68	-0.57	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
BRCA	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	22.17	1.51e-89	1.19e-85	0.69	0.57	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-22.16	1.92e-89	1.51e-85	-0.69	-0.57	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-22.16	1.94e-89	1.53e-85	-0.69	-0.57	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-22.13	3.07e-89	2.41e-85	-0.69	-0.57	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
BRCA	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	22.12	3.31e-89	2.59e-85	0.75	0.57	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-22.12	3.37e-89	2.64e-85	-0.69	-0.57	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-22.12	3.37e-89	2.64e-85	-0.69	-0.57	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-22.11	3.94e-89	3.07e-85	-0.69	-0.57	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-22.11	3.94e-89	3.07e-85	-0.69	-0.57	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-22.1	4.37e-89	3.39e-85	-0.69	-0.56	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-22.1	4.86e-89	3.75e-85	-0.69	-0.56	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	22.09	5.12e-89	3.95e-85	0.68	0.56	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-22.08	5.85e-89	4.5e-85	-0.68	-0.56	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-22.06	8.65e-89	6.57e-85	-0.47	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	22.05	9.52e-89	7.22e-85	0.47	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-22.05	1e-88	7.59e-85	-0.69	-0.56	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-22.05	1.02e-88	7.71e-85	-0.47	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
BRCA	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-22.04	1.08e-88	8.17e-85	-0.7	-0.56	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	22.04	1.16e-88	8.74e-85	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	22.03	1.25e-88	9.43e-85	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
BRCA	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	22.03	1.39e-88	1.05e-84	0.66	0.56	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-22.01	1.82e-88	1.37e-84	-0.68	-0.56	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
BRCA	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-22.01	1.91e-88	1.44e-84	-0.69	-0.56	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-22	2.05e-88	1.53e-84	-0.69	-0.56	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-21.99	2.34e-88	1.75e-84	-0.69	-0.56	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-21.99	2.45e-88	1.83e-84	-0.69	-0.56	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
BRCA	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-21.99	2.55e-88	1.9e-84	-0.69	-0.56	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
BRCA	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-21.98	2.93e-88	2.18e-84	-0.47	-0.56	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-21.98	3e-88	2.23e-84	-0.69	-0.56	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-21.96	3.91e-88	2.89e-84	-0.69	-0.56	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-21.96	4.02e-88	2.97e-84	-0.68	-0.56	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-21.96	4.09e-88	3.02e-84	-0.7	-0.56	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
BRCA	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	21.92	6.47e-88	4.75e-84	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-21.91	7.51e-88	5.5e-84	-0.68	-0.56	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-21.89	1.08e-87	7.87e-84	-0.68	-0.56	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-21.89	1.17e-87	8.55e-84	-0.68	-0.56	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-21.87	1.37e-87	9.99e-84	-0.69	-0.56	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-21.87	1.48e-87	1.08e-83	-0.69	-0.56	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	21.86	1.71e-87	1.24e-83	0.69	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-21.86	1.76e-87	1.28e-83	-0.71	-0.56	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-21.86	1.83e-87	1.33e-83	-0.68	-0.56	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-21.82	3.26e-87	2.35e-83	-0.67	-0.56	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	21.82	3.31e-87	2.38e-83	0.68	0.56	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	21.81	3.42e-87	2.46e-83	0.68	0.56	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-21.8	4.31e-87	3.08e-83	-0.69	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
BRCA	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-21.78	5.3e-87	3.79e-83	-0.67	-0.56	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-21.77	6.26e-87	4.46e-83	-0.68	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	21.77	7.02e-87	5e-83	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	21.76	7.2e-87	5.12e-83	0.68	0.56	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	21.76	7.24e-87	5.15e-83	0.68	0.56	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-21.76	7.68e-87	5.45e-83	-0.67	-0.56	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-21.75	9.33e-87	6.59e-83	-0.68	-0.56	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-21.75	9.33e-87	6.59e-83	-0.68	-0.56	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
BRCA	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-21.73	1.24e-86	8.72e-83	-0.67	-0.56	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-21.73	1.28e-86	9.03e-83	-0.67	-0.56	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-21.73	1.28e-86	9.03e-83	-0.67	-0.56	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
BRCA	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-21.72	1.38e-86	9.68e-83	-0.68	-0.56	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-21.72	1.38e-86	9.68e-83	-0.67	-0.56	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	21.72	1.47e-86	1.03e-82	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-21.71	1.73e-86	1.21e-82	-0.67	-0.56	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-21.7	1.88e-86	1.32e-82	-0.68	-0.56	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-21.7	1.97e-86	1.38e-82	-0.68	-0.56	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	21.69	2.28e-86	1.59e-82	0.67	0.56	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	21.67	3.06e-86	2.13e-82	0.68	0.56	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	21.66	3.19e-86	2.22e-82	0.65	0.56	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
BRCA	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-21.66	3.21e-86	2.23e-82	-0.68	-0.56	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-21.66	3.24e-86	2.25e-82	-0.68	-0.56	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
BRCA	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	21.66	3.25e-86	2.25e-82	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-21.65	4.09e-86	2.83e-82	-0.68	-0.56	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	21.64	4.39e-86	3.03e-82	0.67	0.56	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-21.63	5.36e-86	3.68e-82	-0.68	-0.56	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-21.63	5.57e-86	3.83e-82	-0.68	-0.56	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	21.62	6.44e-86	4.42e-82	0.67	0.56	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-21.62	6.55e-86	4.49e-82	-0.67	-0.56	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-21.6	8.18e-86	5.61e-82	-0.67	-0.56	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-21.6	8.77e-86	6e-82	-0.68	-0.56	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-21.6	8.93e-86	6.11e-82	-0.68	-0.56	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-21.6	8.93e-86	6.11e-82	-0.68	-0.56	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	21.58	1.2e-85	8.17e-82	0.68	0.56	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-21.57	1.26e-85	8.55e-82	-0.67	-0.56	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-21.57	1.36e-85	9.24e-82	-0.67	-0.56	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-21.57	1.36e-85	9.24e-82	-0.67	-0.56	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	21.57	1.42e-85	9.63e-82	0.67	0.56	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	21.56	1.42e-85	9.64e-82	0.67	0.56	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-21.56	1.46e-85	9.88e-82	-0.68	-0.56	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-21.56	1.46e-85	9.88e-82	-0.68	-0.56	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-21.56	1.5e-85	1.01e-81	-0.67	-0.56	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-21.56	1.56e-85	1.06e-81	-0.68	-0.56	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-21.56	1.64e-85	1.11e-81	-0.68	-0.56	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-21.55	1.73e-85	1.17e-81	-0.68	-0.56	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-21.54	1.92e-85	1.3e-81	-0.68	-0.56	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	21.54	2.08e-85	1.4e-81	0.67	0.56	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	21.54	2.08e-85	1.4e-81	0.67	0.56	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-21.5	3.58e-85	2.39e-81	-0.68	-0.55	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-21.5	3.84e-85	2.57e-81	-0.67	-0.55	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-21.5	4.01e-85	2.68e-81	-0.67	-0.55	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-21.49	4.5e-85	3.01e-81	-0.68	-0.55	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-21.48	4.83e-85	3.22e-81	-0.67	-0.55	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-21.48	4.95e-85	3.3e-81	-0.67	-0.55	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-21.48	4.95e-85	3.3e-81	-0.67	-0.55	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	21.48	5.34e-85	3.56e-81	0.68	0.55	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	21.47	5.61e-85	3.73e-81	0.68	0.55	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-21.47	6.21e-85	4.13e-81	-0.67	-0.55	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-21.46	6.4e-85	4.25e-81	-0.67	-0.55	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
BRCA	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	21.46	6.62e-85	4.39e-81	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-21.46	6.72e-85	4.46e-81	-0.67	-0.55	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	21.46	6.74e-85	4.47e-81	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-21.46	6.93e-85	4.6e-81	-0.68	-0.55	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-21.45	8.31e-85	5.49e-81	-0.67	-0.55	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	21.45	8.36e-85	5.53e-81	0.66	0.55	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
BRCA	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	21.45	8.37e-85	5.53e-81	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-21.44	9.13e-85	6.01e-81	-0.67	-0.55	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-21.43	9.92e-85	6.52e-81	-0.68	-0.55	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-21.42	1.19e-84	7.79e-81	-0.67	-0.55	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-21.42	1.24e-84	8.14e-81	-0.67	-0.55	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-21.42	1.28e-84	8.36e-81	-0.67	-0.55	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-21.42	1.28e-84	8.38e-81	-0.67	-0.55	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-21.42	1.29e-84	8.44e-81	-0.67	-0.55	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-21.41	1.33e-84	8.73e-81	-0.68	-0.55	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-21.41	1.38e-84	9.03e-81	-0.67	-0.55	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-21.41	1.38e-84	9.03e-81	-0.67	-0.55	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-21.41	1.4e-84	9.16e-81	-0.67	-0.55	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-21.41	1.4e-84	9.16e-81	-0.67	-0.55	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-21.41	1.45e-84	9.47e-81	-0.67	-0.55	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-21.41	1.48e-84	9.69e-81	-0.67	-0.55	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-21.41	1.48e-84	9.69e-81	-0.67	-0.55	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-21.4	1.62e-84	1.05e-80	-0.67	-0.55	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-21.4	1.64e-84	1.07e-80	-0.67	-0.55	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-21.39	1.82e-84	1.19e-80	-0.67	-0.55	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	21.38	2.32e-84	1.5e-80	0.67	0.55	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	21.35	3.37e-84	2.18e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	21.35	3.37e-84	2.18e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.34	4.13e-84	2.66e-80	0.72	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
BRCA	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-21.34	4.25e-84	2.74e-80	-0.96	-0.55	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-21.33	5.01e-84	3.23e-80	-0.67	-0.55	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	21.32	5.31e-84	3.41e-80	0.66	0.55	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	21.32	5.74e-84	3.69e-80	0.67	0.55	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	21.31	6.61e-84	4.25e-80	0.67	0.55	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	21.3	7.29e-84	4.68e-80	0.67	0.55	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-21.3	7.4e-84	4.75e-80	-0.72	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
BRCA	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	21.3	7.64e-84	4.9e-80	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	21.29	8.34e-84	5.34e-80	0.67	0.55	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	21.29	8.86e-84	5.68e-80	0.67	0.55	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-21.28	9.82e-84	6.28e-80	-0.67	-0.55	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	21.27	1.15e-83	7.38e-80	0.67	0.55	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	21.26	1.25e-83	8e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
BRCA	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-21.26	1.41e-83	9.01e-80	-0.67	-0.55	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.25	1.5e-83	9.58e-80	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
BRCA	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	21.24	1.68e-83	1.07e-79	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
BRCA	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	21.23	2.12e-83	1.34e-79	0.85	0.55	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-21.21	2.95e-83	1.87e-79	-0.66	-0.55	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-21.2	3.23e-83	2.04e-79	-0.67	-0.55	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	21.2	3.27e-83	2.07e-79	0.67	0.55	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	21.2	3.45e-83	2.18e-79	0.67	0.55	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-21.19	3.69e-83	2.33e-79	-0.67	-0.55	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-21.18	4.09e-83	2.58e-79	-0.67	-0.55	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-21.18	4.17e-83	2.63e-79	-0.67	-0.55	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-21.18	4.17e-83	2.63e-79	-0.67	-0.55	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	21.18	4.57e-83	2.88e-79	0.67	0.55	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	21.17	5.16e-83	3.25e-79	0.63	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-21.16	5.62e-83	3.54e-79	-0.7	-0.55	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	21.16	5.85e-83	3.68e-79	0.66	0.55	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	21.16	6.13e-83	3.85e-79	0.66	0.55	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-21.16	6.32e-83	3.96e-79	-0.67	-0.55	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-21.15	6.39e-83	4.01e-79	-0.76	-0.55	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	21.15	6.55e-83	4.11e-79	0.66	0.55	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-21.14	8.14e-83	5.1e-79	-0.67	-0.55	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-21.13	9.14e-83	5.72e-79	-0.67	-0.55	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-21.1	1.41e-82	8.78e-79	-0.67	-0.55	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-21.1	1.49e-82	9.26e-79	-0.67	-0.55	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-21.09	1.64e-82	1.02e-78	-0.67	-0.55	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-21.08	1.87e-82	1.16e-78	-0.67	-0.55	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-21.08	1.94e-82	1.2e-78	-0.75	-0.55	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	21.07	2.36e-82	1.46e-78	0.72	0.55	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-21.06	2.71e-82	1.68e-78	-0.67	-0.55	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	21.06	2.75e-82	1.7e-78	0.67	0.55	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-21.05	2.81e-82	1.74e-78	-0.67	-0.55	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	21.04	3.25e-82	2.01e-78	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-21.04	3.26e-82	2.02e-78	-0.66	-0.55	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	21.04	3.74e-82	2.31e-78	0.67	0.55	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	21.02	4.95e-82	3.05e-78	0.72	0.55	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-21.01	5.3e-82	3.26e-78	-0.67	-0.55	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-21.01	5.3e-82	3.26e-78	-0.67	-0.55	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	21.01	5.52e-82	3.4e-78	0.67	0.55	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-21.01	5.7e-82	3.5e-78	-0.66	-0.55	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-20.98	8.09e-82	4.96e-78	-0.67	-0.55	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-20.98	8.35e-82	5.11e-78	-0.66	-0.54	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	20.96	1.06e-81	6.49e-78	0.84	0.54	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	20.95	1.34e-81	8.16e-78	0.84	0.54	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-20.93	1.8e-81	1.09e-77	-0.66	-0.54	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	20.92	2.05e-81	1.24e-77	0.66	0.54	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-20.91	2.33e-81	1.41e-77	-0.76	-0.54	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-20.9	2.84e-81	1.72e-77	-0.67	-0.54	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-20.89	3.01e-81	1.81e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-20.89	3.09e-81	1.86e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-20.89	3.23e-81	1.94e-77	-0.67	-0.54	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	20.88	3.73e-81	2.24e-77	0.66	0.54	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-20.87	4.16e-81	2.5e-77	-0.66	-0.54	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	20.87	4.37e-81	2.62e-77	0.66	0.54	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	20.86	5.01e-81	3e-77	0.67	0.54	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-20.86	5.02e-81	3.01e-77	-0.67	-0.54	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-20.86	5.36e-81	3.21e-77	-0.69	-0.54	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
BRCA	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	20.85	5.82e-81	3.48e-77	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
BRCA	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-20.84	6.78e-81	4.05e-77	-0.69	-0.54	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-20.83	8.01e-81	4.77e-77	-0.66	-0.54	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-20.82	8.56e-81	5.09e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.82	9.07e-81	5.39e-77	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	20.81	1.08e-80	6.39e-77	0.66	0.54	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-20.81	1.12e-80	6.63e-77	-0.66	-0.54	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	20.8	1.25e-80	7.41e-77	0.76	0.54	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	20.8	1.26e-80	7.48e-77	0.68	0.54	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	20.76	2.04e-80	1.21e-76	0.66	0.54	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	20.76	2.07e-80	1.22e-76	0.86	0.54	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	20.76	2.31e-80	1.37e-76	0.85	0.54	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	20.75	2.46e-80	1.45e-76	0.66	0.54	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-20.75	2.46e-80	1.45e-76	-0.56	-0.54	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-20.75	2.7e-80	1.59e-76	-0.67	-0.54	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-20.75	2.7e-80	1.59e-76	-0.67	-0.54	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	20.74	2.75e-80	1.62e-76	0.63	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	20.74	2.82e-80	1.66e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	20.74	2.86e-80	1.68e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	20.74	2.89e-80	1.7e-76	0.66	0.54	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
BRCA	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-20.74	3.03e-80	1.78e-76	-0.85	-0.54	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
BRCA	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-20.71	4.24e-80	2.48e-76	-0.69	-0.54	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
BRCA	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	20.69	6.22e-80	3.63e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	20.67	8.51e-80	4.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.64	1.18e-79	6.88e-76	-0.71	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
BRCA	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	20.64	1.2e-79	6.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	20.64	1.2e-79	6.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-20.63	1.41e-79	8.16e-76	-0.68	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
BRCA	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	20.63	1.45e-79	8.38e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	20.62	1.62e-79	9.38e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
BRCA	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	20.6	2.25e-79	1.3e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
BRCA	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	20.6	2.38e-79	1.38e-75	0.61	0.54	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	20.59	2.66e-79	1.53e-75	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	20.59	2.7e-79	1.55e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	20.58	2.97e-79	1.71e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	20.54	5.29e-79	3.03e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	20.54	5.29e-79	3.03e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	20.54	5.68e-79	3.24e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-20.53	6.28e-79	3.58e-75	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
BRCA	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	20.52	7.41e-79	4.22e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-20.52	7.65e-79	4.36e-75	-0.7	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-20.51	8.11e-79	4.61e-75	-0.65	-0.54	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	20.51	8.18e-79	4.65e-75	0.66	0.54	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-20.5	9.77e-79	5.56e-75	-0.67	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	20.5	1.01e-78	5.72e-75	0.66	0.54	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	20.5	1.05e-78	5.97e-75	0.61	0.54	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
BRCA	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	20.49	1.08e-78	6.14e-75	0.81	0.54	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-20.44	2.42e-78	1.37e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
BRCA	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-20.41	3.83e-78	2.16e-74	-0.74	-0.53	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	20.39	4.73e-78	2.66e-74	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	20.38	5.78e-78	3.24e-74	0.66	0.53	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	20.38	6.05e-78	3.39e-74	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
BRCA	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	20.37	7.1e-78	3.97e-74	0.67	0.53	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	20.35	8.46e-78	4.73e-74	0.66	0.53	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	20.35	8.46e-78	4.73e-74	0.66	0.53	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	20.34	9.65e-78	5.39e-74	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	20.34	1.02e-77	5.7e-74	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-20.32	1.33e-77	7.41e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	20.32	1.45e-77	8.07e-74	0.62	0.53	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
BRCA	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-20.31	1.52e-77	8.47e-74	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
BRCA	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	20.31	1.65e-77	9.16e-74	0.66	0.53	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-20.31	1.66e-77	9.22e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-20.31	1.66e-77	9.22e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
BRCA	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	20.3	1.96e-77	1.09e-73	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-20.27	2.89e-77	1.6e-73	-0.7	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
BRCA	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	20.24	4.49e-77	2.48e-73	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
BRCA	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	20.24	4.72e-77	2.6e-73	0.76	0.53	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
BRCA	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-20.23	4.89e-77	2.7e-73	-0.68	-0.53	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
BRCA	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	20.23	5.19e-77	2.86e-73	0.61	0.53	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
BRCA	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	20.23	5.26e-77	2.9e-73	0.66	0.53	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
BRCA	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	20.22	6.09e-77	3.35e-73	0.66	0.53	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
BRCA	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	20.21	6.71e-77	3.68e-73	0.62	0.53	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-20.21	6.95e-77	3.81e-73	-0.75	-0.53	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	20.2	7.71e-77	4.23e-73	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
BRCA	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	20.18	1.02e-76	5.59e-73	0.6	0.53	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	20.18	1.04e-76	5.67e-73	0.7	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
BRCA	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	20.18	1.07e-76	5.86e-73	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	20.18	1.08e-76	5.92e-73	0.6	0.53	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
BRCA	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	20.18	1.12e-76	6.11e-73	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	20.17	1.17e-76	6.36e-73	0.7	0.53	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
BRCA	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-20.17	1.25e-76	6.82e-73	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
BRCA	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-20.16	1.33e-76	7.27e-73	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
BRCA	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-20.15	1.62e-76	8.83e-73	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
BRCA	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-20.13	2.08e-76	1.13e-72	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
BRCA	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-20.13	2.26e-76	1.23e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	20.13	2.27e-76	1.23e-72	0.6	0.53	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-20.12	2.52e-76	1.37e-72	-0.65	-0.53	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-20.12	2.62e-76	1.42e-72	-0.65	-0.53	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-20.12	2.7e-76	1.46e-72	-0.75	-0.53	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
BRCA	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-20.11	2.98e-76	1.61e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-20.09	3.88e-76	2.1e-72	-0.75	-0.53	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
BRCA	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	20.09	4.13e-76	2.23e-72	0.65	0.53	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.08	4.37e-76	2.36e-72	-0.69	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
BRCA	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-20.07	4.87e-76	2.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-20.07	4.87e-76	2.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-20.07	5.07e-76	2.73e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-20.07	5.37e-76	2.89e-72	-0.76	-0.53	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
BRCA	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	20.07	5.46e-76	2.94e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-20.06	5.74e-76	3.08e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-20.06	5.74e-76	3.08e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-20.06	5.74e-76	3.09e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	20.06	5.93e-76	3.19e-72	0.62	0.53	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-20.06	6.01e-76	3.23e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-20.05	6.63e-76	3.56e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	20.04	8.63e-76	4.62e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	20.03	8.89e-76	4.76e-72	0.65	0.53	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-20.03	9.05e-76	4.84e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-20.03	9.16e-76	4.9e-72	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
BRCA	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	20.03	9.71e-76	5.19e-72	0.65	0.53	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-20.02	1.15e-75	6.15e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-20.01	1.24e-75	6.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-20.01	1.24e-75	6.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-20	1.43e-75	7.61e-72	-0.7	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
BRCA	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.67e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	20	1.44e-75	7.68e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.68e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.68e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-20	1.53e-75	8.12e-72	-0.76	-0.53	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
BRCA	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-19.99	1.65e-75	8.75e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-19.99	1.76e-75	9.34e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
BRCA	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-19.98	1.82e-75	9.63e-72	-0.43	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-19.98	1.94e-75	1.03e-71	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-19.97	2.19e-75	1.16e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-19.97	2.21e-75	1.17e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-19.96	2.4e-75	1.27e-71	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-19.95	2.99e-75	1.58e-71	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.95	3.05e-75	1.61e-71	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-19.94	3.49e-75	1.84e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-19.93	3.74e-75	1.97e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-19.93	3.84e-75	2.02e-71	-0.75	-0.53	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
BRCA	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	19.93	3.86e-75	2.03e-71	0.83	0.53	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-19.92	4.4e-75	2.31e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-19.92	4.43e-75	2.33e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	19.92	4.62e-75	2.42e-71	0.61	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	19.91	4.95e-75	2.6e-71	0.68	0.53	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-19.91	5.36e-75	2.81e-71	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-19.91	5.45e-75	2.85e-71	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-19.89	7.25e-75	3.79e-71	-0.68	-0.52	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	19.88	7.96e-75	4.16e-71	0.65	0.52	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-19.87	9.32e-75	4.86e-71	-0.62	-0.52	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
BRCA	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-19.86	1.06e-74	5.51e-71	-0.43	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
BRCA	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	19.86	1.07e-74	5.59e-71	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	19.86	1.13e-74	5.86e-71	0.6	0.52	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
BRCA	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-19.86	1.14e-74	5.94e-71	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	19.85	1.34e-74	6.98e-71	0.59	0.52	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-19.84	1.38e-74	7.18e-71	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
BRCA	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	19.84	1.4e-74	7.27e-71	0.59	0.52	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	19.84	1.4e-74	7.29e-71	0.59	0.52	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	19.83	1.69e-74	8.75e-71	0.64	0.52	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-19.82	1.95e-74	1.01e-70	-0.64	-0.52	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	19.81	2.21e-74	1.14e-70	0.63	0.52	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
BRCA	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-19.81	2.26e-74	1.17e-70	-0.69	-0.52	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
BRCA	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	19.79	2.79e-74	1.44e-70	0.58	0.52	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
BRCA	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-19.79	2.9e-74	1.5e-70	-0.43	-0.52	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
BRCA	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	19.79	3.21e-74	1.65e-70	0.61	0.52	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-19.77	3.79e-74	1.94e-70	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	19.75	5.62e-74	2.87e-70	0.58	0.52	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	19.74	5.79e-74	2.96e-70	0.59	0.52	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	19.74	6.45e-74	3.29e-70	0.58	0.52	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-19.73	6.69e-74	3.42e-70	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-19.73	6.8e-74	3.47e-70	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-19.72	8.8e-74	4.48e-70	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
BRCA	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	19.7	1.08e-73	5.49e-70	0.68	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-19.69	1.28e-73	6.46e-70	-0.58	-0.52	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-19.65	2.22e-73	1.12e-69	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	19.62	3.29e-73	1.66e-69	0.61	0.52	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-19.59	5.13e-73	2.57e-69	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
BRCA	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	19.59	5.2e-73	2.6e-69	0.89	0.52	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
BRCA	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-19.58	5.86e-73	2.94e-69	-0.66	-0.52	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
BRCA	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-19.58	6.6e-73	3.3e-69	-0.59	-0.52	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
BRCA	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-19.53	1.32e-72	6.56e-69	-0.61	-0.52	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
BRCA	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-19.48	2.42e-72	1.2e-68	-0.67	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
BRCA	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-19.48	2.73e-72	1.35e-68	-0.53	-0.52	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
BRCA	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	19.46	3.38e-72	1.67e-68	0.64	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-19.45	3.7e-72	1.82e-68	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-19.45	3.96e-72	1.95e-68	-0.68	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
BRCA	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-19.45	3.96e-72	1.95e-68	-0.55	-0.52	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
BRCA	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	19.42	5.86e-72	2.88e-68	0.58	0.52	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
BRCA	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	19.41	6.79e-72	3.32e-68	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	19.34	1.86e-71	9.03e-68	0.67	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	19.31	2.97e-71	1.43e-67	0.63	0.51	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	19.31	3.12e-71	1.5e-67	0.65	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
BRCA	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	19.28	4.47e-71	2.14e-67	0.62	0.51	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
BRCA	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	19.25	6.97e-71	3.33e-67	0.87	0.51	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	19.23	9.13e-71	4.35e-67	0.63	0.51	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	19.22	1.13e-70	5.36e-67	0.88	0.51	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
BRCA	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	19.18	1.73e-70	8.18e-67	0.8	0.51	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	19.18	1.74e-70	8.21e-67	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	19.18	1.84e-70	8.67e-67	0.67	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	19.18	1.94e-70	9.15e-67	0.62	0.51	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-19.16	2.31e-70	1.09e-66	-0.63	-0.51	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
BRCA	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	19.16	2.37e-70	1.11e-66	0.58	0.51	Height;	chr11:118703185	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	19.16	2.37e-70	1.11e-66	0.58	0.51	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	19.16	2.4e-70	1.12e-66	0.63	0.51	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
BRCA	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	19.16	2.47e-70	1.16e-66	0.58	0.51	Height;	chr11:118703207	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-19.15	2.7e-70	1.26e-66	-0.62	-0.51	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-19.14	3.18e-70	1.48e-66	-0.63	-0.51	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	19.12	4.32e-70	2.01e-66	0.63	0.51	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	19.11	4.8e-70	2.24e-66	0.67	0.51	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-19.11	5.28e-70	2.46e-66	-0.63	-0.51	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-19.11	5.28e-70	2.46e-66	-0.63	-0.51	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	19.09	6.55e-70	3.03e-66	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
BRCA	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-19.09	6.79e-70	3.15e-66	-0.74	-0.51	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
BRCA	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	19.09	6.82e-70	3.16e-66	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	19.08	7.33e-70	3.39e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
BRCA	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-19.07	9.02e-70	4.16e-66	-0.42	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
BRCA	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	19.07	9.47e-70	4.36e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	19.06	9.52e-70	4.39e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	19.06	9.64e-70	4.44e-66	0.62	0.51	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-19.04	1.27e-69	5.82e-66	-0.57	-0.51	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
BRCA	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-19.04	1.33e-69	6.11e-66	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
BRCA	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-19.02	1.68e-69	7.7e-66	-0.63	-0.51	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	19.02	1.78e-69	8.14e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	19.02	1.78e-69	8.14e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
BRCA	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-19.02	1.82e-69	8.32e-66	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
BRCA	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-19.02	1.9e-69	8.67e-66	-0.61	-0.51	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-19.01	1.95e-69	8.89e-66	-0.62	-0.51	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	19.01	2.08e-69	9.49e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-19.01	2.18e-69	9.92e-66	-0.62	-0.51	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	19	2.38e-69	1.08e-65	0.62	0.51	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-19	2.49e-69	1.13e-65	-0.41	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
BRCA	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-18.98	2.96e-69	1.34e-65	-0.61	-0.51	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	18.98	3.37e-69	1.53e-65	0.62	0.51	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	18.98	3.37e-69	1.53e-65	0.62	0.51	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	18.97	3.42e-69	1.55e-65	0.62	0.51	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-18.95	4.87e-69	2.2e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-18.95	4.89e-69	2.21e-65	-0.62	-0.51	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-18.95	5.03e-69	2.27e-65	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
BRCA	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	18.92	7.42e-69	3.33e-65	0.49	0.51	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
BRCA	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	18.92	7.76e-69	3.47e-65	0.85	0.51	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-18.91	8.87e-69	3.96e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	18.9	9.91e-69	4.42e-65	0.85	0.51	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	18.9	1.03e-68	4.6e-65	0.85	0.51	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-18.89	1.06e-68	4.71e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-18.89	1.14e-68	5.05e-65	-0.63	-0.51	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	18.89	1.16e-68	5.15e-65	0.62	0.51	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	18.89	1.16e-68	5.15e-65	0.62	0.51	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-18.89	1.2e-68	5.33e-65	-0.64	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	18.89	1.21e-68	5.36e-65	0.57	0.5	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	18.88	1.32e-68	5.83e-65	0.61	0.5	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	18.88	1.32e-68	5.86e-65	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-18.87	1.4e-68	6.21e-65	-0.62	-0.5	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	18.87	1.6e-68	7.08e-65	0.85	0.5	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	18.87	1.6e-68	7.08e-65	0.85	0.5	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-18.87	1.6e-68	7.1e-65	-0.62	-0.5	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-18.85	1.97e-68	8.7e-65	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-18.85	2.03e-68	8.95e-65	-0.62	-0.5	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-18.85	2.04e-68	9e-65	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	18.85	2.11e-68	9.28e-65	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-18.84	2.33e-68	1.03e-64	-0.67	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	18.82	2.97e-68	1.3e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
BRCA	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	18.82	3.06e-68	1.34e-64	0.63	0.5	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-18.79	4.33e-68	1.89e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-18.79	4.33e-68	1.89e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-18.79	4.55e-68	1.99e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-18.79	4.55e-68	1.99e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	18.79	4.8e-68	2.09e-64	0.6	0.5	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	18.79	4.86e-68	2.12e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-18.79	4.93e-68	2.15e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	18.77	6.01e-68	2.61e-64	0.62	0.5	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-18.77	6.04e-68	2.63e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	18.77	6.2e-68	2.7e-64	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	18.77	6.47e-68	2.81e-64	0.62	0.5	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	18.76	6.65e-68	2.89e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-18.76	6.74e-68	2.93e-64	-0.62	-0.5	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	18.76	6.83e-68	2.97e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	18.76	6.83e-68	2.97e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-18.76	7.05e-68	3.06e-64	-0.62	-0.5	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-18.76	7.27e-68	3.15e-64	-0.81	-0.5	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
BRCA	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	18.76	7.33e-68	3.18e-64	0.51	0.5	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
BRCA	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-18.75	8.68e-68	3.76e-64	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-18.74	8.93e-68	3.87e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	18.74	9.01e-68	3.9e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	18.74	9.01e-68	3.9e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
BRCA	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	18.74	9.11e-68	3.94e-64	0.53	0.5	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
BRCA	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	18.74	9.55e-68	4.13e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	18.74	9.84e-68	4.25e-64	0.62	0.5	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-18.72	1.19e-67	5.12e-64	-0.62	-0.5	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-18.72	1.19e-67	5.12e-64	-0.62	-0.5	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-18.71	1.34e-67	5.79e-64	-0.62	-0.5	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-18.71	1.34e-67	5.79e-64	-0.62	-0.5	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	18.71	1.44e-67	6.22e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	18.7	1.53e-67	6.59e-64	0.61	0.5	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	18.7	1.73e-67	7.44e-64	0.62	0.5	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-18.7	1.74e-67	7.48e-64	-0.62	-0.5	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	18.69	1.83e-67	7.88e-64	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	18.69	1.86e-67	7.98e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-18.68	2.04e-67	8.76e-64	-0.62	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
BRCA	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	18.68	2.18e-67	9.33e-64	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-18.68	2.2e-67	9.42e-64	-0.62	-0.5	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	18.68	2.22e-67	9.52e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	18.67	2.55e-67	1.09e-63	0.61	0.5	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-18.66	3.03e-67	1.29e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-18.65	3.15e-67	1.35e-63	-0.61	-0.5	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
BRCA	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	18.64	3.61e-67	1.53e-63	0.61	0.5	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-18.64	3.96e-67	1.68e-63	-0.61	-0.5	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	18.63	4.11e-67	1.74e-63	0.62	0.5	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	18.63	4.21e-67	1.78e-63	0.57	0.5	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	18.63	4.57e-67	1.93e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	18.63	4.57e-67	1.93e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	18.62	4.94e-67	2.09e-63	0.79	0.5	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	18.62	4.95e-67	2.09e-63	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-18.62	5.32e-67	2.24e-63	-0.62	-0.5	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	18.62	5.34e-67	2.25e-63	0.82	0.5	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-18.6	6.74e-67	2.84e-63	-0.62	-0.5	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-18.59	7.47e-67	3.14e-63	-0.61	-0.5	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	18.59	7.78e-67	3.27e-63	0.83	0.5	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	18.59	7.87e-67	3.31e-63	0.61	0.5	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-18.59	7.93e-67	3.33e-63	-0.61	-0.5	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	18.58	8.95e-67	3.75e-63	0.84	0.5	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-18.58	9.15e-67	3.83e-63	-0.62	-0.5	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-18.58	9.28e-67	3.88e-63	-0.62	-0.5	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-18.57	9.51e-67	3.98e-63	-0.62	-0.5	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-18.57	9.55e-67	3.99e-63	-0.62	-0.5	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-18.57	9.55e-67	3.99e-63	-0.62	-0.5	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-18.57	9.79e-67	4.09e-63	-0.62	-0.5	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-18.57	1.09e-66	4.54e-63	-0.62	-0.5	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
BRCA	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-18.56	1.17e-66	4.87e-63	-0.55	-0.5	Breast cancer;	chr11:743813	chr11:779617~780755:+
BRCA	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	18.56	1.22e-66	5.08e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	18.55	1.27e-66	5.28e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	18.55	1.32e-66	5.48e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-18.55	1.32e-66	5.49e-63	-0.62	-0.5	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	18.55	1.41e-66	5.82e-63	0.62	0.5	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-18.55	1.42e-66	5.88e-63	-0.62	-0.5	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	18.54	1.65e-66	6.82e-63	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-18.53	1.69e-66	7e-63	-0.61	-0.5	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-18.53	1.73e-66	7.13e-63	-0.61	-0.5	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-18.53	1.75e-66	7.22e-63	-0.62	-0.5	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-18.53	1.86e-66	7.69e-63	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-18.52	1.96e-66	8.08e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-18.52	2.01e-66	8.26e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	18.52	2.17e-66	8.93e-63	0.61	0.5	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-18.51	2.4e-66	9.87e-63	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	18.51	2.47e-66	1.02e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	18.5	2.55e-66	1.05e-62	0.57	0.5	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	18.5	2.65e-66	1.09e-62	0.62	0.5	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	18.5	2.65e-66	1.09e-62	0.62	0.5	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	18.5	2.78e-66	1.14e-62	0.62	0.5	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	18.5	2.85e-66	1.17e-62	0.66	0.5	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	18.49	2.92e-66	1.19e-62	0.62	0.5	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-18.49	3.03e-66	1.24e-62	-0.62	-0.5	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-18.49	3.03e-66	1.24e-62	-0.62	-0.5	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-18.49	3.06e-66	1.25e-62	-0.56	-0.5	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	18.49	3.06e-66	1.25e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	18.49	3.07e-66	1.26e-62	0.62	0.5	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	18.49	3.2e-66	1.3e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
BRCA	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	18.49	3.3e-66	1.34e-62	0.66	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	18.48	3.68e-66	1.5e-62	0.62	0.5	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	18.47	4.01e-66	1.63e-62	0.62	0.5	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	18.47	4.07e-66	1.65e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-18.47	4.35e-66	1.77e-62	-0.62	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-18.47	4.4e-66	1.78e-62	-0.62	-0.5	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-18.46	4.84e-66	1.96e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	18.45	5.14e-66	2.08e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	18.44	5.94e-66	2.4e-62	0.62	0.5	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	18.44	6.23e-66	2.51e-62	0.62	0.5	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-18.44	6.46e-66	2.6e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	18.43	7.33e-66	2.95e-62	0.62	0.5	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	18.43	7.6e-66	3.06e-62	0.62	0.5	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-18.42	7.69e-66	3.09e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	18.42	8.07e-66	3.24e-62	0.62	0.5	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-18.42	8.15e-66	3.28e-62	-0.61	-0.5	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
BRCA	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-18.42	8.38e-66	3.36e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
BRCA	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-18.42	8.75e-66	3.5e-62	-0.51	-0.5	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	18.41	9.45e-66	3.77e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	18.41	9.45e-66	3.77e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-18.41	9.5e-66	3.79e-62	-0.62	-0.5	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	18.41	9.83e-66	3.92e-62	0.6	0.5	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-18.39	1.22e-65	4.85e-62	-0.61	-0.5	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	18.38	1.37e-65	5.42e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
BRCA	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-18.38	1.53e-65	6.04e-62	-0.61	-0.49	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
BRCA	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	18.37	1.65e-65	6.51e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	18.37	1.66e-65	6.55e-62	0.61	0.49	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	18.37	1.7e-65	6.72e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-18.37	1.71e-65	6.75e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-18.37	1.71e-65	6.75e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	18.36	1.84e-65	7.25e-62	0.62	0.49	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-18.36	1.92e-65	7.55e-62	-0.61	-0.49	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	18.36	1.92e-65	7.55e-62	0.61	0.49	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	18.36	2.02e-65	7.95e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-18.35	2.12e-65	8.33e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-18.35	2.33e-65	9.13e-62	-0.61	-0.49	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-18.35	2.33e-65	9.13e-62	-0.61	-0.49	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-18.34	2.42e-65	9.48e-62	-0.61	-0.49	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
BRCA	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-18.33	2.77e-65	1.08e-61	-0.6	-0.49	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	18.33	3.05e-65	1.19e-61	0.61	0.49	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	18.33	3.05e-65	1.19e-61	0.61	0.49	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	18.32	3.41e-65	1.33e-61	0.62	0.49	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	18.32	3.48e-65	1.35e-61	0.61	0.49	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	18.31	3.61e-65	1.41e-61	0.61	0.49	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-18.31	3.61e-65	1.41e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	18.31	3.86e-65	1.5e-61	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	18.31	3.97e-65	1.54e-61	0.61	0.49	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	18.3	4.43e-65	1.72e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	18.3	4.55e-65	1.77e-61	0.62	0.49	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-18.29	5.01e-65	1.94e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-18.29	5.01e-65	1.94e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	18.28	6.12e-65	2.36e-61	0.81	0.49	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	18.28	6.17e-65	2.38e-61	0.61	0.49	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	18.27	6.22e-65	2.4e-61	0.61	0.49	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-18.27	6.38e-65	2.46e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
BRCA	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	18.27	6.57e-65	2.53e-61	0.78	0.49	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
BRCA	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	18.27	6.73e-65	2.59e-61	0.81	0.49	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	18.27	6.81e-65	2.62e-61	0.61	0.49	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	18.26	7.92e-65	3.04e-61	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	18.26	8.07e-65	3.1e-61	0.61	0.49	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-18.25	8.2e-65	3.15e-61	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	18.25	9.22e-65	3.54e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	18.24	9.68e-65	3.71e-61	0.58	0.49	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	18.24	1.01e-64	3.88e-61	0.61	0.49	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-18.23	1.12e-64	4.3e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-18.23	1.12e-64	4.3e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	18.23	1.19e-64	4.54e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
BRCA	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-18.23	1.22e-64	4.64e-61	-0.6	-0.49	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
BRCA	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-18.22	1.41e-64	5.39e-61	-0.6	-0.49	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
BRCA	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	18.21	1.48e-64	5.62e-61	0.59	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	18.21	1.49e-64	5.68e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-18.21	1.58e-64	6.01e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	18.21	1.63e-64	6.2e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	18.2	1.64e-64	6.24e-61	0.64	0.49	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
BRCA	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-18.2	1.72e-64	6.54e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-18.2	1.76e-64	6.69e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-18.2	1.76e-64	6.69e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-18.2	1.77e-64	6.72e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	18.16	2.86e-64	1.08e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	18.16	2.9e-64	1.1e-60	0.61	0.49	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	18.16	2.9e-64	1.1e-60	0.61	0.49	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	18.16	2.96e-64	1.12e-60	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
BRCA	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	18.15	3.45e-64	1.3e-60	0.65	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
BRCA	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	18.14	3.98e-64	1.5e-60	0.79	0.49	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	18.14	4.12e-64	1.55e-60	0.66	0.49	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
BRCA	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	18.11	5.92e-64	2.22e-60	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	18.11	5.99e-64	2.24e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-18.11	6.39e-64	2.39e-60	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
BRCA	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-18.11	6.48e-64	2.42e-60	-0.62	-0.49	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-18.08	8.62e-64	3.21e-60	-0.6	-0.49	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	18.08	8.93e-64	3.32e-60	0.52	0.49	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	18.07	9.99e-64	3.71e-60	0.61	0.49	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-18.07	1.04e-63	3.85e-60	-0.61	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	18.06	1.22e-63	4.49e-60	0.58	0.49	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-18.06	1.26e-63	4.67e-60	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
BRCA	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	18.05	1.38e-63	5.08e-60	0.52	0.49	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
BRCA	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	18.05	1.41e-63	5.21e-60	0.81	0.49	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
BRCA	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	18.04	1.61e-63	5.94e-60	0.54	0.49	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	18.04	1.67e-63	6.13e-60	0.61	0.49	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	18.04	1.71e-63	6.3e-60	0.61	0.49	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	18.04	1.71e-63	6.3e-60	0.61	0.49	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-18.03	1.74e-63	6.38e-60	-0.61	-0.49	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	18.03	1.94e-63	7.13e-60	0.51	0.49	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	18.02	1.98e-63	7.28e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	18.02	2.23e-63	8.19e-60	0.61	0.49	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	18.01	2.28e-63	8.36e-60	0.61	0.49	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-18.01	2.32e-63	8.49e-60	-0.6	-0.49	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	18.01	2.43e-63	8.89e-60	0.61	0.49	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	17.99	3.05e-63	1.11e-59	0.61	0.49	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
BRCA	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	17.98	3.44e-63	1.26e-59	0.53	0.49	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
BRCA	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-17.98	3.49e-63	1.27e-59	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	17.97	4.37e-63	1.59e-59	0.59	0.49	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
BRCA	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	17.97	4.38e-63	1.59e-59	0.64	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	17.96	5.1e-63	1.85e-59	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
BRCA	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	17.94	5.93e-63	2.15e-59	0.51	0.49	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-17.94	5.97e-63	2.16e-59	-0.6	-0.49	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-17.94	6.16e-63	2.23e-59	-0.61	-0.49	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	17.93	6.84e-63	2.47e-59	0.6	0.49	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	17.93	6.84e-63	2.47e-59	0.6	0.49	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	17.93	6.98e-63	2.52e-59	0.6	0.49	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	17.93	7.02e-63	2.53e-59	0.52	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-17.92	8.17e-63	2.94e-59	-0.61	-0.49	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	17.92	8.51e-63	3.06e-59	0.6	0.49	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-17.92	8.64e-63	3.11e-59	-0.61	-0.49	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
BRCA	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	17.91	9.93e-63	3.57e-59	0.79	0.49	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
BRCA	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-17.91	1.02e-62	3.66e-59	-0.62	-0.49	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
BRCA	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	17.88	1.37e-62	4.91e-59	0.59	0.48	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	17.85	2.1e-62	7.5e-59	0.6	0.48	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	17.85	2.1e-62	7.5e-59	0.6	0.48	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-17.85	2.18e-62	7.8e-59	-0.6	-0.48	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-17.84	2.37e-62	8.48e-59	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
BRCA	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	17.84	2.53e-62	9.03e-59	0.79	0.48	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-17.83	2.68e-62	9.59e-59	-0.6	-0.48	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-17.83	2.71e-62	9.69e-59	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-17.83	2.72e-62	9.71e-59	-0.59	-0.48	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
BRCA	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-17.83	2.75e-62	9.8e-59	-0.62	-0.48	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
BRCA	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	17.82	3.21e-62	1.14e-58	0.54	0.48	Breast cancer;	chr11:750849	chr11:779617~780755:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-17.82	3.38e-62	1.2e-58	-0.61	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
BRCA	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
BRCA	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-17.8	4.17e-62	1.48e-58	-0.61	-0.48	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	17.8	4.4e-62	1.56e-58	0.6	0.48	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
BRCA	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	17.78	5.39e-62	1.91e-58	0.76	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
BRCA	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-17.78	5.72e-62	2.03e-58	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-17.77	6.56e-62	2.32e-58	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-17.77	6.56e-62	2.32e-58	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-17.77	6.68e-62	2.36e-58	-0.66	-0.48	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
BRCA	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	17.76	7.86e-62	2.77e-58	0.6	0.48	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	17.75	8.34e-62	2.94e-58	0.58	0.48	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	17.75	8.82e-62	3.11e-58	0.6	0.48	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-17.75	9.14e-62	3.22e-58	-0.61	-0.48	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
BRCA	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-17.73	1.16e-61	4.08e-58	-0.7	-0.48	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
BRCA	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-17.73	1.18e-61	4.14e-58	-0.65	-0.48	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
BRCA	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-17.73	1.19e-61	4.18e-58	-0.59	-0.48	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
BRCA	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	17.72	1.23e-61	4.32e-58	0.57	0.48	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-17.72	1.25e-61	4.39e-58	-0.59	-0.48	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	17.72	1.28e-61	4.48e-58	0.59	0.48	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	17.72	1.37e-61	4.82e-58	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	17.72	1.37e-61	4.82e-58	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
BRCA	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-17.71	1.41e-61	4.96e-58	-0.71	-0.48	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-17.71	1.58e-61	5.52e-58	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	17.7	1.59e-61	5.59e-58	0.6	0.48	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-17.7	1.63e-61	5.72e-58	-0.65	-0.48	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	17.69	1.87e-61	6.54e-58	0.6	0.48	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	17.69	1.98e-61	6.93e-58	0.57	0.48	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
BRCA	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.95e-58	-0.59	-0.48	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.95e-58	-0.59	-0.48	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.96e-58	-0.59	-0.48	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
BRCA	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	17.67	2.49e-61	8.68e-58	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	17.67	2.66e-61	9.27e-58	0.57	0.48	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-17.66	3.02e-61	1.05e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-17.66	3.11e-61	1.08e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-17.65	3.54e-61	1.23e-57	-0.64	-0.48	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
BRCA	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-17.65	3.55e-61	1.23e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-17.65	3.55e-61	1.23e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-17.64	3.65e-61	1.27e-57	-0.64	-0.48	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
BRCA	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-17.63	4.53e-61	1.56e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-17.62	4.81e-61	1.66e-57	-0.6	-0.48	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	17.62	4.87e-61	1.68e-57	0.5	0.48	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
BRCA	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-17.61	5.57e-61	1.92e-57	-0.57	-0.48	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-17.61	5.57e-61	1.92e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	17.6	6.28e-61	2.16e-57	0.6	0.48	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	17.6	6.78e-61	2.33e-57	0.6	0.48	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	17.6	7.02e-61	2.41e-57	0.6	0.48	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	17.6	7.02e-61	2.41e-57	0.6	0.48	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-17.59	7.73e-61	2.65e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	17.58	8.3e-61	2.84e-57	0.58	0.48	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
BRCA	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	17.58	8.71e-61	2.98e-57	0.5	0.48	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
BRCA	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-17.58	9.1e-61	3.11e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-17.58	9.13e-61	3.12e-57	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
BRCA	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	17.57	9.89e-61	3.38e-57	0.6	0.48	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-17.56	1.07e-60	3.66e-57	-0.6	-0.48	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
BRCA	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	17.56	1.08e-60	3.68e-57	0.62	0.48	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-17.56	1.14e-60	3.89e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	17.56	1.16e-60	3.95e-57	0.6	0.48	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	17.56	1.16e-60	3.97e-57	0.6	0.48	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
BRCA	cis	rs1431005	1	rs56063429	ENSG00000250620.1	RP11-91J3.3	17.56	1.19e-60	4.04e-57	0.6	0.48	Response to statin therapy;	chr4:187450476	chr4:187413564~187415697:+
BRCA	cis	rs1431005	0.927	rs12651176	ENSG00000250620.1	RP11-91J3.3	17.54	1.41e-60	4.78e-57	0.6	0.48	Response to statin therapy;	chr4:187439724	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	17.54	1.52e-60	5.15e-57	0.57	0.48	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
BRCA	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-17.54	1.59e-60	5.4e-57	-0.61	-0.48	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
BRCA	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-17.53	1.7e-60	5.76e-57	-0.82	-0.48	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-17.53	1.74e-60	5.91e-57	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-17.53	1.81e-60	6.13e-57	-0.58	-0.48	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	17.52	1.96e-60	6.64e-57	0.93	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-17.51	2.17e-60	7.35e-57	-0.95	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
BRCA	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-17.51	2.32e-60	7.82e-57	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-17.51	2.32e-60	7.82e-57	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
BRCA	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	17.51	2.37e-60	8e-57	0.54	0.48	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	17.5	2.51e-60	8.46e-57	0.55	0.48	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
BRCA	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-17.5	2.6e-60	8.74e-57	-0.57	-0.48	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
BRCA	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-17.49	3.06e-60	1.03e-56	-0.61	-0.48	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
BRCA	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	17.49	3.09e-60	1.04e-56	0.56	0.48	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	17.48	3.33e-60	1.12e-56	0.58	0.48	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
BRCA	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	17.48	3.62e-60	1.21e-56	0.6	0.48	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
BRCA	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-17.47	3.64e-60	1.22e-56	-0.6	-0.48	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-17.47	3.64e-60	1.22e-56	-0.6	-0.48	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
BRCA	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	17.46	4.47e-60	1.49e-56	0.38	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	17.44	5.99e-60	1.99e-56	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	17.44	6.22e-60	2.04e-56	0.56	0.48	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-17.43	6.46e-60	2.12e-56	-0.64	-0.48	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
BRCA	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-17.43	6.84e-60	2.24e-56	-0.6	-0.48	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-17.43	6.84e-60	2.24e-56	-0.6	-0.48	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
BRCA	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	17.43	6.89e-60	2.26e-56	0.63	0.48	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
BRCA	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-17.42	7.76e-60	2.53e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-17.42	7.76e-60	2.53e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	17.41	9.21e-60	2.99e-56	0.6	0.47	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	17.4	9.38e-60	3.05e-56	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-17.4	9.64e-60	3.13e-56	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-17.4	9.74e-60	3.16e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-17.4	1.03e-59	3.34e-56	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-17.39	1.14e-59	3.71e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	17.38	1.26e-59	4.07e-56	0.57	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
BRCA	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-17.38	1.28e-59	4.12e-56	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
BRCA	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-17.37	1.45e-59	4.67e-56	-0.61	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	17.37	1.45e-59	4.68e-56	0.61	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
BRCA	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	17.36	1.67e-59	5.36e-56	0.56	0.47	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	17.35	2.04e-59	6.55e-56	0.56	0.47	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
BRCA	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-17.35	2.1e-59	6.74e-56	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
BRCA	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-17.34	2.16e-59	6.93e-56	-0.49	-0.47	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
BRCA	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-17.33	2.44e-59	7.81e-56	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	17.33	2.53e-59	8.11e-56	0.54	0.47	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
BRCA	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-17.33	2.74e-59	8.74e-56	-0.59	-0.47	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
BRCA	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	17.32	2.85e-59	9.09e-56	0.54	0.47	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
BRCA	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	17.31	3.36e-59	1.07e-55	0.79	0.47	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
BRCA	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-17.31	3.48e-59	1.11e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	17.31	3.5e-59	1.11e-55	0.64	0.47	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-17.3	3.81e-59	1.21e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-17.29	4.23e-59	1.34e-55	-0.65	-0.47	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	17.29	4.66e-59	1.47e-55	0.58	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-17.29	4.67e-59	1.48e-55	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
BRCA	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	17.27	5.58e-59	1.76e-55	1.07	0.47	QT interval;	chr4:75125224	chr4:75081702~75084717:-
BRCA	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	17.26	6.44e-59	2.02e-55	0.61	0.47	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
BRCA	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	17.26	6.74e-59	2.12e-55	0.59	0.47	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
BRCA	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-17.26	6.77e-59	2.13e-55	-0.62	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-17.26	6.99e-59	2.2e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-17.26	6.99e-59	2.2e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-17.26	7.07e-59	2.22e-55	-0.62	-0.47	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
BRCA	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-17.25	7.37e-59	2.31e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-17.25	7.6e-59	2.38e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-17.24	8.12e-59	2.54e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-17.24	8.19e-59	2.57e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-17.24	8.29e-59	2.59e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-17.24	8.29e-59	2.59e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	17.24	8.61e-59	2.69e-55	0.56	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
BRCA	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	17.24	8.92e-59	2.79e-55	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-17.22	1.14e-58	3.57e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
BRCA	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75124631	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75125677	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75125682	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-17.2	1.47e-58	4.58e-55	-0.56	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-17.2	1.55e-58	4.81e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-17.19	1.71e-58	5.3e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-17.18	1.92e-58	5.95e-55	-0.62	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
BRCA	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	17.18	1.93e-58	5.99e-55	1.06	0.47	QT interval;	chr4:75134108	chr4:75081702~75084717:-
BRCA	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-17.18	2.07e-58	6.41e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-17.17	2.09e-58	6.48e-55	-0.64	-0.47	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-17.17	2.17e-58	6.72e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
BRCA	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-17.17	2.3e-58	7.12e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	17.17	2.34e-58	7.26e-55	0.59	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-17.16	2.55e-58	7.91e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
BRCA	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	17.16	2.61e-58	8.08e-55	0.56	0.47	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	17.15	2.84e-58	8.77e-55	0.61	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
BRCA	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-17.15	3.08e-58	9.51e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-17.15	3.08e-58	9.51e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-17.14	3.23e-58	9.96e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
BRCA	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	17.14	3.27e-58	1.01e-54	0.5	0.47	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
BRCA	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	17.12	4.37e-58	1.35e-54	1.05	0.47	QT interval;	chr4:75139193	chr4:75081702~75084717:-
BRCA	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-17.12	4.52e-58	1.39e-54	-0.61	-0.47	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
BRCA	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-17.11	4.97e-58	1.52e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-17.1	5.67e-58	1.74e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-17.1	5.72e-58	1.75e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-17.09	6.56e-58	2.01e-54	-0.62	-0.47	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
BRCA	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-17.09	6.79e-58	2.08e-54	-0.39	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
BRCA	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-17.09	6.91e-58	2.11e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	17.08	7.15e-58	2.18e-54	0.78	0.47	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
BRCA	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	17.08	7.78e-58	2.37e-54	0.5	0.47	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	17.08	7.85e-58	2.4e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	17.08	7.85e-58	2.4e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-17.07	8.7e-58	2.65e-54	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-17.06	9.24e-58	2.81e-54	-0.58	-0.47	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
BRCA	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	17.06	1e-57	3.06e-54	0.6	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-17.05	1.11e-57	3.38e-54	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-17.04	1.2e-57	3.65e-54	-0.63	-0.47	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
BRCA	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	17.04	1.29e-57	3.91e-54	0.49	0.47	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	17.04	1.3e-57	3.94e-54	0.54	0.47	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-17.04	1.36e-57	4.11e-54	-0.59	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
BRCA	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	17.03	1.37e-57	4.15e-54	0.72	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
BRCA	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-17.02	1.66e-57	5.03e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	17.02	1.67e-57	5.06e-54	0.76	0.47	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	17.02	1.71e-57	5.18e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	17.02	1.71e-57	5.18e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-17.01	1.82e-57	5.49e-54	-0.6	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
BRCA	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	17.01	1.83e-57	5.53e-54	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	17.01	1.86e-57	5.61e-54	0.61	0.47	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
BRCA	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-17.01	1.99e-57	6e-54	-0.61	-0.47	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
BRCA	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-17	2.09e-57	6.29e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
BRCA	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	17	2.22e-57	6.68e-54	0.7	0.47	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
BRCA	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-16.99	2.37e-57	7.15e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	16.99	2.4e-57	7.21e-54	0.5	0.47	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
BRCA	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-16.99	2.46e-57	7.41e-54	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
BRCA	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	16.99	2.52e-57	7.57e-54	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	16.99	2.56e-57	7.69e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
BRCA	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-16.99	2.57e-57	7.71e-54	-0.57	-0.47	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	16.98	2.77e-57	8.31e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	16.98	2.77e-57	8.31e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
BRCA	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	16.98	2.79e-57	8.36e-54	0.5	0.47	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	16.98	2.79e-57	8.37e-54	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	16.98	2.94e-57	8.81e-54	0.59	0.47	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-16.97	3.06e-57	9.17e-54	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
BRCA	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-16.96	3.62e-57	1.08e-53	-0.63	-0.47	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-16.96	3.62e-57	1.08e-53	-0.62	-0.47	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	16.96	3.87e-57	1.16e-53	0.53	0.47	Height;	chr11:118781100	chr11:118688039~118690600:-
BRCA	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	16.96	3.89e-57	1.16e-53	0.53	0.47	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	16.96	3.94e-57	1.18e-53	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	16.96	3.94e-57	1.18e-53	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-16.96	3.94e-57	1.18e-53	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	16.95	3.99e-57	1.19e-53	0.6	0.46	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	16.95	3.99e-57	1.19e-53	0.6	0.46	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	16.95	4.06e-57	1.21e-53	0.87	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	16.95	4.28e-57	1.28e-53	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	16.94	4.75e-57	1.42e-53	0.56	0.46	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
BRCA	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	16.93	5.2e-57	1.55e-53	0.82	0.46	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	16.93	5.24e-57	1.56e-53	0.69	0.46	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	16.93	5.39e-57	1.6e-53	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
BRCA	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-16.93	5.72e-57	1.7e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	16.92	6.63e-57	1.97e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
BRCA	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	16.91	6.79e-57	2.01e-53	0.74	0.46	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-16.91	7.14e-57	2.12e-53	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
BRCA	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-16.91	7.3e-57	2.16e-53	-0.6	-0.46	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-16.91	7.3e-57	2.16e-53	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
BRCA	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-16.91	7.38e-57	2.19e-53	-0.51	-0.46	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	16.91	7.42e-57	2.2e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	16.91	7.42e-57	2.2e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	16.91	7.44e-57	2.2e-53	0.6	0.46	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	16.9	7.76e-57	2.3e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-16.9	8.67e-57	2.56e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	16.89	8.95e-57	2.64e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	16.89	8.95e-57	2.64e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
BRCA	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	16.89	9.85e-57	2.9e-53	0.58	0.46	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
BRCA	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	16.89	9.85e-57	2.9e-53	0.58	0.46	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
BRCA	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	16.88	1e-56	2.96e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	16.88	1e-56	2.96e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	16.88	1.09e-56	3.2e-53	0.8	0.46	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
BRCA	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	16.88	1.14e-56	3.35e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	16.87	1.16e-56	3.42e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	16.87	1.31e-56	3.83e-53	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
BRCA	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	16.86	1.43e-56	4.18e-53	0.77	0.46	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
BRCA	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-16.84	1.81e-56	5.3e-53	-0.61	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	16.84	1.88e-56	5.48e-53	0.53	0.46	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
BRCA	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-16.83	2.07e-56	6.03e-53	-0.49	-0.46	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
BRCA	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	16.83	2.09e-56	6.1e-53	0.57	0.46	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-16.83	2.16e-56	6.28e-53	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	16.82	2.26e-56	6.57e-53	0.51	0.46	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	16.82	2.36e-56	6.86e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-16.82	2.39e-56	6.97e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.81	2.62e-56	7.62e-53	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	16.81	2.65e-56	7.69e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	16.81	2.69e-56	7.82e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
BRCA	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-16.81	2.84e-56	8.23e-53	-0.6	-0.46	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
BRCA	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	16.8	3.09e-56	8.96e-53	0.51	0.46	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.79	3.33e-56	9.63e-53	-0.61	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	16.79	3.34e-56	9.67e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-16.79	3.36e-56	9.72e-53	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
BRCA	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-16.79	3.46e-56	1e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-16.79	3.46e-56	1e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-16.79	3.59e-56	1.04e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	16.79	3.66e-56	1.06e-52	0.51	0.46	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.78	3.82e-56	1.1e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-16.78	3.85e-56	1.11e-52	-0.59	-0.46	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	16.78	3.92e-56	1.13e-52	0.51	0.46	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	16.78	3.97e-56	1.15e-52	0.53	0.46	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
BRCA	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.77	4.33e-56	1.25e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-16.77	4.4e-56	1.27e-52	-0.6	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	16.77	4.65e-56	1.34e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	16.77	4.77e-56	1.37e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	16.77	4.77e-56	1.37e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-16.77	4.81e-56	1.38e-52	-0.62	-0.46	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	16.76	5.04e-56	1.44e-52	0.51	0.46	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	16.76	5.04e-56	1.44e-52	0.51	0.46	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	16.76	5.2e-56	1.49e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.76	5.28e-56	1.51e-52	0.61	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
BRCA	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-16.76	5.5e-56	1.57e-52	-0.49	-0.46	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
BRCA	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	16.75	6.08e-56	1.74e-52	0.75	0.46	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
BRCA	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-16.75	6.19e-56	1.77e-52	-0.53	-0.46	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
BRCA	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-16.75	6.22e-56	1.78e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-16.75	6.4e-56	1.83e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-16.74	6.56e-56	1.87e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	16.74	6.74e-56	1.93e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	16.74	6.8e-56	1.94e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
BRCA	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-16.74	7e-56	2e-52	-0.61	-0.46	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	16.73	7.37e-56	2.1e-52	0.51	0.46	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
BRCA	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-16.73	7.77e-56	2.22e-52	-0.58	-0.46	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	16.73	8.12e-56	2.32e-52	0.51	0.46	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	16.73	8.16e-56	2.33e-52	0.51	0.46	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	16.72	8.71e-56	2.48e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	16.72	8.83e-56	2.52e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.72	8.89e-56	2.53e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.72	9.26e-56	2.64e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.72	9.26e-56	2.64e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
BRCA	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-16.72	9.28e-56	2.64e-52	-1	-0.46	QT interval;	chr4:75105647	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.71	9.98e-56	2.84e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.71	9.98e-56	2.84e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	16.71	1.05e-55	2.99e-52	0.5	0.46	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-16.7	1.14e-55	3.23e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
BRCA	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-16.7	1.16e-55	3.29e-52	-0.61	-0.46	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	16.7	1.17e-55	3.32e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	16.7	1.18e-55	3.36e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
BRCA	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-16.7	1.23e-55	3.49e-52	-0.48	-0.46	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
BRCA	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-16.7	1.23e-55	3.5e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	16.69	1.26e-55	3.58e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	16.69	1.26e-55	3.58e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
BRCA	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	16.69	1.27e-55	3.61e-52	1.01	0.46	QT interval;	chr4:75106902	chr4:75081702~75084717:-
BRCA	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	16.68	1.43e-55	4.04e-52	0.58	0.46	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
BRCA	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	16.68	1.5e-55	4.22e-52	0.59	0.46	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
BRCA	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	16.68	1.5e-55	4.23e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	16.67	1.69e-55	4.77e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
BRCA	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	16.67	1.69e-55	4.77e-52	1	0.46	QT interval;	chr4:75107557	chr4:75081702~75084717:-
BRCA	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	16.67	1.82e-55	5.14e-52	0.5	0.46	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
BRCA	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-16.65	2.24e-55	6.3e-52	-0.61	-0.46	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
BRCA	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-16.65	2.34e-55	6.59e-52	-0.59	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-16.65	2.38e-55	6.68e-52	-0.6	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
BRCA	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-16.64	2.59e-55	7.29e-52	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	16.63	2.82e-55	7.93e-52	0.53	0.46	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-16.63	2.86e-55	8.02e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	16.63	2.97e-55	8.33e-52	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-16.63	3.06e-55	8.57e-52	-0.63	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-16.63	3.08e-55	8.64e-52	-0.56	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
BRCA	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	16.62	3.2e-55	8.97e-52	0.59	0.46	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	16.62	3.3e-55	9.25e-52	0.52	0.46	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-16.62	3.38e-55	9.46e-52	-0.57	-0.46	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
BRCA	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-16.62	3.46e-55	9.68e-52	-0.48	-0.46	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
BRCA	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	16.61	3.82e-55	1.07e-51	0.5	0.46	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
BRCA	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-16.6	4.34e-55	1.21e-51	-0.58	-0.46	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
BRCA	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-16.6	4.48e-55	1.25e-51	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-16.6	4.48e-55	1.25e-51	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
BRCA	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	16.59	4.74e-55	1.32e-51	0.56	0.46	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
BRCA	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	16.59	4.8e-55	1.34e-51	0.76	0.46	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
BRCA	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
BRCA	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	16.57	6.08e-55	1.69e-51	0.95	0.46	QT interval;	chr4:75108766	chr4:75081702~75084717:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-16.57	6.11e-55	1.7e-51	-0.62	-0.46	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	16.57	6.25e-55	1.73e-51	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
BRCA	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	16.57	6.34e-55	1.76e-51	0.76	0.46	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
BRCA	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	16.57	6.39e-55	1.77e-51	0.56	0.46	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
BRCA	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-16.57	6.5e-55	1.8e-51	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	16.57	6.62e-55	1.84e-51	0.55	0.46	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	16.57	6.72e-55	1.86e-51	0.74	0.46	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
BRCA	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-16.56	7.23e-55	2e-51	-0.48	-0.46	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
BRCA	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	16.56	7.31e-55	2.02e-51	0.59	0.46	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
BRCA	cis	rs1431005	1	rs55849435	ENSG00000250620.1	RP11-91J3.3	16.56	7.43e-55	2.06e-51	0.59	0.46	Response to statin therapy;	chr4:187455185	chr4:187413564~187415697:+
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	16.56	7.53e-55	2.08e-51	0.74	0.46	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	16.56	7.62e-55	2.11e-51	0.74	0.46	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
BRCA	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	16.55	8.31e-55	2.3e-51	1	0.46	QT interval;	chr4:75107209	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.54	9.31e-55	2.57e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
BRCA	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-16.53	1.16e-54	3.19e-51	-0.62	-0.46	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
BRCA	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-16.52	1.18e-54	3.25e-51	-0.56	-0.46	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
BRCA	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-16.52	1.22e-54	3.36e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-16.52	1.26e-54	3.47e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-16.52	1.28e-54	3.53e-51	-0.6	-0.46	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
BRCA	cis	rs1431005	1	rs72723291	ENSG00000250620.1	RP11-91J3.3	16.52	1.31e-54	3.59e-51	0.59	0.46	Response to statin therapy;	chr4:187425714	chr4:187413564~187415697:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-16.52	1.33e-54	3.65e-51	-0.63	-0.46	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
BRCA	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	16.51	1.51e-54	4.15e-51	0.56	0.46	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
BRCA	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	16.51	1.52e-54	4.18e-51	0.55	0.46	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-16.5	1.54e-54	4.24e-51	-0.6	-0.46	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
BRCA	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	16.5	1.56e-54	4.28e-51	0.59	0.46	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.5	1.62e-54	4.44e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-16.5	1.68e-54	4.61e-51	-0.59	-0.46	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	16.49	1.82e-54	4.99e-51	0.63	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	16.49	1.85e-54	5.06e-51	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.86e-54	5.08e-51	-0.6	-0.45	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	16.49	1.87e-54	5.11e-51	0.59	0.45	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-16.49	1.9e-54	5.2e-51	-0.59	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	16.48	2.04e-54	5.58e-51	0.59	0.45	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-16.48	2.13e-54	5.82e-51	-0.6	-0.45	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	16.48	2.15e-54	5.87e-51	0.59	0.45	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-16.48	2.15e-54	5.87e-51	-0.57	-0.45	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
BRCA	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-16.48	2.19e-54	5.96e-51	-0.57	-0.45	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.48	2.19e-54	5.97e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-16.48	2.25e-54	6.13e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-16.48	2.25e-54	6.13e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
BRCA	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-16.47	2.28e-54	6.21e-51	-0.48	-0.45	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
BRCA	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	16.47	2.34e-54	6.35e-51	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-16.47	2.4e-54	6.53e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.47	2.45e-54	6.67e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.47	2.45e-54	6.67e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	16.45	2.98e-54	8.07e-51	0.6	0.45	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
BRCA	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	16.45	3.26e-54	8.83e-51	0.56	0.45	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
BRCA	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	16.44	3.41e-54	9.22e-51	0.53	0.45	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
BRCA	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	16.44	3.42e-54	9.26e-51	0.47	0.45	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
BRCA	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	16.44	3.62e-54	9.79e-51	0.59	0.45	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
BRCA	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	16.42	4.39e-54	1.18e-50	0.51	0.45	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
BRCA	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-16.42	4.42e-54	1.19e-50	-0.48	-0.45	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
BRCA	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	16.42	4.47e-54	1.2e-50	0.59	0.45	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
BRCA	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-16.42	4.48e-54	1.21e-50	-0.58	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	16.42	4.56e-54	1.23e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.41	5.3e-54	1.42e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	16.41	5.3e-54	1.42e-50	0.59	0.45	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
BRCA	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	16.41	5.34e-54	1.43e-50	0.57	0.45	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
BRCA	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-16.41	5.44e-54	1.46e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-16.41	5.52e-54	1.48e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-16.4	6.06e-54	1.62e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-16.4	6.06e-54	1.62e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
BRCA	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-16.4	6.21e-54	1.66e-50	-0.6	-0.45	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
BRCA	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	16.39	6.53e-54	1.74e-50	0.8	0.45	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	16.39	6.66e-54	1.78e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-16.39	6.77e-54	1.81e-50	-0.55	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
BRCA	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-16.38	7.72e-54	2.06e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
BRCA	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-16.38	7.85e-54	2.09e-50	-0.55	-0.45	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
BRCA	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-16.38	8.02e-54	2.14e-50	-0.6	-0.45	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-16.37	8.37e-54	2.23e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	16.37	8.53e-54	2.27e-50	0.59	0.45	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	16.37	8.53e-54	2.27e-50	0.59	0.45	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-16.37	8.64e-54	2.3e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
BRCA	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-16.37	8.67e-54	2.31e-50	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
BRCA	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-16.37	9.18e-54	2.44e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
BRCA	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-16.36	1.04e-53	2.75e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
BRCA	cis	rs1431005	1	rs72499925	ENSG00000250620.1	RP11-91J3.3	16.35	1.13e-53	2.99e-50	0.58	0.45	Response to statin therapy;	chr4:187432596	chr4:187413564~187415697:+
BRCA	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-16.35	1.14e-53	3.02e-50	-0.55	-0.45	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
BRCA	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	16.35	1.15e-53	3.05e-50	0.68	0.45	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
BRCA	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-16.35	1.2e-53	3.17e-50	-0.6	-0.45	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-16.35	1.2e-53	3.17e-50	-0.6	-0.45	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	16.34	1.27e-53	3.35e-50	0.59	0.45	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-16.34	1.27e-53	3.36e-50	-0.6	-0.45	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	16.34	1.33e-53	3.51e-50	0.51	0.45	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
BRCA	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	16.34	1.35e-53	3.55e-50	0.59	0.45	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-16.34	1.4e-53	3.68e-50	-0.57	-0.45	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
BRCA	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	16.34	1.41e-53	3.71e-50	0.53	0.45	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-16.33	1.42e-53	3.74e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-16.33	1.43e-53	3.76e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
BRCA	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	16.33	1.46e-53	3.84e-50	0.58	0.45	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	16.33	1.48e-53	3.9e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-16.33	1.51e-53	3.96e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-16.32	1.67e-53	4.4e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	16.31	1.85e-53	4.84e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	16.31	1.85e-53	4.84e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
BRCA	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	16.31	1.86e-53	4.88e-50	1.03	0.45	QT interval;	chr4:75144808	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-16.31	1.88e-53	4.92e-50	-0.59	-0.45	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-16.3	2.11e-53	5.52e-50	-0.59	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	16.3	2.24e-53	5.87e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-16.3	2.28e-53	5.95e-50	-0.59	-0.45	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
BRCA	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	16.29	2.52e-53	6.57e-50	0.59	0.45	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	16.29	2.52e-53	6.57e-50	0.59	0.45	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
BRCA	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	16.29	2.64e-53	6.88e-50	0.58	0.45	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-16.28	2.81e-53	7.3e-50	-0.58	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-16.28	2.86e-53	7.42e-50	-0.6	-0.45	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-16.28	2.86e-53	7.42e-50	-0.6	-0.45	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	16.28	3.04e-53	7.88e-50	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	16.27	3.29e-53	8.53e-50	0.8	0.45	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	16.27	3.4e-53	8.82e-50	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	16.26	3.6e-53	9.33e-50	0.59	0.45	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-16.26	3.66e-53	9.48e-50	-0.57	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
BRCA	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-16.26	3.93e-53	1.02e-49	-0.47	-0.45	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
BRCA	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	16.26	3.98e-53	1.03e-49	0.99	0.45	QT interval;	chr4:75103663	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-16.26	3.99e-53	1.03e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
BRCA	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	16.25	4.32e-53	1.12e-49	0.96	0.45	QT interval;	chr4:75108738	chr4:75081702~75084717:-
BRCA	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	16.25	4.51e-53	1.17e-49	0.58	0.45	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-16.25	4.55e-53	1.17e-49	-0.61	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16.24	4.88e-53	1.26e-49	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	16.23	5.21e-53	1.34e-49	0.59	0.45	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
BRCA	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	16.23	5.53e-53	1.42e-49	1	0.45	QT interval;	chr4:75100963	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	16.23	5.53e-53	1.42e-49	1	0.45	QT interval;	chr4:75101024	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-16.23	5.74e-53	1.47e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	16.23	5.77e-53	1.48e-49	0.59	0.45	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-16.22	6.02e-53	1.55e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
BRCA	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	16.22	6.03e-53	1.55e-49	0.69	0.45	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
BRCA	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-16.22	6.05e-53	1.55e-49	-0.6	-0.45	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
BRCA	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-16.22	6.18e-53	1.59e-49	-0.55	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	16.22	6.41e-53	1.65e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	16.22	6.53e-53	1.68e-49	0.59	0.45	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	16.22	6.57e-53	1.68e-49	0.59	0.45	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-16.22	6.58e-53	1.69e-49	-0.56	-0.45	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
BRCA	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	16.2	7.84e-53	2e-49	0.6	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
BRCA	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-16.2	8.2e-53	2.09e-49	-0.73	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
BRCA	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	16.2	8.36e-53	2.13e-49	0.59	0.45	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	16.2	8.46e-53	2.16e-49	0.58	0.45	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	16.2	8.67e-53	2.21e-49	0.59	0.45	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
BRCA	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	16.19	9e-53	2.29e-49	0.5	0.45	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
BRCA	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-16.19	9.37e-53	2.38e-49	-0.56	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-16.19	9.83e-53	2.5e-49	-0.52	-0.45	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	16.17	1.24e-52	3.14e-49	0.6	0.45	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
BRCA	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	16.17	1.25e-52	3.18e-49	0.93	0.45	QT interval;	chr4:75108836	chr4:75081702~75084717:-
BRCA	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	16.17	1.27e-52	3.22e-49	0.49	0.45	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
BRCA	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-16.16	1.33e-52	3.36e-49	-0.59	-0.45	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	16.16	1.38e-52	3.48e-49	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-16.15	1.5e-52	3.79e-49	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
BRCA	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	16.15	1.55e-52	3.9e-49	0.95	0.45	QT interval;	chr4:75108962	chr4:75081702~75084717:-
BRCA	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-16.14	1.68e-52	4.23e-49	-0.71	-0.45	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
BRCA	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	16.14	1.85e-52	4.66e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
BRCA	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-16.13	2.14e-52	5.37e-49	-0.59	-0.45	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	16.12	2.19e-52	5.5e-49	0.53	0.45	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	16.12	2.41e-52	6.02e-49	0.51	0.45	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
BRCA	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	16.11	2.67e-52	6.68e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	16.11	2.69e-52	6.73e-49	0.59	0.45	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
BRCA	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-16.1	2.84e-52	7.1e-49	-0.36	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
BRCA	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-16.09	3.33e-52	8.29e-49	-0.56	-0.45	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
BRCA	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-16.09	3.43e-52	8.53e-49	-0.56	-0.45	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
BRCA	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	16.09	3.53e-52	8.77e-49	0.59	0.45	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	16.09	3.58e-52	8.91e-49	0.6	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	16.09	3.6e-52	8.95e-49	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	16.08	3.64e-52	9.04e-49	0.58	0.45	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-16.07	4.29e-52	1.06e-48	-0.59	-0.45	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	16.07	4.5e-52	1.12e-48	0.59	0.45	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	16.06	4.78e-52	1.18e-48	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
BRCA	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-16.05	5.56e-52	1.37e-48	-0.6	-0.45	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
BRCA	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	16.05	5.79e-52	1.43e-48	0.59	0.45	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	16.05	5.79e-52	1.43e-48	0.59	0.45	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
BRCA	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-16.05	5.85e-52	1.44e-48	-0.7	-0.45	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
BRCA	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-16.04	6.32e-52	1.55e-48	-0.69	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
BRCA	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	16.04	6.51e-52	1.6e-48	0.73	0.44	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
BRCA	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	16.04	6.83e-52	1.67e-48	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
BRCA	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-16.03	7.01e-52	1.72e-48	-0.57	-0.44	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
BRCA	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	16.02	8.87e-52	2.17e-48	0.58	0.44	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	16	1.11e-51	2.71e-48	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	16	1.11e-51	2.71e-48	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	16	1.13e-51	2.76e-48	0.52	0.44	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
BRCA	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-15.99	1.31e-51	3.19e-48	-0.57	-0.44	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
BRCA	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	15.97	1.5e-51	3.65e-48	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
BRCA	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-15.97	1.52e-51	3.7e-48	-0.7	-0.44	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-15.97	1.58e-51	3.83e-48	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
BRCA	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	15.97	1.6e-51	3.9e-48	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
BRCA	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	15.97	1.65e-51	3.99e-48	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	15.97	1.65e-51	4e-48	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
BRCA	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	15.96	1.93e-51	4.69e-48	0.56	0.44	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
BRCA	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	15.95	2.09e-51	5.06e-48	0.58	0.44	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	15.95	2.19e-51	5.31e-48	0.58	0.44	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
BRCA	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	15.94	2.29e-51	5.53e-48	0.5	0.44	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
BRCA	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	15.94	2.35e-51	5.68e-48	0.56	0.44	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
BRCA	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-15.94	2.39e-51	5.77e-48	-0.7	-0.44	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
BRCA	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
BRCA	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-15.94	2.48e-51	5.98e-48	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	15.94	2.51e-51	6.04e-48	0.58	0.44	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-15.93	2.77e-51	6.67e-48	-0.47	-0.44	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	15.92	2.99e-51	7.18e-48	0.58	0.44	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-15.91	3.46e-51	8.3e-48	-0.57	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-15.89	4.24e-51	1.01e-47	-0.55	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	15.89	4.37e-51	1.04e-47	0.54	0.44	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
BRCA	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	15.89	4.37e-51	1.05e-47	0.74	0.44	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
BRCA	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	15.89	4.69e-51	1.12e-47	0.59	0.44	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
BRCA	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-15.86	6.78e-51	1.61e-47	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-15.86	6.87e-51	1.64e-47	-0.58	-0.44	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
BRCA	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-15.86	6.96e-51	1.66e-47	-0.69	-0.44	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-15.85	7.51e-51	1.79e-47	-0.47	-0.44	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
BRCA	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	15.85	7.93e-51	1.88e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-15.84	8.1e-51	1.92e-47	-0.47	-0.44	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	15.84	8.48e-51	2.01e-47	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
BRCA	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-15.84	8.64e-51	2.05e-47	-0.55	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
BRCA	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-15.84	8.83e-51	2.09e-47	-0.47	-0.44	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-15.84	8.83e-51	2.09e-47	-0.47	-0.44	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-15.84	8.88e-51	2.1e-47	-0.47	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
BRCA	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-15.83	9.27e-51	2.2e-47	-0.52	-0.44	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-15.83	9.86e-51	2.33e-47	-0.47	-0.44	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-15.83	1.02e-50	2.42e-47	-0.59	-0.44	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-15.82	1.11e-50	2.61e-47	-0.47	-0.44	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	15.82	1.17e-50	2.76e-47	0.59	0.44	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
BRCA	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	15.81	1.23e-50	2.89e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
BRCA	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	15.81	1.23e-50	2.89e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
BRCA	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-15.81	1.25e-50	2.95e-47	-0.6	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	15.8	1.37e-50	3.23e-47	0.59	0.44	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-15.79	1.6e-50	3.77e-47	-0.47	-0.44	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	15.78	1.95e-50	4.58e-47	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
BRCA	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-15.78	1.95e-50	4.59e-47	-0.47	-0.44	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	15.77	2.04e-50	4.78e-47	0.58	0.44	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	15.76	2.32e-50	5.45e-47	0.54	0.44	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	15.76	2.49e-50	5.84e-47	0.58	0.44	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-15.75	2.55e-50	5.98e-47	-0.46	-0.44	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
BRCA	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-15.75	2.67e-50	6.26e-47	-0.7	-0.44	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-15.75	2.76e-50	6.47e-47	-0.47	-0.44	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
BRCA	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-15.75	2.77e-50	6.48e-47	-0.57	-0.44	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
BRCA	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-15.74	2.88e-50	6.74e-47	-0.69	-0.44	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
BRCA	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	15.74	2.93e-50	6.85e-47	0.52	0.44	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	15.74	2.94e-50	6.88e-47	0.53	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	15.74	3.19e-50	7.46e-47	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	15.73	3.34e-50	7.81e-47	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	15.73	3.58e-50	8.36e-47	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	15.73	3.59e-50	8.38e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-15.73	3.67e-50	8.55e-47	-0.47	-0.44	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
BRCA	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-15.72	3.84e-50	8.95e-47	-0.69	-0.44	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-15.72	3.86e-50	9e-47	-0.47	-0.44	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	15.71	4.33e-50	1.01e-46	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
BRCA	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-15.71	4.46e-50	1.04e-46	-0.58	-0.44	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
BRCA	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	15.7	5.05e-50	1.17e-46	0.63	0.44	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-15.7	5.22e-50	1.21e-46	-0.46	-0.44	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
BRCA	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-15.69	5.44e-50	1.26e-46	-0.68	-0.44	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
BRCA	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	15.69	5.91e-50	1.37e-46	0.45	0.44	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
BRCA	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	15.68	6.93e-50	1.6e-46	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
BRCA	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-15.67	7.41e-50	1.72e-46	-0.58	-0.44	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
BRCA	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	15.67	7.49e-50	1.74e-46	0.52	0.44	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	15.67	7.62e-50	1.76e-46	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	15.66	7.97e-50	1.84e-46	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
BRCA	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-15.66	8.32e-50	1.93e-46	-0.47	-0.44	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
BRCA	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	15.66	8.33e-50	1.93e-46	0.48	0.44	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
BRCA	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-15.65	1.03e-49	2.37e-46	-0.59	-0.44	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-15.64	1.06e-49	2.45e-46	-0.46	-0.44	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-15.64	1.06e-49	2.45e-46	-0.46	-0.44	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
BRCA	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	15.64	1.13e-49	2.61e-46	0.48	0.44	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
BRCA	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	15.63	1.17e-49	2.71e-46	0.59	0.44	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	15.63	1.2e-49	2.77e-46	0.45	0.44	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	15.62	1.4e-49	3.21e-46	0.74	0.44	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	15.62	1.44e-49	3.31e-46	0.75	0.44	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
BRCA	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-15.62	1.48e-49	3.41e-46	-0.46	-0.44	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
BRCA	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-15.61	1.52e-49	3.48e-46	-0.49	-0.44	Breast cancer;	chr11:825777	chr11:779617~780755:+
BRCA	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-15.61	1.55e-49	3.56e-46	-0.46	-0.44	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-15.61	1.55e-49	3.56e-46	-0.46	-0.44	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	15.6	1.82e-49	4.17e-46	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	15.59	2.06e-49	4.71e-46	0.64	0.43	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-15.58	2.43e-49	5.53e-46	-0.46	-0.43	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	15.57	2.79e-49	6.35e-46	0.75	0.43	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
BRCA	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	15.57	2.82e-49	6.41e-46	0.63	0.43	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
BRCA	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	15.56	2.84e-49	6.46e-46	0.49	0.43	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
BRCA	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-15.56	2.86e-49	6.51e-46	-0.48	-0.43	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
BRCA	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	15.56	2.97e-49	6.74e-46	0.64	0.43	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
BRCA	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	15.56	3.01e-49	6.83e-46	0.5	0.43	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	15.56	3.1e-49	7.03e-46	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
BRCA	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	15.56	3.1e-49	7.04e-46	0.58	0.43	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
BRCA	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	15.56	3.21e-49	7.29e-46	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-15.55	3.36e-49	7.62e-46	-0.55	-0.43	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
BRCA	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	15.55	3.49e-49	7.9e-46	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
BRCA	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-15.54	3.73e-49	8.45e-46	-0.5	-0.43	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
BRCA	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-15.54	4.08e-49	9.22e-46	-0.52	-0.43	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
BRCA	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	15.54	4.1e-49	9.26e-46	0.55	0.43	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
BRCA	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-15.53	4.36e-49	9.84e-46	-0.71	-0.43	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
BRCA	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-15.53	4.44e-49	1e-45	-0.49	-0.43	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-15.53	4.69e-49	1.06e-45	-0.54	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
BRCA	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-15.52	4.78e-49	1.08e-45	-0.5	-0.43	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
BRCA	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	15.52	4.81e-49	1.08e-45	0.67	0.43	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
BRCA	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	15.52	4.98e-49	1.12e-45	0.49	0.43	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	15.52	5.32e-49	1.2e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	15.52	5.32e-49	1.2e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	15.51	5.43e-49	1.22e-45	0.57	0.43	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	15.51	5.43e-49	1.22e-45	0.57	0.43	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
BRCA	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	15.51	5.5e-49	1.24e-45	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
BRCA	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-15.51	5.82e-49	1.31e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-15.51	5.82e-49	1.31e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-15.51	5.99e-49	1.35e-45	-0.45	-0.43	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
BRCA	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	15.51	6.05e-49	1.36e-45	0.49	0.43	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-15.5	6.67e-49	1.5e-45	-0.49	-0.43	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-15.5	6.8e-49	1.52e-45	-0.54	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	15.5	6.82e-49	1.53e-45	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
BRCA	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-15.49	7.47e-49	1.67e-45	-0.55	-0.43	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-15.49	7.57e-49	1.69e-45	-0.56	-0.43	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-15.48	8.35e-49	1.87e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	15.48	8.56e-49	1.91e-45	0.59	0.43	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	15.47	8.89e-49	1.98e-45	0.57	0.43	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-15.47	8.9e-49	1.99e-45	-0.49	-0.43	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
BRCA	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-15.47	8.92e-49	1.99e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
BRCA	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-15.47	9.05e-49	2.02e-45	-0.59	-0.43	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
BRCA	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-15.47	9.18e-49	2.05e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	15.47	9.46e-49	2.11e-45	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
BRCA	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
BRCA	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-15.47	9.78e-49	2.18e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
BRCA	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-15.46	1.03e-48	2.3e-45	-0.49	-0.43	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	15.46	1.09e-48	2.43e-45	0.49	0.43	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-15.46	1.13e-48	2.5e-45	-0.49	-0.43	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	15.45	1.18e-48	2.62e-45	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	15.45	1.19e-48	2.65e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
BRCA	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	15.44	1.3e-48	2.88e-45	0.48	0.43	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
BRCA	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	15.44	1.37e-48	3.05e-45	0.56	0.43	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-15.44	1.4e-48	3.09e-45	-0.49	-0.43	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-15.44	1.46e-48	3.24e-45	-0.49	-0.43	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	15.43	1.49e-48	3.29e-45	0.49	0.43	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	15.43	1.56e-48	3.44e-45	0.56	0.43	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
BRCA	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-15.43	1.58e-48	3.49e-45	-0.49	-0.43	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-15.43	1.63e-48	3.6e-45	-0.49	-0.43	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
BRCA	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	15.42	1.79e-48	3.94e-45	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	15.41	1.95e-48	4.31e-45	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
BRCA	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-15.41	2.05e-48	4.52e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-15.41	2.08e-48	4.58e-45	-0.58	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	15.41	2.11e-48	4.65e-45	0.45	0.43	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	15.4	2.19e-48	4.81e-45	0.57	0.43	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
BRCA	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-15.4	2.24e-48	4.92e-45	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
BRCA	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-15.4	2.28e-48	5.01e-45	-0.54	-0.43	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
BRCA	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
BRCA	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-15.39	2.61e-48	5.74e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-15.39	2.63e-48	5.76e-45	-0.49	-0.43	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	15.39	2.66e-48	5.83e-45	0.6	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	15.39	2.67e-48	5.86e-45	0.73	0.43	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-15.38	2.81e-48	6.16e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
BRCA	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	15.38	3.1e-48	6.79e-45	0.45	0.43	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	15.37	3.27e-48	7.15e-45	0.74	0.43	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-15.37	3.32e-48	7.27e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
BRCA	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-15.37	3.47e-48	7.59e-45	-0.5	-0.43	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-15.37	3.5e-48	7.64e-45	-0.49	-0.43	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-15.37	3.5e-48	7.64e-45	-0.49	-0.43	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	15.36	3.74e-48	8.15e-45	0.61	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	15.36	3.8e-48	8.29e-45	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
BRCA	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	15.36	3.84e-48	8.37e-45	0.46	0.43	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
BRCA	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	15.36	3.85e-48	8.4e-45	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	15.36	3.93e-48	8.58e-45	0.56	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	15.36	3.99e-48	8.69e-45	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-15.35	4.3e-48	9.35e-45	-0.8	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
BRCA	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.5e-48	9.78e-45	-0.57	-0.43	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.56e-48	9.91e-45	-0.58	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-15.34	4.6e-48	1e-44	-0.49	-0.43	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-15.34	4.6e-48	1e-44	-0.49	-0.43	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-15.34	4.69e-48	1.02e-44	-0.49	-0.43	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
BRCA	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-15.34	4.71e-48	1.02e-44	-0.57	-0.43	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-15.34	4.71e-48	1.02e-44	-0.57	-0.43	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	15.34	4.9e-48	1.06e-44	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-15.34	5.01e-48	1.08e-44	-0.49	-0.43	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-15.34	5.01e-48	1.08e-44	-0.49	-0.43	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	15.34	5.01e-48	1.09e-44	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
BRCA	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	15.34	5.01e-48	1.09e-44	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
BRCA	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-15.34	5.03e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-15.34	5.03e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-15.34	5.04e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-15.33	5.29e-48	1.15e-44	-0.49	-0.43	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-15.33	5.29e-48	1.15e-44	-0.49	-0.43	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-15.33	5.36e-48	1.16e-44	-0.49	-0.43	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-15.33	5.45e-48	1.18e-44	-0.49	-0.43	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-15.33	5.49e-48	1.19e-44	-0.49	-0.43	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
BRCA	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-15.33	5.5e-48	1.19e-44	-0.59	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
BRCA	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-15.33	5.65e-48	1.22e-44	-0.56	-0.43	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-15.33	5.7e-48	1.23e-44	-0.49	-0.43	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	15.33	5.83e-48	1.26e-44	0.49	0.43	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
BRCA	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-15.32	6.01e-48	1.3e-44	-0.49	-0.43	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	15.32	6.19e-48	1.33e-44	0.54	0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
BRCA	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	15.31	6.95e-48	1.5e-44	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
BRCA	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-15.31	7.28e-48	1.57e-44	-0.49	-0.43	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-15.31	7.39e-48	1.59e-44	-0.53	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
BRCA	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	15.3	7.56e-48	1.63e-44	0.57	0.43	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
BRCA	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-15.3	7.62e-48	1.64e-44	-0.49	-0.43	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	15.3	7.67e-48	1.65e-44	0.48	0.43	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
BRCA	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
BRCA	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-15.3	7.87e-48	1.69e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
BRCA	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-15.3	7.93e-48	1.7e-44	-0.46	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
BRCA	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	15.3	8.14e-48	1.75e-44	0.46	0.43	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
BRCA	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-15.3	8.36e-48	1.79e-44	-0.49	-0.43	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-15.3	8.52e-48	1.83e-44	-0.49	-0.43	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
BRCA	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-15.29	8.62e-48	1.85e-44	-0.46	-0.43	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
BRCA	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-15.29	9.01e-48	1.93e-44	-0.58	-0.43	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-15.29	9.16e-48	1.96e-44	-0.57	-0.43	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	15.29	9.21e-48	1.97e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
BRCA	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-15.29	9.47e-48	2.03e-44	-0.55	-0.43	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
BRCA	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	15.28	9.7e-48	2.08e-44	0.52	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.01e-47	2.17e-44	-0.57	-0.43	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.05e-47	2.25e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.05e-47	2.25e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-15.28	1.07e-47	2.29e-44	-0.49	-0.43	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	15.27	1.15e-47	2.46e-44	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-15.27	1.16e-47	2.47e-44	-0.57	-0.43	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	15.27	1.24e-47	2.64e-44	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
BRCA	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-15.27	1.24e-47	2.64e-44	-0.57	-0.43	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
BRCA	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-15.26	1.29e-47	2.76e-44	-0.58	-0.43	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
BRCA	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-15.26	1.35e-47	2.88e-44	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
BRCA	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	15.26	1.4e-47	2.99e-44	0.58	0.43	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
BRCA	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-15.25	1.42e-47	3.02e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
BRCA	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-15.25	1.45e-47	3.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	15.25	1.46e-47	3.1e-44	0.54	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-15.25	1.49e-47	3.18e-44	-0.56	-0.43	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-15.25	1.5e-47	3.2e-44	-0.49	-0.43	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
BRCA	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-15.24	1.64e-47	3.48e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-15.24	1.64e-47	3.48e-44	-0.56	-0.43	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
BRCA	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-15.24	1.68e-47	3.56e-44	-0.57	-0.43	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
BRCA	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
BRCA	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-15.24	1.77e-47	3.75e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
BRCA	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-15.23	1.84e-47	3.89e-44	-0.58	-0.43	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
BRCA	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	15.23	2.01e-47	4.26e-44	0.56	0.43	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-15.22	2.15e-47	4.56e-44	-0.48	-0.43	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	15.22	2.31e-47	4.88e-44	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
BRCA	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	15.21	2.35e-47	4.97e-44	0.48	0.43	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
BRCA	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	15.21	2.38e-47	5.02e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
BRCA	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-15.21	2.39e-47	5.04e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
BRCA	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-15.21	2.47e-47	5.21e-44	-0.49	-0.43	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
BRCA	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	15.21	2.53e-47	5.33e-44	0.89	0.43	QT interval;	chr4:75108576	chr4:75081702~75084717:-
BRCA	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-15.21	2.62e-47	5.52e-44	-0.54	-0.43	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
BRCA	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-15.2	2.65e-47	5.6e-44	-0.53	-0.43	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	15.2	2.78e-47	5.85e-44	0.61	0.43	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	15.2	2.81e-47	5.92e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
BRCA	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-15.2	2.82e-47	5.94e-44	-0.44	-0.43	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
BRCA	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-15.2	2.88e-47	6.07e-44	-0.56	-0.43	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	15.2	2.91e-47	6.12e-44	0.44	0.43	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	15.2	2.92e-47	6.15e-44	0.45	0.43	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-15.2	2.95e-47	6.2e-44	-0.56	-0.43	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-15.19	3.17e-47	6.67e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-15.18	3.47e-47	7.28e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-15.18	3.47e-47	7.28e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	15.18	3.63e-47	7.62e-44	0.45	0.43	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	15.18	3.63e-47	7.62e-44	0.45	0.43	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
BRCA	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-15.18	3.65e-47	7.66e-44	-0.49	-0.43	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	15.18	3.65e-47	7.66e-44	0.48	0.43	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
BRCA	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	15.18	3.79e-47	7.93e-44	0.45	0.43	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
BRCA	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-15.17	4.05e-47	8.48e-44	-0.48	-0.43	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	15.16	4.38e-47	9.16e-44	0.56	0.43	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	15.16	4.42e-47	9.24e-44	0.51	0.43	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-15.16	4.62e-47	9.65e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	15.16	4.64e-47	9.71e-44	0.56	0.43	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-15.15	5.28e-47	1.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-15.15	5.28e-47	1.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	15.15	5.36e-47	1.12e-43	0.44	0.42	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	15.15	5.39e-47	1.12e-43	0.56	0.42	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
BRCA	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-15.15	5.43e-47	1.13e-43	-0.47	-0.42	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
BRCA	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	15.15	5.57e-47	1.16e-43	0.56	0.42	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	15.14	5.7e-47	1.19e-43	0.56	0.42	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	15.14	5.7e-47	1.19e-43	0.56	0.42	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-15.14	5.88e-47	1.22e-43	-0.57	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-15.14	5.9e-47	1.23e-43	-0.49	-0.42	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	15.13	6.5e-47	1.35e-43	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	15.13	6.59e-47	1.37e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-15.13	6.78e-47	1.41e-43	-0.57	-0.42	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	15.13	6.84e-47	1.42e-43	0.56	0.42	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-15.13	6.99e-47	1.45e-43	-0.56	-0.42	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
BRCA	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-15.13	7.01e-47	1.45e-43	-0.6	-0.42	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
BRCA	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-15.13	7.12e-47	1.48e-43	-0.56	-0.42	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
BRCA	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-15.12	7.44e-47	1.54e-43	-0.57	-0.42	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
BRCA	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	15.12	7.79e-47	1.61e-43	0.64	0.42	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
BRCA	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	15.12	7.81e-47	1.61e-43	0.56	0.42	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	15.12	7.81e-47	1.61e-43	0.56	0.42	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	15.12	7.98e-47	1.65e-43	0.56	0.42	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-15.12	7.99e-47	1.65e-43	-0.57	-0.42	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	15.11	8.19e-47	1.69e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-15.11	8.3e-47	1.71e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	15.11	8.38e-47	1.73e-43	0.53	0.42	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	15.11	8.38e-47	1.73e-43	0.53	0.42	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
BRCA	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-15.11	9.12e-47	1.88e-43	-0.49	-0.42	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
BRCA	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	15.1	9.4e-47	1.94e-43	0.48	0.42	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
BRCA	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	15.1	9.57e-47	1.97e-43	0.56	0.42	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	15.1	9.57e-47	1.97e-43	0.56	0.42	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
BRCA	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-15.1	1e-46	2.07e-43	-0.54	-0.42	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
BRCA	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-15.1	1.02e-46	2.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	15.09	1.06e-46	2.19e-43	0.56	0.42	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
BRCA	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-15.09	1.11e-46	2.28e-43	-0.52	-0.42	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	15.09	1.12e-46	2.31e-43	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-15.08	1.25e-46	2.56e-43	-0.49	-0.42	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	15.08	1.3e-46	2.66e-43	0.53	0.42	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
BRCA	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	15.07	1.35e-46	2.76e-43	0.53	0.42	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
BRCA	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-15.07	1.5e-46	3.07e-43	-0.52	-0.42	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
BRCA	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	15.06	1.66e-46	3.38e-43	0.5	0.42	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
BRCA	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-15.05	1.78e-46	3.64e-43	-0.47	-0.42	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
BRCA	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	15.05	1.83e-46	3.74e-43	0.52	0.42	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
BRCA	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-15.05	1.91e-46	3.89e-43	-0.58	-0.42	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
BRCA	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	15.05	1.91e-46	3.9e-43	0.52	0.42	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
BRCA	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-15.04	1.99e-46	4.05e-43	-0.49	-0.42	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
BRCA	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-15.04	2e-46	4.08e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-15.04	2e-46	4.08e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	15.04	2.18e-46	4.44e-43	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	15.03	2.39e-46	4.87e-43	0.55	0.42	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
BRCA	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	15.03	2.48e-46	5.03e-43	0.68	0.42	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
BRCA	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	15.02	2.64e-46	5.36e-43	0.53	0.42	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	15.01	2.83e-46	5.75e-43	0.52	0.42	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
BRCA	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-15.01	2.88e-46	5.84e-43	-0.45	-0.42	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-15.01	2.88e-46	5.84e-43	-0.45	-0.42	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
BRCA	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.01	3.01e-46	6.11e-43	-0.48	-0.42	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
BRCA	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-15.01	3.01e-46	6.11e-43	-0.68	-0.42	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
BRCA	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	15.01	3.02e-46	6.13e-43	0.54	0.42	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
BRCA	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	15	3.25e-46	6.57e-43	0.53	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	15	3.32e-46	6.71e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	15	3.32e-46	6.71e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-14.99	3.65e-46	7.37e-43	-0.48	-0.42	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-14.99	3.81e-46	7.68e-43	-0.57	-0.42	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
BRCA	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	14.98	4.17e-46	8.4e-43	0.51	0.42	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
BRCA	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-14.98	4.19e-46	8.43e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-14.98	4.19e-46	8.43e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	14.98	4.55e-46	9.15e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
BRCA	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	14.97	4.64e-46	9.3e-43	0.6	0.42	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
BRCA	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-14.97	4.75e-46	9.51e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
BRCA	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-14.97	4.89e-46	9.81e-43	-0.57	-0.42	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	14.97	4.97e-46	9.96e-43	0.54	0.42	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-14.97	5e-46	1e-42	-0.58	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
BRCA	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	14.96	5.61e-46	1.12e-42	0.52	0.42	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
BRCA	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-14.95	6.26e-46	1.25e-42	-0.54	-0.42	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
BRCA	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-14.95	6.4e-46	1.28e-42	-0.48	-0.42	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	14.94	7.08e-46	1.41e-42	0.52	0.42	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
BRCA	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.93	7.95e-46	1.58e-42	-0.63	-0.42	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
BRCA	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	14.93	8.09e-46	1.61e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	14.93	8.12e-46	1.61e-42	0.54	0.42	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-14.92	8.9e-46	1.77e-42	-0.51	-0.42	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	14.92	9.62e-46	1.91e-42	0.56	0.42	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-14.91	1.09e-45	2.15e-42	-0.53	-0.42	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
BRCA	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	14.9	1.18e-45	2.33e-42	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
BRCA	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-14.9	1.18e-45	2.34e-42	-0.65	-0.42	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
BRCA	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-14.9	1.22e-45	2.4e-42	-0.56	-0.42	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	14.89	1.28e-45	2.53e-42	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
BRCA	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-14.89	1.36e-45	2.69e-42	-0.56	-0.42	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-14.88	1.48e-45	2.91e-42	-0.48	-0.42	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
BRCA	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	14.88	1.51e-45	2.98e-42	0.53	0.42	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	14.88	1.53e-45	3.01e-42	0.5	0.42	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
BRCA	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	14.88	1.56e-45	3.08e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	14.88	1.56e-45	3.08e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
BRCA	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-14.86	1.86e-45	3.65e-42	-0.53	-0.42	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	14.86	1.91e-45	3.75e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	14.85	2.04e-45	4e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-14.85	2.1e-45	4.1e-42	-0.48	-0.42	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
BRCA	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	14.85	2.19e-45	4.28e-42	0.5	0.42	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-14.85	2.26e-45	4.42e-42	-0.48	-0.42	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-14.85	2.26e-45	4.42e-42	-0.48	-0.42	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	14.84	2.29e-45	4.48e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
BRCA	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	14.84	2.3e-45	4.5e-42	0.52	0.42	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-14.84	2.34e-45	4.58e-42	-0.56	-0.42	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
BRCA	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-14.84	2.42e-45	4.73e-42	-0.57	-0.42	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	14.84	2.44e-45	4.77e-42	0.54	0.42	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
BRCA	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	14.84	2.52e-45	4.92e-42	0.7	0.42	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
BRCA	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-14.83	2.63e-45	5.12e-42	-0.55	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-14.83	2.72e-45	5.3e-42	-0.54	-0.42	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	14.83	2.84e-45	5.52e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-14.83	2.91e-45	5.66e-42	-0.47	-0.42	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	14.82	3.25e-45	6.32e-42	0.53	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
BRCA	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-14.82	3.28e-45	6.38e-42	-0.56	-0.42	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
BRCA	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	14.81	3.43e-45	6.67e-42	0.53	0.42	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	14.81	3.45e-45	6.7e-42	0.54	0.42	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
BRCA	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	14.81	3.45e-45	6.71e-42	0.47	0.42	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-14.81	3.55e-45	6.9e-42	-0.47	-0.42	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-14.81	3.68e-45	7.14e-42	-0.44	-0.42	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	14.8	3.75e-45	7.28e-42	0.54	0.42	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-14.8	3.96e-45	7.67e-42	-0.53	-0.42	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	14.8	4.19e-45	8.11e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-14.79	4.69e-45	9.08e-42	-0.53	-0.42	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-14.79	4.69e-45	9.08e-42	-0.53	-0.42	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
BRCA	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-14.79	4.78e-45	9.25e-42	-0.47	-0.42	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
BRCA	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-14.78	4.89e-45	9.45e-42	-0.53	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
BRCA	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	14.78	5.07e-45	9.79e-42	0.67	0.42	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
BRCA	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	14.78	5.14e-45	9.94e-42	0.93	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
BRCA	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-14.78	5.17e-45	9.99e-42	-0.55	-0.42	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
BRCA	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-14.78	5.31e-45	1.02e-41	-0.47	-0.42	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	14.77	5.52e-45	1.06e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	14.77	5.64e-45	1.09e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	14.77	6.01e-45	1.16e-41	0.44	0.42	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
BRCA	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-14.77	6.06e-45	1.17e-41	-0.53	-0.42	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	14.76	6.19e-45	1.19e-41	0.53	0.42	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
BRCA	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-14.76	6.54e-45	1.26e-41	-0.57	-0.42	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
BRCA	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	14.76	6.64e-45	1.28e-41	0.51	0.42	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	14.76	6.68e-45	1.29e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
BRCA	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-14.76	6.8e-45	1.31e-41	-0.55	-0.42	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	14.76	6.85e-45	1.32e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	14.76	6.92e-45	1.33e-41	0.49	0.42	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
BRCA	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-14.75	7.01e-45	1.35e-41	-0.53	-0.42	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-14.75	7.24e-45	1.39e-41	-0.56	-0.42	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
BRCA	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	14.75	7.46e-45	1.43e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
BRCA	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	14.75	7.65e-45	1.47e-41	0.47	0.42	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
BRCA	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-14.74	7.95e-45	1.53e-41	-0.47	-0.42	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-14.74	7.95e-45	1.53e-41	-0.47	-0.42	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	14.74	8.02e-45	1.54e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	14.74	8.15e-45	1.56e-41	0.49	0.42	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	14.74	8.36e-45	1.61e-41	0.49	0.42	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
BRCA	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	14.73	8.89e-45	1.71e-41	0.46	0.42	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	14.73	8.89e-45	1.71e-41	0.46	0.42	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	14.73	9.59e-45	1.84e-41	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
BRCA	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	14.72	1e-44	1.92e-41	0.56	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-14.72	1e-44	1.92e-41	-0.53	-0.42	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-14.72	1.01e-44	1.94e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
BRCA	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-14.72	1.01e-44	1.94e-41	-0.53	-0.41	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-14.72	1.05e-44	2e-41	-0.54	-0.41	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
BRCA	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-14.72	1.06e-44	2.02e-41	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	14.72	1.08e-44	2.06e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
BRCA	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-14.72	1.08e-44	2.07e-41	-0.53	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
BRCA	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	14.71	1.14e-44	2.17e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
BRCA	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	14.71	1.15e-44	2.2e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
BRCA	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	14.71	1.16e-44	2.22e-41	0.55	0.41	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
BRCA	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	14.71	1.18e-44	2.25e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	14.71	1.22e-44	2.32e-41	0.54	0.41	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	14.71	1.25e-44	2.37e-41	0.48	0.41	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
BRCA	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-14.71	1.27e-44	2.42e-41	-0.55	-0.41	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-14.71	1.27e-44	2.42e-41	-0.55	-0.41	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
BRCA	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-14.7	1.32e-44	2.51e-41	-0.88	-0.41	QT interval;	chr4:75137695	chr4:75081702~75084717:-
BRCA	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	14.7	1.32e-44	2.51e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
BRCA	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-14.7	1.35e-44	2.56e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-14.7	1.35e-44	2.58e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	14.7	1.36e-44	2.59e-41	0.51	0.41	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
BRCA	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	14.7	1.42e-44	2.7e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	14.7	1.42e-44	2.7e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-14.7	1.44e-44	2.74e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	14.69	1.47e-44	2.79e-41	0.53	0.41	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
BRCA	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	14.69	1.47e-44	2.79e-41	0.38	0.41	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
BRCA	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-14.69	1.49e-44	2.82e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
BRCA	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	14.69	1.53e-44	2.91e-41	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
BRCA	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-14.69	1.54e-44	2.93e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
BRCA	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	14.69	1.55e-44	2.95e-41	0.53	0.41	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-14.69	1.56e-44	2.97e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	14.69	1.6e-44	3.04e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
BRCA	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-14.69	1.62e-44	3.08e-41	-0.52	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
BRCA	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-14.68	1.65e-44	3.13e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-14.68	1.66e-44	3.15e-41	-0.5	-0.41	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	14.68	1.67e-44	3.16e-41	0.51	0.41	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
BRCA	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	14.68	1.68e-44	3.19e-41	0.55	0.41	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	14.68	1.71e-44	3.25e-41	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
BRCA	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	14.68	1.76e-44	3.33e-41	0.53	0.41	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	14.67	1.88e-44	3.56e-41	0.53	0.41	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
BRCA	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-14.67	1.89e-44	3.57e-41	-0.53	-0.41	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
BRCA	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	14.67	1.89e-44	3.58e-41	0.46	0.41	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
BRCA	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-14.67	1.98e-44	3.74e-41	-0.44	-0.41	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
BRCA	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-14.67	1.98e-44	3.74e-41	-0.53	-0.41	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
BRCA	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	14.67	1.99e-44	3.77e-41	0.52	0.41	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	14.67	2.08e-44	3.92e-41	0.48	0.41	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
BRCA	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	14.66	2.18e-44	4.12e-41	0.57	0.41	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-14.66	2.21e-44	4.18e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
BRCA	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-14.66	2.33e-44	4.4e-41	-0.47	-0.41	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	14.66	2.33e-44	4.41e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-14.65	2.43e-44	4.59e-41	-0.48	-0.41	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	14.65	2.63e-44	4.96e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	14.64	2.73e-44	5.14e-41	0.53	0.41	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	14.64	2.75e-44	5.19e-41	0.53	0.41	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
BRCA	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-14.64	2.76e-44	5.19e-41	-0.51	-0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	14.64	2.87e-44	5.4e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
BRCA	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	14.63	3.27e-44	6.15e-41	0.52	0.41	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	14.63	3.33e-44	6.26e-41	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	14.62	3.45e-44	6.48e-41	0.53	0.41	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	14.62	3.49e-44	6.56e-41	0.53	0.41	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-14.62	3.5e-44	6.58e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	14.62	3.63e-44	6.81e-41	0.53	0.41	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
BRCA	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	14.62	3.74e-44	7.03e-41	0.57	0.41	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
BRCA	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	14.61	3.86e-44	7.25e-41	0.53	0.41	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
BRCA	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	14.61	3.96e-44	7.44e-41	0.59	0.41	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
BRCA	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-14.61	4.11e-44	7.7e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	14.61	4.19e-44	7.86e-41	0.53	0.41	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
BRCA	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-14.61	4.33e-44	8.11e-41	-0.66	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
BRCA	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	14.6	4.42e-44	8.29e-41	0.45	0.41	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
BRCA	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-14.6	4.47e-44	8.38e-41	-0.53	-0.41	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	14.6	4.63e-44	8.67e-41	0.53	0.41	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-14.6	4.69e-44	8.78e-41	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	14.6	4.74e-44	8.87e-41	0.48	0.41	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
BRCA	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	14.6	4.77e-44	8.92e-41	0.53	0.41	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
BRCA	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	14.6	4.85e-44	9.06e-41	0.52	0.41	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	14.59	5.13e-44	9.58e-41	0.53	0.41	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	14.59	5.17e-44	9.66e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	14.59	5.23e-44	9.77e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
BRCA	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-14.59	5.3e-44	9.89e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	14.59	5.43e-44	1.01e-40	0.47	0.41	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
BRCA	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	14.59	5.46e-44	1.02e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
BRCA	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	14.58	5.57e-44	1.04e-40	0.49	0.41	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	14.58	5.57e-44	1.04e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
BRCA	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	14.58	5.65e-44	1.05e-40	0.52	0.41	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
BRCA	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	14.58	5.67e-44	1.06e-40	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
BRCA	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-14.58	5.86e-44	1.09e-40	-0.47	-0.41	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
BRCA	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-14.58	6.06e-44	1.13e-40	-0.47	-0.41	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
BRCA	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	14.58	6.13e-44	1.14e-40	0.52	0.41	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-14.58	6.19e-44	1.15e-40	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
BRCA	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-14.57	6.31e-44	1.17e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
BRCA	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-14.57	6.41e-44	1.19e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-14.57	6.5e-44	1.21e-40	-0.6	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	14.57	6.66e-44	1.24e-40	0.53	0.41	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	14.57	6.84e-44	1.27e-40	0.53	0.41	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
BRCA	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
BRCA	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	14.56	7.07e-44	1.31e-40	0.53	0.41	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
BRCA	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	14.56	7.2e-44	1.34e-40	0.51	0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
BRCA	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-14.56	7.34e-44	1.36e-40	-0.58	-0.41	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
BRCA	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-14.56	7.36e-44	1.37e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
BRCA	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-14.56	7.62e-44	1.41e-40	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-14.56	7.74e-44	1.44e-40	-0.46	-0.41	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	14.55	7.99e-44	1.48e-40	0.52	0.41	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	14.55	8.17e-44	1.52e-40	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-14.55	8.26e-44	1.53e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
BRCA	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	14.55	8.65e-44	1.6e-40	0.45	0.41	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
BRCA	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-14.55	8.86e-44	1.64e-40	-0.67	-0.41	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
BRCA	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	14.54	9.01e-44	1.67e-40	0.52	0.41	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-14.54	9.56e-44	1.77e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	14.54	9.94e-44	1.84e-40	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	14.53	1.02e-43	1.88e-40	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-14.53	1.06e-43	1.96e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
BRCA	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-14.53	1.07e-43	1.97e-40	-0.47	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-14.53	1.07e-43	1.97e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
BRCA	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-14.53	1.07e-43	1.98e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-14.53	1.07e-43	1.98e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
BRCA	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	14.53	1.11e-43	2.05e-40	0.43	0.41	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
BRCA	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	14.53	1.14e-43	2.11e-40	0.5	0.41	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
BRCA	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	14.52	1.2e-43	2.22e-40	0.52	0.41	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-14.52	1.23e-43	2.26e-40	-0.5	-0.41	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
BRCA	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	14.51	1.42e-43	2.61e-40	0.47	0.41	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-14.51	1.42e-43	2.62e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
BRCA	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-14.51	1.42e-43	2.62e-40	-0.5	-0.41	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-14.51	1.43e-43	2.63e-40	-0.79	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
BRCA	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-14.51	1.43e-43	2.64e-40	-0.47	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
BRCA	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-14.51	1.44e-43	2.65e-40	-0.55	-0.41	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	14.5	1.47e-43	2.71e-40	0.52	0.41	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	14.5	1.57e-43	2.88e-40	0.52	0.41	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	14.5	1.6e-43	2.93e-40	0.52	0.41	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	14.5	1.63e-43	2.99e-40	0.53	0.41	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	14.5	1.65e-43	3.02e-40	0.52	0.41	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	14.49	1.66e-43	3.06e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
BRCA	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	14.48	1.87e-43	3.43e-40	0.53	0.41	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	14.48	1.89e-43	3.46e-40	0.52	0.41	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
BRCA	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-14.48	1.93e-43	3.54e-40	-0.46	-0.41	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
BRCA	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	14.48	1.95e-43	3.58e-40	0.52	0.41	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	14.48	1.95e-43	3.58e-40	0.52	0.41	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	14.48	1.96e-43	3.6e-40	0.56	0.41	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
BRCA	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	14.48	1.97e-43	3.6e-40	0.52	0.41	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
BRCA	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	14.48	2.04e-43	3.74e-40	0.46	0.41	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
BRCA	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	14.47	2.1e-43	3.85e-40	0.52	0.41	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
BRCA	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-14.47	2.12e-43	3.88e-40	-0.48	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
BRCA	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	14.47	2.14e-43	3.93e-40	0.43	0.41	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	14.47	2.22e-43	4.07e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
BRCA	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-14.47	2.25e-43	4.12e-40	-0.53	-0.41	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	14.45	2.72e-43	4.97e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-14.45	2.73e-43	4.98e-40	-0.55	-0.41	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
BRCA	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-14.45	2.77e-43	5.04e-40	-0.52	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	14.45	2.89e-43	5.27e-40	0.52	0.41	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
BRCA	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	14.44	3.09e-43	5.62e-40	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
BRCA	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	14.44	3.22e-43	5.86e-40	0.48	0.41	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-14.43	3.49e-43	6.33e-40	-0.48	-0.41	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-14.43	3.55e-43	6.41e-40	-0.48	-0.41	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
BRCA	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	14.43	3.6e-43	6.5e-40	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
BRCA	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-14.43	3.68e-43	6.65e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
BRCA	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	14.43	3.72e-43	6.71e-40	0.54	0.41	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-14.43	3.76e-43	6.78e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
BRCA	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	14.42	3.97e-43	7.15e-40	0.47	0.41	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-14.42	4.18e-43	7.53e-40	-0.55	-0.41	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
BRCA	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-14.42	4.2e-43	7.56e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
BRCA	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	14.42	4.22e-43	7.59e-40	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
BRCA	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	14.42	4.23e-43	7.62e-40	0.48	0.41	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
BRCA	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	14.41	4.65e-43	8.36e-40	0.56	0.41	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
BRCA	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	14.41	4.67e-43	8.39e-40	0.52	0.41	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	14.41	4.69e-43	8.43e-40	0.51	0.41	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
BRCA	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	14.4	4.96e-43	8.9e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	14.4	4.99e-43	8.95e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-14.4	5e-43	8.96e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
BRCA	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	14.4	5.1e-43	9.13e-40	0.43	0.41	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	14.4	5.15e-43	9.23e-40	0.46	0.41	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	14.39	5.88e-43	1.05e-39	0.53	0.41	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
BRCA	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-14.38	6.41e-43	1.15e-39	-0.47	-0.41	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
BRCA	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	14.38	6.52e-43	1.16e-39	0.52	0.41	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	14.38	7.01e-43	1.25e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
BRCA	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	14.37	7.05e-43	1.26e-39	0.56	0.41	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
BRCA	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	14.37	7.18e-43	1.28e-39	0.48	0.41	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
BRCA	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-14.37	7.43e-43	1.32e-39	-0.43	-0.41	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
BRCA	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	14.37	7.44e-43	1.33e-39	0.51	0.41	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
BRCA	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	14.37	7.76e-43	1.38e-39	0.7	0.41	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-14.37	7.77e-43	1.38e-39	-0.51	-0.41	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
BRCA	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-14.36	8.23e-43	1.46e-39	-0.46	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
BRCA	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	14.36	8.32e-43	1.48e-39	0.54	0.41	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	14.36	8.41e-43	1.49e-39	0.52	0.41	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
BRCA	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	14.36	8.43e-43	1.5e-39	0.58	0.41	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	14.35	9.02e-43	1.6e-39	0.47	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-14.35	9.06e-43	1.61e-39	-0.52	-0.41	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	14.35	9.44e-43	1.67e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
BRCA	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	14.35	9.47e-43	1.68e-39	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-14.35	9.66e-43	1.71e-39	-0.46	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
BRCA	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-14.35	1e-42	1.77e-39	-0.52	-0.41	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
BRCA	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	14.35	1e-42	1.78e-39	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
BRCA	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	14.34	1.06e-42	1.88e-39	0.55	0.41	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
BRCA	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	14.34	1.07e-42	1.89e-39	0.48	0.41	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
BRCA	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-14.34	1.07e-42	1.89e-39	-0.55	-0.41	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
BRCA	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	14.34	1.09e-42	1.93e-39	0.48	0.41	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
BRCA	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-14.34	1.12e-42	1.98e-39	-0.47	-0.41	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
BRCA	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	14.33	1.16e-42	2.04e-39	0.55	0.41	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	14.33	1.21e-42	2.13e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
BRCA	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	14.33	1.24e-42	2.18e-39	0.7	0.41	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
BRCA	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	14.32	1.36e-42	2.39e-39	0.5	0.41	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
BRCA	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-14.32	1.41e-42	2.49e-39	-0.5	-0.41	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
BRCA	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
BRCA	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	14.31	1.45e-42	2.55e-39	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	14.31	1.46e-42	2.57e-39	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
BRCA	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-14.31	1.5e-42	2.63e-39	-0.54	-0.41	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
BRCA	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	14.31	1.51e-42	2.65e-39	0.5	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	14.31	1.54e-42	2.7e-39	0.47	0.41	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
BRCA	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	14.31	1.55e-42	2.71e-39	0.61	0.41	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
BRCA	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	14.31	1.55e-42	2.72e-39	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
BRCA	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-14.31	1.55e-42	2.73e-39	-0.51	-0.41	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	14.3	1.64e-42	2.88e-39	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
BRCA	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-14.3	1.73e-42	3.02e-39	-0.56	-0.41	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
BRCA	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-14.3	1.78e-42	3.11e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
BRCA	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.29	1.9e-42	3.33e-39	0.61	0.4	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
BRCA	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-14.29	1.95e-42	3.4e-39	-0.5	-0.4	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
BRCA	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	14.29	2.02e-42	3.52e-39	0.54	0.4	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	14.29	2.04e-42	3.57e-39	0.55	0.4	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
BRCA	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	14.28	2.1e-42	3.66e-39	0.47	0.4	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
BRCA	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-14.28	2.1e-42	3.67e-39	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
BRCA	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	14.28	2.22e-42	3.86e-39	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
BRCA	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	14.28	2.23e-42	3.89e-39	0.51	0.4	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	14.28	2.29e-42	3.99e-39	0.52	0.4	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	14.28	2.31e-42	4.02e-39	0.52	0.4	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
BRCA	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-14.26	2.64e-42	4.58e-39	-0.47	-0.4	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-14.26	2.77e-42	4.81e-39	-0.46	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
BRCA	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	14.26	2.95e-42	5.11e-39	0.47	0.4	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
BRCA	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	14.25	2.98e-42	5.17e-39	0.5	0.4	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
BRCA	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	14.24	3.36e-42	5.82e-39	0.55	0.4	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
BRCA	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-14.24	3.56e-42	6.15e-39	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
BRCA	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	14.24	3.73e-42	6.45e-39	0.55	0.4	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
BRCA	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	14.23	4.01e-42	6.92e-39	0.47	0.4	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
BRCA	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	14.23	4.24e-42	7.32e-39	0.5	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
BRCA	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-14.22	4.42e-42	7.61e-39	-0.5	-0.4	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
BRCA	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	14.21	4.93e-42	8.48e-39	0.47	0.4	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
BRCA	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-14.21	4.97e-42	8.55e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-14.21	4.97e-42	8.55e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
BRCA	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	14.21	5.24e-42	9e-39	0.47	0.4	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	14.21	5.24e-42	9.01e-39	0.5	0.4	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-14.21	5.37e-42	9.22e-39	-0.47	-0.4	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
BRCA	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-14.21	5.38e-42	9.24e-39	-0.5	-0.4	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
BRCA	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-14.2	5.49e-42	9.43e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
BRCA	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	14.2	5.68e-42	9.75e-39	0.47	0.4	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	14.2	5.68e-42	9.75e-39	0.47	0.4	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-14.2	5.75e-42	9.87e-39	-0.48	-0.4	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
BRCA	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	14.2	5.81e-42	9.97e-39	0.5	0.4	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
BRCA	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
BRCA	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	14.2	5.85e-42	1e-38	0.56	0.4	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
BRCA	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-14.2	5.86e-42	1.01e-38	-0.52	-0.4	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
BRCA	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	14.2	6.04e-42	1.04e-38	0.55	0.4	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
BRCA	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-14.19	6.16e-42	1.05e-38	-0.49	-0.4	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
BRCA	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-14.19	6.42e-42	1.1e-38	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
BRCA	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	14.19	6.82e-42	1.17e-38	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	14.18	7.17e-42	1.23e-38	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	14.18	7.36e-42	1.26e-38	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
BRCA	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	14.18	7.38e-42	1.26e-38	0.47	0.4	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
BRCA	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-14.18	7.49e-42	1.28e-38	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
BRCA	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	14.17	7.79e-42	1.33e-38	0.47	0.4	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
BRCA	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-14.17	8.3e-42	1.41e-38	-0.52	-0.4	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
BRCA	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	14.15	1.03e-41	1.75e-38	0.54	0.4	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
BRCA	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-14.14	1.13e-41	1.91e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
BRCA	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-14.14	1.13e-41	1.91e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
BRCA	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	14.14	1.17e-41	1.98e-38	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
BRCA	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-14.14	1.2e-41	2.03e-38	-0.51	-0.4	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
BRCA	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-14.14	1.22e-41	2.07e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	14.13	1.32e-41	2.23e-38	0.51	0.4	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	14.13	1.32e-41	2.23e-38	0.5	0.4	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-14.13	1.36e-41	2.3e-38	-0.55	-0.4	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
BRCA	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	14.13	1.4e-41	2.36e-38	0.5	0.4	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
BRCA	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-14.12	1.42e-41	2.4e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	14.12	1.44e-41	2.44e-38	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
BRCA	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	14.12	1.49e-41	2.52e-38	0.53	0.4	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
BRCA	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-14.12	1.52e-41	2.56e-38	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
BRCA	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	14.12	1.56e-41	2.64e-38	0.55	0.4	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
BRCA	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	14.12	1.57e-41	2.66e-38	0.47	0.4	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	14.12	1.58e-41	2.66e-38	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
BRCA	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-14.11	1.62e-41	2.73e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
BRCA	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-14.11	1.74e-41	2.93e-38	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
BRCA	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	14.11	1.76e-41	2.97e-38	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
BRCA	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-14.11	1.78e-41	2.99e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
BRCA	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-14.11	1.78e-41	2.99e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
BRCA	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-14.1	1.97e-41	3.32e-38	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
BRCA	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-14.09	2.18e-41	3.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	14.09	2.2e-41	3.7e-38	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
BRCA	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	14.08	2.28e-41	3.83e-38	0.51	0.4	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
BRCA	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-14.08	2.35e-41	3.94e-38	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
BRCA	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	14.08	2.51e-41	4.21e-38	0.55	0.4	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
BRCA	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-14.08	2.52e-41	4.23e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
BRCA	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-14.07	2.64e-41	4.41e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
BRCA	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	14.07	2.65e-41	4.43e-38	0.47	0.4	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-14.07	2.66e-41	4.45e-38	-0.49	-0.4	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
BRCA	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-14.07	2.66e-41	4.45e-38	-0.55	-0.4	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-14.07	2.7e-41	4.51e-38	-0.54	-0.4	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
BRCA	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	14.07	2.71e-41	4.53e-38	0.63	0.4	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
BRCA	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-14.07	2.73e-41	4.55e-38	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
BRCA	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-14.07	2.81e-41	4.7e-38	-0.57	-0.4	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
BRCA	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	14.06	3.01e-41	5.02e-38	0.47	0.4	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
BRCA	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	14.06	3.03e-41	5.05e-38	0.51	0.4	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-14.06	3.13e-41	5.22e-38	-0.5	-0.4	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
BRCA	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-14.06	3.14e-41	5.24e-38	-0.51	-0.4	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
BRCA	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-14.06	3.15e-41	5.26e-38	-0.45	-0.4	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
BRCA	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-14.05	3.32e-41	5.53e-38	-0.49	-0.4	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
BRCA	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-14.05	3.4e-41	5.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
BRCA	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-14.05	3.4e-41	5.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
BRCA	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-14.04	3.76e-41	6.24e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
BRCA	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-14.04	3.98e-41	6.61e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	14.03	4.12e-41	6.83e-38	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
BRCA	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-14.03	4.14e-41	6.88e-38	-0.4	-0.4	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
BRCA	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-14.03	4.2e-41	6.97e-38	-0.51	-0.4	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-14.03	4.25e-41	7.05e-38	-0.47	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
BRCA	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	14.03	4.29e-41	7.12e-38	0.47	0.4	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-14.03	4.37e-41	7.24e-38	-0.49	-0.4	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-14.03	4.49e-41	7.43e-38	-0.5	-0.4	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	14.03	4.57e-41	7.57e-38	0.49	0.4	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	14.02	4.77e-41	7.89e-38	0.52	0.4	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-14.01	5.25e-41	8.68e-38	-0.4	-0.4	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
BRCA	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
BRCA	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-14.01	5.6e-41	9.25e-38	-0.44	-0.4	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
BRCA	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	14.01	5.69e-41	9.39e-38	0.49	0.4	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
BRCA	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-14	5.9e-41	9.73e-38	-0.47	-0.4	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
BRCA	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	14	6.17e-41	1.02e-37	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
BRCA	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	14	6.32e-41	1.04e-37	0.5	0.4	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
BRCA	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	14	6.38e-41	1.05e-37	0.47	0.4	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	14	6.38e-41	1.05e-37	0.48	0.4	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-14	6.5e-41	1.07e-37	-0.46	-0.4	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
BRCA	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	14	6.51e-41	1.07e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	13.99	6.61e-41	1.09e-37	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
BRCA	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	13.99	6.75e-41	1.11e-37	0.5	0.4	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
BRCA	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-13.99	7.11e-41	1.17e-37	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
BRCA	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	13.99	7.18e-41	1.18e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	13.98	7.45e-41	1.22e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	13.98	7.45e-41	1.22e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-13.98	7.63e-41	1.25e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
BRCA	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
BRCA	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-13.98	8.04e-41	1.32e-37	-0.49	-0.4	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
BRCA	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	13.98	8.13e-41	1.33e-37	0.5	0.4	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
BRCA	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-13.97	8.39e-41	1.38e-37	-0.54	-0.4	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
BRCA	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
BRCA	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-13.97	8.78e-41	1.44e-37	-0.54	-0.4	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	13.97	8.82e-41	1.44e-37	0.5	0.4	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-13.97	9.09e-41	1.49e-37	-0.54	-0.4	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
BRCA	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	13.97	9.31e-41	1.52e-37	0.63	0.4	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-13.96	9.55e-41	1.56e-37	-0.48	-0.4	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	13.96	9.96e-41	1.63e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
BRCA	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-13.95	1.06e-40	1.73e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-13.95	1.06e-40	1.73e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	13.95	1.07e-40	1.75e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
BRCA	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	13.95	1.09e-40	1.78e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	13.95	1.11e-40	1.81e-37	0.72	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
BRCA	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-13.95	1.11e-40	1.82e-37	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
BRCA	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	13.95	1.17e-40	1.91e-37	0.54	0.4	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-13.95	1.18e-40	1.92e-37	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
BRCA	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	13.95	1.18e-40	1.93e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
BRCA	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	13.94	1.21e-40	1.98e-37	0.5	0.4	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
BRCA	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	13.94	1.22e-40	1.99e-37	0.54	0.4	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-13.94	1.23e-40	2.01e-37	-0.47	-0.4	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
BRCA	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-13.94	1.24e-40	2.02e-37	-0.41	-0.4	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
BRCA	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-13.94	1.24e-40	2.02e-37	-0.41	-0.4	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
BRCA	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-13.94	1.24e-40	2.03e-37	-0.54	-0.4	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
BRCA	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	13.94	1.26e-40	2.05e-37	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
BRCA	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-13.94	1.27e-40	2.07e-37	-0.48	-0.4	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
BRCA	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	13.94	1.31e-40	2.14e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-13.93	1.44e-40	2.34e-37	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
BRCA	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	13.93	1.47e-40	2.39e-37	0.55	0.4	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
BRCA	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	13.92	1.53e-40	2.49e-37	0.55	0.4	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
BRCA	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-13.92	1.61e-40	2.61e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	13.92	1.62e-40	2.64e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
BRCA	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-13.92	1.63e-40	2.65e-37	-0.43	-0.4	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
BRCA	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-13.92	1.68e-40	2.72e-37	-0.5	-0.4	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
BRCA	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	13.91	1.85e-40	3.01e-37	0.5	0.4	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
BRCA	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	13.9	1.92e-40	3.11e-37	0.45	0.4	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
BRCA	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-13.9	1.98e-40	3.2e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-13.9	2.01e-40	3.26e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
BRCA	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-13.9	2.05e-40	3.31e-37	-0.47	-0.4	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
BRCA	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-13.89	2.22e-40	3.59e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
BRCA	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	13.89	2.28e-40	3.69e-37	0.43	0.4	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
BRCA	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	13.89	2.29e-40	3.69e-37	0.5	0.4	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-13.89	2.38e-40	3.84e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-13.89	2.39e-40	3.85e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-13.89	2.39e-40	3.85e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
BRCA	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	13.89	2.4e-40	3.86e-37	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
BRCA	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	13.88	2.44e-40	3.93e-37	0.48	0.4	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-13.88	2.47e-40	3.97e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
BRCA	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-13.88	2.69e-40	4.32e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
BRCA	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-13.87	2.8e-40	4.5e-37	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-13.87	2.88e-40	4.63e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-13.87	2.88e-40	4.63e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
BRCA	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-13.87	2.89e-40	4.64e-37	-0.52	-0.39	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
BRCA	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-13.87	2.9e-40	4.65e-37	-0.5	-0.39	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
BRCA	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	13.86	3.06e-40	4.91e-37	0.55	0.39	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
BRCA	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-13.86	3.16e-40	5.07e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
BRCA	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-13.86	3.16e-40	5.07e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
BRCA	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	13.86	3.16e-40	5.07e-37	0.54	0.39	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
BRCA	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-13.86	3.21e-40	5.14e-37	-0.49	-0.39	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
BRCA	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	13.86	3.36e-40	5.38e-37	0.46	0.39	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
BRCA	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-13.86	3.42e-40	5.47e-37	-0.49	-0.39	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-13.85	3.52e-40	5.64e-37	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
BRCA	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	13.85	3.54e-40	5.66e-37	0.42	0.39	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
BRCA	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	13.85	3.72e-40	5.95e-37	0.51	0.39	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
BRCA	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-13.85	3.77e-40	6.03e-37	-0.5	-0.39	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
BRCA	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	13.85	3.78e-40	6.04e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	13.85	3.78e-40	6.04e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-13.85	3.8e-40	6.07e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
BRCA	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	13.85	3.8e-40	6.08e-37	0.54	0.39	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
BRCA	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	13.85	3.81e-40	6.09e-37	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
BRCA	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-13.85	3.83e-40	6.11e-37	-0.59	-0.39	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
BRCA	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	13.85	3.83e-40	6.12e-37	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	13.84	3.96e-40	6.32e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-13.84	4e-40	6.39e-37	-0.49	-0.39	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
BRCA	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-13.84	4.19e-40	6.69e-37	-0.52	-0.39	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
BRCA	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-13.84	4.2e-40	6.7e-37	-0.44	-0.39	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
BRCA	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	13.84	4.21e-40	6.71e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
BRCA	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	13.84	4.24e-40	6.75e-37	0.48	0.39	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
BRCA	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-13.84	4.33e-40	6.89e-37	-0.43	-0.39	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
BRCA	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-13.83	4.45e-40	7.09e-37	-0.53	-0.39	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
BRCA	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-13.83	4.47e-40	7.11e-37	-0.41	-0.39	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
BRCA	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-13.83	4.55e-40	7.24e-37	-0.56	-0.39	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-13.83	4.86e-40	7.73e-37	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
BRCA	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	13.82	5.04e-40	8.02e-37	0.45	0.39	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
BRCA	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-13.82	5.24e-40	8.33e-37	-0.48	-0.39	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
BRCA	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-13.82	5.28e-40	8.39e-37	-0.46	-0.39	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
BRCA	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	13.82	5.31e-40	8.43e-37	0.44	0.39	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
BRCA	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	13.81	5.52e-40	8.76e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
BRCA	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-13.81	5.53e-40	8.79e-37	-0.41	-0.39	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
BRCA	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	13.81	5.56e-40	8.82e-37	0.5	0.39	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
BRCA	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-13.81	5.82e-40	9.22e-37	-0.42	-0.39	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
BRCA	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	13.81	5.96e-40	9.44e-37	0.74	0.39	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
BRCA	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	13.81	5.97e-40	9.47e-37	0.44	0.39	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
BRCA	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	13.81	5.98e-40	9.47e-37	0.55	0.39	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-13.81	5.98e-40	9.47e-37	-0.5	-0.39	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-13.81	6.01e-40	9.52e-37	-0.5	-0.39	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
BRCA	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	13.81	6.05e-40	9.58e-37	0.45	0.39	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
BRCA	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	13.81	6.1e-40	9.66e-37	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
BRCA	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	13.81	6.13e-40	9.72e-37	0.46	0.39	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
BRCA	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-13.81	6.15e-40	9.74e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
BRCA	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-13.81	6.17e-40	9.76e-37	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-13.8	6.31e-40	9.99e-37	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
BRCA	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
BRCA	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	13.79	7.06e-40	1.12e-36	0.51	0.39	Temperament;	chr17:13996939	chr17:14024514~14025488:+
BRCA	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	13.79	7.12e-40	1.12e-36	0.45	0.39	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
BRCA	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-13.79	7.54e-40	1.19e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
BRCA	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	13.79	7.65e-40	1.21e-36	0.47	0.39	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
BRCA	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	13.79	7.71e-40	1.22e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	13.79	7.71e-40	1.22e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-13.79	7.72e-40	1.22e-36	-0.5	-0.39	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
BRCA	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-13.79	7.73e-40	1.22e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
BRCA	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-13.79	7.76e-40	1.22e-36	-0.53	-0.39	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
BRCA	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	13.79	7.77e-40	1.22e-36	0.54	0.39	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	13.78	8e-40	1.26e-36	0.5	0.39	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
BRCA	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	13.78	8e-40	1.26e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	13.78	8e-40	1.26e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-13.78	8.02e-40	1.26e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
BRCA	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-13.78	8.1e-40	1.28e-36	-0.44	-0.39	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
BRCA	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-13.78	8.29e-40	1.31e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
BRCA	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	13.78	8.29e-40	1.31e-36	0.54	0.39	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
BRCA	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	13.78	8.37e-40	1.32e-36	0.55	0.39	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
BRCA	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-13.78	8.46e-40	1.33e-36	-0.49	-0.39	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-13.78	8.49e-40	1.34e-36	-0.5	-0.39	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	13.78	8.57e-40	1.35e-36	0.5	0.39	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
BRCA	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	13.77	8.84e-40	1.39e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
BRCA	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	13.77	8.89e-40	1.4e-36	0.5	0.39	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
BRCA	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	13.77	9.1e-40	1.43e-36	0.65	0.39	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
BRCA	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	13.77	9.15e-40	1.44e-36	0.69	0.39	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
BRCA	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-13.77	9.27e-40	1.46e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
BRCA	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-13.77	9.34e-40	1.47e-36	-0.51	-0.39	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
BRCA	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.76	1.08e-39	1.7e-36	0.48	0.39	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
BRCA	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-13.76	1.11e-39	1.74e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
BRCA	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	13.75	1.16e-39	1.82e-36	0.5	0.39	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
BRCA	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
BRCA	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	13.74	1.28e-39	2e-36	0.54	0.39	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-13.74	1.35e-39	2.11e-36	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
BRCA	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	13.73	1.43e-39	2.24e-36	0.45	0.39	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
BRCA	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-13.72	1.58e-39	2.46e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
BRCA	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-13.72	1.65e-39	2.57e-36	-0.5	-0.39	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
BRCA	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-13.72	1.7e-39	2.66e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
BRCA	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-13.72	1.73e-39	2.7e-36	-0.43	-0.39	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
BRCA	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	13.72	1.74e-39	2.71e-36	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	13.72	1.76e-39	2.75e-36	0.51	0.39	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
BRCA	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.78e-39	2.77e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
BRCA	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-13.71	1.82e-39	2.84e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
BRCA	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	13.71	1.88e-39	2.93e-36	0.46	0.39	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
BRCA	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.9e-39	2.95e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.9e-39	2.95e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.94e-39	3.02e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
BRCA	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	13.71	1.95e-39	3.03e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
BRCA	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-13.71	1.98e-39	3.08e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	13.7	2e-39	3.11e-36	0.48	0.39	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
BRCA	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	13.7	2e-39	3.11e-36	0.55	0.39	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
BRCA	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	13.7	2.02e-39	3.15e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	13.7	2.02e-39	3.15e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
BRCA	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	13.7	2.04e-39	3.17e-36	0.54	0.39	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-13.7	2.07e-39	3.21e-36	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
BRCA	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-13.7	2.07e-39	3.22e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
BRCA	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	13.7	2.07e-39	3.22e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
BRCA	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-13.7	2.13e-39	3.31e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-13.69	2.37e-39	3.68e-36	-0.54	-0.39	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
BRCA	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	13.69	2.41e-39	3.73e-36	0.53	0.39	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
BRCA	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	13.69	2.43e-39	3.77e-36	0.49	0.39	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-13.69	2.46e-39	3.82e-36	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
BRCA	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-13.69	2.5e-39	3.88e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	13.68	2.6e-39	4.03e-36	0.48	0.39	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
BRCA	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-13.68	2.67e-39	4.13e-36	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-13.68	2.71e-39	4.2e-36	-0.53	-0.39	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
BRCA	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-13.67	2.87e-39	4.44e-36	-0.5	-0.39	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
BRCA	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-13.67	2.92e-39	4.52e-36	-0.53	-0.39	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
BRCA	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	13.67	2.93e-39	4.53e-36	0.51	0.39	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
BRCA	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-13.67	3.06e-39	4.72e-36	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
BRCA	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-13.67	3.13e-39	4.83e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
BRCA	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	13.67	3.13e-39	4.84e-36	0.53	0.39	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
BRCA	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	13.67	3.17e-39	4.89e-36	0.47	0.39	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
BRCA	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-13.66	3.21e-39	4.95e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
BRCA	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	13.66	3.3e-39	5.09e-36	0.51	0.39	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
BRCA	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	13.66	3.34e-39	5.15e-36	0.49	0.39	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
BRCA	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-13.65	3.79e-39	5.83e-36	-0.46	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
BRCA	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	13.65	3.94e-39	6.06e-36	0.42	0.39	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-13.64	4.12e-39	6.32e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
BRCA	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-13.64	4.13e-39	6.34e-36	-0.54	-0.39	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
BRCA	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-13.64	4.2e-39	6.45e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
BRCA	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-13.64	4.24e-39	6.51e-36	-0.43	-0.39	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
BRCA	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	13.64	4.25e-39	6.52e-36	0.46	0.39	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
BRCA	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-13.64	4.28e-39	6.56e-36	-0.5	-0.39	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-13.64	4.31e-39	6.61e-36	-0.46	-0.39	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
BRCA	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
BRCA	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	13.63	4.58e-39	7.01e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	13.63	4.58e-39	7.01e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
BRCA	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	13.63	4.63e-39	7.09e-36	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
BRCA	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-13.63	4.71e-39	7.21e-36	-0.51	-0.39	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
BRCA	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	13.63	4.87e-39	7.45e-36	0.49	0.39	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
BRCA	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	13.62	5.08e-39	7.77e-36	0.53	0.39	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
BRCA	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	13.62	5.15e-39	7.89e-36	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
BRCA	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	13.62	5.22e-39	7.98e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
BRCA	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-13.62	5.56e-39	8.5e-36	-0.5	-0.39	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
BRCA	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-13.62	5.65e-39	8.65e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-13.61	5.8e-39	8.86e-36	-0.49	-0.39	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
BRCA	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	13.61	5.81e-39	8.87e-36	0.47	0.39	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
BRCA	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	13.61	5.93e-39	9.06e-36	0.53	0.39	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
BRCA	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-13.61	5.98e-39	9.14e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
BRCA	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-13.61	5.99e-39	9.14e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-13.61	5.99e-39	9.14e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
BRCA	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	13.61	6.12e-39	9.35e-36	0.5	0.39	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-13.6	6.64e-39	1.01e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
BRCA	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	13.6	6.85e-39	1.04e-35	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
BRCA	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
BRCA	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	13.59	7.4e-39	1.13e-35	0.46	0.39	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
BRCA	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	13.58	8.39e-39	1.28e-35	0.49	0.39	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
BRCA	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-13.58	8.53e-39	1.3e-35	-0.41	-0.39	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-13.58	8.86e-39	1.35e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-13.58	8.86e-39	1.35e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
BRCA	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-13.58	8.9e-39	1.35e-35	-0.46	-0.39	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-13.57	9.11e-39	1.38e-35	-0.47	-0.39	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
BRCA	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	13.57	9.14e-39	1.39e-35	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
BRCA	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	13.57	9.3e-39	1.41e-35	0.47	0.39	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-13.57	9.48e-39	1.44e-35	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
BRCA	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	13.57	9.52e-39	1.45e-35	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
BRCA	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	13.57	9.97e-39	1.51e-35	0.47	0.39	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
BRCA	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	13.57	1e-38	1.52e-35	0.5	0.39	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	13.56	1.03e-38	1.56e-35	0.5	0.39	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
BRCA	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-13.56	1.09e-38	1.66e-35	-0.48	-0.39	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
BRCA	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	13.55	1.14e-38	1.73e-35	0.42	0.39	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
BRCA	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	13.55	1.16e-38	1.76e-35	0.48	0.39	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
BRCA	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-13.55	1.18e-38	1.79e-35	-0.43	-0.39	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
BRCA	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-13.55	1.22e-38	1.85e-35	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-13.54	1.3e-38	1.96e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
BRCA	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	13.54	1.33e-38	2.01e-35	0.53	0.39	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
BRCA	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	13.54	1.39e-38	2.11e-35	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	13.54	1.43e-38	2.16e-35	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
BRCA	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-13.53	1.46e-38	2.2e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
BRCA	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-13.53	1.48e-38	2.23e-35	-0.4	-0.39	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	13.53	1.59e-38	2.39e-35	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
BRCA	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-13.53	1.61e-38	2.42e-35	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-13.52	1.69e-38	2.55e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
BRCA	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-13.52	1.7e-38	2.55e-35	-0.4	-0.39	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
BRCA	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-13.52	1.77e-38	2.67e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
BRCA	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-13.52	1.8e-38	2.71e-35	-0.54	-0.39	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-13.51	1.92e-38	2.88e-35	-0.51	-0.39	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-13.51	1.93e-38	2.9e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
BRCA	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-13.51	1.94e-38	2.91e-35	-0.55	-0.39	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
BRCA	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	13.51	1.95e-38	2.93e-35	0.43	0.39	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
BRCA	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	13.51	1.96e-38	2.94e-35	0.43	0.39	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
BRCA	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-13.51	1.98e-38	2.97e-35	-0.49	-0.39	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-13.51	2.01e-38	3.02e-35	-0.48	-0.39	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
BRCA	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	13.51	2.02e-38	3.03e-35	0.44	0.39	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	13.5	2.05e-38	3.07e-35	0.53	0.39	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
BRCA	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-13.5	2.06e-38	3.09e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	13.5	2.11e-38	3.16e-35	0.47	0.39	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-13.5	2.24e-38	3.35e-35	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
BRCA	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-13.5	2.24e-38	3.36e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-13.5	2.25e-38	3.37e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
BRCA	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-13.49	2.28e-38	3.42e-35	-0.48	-0.39	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-13.49	2.28e-38	3.42e-35	-0.48	-0.39	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
BRCA	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-13.49	2.29e-38	3.42e-35	-0.54	-0.39	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-13.49	2.29e-38	3.42e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
BRCA	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-13.49	2.36e-38	3.53e-35	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	13.49	2.4e-38	3.6e-35	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
BRCA	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-13.49	2.47e-38	3.69e-35	-0.66	-0.39	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
BRCA	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	13.49	2.53e-38	3.78e-35	0.74	0.39	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
BRCA	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-13.49	2.55e-38	3.81e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	13.48	2.58e-38	3.85e-35	0.48	0.39	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	13.48	2.61e-38	3.91e-35	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
BRCA	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-13.48	2.7e-38	4.03e-35	-0.59	-0.39	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
BRCA	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-13.48	2.73e-38	4.07e-35	-0.55	-0.39	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
BRCA	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-13.48	2.73e-38	4.07e-35	-0.41	-0.39	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
BRCA	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-13.48	2.84e-38	4.23e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
BRCA	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-13.48	2.85e-38	4.25e-35	-0.66	-0.39	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	13.47	2.97e-38	4.43e-35	0.4	0.39	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
BRCA	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-13.47	2.98e-38	4.44e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-13.47	2.98e-38	4.44e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
BRCA	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-13.46	3.25e-38	4.84e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
BRCA	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	13.46	3.27e-38	4.88e-35	0.47	0.38	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
BRCA	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-13.46	3.32e-38	4.94e-35	-0.4	-0.38	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
BRCA	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.34e-38	4.97e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.34e-38	4.97e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
BRCA	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-13.46	3.42e-38	5.08e-35	-0.4	-0.38	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.43e-38	5.1e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
BRCA	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	13.46	3.44e-38	5.12e-35	0.4	0.38	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
BRCA	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.53e-38	5.25e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
BRCA	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-13.46	3.58e-38	5.33e-35	-0.55	-0.38	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
BRCA	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	13.45	3.65e-38	5.43e-35	0.41	0.38	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
BRCA	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	13.45	3.81e-38	5.66e-35	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
BRCA	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-13.45	3.82e-38	5.67e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-13.45	3.82e-38	5.67e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	13.44	4.08e-38	6.06e-35	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	13.44	4.08e-38	6.06e-35	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-13.44	4.12e-38	6.12e-35	-0.48	-0.38	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
BRCA	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	13.44	4.19e-38	6.22e-35	0.59	0.38	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
BRCA	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	13.44	4.22e-38	6.26e-35	0.4	0.38	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
BRCA	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-13.44	4.23e-38	6.27e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
BRCA	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	13.44	4.26e-38	6.32e-35	0.41	0.38	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-13.44	4.47e-38	6.63e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.59e-38	6.8e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.82e-38	7.13e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.86e-38	7.19e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
BRCA	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	13.42	5.14e-38	7.6e-35	0.39	0.38	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
BRCA	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-13.42	5.39e-38	7.97e-35	-0.51	-0.38	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
BRCA	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	13.42	5.54e-38	8.18e-35	0.46	0.38	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
BRCA	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	13.42	5.72e-38	8.45e-35	0.41	0.38	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
BRCA	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-13.41	5.89e-38	8.69e-35	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
BRCA	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	13.41	5.92e-38	8.73e-35	0.41	0.38	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
BRCA	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-13.41	6.09e-38	8.98e-35	-0.45	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
BRCA	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-13.41	6.14e-38	9.05e-35	-0.6	-0.38	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
BRCA	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-13.41	6.2e-38	9.14e-35	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	13.41	6.2e-38	9.14e-35	0.45	0.38	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-13.41	6.32e-38	9.31e-35	-0.54	-0.38	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
BRCA	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-13.4	6.48e-38	9.54e-35	-0.46	-0.38	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-13.4	6.48e-38	9.54e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
BRCA	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-13.4	6.66e-38	9.82e-35	-0.51	-0.38	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-13.4	6.68e-38	9.83e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
BRCA	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	13.4	6.69e-38	9.85e-35	0.57	0.38	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
BRCA	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-13.4	6.85e-38	1.01e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
BRCA	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	13.4	6.92e-38	1.02e-34	0.4	0.38	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-13.4	6.97e-38	1.03e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	13.4	7.04e-38	1.04e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
BRCA	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	13.4	7.13e-38	1.05e-34	0.41	0.38	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-13.39	7.55e-38	1.11e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	13.39	7.59e-38	1.11e-34	0.48	0.38	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
BRCA	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	13.39	7.72e-38	1.13e-34	0.59	0.38	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	13.39	7.76e-38	1.14e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	13.39	7.76e-38	1.14e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
BRCA	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-13.39	7.87e-38	1.16e-34	-0.46	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
BRCA	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-13.38	8.11e-38	1.19e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	13.38	8.23e-38	1.21e-34	0.48	0.38	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
BRCA	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-13.38	8.66e-38	1.27e-34	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-13.38	8.72e-38	1.28e-34	-0.53	-0.38	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
BRCA	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	13.38	8.77e-38	1.29e-34	0.72	0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
BRCA	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-13.38	8.96e-38	1.31e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	13.37	9.09e-38	1.33e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
BRCA	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-13.37	9.45e-38	1.38e-34	-0.47	-0.38	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
BRCA	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-13.37	9.6e-38	1.4e-34	-0.43	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
BRCA	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	13.37	9.9e-38	1.45e-34	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
BRCA	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-13.37	1e-37	1.46e-34	-0.64	-0.38	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
BRCA	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.37	1.01e-37	1.48e-34	-0.47	-0.38	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
BRCA	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-13.36	1.04e-37	1.53e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	13.36	1.1e-37	1.6e-34	0.49	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
BRCA	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	13.36	1.12e-37	1.63e-34	0.49	0.38	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
BRCA	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-13.36	1.13e-37	1.65e-34	-0.52	-0.38	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-13.36	1.13e-37	1.65e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-13.35	1.16e-37	1.69e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
BRCA	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	13.35	1.21e-37	1.76e-34	0.45	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
BRCA	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-13.35	1.25e-37	1.82e-34	-0.44	-0.38	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
BRCA	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-13.35	1.25e-37	1.82e-34	-0.45	-0.38	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
BRCA	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	13.35	1.26e-37	1.83e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	13.34	1.31e-37	1.91e-34	0.48	0.38	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
BRCA	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-13.34	1.33e-37	1.94e-34	-0.49	-0.38	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
BRCA	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-37	2.13e-34	-0.47	-0.38	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-13.33	1.47e-37	2.14e-34	-0.53	-0.38	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
BRCA	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-13.33	1.53e-37	2.22e-34	-0.51	-0.38	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
BRCA	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
BRCA	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-13.32	1.66e-37	2.41e-34	-0.52	-0.38	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
BRCA	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	13.32	1.74e-37	2.52e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	13.31	1.86e-37	2.7e-34	0.5	0.38	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
BRCA	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	13.31	1.9e-37	2.75e-34	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	13.31	1.9e-37	2.75e-34	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
BRCA	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-13.31	1.95e-37	2.82e-34	-0.44	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
BRCA	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	13.31	2e-37	2.9e-34	0.39	0.38	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	13.3	2.18e-37	3.15e-34	0.48	0.38	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
BRCA	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-13.29	2.39e-37	3.45e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
BRCA	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	13.29	2.39e-37	3.46e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
BRCA	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-13.29	2.4e-37	3.46e-34	-0.56	-0.38	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-13.29	2.52e-37	3.64e-34	-0.51	-0.38	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
BRCA	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
BRCA	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-13.28	2.79e-37	4.03e-34	-0.45	-0.38	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
BRCA	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-13.28	2.81e-37	4.05e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
BRCA	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-13.27	2.96e-37	4.26e-34	-0.58	-0.38	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
BRCA	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-13.27	3.1e-37	4.46e-34	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
BRCA	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-13.26	3.22e-37	4.64e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-13.26	3.33e-37	4.79e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	13.26	3.34e-37	4.81e-34	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
BRCA	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-13.26	3.38e-37	4.87e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
BRCA	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-13.26	3.57e-37	5.13e-34	-0.46	-0.38	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
BRCA	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-13.25	3.63e-37	5.21e-34	-0.44	-0.38	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-13.25	3.63e-37	5.21e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
BRCA	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-13.25	3.71e-37	5.33e-34	-0.46	-0.38	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
BRCA	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-13.25	3.73e-37	5.35e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
BRCA	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-13.25	3.73e-37	5.35e-34	-0.54	-0.38	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
BRCA	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	13.25	3.78e-37	5.42e-34	0.51	0.38	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
BRCA	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-13.25	3.86e-37	5.54e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-13.25	3.91e-37	5.6e-34	-0.42	-0.38	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-13.25	3.96e-37	5.67e-34	-0.42	-0.38	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
BRCA	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-13.25	3.99e-37	5.72e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
BRCA	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-13.24	4.02e-37	5.76e-34	-0.44	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
BRCA	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	13.24	4.02e-37	5.76e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	13.24	4.02e-37	5.76e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
BRCA	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-13.24	4.08e-37	5.85e-34	-0.55	-0.38	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
BRCA	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-13.24	4.14e-37	5.93e-34	-0.42	-0.38	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
BRCA	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	13.24	4.22e-37	6.04e-34	0.58	0.38	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
BRCA	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	13.24	4.25e-37	6.08e-34	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
BRCA	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-13.24	4.3e-37	6.15e-34	-0.52	-0.38	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-13.24	4.35e-37	6.22e-34	-0.56	-0.38	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-13.24	4.47e-37	6.39e-34	-0.5	-0.38	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
BRCA	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	13.23	4.61e-37	6.59e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
BRCA	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	13.23	4.62e-37	6.61e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
BRCA	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-13.23	4.65e-37	6.65e-34	-0.6	-0.38	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
BRCA	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-13.23	4.7e-37	6.71e-34	-0.41	-0.38	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
BRCA	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	13.23	4.72e-37	6.75e-34	0.46	0.38	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
BRCA	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
BRCA	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-13.23	4.84e-37	6.91e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-13.23	4.86e-37	6.93e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
BRCA	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-13.22	5.15e-37	7.34e-34	-0.51	-0.38	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
BRCA	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	13.22	5.41e-37	7.71e-34	0.58	0.38	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
BRCA	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	13.22	5.58e-37	7.94e-34	0.42	0.38	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-13.21	5.66e-37	8.06e-34	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
BRCA	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	13.21	5.86e-37	8.35e-34	0.46	0.38	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
BRCA	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	13.21	5.95e-37	8.46e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
BRCA	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.21	6.22e-37	8.84e-34	-0.46	-0.38	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.21	6.22e-37	8.84e-34	-0.46	-0.38	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
BRCA	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	13.21	6.32e-37	8.98e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	13.2	6.41e-37	9.11e-34	0.44	0.38	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
BRCA	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-13.2	6.44e-37	9.16e-34	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
BRCA	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-13.2	6.45e-37	9.17e-34	-0.51	-0.38	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
BRCA	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	13.2	6.49e-37	9.22e-34	0.45	0.38	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
BRCA	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	13.2	6.49e-37	9.22e-34	0.4	0.38	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
BRCA	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	13.2	6.52e-37	9.26e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
BRCA	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-13.2	6.61e-37	9.38e-34	-0.44	-0.38	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
BRCA	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-13.2	6.67e-37	9.46e-34	-0.43	-0.38	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
BRCA	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	13.2	6.85e-37	9.72e-34	0.54	0.38	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
BRCA	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-13.2	6.88e-37	9.76e-34	-0.47	-0.38	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
BRCA	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-13.2	7.02e-37	9.96e-34	-0.42	-0.38	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
BRCA	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-13.19	7.12e-37	1.01e-33	-0.44	-0.38	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
BRCA	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	13.19	7.34e-37	1.04e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	13.19	7.89e-37	1.12e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
BRCA	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	13.18	7.97e-37	1.13e-33	0.68	0.38	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
BRCA	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	13.18	8.04e-37	1.14e-33	0.5	0.38	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	13.18	8.19e-37	1.16e-33	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-13.18	8.28e-37	1.17e-33	-0.46	-0.38	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
BRCA	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	13.18	8.36e-37	1.18e-33	0.6	0.38	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
BRCA	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-13.18	8.68e-37	1.23e-33	-0.39	-0.38	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	13.18	8.7e-37	1.23e-33	0.47	0.38	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
BRCA	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-13.17	8.92e-37	1.26e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-13.17	8.98e-37	1.27e-33	-0.45	-0.38	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	13.17	9.19e-37	1.3e-33	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
BRCA	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	13.16	1.01e-36	1.43e-33	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
BRCA	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
BRCA	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-13.16	1.08e-36	1.51e-33	-0.58	-0.38	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-13.16	1.11e-36	1.56e-33	-0.5	-0.38	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	13.15	1.12e-36	1.58e-33	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
BRCA	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-13.15	1.15e-36	1.62e-33	-0.5	-0.38	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
BRCA	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-13.15	1.18e-36	1.66e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
BRCA	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-13.15	1.19e-36	1.68e-33	-0.46	-0.38	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
BRCA	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	13.15	1.21e-36	1.7e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
BRCA	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-13.14	1.27e-36	1.78e-33	-0.47	-0.38	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
BRCA	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-13.14	1.27e-36	1.78e-33	-0.47	-0.38	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
BRCA	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.14	1.27e-36	1.79e-33	-0.46	-0.38	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
BRCA	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	13.14	1.29e-36	1.81e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
BRCA	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-13.14	1.38e-36	1.94e-33	-0.51	-0.38	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
BRCA	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-13.14	1.38e-36	1.94e-33	-0.51	-0.38	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
BRCA	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-13.13	1.42e-36	1.99e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
BRCA	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.13	1.46e-36	2.05e-33	-0.46	-0.38	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
BRCA	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-13.13	1.48e-36	2.07e-33	-0.46	-0.38	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
BRCA	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	13.12	1.6e-36	2.25e-33	0.42	0.38	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
BRCA	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-13.12	1.7e-36	2.38e-33	-0.53	-0.38	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
BRCA	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.78e-36	2.49e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-13.11	1.8e-36	2.52e-33	-0.5	-0.38	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
BRCA	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	13.11	1.81e-36	2.54e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	13.11	1.81e-36	2.54e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
BRCA	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-13.11	1.81e-36	2.54e-33	-0.46	-0.38	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
BRCA	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.87e-36	2.61e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
BRCA	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.87e-36	2.61e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
BRCA	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	13.1	1.99e-36	2.78e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	13.1	1.99e-36	2.78e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
BRCA	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	13.1	2e-36	2.79e-33	0.52	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
BRCA	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-13.1	2.06e-36	2.88e-33	-0.39	-0.38	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	13.1	2.06e-36	2.88e-33	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
BRCA	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-13.1	2.11e-36	2.94e-33	-0.64	-0.38	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
BRCA	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	13.1	2.14e-36	2.98e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-13.1	2.17e-36	3.02e-33	-0.47	-0.38	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
BRCA	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	13.1	2.2e-36	3.06e-33	0.39	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
BRCA	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-13.1	2.2e-36	3.07e-33	-0.51	-0.38	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
BRCA	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-13.09	2.31e-36	3.22e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
BRCA	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-13.09	2.32e-36	3.23e-33	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
BRCA	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-13.09	2.42e-36	3.37e-33	-0.49	-0.38	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
BRCA	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-13.09	2.46e-36	3.43e-33	-0.56	-0.38	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	13.08	2.51e-36	3.5e-33	0.43	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
BRCA	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	13.08	2.6e-36	3.62e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	13.08	2.6e-36	3.62e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-13.08	2.64e-36	3.66e-33	-0.39	-0.38	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
BRCA	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-13.08	2.69e-36	3.74e-33	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	13.08	2.71e-36	3.76e-33	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
BRCA	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-13.08	2.73e-36	3.8e-33	-0.57	-0.38	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
BRCA	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.84e-36	3.94e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
BRCA	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-13.07	2.88e-36	4e-33	-0.51	-0.38	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
BRCA	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.88e-36	4e-33	-0.4	-0.38	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
BRCA	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.88e-36	4e-33	-0.4	-0.38	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
BRCA	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	13.07	2.9e-36	4.03e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
BRCA	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-13.07	2.91e-36	4.03e-33	-0.44	-0.38	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	13.07	2.99e-36	4.15e-33	0.45	0.38	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
BRCA	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	13.07	3.07e-36	4.25e-33	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
BRCA	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	13.06	3.1e-36	4.3e-33	0.45	0.38	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
BRCA	cis	rs1426063	0.614	rs74670563	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75094656	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs115338890	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75094719	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs116304289	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75095072	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	13.05	3.63e-36	5.02e-33	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-13.05	3.68e-36	5.08e-33	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-13.05	3.71e-36	5.13e-33	-0.44	-0.37	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
BRCA	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	13.05	3.72e-36	5.15e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
BRCA	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-13.05	3.77e-36	5.21e-33	-0.44	-0.37	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-13.04	3.97e-36	5.49e-33	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
BRCA	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-13.04	4.04e-36	5.58e-33	-0.39	-0.37	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
BRCA	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	13.04	4.12e-36	5.69e-33	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
BRCA	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	13.04	4.13e-36	5.7e-33	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	13.04	4.15e-36	5.73e-33	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
BRCA	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-13.04	4.23e-36	5.83e-33	-0.39	-0.37	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
BRCA	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
BRCA	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-13.03	4.41e-36	6.09e-33	-0.52	-0.37	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	13.03	4.48e-36	6.18e-33	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
BRCA	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	13.03	4.54e-36	6.26e-33	0.44	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
BRCA	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-13.03	4.6e-36	6.34e-33	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
BRCA	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	13.03	4.66e-36	6.43e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
BRCA	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	13.03	4.72e-36	6.5e-33	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
BRCA	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	13.02	4.86e-36	6.69e-33	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
BRCA	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-13.02	5.03e-36	6.92e-33	-0.39	-0.37	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-13.02	5.09e-36	6.99e-33	-0.5	-0.37	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	13.02	5.16e-36	7.09e-33	0.47	0.37	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
BRCA	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-13.02	5.24e-36	7.2e-33	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
BRCA	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-13.02	5.26e-36	7.22e-33	-0.45	-0.37	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-13.02	5.35e-36	7.35e-33	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	13.02	5.35e-36	7.35e-33	0.46	0.37	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-13.02	5.42e-36	7.45e-33	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
BRCA	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-13.01	5.77e-36	7.92e-33	-0.59	-0.37	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
BRCA	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	13.01	5.86e-36	8.03e-33	0.57	0.37	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	13.01	5.86e-36	8.03e-33	0.45	0.37	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
BRCA	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	13.01	5.88e-36	8.07e-33	0.73	0.37	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
BRCA	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-13.01	5.97e-36	8.19e-33	-0.44	-0.37	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
BRCA	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-13	6.09e-36	8.35e-33	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
BRCA	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-13	6.22e-36	8.52e-33	-0.44	-0.37	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-13	6.22e-36	8.52e-33	-0.44	-0.37	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-13	6.25e-36	8.56e-33	-0.69	-0.37	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
BRCA	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	13	6.48e-36	8.87e-33	0.39	0.37	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
BRCA	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-13	6.67e-36	9.13e-33	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
BRCA	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	12.99	6.9e-36	9.44e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-12.99	7.25e-36	9.91e-33	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-12.99	7.39e-36	1.01e-32	-0.5	-0.37	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.99	7.56e-36	1.03e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
BRCA	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-12.98	7.82e-36	1.07e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	12.98	7.98e-36	1.09e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	12.98	7.98e-36	1.09e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	12.98	8.07e-36	1.1e-32	0.5	0.37	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
BRCA	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	12.98	8.27e-36	1.13e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-12.98	8.29e-36	1.13e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
BRCA	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.98	8.47e-36	1.16e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
BRCA	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-12.98	8.48e-36	1.16e-32	-0.56	-0.37	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
BRCA	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-12.97	8.56e-36	1.17e-32	-0.39	-0.37	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
BRCA	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-12.97	8.62e-36	1.17e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	12.97	8.72e-36	1.19e-32	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
BRCA	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-12.97	8.73e-36	1.19e-32	-0.55	-0.37	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
BRCA	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	12.97	8.9e-36	1.21e-32	0.45	0.37	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-12.97	8.98e-36	1.22e-32	-0.45	-0.37	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-12.97	9.19e-36	1.25e-32	-0.5	-0.37	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
BRCA	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-12.97	9.21e-36	1.25e-32	-0.45	-0.37	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-12.97	9.33e-36	1.27e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
BRCA	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-12.96	9.7e-36	1.32e-32	-0.5	-0.37	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
BRCA	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-12.96	9.84e-36	1.34e-32	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
BRCA	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	12.96	9.85e-36	1.34e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
BRCA	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-12.96	1e-35	1.36e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
BRCA	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	12.96	1.02e-35	1.39e-32	0.39	0.37	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
BRCA	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
BRCA	cis	rs1426063	0.614	rs77625282	ENSG00000260265.1	RP11-44F21.5	12.95	1.08e-35	1.46e-32	0.9	0.37	QT interval;	chr4:75089646	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs75112697	ENSG00000260265.1	RP11-44F21.5	12.95	1.08e-35	1.46e-32	0.9	0.37	QT interval;	chr4:75089725	chr4:75081702~75084717:-
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-12.95	1.08e-35	1.47e-32	-0.51	-0.37	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
BRCA	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	12.95	1.1e-35	1.49e-32	0.55	0.37	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-12.95	1.12e-35	1.52e-32	-0.56	-0.37	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	12.95	1.16e-35	1.57e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
BRCA	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-12.95	1.19e-35	1.62e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
BRCA	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	12.94	1.21e-35	1.64e-32	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
BRCA	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	12.94	1.23e-35	1.67e-32	0.45	0.37	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-12.94	1.24e-35	1.67e-32	-0.5	-0.37	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
BRCA	cis	rs1426063	0.614	rs6534447	ENSG00000260265.1	RP11-44F21.5	-12.94	1.26e-35	1.7e-32	-0.87	-0.37	QT interval;	chr4:75080682	chr4:75081702~75084717:-
BRCA	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	12.94	1.26e-35	1.71e-32	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
BRCA	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-12.94	1.27e-35	1.72e-32	-0.44	-0.37	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
BRCA	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	12.94	1.29e-35	1.74e-32	0.44	0.37	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	12.94	1.29e-35	1.74e-32	0.44	0.37	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
BRCA	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-12.94	1.31e-35	1.76e-32	-0.44	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
BRCA	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	12.94	1.31e-35	1.77e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
BRCA	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-12.94	1.32e-35	1.78e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-12.93	1.35e-35	1.82e-32	-0.5	-0.37	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	12.93	1.39e-35	1.87e-32	0.45	0.37	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
BRCA	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-12.93	1.41e-35	1.91e-32	-0.55	-0.37	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
BRCA	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	12.93	1.42e-35	1.92e-32	0.45	0.37	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
BRCA	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-12.93	1.43e-35	1.93e-32	-0.58	-0.37	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-12.93	1.44e-35	1.94e-32	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	12.93	1.46e-35	1.96e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-12.93	1.48e-35	1.99e-32	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
BRCA	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-12.93	1.49e-35	2.01e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-12.92	1.56e-35	2.1e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
BRCA	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	12.92	1.59e-35	2.13e-32	0.52	0.37	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
BRCA	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	12.92	1.63e-35	2.19e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	12.92	1.63e-35	2.19e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
BRCA	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-12.91	1.68e-35	2.25e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
BRCA	cis	rs1426063	0.614	rs7684790	ENSG00000260265.1	RP11-44F21.5	12.91	1.68e-35	2.26e-32	0.91	0.37	QT interval;	chr4:75090873	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs78046076	ENSG00000260265.1	RP11-44F21.5	12.91	1.68e-35	2.26e-32	0.91	0.37	QT interval;	chr4:75091818	chr4:75081702~75084717:-
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-12.91	1.74e-35	2.33e-32	-0.5	-0.37	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
BRCA	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-12.91	1.74e-35	2.33e-32	-0.44	-0.37	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-12.91	1.74e-35	2.33e-32	-0.44	-0.37	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
BRCA	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-12.91	1.8e-35	2.41e-32	-0.43	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
BRCA	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-12.91	1.86e-35	2.49e-32	-0.52	-0.37	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
BRCA	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-12.9	1.95e-35	2.61e-32	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-12.9	1.98e-35	2.65e-32	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
BRCA	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	12.9	2.02e-35	2.7e-32	0.45	0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
BRCA	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-12.9	2.02e-35	2.7e-32	-0.44	-0.37	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
BRCA	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	12.89	2.14e-35	2.87e-32	0.52	0.37	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
BRCA	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-12.89	2.19e-35	2.94e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
BRCA	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	12.89	2.2e-35	2.95e-32	0.42	0.37	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
BRCA	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-12.89	2.26e-35	3.02e-32	-0.42	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
BRCA	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	12.89	2.3e-35	3.07e-32	0.89	0.37	QT interval;	chr4:75073543	chr4:75081702~75084717:-
BRCA	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-12.89	2.32e-35	3.1e-32	-0.49	-0.37	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
BRCA	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-12.88	2.35e-35	3.14e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
BRCA	cis	rs1426063	0.614	rs76204704	ENSG00000260265.1	RP11-44F21.5	12.88	2.4e-35	3.2e-32	0.92	0.37	QT interval;	chr4:75097804	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs80030693	ENSG00000260265.1	RP11-44F21.5	12.88	2.4e-35	3.2e-32	0.92	0.37	QT interval;	chr4:75099929	chr4:75081702~75084717:-
BRCA	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-12.88	2.4e-35	3.2e-32	-0.65	-0.37	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
BRCA	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-12.88	2.4e-35	3.2e-32	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	12.88	2.44e-35	3.26e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-12.88	2.47e-35	3.29e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
BRCA	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	12.88	2.49e-35	3.32e-32	0.44	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
BRCA	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	12.88	2.57e-35	3.42e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	12.88	2.59e-35	3.45e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	12.88	2.6e-35	3.46e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	12.88	2.6e-35	3.47e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-12.87	2.65e-35	3.54e-32	-0.44	-0.37	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
BRCA	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	12.87	2.68e-35	3.57e-32	0.43	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
BRCA	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	12.87	2.71e-35	3.62e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	12.87	2.76e-35	3.67e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
BRCA	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-12.87	2.85e-35	3.8e-32	-0.46	-0.37	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
BRCA	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	12.86	2.95e-35	3.92e-32	0.44	0.37	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-12.86	2.96e-35	3.94e-32	-0.5	-0.37	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
BRCA	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-12.86	2.99e-35	3.98e-32	-0.52	-0.37	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
BRCA	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.86	3.04e-35	4.05e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
BRCA	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-12.86	3.08e-35	4.09e-32	-0.56	-0.37	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-12.86	3.08e-35	4.09e-32	-0.56	-0.37	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
BRCA	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-12.86	3.15e-35	4.19e-32	-0.44	-0.37	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-12.86	3.15e-35	4.19e-32	-0.45	-0.37	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
BRCA	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-12.86	3.24e-35	4.29e-32	-0.38	-0.37	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
BRCA	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	12.85	3.28e-35	4.35e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
BRCA	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	12.85	3.28e-35	4.36e-32	0.54	0.37	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	12.85	3.34e-35	4.43e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-12.85	3.36e-35	4.46e-32	-0.5	-0.37	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
BRCA	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-12.85	3.43e-35	4.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	12.85	3.48e-35	4.61e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-12.85	3.5e-35	4.63e-32	-0.53	-0.37	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	12.85	3.55e-35	4.7e-32	0.43	0.37	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-12.85	3.56e-35	4.72e-32	-0.5	-0.37	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
BRCA	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	12.85	3.6e-35	4.76e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	12.85	3.62e-35	4.79e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-12.84	3.73e-35	4.94e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-12.84	3.73e-35	4.94e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
BRCA	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	12.84	3.79e-35	5.01e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	12.84	3.81e-35	5.04e-32	0.45	0.37	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	12.84	3.83e-35	5.06e-32	0.54	0.37	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
BRCA	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	12.84	3.85e-35	5.09e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	12.84	3.97e-35	5.24e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
BRCA	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-12.84	3.97e-35	5.25e-32	-0.42	-0.37	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
BRCA	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	12.83	4.29e-35	5.66e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
BRCA	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-12.83	4.3e-35	5.67e-32	-0.42	-0.37	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
BRCA	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-12.83	4.41e-35	5.81e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
BRCA	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
BRCA	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-12.83	4.46e-35	5.88e-32	-0.44	-0.37	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-12.83	4.46e-35	5.88e-32	-0.44	-0.37	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
BRCA	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	12.83	4.48e-35	5.91e-32	0.45	0.37	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	12.83	4.56e-35	6e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-12.82	4.59e-35	6.05e-32	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
BRCA	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-12.82	4.61e-35	6.07e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-12.82	4.61e-35	6.07e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
BRCA	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	12.82	4.63e-35	6.09e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	12.82	4.73e-35	6.22e-32	0.45	0.37	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
BRCA	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-12.82	4.76e-35	6.26e-32	-0.6	-0.37	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
BRCA	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	12.82	4.77e-35	6.28e-32	0.4	0.37	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
BRCA	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-12.82	4.85e-35	6.38e-32	-0.5	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
BRCA	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-12.81	5.12e-35	6.72e-32	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
BRCA	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	12.81	5.21e-35	6.84e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-12.81	5.21e-35	6.84e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-12.81	5.22e-35	6.85e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
BRCA	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-12.81	5.24e-35	6.87e-32	-0.47	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
BRCA	cis	rs1426063	0.614	rs76325897	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75084747	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs76093954	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75087994	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs114977200	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75088736	chr4:75081702~75084717:-
BRCA	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	12.81	5.36e-35	7.03e-32	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
BRCA	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	12.81	5.54e-35	7.26e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
BRCA	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	12.81	5.55e-35	7.28e-32	0.42	0.37	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
BRCA	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-12.8	5.72e-35	7.49e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
BRCA	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-12.8	5.76e-35	7.54e-32	-0.56	-0.37	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
BRCA	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-12.8	5.82e-35	7.61e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
BRCA	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-12.8	5.83e-35	7.63e-32	-0.42	-0.37	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	12.8	5.96e-35	7.8e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
BRCA	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	12.8	6.01e-35	7.86e-32	0.46	0.37	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
BRCA	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	12.8	6.03e-35	7.89e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	12.8	6.05e-35	7.91e-32	0.45	0.37	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	12.8	6.08e-35	7.95e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	12.8	6.21e-35	8.12e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	12.8	6.22e-35	8.13e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	12.8	6.22e-35	8.13e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	12.8	6.31e-35	8.24e-32	0.48	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
BRCA	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	12.8	6.35e-35	8.29e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
BRCA	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	12.79	6.42e-35	8.38e-32	0.38	0.37	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
BRCA	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-12.79	6.48e-35	8.47e-32	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
BRCA	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	12.79	6.67e-35	8.7e-32	0.54	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
BRCA	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	12.79	6.68e-35	8.72e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	12.79	6.77e-35	8.81e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-12.79	6.82e-35	8.88e-32	-0.46	-0.37	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	12.79	6.89e-35	8.96e-32	0.54	0.37	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.92e-35	9e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.92e-35	9e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
BRCA	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-12.79	6.96e-35	9.05e-32	-0.39	-0.37	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
BRCA	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-12.78	7.16e-35	9.31e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
BRCA	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-12.78	7.32e-35	9.52e-32	-0.52	-0.37	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
BRCA	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	12.78	7.36e-35	9.56e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	12.78	7.38e-35	9.59e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	12.78	7.57e-35	9.83e-32	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
BRCA	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	12.78	7.81e-35	1.01e-31	0.54	0.37	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	12.78	7.84e-35	1.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	12.78	7.84e-35	1.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
BRCA	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	12.78	7.92e-35	1.03e-31	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	12.77	8.34e-35	1.08e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	12.77	8.88e-35	1.15e-31	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	12.77	8.89e-35	1.15e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	12.76	9.24e-35	1.2e-31	0.45	0.37	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	12.76	9.24e-35	1.2e-31	0.45	0.37	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
BRCA	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	12.76	9.32e-35	1.21e-31	0.5	0.37	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
BRCA	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	12.76	9.8e-35	1.27e-31	0.44	0.37	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-12.76	9.8e-35	1.27e-31	-0.42	-0.37	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	12.75	1.02e-34	1.31e-31	0.43	0.37	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
BRCA	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-12.75	1.02e-34	1.32e-31	-0.46	-0.37	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
BRCA	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-12.75	1.06e-34	1.37e-31	-0.46	-0.37	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-12.75	1.08e-34	1.39e-31	-0.44	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	12.75	1.09e-34	1.4e-31	0.45	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-12.75	1.09e-34	1.41e-31	-0.49	-0.37	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	12.74	1.12e-34	1.45e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-12.74	1.13e-34	1.45e-31	-0.54	-0.37	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	12.74	1.13e-34	1.45e-31	0.45	0.37	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	12.74	1.13e-34	1.46e-31	0.44	0.37	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
BRCA	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-12.74	1.14e-34	1.47e-31	-0.42	-0.37	Height;	chr6:109501793	chr6:109382795~109383666:+
BRCA	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-12.74	1.14e-34	1.47e-31	-0.46	-0.37	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	12.74	1.14e-34	1.47e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	12.74	1.14e-34	1.47e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-12.74	1.15e-34	1.48e-31	-0.5	-0.37	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
BRCA	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-12.74	1.16e-34	1.5e-31	-0.43	-0.37	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
BRCA	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	12.74	1.16e-34	1.5e-31	0.49	0.37	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
BRCA	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	12.74	1.17e-34	1.5e-31	0.41	0.37	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
BRCA	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	12.74	1.18e-34	1.52e-31	0.48	0.37	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
BRCA	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-12.74	1.18e-34	1.52e-31	-0.44	-0.37	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
BRCA	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-12.74	1.2e-34	1.54e-31	-0.43	-0.37	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
BRCA	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	12.74	1.2e-34	1.55e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	12.74	1.23e-34	1.57e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	12.74	1.23e-34	1.57e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
BRCA	cis	rs1426063	0.614	rs7671634	ENSG00000260265.1	RP11-44F21.5	12.74	1.24e-34	1.59e-31	0.9	0.37	QT interval;	chr4:75090883	chr4:75081702~75084717:-
BRCA	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-12.74	1.24e-34	1.6e-31	-0.5	-0.37	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-12.74	1.24e-34	1.6e-31	-0.5	-0.37	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
BRCA	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	12.73	1.24e-34	1.6e-31	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
BRCA	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-12.73	1.24e-34	1.6e-31	-0.64	-0.37	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
BRCA	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
BRCA	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	12.73	1.27e-34	1.64e-31	0.4	0.37	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
BRCA	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-12.73	1.31e-34	1.69e-31	-0.48	-0.37	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
BRCA	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-12.73	1.36e-34	1.75e-31	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
BRCA	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-12.73	1.38e-34	1.76e-31	-0.43	-0.37	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
BRCA	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	12.73	1.39e-34	1.78e-31	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	12.72	1.4e-34	1.79e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	12.72	1.42e-34	1.81e-31	0.4	0.37	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	12.72	1.42e-34	1.81e-31	0.4	0.37	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
BRCA	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-12.72	1.47e-34	1.89e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
BRCA	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	12.72	1.54e-34	1.97e-31	0.42	0.37	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
BRCA	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	12.71	1.56e-34	1.99e-31	0.54	0.37	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
BRCA	cis	rs8018967	1	rs8018967	ENSG00000258408.1	NT5CP2	-12.71	1.56e-34	1.99e-31	-0.39	-0.37	Blood metabolite ratios;	chr14:73510230	chr14:73539221~73539781:-
BRCA	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	12.71	1.58e-34	2.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-12.71	1.63e-34	2.08e-31	-0.44	-0.37	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
BRCA	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-12.71	1.67e-34	2.12e-31	-0.43	-0.37	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	12.71	1.68e-34	2.14e-31	0.44	0.37	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	12.71	1.68e-34	2.14e-31	0.44	0.37	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
BRCA	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-12.7	1.73e-34	2.21e-31	-0.44	-0.37	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-12.7	1.77e-34	2.26e-31	-0.49	-0.37	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
BRCA	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-12.7	1.85e-34	2.35e-31	-0.48	-0.37	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-12.7	1.87e-34	2.38e-31	-0.56	-0.37	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	12.7	1.88e-34	2.39e-31	0.29	0.37	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	12.7	1.89e-34	2.41e-31	0.54	0.37	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	12.69	2.01e-34	2.55e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	12.69	2.06e-34	2.61e-31	0.44	0.37	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	12.69	2.06e-34	2.61e-31	0.44	0.37	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	12.69	2.12e-34	2.69e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	12.69	2.15e-34	2.72e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	12.68	2.17e-34	2.75e-31	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
BRCA	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-12.68	2.2e-34	2.78e-31	-0.44	-0.37	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
BRCA	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-12.68	2.2e-34	2.78e-31	-0.39	-0.37	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	12.68	2.29e-34	2.9e-31	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
BRCA	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-12.68	2.32e-34	2.94e-31	-0.49	-0.37	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
BRCA	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-12.68	2.34e-34	2.96e-31	-0.41	-0.37	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
BRCA	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-12.68	2.4e-34	3.04e-31	-0.49	-0.37	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
BRCA	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	12.68	2.4e-34	3.04e-31	0.48	0.37	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
BRCA	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	12.67	2.43e-34	3.07e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	12.67	2.43e-34	3.07e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	12.67	2.47e-34	3.12e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-12.67	2.54e-34	3.21e-31	-0.44	-0.37	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-12.67	2.56e-34	3.23e-31	-0.49	-0.37	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-12.67	2.6e-34	3.28e-31	-0.48	-0.37	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-12.67	2.63e-34	3.31e-31	-0.29	-0.37	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
BRCA	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
BRCA	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-12.66	2.73e-34	3.44e-31	-0.49	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
BRCA	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-12.66	2.75e-34	3.46e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
BRCA	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-12.66	2.78e-34	3.5e-31	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
BRCA	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-12.66	2.82e-34	3.55e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-12.66	2.86e-34	3.6e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
BRCA	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-12.66	2.89e-34	3.63e-31	-0.58	-0.37	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	12.66	2.95e-34	3.71e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	12.66	2.98e-34	3.75e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	12.66	2.98e-34	3.75e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	12.66	3e-34	3.78e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-12.66	3e-34	3.78e-31	-0.54	-0.36	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
BRCA	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-12.65	3.06e-34	3.84e-31	-0.41	-0.36	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
BRCA	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	12.65	3.15e-34	3.95e-31	0.53	0.36	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	12.65	3.15e-34	3.95e-31	0.53	0.36	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	12.65	3.2e-34	4.01e-31	0.44	0.36	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	12.65	3.2e-34	4.02e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-12.64	3.44e-34	4.31e-31	-0.43	-0.36	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
BRCA	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-12.64	3.48e-34	4.37e-31	-0.41	-0.36	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
BRCA	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	12.64	3.56e-34	4.46e-31	0.44	0.36	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	12.63	3.76e-34	4.71e-31	0.49	0.36	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
BRCA	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	12.63	3.82e-34	4.78e-31	0.44	0.36	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-12.63	3.87e-34	4.85e-31	-0.47	-0.36	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
BRCA	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	12.63	3.88e-34	4.86e-31	0.47	0.36	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
BRCA	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-12.63	3.88e-34	4.86e-31	-0.57	-0.36	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
BRCA	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-12.63	4.02e-34	5.03e-31	-0.48	-0.36	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
BRCA	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	12.63	4.04e-34	5.05e-31	0.44	0.36	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
BRCA	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	12.63	4.13e-34	5.16e-31	0.41	0.36	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
BRCA	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	12.63	4.18e-34	5.23e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-12.62	4.25e-34	5.32e-31	-0.44	-0.36	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
BRCA	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-12.62	4.35e-34	5.43e-31	-0.48	-0.36	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
BRCA	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	12.62	4.42e-34	5.53e-31	0.47	0.36	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
BRCA	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-12.62	4.52e-34	5.64e-31	-0.57	-0.36	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
BRCA	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-12.61	4.76e-34	5.93e-31	-0.44	-0.36	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
BRCA	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
BRCA	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-12.61	4.96e-34	6.18e-31	-0.37	-0.36	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
BRCA	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	12.61	4.98e-34	6.21e-31	0.44	0.36	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
BRCA	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	12.61	5.05e-34	6.29e-31	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
BRCA	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-12.61	5.09e-34	6.35e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-12.61	5.17e-34	6.44e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
BRCA	cis	rs1426063	0.614	rs115690958	ENSG00000260265.1	RP11-44F21.5	12.61	5.19e-34	6.46e-31	0.88	0.36	QT interval;	chr4:75078364	chr4:75081702~75084717:-
BRCA	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-12.61	5.22e-34	6.51e-31	-0.55	-0.36	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
BRCA	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	12.59	5.89e-34	7.32e-31	0.4	0.36	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	12.59	5.89e-34	7.32e-31	0.4	0.36	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
BRCA	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	12.59	5.93e-34	7.37e-31	0.44	0.36	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
BRCA	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-12.59	6.01e-34	7.47e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-12.59	6.01e-34	7.47e-31	-0.43	-0.36	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
BRCA	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	12.59	6.07e-34	7.54e-31	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
BRCA	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	12.59	6.09e-34	7.56e-31	0.5	0.36	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	12.59	6.27e-34	7.78e-31	0.45	0.36	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
BRCA	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-12.59	6.28e-34	7.8e-31	-0.47	-0.36	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-12.59	6.34e-34	7.87e-31	-0.45	-0.36	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	12.58	6.57e-34	8.14e-31	0.47	0.36	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
BRCA	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	12.58	6.57e-34	8.14e-31	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	12.58	6.71e-34	8.31e-31	0.4	0.36	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	12.58	6.71e-34	8.31e-31	0.4	0.36	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
BRCA	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-12.58	6.98e-34	8.65e-31	-0.42	-0.36	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
BRCA	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	12.58	7.21e-34	8.93e-31	0.44	0.36	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	12.58	7.21e-34	8.93e-31	0.44	0.36	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	12.58	7.23e-34	8.95e-31	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-12.57	7.31e-34	9.05e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	12.57	7.37e-34	9.13e-31	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
BRCA	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
BRCA	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-12.57	7.56e-34	9.35e-31	-0.47	-0.36	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	12.56	8.12e-34	1e-30	0.46	0.36	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
BRCA	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-12.56	8.22e-34	1.02e-30	-0.47	-0.36	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	12.56	8.24e-34	1.02e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	12.56	8.53e-34	1.05e-30	0.44	0.36	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	12.56	8.53e-34	1.05e-30	0.44	0.36	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	12.56	8.65e-34	1.07e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	12.56	8.65e-34	1.07e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	12.56	8.73e-34	1.08e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
BRCA	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	12.56	8.78e-34	1.08e-30	0.5	0.36	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
BRCA	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	12.56	8.8e-34	1.09e-30	0.42	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
BRCA	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	12.55	9.06e-34	1.12e-30	0.52	0.36	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	12.55	9.11e-34	1.12e-30	0.42	0.36	Height;	chr3:53091453	chr3:53064283~53065091:-
BRCA	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-12.55	9.14e-34	1.13e-30	-0.56	-0.36	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
BRCA	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-12.55	9.37e-34	1.15e-30	-0.42	-0.36	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	12.55	9.45e-34	1.16e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	12.55	9.45e-34	1.16e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	12.55	9.52e-34	1.17e-30	0.44	0.36	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-12.55	9.83e-34	1.21e-30	-0.53	-0.36	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-12.55	9.93e-34	1.22e-30	-0.49	-0.36	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
BRCA	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-12.55	1e-33	1.23e-30	-0.38	-0.36	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
BRCA	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-12.54	1.02e-33	1.25e-30	-0.38	-0.36	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
BRCA	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	12.54	1.03e-33	1.27e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	12.54	1.06e-33	1.3e-30	0.42	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-12.54	1.07e-33	1.32e-30	-0.45	-0.36	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
BRCA	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-12.54	1.1e-33	1.35e-30	-0.49	-0.36	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
BRCA	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-12.54	1.11e-33	1.36e-30	-0.4	-0.36	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	12.54	1.12e-33	1.37e-30	0.48	0.36	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
BRCA	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	12.53	1.17e-33	1.43e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-12.53	1.17e-33	1.44e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-12.53	1.22e-33	1.49e-30	-0.43	-0.36	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
BRCA	cis	rs10885997	0.626	rs2301179	ENSG00000266200.5	PNLIPRP2	-12.53	1.23e-33	1.5e-30	-0.42	-0.36	Phospholipid levels (plasma);	chr10:116645109	chr10:116620953~116645143:+
BRCA	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
BRCA	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	12.52	1.28e-33	1.57e-30	0.71	0.36	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	12.52	1.3e-33	1.6e-30	0.73	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
BRCA	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	12.52	1.33e-33	1.63e-30	0.44	0.36	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	12.51	1.43e-33	1.75e-30	0.44	0.36	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-12.51	1.45e-33	1.77e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
BRCA	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	12.51	1.48e-33	1.81e-30	0.44	0.36	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
BRCA	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	12.51	1.5e-33	1.83e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
BRCA	cis	rs1426063	0.614	rs78681370	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081556	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs17000212	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081611	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs77018380	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081621	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	12.51	1.55e-33	1.89e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-12.51	1.55e-33	1.9e-30	-0.47	-0.36	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	12.5	1.6e-33	1.96e-30	0.53	0.36	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	12.5	1.6e-33	1.96e-30	0.53	0.36	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
BRCA	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	12.5	1.6e-33	1.96e-30	0.32	0.36	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
BRCA	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	12.5	1.64e-33	2e-30	0.46	0.36	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-12.5	1.67e-33	2.03e-30	-0.46	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
BRCA	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-12.5	1.7e-33	2.07e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-12.5	1.7e-33	2.07e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
BRCA	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	12.5	1.72e-33	2.09e-30	0.48	0.36	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
BRCA	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-12.5	1.74e-33	2.11e-30	-0.42	-0.36	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-12.5	1.74e-33	2.11e-30	-0.42	-0.36	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
BRCA	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-12.5	1.74e-33	2.12e-30	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	12.49	1.75e-33	2.13e-30	0.29	0.36	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-12.49	1.78e-33	2.17e-30	-0.54	-0.36	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
BRCA	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-12.49	1.79e-33	2.17e-30	-0.49	-0.36	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	12.49	1.87e-33	2.27e-30	0.53	0.36	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	12.49	1.87e-33	2.27e-30	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
BRCA	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	12.49	1.9e-33	2.3e-30	0.44	0.36	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	12.49	1.9e-33	2.31e-30	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	12.49	1.91e-33	2.31e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
BRCA	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	12.48	1.97e-33	2.39e-30	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
BRCA	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	12.48	1.98e-33	2.4e-30	0.47	0.36	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	12.48	1.98e-33	2.4e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
BRCA	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-12.48	2.05e-33	2.48e-30	-0.44	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
BRCA	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	12.48	2.05e-33	2.49e-30	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
BRCA	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	12.48	2.05e-33	2.49e-30	0.47	0.36	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	12.48	2.1e-33	2.55e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-12.48	2.11e-33	2.56e-30	-0.53	-0.36	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
BRCA	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	12.48	2.17e-33	2.63e-30	0.45	0.36	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
BRCA	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	12.47	2.29e-33	2.77e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-12.47	2.38e-33	2.88e-30	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-12.47	2.4e-33	2.9e-30	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
BRCA	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	12.46	2.45e-33	2.96e-30	0.52	0.36	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	12.46	2.45e-33	2.96e-30	0.52	0.36	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	12.46	2.46e-33	2.97e-30	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
BRCA	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	12.46	2.49e-33	3e-30	0.39	0.36	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
BRCA	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-12.46	2.5e-33	3.02e-30	-0.48	-0.36	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-12.46	2.51e-33	3.04e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-12.46	2.52e-33	3.04e-30	-0.42	-0.36	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
BRCA	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-12.46	2.52e-33	3.04e-30	-0.42	-0.36	Height;	chr3:53069965	chr3:53064283~53065091:-
BRCA	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	12.46	2.53e-33	3.05e-30	0.44	0.36	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	12.46	2.56e-33	3.09e-30	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-12.46	2.62e-33	3.16e-30	-0.46	-0.36	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
BRCA	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	12.46	2.66e-33	3.2e-30	0.44	0.36	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
BRCA	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	12.45	2.8e-33	3.38e-30	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
BRCA	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-12.45	2.82e-33	3.39e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	12.45	2.83e-33	3.41e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-12.45	2.85e-33	3.43e-30	-0.53	-0.36	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	12.45	2.87e-33	3.45e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	12.45	2.92e-33	3.51e-30	0.45	0.36	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-12.45	2.95e-33	3.55e-30	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
BRCA	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	12.45	2.95e-33	3.55e-30	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-12.45	2.96e-33	3.56e-30	-0.45	-0.36	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	12.44	3.05e-33	3.66e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	12.44	3.05e-33	3.67e-30	0.44	0.36	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
BRCA	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-12.44	3.06e-33	3.67e-30	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
BRCA	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	12.44	3.08e-33	3.7e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-12.44	3.09e-33	3.71e-30	-0.46	-0.36	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	12.44	3.1e-33	3.71e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
BRCA	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	12.44	3.3e-33	3.96e-30	0.38	0.36	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-12.43	3.37e-33	4.03e-30	-0.46	-0.36	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	12.43	3.4e-33	4.07e-30	0.41	0.36	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
BRCA	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	12.43	3.42e-33	4.09e-30	0.53	0.36	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
BRCA	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-12.43	3.45e-33	4.12e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-12.43	3.45e-33	4.12e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-12.43	3.47e-33	4.14e-30	-0.42	-0.36	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
BRCA	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	12.43	3.48e-33	4.17e-30	0.44	0.36	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
BRCA	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-12.43	3.59e-33	4.3e-30	-0.46	-0.36	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
BRCA	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-12.43	3.6e-33	4.3e-30	-0.44	-0.36	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
BRCA	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-12.43	3.6e-33	4.3e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
BRCA	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-12.43	3.63e-33	4.34e-30	-0.44	-0.36	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-12.43	3.68e-33	4.39e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	12.43	3.69e-33	4.41e-30	0.42	0.36	Height;	chr6:109407238	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-12.42	3.75e-33	4.48e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-12.42	3.75e-33	4.48e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
BRCA	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	12.42	3.77e-33	4.5e-30	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
BRCA	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-12.42	3.83e-33	4.57e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
BRCA	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-12.42	3.91e-33	4.67e-30	-0.44	-0.36	Height;	chr3:52971094	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	12.42	3.96e-33	4.72e-30	0.41	0.36	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-12.42	3.96e-33	4.72e-30	-0.49	-0.36	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	12.42	3.97e-33	4.73e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	12.42	4.02e-33	4.79e-30	0.53	0.36	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
BRCA	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.42	4.07e-33	4.85e-30	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
BRCA	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-12.42	4.1e-33	4.89e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-12.42	4.1e-33	4.89e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
BRCA	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-12.42	4.14e-33	4.92e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
BRCA	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-12.42	4.17e-33	4.96e-30	-0.46	-0.36	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
BRCA	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-12.41	4.2e-33	5e-30	-0.44	-0.36	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
BRCA	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	12.41	4.46e-33	5.3e-30	0.32	0.36	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
BRCA	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-12.41	4.49e-33	5.34e-30	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
BRCA	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-12.41	4.51e-33	5.35e-30	-0.44	-0.36	Height;	chr3:53015087	chr3:53064283~53065091:-
BRCA	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-12.41	4.57e-33	5.43e-30	-0.37	-0.36	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
BRCA	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-12.4	4.69e-33	5.57e-30	-0.46	-0.36	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
BRCA	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-12.4	4.75e-33	5.64e-30	-0.46	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
BRCA	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-12.4	4.81e-33	5.71e-30	-0.46	-0.36	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
BRCA	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-12.4	4.91e-33	5.83e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
BRCA	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-12.4	4.94e-33	5.86e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	12.4	4.98e-33	5.91e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-12.4	5e-33	5.93e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
BRCA	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.4	5.04e-33	5.97e-30	-0.4	-0.36	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
BRCA	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	12.4	5.06e-33	6e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	12.4	5.06e-33	6e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
BRCA	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-12.4	5.08e-33	6.02e-30	-0.44	-0.36	Height;	chr3:53064759	chr3:53064283~53065091:-
BRCA	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-12.4	5.13e-33	6.08e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-12.4	5.13e-33	6.08e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-12.39	5.25e-33	6.22e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	12.39	5.28e-33	6.26e-30	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	12.39	5.41e-33	6.4e-30	0.41	0.36	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	12.39	5.42e-33	6.42e-30	0.28	0.36	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
BRCA	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-12.39	5.43e-33	6.43e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
BRCA	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	12.39	5.49e-33	6.49e-30	0.52	0.36	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
BRCA	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	12.39	5.58e-33	6.6e-30	0.51	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
BRCA	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	12.39	5.6e-33	6.63e-30	0.52	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
BRCA	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	12.39	5.69e-33	6.73e-30	0.39	0.36	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
BRCA	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	12.39	5.7e-33	6.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	12.39	5.7e-33	6.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	12.39	5.75e-33	6.79e-30	0.41	0.36	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
BRCA	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	12.39	5.76e-33	6.8e-30	0.51	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
BRCA	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	12.39	5.77e-33	6.81e-30	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-12.39	5.77e-33	6.82e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
BRCA	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-12.38	5.84e-33	6.89e-30	-0.42	-0.36	Height;	chr6:109497253	chr6:109382795~109383666:+
BRCA	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-12.38	5.87e-33	6.92e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
BRCA	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-12.38	5.88e-33	6.94e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	12.38	5.93e-33	7e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-12.38	6.15e-33	7.25e-30	-0.46	-0.36	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
BRCA	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-12.38	6.16e-33	7.26e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
BRCA	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-12.38	6.18e-33	7.29e-30	-0.53	-0.36	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-12.38	6.18e-33	7.29e-30	-0.53	-0.36	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
BRCA	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-12.38	6.28e-33	7.4e-30	-0.46	-0.36	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	12.38	6.3e-33	7.43e-30	0.41	0.36	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
BRCA	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	12.38	6.35e-33	7.48e-30	0.47	0.36	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
BRCA	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-12.38	6.36e-33	7.5e-30	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
BRCA	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	12.38	6.4e-33	7.54e-30	0.43	0.36	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-12.37	6.48e-33	7.63e-30	-0.46	-0.36	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	12.37	6.55e-33	7.71e-30	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
BRCA	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-12.37	6.62e-33	7.79e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-12.37	6.62e-33	7.79e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
BRCA	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-12.37	6.91e-33	8.12e-30	-0.48	-0.36	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
BRCA	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-12.37	7.19e-33	8.44e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
BRCA	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-12.36	7.25e-33	8.52e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
BRCA	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-12.36	7.34e-33	8.61e-30	-0.54	-0.36	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	12.36	7.42e-33	8.71e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
BRCA	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	12.36	7.45e-33	8.74e-30	0.45	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-12.36	7.5e-33	8.8e-30	-0.46	-0.36	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
BRCA	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-12.36	7.5e-33	8.8e-30	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	12.36	7.58e-33	8.89e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	12.36	7.61e-33	8.93e-30	0.39	0.36	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	12.36	7.66e-33	8.98e-30	0.41	0.36	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-12.36	7.76e-33	9.09e-30	-0.48	-0.36	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
BRCA	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	12.36	7.76e-33	9.1e-30	0.43	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
BRCA	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-12.36	7.84e-33	9.18e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	12.36	7.87e-33	9.22e-30	0.41	0.36	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-12.36	7.88e-33	9.23e-30	-0.53	-0.36	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
BRCA	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-12.36	7.89e-33	9.24e-30	-0.46	-0.36	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-12.36	7.99e-33	9.35e-30	-0.54	-0.36	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	12.35	8.05e-33	9.42e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-12.35	8.05e-33	9.42e-30	-0.48	-0.36	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
BRCA	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-12.35	8.14e-33	9.53e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-12.35	8.14e-33	9.53e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
BRCA	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-12.35	8.17e-33	9.56e-30	-0.43	-0.36	Height;	chr3:52967831	chr3:53064283~53065091:-
BRCA	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	12.35	8.32e-33	9.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
BRCA	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-12.35	8.4e-33	9.83e-30	-0.48	-0.36	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
BRCA	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-12.35	8.44e-33	9.87e-30	-0.41	-0.36	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	12.35	8.44e-33	9.88e-30	0.25	0.36	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
BRCA	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	12.35	8.54e-33	9.98e-30	0.32	0.36	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
BRCA	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-12.35	8.59e-33	1e-29	-0.49	-0.36	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
BRCA	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	12.35	8.65e-33	1.01e-29	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
BRCA	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	12.35	8.78e-33	1.03e-29	0.32	0.36	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	12.35	8.85e-33	1.03e-29	0.35	0.36	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
BRCA	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-12.35	8.92e-33	1.04e-29	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-12.35	8.93e-33	1.04e-29	-0.54	-0.36	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
BRCA	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-12.34	9e-33	1.05e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	12.34	9.06e-33	1.06e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	12.34	9.06e-33	1.06e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
BRCA	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.34	9.25e-33	1.08e-29	-0.37	-0.36	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-12.34	9.26e-33	1.08e-29	-0.41	-0.36	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	12.34	9.37e-33	1.09e-29	0.25	0.36	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
BRCA	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.47e-33	1.1e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.47e-33	1.1e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
BRCA	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-12.34	9.61e-33	1.12e-29	-0.56	-0.36	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
BRCA	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.65e-33	1.12e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.65e-33	1.12e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	12.34	9.76e-33	1.14e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	12.34	9.82e-33	1.14e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.86e-33	1.15e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-12.33	9.98e-33	1.16e-29	-0.47	-0.36	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
BRCA	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	12.33	1.02e-32	1.19e-29	0.42	0.36	Height;	chr3:53085313	chr3:53064283~53065091:-
BRCA	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-12.33	1.03e-32	1.2e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
BRCA	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	12.33	1.05e-32	1.22e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	12.33	1.06e-32	1.23e-29	0.52	0.36	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-12.33	1.07e-32	1.24e-29	-0.44	-0.36	Height;	chr3:53080524	chr3:53064283~53065091:-
BRCA	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	12.33	1.07e-32	1.24e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-12.33	1.07e-32	1.24e-29	-0.55	-0.36	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
BRCA	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	12.33	1.07e-32	1.24e-29	0.41	0.36	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
BRCA	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-12.33	1.07e-32	1.24e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
BRCA	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-12.33	1.07e-32	1.24e-29	-0.44	-0.36	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-12.32	1.11e-32	1.29e-29	-0.58	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
BRCA	cis	rs1426063	0.614	rs75846524	ENSG00000260265.1	RP11-44F21.5	12.32	1.12e-32	1.3e-29	0.88	0.36	QT interval;	chr4:75083172	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	12.32	1.14e-32	1.32e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-12.32	1.15e-32	1.33e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	12.32	1.16e-32	1.35e-29	0.41	0.36	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-12.32	1.16e-32	1.35e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
BRCA	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	12.32	1.18e-32	1.37e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
BRCA	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-12.32	1.2e-32	1.39e-29	-0.43	-0.36	Height;	chr3:52989412	chr3:53064283~53065091:-
BRCA	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	12.32	1.21e-32	1.4e-29	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
BRCA	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-12.32	1.21e-32	1.41e-29	-0.49	-0.36	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-12.32	1.22e-32	1.41e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-12.32	1.23e-32	1.43e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
BRCA	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-12.32	1.24e-32	1.43e-29	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
BRCA	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	12.31	1.24e-32	1.43e-29	0.42	0.36	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
BRCA	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	12.31	1.25e-32	1.45e-29	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
BRCA	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	12.31	1.25e-32	1.45e-29	0.45	0.36	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-12.31	1.26e-32	1.46e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
BRCA	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-12.31	1.26e-32	1.46e-29	-0.41	-0.36	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-12.31	1.26e-32	1.46e-29	-0.53	-0.36	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
BRCA	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	12.31	1.27e-32	1.47e-29	0.46	0.36	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	12.31	1.29e-32	1.49e-29	0.28	0.36	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	12.31	1.29e-32	1.5e-29	0.48	0.36	Depression;	chr6:28159843	chr6:28073316~28074233:+
BRCA	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	12.31	1.3e-32	1.5e-29	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	12.31	1.3e-32	1.51e-29	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
BRCA	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-12.31	1.3e-32	1.51e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
BRCA	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-12.31	1.31e-32	1.51e-29	-0.44	-0.36	Height;	chr3:53007328	chr3:53064283~53065091:-
BRCA	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	12.31	1.31e-32	1.52e-29	0.43	0.36	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	12.31	1.34e-32	1.55e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-12.3	1.38e-32	1.6e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-12.3	1.4e-32	1.62e-29	-0.41	-0.36	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	12.3	1.4e-32	1.62e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	12.3	1.41e-32	1.62e-29	0.52	0.36	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
BRCA	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	12.3	1.41e-32	1.62e-29	0.45	0.36	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	12.3	1.41e-32	1.63e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	12.3	1.42e-32	1.64e-29	0.41	0.36	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-12.3	1.42e-32	1.64e-29	-0.46	-0.36	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-12.3	1.42e-32	1.64e-29	-0.46	-0.36	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
BRCA	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-12.3	1.43e-32	1.65e-29	-0.57	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
BRCA	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	12.3	1.44e-32	1.66e-29	0.44	0.36	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
BRCA	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	12.3	1.44e-32	1.66e-29	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
BRCA	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-12.3	1.44e-32	1.66e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	12.3	1.46e-32	1.69e-29	0.48	0.36	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	12.3	1.46e-32	1.69e-29	0.41	0.36	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	12.3	1.5e-32	1.73e-29	0.48	0.36	Depression;	chr6:28161802	chr6:28073316~28074233:+
BRCA	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-12.3	1.5e-32	1.73e-29	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
BRCA	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	12.3	1.5e-32	1.73e-29	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
BRCA	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	12.3	1.51e-32	1.74e-29	0.47	0.36	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
BRCA	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	12.3	1.51e-32	1.74e-29	0.52	0.36	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-12.3	1.52e-32	1.75e-29	-0.44	-0.36	Height;	chr3:53009621	chr3:53064283~53065091:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-12.3	1.54e-32	1.77e-29	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	12.3	1.54e-32	1.77e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	12.29	1.55e-32	1.78e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
BRCA	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-12.29	1.56e-32	1.8e-29	-0.46	-0.36	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-12.29	1.56e-32	1.8e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-12.29	1.57e-32	1.81e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-12.29	1.58e-32	1.82e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
BRCA	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	12.29	1.6e-32	1.84e-29	0.37	0.36	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
BRCA	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-12.29	1.6e-32	1.84e-29	-0.48	-0.36	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	12.29	1.61e-32	1.85e-29	0.48	0.36	Depression;	chr6:28159925	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	12.29	1.61e-32	1.85e-29	0.48	0.36	Depression;	chr6:28159932	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	12.29	1.63e-32	1.88e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
BRCA	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-12.29	1.66e-32	1.9e-29	-0.47	-0.36	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	12.29	1.67e-32	1.91e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
BRCA	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	12.28	1.77e-32	2.03e-29	0.44	0.36	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
BRCA	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-12.28	1.77e-32	2.03e-29	-0.41	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
BRCA	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-12.28	1.78e-32	2.04e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	12.28	1.78e-32	2.05e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	12.28	1.78e-32	2.05e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28154567	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28156691	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28158424	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28159056	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28162053	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-12.28	1.84e-32	2.11e-29	-0.41	-0.36	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-12.28	1.84e-32	2.11e-29	-0.41	-0.36	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-12.28	1.85e-32	2.12e-29	-0.42	-0.36	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-12.28	1.87e-32	2.14e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
BRCA	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	12.28	1.9e-32	2.18e-29	0.44	0.36	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	12.27	1.91e-32	2.18e-29	0.43	0.36	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
BRCA	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-12.27	1.91e-32	2.19e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-12.27	1.91e-32	2.19e-29	-0.41	-0.36	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-12.27	1.91e-32	2.19e-29	-0.41	-0.36	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-12.27	1.92e-32	2.19e-29	-0.45	-0.36	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-12.27	1.94e-32	2.21e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
BRCA	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	12.27	1.94e-32	2.22e-29	0.4	0.36	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
BRCA	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-12.27	1.95e-32	2.23e-29	-0.41	-0.36	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	12.27	1.95e-32	2.23e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	12.27	1.96e-32	2.24e-29	0.41	0.36	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
BRCA	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-12.27	1.96e-32	2.24e-29	-0.46	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
BRCA	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-12.27	1.96e-32	2.24e-29	-0.53	-0.36	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	12.27	2e-32	2.28e-29	0.41	0.36	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
BRCA	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-12.27	2.09e-32	2.39e-29	-0.49	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
BRCA	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	12.27	2.1e-32	2.4e-29	0.44	0.36	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
BRCA	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-12.27	2.1e-32	2.4e-29	-0.37	-0.36	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	12.26	2.13e-32	2.44e-29	0.41	0.36	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
BRCA	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-12.26	2.14e-32	2.44e-29	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	12.26	2.19e-32	2.5e-29	0.41	0.36	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-12.26	2.23e-32	2.54e-29	-0.41	-0.36	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
BRCA	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	12.26	2.24e-32	2.55e-29	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28163375	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28163759	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164580	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164825	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164948	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28165025	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28165528	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	12.26	2.32e-32	2.64e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	12.26	2.34e-32	2.67e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
BRCA	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	12.25	2.44e-32	2.77e-29	0.4	0.35	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28173770	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28174809	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28175233	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28176973	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-12.25	2.5e-32	2.84e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-12.25	2.51e-32	2.85e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-12.25	2.52e-32	2.87e-29	-0.41	-0.35	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	12.25	2.53e-32	2.88e-29	0.41	0.35	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-12.25	2.53e-32	2.88e-29	-0.49	-0.35	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
BRCA	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	12.25	2.57e-32	2.92e-29	0.46	0.35	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
BRCA	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-12.25	2.58e-32	2.93e-29	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
BRCA	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-12.25	2.59e-32	2.94e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	12.25	2.6e-32	2.95e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	12.25	2.6e-32	2.95e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-12.25	2.63e-32	2.99e-29	-0.41	-0.35	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-12.25	2.63e-32	2.99e-29	-0.41	-0.35	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-12.24	2.64e-32	3e-29	-0.53	-0.35	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
BRCA	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-12.24	2.65e-32	3.01e-29	-0.48	-0.35	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	12.24	2.65e-32	3.01e-29	0.48	0.35	Depression;	chr6:28143758	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	12.24	2.65e-32	3.01e-29	0.48	0.35	Depression;	chr6:28144784	chr6:28073316~28074233:+
BRCA	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	12.24	2.68e-32	3.04e-29	0.46	0.35	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-12.24	2.7e-32	3.06e-29	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	12.24	2.71e-32	3.08e-29	0.48	0.35	Depression;	chr6:28145952	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	12.24	2.72e-32	3.09e-29	0.47	0.35	Depression;	chr6:28180209	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-12.24	2.72e-32	3.09e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
BRCA	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	12.24	2.74e-32	3.11e-29	0.51	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
BRCA	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-12.24	2.78e-32	3.15e-29	-0.38	-0.35	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
BRCA	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	12.24	2.85e-32	3.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	12.24	2.86e-32	3.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	12.24	2.87e-32	3.25e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-12.24	2.87e-32	3.25e-29	-0.49	-0.35	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	12.24	2.87e-32	3.26e-29	0.41	0.35	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-12.24	2.9e-32	3.29e-29	-0.58	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	12.24	2.9e-32	3.29e-29	0.28	0.35	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	12.24	2.9e-32	3.29e-29	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
BRCA	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	12.24	2.91e-32	3.3e-29	0.48	0.35	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-12.24	2.91e-32	3.3e-29	-0.41	-0.35	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	12.24	2.92e-32	3.3e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	12.23	2.95e-32	3.35e-29	0.41	0.35	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-12.23	3e-32	3.4e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
BRCA	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	12.23	3.15e-32	3.56e-29	0.4	0.35	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	12.23	3.16e-32	3.57e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-12.23	3.22e-32	3.64e-29	-0.44	-0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-12.23	3.22e-32	3.64e-29	-0.41	-0.35	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
BRCA	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-12.23	3.26e-32	3.69e-29	-0.4	-0.35	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	12.22	3.27e-32	3.7e-29	0.41	0.35	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	12.22	3.29e-32	3.71e-29	0.41	0.35	Height;	chr6:109497088	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28136698	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28136856	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28138363	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28138981	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28139012	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	12.22	3.38e-32	3.81e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	12.22	3.41e-32	3.85e-29	0.41	0.35	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	12.22	3.42e-32	3.86e-29	0.41	0.35	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
BRCA	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-12.22	3.48e-32	3.93e-29	-0.4	-0.35	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
BRCA	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-12.22	3.5e-32	3.95e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	12.22	3.55e-32	4.01e-29	0.41	0.35	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-12.22	3.57e-32	4.03e-29	-0.53	-0.35	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	12.22	3.59e-32	4.05e-29	0.41	0.35	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	12.22	3.63e-32	4.09e-29	0.41	0.35	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
BRCA	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-12.21	3.65e-32	4.11e-29	-0.41	-0.35	Height;	chr3:53085518	chr3:53064283~53065091:-
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	12.21	3.66e-32	4.12e-29	0.41	0.35	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
BRCA	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-12.21	3.67e-32	4.14e-29	-0.53	-0.35	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
BRCA	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	12.21	3.71e-32	4.19e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	12.21	3.73e-32	4.2e-29	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
BRCA	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-12.21	3.75e-32	4.22e-29	-0.44	-0.35	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	12.21	3.77e-32	4.25e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	12.21	3.78e-32	4.26e-29	0.41	0.35	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
BRCA	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	12.21	3.8e-32	4.29e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28147378	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28147406	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28148143	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28149979	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28152885	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28153120	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-12.2	4.15e-32	4.67e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
BRCA	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-12.2	4.21e-32	4.73e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
BRCA	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-12.2	4.22e-32	4.75e-29	-0.38	-0.35	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
BRCA	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	12.2	4.22e-32	4.75e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
BRCA	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	12.2	4.23e-32	4.76e-29	0.37	0.35	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	12.2	4.28e-32	4.82e-29	0.45	0.35	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-12.2	4.33e-32	4.86e-29	-0.41	-0.35	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-12.2	4.33e-32	4.86e-29	-0.41	-0.35	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	12.2	4.34e-32	4.87e-29	0.41	0.35	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	12.2	4.34e-32	4.87e-29	0.41	0.35	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-12.2	4.4e-32	4.94e-29	-0.54	-0.35	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-12.2	4.4e-32	4.94e-29	-0.54	-0.35	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
BRCA	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-12.19	4.52e-32	5.08e-29	-0.44	-0.35	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	12.19	4.53e-32	5.08e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-12.19	4.53e-32	5.09e-29	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-12.19	4.56e-32	5.12e-29	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	12.19	4.61e-32	5.17e-29	0.47	0.35	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-12.19	4.66e-32	5.23e-29	-0.47	-0.35	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
BRCA	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-12.19	4.68e-32	5.25e-29	-0.44	-0.35	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
BRCA	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	12.19	4.72e-32	5.29e-29	0.42	0.35	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
BRCA	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-12.19	4.72e-32	5.3e-29	-0.48	-0.35	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	12.19	4.77e-32	5.35e-29	0.4	0.35	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	12.19	4.77e-32	5.35e-29	0.4	0.35	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-12.19	4.8e-32	5.38e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
BRCA	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-12.19	4.82e-32	5.4e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
BRCA	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-12.19	4.83e-32	5.42e-29	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-12.19	4.88e-32	5.47e-29	-0.41	-0.35	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	12.19	5.02e-32	5.62e-29	0.27	0.35	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
BRCA	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-12.18	5.05e-32	5.66e-29	-0.47	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	12.18	5.07e-32	5.68e-29	0.47	0.35	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
BRCA	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	12.18	5.37e-32	6.01e-29	0.41	0.35	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-12.18	5.37e-32	6.01e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
BRCA	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-12.18	5.45e-32	6.1e-29	-0.37	-0.35	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	12.18	5.49e-32	6.14e-29	0.47	0.35	Depression;	chr6:28139049	chr6:28073316~28074233:+
BRCA	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-12.18	5.52e-32	6.17e-29	-0.43	-0.35	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
BRCA	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-12.18	5.59e-32	6.24e-29	-0.44	-0.35	Height;	chr3:53070344	chr3:53064283~53065091:-
BRCA	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	12.17	5.61e-32	6.27e-29	0.43	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
BRCA	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-12.17	5.61e-32	6.27e-29	-0.47	-0.35	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
BRCA	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-12.17	5.63e-32	6.29e-29	-0.45	-0.35	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
BRCA	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-12.17	5.69e-32	6.35e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	12.17	5.69e-32	6.35e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
BRCA	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	12.17	5.86e-32	6.55e-29	0.41	0.35	Height;	chr6:109496680	chr6:109382795~109383666:+
BRCA	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-12.17	5.89e-32	6.57e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-12.17	5.9e-32	6.58e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
BRCA	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-12.17	5.99e-32	6.68e-29	-0.43	-0.35	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	12.17	6.03e-32	6.72e-29	0.47	0.35	Depression;	chr6:28137418	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-12.17	6.06e-32	6.76e-29	-0.51	-0.35	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
BRCA	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-12.17	6.07e-32	6.77e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
BRCA	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	12.17	6.11e-32	6.81e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	12.17	6.11e-32	6.81e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
BRCA	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	12.17	6.13e-32	6.83e-29	0.36	0.35	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
BRCA	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-12.17	6.17e-32	6.87e-29	-0.5	-0.35	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	12.17	6.19e-32	6.89e-29	0.28	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
BRCA	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	12.17	6.21e-32	6.92e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-12.17	6.21e-32	6.92e-29	-0.5	-0.35	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
BRCA	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	12.16	6.25e-32	6.96e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
BRCA	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-12.16	6.28e-32	6.99e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
BRCA	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-12.16	6.28e-32	7e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
BRCA	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	12.16	6.39e-32	7.12e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	12.16	6.39e-32	7.12e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-12.16	6.4e-32	7.12e-29	-0.5	-0.35	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28168434	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169019	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169249	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169676	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169755	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169791	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28170075	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-12.16	6.51e-32	7.24e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	12.16	6.51e-32	7.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	12.16	6.52e-32	7.25e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	12.16	6.54e-32	7.27e-29	0.47	0.35	Depression;	chr6:28151096	chr6:28073316~28074233:+
BRCA	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	12.16	6.63e-32	7.37e-29	0.46	0.35	Height;	chr6:109427303	chr6:109382795~109383666:+
BRCA	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	12.16	6.63e-32	7.37e-29	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-12.16	6.84e-32	7.59e-29	-0.41	-0.35	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	12.15	6.95e-32	7.71e-29	0.44	0.35	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	12.15	6.95e-32	7.71e-29	0.44	0.35	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-12.15	7.01e-32	7.77e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	12.15	7.02e-32	7.79e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
BRCA	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-12.15	7.09e-32	7.86e-29	-0.48	-0.35	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
BRCA	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	12.15	7.18e-32	7.96e-29	0.45	0.35	Height;	chr6:109339681	chr6:109382795~109383666:+
BRCA	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	12.15	7.18e-32	7.96e-29	0.44	0.35	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	12.15	7.2e-32	7.98e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	12.15	7.37e-32	8.17e-29	0.28	0.35	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-12.15	7.4e-32	8.2e-29	-0.42	-0.35	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	12.15	7.54e-32	8.35e-29	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
BRCA	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	12.15	7.63e-32	8.45e-29	0.4	0.35	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	12.15	7.65e-32	8.47e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
BRCA	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-12.14	7.84e-32	8.67e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
BRCA	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	12.14	7.89e-32	8.73e-29	0.32	0.35	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-12.14	7.89e-32	8.73e-29	-0.41	-0.35	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-12.14	7.94e-32	8.78e-29	-0.41	-0.35	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-12.14	7.95e-32	8.79e-29	-0.27	-0.35	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
BRCA	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	12.14	7.95e-32	8.79e-29	0.32	0.35	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
BRCA	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-12.14	8.06e-32	8.91e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-12.14	8.06e-32	8.91e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	12.14	8.12e-32	8.97e-29	0.46	0.35	Depression;	chr6:28108492	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-12.14	8.13e-32	8.99e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
BRCA	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	12.14	8.27e-32	9.14e-29	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
BRCA	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-12.14	8.51e-32	9.39e-29	-0.45	-0.35	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
BRCA	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-12.14	8.52e-32	9.4e-29	-0.46	-0.35	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	12.14	8.58e-32	9.47e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	12.13	8.88e-32	9.79e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-12.13	9.07e-32	9.99e-29	-0.41	-0.35	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	12.13	9.11e-32	1e-28	0.24	0.35	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-12.13	9.18e-32	1.01e-28	-0.45	-0.35	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	12.13	9.19e-32	1.01e-28	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
BRCA	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-12.13	9.27e-32	1.02e-28	-0.46	-0.35	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
BRCA	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-12.13	9.29e-32	1.02e-28	-0.43	-0.35	Height;	chr3:53093751	chr3:53064283~53065091:-
BRCA	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	12.13	9.31e-32	1.03e-28	0.46	0.35	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-12.13	9.37e-32	1.03e-28	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
BRCA	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-12.13	9.41e-32	1.04e-28	-0.39	-0.35	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
BRCA	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-12.13	9.41e-32	1.04e-28	-0.39	-0.35	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
BRCA	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-12.13	9.43e-32	1.04e-28	-0.42	-0.35	Height;	chr6:109731677	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	12.13	9.44e-32	1.04e-28	0.41	0.35	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	12.12	9.62e-32	1.06e-28	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-12.12	9.72e-32	1.07e-28	-0.41	-0.35	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-12.12	9.72e-32	1.07e-28	-0.48	-0.35	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-12.12	9.86e-32	1.08e-28	-0.41	-0.35	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	12.12	9.9e-32	1.09e-28	0.48	0.35	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	12.12	1.01e-31	1.11e-28	0.47	0.35	Depression;	chr6:28159666	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	12.12	1.01e-31	1.11e-28	0.47	0.35	Depression;	chr6:28162598	chr6:28073316~28074233:+
BRCA	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-12.12	1.01e-31	1.11e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	12.12	1.02e-31	1.12e-28	0.4	0.35	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	12.12	1.02e-31	1.13e-28	0.42	0.35	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	12.12	1.03e-31	1.13e-28	0.46	0.35	Depression;	chr6:28110254	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-12.12	1.03e-31	1.14e-28	-0.4	-0.35	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-12.12	1.03e-31	1.14e-28	-0.4	-0.35	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-12.12	1.05e-31	1.15e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000278665.1	RP11-666O2.4	12.12	1.05e-31	1.16e-28	0.39	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28599241~28601881:-
BRCA	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	12.12	1.06e-31	1.16e-28	0.45	0.35	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
BRCA	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	12.12	1.06e-31	1.16e-28	0.4	0.35	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-12.11	1.07e-31	1.17e-28	-0.4	-0.35	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	12.11	1.08e-31	1.19e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
BRCA	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	12.11	1.09e-31	1.19e-28	0.38	0.35	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
BRCA	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-12.11	1.09e-31	1.2e-28	-0.46	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
BRCA	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-12.11	1.1e-31	1.2e-28	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-12.11	1.1e-31	1.21e-28	-0.41	-0.35	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	12.11	1.11e-31	1.21e-28	0.41	0.35	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
BRCA	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-12.11	1.11e-31	1.21e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-12.11	1.11e-31	1.22e-28	-0.41	-0.35	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	12.11	1.14e-31	1.25e-28	0.5	0.35	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
BRCA	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	12.11	1.15e-31	1.26e-28	0.4	0.35	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
BRCA	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	12.11	1.16e-31	1.27e-28	0.46	0.35	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-12.11	1.16e-31	1.28e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
BRCA	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-12.11	1.17e-31	1.29e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	12.11	1.18e-31	1.29e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	12.11	1.18e-31	1.29e-28	0.47	0.35	Depression;	chr6:28133900	chr6:28073316~28074233:+
BRCA	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-12.1	1.19e-31	1.3e-28	-0.48	-0.35	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-12.1	1.2e-31	1.31e-28	-0.41	-0.35	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
BRCA	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-12.1	1.2e-31	1.32e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-12.1	1.2e-31	1.32e-28	-0.41	-0.35	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	12.1	1.21e-31	1.33e-28	0.46	0.35	Depression;	chr6:28096077	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	12.1	1.21e-31	1.33e-28	0.46	0.35	Depression;	chr6:28096855	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-12.1	1.21e-31	1.33e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-12.1	1.21e-31	1.33e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
BRCA	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	12.1	1.23e-31	1.34e-28	0.48	0.35	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	12.1	1.23e-31	1.34e-28	0.48	0.35	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
BRCA	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-12.1	1.23e-31	1.34e-28	-0.52	-0.35	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-12.1	1.26e-31	1.38e-28	-0.4	-0.35	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	12.1	1.29e-31	1.41e-28	0.24	0.35	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	12.1	1.31e-31	1.43e-28	0.39	0.35	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-12.09	1.34e-31	1.46e-28	-0.41	-0.35	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	12.09	1.34e-31	1.46e-28	0.47	0.35	Depression;	chr6:28131566	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	12.09	1.36e-31	1.48e-28	0.24	0.35	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
BRCA	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	12.09	1.37e-31	1.49e-28	0.41	0.35	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
BRCA	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.09	1.37e-31	1.49e-28	-0.43	-0.35	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
BRCA	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-12.09	1.37e-31	1.5e-28	-0.43	-0.35	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	12.09	1.38e-31	1.5e-28	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	12.09	1.38e-31	1.5e-28	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	12.09	1.39e-31	1.51e-28	0.47	0.35	Depression;	chr6:28139998	chr6:28073316~28074233:+
BRCA	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-12.09	1.39e-31	1.51e-28	-0.4	-0.35	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
BRCA	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	12.09	1.39e-31	1.51e-28	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
BRCA	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-12.09	1.39e-31	1.52e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-12.09	1.4e-31	1.52e-28	-0.4	-0.35	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-12.09	1.4e-31	1.53e-28	-0.41	-0.35	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-12.09	1.41e-31	1.53e-28	-0.48	-0.35	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
BRCA	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-12.09	1.41e-31	1.54e-28	-0.42	-0.35	Height;	chr3:52991821	chr3:53064283~53065091:-
BRCA	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-12.09	1.41e-31	1.54e-28	-0.42	-0.35	Height;	chr3:52992698	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-12.09	1.42e-31	1.54e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
BRCA	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-12.09	1.45e-31	1.57e-28	-0.43	-0.35	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
BRCA	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	12.08	1.47e-31	1.6e-28	0.54	0.35	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	12.08	1.49e-31	1.62e-28	0.41	0.35	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
BRCA	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	12.08	1.54e-31	1.68e-28	0.4	0.35	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
BRCA	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	12.08	1.55e-31	1.68e-28	0.52	0.35	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
BRCA	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	12.08	1.57e-31	1.71e-28	0.43	0.35	Height;	chr6:109486036	chr6:109382795~109383666:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-12.08	1.62e-31	1.76e-28	-0.41	-0.35	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-12.08	1.62e-31	1.76e-28	-0.41	-0.35	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28123153	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28124529	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28127577	chr6:28073316~28074233:+
BRCA	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-12.08	1.63e-31	1.77e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
BRCA	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-12.07	1.65e-31	1.79e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	12.07	1.7e-31	1.85e-28	0.4	0.35	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-12.07	1.71e-31	1.85e-28	-0.43	-0.35	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	12.07	1.71e-31	1.86e-28	0.47	0.35	Depression;	chr6:28140454	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	12.07	1.74e-31	1.89e-28	0.27	0.35	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	12.07	1.76e-31	1.91e-28	0.4	0.35	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-12.07	1.76e-31	1.91e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-12.07	1.78e-31	1.93e-28	-0.43	-0.35	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28099759	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28100648	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28107222	chr6:28073316~28074233:+
BRCA	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	12.06	1.82e-31	1.97e-28	0.41	0.35	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	12.06	1.83e-31	1.98e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
BRCA	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	12.06	1.83e-31	1.98e-28	0.46	0.35	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
BRCA	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-12.06	1.85e-31	2e-28	-0.42	-0.35	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-12.06	1.86e-31	2.02e-28	-0.4	-0.35	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	12.06	1.89e-31	2.04e-28	0.45	0.35	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
BRCA	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	12.06	1.95e-31	2.1e-28	0.41	0.35	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
BRCA	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-12.06	1.95e-31	2.11e-28	-0.37	-0.35	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-12.06	1.96e-31	2.12e-28	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
BRCA	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-12.06	1.96e-31	2.12e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	12.06	2.01e-31	2.17e-28	0.47	0.35	Depression;	chr6:28139876	chr6:28073316~28074233:+
BRCA	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-12.05	2.02e-31	2.19e-28	-0.4	-0.35	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-12.05	2.02e-31	2.19e-28	-0.4	-0.35	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
BRCA	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	12.05	2.03e-31	2.19e-28	0.47	0.35	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-12.05	2.05e-31	2.21e-28	-0.24	-0.35	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-12.05	2.06e-31	2.23e-28	-0.47	-0.35	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-12.05	2.13e-31	2.3e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
BRCA	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	12.05	2.14e-31	2.3e-28	0.48	0.35	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
BRCA	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	12.05	2.15e-31	2.32e-28	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28111382	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28111650	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28113851	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28114487	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28114933	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28115743	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28116411	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
BRCA	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	12.04	2.27e-31	2.44e-28	0.45	0.35	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-12.04	2.27e-31	2.44e-28	-0.4	-0.35	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
BRCA	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-12.04	2.27e-31	2.44e-28	-0.43	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
BRCA	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-12.04	2.28e-31	2.45e-28	-0.68	-0.35	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
BRCA	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-12.04	2.37e-31	2.54e-28	-0.43	-0.35	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	12.04	2.38e-31	2.56e-28	0.41	0.35	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	12.04	2.38e-31	2.56e-28	0.41	0.35	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-12.04	2.42e-31	2.6e-28	-0.4	-0.35	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-12.04	2.42e-31	2.6e-28	-0.54	-0.35	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
BRCA	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-12.04	2.43e-31	2.61e-28	-0.47	-0.35	Depression;	chr6:28142370	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	12.04	2.46e-31	2.64e-28	0.47	0.35	Depression;	chr6:28141189	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	12.04	2.46e-31	2.64e-28	0.47	0.35	Depression;	chr6:28141484	chr6:28073316~28074233:+
BRCA	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	12.04	2.47e-31	2.65e-28	0.49	0.35	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	12.04	2.47e-31	2.65e-28	0.46	0.35	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	12.04	2.47e-31	2.65e-28	0.46	0.35	Depression;	chr6:28112175	chr6:28073316~28074233:+
BRCA	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	12.03	2.59e-31	2.78e-28	0.4	0.35	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-12.03	2.6e-31	2.78e-28	-0.48	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-12.03	2.61e-31	2.8e-28	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
BRCA	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	12.03	2.63e-31	2.82e-28	0.42	0.35	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
BRCA	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	12.03	2.63e-31	2.82e-28	0.42	0.35	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	12.03	2.63e-31	2.82e-28	0.41	0.35	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-12.03	2.64e-31	2.83e-28	-0.37	-0.35	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
BRCA	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-12.03	2.64e-31	2.83e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-12.03	2.67e-31	2.86e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	12.03	2.69e-31	2.88e-28	0.4	0.35	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	12.03	2.7e-31	2.89e-28	0.4	0.35	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-12.03	2.75e-31	2.94e-28	-0.4	-0.35	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-12.03	2.75e-31	2.95e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
BRCA	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-12.03	2.77e-31	2.96e-28	-0.43	-0.35	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-12.02	2.81e-31	3.01e-28	-0.41	-0.35	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-12.02	2.81e-31	3.01e-28	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
BRCA	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	12.02	2.84e-31	3.04e-28	0.41	0.35	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-12.02	2.88e-31	3.08e-28	-0.41	-0.35	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	12.02	2.98e-31	3.19e-28	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
BRCA	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	12.02	2.99e-31	3.19e-28	0.45	0.35	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	12.02	3.02e-31	3.23e-28	0.4	0.35	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
BRCA	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.03e-31	3.23e-28	-0.46	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
BRCA	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-12.02	3.04e-31	3.25e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-12.02	3.07e-31	3.28e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
BRCA	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
BRCA	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-12.01	3.11e-31	3.32e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
BRCA	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-12.01	3.12e-31	3.33e-28	-0.44	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-12.01	3.15e-31	3.36e-28	-0.4	-0.35	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	12.01	3.15e-31	3.36e-28	0.28	0.35	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
BRCA	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-12.01	3.18e-31	3.39e-28	-0.47	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
BRCA	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	12.01	3.21e-31	3.42e-28	0.39	0.35	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
BRCA	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-12.01	3.23e-31	3.44e-28	-0.38	-0.35	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-12.01	3.27e-31	3.48e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	12.01	3.27e-31	3.49e-28	0.4	0.35	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
BRCA	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-12.01	3.29e-31	3.5e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	12.01	3.3e-31	3.51e-28	0.46	0.35	Depression;	chr6:28104824	chr6:28073316~28074233:+
BRCA	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-12.01	3.31e-31	3.53e-28	-0.49	-0.35	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-12.01	3.31e-31	3.53e-28	-0.4	-0.35	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	12	3.5e-31	3.73e-28	0.4	0.35	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	12	3.53e-31	3.75e-28	0.38	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	12	3.62e-31	3.84e-28	0.46	0.35	Depression;	chr6:28113616	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	12	3.63e-31	3.86e-28	0.41	0.35	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	12	3.67e-31	3.9e-28	0.4	0.35	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-12	3.72e-31	3.94e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	12	3.74e-31	3.97e-28	0.45	0.35	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
BRCA	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-12	3.76e-31	3.99e-28	-0.41	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
BRCA	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-12	3.79e-31	4.03e-28	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
BRCA	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-12	3.8e-31	4.03e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	11.99	3.83e-31	4.06e-28	0.27	0.35	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-11.99	3.95e-31	4.19e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
BRCA	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	11.99	3.99e-31	4.22e-28	0.38	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	11.99	4.08e-31	4.32e-28	0.4	0.35	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	11.99	4.1e-31	4.34e-28	0.44	0.35	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
BRCA	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	11.99	4.11e-31	4.35e-28	0.39	0.35	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
BRCA	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-11.99	4.24e-31	4.49e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-11.98	4.31e-31	4.56e-28	-0.39	-0.35	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
BRCA	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-11.98	4.38e-31	4.63e-28	-0.45	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
BRCA	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-11.98	4.41e-31	4.66e-28	-0.42	-0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
BRCA	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-11.98	4.43e-31	4.68e-28	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
BRCA	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	11.98	4.46e-31	4.72e-28	0.45	0.35	Height;	chr6:109403951	chr6:109382795~109383666:+
BRCA	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-11.98	4.61e-31	4.86e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
BRCA	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	11.97	4.78e-31	5.04e-28	0.45	0.35	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
BRCA	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-11.97	4.81e-31	5.07e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	11.97	4.81e-31	5.08e-28	0.45	0.35	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-11.97	4.82e-31	5.09e-28	-0.4	-0.35	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-11.97	5.04e-31	5.31e-28	-0.41	-0.35	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-11.97	5.04e-31	5.31e-28	-0.41	-0.35	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
BRCA	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	11.97	5.1e-31	5.38e-28	0.36	0.35	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
BRCA	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	11.97	5.14e-31	5.42e-28	0.43	0.35	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	11.97	5.15e-31	5.42e-28	0.44	0.35	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
BRCA	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-11.97	5.15e-31	5.43e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28082984	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28083994	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28084025	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28085319	chr6:28073316~28074233:+
BRCA	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	11.97	5.23e-31	5.51e-28	0.41	0.35	Height;	chr3:53073584	chr3:53064283~53065091:-
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	11.96	5.25e-31	5.52e-28	0.46	0.35	Depression;	chr6:28096845	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-11.96	5.27e-31	5.54e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-11.96	5.41e-31	5.69e-28	-0.4	-0.35	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	11.96	5.45e-31	5.73e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
BRCA	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	11.96	5.46e-31	5.75e-28	0.46	0.35	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	11.96	5.53e-31	5.82e-28	0.4	0.35	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
BRCA	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	11.96	5.54e-31	5.83e-28	0.66	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
BRCA	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-11.96	5.55e-31	5.83e-28	-0.5	-0.35	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
BRCA	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-11.96	5.59e-31	5.88e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
BRCA	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	11.95	5.86e-31	6.16e-28	0.37	0.35	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	11.95	5.97e-31	6.26e-28	0.4	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	11.95	6.09e-31	6.39e-28	0.46	0.35	Depression;	chr6:28076704	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	11.95	6.34e-31	6.65e-28	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	11.95	6.35e-31	6.66e-28	0.27	0.35	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	11.95	6.35e-31	6.66e-28	0.27	0.35	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	11.95	6.39e-31	6.7e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	11.95	6.48e-31	6.79e-28	0.28	0.35	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-11.94	6.49e-31	6.8e-28	-0.4	-0.35	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-11.94	6.61e-31	6.92e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
BRCA	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-11.94	6.66e-31	6.97e-28	-0.56	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
BRCA	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	11.94	6.8e-31	7.12e-28	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
BRCA	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	11.94	6.84e-31	7.16e-28	0.45	0.35	Height;	chr6:109416945	chr6:109382795~109383666:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	11.94	6.94e-31	7.26e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.94	6.94e-31	7.26e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
BRCA	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	11.94	6.95e-31	7.27e-28	0.48	0.35	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
BRCA	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	11.94	6.98e-31	7.3e-28	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
BRCA	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-11.94	7.05e-31	7.37e-28	-0.37	-0.35	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28089816	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28090857	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28091439	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28091659	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28093966	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28094014	chr6:28073316~28074233:+
BRCA	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-11.94	7.13e-31	7.45e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	11.94	7.18e-31	7.5e-28	0.4	0.35	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-11.93	7.21e-31	7.53e-28	-0.4	-0.35	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-11.93	7.21e-31	7.54e-28	-0.37	-0.35	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
BRCA	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	11.93	7.26e-31	7.58e-28	0.45	0.35	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
BRCA	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-11.93	7.28e-31	7.6e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	11.93	7.3e-31	7.63e-28	0.41	0.35	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
BRCA	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	11.93	7.36e-31	7.69e-28	0.39	0.35	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-11.93	7.57e-31	7.9e-28	-0.41	-0.35	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-11.93	7.57e-31	7.9e-28	-0.41	-0.35	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-11.93	7.58e-31	7.91e-28	-0.39	-0.35	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.93	7.6e-31	7.94e-28	-0.49	-0.35	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
BRCA	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-11.93	7.63e-31	7.97e-28	-0.52	-0.35	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	11.93	7.63e-31	7.97e-28	0.27	0.35	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-11.93	7.78e-31	8.11e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-11.93	7.79e-31	8.12e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
BRCA	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-11.93	7.89e-31	8.22e-28	-0.39	-0.35	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
BRCA	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-11.93	8e-31	8.34e-28	-0.4	-0.35	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-11.92	8.15e-31	8.49e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	11.92	8.19e-31	8.53e-28	0.4	0.35	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
BRCA	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-11.92	8.22e-31	8.56e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
BRCA	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-11.92	8.47e-31	8.82e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	11.92	8.5e-31	8.85e-28	0.27	0.35	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-11.92	8.56e-31	8.91e-28	-0.45	-0.35	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-11.92	8.58e-31	8.93e-28	-0.4	-0.35	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	11.92	8.66e-31	9.02e-28	0.46	0.35	Depression;	chr6:28092227	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-11.92	8.72e-31	9.07e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
BRCA	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-11.92	8.74e-31	9.09e-28	-0.44	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
BRCA	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	11.92	8.84e-31	9.2e-28	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	11.91	9.02e-31	9.37e-28	0.46	0.35	Depression;	chr6:28140307	chr6:28073316~28074233:+
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-11.91	9.31e-31	9.68e-28	-0.46	-0.35	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.91	9.36e-31	9.72e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
BRCA	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-11.91	9.57e-31	9.94e-28	-0.5	-0.35	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
BRCA	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	11.91	9.6e-31	9.97e-28	0.45	0.35	Height;	chr6:109415050	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28071237	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28076559	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28078391	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28080757	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28080760	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	11.91	9.9e-31	1.03e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
BRCA	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	11.9	1.02e-30	1.06e-27	0.39	0.35	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-11.9	1.04e-30	1.08e-27	-0.45	-0.35	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
BRCA	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-11.9	1.05e-30	1.09e-27	-0.39	-0.35	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
BRCA	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	11.9	1.06e-30	1.1e-27	0.44	0.35	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
BRCA	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	11.9	1.07e-30	1.11e-27	0.47	0.35	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
BRCA	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-11.9	1.07e-30	1.11e-27	-0.45	-0.35	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	11.9	1.1e-30	1.13e-27	0.4	0.35	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
BRCA	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-11.89	1.1e-30	1.14e-27	-0.52	-0.35	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
BRCA	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	11.89	1.13e-30	1.17e-27	0.46	0.35	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
BRCA	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-11.89	1.13e-30	1.17e-27	-0.47	-0.35	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-11.89	1.17e-30	1.21e-27	-0.46	-0.35	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
BRCA	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	11.89	1.2e-30	1.24e-27	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
BRCA	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-11.89	1.2e-30	1.24e-27	-0.37	-0.35	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
BRCA	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-11.89	1.2e-30	1.24e-27	-0.39	-0.35	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
BRCA	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-11.89	1.21e-30	1.25e-27	-0.44	-0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	11.88	1.22e-30	1.26e-27	0.45	0.35	Depression;	chr6:28074687	chr6:28073316~28074233:+
BRCA	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	11.88	1.23e-30	1.27e-27	0.39	0.35	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	11.88	1.23e-30	1.27e-27	0.39	0.35	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-11.88	1.23e-30	1.28e-27	-0.45	-0.35	Depression;	chr6:28167882	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	11.88	1.26e-30	1.3e-27	0.4	0.35	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-11.88	1.26e-30	1.3e-27	-0.4	-0.35	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	11.88	1.26e-30	1.3e-27	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	11.88	1.26e-30	1.3e-27	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
BRCA	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	11.88	1.26e-30	1.31e-27	0.42	0.35	Height;	chr6:109429207	chr6:109382795~109383666:+
BRCA	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	11.88	1.27e-30	1.31e-27	0.49	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Depression;	chr6:28082231	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Depression;	chr6:28082261	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
BRCA	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-11.88	1.29e-30	1.33e-27	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-11.88	1.33e-30	1.37e-27	-0.35	-0.35	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
BRCA	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	11.88	1.34e-30	1.38e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	11.88	1.34e-30	1.38e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	11.88	1.35e-30	1.39e-27	0.45	0.35	Depression;	chr6:28126588	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	11.88	1.35e-30	1.39e-27	0.45	0.35	Depression;	chr6:28126953	chr6:28073316~28074233:+
BRCA	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	11.87	1.36e-30	1.4e-27	0.47	0.35	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
BRCA	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	11.87	1.37e-30	1.41e-27	0.4	0.35	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
BRCA	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-11.87	1.39e-30	1.43e-27	-0.47	-0.35	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
BRCA	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-11.87	1.39e-30	1.43e-27	-0.37	-0.35	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
BRCA	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-11.87	1.41e-30	1.45e-27	-0.41	-0.35	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
BRCA	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-11.87	1.42e-30	1.46e-27	-0.36	-0.35	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-11.87	1.42e-30	1.47e-27	-0.4	-0.35	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	11.87	1.43e-30	1.47e-27	0.4	0.35	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-11.87	1.44e-30	1.48e-27	-0.4	-0.35	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
BRCA	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-11.87	1.46e-30	1.5e-27	-0.51	-0.35	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	11.87	1.47e-30	1.51e-27	0.47	0.35	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-11.87	1.47e-30	1.51e-27	-0.35	-0.35	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	11.87	1.47e-30	1.51e-27	0.45	0.35	Depression;	chr6:28071808	chr6:28073316~28074233:+
BRCA	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	11.87	1.49e-30	1.53e-27	0.37	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	11.87	1.49e-30	1.53e-27	0.41	0.35	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-11.87	1.49e-30	1.53e-27	-0.54	-0.35	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
BRCA	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-11.86	1.55e-30	1.59e-27	-0.36	-0.34	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
BRCA	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-11.86	1.61e-30	1.65e-27	-0.36	-0.34	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	11.86	1.61e-30	1.65e-27	0.27	0.34	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
BRCA	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-11.86	1.65e-30	1.69e-27	-0.46	-0.34	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	11.86	1.66e-30	1.7e-27	0.4	0.34	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-11.85	1.68e-30	1.72e-27	-0.37	-0.34	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-11.85	1.72e-30	1.76e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
BRCA	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-11.85	1.72e-30	1.76e-27	-0.5	-0.34	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
BRCA	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	11.85	1.74e-30	1.78e-27	0.44	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
BRCA	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	11.85	1.75e-30	1.79e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
BRCA	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-11.85	1.81e-30	1.85e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-11.85	1.83e-30	1.87e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	11.85	1.84e-30	1.88e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-11.85	1.84e-30	1.89e-27	-0.63	-0.34	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	11.85	1.86e-30	1.9e-27	0.27	0.34	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
BRCA	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-11.84	1.86e-30	1.9e-27	-0.35	-0.34	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-11.84	1.86e-30	1.9e-27	-0.35	-0.34	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
BRCA	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	11.84	1.93e-30	1.97e-27	0.31	0.34	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	11.84	1.93e-30	1.97e-27	0.31	0.34	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
BRCA	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	11.84	1.98e-30	2.02e-27	0.45	0.34	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
BRCA	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	11.84	2.04e-30	2.08e-27	0.39	0.34	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-11.84	2.06e-30	2.1e-27	-0.4	-0.34	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-11.84	2.06e-30	2.1e-27	-0.4	-0.34	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	11.83	2.11e-30	2.15e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
BRCA	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-11.83	2.12e-30	2.16e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
BRCA	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-11.83	2.15e-30	2.19e-27	-0.44	-0.34	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-11.83	2.15e-30	2.19e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-11.83	2.15e-30	2.19e-27	-0.27	-0.34	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
BRCA	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-11.83	2.17e-30	2.21e-27	-0.38	-0.34	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
BRCA	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-11.83	2.17e-30	2.21e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
BRCA	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	11.83	2.24e-30	2.28e-27	0.43	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	11.82	2.31e-30	2.35e-27	0.45	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
BRCA	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	11.82	2.34e-30	2.38e-27	0.47	0.34	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	11.82	2.34e-30	2.38e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	11.82	2.35e-30	2.38e-27	0.27	0.34	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
BRCA	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-11.82	2.36e-30	2.4e-27	-0.41	-0.34	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
BRCA	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-11.82	2.39e-30	2.43e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	11.82	2.43e-30	2.47e-27	0.27	0.34	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	11.82	2.43e-30	2.47e-27	0.27	0.34	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
BRCA	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	11.82	2.45e-30	2.49e-27	0.42	0.34	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
BRCA	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-11.82	2.46e-30	2.5e-27	-0.39	-0.34	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
BRCA	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-11.82	2.48e-30	2.52e-27	-0.41	-0.34	Height;	chr3:52972039	chr3:53064283~53065091:-
BRCA	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	11.82	2.54e-30	2.58e-27	0.44	0.34	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	11.81	2.55e-30	2.59e-27	0.27	0.34	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	11.81	2.58e-30	2.62e-27	0.51	0.34	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	11.81	2.58e-30	2.62e-27	0.27	0.34	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	11.81	2.65e-30	2.69e-27	0.27	0.34	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
BRCA	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-11.81	2.66e-30	2.7e-27	-0.45	-0.34	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
BRCA	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	11.81	2.68e-30	2.72e-27	0.38	0.34	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
BRCA	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	11.81	2.68e-30	2.72e-27	0.5	0.34	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
BRCA	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-11.81	2.68e-30	2.72e-27	-0.44	-0.34	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
BRCA	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	11.81	2.69e-30	2.73e-27	0.52	0.34	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
BRCA	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	11.8	2.86e-30	2.9e-27	0.4	0.34	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-11.8	2.86e-30	2.9e-27	-0.39	-0.34	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
BRCA	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-11.8	2.86e-30	2.9e-27	-0.35	-0.34	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
BRCA	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	11.8	3.03e-30	3.07e-27	0.39	0.34	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	11.8	3.05e-30	3.09e-27	0.45	0.34	Depression;	chr6:28070115	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	11.8	3.06e-30	3.09e-27	0.43	0.34	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
BRCA	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	11.8	3.07e-30	3.1e-27	0.38	0.34	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
BRCA	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	11.79	3.15e-30	3.19e-27	0.47	0.34	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	11.79	3.15e-30	3.19e-27	0.47	0.34	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	11.79	3.26e-30	3.3e-27	0.5	0.34	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
BRCA	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	11.79	3.27e-30	3.3e-27	0.39	0.34	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
BRCA	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-11.79	3.28e-30	3.31e-27	-0.51	-0.34	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-11.79	3.29e-30	3.32e-27	-0.45	-0.34	Depression;	chr6:28110525	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-11.79	3.29e-30	3.32e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	11.79	3.31e-30	3.34e-27	0.44	0.34	Depression;	chr6:28184805	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-11.79	3.36e-30	3.4e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
BRCA	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-11.79	3.42e-30	3.46e-27	-0.35	-0.34	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
BRCA	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-11.79	3.46e-30	3.49e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
BRCA	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-11.79	3.47e-30	3.5e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
BRCA	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-11.78	3.51e-30	3.54e-27	-0.36	-0.34	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
BRCA	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	11.78	3.52e-30	3.56e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
BRCA	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	11.78	3.56e-30	3.59e-27	0.31	0.34	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
BRCA	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	11.78	3.58e-30	3.61e-27	0.4	0.34	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
BRCA	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	11.78	3.63e-30	3.66e-27	0.44	0.34	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
BRCA	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-11.78	3.72e-30	3.75e-27	-0.57	-0.34	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
BRCA	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	11.78	3.76e-30	3.79e-27	0.4	0.34	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-11.78	3.79e-30	3.81e-27	-0.4	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
BRCA	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-11.78	3.8e-30	3.83e-27	-0.39	-0.34	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
BRCA	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	11.78	3.82e-30	3.85e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
BRCA	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-11.78	3.85e-30	3.87e-27	-0.37	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
BRCA	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	11.77	3.91e-30	3.93e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	11.77	3.91e-30	3.93e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-11.77	3.92e-30	3.94e-27	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
BRCA	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-11.77	3.94e-30	3.97e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
BRCA	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-11.77	3.95e-30	3.98e-27	-0.41	-0.34	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
BRCA	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	11.77	3.99e-30	4.01e-27	0.37	0.34	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	11.77	4e-30	4.02e-27	0.47	0.34	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-11.77	4.05e-30	4.07e-27	-0.35	-0.34	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	11.77	4.05e-30	4.07e-27	0.47	0.34	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
BRCA	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-11.77	4.05e-30	4.07e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
BRCA	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	11.77	4.06e-30	4.09e-27	0.52	0.34	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
BRCA	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	11.77	4.14e-30	4.16e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	11.77	4.19e-30	4.22e-27	0.26	0.34	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	11.77	4.21e-30	4.24e-27	0.39	0.34	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	11.77	4.29e-30	4.31e-27	0.27	0.34	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
BRCA	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-11.76	4.48e-30	4.5e-27	-0.36	-0.34	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	11.76	4.5e-30	4.52e-27	0.45	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
BRCA	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-11.76	4.75e-30	4.76e-27	-0.41	-0.34	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
BRCA	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	11.76	4.76e-30	4.77e-27	0.36	0.34	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
BRCA	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-11.75	4.83e-30	4.84e-27	-0.37	-0.34	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
BRCA	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-11.75	4.9e-30	4.91e-27	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
BRCA	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	11.75	5e-30	5.01e-27	0.51	0.34	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	11.75	5.02e-30	5.03e-27	0.43	0.34	Depression;	chr6:28193021	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-11.75	5.05e-30	5.06e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	11.75	5.09e-30	5.1e-27	0.26	0.34	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	11.75	5.09e-30	5.1e-27	0.26	0.34	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
BRCA	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-11.75	5.23e-30	5.24e-27	-0.35	-0.34	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
BRCA	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	11.74	5.32e-30	5.32e-27	0.36	0.34	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
BRCA	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	11.74	5.32e-30	5.32e-27	0.6	0.34	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
BRCA	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-11.74	5.33e-30	5.33e-27	-0.36	-0.34	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
BRCA	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	11.74	5.34e-30	5.34e-27	0.47	0.34	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-11.74	5.36e-30	5.36e-27	-0.39	-0.34	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
BRCA	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-11.74	5.36e-30	5.36e-27	-0.36	-0.34	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
BRCA	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	11.74	5.37e-30	5.37e-27	0.49	0.34	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	11.74	5.4e-30	5.4e-27	0.26	0.34	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	11.74	5.4e-30	5.4e-27	0.26	0.34	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
BRCA	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	11.74	5.4e-30	5.4e-27	0.4	0.34	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-11.74	5.51e-30	5.5e-27	-0.41	-0.34	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
BRCA	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-11.74	5.52e-30	5.51e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	11.74	5.61e-30	5.6e-27	0.42	0.34	Height;	chr6:109407148	chr6:109382795~109383666:+
BRCA	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-11.74	5.64e-30	5.62e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-11.74	5.64e-30	5.62e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
BRCA	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	11.74	5.65e-30	5.64e-27	0.41	0.34	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
BRCA	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-11.74	5.7e-30	5.69e-27	-0.45	-0.34	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
BRCA	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-11.74	5.75e-30	5.73e-27	-0.43	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-11.74	5.77e-30	5.76e-27	-0.39	-0.34	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
BRCA	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-11.74	5.8e-30	5.79e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
BRCA	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-11.74	5.84e-30	5.83e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-11.73	5.94e-30	5.92e-27	-0.46	-0.34	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
BRCA	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-11.73	5.99e-30	5.97e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	11.73	6.01e-30	5.99e-27	0.47	0.34	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	11.73	6.01e-30	5.99e-27	0.47	0.34	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
BRCA	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-11.73	6.03e-30	6.01e-27	-0.44	-0.34	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	11.73	6.06e-30	6.04e-27	0.49	0.34	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-11.73	6.29e-30	6.26e-27	-0.24	-0.34	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
BRCA	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-11.73	6.42e-30	6.39e-27	-0.54	-0.34	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
BRCA	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	11.73	6.43e-30	6.39e-27	0.42	0.34	Height;	chr6:109449796	chr6:109382795~109383666:+
BRCA	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	11.72	6.54e-30	6.5e-27	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	11.72	6.54e-30	6.5e-27	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
BRCA	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-11.72	6.56e-30	6.52e-27	-0.51	-0.34	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	11.72	6.6e-30	6.56e-27	0.26	0.34	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-11.72	6.6e-30	6.56e-27	-0.45	-0.34	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-11.72	6.61e-30	6.57e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
BRCA	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	11.72	6.79e-30	6.74e-27	0.6	0.34	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
BRCA	cis	rs4727443	0.932	rs7803714	ENSG00000214313.7	AZGP1P1	-11.72	6.92e-30	6.87e-27	-0.35	-0.34	Interstitial lung disease;	chr7:99987527	chr7:99980762~99987535:+
BRCA	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-11.72	6.95e-30	6.9e-27	-0.4	-0.34	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
BRCA	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-11.72	7.06e-30	7e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-11.72	7.06e-30	7e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
BRCA	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	11.72	7.16e-30	7.11e-27	0.6	0.34	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
BRCA	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	11.72	7.22e-30	7.16e-27	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	11.72	7.22e-30	7.16e-27	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
BRCA	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	11.71	7.55e-30	7.47e-27	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
BRCA	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-11.71	7.55e-30	7.47e-27	-0.4	-0.34	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-11.71	7.55e-30	7.47e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
BRCA	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	11.71	7.59e-30	7.51e-27	0.45	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	11.71	7.6e-30	7.52e-27	0.26	0.34	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
BRCA	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-11.71	7.71e-30	7.63e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-11.71	7.71e-30	7.63e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
BRCA	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	11.71	7.8e-30	7.71e-27	0.42	0.34	Height;	chr3:53072864	chr3:53064283~53065091:-
BRCA	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-11.71	7.87e-30	7.78e-27	-0.5	-0.34	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-11.71	8e-30	7.91e-27	-0.44	-0.34	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
BRCA	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	11.71	8.03e-30	7.93e-27	0.47	0.34	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-11.7	8.16e-30	8.06e-27	-0.35	-0.34	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-11.7	8.24e-30	8.14e-27	-0.4	-0.34	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-11.7	8.31e-30	8.2e-27	-0.4	-0.34	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-11.7	8.32e-30	8.21e-27	-0.39	-0.34	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-11.7	8.36e-30	8.25e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
BRCA	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-11.7	8.45e-30	8.34e-27	-0.39	-0.34	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
BRCA	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	11.7	8.51e-30	8.39e-27	0.27	0.34	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	11.7	8.51e-30	8.39e-27	0.4	0.34	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
BRCA	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-11.7	8.54e-30	8.42e-27	-0.36	-0.34	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
BRCA	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-11.7	8.79e-30	8.66e-27	-0.42	-0.34	Height;	chr6:109485060	chr6:109382795~109383666:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	11.7	8.81e-30	8.68e-27	0.26	0.34	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	11.69	8.97e-30	8.83e-27	0.38	0.34	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	11.69	9.05e-30	8.92e-27	0.44	0.34	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
BRCA	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	11.69	9.14e-30	8.97e-27	0.38	0.34	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
BRCA	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
BRCA	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-11.69	9.18e-30	9.02e-27	-0.54	-0.34	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
BRCA	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-11.69	9.22e-30	9.05e-27	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-11.69	9.22e-30	9.05e-27	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
BRCA	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	11.69	9.26e-30	9.09e-27	0.5	0.34	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
BRCA	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	11.69	9.29e-30	9.12e-27	0.38	0.34	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
BRCA	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	11.69	9.36e-30	9.19e-27	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
BRCA	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-11.69	9.41e-30	9.23e-27	-0.45	-0.34	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000278665.1	RP11-666O2.4	-11.69	9.7e-30	9.52e-27	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-11.69	9.77e-30	9.58e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
BRCA	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	11.69	9.85e-30	9.66e-27	0.48	0.34	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
BRCA	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-11.69	9.91e-30	9.72e-27	-0.36	-0.34	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
BRCA	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	11.68	1.01e-29	9.9e-27	0.42	0.34	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
BRCA	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	11.68	1.02e-29	9.95e-27	0.4	0.34	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	11.68	1.02e-29	9.99e-27	0.26	0.34	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
BRCA	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	11.68	1.02e-29	1e-26	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
BRCA	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-11.68	1.07e-29	1.05e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
BRCA	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	11.68	1.07e-29	1.05e-26	0.6	0.34	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
BRCA	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	11.67	1.11e-29	1.08e-26	0.45	0.34	Depression;	chr6:28091242	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-11.67	1.12e-29	1.09e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
BRCA	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-11.67	1.12e-29	1.09e-26	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-11.67	1.14e-29	1.11e-26	-0.4	-0.34	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
BRCA	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-11.67	1.15e-29	1.12e-26	-0.39	-0.34	Height;	chr5:36861889	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	11.67	1.15e-29	1.13e-26	0.26	0.34	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
BRCA	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	11.67	1.17e-29	1.14e-26	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-11.67	1.19e-29	1.17e-26	-0.44	-0.34	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
BRCA	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	11.66	1.24e-29	1.21e-26	0.49	0.34	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	11.66	1.24e-29	1.21e-26	0.43	0.34	Depression;	chr6:28205175	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-11.66	1.25e-29	1.22e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
BRCA	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-11.66	1.26e-29	1.23e-26	-0.4	-0.34	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
BRCA	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-11.66	1.3e-29	1.27e-26	-0.42	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
BRCA	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-11.66	1.3e-29	1.27e-26	-0.55	-0.34	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
BRCA	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	11.66	1.32e-29	1.28e-26	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
BRCA	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-11.66	1.32e-29	1.29e-26	-0.46	-0.34	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
BRCA	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	11.66	1.32e-29	1.29e-26	0.59	0.34	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
BRCA	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	11.66	1.33e-29	1.3e-26	0.43	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
BRCA	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	11.66	1.34e-29	1.3e-26	0.38	0.34	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
BRCA	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	11.66	1.34e-29	1.31e-26	0.41	0.34	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
BRCA	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-11.66	1.35e-29	1.31e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-11.65	1.36e-29	1.32e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
BRCA	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-11.65	1.36e-29	1.33e-26	-0.46	-0.34	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28197321	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28197412	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28198669	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-11.65	1.41e-29	1.37e-26	-0.42	-0.34	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
BRCA	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	11.65	1.41e-29	1.37e-26	0.43	0.34	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
BRCA	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-11.65	1.44e-29	1.4e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-11.65	1.44e-29	1.4e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
BRCA	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-11.65	1.45e-29	1.41e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
BRCA	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-11.65	1.45e-29	1.41e-26	-0.5	-0.34	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
BRCA	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	11.65	1.47e-29	1.43e-26	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
BRCA	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	11.65	1.47e-29	1.43e-26	0.41	0.34	Height;	chr6:109340338	chr6:109382795~109383666:+
BRCA	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	11.65	1.47e-29	1.43e-26	0.59	0.34	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	11.65	1.48e-29	1.44e-26	0.44	0.34	Depression;	chr6:28079011	chr6:28073316~28074233:+
BRCA	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-11.64	1.51e-29	1.46e-26	-0.39	-0.34	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
BRCA	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-11.64	1.51e-29	1.47e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-11.64	1.51e-29	1.47e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
BRCA	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-11.64	1.52e-29	1.48e-26	-0.53	-0.34	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
BRCA	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	11.64	1.53e-29	1.49e-26	0.42	0.34	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
BRCA	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-11.64	1.54e-29	1.5e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
BRCA	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-11.64	1.54e-29	1.5e-26	-0.45	-0.34	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	11.64	1.55e-29	1.51e-26	0.43	0.34	Depression;	chr6:28201380	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-11.64	1.57e-29	1.52e-26	-0.45	-0.34	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-11.64	1.57e-29	1.53e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
BRCA	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-11.64	1.57e-29	1.53e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-11.64	1.58e-29	1.53e-26	-0.44	-0.34	Depression;	chr6:28086929	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-11.64	1.58e-29	1.54e-26	-0.26	-0.34	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-11.64	1.63e-29	1.58e-26	-0.39	-0.34	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-11.63	1.67e-29	1.62e-26	-0.43	-0.34	Depression;	chr6:28205232	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-11.63	1.71e-29	1.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-11.63	1.71e-29	1.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
BRCA	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	11.63	1.75e-29	1.7e-26	0.5	0.34	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	11.63	1.77e-29	1.71e-26	0.4	0.34	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	11.63	1.77e-29	1.71e-26	0.4	0.34	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
BRCA	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	11.63	1.78e-29	1.72e-26	0.42	0.34	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
BRCA	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	11.63	1.78e-29	1.72e-26	0.59	0.34	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
BRCA	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	11.63	1.78e-29	1.72e-26	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
BRCA	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	11.63	1.81e-29	1.75e-26	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
BRCA	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	11.63	1.81e-29	1.76e-26	0.36	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
BRCA	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	11.62	1.87e-29	1.81e-26	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
BRCA	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	11.62	1.88e-29	1.82e-26	0.38	0.34	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-11.62	1.95e-29	1.89e-26	-0.46	-0.34	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
BRCA	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-11.62	1.96e-29	1.9e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	11.62	1.98e-29	1.92e-26	0.38	0.34	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
BRCA	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-11.62	2.04e-29	1.98e-26	-0.44	-0.34	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
BRCA	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-11.61	2.06e-29	1.99e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
BRCA	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-11.61	2.08e-29	2.01e-26	-0.53	-0.34	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
BRCA	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	11.61	2.08e-29	2.01e-26	0.44	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
BRCA	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.08e-29	2.01e-26	-0.39	-0.34	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.08e-29	2.01e-26	-0.39	-0.34	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
BRCA	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-11.61	2.09e-29	2.02e-26	-0.41	-0.34	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
BRCA	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-11.61	2.12e-29	2.04e-26	-0.4	-0.34	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
BRCA	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.12e-29	2.05e-26	-0.39	-0.34	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.13e-29	2.06e-26	-0.39	-0.34	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	11.61	2.2e-29	2.12e-26	0.4	0.34	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
BRCA	cis	rs4727443	0.899	rs886453	ENSG00000214313.7	AZGP1P1	-11.61	2.22e-29	2.14e-26	-0.34	-0.34	Interstitial lung disease;	chr7:99990602	chr7:99980762~99987535:+
BRCA	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-11.61	2.23e-29	2.15e-26	-0.46	-0.34	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	11.61	2.25e-29	2.17e-26	0.42	0.34	Height;	chr6:109581800	chr6:109382795~109383666:+
BRCA	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	11.6	2.29e-29	2.21e-26	0.59	0.34	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
BRCA	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	11.6	2.3e-29	2.21e-26	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
BRCA	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-11.6	2.3e-29	2.22e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
BRCA	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.6	2.31e-29	2.23e-26	0.35	0.34	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
BRCA	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	11.6	2.36e-29	2.28e-26	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-11.6	2.38e-29	2.29e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
BRCA	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	11.6	2.39e-29	2.3e-26	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
BRCA	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-11.6	2.47e-29	2.38e-26	-0.38	-0.34	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
BRCA	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-11.59	2.53e-29	2.44e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-11.59	2.53e-29	2.44e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
BRCA	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-11.59	2.55e-29	2.46e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-11.59	2.55e-29	2.46e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	11.59	2.6e-29	2.5e-26	0.4	0.34	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	11.59	2.61e-29	2.51e-26	0.41	0.34	Height;	chr6:109423238	chr6:109382795~109383666:+
BRCA	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-11.59	2.65e-29	2.55e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
BRCA	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-11.59	2.65e-29	2.55e-26	-0.53	-0.34	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
BRCA	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-11.59	2.71e-29	2.6e-26	-0.47	-0.34	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
BRCA	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	11.59	2.72e-29	2.61e-26	0.39	0.34	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
BRCA	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-11.59	2.74e-29	2.64e-26	-0.36	-0.34	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
BRCA	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
BRCA	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	11.58	2.84e-29	2.72e-26	0.42	0.34	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
BRCA	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-11.58	2.87e-29	2.76e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
BRCA	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	11.58	2.93e-29	2.81e-26	0.42	0.34	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
BRCA	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-11.58	2.93e-29	2.81e-26	-0.39	-0.34	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
BRCA	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	11.58	3e-29	2.88e-26	0.58	0.34	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
BRCA	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-11.58	3.02e-29	2.9e-26	-0.39	-0.34	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
BRCA	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	11.58	3.07e-29	2.94e-26	0.38	0.34	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	11.58	3.07e-29	2.94e-26	0.38	0.34	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	11.58	3.09e-29	2.96e-26	0.44	0.34	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
BRCA	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-11.57	3.17e-29	3.03e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
BRCA	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	11.57	3.17e-29	3.03e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000278665.1	RP11-666O2.4	-11.57	3.22e-29	3.08e-26	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000278665.1	RP11-666O2.4	-11.57	3.22e-29	3.08e-26	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28599241~28601881:-
BRCA	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-11.57	3.28e-29	3.14e-26	-0.58	-0.34	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-11.57	3.33e-29	3.18e-26	-0.35	-0.34	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-11.57	3.38e-29	3.23e-26	-0.39	-0.34	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
BRCA	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-11.57	3.43e-29	3.28e-26	-0.43	-0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
BRCA	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-11.56	3.45e-29	3.3e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
BRCA	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	11.56	3.5e-29	3.34e-26	0.58	0.34	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
BRCA	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-11.56	3.5e-29	3.34e-26	-0.45	-0.34	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-11.56	3.51e-29	3.36e-26	-0.42	-0.34	Depression;	chr6:28199145	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-11.56	3.53e-29	3.38e-26	-0.44	-0.34	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	11.56	3.74e-29	3.58e-26	0.45	0.34	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
BRCA	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-11.56	3.75e-29	3.58e-26	-0.4	-0.34	Height;	chr2:231516587	chr2:231508426~231514339:-
BRCA	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-11.55	3.83e-29	3.66e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-11.55	3.83e-29	3.66e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
BRCA	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-11.55	3.9e-29	3.72e-26	-0.39	-0.34	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
BRCA	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	11.55	4.01e-29	3.83e-26	0.44	0.34	Height;	chr6:109769861	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-11.55	4.01e-29	3.83e-26	-0.45	-0.34	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-11.55	4.02e-29	3.84e-26	-0.42	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
BRCA	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	11.55	4.14e-29	3.95e-26	0.39	0.34	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
BRCA	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-11.55	4.18e-29	3.99e-26	-0.39	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
BRCA	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	11.55	4.19e-29	3.99e-26	0.34	0.34	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
BRCA	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-11.55	4.2e-29	4.01e-26	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-11.55	4.2e-29	4.01e-26	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-11.55	4.21e-29	4.01e-26	-0.4	-0.34	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-11.55	4.21e-29	4.01e-26	-0.4	-0.34	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-11.54	4.29e-29	4.08e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
BRCA	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	11.54	4.35e-29	4.14e-26	0.44	0.34	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	11.54	4.35e-29	4.14e-26	0.4	0.34	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
BRCA	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-11.54	4.4e-29	4.19e-26	-0.39	-0.34	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-11.54	4.41e-29	4.2e-26	-0.4	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
BRCA	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-11.54	4.49e-29	4.28e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
BRCA	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	11.54	4.5e-29	4.28e-26	0.41	0.34	Height;	chr6:109357908	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	11.54	4.51e-29	4.29e-26	0.43	0.34	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-11.54	4.59e-29	4.37e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-11.54	4.59e-29	4.37e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
BRCA	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-11.54	4.64e-29	4.41e-26	-0.39	-0.34	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
BRCA	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	11.53	4.7e-29	4.47e-26	0.41	0.34	Height;	chr6:109382524	chr6:109382795~109383666:+
BRCA	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-11.53	4.77e-29	4.54e-26	-0.35	-0.34	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
BRCA	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-11.53	4.8e-29	4.56e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-11.53	4.88e-29	4.64e-26	-0.39	-0.34	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
BRCA	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	11.53	4.88e-29	4.64e-26	0.38	0.34	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
BRCA	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	11.53	4.97e-29	4.72e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
BRCA	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-11.53	5.08e-29	4.82e-26	-0.4	-0.34	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
BRCA	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	11.53	5.12e-29	4.87e-26	0.55	0.34	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	11.53	5.12e-29	4.87e-26	0.55	0.34	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	11.53	5.14e-29	4.88e-26	0.4	0.34	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
BRCA	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-11.52	5.25e-29	4.98e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
BRCA	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-11.52	5.28e-29	5.01e-26	-0.42	-0.34	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
BRCA	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	11.52	5.3e-29	5.03e-26	0.41	0.34	Height;	chr6:109384228	chr6:109382795~109383666:+
BRCA	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	11.52	5.3e-29	5.03e-26	0.41	0.34	Height;	chr6:109385087	chr6:109382795~109383666:+
BRCA	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-11.52	5.31e-29	5.03e-26	-0.52	-0.34	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
BRCA	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	11.52	5.36e-29	5.08e-26	0.37	0.34	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
BRCA	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-11.52	5.36e-29	5.08e-26	-0.43	-0.34	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-11.52	5.4e-29	5.12e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	11.52	5.4e-29	5.12e-26	0.39	0.34	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
BRCA	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	11.52	5.48e-29	5.19e-26	0.38	0.34	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
BRCA	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-11.52	5.55e-29	5.26e-26	-0.52	-0.34	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	11.52	5.58e-29	5.29e-26	0.45	0.34	Depression;	chr6:28135913	chr6:28073316~28074233:+
BRCA	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-11.52	5.63e-29	5.34e-26	-0.4	-0.34	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-11.52	5.64e-29	5.35e-26	-0.39	-0.34	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
BRCA	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	11.52	5.73e-29	5.43e-26	0.5	0.34	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
BRCA	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	11.51	5.83e-29	5.52e-26	0.43	0.34	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-11.51	5.86e-29	5.54e-26	-0.25	-0.34	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
BRCA	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	11.51	5.88e-29	5.57e-26	0.47	0.34	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
BRCA	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	11.51	5.91e-29	5.6e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
BRCA	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-11.51	6.05e-29	5.73e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
BRCA	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-11.51	6.06e-29	5.73e-26	-0.55	-0.34	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
BRCA	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	11.51	6.12e-29	5.79e-26	0.45	0.34	Height;	chr6:109713188	chr6:109382795~109383666:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	11.51	6.23e-29	5.89e-26	0.39	0.34	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	11.51	6.25e-29	5.91e-26	0.41	0.34	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	11.51	6.31e-29	5.96e-26	0.4	0.34	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	11.51	6.32e-29	5.98e-26	0.44	0.34	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	11.51	6.32e-29	5.98e-26	0.38	0.34	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-11.5	6.39e-29	6.04e-26	-0.39	-0.34	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-11.5	6.39e-29	6.04e-26	-0.39	-0.34	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	11.5	6.56e-29	6.19e-26	0.44	0.34	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
BRCA	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-11.5	6.59e-29	6.23e-26	-0.36	-0.34	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
BRCA	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-11.5	6.68e-29	6.31e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-11.5	6.68e-29	6.31e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
BRCA	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-11.5	6.77e-29	6.4e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-11.5	6.82e-29	6.44e-26	-0.38	-0.34	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
BRCA	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	11.5	6.85e-29	6.46e-26	0.42	0.34	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
BRCA	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	11.5	6.91e-29	6.53e-26	0.38	0.34	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
BRCA	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	11.5	6.94e-29	6.55e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	11.49	7.08e-29	6.68e-26	0.39	0.34	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-11.49	7.27e-29	6.85e-26	-0.35	-0.34	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
BRCA	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-11.49	7.35e-29	6.93e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
BRCA	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	11.49	7.38e-29	6.96e-26	0.41	0.34	Height;	chr6:109359747	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-11.49	7.43e-29	7e-26	-0.39	-0.34	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
BRCA	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	11.49	7.49e-29	7.06e-26	0.45	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.49	7.5e-29	7.07e-26	0.36	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
BRCA	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-11.49	7.57e-29	7.13e-26	-0.43	-0.34	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	11.49	7.57e-29	7.13e-26	0.41	0.34	Height;	chr6:109430398	chr6:109382795~109383666:+
BRCA	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-11.49	7.59e-29	7.15e-26	-0.39	-0.34	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
BRCA	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	11.49	7.71e-29	7.26e-26	0.44	0.34	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-11.49	7.72e-29	7.26e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
BRCA	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-11.49	7.74e-29	7.28e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
BRCA	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-11.49	7.8e-29	7.34e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-11.49	7.81e-29	7.35e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	11.48	8.13e-29	7.65e-26	0.38	0.34	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	11.48	8.21e-29	7.72e-26	0.37	0.34	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	11.48	8.29e-29	7.79e-26	0.38	0.34	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	11.48	8.32e-29	7.82e-26	0.39	0.34	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	11.48	8.32e-29	7.82e-26	0.39	0.34	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
BRCA	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	11.48	8.32e-29	7.82e-26	0.35	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
BRCA	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-11.48	8.42e-29	7.91e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
BRCA	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-11.48	8.42e-29	7.91e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-11.48	8.45e-29	7.95e-26	-0.39	-0.34	Height;	chr11:118781100	chr11:118704607~118750263:+
BRCA	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	11.48	8.47e-29	7.96e-26	0.58	0.34	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
BRCA	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-11.48	8.52e-29	8e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-11.48	8.64e-29	8.12e-26	-0.36	-0.33	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
BRCA	cis	rs4727443	1	rs6974373	ENSG00000214313.7	AZGP1P1	-11.48	8.66e-29	8.14e-26	-0.34	-0.33	Interstitial lung disease;	chr7:99993270	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-11.47	8.76e-29	8.23e-26	-0.39	-0.33	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-11.47	8.76e-29	8.23e-26	-0.39	-0.33	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-11.47	8.77e-29	8.24e-26	-0.43	-0.33	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	11.47	8.8e-29	8.27e-26	0.39	0.33	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	11.47	8.8e-29	8.27e-26	0.39	0.33	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-11.47	8.8e-29	8.27e-26	-0.39	-0.33	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
BRCA	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	11.47	8.81e-29	8.27e-26	0.41	0.33	Height;	chr6:109387685	chr6:109382795~109383666:+
BRCA	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	11.47	8.81e-29	8.27e-26	0.41	0.33	Height;	chr6:109388256	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-11.47	8.82e-29	8.29e-26	-0.44	-0.33	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
BRCA	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	11.47	8.86e-29	8.32e-26	0.45	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
BRCA	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-11.47	8.96e-29	8.41e-26	-0.43	-0.33	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
BRCA	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	11.47	9.04e-29	8.48e-26	0.46	0.33	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
BRCA	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-11.47	9.1e-29	8.54e-26	-0.39	-0.33	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	11.47	9.22e-29	8.65e-26	0.4	0.33	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-11.47	9.29e-29	8.71e-26	-0.39	-0.33	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	11.47	9.36e-29	8.78e-26	0.38	0.33	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	11.47	9.36e-29	8.78e-26	0.38	0.33	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
BRCA	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	11.47	9.36e-29	8.78e-26	0.41	0.33	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-11.47	9.42e-29	8.83e-26	-0.39	-0.33	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-11.47	9.42e-29	8.83e-26	-0.39	-0.33	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-11.47	9.57e-29	8.97e-26	-0.39	-0.33	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	11.46	9.78e-29	9.17e-26	0.4	0.33	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-11.46	1.04e-28	9.73e-26	-0.55	-0.33	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	11.46	1.05e-28	9.81e-26	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
BRCA	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	11.46	1.06e-28	9.88e-26	0.42	0.33	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
BRCA	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-11.46	1.06e-28	9.95e-26	-0.36	-0.33	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-11.45	1.08e-28	1.01e-25	-0.39	-0.33	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
BRCA	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	11.45	1.09e-28	1.02e-25	0.42	0.33	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
BRCA	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-11.45	1.1e-28	1.03e-25	-0.45	-0.33	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
BRCA	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-11.45	1.11e-28	1.03e-25	-0.39	-0.33	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
BRCA	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-11.45	1.12e-28	1.05e-25	-0.39	-0.33	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-11.45	1.12e-28	1.05e-25	-0.37	-0.33	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	11.45	1.13e-28	1.06e-25	0.41	0.33	Height;	chr6:109428824	chr6:109382795~109383666:+
BRCA	cis	rs4727443	1	rs4727443	ENSG00000214313.7	AZGP1P1	-11.45	1.14e-28	1.06e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99995723	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	11.45	1.15e-28	1.07e-25	0.39	0.33	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	11.45	1.15e-28	1.07e-25	0.39	0.33	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	11.45	1.18e-28	1.1e-25	0.47	0.33	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
BRCA	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-11.44	1.18e-28	1.11e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-11.44	1.2e-28	1.12e-25	-0.39	-0.33	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	11.44	1.21e-28	1.13e-25	0.39	0.33	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	11.44	1.21e-28	1.13e-25	0.39	0.33	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
BRCA	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-11.44	1.21e-28	1.13e-25	-0.42	-0.33	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
BRCA	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-11.44	1.22e-28	1.14e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
BRCA	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	11.44	1.22e-28	1.14e-25	0.42	0.33	Height;	chr6:109582583	chr6:109382795~109383666:+
BRCA	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-11.44	1.23e-28	1.15e-25	-0.49	-0.33	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
BRCA	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-11.44	1.25e-28	1.16e-25	-0.38	-0.33	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
BRCA	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-11.44	1.25e-28	1.16e-25	-0.39	-0.33	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
BRCA	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-11.44	1.26e-28	1.17e-25	-0.53	-0.33	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-11.44	1.28e-28	1.2e-25	-0.39	-0.33	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
BRCA	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	11.44	1.29e-28	1.2e-25	0.49	0.33	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
BRCA	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	11.44	1.29e-28	1.21e-25	0.47	0.33	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
BRCA	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-11.44	1.3e-28	1.21e-25	-0.29	-0.33	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	11.44	1.31e-28	1.22e-25	0.39	0.33	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-11.43	1.32e-28	1.23e-25	-0.39	-0.33	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-11.43	1.33e-28	1.24e-25	-0.38	-0.33	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-11.43	1.35e-28	1.26e-25	-0.45	-0.33	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	11.43	1.35e-28	1.26e-25	0.39	0.33	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-11.43	1.36e-28	1.27e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
BRCA	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-11.43	1.36e-28	1.27e-25	-0.42	-0.33	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
BRCA	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	11.43	1.37e-28	1.28e-25	0.44	0.33	Height;	chr6:109737797	chr6:109382795~109383666:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	11.43	1.39e-28	1.29e-25	0.65	0.33	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-11.43	1.39e-28	1.29e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
BRCA	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	11.43	1.41e-28	1.31e-25	0.48	0.33	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
BRCA	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-11.43	1.43e-28	1.33e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
BRCA	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-11.43	1.43e-28	1.33e-25	-0.38	-0.33	Migraine;	chr4:56957291	chr4:56960927~56961373:-
BRCA	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-11.43	1.44e-28	1.34e-25	-0.39	-0.33	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-11.43	1.44e-28	1.34e-25	-0.39	-0.33	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
BRCA	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-11.43	1.44e-28	1.34e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-11.43	1.45e-28	1.35e-25	-0.39	-0.33	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-11.43	1.45e-28	1.35e-25	-0.47	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-11.42	1.46e-28	1.36e-25	-0.23	-0.33	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
BRCA	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	11.42	1.46e-28	1.36e-25	0.39	0.33	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
BRCA	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	11.42	1.46e-28	1.36e-25	0.65	0.33	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
BRCA	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	11.42	1.46e-28	1.36e-25	0.65	0.33	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
BRCA	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	11.42	1.46e-28	1.36e-25	0.41	0.33	Height;	chr6:109416225	chr6:109382795~109383666:+
BRCA	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-11.42	1.49e-28	1.38e-25	-0.39	-0.33	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
BRCA	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	11.42	1.52e-28	1.41e-25	0.55	0.33	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
BRCA	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	11.42	1.53e-28	1.42e-25	0.49	0.33	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-11.42	1.54e-28	1.43e-25	-0.43	-0.33	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
BRCA	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	11.42	1.54e-28	1.43e-25	0.39	0.33	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
BRCA	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-11.42	1.54e-28	1.43e-25	-0.49	-0.33	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
BRCA	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	11.42	1.55e-28	1.44e-25	0.47	0.33	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	11.42	1.56e-28	1.45e-25	0.62	0.33	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-11.42	1.57e-28	1.46e-25	-0.39	-0.33	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	11.42	1.58e-28	1.47e-25	0.39	0.33	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	11.42	1.59e-28	1.48e-25	0.37	0.33	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
BRCA	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-11.42	1.59e-28	1.48e-25	-0.41	-0.33	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
BRCA	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	11.42	1.59e-28	1.48e-25	0.46	0.33	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
BRCA	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	11.41	1.62e-28	1.51e-25	0.42	0.33	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
BRCA	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-11.41	1.63e-28	1.51e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
BRCA	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-11.41	1.64e-28	1.52e-25	-0.41	-0.33	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-11.41	1.64e-28	1.52e-25	-0.41	-0.33	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
BRCA	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	11.41	1.67e-28	1.55e-25	0.42	0.33	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	11.41	1.68e-28	1.56e-25	0.39	0.33	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	11.41	1.68e-28	1.56e-25	0.4	0.33	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
BRCA	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	11.41	1.69e-28	1.57e-25	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
BRCA	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-11.41	1.71e-28	1.59e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	11.41	1.72e-28	1.59e-25	0.37	0.33	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
BRCA	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	11.41	1.74e-28	1.61e-25	0.38	0.33	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
BRCA	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-11.41	1.75e-28	1.62e-25	-0.35	-0.33	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
BRCA	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	11.41	1.75e-28	1.62e-25	0.39	0.33	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
BRCA	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-11.41	1.75e-28	1.62e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
BRCA	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-11.41	1.76e-28	1.64e-25	-0.46	-0.33	QT interval;	chr16:28824579	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	11.4	1.81e-28	1.67e-25	0.44	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-11.4	1.81e-28	1.68e-25	-0.39	-0.33	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
BRCA	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-11.4	1.83e-28	1.69e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-11.4	1.83e-28	1.69e-25	-0.42	-0.33	Depression;	chr6:28200948	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-11.4	1.85e-28	1.71e-25	-0.43	-0.33	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
BRCA	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	11.4	1.85e-28	1.71e-25	0.39	0.33	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	11.4	1.85e-28	1.71e-25	0.39	0.33	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	11.4	1.87e-28	1.73e-25	0.37	0.33	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
BRCA	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	11.4	1.87e-28	1.73e-25	0.3	0.33	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-11.4	1.88e-28	1.74e-25	-0.42	-0.33	Depression;	chr6:28187640	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-11.4	1.92e-28	1.77e-25	-0.39	-0.33	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
BRCA	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-11.4	1.92e-28	1.78e-25	-0.44	-0.33	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
BRCA	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-11.4	1.97e-28	1.82e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-11.39	1.98e-28	1.83e-25	-0.4	-0.33	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
BRCA	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-11.39	2e-28	1.85e-25	-0.41	-0.33	Height;	chr6:109405874	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-11.39	2.01e-28	1.86e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	11.39	2.02e-28	1.87e-25	0.39	0.33	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-11.39	2.06e-28	1.9e-25	-0.39	-0.33	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
BRCA	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-11.39	2.07e-28	1.91e-25	-0.42	-0.33	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
BRCA	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-11.39	2.07e-28	1.92e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-11.39	2.08e-28	1.92e-25	-0.43	-0.33	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
BRCA	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-11.39	2.11e-28	1.95e-25	-0.4	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
BRCA	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-11.39	2.11e-28	1.95e-25	-0.46	-0.33	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
BRCA	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-11.39	2.12e-28	1.96e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	11.39	2.13e-28	1.97e-25	0.37	0.33	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	11.39	2.14e-28	1.98e-25	0.45	0.33	Height;	chr6:109712525	chr6:109382795~109383666:+
BRCA	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-11.39	2.16e-28	1.99e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	11.39	2.17e-28	2.01e-25	0.44	0.33	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
BRCA	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-11.39	2.18e-28	2.01e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
BRCA	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	11.38	2.19e-28	2.02e-25	0.3	0.33	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
BRCA	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-11.38	2.2e-28	2.03e-25	-0.38	-0.33	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-11.38	2.21e-28	2.04e-25	-0.39	-0.33	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-11.38	2.23e-28	2.06e-25	-0.44	-0.33	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-11.38	2.24e-28	2.07e-25	-0.39	-0.33	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-11.38	2.24e-28	2.07e-25	-0.39	-0.33	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
BRCA	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-11.38	2.26e-28	2.08e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
BRCA	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	11.38	2.26e-28	2.09e-25	0.52	0.33	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
BRCA	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
BRCA	cis	rs4727443	0.966	rs66748925	ENSG00000214313.7	AZGP1P1	-11.38	2.33e-28	2.15e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99992220	chr7:99980762~99987535:+
BRCA	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	11.38	2.38e-28	2.19e-25	0.38	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	11.38	2.39e-28	2.2e-25	0.39	0.33	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	11.38	2.39e-28	2.2e-25	0.39	0.33	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-11.38	2.41e-28	2.22e-25	-0.39	-0.33	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	11.38	2.41e-28	2.22e-25	0.39	0.33	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
BRCA	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	11.37	2.44e-28	2.25e-25	0.47	0.33	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
BRCA	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	11.37	2.45e-28	2.26e-25	0.42	0.33	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
BRCA	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	11.37	2.49e-28	2.29e-25	0.37	0.33	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	11.37	2.57e-28	2.37e-25	0.44	0.33	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	11.37	2.59e-28	2.38e-25	0.39	0.33	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
BRCA	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-11.37	2.6e-28	2.39e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
BRCA	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-11.37	2.62e-28	2.41e-25	-0.39	-0.33	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
BRCA	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-11.37	2.63e-28	2.42e-25	-0.4	-0.33	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-11.37	2.63e-28	2.42e-25	-0.4	-0.33	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-11.37	2.64e-28	2.43e-25	-0.43	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-11.37	2.64e-28	2.43e-25	-0.43	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
BRCA	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	11.37	2.65e-28	2.43e-25	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
BRCA	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-11.36	2.68e-28	2.46e-25	-0.39	-0.33	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-11.36	2.68e-28	2.46e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	11.36	2.69e-28	2.47e-25	0.38	0.33	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-11.36	2.7e-28	2.48e-25	-0.64	-0.33	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-11.36	2.72e-28	2.5e-25	-0.39	-0.33	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
BRCA	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-11.36	2.75e-28	2.53e-25	-0.39	-0.33	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	11.36	2.79e-28	2.56e-25	0.43	0.33	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-11.36	2.82e-28	2.59e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
BRCA	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-11.36	2.84e-28	2.61e-25	-0.54	-0.33	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
BRCA	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	11.36	2.85e-28	2.62e-25	0.34	0.33	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
BRCA	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-11.36	2.87e-28	2.63e-25	-0.4	-0.33	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
BRCA	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-11.36	2.87e-28	2.64e-25	-0.36	-0.33	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
BRCA	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	11.36	2.89e-28	2.65e-25	0.47	0.33	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-11.36	2.91e-28	2.67e-25	-0.39	-0.33	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.36	2.93e-28	2.69e-25	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
BRCA	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-11.36	2.94e-28	2.7e-25	-0.37	-0.33	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	11.36	2.96e-28	2.72e-25	0.39	0.33	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000278665.1	RP11-666O2.4	11.35	2.99e-28	2.75e-25	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-11.35	3.03e-28	2.78e-25	-0.52	-0.33	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
BRCA	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	11.35	3.03e-28	2.78e-25	0.39	0.33	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	11.35	3.07e-28	2.81e-25	0.44	0.33	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
BRCA	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	11.35	3.12e-28	2.85e-25	0.41	0.33	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
BRCA	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	11.35	3.13e-28	2.87e-25	0.39	0.33	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-11.35	3.15e-28	2.89e-25	-0.39	-0.33	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.569	rs1049137	ENSG00000274877.1	RP11-65I12.1	-11.35	3.17e-28	2.9e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113217533	chr2:113237595~113240825:+
BRCA	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-11.35	3.22e-28	2.94e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
BRCA	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-11.35	3.23e-28	2.96e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
BRCA	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	11.35	3.23e-28	2.96e-25	0.39	0.33	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	11.35	3.25e-28	2.97e-25	0.38	0.33	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-11.34	3.33e-28	3.05e-25	-0.49	-0.33	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
BRCA	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
BRCA	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.34e-28	3.05e-25	-0.37	-0.33	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.34e-28	3.05e-25	-0.37	-0.33	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	11.34	3.38e-28	3.09e-25	0.39	0.33	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
BRCA	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	11.34	3.41e-28	3.12e-25	0.3	0.33	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	11.34	3.43e-28	3.14e-25	0.44	0.33	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-11.34	3.44e-28	3.15e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
BRCA	cis	rs4727443	0.899	rs6954978	ENSG00000214313.7	AZGP1P1	-11.34	3.44e-28	3.15e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99984589	chr7:99980762~99987535:+
BRCA	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-11.34	3.47e-28	3.17e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	11.34	3.5e-28	3.2e-25	0.44	0.33	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	11.34	3.53e-28	3.22e-25	0.39	0.33	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-11.34	3.54e-28	3.24e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-11.34	3.55e-28	3.24e-25	-0.39	-0.33	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
BRCA	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-11.34	3.59e-28	3.28e-25	-0.49	-0.33	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
BRCA	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	11.34	3.59e-28	3.28e-25	0.41	0.33	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
BRCA	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	11.34	3.59e-28	3.28e-25	0.35	0.33	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
BRCA	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.61e-28	3.29e-25	-0.38	-0.33	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
BRCA	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-11.33	3.65e-28	3.33e-25	-0.38	-0.33	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	11.33	3.71e-28	3.38e-25	0.39	0.33	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-11.33	3.71e-28	3.39e-25	-0.4	-0.33	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-11.33	3.76e-28	3.43e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
BRCA	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	11.33	3.8e-28	3.47e-25	0.39	0.33	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	11.33	3.8e-28	3.47e-25	0.39	0.33	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	11.33	3.85e-28	3.51e-25	0.43	0.33	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
BRCA	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	11.33	3.86e-28	3.52e-25	0.3	0.33	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
BRCA	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	11.33	3.87e-28	3.53e-25	0.37	0.33	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-11.33	3.91e-28	3.56e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	11.33	3.92e-28	3.57e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
BRCA	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-11.33	3.96e-28	3.6e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	11.33	3.98e-28	3.62e-25	0.4	0.33	Height;	chr6:109361318	chr6:109382795~109383666:+
BRCA	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-11.33	3.98e-28	3.63e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
BRCA	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	11.33	3.98e-28	3.63e-25	0.48	0.33	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	11.33	3.99e-28	3.63e-25	0.4	0.33	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
BRCA	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-11.33	3.99e-28	3.63e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
BRCA	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	11.33	3.99e-28	3.64e-25	0.38	0.33	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	11.33	4.02e-28	3.66e-25	0.38	0.33	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	11.32	4.05e-28	3.68e-25	0.37	0.33	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	11.32	4.11e-28	3.74e-25	0.39	0.33	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-11.32	4.12e-28	3.75e-25	-0.4	-0.33	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
BRCA	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-11.32	4.15e-28	3.77e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-11.32	4.19e-28	3.81e-25	-0.4	-0.33	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
BRCA	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-11.32	4.2e-28	3.82e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
BRCA	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	11.32	4.21e-28	3.82e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
BRCA	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-11.32	4.26e-28	3.87e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	11.32	4.26e-28	3.87e-25	0.37	0.33	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	11.32	4.26e-28	3.87e-25	0.44	0.33	Height;	chr6:109708527	chr6:109382795~109383666:+
BRCA	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	11.32	4.32e-28	3.92e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-11.32	4.34e-28	3.94e-25	-0.41	-0.33	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
BRCA	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	11.32	4.36e-28	3.96e-25	0.39	0.33	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-11.32	4.38e-28	3.98e-25	-0.39	-0.33	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
BRCA	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	11.31	4.55e-28	4.13e-25	0.34	0.33	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	11.31	4.59e-28	4.17e-25	0.38	0.33	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-11.31	4.6e-28	4.18e-25	-0.39	-0.33	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-11.31	4.62e-28	4.19e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
BRCA	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	11.31	4.62e-28	4.2e-25	0.54	0.33	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-11.31	4.69e-28	4.25e-25	-0.63	-0.33	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
BRCA	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	11.31	4.75e-28	4.31e-25	0.42	0.33	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
BRCA	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-11.31	4.8e-28	4.35e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
BRCA	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-11.31	4.84e-28	4.38e-25	-0.48	-0.33	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
BRCA	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	11.31	4.84e-28	4.38e-25	0.53	0.33	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
BRCA	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	11.31	4.84e-28	4.39e-25	0.48	0.33	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
BRCA	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-11.3	4.99e-28	4.52e-25	-0.39	-0.33	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
BRCA	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-11.3	5.04e-28	4.56e-25	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-11.3	5.27e-28	4.76e-25	-0.52	-0.33	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
BRCA	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	11.3	5.32e-28	4.81e-25	0.38	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	11.3	5.33e-28	4.82e-25	0.39	0.33	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-11.3	5.43e-28	4.91e-25	-0.54	-0.33	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
BRCA	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-11.3	5.44e-28	4.91e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-11.3	5.44e-28	4.91e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
BRCA	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-11.29	5.46e-28	4.93e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
BRCA	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-11.29	5.48e-28	4.95e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
BRCA	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-11.29	5.55e-28	5.01e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	11.29	5.59e-28	5.04e-25	0.42	0.33	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
BRCA	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-11.29	5.67e-28	5.12e-25	-0.38	-0.33	Migraine;	chr4:56956882	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-11.29	5.82e-28	5.25e-25	-0.38	-0.33	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-11.29	5.95e-28	5.36e-25	-0.4	-0.33	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
BRCA	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-11.29	5.99e-28	5.4e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	11.29	6.02e-28	5.43e-25	0.38	0.33	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
BRCA	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-11.29	6.03e-28	5.43e-25	-0.53	-0.33	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
BRCA	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
BRCA	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	11.28	6.11e-28	5.5e-25	0.48	0.33	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-11.28	6.11e-28	5.5e-25	-0.38	-0.33	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-11.28	6.11e-28	5.5e-25	-0.38	-0.33	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
BRCA	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-11.28	6.15e-28	5.54e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-11.28	6.15e-28	5.54e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
BRCA	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	11.28	6.17e-28	5.55e-25	0.42	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
BRCA	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	11.28	6.21e-28	5.59e-25	0.4	0.33	Height;	chr6:109414295	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	11.28	6.27e-28	5.64e-25	0.39	0.33	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-11.28	6.43e-28	5.78e-25	-0.37	-0.33	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
BRCA	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-11.28	6.48e-28	5.83e-25	-0.37	-0.33	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
BRCA	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	11.28	6.5e-28	5.84e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	11.28	6.52e-28	5.85e-25	0.64	0.33	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-11.28	6.55e-28	5.88e-25	-0.46	-0.33	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
BRCA	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-11.28	6.56e-28	5.9e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-11.27	6.71e-28	6.02e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-11.27	6.72e-28	6.03e-25	-0.37	-0.33	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
BRCA	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	11.27	6.73e-28	6.04e-25	0.43	0.33	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
BRCA	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-11.27	6.74e-28	6.05e-25	-0.42	-0.33	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
BRCA	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-11.27	6.8e-28	6.1e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	11.27	6.81e-28	6.11e-25	0.39	0.33	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-11.27	6.82e-28	6.12e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-11.27	6.93e-28	6.22e-25	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
BRCA	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-11.27	6.98e-28	6.26e-25	-0.35	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-11.27	7.03e-28	6.3e-25	-0.41	-0.33	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-11.27	7.03e-28	6.3e-25	-0.41	-0.33	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	11.27	7.04e-28	6.31e-25	0.25	0.33	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-11.27	7.06e-28	6.33e-25	-0.38	-0.33	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
BRCA	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	11.27	7.12e-28	6.38e-25	0.35	0.33	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
BRCA	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	11.27	7.13e-28	6.39e-25	0.38	0.33	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-11.27	7.15e-28	6.41e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	11.27	7.18e-28	6.44e-25	0.38	0.33	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	11.27	7.23e-28	6.48e-25	0.38	0.33	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	11.27	7.28e-28	6.53e-25	0.37	0.33	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
BRCA	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-11.27	7.38e-28	6.61e-25	-0.47	-0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
BRCA	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-11.26	7.47e-28	6.69e-25	-0.39	-0.33	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-11.26	7.47e-28	6.69e-25	-0.39	-0.33	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-11.26	7.47e-28	6.69e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	11.26	7.55e-28	6.76e-25	0.25	0.33	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	11.26	7.56e-28	6.76e-25	0.39	0.33	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-11.26	7.6e-28	6.8e-25	-0.41	-0.33	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
BRCA	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	11.26	7.6e-28	6.8e-25	0.47	0.33	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000278665.1	RP11-666O2.4	11.26	7.62e-28	6.81e-25	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28599241~28601881:-
BRCA	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	11.26	7.69e-28	6.88e-25	0.44	0.33	Height;	chr6:109762861	chr6:109382795~109383666:+
BRCA	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-11.26	7.85e-28	7.02e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
BRCA	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-11.26	7.95e-28	7.11e-25	-0.44	-0.33	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
BRCA	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-11.26	8.01e-28	7.16e-25	-0.42	-0.33	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
BRCA	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-11.26	8.07e-28	7.2e-25	-0.39	-0.33	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
BRCA	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-11.26	8.16e-28	7.29e-25	-0.52	-0.33	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
BRCA	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	11.26	8.17e-28	7.3e-25	0.38	0.33	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	11.25	8.18e-28	7.3e-25	0.39	0.33	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
BRCA	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-11.25	8.25e-28	7.37e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-11.25	8.31e-28	7.42e-25	-0.39	-0.33	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-11.25	8.31e-28	7.42e-25	-0.39	-0.33	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-11.25	8.32e-28	7.42e-25	-0.44	-0.33	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
BRCA	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	11.25	8.32e-28	7.43e-25	0.42	0.33	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
BRCA	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	11.25	8.39e-28	7.49e-25	0.54	0.33	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
BRCA	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	11.25	8.4e-28	7.49e-25	0.38	0.33	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	11.25	8.4e-28	7.49e-25	0.38	0.33	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	11.25	8.43e-28	7.52e-25	0.38	0.33	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
BRCA	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-11.25	8.48e-28	7.56e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
BRCA	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-11.25	8.51e-28	7.59e-25	-0.54	-0.33	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
BRCA	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	11.25	8.51e-28	7.59e-25	0.36	0.33	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
BRCA	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	11.25	8.52e-28	7.6e-25	0.48	0.33	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	11.25	8.6e-28	7.67e-25	0.25	0.33	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
BRCA	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-11.25	8.7e-28	7.76e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	11.25	8.72e-28	7.78e-25	0.39	0.33	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-11.25	8.76e-28	7.81e-25	-0.41	-0.33	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
BRCA	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-11.25	8.81e-28	7.85e-25	-0.47	-0.33	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
BRCA	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	11.25	8.85e-28	7.88e-25	0.35	0.33	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
BRCA	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	11.25	8.89e-28	7.92e-25	0.47	0.33	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
BRCA	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-11.25	8.93e-28	7.95e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-11.25	9e-28	8.02e-25	-0.24	-0.33	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	11.24	9.14e-28	8.14e-25	0.39	0.33	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-11.24	9.15e-28	8.14e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	11.24	9.17e-28	8.16e-25	0.25	0.33	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
BRCA	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-11.24	9.22e-28	8.21e-25	-0.4	-0.33	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
BRCA	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	11.24	9.22e-28	8.21e-25	0.45	0.33	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
BRCA	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
BRCA	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	11.24	9.29e-28	8.26e-25	0.37	0.33	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-11.24	9.42e-28	8.38e-25	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	11.24	9.5e-28	8.45e-25	0.39	0.33	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	11.24	9.51e-28	8.45e-25	0.39	0.33	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	11.24	9.53e-28	8.47e-25	0.38	0.33	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-11.24	9.54e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-11.24	9.55e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-11.24	9.55e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-11.24	9.75e-28	8.66e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-11.24	9.84e-28	8.74e-25	-0.39	-0.33	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-11.24	9.84e-28	8.74e-25	-0.39	-0.33	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
BRCA	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
BRCA	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-11.24	9.89e-28	8.78e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
BRCA	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-11.24	9.89e-28	8.78e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
BRCA	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	11.24	9.93e-28	8.81e-25	0.38	0.33	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
BRCA	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	11.24	9.94e-28	8.82e-25	0.41	0.33	Height;	chr6:109530435	chr6:109382795~109383666:+
BRCA	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-11.23	1.01e-27	9e-25	-0.39	-0.33	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
BRCA	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-11.23	1.03e-27	9.12e-25	-0.39	-0.33	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	11.23	1.04e-27	9.21e-25	0.55	0.33	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
BRCA	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-11.23	1.05e-27	9.33e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
BRCA	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-11.23	1.06e-27	9.37e-25	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
BRCA	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	11.23	1.06e-27	9.39e-25	0.4	0.33	Height;	chr6:109366911	chr6:109382795~109383666:+
BRCA	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-11.23	1.07e-27	9.44e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
BRCA	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	11.23	1.07e-27	9.5e-25	0.39	0.33	Height;	chr6:109415411	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-11.23	1.08e-27	9.55e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	11.23	1.08e-27	9.57e-25	0.44	0.33	Height;	chr6:109764163	chr6:109382795~109383666:+
BRCA	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-11.23	1.09e-27	9.6e-25	-0.39	-0.33	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
BRCA	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	11.23	1.09e-27	9.61e-25	0.58	0.33	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	11.23	1.09e-27	9.61e-25	0.58	0.33	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
BRCA	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-11.23	1.09e-27	9.62e-25	-0.4	-0.33	Height;	chr2:231490121	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-11.23	1.09e-27	9.62e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
BRCA	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-11.23	1.1e-27	9.69e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-11.22	1.11e-27	9.81e-25	-0.38	-0.33	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	11.22	1.13e-27	9.94e-25	0.25	0.33	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
BRCA	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	11.22	1.13e-27	9.95e-25	0.42	0.33	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-11.22	1.13e-27	1e-24	-0.38	-0.33	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
BRCA	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-11.22	1.14e-27	1e-24	-0.43	-0.33	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-11.22	1.14e-27	1e-24	-0.43	-0.33	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
BRCA	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	11.22	1.14e-27	1.01e-24	0.39	0.33	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	11.22	1.14e-27	1.01e-24	0.45	0.33	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
BRCA	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	11.22	1.16e-27	1.02e-24	0.57	0.33	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
BRCA	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	11.22	1.16e-27	1.03e-24	0.38	0.33	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
BRCA	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-11.22	1.16e-27	1.03e-24	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
BRCA	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-11.22	1.17e-27	1.03e-24	-0.37	-0.33	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	11.22	1.17e-27	1.03e-24	0.39	0.33	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	11.22	1.17e-27	1.03e-24	0.4	0.33	Height;	chr6:109371573	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-11.22	1.18e-27	1.04e-24	-0.43	-0.33	Depression;	chr6:28109824	chr6:28073316~28074233:+
BRCA	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-11.22	1.18e-27	1.04e-24	-0.39	-0.33	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
BRCA	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	11.22	1.2e-27	1.06e-24	0.54	0.33	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
BRCA	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	11.22	1.2e-27	1.06e-24	0.37	0.33	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
BRCA	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	11.22	1.2e-27	1.06e-24	0.47	0.33	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
BRCA	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
BRCA	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-11.22	1.21e-27	1.06e-24	-0.49	-0.33	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
BRCA	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-11.22	1.21e-27	1.07e-24	-0.47	-0.33	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-11.22	1.21e-27	1.07e-24	-0.39	-0.33	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-11.22	1.22e-27	1.07e-24	-0.4	-0.33	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	11.21	1.23e-27	1.08e-24	0.63	0.33	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	11.21	1.23e-27	1.08e-24	0.63	0.33	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	11.21	1.23e-27	1.08e-24	0.47	0.33	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-11.21	1.26e-27	1.11e-24	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
BRCA	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-11.21	1.26e-27	1.11e-24	-0.55	-0.33	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
BRCA	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-11.21	1.27e-27	1.11e-24	-0.39	-0.33	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
BRCA	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-11.21	1.28e-27	1.13e-24	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	11.21	1.29e-27	1.13e-24	0.39	0.33	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
BRCA	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	11.21	1.29e-27	1.13e-24	0.54	0.33	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	11.21	1.3e-27	1.14e-24	0.63	0.33	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	11.21	1.3e-27	1.14e-24	0.63	0.33	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
BRCA	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-11.21	1.32e-27	1.16e-24	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-11.21	1.34e-27	1.17e-24	-0.53	-0.33	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-11.2	1.36e-27	1.19e-24	-0.41	-0.33	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
BRCA	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
BRCA	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
BRCA	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	11.2	1.39e-27	1.22e-24	0.4	0.33	Height;	chr6:109375003	chr6:109382795~109383666:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	11.2	1.41e-27	1.23e-24	0.63	0.33	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-11.2	1.42e-27	1.24e-24	-0.39	-0.33	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
BRCA	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	11.2	1.42e-27	1.25e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
BRCA	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	11.2	1.44e-27	1.26e-24	0.38	0.33	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	11.2	1.44e-27	1.26e-24	0.38	0.33	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	11.2	1.45e-27	1.27e-24	0.38	0.33	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	11.2	1.45e-27	1.27e-24	0.39	0.33	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	11.2	1.45e-27	1.27e-24	0.39	0.33	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	11.2	1.47e-27	1.29e-24	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-11.2	1.49e-27	1.31e-24	-0.41	-0.33	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-11.2	1.5e-27	1.31e-24	-0.39	-0.33	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	11.19	1.51e-27	1.32e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
BRCA	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-11.19	1.51e-27	1.33e-24	-0.43	-0.33	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	11.19	1.53e-27	1.34e-24	0.4	0.33	Height;	chr6:109395761	chr6:109382795~109383666:+
BRCA	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-11.19	1.56e-27	1.36e-24	-0.38	-0.33	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
BRCA	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-11.19	1.56e-27	1.36e-24	-0.36	-0.33	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
BRCA	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-11.19	1.58e-27	1.38e-24	-0.39	-0.33	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	11.19	1.58e-27	1.38e-24	0.39	0.33	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-11.19	1.59e-27	1.39e-24	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-11.19	1.61e-27	1.4e-24	-0.39	-0.33	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-11.19	1.61e-27	1.4e-24	-0.39	-0.33	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-11.19	1.63e-27	1.42e-24	-0.39	-0.33	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
BRCA	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	11.19	1.63e-27	1.42e-24	0.37	0.33	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
BRCA	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	11.19	1.63e-27	1.43e-24	0.42	0.33	QT interval;	chr16:28860645	chr16:28700294~28701540:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	11.19	1.65e-27	1.44e-24	0.44	0.33	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-11.19	1.65e-27	1.44e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
BRCA	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	11.18	1.67e-27	1.46e-24	0.42	0.33	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
BRCA	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	11.18	1.67e-27	1.46e-24	0.37	0.33	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	11.18	1.67e-27	1.46e-24	0.37	0.33	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
BRCA	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	11.18	1.68e-27	1.46e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
BRCA	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	11.18	1.69e-27	1.48e-24	0.38	0.33	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
BRCA	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	11.18	1.69e-27	1.48e-24	0.43	0.33	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	11.18	1.7e-27	1.48e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-11.18	1.7e-27	1.48e-24	-0.39	-0.33	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	11.18	1.71e-27	1.49e-24	0.39	0.33	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-11.18	1.71e-27	1.49e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
BRCA	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-11.18	1.74e-27	1.52e-24	-0.4	-0.33	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	11.18	1.74e-27	1.52e-24	0.39	0.33	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	11.18	1.75e-27	1.53e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-11.18	1.76e-27	1.53e-24	-0.45	-0.33	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	11.18	1.77e-27	1.54e-24	0.63	0.33	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
BRCA	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
BRCA	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-11.18	1.8e-27	1.57e-24	-0.42	-0.33	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
BRCA	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-11.18	1.8e-27	1.57e-24	-0.39	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
BRCA	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	11.18	1.81e-27	1.58e-24	0.43	0.33	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
BRCA	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-11.18	1.83e-27	1.6e-24	-0.37	-0.33	Migraine;	chr4:56937339	chr4:56960927~56961373:-
BRCA	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-11.17	1.84e-27	1.6e-24	-0.39	-0.33	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	11.17	1.85e-27	1.61e-24	0.39	0.33	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-11.17	1.88e-27	1.64e-24	-0.45	-0.33	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
BRCA	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
BRCA	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	11.17	1.89e-27	1.65e-24	0.43	0.33	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
BRCA	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-11.17	1.9e-27	1.65e-24	-0.38	-0.33	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-11.17	1.9e-27	1.65e-24	-0.24	-0.33	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
BRCA	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-11.17	1.9e-27	1.66e-24	-0.35	-0.33	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
BRCA	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	11.17	1.93e-27	1.68e-24	0.39	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
BRCA	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	11.17	1.93e-27	1.68e-24	0.48	0.33	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
BRCA	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-11.17	1.96e-27	1.71e-24	-0.37	-0.33	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
BRCA	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-11.17	1.98e-27	1.72e-24	-0.41	-0.33	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
BRCA	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	11.17	1.99e-27	1.73e-24	0.35	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
BRCA	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-11.17	2.01e-27	1.75e-24	-0.39	-0.33	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	11.17	2.02e-27	1.76e-24	0.39	0.33	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-11.16	2.03e-27	1.76e-24	-0.39	-0.33	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-11.16	2.08e-27	1.8e-24	-0.34	-0.33	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
BRCA	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	11.16	2.09e-27	1.81e-24	0.55	0.33	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-11.16	2.09e-27	1.82e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
BRCA	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-11.16	2.1e-27	1.82e-24	-0.42	-0.33	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
BRCA	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-11.16	2.1e-27	1.83e-24	-0.37	-0.33	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
BRCA	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-11.16	2.12e-27	1.84e-24	-0.39	-0.33	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
BRCA	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-11.16	2.12e-27	1.84e-24	-0.42	-0.33	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-11.16	2.12e-27	1.84e-24	-0.38	-0.33	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
BRCA	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	11.16	2.13e-27	1.85e-24	0.42	0.33	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
BRCA	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-11.16	2.15e-27	1.86e-24	-0.39	-0.33	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-11.16	2.15e-27	1.87e-24	-0.42	-0.33	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-11.16	2.16e-27	1.87e-24	-0.39	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	11.16	2.16e-27	1.88e-24	0.42	0.33	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-11.16	2.17e-27	1.88e-24	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	11.16	2.17e-27	1.89e-24	0.24	0.33	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
BRCA	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-11.16	2.18e-27	1.89e-24	-0.4	-0.33	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
BRCA	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-11.16	2.19e-27	1.9e-24	-0.39	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-11.16	2.19e-27	1.9e-24	-0.39	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
BRCA	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	11.16	2.19e-27	1.9e-24	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-11.16	2.2e-27	1.91e-24	-0.39	-0.33	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
BRCA	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-11.16	2.22e-27	1.93e-24	-0.42	-0.33	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
BRCA	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	11.16	2.23e-27	1.93e-24	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	11.16	2.23e-27	1.93e-24	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
BRCA	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	11.16	2.23e-27	1.93e-24	0.39	0.33	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	11.15	2.25e-27	1.95e-24	0.47	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-11.15	2.29e-27	1.98e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	11.15	2.29e-27	1.98e-24	0.34	0.33	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
BRCA	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	11.15	2.29e-27	1.99e-24	0.55	0.33	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
BRCA	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-11.15	2.3e-27	1.99e-24	-0.49	-0.33	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
BRCA	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-11.15	2.31e-27	2e-24	-0.39	-0.33	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
BRCA	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.31e-27	2e-24	-0.37	-0.33	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.04e-24	-0.39	-0.33	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
BRCA	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-11.15	2.36e-27	2.04e-24	-0.39	-0.33	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
BRCA	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-11.15	2.37e-27	2.05e-24	-0.39	-0.33	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
BRCA	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.37e-27	2.05e-24	-0.36	-0.33	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	11.15	2.39e-27	2.06e-24	0.37	0.33	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
BRCA	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	11.15	2.4e-27	2.08e-24	0.35	0.33	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	11.15	2.41e-27	2.08e-24	0.38	0.33	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-11.15	2.41e-27	2.08e-24	-0.43	-0.33	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
BRCA	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	11.15	2.42e-27	2.09e-24	0.38	0.33	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	11.15	2.43e-27	2.1e-24	0.38	0.33	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	11.15	2.43e-27	2.1e-24	0.4	0.33	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	11.15	2.43e-27	2.1e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-11.15	2.43e-27	2.11e-24	-0.37	-0.33	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
BRCA	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	11.15	2.44e-27	2.11e-24	0.38	0.33	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.46e-27	2.13e-24	-0.36	-0.33	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-11.14	2.52e-27	2.18e-24	-0.39	-0.33	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
BRCA	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	11.14	2.53e-27	2.19e-24	0.35	0.33	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
BRCA	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	11.14	2.55e-27	2.2e-24	0.38	0.33	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-11.14	2.58e-27	2.23e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-11.14	2.61e-27	2.25e-24	-0.39	-0.33	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	11.14	2.63e-27	2.27e-24	0.37	0.33	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	11.14	2.63e-27	2.27e-24	0.37	0.33	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
BRCA	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-11.14	2.64e-27	2.28e-24	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
BRCA	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-11.14	2.64e-27	2.28e-24	-0.43	-0.33	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
BRCA	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	11.14	2.66e-27	2.29e-24	0.35	0.33	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-11.14	2.66e-27	2.3e-24	-0.24	-0.33	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
BRCA	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	11.14	2.68e-27	2.31e-24	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-11.14	2.68e-27	2.32e-24	-0.38	-0.33	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-11.14	2.7e-27	2.33e-24	-0.39	-0.33	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-11.14	2.7e-27	2.33e-24	-0.39	-0.33	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
BRCA	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	11.13	2.75e-27	2.37e-24	0.4	0.33	Height;	chr6:109380457	chr6:109382795~109383666:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	11.13	2.77e-27	2.38e-24	0.62	0.33	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
BRCA	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-11.13	2.8e-27	2.41e-24	-0.38	-0.33	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
BRCA	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	11.13	2.82e-27	2.43e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
BRCA	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-11.13	2.82e-27	2.43e-24	-0.35	-0.33	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-11.13	2.83e-27	2.44e-24	-0.39	-0.33	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
BRCA	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-11.13	2.85e-27	2.46e-24	-0.35	-0.33	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
BRCA	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-11.13	2.87e-27	2.47e-24	-0.39	-0.33	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	11.13	2.89e-27	2.49e-24	0.38	0.33	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-11.13	2.95e-27	2.54e-24	-0.44	-0.33	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
BRCA	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-11.13	2.95e-27	2.54e-24	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-11.13	2.96e-27	2.55e-24	-0.38	-0.33	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-11.13	2.96e-27	2.55e-24	-0.38	-0.33	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-11.13	2.98e-27	2.56e-24	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
BRCA	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-11.13	3e-27	2.58e-24	-0.37	-0.33	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	11.13	3e-27	2.58e-24	0.39	0.33	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	11.12	3.05e-27	2.63e-24	0.44	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
BRCA	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	11.12	3.05e-27	2.63e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
BRCA	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	11.12	3.05e-27	2.63e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
BRCA	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-11.12	3.08e-27	2.65e-24	-0.45	-0.33	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-11.12	3.1e-27	2.67e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
BRCA	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	11.12	3.12e-27	2.68e-24	0.48	0.33	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
BRCA	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	11.12	3.12e-27	2.68e-24	0.46	0.33	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	11.12	3.13e-27	2.69e-24	0.46	0.33	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-11.12	3.22e-27	2.76e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
BRCA	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-11.12	3.22e-27	2.77e-24	-0.36	-0.33	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	11.12	3.25e-27	2.79e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
BRCA	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	11.12	3.27e-27	2.81e-24	0.37	0.33	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
BRCA	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	11.12	3.33e-27	2.86e-24	0.38	0.33	Height;	chr6:109706740	chr6:109382795~109383666:+
BRCA	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	11.11	3.38e-27	2.9e-24	0.37	0.33	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
BRCA	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-11.11	3.38e-27	2.9e-24	-0.37	-0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
BRCA	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	11.11	3.4e-27	2.92e-24	0.38	0.33	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-11.11	3.41e-27	2.92e-24	-0.39	-0.33	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
BRCA	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-11.11	3.42e-27	2.93e-24	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
BRCA	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	11.11	3.44e-27	2.94e-24	0.39	0.33	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
BRCA	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	11.11	3.44e-27	2.95e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-11.11	3.45e-27	2.95e-24	-0.24	-0.33	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
BRCA	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	11.11	3.53e-27	3.02e-24	0.39	0.33	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
BRCA	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	11.11	3.55e-27	3.04e-24	0.35	0.33	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	11.11	3.61e-27	3.09e-24	0.25	0.33	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
BRCA	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	11.11	3.67e-27	3.14e-24	0.39	0.33	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
BRCA	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-11.1	3.76e-27	3.21e-24	-0.39	-0.33	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
BRCA	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-11.1	3.77e-27	3.22e-24	-0.37	-0.33	Migraine;	chr4:56943905	chr4:56960927~56961373:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-11.1	3.81e-27	3.25e-24	-0.45	-0.33	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
BRCA	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	11.1	3.81e-27	3.26e-24	0.36	0.33	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
BRCA	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-11.1	3.9e-27	3.33e-24	-0.42	-0.33	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
BRCA	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	11.1	3.99e-27	3.4e-24	0.46	0.33	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
BRCA	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-11.1	4.09e-27	3.48e-24	-0.38	-0.33	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
BRCA	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-11.09	4.09e-27	3.49e-24	-0.4	-0.33	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
BRCA	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	11.09	4.09e-27	3.49e-24	0.38	0.33	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
BRCA	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	11.09	4.09e-27	3.49e-24	0.29	0.33	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
BRCA	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	11.09	4.1e-27	3.49e-24	0.34	0.33	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-11.09	4.14e-27	3.52e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	11.09	4.16e-27	3.55e-24	0.38	0.33	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-11.09	4.17e-27	3.55e-24	-0.38	-0.32	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
BRCA	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	11.09	4.18e-27	3.56e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	11.09	4.2e-27	3.58e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
BRCA	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	11.09	4.24e-27	3.61e-24	0.36	0.32	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
BRCA	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	11.09	4.26e-27	3.63e-24	0.38	0.32	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
BRCA	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	11.09	4.28e-27	3.64e-24	0.43	0.32	Cancer;	chr7:142407435	chr7:142554836~142555318:+
BRCA	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	11.09	4.31e-27	3.67e-24	0.38	0.32	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
BRCA	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	11.09	4.42e-27	3.75e-24	0.51	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
BRCA	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-11.09	4.43e-27	3.76e-24	-0.37	-0.32	Migraine;	chr4:56950140	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-11.09	4.44e-27	3.78e-24	-0.38	-0.32	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-11.09	4.47e-27	3.8e-24	-0.38	-0.32	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
BRCA	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-11.09	4.48e-27	3.8e-24	-0.37	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
BRCA	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	11.09	4.49e-27	3.81e-24	0.39	0.32	Height;	chr6:109380990	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	11.09	4.49e-27	3.82e-24	0.38	0.32	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	11.09	4.52e-27	3.83e-24	0.62	0.32	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	11.09	4.52e-27	3.83e-24	0.62	0.32	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
BRCA	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-11.09	4.52e-27	3.84e-24	-0.37	-0.32	Migraine;	chr4:56940917	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-11.08	4.55e-27	3.86e-24	-0.38	-0.32	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-11.08	4.55e-27	3.86e-24	-0.38	-0.32	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
BRCA	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	11.08	4.55e-27	3.86e-24	0.29	0.32	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
BRCA	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-11.08	4.62e-27	3.92e-24	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
BRCA	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-11.08	4.64e-27	3.94e-24	-0.34	-0.32	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	11.08	4.65e-27	3.94e-24	0.63	0.32	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	11.08	4.65e-27	3.94e-24	0.63	0.32	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
BRCA	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-11.08	4.66e-27	3.95e-24	-0.44	-0.32	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
BRCA	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	11.08	4.67e-27	3.96e-24	0.52	0.32	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
BRCA	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-11.08	4.71e-27	3.99e-24	-0.42	-0.32	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-11.08	4.74e-27	4.02e-24	-0.43	-0.32	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
BRCA	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	11.08	4.83e-27	4.09e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	11.08	4.93e-27	4.17e-24	0.39	0.32	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
BRCA	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-11.07	5e-27	4.22e-24	-0.41	-0.32	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
BRCA	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-11.07	5.05e-27	4.27e-24	-0.4	-0.32	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
BRCA	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-11.07	5.16e-27	4.36e-24	-0.41	-0.32	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	11.07	5.26e-27	4.44e-24	0.38	0.32	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	11.07	5.3e-27	4.47e-24	0.43	0.32	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-11.07	5.31e-27	4.48e-24	-0.39	-0.32	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
BRCA	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-11.07	5.36e-27	4.52e-24	-0.37	-0.32	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
BRCA	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	11.07	5.41e-27	4.56e-24	0.54	0.32	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
BRCA	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-11.07	5.41e-27	4.56e-24	-0.41	-0.32	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	11.07	5.43e-27	4.58e-24	0.25	0.32	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
BRCA	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-11.07	5.51e-27	4.64e-24	-0.39	-0.32	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	11.06	5.55e-27	4.67e-24	0.55	0.32	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
BRCA	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-11.06	5.62e-27	4.73e-24	-0.39	-0.32	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	11.06	5.73e-27	4.82e-24	0.38	0.32	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
BRCA	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-11.06	5.73e-27	4.82e-24	-0.41	-0.32	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
BRCA	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	11.06	5.73e-27	4.83e-24	0.36	0.32	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
BRCA	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	11.06	5.82e-27	4.9e-24	0.54	0.32	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
BRCA	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-11.06	5.83e-27	4.91e-24	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-11.06	5.84e-27	4.91e-24	-0.37	-0.32	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	11.06	5.87e-27	4.94e-24	0.37	0.32	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-11.06	5.94e-27	5e-24	-0.43	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-11.06	5.94e-27	5e-24	-0.43	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-11.06	6.07e-27	5.1e-24	-0.39	-0.32	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
BRCA	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	11.05	6.11e-27	5.14e-24	0.39	0.32	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-11.05	6.14e-27	5.16e-24	-0.24	-0.32	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
BRCA	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-11.05	6.17e-27	5.18e-24	-0.41	-0.32	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
BRCA	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-11.05	6.29e-27	5.28e-24	-0.41	-0.32	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-11.05	6.3e-27	5.29e-24	-0.39	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	11.05	6.32e-27	5.31e-24	0.62	0.32	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	11.05	6.32e-27	5.31e-24	0.62	0.32	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
BRCA	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	11.05	6.36e-27	5.34e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
BRCA	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	11.05	6.4e-27	5.37e-24	0.36	0.32	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
BRCA	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	11.05	6.41e-27	5.38e-24	0.63	0.32	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	11.05	6.47e-27	5.43e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-11.05	6.53e-27	5.48e-24	-0.39	-0.32	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
BRCA	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-11.05	6.55e-27	5.5e-24	-0.41	-0.32	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
BRCA	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-11.05	6.6e-27	5.54e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-11.05	6.6e-27	5.54e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
BRCA	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-11.05	6.63e-27	5.56e-24	-0.37	-0.32	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-11.05	6.68e-27	5.6e-24	-0.38	-0.32	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
BRCA	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-11.04	6.75e-27	5.66e-24	-0.4	-0.32	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
BRCA	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-11.04	6.78e-27	5.68e-24	-0.39	-0.32	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-11.04	6.81e-27	5.7e-24	-0.62	-0.32	Gout;	chr7:66671562	chr7:66654538~66669855:+
BRCA	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-11.04	6.82e-27	5.71e-24	-0.38	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
BRCA	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-11.04	6.88e-27	5.76e-24	-0.35	-0.32	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
BRCA	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-11.04	6.88e-27	5.76e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-11.04	6.9e-27	5.78e-24	-0.39	-0.32	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-11.04	6.96e-27	5.82e-24	-0.45	-0.32	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
BRCA	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-11.04	6.96e-27	5.82e-24	-0.41	-0.32	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
BRCA	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-11.04	6.96e-27	5.83e-24	-0.41	-0.32	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
BRCA	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	11.04	7.07e-27	5.92e-24	0.42	0.32	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-11.04	7.07e-27	5.92e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
BRCA	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	11.04	7.07e-27	5.92e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
BRCA	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-11.04	7.11e-27	5.95e-24	-0.4	-0.32	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
BRCA	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	11.04	7.14e-27	5.97e-24	0.36	0.32	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
BRCA	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	11.04	7.14e-27	5.97e-24	0.57	0.32	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-11.04	7.19e-27	6.01e-24	-0.64	-0.32	Gout;	chr7:66679692	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	11.04	7.19e-27	6.01e-24	0.64	0.32	Gout;	chr7:66682070	chr7:66654538~66669855:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	11.04	7.19e-27	6.01e-24	0.64	0.32	Gout;	chr7:66682162	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-11.04	7.22e-27	6.04e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
BRCA	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-11.04	7.22e-27	6.04e-24	-0.4	-0.32	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
BRCA	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-11.04	7.24e-27	6.05e-24	-0.45	-0.32	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-11.04	7.25e-27	6.06e-24	-0.39	-0.32	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-11.04	7.28e-27	6.09e-24	-0.39	-0.32	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	11.04	7.29e-27	6.09e-24	0.4	0.32	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
BRCA	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-11.04	7.33e-27	6.12e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-11.04	7.38e-27	6.16e-24	-0.25	-0.32	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-11.03	7.49e-27	6.26e-24	-0.36	-0.32	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
BRCA	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-11.03	7.52e-27	6.28e-24	-0.43	-0.32	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-11.03	7.55e-27	6.31e-24	-0.39	-0.32	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
BRCA	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	11.03	7.7e-27	6.42e-24	0.39	0.32	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
BRCA	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-11.03	7.79e-27	6.49e-24	-0.39	-0.32	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-11.03	7.81e-27	6.51e-24	-0.46	-0.32	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	11.03	7.91e-27	6.59e-24	0.33	0.32	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
BRCA	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	11.03	7.98e-27	6.64e-24	0.48	0.32	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	11.03	7.98e-27	6.64e-24	0.62	0.32	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-11.03	8.02e-27	6.68e-24	-0.39	-0.32	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
BRCA	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-11.03	8.1e-27	6.73e-24	-0.41	-0.32	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
BRCA	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-11.02	8.23e-27	6.84e-24	-0.39	-0.32	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	11.02	8.28e-27	6.88e-24	0.38	0.32	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
BRCA	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-11.02	8.3e-27	6.89e-24	-0.36	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
BRCA	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-11.02	8.3e-27	6.9e-24	-0.39	-0.32	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-11.02	8.31e-27	6.9e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-11.02	8.34e-27	6.92e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
BRCA	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-11.02	8.34e-27	6.93e-24	-0.41	-0.32	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-11.02	8.34e-27	6.93e-24	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
BRCA	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	11.02	8.36e-27	6.95e-24	0.46	0.32	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
BRCA	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-11.02	8.39e-27	6.97e-24	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-11.02	8.46e-27	7.03e-24	-0.39	-0.32	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
BRCA	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	11.02	8.53e-27	7.08e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	11.02	8.56e-27	7.1e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
BRCA	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-11.02	8.56e-27	7.11e-24	-0.39	-0.32	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-11.02	8.56e-27	7.11e-24	-0.39	-0.32	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
BRCA	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-11.02	8.6e-27	7.13e-24	-0.36	-0.32	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	11.02	8.69e-27	7.19e-24	0.63	0.32	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
BRCA	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	11.02	8.77e-27	7.26e-24	0.36	0.32	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	11.02	8.77e-27	7.26e-24	0.38	0.32	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-11.02	8.83e-27	7.31e-24	-0.39	-0.32	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	11.02	8.88e-27	7.35e-24	0.42	0.32	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
BRCA	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	11.02	8.89e-27	7.35e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-11.02	8.91e-27	7.37e-24	-0.39	-0.32	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-11.02	8.91e-27	7.37e-24	-0.39	-0.32	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-11.02	8.95e-27	7.4e-24	-0.39	-0.32	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-11.02	8.97e-27	7.42e-24	-0.24	-0.32	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
BRCA	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	11.02	8.99e-27	7.43e-24	0.47	0.32	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-11.01	9.2e-27	7.61e-24	-0.35	-0.32	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
BRCA	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	11.01	9.29e-27	7.68e-24	0.38	0.32	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
BRCA	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-11.01	9.35e-27	7.73e-24	-0.41	-0.32	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
BRCA	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	11.01	9.39e-27	7.75e-24	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-11.01	9.44e-27	7.8e-24	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	11.01	9.5e-27	7.85e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
BRCA	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-11.01	9.54e-27	7.87e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-11.01	9.55e-27	7.89e-24	-0.63	-0.32	Gout;	chr7:66715944	chr7:66654538~66669855:+
BRCA	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-11.01	9.74e-27	8.04e-24	-0.33	-0.32	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
BRCA	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
BRCA	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-11.01	9.9e-27	8.17e-24	-0.41	-0.32	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-11.01	9.93e-27	8.19e-24	-0.39	-0.32	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-11.01	1e-26	8.27e-24	-0.37	-0.32	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
BRCA	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	11	1.01e-26	8.32e-24	0.41	0.32	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
BRCA	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	11	1.02e-26	8.38e-24	0.37	0.32	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.45e-24	-0.39	-0.32	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
BRCA	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-11	1.03e-26	8.45e-24	-0.53	-0.32	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
BRCA	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.47e-24	-0.39	-0.32	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.47e-24	-0.39	-0.32	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-11	1.04e-26	8.54e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
BRCA	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	11	1.04e-26	8.6e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-11	1.05e-26	8.61e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-11	1.05e-26	8.61e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
BRCA	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-11	1.06e-26	8.69e-24	-0.39	-0.32	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	11	1.08e-26	8.9e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-11	1.09e-26	8.94e-24	-0.44	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
BRCA	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-11	1.11e-26	9.08e-24	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
BRCA	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-10.99	1.11e-26	9.12e-24	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
BRCA	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-10.99	1.12e-26	9.16e-24	-0.53	-0.32	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-10.99	1.13e-26	9.27e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
BRCA	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	10.99	1.13e-26	9.29e-24	0.4	0.32	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
BRCA	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-10.99	1.14e-26	9.34e-24	-0.37	-0.32	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-10.99	1.14e-26	9.36e-24	-0.61	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
BRCA	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	10.99	1.17e-26	9.55e-24	0.38	0.32	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
BRCA	cis	rs4380275	0.965	rs12621177	ENSG00000272342.1	RP13-539J13.1	10.99	1.17e-26	9.6e-24	0.41	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:739588~740164:-
BRCA	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	10.99	1.19e-26	9.73e-24	0.37	0.32	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	10.99	1.19e-26	9.76e-24	0.47	0.32	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-10.99	1.2e-26	9.8e-24	-0.38	-0.32	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66692349	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66693433	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66694214	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66701371	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66702658	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66706390	chr7:66654538~66669855:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66710076	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-10.99	1.21e-26	9.87e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
BRCA	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-10.99	1.21e-26	9.93e-24	-0.42	-0.32	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
BRCA	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-10.98	1.23e-26	1e-23	-0.39	-0.32	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-10.98	1.23e-26	1e-23	-0.39	-0.32	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
BRCA	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	10.98	1.23e-26	1.01e-23	0.38	0.32	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	10.98	1.23e-26	1.01e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-10.98	1.24e-26	1.01e-23	-0.45	-0.32	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
BRCA	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	10.98	1.24e-26	1.01e-23	0.37	0.32	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
BRCA	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	10.98	1.24e-26	1.01e-23	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
BRCA	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-10.98	1.25e-26	1.02e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
BRCA	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	10.98	1.25e-26	1.02e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
BRCA	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	10.98	1.26e-26	1.03e-23	0.41	0.32	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-10.98	1.27e-26	1.03e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
BRCA	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-10.98	1.29e-26	1.05e-23	-0.41	-0.32	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
BRCA	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-10.98	1.31e-26	1.07e-23	-0.41	-0.32	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-10.98	1.31e-26	1.07e-23	-0.4	-0.32	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-10.98	1.32e-26	1.07e-23	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
BRCA	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.98	1.34e-26	1.09e-23	-0.43	-0.32	QT interval;	chr16:28877088	chr16:28700294~28701540:-
BRCA	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	10.98	1.35e-26	1.1e-23	0.41	0.32	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
BRCA	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-10.97	1.35e-26	1.1e-23	-0.41	-0.32	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
BRCA	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-10.97	1.36e-26	1.11e-23	-0.43	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
BRCA	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	10.97	1.36e-26	1.11e-23	0.29	0.32	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
BRCA	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-10.97	1.38e-26	1.12e-23	-0.38	-0.32	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-10.97	1.38e-26	1.12e-23	-0.38	-0.32	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
BRCA	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-10.97	1.38e-26	1.12e-23	-0.63	-0.32	Gout;	chr7:66693028	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.97	1.4e-26	1.14e-23	0.33	0.32	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
BRCA	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-10.97	1.41e-26	1.15e-23	-0.42	-0.32	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
BRCA	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-10.97	1.41e-26	1.15e-23	-0.42	-0.32	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-10.97	1.41e-26	1.15e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-10.97	1.42e-26	1.15e-23	-0.38	-0.32	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
BRCA	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-10.97	1.42e-26	1.16e-23	-0.45	-0.32	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	10.97	1.43e-26	1.16e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
BRCA	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-10.97	1.43e-26	1.16e-23	-0.41	-0.32	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
BRCA	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	10.97	1.43e-26	1.16e-23	0.36	0.32	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
BRCA	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	10.97	1.44e-26	1.17e-23	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
BRCA	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-10.97	1.44e-26	1.17e-23	-0.41	-0.32	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-10.97	1.46e-26	1.19e-23	-0.38	-0.32	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-10.97	1.46e-26	1.19e-23	-0.38	-0.32	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-10.97	1.49e-26	1.21e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
BRCA	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-10.96	1.5e-26	1.22e-23	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
BRCA	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-10.96	1.5e-26	1.22e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
BRCA	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
BRCA	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	10.96	1.51e-26	1.22e-23	0.38	0.32	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
BRCA	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	10.96	1.51e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
BRCA	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-10.96	1.53e-26	1.24e-23	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
BRCA	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-10.96	1.56e-26	1.26e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-10.96	1.56e-26	1.27e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
BRCA	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-10.96	1.56e-26	1.27e-23	-0.4	-0.32	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
BRCA	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-10.96	1.56e-26	1.27e-23	-0.51	-0.32	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
BRCA	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-10.96	1.57e-26	1.27e-23	-0.41	-0.32	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	10.96	1.57e-26	1.27e-23	0.37	0.32	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	10.96	1.57e-26	1.27e-23	0.37	0.32	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-10.96	1.58e-26	1.28e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	10.96	1.6e-26	1.3e-23	0.63	0.32	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-10.96	1.61e-26	1.3e-23	-0.38	-0.32	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
BRCA	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-10.96	1.63e-26	1.32e-23	-0.42	-0.32	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	10.96	1.65e-26	1.33e-23	0.37	0.32	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
BRCA	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	10.95	1.65e-26	1.34e-23	0.38	0.32	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	10.95	1.66e-26	1.35e-23	0.38	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
BRCA	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	10.95	1.66e-26	1.35e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	10.95	1.66e-26	1.35e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	10.95	1.66e-26	1.35e-23	0.39	0.32	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
BRCA	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	10.95	1.67e-26	1.35e-23	0.37	0.32	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
BRCA	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	10.95	1.67e-26	1.35e-23	0.41	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
BRCA	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-10.95	1.68e-26	1.36e-23	-0.38	-0.32	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-10.95	1.69e-26	1.37e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
BRCA	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-10.95	1.72e-26	1.39e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-10.95	1.72e-26	1.39e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
BRCA	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-10.95	1.77e-26	1.43e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-10.95	1.79e-26	1.44e-23	-0.38	-0.32	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
BRCA	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-10.95	1.81e-26	1.46e-23	-0.38	-0.32	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-10.94	1.85e-26	1.49e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-10.94	1.85e-26	1.49e-23	-0.38	-0.32	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
BRCA	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	10.94	1.86e-26	1.5e-23	0.44	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
BRCA	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-10.94	1.86e-26	1.5e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-10.94	1.87e-26	1.51e-23	-0.38	-0.32	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
BRCA	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-10.94	1.87e-26	1.51e-23	-0.46	-0.32	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
BRCA	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	10.93	2.01e-26	1.62e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-10.93	2.03e-26	1.63e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	10.93	2.04e-26	1.64e-23	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
BRCA	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-10.93	2.06e-26	1.66e-23	-0.38	-0.32	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-10.93	2.06e-26	1.66e-23	-0.38	-0.32	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	10.93	2.07e-26	1.66e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	10.93	2.07e-26	1.67e-23	0.42	0.32	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-10.93	2.08e-26	1.67e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
BRCA	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-10.93	2.1e-26	1.68e-23	-0.38	-0.32	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	10.93	2.11e-26	1.69e-23	0.37	0.32	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-10.93	2.11e-26	1.7e-23	-0.23	-0.32	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-10.93	2.11e-26	1.7e-23	-0.23	-0.32	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
BRCA	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-10.93	2.14e-26	1.72e-23	-0.38	-0.32	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
BRCA	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-10.93	2.16e-26	1.73e-23	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
BRCA	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-10.93	2.16e-26	1.73e-23	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
BRCA	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-10.93	2.2e-26	1.76e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
BRCA	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-10.93	2.21e-26	1.77e-23	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
BRCA	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	10.92	2.22e-26	1.78e-23	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
BRCA	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	10.92	2.24e-26	1.8e-23	0.4	0.32	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-10.92	2.25e-26	1.8e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-10.92	2.3e-26	1.84e-23	-0.36	-0.32	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
BRCA	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	10.92	2.31e-26	1.85e-23	0.48	0.32	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
BRCA	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-10.92	2.31e-26	1.85e-23	-0.35	-0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-10.92	2.33e-26	1.86e-23	-0.38	-0.32	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
BRCA	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	10.92	2.33e-26	1.87e-23	0.43	0.32	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
BRCA	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	10.92	2.35e-26	1.88e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	10.92	2.35e-26	1.88e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-10.92	2.35e-26	1.88e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-10.92	2.36e-26	1.89e-23	-0.37	-0.32	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-10.92	2.38e-26	1.91e-23	-0.63	-0.32	Gout;	chr7:66645053	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-10.92	2.39e-26	1.91e-23	-0.38	-0.32	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-10.92	2.41e-26	1.93e-23	-0.38	-0.32	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-10.92	2.41e-26	1.93e-23	-0.38	-0.32	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
BRCA	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-10.91	2.45e-26	1.96e-23	-0.38	-0.32	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.96e-23	-0.38	-0.32	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-10.91	2.46e-26	1.97e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
BRCA	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	10.91	2.47e-26	1.97e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
BRCA	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-10.91	2.47e-26	1.97e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
BRCA	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	10.91	2.5e-26	1.99e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
BRCA	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	10.91	2.52e-26	2.01e-23	0.35	0.32	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
BRCA	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-10.91	2.53e-26	2.02e-23	-0.34	-0.32	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
BRCA	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	10.91	2.53e-26	2.02e-23	0.34	0.32	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
BRCA	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-10.91	2.56e-26	2.04e-23	-0.43	-0.32	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-10.91	2.58e-26	2.05e-23	-0.38	-0.32	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	10.91	2.58e-26	2.06e-23	0.42	0.32	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	10.91	2.58e-26	2.06e-23	0.24	0.32	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-10.91	2.59e-26	2.07e-23	-0.4	-0.32	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-10.91	2.61e-26	2.08e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
BRCA	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	10.91	2.68e-26	2.13e-23	0.4	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
BRCA	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-10.9	2.7e-26	2.15e-23	-0.5	-0.32	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
BRCA	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	10.9	2.71e-26	2.16e-23	0.37	0.32	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-10.9	2.71e-26	2.16e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
BRCA	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	10.9	2.72e-26	2.17e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-10.9	2.72e-26	2.17e-23	-0.38	-0.32	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-10.9	2.73e-26	2.17e-23	-0.38	-0.32	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-10.9	2.75e-26	2.19e-23	-0.37	-0.32	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-10.9	2.76e-26	2.2e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-10.9	2.76e-26	2.2e-23	-0.23	-0.32	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
BRCA	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	10.9	2.77e-26	2.2e-23	0.38	0.32	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-10.9	2.84e-26	2.26e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
BRCA	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-10.9	2.85e-26	2.26e-23	-0.35	-0.32	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
BRCA	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-10.9	2.87e-26	2.28e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-10.9	2.88e-26	2.29e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-10.9	2.92e-26	2.32e-23	-0.38	-0.32	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
BRCA	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-10.9	2.92e-26	2.32e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
BRCA	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-10.9	2.93e-26	2.33e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	10.9	2.93e-26	2.33e-23	0.37	0.32	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
BRCA	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-10.9	2.93e-26	2.33e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-10.9	2.96e-26	2.35e-23	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	10.9	2.97e-26	2.36e-23	0.62	0.32	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-10.9	2.97e-26	2.36e-23	-0.38	-0.32	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-10.89	3.02e-26	2.4e-23	-0.36	-0.32	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-10.89	3.05e-26	2.42e-23	-0.63	-0.32	Gout;	chr7:66654674	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	10.89	3.06e-26	2.42e-23	0.42	0.32	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-10.89	3.14e-26	2.49e-23	-0.38	-0.32	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-10.89	3.14e-26	2.49e-23	-0.38	-0.32	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	10.89	3.18e-26	2.52e-23	0.38	0.32	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-10.89	3.21e-26	2.54e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
BRCA	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-10.89	3.21e-26	2.55e-23	-0.41	-0.32	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
BRCA	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-10.89	3.22e-26	2.55e-23	-0.39	-0.32	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-10.89	3.22e-26	2.55e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-10.89	3.24e-26	2.56e-23	-0.37	-0.32	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	10.89	3.25e-26	2.57e-23	0.38	0.32	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
BRCA	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	10.88	3.29e-26	2.6e-23	0.38	0.32	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-10.88	3.3e-26	2.61e-23	-0.44	-0.32	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
BRCA	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	10.88	3.33e-26	2.63e-23	0.38	0.32	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
BRCA	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	10.88	3.33e-26	2.63e-23	0.42	0.32	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
BRCA	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	10.88	3.33e-26	2.64e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
BRCA	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	10.88	3.34e-26	2.64e-23	0.46	0.32	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	10.88	3.34e-26	2.64e-23	0.41	0.32	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	10.88	3.36e-26	2.66e-23	0.42	0.32	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
BRCA	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-10.88	3.37e-26	2.66e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
BRCA	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	10.88	3.37e-26	2.67e-23	0.54	0.32	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
BRCA	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-10.88	3.38e-26	2.67e-23	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
BRCA	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	10.88	3.38e-26	2.67e-23	0.36	0.32	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
BRCA	cis	rs4380275	0.965	rs12621177	ENSG00000223751.1	AC116609.2	10.88	3.4e-26	2.69e-23	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:742488~747767:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	10.88	3.41e-26	2.7e-23	0.61	0.32	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
BRCA	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	10.88	3.45e-26	2.73e-23	0.38	0.32	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-10.88	3.47e-26	2.74e-23	-0.43	-0.32	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
BRCA	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	10.88	3.47e-26	2.74e-23	0.4	0.32	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
BRCA	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-10.88	3.48e-26	2.75e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-10.88	3.49e-26	2.76e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
BRCA	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-10.88	3.52e-26	2.78e-23	-0.39	-0.32	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
BRCA	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	10.88	3.53e-26	2.79e-23	0.37	0.32	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
BRCA	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-10.88	3.61e-26	2.85e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
BRCA	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-10.88	3.61e-26	2.85e-23	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
BRCA	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	10.87	3.63e-26	2.87e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000278665.1	RP11-666O2.4	10.87	3.71e-26	2.93e-23	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28599241~28601881:-
BRCA	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	10.87	3.76e-26	2.96e-23	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
BRCA	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-10.87	3.78e-26	2.98e-23	-0.34	-0.32	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	10.87	3.78e-26	2.98e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-10.87	3.79e-26	2.99e-23	-0.41	-0.32	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
BRCA	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-10.87	3.88e-26	3.05e-23	-0.38	-0.32	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-10.87	3.89e-26	3.06e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	10.87	3.9e-26	3.07e-23	0.35	0.32	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
BRCA	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-10.87	3.94e-26	3.1e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	10.87	3.96e-26	3.11e-23	0.62	0.32	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	10.87	3.98e-26	3.13e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
BRCA	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-10.87	3.98e-26	3.13e-23	-0.37	-0.32	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-10.87	4e-26	3.15e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	10.86	4.01e-26	3.15e-23	0.35	0.32	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
BRCA	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-10.86	4.02e-26	3.16e-23	-0.5	-0.32	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-10.86	4.02e-26	3.16e-23	-0.34	-0.32	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-10.86	4.03e-26	3.17e-23	-0.33	-0.32	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
BRCA	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-10.86	4.07e-26	3.2e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
BRCA	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	10.86	4.07e-26	3.2e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
BRCA	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-10.86	4.08e-26	3.21e-23	-0.52	-0.32	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
BRCA	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	10.86	4.11e-26	3.23e-23	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	10.86	4.13e-26	3.25e-23	0.38	0.32	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-10.86	4.13e-26	3.25e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-10.86	4.14e-26	3.25e-23	-0.38	-0.32	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
BRCA	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	10.86	4.15e-26	3.26e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-10.86	4.17e-26	3.28e-23	-0.23	-0.32	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
BRCA	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-10.86	4.2e-26	3.3e-23	-0.46	-0.32	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-10.86	4.2e-26	3.3e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-10.86	4.2e-26	3.3e-23	-0.38	-0.32	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-10.86	4.2e-26	3.3e-23	-0.38	-0.32	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-10.86	4.37e-26	3.43e-23	-0.38	-0.32	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
BRCA	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	10.86	4.4e-26	3.45e-23	0.39	0.32	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
BRCA	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-10.85	4.44e-26	3.49e-23	-0.38	-0.32	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-10.85	4.47e-26	3.5e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
BRCA	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-10.85	4.55e-26	3.57e-23	-0.38	-0.32	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
BRCA	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-10.85	4.57e-26	3.58e-23	-0.38	-0.32	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
BRCA	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.85	4.64e-26	3.63e-23	0.46	0.32	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
BRCA	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.85	4.64e-26	3.64e-23	-0.47	-0.32	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
BRCA	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-10.85	4.65e-26	3.64e-23	-0.39	-0.32	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
BRCA	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	10.85	4.66e-26	3.65e-23	0.38	0.32	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-10.85	4.67e-26	3.66e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-10.85	4.68e-26	3.67e-23	-0.37	-0.32	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
BRCA	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-10.85	4.69e-26	3.67e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
BRCA	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-10.85	4.72e-26	3.7e-23	-0.48	-0.32	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
BRCA	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
BRCA	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	10.85	4.76e-26	3.73e-23	0.5	0.32	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
BRCA	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	10.85	4.78e-26	3.74e-23	0.38	0.32	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	10.85	4.78e-26	3.74e-23	0.38	0.32	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
BRCA	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-10.85	4.79e-26	3.75e-23	-0.37	-0.32	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-10.85	4.8e-26	3.75e-23	-0.37	-0.32	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-10.85	4.8e-26	3.76e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-10.85	4.81e-26	3.77e-23	-0.37	-0.32	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-10.85	4.83e-26	3.78e-23	-0.38	-0.32	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-10.85	4.83e-26	3.78e-23	-0.37	-0.32	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-10.85	4.86e-26	3.8e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-10.84	4.9e-26	3.83e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
BRCA	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	10.84	4.98e-26	3.89e-23	0.4	0.32	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
BRCA	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-10.84	4.99e-26	3.9e-23	-0.41	-0.32	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
BRCA	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-10.84	5e-26	3.91e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-10.84	5.02e-26	3.92e-23	-0.24	-0.32	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
BRCA	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-10.84	5.07e-26	3.96e-23	-0.48	-0.32	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	10.84	5.2e-26	4.06e-23	0.38	0.32	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
BRCA	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	10.84	5.26e-26	4.11e-23	0.37	0.32	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
BRCA	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	10.84	5.28e-26	4.12e-23	0.5	0.32	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	10.84	5.28e-26	4.12e-23	0.5	0.32	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
BRCA	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-10.84	5.32e-26	4.15e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-10.84	5.35e-26	4.17e-23	-0.37	-0.32	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
BRCA	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	10.84	5.37e-26	4.19e-23	0.35	0.32	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
BRCA	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-10.83	5.41e-26	4.22e-23	-0.38	-0.32	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-10.83	5.44e-26	4.24e-23	-0.4	-0.32	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	10.83	5.49e-26	4.28e-23	0.38	0.32	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-10.83	5.62e-26	4.38e-23	-0.23	-0.32	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
BRCA	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-10.83	5.71e-26	4.44e-23	-0.41	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-10.83	5.74e-26	4.47e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-10.83	5.76e-26	4.49e-23	-0.38	-0.32	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
BRCA	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.83	5.8e-26	4.52e-23	-0.43	-0.32	QT interval;	chr16:28857143	chr16:28700294~28701540:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-10.83	5.85e-26	4.55e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
BRCA	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-10.83	5.93e-26	4.61e-23	-0.39	-0.32	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
BRCA	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	10.82	6.09e-26	4.74e-23	0.35	0.32	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
BRCA	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-10.82	6.11e-26	4.75e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-10.82	6.33e-26	4.92e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-10.82	6.4e-26	4.98e-23	-0.38	-0.32	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-10.82	6.5e-26	5.05e-23	-0.38	-0.32	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-10.81	6.55e-26	5.09e-23	-0.38	-0.32	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	10.81	6.55e-26	5.09e-23	0.38	0.32	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	10.81	6.61e-26	5.14e-23	0.38	0.32	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-10.81	6.67e-26	5.18e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-10.81	6.67e-26	5.18e-23	-0.63	-0.32	Gout;	chr7:66721259	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	10.81	6.71e-26	5.21e-23	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	10.81	6.72e-26	5.22e-23	0.62	0.32	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-10.81	6.74e-26	5.23e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-10.81	6.76e-26	5.25e-23	-0.38	-0.32	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
BRCA	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-10.81	6.79e-26	5.27e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-10.81	6.83e-26	5.3e-23	-0.38	-0.32	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-10.81	6.84e-26	5.31e-23	-0.38	-0.32	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-10.81	6.84e-26	5.31e-23	-0.38	-0.32	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-10.81	6.89e-26	5.35e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
BRCA	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-10.81	6.92e-26	5.36e-23	-0.38	-0.32	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
BRCA	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-10.81	7.04e-26	5.46e-23	-0.38	-0.32	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-10.81	7.09e-26	5.5e-23	-0.34	-0.32	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
BRCA	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-10.81	7.11e-26	5.51e-23	-0.41	-0.32	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
BRCA	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-10.81	7.12e-26	5.52e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-10.81	7.14e-26	5.53e-23	-0.38	-0.32	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000278665.1	RP11-666O2.4	10.81	7.14e-26	5.53e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000278665.1	RP11-666O2.4	10.81	7.14e-26	5.53e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-10.81	7.19e-26	5.57e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
BRCA	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-10.8	7.22e-26	5.59e-23	-0.33	-0.32	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
BRCA	cis	rs473651	0.935	rs477041	ENSG00000229915.1	AC016999.2	10.8	7.28e-26	5.63e-23	0.39	0.32	Multiple system atrophy;	chr2:238447354	chr2:238427077~238427729:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-10.8	7.44e-26	5.76e-23	-0.37	-0.32	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-10.8	7.5e-26	5.8e-23	-0.62	-0.32	Gout;	chr7:66661502	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	10.8	7.51e-26	5.81e-23	0.46	0.32	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
BRCA	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	10.8	7.57e-26	5.85e-23	0.37	0.32	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
BRCA	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-10.8	7.72e-26	5.97e-23	-0.38	-0.32	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	10.8	7.78e-26	6.02e-23	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-10.8	7.89e-26	6.1e-23	-0.37	-0.32	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-10.8	7.9e-26	6.1e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-10.8	7.9e-26	6.1e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
BRCA	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-10.79	7.98e-26	6.17e-23	-0.36	-0.32	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-10.79	8e-26	6.18e-23	-0.37	-0.32	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-10.79	8e-26	6.18e-23	-0.37	-0.32	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-10.79	8.03e-26	6.2e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-10.79	8.03e-26	6.2e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	10.79	8.04e-26	6.21e-23	0.52	0.32	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
BRCA	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	10.79	8.07e-26	6.23e-23	0.42	0.32	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
BRCA	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-10.79	8.09e-26	6.25e-23	-0.38	-0.32	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-10.79	8.15e-26	6.3e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-10.79	8.17e-26	6.3e-23	-0.38	-0.32	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-10.79	8.21e-26	6.33e-23	-0.41	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
BRCA	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	10.79	8.22e-26	6.35e-23	0.41	0.32	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
BRCA	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	10.79	8.25e-26	6.36e-23	0.36	0.32	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
BRCA	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	10.79	8.25e-26	6.36e-23	0.41	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
BRCA	cis	rs4380275	1	rs4854376	ENSG00000223751.1	AC116609.2	10.79	8.44e-26	6.51e-23	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:742488~747767:+
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-10.79	8.57e-26	6.6e-23	-0.43	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-10.79	8.6e-26	6.63e-23	-0.62	-0.32	Gout;	chr7:66642037	chr7:66654538~66669855:+
BRCA	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	10.79	8.72e-26	6.72e-23	0.47	0.32	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
BRCA	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-10.78	8.8e-26	6.78e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	10.78	8.86e-26	6.82e-23	0.37	0.32	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-10.78	8.92e-26	6.87e-23	-0.38	-0.32	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-10.78	8.92e-26	6.87e-23	-0.38	-0.32	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-10.78	8.98e-26	6.91e-23	-0.46	-0.32	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-10.78	9.06e-26	6.98e-23	-0.37	-0.32	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-10.78	9.06e-26	6.98e-23	-0.37	-0.32	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
BRCA	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-10.78	9.1e-26	7.01e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-10.78	9.16e-26	7.05e-23	-0.37	-0.32	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
BRCA	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	10.78	9.24e-26	7.11e-23	0.41	0.32	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
BRCA	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	10.78	9.25e-26	7.12e-23	0.36	0.32	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
BRCA	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	10.78	9.39e-26	7.23e-23	0.53	0.32	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
BRCA	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-10.78	9.45e-26	7.27e-23	-0.36	-0.32	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
BRCA	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-10.78	9.57e-26	7.36e-23	-0.38	-0.32	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
BRCA	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-10.77	9.7e-26	7.46e-23	-0.38	-0.32	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-10.77	9.72e-26	7.48e-23	-0.38	-0.32	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000278665.1	RP11-666O2.4	10.77	9.76e-26	7.5e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000278665.1	RP11-666O2.4	10.77	9.76e-26	7.5e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	10.77	9.84e-26	7.56e-23	0.37	0.32	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
BRCA	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	10.77	9.88e-26	7.59e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	10.77	9.88e-26	7.59e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-10.77	9.99e-26	7.67e-23	-0.43	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
BRCA	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	10.77	1e-25	7.69e-23	0.52	0.32	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	10.77	1e-25	7.69e-23	0.52	0.32	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
BRCA	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-10.77	1.01e-25	7.76e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-10.77	1.01e-25	7.77e-23	-0.38	-0.32	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	10.77	1.02e-25	7.85e-23	0.37	0.32	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
BRCA	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	10.77	1.03e-25	7.91e-23	0.74	0.32	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	10.77	1.03e-25	7.91e-23	0.74	0.32	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
BRCA	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-10.77	1.04e-25	8.02e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
BRCA	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
BRCA	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-10.77	1.05e-25	8.08e-23	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-10.77	1.05e-25	8.08e-23	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
BRCA	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	10.76	1.07e-25	8.21e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	10.76	1.07e-25	8.21e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
BRCA	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-10.76	1.09e-25	8.37e-23	-0.4	-0.32	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
BRCA	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	10.76	1.09e-25	8.39e-23	0.36	0.32	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-10.76	1.11e-25	8.46e-23	-0.43	-0.32	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
BRCA	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	10.76	1.11e-25	8.52e-23	0.37	0.32	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
BRCA	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	10.76	1.13e-25	8.61e-23	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
BRCA	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-10.76	1.13e-25	8.65e-23	-0.38	-0.32	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
BRCA	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-10.76	1.13e-25	8.68e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	10.76	1.14e-25	8.72e-23	0.62	0.32	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	10.76	1.14e-25	8.72e-23	0.62	0.32	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-10.76	1.14e-25	8.76e-23	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000278665.1	RP11-666O2.4	-10.76	1.15e-25	8.83e-23	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	10.76	1.15e-25	8.83e-23	0.35	0.32	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
BRCA	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-10.76	1.16e-25	8.89e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000278665.1	RP11-666O2.4	10.76	1.17e-25	8.97e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28599241~28601881:-
BRCA	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-10.76	1.17e-25	8.97e-23	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	10.75	1.21e-25	9.21e-23	0.38	0.32	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-10.75	1.21e-25	9.28e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-10.75	1.22e-25	9.29e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-10.75	1.22e-25	9.31e-23	-0.59	-0.32	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
BRCA	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-10.75	1.22e-25	9.34e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.75	1.23e-25	9.43e-23	0.36	0.32	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
BRCA	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	10.75	1.25e-25	9.57e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
BRCA	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-10.75	1.26e-25	9.59e-23	-0.42	-0.32	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
BRCA	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-10.75	1.26e-25	9.61e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	10.75	1.27e-25	9.67e-23	0.4	0.32	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
BRCA	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-10.75	1.27e-25	9.68e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
BRCA	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.74	1.3e-25	9.9e-23	0.36	0.32	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
BRCA	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-10.74	1.31e-25	9.97e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
BRCA	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	10.74	1.31e-25	9.97e-23	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
BRCA	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-10.74	1.32e-25	1.01e-22	-0.36	-0.32	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	10.74	1.33e-25	1.01e-22	0.37	0.32	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	10.74	1.33e-25	1.01e-22	0.37	0.32	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
BRCA	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	10.74	1.33e-25	1.01e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
BRCA	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	10.74	1.36e-25	1.03e-22	0.4	0.32	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-10.74	1.37e-25	1.04e-22	-0.53	-0.32	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-10.74	1.37e-25	1.04e-22	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
BRCA	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	10.74	1.37e-25	1.05e-22	0.48	0.32	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-10.74	1.38e-25	1.05e-22	-0.41	-0.32	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-10.74	1.38e-25	1.05e-22	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
BRCA	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	10.74	1.4e-25	1.06e-22	0.44	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
BRCA	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	10.74	1.41e-25	1.07e-22	0.38	0.32	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
BRCA	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-10.74	1.41e-25	1.07e-22	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
BRCA	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-10.74	1.42e-25	1.08e-22	-0.36	-0.32	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
BRCA	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-10.73	1.46e-25	1.11e-22	-0.33	-0.32	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
BRCA	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	10.73	1.47e-25	1.12e-22	0.41	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
BRCA	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-10.73	1.49e-25	1.13e-22	-0.6	-0.32	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
BRCA	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	10.73	1.52e-25	1.15e-22	0.37	0.32	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
BRCA	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	10.73	1.52e-25	1.16e-22	0.52	0.32	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
BRCA	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-10.73	1.55e-25	1.18e-22	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
BRCA	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-10.73	1.57e-25	1.19e-22	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-10.73	1.57e-25	1.19e-22	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
BRCA	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	10.73	1.57e-25	1.19e-22	0.52	0.32	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
BRCA	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	10.73	1.57e-25	1.19e-22	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
BRCA	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	10.72	1.58e-25	1.2e-22	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
BRCA	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	10.72	1.63e-25	1.24e-22	0.28	0.32	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	10.72	1.64e-25	1.24e-22	0.38	0.32	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	10.72	1.64e-25	1.24e-22	0.38	0.32	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs7562792	ENSG00000223751.1	AC116609.2	10.72	1.64e-25	1.24e-22	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:742488~747767:+
BRCA	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	10.72	1.65e-25	1.25e-22	0.45	0.32	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-10.72	1.66e-25	1.26e-22	-0.62	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-10.72	1.68e-25	1.27e-22	-0.4	-0.32	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
BRCA	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-10.72	1.7e-25	1.29e-22	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
BRCA	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-10.72	1.71e-25	1.29e-22	-0.5	-0.32	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
BRCA	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	10.72	1.72e-25	1.3e-22	0.36	0.32	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
BRCA	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-10.71	1.75e-25	1.32e-22	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
BRCA	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-10.71	1.77e-25	1.34e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
BRCA	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-10.71	1.78e-25	1.34e-22	-0.36	-0.31	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	10.71	1.78e-25	1.34e-22	0.45	0.31	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
BRCA	cis	rs4380275	0.965	rs4375894	ENSG00000223751.1	AC116609.2	10.71	1.79e-25	1.35e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:742488~747767:+
BRCA	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-10.71	1.8e-25	1.36e-22	-0.45	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
BRCA	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-10.71	1.81e-25	1.36e-22	-0.39	-0.31	Height;	chr6:109636120	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-10.71	1.82e-25	1.37e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
BRCA	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-10.71	1.84e-25	1.39e-22	-0.4	-0.31	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
BRCA	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-10.71	1.87e-25	1.41e-22	-0.39	-0.31	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	10.71	1.87e-25	1.41e-22	0.38	0.31	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	10.71	1.87e-25	1.41e-22	0.38	0.31	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	10.71	1.88e-25	1.42e-22	0.38	0.31	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	10.71	1.88e-25	1.42e-22	0.38	0.31	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs4359695	ENSG00000223751.1	AC116609.2	10.71	1.9e-25	1.43e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:742488~747767:+
BRCA	cis	rs4380275	0.931	rs4538239	ENSG00000223751.1	AC116609.2	10.71	1.9e-25	1.43e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:742488~747767:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	10.71	1.91e-25	1.44e-22	0.61	0.31	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	10.71	1.91e-25	1.44e-22	0.61	0.31	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
BRCA	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-10.7	1.92e-25	1.45e-22	-0.43	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
BRCA	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-10.7	1.92e-25	1.45e-22	-0.39	-0.31	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
BRCA	cis	rs4380275	1	rs4450634	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:742488~747767:+
BRCA	cis	rs4380275	1	rs4380275	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:742488~747767:+
BRCA	cis	rs4380275	1	rs73143802	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:742488~747767:+
BRCA	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	10.7	1.94e-25	1.46e-22	0.51	0.31	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
BRCA	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-10.7	1.94e-25	1.46e-22	-0.37	-0.31	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	10.7	1.95e-25	1.47e-22	0.52	0.31	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	10.7	1.95e-25	1.47e-22	0.52	0.31	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
BRCA	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	10.7	1.96e-25	1.47e-22	0.4	0.31	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
BRCA	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	10.7	1.97e-25	1.48e-22	0.4	0.31	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
BRCA	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-10.7	1.98e-25	1.49e-22	-0.43	-0.31	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	10.7	1.98e-25	1.49e-22	0.37	0.31	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
BRCA	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	10.7	1.99e-25	1.49e-22	0.51	0.31	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	10.7	1.99e-25	1.49e-22	0.51	0.31	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
BRCA	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	10.7	1.99e-25	1.49e-22	0.47	0.31	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
BRCA	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	10.7	2.05e-25	1.54e-22	0.37	0.31	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	10.7	2.05e-25	1.54e-22	0.37	0.31	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	10.7	2.07e-25	1.56e-22	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
BRCA	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-10.7	2.07e-25	1.56e-22	-0.39	-0.31	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-10.7	2.07e-25	1.56e-22	-0.39	-0.31	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
BRCA	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-10.7	2.1e-25	1.58e-22	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
BRCA	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	10.7	2.11e-25	1.58e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
BRCA	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	10.7	2.11e-25	1.58e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
BRCA	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	10.69	2.11e-25	1.59e-22	0.47	0.31	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	10.69	2.13e-25	1.6e-22	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
BRCA	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
BRCA	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	10.69	2.14e-25	1.61e-22	0.28	0.31	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-10.69	2.17e-25	1.63e-22	-0.23	-0.31	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
BRCA	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	10.69	2.17e-25	1.63e-22	0.39	0.31	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
BRCA	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-10.69	2.2e-25	1.65e-22	-0.39	-0.31	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-10.69	2.2e-25	1.65e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
BRCA	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	10.69	2.22e-25	1.66e-22	0.48	0.31	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
BRCA	cis	rs4380275	1	rs6548253	ENSG00000223751.1	AC116609.2	10.69	2.23e-25	1.67e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:742488~747767:+
BRCA	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-10.69	2.25e-25	1.69e-22	-0.37	-0.31	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	10.68	2.34e-25	1.75e-22	0.38	0.31	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
BRCA	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-10.68	2.35e-25	1.76e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
BRCA	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	10.68	2.4e-25	1.79e-22	0.51	0.31	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	10.68	2.4e-25	1.79e-22	0.51	0.31	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
BRCA	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-10.68	2.4e-25	1.79e-22	-0.38	-0.31	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-10.68	2.41e-25	1.8e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
BRCA	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	10.68	2.41e-25	1.8e-22	0.52	0.31	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
BRCA	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-10.68	2.42e-25	1.81e-22	-0.48	-0.31	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
BRCA	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-10.68	2.43e-25	1.82e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
BRCA	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	10.68	2.44e-25	1.82e-22	0.4	0.31	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
BRCA	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	10.68	2.45e-25	1.83e-22	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
BRCA	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-10.68	2.46e-25	1.84e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	10.68	2.49e-25	1.85e-22	0.4	0.31	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
BRCA	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	10.68	2.49e-25	1.86e-22	0.44	0.31	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
BRCA	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	10.68	2.53e-25	1.89e-22	0.39	0.31	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
BRCA	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-10.68	2.56e-25	1.91e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
BRCA	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-10.67	2.59e-25	1.93e-22	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	10.67	2.6e-25	1.94e-22	0.38	0.31	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
BRCA	cis	rs4380275	0.965	rs4315562	ENSG00000223751.1	AC116609.2	10.67	2.61e-25	1.94e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:742488~747767:+
BRCA	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	10.67	2.62e-25	1.95e-22	0.49	0.31	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
BRCA	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	10.67	2.65e-25	1.97e-22	0.51	0.31	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
BRCA	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-10.67	2.65e-25	1.97e-22	-0.37	-0.31	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
BRCA	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-10.67	2.71e-25	2.02e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
BRCA	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	10.67	2.71e-25	2.02e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
BRCA	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	10.67	2.71e-25	2.02e-22	0.41	0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	10.67	2.71e-25	2.02e-22	0.38	0.31	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-10.67	2.75e-25	2.04e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-10.67	2.75e-25	2.05e-22	-0.36	-0.31	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
BRCA	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	10.67	2.76e-25	2.05e-22	0.39	0.31	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	10.66	2.83e-25	2.1e-22	0.74	0.31	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
BRCA	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	10.66	2.84e-25	2.11e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
BRCA	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	10.66	2.84e-25	2.11e-22	0.51	0.31	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
BRCA	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-10.66	2.85e-25	2.12e-22	-0.37	-0.31	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-10.66	2.86e-25	2.13e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
BRCA	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-10.66	2.87e-25	2.13e-22	-0.35	-0.31	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
BRCA	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-10.66	2.87e-25	2.14e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	10.66	2.88e-25	2.14e-22	0.37	0.31	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-10.66	2.88e-25	2.14e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
BRCA	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	10.66	2.97e-25	2.2e-22	0.38	0.31	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-10.66	2.99e-25	2.22e-22	-0.64	-0.31	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
BRCA	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-10.66	2.99e-25	2.22e-22	-0.33	-0.31	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-10.66	3e-25	2.22e-22	-0.41	-0.31	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
BRCA	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-10.66	3.01e-25	2.23e-22	-0.48	-0.31	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-10.66	3.01e-25	2.23e-22	-0.62	-0.31	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	10.66	3.02e-25	2.24e-22	0.34	0.31	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
BRCA	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	10.66	3.03e-25	2.25e-22	0.36	0.31	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-10.66	3.08e-25	2.28e-22	-0.46	-0.31	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
BRCA	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-10.65	3.12e-25	2.31e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
BRCA	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-10.65	3.12e-25	2.31e-22	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
BRCA	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	10.65	3.15e-25	2.33e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
BRCA	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-10.65	3.15e-25	2.33e-22	-0.29	-0.31	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
BRCA	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
BRCA	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-10.65	3.19e-25	2.36e-22	-0.37	-0.31	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
BRCA	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-10.65	3.23e-25	2.39e-22	-0.4	-0.31	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
BRCA	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.52	0.31	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.47	0.31	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.47	0.31	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
BRCA	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	10.65	3.32e-25	2.46e-22	0.41	0.31	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-10.65	3.32e-25	2.46e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
BRCA	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	10.65	3.32e-25	2.46e-22	0.39	0.31	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
BRCA	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	10.65	3.34e-25	2.47e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	10.65	3.34e-25	2.47e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	10.65	3.34e-25	2.47e-22	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
BRCA	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-10.65	3.35e-25	2.47e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
BRCA	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	10.65	3.35e-25	2.48e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	10.65	3.36e-25	2.48e-22	0.37	0.31	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
BRCA	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-10.65	3.36e-25	2.48e-22	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
BRCA	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-10.65	3.37e-25	2.49e-22	-0.42	-0.31	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
BRCA	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-10.64	3.44e-25	2.54e-22	-0.39	-0.31	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
BRCA	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	10.64	3.46e-25	2.55e-22	0.52	0.31	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
BRCA	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-10.64	3.54e-25	2.61e-22	-0.51	-0.31	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
BRCA	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-10.64	3.57e-25	2.63e-22	-0.36	-0.31	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-10.64	3.6e-25	2.66e-22	-0.37	-0.31	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
BRCA	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	10.64	3.6e-25	2.66e-22	0.38	0.31	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
BRCA	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	10.64	3.62e-25	2.67e-22	0.37	0.31	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	10.64	3.63e-25	2.68e-22	0.5	0.31	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-10.64	3.68e-25	2.71e-22	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-10.64	3.7e-25	2.72e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-10.64	3.7e-25	2.72e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-10.64	3.74e-25	2.75e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
BRCA	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-10.64	3.75e-25	2.76e-22	-0.4	-0.31	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
BRCA	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	10.64	3.78e-25	2.78e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-10.63	3.78e-25	2.78e-22	-0.37	-0.31	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	10.63	3.81e-25	2.8e-22	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
BRCA	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-10.63	3.84e-25	2.82e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
BRCA	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	10.63	3.87e-25	2.84e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
BRCA	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	10.63	3.88e-25	2.85e-22	0.28	0.31	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	10.63	3.96e-25	2.91e-22	0.38	0.31	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	10.63	3.99e-25	2.93e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-10.63	4e-25	2.94e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
BRCA	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	10.63	4.03e-25	2.96e-22	0.39	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
BRCA	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	10.63	4.03e-25	2.96e-22	0.56	0.31	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	10.63	4.1e-25	3.01e-22	0.61	0.31	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	10.63	4.12e-25	3.02e-22	0.47	0.31	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
BRCA	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	10.63	4.13e-25	3.03e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
BRCA	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	10.62	4.18e-25	3.06e-22	0.38	0.31	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
BRCA	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-10.62	4.2e-25	3.08e-22	-0.52	-0.31	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
BRCA	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	10.62	4.22e-25	3.09e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
BRCA	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	10.62	4.23e-25	3.1e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
BRCA	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	10.62	4.25e-25	3.12e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
BRCA	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-10.62	4.33e-25	3.17e-22	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
BRCA	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-10.62	4.33e-25	3.17e-22	-0.52	-0.31	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
BRCA	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-10.62	4.34e-25	3.18e-22	-0.37	-0.31	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
BRCA	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-10.62	4.35e-25	3.19e-22	-0.38	-0.31	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
BRCA	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-10.62	4.35e-25	3.19e-22	-0.39	-0.31	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
BRCA	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-10.62	4.36e-25	3.19e-22	-0.42	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
BRCA	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	10.62	4.37e-25	3.2e-22	0.5	0.31	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	10.62	4.37e-25	3.2e-22	0.5	0.31	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
BRCA	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-10.62	4.38e-25	3.21e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
BRCA	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-10.62	4.44e-25	3.25e-22	-0.38	-0.31	Height;	chr3:53084188	chr3:53064283~53065091:-
BRCA	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	10.62	4.45e-25	3.26e-22	0.34	0.31	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
BRCA	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	10.62	4.47e-25	3.27e-22	0.4	0.31	Height;	chr6:109732047	chr6:109382795~109383666:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-10.62	4.48e-25	3.28e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
BRCA	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	10.62	4.51e-25	3.3e-22	0.28	0.31	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
BRCA	cis	rs473651	0.935	rs508483	ENSG00000229915.1	AC016999.2	-10.62	4.57e-25	3.34e-22	-0.39	-0.31	Multiple system atrophy;	chr2:238431068	chr2:238427077~238427729:-
BRCA	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-10.61	4.59e-25	3.35e-22	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	10.61	4.63e-25	3.38e-22	0.4	0.31	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
BRCA	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	10.61	4.65e-25	3.4e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
BRCA	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	10.61	4.71e-25	3.44e-22	0.42	0.31	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-10.61	4.8e-25	3.5e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-10.61	4.81e-25	3.51e-22	-0.43	-0.31	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
BRCA	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	10.61	4.81e-25	3.51e-22	0.37	0.31	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	10.61	4.91e-25	3.58e-22	0.73	0.31	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	10.61	4.91e-25	3.58e-22	0.73	0.31	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
BRCA	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	10.61	4.95e-25	3.61e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
BRCA	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	10.61	4.95e-25	3.61e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
BRCA	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-10.61	5.04e-25	3.67e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
BRCA	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	10.6	5.1e-25	3.72e-22	0.39	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
BRCA	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	10.6	5.12e-25	3.73e-22	0.49	0.31	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
BRCA	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	10.6	5.14e-25	3.75e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	10.6	5.14e-25	3.75e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
BRCA	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-10.6	5.18e-25	3.78e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	10.6	5.3e-25	3.86e-22	0.37	0.31	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
BRCA	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	10.6	5.32e-25	3.87e-22	0.4	0.31	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
BRCA	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	10.6	5.34e-25	3.89e-22	0.37	0.31	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	10.6	5.34e-25	3.89e-22	0.38	0.31	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	10.6	5.34e-25	3.89e-22	0.38	0.31	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
BRCA	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-10.6	5.34e-25	3.89e-22	-0.37	-0.31	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
BRCA	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-10.6	5.34e-25	3.89e-22	-0.38	-0.31	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
BRCA	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-10.6	5.36e-25	3.9e-22	-0.28	-0.31	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
BRCA	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-10.6	5.37e-25	3.91e-22	-0.38	-0.31	Height;	chr6:109444615	chr6:109382795~109383666:+
BRCA	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	10.6	5.44e-25	3.96e-22	0.37	0.31	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
BRCA	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	10.6	5.47e-25	3.98e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-10.6	5.5e-25	4e-22	-0.37	-0.31	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000278665.1	RP11-666O2.4	10.6	5.51e-25	4.01e-22	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-10.59	5.58e-25	4.05e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	10.59	5.6e-25	4.07e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	10.59	5.63e-25	4.09e-22	0.37	0.31	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
BRCA	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-10.59	5.63e-25	4.09e-22	-0.35	-0.31	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-10.59	5.63e-25	4.09e-22	-0.35	-0.31	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
BRCA	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	10.59	5.66e-25	4.12e-22	0.41	0.31	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
BRCA	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-10.59	5.68e-25	4.12e-22	-0.55	-0.31	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
BRCA	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	10.59	5.71e-25	4.14e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
BRCA	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	10.59	5.77e-25	4.19e-22	0.47	0.31	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	10.59	5.77e-25	4.19e-22	0.47	0.31	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
BRCA	cis	rs473651	0.935	rs541013	ENSG00000229915.1	AC016999.2	-10.59	5.84e-25	4.24e-22	-0.39	-0.31	Multiple system atrophy;	chr2:238427851	chr2:238427077~238427729:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-10.59	5.86e-25	4.25e-22	-0.22	-0.31	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-10.59	5.92e-25	4.3e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
BRCA	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	10.59	5.98e-25	4.34e-22	0.38	0.31	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
BRCA	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-10.59	5.98e-25	4.34e-22	-0.56	-0.31	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
BRCA	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10.59	6.01e-25	4.36e-22	-0.34	-0.31	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
BRCA	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-10.59	6.02e-25	4.37e-22	-0.3	-0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
BRCA	cis	rs4380275	1	rs4268954	ENSG00000223751.1	AC116609.2	10.58	6.16e-25	4.46e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:742488~747767:+
BRCA	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-10.58	6.18e-25	4.48e-22	-0.35	-0.31	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
BRCA	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	10.58	6.24e-25	4.52e-22	0.4	0.31	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
BRCA	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	10.58	6.28e-25	4.55e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
BRCA	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	10.58	6.28e-25	4.55e-22	0.32	0.31	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
BRCA	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
BRCA	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	10.58	6.43e-25	4.65e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	10.58	6.43e-25	4.66e-22	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
BRCA	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	10.58	6.63e-25	4.79e-22	0.39	0.31	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
BRCA	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	10.58	6.67e-25	4.82e-22	0.3	0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
BRCA	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	10.58	6.69e-25	4.83e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	10.58	6.69e-25	4.83e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
BRCA	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	10.58	6.74e-25	4.87e-22	0.5	0.31	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	10.57	6.85e-25	4.94e-22	0.47	0.31	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
BRCA	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	10.57	6.9e-25	4.98e-22	0.45	0.31	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
BRCA	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	10.57	6.91e-25	4.99e-22	0.4	0.31	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-10.57	6.98e-25	5.04e-22	-0.43	-0.31	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	10.57	7.01e-25	5.06e-22	0.73	0.31	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-10.57	7.1e-25	5.12e-22	-0.36	-0.31	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
BRCA	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	10.57	7.11e-25	5.12e-22	0.47	0.31	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
BRCA	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-10.57	7.15e-25	5.15e-22	-0.38	-0.31	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	10.57	7.21e-25	5.2e-22	0.38	0.31	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-10.57	7.21e-25	5.2e-22	-0.35	-0.31	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
BRCA	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-10.57	7.23e-25	5.21e-22	-0.38	-0.31	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-10.57	7.23e-25	5.21e-22	-0.38	-0.31	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
BRCA	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-10.57	7.28e-25	5.25e-22	-0.37	-0.31	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
BRCA	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-10.57	7.34e-25	5.28e-22	-0.37	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
BRCA	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	10.57	7.38e-25	5.32e-22	0.39	0.31	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
BRCA	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	10.57	7.41e-25	5.34e-22	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
BRCA	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-10.56	7.43e-25	5.35e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	10.56	7.45e-25	5.36e-22	0.32	0.31	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
BRCA	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-10.56	7.47e-25	5.38e-22	-0.37	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
BRCA	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	10.56	7.49e-25	5.39e-22	0.44	0.31	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	10.56	7.51e-25	5.4e-22	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	10.56	7.55e-25	5.43e-22	0.38	0.31	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	10.56	7.55e-25	5.43e-22	0.38	0.31	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
BRCA	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-10.56	7.64e-25	5.5e-22	-0.39	-0.31	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
BRCA	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-10.56	7.65e-25	5.5e-22	-0.36	-0.31	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
BRCA	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	10.56	7.65e-25	5.51e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
BRCA	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-10.56	7.76e-25	5.58e-22	-0.45	-0.31	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
BRCA	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-10.56	7.82e-25	5.62e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
BRCA	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-10.56	7.83e-25	5.63e-22	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
BRCA	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-10.56	7.88e-25	5.66e-22	-0.36	-0.31	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-10.56	8.11e-25	5.82e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
BRCA	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-10.55	8.22e-25	5.9e-22	-0.39	-0.31	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
BRCA	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	10.55	8.28e-25	5.94e-22	0.45	0.31	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-10.55	8.32e-25	5.97e-22	-0.42	-0.31	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	10.55	8.34e-25	5.98e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
BRCA	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	10.55	8.38e-25	6.01e-22	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
BRCA	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	10.55	8.38e-25	6.01e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-10.55	8.63e-25	6.19e-22	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
BRCA	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-10.55	8.63e-25	6.19e-22	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
BRCA	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-10.55	8.65e-25	6.2e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
BRCA	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-10.55	8.68e-25	6.22e-22	-0.35	-0.31	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
BRCA	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	10.55	8.76e-25	6.27e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-10.55	8.77e-25	6.28e-22	-0.62	-0.31	Gout;	chr7:66732812	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-10.54	9.07e-25	6.48e-22	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-10.54	9.1e-25	6.5e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	10.54	9.12e-25	6.52e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
BRCA	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-10.54	9.14e-25	6.53e-22	-0.42	-0.31	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
BRCA	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	10.54	9.14e-25	6.53e-22	0.39	0.31	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-10.54	9.17e-25	6.55e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-10.54	9.2e-25	6.57e-22	-0.45	-0.31	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10.54	9.25e-25	6.61e-22	-0.36	-0.31	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-10.54	9.41e-25	6.72e-22	-0.6	-0.31	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-10.54	9.48e-25	6.77e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
BRCA	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-10.54	9.66e-25	6.89e-22	-0.41	-0.31	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	10.54	9.73e-25	6.94e-22	0.38	0.31	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-10.54	9.78e-25	6.97e-22	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
BRCA	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	10.54	9.88e-25	7.04e-22	0.35	0.31	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
BRCA	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	10.53	9.93e-25	7.08e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-10.53	9.97e-25	7.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-10.53	9.99e-25	7.12e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-10.53	1e-24	7.13e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
BRCA	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	10.53	1.01e-24	7.18e-22	0.33	0.31	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	10.53	1.02e-24	7.24e-22	0.41	0.31	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	10.53	1.03e-24	7.33e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
BRCA	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	10.53	1.03e-24	7.36e-22	0.47	0.31	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	10.53	1.03e-24	7.36e-22	0.47	0.31	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
BRCA	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-10.53	1.03e-24	7.37e-22	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
BRCA	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	10.53	1.06e-24	7.51e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
BRCA	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-10.53	1.06e-24	7.55e-22	-0.48	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-10.53	1.08e-24	7.71e-22	-0.23	-0.31	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
BRCA	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-10.53	1.09e-24	7.75e-22	-0.37	-0.31	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-10.52	1.1e-24	7.81e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
BRCA	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-10.52	1.11e-24	7.85e-22	-0.39	-0.31	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-10.52	1.11e-24	7.86e-22	-0.43	-0.31	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-10.52	1.11e-24	7.87e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	10.52	1.11e-24	7.89e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-10.52	1.11e-24	7.89e-22	-0.38	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-10.52	1.11e-24	7.89e-22	-0.43	-0.31	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	10.52	1.12e-24	7.93e-22	0.43	0.31	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	10.52	1.13e-24	7.99e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
BRCA	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	10.52	1.13e-24	8e-22	0.41	0.31	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
BRCA	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	10.52	1.14e-24	8.05e-22	0.42	0.31	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	10.52	1.14e-24	8.1e-22	0.39	0.31	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	10.52	1.14e-24	8.1e-22	0.74	0.31	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	10.52	1.14e-24	8.1e-22	0.74	0.31	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
BRCA	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	10.52	1.14e-24	8.11e-22	0.37	0.31	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	10.52	1.15e-24	8.14e-22	0.48	0.31	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	10.52	1.15e-24	8.16e-22	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	10.52	1.15e-24	8.16e-22	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
BRCA	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-10.52	1.18e-24	8.37e-22	-0.37	-0.31	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
BRCA	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-10.52	1.18e-24	8.37e-22	-0.36	-0.31	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	10.52	1.18e-24	8.38e-22	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-10.52	1.19e-24	8.41e-22	-0.4	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	10.52	1.2e-24	8.51e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000278665.1	RP11-666O2.4	10.51	1.21e-24	8.56e-22	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-10.51	1.21e-24	8.56e-22	-0.43	-0.31	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-10.51	1.22e-24	8.61e-22	-0.43	-0.31	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
BRCA	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-10.51	1.23e-24	8.69e-22	-0.4	-0.31	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-10.51	1.23e-24	8.69e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-10.51	1.23e-24	8.71e-22	-0.35	-0.31	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-10.51	1.24e-24	8.77e-22	-0.44	-0.31	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
BRCA	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	10.51	1.24e-24	8.79e-22	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
BRCA	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	10.51	1.24e-24	8.81e-22	0.51	0.31	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	10.51	1.25e-24	8.85e-22	0.73	0.31	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
BRCA	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	10.51	1.25e-24	8.86e-22	0.39	0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
BRCA	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	10.51	1.26e-24	8.94e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
BRCA	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	10.51	1.28e-24	9.05e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
BRCA	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-10.51	1.29e-24	9.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-10.51	1.29e-24	9.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	10.51	1.29e-24	9.15e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
BRCA	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	10.51	1.31e-24	9.23e-22	0.37	0.31	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
BRCA	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	10.5	1.33e-24	9.43e-22	0.44	0.31	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
BRCA	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	10.5	1.37e-24	9.66e-22	0.38	0.31	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
BRCA	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-10.5	1.37e-24	9.7e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-10.5	1.37e-24	9.7e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
BRCA	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	10.5	1.39e-24	9.8e-22	0.3	0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	10.5	1.4e-24	9.86e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
BRCA	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	10.5	1.4e-24	9.88e-22	0.39	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
BRCA	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	10.5	1.4e-24	9.88e-22	0.46	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
BRCA	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-10.5	1.42e-24	9.99e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-10.5	1.42e-24	1e-21	-0.43	-0.31	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000278665.1	RP11-666O2.4	10.5	1.43e-24	1.01e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28599241~28601881:-
BRCA	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-10.5	1.44e-24	1.01e-21	-0.37	-0.31	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	10.49	1.46e-24	1.03e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
BRCA	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-10.49	1.46e-24	1.03e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-10.49	1.46e-24	1.03e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-10.49	1.46e-24	1.03e-21	-0.35	-0.31	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
BRCA	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	10.49	1.46e-24	1.03e-21	0.43	0.31	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
BRCA	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	10.49	1.48e-24	1.04e-21	0.39	0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
BRCA	cis	rs473651	0.904	rs508274	ENSG00000229915.1	AC016999.2	-10.49	1.48e-24	1.04e-21	-0.39	-0.31	Multiple system atrophy;	chr2:238429082	chr2:238427077~238427729:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-10.49	1.49e-24	1.05e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
BRCA	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-10.49	1.52e-24	1.07e-21	-0.38	-0.31	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-10.49	1.52e-24	1.07e-21	-0.38	-0.31	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
BRCA	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-10.49	1.52e-24	1.07e-21	-0.36	-0.31	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
BRCA	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-10.49	1.53e-24	1.07e-21	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
BRCA	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-10.49	1.56e-24	1.1e-21	-0.49	-0.31	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-10.49	1.57e-24	1.1e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
BRCA	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	10.49	1.58e-24	1.11e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	10.49	1.58e-24	1.11e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	10.49	1.58e-24	1.11e-21	0.39	0.31	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
BRCA	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-10.49	1.59e-24	1.12e-21	-0.38	-0.31	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	10.49	1.6e-24	1.12e-21	0.72	0.31	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-10.48	1.63e-24	1.14e-21	-0.22	-0.31	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
BRCA	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	10.48	1.64e-24	1.15e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
BRCA	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	10.48	1.64e-24	1.15e-21	0.47	0.31	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	10.48	1.64e-24	1.15e-21	0.47	0.31	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	10.48	1.65e-24	1.16e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
BRCA	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	10.48	1.66e-24	1.16e-21	0.35	0.31	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
BRCA	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	10.48	1.66e-24	1.16e-21	0.47	0.31	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
BRCA	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	10.48	1.67e-24	1.17e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	10.48	1.67e-24	1.17e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
BRCA	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	10.48	1.68e-24	1.18e-21	0.35	0.31	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
BRCA	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-10.48	1.69e-24	1.18e-21	-0.34	-0.31	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
BRCA	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	10.48	1.69e-24	1.19e-21	0.49	0.31	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	10.48	1.69e-24	1.19e-21	0.49	0.31	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-10.48	1.71e-24	1.2e-21	-0.35	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
BRCA	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.48	1.73e-24	1.21e-21	-0.34	-0.31	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
BRCA	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-10.48	1.74e-24	1.22e-21	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-10.48	1.74e-24	1.22e-21	-0.23	-0.31	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
BRCA	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	10.48	1.76e-24	1.23e-21	0.48	0.31	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
BRCA	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-10.48	1.76e-24	1.23e-21	-0.32	-0.31	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
BRCA	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-10.47	1.78e-24	1.24e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
BRCA	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	10.47	1.78e-24	1.25e-21	0.4	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	10.47	1.79e-24	1.26e-21	0.73	0.31	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	10.47	1.79e-24	1.26e-21	0.73	0.31	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
BRCA	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-10.47	1.8e-24	1.26e-21	-0.36	-0.31	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
BRCA	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	10.47	1.81e-24	1.27e-21	0.34	0.31	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
BRCA	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	10.47	1.82e-24	1.28e-21	0.47	0.31	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-10.47	1.87e-24	1.3e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-10.47	1.9e-24	1.32e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-10.47	1.9e-24	1.32e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
BRCA	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	10.47	1.91e-24	1.33e-21	0.51	0.31	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
BRCA	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	10.47	1.91e-24	1.33e-21	0.47	0.31	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	10.46	1.96e-24	1.37e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
BRCA	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-10.46	1.97e-24	1.37e-21	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
BRCA	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-10.46	1.98e-24	1.38e-21	-0.35	-0.31	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-10.46	1.99e-24	1.39e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
BRCA	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-10.46	2.02e-24	1.41e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-10.46	2.02e-24	1.41e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-10.46	2.03e-24	1.42e-21	-0.22	-0.31	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
BRCA	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	10.46	2.04e-24	1.42e-21	0.45	0.31	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	10.46	2.05e-24	1.43e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
BRCA	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	10.46	2.05e-24	1.43e-21	0.4	0.31	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
BRCA	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-10.46	2.05e-24	1.43e-21	-0.42	-0.31	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
BRCA	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-10.46	2.06e-24	1.43e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	10.46	2.06e-24	1.44e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	10.46	2.06e-24	1.44e-21	0.35	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	10.46	2.06e-24	1.44e-21	0.35	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
BRCA	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	10.46	2.07e-24	1.44e-21	0.38	0.31	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-10.46	2.08e-24	1.45e-21	-0.42	-0.31	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-10.46	2.1e-24	1.46e-21	-0.36	-0.31	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
BRCA	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	10.46	2.11e-24	1.47e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	10.46	2.13e-24	1.48e-21	0.35	0.31	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
BRCA	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	10.45	2.14e-24	1.49e-21	0.49	0.31	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
BRCA	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	10.45	2.16e-24	1.5e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	10.45	2.16e-24	1.5e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	10.45	2.16e-24	1.51e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
BRCA	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-10.45	2.17e-24	1.51e-21	-0.37	-0.31	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
BRCA	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-10.45	2.2e-24	1.53e-21	-0.39	-0.31	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
BRCA	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-10.45	2.2e-24	1.53e-21	-0.49	-0.31	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
BRCA	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-10.45	2.21e-24	1.53e-21	-0.44	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	10.45	2.22e-24	1.54e-21	0.31	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	10.45	2.23e-24	1.55e-21	0.21	0.31	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
BRCA	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-10.45	2.24e-24	1.55e-21	-0.44	-0.31	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
BRCA	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-10.45	2.25e-24	1.56e-21	-0.46	-0.31	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	10.45	2.26e-24	1.57e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
BRCA	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-10.45	2.26e-24	1.57e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
BRCA	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-10.45	2.29e-24	1.59e-21	-0.36	-0.31	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
BRCA	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-10.45	2.3e-24	1.6e-21	-0.46	-0.31	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
BRCA	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-10.45	2.33e-24	1.61e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
BRCA	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	10.44	2.35e-24	1.63e-21	0.37	0.31	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
BRCA	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-10.44	2.38e-24	1.65e-21	-0.45	-0.31	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	10.44	2.42e-24	1.68e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-10.44	2.44e-24	1.69e-21	-0.43	-0.31	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-10.44	2.44e-24	1.69e-21	-0.38	-0.31	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-10.44	2.44e-24	1.69e-21	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-10.44	2.46e-24	1.7e-21	-0.22	-0.31	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
BRCA	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	10.44	2.46e-24	1.71e-21	0.4	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
BRCA	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-10.44	2.47e-24	1.71e-21	-0.38	-0.31	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	10.44	2.55e-24	1.77e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-10.44	2.56e-24	1.77e-21	-0.43	-0.31	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-10.44	2.56e-24	1.77e-21	-0.36	-0.31	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-10.44	2.56e-24	1.77e-21	-0.52	-0.31	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	10.43	2.59e-24	1.79e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
BRCA	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-10.43	2.59e-24	1.79e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	10.43	2.59e-24	1.79e-21	0.37	0.31	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	10.43	2.59e-24	1.79e-21	0.37	0.31	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
BRCA	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	10.43	2.62e-24	1.81e-21	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
BRCA	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	10.43	2.65e-24	1.83e-21	0.38	0.31	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
BRCA	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-10.43	2.65e-24	1.83e-21	-0.4	-0.31	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
BRCA	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	10.43	2.65e-24	1.83e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-10.43	2.65e-24	1.83e-21	-0.42	-0.31	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	10.43	2.67e-24	1.84e-21	0.37	0.31	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-10.43	2.68e-24	1.85e-21	-0.24	-0.31	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
BRCA	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-10.43	2.7e-24	1.86e-21	-0.37	-0.31	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000278665.1	RP11-666O2.4	10.43	2.72e-24	1.88e-21	0.35	0.31	Body mass index;	chr16:28592021	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	10.43	2.72e-24	1.88e-21	0.41	0.31	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
BRCA	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-10.43	2.74e-24	1.89e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
BRCA	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	10.43	2.75e-24	1.9e-21	0.46	0.31	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
BRCA	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-10.43	2.78e-24	1.92e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-10.43	2.81e-24	1.94e-21	-0.35	-0.31	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
BRCA	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	10.43	2.81e-24	1.94e-21	0.44	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
BRCA	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-10.43	2.83e-24	1.95e-21	-0.37	-0.31	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
BRCA	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-10.43	2.83e-24	1.95e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	10.43	2.83e-24	1.95e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	10.43	2.83e-24	1.95e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
BRCA	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-10.42	2.86e-24	1.97e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-10.42	2.86e-24	1.97e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
BRCA	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-10.42	2.87e-24	1.97e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
BRCA	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	10.42	2.87e-24	1.98e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	10.42	2.88e-24	1.98e-21	0.37	0.31	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
BRCA	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
BRCA	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
BRCA	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-10.42	2.9e-24	1.99e-21	-0.62	-0.31	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-10.42	2.92e-24	2.01e-21	-0.4	-0.31	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-10.42	2.96e-24	2.03e-21	-0.63	-0.31	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-10.42	2.98e-24	2.05e-21	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
BRCA	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-10.42	3e-24	2.06e-21	-0.43	-0.31	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
BRCA	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	10.42	3.01e-24	2.07e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
BRCA	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-10.42	3.02e-24	2.07e-21	-0.35	-0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
BRCA	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-10.42	3.05e-24	2.1e-21	-0.35	-0.31	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
BRCA	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-10.42	3.08e-24	2.11e-21	-0.43	-0.31	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000278665.1	RP11-666O2.4	10.42	3.08e-24	2.11e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28599241~28601881:-
BRCA	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-10.42	3.1e-24	2.13e-21	-0.31	-0.31	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
BRCA	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	10.41	3.12e-24	2.14e-21	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
BRCA	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-10.41	3.12e-24	2.14e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
BRCA	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	10.41	3.12e-24	2.14e-21	0.79	0.31	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-24	2.14e-21	-0.51	-0.31	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
BRCA	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	10.41	3.14e-24	2.15e-21	0.43	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-10.41	3.15e-24	2.16e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
BRCA	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-10.41	3.17e-24	2.17e-21	-0.38	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-10.41	3.19e-24	2.18e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	10.41	3.19e-24	2.19e-21	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
BRCA	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	10.41	3.22e-24	2.21e-21	0.34	0.31	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	10.41	3.22e-24	2.21e-21	0.34	0.31	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
BRCA	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	10.41	3.22e-24	2.21e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
BRCA	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	10.41	3.23e-24	2.21e-21	0.46	0.31	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
BRCA	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	10.41	3.24e-24	2.22e-21	0.38	0.31	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
BRCA	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-10.41	3.25e-24	2.22e-21	-0.35	-0.31	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
BRCA	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	10.41	3.28e-24	2.25e-21	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
BRCA	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	10.41	3.29e-24	2.25e-21	0.49	0.31	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	10.41	3.29e-24	2.25e-21	0.49	0.31	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
BRCA	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	10.41	3.3e-24	2.26e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
BRCA	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	10.41	3.3e-24	2.26e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
BRCA	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-10.41	3.3e-24	2.26e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-10.41	3.31e-24	2.26e-21	-0.35	-0.31	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
BRCA	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-10.41	3.33e-24	2.28e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	10.41	3.33e-24	2.28e-21	0.38	0.31	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	10.41	3.37e-24	2.31e-21	0.4	0.31	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
BRCA	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	10.41	3.37e-24	2.31e-21	0.4	0.31	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
BRCA	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	10.41	3.4e-24	2.33e-21	0.46	0.31	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	10.41	3.41e-24	2.33e-21	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-10.4	3.44e-24	2.35e-21	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-10.4	3.44e-24	2.35e-21	-0.22	-0.31	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-10.4	3.45e-24	2.36e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-10.4	3.48e-24	2.38e-21	-0.4	-0.31	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
BRCA	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	10.4	3.5e-24	2.39e-21	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-10.4	3.57e-24	2.44e-21	-0.42	-0.31	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	10.4	3.57e-24	2.44e-21	0.44	0.31	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
BRCA	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-10.4	3.59e-24	2.45e-21	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-10.4	3.6e-24	2.46e-21	-0.24	-0.31	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	10.4	3.61e-24	2.47e-21	0.41	0.31	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	10.4	3.62e-24	2.47e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
BRCA	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	10.4	3.63e-24	2.48e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	10.4	3.64e-24	2.48e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
BRCA	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	10.4	3.67e-24	2.5e-21	0.4	0.31	Height;	chr6:109331033	chr6:109382795~109383666:+
BRCA	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	10.4	3.67e-24	2.5e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
BRCA	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-10.4	3.69e-24	2.52e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
BRCA	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-10.4	3.7e-24	2.53e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-10.4	3.7e-24	2.53e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
BRCA	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-10.4	3.71e-24	2.53e-21	-0.48	-0.31	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
BRCA	cis	rs473651	0.935	rs474478	ENSG00000229915.1	AC016999.2	-10.4	3.73e-24	2.54e-21	-0.39	-0.31	Multiple system atrophy;	chr2:238426832	chr2:238427077~238427729:-
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-10.4	3.76e-24	2.56e-21	-0.42	-0.31	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-10.4	3.76e-24	2.56e-21	-0.42	-0.31	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	10.39	3.79e-24	2.58e-21	0.44	0.31	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	10.39	3.81e-24	2.6e-21	0.3	0.31	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
BRCA	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	10.39	3.82e-24	2.6e-21	0.38	0.31	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000278665.1	RP11-666O2.4	10.39	3.87e-24	2.63e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000278665.1	RP11-666O2.4	10.39	3.87e-24	2.63e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28599241~28601881:-
BRCA	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	10.39	3.92e-24	2.67e-21	0.46	0.31	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
BRCA	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	10.39	3.92e-24	2.67e-21	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
BRCA	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	10.39	3.92e-24	2.67e-21	0.35	0.31	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	10.39	3.94e-24	2.68e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
BRCA	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	10.39	3.96e-24	2.69e-21	0.49	0.31	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
BRCA	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-10.39	4.01e-24	2.72e-21	-0.42	-0.31	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
BRCA	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	10.39	4.02e-24	2.73e-21	0.39	0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
BRCA	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-10.39	4.09e-24	2.78e-21	-0.37	-0.31	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-10.39	4.14e-24	2.81e-21	-0.37	-0.31	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
BRCA	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-10.39	4.15e-24	2.82e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-10.39	4.15e-24	2.82e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
BRCA	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-10.38	4.15e-24	2.82e-21	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
BRCA	cis	rs4862750	0.872	rs6553030	ENSG00000250971.1	RP11-696F12.1	10.38	4.18e-24	2.84e-21	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:187060099~187060930:+
BRCA	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.19e-24	2.85e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.19e-24	2.85e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
BRCA	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-10.38	4.2e-24	2.85e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.21e-24	2.86e-21	-0.35	-0.31	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	10.38	4.21e-24	2.86e-21	0.41	0.31	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
BRCA	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-10.38	4.21e-24	2.86e-21	-0.44	-0.31	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	10.38	4.21e-24	2.86e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
BRCA	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-10.38	4.22e-24	2.87e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	10.38	4.25e-24	2.89e-21	0.37	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
BRCA	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	10.38	4.27e-24	2.9e-21	0.35	0.31	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
BRCA	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	10.38	4.3e-24	2.92e-21	0.35	0.31	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
BRCA	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-10.38	4.3e-24	2.92e-21	-0.32	-0.31	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
BRCA	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-10.37	4.57e-24	3.09e-21	-0.47	-0.31	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000278665.1	RP11-666O2.4	10.37	4.61e-24	3.12e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28599241~28601881:-
BRCA	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-10.37	4.61e-24	3.12e-21	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
BRCA	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	10.37	4.65e-24	3.15e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-10.37	4.68e-24	3.16e-21	-0.37	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
BRCA	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	10.37	4.68e-24	3.16e-21	0.46	0.31	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
BRCA	cis	rs4727443	0.653	rs6465759	ENSG00000214313.7	AZGP1P1	10.37	4.69e-24	3.17e-21	0.31	0.31	Interstitial lung disease;	chr7:99990357	chr7:99980762~99987535:+
BRCA	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-10.37	4.7e-24	3.18e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-10.37	4.84e-24	3.27e-21	-0.45	-0.31	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
BRCA	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	10.37	4.85e-24	3.27e-21	0.46	0.31	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	10.37	4.85e-24	3.27e-21	0.46	0.31	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000278665.1	RP11-666O2.4	10.37	4.85e-24	3.28e-21	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28599241~28601881:-
BRCA	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	10.37	4.86e-24	3.28e-21	0.35	0.31	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
BRCA	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-10.37	4.87e-24	3.29e-21	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
BRCA	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-10.37	4.9e-24	3.31e-21	-0.31	-0.31	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-10.37	4.92e-24	3.32e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	10.37	4.99e-24	3.37e-21	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
BRCA	cis	rs4727443	0.691	rs6975827	ENSG00000214313.7	AZGP1P1	10.37	4.99e-24	3.37e-21	0.31	0.31	Interstitial lung disease;	chr7:99988175	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-10.36	5.07e-24	3.42e-21	-0.42	-0.31	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	10.36	5.08e-24	3.43e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	10.36	5.09e-24	3.43e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
BRCA	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-10.36	5.12e-24	3.45e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-10.36	5.12e-24	3.45e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
BRCA	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-10.36	5.13e-24	3.46e-21	-0.38	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-10.36	5.17e-24	3.49e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
BRCA	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	10.36	5.19e-24	3.5e-21	0.38	0.31	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
BRCA	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	10.36	5.25e-24	3.54e-21	0.38	0.31	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
BRCA	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	10.36	5.27e-24	3.55e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	10.36	5.27e-24	3.55e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
BRCA	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	10.36	5.33e-24	3.59e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
BRCA	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-10.36	5.37e-24	3.62e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	10.36	5.37e-24	3.62e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	10.36	5.39e-24	3.63e-21	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
BRCA	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	10.36	5.51e-24	3.71e-21	0.39	0.31	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
BRCA	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-10.35	5.52e-24	3.72e-21	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
BRCA	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	10.35	5.61e-24	3.77e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
BRCA	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-10.35	5.62e-24	3.78e-21	-0.36	-0.31	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
BRCA	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-10.35	5.65e-24	3.8e-21	-0.47	-0.31	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	10.35	5.71e-24	3.84e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
BRCA	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-10.35	5.75e-24	3.87e-21	-0.42	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
BRCA	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-10.35	5.78e-24	3.89e-21	-0.45	-0.31	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
BRCA	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	10.35	5.79e-24	3.89e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	10.35	5.83e-24	3.92e-21	0.41	0.31	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
BRCA	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	10.35	5.84e-24	3.92e-21	0.38	0.31	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-10.35	5.84e-24	3.93e-21	-0.35	-0.31	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
BRCA	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	10.35	5.86e-24	3.94e-21	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-10.35	5.99e-24	4.02e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-10.35	6e-24	4.03e-21	-0.38	-0.31	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
BRCA	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-10.35	6e-24	4.03e-21	-0.36	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
BRCA	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	10.35	6e-24	4.03e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	10.35	6.04e-24	4.05e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
BRCA	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-10.35	6.04e-24	4.05e-21	-0.48	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
BRCA	cis	rs4862750	0.794	rs1030382	ENSG00000250971.1	RP11-696F12.1	10.35	6.05e-24	4.06e-21	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:187060099~187060930:+
BRCA	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	10.34	6.08e-24	4.08e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	10.34	6.15e-24	4.13e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	10.34	6.19e-24	4.16e-21	0.39	0.31	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	10.34	6.2e-24	4.16e-21	0.57	0.31	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	10.34	6.28e-24	4.21e-21	0.46	0.31	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
BRCA	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	10.34	6.31e-24	4.23e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	10.34	6.34e-24	4.25e-21	0.49	0.31	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	10.34	6.35e-24	4.26e-21	0.39	0.31	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	10.34	6.36e-24	4.27e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-10.34	6.37e-24	4.28e-21	-0.42	-0.31	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-10.34	6.38e-24	4.28e-21	-0.42	-0.31	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
BRCA	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	10.34	6.46e-24	4.33e-21	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-10.34	6.5e-24	4.36e-21	-0.36	-0.3	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
BRCA	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-10.34	6.51e-24	4.37e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
BRCA	cis	rs4862750	0.872	rs13110072	ENSG00000250971.1	RP11-696F12.1	10.34	6.52e-24	4.37e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs6825289	ENSG00000250971.1	RP11-696F12.1	10.34	6.52e-24	4.37e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:187060099~187060930:+
BRCA	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
BRCA	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-10.34	6.53e-24	4.37e-21	-0.37	-0.3	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
BRCA	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	10.34	6.56e-24	4.4e-21	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
BRCA	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-10.33	6.72e-24	4.5e-21	-0.41	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-10.33	6.74e-24	4.51e-21	-0.42	-0.3	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	10.33	6.75e-24	4.52e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-10.33	6.75e-24	4.52e-21	-0.42	-0.3	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-10.33	6.75e-24	4.52e-21	-0.42	-0.3	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
BRCA	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	10.33	6.8e-24	4.55e-21	0.44	0.3	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
BRCA	cis	rs473651	1	rs473651	ENSG00000229915.1	AC016999.2	-10.33	6.82e-24	4.57e-21	-0.38	-0.3	Multiple system atrophy;	chr2:238426760	chr2:238427077~238427729:-
BRCA	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-10.33	6.88e-24	4.61e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
BRCA	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-10.33	6.89e-24	4.61e-21	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-10.33	6.94e-24	4.64e-21	-0.42	-0.3	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-10.33	6.97e-24	4.66e-21	-0.4	-0.3	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
BRCA	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	10.33	7.04e-24	4.71e-21	0.38	0.3	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-10.33	7.08e-24	4.74e-21	-0.42	-0.3	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-10.33	7.09e-24	4.74e-21	-0.35	-0.3	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-10.33	7.13e-24	4.76e-21	-0.42	-0.3	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-10.33	7.13e-24	4.76e-21	-0.42	-0.3	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	10.33	7.13e-24	4.76e-21	0.42	0.3	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
BRCA	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	10.33	7.13e-24	4.77e-21	0.51	0.3	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	10.33	7.13e-24	4.77e-21	0.51	0.3	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
BRCA	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	10.33	7.15e-24	4.78e-21	0.37	0.3	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
BRCA	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	10.33	7.21e-24	4.82e-21	0.34	0.3	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
BRCA	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-10.33	7.22e-24	4.82e-21	-0.34	-0.3	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
BRCA	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-10.33	7.22e-24	4.82e-21	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	10.33	7.29e-24	4.86e-21	0.42	0.3	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	10.33	7.29e-24	4.87e-21	0.46	0.3	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	10.33	7.29e-24	4.87e-21	0.46	0.3	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-10.33	7.32e-24	4.89e-21	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-10.32	7.41e-24	4.94e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-10.32	7.41e-24	4.94e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	10.32	7.42e-24	4.95e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	10.32	7.44e-24	4.96e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	10.32	7.45e-24	4.97e-21	0.38	0.3	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	10.32	7.45e-24	4.97e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
BRCA	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	10.32	7.51e-24	5.01e-21	0.35	0.3	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	10.32	7.55e-24	5.03e-21	0.42	0.3	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	10.32	7.6e-24	5.06e-21	0.39	0.3	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
BRCA	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	10.32	7.62e-24	5.08e-21	0.39	0.3	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
BRCA	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-10.32	7.62e-24	5.08e-21	-0.32	-0.3	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
BRCA	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-10.32	7.65e-24	5.1e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-10.32	7.65e-24	5.1e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	10.32	7.65e-24	5.1e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	10.32	7.65e-24	5.1e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	10.32	7.72e-24	5.14e-21	0.42	0.3	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-10.32	7.75e-24	5.16e-21	-0.4	-0.3	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
BRCA	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	10.32	7.77e-24	5.18e-21	0.46	0.3	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	10.32	7.78e-24	5.18e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-10.32	7.83e-24	5.21e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
BRCA	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-10.32	7.83e-24	5.22e-21	-0.48	-0.3	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	10.32	7.87e-24	5.24e-21	0.42	0.3	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	10.32	7.88e-24	5.24e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
BRCA	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	10.32	7.92e-24	5.27e-21	0.4	0.3	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
BRCA	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-10.32	7.93e-24	5.28e-21	-0.4	-0.3	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
BRCA	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	10.31	8.08e-24	5.37e-21	0.36	0.3	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-10.31	8.13e-24	5.41e-21	-0.36	-0.3	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	10.31	8.16e-24	5.43e-21	0.42	0.3	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	10.31	8.16e-24	5.43e-21	0.42	0.3	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-10.31	8.18e-24	5.44e-21	-0.35	-0.3	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-10.31	8.2e-24	5.45e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	10.31	8.26e-24	5.49e-21	0.34	0.3	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
BRCA	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-10.31	8.33e-24	5.54e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
BRCA	cis	rs473651	0.935	rs515412	ENSG00000229915.1	AC016999.2	-10.31	8.34e-24	5.54e-21	-0.38	-0.3	Multiple system atrophy;	chr2:238436753	chr2:238427077~238427729:-
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	10.31	8.34e-24	5.54e-21	0.39	0.3	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-10.31	8.39e-24	5.58e-21	-0.6	-0.3	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
BRCA	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	10.31	8.5e-24	5.64e-21	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
BRCA	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-10.31	8.55e-24	5.68e-21	-0.39	-0.3	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-10.31	8.56e-24	5.69e-21	-0.42	-0.3	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-10.31	8.6e-24	5.71e-21	-0.4	-0.3	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
BRCA	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-10.31	8.81e-24	5.85e-21	-0.36	-0.3	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-10.31	8.81e-24	5.85e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-10.31	8.81e-24	5.85e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	10.31	8.85e-24	5.87e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	10.3	8.88e-24	5.89e-21	0.58	0.3	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	10.3	8.94e-24	5.93e-21	0.81	0.3	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	10.3	8.94e-24	5.93e-21	0.81	0.3	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
BRCA	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	10.3	8.97e-24	5.95e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	10.3	9.01e-24	5.98e-21	0.46	0.3	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-10.3	9.02e-24	5.98e-21	-0.42	-0.3	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	10.3	9.05e-24	6e-21	0.4	0.3	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	10.3	9.05e-24	6e-21	0.4	0.3	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-10.3	9.07e-24	6.01e-21	-0.41	-0.3	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
BRCA	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	10.3	9.08e-24	6.02e-21	0.27	0.3	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
BRCA	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	10.3	9.21e-24	6.1e-21	0.43	0.3	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	10.3	9.21e-24	6.1e-21	0.43	0.3	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
BRCA	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-10.3	9.25e-24	6.13e-21	-0.38	-0.3	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
BRCA	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	10.3	9.27e-24	6.14e-21	0.46	0.3	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	10.3	9.34e-24	6.19e-21	0.42	0.3	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-10.3	9.45e-24	6.26e-21	-0.42	-0.3	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-10.3	9.46e-24	6.26e-21	-0.42	-0.3	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-10.3	9.48e-24	6.28e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-10.3	9.48e-24	6.28e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	10.3	9.55e-24	6.32e-21	0.81	0.3	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
BRCA	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
BRCA	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-10.3	9.63e-24	6.37e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	10.3	9.63e-24	6.37e-21	0.81	0.3	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	10.3	9.64e-24	6.38e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	10.3	9.71e-24	6.42e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
BRCA	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-10.29	9.77e-24	6.46e-21	-0.32	-0.3	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	10.29	9.78e-24	6.47e-21	0.39	0.3	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-10.29	9.79e-24	6.47e-21	-0.29	-0.3	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-10.29	9.82e-24	6.5e-21	-0.4	-0.3	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
BRCA	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-10.29	9.84e-24	6.51e-21	-0.44	-0.3	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-10.29	9.84e-24	6.51e-21	-0.44	-0.3	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	10.29	9.87e-24	6.52e-21	0.33	0.3	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
BRCA	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-10.29	1e-23	6.63e-21	-0.39	-0.3	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
BRCA	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	10.29	1.01e-23	6.65e-21	0.43	0.3	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	10.29	1.01e-23	6.65e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
BRCA	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-10.29	1.02e-23	6.72e-21	-0.43	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-10.29	1.02e-23	6.75e-21	-0.22	-0.3	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
BRCA	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-10.29	1.03e-23	6.79e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
BRCA	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	10.29	1.03e-23	6.8e-21	0.31	0.3	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	10.29	1.03e-23	6.81e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	10.29	1.03e-23	6.81e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
BRCA	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	10.29	1.03e-23	6.82e-21	0.39	0.3	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
BRCA	cis	rs4862750	0.832	rs6836076	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs6836781	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs11947595	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:187060099~187060930:+
BRCA	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-10.29	1.04e-23	6.84e-21	-0.47	-0.3	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
BRCA	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-10.29	1.04e-23	6.85e-21	-0.36	-0.3	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
BRCA	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	10.29	1.05e-23	6.95e-21	0.39	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-10.29	1.06e-23	7.03e-21	-0.29	-0.3	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
BRCA	cis	rs4862750	0.872	rs7658314	ENSG00000250971.1	RP11-696F12.1	10.28	1.07e-23	7.06e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.832	rs6419953	ENSG00000250971.1	RP11-696F12.1	10.28	1.07e-23	7.06e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:187060099~187060930:+
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000226816.2	AC005082.12	10.28	1.07e-23	7.06e-21	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23206013~23208045:+
BRCA	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-10.28	1.08e-23	7.11e-21	-0.5	-0.3	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
BRCA	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	10.28	1.08e-23	7.14e-21	0.38	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
BRCA	cis	rs4862750	0.872	rs4862747	ENSG00000250971.1	RP11-696F12.1	-10.28	1.1e-23	7.24e-21	-0.32	-0.3	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:187060099~187060930:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	10.28	1.11e-23	7.32e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-10.28	1.13e-23	7.46e-21	-0.43	-0.3	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
BRCA	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	10.28	1.14e-23	7.5e-21	0.3	0.3	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
BRCA	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	10.28	1.14e-23	7.52e-21	0.37	0.3	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
BRCA	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-10.28	1.14e-23	7.52e-21	-0.39	-0.3	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-10.28	1.14e-23	7.52e-21	-0.39	-0.3	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
BRCA	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-10.28	1.14e-23	7.53e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	10.28	1.15e-23	7.59e-21	0.41	0.3	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-10.28	1.17e-23	7.69e-21	-0.42	-0.3	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
BRCA	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-10.28	1.17e-23	7.71e-21	-0.32	-0.3	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
BRCA	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	10.27	1.18e-23	7.79e-21	0.45	0.3	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
BRCA	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-10.27	1.2e-23	7.88e-21	-0.39	-0.3	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
BRCA	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-10.27	1.2e-23	7.88e-21	-0.39	-0.3	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
BRCA	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	10.27	1.2e-23	7.93e-21	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	10.27	1.22e-23	8e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
BRCA	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	10.27	1.28e-23	8.4e-21	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
BRCA	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-10.27	1.28e-23	8.42e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	10.27	1.29e-23	8.45e-21	0.46	0.3	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-10.27	1.29e-23	8.47e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-10.27	1.29e-23	8.48e-21	-0.36	-0.3	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
BRCA	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-10.26	1.3e-23	8.52e-21	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-10.26	1.3e-23	8.55e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
BRCA	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	10.26	1.3e-23	8.55e-21	0.49	0.3	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
BRCA	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-10.26	1.31e-23	8.58e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-10.26	1.31e-23	8.59e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	10.26	1.31e-23	8.61e-21	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	10.26	1.31e-23	8.61e-21	0.41	0.3	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-10.26	1.32e-23	8.64e-21	-0.4	-0.3	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	10.26	1.33e-23	8.71e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
BRCA	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	10.26	1.34e-23	8.78e-21	0.48	0.3	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
BRCA	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-10.26	1.34e-23	8.8e-21	-0.36	-0.3	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	10.26	1.34e-23	8.81e-21	0.81	0.3	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
BRCA	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	10.26	1.34e-23	8.82e-21	0.35	0.3	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
BRCA	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-10.26	1.35e-23	8.83e-21	-0.34	-0.3	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
BRCA	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	10.26	1.35e-23	8.84e-21	0.45	0.3	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
BRCA	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	10.26	1.35e-23	8.86e-21	0.29	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-10.26	1.35e-23	8.86e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-10.26	1.36e-23	8.9e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-10.26	1.36e-23	8.9e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
BRCA	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-10.26	1.36e-23	8.92e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
BRCA	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	10.26	1.37e-23	8.98e-21	0.38	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
BRCA	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-10.26	1.38e-23	9.01e-21	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
BRCA	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-10.26	1.38e-23	9.07e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	10.26	1.39e-23	9.1e-21	0.39	0.3	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
BRCA	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-10.26	1.39e-23	9.11e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-10.26	1.39e-23	9.11e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
BRCA	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-10.26	1.4e-23	9.14e-21	-0.42	-0.3	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
BRCA	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	10.26	1.41e-23	9.21e-21	0.33	0.3	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	10.26	1.41e-23	9.24e-21	0.41	0.3	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	10.26	1.41e-23	9.24e-21	0.41	0.3	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.24e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.25e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	10.26	1.41e-23	9.25e-21	0.39	0.3	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
BRCA	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-10.26	1.42e-23	9.27e-21	-0.37	-0.3	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
BRCA	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	10.25	1.43e-23	9.32e-21	0.46	0.3	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	10.25	1.43e-23	9.32e-21	0.46	0.3	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
BRCA	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	10.25	1.43e-23	9.33e-21	0.38	0.3	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	10.25	1.43e-23	9.34e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-10.25	1.44e-23	9.4e-21	-0.41	-0.3	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	10.25	1.44e-23	9.43e-21	0.45	0.3	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	10.25	1.47e-23	9.58e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-10.25	1.47e-23	9.61e-21	-0.35	-0.3	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
BRCA	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	10.25	1.48e-23	9.65e-21	0.39	0.3	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
BRCA	cis	rs4862750	0.794	rs7692427	ENSG00000250971.1	RP11-696F12.1	10.25	1.51e-23	9.83e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.832	rs9995958	ENSG00000250971.1	RP11-696F12.1	10.25	1.51e-23	9.83e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:187060099~187060930:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-10.25	1.51e-23	9.88e-21	-0.22	-0.3	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-10.25	1.54e-23	1e-20	-0.41	-0.3	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-10.24	1.56e-23	1.02e-20	-0.31	-0.3	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	10.24	1.57e-23	1.03e-20	0.31	0.3	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
BRCA	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-10.24	1.58e-23	1.03e-20	-0.38	-0.3	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
BRCA	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	10.24	1.59e-23	1.04e-20	0.38	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	10.24	1.63e-23	1.06e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-10.24	1.63e-23	1.06e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
BRCA	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	10.24	1.63e-23	1.06e-20	0.39	0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	10.24	1.64e-23	1.07e-20	0.48	0.3	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
BRCA	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-10.24	1.64e-23	1.07e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	10.24	1.65e-23	1.07e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
BRCA	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-10.24	1.65e-23	1.08e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	10.24	1.66e-23	1.08e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
BRCA	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-10.24	1.69e-23	1.1e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
BRCA	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-10.24	1.69e-23	1.1e-20	-0.4	-0.3	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-10.24	1.69e-23	1.1e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	10.24	1.69e-23	1.1e-20	0.8	0.3	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
BRCA	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	10.24	1.69e-23	1.1e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
BRCA	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-10.24	1.7e-23	1.11e-20	-0.3	-0.3	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	10.23	1.72e-23	1.12e-20	0.42	0.3	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	10.23	1.73e-23	1.12e-20	0.41	0.3	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	10.23	1.74e-23	1.13e-20	0.31	0.3	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	10.23	1.74e-23	1.13e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
BRCA	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	10.23	1.75e-23	1.14e-20	0.37	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
BRCA	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-10.23	1.76e-23	1.14e-20	-0.35	-0.3	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
BRCA	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	10.23	1.78e-23	1.16e-20	0.39	0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
BRCA	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	10.23	1.8e-23	1.17e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	10.23	1.81e-23	1.17e-20	0.22	0.3	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	10.23	1.82e-23	1.18e-20	0.7	0.3	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
BRCA	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-10.23	1.83e-23	1.19e-20	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-10.23	1.88e-23	1.21e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
BRCA	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	10.22	1.88e-23	1.22e-20	0.35	0.3	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
BRCA	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-10.22	1.89e-23	1.22e-20	-0.36	-0.3	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
BRCA	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-10.22	1.93e-23	1.25e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-10.22	1.93e-23	1.25e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
BRCA	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-10.22	1.94e-23	1.25e-20	-0.47	-0.3	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
BRCA	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
BRCA	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-10.22	1.95e-23	1.26e-20	-0.39	-0.3	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
BRCA	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	10.22	1.95e-23	1.26e-20	0.36	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
BRCA	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	10.22	1.99e-23	1.28e-20	0.39	0.3	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
BRCA	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	10.22	1.99e-23	1.28e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-10.22	2e-23	1.29e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-10.22	2e-23	1.29e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
BRCA	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	10.22	2e-23	1.29e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-10.22	2.02e-23	1.31e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-10.22	2.03e-23	1.31e-20	-0.4	-0.3	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-10.22	2.04e-23	1.32e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	10.22	2.06e-23	1.33e-20	0.56	0.3	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-10.22	2.06e-23	1.33e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
BRCA	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	10.21	2.09e-23	1.35e-20	0.3	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
BRCA	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-10.21	2.09e-23	1.35e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-10.21	2.09e-23	1.35e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
BRCA	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-10.21	2.11e-23	1.36e-20	-0.33	-0.3	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-10.21	2.12e-23	1.37e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
BRCA	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	10.21	2.13e-23	1.37e-20	0.42	0.3	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	10.21	2.13e-23	1.37e-20	0.42	0.3	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
BRCA	cis	rs4862750	0.915	rs6835681	ENSG00000250971.1	RP11-696F12.1	10.21	2.15e-23	1.38e-20	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:187060099~187060930:+
BRCA	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-10.21	2.16e-23	1.39e-20	-0.39	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-10.21	2.17e-23	1.4e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-10.21	2.18e-23	1.4e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	10.21	2.18e-23	1.4e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-10.21	2.18e-23	1.41e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-10.21	2.18e-23	1.41e-20	-0.35	-0.3	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
BRCA	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-10.21	2.2e-23	1.42e-20	-0.34	-0.3	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-10.21	2.21e-23	1.42e-20	-0.6	-0.3	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-10.21	2.21e-23	1.42e-20	-0.37	-0.3	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
BRCA	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-10.21	2.22e-23	1.43e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
BRCA	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-10.21	2.22e-23	1.43e-20	-0.3	-0.3	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-10.21	2.22e-23	1.43e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
BRCA	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	10.21	2.23e-23	1.43e-20	0.45	0.3	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
BRCA	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-10.21	2.23e-23	1.43e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-10.21	2.23e-23	1.43e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	10.21	2.24e-23	1.44e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	10.21	2.24e-23	1.44e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
BRCA	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	10.21	2.24e-23	1.44e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
BRCA	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-10.21	2.26e-23	1.45e-20	-0.36	-0.3	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
BRCA	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	10.21	2.27e-23	1.46e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	10.21	2.27e-23	1.46e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
BRCA	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	10.2	2.27e-23	1.46e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
BRCA	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	10.2	2.29e-23	1.47e-20	0.38	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
BRCA	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	10.2	2.3e-23	1.48e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-10.2	2.3e-23	1.48e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-10.2	2.3e-23	1.48e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
BRCA	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-10.2	2.34e-23	1.5e-20	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
BRCA	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	10.2	2.35e-23	1.51e-20	0.41	0.3	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
BRCA	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-10.2	2.38e-23	1.53e-20	-0.38	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	10.2	2.38e-23	1.53e-20	0.48	0.3	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
BRCA	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	10.2	2.43e-23	1.56e-20	0.39	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
BRCA	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	10.2	2.44e-23	1.57e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
BRCA	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-10.2	2.45e-23	1.57e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
BRCA	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-10.2	2.47e-23	1.58e-20	-0.39	-0.3	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	10.19	2.5e-23	1.6e-20	0.42	0.3	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
BRCA	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	10.19	2.5e-23	1.6e-20	0.36	0.3	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
BRCA	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-10.19	2.5e-23	1.6e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
BRCA	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	10.19	2.51e-23	1.61e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-10.19	2.52e-23	1.61e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-10.19	2.52e-23	1.61e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
BRCA	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-10.19	2.52e-23	1.62e-20	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-10.19	2.53e-23	1.62e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	10.19	2.53e-23	1.62e-20	0.42	0.3	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-10.19	2.54e-23	1.62e-20	-0.41	-0.3	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-10.19	2.54e-23	1.63e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
BRCA	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-10.19	2.55e-23	1.63e-20	-0.34	-0.3	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
BRCA	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-10.19	2.55e-23	1.63e-20	-0.34	-0.3	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-10.19	2.59e-23	1.65e-20	-0.42	-0.3	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-10.19	2.61e-23	1.66e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-10.19	2.61e-23	1.66e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	10.19	2.62e-23	1.67e-20	0.69	0.3	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	10.19	2.62e-23	1.67e-20	0.69	0.3	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	10.19	2.63e-23	1.68e-20	0.69	0.3	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
BRCA	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	10.19	2.65e-23	1.69e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
BRCA	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-10.19	2.66e-23	1.69e-20	-0.5	-0.3	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-10.19	2.66e-23	1.7e-20	-0.41	-0.3	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-10.19	2.66e-23	1.7e-20	-0.41	-0.3	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
BRCA	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	10.19	2.66e-23	1.7e-20	0.37	0.3	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
BRCA	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-10.19	2.67e-23	1.71e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	10.19	2.68e-23	1.71e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-10.19	2.69e-23	1.71e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
BRCA	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-10.18	2.74e-23	1.75e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
BRCA	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-10.18	2.75e-23	1.76e-20	-0.34	-0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
BRCA	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-10.18	2.76e-23	1.76e-20	-0.4	-0.3	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-10.18	2.76e-23	1.76e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-10.18	2.77e-23	1.77e-20	-0.4	-0.3	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
BRCA	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	10.18	2.78e-23	1.77e-20	0.39	0.3	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-10.18	2.78e-23	1.77e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-10.18	2.79e-23	1.78e-20	-0.3	-0.3	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-10.18	2.8e-23	1.78e-20	-0.4	-0.3	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	10.18	2.8e-23	1.78e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
BRCA	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-10.18	2.81e-23	1.79e-20	-0.39	-0.3	QT interval;	chr16:28845498	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-10.18	2.82e-23	1.79e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
BRCA	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	10.18	2.82e-23	1.79e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-10.18	2.82e-23	1.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-10.18	2.82e-23	1.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
BRCA	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-10.18	2.84e-23	1.81e-20	-0.35	-0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
BRCA	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-10.18	2.85e-23	1.82e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-10.18	2.85e-23	1.82e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
BRCA	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-10.18	2.85e-23	1.82e-20	-0.37	-0.3	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
BRCA	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	10.18	2.87e-23	1.83e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	10.18	2.88e-23	1.83e-20	0.39	0.3	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	10.18	2.88e-23	1.83e-20	0.39	0.3	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	10.18	2.89e-23	1.84e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-10.18	2.89e-23	1.84e-20	-0.36	-0.3	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
BRCA	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	10.18	2.89e-23	1.84e-20	0.37	0.3	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
BRCA	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-10.18	2.89e-23	1.84e-20	-0.36	-0.3	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
BRCA	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-10.18	2.89e-23	1.84e-20	-0.32	-0.3	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
BRCA	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-10.18	2.91e-23	1.85e-20	-0.39	-0.3	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-10.18	2.91e-23	1.85e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
BRCA	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-10.18	2.92e-23	1.86e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
BRCA	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-10.18	2.94e-23	1.87e-20	-0.45	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
BRCA	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-10.18	2.94e-23	1.87e-20	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	10.18	2.95e-23	1.88e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
BRCA	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-10.18	2.96e-23	1.88e-20	-0.32	-0.3	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
BRCA	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-10.18	2.96e-23	1.88e-20	-0.32	-0.3	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-10.18	2.97e-23	1.89e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	10.17	3.02e-23	1.92e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-10.17	3.02e-23	1.92e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.927	rs34765012	ENSG00000227542.1	AC092614.2	10.17	3.03e-23	1.92e-20	0.39	0.3	Obesity-related traits;	chr2:191247926	chr2:191229165~191246172:-
BRCA	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	10.17	3.05e-23	1.94e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	10.17	3.07e-23	1.95e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
BRCA	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	10.17	3.07e-23	1.95e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
BRCA	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	10.17	3.08e-23	1.95e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
BRCA	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-10.17	3.1e-23	1.97e-20	-0.37	-0.3	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-10.17	3.11e-23	1.97e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-10.17	3.11e-23	1.97e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	10.17	3.11e-23	1.98e-20	0.36	0.3	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
BRCA	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-10.17	3.12e-23	1.98e-20	-0.46	-0.3	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
BRCA	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	10.17	3.12e-23	1.98e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	10.17	3.12e-23	1.98e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	10.17	3.12e-23	1.98e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	10.17	3.12e-23	1.98e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
BRCA	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	10.17	3.14e-23	1.99e-20	0.36	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	10.17	3.15e-23	2e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	10.17	3.16e-23	2e-20	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	10.17	3.16e-23	2e-20	0.8	0.3	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	10.17	3.16e-23	2e-20	0.8	0.3	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000278665.1	RP11-666O2.4	10.17	3.17e-23	2.01e-20	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	10.17	3.2e-23	2.03e-20	0.39	0.3	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	10.17	3.2e-23	2.03e-20	0.39	0.3	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
BRCA	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-10.17	3.22e-23	2.04e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
BRCA	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-10.17	3.23e-23	2.04e-20	-0.4	-0.3	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
BRCA	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-10.17	3.25e-23	2.06e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-10.17	3.25e-23	2.06e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
BRCA	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	10.17	3.25e-23	2.06e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-10.17	3.27e-23	2.07e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
BRCA	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-10.17	3.29e-23	2.08e-20	-0.37	-0.3	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
BRCA	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-10.16	3.3e-23	2.09e-20	-0.37	-0.3	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
BRCA	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	10.16	3.33e-23	2.11e-20	0.36	0.3	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	10.16	3.4e-23	2.15e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
BRCA	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	10.16	3.42e-23	2.17e-20	0.33	0.3	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
BRCA	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	10.16	3.45e-23	2.18e-20	0.36	0.3	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
BRCA	cis	rs1029738	0.659	rs1608553	ENSG00000228649.7	AC005682.5	10.16	3.46e-23	2.19e-20	0.27	0.3	Fibrinogen levels;	chr7:22856612	chr7:22854178~22861579:+
BRCA	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-10.16	3.47e-23	2.2e-20	-0.36	-0.3	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
BRCA	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-10.16	3.48e-23	2.2e-20	-0.39	-0.3	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
BRCA	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	10.16	3.51e-23	2.22e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-10.16	3.52e-23	2.22e-20	-0.41	-0.3	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
BRCA	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	10.16	3.52e-23	2.23e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	10.16	3.52e-23	2.23e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-10.16	3.53e-23	2.23e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-10.16	3.53e-23	2.23e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
BRCA	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	10.16	3.55e-23	2.24e-20	0.42	0.3	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
BRCA	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	10.16	3.55e-23	2.24e-20	0.39	0.3	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	10.16	3.55e-23	2.25e-20	0.8	0.3	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-10.16	3.56e-23	2.25e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-10.16	3.58e-23	2.26e-20	-0.41	-0.3	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	10.16	3.59e-23	2.27e-20	0.21	0.3	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	10.15	3.63e-23	2.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	10.15	3.64e-23	2.3e-20	0.39	0.3	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
BRCA	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-10.15	3.67e-23	2.32e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
BRCA	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	10.15	3.71e-23	2.34e-20	0.46	0.3	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
BRCA	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	10.15	3.73e-23	2.35e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-10.15	3.73e-23	2.36e-20	-0.4	-0.3	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
BRCA	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	10.15	3.74e-23	2.36e-20	0.36	0.3	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
BRCA	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	10.15	3.74e-23	2.36e-20	0.31	0.3	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
BRCA	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	10.15	3.74e-23	2.36e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	10.15	3.74e-23	2.36e-20	0.8	0.3	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	10.15	3.74e-23	2.36e-20	0.8	0.3	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	10.15	3.74e-23	2.36e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	10.15	3.75e-23	2.37e-20	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
BRCA	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	10.15	3.78e-23	2.38e-20	0.37	0.3	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
BRCA	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	10.15	3.78e-23	2.38e-20	0.4	0.3	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
BRCA	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	10.15	3.82e-23	2.41e-20	0.36	0.3	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
BRCA	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	10.15	3.84e-23	2.42e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	10.15	3.84e-23	2.42e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	10.15	3.87e-23	2.44e-20	0.33	0.3	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
BRCA	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-10.15	3.93e-23	2.48e-20	-0.5	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
BRCA	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-10.15	3.95e-23	2.49e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	10.15	3.95e-23	2.49e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
BRCA	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	10.15	3.95e-23	2.49e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
BRCA	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	10.15	3.96e-23	2.5e-20	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
BRCA	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	10.14	3.97e-23	2.5e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	10.14	3.97e-23	2.5e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-10.14	3.98e-23	2.5e-20	-0.22	-0.3	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000278665.1	RP11-666O2.4	10.14	3.98e-23	2.51e-20	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	10.14	4e-23	2.52e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-10.14	4.02e-23	2.53e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
BRCA	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-10.14	4.04e-23	2.54e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
BRCA	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-10.14	4.06e-23	2.55e-20	-0.4	-0.3	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
BRCA	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-10.14	4.07e-23	2.56e-20	-0.36	-0.3	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	10.14	4.12e-23	2.59e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	10.14	4.13e-23	2.59e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
BRCA	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-10.14	4.14e-23	2.6e-20	-0.4	-0.3	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	10.14	4.15e-23	2.61e-20	0.42	0.3	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-10.14	4.19e-23	2.63e-20	-0.31	-0.3	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-10.14	4.19e-23	2.63e-20	-0.35	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
BRCA	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-10.14	4.23e-23	2.66e-20	-0.36	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
BRCA	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	10.14	4.24e-23	2.66e-20	0.37	0.3	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-10.14	4.26e-23	2.67e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
BRCA	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	10.14	4.3e-23	2.7e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
BRCA	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	10.14	4.31e-23	2.7e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
BRCA	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	10.14	4.35e-23	2.73e-20	0.67	0.3	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
BRCA	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
BRCA	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-10.13	4.38e-23	2.75e-20	-0.27	-0.3	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	10.13	4.43e-23	2.78e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-10.13	4.44e-23	2.78e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	10.13	4.44e-23	2.78e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-10.13	4.44e-23	2.78e-20	-0.42	-0.3	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
BRCA	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-10.13	4.45e-23	2.79e-20	-0.37	-0.3	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
BRCA	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	10.13	4.45e-23	2.79e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
BRCA	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-10.13	4.47e-23	2.8e-20	-0.44	-0.3	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-10.13	4.47e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-10.13	4.47e-23	2.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-10.13	4.47e-23	2.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-10.13	4.48e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-10.13	4.48e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	10.13	4.49e-23	2.81e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	10.13	4.49e-23	2.81e-20	0.32	0.3	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-10.13	4.51e-23	2.82e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
BRCA	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	10.13	4.53e-23	2.83e-20	0.42	0.3	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
BRCA	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	10.13	4.54e-23	2.84e-20	0.36	0.3	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
BRCA	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	10.13	4.57e-23	2.86e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	10.13	4.58e-23	2.86e-20	0.39	0.3	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	10.13	4.58e-23	2.86e-20	0.39	0.3	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-10.13	4.58e-23	2.87e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-10.13	4.65e-23	2.91e-20	-0.35	-0.3	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-10.13	4.66e-23	2.92e-20	-0.39	-0.3	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-10.13	4.68e-23	2.92e-20	-0.35	-0.3	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	10.13	4.73e-23	2.96e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	10.13	4.74e-23	2.96e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
BRCA	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-10.13	4.75e-23	2.97e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
BRCA	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	10.13	4.76e-23	2.98e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000278665.1	RP11-666O2.4	-10.13	4.78e-23	2.99e-20	-0.32	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	10.12	4.8e-23	3e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	10.12	4.82e-23	3.01e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
BRCA	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	10.12	4.83e-23	3.02e-20	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
BRCA	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-10.12	4.9e-23	3.06e-20	-0.5	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
BRCA	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-10.12	4.92e-23	3.07e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
BRCA	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	10.12	4.95e-23	3.09e-20	0.35	0.3	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
BRCA	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-10.12	4.95e-23	3.09e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-10.12	4.97e-23	3.1e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-10.12	4.98e-23	3.11e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-10.12	4.98e-23	3.11e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
BRCA	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-10.12	4.99e-23	3.11e-20	-0.39	-0.3	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	10.12	5.03e-23	3.14e-20	0.39	0.3	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
BRCA	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	10.12	5.03e-23	3.14e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
BRCA	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-10.12	5.04e-23	3.14e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-10.12	5.06e-23	3.15e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
BRCA	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	10.12	5.06e-23	3.16e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	10.12	5.06e-23	3.16e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
BRCA	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-10.12	5.06e-23	3.16e-20	-0.44	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-10.12	5.07e-23	3.16e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
BRCA	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	10.12	5.07e-23	3.16e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
BRCA	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	10.12	5.09e-23	3.17e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	10.12	5.09e-23	3.17e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
BRCA	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	10.12	5.14e-23	3.2e-20	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
BRCA	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-10.12	5.16e-23	3.21e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-10.12	5.16e-23	3.21e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-10.12	5.2e-23	3.24e-20	-0.35	-0.3	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
BRCA	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	10.12	5.22e-23	3.25e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	10.12	5.22e-23	3.25e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	10.12	5.22e-23	3.25e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
BRCA	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	10.12	5.23e-23	3.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	10.12	5.23e-23	3.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	10.12	5.24e-23	3.26e-20	0.32	0.3	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
BRCA	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-10.12	5.25e-23	3.27e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-10.11	5.26e-23	3.28e-20	-0.31	-0.3	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
BRCA	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-10.11	5.27e-23	3.28e-20	-0.48	-0.3	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
BRCA	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	10.11	5.29e-23	3.29e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	10.11	5.3e-23	3.3e-20	0.32	0.3	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.34e-23	3.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.34e-23	3.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
BRCA	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	10.11	5.36e-23	3.34e-20	0.35	0.3	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
BRCA	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-10.11	5.37e-23	3.34e-20	-0.34	-0.3	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
BRCA	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	10.11	5.4e-23	3.36e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
BRCA	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-10.11	5.41e-23	3.37e-20	-0.54	-0.3	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
BRCA	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
BRCA	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-10.11	5.47e-23	3.4e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.52e-23	3.43e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
BRCA	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-10.11	5.58e-23	3.47e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
BRCA	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
BRCA	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
BRCA	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	10.11	5.66e-23	3.51e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
BRCA	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	10.11	5.68e-23	3.53e-20	0.38	0.3	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
BRCA	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-10.11	5.69e-23	3.53e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-10.11	5.71e-23	3.55e-20	-0.36	-0.3	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-10.11	5.73e-23	3.56e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
BRCA	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-10.11	5.76e-23	3.58e-20	-0.36	-0.3	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-10.1	5.77e-23	3.58e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	10.1	5.77e-23	3.58e-20	0.36	0.3	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
BRCA	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	10.1	5.79e-23	3.6e-20	0.38	0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	10.1	5.82e-23	3.61e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	10.1	5.82e-23	3.61e-20	0.37	0.3	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
BRCA	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	10.1	5.83e-23	3.62e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
BRCA	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-10.1	5.84e-23	3.62e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	10.1	5.87e-23	3.64e-20	0.36	0.3	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
BRCA	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-10.1	5.87e-23	3.64e-20	-0.51	-0.3	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	10.1	5.96e-23	3.7e-20	0.34	0.3	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
BRCA	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	10.1	5.98e-23	3.71e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
BRCA	cis	rs143626010	1	rs143626010	ENSG00000278665.1	RP11-666O2.4	10.1	5.99e-23	3.71e-20	0.32	0.3	Mosquito bite size;	chr16:28528081	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-10.1	6.02e-23	3.73e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-10.1	6.03e-23	3.74e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-10.1	6.04e-23	3.74e-20	-0.2	-0.3	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
BRCA	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-10.1	6.11e-23	3.78e-20	-0.36	-0.3	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-10.1	6.12e-23	3.79e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.17e-23	3.82e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-10.1	6.2e-23	3.84e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	10.1	6.25e-23	3.87e-20	0.3	0.3	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
BRCA	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	10.1	6.28e-23	3.88e-20	0.47	0.3	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	10.1	6.28e-23	3.88e-20	0.47	0.3	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
BRCA	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	10.09	6.35e-23	3.92e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
BRCA	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-10.09	6.38e-23	3.94e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
BRCA	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
BRCA	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	10.09	6.59e-23	4.07e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	10.09	6.6e-23	4.07e-20	0.37	0.3	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
BRCA	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-10.09	6.61e-23	4.08e-20	-0.54	-0.3	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-10.09	6.63e-23	4.09e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-10.09	6.63e-23	4.09e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
BRCA	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	10.09	6.64e-23	4.1e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
BRCA	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	10.09	6.64e-23	4.1e-20	0.38	0.3	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	10.09	6.65e-23	4.11e-20	0.32	0.3	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-10.09	6.67e-23	4.12e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
BRCA	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-10.09	6.7e-23	4.13e-20	-0.29	-0.3	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	10.09	6.81e-23	4.2e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	10.09	6.82e-23	4.21e-20	0.33	0.3	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	10.09	6.84e-23	4.22e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	10.09	6.88e-23	4.24e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
BRCA	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	10.09	6.92e-23	4.27e-20	0.33	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	10.08	6.94e-23	4.28e-20	0.55	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
BRCA	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	10.08	7e-23	4.31e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
BRCA	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-10.08	7.01e-23	4.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
BRCA	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-10.08	7.01e-23	4.32e-20	-0.36	-0.3	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
BRCA	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	10.08	7.05e-23	4.34e-20	0.43	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-10.08	7.08e-23	4.36e-20	-0.21	-0.3	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
BRCA	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-10.08	7.09e-23	4.37e-20	-0.32	-0.3	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	10.08	7.17e-23	4.41e-20	0.39	0.3	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
BRCA	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-10.08	7.21e-23	4.44e-20	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-10.08	7.22e-23	4.44e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-10.08	7.27e-23	4.48e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
BRCA	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-10.08	7.31e-23	4.5e-20	-0.52	-0.3	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
BRCA	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-10.08	7.31e-23	4.5e-20	-0.43	-0.3	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-10.08	7.34e-23	4.51e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	10.08	7.34e-23	4.51e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
BRCA	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	10.08	7.38e-23	4.54e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
BRCA	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	10.08	7.38e-23	4.54e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	10.08	7.38e-23	4.54e-20	0.32	0.3	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	10.08	7.5e-23	4.61e-20	0.32	0.3	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
BRCA	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	10.08	7.51e-23	4.62e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
BRCA	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	10.08	7.53e-23	4.63e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
BRCA	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	10.08	7.56e-23	4.65e-20	0.42	0.3	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	10.08	7.61e-23	4.67e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	10.07	7.63e-23	4.68e-20	0.32	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	10.07	7.65e-23	4.7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
BRCA	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	10.07	7.68e-23	4.71e-20	0.33	0.3	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-10.07	7.68e-23	4.71e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
BRCA	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-10.07	7.75e-23	4.75e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
BRCA	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	10.07	7.8e-23	4.78e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
BRCA	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-10.07	7.8e-23	4.79e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
BRCA	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.82e-23	4.8e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
BRCA	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	10.07	7.83e-23	4.8e-20	0.38	0.3	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
BRCA	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-10.07	7.86e-23	4.82e-20	-0.35	-0.3	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-10.07	7.9e-23	4.84e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
BRCA	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	10.07	7.94e-23	4.87e-20	0.35	0.3	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	10.07	7.95e-23	4.87e-20	0.43	0.3	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
BRCA	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-10.07	7.99e-23	4.9e-20	-0.38	-0.3	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
BRCA	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-10.07	8.03e-23	4.92e-20	-0.34	-0.3	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-10.07	8.05e-23	4.93e-20	-0.2	-0.3	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-10.07	8.09e-23	4.96e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-10.07	8.09e-23	4.96e-20	-0.2	-0.3	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	10.07	8.12e-23	4.97e-20	0.32	0.3	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
BRCA	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-10.07	8.16e-23	5e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
BRCA	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-10.07	8.19e-23	5.01e-20	-0.39	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-10.07	8.2e-23	5.02e-20	-0.2	-0.3	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-10.07	8.2e-23	5.02e-20	-0.2	-0.3	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	10.07	8.26e-23	5.06e-20	0.38	0.3	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
BRCA	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	10.07	8.29e-23	5.07e-20	0.5	0.3	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
BRCA	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-10.06	8.37e-23	5.12e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	10.06	8.37e-23	5.12e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
BRCA	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-10.06	8.43e-23	5.15e-20	-0.4	-0.3	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-10.06	8.49e-23	5.19e-20	-0.36	-0.3	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	10.06	8.51e-23	5.2e-20	0.56	0.3	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	10.06	8.53e-23	5.21e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	10.06	8.54e-23	5.22e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	10.06	8.66e-23	5.29e-20	0.29	0.3	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	10.06	8.76e-23	5.35e-20	0.39	0.3	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
BRCA	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	10.06	8.79e-23	5.37e-20	0.44	0.3	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
BRCA	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	10.06	8.8e-23	5.37e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	10.06	8.85e-23	5.4e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
BRCA	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-10.06	8.89e-23	5.42e-20	-0.35	-0.3	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-10.06	8.9e-23	5.43e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-10.06	8.9e-23	5.43e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-10.06	8.93e-23	5.45e-20	-0.42	-0.3	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-10.06	8.93e-23	5.45e-20	-0.42	-0.3	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-10.06	8.96e-23	5.47e-20	-0.34	-0.3	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
BRCA	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-10.06	9e-23	5.49e-20	-0.37	-0.3	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-10.06	9e-23	5.49e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-10.06	9e-23	5.49e-20	-0.42	-0.3	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-10.06	9.03e-23	5.51e-20	-0.2	-0.3	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	10.06	9.07e-23	5.53e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	10.06	9.07e-23	5.53e-20	0.37	0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
BRCA	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	10.06	9.09e-23	5.54e-20	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
BRCA	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	10.06	9.09e-23	5.54e-20	0.39	0.3	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
BRCA	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	10.06	9.1e-23	5.55e-20	0.45	0.3	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-10.06	9.12e-23	5.56e-20	-0.42	-0.3	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-10.06	9.12e-23	5.56e-20	-0.42	-0.3	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
BRCA	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-10.06	9.13e-23	5.57e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	10.06	9.14e-23	5.57e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	10.06	9.15e-23	5.58e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	10.06	9.16e-23	5.58e-20	0.29	0.3	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-10.05	9.17e-23	5.59e-20	-0.37	-0.3	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
BRCA	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	10.05	9.19e-23	5.6e-20	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
BRCA	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-10.05	9.21e-23	5.61e-20	-0.38	-0.3	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	10.05	9.27e-23	5.65e-20	0.39	0.3	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-10.05	9.3e-23	5.67e-20	-0.22	-0.3	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
BRCA	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-10.05	9.39e-23	5.72e-20	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
BRCA	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-10.05	9.48e-23	5.77e-20	-0.36	-0.3	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
BRCA	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-10.05	9.51e-23	5.79e-20	-0.37	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
BRCA	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-10.05	9.51e-23	5.79e-20	-0.36	-0.3	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
BRCA	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	10.05	9.55e-23	5.81e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-10.05	9.59e-23	5.83e-20	-0.37	-0.3	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
BRCA	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	10.05	9.64e-23	5.86e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-10.05	9.66e-23	5.87e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-10.05	9.67e-23	5.88e-20	-0.2	-0.3	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-10.05	9.69e-23	5.89e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-10.05	9.75e-23	5.93e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	10.05	9.79e-23	5.95e-20	0.38	0.3	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
BRCA	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	10.05	9.94e-23	6.04e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-10.05	9.95e-23	6.05e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-10.05	1e-22	6.08e-20	-0.2	-0.3	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-10.05	1e-22	6.08e-20	-0.2	-0.3	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	10.05	1e-22	6.1e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	10.05	1e-22	6.11e-20	0.46	0.3	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
BRCA	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	10.04	1.01e-22	6.15e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
BRCA	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	10.04	1.02e-22	6.17e-20	0.39	0.3	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
BRCA	cis	rs10885997	0.967	rs11197775	ENSG00000266200.5	PNLIPRP2	-10.04	1.02e-22	6.22e-20	-0.37	-0.3	Phospholipid levels (plasma);	chr10:116636627	chr10:116620953~116645143:+
BRCA	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	10.04	1.03e-22	6.24e-20	0.48	0.3	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	10.04	1.03e-22	6.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-10.04	1.03e-22	6.26e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	10.04	1.04e-22	6.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	10.04	1.04e-22	6.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	10.04	1.04e-22	6.3e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
BRCA	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	10.04	1.05e-22	6.38e-20	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
BRCA	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	10.04	1.05e-22	6.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs62036616	ENSG00000278665.1	RP11-666O2.4	10.04	1.06e-22	6.43e-20	0.33	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28599241~28601881:-
BRCA	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-10.04	1.07e-22	6.47e-20	-0.45	-0.3	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
BRCA	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	10.04	1.07e-22	6.49e-20	0.31	0.3	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
BRCA	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
BRCA	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	10.04	1.08e-22	6.54e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
BRCA	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-10.04	1.08e-22	6.56e-20	-0.36	-0.3	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-10.04	1.09e-22	6.58e-20	-0.6	-0.3	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-10.04	1.09e-22	6.61e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	10.04	1.09e-22	6.62e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
BRCA	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	10.04	1.1e-22	6.64e-20	0.36	0.3	Height;	chr2:231516534	chr2:231508426~231514339:-
BRCA	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-10.03	1.1e-22	6.68e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-10.03	1.11e-22	6.68e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-10.03	1.11e-22	6.68e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
BRCA	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-10.03	1.11e-22	6.69e-20	-0.29	-0.3	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
BRCA	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-10.03	1.11e-22	6.71e-20	-0.36	-0.3	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
BRCA	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	10.03	1.11e-22	6.71e-20	0.41	0.3	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
BRCA	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	10.03	1.11e-22	6.72e-20	0.38	0.3	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
BRCA	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-10.03	1.12e-22	6.77e-20	-0.38	-0.3	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
BRCA	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-10.03	1.12e-22	6.77e-20	-0.43	-0.3	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
BRCA	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-10.03	1.12e-22	6.78e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-10.03	1.12e-22	6.78e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-10.03	1.12e-22	6.78e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-10.03	1.13e-22	6.81e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	10.03	1.13e-22	6.82e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-10.03	1.13e-22	6.82e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
BRCA	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	10.03	1.13e-22	6.83e-20	0.42	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
BRCA	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	10.03	1.14e-22	6.9e-20	0.33	0.3	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	10.03	1.14e-22	6.9e-20	0.33	0.3	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-10.03	1.14e-22	6.9e-20	-0.2	-0.3	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-10.03	1.15e-22	6.92e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
BRCA	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.94e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.96e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.96e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-10.03	1.16e-22	6.97e-20	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7.01e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-10.03	1.17e-22	7.08e-20	-0.39	-0.3	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
BRCA	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	10.03	1.18e-22	7.11e-20	0.45	0.3	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
BRCA	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-10.03	1.18e-22	7.12e-20	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	10.03	1.19e-22	7.15e-20	0.39	0.3	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	10.03	1.19e-22	7.19e-20	0.36	0.3	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-10.03	1.21e-22	7.25e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-10.03	1.21e-22	7.25e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-10.02	1.21e-22	7.28e-20	-0.35	-0.3	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
BRCA	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	10.02	1.21e-22	7.3e-20	0.33	0.3	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
BRCA	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-10.02	1.22e-22	7.36e-20	-0.43	-0.3	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	10.02	1.24e-22	7.44e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-10.02	1.25e-22	7.49e-20	-0.36	-0.3	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
BRCA	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	10.02	1.25e-22	7.49e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	10.02	1.25e-22	7.52e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-10.02	1.26e-22	7.56e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
BRCA	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	10.02	1.27e-22	7.61e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
BRCA	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-10.02	1.27e-22	7.62e-20	-0.33	-0.3	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
BRCA	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-10.02	1.27e-22	7.62e-20	-0.31	-0.3	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-10.02	1.28e-22	7.66e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
BRCA	cis	rs34787248	1	rs34787248	ENSG00000220721.1	OR1F12	10.02	1.29e-22	7.74e-20	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	10.02	1.29e-22	7.74e-20	0.2	0.3	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-10.02	1.29e-22	7.75e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-10.02	1.3e-22	7.8e-20	-0.39	-0.3	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
BRCA	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-10.02	1.31e-22	7.84e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
BRCA	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-10.02	1.31e-22	7.86e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
BRCA	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	10.02	1.32e-22	7.9e-20	0.34	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
BRCA	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-10.02	1.32e-22	7.9e-20	-0.37	-0.3	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
BRCA	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-10.02	1.32e-22	7.93e-20	-0.42	-0.3	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-10.01	1.33e-22	7.98e-20	-0.37	-0.3	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-10.01	1.33e-22	7.98e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
BRCA	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-10.01	1.34e-22	8.04e-20	-0.34	-0.3	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	10.01	1.36e-22	8.13e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
BRCA	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-10.01	1.36e-22	8.16e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
BRCA	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	10.01	1.37e-22	8.18e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
BRCA	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	10.01	1.38e-22	8.25e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
BRCA	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	10.01	1.38e-22	8.25e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	10.01	1.39e-22	8.3e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
BRCA	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	10.01	1.39e-22	8.3e-20	0.5	0.3	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	10.01	1.39e-22	8.3e-20	0.38	0.3	Depression;	chr6:28229408	chr6:28073316~28074233:+
BRCA	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-10.01	1.39e-22	8.31e-20	-0.31	-0.3	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
BRCA	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
BRCA	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-10.01	1.4e-22	8.39e-20	-0.37	-0.3	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-10.01	1.4e-22	8.39e-20	-0.37	-0.3	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
BRCA	cis	rs712022	1	rs1019217	ENSG00000246225.5	RP11-17A1.3	10.01	1.4e-22	8.41e-20	0.35	0.3	Dialysis-related mortality;	chr11:22821076	chr11:22829380~22945393:+
BRCA	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	10.01	1.41e-22	8.41e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
BRCA	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	10.01	1.42e-22	8.47e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.01	1.43e-22	8.56e-20	-0.38	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
BRCA	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	10.01	1.44e-22	8.61e-20	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-10	1.47e-22	8.77e-20	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-10	1.47e-22	8.77e-20	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
BRCA	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	10	1.47e-22	8.79e-20	0.38	0.3	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	10	1.47e-22	8.79e-20	0.38	0.3	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-10	1.47e-22	8.8e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-10	1.48e-22	8.82e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-10	1.48e-22	8.83e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-10	1.48e-22	8.83e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	10	1.48e-22	8.84e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	10	1.49e-22	8.93e-20	0.2	0.3	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-10	1.5e-22	8.97e-20	-0.22	-0.3	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
BRCA	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	10	1.52e-22	9.06e-20	0.3	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-10	1.52e-22	9.07e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-10	1.53e-22	9.13e-20	-0.21	-0.3	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-10	1.53e-22	9.15e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
BRCA	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-10	1.54e-22	9.21e-20	-0.3	-0.3	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	10	1.55e-22	9.26e-20	0.37	0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
BRCA	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	10	1.56e-22	9.28e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
BRCA	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	10	1.56e-22	9.31e-20	0.36	0.3	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	10	1.56e-22	9.31e-20	0.55	0.3	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	10	1.57e-22	9.33e-20	0.31	0.3	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	10	1.57e-22	9.33e-20	0.31	0.3	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
BRCA	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	10	1.57e-22	9.39e-20	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000220721.1	OR1F12	10	1.58e-22	9.43e-20	0.39	0.3	Depression;	chr6:28192182	chr6:28073316~28074233:+
BRCA	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	10	1.58e-22	9.44e-20	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
BRCA	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-10	1.59e-22	9.49e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
BRCA	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	9.99	1.6e-22	9.53e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	9.99	1.6e-22	9.54e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-9.99	1.61e-22	9.57e-20	-0.56	-0.3	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-9.99	1.61e-22	9.57e-20	-0.56	-0.3	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
BRCA	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	9.99	1.61e-22	9.61e-20	0.34	0.3	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
BRCA	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	9.99	1.61e-22	9.61e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	9.99	1.62e-22	9.62e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-9.99	1.62e-22	9.63e-20	-0.4	-0.3	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
BRCA	cis	rs13256369	0.802	rs11249885	ENSG00000253893.2	FAM85B	-9.99	1.64e-22	9.77e-20	-0.39	-0.3	Obesity-related traits;	chr8:8704498	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-9.99	1.65e-22	9.8e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
BRCA	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-9.99	1.65e-22	9.81e-20	-0.45	-0.3	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	9.99	1.65e-22	9.83e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	9.99	1.66e-22	9.9e-20	0.29	0.3	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-9.99	1.67e-22	9.9e-20	-0.39	-0.3	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
BRCA	cis	rs712022	0.967	rs10766971	ENSG00000246225.5	RP11-17A1.3	-9.99	1.67e-22	9.95e-20	-0.34	-0.3	Dialysis-related mortality;	chr11:22832005	chr11:22829380~22945393:+
BRCA	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	9.99	1.68e-22	9.98e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	9.99	1.68e-22	1e-19	0.4	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
BRCA	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-9.99	1.69e-22	1e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
BRCA	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	9.99	1.69e-22	1e-19	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
BRCA	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	9.99	1.71e-22	1.01e-19	0.29	0.3	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
BRCA	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	9.99	1.73e-22	1.03e-19	0.36	0.3	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
BRCA	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-9.99	1.74e-22	1.03e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-9.99	1.74e-22	1.03e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-9.98	1.75e-22	1.04e-19	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-9.98	1.75e-22	1.04e-19	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	9.98	1.76e-22	1.04e-19	0.33	0.3	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
BRCA	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-9.98	1.77e-22	1.05e-19	-0.53	-0.3	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
BRCA	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	9.98	1.77e-22	1.05e-19	0.32	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-9.98	1.77e-22	1.05e-19	-0.6	-0.3	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	9.98	1.78e-22	1.06e-19	0.38	0.3	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
BRCA	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	9.98	1.78e-22	1.06e-19	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-9.98	1.78e-22	1.06e-19	-0.29	-0.3	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
BRCA	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	9.98	1.78e-22	1.06e-19	0.37	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
BRCA	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-9.98	1.8e-22	1.07e-19	-0.35	-0.3	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
BRCA	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	9.98	1.81e-22	1.07e-19	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
BRCA	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	9.98	1.81e-22	1.07e-19	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-9.98	1.81e-22	1.07e-19	-0.36	-0.3	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
BRCA	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-9.98	1.82e-22	1.08e-19	-0.49	-0.3	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	9.98	1.83e-22	1.09e-19	0.32	0.3	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	9.98	1.84e-22	1.09e-19	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000278665.1	RP11-666O2.4	9.98	1.84e-22	1.09e-19	0.3	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-9.98	1.84e-22	1.09e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
BRCA	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-9.98	1.85e-22	1.1e-19	-0.38	-0.3	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	9.98	1.85e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
BRCA	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-9.98	1.85e-22	1.1e-19	-0.37	-0.3	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	9.98	1.85e-22	1.1e-19	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
BRCA	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-9.98	1.85e-22	1.1e-19	-0.31	-0.3	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	9.98	1.86e-22	1.1e-19	0.35	0.3	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	9.98	1.86e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	9.98	1.86e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
BRCA	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	9.98	1.86e-22	1.1e-19	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
BRCA	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	9.98	1.87e-22	1.1e-19	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
BRCA	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	9.98	1.87e-22	1.1e-19	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	9.98	1.87e-22	1.1e-19	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	9.98	1.87e-22	1.1e-19	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
BRCA	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	9.98	1.87e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	9.98	1.87e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	9.98	1.88e-22	1.11e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	9.98	1.88e-22	1.11e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	9.98	1.88e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-9.98	1.88e-22	1.12e-19	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
BRCA	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-9.97	1.92e-22	1.14e-19	-0.39	-0.3	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000278665.1	RP11-666O2.4	9.97	1.95e-22	1.15e-19	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28599241~28601881:-
BRCA	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-9.97	1.96e-22	1.16e-19	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
BRCA	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-9.97	1.96e-22	1.16e-19	-0.4	-0.3	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
BRCA	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-9.97	1.98e-22	1.17e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
BRCA	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	9.97	1.98e-22	1.17e-19	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
BRCA	cis	rs4862750	0.872	rs7671914	ENSG00000250971.1	RP11-696F12.1	9.97	1.99e-22	1.18e-19	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957011	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-9.97	1.99e-22	1.18e-19	-0.29	-0.3	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-9.97	1.99e-22	1.18e-19	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	9.97	2e-22	1.18e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	9.97	2e-22	1.18e-19	0.38	0.3	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	9.97	2e-22	1.18e-19	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
BRCA	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-9.97	2.01e-22	1.19e-19	-0.55	-0.3	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
BRCA	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-9.97	2.03e-22	1.2e-19	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	9.97	2.03e-22	1.2e-19	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
BRCA	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	9.97	2.04e-22	1.21e-19	0.34	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
BRCA	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-9.97	2.05e-22	1.21e-19	-0.36	-0.3	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-9.97	2.07e-22	1.22e-19	-0.22	-0.3	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-9.97	2.07e-22	1.22e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-9.97	2.09e-22	1.23e-19	-0.31	-0.29	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
BRCA	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	9.97	2.09e-22	1.23e-19	0.42	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000278665.1	RP11-666O2.4	9.97	2.1e-22	1.24e-19	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-9.97	2.1e-22	1.24e-19	-0.31	-0.29	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	9.97	2.1e-22	1.24e-19	0.32	0.29	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
BRCA	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-9.97	2.1e-22	1.24e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
BRCA	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	9.96	2.11e-22	1.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	9.96	2.11e-22	1.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-9.96	2.12e-22	1.25e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-9.96	2.13e-22	1.26e-19	-0.42	-0.29	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
BRCA	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-9.96	2.14e-22	1.26e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-9.96	2.14e-22	1.26e-19	-0.2	-0.29	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	9.96	2.15e-22	1.27e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-9.96	2.15e-22	1.27e-19	-0.42	-0.29	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-9.96	2.16e-22	1.27e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000278665.1	RP11-666O2.4	9.96	2.17e-22	1.27e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	9.96	2.17e-22	1.28e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	9.96	2.19e-22	1.29e-19	0.36	0.29	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
BRCA	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	9.96	2.2e-22	1.29e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	9.96	2.2e-22	1.29e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
BRCA	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-9.96	2.2e-22	1.3e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	9.96	2.21e-22	1.3e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	9.96	2.21e-22	1.3e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	9.96	2.23e-22	1.31e-19	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	9.96	2.23e-22	1.31e-19	0.41	0.29	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-9.96	2.24e-22	1.32e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
BRCA	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-9.96	2.25e-22	1.32e-19	-0.36	-0.29	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	9.96	2.26e-22	1.33e-19	0.31	0.29	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-9.96	2.27e-22	1.33e-19	-0.31	-0.29	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	9.96	2.28e-22	1.34e-19	0.41	0.29	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-9.96	2.28e-22	1.34e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
BRCA	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	9.96	2.29e-22	1.34e-19	0.35	0.29	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	9.96	2.29e-22	1.35e-19	0.37	0.29	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-9.96	2.3e-22	1.35e-19	-0.4	-0.29	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-9.95	2.31e-22	1.36e-19	-0.38	-0.29	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
BRCA	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-9.95	2.31e-22	1.36e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-9.95	2.31e-22	1.36e-19	-0.31	-0.29	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-9.95	2.31e-22	1.36e-19	-0.31	-0.29	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-9.95	2.32e-22	1.36e-19	-0.42	-0.29	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
BRCA	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-9.95	2.33e-22	1.37e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	9.95	2.34e-22	1.37e-19	0.38	0.29	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-9.95	2.35e-22	1.38e-19	-0.36	-0.29	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-9.95	2.36e-22	1.38e-19	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	9.95	2.37e-22	1.39e-19	0.33	0.29	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-9.95	2.38e-22	1.39e-19	-0.2	-0.29	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
BRCA	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
BRCA	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-9.95	2.39e-22	1.4e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-9.95	2.39e-22	1.4e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
BRCA	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-9.95	2.39e-22	1.4e-19	-0.4	-0.29	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
BRCA	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	9.95	2.41e-22	1.41e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
BRCA	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	9.95	2.42e-22	1.42e-19	0.43	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
BRCA	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-9.95	2.44e-22	1.43e-19	-0.41	-0.29	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	9.95	2.45e-22	1.44e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	9.95	2.45e-22	1.44e-19	0.31	0.29	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	9.95	2.49e-22	1.46e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
BRCA	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	9.94	2.53e-22	1.48e-19	0.35	0.29	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
BRCA	cis	rs4727443	0.932	rs7803714	ENSG00000235713.1	RP4-604G5.3	-9.94	2.54e-22	1.49e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99987527	chr7:99992397~99993050:+
BRCA	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	9.94	2.54e-22	1.49e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
BRCA	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.56e-22	1.5e-19	-0.37	-0.29	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.56e-22	1.5e-19	-0.37	-0.29	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
BRCA	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	9.94	2.56e-22	1.5e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
BRCA	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	9.94	2.56e-22	1.5e-19	0.35	0.29	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-9.94	2.58e-22	1.51e-19	-0.2	-0.29	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
BRCA	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-9.94	2.59e-22	1.51e-19	-0.44	-0.29	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000278665.1	RP11-666O2.4	9.94	2.59e-22	1.51e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-9.94	2.59e-22	1.52e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-9.94	2.59e-22	1.52e-19	-0.35	-0.29	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
BRCA	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-9.94	2.61e-22	1.53e-19	-0.2	-0.29	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
BRCA	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-9.94	2.62e-22	1.53e-19	-0.37	-0.29	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
BRCA	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	9.94	2.64e-22	1.54e-19	0.36	0.29	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	9.94	2.65e-22	1.55e-19	0.31	0.29	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-9.94	2.66e-22	1.55e-19	-0.35	-0.29	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	9.94	2.67e-22	1.56e-19	0.31	0.29	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-9.94	2.69e-22	1.57e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000220721.1	OR1F12	9.94	2.7e-22	1.58e-19	0.42	0.29	Depression;	chr6:28231986	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-9.94	2.7e-22	1.58e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-9.94	2.71e-22	1.58e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-9.94	2.71e-22	1.58e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
BRCA	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	9.94	2.71e-22	1.58e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
BRCA	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-9.94	2.72e-22	1.59e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
BRCA	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	9.94	2.72e-22	1.59e-19	0.37	0.29	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
BRCA	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-9.94	2.72e-22	1.59e-19	-0.33	-0.29	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
BRCA	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	9.94	2.73e-22	1.59e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-9.94	2.73e-22	1.59e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	9.94	2.73e-22	1.59e-19	0.38	0.29	Depression;	chr6:28226851	chr6:28073316~28074233:+
BRCA	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	9.94	2.74e-22	1.6e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	9.94	2.75e-22	1.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-9.94	2.75e-22	1.6e-19	-0.21	-0.29	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-9.94	2.76e-22	1.61e-19	-0.31	-0.29	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000278665.1	RP11-666O2.4	9.94	2.76e-22	1.61e-19	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28599241~28601881:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-9.94	2.77e-22	1.61e-19	-0.21	-0.29	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
BRCA	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	9.93	2.77e-22	1.62e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
BRCA	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-9.93	2.78e-22	1.62e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-9.93	2.78e-22	1.62e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
BRCA	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	9.93	2.79e-22	1.63e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
BRCA	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	9.93	2.8e-22	1.63e-19	0.36	0.29	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
BRCA	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-9.93	2.81e-22	1.63e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-9.93	2.81e-22	1.64e-19	-0.43	-0.29	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	9.93	2.81e-22	1.64e-19	0.79	0.29	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	9.93	2.81e-22	1.64e-19	0.79	0.29	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
BRCA	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-9.93	2.82e-22	1.64e-19	-0.39	-0.29	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
BRCA	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-9.93	2.82e-22	1.64e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-9.93	2.82e-22	1.64e-19	-0.31	-0.29	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
BRCA	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-9.93	2.82e-22	1.65e-19	-0.34	-0.29	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
BRCA	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-9.93	2.83e-22	1.65e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-9.93	2.84e-22	1.66e-19	-0.42	-0.29	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-9.93	2.84e-22	1.66e-19	-0.31	-0.29	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
BRCA	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-9.93	2.85e-22	1.66e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-9.93	2.85e-22	1.66e-19	-0.6	-0.29	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-9.93	2.88e-22	1.68e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	9.93	2.89e-22	1.68e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-9.93	2.9e-22	1.69e-19	-0.2	-0.29	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
BRCA	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	9.93	2.92e-22	1.7e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-9.93	2.93e-22	1.7e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-9.93	2.93e-22	1.7e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
BRCA	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	9.93	2.93e-22	1.7e-19	0.32	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
BRCA	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	9.93	2.94e-22	1.71e-19	0.35	0.29	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
BRCA	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-9.93	2.95e-22	1.72e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-9.93	2.95e-22	1.72e-19	-0.31	-0.29	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-9.93	2.96e-22	1.72e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-9.93	2.96e-22	1.72e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-9.93	2.97e-22	1.73e-19	-0.31	-0.29	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-9.93	2.98e-22	1.73e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-9.93	2.98e-22	1.73e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-9.93	2.99e-22	1.74e-19	-0.35	-0.29	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
BRCA	cis	rs8062405	1	rs72793811	ENSG00000278665.1	RP11-666O2.4	9.93	3e-22	1.75e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-9.93	3.01e-22	1.75e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	9.93	3.02e-22	1.75e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000278665.1	RP11-666O2.4	9.93	3.02e-22	1.75e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28599241~28601881:-
BRCA	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	9.92	3.07e-22	1.78e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	9.92	3.07e-22	1.78e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	9.92	3.07e-22	1.78e-19	0.27	0.29	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
BRCA	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-9.92	3.08e-22	1.79e-19	-0.45	-0.29	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
BRCA	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-9.92	3.09e-22	1.8e-19	-0.35	-0.29	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
BRCA	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	9.92	3.1e-22	1.8e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
BRCA	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	9.92	3.11e-22	1.8e-19	0.36	0.29	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	9.92	3.11e-22	1.81e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	9.92	3.11e-22	1.81e-19	0.31	0.29	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
BRCA	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	9.92	3.15e-22	1.83e-19	0.37	0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
BRCA	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-9.92	3.16e-22	1.83e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-9.92	3.16e-22	1.83e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
BRCA	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-9.92	3.16e-22	1.84e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
BRCA	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-9.92	3.17e-22	1.84e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	9.92	3.2e-22	1.86e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-9.92	3.2e-22	1.86e-19	-0.2	-0.29	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-9.92	3.23e-22	1.87e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	9.92	3.26e-22	1.89e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-9.92	3.29e-22	1.9e-19	-0.34	-0.29	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-9.92	3.3e-22	1.91e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-9.92	3.3e-22	1.91e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
BRCA	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-9.91	3.37e-22	1.95e-19	-0.37	-0.29	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-9.91	3.37e-22	1.95e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-9.91	3.37e-22	1.95e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
BRCA	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	9.91	3.39e-22	1.96e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
BRCA	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-9.91	3.41e-22	1.97e-19	-0.36	-0.29	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-9.91	3.41e-22	1.97e-19	-0.36	-0.29	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
BRCA	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-9.91	3.47e-22	2e-19	-0.36	-0.29	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	9.91	3.48e-22	2.01e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-9.91	3.48e-22	2.01e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	9.91	3.5e-22	2.02e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
BRCA	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-9.91	3.5e-22	2.02e-19	-0.29	-0.29	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
BRCA	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	9.91	3.52e-22	2.03e-19	0.38	0.29	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
BRCA	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	9.91	3.53e-22	2.04e-19	0.37	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
BRCA	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-9.91	3.53e-22	2.04e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-9.91	3.53e-22	2.04e-19	-0.41	-0.29	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
BRCA	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.91	3.55e-22	2.05e-19	-0.31	-0.29	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
BRCA	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-9.91	3.57e-22	2.06e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-9.91	3.57e-22	2.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	9.91	3.59e-22	2.07e-19	0.36	0.29	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-9.91	3.6e-22	2.08e-19	-0.39	-0.29	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	9.91	3.62e-22	2.09e-19	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	9.91	3.63e-22	2.09e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	9.9	3.64e-22	2.1e-19	0.36	0.29	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
BRCA	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	9.9	3.65e-22	2.11e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
BRCA	cis	rs58873874	0.737	rs78565801	ENSG00000251405.2	CTB-109A12.1	9.9	3.65e-22	2.11e-19	0.78	0.29	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.737	rs79951742	ENSG00000251405.2	CTB-109A12.1	9.9	3.65e-22	2.11e-19	0.78	0.29	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-9.9	3.67e-22	2.11e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	9.9	3.67e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	9.9	3.67e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	9.9	3.67e-22	2.12e-19	0.38	0.29	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
BRCA	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	9.9	3.67e-22	2.12e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000278665.1	RP11-666O2.4	9.9	3.68e-22	2.12e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	9.9	3.68e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-9.9	3.69e-22	2.13e-19	-0.38	-0.29	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
BRCA	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-9.9	3.69e-22	2.13e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
BRCA	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-9.9	3.7e-22	2.13e-19	-0.33	-0.29	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-9.9	3.71e-22	2.14e-19	-0.33	-0.29	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-9.9	3.72e-22	2.15e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-9.9	3.73e-22	2.15e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
BRCA	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	9.9	3.77e-22	2.17e-19	0.42	0.29	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
BRCA	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-9.9	3.79e-22	2.18e-19	-0.34	-0.29	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
BRCA	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-9.9	3.79e-22	2.18e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-9.9	3.81e-22	2.19e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-9.9	3.84e-22	2.21e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-9.9	3.84e-22	2.21e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	9.9	3.86e-22	2.22e-19	0.31	0.29	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
BRCA	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-9.9	3.89e-22	2.24e-19	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	9.9	3.9e-22	2.24e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	9.9	3.9e-22	2.24e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
BRCA	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	9.9	3.9e-22	2.24e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	9.9	3.92e-22	2.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-9.9	3.93e-22	2.26e-19	-0.2	-0.29	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-9.9	3.94e-22	2.26e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	9.9	3.95e-22	2.27e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
BRCA	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	9.9	3.96e-22	2.27e-19	0.37	0.29	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	9.9	3.96e-22	2.27e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	9.9	3.96e-22	2.27e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
BRCA	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-9.9	3.97e-22	2.28e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
BRCA	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-9.9	3.97e-22	2.28e-19	-0.32	-0.29	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
BRCA	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	9.9	3.98e-22	2.28e-19	0.35	0.29	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	9.9	3.98e-22	2.29e-19	0.41	0.29	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	9.89	4e-22	2.3e-19	0.31	0.29	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-9.89	4e-22	2.3e-19	-0.31	-0.29	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-9.89	4.01e-22	2.3e-19	-0.34	-0.29	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
BRCA	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-9.89	4.01e-22	2.3e-19	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
BRCA	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-9.89	4.02e-22	2.31e-19	-0.41	-0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
BRCA	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
BRCA	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	9.89	4.05e-22	2.33e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	9.89	4.06e-22	2.33e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-9.89	4.08e-22	2.34e-19	-0.31	-0.29	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	9.89	4.09e-22	2.34e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	9.89	4.09e-22	2.35e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	9.89	4.12e-22	2.36e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-9.89	4.13e-22	2.37e-19	-0.33	-0.29	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.13e-22	2.37e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.13e-22	2.37e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	9.89	4.14e-22	2.37e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
BRCA	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-9.89	4.15e-22	2.38e-19	-0.32	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
BRCA	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	9.89	4.16e-22	2.39e-19	0.35	0.29	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
BRCA	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-9.89	4.22e-22	2.42e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
BRCA	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	9.89	4.22e-22	2.42e-19	0.26	0.29	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
BRCA	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	9.89	4.22e-22	2.42e-19	0.26	0.29	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000278665.1	RP11-666O2.4	9.89	4.23e-22	2.42e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28599241~28601881:-
BRCA	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	9.89	4.26e-22	2.44e-19	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-9.89	4.27e-22	2.44e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.28e-22	2.45e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.28e-22	2.45e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
BRCA	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-9.89	4.29e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-9.89	4.29e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	9.89	4.3e-22	2.46e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-9.89	4.3e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-9.89	4.3e-22	2.46e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	9.89	4.33e-22	2.48e-19	0.37	0.29	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
BRCA	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-9.89	4.35e-22	2.49e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-9.89	4.35e-22	2.49e-19	-0.35	-0.29	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	9.88	4.44e-22	2.54e-19	0.31	0.29	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-9.88	4.44e-22	2.54e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
BRCA	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-9.88	4.45e-22	2.54e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-9.88	4.45e-22	2.55e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-9.88	4.46e-22	2.55e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-9.88	4.46e-22	2.55e-19	-0.31	-0.29	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000278665.1	RP11-666O2.4	9.88	4.47e-22	2.55e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-9.88	4.47e-22	2.55e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-9.88	4.47e-22	2.55e-19	-0.31	-0.29	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-9.88	4.47e-22	2.56e-19	-0.39	-0.29	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
BRCA	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	9.88	4.52e-22	2.58e-19	0.47	0.29	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
BRCA	cis	rs8062405	1	rs62036622	ENSG00000278665.1	RP11-666O2.4	9.88	4.53e-22	2.59e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28599241~28601881:-
BRCA	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	9.88	4.56e-22	2.6e-19	0.35	0.29	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
BRCA	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-9.88	4.58e-22	2.62e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-9.88	4.6e-22	2.63e-19	-0.4	-0.29	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	9.88	4.66e-22	2.66e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-9.88	4.68e-22	2.67e-19	-0.3	-0.29	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
BRCA	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-9.88	4.68e-22	2.67e-19	-0.38	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
BRCA	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	9.88	4.7e-22	2.68e-19	0.32	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
BRCA	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	9.88	4.7e-22	2.68e-19	0.34	0.29	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-9.88	4.71e-22	2.69e-19	-0.21	-0.29	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
BRCA	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-9.88	4.74e-22	2.7e-19	-0.37	-0.29	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
BRCA	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	9.88	4.74e-22	2.71e-19	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
BRCA	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	9.88	4.75e-22	2.71e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-9.88	4.75e-22	2.71e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-9.88	4.75e-22	2.71e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-9.88	4.76e-22	2.71e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Depression;	chr6:28399886	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	9.88	4.77e-22	2.72e-19	0.31	0.29	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	9.88	4.77e-22	2.72e-19	0.31	0.29	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	9.88	4.78e-22	2.73e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
BRCA	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	9.88	4.79e-22	2.73e-19	0.35	0.29	Height;	chr6:109471826	chr6:109382795~109383666:+
BRCA	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	9.87	4.86e-22	2.77e-19	0.27	0.29	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-9.87	4.87e-22	2.78e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-9.87	4.87e-22	2.78e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-9.87	4.87e-22	2.78e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
BRCA	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	9.87	4.88e-22	2.78e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	9.87	4.92e-22	2.8e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-9.87	4.93e-22	2.81e-19	-0.31	-0.29	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-9.87	4.94e-22	2.81e-19	-0.31	-0.29	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-9.87	4.97e-22	2.83e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-9.87	4.97e-22	2.83e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-9.87	4.97e-22	2.83e-19	-0.31	-0.29	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	9.87	5e-22	2.85e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	9.87	5.02e-22	2.86e-19	0.35	0.29	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	9.87	5.02e-22	2.86e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
BRCA	cis	rs58873874	0.737	rs75022277	ENSG00000251405.2	CTB-109A12.1	9.87	5.04e-22	2.87e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157362615~157460078:-
BRCA	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-9.87	5.06e-22	2.88e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	9.87	5.06e-22	2.88e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
BRCA	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	9.87	5.08e-22	2.89e-19	0.3	0.29	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	9.87	5.09e-22	2.9e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	9.87	5.15e-22	2.93e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
BRCA	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-9.87	5.15e-22	2.93e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
BRCA	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-9.87	5.17e-22	2.94e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
BRCA	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-9.87	5.18e-22	2.95e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
BRCA	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-9.87	5.2e-22	2.95e-19	-0.5	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	9.87	5.2e-22	2.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	9.87	5.2e-22	2.96e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	9.86	5.27e-22	2.99e-19	0.42	0.29	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-9.86	5.27e-22	2.99e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
BRCA	cis	rs4727443	0.899	rs886453	ENSG00000235713.1	RP4-604G5.3	-9.86	5.31e-22	3.02e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99990602	chr7:99992397~99993050:+
BRCA	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-9.86	5.32e-22	3.02e-19	-0.42	-0.29	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	9.86	5.33e-22	3.03e-19	0.37	0.29	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-9.86	5.34e-22	3.03e-19	-0.31	-0.29	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-9.86	5.39e-22	3.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-9.86	5.39e-22	3.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000278665.1	RP11-666O2.4	9.86	5.4e-22	3.06e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28599241~28601881:-
BRCA	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-9.86	5.41e-22	3.07e-19	-0.38	-0.29	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
BRCA	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-9.86	5.42e-22	3.08e-19	-0.37	-0.29	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	9.86	5.43e-22	3.08e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	9.86	5.44e-22	3.09e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
BRCA	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.86	5.44e-22	3.09e-19	0.31	0.29	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-9.86	5.44e-22	3.09e-19	-0.31	-0.29	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
BRCA	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	9.86	5.46e-22	3.1e-19	0.48	0.29	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
BRCA	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-9.86	5.46e-22	3.1e-19	-0.35	-0.29	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	9.86	5.47e-22	3.1e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	9.86	5.48e-22	3.11e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	9.86	5.48e-22	3.11e-19	0.35	0.29	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-9.86	5.53e-22	3.14e-19	-0.37	-0.29	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	9.86	5.54e-22	3.14e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
BRCA	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-9.86	5.54e-22	3.14e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-9.86	5.54e-22	3.14e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
BRCA	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	9.86	5.56e-22	3.15e-19	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-9.86	5.57e-22	3.16e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-9.86	5.58e-22	3.16e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-9.86	5.59e-22	3.17e-19	-0.33	-0.29	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-9.86	5.59e-22	3.17e-19	-0.47	-0.29	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-9.86	5.62e-22	3.18e-19	-0.31	-0.29	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-9.86	5.63e-22	3.19e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-9.86	5.67e-22	3.21e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-9.86	5.67e-22	3.21e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	9.86	5.68e-22	3.22e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
BRCA	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	9.86	5.7e-22	3.23e-19	0.38	0.29	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-9.86	5.7e-22	3.23e-19	-0.34	-0.29	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000278665.1	RP11-666O2.4	9.86	5.7e-22	3.23e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-9.86	5.71e-22	3.24e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-9.86	5.72e-22	3.24e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-9.86	5.74e-22	3.25e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-9.86	5.74e-22	3.25e-19	-0.31	-0.29	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-9.85	5.75e-22	3.25e-19	-0.35	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-9.85	5.81e-22	3.29e-19	-0.2	-0.29	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
BRCA	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-9.85	5.82e-22	3.29e-19	-0.39	-0.29	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
BRCA	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-9.85	5.82e-22	3.3e-19	-0.32	-0.29	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
BRCA	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	9.85	5.85e-22	3.31e-19	0.35	0.29	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
BRCA	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	9.85	5.85e-22	3.31e-19	0.37	0.29	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
BRCA	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	9.85	5.86e-22	3.31e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
BRCA	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	9.85	5.87e-22	3.32e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	9.85	5.9e-22	3.34e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	9.85	5.93e-22	3.35e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	9.85	5.94e-22	3.36e-19	0.34	0.29	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-9.85	5.94e-22	3.36e-19	-0.35	-0.29	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
BRCA	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	9.85	5.96e-22	3.37e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
BRCA	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-9.85	5.97e-22	3.37e-19	-0.35	-0.29	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
BRCA	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	9.85	5.98e-22	3.38e-19	0.33	0.29	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
BRCA	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-9.85	6e-22	3.39e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
BRCA	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-9.85	6.04e-22	3.41e-19	-0.39	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
BRCA	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	9.85	6.07e-22	3.43e-19	0.35	0.29	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-9.85	6.09e-22	3.44e-19	-0.4	-0.29	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-9.85	6.1e-22	3.44e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-9.85	6.12e-22	3.45e-19	-0.31	-0.29	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	9.85	6.13e-22	3.46e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	9.85	6.13e-22	3.46e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	9.85	6.14e-22	3.47e-19	0.33	0.29	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	9.85	6.2e-22	3.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	9.85	6.23e-22	3.52e-19	0.4	0.29	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-9.85	6.25e-22	3.53e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
BRCA	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-9.85	6.26e-22	3.53e-19	-0.29	-0.29	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	9.85	6.26e-22	3.53e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	9.85	6.29e-22	3.55e-19	0.4	0.29	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-9.84	6.3e-22	3.56e-19	-0.41	-0.29	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	9.84	6.33e-22	3.57e-19	0.32	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
BRCA	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	9.84	6.37e-22	3.59e-19	0.31	0.29	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
BRCA	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-9.84	6.4e-22	3.61e-19	-0.39	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-9.84	6.42e-22	3.62e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	9.84	6.46e-22	3.64e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	9.84	6.57e-22	3.7e-19	0.38	0.29	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	9.84	6.59e-22	3.71e-19	0.35	0.29	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
BRCA	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	9.84	6.59e-22	3.71e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
BRCA	cis	rs58873874	0.737	rs79339674	ENSG00000251405.2	CTB-109A12.1	9.84	6.6e-22	3.71e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157362615~157460078:-
BRCA	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-9.84	6.7e-22	3.77e-19	-0.38	-0.29	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-9.84	6.7e-22	3.77e-19	-0.31	-0.29	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
BRCA	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	9.84	6.7e-22	3.77e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	9.84	6.75e-22	3.8e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
BRCA	cis	rs4862750	0.914	rs6553028	ENSG00000250971.1	RP11-696F12.1	9.84	6.77e-22	3.81e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:187060099~187060930:+
BRCA	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	9.84	6.79e-22	3.82e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-9.84	6.79e-22	3.82e-19	-0.31	-0.29	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	9.84	6.79e-22	3.82e-19	0.31	0.29	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	9.84	6.8e-22	3.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
BRCA	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.85e-22	3.85e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
BRCA	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-9.84	6.89e-22	3.87e-19	-0.37	-0.29	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
BRCA	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	9.83	6.9e-22	3.88e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
BRCA	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	9.83	6.91e-22	3.89e-19	0.34	0.29	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
BRCA	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	9.83	6.93e-22	3.9e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	9.83	6.94e-22	3.9e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000278665.1	RP11-666O2.4	9.83	6.98e-22	3.92e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-9.83	6.98e-22	3.93e-19	-0.4	-0.29	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	9.83	7.01e-22	3.94e-19	0.35	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
BRCA	cis	rs58873874	0.737	rs76634949	ENSG00000251405.2	CTB-109A12.1	9.83	7.02e-22	3.94e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157362615~157460078:-
BRCA	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-9.83	7.04e-22	3.96e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-9.83	7.13e-22	4.01e-19	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
BRCA	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	9.83	7.15e-22	4.02e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	9.83	7.15e-22	4.02e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-9.83	7.15e-22	4.02e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-9.83	7.16e-22	4.02e-19	-0.42	-0.29	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-9.83	7.19e-22	4.04e-19	-0.42	-0.29	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
BRCA	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	9.83	7.23e-22	4.06e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	9.83	7.27e-22	4.08e-19	0.31	0.29	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
BRCA	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-9.83	7.28e-22	4.09e-19	-0.34	-0.29	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
BRCA	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	9.83	7.3e-22	4.1e-19	0.34	0.29	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
BRCA	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	9.83	7.31e-22	4.11e-19	0.35	0.29	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
BRCA	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	9.83	7.33e-22	4.11e-19	0.35	0.29	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-9.83	7.36e-22	4.13e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
BRCA	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-9.83	7.4e-22	4.15e-19	-0.35	-0.29	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-9.83	7.42e-22	4.17e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-9.83	7.42e-22	4.17e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	9.83	7.45e-22	4.18e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
BRCA	cis	rs4862750	0.914	rs11945845	ENSG00000250971.1	RP11-696F12.1	9.83	7.45e-22	4.18e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:187060099~187060930:+
BRCA	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	9.83	7.49e-22	4.2e-19	0.34	0.29	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
BRCA	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	9.83	7.51e-22	4.21e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-9.83	7.53e-22	4.22e-19	-0.41	-0.29	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
BRCA	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	9.82	7.56e-22	4.24e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	9.82	7.56e-22	4.24e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-9.82	7.56e-22	4.24e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-9.82	7.59e-22	4.25e-19	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-9.82	7.59e-22	4.25e-19	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
BRCA	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	9.82	7.59e-22	4.26e-19	0.79	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
BRCA	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	9.82	7.59e-22	4.26e-19	0.79	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
BRCA	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	9.82	7.59e-22	4.26e-19	0.35	0.29	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
BRCA	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-9.82	7.59e-22	4.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-9.82	7.59e-22	4.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
BRCA	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	9.82	7.6e-22	4.26e-19	0.26	0.29	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
BRCA	cis	rs4727443	1	rs6974373	ENSG00000235713.1	RP4-604G5.3	-9.82	7.62e-22	4.27e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99993270	chr7:99992397~99993050:+
BRCA	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	9.82	7.67e-22	4.3e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
BRCA	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-9.82	7.68e-22	4.3e-19	-0.42	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
BRCA	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	9.82	7.71e-22	4.32e-19	0.34	0.29	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-9.82	7.77e-22	4.35e-19	-0.31	-0.29	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	9.82	7.78e-22	4.36e-19	0.35	0.29	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
BRCA	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	9.82	7.78e-22	4.36e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	9.82	7.79e-22	4.36e-19	0.34	0.29	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
BRCA	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	9.82	7.8e-22	4.37e-19	0.28	0.29	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
BRCA	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-9.82	7.82e-22	4.38e-19	-0.36	-0.29	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
BRCA	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	9.82	7.86e-22	4.4e-19	0.39	0.29	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
BRCA	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	9.82	7.96e-22	4.46e-19	0.35	0.29	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
BRCA	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-9.82	7.97e-22	4.46e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-9.82	8e-22	4.48e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-9.82	8e-22	4.48e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
BRCA	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	9.82	8e-22	4.48e-19	0.33	0.29	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
BRCA	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-9.82	8.01e-22	4.48e-19	-0.38	-0.29	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
BRCA	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	9.82	8.03e-22	4.49e-19	0.36	0.29	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
BRCA	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-9.82	8.03e-22	4.5e-19	-0.4	-0.29	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
BRCA	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	9.82	8.03e-22	4.5e-19	0.44	0.29	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	9.82	8.03e-22	4.5e-19	0.44	0.29	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
BRCA	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	9.82	8.04e-22	4.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	9.82	8.04e-22	4.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	9.82	8.05e-22	4.51e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
BRCA	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-9.82	8.06e-22	4.51e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
BRCA	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	9.82	8.1e-22	4.53e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	9.82	8.1e-22	4.53e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-9.82	8.13e-22	4.55e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-9.82	8.17e-22	4.57e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-9.82	8.18e-22	4.57e-19	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-9.82	8.2e-22	4.58e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	9.82	8.21e-22	4.59e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-9.82	8.22e-22	4.6e-19	-0.31	-0.29	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-9.82	8.22e-22	4.6e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-9.82	8.23e-22	4.6e-19	-0.36	-0.29	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
BRCA	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	9.82	8.24e-22	4.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	9.82	8.24e-22	4.6e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
BRCA	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-9.81	8.29e-22	4.63e-19	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	9.81	8.31e-22	4.64e-19	0.31	0.29	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	9.81	8.34e-22	4.65e-19	0.76	0.29	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
BRCA	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-9.81	8.35e-22	4.66e-19	-0.34	-0.29	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-9.81	8.37e-22	4.67e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-9.81	8.4e-22	4.68e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	9.81	8.41e-22	4.69e-19	0.47	0.29	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-9.81	8.42e-22	4.69e-19	-0.2	-0.29	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-9.81	8.44e-22	4.71e-19	-0.31	-0.29	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-9.81	8.45e-22	4.71e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-9.81	8.48e-22	4.73e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-9.81	8.48e-22	4.73e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-9.81	8.49e-22	4.73e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-9.81	8.5e-22	4.74e-19	-0.39	-0.29	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
BRCA	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-9.81	8.56e-22	4.77e-19	-0.36	-0.29	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	9.81	8.57e-22	4.77e-19	0.41	0.29	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-9.81	8.63e-22	4.8e-19	-0.22	-0.29	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
BRCA	cis	rs4862750	0.874	rs6553027	ENSG00000250971.1	RP11-696F12.1	9.81	8.63e-22	4.81e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:187060099~187060930:+
BRCA	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	9.81	8.74e-22	4.87e-19	0.34	0.29	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	9.81	8.74e-22	4.87e-19	0.34	0.29	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
BRCA	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.76e-22	4.87e-19	-0.36	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.76e-22	4.87e-19	-0.36	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-9.81	8.76e-22	4.88e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	9.81	8.76e-22	4.88e-19	0.35	0.29	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	9.81	8.76e-22	4.88e-19	0.35	0.29	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
BRCA	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	9.81	8.8e-22	4.89e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
BRCA	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	9.81	8.8e-22	4.9e-19	0.28	0.29	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-9.81	8.82e-22	4.9e-19	-0.31	-0.29	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-9.81	8.82e-22	4.91e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
BRCA	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.82e-22	4.91e-19	-0.36	-0.29	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
BRCA	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-9.81	8.82e-22	4.91e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-9.81	8.83e-22	4.91e-19	-0.31	-0.29	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-9.81	8.83e-22	4.91e-19	-0.31	-0.29	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
BRCA	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.84e-22	4.92e-19	-0.36	-0.29	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
BRCA	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-9.81	8.84e-22	4.92e-19	-0.27	-0.29	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	9.81	8.84e-22	4.92e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	9.81	8.84e-22	4.92e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
BRCA	cis	rs4862750	0.914	rs1991256	ENSG00000250971.1	RP11-696F12.1	9.81	8.88e-22	4.94e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.914	rs1991255	ENSG00000250971.1	RP11-696F12.1	9.81	8.88e-22	4.94e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:187060099~187060930:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	9.81	8.94e-22	4.97e-19	0.76	0.29	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	9.81	8.94e-22	4.97e-19	0.76	0.29	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
BRCA	cis	rs1823913	0.927	rs35092718	ENSG00000227542.1	AC092614.2	9.81	8.97e-22	4.99e-19	0.36	0.29	Obesity-related traits;	chr2:191243882	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	9.81	9.03e-22	5.01e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	9.81	9.03e-22	5.02e-19	0.31	0.29	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-9.81	9.03e-22	5.02e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	9.81	9.04e-22	5.02e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	9.8	9.07e-22	5.04e-19	0.35	0.29	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
BRCA	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-9.8	9.08e-22	5.05e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
BRCA	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	9.8	9.09e-22	5.05e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
BRCA	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.1e-22	5.05e-19	-0.36	-0.29	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.1e-22	5.05e-19	-0.36	-0.29	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	9.8	9.12e-22	5.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	9.8	9.12e-22	5.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-9.8	9.12e-22	5.07e-19	-0.31	-0.29	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-9.8	9.12e-22	5.07e-19	-0.31	-0.29	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-9.8	9.16e-22	5.09e-19	-0.31	-0.29	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
BRCA	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.16e-22	5.09e-19	-0.37	-0.29	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	9.8	9.17e-22	5.09e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-9.8	9.18e-22	5.1e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-9.8	9.19e-22	5.1e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-9.8	9.22e-22	5.12e-19	-0.4	-0.29	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-9.8	9.22e-22	5.12e-19	-0.32	-0.29	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	9.8	9.24e-22	5.13e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	9.8	9.26e-22	5.14e-19	0.27	0.29	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
BRCA	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-9.8	9.26e-22	5.14e-19	-0.38	-0.29	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	9.8	9.27e-22	5.15e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
BRCA	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-9.8	9.34e-22	5.18e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
BRCA	cis	rs4862750	0.914	rs1346126	ENSG00000250971.1	RP11-696F12.1	9.8	9.36e-22	5.19e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955250	chr4:187060099~187060930:+
BRCA	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-9.8	9.43e-22	5.23e-19	-0.39	-0.29	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-9.8	9.45e-22	5.24e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.45e-22	5.24e-19	-0.37	-0.29	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-9.8	9.49e-22	5.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000278665.1	RP11-666O2.4	9.8	9.57e-22	5.3e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000278665.1	RP11-666O2.4	9.8	9.57e-22	5.3e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28599241~28601881:-
BRCA	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	9.8	9.57e-22	5.3e-19	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
BRCA	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	9.8	9.6e-22	5.32e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-9.8	9.6e-22	5.32e-19	-0.2	-0.29	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	9.8	9.65e-22	5.34e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	9.8	9.65e-22	5.34e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-9.8	9.65e-22	5.35e-19	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
BRCA	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-9.8	9.68e-22	5.37e-19	-0.32	-0.29	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-9.8	9.68e-22	5.37e-19	-0.32	-0.29	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	9.8	9.71e-22	5.38e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-9.8	9.81e-22	5.43e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
BRCA	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-9.8	9.84e-22	5.45e-19	-0.38	-0.29	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
BRCA	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-9.8	9.9e-22	5.48e-19	-0.4	-0.29	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
BRCA	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-9.79	9.91e-22	5.49e-19	-0.36	-0.29	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
BRCA	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-9.79	9.98e-22	5.52e-19	-0.33	-0.29	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	9.79	1e-21	5.54e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	9.79	1e-21	5.54e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
BRCA	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.79	1.01e-21	5.58e-19	0.31	0.29	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
BRCA	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	9.79	1.01e-21	5.58e-19	0.43	0.29	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000220721.1	OR1F12	9.79	1.01e-21	5.59e-19	0.41	0.29	Depression;	chr6:28231053	chr6:28073316~28074233:+
BRCA	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	9.79	1.01e-21	5.6e-19	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
BRCA	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	9.79	1.03e-21	5.67e-19	0.33	0.29	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
BRCA	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	9.79	1.03e-21	5.68e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
BRCA	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-9.79	1.03e-21	5.69e-19	-0.35	-0.29	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
BRCA	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	9.79	1.03e-21	5.7e-19	0.32	0.29	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
BRCA	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	9.79	1.03e-21	5.71e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	9.79	1.04e-21	5.73e-19	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
BRCA	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	9.79	1.05e-21	5.8e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
BRCA	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	9.79	1.05e-21	5.8e-19	0.33	0.29	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
BRCA	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	9.79	1.05e-21	5.81e-19	0.46	0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-9.79	1.05e-21	5.82e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-9.79	1.05e-21	5.82e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-9.79	1.06e-21	5.83e-19	-0.3	-0.29	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-9.79	1.06e-21	5.84e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
BRCA	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	9.79	1.06e-21	5.86e-19	0.26	0.29	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-9.79	1.06e-21	5.87e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-9.79	1.06e-21	5.87e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-9.79	1.07e-21	5.88e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-9.79	1.07e-21	5.88e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-9.79	1.07e-21	5.9e-19	-0.28	-0.29	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-9.79	1.07e-21	5.9e-19	-0.36	-0.29	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
BRCA	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-9.79	1.07e-21	5.9e-19	-0.37	-0.29	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
BRCA	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	9.79	1.07e-21	5.9e-19	0.3	0.29	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	9.79	1.07e-21	5.9e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-9.79	1.07e-21	5.93e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.94e-19	-0.37	-0.29	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.95e-19	-0.36	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.95e-19	-0.36	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	9.79	1.08e-21	5.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	9.79	1.08e-21	5.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	9.79	1.08e-21	5.98e-19	0.4	0.29	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	9.78	1.09e-21	6.01e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
BRCA	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	9.78	1.09e-21	6.03e-19	0.42	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-9.78	1.1e-21	6.04e-19	-0.33	-0.29	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	9.78	1.1e-21	6.04e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
BRCA	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-9.78	1.1e-21	6.05e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
BRCA	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	9.78	1.1e-21	6.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	9.78	1.1e-21	6.08e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
BRCA	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	9.78	1.11e-21	6.1e-19	0.59	0.29	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
BRCA	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	9.78	1.11e-21	6.11e-19	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-9.78	1.11e-21	6.12e-19	-0.41	-0.29	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-9.78	1.11e-21	6.13e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	9.78	1.12e-21	6.18e-19	0.33	0.29	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-9.78	1.13e-21	6.2e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-9.78	1.13e-21	6.2e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-9.78	1.13e-21	6.22e-19	-0.37	-0.29	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	9.78	1.13e-21	6.23e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
BRCA	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	9.78	1.13e-21	6.24e-19	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-9.78	1.14e-21	6.26e-19	-0.4	-0.29	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
BRCA	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	9.78	1.14e-21	6.27e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	9.78	1.14e-21	6.28e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	9.78	1.14e-21	6.3e-19	0.35	0.29	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
BRCA	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	9.78	1.15e-21	6.3e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
BRCA	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	9.78	1.15e-21	6.35e-19	0.59	0.29	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
BRCA	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-9.78	1.16e-21	6.35e-19	-0.49	-0.29	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
BRCA	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	9.78	1.17e-21	6.45e-19	0.35	0.29	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
BRCA	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	9.78	1.18e-21	6.46e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	9.78	1.18e-21	6.47e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
BRCA	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-9.78	1.18e-21	6.47e-19	-0.57	-0.29	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
BRCA	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-9.78	1.18e-21	6.5e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-9.78	1.19e-21	6.52e-19	-0.35	-0.29	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
BRCA	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	9.77	1.2e-21	6.57e-19	0.59	0.29	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	9.77	1.2e-21	6.58e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
BRCA	cis	rs4862750	0.872	rs13143414	ENSG00000250971.1	RP11-696F12.1	9.77	1.2e-21	6.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:187060099~187060930:+
BRCA	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	9.77	1.21e-21	6.62e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
BRCA	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	9.77	1.21e-21	6.64e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	9.77	1.22e-21	6.67e-19	0.33	0.29	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-9.77	1.22e-21	6.71e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-9.77	1.23e-21	6.74e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	9.77	1.25e-21	6.87e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	9.77	1.27e-21	6.95e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
BRCA	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-9.77	1.27e-21	6.97e-19	-0.33	-0.29	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
BRCA	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-9.77	1.27e-21	6.98e-19	-0.35	-0.29	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	9.77	1.28e-21	6.99e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
BRCA	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	9.77	1.28e-21	6.99e-19	0.44	0.29	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
BRCA	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	9.77	1.28e-21	7e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-9.77	1.28e-21	7.02e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
BRCA	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	9.77	1.28e-21	7.04e-19	0.37	0.29	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
BRCA	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-9.77	1.29e-21	7.08e-19	-0.35	-0.29	Height;	chr3:52819385	chr3:53064283~53065091:-
BRCA	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	9.77	1.29e-21	7.08e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-9.77	1.3e-21	7.1e-19	-0.28	-0.29	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
BRCA	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	9.77	1.3e-21	7.12e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	9.76	1.3e-21	7.13e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	9.76	1.31e-21	7.19e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	9.76	1.32e-21	7.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	9.76	1.33e-21	7.26e-19	0.33	0.29	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
BRCA	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-9.76	1.34e-21	7.31e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	9.76	1.34e-21	7.31e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-9.76	1.34e-21	7.33e-19	-0.33	-0.29	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	9.76	1.34e-21	7.34e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	9.76	1.34e-21	7.35e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
BRCA	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	9.76	1.35e-21	7.39e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-9.76	1.35e-21	7.4e-19	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-9.76	1.35e-21	7.4e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
BRCA	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	9.76	1.35e-21	7.41e-19	0.33	0.29	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
BRCA	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	9.76	1.36e-21	7.43e-19	0.43	0.29	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
BRCA	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-9.76	1.36e-21	7.43e-19	-0.37	-0.29	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-9.76	1.36e-21	7.44e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-9.76	1.36e-21	7.44e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	9.76	1.37e-21	7.49e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
BRCA	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	9.76	1.37e-21	7.52e-19	0.37	0.29	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
BRCA	cis	rs753274	0.65	rs7257738	ENSG00000267147.2	CTC-548K16.1	-9.76	1.39e-21	7.6e-19	-0.35	-0.29	Tumor necrosis factor beta levels;	chr19:14308109	chr19:14333743~14343916:+
BRCA	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	9.76	1.39e-21	7.61e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-9.76	1.4e-21	7.67e-19	-0.31	-0.29	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	9.76	1.41e-21	7.73e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
BRCA	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	9.76	1.42e-21	7.75e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	9.76	1.42e-21	7.76e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
BRCA	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-9.76	1.42e-21	7.77e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	9.75	1.43e-21	7.82e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	9.75	1.43e-21	7.82e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-9.75	1.44e-21	7.86e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-9.75	1.44e-21	7.86e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
BRCA	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	9.75	1.45e-21	7.9e-19	0.35	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
BRCA	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-9.75	1.46e-21	7.99e-19	-0.38	-0.29	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
BRCA	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	9.75	1.46e-21	7.99e-19	0.33	0.29	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	9.75	1.47e-21	8.02e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	9.75	1.47e-21	8.02e-19	0.33	0.29	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
BRCA	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	9.75	1.47e-21	8.02e-19	0.27	0.29	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-9.75	1.47e-21	8.03e-19	-0.31	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-9.75	1.48e-21	8.07e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	9.75	1.48e-21	8.08e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	9.75	1.48e-21	8.1e-19	0.76	0.29	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	9.75	1.49e-21	8.12e-19	0.36	0.29	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-9.75	1.49e-21	8.13e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
BRCA	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	9.75	1.5e-21	8.19e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-9.75	1.5e-21	8.2e-19	-0.31	-0.29	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-9.75	1.51e-21	8.21e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	9.75	1.51e-21	8.25e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	9.75	1.53e-21	8.35e-19	0.2	0.29	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
BRCA	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	9.75	1.54e-21	8.39e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	9.75	1.54e-21	8.39e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
BRCA	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	9.75	1.54e-21	8.42e-19	0.34	0.29	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
BRCA	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	9.75	1.55e-21	8.43e-19	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
BRCA	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	9.75	1.55e-21	8.43e-19	0.35	0.29	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
BRCA	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.75	1.55e-21	8.45e-19	-0.31	-0.29	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-9.75	1.55e-21	8.46e-19	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
BRCA	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-9.75	1.55e-21	8.47e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-9.75	1.55e-21	8.47e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	9.74	1.56e-21	8.49e-19	0.29	0.29	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	9.74	1.56e-21	8.49e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.53e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.53e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-9.74	1.57e-21	8.56e-19	-0.35	-0.29	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
BRCA	cis	rs4727443	1	rs4727443	ENSG00000235713.1	RP4-604G5.3	-9.74	1.57e-21	8.56e-19	-0.32	-0.29	Interstitial lung disease;	chr7:99995723	chr7:99992397~99993050:+
BRCA	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.57e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-9.74	1.58e-21	8.58e-19	-0.41	-0.29	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-9.74	1.59e-21	8.63e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-9.74	1.59e-21	8.66e-19	-0.31	-0.29	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-9.74	1.59e-21	8.66e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
BRCA	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-9.74	1.6e-21	8.68e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	9.74	1.6e-21	8.71e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
BRCA	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-9.74	1.62e-21	8.83e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
BRCA	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	9.74	1.63e-21	8.86e-19	0.37	0.29	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-9.74	1.63e-21	8.89e-19	-0.31	-0.29	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-9.74	1.64e-21	8.89e-19	-0.35	-0.29	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
BRCA	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	9.74	1.64e-21	8.92e-19	0.32	0.29	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
BRCA	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	9.74	1.64e-21	8.92e-19	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
BRCA	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	9.74	1.64e-21	8.93e-19	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
BRCA	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	9.74	1.65e-21	8.96e-19	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
BRCA	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-9.74	1.65e-21	8.98e-19	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
BRCA	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	9.74	1.65e-21	8.99e-19	0.38	0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
BRCA	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.01e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.01e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.02e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
BRCA	cis	rs4862750	0.914	rs6553026	ENSG00000250971.1	RP11-696F12.1	9.74	1.66e-21	9.02e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:187060099~187060930:+
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	9.74	1.66e-21	9.03e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
BRCA	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	9.74	1.67e-21	9.05e-19	0.43	0.29	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	9.74	1.67e-21	9.06e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	9.74	1.68e-21	9.11e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	9.74	1.69e-21	9.19e-19	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	9.74	1.7e-21	9.2e-19	0.41	0.29	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
BRCA	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-9.73	1.71e-21	9.31e-19	-0.33	-0.29	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-9.73	1.72e-21	9.32e-19	-0.2	-0.29	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	9.73	1.72e-21	9.33e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
BRCA	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	9.73	1.72e-21	9.35e-19	0.36	0.29	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
BRCA	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	9.73	1.72e-21	9.35e-19	0.32	0.29	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-9.73	1.73e-21	9.36e-19	-0.31	-0.29	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
BRCA	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	9.73	1.74e-21	9.41e-19	0.35	0.29	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
BRCA	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	9.73	1.74e-21	9.41e-19	0.44	0.29	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-9.73	1.74e-21	9.43e-19	-0.35	-0.29	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	9.73	1.76e-21	9.54e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	9.73	1.77e-21	9.57e-19	0.33	0.29	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
BRCA	cis	rs10515750	0.643	rs10054755	ENSG00000248544.2	CTB-47B11.3	9.73	1.77e-21	9.6e-19	0.53	0.29	Lung function (FEV1/FVC);	chr5:157384037	chr5:157375741~157384950:-
BRCA	cis	rs10515750	0.643	rs10063539	ENSG00000248544.2	CTB-47B11.3	9.73	1.77e-21	9.6e-19	0.53	0.29	Lung function (FEV1/FVC);	chr5:157384666	chr5:157375741~157384950:-
BRCA	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	9.73	1.77e-21	9.6e-19	0.44	0.29	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	9.73	1.77e-21	9.6e-19	0.44	0.29	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-9.73	1.77e-21	9.61e-19	-0.31	-0.29	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
BRCA	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	9.73	1.78e-21	9.65e-19	0.3	0.29	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
BRCA	cis	rs4862750	0.872	rs6821507	ENSG00000250971.1	RP11-696F12.1	-9.73	1.78e-21	9.65e-19	-0.31	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:187060099~187060930:+
BRCA	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	9.73	1.78e-21	9.66e-19	0.34	0.29	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
BRCA	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	9.73	1.79e-21	9.7e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
BRCA	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-9.73	1.8e-21	9.72e-19	-0.36	-0.29	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	9.73	1.8e-21	9.75e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	9.73	1.8e-21	9.75e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000278665.1	RP11-666O2.4	9.73	1.8e-21	9.76e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28599241~28601881:-
BRCA	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	9.73	1.81e-21	9.77e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
BRCA	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-9.73	1.82e-21	9.84e-19	-0.36	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
BRCA	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-9.73	1.83e-21	9.87e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
BRCA	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-9.73	1.83e-21	9.92e-19	-0.38	-0.29	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
BRCA	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-9.73	1.84e-21	9.94e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
BRCA	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-9.73	1.84e-21	9.97e-19	-0.34	-0.29	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	9.73	1.85e-21	1e-18	0.35	0.29	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
BRCA	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-9.73	1.85e-21	1e-18	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
BRCA	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	9.73	1.86e-21	1e-18	0.36	0.29	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-9.73	1.86e-21	1.01e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
BRCA	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	9.73	1.86e-21	1.01e-18	0.34	0.29	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	9.72	1.87e-21	1.01e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	9.72	1.87e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	9.72	1.88e-21	1.01e-18	0.33	0.29	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
BRCA	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	9.72	1.88e-21	1.02e-18	0.36	0.29	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
BRCA	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-9.72	1.88e-21	1.02e-18	-0.33	-0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	9.72	1.89e-21	1.02e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
BRCA	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	9.72	1.9e-21	1.03e-18	0.33	0.29	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-9.72	1.9e-21	1.03e-18	-0.41	-0.29	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.72	1.9e-21	1.03e-18	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
BRCA	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	9.72	1.91e-21	1.03e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	9.72	1.91e-21	1.03e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	9.72	1.92e-21	1.03e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
BRCA	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	9.72	1.93e-21	1.04e-18	0.33	0.29	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	9.72	1.93e-21	1.04e-18	0.3	0.29	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	9.72	1.94e-21	1.05e-18	0.41	0.29	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	9.72	1.94e-21	1.05e-18	0.3	0.29	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-9.72	1.95e-21	1.05e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
BRCA	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-9.72	1.97e-21	1.06e-18	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
BRCA	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-9.72	1.97e-21	1.06e-18	-0.41	-0.29	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
BRCA	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	9.72	1.98e-21	1.07e-18	0.33	0.29	Migraine;	chr4:56881468	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
BRCA	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-9.72	2e-21	1.08e-18	-0.37	-0.29	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
BRCA	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-9.72	2e-21	1.08e-18	-0.37	-0.29	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-9.72	2e-21	1.08e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	9.72	2.01e-21	1.08e-18	0.33	0.29	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
BRCA	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-9.72	2.01e-21	1.09e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
BRCA	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-9.72	2.02e-21	1.09e-18	-0.4	-0.29	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-9.72	2.02e-21	1.09e-18	-0.4	-0.29	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
BRCA	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	9.72	2.03e-21	1.09e-18	0.35	0.29	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	9.72	2.03e-21	1.1e-18	0.33	0.29	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
BRCA	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.72	2.03e-21	1.1e-18	-0.31	-0.29	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-9.71	2.05e-21	1.1e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	9.71	2.05e-21	1.1e-18	0.31	0.29	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	9.71	2.05e-21	1.1e-18	0.3	0.29	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
BRCA	cis	rs4862750	0.914	rs9998558	ENSG00000250971.1	RP11-696F12.1	9.71	2.05e-21	1.11e-18	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:187060099~187060930:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	9.71	2.06e-21	1.11e-18	0.3	0.29	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	9.71	2.06e-21	1.11e-18	0.33	0.29	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-9.71	2.07e-21	1.11e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-9.71	2.07e-21	1.12e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
BRCA	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-9.71	2.08e-21	1.12e-18	-0.35	-0.29	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
BRCA	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-9.71	2.1e-21	1.13e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-9.71	2.1e-21	1.13e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	9.71	2.1e-21	1.13e-18	0.32	0.29	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
BRCA	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-9.71	2.1e-21	1.13e-18	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	9.71	2.1e-21	1.13e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
BRCA	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	9.71	2.12e-21	1.14e-18	0.35	0.29	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
BRCA	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-9.71	2.16e-21	1.16e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	9.71	2.16e-21	1.16e-18	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	9.71	2.16e-21	1.16e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
BRCA	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-9.71	2.16e-21	1.16e-18	-0.33	-0.29	Migraine;	chr4:56879297	chr4:56960927~56961373:-
BRCA	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	9.71	2.17e-21	1.17e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	9.71	2.19e-21	1.18e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
BRCA	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-9.71	2.21e-21	1.19e-18	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-9.71	2.21e-21	1.19e-18	-0.33	-0.29	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	9.71	2.22e-21	1.19e-18	0.3	0.29	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-9.7	2.24e-21	1.2e-18	-0.3	-0.29	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	9.7	2.26e-21	1.22e-18	0.35	0.29	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-9.7	2.27e-21	1.22e-18	-0.29	-0.29	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
BRCA	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-9.7	2.29e-21	1.23e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-9.7	2.29e-21	1.23e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	9.7	2.29e-21	1.23e-18	0.33	0.29	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
BRCA	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	9.7	2.3e-21	1.23e-18	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-9.7	2.31e-21	1.24e-18	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
BRCA	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	9.7	2.31e-21	1.24e-18	0.36	0.29	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
BRCA	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	9.7	2.31e-21	1.24e-18	0.35	0.29	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-9.7	2.32e-21	1.24e-18	-0.32	-0.29	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	9.7	2.32e-21	1.24e-18	0.3	0.29	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
BRCA	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	9.7	2.33e-21	1.25e-18	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
BRCA	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	9.7	2.33e-21	1.25e-18	0.33	0.29	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	9.7	2.34e-21	1.25e-18	0.33	0.29	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-9.7	2.35e-21	1.26e-18	-0.31	-0.29	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000220721.1	OR1F12	9.7	2.35e-21	1.26e-18	0.41	0.29	Depression;	chr6:28232159	chr6:28073316~28074233:+
BRCA	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	9.7	2.35e-21	1.26e-18	0.33	0.29	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000278665.1	RP11-666O2.4	9.7	2.35e-21	1.26e-18	0.28	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	9.7	2.36e-21	1.26e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	9.7	2.37e-21	1.27e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	9.7	2.37e-21	1.27e-18	0.33	0.29	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
BRCA	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	9.7	2.37e-21	1.27e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	9.7	2.37e-21	1.27e-18	0.35	0.29	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
BRCA	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-9.7	2.39e-21	1.28e-18	-0.37	-0.29	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-9.7	2.39e-21	1.28e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-9.7	2.41e-21	1.29e-18	-0.34	-0.29	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
BRCA	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	9.7	2.41e-21	1.29e-18	0.43	0.29	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	9.7	2.42e-21	1.29e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	9.69	2.45e-21	1.31e-18	0.33	0.29	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-9.69	2.45e-21	1.31e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
BRCA	cis	rs4862750	0.872	rs6553029	ENSG00000250971.1	RP11-696F12.1	-9.69	2.46e-21	1.31e-18	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955316	chr4:187060099~187060930:+
BRCA	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-9.69	2.46e-21	1.32e-18	-0.36	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	9.69	2.48e-21	1.33e-18	0.32	0.29	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-9.69	2.48e-21	1.33e-18	-0.33	-0.29	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	9.69	2.53e-21	1.35e-18	0.3	0.29	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000278665.1	RP11-666O2.4	9.69	2.54e-21	1.36e-18	0.28	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	9.69	2.55e-21	1.36e-18	0.32	0.29	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-9.69	2.55e-21	1.36e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	9.69	2.55e-21	1.36e-18	0.33	0.29	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
BRCA	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	9.69	2.56e-21	1.37e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-9.69	2.59e-21	1.38e-18	-0.3	-0.29	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	9.69	2.6e-21	1.39e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	9.69	2.62e-21	1.4e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	9.69	2.62e-21	1.4e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
BRCA	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	9.69	2.62e-21	1.4e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
BRCA	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-9.69	2.63e-21	1.4e-18	-0.34	-0.29	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
BRCA	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-9.69	2.63e-21	1.4e-18	-0.33	-0.29	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-9.69	2.66e-21	1.42e-18	-0.4	-0.29	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
BRCA	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-9.68	2.69e-21	1.43e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
BRCA	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	9.68	2.7e-21	1.44e-18	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
BRCA	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	9.68	2.7e-21	1.44e-18	0.36	0.29	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
BRCA	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-9.68	2.7e-21	1.44e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-9.68	2.7e-21	1.44e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	9.68	2.7e-21	1.44e-18	0.29	0.29	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-9.68	2.72e-21	1.45e-18	-0.57	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	9.68	2.74e-21	1.46e-18	0.35	0.29	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
BRCA	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	9.68	2.74e-21	1.46e-18	0.43	0.29	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-9.68	2.74e-21	1.46e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-9.68	2.77e-21	1.48e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	9.68	2.77e-21	1.48e-18	0.36	0.29	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
BRCA	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-9.68	2.77e-21	1.48e-18	-0.33	-0.29	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
BRCA	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	9.68	2.78e-21	1.48e-18	0.37	0.29	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
BRCA	cis	rs58873874	0.737	rs11739062	ENSG00000251405.2	CTB-109A12.1	9.68	2.81e-21	1.5e-18	0.74	0.29	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157362615~157460078:-
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000278665.1	RP11-666O2.4	9.68	2.82e-21	1.5e-18	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28599241~28601881:-
BRCA	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	9.68	2.83e-21	1.51e-18	0.33	0.29	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000278665.1	RP11-666O2.4	9.68	2.84e-21	1.51e-18	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28599241~28601881:-
BRCA	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	9.68	2.85e-21	1.52e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	9.68	2.85e-21	1.52e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-9.68	2.85e-21	1.52e-18	-0.31	-0.29	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	9.68	2.85e-21	1.52e-18	0.33	0.29	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	9.68	2.86e-21	1.52e-18	0.33	0.29	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
BRCA	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-9.68	2.91e-21	1.55e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
BRCA	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	9.67	2.94e-21	1.57e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	9.67	2.95e-21	1.57e-18	0.38	0.29	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
BRCA	cis	rs4862750	0.872	rs6811569	ENSG00000250971.1	RP11-696F12.1	-9.67	2.96e-21	1.58e-18	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:187060099~187060930:+
BRCA	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-9.67	2.96e-21	1.58e-18	-0.32	-0.29	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-9.67	2.96e-21	1.58e-18	-0.32	-0.29	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-9.67	2.97e-21	1.58e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	9.67	3e-21	1.59e-18	0.3	0.29	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	9.67	3e-21	1.59e-18	0.3	0.29	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	9.67	3e-21	1.6e-18	0.35	0.29	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-9.67	3.01e-21	1.6e-18	-0.31	-0.29	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
BRCA	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-9.67	3.02e-21	1.6e-18	-0.42	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	9.67	3.02e-21	1.61e-18	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
BRCA	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	9.67	3.03e-21	1.61e-18	0.36	0.29	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
BRCA	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	9.67	3.06e-21	1.63e-18	0.37	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
BRCA	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-9.67	3.06e-21	1.63e-18	-0.37	-0.29	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
BRCA	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-9.67	3.07e-21	1.63e-18	-0.33	-0.29	Migraine;	chr4:56880659	chr4:56960927~56961373:-
BRCA	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-9.67	3.08e-21	1.64e-18	-0.33	-0.29	Migraine;	chr4:56879851	chr4:56960927~56961373:-
BRCA	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	9.67	3.08e-21	1.64e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
BRCA	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	9.67	3.09e-21	1.64e-18	0.43	0.29	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
BRCA	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-9.67	3.1e-21	1.64e-18	-0.31	-0.29	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
BRCA	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-9.67	3.1e-21	1.65e-18	-0.33	-0.29	Migraine;	chr4:56880007	chr4:56960927~56961373:-
BRCA	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-9.67	3.1e-21	1.65e-18	-0.33	-0.29	Migraine;	chr4:56880190	chr4:56960927~56961373:-
BRCA	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	9.67	3.1e-21	1.65e-18	0.32	0.29	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-9.67	3.11e-21	1.65e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	9.67	3.12e-21	1.66e-18	0.55	0.29	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-9.67	3.13e-21	1.66e-18	-0.35	-0.29	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	9.67	3.14e-21	1.66e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
BRCA	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-9.67	3.15e-21	1.67e-18	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
BRCA	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	9.67	3.16e-21	1.67e-18	0.28	0.29	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-9.67	3.16e-21	1.67e-18	-0.3	-0.29	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	9.67	3.16e-21	1.68e-18	0.33	0.29	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	9.67	3.19e-21	1.69e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
BRCA	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	9.67	3.19e-21	1.69e-18	0.39	0.29	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
BRCA	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	9.67	3.19e-21	1.69e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	9.67	3.2e-21	1.7e-18	0.32	0.29	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
BRCA	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-9.66	3.2e-21	1.7e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-9.66	3.21e-21	1.7e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
BRCA	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-9.66	3.22e-21	1.71e-18	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	9.66	3.22e-21	1.71e-18	0.3	0.29	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	9.66	3.22e-21	1.71e-18	0.3	0.29	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-9.66	3.24e-21	1.72e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-9.66	3.24e-21	1.72e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	9.66	3.26e-21	1.73e-18	0.39	0.29	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
BRCA	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	9.66	3.29e-21	1.74e-18	0.39	0.29	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	9.66	3.3e-21	1.75e-18	0.54	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
BRCA	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-9.66	3.3e-21	1.75e-18	-0.27	-0.29	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
BRCA	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	9.66	3.32e-21	1.76e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
BRCA	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	9.66	3.35e-21	1.77e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	9.66	3.35e-21	1.78e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	9.66	3.35e-21	1.78e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	9.66	3.36e-21	1.78e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	9.66	3.36e-21	1.78e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
BRCA	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-9.66	3.38e-21	1.79e-18	-0.37	-0.29	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
BRCA	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	9.66	3.4e-21	1.8e-18	0.3	0.29	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	9.66	3.4e-21	1.8e-18	0.34	0.29	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	9.66	3.41e-21	1.8e-18	0.4	0.29	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	9.66	3.41e-21	1.8e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
BRCA	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	9.66	3.42e-21	1.81e-18	0.35	0.29	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
BRCA	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	9.66	3.42e-21	1.81e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	9.66	3.42e-21	1.81e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	9.66	3.42e-21	1.81e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	9.66	3.42e-21	1.81e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	9.66	3.44e-21	1.82e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	9.66	3.45e-21	1.82e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
BRCA	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	9.66	3.46e-21	1.83e-18	0.35	0.29	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
BRCA	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-9.66	3.46e-21	1.83e-18	-0.74	-0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
BRCA	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-9.66	3.47e-21	1.83e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	9.65	3.54e-21	1.87e-18	0.35	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
BRCA	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	9.65	3.55e-21	1.88e-18	0.34	0.29	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-9.65	3.55e-21	1.88e-18	-0.38	-0.29	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
BRCA	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
BRCA	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-9.65	3.58e-21	1.89e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
BRCA	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.58e-21	1.89e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
BRCA	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	9.65	3.59e-21	1.9e-18	0.33	0.29	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
BRCA	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	9.65	3.61e-21	1.91e-18	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
BRCA	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	9.65	3.62e-21	1.91e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	9.65	3.63e-21	1.91e-18	0.36	0.29	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
BRCA	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-9.65	3.63e-21	1.92e-18	-0.36	-0.29	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	9.65	3.64e-21	1.92e-18	0.29	0.29	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
BRCA	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	9.65	3.64e-21	1.92e-18	0.27	0.29	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	9.65	3.65e-21	1.93e-18	0.33	0.29	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	9.65	3.65e-21	1.93e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	9.65	3.66e-21	1.93e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-9.65	3.66e-21	1.93e-18	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
BRCA	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-9.65	3.68e-21	1.94e-18	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	9.65	3.68e-21	1.94e-18	0.28	0.29	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	9.65	3.69e-21	1.95e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-9.65	3.7e-21	1.95e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
BRCA	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-9.65	3.7e-21	1.95e-18	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-9.65	3.7e-21	1.95e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-9.65	3.7e-21	1.95e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
BRCA	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	9.65	3.73e-21	1.97e-18	0.43	0.29	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
BRCA	cis	rs4862750	0.837	rs1863404	ENSG00000250971.1	RP11-696F12.1	9.65	3.73e-21	1.97e-18	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:187060099~187060930:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-9.65	3.74e-21	1.97e-18	-0.29	-0.29	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
BRCA	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	9.65	3.75e-21	1.97e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	9.65	3.75e-21	1.98e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-9.65	3.76e-21	1.98e-18	-0.34	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
BRCA	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-9.65	3.77e-21	1.99e-18	-0.3	-0.29	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
BRCA	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	9.65	3.78e-21	1.99e-18	0.43	0.29	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
BRCA	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	9.65	3.79e-21	2e-18	0.27	0.29	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
BRCA	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	9.65	3.79e-21	2e-18	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
BRCA	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	9.65	3.81e-21	2e-18	0.33	0.29	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
BRCA	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	9.65	3.82e-21	2.01e-18	0.43	0.29	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
BRCA	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-9.65	3.82e-21	2.01e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-9.65	3.82e-21	2.01e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-9.64	3.83e-21	2.02e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-9.64	3.84e-21	2.02e-18	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
BRCA	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-9.64	3.89e-21	2.05e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
BRCA	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	9.64	3.89e-21	2.05e-18	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
BRCA	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	9.64	3.91e-21	2.06e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	9.64	3.91e-21	2.06e-18	0.37	0.29	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-9.64	3.91e-21	2.06e-18	-0.3	-0.29	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-9.64	3.91e-21	2.06e-18	-0.3	-0.29	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
BRCA	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	9.64	3.94e-21	2.07e-18	0.46	0.29	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
BRCA	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-9.64	3.97e-21	2.09e-18	-0.41	-0.29	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-9.64	3.97e-21	2.09e-18	-0.41	-0.29	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
BRCA	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-9.64	4.02e-21	2.11e-18	-0.47	-0.29	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
BRCA	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-9.64	4.02e-21	2.12e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-9.64	4.02e-21	2.12e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	9.64	4.04e-21	2.12e-18	0.3	0.29	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	9.64	4.04e-21	2.12e-18	0.3	0.29	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	9.64	4.04e-21	2.13e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	9.64	4.05e-21	2.13e-18	0.3	0.29	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	9.64	4.06e-21	2.13e-18	0.3	0.29	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-9.64	4.07e-21	2.14e-18	-0.31	-0.29	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	9.64	4.07e-21	2.14e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	9.64	4.08e-21	2.15e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
BRCA	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	9.64	4.12e-21	2.16e-18	0.75	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
BRCA	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	9.64	4.13e-21	2.17e-18	0.46	0.29	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
BRCA	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	9.64	4.14e-21	2.17e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-9.64	4.14e-21	2.18e-18	-0.3	-0.29	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
BRCA	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-9.64	4.17e-21	2.19e-18	-0.39	-0.29	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
BRCA	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-9.63	4.19e-21	2.2e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
BRCA	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-9.63	4.19e-21	2.2e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
BRCA	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	9.63	4.19e-21	2.2e-18	0.45	0.29	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
BRCA	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-9.63	4.19e-21	2.2e-18	-0.3	-0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
BRCA	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	9.63	4.2e-21	2.21e-18	0.44	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
BRCA	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-9.63	4.22e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-9.63	4.22e-21	2.22e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	9.63	4.23e-21	2.22e-18	0.41	0.29	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
BRCA	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	9.63	4.23e-21	2.22e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
BRCA	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-9.63	4.24e-21	2.22e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	9.63	4.25e-21	2.23e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
BRCA	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	9.63	4.26e-21	2.23e-18	0.32	0.29	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
BRCA	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	9.63	4.28e-21	2.24e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	9.63	4.3e-21	2.26e-18	0.28	0.29	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-9.63	4.31e-21	2.26e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
BRCA	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	9.63	4.33e-21	2.27e-18	0.4	0.29	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-9.63	4.33e-21	2.27e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
BRCA	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-9.63	4.34e-21	2.28e-18	-0.36	-0.29	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
BRCA	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	9.63	4.36e-21	2.29e-18	0.46	0.29	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
BRCA	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-9.63	4.37e-21	2.29e-18	-0.35	-0.29	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
BRCA	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	9.63	4.38e-21	2.3e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	9.63	4.38e-21	2.3e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
BRCA	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-9.63	4.4e-21	2.31e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	9.63	4.41e-21	2.31e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-9.63	4.41e-21	2.31e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	9.63	4.43e-21	2.32e-18	0.28	0.29	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-9.63	4.43e-21	2.32e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
BRCA	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	9.63	4.44e-21	2.33e-18	0.32	0.29	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	9.63	4.45e-21	2.33e-18	0.3	0.29	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-9.63	4.48e-21	2.34e-18	-0.36	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
BRCA	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-9.63	4.5e-21	2.36e-18	-0.3	-0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	9.63	4.5e-21	2.36e-18	0.41	0.29	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	9.63	4.51e-21	2.36e-18	0.41	0.29	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
BRCA	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	9.63	4.55e-21	2.38e-18	0.34	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000278665.1	RP11-666O2.4	9.63	4.56e-21	2.39e-18	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000278665.1	RP11-666O2.4	9.63	4.56e-21	2.39e-18	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-9.62	4.58e-21	2.4e-18	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000220721.1	OR1F12	9.62	4.63e-21	2.42e-18	0.4	0.29	Depression;	chr6:28230678	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-9.62	4.64e-21	2.43e-18	-0.3	-0.29	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-9.62	4.67e-21	2.44e-18	-0.3	-0.29	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
BRCA	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	9.62	4.67e-21	2.44e-18	0.43	0.29	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
BRCA	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-9.62	4.68e-21	2.44e-18	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
BRCA	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-9.62	4.68e-21	2.44e-18	-0.35	-0.29	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	9.62	4.71e-21	2.46e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	9.62	4.71e-21	2.46e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
BRCA	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	9.62	4.71e-21	2.46e-18	0.37	0.29	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-9.62	4.72e-21	2.46e-18	-0.33	-0.29	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-9.62	4.72e-21	2.46e-18	-0.33	-0.29	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
BRCA	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	9.62	4.73e-21	2.47e-18	0.27	0.29	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	9.62	4.73e-21	2.47e-18	0.27	0.29	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-9.62	4.74e-21	2.47e-18	-0.3	-0.29	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	9.62	4.75e-21	2.48e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	9.62	4.75e-21	2.48e-18	0.33	0.29	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-9.62	4.76e-21	2.48e-18	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-9.62	4.78e-21	2.49e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.62	4.79e-21	2.5e-18	0.28	0.29	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-9.62	4.84e-21	2.53e-18	-0.36	-0.29	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
BRCA	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	9.62	4.87e-21	2.54e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
BRCA	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-9.62	4.88e-21	2.54e-18	-0.28	-0.29	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
BRCA	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	9.62	4.89e-21	2.55e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
BRCA	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-9.62	4.89e-21	2.55e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
BRCA	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	9.62	4.92e-21	2.56e-18	0.42	0.29	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
BRCA	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	9.62	4.92e-21	2.57e-18	0.38	0.29	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-9.62	4.93e-21	2.57e-18	-0.3	-0.29	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	9.62	4.93e-21	2.57e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-9.62	4.93e-21	2.57e-18	-0.33	-0.29	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
BRCA	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-9.62	4.94e-21	2.58e-18	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
BRCA	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	9.62	4.95e-21	2.58e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
BRCA	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	9.62	4.95e-21	2.58e-18	0.41	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
BRCA	cis	rs473651	0.692	rs579511	ENSG00000229915.1	AC016999.2	-9.62	4.96e-21	2.59e-18	-0.36	-0.29	Multiple system atrophy;	chr2:238426273	chr2:238427077~238427729:-
BRCA	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-9.62	4.97e-21	2.59e-18	-0.32	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	9.61	5.02e-21	2.62e-18	0.36	0.29	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
BRCA	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	9.61	5.02e-21	2.62e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	9.61	5.02e-21	2.62e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
BRCA	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	9.61	5.04e-21	2.63e-18	0.36	0.29	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-9.61	5.05e-21	2.63e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	9.61	5.07e-21	2.64e-18	0.33	0.29	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-9.61	5.08e-21	2.65e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
BRCA	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	9.61	5.13e-21	2.67e-18	0.27	0.29	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
BRCA	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	9.61	5.16e-21	2.69e-18	0.32	0.29	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
BRCA	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	9.61	5.17e-21	2.69e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-9.61	5.17e-21	2.69e-18	-0.33	-0.29	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
BRCA	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	9.61	5.17e-21	2.69e-18	0.35	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-9.61	5.21e-21	2.71e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
BRCA	cis	rs1426063	1	rs1426063	ENSG00000260265.1	RP11-44F21.5	-9.61	5.22e-21	2.72e-18	-0.46	-0.29	QT interval;	chr4:75105711	chr4:75081702~75084717:-
BRCA	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	9.61	5.25e-21	2.73e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
BRCA	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-9.61	5.27e-21	2.74e-18	-0.35	-0.29	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
BRCA	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-9.61	5.28e-21	2.75e-18	-0.37	-0.29	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
BRCA	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-9.61	5.28e-21	2.75e-18	-0.43	-0.29	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
BRCA	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	9.61	5.29e-21	2.75e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
BRCA	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	9.61	5.31e-21	2.76e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	9.61	5.35e-21	2.78e-18	0.54	0.29	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-9.61	5.36e-21	2.79e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-9.61	5.36e-21	2.79e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	9.61	5.37e-21	2.79e-18	0.4	0.29	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	9.61	5.4e-21	2.81e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	9.61	5.4e-21	2.81e-18	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	9.61	5.43e-21	2.82e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	9.61	5.43e-21	2.82e-18	0.2	0.29	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-9.61	5.45e-21	2.83e-18	-0.33	-0.29	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-9.6	5.49e-21	2.85e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
BRCA	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-9.6	5.49e-21	2.85e-18	-0.36	-0.29	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	9.6	5.51e-21	2.86e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	9.6	5.52e-21	2.87e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
BRCA	cis	rs4727443	0.966	rs66748925	ENSG00000235713.1	RP4-604G5.3	-9.6	5.54e-21	2.88e-18	-0.32	-0.29	Interstitial lung disease;	chr7:99992220	chr7:99992397~99993050:+
BRCA	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	9.6	5.55e-21	2.88e-18	0.36	0.29	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-9.6	5.55e-21	2.88e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
BRCA	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	9.6	5.55e-21	2.88e-18	0.33	0.29	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
BRCA	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-9.6	5.62e-21	2.91e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-9.6	5.62e-21	2.91e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
BRCA	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	9.6	5.62e-21	2.91e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-9.6	5.62e-21	2.91e-18	-0.33	-0.29	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	9.6	5.62e-21	2.92e-18	0.32	0.29	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-9.6	5.63e-21	2.92e-18	-0.33	-0.29	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	9.6	5.64e-21	2.92e-18	0.28	0.29	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-9.6	5.65e-21	2.93e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	9.6	5.71e-21	2.96e-18	0.33	0.29	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	9.6	5.72e-21	2.97e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
BRCA	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	9.6	5.75e-21	2.98e-18	0.41	0.29	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	9.6	5.75e-21	2.98e-18	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-9.6	5.76e-21	2.99e-18	-0.33	-0.29	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	9.6	5.76e-21	2.99e-18	0.33	0.29	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	9.6	5.76e-21	2.99e-18	0.33	0.29	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-9.6	5.83e-21	3.02e-18	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-9.6	5.83e-21	3.02e-18	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
BRCA	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	9.6	5.86e-21	3.03e-18	0.34	0.28	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	9.6	5.88e-21	3.05e-18	0.4	0.28	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-9.6	5.91e-21	3.06e-18	-0.29	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	9.6	5.91e-21	3.06e-18	0.29	0.28	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-9.6	5.93e-21	3.07e-18	-0.3	-0.28	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-9.6	5.93e-21	3.07e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
BRCA	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-9.6	5.95e-21	3.08e-18	-0.35	-0.28	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	9.6	5.96e-21	3.09e-18	0.4	0.28	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-9.6	5.97e-21	3.09e-18	-0.29	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
BRCA	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-9.59	5.98e-21	3.09e-18	-0.32	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
BRCA	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-9.59	5.98e-21	3.1e-18	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
BRCA	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-9.59	6.01e-21	3.11e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-9.59	6.04e-21	3.12e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	9.59	6.05e-21	3.13e-18	0.34	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
BRCA	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	9.59	6.09e-21	3.15e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-9.59	6.12e-21	3.17e-18	-0.33	-0.28	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	9.59	6.13e-21	3.17e-18	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	9.59	6.13e-21	3.17e-18	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	9.59	6.13e-21	3.17e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
BRCA	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	9.59	6.14e-21	3.18e-18	0.35	0.28	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
BRCA	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-9.59	6.14e-21	3.18e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
BRCA	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	9.59	6.17e-21	3.19e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
BRCA	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-9.59	6.18e-21	3.2e-18	-0.34	-0.28	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-9.59	6.18e-21	3.2e-18	-0.38	-0.28	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
BRCA	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	9.59	6.29e-21	3.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	9.59	6.29e-21	3.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	9.59	6.31e-21	3.26e-18	0.33	0.28	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-9.59	6.32e-21	3.27e-18	-0.33	-0.28	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	9.59	6.35e-21	3.28e-18	0.55	0.28	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	9.59	6.35e-21	3.28e-18	0.55	0.28	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	9.59	6.35e-21	3.28e-18	0.38	0.28	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
BRCA	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-9.59	6.36e-21	3.29e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
BRCA	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-9.59	6.36e-21	3.29e-18	-0.33	-0.28	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000278665.1	RP11-666O2.4	9.59	6.37e-21	3.29e-18	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-9.59	6.38e-21	3.29e-18	-0.49	-0.28	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
BRCA	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-9.59	6.38e-21	3.3e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-9.59	6.38e-21	3.3e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
BRCA	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	9.59	6.4e-21	3.3e-18	0.4	0.28	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
BRCA	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	9.59	6.41e-21	3.31e-18	0.34	0.28	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
BRCA	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-9.59	6.43e-21	3.32e-18	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
BRCA	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	9.59	6.45e-21	3.33e-18	0.45	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	9.59	6.48e-21	3.35e-18	0.28	0.28	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
BRCA	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	9.59	6.48e-21	3.35e-18	0.35	0.28	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
BRCA	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	9.59	6.49e-21	3.35e-18	0.33	0.28	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
BRCA	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	9.59	6.51e-21	3.36e-18	0.42	0.28	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-9.59	6.51e-21	3.36e-18	-0.28	-0.28	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
BRCA	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	9.58	6.55e-21	3.38e-18	0.32	0.28	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
BRCA	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-9.58	6.67e-21	3.44e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-9.58	6.67e-21	3.44e-18	-0.3	-0.28	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-9.58	6.67e-21	3.44e-18	-0.3	-0.28	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
BRCA	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-9.58	6.68e-21	3.45e-18	-0.35	-0.28	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-9.58	6.73e-21	3.47e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	9.58	6.81e-21	3.51e-18	0.33	0.28	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
BRCA	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-9.58	6.93e-21	3.57e-18	-0.38	-0.28	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-9.58	7e-21	3.61e-18	-0.3	-0.28	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-9.58	7.12e-21	3.67e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
BRCA	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	9.57	7.15e-21	3.69e-18	0.33	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
BRCA	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-9.57	7.16e-21	3.69e-18	-0.35	-0.28	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
BRCA	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	9.57	7.16e-21	3.69e-18	0.35	0.28	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
BRCA	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	9.57	7.16e-21	3.69e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
BRCA	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-9.57	7.21e-21	3.71e-18	-0.37	-0.28	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
BRCA	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	9.57	7.24e-21	3.73e-18	0.42	0.28	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-9.57	7.25e-21	3.73e-18	-0.3	-0.28	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
BRCA	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-9.57	7.26e-21	3.74e-18	-0.35	-0.28	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
BRCA	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	9.57	7.29e-21	3.75e-18	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-9.57	7.3e-21	3.76e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
BRCA	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-9.57	7.31e-21	3.76e-18	-0.32	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-9.57	7.33e-21	3.77e-18	-0.32	-0.28	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	9.57	7.33e-21	3.77e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-9.57	7.34e-21	3.77e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
BRCA	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-9.57	7.35e-21	3.78e-18	-0.35	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
BRCA	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	9.57	7.36e-21	3.78e-18	0.34	0.28	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-9.57	7.42e-21	3.82e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	9.57	7.43e-21	3.82e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
BRCA	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	9.57	7.43e-21	3.82e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
BRCA	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-9.57	7.48e-21	3.84e-18	-0.36	-0.28	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
BRCA	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	9.57	7.49e-21	3.85e-18	0.39	0.28	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
BRCA	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-9.57	7.52e-21	3.87e-18	-0.36	-0.28	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	9.57	7.58e-21	3.9e-18	0.33	0.28	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-9.57	7.68e-21	3.95e-18	-0.36	-0.28	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-9.57	7.71e-21	3.96e-18	-0.3	-0.28	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	9.57	7.72e-21	3.97e-18	0.33	0.28	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-9.57	7.76e-21	3.98e-18	-0.55	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
BRCA	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-9.57	7.8e-21	4e-18	-0.42	-0.28	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
BRCA	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	9.56	7.81e-21	4.01e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
BRCA	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-9.56	7.87e-21	4.04e-18	-0.36	-0.28	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	9.56	7.89e-21	4.05e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	9.56	7.89e-21	4.05e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-9.56	7.93e-21	4.07e-18	-0.28	-0.28	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
BRCA	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-9.56	7.99e-21	4.1e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
BRCA	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	9.56	8.01e-21	4.11e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
BRCA	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	9.56	8.05e-21	4.13e-18	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
BRCA	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	9.56	8.05e-21	4.13e-18	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
BRCA	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	9.56	8.07e-21	4.14e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-9.56	8.09e-21	4.15e-18	-0.38	-0.28	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
BRCA	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	9.56	8.1e-21	4.15e-18	0.42	0.28	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
BRCA	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-9.56	8.15e-21	4.18e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
BRCA	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	9.56	8.17e-21	4.19e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
BRCA	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-9.56	8.18e-21	4.19e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-9.56	8.18e-21	4.19e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
BRCA	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	9.56	8.2e-21	4.2e-18	0.35	0.28	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
BRCA	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	9.56	8.23e-21	4.22e-18	0.47	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-9.56	8.24e-21	4.23e-18	-0.3	-0.28	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-9.56	8.24e-21	4.23e-18	-0.3	-0.28	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-9.56	8.29e-21	4.25e-18	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	9.56	8.31e-21	4.26e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	9.56	8.32e-21	4.26e-18	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
BRCA	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	9.56	8.36e-21	4.28e-18	0.45	0.28	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
BRCA	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	9.56	8.47e-21	4.33e-18	0.42	0.28	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-9.56	8.51e-21	4.35e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
BRCA	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	9.55	8.54e-21	4.37e-18	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
BRCA	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	9.55	8.58e-21	4.39e-18	0.37	0.28	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	9.55	8.6e-21	4.4e-18	0.28	0.28	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	9.55	8.65e-21	4.42e-18	0.33	0.28	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-9.55	8.65e-21	4.43e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
BRCA	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	9.55	8.69e-21	4.44e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
BRCA	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-9.55	8.7e-21	4.45e-18	-0.5	-0.28	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-9.55	8.72e-21	4.46e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
BRCA	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	9.55	8.8e-21	4.5e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	9.55	8.8e-21	4.5e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
BRCA	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-9.55	8.83e-21	4.51e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-9.55	8.83e-21	4.51e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000220721.1	OR1F12	9.55	8.84e-21	4.52e-18	0.37	0.28	Parkinson's disease;	chr6:28012442	chr6:28073316~28074233:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	9.55	8.85e-21	4.52e-18	0.33	0.28	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
BRCA	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	9.55	8.88e-21	4.54e-18	0.26	0.28	Asthma;	chr2:102440033	chr2:102438713~102440475:+
BRCA	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	9.55	8.89e-21	4.54e-18	0.39	0.28	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	9.55	8.9e-21	4.55e-18	0.4	0.28	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
BRCA	cis	rs4862750	0.914	rs1863405	ENSG00000250971.1	RP11-696F12.1	-9.55	8.96e-21	4.58e-18	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:187060099~187060930:+
BRCA	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-9.55	9.05e-21	4.62e-18	-0.49	-0.28	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-9.55	9.05e-21	4.62e-18	-0.33	-0.28	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-9.55	9.06e-21	4.63e-18	-0.3	-0.28	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	9.55	9.09e-21	4.64e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
BRCA	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-9.55	9.15e-21	4.67e-18	-0.35	-0.28	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
BRCA	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	9.55	9.23e-21	4.71e-18	0.37	0.28	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-9.55	9.24e-21	4.72e-18	-0.32	-0.28	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
BRCA	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	9.55	9.28e-21	4.74e-18	0.36	0.28	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
BRCA	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	9.55	9.29e-21	4.74e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-9.54	9.34e-21	4.77e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-9.54	9.36e-21	4.77e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000220721.1	OR1F12	9.54	9.39e-21	4.79e-18	0.41	0.28	Depression;	chr6:28237724	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-9.54	9.45e-21	4.82e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-9.54	9.5e-21	4.84e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	9.54	9.53e-21	4.86e-18	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
BRCA	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	9.54	9.53e-21	4.86e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
BRCA	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	9.54	9.54e-21	4.87e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-9.54	9.55e-21	4.87e-18	-0.55	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
BRCA	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-9.54	9.58e-21	4.88e-18	-0.49	-0.28	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	9.54	9.6e-21	4.89e-18	0.3	0.28	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	9.54	9.65e-21	4.92e-18	0.35	0.28	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-9.54	9.67e-21	4.93e-18	-0.2	-0.28	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	9.54	9.69e-21	4.94e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	9.54	9.69e-21	4.94e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	9.54	9.7e-21	4.94e-18	0.4	0.28	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
BRCA	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	9.54	9.76e-21	4.97e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	9.54	9.78e-21	4.98e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	9.54	9.78e-21	4.98e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
BRCA	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-9.54	9.8e-21	4.99e-18	-0.36	-0.28	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	9.54	9.89e-21	5.04e-18	0.33	0.28	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-9.54	9.89e-21	5.04e-18	-0.3	-0.28	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
BRCA	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	9.54	9.91e-21	5.05e-18	0.34	0.28	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
BRCA	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	9.54	9.93e-21	5.06e-18	0.32	0.28	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
BRCA	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	9.54	9.93e-21	5.06e-18	0.32	0.28	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
BRCA	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	9.54	9.99e-21	5.09e-18	0.32	0.28	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-9.54	1e-20	5.11e-18	-0.3	-0.28	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-9.54	1e-20	5.11e-18	-0.3	-0.28	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.54	1.01e-20	5.12e-18	-0.27	-0.28	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
BRCA	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-9.54	1.01e-20	5.12e-18	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000278665.1	RP11-666O2.4	9.54	1.01e-20	5.15e-18	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28599241~28601881:-
BRCA	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-9.54	1.01e-20	5.16e-18	-0.37	-0.28	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
BRCA	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	9.54	1.02e-20	5.17e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.524	rs7959062	ENSG00000260329.1	RP11-412D9.4	-9.53	1.02e-20	5.2e-18	-0.31	-0.28	Heart rate;	chr12:106713556	chr12:106954029~106955497:-
BRCA	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-9.53	1.02e-20	5.2e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
BRCA	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	9.53	1.02e-20	5.21e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	9.53	1.02e-20	5.21e-18	0.33	0.28	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	9.53	1.02e-20	5.21e-18	0.33	0.28	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-9.53	1.03e-20	5.21e-18	-0.38	-0.28	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
BRCA	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	9.53	1.03e-20	5.23e-18	0.33	0.28	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	9.53	1.03e-20	5.23e-18	0.33	0.28	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
BRCA	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-9.53	1.03e-20	5.24e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	9.53	1.04e-20	5.28e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	9.53	1.04e-20	5.31e-18	0.38	0.28	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
BRCA	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	9.53	1.05e-20	5.31e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	9.53	1.05e-20	5.33e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	9.53	1.05e-20	5.33e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
BRCA	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	9.53	1.06e-20	5.37e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
BRCA	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	9.53	1.06e-20	5.4e-18	0.37	0.28	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
BRCA	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	9.53	1.06e-20	5.41e-18	0.35	0.28	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
BRCA	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-9.53	1.07e-20	5.43e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
BRCA	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-9.53	1.07e-20	5.43e-18	-0.35	-0.28	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
BRCA	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-9.53	1.07e-20	5.44e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
BRCA	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-9.53	1.07e-20	5.44e-18	-0.33	-0.28	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-9.53	1.07e-20	5.45e-18	-0.32	-0.28	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-9.53	1.07e-20	5.45e-18	-0.32	-0.28	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	9.53	1.08e-20	5.48e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	9.53	1.08e-20	5.49e-18	0.28	0.28	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	9.53	1.08e-20	5.5e-18	0.35	0.28	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-9.53	1.08e-20	5.5e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	9.53	1.08e-20	5.51e-18	0.3	0.28	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.525	rs1621048	ENSG00000271889.1	RP11-493E12.1	-9.53	1.09e-20	5.52e-18	-0.36	-0.28	Tuberculosis;	chr2:61137081	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	9.53	1.09e-20	5.52e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	9.53	1.09e-20	5.53e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-9.53	1.09e-20	5.54e-18	-0.33	-0.28	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
BRCA	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	9.53	1.1e-20	5.59e-18	0.42	0.28	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	9.52	1.12e-20	5.67e-18	0.4	0.28	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
BRCA	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	9.52	1.12e-20	5.69e-18	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
BRCA	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	9.52	1.13e-20	5.72e-18	0.33	0.28	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
BRCA	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	9.52	1.13e-20	5.73e-18	0.46	0.28	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
BRCA	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	9.52	1.13e-20	5.74e-18	0.26	0.28	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-9.52	1.13e-20	5.74e-18	-0.3	-0.28	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	9.52	1.14e-20	5.75e-18	0.32	0.28	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-9.52	1.14e-20	5.77e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	9.52	1.14e-20	5.79e-18	0.33	0.28	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-9.52	1.14e-20	5.8e-18	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
BRCA	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-9.52	1.15e-20	5.83e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	9.52	1.15e-20	5.84e-18	0.32	0.28	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	9.52	1.15e-20	5.85e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
BRCA	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-9.52	1.16e-20	5.86e-18	-0.33	-0.28	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
BRCA	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	9.52	1.17e-20	5.94e-18	0.33	0.28	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	9.52	1.18e-20	5.99e-18	0.33	0.28	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	9.52	1.18e-20	5.99e-18	0.33	0.28	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
BRCA	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-9.52	1.19e-20	6.01e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	9.52	1.19e-20	6.03e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-9.52	1.2e-20	6.06e-18	-0.32	-0.28	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-9.52	1.2e-20	6.07e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
BRCA	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	9.52	1.2e-20	6.08e-18	0.3	0.28	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
BRCA	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	9.52	1.21e-20	6.11e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-9.51	1.22e-20	6.16e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	9.51	1.22e-20	6.17e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
BRCA	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	9.51	1.22e-20	6.18e-18	0.4	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
BRCA	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	9.51	1.24e-20	6.25e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	9.51	1.24e-20	6.25e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
BRCA	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	9.51	1.25e-20	6.34e-18	0.32	0.28	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	9.51	1.25e-20	6.34e-18	0.28	0.28	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	9.51	1.25e-20	6.34e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
BRCA	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	9.51	1.25e-20	6.34e-18	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
BRCA	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	9.51	1.25e-20	6.34e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
BRCA	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-9.51	1.26e-20	6.37e-18	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-9.51	1.26e-20	6.38e-18	-0.3	-0.28	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-9.51	1.27e-20	6.44e-18	-0.32	-0.28	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
BRCA	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-9.51	1.27e-20	6.44e-18	-0.31	-0.28	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	9.51	1.28e-20	6.48e-18	0.33	0.28	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
BRCA	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-9.51	1.29e-20	6.5e-18	-0.33	-0.28	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
BRCA	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	9.51	1.29e-20	6.52e-18	0.33	0.28	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
BRCA	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-9.51	1.31e-20	6.59e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
BRCA	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	9.51	1.31e-20	6.59e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
BRCA	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	9.51	1.31e-20	6.6e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
BRCA	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-9.51	1.31e-20	6.62e-18	-0.36	-0.28	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
BRCA	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	9.51	1.32e-20	6.64e-18	0.42	0.28	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
BRCA	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-9.51	1.32e-20	6.67e-18	-0.4	-0.28	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
BRCA	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-9.51	1.33e-20	6.69e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
BRCA	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-9.51	1.33e-20	6.69e-18	-0.38	-0.28	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
BRCA	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	9.51	1.33e-20	6.7e-18	0.35	0.28	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-9.51	1.33e-20	6.7e-18	-0.34	-0.28	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-9.5	1.33e-20	6.71e-18	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
BRCA	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-9.5	1.33e-20	6.72e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-9.5	1.33e-20	6.72e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-9.5	1.33e-20	6.73e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	9.5	1.34e-20	6.74e-18	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
BRCA	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-9.5	1.34e-20	6.75e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
BRCA	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	9.5	1.34e-20	6.78e-18	0.33	0.28	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-9.5	1.35e-20	6.81e-18	-0.33	-0.28	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-9.5	1.36e-20	6.84e-18	-0.33	-0.28	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-9.5	1.36e-20	6.86e-18	-0.38	-0.28	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
BRCA	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	9.5	1.36e-20	6.88e-18	0.42	0.28	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
BRCA	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-9.5	1.37e-20	6.9e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
BRCA	cis	rs8062405	1	rs62036617	ENSG00000278665.1	RP11-666O2.4	9.5	1.37e-20	6.93e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-9.5	1.38e-20	6.96e-18	-0.31	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-9.5	1.38e-20	6.96e-18	-0.3	-0.28	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-9.5	1.38e-20	6.97e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
BRCA	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-9.5	1.39e-20	6.99e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	9.5	1.39e-20	7e-18	0.29	0.28	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
BRCA	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	9.5	1.39e-20	7.02e-18	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
BRCA	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-9.5	1.4e-20	7.03e-18	-0.4	-0.28	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-9.5	1.4e-20	7.05e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
BRCA	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	9.5	1.41e-20	7.08e-18	0.3	0.28	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	9.5	1.41e-20	7.09e-18	0.28	0.28	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
BRCA	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	9.5	1.41e-20	7.1e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	9.5	1.41e-20	7.1e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	9.5	1.42e-20	7.16e-18	0.3	0.28	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	9.5	1.42e-20	7.17e-18	0.33	0.28	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	9.5	1.43e-20	7.19e-18	0.35	0.28	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-9.5	1.43e-20	7.2e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	9.5	1.43e-20	7.21e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-9.5	1.44e-20	7.23e-18	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
BRCA	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-9.5	1.44e-20	7.24e-18	-0.37	-0.28	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
BRCA	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	9.5	1.44e-20	7.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
BRCA	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	9.5	1.44e-20	7.25e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
BRCA	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	9.5	1.44e-20	7.25e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	9.5	1.45e-20	7.27e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
BRCA	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-9.5	1.45e-20	7.29e-18	-0.37	-0.28	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
BRCA	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	9.49	1.46e-20	7.34e-18	0.33	0.28	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
BRCA	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	9.49	1.48e-20	7.44e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-9.49	1.48e-20	7.44e-18	-0.28	-0.28	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
BRCA	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-9.49	1.5e-20	7.51e-18	-0.35	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-9.49	1.5e-20	7.54e-18	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	9.49	1.51e-20	7.6e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
BRCA	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	9.49	1.52e-20	7.63e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	9.49	1.53e-20	7.66e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
BRCA	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	9.49	1.53e-20	7.67e-18	0.34	0.28	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
BRCA	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-9.49	1.53e-20	7.67e-18	-0.34	-0.28	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	9.49	1.53e-20	7.7e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
BRCA	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-9.49	1.53e-20	7.7e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-9.49	1.54e-20	7.7e-18	-0.33	-0.28	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
BRCA	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	9.49	1.54e-20	7.72e-18	0.29	0.28	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
BRCA	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-9.49	1.54e-20	7.72e-18	-0.33	-0.28	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-9.49	1.54e-20	7.72e-18	-0.33	-0.28	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
BRCA	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-9.49	1.54e-20	7.73e-18	-0.34	-0.28	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
BRCA	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	9.49	1.55e-20	7.76e-18	0.28	0.28	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
BRCA	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-9.49	1.56e-20	7.8e-18	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-9.49	1.56e-20	7.8e-18	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-9.49	1.56e-20	7.84e-18	-0.3	-0.28	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-9.49	1.56e-20	7.84e-18	-0.3	-0.28	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
BRCA	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	9.49	1.56e-20	7.84e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-9.49	1.57e-20	7.85e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	9.49	1.57e-20	7.86e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-9.49	1.57e-20	7.88e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	9.49	1.58e-20	7.9e-18	0.29	0.28	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	9.49	1.58e-20	7.9e-18	0.3	0.28	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
BRCA	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-9.48	1.59e-20	7.95e-18	-0.41	-0.28	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
BRCA	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-9.48	1.59e-20	7.95e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
BRCA	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	9.48	1.59e-20	7.96e-18	0.27	0.28	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-9.48	1.59e-20	7.96e-18	-0.32	-0.28	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-9.48	1.59e-20	7.96e-18	-0.32	-0.28	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-9.48	1.6e-20	8e-18	-0.29	-0.28	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	9.48	1.6e-20	8.03e-18	0.28	0.28	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
BRCA	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.48	1.61e-20	8.08e-18	-0.32	-0.28	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	9.48	1.61e-20	8.08e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
BRCA	cis	rs712022	0.837	rs2159668	ENSG00000246225.5	RP11-17A1.3	9.48	1.62e-20	8.12e-18	0.33	0.28	Dialysis-related mortality;	chr11:22817914	chr11:22829380~22945393:+
BRCA	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.48	1.62e-20	8.12e-18	-0.33	-0.28	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-9.48	1.62e-20	8.13e-18	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
BRCA	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	9.48	1.63e-20	8.15e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-9.48	1.63e-20	8.16e-18	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
BRCA	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-9.48	1.63e-20	8.16e-18	-0.33	-0.28	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-9.48	1.63e-20	8.16e-18	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
BRCA	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-9.48	1.64e-20	8.19e-18	-0.37	-0.28	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
BRCA	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-9.48	1.64e-20	8.19e-18	-0.33	-0.28	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
BRCA	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	9.48	1.64e-20	8.2e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
BRCA	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-9.48	1.64e-20	8.23e-18	-0.34	-0.28	Height;	chr2:231551270	chr2:231508426~231514339:-
BRCA	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	9.48	1.64e-20	8.23e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
BRCA	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	9.48	1.65e-20	8.24e-18	0.32	0.28	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
BRCA	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	9.48	1.65e-20	8.24e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	9.48	1.66e-20	8.29e-18	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
BRCA	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-9.48	1.66e-20	8.3e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
BRCA	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-9.48	1.67e-20	8.33e-18	-0.35	-0.28	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-9.48	1.68e-20	8.4e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
BRCA	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	9.48	1.69e-20	8.45e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	9.48	1.69e-20	8.46e-18	0.4	0.28	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	9.48	1.69e-20	8.47e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
BRCA	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-9.48	1.7e-20	8.49e-18	-0.39	-0.28	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	9.48	1.7e-20	8.51e-18	0.28	0.28	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
BRCA	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-9.48	1.71e-20	8.54e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-9.48	1.71e-20	8.54e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	9.48	1.71e-20	8.56e-18	0.33	0.28	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
BRCA	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-9.48	1.72e-20	8.59e-18	-0.3	-0.28	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
BRCA	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	9.48	1.72e-20	8.59e-18	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	9.48	1.72e-20	8.61e-18	0.28	0.28	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
BRCA	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-9.48	1.73e-20	8.65e-18	-0.31	-0.28	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
BRCA	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-9.47	1.74e-20	8.69e-18	-0.32	-0.28	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
BRCA	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	9.47	1.74e-20	8.7e-18	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
BRCA	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	9.47	1.75e-20	8.72e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
BRCA	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	9.47	1.75e-20	8.72e-18	0.42	0.28	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
BRCA	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	9.47	1.75e-20	8.76e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	9.47	1.75e-20	8.76e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
BRCA	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-9.47	1.76e-20	8.77e-18	-0.37	-0.28	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
BRCA	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	9.47	1.78e-20	8.88e-18	0.57	0.28	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
BRCA	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-9.47	1.78e-20	8.89e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-9.47	1.78e-20	8.9e-18	-0.32	-0.28	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	9.47	1.79e-20	8.92e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	9.47	1.79e-20	8.94e-18	0.28	0.28	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
BRCA	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-9.47	1.8e-20	8.96e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
BRCA	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	9.47	1.8e-20	9e-18	0.42	0.28	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	9.47	1.81e-20	9e-18	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
BRCA	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	9.47	1.81e-20	9.04e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	9.47	1.82e-20	9.06e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-9.47	1.82e-20	9.07e-18	-0.36	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-9.47	1.82e-20	9.08e-18	-0.27	-0.28	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-9.47	1.82e-20	9.09e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	9.47	1.83e-20	9.13e-18	0.28	0.28	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
BRCA	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-9.47	1.84e-20	9.15e-18	-0.58	-0.28	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
BRCA	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-9.47	1.84e-20	9.19e-18	-0.34	-0.28	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
BRCA	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-9.47	1.85e-20	9.2e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	9.47	1.85e-20	9.22e-18	0.32	0.28	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
BRCA	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-9.47	1.85e-20	9.22e-18	-0.36	-0.28	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
BRCA	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	9.47	1.85e-20	9.23e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-9.47	1.85e-20	9.23e-18	-0.38	-0.28	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
BRCA	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	9.47	1.85e-20	9.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-9.46	1.89e-20	9.43e-18	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	9.46	1.9e-20	9.44e-18	0.32	0.28	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
BRCA	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-9.46	1.9e-20	9.44e-18	-0.35	-0.28	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-9.46	1.9e-20	9.44e-18	-0.35	-0.28	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
BRCA	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	9.46	1.9e-20	9.48e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	9.46	1.9e-20	9.48e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
BRCA	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-9.46	1.91e-20	9.51e-18	-0.34	-0.28	Height;	chr2:231549981	chr2:231508426~231514339:-
BRCA	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-9.46	1.91e-20	9.52e-18	-0.4	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
BRCA	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	9.46	1.92e-20	9.55e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	9.46	1.92e-20	9.55e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	9.46	1.93e-20	9.59e-18	0.29	0.28	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000278665.1	RP11-666O2.4	9.46	1.94e-20	9.67e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000278665.1	RP11-666O2.4	9.46	1.94e-20	9.67e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28599241~28601881:-
BRCA	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	9.46	1.96e-20	9.77e-18	0.49	0.28	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000278665.1	RP11-666O2.4	9.46	1.97e-20	9.77e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28599241~28601881:-
BRCA	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	9.46	1.97e-20	9.77e-18	0.33	0.28	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
BRCA	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	9.46	1.97e-20	9.79e-18	0.33	0.28	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
BRCA	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-9.46	1.97e-20	9.81e-18	-0.32	-0.28	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	9.46	2e-20	9.93e-18	0.28	0.28	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
BRCA	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-9.46	2e-20	9.95e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
BRCA	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	9.46	2e-20	9.95e-18	0.32	0.28	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
BRCA	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-9.46	2.01e-20	9.97e-18	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
BRCA	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-9.46	2.01e-20	9.98e-18	-0.37	-0.28	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
BRCA	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	9.46	2.01e-20	1e-17	0.45	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
BRCA	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	9.46	2.01e-20	1e-17	0.3	0.28	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-9.46	2.02e-20	1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-9.46	2.02e-20	1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	9.46	2.06e-20	1.02e-17	0.33	0.28	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
BRCA	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-9.46	2.06e-20	1.02e-17	-0.36	-0.28	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
BRCA	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-9.46	2.06e-20	1.02e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
BRCA	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-9.46	2.06e-20	1.02e-17	-0.35	-0.28	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-9.45	2.07e-20	1.03e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
BRCA	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-9.45	2.08e-20	1.03e-17	-0.51	-0.28	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-9.45	2.08e-20	1.03e-17	-0.28	-0.28	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
BRCA	cis	rs2067615	0.56	rs1882542	ENSG00000260329.1	RP11-412D9.4	-9.45	2.09e-20	1.03e-17	-0.3	-0.28	Heart rate;	chr12:106676271	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-9.45	2.11e-20	1.04e-17	-0.29	-0.28	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
BRCA	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-9.45	2.11e-20	1.05e-17	-0.4	-0.28	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
BRCA	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-9.45	2.11e-20	1.05e-17	-0.33	-0.28	Height;	chr2:231541633	chr2:231508426~231514339:-
BRCA	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-9.45	2.12e-20	1.05e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
BRCA	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-9.45	2.12e-20	1.05e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
BRCA	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	9.45	2.13e-20	1.05e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
BRCA	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-9.45	2.13e-20	1.06e-17	-0.39	-0.28	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	9.45	2.14e-20	1.06e-17	0.32	0.28	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
BRCA	cis	rs4727443	0.899	rs6954978	ENSG00000235713.1	RP4-604G5.3	-9.45	2.14e-20	1.06e-17	-0.32	-0.28	Interstitial lung disease;	chr7:99984589	chr7:99992397~99993050:+
BRCA	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	9.45	2.15e-20	1.06e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
BRCA	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-9.45	2.15e-20	1.07e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
BRCA	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-9.45	2.16e-20	1.07e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-9.45	2.17e-20	1.07e-17	-0.29	-0.28	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	9.45	2.18e-20	1.08e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	9.45	2.18e-20	1.08e-17	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-9.45	2.2e-20	1.09e-17	-0.32	-0.28	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
BRCA	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-9.45	2.21e-20	1.09e-17	-0.58	-0.28	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	9.45	2.21e-20	1.09e-17	0.32	0.28	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
BRCA	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-9.45	2.21e-20	1.1e-17	-0.37	-0.28	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-9.45	2.23e-20	1.1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
BRCA	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-9.45	2.24e-20	1.11e-17	-0.46	-0.28	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
BRCA	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-9.45	2.24e-20	1.11e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	9.45	2.25e-20	1.11e-17	0.3	0.28	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	9.45	2.25e-20	1.11e-17	0.33	0.28	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
BRCA	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	9.45	2.25e-20	1.11e-17	0.31	0.28	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
BRCA	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-9.44	2.26e-20	1.12e-17	-0.33	-0.28	Height;	chr2:231539118	chr2:231508426~231514339:-
BRCA	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-9.44	2.26e-20	1.12e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	9.44	2.27e-20	1.13e-17	0.34	0.28	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
BRCA	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-9.44	2.27e-20	1.13e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-9.44	2.28e-20	1.13e-17	-0.32	-0.28	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	9.44	2.28e-20	1.13e-17	0.4	0.28	Depression;	chr6:28431469	chr6:28176188~28176674:+
BRCA	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.44	2.28e-20	1.13e-17	-0.26	-0.28	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	9.44	2.29e-20	1.13e-17	0.2	0.28	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
BRCA	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	9.44	2.3e-20	1.14e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	9.44	2.3e-20	1.14e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
BRCA	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	9.44	2.3e-20	1.14e-17	0.31	0.28	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-9.44	2.31e-20	1.14e-17	-0.32	-0.28	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	9.44	2.31e-20	1.14e-17	0.29	0.28	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	9.44	2.31e-20	1.14e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	9.44	2.31e-20	1.14e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
BRCA	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
BRCA	cis	rs13256369	0.708	rs11249886	ENSG00000253893.2	FAM85B	-9.44	2.33e-20	1.15e-17	-0.4	-0.28	Obesity-related traits;	chr8:8704511	chr8:8167819~8226614:-
BRCA	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-9.44	2.34e-20	1.16e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-9.44	2.34e-20	1.16e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
BRCA	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	9.44	2.36e-20	1.17e-17	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-9.44	2.37e-20	1.17e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
BRCA	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-9.44	2.38e-20	1.17e-17	-0.3	-0.28	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-9.44	2.38e-20	1.17e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-9.44	2.38e-20	1.17e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	9.44	2.38e-20	1.18e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-9.44	2.39e-20	1.18e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-9.44	2.39e-20	1.18e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
BRCA	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-9.44	2.39e-20	1.18e-17	-0.36	-0.28	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
BRCA	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-9.44	2.44e-20	1.2e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	9.44	2.44e-20	1.2e-17	0.29	0.28	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
BRCA	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-9.44	2.44e-20	1.2e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
BRCA	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-9.44	2.45e-20	1.21e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	9.44	2.46e-20	1.21e-17	0.33	0.28	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	9.44	2.46e-20	1.21e-17	0.33	0.28	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
BRCA	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	9.43	2.48e-20	1.22e-17	0.58	0.28	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	9.43	2.48e-20	1.22e-17	0.3	0.28	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
BRCA	cis	rs4862750	0.914	rs9995391	ENSG00000250971.1	RP11-696F12.1	-9.43	2.48e-20	1.23e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:187060099~187060930:+
BRCA	cis	rs8062405	1	rs62036620	ENSG00000278665.1	RP11-666O2.4	9.43	2.49e-20	1.23e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036621	ENSG00000278665.1	RP11-666O2.4	9.43	2.49e-20	1.23e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	9.43	2.51e-20	1.24e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-9.43	2.53e-20	1.25e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-9.43	2.53e-20	1.25e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
BRCA	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-9.43	2.53e-20	1.25e-17	-0.34	-0.28	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-9.43	2.55e-20	1.26e-17	-0.36	-0.28	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
BRCA	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-9.43	2.57e-20	1.26e-17	-0.36	-0.28	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	9.43	2.58e-20	1.27e-17	0.28	0.28	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	9.43	2.58e-20	1.27e-17	0.28	0.28	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	9.43	2.59e-20	1.27e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	9.43	2.59e-20	1.27e-17	0.33	0.28	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
BRCA	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-9.43	2.6e-20	1.28e-17	-0.34	-0.28	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
BRCA	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-9.43	2.61e-20	1.29e-17	-0.39	-0.28	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
BRCA	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	9.43	2.63e-20	1.29e-17	0.39	0.28	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-9.43	2.63e-20	1.3e-17	-0.3	-0.28	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
BRCA	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-9.43	2.64e-20	1.3e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
BRCA	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-9.43	2.64e-20	1.3e-17	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
BRCA	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-9.43	2.65e-20	1.3e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	9.43	2.66e-20	1.31e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000278665.1	RP11-666O2.4	9.43	2.67e-20	1.31e-17	0.28	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28599241~28601881:-
BRCA	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-9.43	2.67e-20	1.31e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-9.43	2.68e-20	1.32e-17	-0.32	-0.28	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	9.43	2.69e-20	1.32e-17	0.28	0.28	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
BRCA	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-9.42	2.69e-20	1.32e-17	-0.34	-0.28	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-9.42	2.71e-20	1.33e-17	-0.24	-0.28	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
BRCA	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-9.42	2.72e-20	1.34e-17	-0.33	-0.28	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	9.42	2.73e-20	1.34e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
BRCA	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	9.42	2.73e-20	1.34e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
BRCA	cis	rs6565180	0.963	rs4787642	ENSG00000273724.1	RP11-347C12.12	-9.42	2.74e-20	1.35e-17	-0.33	-0.28	Tonsillectomy;	chr16:30348087	chr16:30336400~30343336:+
BRCA	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-9.42	2.74e-20	1.35e-17	-0.33	-0.28	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
BRCA	cis	rs58873874	0.737	rs11749762	ENSG00000251405.2	CTB-109A12.1	9.42	2.74e-20	1.35e-17	0.67	0.28	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157362615~157460078:-
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	9.42	2.78e-20	1.36e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	9.42	2.8e-20	1.38e-17	0.19	0.28	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-9.42	2.82e-20	1.38e-17	-0.36	-0.28	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
BRCA	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-9.42	2.83e-20	1.39e-17	-0.34	-0.28	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-9.42	2.83e-20	1.39e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
BRCA	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.42	2.84e-20	1.39e-17	0.32	0.28	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
BRCA	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	9.42	2.87e-20	1.41e-17	0.32	0.28	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	9.42	2.87e-20	1.41e-17	0.32	0.28	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
BRCA	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	9.42	2.88e-20	1.41e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
BRCA	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	9.42	2.88e-20	1.41e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
BRCA	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	9.42	2.88e-20	1.41e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
BRCA	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-9.42	2.88e-20	1.41e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
BRCA	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-9.42	2.89e-20	1.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
BRCA	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	9.42	2.93e-20	1.44e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
BRCA	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	9.41	2.94e-20	1.44e-17	0.3	0.28	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	9.41	2.94e-20	1.44e-17	0.32	0.28	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	9.41	2.95e-20	1.44e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.579	rs1073261	ENSG00000260329.1	RP11-412D9.4	-9.41	2.95e-20	1.45e-17	-0.3	-0.28	Heart rate;	chr12:106742164	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	9.41	2.97e-20	1.46e-17	0.32	0.28	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	9.41	2.97e-20	1.46e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
BRCA	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-9.41	2.98e-20	1.46e-17	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-9.41	2.99e-20	1.46e-17	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
BRCA	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
BRCA	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	9.41	3e-20	1.47e-17	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
BRCA	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	9.41	3.01e-20	1.47e-17	0.27	0.28	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
BRCA	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-9.41	3.03e-20	1.48e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-9.41	3.03e-20	1.48e-17	-0.35	-0.28	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
BRCA	cis	rs2067615	0.579	rs10778510	ENSG00000260329.1	RP11-412D9.4	9.41	3.05e-20	1.49e-17	0.3	0.28	Heart rate;	chr12:106769187	chr12:106954029~106955497:-
BRCA	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-9.41	3.07e-20	1.5e-17	-0.34	-0.28	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	9.41	3.09e-20	1.51e-17	0.19	0.28	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
BRCA	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-9.41	3.1e-20	1.52e-17	-0.37	-0.28	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
BRCA	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	9.41	3.1e-20	1.52e-17	0.38	0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
BRCA	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	9.41	3.1e-20	1.52e-17	0.32	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	9.41	3.12e-20	1.52e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-9.41	3.12e-20	1.52e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
BRCA	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-9.41	3.12e-20	1.53e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
BRCA	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	9.41	3.12e-20	1.53e-17	0.31	0.28	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	9.41	3.12e-20	1.53e-17	0.4	0.28	Depression;	chr6:28428413	chr6:28176188~28176674:+
BRCA	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	9.41	3.12e-20	1.53e-17	0.35	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
BRCA	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	9.41	3.13e-20	1.53e-17	0.4	0.28	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-9.41	3.15e-20	1.54e-17	-0.32	-0.28	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	9.41	3.16e-20	1.54e-17	0.28	0.28	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-9.41	3.16e-20	1.54e-17	-0.31	-0.28	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
BRCA	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	9.41	3.16e-20	1.55e-17	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
BRCA	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	9.41	3.16e-20	1.55e-17	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
BRCA	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	9.41	3.16e-20	1.55e-17	0.32	0.28	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
BRCA	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	9.41	3.17e-20	1.55e-17	0.45	0.28	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
BRCA	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-9.41	3.17e-20	1.55e-17	-0.35	-0.28	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
BRCA	cis	rs13256369	0.802	rs11249887	ENSG00000253893.2	FAM85B	-9.41	3.17e-20	1.55e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704674	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-9.41	3.17e-20	1.55e-17	-0.29	-0.28	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
BRCA	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	9.41	3.19e-20	1.56e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
BRCA	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-9.41	3.19e-20	1.56e-17	-0.27	-0.28	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	9.41	3.2e-20	1.56e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-9.4	3.24e-20	1.58e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-9.4	3.25e-20	1.59e-17	-0.35	-0.28	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
BRCA	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	9.4	3.27e-20	1.6e-17	0.33	0.28	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	9.4	3.27e-20	1.6e-17	0.32	0.28	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-9.4	3.28e-20	1.6e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	9.4	3.29e-20	1.61e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	9.4	3.29e-20	1.61e-17	0.28	0.28	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	9.4	3.29e-20	1.61e-17	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	9.4	3.3e-20	1.61e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
BRCA	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	9.4	3.33e-20	1.62e-17	0.35	0.28	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
BRCA	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	9.4	3.33e-20	1.62e-17	0.35	0.28	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
BRCA	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	9.4	3.34e-20	1.63e-17	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
BRCA	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-9.4	3.35e-20	1.63e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-9.4	3.35e-20	1.63e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	9.4	3.36e-20	1.64e-17	0.32	0.28	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	9.4	3.36e-20	1.64e-17	0.33	0.28	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	9.4	3.36e-20	1.64e-17	0.28	0.28	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
BRCA	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-9.4	3.4e-20	1.66e-17	-0.35	-0.28	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
BRCA	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	9.4	3.42e-20	1.67e-17	0.29	0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
BRCA	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-9.4	3.44e-20	1.67e-17	-0.34	-0.28	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	9.4	3.44e-20	1.67e-17	0.28	0.28	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
BRCA	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-9.4	3.45e-20	1.68e-17	-0.36	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
BRCA	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-9.4	3.46e-20	1.69e-17	-0.34	-0.28	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.524	rs1882543	ENSG00000260329.1	RP11-412D9.4	9.4	3.47e-20	1.69e-17	0.31	0.28	Heart rate;	chr12:106673382	chr12:106954029~106955497:-
BRCA	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	9.4	3.47e-20	1.69e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
BRCA	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-9.4	3.47e-20	1.69e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-9.4	3.47e-20	1.69e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
BRCA	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	9.4	3.48e-20	1.7e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
BRCA	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-9.4	3.49e-20	1.7e-17	-0.32	-0.28	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
BRCA	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	9.4	3.49e-20	1.7e-17	0.3	0.28	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
BRCA	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	9.4	3.49e-20	1.7e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
BRCA	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	9.4	3.49e-20	1.7e-17	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-9.39	3.52e-20	1.71e-17	-0.28	-0.28	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
BRCA	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	9.39	3.52e-20	1.72e-17	0.37	0.28	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.28	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28599241~28601881:-
BRCA	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-9.39	3.54e-20	1.72e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
BRCA	cis	rs8062405	1	rs55991577	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs56358680	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28599241~28601881:-
BRCA	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
BRCA	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-9.39	3.55e-20	1.73e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
BRCA	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	9.39	3.57e-20	1.73e-17	0.35	0.28	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-9.39	3.59e-20	1.74e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-9.39	3.59e-20	1.74e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
BRCA	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	9.39	3.6e-20	1.75e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	9.39	3.6e-20	1.75e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
BRCA	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	9.39	3.61e-20	1.75e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	9.39	3.62e-20	1.76e-17	0.33	0.28	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-9.39	3.62e-20	1.76e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	9.39	3.66e-20	1.78e-17	0.32	0.28	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
BRCA	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-9.39	3.66e-20	1.78e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
BRCA	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	9.39	3.67e-20	1.78e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
BRCA	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	9.39	3.67e-20	1.79e-17	0.42	0.28	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
BRCA	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
BRCA	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	9.39	3.71e-20	1.8e-17	0.32	0.28	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	9.39	3.73e-20	1.81e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	9.39	3.73e-20	1.81e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	9.39	3.73e-20	1.81e-17	0.32	0.28	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	9.39	3.74e-20	1.82e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
BRCA	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-9.39	3.76e-20	1.82e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
BRCA	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-9.39	3.77e-20	1.83e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
BRCA	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-9.39	3.79e-20	1.84e-17	-0.33	-0.28	Height;	chr2:231543307	chr2:231508426~231514339:-
BRCA	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-9.39	3.82e-20	1.85e-17	-0.37	-0.28	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	9.38	3.82e-20	1.86e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
BRCA	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-9.38	3.83e-20	1.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-9.38	3.83e-20	1.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-9.38	3.86e-20	1.87e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-9.38	3.86e-20	1.87e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
BRCA	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-9.38	3.86e-20	1.87e-17	-0.4	-0.28	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-9.38	3.87e-20	1.88e-17	-0.35	-0.28	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
BRCA	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-9.38	3.89e-20	1.89e-17	-0.36	-0.28	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-9.38	3.89e-20	1.89e-17	-0.32	-0.28	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
BRCA	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	9.38	3.91e-20	1.89e-17	0.32	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	9.38	3.91e-20	1.89e-17	0.32	0.28	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
BRCA	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-9.38	3.91e-20	1.9e-17	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
BRCA	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	9.38	3.97e-20	1.92e-17	0.32	0.28	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	9.38	3.97e-20	1.92e-17	0.32	0.28	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	9.38	3.97e-20	1.92e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
BRCA	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	9.38	3.98e-20	1.93e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-9.38	3.98e-20	1.93e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
BRCA	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	9.38	4.01e-20	1.94e-17	0.37	0.28	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
BRCA	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-9.38	4.02e-20	1.95e-17	-0.33	-0.28	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
BRCA	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-9.38	4.05e-20	1.96e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	9.38	4.07e-20	1.97e-17	0.26	0.28	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-9.38	4.08e-20	1.98e-17	-0.36	-0.28	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
BRCA	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	9.38	4.09e-20	1.98e-17	0.32	0.28	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000278665.1	RP11-666O2.4	9.38	4.11e-20	1.99e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000278665.1	RP11-666O2.4	9.38	4.11e-20	1.99e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-9.38	4.12e-20	1.99e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	9.38	4.13e-20	2e-17	0.31	0.28	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
BRCA	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	9.38	4.15e-20	2.01e-17	0.58	0.28	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
BRCA	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-9.37	4.17e-20	2.02e-17	-0.34	-0.28	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
BRCA	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-9.37	4.17e-20	2.02e-17	-0.32	-0.28	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
BRCA	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	9.37	4.19e-20	2.03e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-9.37	4.22e-20	2.04e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	9.37	4.24e-20	2.05e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
BRCA	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	9.37	4.24e-20	2.05e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	9.37	4.28e-20	2.07e-17	0.28	0.28	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	9.37	4.28e-20	2.07e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000278665.1	RP11-666O2.4	9.37	4.3e-20	2.08e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28599241~28601881:-
BRCA	cis	rs56163509	1	rs56163509	ENSG00000278665.1	RP11-666O2.4	9.37	4.3e-20	2.08e-17	0.32	0.28	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-9.37	4.3e-20	2.08e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
BRCA	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-9.37	4.3e-20	2.08e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	9.37	4.32e-20	2.09e-17	0.32	0.28	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
BRCA	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-9.37	4.33e-20	2.09e-17	-0.52	-0.28	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
BRCA	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-9.37	4.33e-20	2.09e-17	-0.52	-0.28	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-9.37	4.35e-20	2.1e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
BRCA	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-9.37	4.35e-20	2.11e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
BRCA	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-9.37	4.35e-20	2.11e-17	-0.33	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
BRCA	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-9.37	4.36e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-9.37	4.36e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	9.37	4.36e-20	2.11e-17	0.3	0.28	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
BRCA	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-9.37	4.36e-20	2.11e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-9.37	4.37e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
BRCA	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-9.37	4.38e-20	2.12e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-9.37	4.4e-20	2.13e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000278665.1	RP11-666O2.4	9.37	4.43e-20	2.14e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28599241~28601881:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	9.37	4.44e-20	2.14e-17	0.29	0.28	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
BRCA	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-9.37	4.46e-20	2.16e-17	-0.32	-0.28	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-9.37	4.47e-20	2.16e-17	-0.35	-0.28	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
BRCA	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-9.37	4.47e-20	2.16e-17	-0.4	-0.28	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
BRCA	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-9.37	4.5e-20	2.17e-17	-0.35	-0.28	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-9.37	4.54e-20	2.19e-17	-0.35	-0.28	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
BRCA	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	9.37	4.54e-20	2.19e-17	0.43	0.28	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-9.36	4.58e-20	2.21e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
BRCA	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	9.36	4.62e-20	2.23e-17	0.35	0.28	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
BRCA	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	9.36	4.62e-20	2.23e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
BRCA	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	9.36	4.65e-20	2.24e-17	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
BRCA	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-9.36	4.68e-20	2.26e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
BRCA	cis	rs13256369	0.755	rs12680167	ENSG00000253893.2	FAM85B	-9.36	4.7e-20	2.27e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704957	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	9.36	4.7e-20	2.27e-17	0.34	0.28	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-9.36	4.73e-20	2.28e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	9.36	4.76e-20	2.3e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	9.36	4.76e-20	2.3e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
BRCA	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	9.36	4.76e-20	2.3e-17	0.36	0.28	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
BRCA	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	9.36	4.79e-20	2.31e-17	0.34	0.28	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
BRCA	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	9.36	4.79e-20	2.31e-17	0.34	0.28	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	9.36	4.81e-20	2.32e-17	0.33	0.28	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-9.36	4.84e-20	2.33e-17	-0.33	-0.28	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
BRCA	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-9.36	4.84e-20	2.33e-17	-0.27	-0.28	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
BRCA	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	9.36	4.84e-20	2.33e-17	0.32	0.28	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
BRCA	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-9.36	4.84e-20	2.33e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-9.36	4.84e-20	2.33e-17	-0.32	-0.28	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
BRCA	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-9.36	4.86e-20	2.34e-17	-0.37	-0.28	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	9.36	4.87e-20	2.34e-17	0.33	0.28	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	9.36	4.87e-20	2.35e-17	0.32	0.28	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	9.36	4.89e-20	2.35e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	9.36	4.89e-20	2.35e-17	0.32	0.28	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
BRCA	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	9.36	4.9e-20	2.36e-17	0.34	0.28	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
BRCA	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-9.36	4.9e-20	2.36e-17	-0.34	-0.28	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
BRCA	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
BRCA	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	9.36	4.91e-20	2.36e-17	0.34	0.28	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
BRCA	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-9.36	4.92e-20	2.37e-17	-0.32	-0.28	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-9.36	4.92e-20	2.37e-17	-0.32	-0.28	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
BRCA	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	9.36	4.93e-20	2.37e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	9.36	4.94e-20	2.38e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
BRCA	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-9.36	4.94e-20	2.38e-17	-0.37	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
BRCA	cis	rs4237845	0.611	rs4583019	ENSG00000257159.1	RP11-58A17.3	9.36	4.95e-20	2.38e-17	0.33	0.28	Intelligence (multi-trait analysis);	chr12:57922962	chr12:57967058~57968399:+
BRCA	cis	rs8062405	1	rs12446589	ENSG00000278665.1	RP11-666O2.4	9.35	4.99e-20	2.4e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28599241~28601881:-
BRCA	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	9.35	5.01e-20	2.41e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	9.35	5.02e-20	2.41e-17	0.33	0.28	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-9.35	5.04e-20	2.42e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
BRCA	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	9.35	5.07e-20	2.44e-17	0.44	0.28	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	9.35	5.07e-20	2.44e-17	0.44	0.28	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
BRCA	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	9.35	5.1e-20	2.45e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
BRCA	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-9.35	5.13e-20	2.47e-17	-0.33	-0.28	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
BRCA	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	9.35	5.14e-20	2.47e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
BRCA	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-9.35	5.19e-20	2.49e-17	-0.37	-0.28	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
BRCA	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	9.35	5.22e-20	2.51e-17	0.42	0.28	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	9.35	5.22e-20	2.51e-17	0.28	0.28	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	9.35	5.22e-20	2.51e-17	0.28	0.28	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	9.35	5.27e-20	2.53e-17	0.4	0.28	Depression;	chr6:28430971	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	9.35	5.27e-20	2.53e-17	0.4	0.28	Depression;	chr6:28432562	chr6:28176188~28176674:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-9.35	5.27e-20	2.53e-17	-0.32	-0.28	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
BRCA	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	9.35	5.3e-20	2.54e-17	0.34	0.28	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
BRCA	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	9.35	5.33e-20	2.56e-17	0.32	0.28	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	9.35	5.36e-20	2.57e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	9.35	5.37e-20	2.58e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
BRCA	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	9.35	5.39e-20	2.59e-17	0.25	0.28	Asthma;	chr2:102446466	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	9.35	5.39e-20	2.59e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
BRCA	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	9.35	5.39e-20	2.59e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
BRCA	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	9.35	5.4e-20	2.59e-17	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-9.34	5.49e-20	2.63e-17	-0.28	-0.28	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
BRCA	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
BRCA	cis	rs2067615	0.579	rs10861667	ENSG00000260329.1	RP11-412D9.4	-9.34	5.57e-20	2.67e-17	-0.3	-0.28	Heart rate;	chr12:106800998	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.5	rs11113116	ENSG00000260329.1	RP11-412D9.4	-9.34	5.57e-20	2.67e-17	-0.3	-0.28	Total body bone mineral density;	chr12:106802151	chr12:106954029~106955497:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-9.34	5.57e-20	2.67e-17	-0.5	-0.28	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-9.34	5.57e-20	2.67e-17	-0.36	-0.28	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
BRCA	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	9.34	5.58e-20	2.68e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	9.34	5.58e-20	2.68e-17	0.32	0.28	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
BRCA	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	9.34	5.63e-20	2.7e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	9.34	5.64e-20	2.7e-17	0.29	0.28	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-9.34	5.67e-20	2.72e-17	-0.41	-0.28	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
BRCA	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-9.34	5.71e-20	2.73e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	9.34	5.71e-20	2.74e-17	0.28	0.28	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-9.34	5.72e-20	2.74e-17	-0.44	-0.28	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
BRCA	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	9.34	5.74e-20	2.75e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
BRCA	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-9.34	5.74e-20	2.75e-17	-0.41	-0.28	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-9.34	5.74e-20	2.75e-17	-0.41	-0.28	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
BRCA	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
BRCA	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-9.34	5.8e-20	2.78e-17	-0.35	-0.28	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-9.34	5.83e-20	2.79e-17	-0.35	-0.28	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	9.34	5.83e-20	2.79e-17	0.32	0.28	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
BRCA	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-9.34	5.83e-20	2.79e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-9.34	5.83e-20	2.79e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
BRCA	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-9.34	5.85e-20	2.8e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	9.34	5.87e-20	2.81e-17	0.29	0.28	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-9.34	5.88e-20	2.81e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
BRCA	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	9.34	5.9e-20	2.82e-17	0.38	0.28	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
BRCA	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-9.34	5.9e-20	2.82e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
BRCA	cis	rs2067615	0.579	rs10778509	ENSG00000260329.1	RP11-412D9.4	-9.34	5.91e-20	2.83e-17	-0.3	-0.28	Heart rate;	chr12:106769140	chr12:106954029~106955497:-
BRCA	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-9.33	5.92e-20	2.83e-17	-0.36	-0.28	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
BRCA	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
BRCA	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-9.33	5.94e-20	2.84e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-9.33	5.98e-20	2.86e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-9.33	6e-20	2.87e-17	-0.36	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
BRCA	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	9.33	6.01e-20	2.88e-17	0.26	0.28	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	9.33	6.06e-20	2.9e-17	0.34	0.28	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
BRCA	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
BRCA	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	9.33	6.09e-20	2.91e-17	0.32	0.28	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	9.33	6.09e-20	2.91e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
BRCA	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	9.33	6.12e-20	2.92e-17	0.39	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-9.33	6.13e-20	2.93e-17	-0.29	-0.28	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
BRCA	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	9.33	6.16e-20	2.94e-17	0.32	0.28	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
BRCA	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	9.33	6.17e-20	2.95e-17	0.31	0.28	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
BRCA	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	9.33	6.21e-20	2.97e-17	0.35	0.28	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
BRCA	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-9.33	6.23e-20	2.97e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
BRCA	cis	rs4862750	0.624	rs34414639	ENSG00000250971.1	RP11-696F12.1	9.33	6.25e-20	2.99e-17	0.3	0.28	Lobe attachment (rater-scored or self-reported);	chr4:186952263	chr4:187060099~187060930:+
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000278665.1	RP11-666O2.4	9.33	6.26e-20	2.99e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28599241~28601881:-
BRCA	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	9.33	6.27e-20	2.99e-17	0.56	0.28	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	9.33	6.27e-20	2.99e-17	0.56	0.28	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	9.33	6.27e-20	2.99e-17	0.29	0.28	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-9.33	6.28e-20	3e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
BRCA	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	9.33	6.32e-20	3.02e-17	0.4	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
BRCA	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-9.33	6.34e-20	3.02e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	9.33	6.34e-20	3.03e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	9.33	6.35e-20	3.03e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	9.33	6.36e-20	3.03e-17	0.34	0.28	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
BRCA	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-9.33	6.38e-20	3.04e-17	-0.29	-0.28	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
BRCA	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	9.33	6.38e-20	3.04e-17	0.32	0.28	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-9.32	6.45e-20	3.08e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	9.32	6.5e-20	3.1e-17	0.37	0.28	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
BRCA	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	9.32	6.52e-20	3.11e-17	0.32	0.28	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	9.32	6.52e-20	3.11e-17	0.32	0.28	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
BRCA	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-9.32	6.52e-20	3.11e-17	-0.26	-0.28	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
BRCA	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-9.32	6.57e-20	3.13e-17	-0.35	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
BRCA	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-9.32	6.6e-20	3.14e-17	-0.29	-0.28	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
BRCA	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	9.32	6.6e-20	3.15e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-9.32	6.61e-20	3.15e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
BRCA	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	9.32	6.63e-20	3.16e-17	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-9.32	6.63e-20	3.16e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-9.32	6.63e-20	3.16e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
BRCA	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-9.32	6.69e-20	3.19e-17	-0.36	-0.28	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
BRCA	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-9.32	6.71e-20	3.2e-17	-0.57	-0.28	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000278665.1	RP11-666O2.4	9.32	6.75e-20	3.21e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036624	ENSG00000278665.1	RP11-666O2.4	9.32	6.75e-20	3.21e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	9.32	6.78e-20	3.23e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
BRCA	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	9.32	6.79e-20	3.23e-17	0.34	0.28	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	9.32	6.8e-20	3.24e-17	0.33	0.28	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
BRCA	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	9.32	6.88e-20	3.27e-17	0.34	0.28	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
BRCA	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	9.32	6.89e-20	3.28e-17	0.35	0.28	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
BRCA	cis	rs2221433	1	rs1110269	ENSG00000260310.1	RP11-27M24.2	-9.32	6.92e-20	3.29e-17	-0.33	-0.28	Eating disorders;	chr16:10578731	chr16:10576499~10578183:-
BRCA	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	9.32	6.96e-20	3.31e-17	0.34	0.28	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
BRCA	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	9.32	6.99e-20	3.32e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	9.32	6.99e-20	3.32e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-9.32	6.99e-20	3.32e-17	-0.29	-0.28	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	9.32	7.01e-20	3.33e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	9.32	7.03e-20	3.34e-17	0.34	0.28	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.802	rs13281933	ENSG00000253893.2	FAM85B	-9.31	7.04e-20	3.35e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705155	chr8:8167819~8226614:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-9.31	7.09e-20	3.37e-17	-0.32	-0.28	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	9.31	7.09e-20	3.37e-17	0.33	0.28	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-9.31	7.11e-20	3.38e-17	-0.33	-0.28	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
BRCA	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-9.31	7.12e-20	3.38e-17	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	9.31	7.16e-20	3.4e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
BRCA	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	9.31	7.17e-20	3.41e-17	0.4	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-9.31	7.21e-20	3.43e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-9.31	7.21e-20	3.43e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
BRCA	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-9.31	7.23e-20	3.43e-17	-0.32	-0.28	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
BRCA	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	9.31	7.25e-20	3.44e-17	0.31	0.28	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
BRCA	cis	rs858239	0.536	rs6956974	ENSG00000226816.2	AC005082.12	-9.31	7.25e-20	3.44e-17	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23206013~23208045:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
BRCA	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-9.31	7.33e-20	3.48e-17	-0.57	-0.28	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
BRCA	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	9.31	7.34e-20	3.48e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
BRCA	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-9.31	7.34e-20	3.49e-17	-0.33	-0.28	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
BRCA	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-9.31	7.35e-20	3.49e-17	-0.32	-0.28	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
BRCA	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	9.31	7.37e-20	3.5e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	9.31	7.4e-20	3.51e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
BRCA	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	9.31	7.41e-20	3.52e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
BRCA	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-9.31	7.42e-20	3.52e-17	-0.31	-0.28	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
BRCA	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-9.31	7.43e-20	3.53e-17	-0.37	-0.28	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
BRCA	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	9.31	7.44e-20	3.53e-17	0.32	0.28	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-9.31	7.44e-20	3.53e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
BRCA	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	9.31	7.46e-20	3.54e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-9.31	7.48e-20	3.55e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
BRCA	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-9.31	7.53e-20	3.57e-17	-0.3	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
BRCA	cis	rs2067615	0.579	rs7964605	ENSG00000260329.1	RP11-412D9.4	9.31	7.54e-20	3.58e-17	0.3	0.28	Heart rate;	chr12:106811635	chr12:106954029~106955497:-
BRCA	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-9.31	7.55e-20	3.58e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
BRCA	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-9.31	7.6e-20	3.6e-17	-0.35	-0.28	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
BRCA	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	9.31	7.6e-20	3.6e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	9.31	7.6e-20	3.6e-17	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
BRCA	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-9.31	7.62e-20	3.61e-17	-0.35	-0.28	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
BRCA	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	9.3	7.68e-20	3.64e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs2008514	ENSG00000278665.1	RP11-666O2.4	-9.3	7.7e-20	3.65e-17	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	9.3	7.7e-20	3.65e-17	0.32	0.28	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
BRCA	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	9.3	7.73e-20	3.66e-17	0.33	0.28	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
BRCA	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	9.3	7.73e-20	3.66e-17	0.34	0.28	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
BRCA	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	9.3	7.76e-20	3.68e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-9.3	7.77e-20	3.68e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
BRCA	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-9.3	7.77e-20	3.68e-17	-0.32	-0.28	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	9.3	7.82e-20	3.71e-17	0.35	0.28	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	9.3	7.85e-20	3.72e-17	0.33	0.28	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
BRCA	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-9.3	7.86e-20	3.72e-17	-0.3	-0.28	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
BRCA	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	9.3	7.86e-20	3.72e-17	0.25	0.28	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
BRCA	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	9.3	7.87e-20	3.73e-17	0.34	0.28	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
BRCA	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-9.3	7.88e-20	3.73e-17	-0.32	-0.28	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
BRCA	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	9.3	7.89e-20	3.74e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-9.3	7.91e-20	3.74e-17	-0.26	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
BRCA	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	9.3	7.98e-20	3.78e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-9.3	7.98e-20	3.78e-17	-0.32	-0.28	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-9.3	8.01e-20	3.79e-17	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
BRCA	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	9.3	8.03e-20	3.8e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	9.3	8.03e-20	3.8e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
BRCA	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	9.3	8.04e-20	3.8e-17	0.31	0.28	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
BRCA	cis	rs13256369	0.851	rs11786125	ENSG00000253893.2	FAM85B	-9.3	8.06e-20	3.82e-17	-0.39	-0.28	Obesity-related traits;	chr8:8707060	chr8:8167819~8226614:-
BRCA	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-9.3	8.1e-20	3.83e-17	-0.35	-0.28	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
BRCA	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	9.3	8.12e-20	3.84e-17	0.32	0.28	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
BRCA	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-9.3	8.14e-20	3.85e-17	-0.35	-0.28	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	9.3	8.15e-20	3.86e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-9.3	8.16e-20	3.86e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-9.3	8.17e-20	3.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	9.3	8.17e-20	3.87e-17	0.33	0.28	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
BRCA	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	9.3	8.18e-20	3.87e-17	0.34	0.28	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
BRCA	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	9.3	8.19e-20	3.87e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	9.3	8.21e-20	3.88e-17	0.25	0.28	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
BRCA	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	9.3	8.23e-20	3.89e-17	0.32	0.28	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
BRCA	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	9.3	8.25e-20	3.9e-17	0.28	0.28	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
BRCA	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	9.3	8.31e-20	3.93e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
BRCA	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-9.3	8.32e-20	3.93e-17	-0.32	-0.28	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-9.3	8.35e-20	3.95e-17	-0.32	-0.28	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
BRCA	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	9.3	8.36e-20	3.95e-17	0.44	0.28	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
BRCA	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	9.29	8.45e-20	3.99e-17	0.28	0.28	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	9.29	8.46e-20	4e-17	0.39	0.28	Depression;	chr6:28242515	chr6:28073316~28074233:+
BRCA	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-9.29	8.46e-20	4e-17	-0.32	-0.28	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-9.29	8.46e-20	4e-17	-0.32	-0.28	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
BRCA	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
BRCA	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	9.29	8.48e-20	4e-17	0.29	0.28	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
BRCA	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	9.29	8.49e-20	4.01e-17	0.31	0.28	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	9.29	8.56e-20	4.04e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	9.29	8.57e-20	4.04e-17	0.32	0.28	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
BRCA	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	9.29	8.57e-20	4.05e-17	0.26	0.28	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
BRCA	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-9.29	8.61e-20	4.06e-17	-0.32	-0.28	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
BRCA	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	9.29	8.65e-20	4.08e-17	0.36	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-9.29	8.69e-20	4.1e-17	-0.32	-0.28	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
BRCA	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	9.29	8.74e-20	4.12e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
BRCA	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-9.29	8.77e-20	4.14e-17	-0.32	-0.28	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-9.29	8.77e-20	4.14e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
BRCA	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-9.29	8.79e-20	4.14e-17	-0.36	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
BRCA	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	9.29	8.79e-20	4.15e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
BRCA	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-9.29	8.83e-20	4.16e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
BRCA	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	9.29	8.88e-20	4.19e-17	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
BRCA	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-9.29	8.98e-20	4.23e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
BRCA	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-9.29	8.99e-20	4.24e-17	-0.32	-0.28	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
BRCA	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	9.29	9.01e-20	4.24e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-9.29	9.06e-20	4.27e-17	-0.33	-0.28	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
BRCA	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
BRCA	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
BRCA	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	9.29	9.11e-20	4.29e-17	0.29	0.28	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	9.29	9.11e-20	4.29e-17	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
BRCA	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-9.29	9.12e-20	4.3e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	9.28	9.13e-20	4.3e-17	0.34	0.28	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	9.28	9.13e-20	4.3e-17	0.34	0.28	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
BRCA	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-9.28	9.17e-20	4.32e-17	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.28	9.18e-20	4.32e-17	-0.26	-0.28	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
BRCA	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-9.28	9.2e-20	4.33e-17	-0.3	-0.28	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
BRCA	cis	rs4862750	0.914	rs1346127	ENSG00000250971.1	RP11-696F12.1	-9.28	9.23e-20	4.35e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186955235	chr4:187060099~187060930:+
BRCA	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-9.28	9.24e-20	4.35e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-9.28	9.25e-20	4.36e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
BRCA	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	9.28	9.27e-20	4.36e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-9.28	9.29e-20	4.37e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
BRCA	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-9.28	9.3e-20	4.38e-17	-0.32	-0.28	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	9.28	9.32e-20	4.39e-17	0.32	0.28	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-9.28	9.41e-20	4.43e-17	-0.32	-0.28	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	9.28	9.43e-20	4.44e-17	0.27	0.28	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	9.28	9.44e-20	4.44e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
BRCA	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
BRCA	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-9.28	9.53e-20	4.48e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
BRCA	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-9.28	9.54e-20	4.49e-17	-0.35	-0.28	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	9.28	9.54e-20	4.49e-17	0.35	0.28	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
BRCA	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	9.28	9.55e-20	4.49e-17	0.43	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
BRCA	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	9.28	9.59e-20	4.51e-17	0.32	0.28	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	9.28	9.69e-20	4.56e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-9.28	9.81e-20	4.61e-17	-0.35	-0.28	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
BRCA	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	9.28	9.83e-20	4.62e-17	0.39	0.28	Depression;	chr6:28242910	chr6:28073316~28074233:+
BRCA	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	9.28	9.84e-20	4.62e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
BRCA	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-9.28	9.86e-20	4.64e-17	-0.26	-0.28	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
BRCA	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-9.28	9.91e-20	4.66e-17	-0.36	-0.28	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
BRCA	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	9.28	9.92e-20	4.66e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
BRCA	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-9.28	9.95e-20	4.67e-17	-0.32	-0.28	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-9.27	9.95e-20	4.68e-17	-0.29	-0.28	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.755	rs12550057	ENSG00000253893.2	FAM85B	-9.27	9.99e-20	4.69e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704758	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	9.27	1e-19	4.71e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	9.27	1.01e-19	4.72e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	9.27	1.01e-19	4.74e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
BRCA	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	9.27	1.01e-19	4.75e-17	0.33	0.28	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma;	chr2:102427407	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma;	chr2:102427715	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-9.27	1.02e-19	4.77e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
BRCA	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-9.27	1.02e-19	4.77e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
BRCA	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-9.27	1.02e-19	4.81e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	9.27	1.03e-19	4.82e-17	0.32	0.28	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	9.27	1.03e-19	4.84e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-9.27	1.03e-19	4.85e-17	-0.26	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
BRCA	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-9.27	1.04e-19	4.86e-17	-0.56	-0.28	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-9.27	1.04e-19	4.86e-17	-0.26	-0.28	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
BRCA	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-9.27	1.04e-19	4.88e-17	-0.25	-0.28	Asthma;	chr2:102374909	chr2:102438713~102440475:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000278665.1	RP11-666O2.4	9.27	1.04e-19	4.88e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-9.27	1.04e-19	4.9e-17	-0.33	-0.28	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
BRCA	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-9.27	1.05e-19	4.91e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-9.27	1.05e-19	4.91e-17	-0.33	-0.28	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
BRCA	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-9.27	1.05e-19	4.91e-17	-0.39	-0.28	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
BRCA	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	9.27	1.05e-19	4.91e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	9.27	1.05e-19	4.91e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	9.27	1.05e-19	4.93e-17	0.35	0.28	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
BRCA	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-9.27	1.05e-19	4.94e-17	-0.28	-0.28	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
BRCA	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-9.27	1.06e-19	4.98e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-9.27	1.06e-19	4.98e-17	-0.33	-0.28	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
BRCA	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-9.27	1.07e-19	4.99e-17	-0.39	-0.28	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
BRCA	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-9.27	1.07e-19	5.01e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
BRCA	cis	rs5751614	0.537	rs3788358	ENSG00000230701.2	FBXW4P1	9.27	1.08e-19	5.04e-17	0.35	0.28	Height;	chr22:23274168	chr22:23262767~23265005:+
BRCA	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	9.27	1.08e-19	5.04e-17	0.37	0.28	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
BRCA	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	9.27	1.08e-19	5.06e-17	0.28	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
BRCA	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	9.27	1.08e-19	5.06e-17	0.48	0.28	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
BRCA	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-9.27	1.08e-19	5.07e-17	-0.35	-0.28	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
BRCA	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	9.27	1.08e-19	5.07e-17	0.29	0.28	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	9.27	1.08e-19	5.08e-17	0.25	0.28	Asthma;	chr2:102437614	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-9.26	1.09e-19	5.11e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	9.26	1.1e-19	5.13e-17	0.33	0.28	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
BRCA	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	9.26	1.1e-19	5.14e-17	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
BRCA	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	9.26	1.1e-19	5.16e-17	0.26	0.28	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	9.26	1.1e-19	5.17e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-9.26	1.11e-19	5.18e-17	-0.37	-0.28	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
BRCA	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	9.26	1.11e-19	5.2e-17	0.31	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
BRCA	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	9.26	1.12e-19	5.22e-17	0.38	0.28	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	9.26	1.12e-19	5.22e-17	0.19	0.28	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
BRCA	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-9.26	1.12e-19	5.23e-17	-0.32	-0.28	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
BRCA	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	9.26	1.12e-19	5.24e-17	0.26	0.28	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
BRCA	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-9.26	1.12e-19	5.25e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	9.26	1.13e-19	5.28e-17	0.31	0.28	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
BRCA	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-9.26	1.13e-19	5.28e-17	-0.32	-0.28	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
BRCA	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102431747	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102432120	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102432614	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102433405	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-9.26	1.13e-19	5.3e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-9.26	1.14e-19	5.33e-17	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-9.26	1.14e-19	5.33e-17	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	9.26	1.14e-19	5.34e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	9.26	1.14e-19	5.34e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	9.26	1.14e-19	5.35e-17	0.28	0.28	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
BRCA	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	9.26	1.15e-19	5.37e-17	0.25	0.28	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	9.26	1.15e-19	5.38e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	9.26	1.15e-19	5.38e-17	0.32	0.28	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-9.26	1.15e-19	5.38e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-9.26	1.15e-19	5.39e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-9.26	1.15e-19	5.39e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
BRCA	cis	rs4237845	0.611	rs7298370	ENSG00000257159.1	RP11-58A17.3	9.26	1.15e-19	5.39e-17	0.33	0.28	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57967058~57968399:+
BRCA	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	9.26	1.15e-19	5.4e-17	0.38	0.28	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
BRCA	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	9.26	1.16e-19	5.4e-17	0.32	0.28	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
BRCA	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	9.26	1.16e-19	5.43e-17	0.31	0.28	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	9.26	1.16e-19	5.43e-17	0.31	0.28	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
BRCA	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.45e-17	0.25	0.28	Asthma;	chr2:102423587	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.45e-17	0.25	0.28	Asthma;	chr2:102423717	chr2:102438713~102440475:+
BRCA	cis	rs13256369	0.951	rs13259955	ENSG00000253893.2	FAM85B	-9.26	1.17e-19	5.46e-17	-0.39	-0.28	Obesity-related traits;	chr8:8708375	chr8:8167819~8226614:-
BRCA	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-9.26	1.17e-19	5.49e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
BRCA	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.49e-17	0.25	0.28	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
BRCA	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-9.26	1.18e-19	5.49e-17	-0.3	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-9.26	1.18e-19	5.49e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
BRCA	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	9.26	1.18e-19	5.5e-17	0.26	0.28	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
BRCA	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	9.26	1.18e-19	5.52e-17	0.31	0.28	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
BRCA	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	9.25	1.19e-19	5.54e-17	0.31	0.28	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
BRCA	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-9.25	1.19e-19	5.56e-17	-0.4	-0.28	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
BRCA	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	9.25	1.19e-19	5.57e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
BRCA	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-9.25	1.2e-19	5.6e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
BRCA	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-9.25	1.2e-19	5.61e-17	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
BRCA	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-9.25	1.21e-19	5.63e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
BRCA	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-9.25	1.22e-19	5.67e-17	-0.36	-0.28	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
BRCA	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma;	chr2:102388870	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma;	chr2:102389988	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-9.25	1.22e-19	5.68e-17	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
BRCA	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	9.25	1.22e-19	5.7e-17	0.32	0.28	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
BRCA	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	9.25	1.23e-19	5.72e-17	0.25	0.28	Asthma;	chr2:102389644	chr2:102438713~102440475:+
BRCA	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	9.25	1.23e-19	5.73e-17	0.37	0.28	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
BRCA	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-9.25	1.23e-19	5.74e-17	-0.35	-0.28	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	9.25	1.23e-19	5.75e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	9.25	1.24e-19	5.78e-17	0.29	0.28	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	9.25	1.24e-19	5.79e-17	0.34	0.28	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
BRCA	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-9.25	1.24e-19	5.79e-17	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
BRCA	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-9.25	1.24e-19	5.79e-17	-0.25	-0.28	Asthma;	chr2:102438096	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-9.25	1.25e-19	5.81e-17	-0.32	-0.28	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-9.25	1.25e-19	5.83e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
BRCA	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-9.25	1.25e-19	5.83e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
BRCA	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-9.25	1.25e-19	5.84e-17	-0.35	-0.28	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	9.25	1.25e-19	5.84e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
BRCA	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-9.25	1.25e-19	5.84e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	9.25	1.25e-19	5.85e-17	0.35	0.28	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	9.25	1.26e-19	5.86e-17	0.27	0.28	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
BRCA	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-9.25	1.26e-19	5.86e-17	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
BRCA	cis	rs13256369	0.802	rs13255789	ENSG00000253893.2	FAM85B	-9.25	1.26e-19	5.87e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705281	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.579	rs10861663	ENSG00000260329.1	RP11-412D9.4	-9.25	1.26e-19	5.88e-17	-0.3	-0.28	Heart rate;	chr12:106789811	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000220721.1	OR1F12	9.25	1.27e-19	5.91e-17	0.51	0.28	Depression;	chr6:28173682	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000220721.1	OR1F12	9.25	1.27e-19	5.91e-17	0.51	0.28	Depression;	chr6:28175340	chr6:28073316~28074233:+
BRCA	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	9.25	1.27e-19	5.91e-17	0.25	0.28	Asthma;	chr2:102394452	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-9.25	1.28e-19	5.94e-17	-0.33	-0.28	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
BRCA	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	9.25	1.28e-19	5.97e-17	0.32	0.28	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
BRCA	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-9.25	1.28e-19	5.98e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
BRCA	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	9.25	1.29e-19	5.99e-17	0.34	0.28	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
BRCA	cis	rs13256369	0.756	rs13280759	ENSG00000253893.2	FAM85B	-9.24	1.29e-19	6.01e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705485	chr8:8167819~8226614:-
BRCA	cis	rs4862750	0.881	rs6813866	ENSG00000250971.1	RP11-696F12.1	9.24	1.29e-19	6.02e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr4:186951007	chr4:187060099~187060930:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-9.24	1.29e-19	6.03e-17	-0.26	-0.28	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
BRCA	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-9.24	1.3e-19	6.04e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
BRCA	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	9.24	1.3e-19	6.04e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	9.24	1.3e-19	6.07e-17	0.33	0.28	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.851	rs13254997	ENSG00000253893.2	FAM85B	-9.24	1.31e-19	6.09e-17	-0.39	-0.28	Obesity-related traits;	chr8:8706243	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.524	rs9971765	ENSG00000260329.1	RP11-412D9.4	-9.24	1.31e-19	6.1e-17	-0.31	-0.28	Heart rate;	chr12:106698521	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	9.24	1.31e-19	6.11e-17	0.39	0.28	Depression;	chr6:28241753	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-9.24	1.32e-19	6.13e-17	-0.33	-0.28	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	9.24	1.33e-19	6.18e-17	0.33	0.28	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
BRCA	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-9.24	1.33e-19	6.19e-17	-0.39	-0.28	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
BRCA	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	9.24	1.33e-19	6.19e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	9.24	1.33e-19	6.2e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	9.24	1.34e-19	6.21e-17	0.28	0.28	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-9.24	1.34e-19	6.24e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-9.24	1.34e-19	6.25e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-9.24	1.35e-19	6.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	9.24	1.35e-19	6.26e-17	0.33	0.28	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	9.24	1.35e-19	6.27e-17	0.39	0.28	Depression;	chr6:28240780	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	9.24	1.35e-19	6.27e-17	0.39	0.28	Depression;	chr6:28241324	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-9.24	1.35e-19	6.27e-17	-0.3	-0.28	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
BRCA	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-9.24	1.35e-19	6.28e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
BRCA	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	9.24	1.35e-19	6.29e-17	0.35	0.28	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-9.24	1.36e-19	6.3e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
BRCA	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	9.24	1.36e-19	6.33e-17	0.35	0.28	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
BRCA	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	9.24	1.36e-19	6.33e-17	0.25	0.28	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
BRCA	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	9.24	1.38e-19	6.41e-17	0.34	0.28	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
BRCA	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-9.24	1.38e-19	6.42e-17	-0.25	-0.28	Asthma;	chr2:102374328	chr2:102438713~102440475:+
BRCA	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-9.24	1.38e-19	6.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-9.24	1.38e-19	6.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
BRCA	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-9.24	1.39e-19	6.46e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
BRCA	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
BRCA	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-9.24	1.4e-19	6.48e-17	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-9.24	1.4e-19	6.48e-17	-0.34	-0.28	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
BRCA	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	9.24	1.4e-19	6.51e-17	0.32	0.28	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	9.24	1.4e-19	6.51e-17	0.32	0.28	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
BRCA	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	9.24	1.41e-19	6.52e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-9.23	1.41e-19	6.55e-17	-0.34	-0.28	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
BRCA	cis	rs13256369	0.851	rs13256611	ENSG00000253893.2	FAM85B	-9.23	1.41e-19	6.55e-17	-0.39	-0.28	Obesity-related traits;	chr8:8706831	chr8:8167819~8226614:-
BRCA	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	9.23	1.41e-19	6.56e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
BRCA	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-9.23	1.42e-19	6.57e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
BRCA	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	9.23	1.42e-19	6.58e-17	0.46	0.28	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
BRCA	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-9.23	1.42e-19	6.59e-17	-0.33	-0.28	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	9.23	1.42e-19	6.6e-17	0.31	0.28	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	9.23	1.43e-19	6.63e-17	0.32	0.28	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
BRCA	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	9.23	1.43e-19	6.65e-17	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
BRCA	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	9.23	1.44e-19	6.65e-17	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-9.23	1.44e-19	6.68e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	9.23	1.44e-19	6.68e-17	0.39	0.27	Depression;	chr6:28240414	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-9.23	1.45e-19	6.71e-17	-0.26	-0.27	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-9.23	1.45e-19	6.73e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
BRCA	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-9.23	1.45e-19	6.73e-17	-0.33	-0.27	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-9.23	1.46e-19	6.76e-17	-0.33	-0.27	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
BRCA	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-9.23	1.46e-19	6.77e-17	-0.32	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-9.23	1.46e-19	6.77e-17	-0.32	-0.27	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.951	rs10503394	ENSG00000253893.2	FAM85B	-9.23	1.46e-19	6.78e-17	-0.39	-0.27	Obesity-related traits;	chr8:8708265	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-9.23	1.46e-19	6.79e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
BRCA	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	9.23	1.47e-19	6.81e-17	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-9.23	1.47e-19	6.82e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	9.23	1.48e-19	6.85e-17	0.28	0.27	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-9.23	1.48e-19	6.86e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-9.23	1.48e-19	6.86e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
BRCA	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	9.23	1.49e-19	6.88e-17	0.26	0.27	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
BRCA	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-9.23	1.49e-19	6.9e-17	-0.33	-0.27	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
BRCA	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	9.23	1.49e-19	6.92e-17	0.33	0.27	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-9.23	1.5e-19	6.93e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.951	rs13260947	ENSG00000253893.2	FAM85B	-9.23	1.5e-19	6.94e-17	-0.39	-0.27	Obesity-related traits;	chr8:8708373	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	9.23	1.5e-19	6.94e-17	0.31	0.27	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	9.23	1.5e-19	6.95e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
BRCA	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	9.23	1.51e-19	6.97e-17	0.25	0.27	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
BRCA	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-9.23	1.51e-19	6.98e-17	-0.39	-0.27	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-9.23	1.51e-19	6.99e-17	-0.32	-0.27	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	9.23	1.51e-19	6.99e-17	0.33	0.27	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	9.23	1.51e-19	7e-17	0.35	0.27	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	9.23	1.51e-19	7e-17	0.35	0.27	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
BRCA	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	9.23	1.52e-19	7.01e-17	0.32	0.27	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-9.23	1.52e-19	7.01e-17	-0.39	-0.27	Depression;	chr6:28422360	chr6:28176188~28176674:+
BRCA	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-9.23	1.53e-19	7.06e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-9.23	1.53e-19	7.06e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
BRCA	cis	rs13256369	0.851	rs13258283	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706120	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs13249700	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706127	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs13255061	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706324	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs12541477	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706385	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	9.22	1.54e-19	7.1e-17	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-9.22	1.54e-19	7.11e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
BRCA	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	9.22	1.54e-19	7.12e-17	0.32	0.27	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
BRCA	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
BRCA	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-9.22	1.54e-19	7.13e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-9.22	1.54e-19	7.13e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
BRCA	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	9.22	1.55e-19	7.18e-17	0.34	0.27	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
BRCA	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	9.22	1.56e-19	7.19e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
BRCA	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-9.22	1.56e-19	7.23e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-9.22	1.56e-19	7.23e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
BRCA	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-9.22	1.57e-19	7.23e-17	-0.32	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
BRCA	cis	rs13256369	0.756	rs13282580	ENSG00000253893.2	FAM85B	-9.22	1.57e-19	7.24e-17	-0.39	-0.27	Obesity-related traits;	chr8:8705393	chr8:8167819~8226614:-
BRCA	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-9.22	1.57e-19	7.25e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
BRCA	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
BRCA	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-9.22	1.57e-19	7.26e-17	-0.34	-0.27	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
BRCA	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	9.22	1.58e-19	7.3e-17	0.25	0.27	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
BRCA	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-9.22	1.59e-19	7.33e-17	-0.66	-0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
BRCA	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	9.22	1.59e-19	7.36e-17	0.25	0.27	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	9.22	1.61e-19	7.43e-17	0.33	0.27	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
BRCA	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	9.22	1.62e-19	7.46e-17	0.25	0.27	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
BRCA	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	9.22	1.62e-19	7.48e-17	0.34	0.27	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
BRCA	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-9.22	1.62e-19	7.49e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000226816.2	AC005082.12	9.22	1.63e-19	7.51e-17	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23206013~23208045:+
BRCA	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	9.22	1.63e-19	7.52e-17	0.26	0.27	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	9.22	1.63e-19	7.52e-17	0.26	0.27	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
BRCA	cis	rs2067615	0.579	rs3910854	ENSG00000260329.1	RP11-412D9.4	-9.22	1.63e-19	7.52e-17	-0.3	-0.27	Heart rate;	chr12:106771891	chr12:106954029~106955497:-
BRCA	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	9.22	1.63e-19	7.53e-17	0.32	0.27	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
BRCA	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	9.22	1.64e-19	7.54e-17	0.25	0.27	Asthma;	chr2:102426252	chr2:102438713~102440475:+
BRCA	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	9.22	1.64e-19	7.55e-17	0.53	0.27	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
BRCA	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	9.22	1.64e-19	7.58e-17	0.35	0.27	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
BRCA	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	9.22	1.65e-19	7.6e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	9.22	1.65e-19	7.6e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
BRCA	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-9.22	1.65e-19	7.61e-17	-0.33	-0.27	Height;	chr2:231553603	chr2:231508426~231514339:-
BRCA	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-9.22	1.67e-19	7.68e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
BRCA	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-9.22	1.67e-19	7.7e-17	-0.35	-0.27	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
BRCA	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-9.21	1.7e-19	7.84e-17	-0.37	-0.27	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
BRCA	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	9.21	1.7e-19	7.84e-17	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	9.21	1.7e-19	7.85e-17	0.32	0.27	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
BRCA	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.21	1.71e-19	7.86e-17	0.42	0.27	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
BRCA	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-9.21	1.71e-19	7.86e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-9.21	1.71e-19	7.86e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
BRCA	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	9.21	1.71e-19	7.86e-17	0.31	0.27	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
BRCA	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-9.21	1.71e-19	7.89e-17	-0.34	-0.27	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
BRCA	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-9.21	1.72e-19	7.94e-17	-0.37	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
BRCA	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-9.21	1.72e-19	7.94e-17	-0.35	-0.27	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
BRCA	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	9.21	1.73e-19	7.97e-17	0.34	0.27	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
BRCA	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	9.21	1.73e-19	7.97e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-9.21	1.74e-19	8e-17	-0.27	-0.27	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-9.21	1.75e-19	8.04e-17	-0.33	-0.27	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	9.21	1.75e-19	8.05e-17	0.31	0.27	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
BRCA	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-9.21	1.75e-19	8.06e-17	-0.35	-0.27	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
BRCA	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	9.21	1.76e-19	8.1e-17	0.26	0.27	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-9.21	1.77e-19	8.13e-17	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	9.21	1.77e-19	8.14e-17	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	9.21	1.77e-19	8.14e-17	0.35	0.27	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
BRCA	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-9.21	1.77e-19	8.16e-17	-0.64	-0.27	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
BRCA	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
BRCA	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.22e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.579	rs12312782	ENSG00000260329.1	RP11-412D9.4	-9.21	1.79e-19	8.22e-17	-0.3	-0.27	Heart rate;	chr12:106741869	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-9.21	1.79e-19	8.23e-17	-0.33	-0.27	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.24e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.24e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
BRCA	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-9.21	1.79e-19	8.24e-17	-0.39	-0.27	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
BRCA	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-9.21	1.79e-19	8.25e-17	-0.35	-0.27	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
BRCA	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-9.21	1.81e-19	8.31e-17	-0.32	-0.27	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-9.21	1.82e-19	8.36e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-9.21	1.82e-19	8.36e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
BRCA	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-9.21	1.82e-19	8.37e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-9.21	1.82e-19	8.37e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
BRCA	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	9.2	1.82e-19	8.37e-17	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
BRCA	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	9.2	1.84e-19	8.46e-17	0.28	0.27	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
BRCA	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	9.2	1.84e-19	8.47e-17	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
BRCA	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-9.2	1.85e-19	8.47e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-9.2	1.85e-19	8.48e-17	-0.25	-0.27	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
BRCA	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	9.2	1.85e-19	8.49e-17	0.33	0.27	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
BRCA	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-9.2	1.88e-19	8.62e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
BRCA	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	9.2	1.88e-19	8.63e-17	0.42	0.27	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
BRCA	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-9.2	1.89e-19	8.67e-17	-0.37	-0.27	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
BRCA	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	9.2	1.89e-19	8.68e-17	0.25	0.27	Asthma;	chr2:102446780	chr2:102438713~102440475:+
BRCA	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-9.2	1.89e-19	8.69e-17	-0.48	-0.27	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
BRCA	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	9.2	1.91e-19	8.77e-17	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
BRCA	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	9.2	1.92e-19	8.79e-17	0.36	0.27	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
BRCA	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	9.2	1.92e-19	8.83e-17	0.41	0.27	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
BRCA	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-9.2	1.93e-19	8.84e-17	-0.33	-0.27	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
BRCA	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	9.2	1.93e-19	8.84e-17	0.33	0.27	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
BRCA	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	9.2	1.93e-19	8.85e-17	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
BRCA	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	9.2	1.94e-19	8.91e-17	0.4	0.27	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	9.2	1.94e-19	8.92e-17	0.28	0.27	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
BRCA	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	9.2	1.95e-19	8.96e-17	0.34	0.27	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
BRCA	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	9.2	1.95e-19	8.96e-17	0.34	0.27	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
BRCA	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	9.2	1.97e-19	9.01e-17	0.25	0.27	Asthma;	chr2:102418383	chr2:102438713~102440475:+
BRCA	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	9.2	1.97e-19	9.02e-17	0.42	0.27	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
BRCA	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	9.2	1.97e-19	9.03e-17	0.41	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	9.2	1.97e-19	9.04e-17	0.32	0.27	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-9.2	1.98e-19	9.09e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-9.2	1.98e-19	9.09e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	9.19	1.98e-19	9.1e-17	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
BRCA	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	9.19	1.99e-19	9.11e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.503	rs1665272	ENSG00000271889.1	RP11-493E12.1	9.19	1.99e-19	9.13e-17	0.34	0.27	Tuberculosis;	chr2:61152151	chr2:61151433~61162105:-
BRCA	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-9.19	1.99e-19	9.13e-17	-0.42	-0.27	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
BRCA	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	9.19	1.99e-19	9.13e-17	0.34	0.27	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
BRCA	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-9.19	2e-19	9.16e-17	-0.38	-0.27	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
BRCA	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102379885	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102381819	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102382514	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102382943	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
BRCA	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-9.19	2.01e-19	9.19e-17	-0.34	-0.27	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-9.19	2.01e-19	9.19e-17	-0.34	-0.27	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-9.19	2.01e-19	9.21e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
BRCA	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-9.19	2.02e-19	9.23e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-9.19	2.03e-19	9.29e-17	-0.32	-0.27	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	9.19	2.03e-19	9.29e-17	0.32	0.27	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	9.19	2.03e-19	9.29e-17	0.32	0.27	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
BRCA	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-9.19	2.03e-19	9.3e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
BRCA	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.32e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
BRCA	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.33e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.33e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-9.19	2.05e-19	9.37e-17	-0.52	-0.27	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	9.19	2.05e-19	9.37e-17	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
BRCA	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	9.19	2.06e-19	9.41e-17	0.35	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
BRCA	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-9.19	2.06e-19	9.43e-17	-0.34	-0.27	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
BRCA	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	9.19	2.06e-19	9.44e-17	0.35	0.27	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
BRCA	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-9.19	2.06e-19	9.45e-17	-0.3	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
BRCA	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	9.19	2.08e-19	9.51e-17	0.33	0.27	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	9.19	2.1e-19	9.57e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
BRCA	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-9.19	2.1e-19	9.61e-17	-0.34	-0.27	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
BRCA	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-9.19	2.12e-19	9.69e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
BRCA	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-9.19	2.12e-19	9.7e-17	-0.34	-0.27	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	9.19	2.12e-19	9.7e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-9.19	2.13e-19	9.74e-17	-0.33	-0.27	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
BRCA	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	9.19	2.13e-19	9.75e-17	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
BRCA	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	9.19	2.14e-19	9.76e-17	0.31	0.27	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	9.19	2.15e-19	9.84e-17	0.32	0.27	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-9.19	2.15e-19	9.84e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
BRCA	cis	rs2067615	0.524	rs10778499	ENSG00000260329.1	RP11-412D9.4	-9.19	2.16e-19	9.85e-17	-0.3	-0.27	Heart rate;	chr12:106674609	chr12:106954029~106955497:-
BRCA	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	9.19	2.16e-19	9.87e-17	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
BRCA	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	9.18	2.17e-19	9.91e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-9.18	2.18e-19	9.93e-17	-0.27	-0.27	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-9.18	2.18e-19	9.94e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
BRCA	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	9.18	2.18e-19	9.95e-17	0.34	0.27	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
BRCA	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	9.18	2.2e-19	1e-16	0.33	0.27	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
BRCA	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	9.18	2.2e-19	1e-16	0.31	0.27	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
BRCA	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	9.18	2.2e-19	1.01e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
BRCA	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-9.18	2.21e-19	1.01e-16	-0.36	-0.27	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
BRCA	cis	rs1823913	0.927	rs34765012	ENSG00000280083.1	RP11-317J9.1	-9.18	2.22e-19	1.01e-16	-0.34	-0.27	Obesity-related traits;	chr2:191247926	chr2:191154118~191156070:-
BRCA	cis	rs13256369	0.802	rs11249888	ENSG00000253893.2	FAM85B	-9.18	2.24e-19	1.02e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707424	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs11249889	ENSG00000253893.2	FAM85B	-9.18	2.24e-19	1.02e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707482	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-9.18	2.26e-19	1.03e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
BRCA	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-9.18	2.27e-19	1.04e-16	-0.37	-0.27	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	9.18	2.29e-19	1.04e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-9.18	2.29e-19	1.04e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
BRCA	cis	rs7085104	0.7	rs10786712	ENSG00000213061.2	PFN1P11	-9.18	2.3e-19	1.05e-16	-0.35	-0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102838011~102845473:-
BRCA	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-9.18	2.3e-19	1.05e-16	-0.33	-0.27	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
BRCA	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	9.18	2.32e-19	1.05e-16	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
BRCA	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	9.18	2.32e-19	1.06e-16	0.28	0.27	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
BRCA	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-9.18	2.33e-19	1.06e-16	-0.33	-0.27	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
BRCA	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	9.18	2.33e-19	1.06e-16	0.36	0.27	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
BRCA	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-9.18	2.33e-19	1.06e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-9.18	2.34e-19	1.06e-16	-0.34	-0.27	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-9.18	2.34e-19	1.06e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
BRCA	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	9.18	2.34e-19	1.06e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	9.18	2.35e-19	1.07e-16	0.35	0.27	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
BRCA	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-9.17	2.37e-19	1.08e-16	-0.36	-0.27	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	9.17	2.38e-19	1.08e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-9.17	2.42e-19	1.1e-16	-0.33	-0.27	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-9.17	2.42e-19	1.1e-16	-0.32	-0.27	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-9.17	2.42e-19	1.1e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	9.17	2.42e-19	1.1e-16	0.2	0.27	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	9.17	2.43e-19	1.1e-16	0.35	0.27	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-9.17	2.43e-19	1.1e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	9.17	2.43e-19	1.1e-16	0.28	0.27	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	9.17	2.43e-19	1.11e-16	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-9.17	2.44e-19	1.11e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs12444171	ENSG00000278665.1	RP11-666O2.4	9.17	2.44e-19	1.11e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28599241~28601881:-
BRCA	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	9.17	2.45e-19	1.11e-16	0.29	0.27	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
BRCA	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-9.17	2.45e-19	1.11e-16	-0.4	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
BRCA	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma;	chr2:102419319	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma;	chr2:102419875	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	9.17	2.45e-19	1.11e-16	0.32	0.27	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-9.17	2.46e-19	1.12e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-9.17	2.46e-19	1.12e-16	-0.28	-0.27	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
BRCA	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	9.17	2.47e-19	1.12e-16	0.33	0.27	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
BRCA	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	9.17	2.47e-19	1.12e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	9.17	2.47e-19	1.12e-16	0.26	0.27	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
BRCA	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	9.17	2.49e-19	1.13e-16	0.35	0.27	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
BRCA	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-9.17	2.49e-19	1.13e-16	-0.32	-0.27	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
BRCA	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-9.17	2.51e-19	1.14e-16	-0.33	-0.27	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
BRCA	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	9.17	2.52e-19	1.14e-16	0.32	0.27	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	9.17	2.52e-19	1.14e-16	0.32	0.27	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
BRCA	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	9.17	2.52e-19	1.15e-16	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
BRCA	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	9.17	2.52e-19	1.15e-16	0.35	0.27	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	9.17	2.52e-19	1.15e-16	0.35	0.27	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
BRCA	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	9.17	2.53e-19	1.15e-16	0.35	0.27	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-9.17	2.53e-19	1.15e-16	-0.31	-0.27	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
BRCA	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.17	2.54e-19	1.15e-16	-0.31	-0.27	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
BRCA	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-9.17	2.54e-19	1.15e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-9.17	2.54e-19	1.15e-16	-0.35	-0.27	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
BRCA	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	9.17	2.54e-19	1.15e-16	0.41	0.27	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	9.17	2.55e-19	1.16e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
BRCA	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	9.17	2.55e-19	1.16e-16	0.4	0.27	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
BRCA	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	9.17	2.56e-19	1.16e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
BRCA	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-9.17	2.56e-19	1.16e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
BRCA	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-9.16	2.58e-19	1.17e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-9.16	2.58e-19	1.17e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
BRCA	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-9.16	2.58e-19	1.17e-16	-0.25	-0.27	Asthma;	chr2:102393077	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-9.16	2.58e-19	1.17e-16	-0.33	-0.27	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	9.16	2.59e-19	1.17e-16	0.32	0.27	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
BRCA	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	9.16	2.61e-19	1.18e-16	0.28	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-9.16	2.63e-19	1.19e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
BRCA	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-9.16	2.63e-19	1.19e-16	-0.39	-0.27	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
BRCA	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	9.16	2.64e-19	1.2e-16	0.25	0.27	Asthma;	chr2:102381261	chr2:102438713~102440475:+
BRCA	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-9.16	2.64e-19	1.2e-16	-0.36	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000278665.1	RP11-666O2.4	9.16	2.65e-19	1.2e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036657	ENSG00000278665.1	RP11-666O2.4	9.16	2.65e-19	1.2e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28599241~28601881:-
BRCA	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-9.16	2.65e-19	1.2e-16	-0.32	-0.27	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
BRCA	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	9.16	2.66e-19	1.2e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
BRCA	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	9.16	2.67e-19	1.21e-16	0.26	0.27	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	9.16	2.67e-19	1.21e-16	0.26	0.27	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
BRCA	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	9.16	2.67e-19	1.21e-16	0.39	0.27	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
BRCA	cis	rs2067615	0.56	rs2044304	ENSG00000260329.1	RP11-412D9.4	-9.16	2.68e-19	1.22e-16	-0.3	-0.27	Heart rate;	chr12:106790585	chr12:106954029~106955497:-
BRCA	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	9.16	2.69e-19	1.22e-16	0.32	0.27	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	9.16	2.69e-19	1.22e-16	0.32	0.27	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
BRCA	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	9.16	2.7e-19	1.22e-16	0.33	0.27	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	9.16	2.7e-19	1.22e-16	0.33	0.27	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	9.16	2.71e-19	1.23e-16	0.24	0.27	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
BRCA	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	9.16	2.72e-19	1.23e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
BRCA	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	9.16	2.74e-19	1.24e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
BRCA	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	9.16	2.75e-19	1.25e-16	0.33	0.27	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
BRCA	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	9.16	2.77e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	9.16	2.77e-19	1.25e-16	0.35	0.27	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
BRCA	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-9.16	2.77e-19	1.25e-16	-0.33	-0.27	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
BRCA	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	9.16	2.79e-19	1.26e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
BRCA	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-9.16	2.79e-19	1.26e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
BRCA	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	9.16	2.79e-19	1.26e-16	0.32	0.27	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	9.15	2.8e-19	1.27e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
BRCA	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	9.15	2.8e-19	1.27e-16	0.25	0.27	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
BRCA	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-9.15	2.82e-19	1.28e-16	-0.31	-0.27	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	9.15	2.82e-19	1.28e-16	0.28	0.27	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-9.15	2.82e-19	1.28e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-9.15	2.82e-19	1.28e-16	-0.35	-0.27	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
BRCA	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	9.15	2.83e-19	1.28e-16	0.36	0.27	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
BRCA	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	9.15	2.84e-19	1.28e-16	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	9.15	2.85e-19	1.29e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	9.15	2.85e-19	1.29e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	9.15	2.86e-19	1.29e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-9.15	2.86e-19	1.29e-16	-0.32	-0.27	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-9.15	2.87e-19	1.3e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-9.15	2.87e-19	1.3e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
BRCA	cis	rs13256369	0.851	rs11249890	ENSG00000253893.2	FAM85B	-9.15	2.87e-19	1.3e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707735	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	9.15	2.88e-19	1.3e-16	0.29	0.27	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	9.15	2.91e-19	1.32e-16	0.28	0.27	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	9.15	2.91e-19	1.32e-16	0.28	0.27	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-9.15	2.92e-19	1.32e-16	-0.34	-0.27	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
BRCA	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	9.15	2.94e-19	1.33e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	9.15	2.95e-19	1.33e-16	0.28	0.27	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	9.15	2.95e-19	1.33e-16	0.35	0.27	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
BRCA	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	9.15	2.97e-19	1.34e-16	0.28	0.27	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-9.15	2.97e-19	1.34e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-9.15	3e-19	1.35e-16	-0.52	-0.27	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	9.15	3e-19	1.36e-16	0.29	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
BRCA	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-9.15	3.01e-19	1.36e-16	-0.37	-0.27	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
BRCA	cis	rs881375	0.967	rs3761849	ENSG00000226752.6	PSMD5-AS1	-9.15	3.03e-19	1.37e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120928679	chr9:120824828~120854385:+
BRCA	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-9.15	3.04e-19	1.37e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
BRCA	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	9.15	3.04e-19	1.37e-16	0.33	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
BRCA	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	9.15	3.04e-19	1.37e-16	0.25	0.27	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
BRCA	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-9.15	3.04e-19	1.37e-16	-0.32	-0.27	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
BRCA	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-9.14	3.05e-19	1.38e-16	-0.34	-0.27	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	9.14	3.05e-19	1.38e-16	0.32	0.27	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
BRCA	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
BRCA	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	9.14	3.07e-19	1.38e-16	0.25	0.27	Asthma;	chr2:102399227	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-9.14	3.08e-19	1.39e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
BRCA	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-9.14	3.08e-19	1.39e-16	-0.36	-0.27	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
BRCA	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	9.14	3.1e-19	1.4e-16	0.33	0.27	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
BRCA	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-9.14	3.11e-19	1.4e-16	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	9.14	3.11e-19	1.4e-16	0.32	0.27	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-9.14	3.11e-19	1.4e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.579	rs9651957	ENSG00000260329.1	RP11-412D9.4	-9.14	3.11e-19	1.4e-16	-0.3	-0.27	Heart rate;	chr12:106776350	chr12:106954029~106955497:-
BRCA	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-9.14	3.12e-19	1.41e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
BRCA	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	9.14	3.15e-19	1.42e-16	0.41	0.27	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	9.14	3.15e-19	1.42e-16	0.27	0.27	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
BRCA	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	9.14	3.16e-19	1.42e-16	0.32	0.27	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
BRCA	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	9.14	3.16e-19	1.42e-16	0.33	0.27	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	9.14	3.18e-19	1.43e-16	0.33	0.27	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
BRCA	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	9.14	3.19e-19	1.44e-16	0.42	0.27	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
BRCA	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	9.14	3.2e-19	1.44e-16	0.29	0.27	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	9.14	3.21e-19	1.44e-16	0.31	0.27	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	9.14	3.23e-19	1.46e-16	0.32	0.27	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	9.14	3.23e-19	1.46e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	9.14	3.24e-19	1.46e-16	0.24	0.27	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
BRCA	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	9.14	3.24e-19	1.46e-16	0.25	0.27	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
BRCA	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-9.14	3.25e-19	1.46e-16	-0.31	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	9.14	3.25e-19	1.46e-16	0.32	0.27	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
BRCA	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-9.14	3.25e-19	1.46e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-9.14	3.26e-19	1.47e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
BRCA	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-9.14	3.26e-19	1.47e-16	-0.3	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
BRCA	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	9.14	3.27e-19	1.47e-16	0.69	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
BRCA	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	9.14	3.27e-19	1.47e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	9.14	3.28e-19	1.47e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-9.14	3.28e-19	1.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-9.14	3.28e-19	1.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
BRCA	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	9.14	3.29e-19	1.48e-16	0.43	0.27	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
BRCA	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	9.14	3.29e-19	1.48e-16	0.25	0.27	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
BRCA	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	9.14	3.3e-19	1.48e-16	0.3	0.27	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
BRCA	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-9.14	3.3e-19	1.48e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
BRCA	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-9.14	3.3e-19	1.49e-16	-0.39	-0.27	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-9.14	3.3e-19	1.49e-16	-0.31	-0.27	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
BRCA	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	9.14	3.31e-19	1.49e-16	0.32	0.27	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	9.13	3.33e-19	1.5e-16	0.28	0.27	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-9.13	3.34e-19	1.5e-16	-0.28	-0.27	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
BRCA	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	9.13	3.35e-19	1.5e-16	0.32	0.27	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
BRCA	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-9.13	3.36e-19	1.51e-16	-0.33	-0.27	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
BRCA	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	9.13	3.36e-19	1.51e-16	0.26	0.27	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	9.13	3.36e-19	1.51e-16	0.26	0.27	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
BRCA	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-9.13	3.36e-19	1.51e-16	-0.39	-0.27	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
BRCA	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	9.13	3.37e-19	1.51e-16	0.35	0.27	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
BRCA	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-9.13	3.37e-19	1.51e-16	-0.34	-0.27	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
BRCA	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	9.13	3.37e-19	1.51e-16	0.32	0.27	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
BRCA	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	9.13	3.37e-19	1.51e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
BRCA	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-9.13	3.38e-19	1.52e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
BRCA	cis	rs4237845	0.622	rs10783859	ENSG00000257159.1	RP11-58A17.3	9.13	3.4e-19	1.53e-16	0.32	0.27	Intelligence (multi-trait analysis);	chr12:57939011	chr12:57967058~57968399:+
BRCA	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	9.13	3.42e-19	1.54e-16	0.32	0.27	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
BRCA	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	9.13	3.42e-19	1.54e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	9.13	3.43e-19	1.54e-16	0.35	0.27	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	9.13	3.45e-19	1.55e-16	0.28	0.27	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	9.13	3.46e-19	1.55e-16	0.32	0.27	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	9.13	3.46e-19	1.55e-16	0.32	0.27	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
BRCA	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-9.13	3.46e-19	1.55e-16	-0.25	-0.27	Asthma;	chr2:102377873	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	9.13	3.47e-19	1.56e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
BRCA	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	9.13	3.49e-19	1.56e-16	0.34	0.27	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
BRCA	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	9.13	3.49e-19	1.57e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-9.13	3.51e-19	1.57e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-9.13	3.51e-19	1.57e-16	-0.46	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-9.13	3.51e-19	1.58e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
BRCA	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	9.13	3.53e-19	1.58e-16	0.33	0.27	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
BRCA	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	9.13	3.53e-19	1.58e-16	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
BRCA	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-9.13	3.58e-19	1.6e-16	-0.35	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	9.13	3.59e-19	1.61e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	9.13	3.61e-19	1.62e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
BRCA	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	9.12	3.62e-19	1.62e-16	0.3	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
BRCA	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-9.12	3.63e-19	1.63e-16	-0.39	-0.27	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
BRCA	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-9.12	3.63e-19	1.63e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-9.12	3.63e-19	1.63e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
BRCA	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	9.12	3.63e-19	1.63e-16	0.33	0.27	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
BRCA	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	9.12	3.65e-19	1.63e-16	0.25	0.27	Asthma;	chr2:102374753	chr2:102438713~102440475:+
BRCA	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.12	3.65e-19	1.63e-16	-0.32	-0.27	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
BRCA	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-9.12	3.65e-19	1.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
BRCA	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-9.12	3.65e-19	1.64e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	9.12	3.66e-19	1.64e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
BRCA	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	9.12	3.67e-19	1.64e-16	0.28	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
BRCA	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	9.12	3.67e-19	1.65e-16	0.25	0.27	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-9.12	3.68e-19	1.65e-16	-0.33	-0.27	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
BRCA	cis	rs4862750	0.914	rs6814259	ENSG00000250971.1	RP11-696F12.1	9.12	3.71e-19	1.66e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186951183	chr4:187060099~187060930:+
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000220721.1	OR1F12	9.12	3.72e-19	1.67e-16	0.5	0.27	Depression;	chr6:28159062	chr6:28073316~28074233:+
BRCA	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	9.12	3.73e-19	1.67e-16	0.41	0.27	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
BRCA	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	9.12	3.75e-19	1.68e-16	0.32	0.27	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000220721.1	OR1F12	9.12	3.75e-19	1.68e-16	0.5	0.27	Depression;	chr6:28139579	chr6:28073316~28074233:+
BRCA	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	9.12	3.76e-19	1.68e-16	0.26	0.27	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
BRCA	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	9.12	3.76e-19	1.68e-16	0.25	0.27	Asthma;	chr2:102402540	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	9.12	3.76e-19	1.68e-16	0.25	0.27	Asthma;	chr2:102402571	chr2:102438713~102440475:+
BRCA	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	9.12	3.76e-19	1.68e-16	0.33	0.27	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
BRCA	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-9.12	3.77e-19	1.69e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
BRCA	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-9.12	3.78e-19	1.69e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
BRCA	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-9.12	3.79e-19	1.69e-16	-0.39	-0.27	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
BRCA	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-9.12	3.8e-19	1.7e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-9.12	3.8e-19	1.7e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
BRCA	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	9.12	3.81e-19	1.71e-16	0.36	0.27	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
BRCA	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-9.12	3.81e-19	1.71e-16	-0.32	-0.27	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
BRCA	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	9.12	3.82e-19	1.71e-16	0.34	0.27	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
BRCA	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.12	3.82e-19	1.71e-16	0.34	0.27	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
BRCA	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-9.12	3.82e-19	1.71e-16	-0.35	-0.27	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
BRCA	cis	rs55665837	0.539	rs10832310	ENSG00000251991.1	RNU7-49P	9.12	3.83e-19	1.71e-16	0.31	0.27	Vitamin D levels;	chr11:14856896	chr11:14478892~14478953:+
BRCA	cis	rs8062405	1	rs8062405	ENSG00000278665.1	RP11-666O2.4	-9.12	3.83e-19	1.71e-16	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-9.12	3.84e-19	1.72e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
BRCA	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	9.12	3.84e-19	1.72e-16	0.33	0.27	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
BRCA	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	9.12	3.84e-19	1.72e-16	0.36	0.27	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
BRCA	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	9.12	3.85e-19	1.72e-16	0.35	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	9.12	3.87e-19	1.73e-16	0.27	0.27	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	9.12	3.87e-19	1.73e-16	0.27	0.27	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-9.12	3.88e-19	1.73e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
BRCA	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	9.12	3.88e-19	1.73e-16	0.4	0.27	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
BRCA	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	9.12	3.88e-19	1.74e-16	0.33	0.27	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
BRCA	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	9.12	3.89e-19	1.74e-16	0.33	0.27	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	9.12	3.89e-19	1.74e-16	0.33	0.27	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
BRCA	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	9.12	3.9e-19	1.74e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-9.12	3.91e-19	1.74e-16	-0.33	-0.27	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-9.12	3.91e-19	1.75e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
BRCA	cis	rs13256369	0.901	rs12679831	ENSG00000253893.2	FAM85B	-9.12	3.91e-19	1.75e-16	-0.39	-0.27	Obesity-related traits;	chr8:8708901	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.901	rs12681327	ENSG00000253893.2	FAM85B	-9.12	3.91e-19	1.75e-16	-0.39	-0.27	Obesity-related traits;	chr8:8708904	chr8:8167819~8226614:-
BRCA	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	9.12	3.92e-19	1.75e-16	0.35	0.27	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
BRCA	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-9.12	3.92e-19	1.75e-16	-0.34	-0.27	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
BRCA	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-9.12	3.93e-19	1.75e-16	-0.34	-0.27	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	9.12	3.94e-19	1.76e-16	0.27	0.27	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	9.11	3.94e-19	1.76e-16	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
BRCA	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	9.11	3.95e-19	1.76e-16	0.33	0.27	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
BRCA	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	9.11	3.95e-19	1.76e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
BRCA	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	9.11	3.96e-19	1.77e-16	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
BRCA	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-9.11	3.99e-19	1.78e-16	-0.33	-0.27	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
BRCA	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	9.11	3.99e-19	1.78e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-9.11	4.01e-19	1.79e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
BRCA	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	9.11	4.01e-19	1.79e-16	0.42	0.27	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
BRCA	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	9.11	4.02e-19	1.79e-16	0.32	0.27	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
BRCA	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-9.11	4.04e-19	1.8e-16	-0.33	-0.27	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
BRCA	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	9.11	4.04e-19	1.8e-16	0.41	0.27	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
BRCA	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	9.11	4.07e-19	1.82e-16	0.32	0.27	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
BRCA	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
BRCA	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	9.11	4.1e-19	1.83e-16	0.41	0.27	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
BRCA	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-9.11	4.1e-19	1.83e-16	-0.36	-0.27	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
BRCA	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	9.11	4.12e-19	1.84e-16	0.36	0.27	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
BRCA	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-9.11	4.16e-19	1.85e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
BRCA	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	9.11	4.16e-19	1.86e-16	0.33	0.27	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	9.11	4.16e-19	1.86e-16	0.33	0.27	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
BRCA	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	9.11	4.17e-19	1.86e-16	0.3	0.27	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	9.11	4.19e-19	1.87e-16	0.29	0.27	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
BRCA	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-9.11	4.2e-19	1.87e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
BRCA	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-9.11	4.21e-19	1.87e-16	-0.35	-0.27	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
BRCA	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	9.11	4.24e-19	1.89e-16	0.25	0.27	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
BRCA	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-9.11	4.24e-19	1.89e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
BRCA	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	9.11	4.26e-19	1.9e-16	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
BRCA	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412435	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412461	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412524	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102415109	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102417501	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-9.11	4.27e-19	1.9e-16	-0.32	-0.27	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-9.11	4.27e-19	1.9e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
BRCA	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-9.11	4.29e-19	1.91e-16	-0.33	-0.27	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
BRCA	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	9.1	4.29e-19	1.91e-16	0.25	0.27	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
BRCA	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-9.1	4.3e-19	1.92e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
BRCA	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-9.1	4.3e-19	1.92e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-9.1	4.3e-19	1.92e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
BRCA	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	9.1	4.32e-19	1.92e-16	0.39	0.27	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
BRCA	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	9.1	4.32e-19	1.92e-16	0.42	0.27	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
BRCA	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	9.1	4.32e-19	1.92e-16	0.33	0.27	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
BRCA	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	9.1	4.33e-19	1.93e-16	0.32	0.27	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	9.1	4.34e-19	1.93e-16	0.32	0.27	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
BRCA	cis	rs4862750	0.914	rs6837117	ENSG00000250971.1	RP11-696F12.1	9.1	4.36e-19	1.94e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186951225	chr4:187060099~187060930:+
BRCA	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-9.1	4.36e-19	1.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.537	rs5996508	ENSG00000230701.2	FBXW4P1	9.1	4.36e-19	1.94e-16	0.35	0.27	Height;	chr22:23270441	chr22:23262767~23265005:+
BRCA	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-9.1	4.4e-19	1.96e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
BRCA	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-9.1	4.43e-19	1.97e-16	-0.34	-0.27	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
BRCA	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-9.1	4.43e-19	1.97e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
BRCA	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	9.1	4.45e-19	1.98e-16	0.31	0.27	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
BRCA	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-9.1	4.46e-19	1.99e-16	-0.29	-0.27	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	9.1	4.47e-19	1.99e-16	0.27	0.27	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
BRCA	cis	rs55665837	0.539	rs731042	ENSG00000251991.1	RNU7-49P	9.1	4.48e-19	1.99e-16	0.31	0.27	Vitamin D levels;	chr11:14853429	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-9.1	4.48e-19	1.99e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
BRCA	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	9.1	4.49e-19	2e-16	0.4	0.27	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	9.1	4.49e-19	2e-16	0.4	0.27	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	9.1	4.49e-19	2e-16	0.28	0.27	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
BRCA	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-9.1	4.49e-19	2e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
BRCA	cis	rs2067615	0.579	rs4964489	ENSG00000260329.1	RP11-412D9.4	-9.1	4.5e-19	2e-16	-0.29	-0.27	Heart rate;	chr12:106778030	chr12:106954029~106955497:-
BRCA	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-9.1	4.5e-19	2e-16	-0.33	-0.27	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	9.1	4.51e-19	2.01e-16	0.32	0.27	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
BRCA	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	9.1	4.52e-19	2.01e-16	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
BRCA	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-9.1	4.52e-19	2.01e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
BRCA	cis	rs58873874	0.737	rs10476052	ENSG00000251405.2	CTB-109A12.1	9.1	4.52e-19	2.01e-16	0.69	0.27	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157362615~157460078:-
BRCA	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	9.1	4.52e-19	2.01e-16	0.33	0.27	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
BRCA	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-9.1	4.55e-19	2.02e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
BRCA	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	9.1	4.56e-19	2.02e-16	0.33	0.27	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
BRCA	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	9.1	4.56e-19	2.03e-16	0.43	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
BRCA	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-9.1	4.56e-19	2.03e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.557	rs5759666	ENSG00000230701.2	FBXW4P1	9.1	4.58e-19	2.03e-16	0.34	0.27	Height;	chr22:23260155	chr22:23262767~23265005:+
BRCA	cis	rs12188164	0.61	rs6555242	ENSG00000225138.6	CTD-2228K2.7	9.1	4.58e-19	2.03e-16	0.31	0.27	Cystic fibrosis severity;	chr5:416431	chr5:473236~480884:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-9.1	4.58e-19	2.04e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
BRCA	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-9.1	4.59e-19	2.04e-16	-0.32	-0.27	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-9.1	4.62e-19	2.05e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
BRCA	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-9.1	4.63e-19	2.06e-16	-0.55	-0.27	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-9.1	4.63e-19	2.06e-16	-0.32	-0.27	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-9.1	4.63e-19	2.06e-16	-0.32	-0.27	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-9.1	4.64e-19	2.06e-16	-0.34	-0.27	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
BRCA	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-9.1	4.65e-19	2.06e-16	-0.38	-0.27	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	9.1	4.66e-19	2.07e-16	0.27	0.27	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-9.1	4.66e-19	2.07e-16	-0.32	-0.27	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-9.09	4.68e-19	2.08e-16	-0.31	-0.27	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
BRCA	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	9.09	4.68e-19	2.08e-16	0.33	0.27	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-9.09	4.69e-19	2.08e-16	-0.3	-0.27	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
BRCA	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-9.09	4.7e-19	2.09e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	9.09	4.7e-19	2.09e-16	0.27	0.27	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	9.09	4.72e-19	2.1e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
BRCA	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	9.09	4.72e-19	2.1e-16	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	9.09	4.72e-19	2.1e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	9.09	4.74e-19	2.1e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	9.09	4.74e-19	2.11e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-9.09	4.75e-19	2.11e-16	-0.3	-0.27	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
BRCA	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-9.09	4.76e-19	2.11e-16	-0.25	-0.27	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	9.09	4.76e-19	2.11e-16	0.28	0.27	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	9.09	4.76e-19	2.11e-16	0.28	0.27	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
BRCA	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-9.09	4.79e-19	2.13e-16	-0.31	-0.27	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
BRCA	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	9.09	4.8e-19	2.13e-16	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
BRCA	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-9.09	4.8e-19	2.13e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-9.09	4.81e-19	2.13e-16	-0.33	-0.27	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	9.09	4.82e-19	2.14e-16	0.36	0.27	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
BRCA	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-9.09	4.87e-19	2.16e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
BRCA	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	9.09	4.87e-19	2.16e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-9.09	4.89e-19	2.17e-16	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
BRCA	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	9.09	4.9e-19	2.17e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
BRCA	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	9.09	4.92e-19	2.18e-16	0.33	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
BRCA	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	9.09	4.92e-19	2.18e-16	0.25	0.27	Asthma;	chr2:102418659	chr2:102438713~102440475:+
BRCA	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-9.09	4.94e-19	2.19e-16	-0.4	-0.27	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-9.09	4.95e-19	2.2e-16	-0.33	-0.27	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
BRCA	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	9.09	4.96e-19	2.2e-16	0.35	0.27	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
BRCA	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	9.09	4.97e-19	2.2e-16	0.39	0.27	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
BRCA	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	9.09	4.97e-19	2.2e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
BRCA	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-9.09	4.97e-19	2.2e-16	-0.34	-0.27	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
BRCA	cis	rs8062405	1	rs56404918	ENSG00000278665.1	RP11-666O2.4	9.09	4.99e-19	2.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs55719896	ENSG00000278665.1	RP11-666O2.4	9.09	4.99e-19	2.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28599241~28601881:-
BRCA	cis	rs5751614	0.537	rs9608093	ENSG00000230701.2	FBXW4P1	9.09	5e-19	2.21e-16	0.35	0.27	Height;	chr22:23271352	chr22:23262767~23265005:+
BRCA	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	9.09	5.03e-19	2.23e-16	0.25	0.27	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
BRCA	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-9.09	5.03e-19	2.23e-16	-0.31	-0.27	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
BRCA	cis	rs55665837	0.539	rs10832311	ENSG00000251991.1	RNU7-49P	9.09	5.03e-19	2.23e-16	0.31	0.27	Vitamin D levels;	chr11:14860380	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	9.09	5.04e-19	2.23e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	9.09	5.04e-19	2.23e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	9.09	5.06e-19	2.24e-16	0.36	0.27	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
BRCA	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	9.09	5.09e-19	2.25e-16	0.32	0.27	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
BRCA	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-9.08	5.09e-19	2.25e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	9.08	5.1e-19	2.26e-16	0.28	0.27	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
BRCA	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	9.08	5.1e-19	2.26e-16	0.31	0.27	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	9.08	5.12e-19	2.27e-16	0.32	0.27	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
BRCA	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	9.08	5.12e-19	2.27e-16	0.36	0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
BRCA	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-9.08	5.16e-19	2.28e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-9.08	5.16e-19	2.28e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
BRCA	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	9.08	5.17e-19	2.29e-16	0.48	0.27	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
BRCA	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-9.08	5.18e-19	2.29e-16	-0.34	-0.27	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
BRCA	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	9.08	5.2e-19	2.3e-16	0.42	0.27	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
BRCA	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
BRCA	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	9.08	5.2e-19	2.3e-16	0.32	0.27	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
BRCA	cis	rs8062405	1	rs55830740	ENSG00000278665.1	RP11-666O2.4	9.08	5.21e-19	2.3e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28599241~28601881:-
BRCA	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	9.08	5.21e-19	2.3e-16	0.4	0.27	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-9.08	5.25e-19	2.32e-16	-0.4	-0.27	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	9.08	5.26e-19	2.33e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
BRCA	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-9.08	5.27e-19	2.33e-16	-0.34	-0.27	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
BRCA	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-9.08	5.29e-19	2.34e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
BRCA	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-9.08	5.29e-19	2.34e-16	-0.31	-0.27	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
BRCA	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	9.08	5.3e-19	2.34e-16	0.33	0.27	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	9.08	5.3e-19	2.34e-16	0.28	0.27	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	9.08	5.31e-19	2.35e-16	0.36	0.27	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-9.08	5.32e-19	2.35e-16	-0.31	-0.27	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
BRCA	cis	rs2067615	0.56	rs10467028	ENSG00000260329.1	RP11-412D9.4	-9.08	5.35e-19	2.36e-16	-0.29	-0.27	Heart rate;	chr12:106682627	chr12:106954029~106955497:-
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-9.08	5.35e-19	2.37e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-9.08	5.37e-19	2.37e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
BRCA	cis	rs1900504	0.584	rs2915754	ENSG00000266200.5	PNLIPRP2	-9.08	5.39e-19	2.38e-16	-0.35	-0.27	Tonsillectomy;	chr10:116605306	chr10:116620953~116645143:+
BRCA	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-9.08	5.4e-19	2.38e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-9.08	5.4e-19	2.38e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
BRCA	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-9.08	5.4e-19	2.39e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
BRCA	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	9.08	5.4e-19	2.39e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	9.08	5.41e-19	2.39e-16	0.4	0.27	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
BRCA	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-9.08	5.43e-19	2.4e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-9.08	5.43e-19	2.4e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-9.08	5.44e-19	2.4e-16	-0.32	-0.27	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-9.08	5.45e-19	2.41e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	9.08	5.5e-19	2.43e-16	0.28	0.27	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
BRCA	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
BRCA	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	9.07	5.55e-19	2.45e-16	0.42	0.27	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
BRCA	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	9.07	5.56e-19	2.45e-16	0.33	0.27	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	9.07	5.57e-19	2.46e-16	0.33	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	9.07	5.57e-19	2.46e-16	0.33	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
BRCA	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-9.07	5.59e-19	2.46e-16	-0.4	-0.27	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
BRCA	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	9.07	5.6e-19	2.47e-16	0.39	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
BRCA	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-9.07	5.6e-19	2.47e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	9.07	5.6e-19	2.47e-16	0.25	0.27	Asthma;	chr2:102403679	chr2:102438713~102440475:+
BRCA	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	9.07	5.61e-19	2.47e-16	0.33	0.27	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
BRCA	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	9.07	5.62e-19	2.48e-16	0.25	0.27	Asthma;	chr2:102404807	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	9.07	5.62e-19	2.48e-16	0.25	0.27	Asthma;	chr2:102407218	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
BRCA	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	9.07	5.62e-19	2.48e-16	0.37	0.27	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
BRCA	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-9.07	5.63e-19	2.48e-16	-0.39	-0.27	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
BRCA	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	9.07	5.64e-19	2.49e-16	0.25	0.27	Asthma;	chr2:102403325	chr2:102438713~102440475:+
BRCA	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-9.07	5.65e-19	2.49e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
BRCA	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-9.07	5.65e-19	2.49e-16	-0.34	-0.27	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000278665.1	RP11-666O2.4	9.07	5.66e-19	2.49e-16	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28599241~28601881:-
BRCA	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-9.07	5.67e-19	2.5e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
BRCA	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	9.07	5.7e-19	2.51e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
BRCA	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	9.07	5.7e-19	2.51e-16	0.29	0.27	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
BRCA	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
BRCA	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-9.07	5.71e-19	2.52e-16	-0.28	-0.27	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
BRCA	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-9.07	5.72e-19	2.52e-16	-0.29	-0.27	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
BRCA	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-9.07	5.79e-19	2.55e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-9.07	5.79e-19	2.55e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-9.07	5.84e-19	2.57e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
BRCA	cis	rs2067615	0.579	rs10778502	ENSG00000260329.1	RP11-412D9.4	-9.07	5.85e-19	2.58e-16	-0.3	-0.27	Heart rate;	chr12:106696423	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-9.07	5.9e-19	2.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
BRCA	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-9.07	5.93e-19	2.61e-16	-0.34	-0.27	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
BRCA	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-9.07	5.94e-19	2.61e-16	-0.34	-0.27	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
BRCA	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-9.07	5.96e-19	2.62e-16	-0.32	-0.27	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
BRCA	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-9.07	5.96e-19	2.62e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-9.07	5.98e-19	2.63e-16	-0.32	-0.27	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-9.07	6.01e-19	2.64e-16	-0.32	-0.27	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	9.07	6.01e-19	2.64e-16	0.25	0.27	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-9.06	6.04e-19	2.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-9.06	6.05e-19	2.66e-16	-0.33	-0.27	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	9.06	6.06e-19	2.67e-16	0.24	0.27	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
BRCA	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	9.06	6.07e-19	2.67e-16	0.28	0.27	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	9.06	6.07e-19	2.67e-16	0.28	0.27	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
BRCA	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	9.06	6.08e-19	2.67e-16	0.33	0.27	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
BRCA	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-9.06	6.09e-19	2.68e-16	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
BRCA	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	9.06	6.13e-19	2.7e-16	0.31	0.27	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
BRCA	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-9.06	6.13e-19	2.7e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
BRCA	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-9.06	6.14e-19	2.7e-16	-0.36	-0.27	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
BRCA	cis	rs58873874	0.737	rs10476050	ENSG00000251405.2	CTB-109A12.1	9.06	6.17e-19	2.71e-16	0.68	0.27	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157362615~157460078:-
BRCA	cis	rs2067615	0.579	rs10861665	ENSG00000260329.1	RP11-412D9.4	-9.06	6.18e-19	2.72e-16	-0.29	-0.27	Heart rate;	chr12:106800058	chr12:106954029~106955497:-
BRCA	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	9.06	6.19e-19	2.72e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
BRCA	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-9.06	6.2e-19	2.72e-16	-0.36	-0.27	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
BRCA	cis	rs2067615	0.579	rs11113119	ENSG00000260329.1	RP11-412D9.4	-9.06	6.2e-19	2.73e-16	-0.29	-0.27	Heart rate;	chr12:106806278	chr12:106954029~106955497:-
BRCA	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-9.06	6.21e-19	2.73e-16	-0.34	-0.27	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-9.06	6.25e-19	2.74e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
BRCA	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-9.06	6.28e-19	2.76e-16	-0.34	-0.27	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
BRCA	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-9.06	6.29e-19	2.76e-16	-0.39	-0.27	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-9.06	6.29e-19	2.76e-16	-0.32	-0.27	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
BRCA	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	9.06	6.3e-19	2.77e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs35326382	ENSG00000249839.1	AC011330.5	-9.06	6.3e-19	2.77e-16	-0.39	-0.27	Lung cancer;	chr15:43338686	chr15:43663654~43684339:-
BRCA	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-9.06	6.32e-19	2.77e-16	-0.31	-0.27	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-9.06	6.32e-19	2.78e-16	-0.32	-0.27	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	9.06	6.33e-19	2.78e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
BRCA	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	9.06	6.35e-19	2.79e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	9.06	6.35e-19	2.79e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
BRCA	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-9.06	6.35e-19	2.79e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
BRCA	cis	rs4727443	0.691	rs6975827	ENSG00000235713.1	RP4-604G5.3	9.06	6.36e-19	2.79e-16	0.3	0.27	Interstitial lung disease;	chr7:99988175	chr7:99992397~99993050:+
BRCA	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	9.06	6.38e-19	2.8e-16	0.35	0.27	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.579	rs10507214	ENSG00000260329.1	RP11-412D9.4	-9.06	6.4e-19	2.81e-16	-0.29	-0.27	Heart rate;	chr12:106800683	chr12:106954029~106955497:-
BRCA	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
BRCA	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	9.06	6.41e-19	2.81e-16	0.33	0.27	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
BRCA	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	9.06	6.43e-19	2.82e-16	0.34	0.27	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
BRCA	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	9.06	6.44e-19	2.83e-16	0.32	0.27	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
BRCA	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	9.06	6.47e-19	2.84e-16	0.28	0.27	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-9.06	6.48e-19	2.84e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
BRCA	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-9.06	6.49e-19	2.84e-16	-0.36	-0.27	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-9.06	6.49e-19	2.84e-16	-0.36	-0.27	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	9.06	6.49e-19	2.85e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-9.06	6.5e-19	2.85e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
BRCA	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	9.06	6.5e-19	2.85e-16	0.28	0.27	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	9.06	6.52e-19	2.86e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-9.06	6.53e-19	2.86e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
BRCA	cis	rs4727443	0.653	rs6465759	ENSG00000235713.1	RP4-604G5.3	9.06	6.53e-19	2.86e-16	0.3	0.27	Interstitial lung disease;	chr7:99990357	chr7:99992397~99993050:+
BRCA	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-9.06	6.54e-19	2.87e-16	-0.31	-0.27	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
BRCA	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	9.05	6.6e-19	2.89e-16	0.32	0.27	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
BRCA	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-9.05	6.62e-19	2.9e-16	-0.29	-0.27	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-9.05	6.62e-19	2.9e-16	-0.33	-0.27	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	9.05	6.67e-19	2.92e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
BRCA	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-9.05	6.67e-19	2.92e-16	-0.25	-0.27	Asthma;	chr2:102401592	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-9.05	6.68e-19	2.93e-16	-0.33	-0.27	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
BRCA	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-9.05	6.72e-19	2.94e-16	-0.25	-0.27	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-9.05	6.72e-19	2.94e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-9.05	6.72e-19	2.94e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
BRCA	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	9.05	6.73e-19	2.95e-16	0.33	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
BRCA	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-9.05	6.73e-19	2.95e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
BRCA	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	9.05	6.74e-19	2.95e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
BRCA	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	9.05	6.77e-19	2.96e-16	0.31	0.27	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-9.05	6.77e-19	2.96e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-9.05	6.8e-19	2.98e-16	-0.25	-0.27	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
BRCA	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	9.05	6.8e-19	2.98e-16	0.35	0.27	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
BRCA	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	9.05	6.83e-19	2.99e-16	0.33	0.27	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
BRCA	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	9.05	6.86e-19	3e-16	0.34	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
BRCA	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-9.05	6.87e-19	3.01e-16	-0.32	-0.27	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	9.05	6.9e-19	3.02e-16	0.42	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-9.05	6.9e-19	3.02e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	9.05	6.92e-19	3.03e-16	0.35	0.27	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	9.05	6.92e-19	3.03e-16	0.35	0.27	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-9.05	6.92e-19	3.03e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-9.05	6.93e-19	3.03e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-9.05	6.93e-19	3.03e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
BRCA	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-9.05	6.96e-19	3.04e-16	-0.31	-0.27	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	9.05	6.96e-19	3.05e-16	0.31	0.27	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
BRCA	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
BRCA	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-9.05	7e-19	3.06e-16	-0.35	-0.27	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
BRCA	cis	rs2041895	0.509	rs1838445	ENSG00000260329.1	RP11-412D9.4	-9.05	7.02e-19	3.07e-16	-0.33	-0.27	Glaucoma (low intraocular pressure);	chr12:106920807	chr12:106954029~106955497:-
BRCA	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-9.05	7.02e-19	3.07e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
BRCA	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	9.05	7.06e-19	3.09e-16	0.29	0.27	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-9.05	7.1e-19	3.1e-16	-0.26	-0.27	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
BRCA	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	9.05	7.11e-19	3.11e-16	0.35	0.27	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-9.05	7.12e-19	3.11e-16	-0.29	-0.27	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	9.05	7.12e-19	3.11e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
BRCA	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
BRCA	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-9.04	7.19e-19	3.14e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
BRCA	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	9.04	7.23e-19	3.16e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-9.04	7.26e-19	3.17e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-9.04	7.27e-19	3.18e-16	-0.25	-0.27	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	9.04	7.28e-19	3.18e-16	0.33	0.27	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
BRCA	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	9.04	7.29e-19	3.18e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
BRCA	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-9.04	7.3e-19	3.19e-16	-0.39	-0.27	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	9.04	7.31e-19	3.19e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	9.04	7.31e-19	3.19e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
BRCA	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-9.04	7.32e-19	3.19e-16	-0.31	-0.27	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	9.04	7.32e-19	3.2e-16	0.19	0.27	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-9.04	7.36e-19	3.21e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
BRCA	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	9.04	7.36e-19	3.21e-16	0.31	0.27	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	9.04	7.37e-19	3.22e-16	0.27	0.27	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-9.04	7.41e-19	3.23e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-9.04	7.42e-19	3.24e-16	-0.33	-0.27	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
BRCA	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	9.04	7.42e-19	3.24e-16	0.32	0.27	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
BRCA	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	9.04	7.44e-19	3.24e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
BRCA	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	9.04	7.45e-19	3.25e-16	0.31	0.27	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	9.04	7.45e-19	3.25e-16	0.31	0.27	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
BRCA	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-9.04	7.45e-19	3.25e-16	-0.39	-0.27	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
BRCA	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	9.04	7.47e-19	3.26e-16	0.34	0.27	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-9.04	7.47e-19	3.26e-16	-0.32	-0.27	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-9.04	7.51e-19	3.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	9.04	7.52e-19	3.28e-16	0.37	0.27	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
BRCA	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-9.04	7.53e-19	3.28e-16	-0.35	-0.27	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
BRCA	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-9.04	7.53e-19	3.28e-16	-0.4	-0.27	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
BRCA	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	9.04	7.55e-19	3.29e-16	0.52	0.27	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
BRCA	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	9.04	7.55e-19	3.29e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-9.04	7.56e-19	3.3e-16	-0.29	-0.27	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-9.04	7.57e-19	3.3e-16	-0.27	-0.27	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
BRCA	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	9.04	7.58e-19	3.3e-16	0.31	0.27	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
BRCA	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-9.04	7.58e-19	3.3e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-9.04	7.58e-19	3.3e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.537	rs11090228	ENSG00000230701.2	FBXW4P1	9.04	7.59e-19	3.31e-16	0.34	0.27	Height;	chr22:23289452	chr22:23262767~23265005:+
BRCA	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-9.04	7.6e-19	3.31e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-9.04	7.6e-19	3.31e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
BRCA	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	9.04	7.61e-19	3.31e-16	0.4	0.27	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
BRCA	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	9.04	7.62e-19	3.32e-16	0.34	0.27	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
BRCA	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	9.04	7.63e-19	3.32e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
BRCA	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-9.04	7.64e-19	3.33e-16	-0.32	-0.27	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
BRCA	cis	rs5751614	0.537	rs2227939	ENSG00000230701.2	FBXW4P1	9.04	7.65e-19	3.33e-16	0.34	0.27	Height;	chr22:23289614	chr22:23262767~23265005:+
BRCA	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-9.04	7.65e-19	3.33e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	9.04	7.67e-19	3.34e-16	0.33	0.27	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
BRCA	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	9.04	7.69e-19	3.35e-16	0.34	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
BRCA	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	9.04	7.72e-19	3.36e-16	0.31	0.27	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
BRCA	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	9.04	7.74e-19	3.37e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	9.04	7.74e-19	3.37e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
BRCA	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-9.04	7.76e-19	3.38e-16	-0.36	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
BRCA	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	9.04	7.77e-19	3.38e-16	0.3	0.27	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
BRCA	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	9.04	7.77e-19	3.38e-16	0.38	0.27	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
BRCA	cis	rs2067615	0.56	rs10431462	ENSG00000260329.1	RP11-412D9.4	-9.04	7.78e-19	3.39e-16	-0.29	-0.27	Heart rate;	chr12:106712768	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	9.03	7.79e-19	3.39e-16	0.32	0.27	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-9.03	7.85e-19	3.42e-16	-0.31	-0.27	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
BRCA	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-9.03	7.86e-19	3.42e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000220721.1	OR1F12	9.03	7.86e-19	3.42e-16	0.49	0.27	Depression;	chr6:28124907	chr6:28073316~28074233:+
BRCA	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-9.03	7.91e-19	3.44e-16	-0.35	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
BRCA	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-9.03	7.91e-19	3.44e-16	-0.34	-0.27	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	9.03	7.93e-19	3.45e-16	0.32	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
BRCA	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-9.03	7.93e-19	3.45e-16	-0.44	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
BRCA	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	9.03	7.98e-19	3.47e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-9.03	7.98e-19	3.47e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-9.03	7.98e-19	3.47e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
BRCA	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	9.03	7.99e-19	3.47e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	9.03	7.99e-19	3.47e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	9.03	8e-19	3.48e-16	0.25	0.27	Asthma;	chr2:102411191	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-9.03	8.01e-19	3.48e-16	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
BRCA	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
BRCA	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-9.03	8.07e-19	3.51e-16	-0.25	-0.27	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
BRCA	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	9.03	8.07e-19	3.51e-16	0.41	0.27	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
BRCA	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	9.03	8.09e-19	3.51e-16	0.25	0.27	Asthma;	chr2:102411180	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-9.03	8.13e-19	3.53e-16	-0.33	-0.27	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
BRCA	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	9.03	8.15e-19	3.54e-16	0.27	0.27	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-9.03	8.16e-19	3.55e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
BRCA	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	9.03	8.22e-19	3.57e-16	0.29	0.27	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-9.03	8.23e-19	3.57e-16	-0.32	-0.27	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
BRCA	cis	rs58873874	0.737	rs11745566	ENSG00000251405.2	CTB-109A12.1	9.03	8.23e-19	3.58e-16	0.68	0.27	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157362615~157460078:-
BRCA	cis	rs2041895	0.527	rs10861678	ENSG00000260329.1	RP11-412D9.4	-9.03	8.24e-19	3.58e-16	-0.34	-0.27	Glaucoma (low intraocular pressure);	chr12:106925883	chr12:106954029~106955497:-
BRCA	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-9.03	8.27e-19	3.59e-16	-0.35	-0.27	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
BRCA	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	9.03	8.28e-19	3.59e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-9.03	8.28e-19	3.6e-16	-0.33	-0.27	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
BRCA	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-9.03	8.29e-19	3.6e-16	-0.26	-0.27	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
BRCA	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-9.03	8.3e-19	3.6e-16	-0.34	-0.27	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-9.03	8.33e-19	3.62e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
BRCA	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-9.03	8.34e-19	3.62e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
BRCA	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-9.03	8.36e-19	3.63e-16	-0.39	-0.27	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	9.03	8.36e-19	3.63e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-9.03	8.39e-19	3.64e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	9.03	8.4e-19	3.64e-16	0.26	0.27	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	9.03	8.45e-19	3.66e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-9.03	8.45e-19	3.67e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	9.03	8.45e-19	3.67e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
BRCA	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-9.03	8.47e-19	3.67e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
BRCA	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-9.02	8.49e-19	3.69e-16	-0.39	-0.27	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
BRCA	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	9.02	8.51e-19	3.69e-16	0.31	0.27	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
BRCA	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	9.02	8.53e-19	3.7e-16	0.41	0.27	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
BRCA	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.02	8.55e-19	3.71e-16	0.24	0.27	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
BRCA	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-9.02	8.56e-19	3.71e-16	-0.39	-0.27	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	9.02	8.57e-19	3.71e-16	0.28	0.27	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-9.02	8.57e-19	3.72e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
BRCA	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	9.02	8.58e-19	3.72e-16	0.4	0.27	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
BRCA	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	9.02	8.59e-19	3.72e-16	0.35	0.27	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.599	rs10778508	ENSG00000260329.1	RP11-412D9.4	9.02	8.6e-19	3.73e-16	0.29	0.27	Heart rate;	chr12:106765627	chr12:106954029~106955497:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.73e-16	0.28	0.27	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.73e-16	0.28	0.27	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	9.02	8.62e-19	3.74e-16	0.4	0.27	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-9.02	8.67e-19	3.76e-16	-0.34	-0.27	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
BRCA	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	9.02	8.69e-19	3.76e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-9.02	8.69e-19	3.76e-16	-0.31	-0.27	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
BRCA	cis	rs67981189	0.542	rs17109053	ENSG00000269927.1	RP6-91H8.3	9.02	8.69e-19	3.77e-16	0.36	0.27	Schizophrenia;	chr14:71142981	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-9.02	8.72e-19	3.78e-16	-0.31	-0.27	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	9.02	8.72e-19	3.78e-16	0.31	0.27	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	9.02	8.75e-19	3.79e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	9.02	8.76e-19	3.79e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
BRCA	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	9.02	8.77e-19	3.8e-16	0.33	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
BRCA	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-9.02	8.79e-19	3.81e-16	-0.32	-0.27	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-9.02	8.8e-19	3.81e-16	-0.4	-0.27	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
BRCA	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	9.02	8.8e-19	3.81e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	9.02	8.83e-19	3.82e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	9.02	8.84e-19	3.83e-16	0.25	0.27	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
BRCA	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-9.02	8.88e-19	3.84e-16	-0.47	-0.27	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
BRCA	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-9.02	8.88e-19	3.85e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
BRCA	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	9.02	8.94e-19	3.87e-16	0.42	0.27	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
BRCA	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	9.02	8.96e-19	3.88e-16	0.4	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	9.02	8.98e-19	3.89e-16	0.28	0.27	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-9.02	8.98e-19	3.89e-16	-0.39	-0.27	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.559	rs4369365	ENSG00000251991.1	RNU7-49P	9.02	8.99e-19	3.89e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14422969	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-9.02	9e-19	3.9e-16	-0.31	-0.27	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
BRCA	cis	rs2067615	0.579	rs10861655	ENSG00000260329.1	RP11-412D9.4	9.02	9.01e-19	3.9e-16	0.29	0.27	Heart rate;	chr12:106735641	chr12:106954029~106955497:-
BRCA	cis	rs58873874	0.737	rs78832945	ENSG00000251405.2	CTB-109A12.1	9.02	9.02e-19	3.9e-16	0.66	0.27	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157362615~157460078:-
BRCA	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-9.02	9.02e-19	3.9e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-9.02	9.02e-19	3.9e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
BRCA	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
BRCA	cis	rs4862750	0.957	rs2375916	ENSG00000250971.1	RP11-696F12.1	9.02	9.05e-19	3.91e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:187060099~187060930:+
BRCA	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	9.02	9.07e-19	3.92e-16	0.42	0.27	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
BRCA	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	9.02	9.07e-19	3.92e-16	0.25	0.27	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	9.02	9.08e-19	3.93e-16	0.31	0.27	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-9.02	9.09e-19	3.93e-16	-0.25	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
BRCA	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	9.02	9.13e-19	3.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
BRCA	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	9.02	9.13e-19	3.95e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
BRCA	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	9.02	9.14e-19	3.95e-16	0.25	0.27	Asthma;	chr2:102415289	chr2:102438713~102440475:+
BRCA	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	9.02	9.15e-19	3.96e-16	0.32	0.27	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
BRCA	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	9.02	9.16e-19	3.96e-16	0.33	0.27	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	9.02	9.18e-19	3.97e-16	0.27	0.27	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	9.02	9.19e-19	3.97e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
BRCA	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-9.02	9.2e-19	3.98e-16	-0.33	-0.27	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
BRCA	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	9.02	9.2e-19	3.98e-16	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
BRCA	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-9.01	9.22e-19	3.99e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
BRCA	cis	rs5751614	0.537	rs9608100	ENSG00000230701.2	FBXW4P1	9.01	9.24e-19	3.99e-16	0.34	0.27	Height;	chr22:23290070	chr22:23262767~23265005:+
BRCA	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	9.01	9.24e-19	4e-16	0.24	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
BRCA	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-9.01	9.26e-19	4e-16	-0.4	-0.27	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
BRCA	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
BRCA	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-9.01	9.28e-19	4.01e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
BRCA	cis	rs55665837	0.502	rs12795794	ENSG00000251991.1	RNU7-49P	9.01	9.29e-19	4.01e-16	0.31	0.27	Vitamin D levels;	chr11:14825327	chr11:14478892~14478953:+
BRCA	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-9.01	9.32e-19	4.03e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
BRCA	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	9.01	9.35e-19	4.04e-16	0.3	0.27	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
BRCA	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	9.01	9.35e-19	4.04e-16	0.35	0.27	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-9.01	9.36e-19	4.04e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-9.01	9.37e-19	4.05e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-9.01	9.39e-19	4.06e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
BRCA	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-9.01	9.4e-19	4.06e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
BRCA	cis	rs5751614	0.537	rs5759681	ENSG00000230701.2	FBXW4P1	-9.01	9.41e-19	4.06e-16	-0.34	-0.27	Height;	chr22:23287365	chr22:23262767~23265005:+
BRCA	cis	rs8396	1	rs9410	ENSG00000271817.2	U3	9.01	9.43e-19	4.07e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158710839	chr4:158700691~158700909:+
BRCA	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	9.01	9.44e-19	4.07e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	9.01	9.44e-19	4.07e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
BRCA	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	9.01	9.45e-19	4.08e-16	0.34	0.27	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-9.01	9.45e-19	4.08e-16	-0.33	-0.27	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-9.01	9.48e-19	4.09e-16	-0.33	-0.27	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
BRCA	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	9.01	9.48e-19	4.09e-16	0.35	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	9.01	9.53e-19	4.12e-16	0.31	0.27	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-9.01	9.56e-19	4.12e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	9.01	9.58e-19	4.13e-16	0.31	0.27	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
BRCA	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-9.01	9.59e-19	4.14e-16	-0.31	-0.27	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
BRCA	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	9.01	9.62e-19	4.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-9.01	9.65e-19	4.16e-16	-0.31	-0.27	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-9.01	9.67e-19	4.17e-16	-0.31	-0.27	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
BRCA	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	9.01	9.69e-19	4.18e-16	0.33	0.27	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
BRCA	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-9.01	9.7e-19	4.19e-16	-0.39	-0.27	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-9.01	9.71e-19	4.19e-16	-0.39	-0.27	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
BRCA	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-9.01	9.73e-19	4.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-9.01	9.76e-19	4.21e-16	-0.25	-0.27	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
BRCA	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	9.01	9.79e-19	4.22e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
BRCA	cis	rs1900504	0.584	rs3010501	ENSG00000266200.5	PNLIPRP2	-9.01	9.82e-19	4.23e-16	-0.34	-0.27	Tonsillectomy;	chr10:116604130	chr10:116620953~116645143:+
BRCA	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	9.01	9.84e-19	4.24e-16	0.4	0.27	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
BRCA	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-9.01	9.87e-19	4.26e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
BRCA	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-9.01	9.89e-19	4.26e-16	-0.34	-0.27	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	9.01	9.93e-19	4.28e-16	0.27	0.27	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	9.01	9.93e-19	4.28e-16	0.27	0.27	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	9.01	9.95e-19	4.29e-16	0.38	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	9.01	9.96e-19	4.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-9.01	9.96e-19	4.29e-16	-0.36	-0.27	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	9.01	9.97e-19	4.3e-16	0.3	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
BRCA	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	9.01	9.98e-19	4.3e-16	0.32	0.27	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-9.01	9.99e-19	4.31e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	9.01	1e-18	4.31e-16	0.27	0.27	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-9.01	1e-18	4.32e-16	-0.36	-0.27	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-9	1.01e-18	4.34e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
BRCA	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-9	1.01e-18	4.34e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
BRCA	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-9	1.01e-18	4.36e-16	-0.26	-0.27	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
BRCA	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	9	1.01e-18	4.36e-16	0.41	0.27	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
BRCA	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-9	1.01e-18	4.37e-16	-0.31	-0.27	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
BRCA	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	9	1.02e-18	4.39e-16	0.31	0.27	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
BRCA	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	9	1.02e-18	4.4e-16	0.32	0.27	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
BRCA	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	9	1.02e-18	4.4e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
BRCA	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-9	1.02e-18	4.4e-16	-0.31	-0.27	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
BRCA	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.42e-16	-0.34	-0.27	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000220721.1	OR1F12	9	1.03e-18	4.42e-16	0.49	0.27	Depression;	chr6:28119105	chr6:28073316~28074233:+
BRCA	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.44e-16	-0.34	-0.27	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.44e-16	-0.34	-0.27	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
BRCA	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	9	1.03e-18	4.44e-16	0.32	0.27	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-9	1.03e-18	4.45e-16	-0.31	-0.27	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
BRCA	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	9	1.04e-18	4.48e-16	0.39	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
BRCA	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	9	1.04e-18	4.49e-16	0.42	0.27	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
BRCA	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-9	1.05e-18	4.5e-16	-0.39	-0.27	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-9	1.05e-18	4.52e-16	-0.31	-0.27	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
BRCA	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-9	1.05e-18	4.52e-16	-0.36	-0.27	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	9	1.05e-18	4.52e-16	0.28	0.27	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-9	1.05e-18	4.53e-16	-0.52	-0.27	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	9	1.05e-18	4.53e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
BRCA	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	9	1.05e-18	4.53e-16	0.33	0.27	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
BRCA	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-9	1.06e-18	4.56e-16	-0.35	-0.27	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
BRCA	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-9	1.06e-18	4.56e-16	-0.34	-0.27	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
BRCA	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	9	1.06e-18	4.56e-16	0.32	0.27	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-9	1.06e-18	4.57e-16	-0.32	-0.27	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
BRCA	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-9	1.07e-18	4.59e-16	-0.34	-0.27	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
BRCA	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-9	1.07e-18	4.59e-16	-0.31	-0.27	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
BRCA	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	9	1.07e-18	4.59e-16	0.3	0.27	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	9	1.07e-18	4.61e-16	0.19	0.27	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
BRCA	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.505	rs4403769	ENSG00000251991.1	RNU7-49P	9	1.07e-18	4.62e-16	0.29	0.27	Mitochondrial DNA levels;	chr11:14428630	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-9	1.08e-18	4.66e-16	-0.33	-0.27	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
BRCA	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	9	1.09e-18	4.68e-16	0.3	0.27	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
BRCA	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-9	1.09e-18	4.68e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-9	1.09e-18	4.68e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-8.99	1.1e-18	4.71e-16	-0.32	-0.27	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-8.99	1.1e-18	4.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-8.99	1.1e-18	4.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
BRCA	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	8.99	1.1e-18	4.71e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	8.99	1.11e-18	4.77e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
BRCA	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-8.99	1.11e-18	4.78e-16	-0.39	-0.27	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
BRCA	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	8.99	1.12e-18	4.81e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	8.99	1.12e-18	4.82e-16	0.26	0.27	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	8.99	1.13e-18	4.83e-16	0.34	0.27	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-8.99	1.13e-18	4.85e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-8.99	1.13e-18	4.85e-16	-0.28	-0.27	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
BRCA	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	8.99	1.14e-18	4.87e-16	0.25	0.27	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-8.99	1.14e-18	4.88e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-8.99	1.14e-18	4.88e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.99	1.14e-18	4.9e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-8.99	1.14e-18	4.91e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	8.99	1.15e-18	4.91e-16	0.31	0.27	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-8.99	1.15e-18	4.91e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
BRCA	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	8.99	1.15e-18	4.91e-16	0.41	0.27	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
BRCA	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	8.99	1.15e-18	4.93e-16	0.39	0.27	Depression;	chr6:28407125	chr6:28176188~28176674:+
BRCA	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-8.99	1.15e-18	4.95e-16	-0.34	-0.27	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
BRCA	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-8.99	1.16e-18	4.96e-16	-0.48	-0.27	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
BRCA	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	8.99	1.16e-18	4.98e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	8.99	1.16e-18	4.98e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
BRCA	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-8.99	1.17e-18	5.02e-16	-0.34	-0.27	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
BRCA	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	8.99	1.18e-18	5.05e-16	0.4	0.27	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
BRCA	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	8.99	1.18e-18	5.05e-16	0.4	0.27	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
BRCA	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-8.99	1.18e-18	5.06e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	8.99	1.18e-18	5.06e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	8.99	1.18e-18	5.07e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
BRCA	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	8.99	1.18e-18	5.07e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
BRCA	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	8.99	1.18e-18	5.07e-16	0.32	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
BRCA	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	8.99	1.19e-18	5.09e-16	0.28	0.27	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
BRCA	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	8.99	1.19e-18	5.09e-16	0.34	0.27	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	8.99	1.19e-18	5.09e-16	0.34	0.27	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	8.99	1.19e-18	5.09e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.579	rs3782709	ENSG00000260329.1	RP11-412D9.4	-8.98	1.19e-18	5.09e-16	-0.29	-0.27	Heart rate;	chr12:106811975	chr12:106954029~106955497:-
BRCA	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	8.98	1.19e-18	5.1e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
BRCA	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	8.98	1.19e-18	5.1e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	8.98	1.19e-18	5.1e-16	0.37	0.27	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-8.98	1.19e-18	5.11e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
BRCA	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	8.98	1.19e-18	5.11e-16	0.34	0.27	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
BRCA	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-8.98	1.2e-18	5.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
BRCA	cis	rs2067615	0.579	rs1811458	ENSG00000260329.1	RP11-412D9.4	-8.98	1.2e-18	5.15e-16	-0.29	-0.27	Heart rate;	chr12:106809905	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	8.98	1.21e-18	5.18e-16	0.31	0.27	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-8.98	1.21e-18	5.19e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
BRCA	cis	rs8062405	1	rs80275162	ENSG00000278665.1	RP11-666O2.4	8.98	1.22e-18	5.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28599241~28601881:-
BRCA	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-8.98	1.22e-18	5.22e-16	-0.34	-0.27	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
BRCA	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-8.98	1.23e-18	5.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-8.98	1.23e-18	5.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
BRCA	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	8.98	1.24e-18	5.31e-16	0.29	0.27	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
BRCA	cis	rs13256369	0.951	rs13270852	ENSG00000253893.2	FAM85B	-8.98	1.24e-18	5.32e-16	-0.38	-0.27	Obesity-related traits;	chr8:8709343	chr8:8167819~8226614:-
BRCA	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-8.98	1.24e-18	5.32e-16	-0.34	-0.27	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
BRCA	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-8.98	1.25e-18	5.33e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
BRCA	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	8.98	1.25e-18	5.33e-16	0.35	0.27	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-8.98	1.25e-18	5.34e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	8.98	1.26e-18	5.39e-16	0.39	0.27	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
BRCA	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-8.98	1.26e-18	5.4e-16	-0.47	-0.27	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
BRCA	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	8.98	1.26e-18	5.4e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
BRCA	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-8.98	1.26e-18	5.41e-16	-0.36	-0.27	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-8.98	1.27e-18	5.43e-16	-0.25	-0.27	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-8.98	1.27e-18	5.44e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
BRCA	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-8.98	1.27e-18	5.45e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
BRCA	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-8.98	1.27e-18	5.45e-16	-0.4	-0.27	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
BRCA	cis	rs10740039	0.768	rs920646	ENSG00000254271.1	RP11-131N11.4	8.98	1.27e-18	5.45e-16	0.36	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703767	chr10:60734342~60741828:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-8.98	1.28e-18	5.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-8.98	1.28e-18	5.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	8.98	1.29e-18	5.5e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	8.98	1.29e-18	5.5e-16	0.26	0.27	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
BRCA	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	8.98	1.29e-18	5.51e-16	0.24	0.27	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
BRCA	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	8.98	1.29e-18	5.52e-16	0.25	0.27	Asthma;	chr2:102410644	chr2:102438713~102440475:+
BRCA	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	8.97	1.3e-18	5.55e-16	0.27	0.27	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-8.97	1.3e-18	5.55e-16	-0.39	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
BRCA	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	8.97	1.3e-18	5.57e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-8.97	1.31e-18	5.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-8.97	1.31e-18	5.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	8.97	1.31e-18	5.6e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
BRCA	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	8.97	1.32e-18	5.64e-16	0.35	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
BRCA	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-8.97	1.32e-18	5.65e-16	-0.31	-0.27	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
BRCA	cis	rs7085104	0.66	rs7902804	ENSG00000213061.2	PFN1P11	8.97	1.33e-18	5.66e-16	0.35	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102838011~102845473:-
BRCA	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	8.97	1.33e-18	5.68e-16	0.31	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
BRCA	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-8.97	1.33e-18	5.69e-16	-0.32	-0.27	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
BRCA	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-8.97	1.34e-18	5.72e-16	-0.3	-0.27	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	8.97	1.34e-18	5.72e-16	0.35	0.27	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
BRCA	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-8.97	1.34e-18	5.73e-16	-0.31	-0.27	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-8.97	1.34e-18	5.73e-16	-0.31	-0.27	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-8.97	1.34e-18	5.74e-16	-0.31	-0.27	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-8.97	1.34e-18	5.74e-16	-0.31	-0.27	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-8.97	1.35e-18	5.74e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-8.97	1.35e-18	5.75e-16	-0.24	-0.27	Asthma;	chr2:102394777	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-8.97	1.35e-18	5.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	8.97	1.35e-18	5.77e-16	0.29	0.27	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	8.97	1.36e-18	5.78e-16	0.37	0.27	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
BRCA	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	8.97	1.36e-18	5.8e-16	0.3	0.27	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
BRCA	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-8.97	1.36e-18	5.82e-16	-0.33	-0.27	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
BRCA	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
BRCA	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
BRCA	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
BRCA	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-8.97	1.38e-18	5.88e-16	-0.34	-0.27	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-8.97	1.38e-18	5.9e-16	-0.36	-0.27	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-8.97	1.4e-18	5.95e-16	-0.34	-0.27	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	8.97	1.4e-18	5.96e-16	0.35	0.27	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
BRCA	cis	rs5751614	0.537	rs5759682	ENSG00000230701.2	FBXW4P1	8.97	1.41e-18	5.99e-16	0.34	0.27	Height;	chr22:23288992	chr22:23262767~23265005:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-8.96	1.41e-18	6e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	8.96	1.41e-18	6e-16	0.31	0.27	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
BRCA	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	8.96	1.42e-18	6.03e-16	0.34	0.27	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
BRCA	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	8.96	1.42e-18	6.05e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.06e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	8.96	1.43e-18	6.07e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-8.96	1.43e-18	6.09e-16	-0.26	-0.27	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
BRCA	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	8.96	1.43e-18	6.1e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-8.96	1.44e-18	6.11e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-8.96	1.44e-18	6.11e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
BRCA	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-8.96	1.44e-18	6.14e-16	-0.24	-0.27	Asthma;	chr2:102392894	chr2:102438713~102440475:+
BRCA	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	8.96	1.44e-18	6.15e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	8.96	1.44e-18	6.15e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	8.96	1.45e-18	6.16e-16	0.28	0.27	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
BRCA	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-8.96	1.46e-18	6.2e-16	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
BRCA	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-8.96	1.46e-18	6.2e-16	-0.36	-0.27	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
BRCA	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	8.96	1.46e-18	6.2e-16	0.4	0.27	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	8.96	1.46e-18	6.2e-16	0.4	0.27	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
BRCA	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	8.96	1.46e-18	6.2e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-8.96	1.46e-18	6.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-8.96	1.46e-18	6.21e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	8.96	1.46e-18	6.22e-16	0.35	0.27	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	8.96	1.46e-18	6.23e-16	0.27	0.27	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	8.96	1.47e-18	6.24e-16	0.34	0.27	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-8.96	1.47e-18	6.24e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
BRCA	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8.96	1.47e-18	6.24e-16	0.31	0.27	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.96	1.47e-18	6.26e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	8.96	1.47e-18	6.26e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
BRCA	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-8.96	1.48e-18	6.31e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-8.96	1.49e-18	6.32e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
BRCA	cis	rs2333194	0.844	rs17182286	ENSG00000258408.1	NT5CP2	-8.96	1.49e-18	6.33e-16	-0.3	-0.27	Bipolar disorder with mood-incongruent psychosis;	chr14:73282200	chr14:73539221~73539781:-
BRCA	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	8.96	1.49e-18	6.33e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	8.96	1.49e-18	6.34e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-8.96	1.49e-18	6.34e-16	-0.34	-0.27	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
BRCA	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	8.96	1.51e-18	6.4e-16	0.32	0.27	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-8.96	1.51e-18	6.41e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
BRCA	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	8.96	1.51e-18	6.41e-16	0.34	0.27	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
BRCA	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	8.96	1.52e-18	6.46e-16	0.32	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	8.96	1.53e-18	6.48e-16	0.26	0.27	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
BRCA	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	8.95	1.53e-18	6.5e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
BRCA	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-8.95	1.53e-18	6.51e-16	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	8.95	1.54e-18	6.53e-16	0.26	0.27	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
BRCA	cis	rs13256369	0.802	rs11249884	ENSG00000253893.2	FAM85B	8.95	1.54e-18	6.54e-16	0.38	0.27	Obesity-related traits;	chr8:8704042	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	8.95	1.55e-18	6.57e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
BRCA	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	8.95	1.55e-18	6.58e-16	0.31	0.27	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
BRCA	cis	rs3814244	0.569	rs11177008	ENSG00000236946.2	HNRNPA1P70	-8.95	1.55e-18	6.58e-16	-0.23	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:68035767~68036853:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	8.95	1.55e-18	6.59e-16	0.26	0.27	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	8.95	1.55e-18	6.59e-16	0.34	0.27	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
BRCA	cis	rs5751614	0.537	rs5759679	ENSG00000230701.2	FBXW4P1	8.95	1.56e-18	6.62e-16	0.33	0.27	Height;	chr22:23286826	chr22:23262767~23265005:+
BRCA	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	8.95	1.56e-18	6.62e-16	0.39	0.27	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
BRCA	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	8.95	1.56e-18	6.63e-16	0.32	0.27	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
BRCA	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-8.95	1.56e-18	6.63e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-8.95	1.56e-18	6.63e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
BRCA	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
BRCA	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	8.95	1.57e-18	6.64e-16	0.26	0.27	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
BRCA	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-8.95	1.57e-18	6.65e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-8.95	1.57e-18	6.65e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
BRCA	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	8.95	1.57e-18	6.66e-16	0.34	0.27	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	8.95	1.58e-18	6.68e-16	0.35	0.27	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-8.95	1.59e-18	6.72e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-8.95	1.59e-18	6.73e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	8.95	1.59e-18	6.75e-16	0.28	0.27	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	8.95	1.59e-18	6.75e-16	0.28	0.27	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
BRCA	cis	rs55665837	0.539	rs11023350	ENSG00000251991.1	RNU7-49P	8.95	1.6e-18	6.79e-16	0.31	0.27	Vitamin D levels;	chr11:14839971	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	8.95	1.61e-18	6.83e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000220721.1	OR1F12	8.95	1.62e-18	6.84e-16	0.4	0.27	Depression;	chr6:28103220	chr6:28073316~28074233:+
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	8.95	1.62e-18	6.85e-16	0.35	0.27	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	8.95	1.62e-18	6.85e-16	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
BRCA	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	8.95	1.62e-18	6.86e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	8.95	1.63e-18	6.91e-16	0.26	0.27	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
BRCA	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-8.95	1.65e-18	6.97e-16	-0.34	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
BRCA	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-8.95	1.65e-18	6.98e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
BRCA	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-8.95	1.65e-18	7e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
BRCA	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	8.95	1.66e-18	7.02e-16	0.3	0.27	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
BRCA	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	8.95	1.66e-18	7.03e-16	0.35	0.27	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.94	1.67e-18	7.08e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-8.94	1.68e-18	7.09e-16	-0.33	-0.27	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
BRCA	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-8.94	1.68e-18	7.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-8.94	1.68e-18	7.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
BRCA	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	8.94	1.69e-18	7.15e-16	0.32	0.27	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
BRCA	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.94	1.7e-18	7.2e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-8.94	1.71e-18	7.21e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	8.94	1.71e-18	7.22e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
BRCA	cis	rs10861661	0.569	rs10778514	ENSG00000260329.1	RP11-412D9.4	-8.94	1.71e-18	7.22e-16	-0.32	-0.27	Triglyceride levels;	chr12:106909799	chr12:106954029~106955497:-
BRCA	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-8.94	1.71e-18	7.23e-16	-0.29	-0.27	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
BRCA	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
BRCA	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-8.94	1.72e-18	7.27e-16	-0.25	-0.27	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
BRCA	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-8.94	1.73e-18	7.28e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	8.94	1.73e-18	7.29e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
BRCA	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	8.94	1.73e-18	7.3e-16	0.3	0.27	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	8.94	1.74e-18	7.33e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	8.94	1.74e-18	7.33e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
BRCA	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	8.94	1.74e-18	7.35e-16	0.3	0.27	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
BRCA	cis	rs13256369	0.802	rs12681326	ENSG00000253893.2	FAM85B	-8.94	1.74e-18	7.35e-16	-0.38	-0.27	Obesity-related traits;	chr8:8708879	chr8:8167819~8226614:-
BRCA	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	8.94	1.74e-18	7.35e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	8.94	1.74e-18	7.35e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
BRCA	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.94	1.74e-18	7.36e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
BRCA	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-8.94	1.74e-18	7.36e-16	-0.31	-0.27	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
BRCA	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	8.94	1.75e-18	7.38e-16	0.35	0.27	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.94	1.75e-18	7.39e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-8.94	1.75e-18	7.4e-16	-0.34	-0.27	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	8.94	1.76e-18	7.4e-16	0.26	0.27	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	8.94	1.76e-18	7.4e-16	0.26	0.27	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	8.94	1.76e-18	7.42e-16	0.22	0.27	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.94	1.76e-18	7.43e-16	0.31	0.27	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
BRCA	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	8.94	1.77e-18	7.45e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	8.94	1.78e-18	7.49e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
BRCA	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	8.94	1.78e-18	7.49e-16	0.69	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
BRCA	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	8.94	1.78e-18	7.52e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-8.94	1.8e-18	7.57e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-8.94	1.8e-18	7.57e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
BRCA	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	8.94	1.8e-18	7.59e-16	0.33	0.27	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
BRCA	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-8.94	1.81e-18	7.63e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
BRCA	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-8.93	1.81e-18	7.64e-16	-0.39	-0.27	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
BRCA	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	8.93	1.82e-18	7.65e-16	0.35	0.27	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.65e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
BRCA	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-8.93	1.82e-18	7.66e-16	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
BRCA	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	8.93	1.82e-18	7.66e-16	0.39	0.27	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
BRCA	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-8.93	1.82e-18	7.67e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
BRCA	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	8.93	1.82e-18	7.67e-16	0.28	0.27	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
BRCA	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	8.93	1.83e-18	7.71e-16	0.31	0.27	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	8.93	1.83e-18	7.72e-16	0.35	0.27	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
BRCA	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	8.93	1.84e-18	7.75e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	8.93	1.84e-18	7.76e-16	0.27	0.27	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
BRCA	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	8.93	1.85e-18	7.77e-16	0.3	0.27	Temperament;	chr17:13996939	chr17:13756478~14069495:-
BRCA	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-8.93	1.85e-18	7.79e-16	-0.34	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
BRCA	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	8.93	1.85e-18	7.79e-16	0.33	0.27	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
BRCA	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-8.93	1.85e-18	7.79e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
BRCA	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-8.93	1.85e-18	7.8e-16	-0.28	-0.27	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.93	1.86e-18	7.81e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	8.93	1.87e-18	7.85e-16	0.28	0.27	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
BRCA	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.93	1.87e-18	7.85e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
BRCA	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	8.93	1.88e-18	7.89e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
BRCA	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	8.93	1.88e-18	7.89e-16	0.19	0.27	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	8.93	1.88e-18	7.89e-16	0.19	0.27	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
BRCA	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	8.93	1.88e-18	7.9e-16	0.37	0.27	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
BRCA	cis	rs7937890	0.559	rs10766184	ENSG00000251991.1	RNU7-49P	8.93	1.89e-18	7.92e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14521031	chr11:14478892~14478953:+
BRCA	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	8.93	1.89e-18	7.93e-16	0.31	0.27	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-8.93	1.89e-18	7.95e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	8.93	1.89e-18	7.96e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
BRCA	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-8.93	1.9e-18	7.98e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-8.93	1.9e-18	7.99e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
BRCA	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	8.93	1.91e-18	8.01e-16	0.31	0.27	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
BRCA	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	8.93	1.91e-18	8.03e-16	0.24	0.27	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	8.93	1.91e-18	8.03e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-8.93	1.92e-18	8.06e-16	-0.3	-0.27	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
BRCA	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	8.93	1.92e-18	8.07e-16	0.3	0.27	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
BRCA	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-8.93	1.92e-18	8.07e-16	-0.28	-0.27	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
BRCA	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-8.93	1.92e-18	8.08e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
BRCA	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	8.93	1.93e-18	8.09e-16	0.3	0.27	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
BRCA	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	8.93	1.96e-18	8.22e-16	0.19	0.27	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
BRCA	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	8.92	1.97e-18	8.26e-16	0.27	0.27	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
BRCA	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-8.92	1.98e-18	8.3e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	8.92	1.98e-18	8.32e-16	0.18	0.27	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-8.92	1.99e-18	8.34e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-8.92	1.99e-18	8.34e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
BRCA	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	8.92	2e-18	8.39e-16	0.3	0.27	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
BRCA	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	8.92	2e-18	8.39e-16	0.3	0.27	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-8.92	2.01e-18	8.41e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
BRCA	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	8.92	2.01e-18	8.42e-16	0.4	0.27	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
BRCA	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	8.92	2.01e-18	8.43e-16	0.33	0.27	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
BRCA	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-8.92	2.02e-18	8.47e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
BRCA	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-8.92	2.03e-18	8.52e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
BRCA	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	8.92	2.03e-18	8.52e-16	0.29	0.27	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
BRCA	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	8.92	2.04e-18	8.54e-16	0.28	0.27	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
BRCA	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	8.92	2.04e-18	8.54e-16	0.39	0.27	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
BRCA	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	8.92	2.04e-18	8.55e-16	0.3	0.27	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
BRCA	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-8.92	2.04e-18	8.56e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
BRCA	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-8.92	2.05e-18	8.59e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	8.92	2.05e-18	8.6e-16	0.26	0.27	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
BRCA	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	8.92	2.06e-18	8.62e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
BRCA	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	8.92	2.06e-18	8.62e-16	0.31	0.27	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
BRCA	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-8.92	2.08e-18	8.71e-16	-0.34	-0.27	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
BRCA	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	8.92	2.08e-18	8.71e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
BRCA	cis	rs4862750	0.957	rs6858853	ENSG00000250971.1	RP11-696F12.1	-8.92	2.09e-18	8.73e-16	-0.28	-0.27	Lobe attachment (rater-scored or self-reported);	chr4:186982258	chr4:187060099~187060930:+
BRCA	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-8.92	2.09e-18	8.73e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-8.92	2.09e-18	8.73e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
BRCA	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-8.92	2.1e-18	8.78e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	8.92	2.1e-18	8.8e-16	0.31	0.27	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	8.92	2.1e-18	8.8e-16	0.27	0.27	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	8.92	2.11e-18	8.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
BRCA	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	8.92	2.12e-18	8.85e-16	0.3	0.27	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-8.92	2.12e-18	8.86e-16	-0.26	-0.27	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
BRCA	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	8.92	2.12e-18	8.87e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
BRCA	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
BRCA	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.92	2.13e-18	8.89e-16	0.39	0.27	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
BRCA	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	8.92	2.13e-18	8.91e-16	0.4	0.27	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
BRCA	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	8.92	2.13e-18	8.92e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
BRCA	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-8.92	2.14e-18	8.95e-16	-0.31	-0.27	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	8.91	2.14e-18	8.96e-16	0.68	0.27	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	8.91	2.15e-18	8.99e-16	0.26	0.27	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	8.91	2.15e-18	8.99e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
BRCA	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-8.91	2.16e-18	9.03e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
BRCA	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	8.91	2.18e-18	9.09e-16	0.32	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
BRCA	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-8.91	2.18e-18	9.09e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
BRCA	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	8.91	2.19e-18	9.14e-16	0.3	0.27	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
BRCA	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
BRCA	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-8.91	2.19e-18	9.15e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-8.91	2.2e-18	9.19e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
BRCA	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-8.91	2.2e-18	9.19e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-8.91	2.2e-18	9.19e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-8.91	2.2e-18	9.2e-16	-0.22	-0.27	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
BRCA	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	8.91	2.21e-18	9.22e-16	0.41	0.27	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-8.91	2.22e-18	9.25e-16	-0.28	-0.27	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	8.91	2.22e-18	9.28e-16	0.35	0.27	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
BRCA	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.29e-16	0.3	0.27	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.29e-16	0.3	0.27	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.32e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
BRCA	cis	rs2067615	0.579	rs66716938	ENSG00000260329.1	RP11-412D9.4	-8.91	2.23e-18	9.32e-16	-0.29	-0.27	Heart rate;	chr12:106803047	chr12:106954029~106955497:-
BRCA	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	8.91	2.25e-18	9.37e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-8.91	2.25e-18	9.38e-16	-0.35	-0.27	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
BRCA	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-8.91	2.26e-18	9.41e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-8.91	2.26e-18	9.41e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
BRCA	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-8.91	2.26e-18	9.43e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-8.91	2.28e-18	9.49e-16	-0.3	-0.27	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-8.91	2.28e-18	9.5e-16	-0.25	-0.27	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
BRCA	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	8.91	2.28e-18	9.52e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	8.91	2.28e-18	9.52e-16	0.36	0.27	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	8.91	2.28e-18	9.52e-16	0.36	0.27	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-8.91	2.29e-18	9.53e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-8.91	2.29e-18	9.54e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-8.91	2.29e-18	9.56e-16	-0.25	-0.27	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
BRCA	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	8.91	2.3e-18	9.59e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
BRCA	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	8.91	2.31e-18	9.62e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
BRCA	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	8.91	2.31e-18	9.63e-16	0.39	0.27	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	8.91	2.31e-18	9.63e-16	0.39	0.27	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	8.91	2.32e-18	9.64e-16	0.32	0.27	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
BRCA	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	8.91	2.32e-18	9.65e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-8.91	2.33e-18	9.69e-16	-0.32	-0.27	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	8.9	2.33e-18	9.71e-16	0.32	0.27	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000278665.1	RP11-666O2.4	8.9	2.33e-18	9.71e-16	0.28	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28599241~28601881:-
BRCA	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	8.9	2.34e-18	9.75e-16	0.36	0.27	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	8.9	2.34e-18	9.75e-16	0.36	0.27	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
BRCA	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-8.9	2.34e-18	9.75e-16	-0.41	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
BRCA	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
BRCA	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	8.9	2.35e-18	9.8e-16	0.3	0.27	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-8.9	2.36e-18	9.83e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
BRCA	cis	rs58873874	0.737	rs9313608	ENSG00000251405.2	CTB-109A12.1	-8.9	2.36e-18	9.83e-16	-0.67	-0.27	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157362615~157460078:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	8.9	2.37e-18	9.88e-16	0.42	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
BRCA	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-8.9	2.38e-18	9.9e-16	-0.31	-0.27	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
BRCA	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	8.9	2.4e-18	9.97e-16	0.29	0.27	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-8.9	2.4e-18	9.97e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-8.9	2.4e-18	9.97e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-8.9	2.41e-18	1e-15	-0.3	-0.27	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
BRCA	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-8.9	2.41e-18	1e-15	-0.29	-0.27	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
BRCA	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-8.9	2.42e-18	1e-15	-0.31	-0.27	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	8.9	2.42e-18	1.01e-15	0.27	0.27	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-8.9	2.42e-18	1.01e-15	-0.27	-0.27	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.729	rs202030	ENSG00000272379.1	RP1-257A7.5	8.9	2.43e-18	1.01e-15	0.46	0.27	HIV-1 viral setpoint;	chr6:13291920	chr6:13290018~13290490:-
BRCA	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-8.9	2.44e-18	1.01e-15	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
BRCA	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	8.9	2.44e-18	1.01e-15	0.3	0.27	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
BRCA	cis	rs13256369	1	rs12550458	ENSG00000253893.2	FAM85B	-8.9	2.44e-18	1.01e-15	-0.38	-0.27	Obesity-related traits;	chr8:8710322	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	8.9	2.44e-18	1.01e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
BRCA	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	8.9	2.45e-18	1.02e-15	0.3	0.27	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	8.9	2.45e-18	1.02e-15	0.3	0.27	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
BRCA	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-8.9	2.45e-18	1.02e-15	-0.38	-0.27	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
BRCA	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-8.9	2.45e-18	1.02e-15	-0.34	-0.27	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	8.9	2.47e-18	1.03e-15	0.6	0.27	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
BRCA	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-8.9	2.48e-18	1.03e-15	-0.42	-0.27	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-8.9	2.51e-18	1.04e-15	-0.26	-0.27	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
BRCA	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-8.9	2.52e-18	1.04e-15	-0.38	-0.27	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-8.9	2.52e-18	1.04e-15	-0.38	-0.27	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	8.9	2.52e-18	1.05e-15	0.27	0.27	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
BRCA	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.9	2.52e-18	1.05e-15	0.47	0.27	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
BRCA	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.9	2.53e-18	1.05e-15	0.36	0.27	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
BRCA	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	8.9	2.53e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	8.89	2.54e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	8.89	2.54e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	8.89	2.54e-18	1.06e-15	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-8.89	2.55e-18	1.06e-15	-0.34	-0.27	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
BRCA	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-8.89	2.55e-18	1.06e-15	-0.35	-0.27	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
BRCA	cis	rs2067615	0.56	rs10861671	ENSG00000260329.1	RP11-412D9.4	-8.89	2.57e-18	1.07e-15	-0.29	-0.27	Heart rate;	chr12:106827149	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	8.89	2.57e-18	1.07e-15	0.26	0.27	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
BRCA	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-8.89	2.58e-18	1.07e-15	-0.41	-0.27	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-8.89	2.58e-18	1.07e-15	-0.33	-0.27	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
BRCA	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	8.89	2.58e-18	1.07e-15	0.39	0.27	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	8.89	2.59e-18	1.07e-15	0.33	0.27	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
BRCA	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-8.89	2.6e-18	1.08e-15	-0.34	-0.27	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
BRCA	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-8.89	2.6e-18	1.08e-15	-0.35	-0.27	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
BRCA	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	8.89	2.61e-18	1.08e-15	0.32	0.27	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
BRCA	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	8.89	2.62e-18	1.09e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-8.89	2.63e-18	1.09e-15	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
BRCA	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	8.89	2.63e-18	1.09e-15	0.34	0.27	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
BRCA	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-8.89	2.63e-18	1.09e-15	-0.32	-0.27	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	8.89	2.63e-18	1.09e-15	0.24	0.27	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
BRCA	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	8.89	2.64e-18	1.09e-15	0.28	0.27	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.524	rs10778504	ENSG00000260329.1	RP11-412D9.4	-8.89	2.64e-18	1.09e-15	-0.29	-0.27	Heart rate;	chr12:106726646	chr12:106954029~106955497:-
BRCA	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	8.89	2.64e-18	1.09e-15	0.27	0.27	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-8.89	2.64e-18	1.09e-15	-0.28	-0.27	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
BRCA	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.89	2.65e-18	1.1e-15	0.47	0.27	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	8.89	2.67e-18	1.1e-15	0.26	0.27	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	8.89	2.67e-18	1.11e-15	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
BRCA	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	8.89	2.68e-18	1.11e-15	0.4	0.27	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-8.89	2.68e-18	1.11e-15	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
BRCA	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	8.89	2.69e-18	1.11e-15	0.3	0.27	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
BRCA	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-8.89	2.7e-18	1.12e-15	-0.32	-0.27	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
BRCA	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-8.89	2.7e-18	1.12e-15	-0.34	-0.27	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
BRCA	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-8.89	2.7e-18	1.12e-15	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
BRCA	cis	rs7085104	0.66	rs3781286	ENSG00000213061.2	PFN1P11	8.89	2.7e-18	1.12e-15	0.34	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102838011~102845473:-
BRCA	cis	rs2067615	0.524	rs10778498	ENSG00000260329.1	RP11-412D9.4	-8.89	2.7e-18	1.12e-15	-0.29	-0.27	Heart rate;	chr12:106669562	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-8.89	2.72e-18	1.12e-15	-0.36	-0.27	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-8.89	2.72e-18	1.12e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
BRCA	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-8.89	2.73e-18	1.13e-15	-0.36	-0.27	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	8.89	2.73e-18	1.13e-15	0.32	0.27	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
BRCA	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-8.89	2.73e-18	1.13e-15	-0.28	-0.27	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
BRCA	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	8.89	2.73e-18	1.13e-15	0.3	0.27	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	8.89	2.75e-18	1.14e-15	0.3	0.27	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	8.89	2.75e-18	1.14e-15	0.3	0.27	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
BRCA	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-8.88	2.75e-18	1.14e-15	-0.26	-0.27	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
BRCA	cis	rs2041895	0.509	rs2024518	ENSG00000260329.1	RP11-412D9.4	-8.88	2.76e-18	1.14e-15	-0.32	-0.27	Glaucoma (low intraocular pressure);	chr12:106903124	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	8.88	2.76e-18	1.14e-15	0.38	0.27	Depression;	chr6:28402301	chr6:28176188~28176674:+
BRCA	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-8.88	2.78e-18	1.15e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-8.88	2.79e-18	1.15e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-8.88	2.79e-18	1.15e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-8.88	2.79e-18	1.16e-15	-0.32	-0.27	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
BRCA	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	8.88	2.8e-18	1.16e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
BRCA	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	8.88	2.8e-18	1.16e-15	0.4	0.27	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
BRCA	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-8.88	2.8e-18	1.16e-15	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-8.88	2.83e-18	1.17e-15	-0.26	-0.27	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	8.88	2.85e-18	1.18e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
BRCA	cis	rs3758911	0.861	rs1388170	ENSG00000255353.1	RP11-382M14.1	-8.88	2.87e-18	1.19e-15	-0.35	-0.27	Coronary artery disease;	chr11:107272130	chr11:107176286~107177530:+
BRCA	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	8.88	2.87e-18	1.19e-15	0.37	0.27	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
BRCA	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	8.88	2.88e-18	1.19e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
BRCA	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	8.88	2.89e-18	1.19e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
BRCA	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	8.88	2.89e-18	1.19e-15	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	8.88	2.9e-18	1.2e-15	0.39	0.27	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	8.88	2.91e-18	1.2e-15	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
BRCA	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-8.88	2.91e-18	1.2e-15	-0.39	-0.27	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
BRCA	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	8.88	2.91e-18	1.2e-15	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-8.88	2.94e-18	1.21e-15	-0.26	-0.27	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	8.88	2.94e-18	1.21e-15	0.28	0.27	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	8.88	2.96e-18	1.22e-15	0.37	0.27	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000220721.1	OR1F12	8.88	2.96e-18	1.22e-15	0.48	0.27	Depression;	chr6:28129415	chr6:28073316~28074233:+
BRCA	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-8.88	2.97e-18	1.22e-15	-0.35	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	8.88	2.97e-18	1.23e-15	0.29	0.27	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
BRCA	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	8.88	2.98e-18	1.23e-15	0.33	0.27	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
BRCA	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-8.88	2.98e-18	1.23e-15	-0.34	-0.27	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
BRCA	cis	rs3814244	0.569	rs2051993	ENSG00000236946.2	HNRNPA1P70	-8.87	3e-18	1.24e-15	-0.23	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:68035767~68036853:+
BRCA	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	8.87	3e-18	1.24e-15	0.3	0.27	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
BRCA	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-8.87	3.03e-18	1.25e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	8.87	3.04e-18	1.25e-15	0.28	0.27	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-8.87	3.04e-18	1.25e-15	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	8.87	3.06e-18	1.26e-15	0.18	0.27	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
BRCA	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	8.87	3.07e-18	1.27e-15	0.34	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	8.87	3.09e-18	1.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	8.87	3.09e-18	1.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-8.87	3.09e-18	1.27e-15	-0.28	-0.26	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-8.87	3.1e-18	1.27e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	8.87	3.11e-18	1.28e-15	0.26	0.26	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
BRCA	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-8.87	3.11e-18	1.28e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	8.87	3.12e-18	1.29e-15	0.32	0.26	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	8.87	3.12e-18	1.29e-15	0.26	0.26	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-8.87	3.14e-18	1.29e-15	-0.35	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-8.87	3.14e-18	1.29e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-8.87	3.15e-18	1.3e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-8.87	3.15e-18	1.3e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
BRCA	cis	rs2067615	0.542	rs11113120	ENSG00000260329.1	RP11-412D9.4	-8.87	3.16e-18	1.3e-15	-0.29	-0.26	Heart rate;	chr12:106809682	chr12:106954029~106955497:-
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-8.87	3.17e-18	1.3e-15	-0.29	-0.26	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
BRCA	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	8.87	3.18e-18	1.31e-15	0.29	0.26	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	8.87	3.18e-18	1.31e-15	0.27	0.26	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
BRCA	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-8.87	3.18e-18	1.31e-15	-0.28	-0.26	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.27	0.26	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	8.87	3.19e-18	1.31e-15	0.35	0.26	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
BRCA	cis	rs13256369	0.901	rs4841015	ENSG00000253893.2	FAM85B	-8.87	3.2e-18	1.31e-15	-0.38	-0.26	Obesity-related traits;	chr8:8709630	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-8.87	3.2e-18	1.32e-15	-0.51	-0.26	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs34591748	ENSG00000249839.1	AC011330.5	-8.87	3.23e-18	1.33e-15	-0.39	-0.26	Lung cancer;	chr15:43334917	chr15:43663654~43684339:-
BRCA	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-8.87	3.23e-18	1.33e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
BRCA	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	8.87	3.23e-18	1.33e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
BRCA	cis	rs13256369	1	rs885000	ENSG00000253893.2	FAM85B	-8.87	3.24e-18	1.33e-15	-0.38	-0.26	Obesity-related traits;	chr8:8711365	chr8:8167819~8226614:-
BRCA	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-8.87	3.24e-18	1.33e-15	-0.31	-0.26	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-8.87	3.24e-18	1.33e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-8.87	3.25e-18	1.33e-15	-0.26	-0.26	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
BRCA	cis	rs4862750	0.957	rs4861733	ENSG00000250971.1	RP11-696F12.1	8.87	3.25e-18	1.34e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:187060099~187060930:+
BRCA	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-8.86	3.26e-18	1.34e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
BRCA	cis	rs1900504	0.584	rs2915756	ENSG00000266200.5	PNLIPRP2	-8.86	3.26e-18	1.34e-15	-0.33	-0.26	Tonsillectomy;	chr10:116603428	chr10:116620953~116645143:+
BRCA	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-8.86	3.28e-18	1.35e-15	-0.39	-0.26	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
BRCA	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	8.86	3.29e-18	1.35e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
BRCA	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	8.86	3.29e-18	1.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	8.86	3.29e-18	1.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
BRCA	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-8.86	3.3e-18	1.35e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
BRCA	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	8.86	3.31e-18	1.36e-15	0.4	0.26	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
BRCA	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-8.86	3.31e-18	1.36e-15	-0.34	-0.26	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.524	rs9804754	ENSG00000260329.1	RP11-412D9.4	-8.86	3.31e-18	1.36e-15	-0.29	-0.26	Heart rate;	chr12:106689253	chr12:106954029~106955497:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	8.86	3.32e-18	1.36e-15	0.32	0.26	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
BRCA	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	8.86	3.32e-18	1.36e-15	0.31	0.26	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
BRCA	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	8.86	3.32e-18	1.36e-15	0.3	0.26	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
BRCA	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	8.86	3.32e-18	1.36e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
BRCA	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-8.86	3.33e-18	1.37e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000278665.1	RP11-666O2.4	8.86	3.35e-18	1.37e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28599241~28601881:-
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-8.86	3.37e-18	1.38e-15	-0.26	-0.26	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
BRCA	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-8.86	3.38e-18	1.39e-15	-0.37	-0.26	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-8.86	3.39e-18	1.39e-15	-0.26	-0.26	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
BRCA	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-8.86	3.4e-18	1.39e-15	-0.33	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
BRCA	cis	rs6545883	0.791	rs2600665	ENSG00000271889.1	RP11-493E12.1	8.86	3.4e-18	1.4e-15	0.34	0.26	Tuberculosis;	chr2:61178660	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	8.86	3.43e-18	1.4e-15	0.27	0.26	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-8.86	3.44e-18	1.41e-15	-0.26	-0.26	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
BRCA	cis	rs250518	0.708	rs258893	ENSG00000272081.1	CTD-2376I4.2	8.86	3.44e-18	1.41e-15	0.32	0.26	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72955206~72955699:-
BRCA	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-8.86	3.45e-18	1.42e-15	-0.33	-0.26	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
BRCA	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	8.86	3.46e-18	1.42e-15	0.27	0.26	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	8.86	3.46e-18	1.42e-15	0.27	0.26	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	8.86	3.46e-18	1.42e-15	0.4	0.26	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
BRCA	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-8.86	3.47e-18	1.42e-15	-0.25	-0.26	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
BRCA	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	8.86	3.47e-18	1.42e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	8.86	3.48e-18	1.43e-15	0.34	0.26	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.86	3.48e-18	1.43e-15	0.25	0.26	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
BRCA	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-8.86	3.49e-18	1.43e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	8.86	3.49e-18	1.43e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	8.86	3.49e-18	1.43e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	8.86	3.5e-18	1.43e-15	0.36	0.26	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	8.86	3.5e-18	1.43e-15	0.36	0.26	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
BRCA	cis	rs8062405	1	rs62037371	ENSG00000278665.1	RP11-666O2.4	8.86	3.5e-18	1.43e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28599241~28601881:-
BRCA	cis	rs5751614	0.557	rs16802	ENSG00000230701.2	FBXW4P1	-8.86	3.51e-18	1.44e-15	-0.33	-0.26	Height;	chr22:23290326	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-8.86	3.51e-18	1.44e-15	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-8.86	3.51e-18	1.44e-15	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	8.86	3.52e-18	1.44e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
BRCA	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-8.86	3.52e-18	1.44e-15	-0.28	-0.26	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
BRCA	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-8.86	3.53e-18	1.45e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
BRCA	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	8.86	3.54e-18	1.45e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
BRCA	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-8.85	3.54e-18	1.45e-15	-0.36	-0.26	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
BRCA	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-8.85	3.55e-18	1.45e-15	-0.32	-0.26	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
BRCA	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-8.85	3.55e-18	1.45e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-8.85	3.55e-18	1.45e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
BRCA	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-8.85	3.55e-18	1.46e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-8.85	3.56e-18	1.46e-15	-0.27	-0.26	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
BRCA	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	8.85	3.57e-18	1.46e-15	0.33	0.26	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
BRCA	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-8.85	3.57e-18	1.46e-15	-0.37	-0.26	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
BRCA	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	8.85	3.58e-18	1.46e-15	0.29	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	8.85	3.58e-18	1.47e-15	0.34	0.26	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
BRCA	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-8.85	3.59e-18	1.47e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-8.85	3.59e-18	1.47e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
BRCA	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	8.85	3.59e-18	1.47e-15	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
BRCA	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	8.85	3.6e-18	1.47e-15	0.37	0.26	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
BRCA	cis	rs2067615	0.579	rs1922435	ENSG00000260329.1	RP11-412D9.4	-8.85	3.62e-18	1.48e-15	-0.29	-0.26	Heart rate;	chr12:106688677	chr12:106954029~106955497:-
BRCA	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	8.85	3.62e-18	1.48e-15	0.27	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	8.85	3.63e-18	1.48e-15	0.18	0.26	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	8.85	3.63e-18	1.48e-15	0.18	0.26	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
BRCA	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	8.85	3.63e-18	1.48e-15	0.39	0.26	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	8.85	3.63e-18	1.49e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	8.85	3.63e-18	1.49e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-8.85	3.64e-18	1.49e-15	-0.28	-0.26	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
BRCA	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	8.85	3.64e-18	1.49e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-8.85	3.65e-18	1.49e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-8.85	3.65e-18	1.49e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
BRCA	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	8.85	3.65e-18	1.49e-15	0.34	0.26	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
BRCA	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-8.85	3.67e-18	1.5e-15	-0.32	-0.26	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	8.85	3.67e-18	1.5e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-8.85	3.67e-18	1.5e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-8.85	3.67e-18	1.5e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	8.85	3.68e-18	1.5e-15	0.39	0.26	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
BRCA	cis	rs2067615	0.524	rs4964186	ENSG00000260329.1	RP11-412D9.4	-8.85	3.69e-18	1.51e-15	-0.29	-0.26	Heart rate;	chr12:106686457	chr12:106954029~106955497:-
BRCA	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-8.85	3.7e-18	1.51e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	8.85	3.7e-18	1.51e-15	0.34	0.26	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
BRCA	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-8.85	3.7e-18	1.51e-15	-0.37	-0.26	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
BRCA	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-8.85	3.7e-18	1.51e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-8.85	3.7e-18	1.51e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
BRCA	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	8.85	3.71e-18	1.52e-15	0.39	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
BRCA	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	8.85	3.72e-18	1.52e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
BRCA	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	8.85	3.73e-18	1.52e-15	0.32	0.26	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
BRCA	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-8.85	3.73e-18	1.52e-15	-0.31	-0.26	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
BRCA	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	8.85	3.75e-18	1.53e-15	0.29	0.26	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
BRCA	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-8.85	3.78e-18	1.54e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	8.85	3.79e-18	1.55e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	8.85	3.8e-18	1.55e-15	0.27	0.26	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-8.84	3.86e-18	1.57e-15	-0.25	-0.26	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	8.84	3.86e-18	1.57e-15	0.27	0.26	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
BRCA	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	8.84	3.87e-18	1.58e-15	0.28	0.26	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	8.84	3.87e-18	1.58e-15	0.28	0.26	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
BRCA	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	8.84	3.87e-18	1.58e-15	0.36	0.26	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	8.84	3.88e-18	1.58e-15	0.36	0.26	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	8.84	3.9e-18	1.59e-15	0.18	0.26	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
BRCA	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-8.84	3.91e-18	1.59e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
BRCA	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-8.84	3.91e-18	1.59e-15	-0.34	-0.26	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
BRCA	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-8.84	3.91e-18	1.59e-15	-0.34	-0.26	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
BRCA	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	8.84	3.91e-18	1.6e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-8.84	3.92e-18	1.6e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-8.84	3.92e-18	1.6e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
BRCA	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	8.84	3.93e-18	1.6e-15	0.35	0.26	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-8.84	3.94e-18	1.6e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-8.84	3.95e-18	1.61e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-8.84	3.96e-18	1.61e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-8.84	3.96e-18	1.61e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
BRCA	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	8.84	3.96e-18	1.61e-15	0.33	0.26	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
BRCA	cis	rs13256369	0.851	rs13271698	ENSG00000253893.2	FAM85B	-8.84	3.98e-18	1.62e-15	-0.38	-0.26	Obesity-related traits;	chr8:8710029	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-8.84	3.98e-18	1.62e-15	-0.28	-0.26	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-8.84	3.98e-18	1.62e-15	-0.35	-0.26	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-8.84	3.98e-18	1.62e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.851	rs13267036	ENSG00000253893.2	FAM85B	-8.84	3.99e-18	1.62e-15	-0.38	-0.26	Obesity-related traits;	chr8:8709175	chr8:8167819~8226614:-
BRCA	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	8.84	3.99e-18	1.62e-15	0.46	0.26	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
BRCA	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	8.84	3.99e-18	1.62e-15	0.46	0.26	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
BRCA	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	8.84	3.99e-18	1.62e-15	0.33	0.26	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
BRCA	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	8.84	4.01e-18	1.63e-15	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.529	rs2526868	ENSG00000269927.1	RP6-91H8.3	-8.84	4.01e-18	1.63e-15	-0.35	-0.26	Schizophrenia;	chr14:70923672	chr14:71141125~71143253:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000278665.1	RP11-666O2.4	8.84	4.02e-18	1.63e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
BRCA	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	8.84	4.05e-18	1.65e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
BRCA	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	8.84	4.05e-18	1.65e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
BRCA	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	8.84	4.06e-18	1.65e-15	0.29	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
BRCA	cis	rs5751614	0.517	rs928780	ENSG00000230701.2	FBXW4P1	8.84	4.06e-18	1.65e-15	0.33	0.26	Height;	chr22:23257682	chr22:23262767~23265005:+
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.84	4.08e-18	1.66e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
BRCA	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	8.84	4.09e-18	1.66e-15	0.31	0.26	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	8.84	4.1e-18	1.67e-15	0.29	0.26	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
BRCA	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	8.84	4.11e-18	1.67e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-8.84	4.12e-18	1.68e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-8.84	4.12e-18	1.68e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	8.84	4.13e-18	1.68e-15	0.28	0.26	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	8.84	4.15e-18	1.68e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	8.84	4.16e-18	1.69e-15	0.26	0.26	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
BRCA	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	8.84	4.16e-18	1.69e-15	0.37	0.26	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-8.83	4.21e-18	1.71e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-8.83	4.21e-18	1.71e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	8.83	4.24e-18	1.72e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs4788101	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs11861174	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs4788102	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62037367	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7198606	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs8055982	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7498665	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28599241~28601881:-
BRCA	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	8.83	4.27e-18	1.73e-15	0.33	0.26	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
BRCA	cis	rs838147	0.563	rs281379	ENSG00000232871.7	SEC1P	8.83	4.27e-18	1.73e-15	0.3	0.26	Dietary macronutrient intake;	chr19:48711017	chr19:48638071~48682245:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-8.83	4.28e-18	1.73e-15	-0.31	-0.26	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
BRCA	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-8.83	4.31e-18	1.75e-15	-0.28	-0.26	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	8.83	4.34e-18	1.76e-15	0.27	0.26	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000278665.1	RP11-666O2.4	8.83	4.34e-18	1.76e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-8.83	4.35e-18	1.76e-15	-0.32	-0.26	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
BRCA	cis	rs853679	0.882	rs2743555	ENSG00000220721.1	OR1F12	8.83	4.38e-18	1.78e-15	0.42	0.26	Depression;	chr6:28273304	chr6:28073316~28074233:+
BRCA	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-8.83	4.38e-18	1.78e-15	-0.3	-0.26	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	8.83	4.39e-18	1.78e-15	0.24	0.26	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
BRCA	cis	rs8062405	1	rs9972693	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7205323	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28599241~28601881:-
BRCA	cis	rs13256369	1	rs12545771	ENSG00000253893.2	FAM85B	-8.83	4.39e-18	1.78e-15	-0.38	-0.26	Obesity-related traits;	chr8:8710467	chr8:8167819~8226614:-
BRCA	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-8.83	4.4e-18	1.78e-15	-0.28	-0.26	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
BRCA	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	8.83	4.4e-18	1.78e-15	0.36	0.26	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	8.83	4.41e-18	1.79e-15	0.25	0.26	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	8.83	4.41e-18	1.79e-15	0.25	0.26	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
BRCA	cis	rs4862750	0.914	rs11943333	ENSG00000250971.1	RP11-696F12.1	8.83	4.43e-18	1.8e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:187060099~187060930:+
BRCA	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-8.83	4.43e-18	1.8e-15	-0.38	-0.26	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
BRCA	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
BRCA	cis	rs2067615	0.579	rs6539283	ENSG00000260329.1	RP11-412D9.4	-8.83	4.44e-18	1.8e-15	-0.29	-0.26	Heart rate;	chr12:106829211	chr12:106954029~106955497:-
BRCA	cis	rs748404	0.626	rs17780920	ENSG00000249839.1	AC011330.5	-8.83	4.46e-18	1.81e-15	-0.38	-0.26	Lung cancer;	chr15:43370164	chr15:43663654~43684339:-
BRCA	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-8.83	4.46e-18	1.81e-15	-0.35	-0.26	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
BRCA	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-8.83	4.46e-18	1.81e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
BRCA	cis	rs13256369	0.901	rs13251887	ENSG00000253893.2	FAM85B	-8.83	4.48e-18	1.81e-15	-0.38	-0.26	Obesity-related traits;	chr8:8711168	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-8.83	4.49e-18	1.82e-15	-0.32	-0.26	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
BRCA	cis	rs8062405	1	rs3088215	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs28403629	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs61737565	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs4788099	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	8.83	4.49e-18	1.82e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	8.83	4.49e-18	1.82e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-8.83	4.5e-18	1.82e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-8.83	4.5e-18	1.82e-15	-0.38	-0.26	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-8.83	4.5e-18	1.82e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-8.83	4.5e-18	1.82e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-8.83	4.51e-18	1.82e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
BRCA	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-8.83	4.51e-18	1.82e-15	-0.4	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
BRCA	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	8.83	4.51e-18	1.82e-15	0.3	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
BRCA	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	8.83	4.51e-18	1.83e-15	0.33	0.26	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	8.83	4.52e-18	1.83e-15	0.27	0.26	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-8.83	4.52e-18	1.83e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	8.82	4.55e-18	1.84e-15	0.31	0.26	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
BRCA	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-8.82	4.55e-18	1.84e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-8.82	4.56e-18	1.85e-15	-0.32	-0.26	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
BRCA	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-8.82	4.56e-18	1.85e-15	-0.31	-0.26	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
BRCA	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	8.82	4.57e-18	1.85e-15	0.33	0.26	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
BRCA	cis	rs2041895	0.509	rs1035236	ENSG00000260329.1	RP11-412D9.4	-8.82	4.58e-18	1.85e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106917019	chr12:106954029~106955497:-
BRCA	cis	rs2041895	0.509	rs10861676	ENSG00000260329.1	RP11-412D9.4	-8.82	4.58e-18	1.85e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106917457	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	8.82	4.58e-18	1.85e-15	0.38	0.26	Depression;	chr6:28364057	chr6:28176188~28176674:+
BRCA	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	8.82	4.58e-18	1.85e-15	0.39	0.26	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-8.82	4.58e-18	1.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-8.82	4.59e-18	1.85e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
BRCA	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-8.82	4.64e-18	1.88e-15	-0.25	-0.26	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
BRCA	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	8.82	4.66e-18	1.88e-15	0.28	0.26	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
BRCA	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	8.82	4.66e-18	1.88e-15	0.28	0.26	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
BRCA	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	8.82	4.66e-18	1.88e-15	0.36	0.26	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	8.82	4.66e-18	1.88e-15	0.36	0.26	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	8.82	4.69e-18	1.89e-15	0.27	0.26	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	8.82	4.69e-18	1.89e-15	0.27	0.26	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
BRCA	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	8.82	4.7e-18	1.9e-15	0.35	0.26	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
BRCA	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	8.82	4.73e-18	1.91e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
BRCA	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	8.82	4.74e-18	1.91e-15	0.34	0.26	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-8.82	4.76e-18	1.92e-15	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	8.82	4.78e-18	1.93e-15	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-8.82	4.78e-18	1.93e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	8.82	4.78e-18	1.93e-15	0.37	0.26	Depression;	chr6:28386473	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	8.82	4.78e-18	1.93e-15	0.37	0.26	Depression;	chr6:28391932	chr6:28176188~28176674:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-8.82	4.79e-18	1.93e-15	-0.29	-0.26	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
BRCA	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	8.82	4.8e-18	1.94e-15	0.33	0.26	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
BRCA	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-8.82	4.8e-18	1.94e-15	-0.38	-0.26	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
BRCA	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-8.82	4.81e-18	1.94e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
BRCA	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	8.82	4.81e-18	1.94e-15	0.47	0.26	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
BRCA	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	8.82	4.82e-18	1.94e-15	0.41	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
BRCA	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
BRCA	cis	rs2041895	0.509	rs7970139	ENSG00000260329.1	RP11-412D9.4	-8.82	4.85e-18	1.96e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106918652	chr12:106954029~106955497:-
BRCA	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-8.82	4.85e-18	1.96e-15	-0.38	-0.26	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
BRCA	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	8.82	4.88e-18	1.97e-15	0.29	0.26	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-8.82	4.88e-18	1.97e-15	-0.51	-0.26	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
BRCA	cis	rs13030978	0.505	rs72916554	ENSG00000227542.1	AC092614.2	8.82	4.9e-18	1.98e-15	0.34	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191229165~191246172:-
BRCA	cis	rs8062405	1	rs8055138	ENSG00000278665.1	RP11-666O2.4	8.82	4.91e-18	1.98e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-8.82	4.92e-18	1.98e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	8.82	4.92e-18	1.99e-15	0.33	0.26	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
BRCA	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-8.82	4.93e-18	1.99e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-8.81	4.94e-18	1.99e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-8.81	4.94e-18	1.99e-15	-0.32	-0.26	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	8.81	4.94e-18	1.99e-15	0.27	0.26	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	8.81	4.95e-18	2e-15	0.34	0.26	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
BRCA	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	8.81	4.96e-18	2e-15	0.41	0.26	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
BRCA	cis	rs5751614	0.537	rs7292656	ENSG00000230701.2	FBXW4P1	8.81	4.97e-18	2e-15	0.33	0.26	Height;	chr22:23287415	chr22:23262767~23265005:+
BRCA	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-8.81	4.99e-18	2.01e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
BRCA	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-8.81	4.99e-18	2.01e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
BRCA	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	8.81	5e-18	2.01e-15	0.32	0.26	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
BRCA	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	8.81	5e-18	2.01e-15	0.48	0.26	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	8.81	5e-18	2.01e-15	0.48	0.26	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	8.81	5.01e-18	2.02e-15	0.28	0.26	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-8.81	5.03e-18	2.03e-15	-0.25	-0.26	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
BRCA	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	8.81	5.04e-18	2.03e-15	0.4	0.26	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
BRCA	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	8.81	5.05e-18	2.03e-15	0.28	0.26	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
BRCA	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-8.81	5.07e-18	2.04e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-8.81	5.07e-18	2.04e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-8.81	5.13e-18	2.06e-15	-0.34	-0.26	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
BRCA	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-8.81	5.13e-18	2.06e-15	-0.35	-0.26	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-8.81	5.13e-18	2.06e-15	-0.35	-0.26	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.81	5.15e-18	2.07e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-8.81	5.16e-18	2.07e-15	-0.35	-0.26	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-8.81	5.16e-18	2.07e-15	-0.35	-0.26	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	8.81	5.16e-18	2.07e-15	0.28	0.26	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	8.81	5.16e-18	2.07e-15	0.28	0.26	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-8.81	5.17e-18	2.08e-15	-0.35	-0.26	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-8.81	5.18e-18	2.08e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-8.81	5.18e-18	2.08e-15	-0.4	-0.26	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
BRCA	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-8.81	5.19e-18	2.09e-15	-0.34	-0.26	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
BRCA	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-8.81	5.19e-18	2.09e-15	-0.35	-0.26	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
BRCA	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-8.81	5.19e-18	2.09e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	8.81	5.2e-18	2.09e-15	0.27	0.26	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
BRCA	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-8.81	5.2e-18	2.09e-15	-0.33	-0.26	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
BRCA	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-8.81	5.23e-18	2.1e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-8.81	5.25e-18	2.11e-15	-0.34	-0.26	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
BRCA	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-8.81	5.28e-18	2.12e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	8.81	5.28e-18	2.12e-15	0.28	0.26	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	8.81	5.28e-18	2.12e-15	0.28	0.26	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-8.81	5.28e-18	2.12e-15	-0.33	-0.26	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-8.81	5.28e-18	2.12e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
BRCA	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	8.81	5.3e-18	2.13e-15	0.29	0.26	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
BRCA	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-8.81	5.31e-18	2.13e-15	-0.4	-0.26	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
BRCA	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	8.81	5.32e-18	2.14e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
BRCA	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-8.81	5.33e-18	2.14e-15	-0.34	-0.26	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-8.81	5.34e-18	2.14e-15	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
BRCA	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	8.81	5.34e-18	2.14e-15	0.34	0.26	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-8.81	5.35e-18	2.15e-15	-0.32	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
BRCA	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-8.8	5.38e-18	2.16e-15	-0.33	-0.26	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-8.8	5.38e-18	2.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	8.8	5.39e-18	2.16e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
BRCA	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000226816.2	AC005082.12	8.8	5.4e-18	2.17e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23206013~23208045:+
BRCA	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	8.8	5.4e-18	2.17e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
BRCA	cis	rs853679	1	rs11965538	ENSG00000220721.1	OR1F12	8.8	5.42e-18	2.17e-15	0.41	0.26	Depression;	chr6:28272137	chr6:28073316~28074233:+
BRCA	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-8.8	5.42e-18	2.18e-15	-0.36	-0.26	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
BRCA	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-8.8	5.43e-18	2.18e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
BRCA	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	8.8	5.43e-18	2.18e-15	0.36	0.26	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
BRCA	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	8.8	5.43e-18	2.18e-15	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-8.8	5.44e-18	2.18e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	8.8	5.45e-18	2.19e-15	0.33	0.26	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	8.8	5.47e-18	2.19e-15	0.32	0.26	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
BRCA	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	8.8	5.48e-18	2.19e-15	0.37	0.26	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
BRCA	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-8.8	5.49e-18	2.2e-15	-0.35	-0.26	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
BRCA	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	8.8	5.49e-18	2.2e-15	0.34	0.26	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-8.8	5.49e-18	2.2e-15	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.8	5.49e-18	2.2e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
BRCA	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-8.8	5.5e-18	2.2e-15	-0.34	-0.26	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
BRCA	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-8.8	5.5e-18	2.21e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	8.8	5.52e-18	2.21e-15	0.67	0.26	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
BRCA	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-8.8	5.55e-18	2.22e-15	-0.25	-0.26	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	8.8	5.55e-18	2.22e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
BRCA	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-8.8	5.56e-18	2.23e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	8.8	5.58e-18	2.24e-15	0.28	0.26	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
BRCA	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	8.8	5.59e-18	2.24e-15	0.28	0.26	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
BRCA	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-8.8	5.59e-18	2.24e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-8.8	5.59e-18	2.24e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
BRCA	cis	rs2041895	0.509	rs7976343	ENSG00000260329.1	RP11-412D9.4	-8.8	5.61e-18	2.24e-15	-0.32	-0.26	Glaucoma (low intraocular pressure);	chr12:106902250	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	8.8	5.61e-18	2.24e-15	0.29	0.26	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	8.8	5.63e-18	2.25e-15	0.26	0.26	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	8.8	5.63e-18	2.25e-15	0.26	0.26	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	8.8	5.63e-18	2.25e-15	0.34	0.26	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
BRCA	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	8.8	5.65e-18	2.26e-15	0.32	0.26	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-8.8	5.66e-18	2.26e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-8.8	5.66e-18	2.26e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.729	rs202040	ENSG00000272379.1	RP1-257A7.5	8.8	5.66e-18	2.27e-15	0.45	0.26	HIV-1 viral setpoint;	chr6:13288303	chr6:13290018~13290490:-
BRCA	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	8.8	5.67e-18	2.27e-15	0.36	0.26	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	8.8	5.68e-18	2.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
BRCA	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	8.8	5.71e-18	2.28e-15	0.33	0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
BRCA	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	8.8	5.72e-18	2.29e-15	0.31	0.26	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	8.8	5.72e-18	2.29e-15	0.31	0.26	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000220721.1	OR1F12	8.8	5.73e-18	2.29e-15	0.5	0.26	Depression;	chr6:28076050	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000220721.1	OR1F12	8.8	5.73e-18	2.29e-15	0.5	0.26	Depression;	chr6:28085045	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-8.8	5.73e-18	2.29e-15	-0.25	-0.26	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
BRCA	cis	rs4862750	0.957	rs1030381	ENSG00000250971.1	RP11-696F12.1	8.8	5.74e-18	2.29e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-8.8	5.74e-18	2.3e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	8.8	5.76e-18	2.3e-15	0.47	0.26	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	8.8	5.76e-18	2.3e-15	0.47	0.26	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
BRCA	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	8.8	5.77e-18	2.31e-15	0.33	0.26	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.8	5.79e-18	2.31e-15	-0.34	-0.26	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
BRCA	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-8.8	5.8e-18	2.32e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
BRCA	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	8.8	5.81e-18	2.32e-15	0.29	0.26	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
BRCA	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-8.79	5.83e-18	2.33e-15	-0.36	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-8.79	5.84e-18	2.33e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-8.79	5.84e-18	2.33e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-8.79	5.85e-18	2.34e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-8.79	5.86e-18	2.34e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-8.79	5.88e-18	2.35e-15	-0.28	-0.26	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
BRCA	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-8.79	5.89e-18	2.35e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-8.79	5.89e-18	2.35e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-8.79	5.93e-18	2.37e-15	-0.25	-0.26	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
BRCA	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	8.79	5.94e-18	2.37e-15	0.29	0.26	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
BRCA	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	8.79	5.94e-18	2.37e-15	0.34	0.26	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
BRCA	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-8.79	5.95e-18	2.38e-15	-0.34	-0.26	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
BRCA	cis	rs7580658	0.545	rs67996371	ENSG00000236682.1	AC068282.3	-8.79	5.96e-18	2.38e-15	-0.34	-0.26	Protein C levels;	chr2:127195841	chr2:127389130~127400580:+
BRCA	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-8.79	5.96e-18	2.38e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.525	rs1729658	ENSG00000271889.1	RP11-493E12.1	8.79	5.97e-18	2.38e-15	0.33	0.26	Tuberculosis;	chr2:61146385	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	8.79	5.98e-18	2.39e-15	0.3	0.26	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	8.79	6.01e-18	2.4e-15	0.23	0.26	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
BRCA	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-8.79	6.01e-18	2.4e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-8.79	6.01e-18	2.4e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-8.79	6.02e-18	2.4e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
BRCA	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	8.79	6.02e-18	2.4e-15	0.37	0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
BRCA	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	8.79	6.03e-18	2.41e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	8.79	6.04e-18	2.41e-15	0.36	0.26	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-8.79	6.07e-18	2.42e-15	-0.38	-0.26	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
BRCA	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-8.79	6.1e-18	2.43e-15	-0.34	-0.26	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
BRCA	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	8.79	6.1e-18	2.43e-15	0.48	0.26	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-8.79	6.1e-18	2.43e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-8.79	6.1e-18	2.43e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
BRCA	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-8.79	6.12e-18	2.44e-15	-0.32	-0.26	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
BRCA	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-8.79	6.14e-18	2.45e-15	-0.33	-0.26	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
BRCA	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-8.79	6.14e-18	2.45e-15	-0.38	-0.26	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
BRCA	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-8.79	6.18e-18	2.46e-15	-0.45	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-8.79	6.18e-18	2.46e-15	-0.25	-0.26	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-8.79	6.19e-18	2.47e-15	-0.33	-0.26	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
BRCA	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-8.79	6.21e-18	2.48e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-8.79	6.21e-18	2.48e-15	-0.35	-0.26	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	8.79	6.22e-18	2.48e-15	0.29	0.26	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
BRCA	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-8.79	6.24e-18	2.49e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs62037365	ENSG00000278665.1	RP11-666O2.4	8.79	6.26e-18	2.49e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28599241~28601881:-
BRCA	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-8.79	6.31e-18	2.51e-15	-0.33	-0.26	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-8.79	6.31e-18	2.51e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	8.79	6.32e-18	2.52e-15	0.32	0.26	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
BRCA	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	8.78	6.33e-18	2.52e-15	0.41	0.26	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
BRCA	cis	rs2067615	0.56	rs12298717	ENSG00000260329.1	RP11-412D9.4	8.78	6.34e-18	2.52e-15	0.29	0.26	Heart rate;	chr12:106706105	chr12:106954029~106955497:-
BRCA	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-8.78	6.34e-18	2.52e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
BRCA	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-8.78	6.38e-18	2.54e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	8.78	6.39e-18	2.55e-15	0.27	0.26	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	8.78	6.41e-18	2.55e-15	0.38	0.26	Depression;	chr6:28379133	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	8.78	6.41e-18	2.55e-15	0.38	0.26	Depression;	chr6:28379168	chr6:28176188~28176674:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-8.78	6.42e-18	2.55e-15	-0.32	-0.26	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
BRCA	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-8.78	6.44e-18	2.56e-15	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	8.78	6.47e-18	2.57e-15	0.34	0.26	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000226816.2	AC005082.12	8.78	6.48e-18	2.58e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23206013~23208045:+
BRCA	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	8.78	6.48e-18	2.58e-15	0.49	0.26	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
BRCA	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-8.78	6.48e-18	2.58e-15	-0.35	-0.26	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-8.78	6.48e-18	2.58e-15	-0.35	-0.26	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-8.78	6.52e-18	2.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	8.78	6.55e-18	2.6e-15	0.37	0.26	Depression;	chr6:28399846	chr6:28176188~28176674:+
BRCA	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.78	6.55e-18	2.6e-15	0.47	0.26	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	8.78	6.55e-18	2.61e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
BRCA	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-8.78	6.55e-18	2.61e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
BRCA	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-8.78	6.57e-18	2.61e-15	-0.44	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-8.78	6.57e-18	2.61e-15	-0.44	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
BRCA	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-8.78	6.57e-18	2.61e-15	-0.38	-0.26	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	8.78	6.63e-18	2.64e-15	0.32	0.26	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	8.78	6.63e-18	2.64e-15	0.59	0.26	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	8.78	6.64e-18	2.64e-15	0.27	0.26	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	8.78	6.67e-18	2.65e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-8.78	6.68e-18	2.65e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
BRCA	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	8.78	6.74e-18	2.68e-15	0.28	0.26	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
BRCA	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	8.78	6.75e-18	2.68e-15	0.33	0.26	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-8.78	6.77e-18	2.69e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	8.78	6.77e-18	2.69e-15	0.34	0.26	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
BRCA	cis	rs202072	0.729	rs8541	ENSG00000272379.1	RP1-257A7.5	8.78	6.79e-18	2.7e-15	0.45	0.26	HIV-1 viral setpoint;	chr6:13290006	chr6:13290018~13290490:-
BRCA	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	8.78	6.8e-18	2.7e-15	0.4	0.26	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	8.78	6.8e-18	2.7e-15	0.27	0.26	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	8.78	6.8e-18	2.7e-15	0.27	0.26	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
BRCA	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	8.78	6.81e-18	2.71e-15	0.36	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
BRCA	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	8.78	6.82e-18	2.71e-15	0.34	0.26	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
BRCA	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	8.78	6.82e-18	2.71e-15	0.35	0.26	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
BRCA	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-8.78	6.87e-18	2.73e-15	-0.35	-0.26	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-8.77	6.9e-18	2.74e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-8.77	6.91e-18	2.74e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-8.77	6.91e-18	2.74e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
BRCA	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-8.77	6.91e-18	2.74e-15	-0.34	-0.26	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
BRCA	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	8.77	6.93e-18	2.75e-15	0.36	0.26	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
BRCA	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	8.77	6.93e-18	2.75e-15	0.32	0.26	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
BRCA	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-8.77	6.93e-18	2.75e-15	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-8.77	6.94e-18	2.75e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	8.77	6.94e-18	2.76e-15	0.32	0.26	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	8.77	6.96e-18	2.76e-15	0.27	0.26	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	8.77	6.99e-18	2.78e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	8.77	7.02e-18	2.79e-15	0.22	0.26	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
BRCA	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-8.77	7.04e-18	2.79e-15	-0.31	-0.26	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
BRCA	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	8.77	7.04e-18	2.79e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	8.77	7.05e-18	2.8e-15	0.27	0.26	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-8.77	7.05e-18	2.8e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-8.77	7.06e-18	2.8e-15	-0.31	-0.26	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	8.77	7.06e-18	2.8e-15	0.29	0.26	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
BRCA	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-8.77	7.08e-18	2.81e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	8.77	7.09e-18	2.81e-15	0.32	0.26	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-8.77	7.12e-18	2.82e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-8.77	7.12e-18	2.82e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
BRCA	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	8.77	7.13e-18	2.83e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
BRCA	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-8.77	7.2e-18	2.85e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	8.77	7.2e-18	2.85e-15	0.27	0.26	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-8.77	7.22e-18	2.86e-15	-0.33	-0.26	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
BRCA	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	8.77	7.25e-18	2.88e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	8.77	7.26e-18	2.88e-15	0.18	0.26	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	8.77	7.28e-18	2.89e-15	0.34	0.26	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
BRCA	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-8.77	7.3e-18	2.89e-15	-0.38	-0.26	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
BRCA	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-8.77	7.31e-18	2.9e-15	-0.31	-0.26	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
BRCA	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-8.77	7.32e-18	2.9e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	8.77	7.32e-18	2.9e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.77	7.33e-18	2.9e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
BRCA	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	8.77	7.33e-18	2.9e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
BRCA	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	8.77	7.35e-18	2.91e-15	0.33	0.26	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	8.77	7.38e-18	2.92e-15	0.29	0.26	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
BRCA	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	8.77	7.42e-18	2.94e-15	0.31	0.26	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
BRCA	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	8.77	7.43e-18	2.94e-15	0.33	0.26	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
BRCA	cis	rs5751614	0.557	rs928781	ENSG00000230701.2	FBXW4P1	-8.77	7.43e-18	2.94e-15	-0.32	-0.26	Height;	chr22:23257826	chr22:23262767~23265005:+
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	8.77	7.43e-18	2.94e-15	0.18	0.26	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
BRCA	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	8.76	7.48e-18	2.96e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	8.76	7.48e-18	2.96e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
BRCA	cis	rs13256369	1	rs883648	ENSG00000253893.2	FAM85B	-8.76	7.49e-18	2.97e-15	-0.38	-0.26	Obesity-related traits;	chr8:8712011	chr8:8167819~8226614:-
BRCA	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	8.76	7.49e-18	2.97e-15	0.27	0.26	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	8.76	7.51e-18	2.97e-15	0.34	0.26	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
BRCA	cis	rs5751614	1	rs2267018	ENSG00000230701.2	FBXW4P1	8.76	7.51e-18	2.97e-15	0.29	0.26	Height;	chr22:23246006	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-8.76	7.53e-18	2.98e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
BRCA	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-8.76	7.53e-18	2.98e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
BRCA	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-8.76	7.61e-18	3.01e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-8.76	7.61e-18	3.01e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-8.76	7.63e-18	3.02e-15	-0.32	-0.26	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	8.76	7.65e-18	3.03e-15	0.27	0.26	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	8.76	7.65e-18	3.03e-15	0.27	0.26	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-8.76	7.67e-18	3.03e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
BRCA	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	8.76	7.68e-18	3.04e-15	0.33	0.26	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
BRCA	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000220721.1	OR1F12	8.76	7.72e-18	3.05e-15	0.49	0.26	Depression;	chr6:28111963	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-8.76	7.74e-18	3.06e-15	-0.32	-0.26	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
BRCA	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	8.76	7.74e-18	3.06e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
BRCA	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-8.76	7.78e-18	3.07e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-8.76	7.79e-18	3.08e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-8.76	7.79e-18	3.08e-15	-0.3	-0.26	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
BRCA	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	8.76	7.8e-18	3.08e-15	0.38	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
BRCA	cis	rs13256369	0.95	rs12548792	ENSG00000253893.2	FAM85B	-8.76	7.81e-18	3.09e-15	-0.37	-0.26	Obesity-related traits;	chr8:8710521	chr8:8167819~8226614:-
BRCA	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-8.76	7.82e-18	3.09e-15	-0.35	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
BRCA	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-8.76	7.83e-18	3.09e-15	-0.38	-0.26	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	8.76	7.85e-18	3.1e-15	0.35	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
BRCA	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	8.76	7.86e-18	3.11e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
BRCA	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-8.76	7.93e-18	3.13e-15	-0.34	-0.26	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	8.76	7.94e-18	3.13e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	8.76	7.96e-18	3.14e-15	0.26	0.26	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
BRCA	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-8.76	7.97e-18	3.15e-15	-0.31	-0.26	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	8.76	8e-18	3.16e-15	0.26	0.26	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	8.76	8e-18	3.16e-15	0.26	0.26	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-8.76	8.01e-18	3.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-8.76	8.01e-18	3.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs34515241	ENSG00000249839.1	AC011330.5	-8.76	8.02e-18	3.17e-15	-0.38	-0.26	Lung cancer;	chr15:43342011	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-8.76	8.03e-18	3.17e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-8.76	8.03e-18	3.17e-15	-0.31	-0.26	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000271889.1	RP11-493E12.1	8.76	8.09e-18	3.19e-15	0.34	0.26	Tuberculosis;	chr2:61455043	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	8.75	8.12e-18	3.2e-15	0.26	0.26	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-8.75	8.14e-18	3.21e-15	-0.31	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
BRCA	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-8.75	8.15e-18	3.22e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
BRCA	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-8.75	8.17e-18	3.22e-15	-0.29	-0.26	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	8.75	8.18e-18	3.23e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	8.75	8.19e-18	3.23e-15	0.27	0.26	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-8.75	8.21e-18	3.24e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
BRCA	cis	rs202072	0.729	rs202038	ENSG00000272379.1	RP1-257A7.5	-8.75	8.22e-18	3.24e-15	-0.42	-0.26	HIV-1 viral setpoint;	chr6:13288416	chr6:13290018~13290490:-
BRCA	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-8.75	8.27e-18	3.26e-15	-0.26	-0.26	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-8.75	8.28e-18	3.27e-15	-0.3	-0.26	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	8.75	8.29e-18	3.27e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
BRCA	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	8.75	8.29e-18	3.27e-15	0.35	0.26	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
BRCA	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	8.75	8.32e-18	3.28e-15	0.35	0.26	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
BRCA	cis	rs4862750	1	rs4862750	ENSG00000250971.1	RP11-696F12.1	8.75	8.33e-18	3.28e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:187060099~187060930:+
BRCA	cis	rs4862750	1	rs4862751	ENSG00000250971.1	RP11-696F12.1	8.75	8.33e-18	3.28e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:187060099~187060930:+
BRCA	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-8.75	8.35e-18	3.29e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-8.75	8.36e-18	3.3e-15	-0.39	-0.26	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000271889.1	RP11-493E12.1	8.75	8.36e-18	3.3e-15	0.34	0.26	Tuberculosis;	chr2:61454293	chr2:61151433~61162105:-
BRCA	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-8.75	8.36e-18	3.3e-15	-0.32	-0.26	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
BRCA	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	8.75	8.39e-18	3.31e-15	0.39	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	8.75	8.4e-18	3.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	8.75	8.4e-18	3.31e-15	0.23	0.26	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	8.75	8.43e-18	3.32e-15	0.33	0.26	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	8.75	8.53e-18	3.36e-15	0.27	0.26	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	8.75	8.53e-18	3.36e-15	0.27	0.26	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	8.75	8.54e-18	3.37e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	8.75	8.55e-18	3.37e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	8.75	8.56e-18	3.37e-15	0.32	0.26	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-8.75	8.6e-18	3.39e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	8.75	8.62e-18	3.39e-15	0.22	0.26	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
BRCA	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-8.75	8.72e-18	3.43e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000271889.1	RP11-493E12.1	8.75	8.73e-18	3.44e-15	0.35	0.26	Tuberculosis;	chr2:61452417	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000271889.1	RP11-493E12.1	8.75	8.73e-18	3.44e-15	0.35	0.26	Tuberculosis;	chr2:61452759	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-8.75	8.73e-18	3.44e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
BRCA	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-8.75	8.73e-18	3.44e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-8.75	8.74e-18	3.44e-15	-0.28	-0.26	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-8.75	8.74e-18	3.44e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	8.75	8.76e-18	3.45e-15	0.32	0.26	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-8.75	8.76e-18	3.45e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	8.75	8.77e-18	3.45e-15	0.26	0.26	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	8.74	8.82e-18	3.47e-15	0.34	0.26	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	8.74	8.82e-18	3.47e-15	0.35	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
BRCA	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	8.74	8.85e-18	3.48e-15	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-8.74	8.9e-18	3.5e-15	-0.35	-0.26	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	8.74	8.91e-18	3.5e-15	0.31	0.26	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	8.74	8.93e-18	3.51e-15	0.22	0.26	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
BRCA	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	8.74	8.96e-18	3.52e-15	0.36	0.26	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-8.74	8.96e-18	3.52e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-8.74	8.96e-18	3.52e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
BRCA	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-8.74	8.98e-18	3.53e-15	-0.3	-0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
BRCA	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	8.74	8.98e-18	3.53e-15	0.3	0.26	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	8.74	9e-18	3.54e-15	0.27	0.26	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-8.74	9.03e-18	3.55e-15	-0.25	-0.26	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
BRCA	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	8.74	9.04e-18	3.55e-15	0.27	0.26	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
BRCA	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	8.74	9.05e-18	3.55e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	8.74	9.05e-18	3.56e-15	0.27	0.26	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
BRCA	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	8.74	9.08e-18	3.57e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
BRCA	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	8.74	9.11e-18	3.58e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	8.74	9.11e-18	3.58e-15	0.26	0.26	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
BRCA	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-8.74	9.12e-18	3.58e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-8.74	9.12e-18	3.58e-15	-0.28	-0.26	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
BRCA	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	8.74	9.15e-18	3.59e-15	0.45	0.26	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
BRCA	cis	rs853679	1	rs6901575	ENSG00000220721.1	OR1F12	8.74	9.18e-18	3.6e-15	0.41	0.26	Depression;	chr6:28283207	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	8.74	9.21e-18	3.61e-15	0.27	0.26	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.826	rs1186697	ENSG00000271889.1	RP11-493E12.1	8.74	9.21e-18	3.61e-15	0.35	0.26	Tuberculosis;	chr2:61434282	chr2:61151433~61162105:-
BRCA	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-8.74	9.22e-18	3.62e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
BRCA	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-8.74	9.22e-18	3.62e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-8.74	9.22e-18	3.62e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	8.74	9.23e-18	3.62e-15	0.32	0.26	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-8.74	9.28e-18	3.64e-15	-0.32	-0.26	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
BRCA	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
BRCA	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	8.74	9.31e-18	3.65e-15	0.33	0.26	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
BRCA	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	8.74	9.33e-18	3.66e-15	0.33	0.26	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	8.74	9.39e-18	3.68e-15	0.28	0.26	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
BRCA	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	8.74	9.41e-18	3.69e-15	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-8.74	9.41e-18	3.69e-15	-0.34	-0.26	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
BRCA	cis	rs2067615	0.524	rs10778500	ENSG00000260329.1	RP11-412D9.4	-8.74	9.49e-18	3.72e-15	-0.29	-0.26	Heart rate;	chr12:106680632	chr12:106954029~106955497:-
BRCA	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	8.73	9.57e-18	3.75e-15	0.38	0.26	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
BRCA	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	8.73	9.59e-18	3.76e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-8.73	9.61e-18	3.77e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
BRCA	cis	rs7085104	0.7	rs743572	ENSG00000213061.2	PFN1P11	8.73	9.62e-18	3.77e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102838011~102845473:-
BRCA	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-8.73	9.65e-18	3.78e-15	-0.38	-0.26	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
BRCA	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	8.73	9.7e-18	3.8e-15	0.37	0.26	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	8.73	9.7e-18	3.8e-15	0.37	0.26	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
BRCA	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	8.73	9.72e-18	3.81e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	8.73	9.73e-18	3.81e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	8.73	9.78e-18	3.83e-15	0.23	0.26	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
BRCA	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
BRCA	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-8.73	9.83e-18	3.85e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	8.73	9.84e-18	3.86e-15	0.32	0.26	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000226816.2	AC005082.12	8.73	9.88e-18	3.87e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-8.73	9.91e-18	3.88e-15	-0.32	-0.26	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
BRCA	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-8.73	9.95e-18	3.89e-15	-0.52	-0.26	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
BRCA	cis	rs2067615	0.524	rs10778503	ENSG00000260329.1	RP11-412D9.4	-8.73	9.95e-18	3.9e-15	-0.29	-0.26	Heart rate;	chr12:106696838	chr12:106954029~106955497:-
BRCA	cis	rs2067615	0.524	rs1922433	ENSG00000260329.1	RP11-412D9.4	-8.73	9.98e-18	3.91e-15	-0.29	-0.26	Heart rate;	chr12:106683394	chr12:106954029~106955497:-
BRCA	cis	rs2067615	0.524	rs10467029	ENSG00000260329.1	RP11-412D9.4	-8.73	9.98e-18	3.91e-15	-0.29	-0.26	Heart rate;	chr12:106684670	chr12:106954029~106955497:-
BRCA	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-8.73	1e-17	3.92e-15	-0.3	-0.26	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	8.73	1e-17	3.92e-15	0.23	0.26	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	8.73	1e-17	3.93e-15	0.34	0.26	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	8.73	1e-17	3.93e-15	0.28	0.26	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-8.73	1.01e-17	3.94e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	8.73	1.01e-17	3.94e-15	0.33	0.26	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
BRCA	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-8.73	1.01e-17	3.94e-15	-0.26	-0.26	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
BRCA	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	8.73	1.01e-17	3.95e-15	0.32	0.26	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
BRCA	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	8.73	1.01e-17	3.95e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
BRCA	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-8.73	1.01e-17	3.95e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
BRCA	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-8.73	1.01e-17	3.96e-15	-0.25	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-8.73	1.01e-17	3.96e-15	-0.34	-0.26	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
BRCA	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	8.73	1.01e-17	3.97e-15	0.28	0.26	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
BRCA	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-8.73	1.01e-17	3.97e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-8.73	1.01e-17	3.97e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-8.73	1.02e-17	3.97e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-8.73	1.02e-17	3.98e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-8.73	1.02e-17	3.99e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-8.73	1.03e-17	4.01e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	8.73	1.03e-17	4.02e-15	0.23	0.26	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
BRCA	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.03e-15	0.37	0.26	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
BRCA	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	8.73	1.03e-17	4.04e-15	0.34	0.26	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.04e-15	0.36	0.26	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.04e-15	0.36	0.26	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	8.72	1.04e-17	4.07e-15	0.37	0.26	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	8.72	1.04e-17	4.07e-15	0.37	0.26	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
BRCA	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-8.72	1.05e-17	4.09e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	8.72	1.05e-17	4.12e-15	0.33	0.26	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
BRCA	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	8.72	1.06e-17	4.13e-15	0.29	0.26	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	8.72	1.06e-17	4.13e-15	0.32	0.26	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	8.72	1.06e-17	4.13e-15	0.31	0.26	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	8.72	1.06e-17	4.13e-15	0.31	0.26	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
BRCA	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	8.72	1.06e-17	4.13e-15	0.19	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	8.72	1.06e-17	4.13e-15	0.37	0.26	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	8.72	1.06e-17	4.13e-15	0.37	0.26	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
BRCA	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	8.72	1.06e-17	4.13e-15	0.34	0.26	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
BRCA	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-8.72	1.06e-17	4.14e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-8.72	1.06e-17	4.14e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-8.72	1.06e-17	4.14e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
BRCA	cis	rs6545883	0.929	rs1186700	ENSG00000271889.1	RP11-493E12.1	8.72	1.06e-17	4.15e-15	0.35	0.26	Tuberculosis;	chr2:61436237	chr2:61151433~61162105:-
BRCA	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-8.72	1.06e-17	4.15e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-8.72	1.07e-17	4.16e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	8.72	1.07e-17	4.17e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.507	rs11113083	ENSG00000260329.1	RP11-412D9.4	-8.72	1.07e-17	4.18e-15	-0.29	-0.26	Heart rate;	chr12:106679538	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	8.72	1.07e-17	4.19e-15	0.36	0.26	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
BRCA	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-8.72	1.07e-17	4.19e-15	-0.27	-0.26	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
BRCA	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-8.72	1.08e-17	4.2e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
BRCA	cis	rs7246657	0.722	rs2909098	ENSG00000267422.1	CTD-2554C21.1	8.72	1.08e-17	4.22e-15	0.39	0.26	Coronary artery calcification;	chr19:37713347	chr19:37779686~37792865:+
BRCA	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	8.72	1.08e-17	4.23e-15	0.33	0.26	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-8.72	1.09e-17	4.24e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-8.72	1.09e-17	4.25e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
BRCA	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	8.72	1.09e-17	4.25e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
BRCA	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-8.72	1.09e-17	4.25e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
BRCA	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	8.72	1.09e-17	4.25e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
BRCA	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-8.72	1.09e-17	4.26e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
BRCA	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	8.72	1.09e-17	4.27e-15	0.33	0.26	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
BRCA	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-8.72	1.1e-17	4.28e-15	-0.34	-0.26	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
BRCA	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-8.72	1.1e-17	4.3e-15	-0.32	-0.26	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000271889.1	RP11-493E12.1	8.72	1.11e-17	4.33e-15	0.35	0.26	Tuberculosis;	chr2:61453925	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-8.72	1.11e-17	4.33e-15	-0.33	-0.26	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	8.72	1.11e-17	4.35e-15	0.39	0.26	Depression;	chr6:28407125	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	8.72	1.12e-17	4.35e-15	0.31	0.26	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-8.72	1.12e-17	4.36e-15	-0.27	-0.26	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-8.72	1.12e-17	4.36e-15	-0.27	-0.26	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	8.72	1.12e-17	4.37e-15	0.28	0.26	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-8.72	1.12e-17	4.38e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-8.72	1.12e-17	4.38e-15	-0.24	-0.26	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
BRCA	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-8.72	1.12e-17	4.38e-15	-0.39	-0.26	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
BRCA	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-8.72	1.12e-17	4.39e-15	-0.31	-0.26	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
BRCA	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-8.72	1.13e-17	4.39e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
BRCA	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	8.72	1.13e-17	4.39e-15	0.33	0.26	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
BRCA	cis	rs3814244	0.528	rs56393928	ENSG00000236946.2	HNRNPA1P70	-8.71	1.13e-17	4.41e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:68035767~68036853:+
BRCA	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	8.71	1.13e-17	4.41e-15	0.3	0.26	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	8.71	1.13e-17	4.42e-15	0.28	0.26	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
BRCA	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	8.71	1.14e-17	4.42e-15	0.32	0.26	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
BRCA	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-8.71	1.14e-17	4.43e-15	-0.35	-0.26	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	8.71	1.14e-17	4.44e-15	0.34	0.26	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
BRCA	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-8.71	1.14e-17	4.44e-15	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
BRCA	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	8.71	1.14e-17	4.44e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	8.71	1.14e-17	4.44e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
BRCA	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-8.71	1.15e-17	4.46e-15	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-8.71	1.15e-17	4.47e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	8.71	1.15e-17	4.47e-15	0.32	0.26	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
BRCA	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-8.71	1.15e-17	4.47e-15	-0.37	-0.26	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
BRCA	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-8.71	1.15e-17	4.48e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	8.71	1.15e-17	4.48e-15	0.37	0.26	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	8.71	1.15e-17	4.48e-15	0.37	0.26	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	8.71	1.15e-17	4.49e-15	0.32	0.26	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
BRCA	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	8.71	1.16e-17	4.51e-15	0.33	0.26	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
BRCA	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-8.71	1.16e-17	4.51e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-8.71	1.16e-17	4.52e-15	-0.28	-0.26	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-8.71	1.16e-17	4.52e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	8.71	1.16e-17	4.52e-15	0.47	0.26	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
BRCA	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	8.71	1.16e-17	4.53e-15	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-8.71	1.16e-17	4.53e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
BRCA	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-8.71	1.17e-17	4.54e-15	-0.24	-0.26	Asthma;	chr2:102399682	chr2:102438713~102440475:+
BRCA	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	8.71	1.17e-17	4.55e-15	0.33	0.26	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
BRCA	cis	rs67981189	0.529	rs2526857	ENSG00000269927.1	RP6-91H8.3	-8.71	1.17e-17	4.55e-15	-0.34	-0.26	Schizophrenia;	chr14:70945909	chr14:71141125~71143253:-
BRCA	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-8.71	1.17e-17	4.56e-15	-0.29	-0.26	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
BRCA	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-8.71	1.18e-17	4.58e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
BRCA	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	8.71	1.18e-17	4.58e-15	0.29	0.26	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
BRCA	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	8.71	1.18e-17	4.59e-15	0.33	0.26	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	8.71	1.18e-17	4.59e-15	0.33	0.26	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
BRCA	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	8.71	1.18e-17	4.6e-15	0.27	0.26	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
BRCA	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-8.71	1.18e-17	4.61e-15	-0.33	-0.26	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
BRCA	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	8.71	1.19e-17	4.64e-15	0.52	0.26	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	8.71	1.19e-17	4.64e-15	0.27	0.26	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	8.71	1.19e-17	4.64e-15	0.34	0.26	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
BRCA	cis	rs748404	0.626	rs72707530	ENSG00000249839.1	AC011330.5	-8.71	1.2e-17	4.65e-15	-0.38	-0.26	Lung cancer;	chr15:43353622	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-8.71	1.2e-17	4.66e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-8.71	1.2e-17	4.66e-15	-0.55	-0.26	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.722	rs2972430	ENSG00000267422.1	CTD-2554C21.1	8.71	1.2e-17	4.66e-15	0.39	0.26	Coronary artery calcification;	chr19:37691210	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	8.71	1.2e-17	4.67e-15	0.37	0.26	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-8.71	1.2e-17	4.67e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
BRCA	cis	rs7085104	0.684	rs7092690	ENSG00000213061.2	PFN1P11	8.71	1.2e-17	4.67e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102838011~102845473:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	8.71	1.2e-17	4.68e-15	0.32	0.26	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	8.71	1.21e-17	4.69e-15	0.27	0.26	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	8.71	1.21e-17	4.69e-15	0.27	0.26	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
BRCA	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	8.71	1.21e-17	4.7e-15	0.27	0.26	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
BRCA	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-8.71	1.21e-17	4.7e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
BRCA	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.71	1.21e-17	4.7e-15	-0.43	-0.26	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.511	rs10256996	ENSG00000226816.2	AC005082.12	-8.71	1.22e-17	4.72e-15	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23206013~23208045:+
BRCA	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-8.71	1.22e-17	4.74e-15	-0.27	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
BRCA	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	8.7	1.22e-17	4.76e-15	0.39	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
BRCA	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-8.7	1.23e-17	4.76e-15	-0.28	-0.26	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
BRCA	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	8.7	1.23e-17	4.77e-15	0.27	0.26	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	8.7	1.24e-17	4.8e-15	0.66	0.26	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-8.7	1.24e-17	4.81e-15	-0.25	-0.26	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
BRCA	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	8.7	1.24e-17	4.82e-15	0.19	0.26	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	8.7	1.24e-17	4.82e-15	0.18	0.26	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
BRCA	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-8.7	1.24e-17	4.83e-15	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-8.7	1.25e-17	4.85e-15	-0.34	-0.26	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
BRCA	cis	rs2810114	1	rs2810114	ENSG00000269927.1	RP6-91H8.3	-8.7	1.25e-17	4.87e-15	-0.34	-0.26	Alcohol dependence;	chr14:70928887	chr14:71141125~71143253:-
BRCA	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	8.7	1.26e-17	4.88e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
BRCA	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-8.7	1.26e-17	4.9e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
BRCA	cis	rs7085104	0.7	rs7096183	ENSG00000213061.2	PFN1P11	8.7	1.26e-17	4.91e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102838011~102845473:-
BRCA	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	8.7	1.27e-17	4.91e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
BRCA	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-8.7	1.27e-17	4.93e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
BRCA	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-8.7	1.27e-17	4.93e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
BRCA	cis	rs58873874	0.737	rs9313608	ENSG00000248544.2	CTB-47B11.3	-8.7	1.27e-17	4.94e-15	-0.61	-0.26	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157375741~157384950:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-8.7	1.28e-17	4.95e-15	-0.32	-0.26	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	8.7	1.28e-17	4.95e-15	0.31	0.26	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-8.7	1.28e-17	4.96e-15	-0.34	-0.26	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
BRCA	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-8.7	1.28e-17	4.96e-15	-0.33	-0.26	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	8.7	1.28e-17	4.97e-15	0.28	0.26	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	8.7	1.29e-17	4.99e-15	0.29	0.26	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	8.7	1.29e-17	5e-15	0.26	0.26	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	8.7	1.29e-17	5.01e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-8.7	1.3e-17	5.03e-15	-0.33	-0.26	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-8.7	1.3e-17	5.04e-15	-0.24	-0.26	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
BRCA	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	8.7	1.3e-17	5.05e-15	0.31	0.26	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
BRCA	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-8.7	1.31e-17	5.07e-15	-0.27	-0.26	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
BRCA	cis	rs748404	0.666	rs10518812	ENSG00000249839.1	AC011330.5	8.7	1.32e-17	5.1e-15	0.38	0.26	Lung cancer;	chr15:43360739	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-8.7	1.32e-17	5.11e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-8.7	1.32e-17	5.12e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
BRCA	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	8.7	1.32e-17	5.12e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	8.7	1.32e-17	5.13e-15	0.3	0.26	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-8.7	1.33e-17	5.13e-15	-0.25	-0.26	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
BRCA	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	8.7	1.33e-17	5.14e-15	0.33	0.26	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
BRCA	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-8.7	1.33e-17	5.14e-15	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	8.69	1.33e-17	5.15e-15	0.26	0.26	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
BRCA	cis	rs67981189	0.501	rs2810104	ENSG00000269927.1	RP6-91H8.3	8.69	1.33e-17	5.15e-15	0.34	0.26	Schizophrenia;	chr14:70958096	chr14:71141125~71143253:-
BRCA	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	8.69	1.33e-17	5.15e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-8.69	1.33e-17	5.15e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-8.69	1.33e-17	5.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-8.69	1.34e-17	5.17e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
BRCA	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	8.69	1.34e-17	5.18e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
BRCA	cis	rs3758911	0.964	rs10890702	ENSG00000255353.1	RP11-382M14.1	8.69	1.34e-17	5.18e-15	0.33	0.26	Coronary artery disease;	chr11:107310159	chr11:107176286~107177530:+
BRCA	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	8.69	1.34e-17	5.19e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.722	rs2909093	ENSG00000267422.1	CTD-2554C21.1	8.69	1.34e-17	5.2e-15	0.39	0.26	Coronary artery calcification;	chr19:37708561	chr19:37779686~37792865:+
BRCA	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-8.69	1.35e-17	5.21e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-8.69	1.35e-17	5.22e-15	-0.32	-0.26	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
BRCA	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	8.69	1.35e-17	5.22e-15	0.34	0.26	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	8.69	1.35e-17	5.22e-15	0.27	0.26	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	8.69	1.35e-17	5.24e-15	0.37	0.26	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
BRCA	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	8.69	1.35e-17	5.24e-15	0.32	0.26	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	8.69	1.35e-17	5.24e-15	0.31	0.26	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	8.69	1.36e-17	5.25e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	8.69	1.36e-17	5.25e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	8.69	1.36e-17	5.27e-15	0.36	0.26	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
BRCA	cis	rs58873874	1	rs75720504	ENSG00000251405.2	CTB-109A12.1	8.69	1.37e-17	5.29e-15	0.66	0.26	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-8.69	1.37e-17	5.29e-15	-0.31	-0.26	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
BRCA	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	8.69	1.37e-17	5.3e-15	0.33	0.26	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	8.69	1.37e-17	5.31e-15	0.32	0.26	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
BRCA	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-8.69	1.38e-17	5.32e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-8.69	1.38e-17	5.32e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	8.69	1.38e-17	5.32e-15	0.29	0.26	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	8.69	1.38e-17	5.32e-15	0.33	0.26	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
BRCA	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-8.69	1.38e-17	5.33e-15	-0.35	-0.26	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
BRCA	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	8.69	1.38e-17	5.33e-15	0.33	0.26	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	8.69	1.38e-17	5.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	8.69	1.38e-17	5.34e-15	0.33	0.26	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	8.69	1.39e-17	5.36e-15	0.28	0.26	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	8.69	1.39e-17	5.39e-15	0.3	0.26	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	8.69	1.4e-17	5.4e-15	0.28	0.26	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	8.69	1.4e-17	5.43e-15	0.28	0.26	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
BRCA	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-8.69	1.41e-17	5.43e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-8.69	1.41e-17	5.43e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-8.69	1.41e-17	5.44e-15	-0.34	-0.26	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
BRCA	cis	rs7085104	0.7	rs6163	ENSG00000213061.2	PFN1P11	8.69	1.41e-17	5.44e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102838011~102845473:-
BRCA	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-8.69	1.41e-17	5.45e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-8.69	1.41e-17	5.46e-15	-0.32	-0.26	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
BRCA	cis	rs7246657	0.722	rs2287229	ENSG00000267422.1	CTD-2554C21.1	8.69	1.42e-17	5.47e-15	0.39	0.26	Coronary artery calcification;	chr19:37697751	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	8.69	1.42e-17	5.48e-15	0.36	0.26	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-8.69	1.42e-17	5.49e-15	-0.27	-0.26	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
BRCA	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-8.69	1.42e-17	5.49e-15	-0.38	-0.26	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	8.69	1.42e-17	5.49e-15	0.33	0.26	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	8.69	1.43e-17	5.51e-15	0.18	0.26	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	8.69	1.43e-17	5.51e-15	0.18	0.26	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	8.69	1.43e-17	5.53e-15	0.27	0.26	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
BRCA	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	8.69	1.44e-17	5.55e-15	0.48	0.26	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	8.69	1.44e-17	5.55e-15	0.32	0.26	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	8.69	1.44e-17	5.56e-15	0.18	0.26	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
BRCA	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-8.68	1.44e-17	5.57e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
BRCA	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-8.68	1.45e-17	5.58e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
BRCA	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-8.68	1.45e-17	5.59e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	8.68	1.45e-17	5.6e-15	0.27	0.26	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	8.68	1.45e-17	5.61e-15	0.27	0.26	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
BRCA	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-8.68	1.47e-17	5.65e-15	-0.33	-0.26	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
BRCA	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-8.68	1.47e-17	5.68e-15	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	8.68	1.48e-17	5.69e-15	0.31	0.26	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.722	rs2075284	ENSG00000267422.1	CTD-2554C21.1	8.68	1.48e-17	5.71e-15	0.39	0.26	Coronary artery calcification;	chr19:37698715	chr19:37779686~37792865:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	8.68	1.49e-17	5.74e-15	0.22	0.26	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
BRCA	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	8.68	1.49e-17	5.75e-15	0.33	0.26	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
BRCA	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	8.68	1.49e-17	5.75e-15	0.32	0.26	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
BRCA	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	8.68	1.5e-17	5.77e-15	0.33	0.26	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-8.68	1.5e-17	5.78e-15	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-8.68	1.5e-17	5.78e-15	-0.32	-0.26	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-8.68	1.5e-17	5.78e-15	-0.32	-0.26	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
BRCA	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	8.68	1.5e-17	5.79e-15	0.29	0.26	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	8.68	1.5e-17	5.8e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-8.68	1.51e-17	5.8e-15	-0.29	-0.26	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
BRCA	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	8.68	1.51e-17	5.81e-15	0.33	0.26	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
BRCA	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	8.68	1.52e-17	5.84e-15	0.38	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	8.68	1.52e-17	5.85e-15	0.31	0.26	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
BRCA	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	8.68	1.52e-17	5.86e-15	0.45	0.26	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000278665.1	RP11-666O2.4	8.68	1.53e-17	5.89e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.68	1.53e-17	5.91e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.68	1.53e-17	5.91e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	8.68	1.54e-17	5.92e-15	0.33	0.26	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
BRCA	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	8.68	1.54e-17	5.92e-15	0.27	0.26	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	8.68	1.54e-17	5.93e-15	0.3	0.26	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	8.68	1.55e-17	5.96e-15	0.4	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
BRCA	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	8.68	1.55e-17	5.97e-15	0.33	0.26	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	8.68	1.56e-17	5.98e-15	0.25	0.26	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-8.68	1.56e-17	5.98e-15	-0.33	-0.26	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
BRCA	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-8.68	1.56e-17	6e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	8.68	1.56e-17	6.01e-15	0.18	0.26	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
BRCA	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	8.67	1.57e-17	6.03e-15	0.36	0.26	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs60018990	ENSG00000249839.1	AC011330.5	-8.67	1.57e-17	6.03e-15	-0.37	-0.26	Lung cancer;	chr15:43504606	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-8.67	1.57e-17	6.04e-15	-0.3	-0.26	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-8.67	1.57e-17	6.04e-15	-0.27	-0.26	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-8.67	1.58e-17	6.06e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-8.67	1.58e-17	6.09e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	8.67	1.59e-17	6.1e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	8.67	1.59e-17	6.11e-15	0.34	0.26	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-8.67	1.59e-17	6.11e-15	-0.3	-0.26	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	8.67	1.59e-17	6.12e-15	0.32	0.26	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
BRCA	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	8.67	1.59e-17	6.13e-15	0.3	0.26	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	8.67	1.6e-17	6.13e-15	0.26	0.26	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-8.67	1.6e-17	6.13e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
BRCA	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-8.67	1.6e-17	6.15e-15	-0.23	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
BRCA	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-8.67	1.6e-17	6.15e-15	-0.32	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	8.67	1.6e-17	6.16e-15	0.29	0.26	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	8.67	1.6e-17	6.16e-15	0.29	0.26	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	8.67	1.61e-17	6.18e-15	0.25	0.26	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-8.67	1.61e-17	6.18e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-8.67	1.63e-17	6.24e-15	-0.31	-0.26	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
BRCA	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-8.67	1.63e-17	6.25e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	8.67	1.63e-17	6.26e-15	0.32	0.26	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
BRCA	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	8.67	1.63e-17	6.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	8.67	1.63e-17	6.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
BRCA	cis	rs3814244	0.528	rs12228471	ENSG00000236946.2	HNRNPA1P70	-8.67	1.63e-17	6.27e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:68035767~68036853:+
BRCA	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-8.67	1.64e-17	6.28e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	8.67	1.64e-17	6.28e-15	0.28	0.26	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	8.67	1.64e-17	6.31e-15	0.23	0.26	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
BRCA	cis	rs2067615	0.524	rs4964483	ENSG00000260329.1	RP11-412D9.4	-8.67	1.65e-17	6.32e-15	-0.29	-0.26	Heart rate;	chr12:106705279	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-17	6.32e-15	-0.34	-0.26	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
BRCA	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
BRCA	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
BRCA	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-8.67	1.65e-17	6.33e-15	-0.25	-0.26	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	8.67	1.66e-17	6.35e-15	0.28	0.26	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-8.67	1.66e-17	6.38e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	8.67	1.66e-17	6.38e-15	0.28	0.26	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
BRCA	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	8.67	1.66e-17	6.38e-15	0.37	0.26	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-8.67	1.67e-17	6.39e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
BRCA	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	8.67	1.67e-17	6.39e-15	0.33	0.26	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
BRCA	cis	rs67981189	0.529	rs61990379	ENSG00000269927.1	RP6-91H8.3	8.67	1.67e-17	6.39e-15	0.34	0.26	Schizophrenia;	chr14:71000353	chr14:71141125~71143253:-
BRCA	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-8.67	1.67e-17	6.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	8.67	1.67e-17	6.41e-15	0.28	0.26	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
BRCA	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-8.67	1.68e-17	6.42e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
BRCA	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-8.67	1.68e-17	6.46e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-8.67	1.69e-17	6.46e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	8.67	1.69e-17	6.47e-15	0.31	0.26	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
BRCA	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	8.67	1.69e-17	6.49e-15	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
BRCA	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	8.67	1.7e-17	6.51e-15	0.33	0.26	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000271889.1	RP11-493E12.1	8.66	1.7e-17	6.52e-15	0.34	0.26	Tuberculosis;	chr2:61455841	chr2:61151433~61162105:-
BRCA	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-8.66	1.7e-17	6.52e-15	-0.34	-0.26	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	8.66	1.7e-17	6.52e-15	0.34	0.26	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
BRCA	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-8.66	1.7e-17	6.53e-15	-0.33	-0.26	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-8.66	1.7e-17	6.53e-15	-0.32	-0.26	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
BRCA	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	8.66	1.71e-17	6.53e-15	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	8.66	1.71e-17	6.54e-15	0.36	0.26	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
BRCA	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	8.66	1.71e-17	6.57e-15	0.4	0.26	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
BRCA	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-8.66	1.72e-17	6.57e-15	-0.26	-0.26	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
BRCA	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-8.66	1.72e-17	6.57e-15	-0.35	-0.26	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-8.66	1.72e-17	6.58e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.63e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	8.66	1.73e-17	6.64e-15	0.37	0.26	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
BRCA	cis	rs7085104	0.632	rs4290163	ENSG00000213061.2	PFN1P11	8.66	1.74e-17	6.64e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102838011~102845473:-
BRCA	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-8.66	1.74e-17	6.64e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-8.66	1.74e-17	6.67e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
BRCA	cis	rs2810114	0.916	rs2526851	ENSG00000269927.1	RP6-91H8.3	-8.66	1.74e-17	6.67e-15	-0.34	-0.26	Alcohol dependence;	chr14:70949563	chr14:71141125~71143253:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	8.66	1.75e-17	6.69e-15	0.25	0.26	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
BRCA	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	8.66	1.75e-17	6.71e-15	0.33	0.26	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-8.66	1.76e-17	6.72e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-8.66	1.76e-17	6.73e-15	-0.33	-0.26	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-8.66	1.76e-17	6.74e-15	-0.36	-0.26	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
BRCA	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	8.66	1.76e-17	6.74e-15	0.48	0.26	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	8.66	1.76e-17	6.74e-15	0.32	0.26	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
BRCA	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	8.66	1.77e-17	6.75e-15	0.45	0.26	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	8.66	1.77e-17	6.75e-15	0.27	0.26	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
BRCA	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	8.66	1.78e-17	6.8e-15	0.28	0.26	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	8.66	1.78e-17	6.8e-15	0.28	0.26	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
BRCA	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	8.66	1.78e-17	6.81e-15	0.37	0.26	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	8.66	1.79e-17	6.84e-15	0.27	0.26	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	8.66	1.79e-17	6.85e-15	0.26	0.26	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	8.66	1.8e-17	6.86e-15	0.3	0.26	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
BRCA	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	8.66	1.8e-17	6.86e-15	0.27	0.26	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	8.66	1.8e-17	6.86e-15	0.32	0.26	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
BRCA	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-8.66	1.8e-17	6.88e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
BRCA	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	8.66	1.8e-17	6.88e-15	0.31	0.26	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
BRCA	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	8.66	1.8e-17	6.89e-15	0.31	0.26	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
BRCA	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	8.66	1.81e-17	6.92e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	8.66	1.82e-17	6.95e-15	0.23	0.26	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
BRCA	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-8.66	1.82e-17	6.96e-15	-0.31	-0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
BRCA	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-8.66	1.82e-17	6.96e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
BRCA	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-8.66	1.83e-17	6.99e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-8.66	1.83e-17	7e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-8.66	1.83e-17	7e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
BRCA	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	8.66	1.84e-17	7.02e-15	0.32	0.26	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.66	1.84e-17	7.03e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.66	1.84e-17	7.03e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
BRCA	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-8.65	1.85e-17	7.07e-15	-0.22	-0.26	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
BRCA	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-8.65	1.86e-17	7.09e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-8.65	1.86e-17	7.1e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	8.65	1.86e-17	7.1e-15	0.32	0.26	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
BRCA	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-8.65	1.87e-17	7.11e-15	-0.39	-0.26	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	8.65	1.87e-17	7.12e-15	0.23	0.26	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	8.65	1.87e-17	7.12e-15	0.23	0.26	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
BRCA	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-8.65	1.88e-17	7.15e-15	-0.33	-0.26	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
BRCA	cis	rs7246657	0.722	rs968073	ENSG00000267422.1	CTD-2554C21.1	8.65	1.88e-17	7.15e-15	0.39	0.26	Coronary artery calcification;	chr19:37701120	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.65	1.88e-17	7.16e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-8.65	1.88e-17	7.18e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	8.65	1.89e-17	7.2e-15	0.52	0.26	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
BRCA	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	8.65	1.89e-17	7.2e-15	0.47	0.26	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
BRCA	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	8.65	1.89e-17	7.22e-15	0.24	0.26	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	8.65	1.9e-17	7.23e-15	0.29	0.26	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
BRCA	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	8.65	1.9e-17	7.24e-15	0.32	0.26	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	8.65	1.91e-17	7.29e-15	0.23	0.26	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000222364.1	RNU6-96P	-8.65	1.92e-17	7.29e-15	-0.35	-0.26	Aortic root size;	chr7:66474464	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	8.65	1.92e-17	7.3e-15	0.34	0.26	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
BRCA	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	8.65	1.93e-17	7.33e-15	0.33	0.26	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
BRCA	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	8.65	1.93e-17	7.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	8.65	1.93e-17	7.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-8.65	1.94e-17	7.36e-15	-0.36	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
BRCA	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-8.65	1.94e-17	7.38e-15	-0.35	-0.26	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
BRCA	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-8.65	1.95e-17	7.4e-15	-0.4	-0.26	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
BRCA	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	8.65	1.95e-17	7.42e-15	0.24	0.26	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-8.65	1.95e-17	7.42e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-8.65	1.95e-17	7.42e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-8.65	1.95e-17	7.43e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	8.65	1.96e-17	7.44e-15	0.25	0.26	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	8.65	1.96e-17	7.44e-15	0.25	0.26	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
BRCA	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-8.65	1.96e-17	7.46e-15	-0.34	-0.26	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-8.65	1.97e-17	7.48e-15	-0.29	-0.26	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	8.65	1.98e-17	7.51e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	8.65	1.98e-17	7.51e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	8.65	1.98e-17	7.52e-15	0.34	0.26	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	8.65	1.98e-17	7.53e-15	0.33	0.26	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
BRCA	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	8.65	1.98e-17	7.53e-15	0.37	0.26	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs8027748	ENSG00000249839.1	AC011330.5	-8.65	1.98e-17	7.54e-15	-0.38	-0.26	Lung cancer;	chr15:43447622	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	8.65	1.99e-17	7.55e-15	0.18	0.26	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
BRCA	cis	rs5751614	0.557	rs5759665	ENSG00000230701.2	FBXW4P1	8.65	1.99e-17	7.56e-15	0.32	0.26	Height;	chr22:23260033	chr22:23262767~23265005:+
BRCA	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	8.65	1.99e-17	7.57e-15	0.36	0.26	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000222364.1	RNU6-96P	-8.65	1.99e-17	7.57e-15	-0.35	-0.26	Aortic root size;	chr7:66302477	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000222364.1	RNU6-96P	-8.65	1.99e-17	7.57e-15	-0.35	-0.26	Aortic root size;	chr7:66305392	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-8.65	2e-17	7.59e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000222364.1	RNU6-96P	-8.65	2e-17	7.6e-15	-0.35	-0.26	Aortic root size;	chr7:66481592	chr7:66395191~66395286:+
BRCA	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-8.65	2e-17	7.6e-15	-0.31	-0.26	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
BRCA	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-8.65	2e-17	7.6e-15	-0.33	-0.26	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
BRCA	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	8.64	2.01e-17	7.62e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
BRCA	cis	rs67981189	0.529	rs2526858	ENSG00000269927.1	RP6-91H8.3	-8.64	2.01e-17	7.64e-15	-0.34	-0.26	Schizophrenia;	chr14:70945623	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	8.64	2.02e-17	7.66e-15	0.27	0.26	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	8.64	2.02e-17	7.67e-15	0.26	0.26	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
BRCA	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-8.64	2.02e-17	7.68e-15	-0.35	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	8.64	2.03e-17	7.72e-15	0.23	0.26	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	8.64	2.03e-17	7.73e-15	0.43	0.26	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-8.64	2.04e-17	7.73e-15	-0.3	-0.26	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	8.64	2.04e-17	7.75e-15	0.32	0.26	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-8.64	2.04e-17	7.75e-15	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
BRCA	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	8.64	2.05e-17	7.76e-15	0.34	0.26	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
BRCA	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-8.64	2.05e-17	7.76e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-8.64	2.06e-17	7.8e-15	-0.34	-0.26	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-8.64	2.06e-17	7.82e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
BRCA	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	8.64	2.06e-17	7.82e-15	0.37	0.26	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-8.64	2.08e-17	7.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
BRCA	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-8.64	2.08e-17	7.89e-15	-0.34	-0.26	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.64	2.08e-17	7.9e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-8.64	2.09e-17	7.91e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-8.64	2.09e-17	7.92e-15	-0.27	-0.26	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-8.64	2.1e-17	7.96e-15	-0.32	-0.26	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
BRCA	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-8.64	2.11e-17	7.98e-15	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
BRCA	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-8.64	2.11e-17	8.01e-15	-0.45	-0.26	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
BRCA	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	8.64	2.12e-17	8.02e-15	0.29	0.26	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
BRCA	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	8.64	2.13e-17	8.05e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
BRCA	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-8.64	2.13e-17	8.06e-15	-0.28	-0.26	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
BRCA	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-8.64	2.14e-17	8.12e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-8.64	2.14e-17	8.12e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
BRCA	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	8.64	2.15e-17	8.13e-15	0.35	0.26	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-8.64	2.15e-17	8.13e-15	-0.34	-0.26	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-8.64	2.16e-17	8.17e-15	-0.32	-0.26	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
BRCA	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-8.64	2.16e-17	8.18e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	8.63	2.18e-17	8.27e-15	0.26	0.26	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	8.63	2.21e-17	8.35e-15	0.26	0.26	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-8.63	2.21e-17	8.36e-15	-0.27	-0.26	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
BRCA	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	8.63	2.21e-17	8.37e-15	0.37	0.26	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	8.63	2.21e-17	8.38e-15	0.31	0.26	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
BRCA	cis	rs3814244	0.528	rs2870960	ENSG00000236946.2	HNRNPA1P70	-8.63	2.21e-17	8.38e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:68035767~68036853:+
BRCA	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	8.63	2.21e-17	8.38e-15	0.24	0.26	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
BRCA	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-8.63	2.22e-17	8.38e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
BRCA	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	8.63	2.22e-17	8.38e-15	0.38	0.26	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
BRCA	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	8.63	2.22e-17	8.39e-15	0.36	0.26	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
BRCA	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-8.63	2.22e-17	8.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-8.63	2.22e-17	8.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
BRCA	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-8.63	2.23e-17	8.42e-15	-0.34	-0.26	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
BRCA	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-8.63	2.23e-17	8.44e-15	-0.34	-0.26	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-8.63	2.23e-17	8.44e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-8.63	2.24e-17	8.47e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-8.63	2.24e-17	8.48e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	8.63	2.24e-17	8.49e-15	0.18	0.26	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	8.63	2.24e-17	8.49e-15	0.18	0.26	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
BRCA	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.63	2.26e-17	8.55e-15	0.35	0.26	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	8.63	2.26e-17	8.56e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.63	2.26e-17	8.56e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	8.63	2.26e-17	8.56e-15	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	8.63	2.27e-17	8.58e-15	0.3	0.26	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
BRCA	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	8.63	2.28e-17	8.61e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
BRCA	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	8.63	2.28e-17	8.63e-15	0.31	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
BRCA	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	8.63	2.29e-17	8.64e-15	0.44	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
BRCA	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	8.63	2.29e-17	8.67e-15	0.29	0.26	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-8.63	2.3e-17	8.7e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	8.63	2.3e-17	8.71e-15	0.26	0.26	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	8.63	2.3e-17	8.71e-15	0.26	0.26	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
BRCA	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-8.63	2.31e-17	8.73e-15	-0.48	-0.26	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	8.63	2.32e-17	8.77e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-8.63	2.33e-17	8.78e-15	-0.3	-0.26	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
BRCA	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-8.63	2.33e-17	8.79e-15	-0.43	-0.26	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
BRCA	cis	rs67981189	0.529	rs2526872	ENSG00000269927.1	RP6-91H8.3	-8.63	2.33e-17	8.79e-15	-0.34	-0.26	Schizophrenia;	chr14:70918168	chr14:71141125~71143253:-
BRCA	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	8.63	2.33e-17	8.8e-15	0.5	0.26	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-8.63	2.33e-17	8.81e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-8.63	2.34e-17	8.83e-15	-0.33	-0.26	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.63	2.34e-17	8.83e-15	0.24	0.26	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	8.63	2.34e-17	8.85e-15	0.3	0.26	Shingles;	chr7:38346957	chr7:38358512~38359162:-
BRCA	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-8.62	2.36e-17	8.9e-15	-0.3	-0.26	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	8.62	2.36e-17	8.9e-15	0.26	0.26	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	8.62	2.37e-17	8.93e-15	0.28	0.26	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	8.62	2.37e-17	8.94e-15	0.26	0.26	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	8.62	2.37e-17	8.94e-15	0.26	0.26	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	8.62	2.38e-17	8.97e-15	0.35	0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
BRCA	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	8.62	2.4e-17	9.07e-15	0.29	0.26	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	8.62	2.41e-17	9.1e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	8.62	2.42e-17	9.12e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
BRCA	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	8.62	2.43e-17	9.15e-15	0.46	0.26	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	8.62	2.43e-17	9.15e-15	0.46	0.26	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	8.62	2.44e-17	9.21e-15	0.26	0.26	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
BRCA	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-8.62	2.45e-17	9.24e-15	-0.37	-0.26	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
BRCA	cis	rs7085104	0.7	rs10883785	ENSG00000213061.2	PFN1P11	8.62	2.48e-17	9.33e-15	0.33	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102838011~102845473:-
BRCA	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	8.62	2.48e-17	9.34e-15	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
BRCA	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
BRCA	cis	rs6545883	0.562	rs777588	ENSG00000271889.1	RP11-493E12.1	8.62	2.48e-17	9.36e-15	0.32	0.26	Tuberculosis;	chr2:61199685	chr2:61151433~61162105:-
BRCA	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.62	2.48e-17	9.36e-15	0.27	0.26	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
BRCA	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.529	rs2526850	ENSG00000269927.1	RP6-91H8.3	-8.62	2.51e-17	9.46e-15	-0.34	-0.26	Schizophrenia;	chr14:70950532	chr14:71141125~71143253:-
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	8.62	2.52e-17	9.49e-15	0.57	0.26	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
BRCA	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	8.62	2.53e-17	9.53e-15	0.29	0.26	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
BRCA	cis	rs7085104	0.632	rs7096475	ENSG00000213061.2	PFN1P11	8.62	2.53e-17	9.53e-15	0.33	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102838011~102845473:-
BRCA	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	8.62	2.54e-17	9.55e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-8.62	2.54e-17	9.55e-15	-0.38	-0.26	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
BRCA	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	8.62	2.54e-17	9.55e-15	0.45	0.26	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
BRCA	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	8.62	2.54e-17	9.56e-15	0.28	0.26	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
BRCA	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	8.62	2.54e-17	9.57e-15	0.32	0.26	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	8.62	2.55e-17	9.58e-15	0.27	0.26	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	8.62	2.55e-17	9.61e-15	0.3	0.26	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-8.61	2.56e-17	9.63e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	8.61	2.56e-17	9.64e-15	0.29	0.26	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	8.61	2.56e-17	9.64e-15	0.26	0.26	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	8.61	2.56e-17	9.64e-15	0.26	0.26	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	8.61	2.57e-17	9.65e-15	0.31	0.26	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-8.61	2.57e-17	9.67e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	8.61	2.58e-17	9.69e-15	0.31	0.26	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-8.61	2.58e-17	9.71e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-8.61	2.6e-17	9.76e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
BRCA	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	8.61	2.6e-17	9.76e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
BRCA	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-8.61	2.6e-17	9.77e-15	-0.35	-0.26	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
BRCA	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	8.61	2.6e-17	9.77e-15	0.27	0.26	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-8.61	2.6e-17	9.77e-15	-0.27	-0.26	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-8.61	2.6e-17	9.78e-15	-0.29	-0.26	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	8.61	2.61e-17	9.82e-15	0.3	0.26	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.61	2.62e-17	9.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.61	2.62e-17	9.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-8.61	2.63e-17	9.88e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	8.61	2.64e-17	9.91e-15	0.29	0.26	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	8.61	2.64e-17	9.92e-15	0.31	0.26	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
BRCA	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	8.61	2.64e-17	9.92e-15	0.32	0.26	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
BRCA	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	8.61	2.65e-17	9.95e-15	0.31	0.26	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
BRCA	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-8.61	2.65e-17	9.97e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	8.61	2.66e-17	9.99e-15	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
BRCA	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	8.61	2.66e-17	1e-14	0.25	0.26	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
BRCA	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-8.61	2.67e-17	1e-14	-0.34	-0.26	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.655	rs11893880	ENSG00000271889.1	RP11-493E12.1	8.61	2.67e-17	1e-14	0.32	0.26	Tuberculosis;	chr2:61194884	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-8.61	2.68e-17	1.01e-14	-0.33	-0.26	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
BRCA	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	8.61	2.68e-17	1.01e-14	0.36	0.26	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
BRCA	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-8.61	2.68e-17	1.01e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-8.61	2.68e-17	1.01e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
BRCA	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	8.61	2.69e-17	1.01e-14	0.36	0.26	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
BRCA	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	8.61	2.69e-17	1.01e-14	0.23	0.26	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
BRCA	cis	rs853679	1	rs2799077	ENSG00000220721.1	OR1F12	8.61	2.7e-17	1.01e-14	0.41	0.26	Depression;	chr6:28266819	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.759	rs777585	ENSG00000271889.1	RP11-493E12.1	-8.61	2.7e-17	1.01e-14	-0.33	-0.26	Tuberculosis;	chr2:61185424	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	8.61	2.71e-17	1.02e-14	0.21	0.26	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
BRCA	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	8.61	2.71e-17	1.02e-14	0.32	0.26	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
BRCA	cis	rs3814244	0.528	rs17104682	ENSG00000236946.2	HNRNPA1P70	8.61	2.73e-17	1.02e-14	0.22	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:68035767~68036853:+
BRCA	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
BRCA	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	8.61	2.76e-17	1.04e-14	0.3	0.26	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
BRCA	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	8.61	2.76e-17	1.04e-14	0.28	0.26	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
BRCA	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-8.61	2.77e-17	1.04e-14	-0.31	-0.26	Migraine;	chr4:56881195	chr4:56960927~56961373:-
BRCA	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	8.61	2.77e-17	1.04e-14	0.41	0.26	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-8.6	2.77e-17	1.04e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	8.6	2.78e-17	1.04e-14	0.25	0.26	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
BRCA	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	8.6	2.79e-17	1.05e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
BRCA	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	8.6	2.79e-17	1.05e-14	0.5	0.26	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
BRCA	cis	rs2067615	0.599	rs1579808	ENSG00000260329.1	RP11-412D9.4	8.6	2.79e-17	1.05e-14	0.28	0.26	Heart rate;	chr12:106846169	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000222364.1	RNU6-96P	-8.6	2.79e-17	1.05e-14	-0.35	-0.26	Aortic root size;	chr7:66480545	chr7:66395191~66395286:+
BRCA	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	8.6	2.79e-17	1.05e-14	0.32	0.26	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
BRCA	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-8.6	2.8e-17	1.05e-14	-0.3	-0.26	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
BRCA	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	8.6	2.8e-17	1.05e-14	0.31	0.26	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	8.6	2.8e-17	1.05e-14	0.18	0.26	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	8.6	2.8e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	8.6	2.81e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	8.6	2.81e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	8.6	2.82e-17	1.05e-14	0.21	0.26	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	8.6	2.82e-17	1.05e-14	0.21	0.26	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	8.6	2.83e-17	1.06e-14	0.28	0.26	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	8.6	2.83e-17	1.06e-14	0.28	0.26	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-8.6	2.83e-17	1.06e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	8.6	2.83e-17	1.06e-14	0.26	0.26	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-8.6	2.84e-17	1.06e-14	-0.31	-0.26	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
BRCA	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	8.6	2.84e-17	1.06e-14	0.34	0.26	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
BRCA	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-8.6	2.84e-17	1.07e-14	-0.33	-0.26	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
BRCA	cis	rs6472827	0.645	rs2956056	ENSG00000253983.2	RP1-16A9.1	8.6	2.85e-17	1.07e-14	0.35	0.26	Uterine fibroids;	chr8:74199608	chr8:74199396~74208441:+
BRCA	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	8.6	2.86e-17	1.07e-14	0.31	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.6	2.86e-17	1.07e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-8.6	2.87e-17	1.08e-14	-0.32	-0.26	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
BRCA	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	8.6	2.88e-17	1.08e-14	0.31	0.26	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
BRCA	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-8.6	2.89e-17	1.08e-14	-0.34	-0.26	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
BRCA	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	8.6	2.9e-17	1.09e-14	0.36	0.26	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	8.6	2.9e-17	1.09e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	8.6	2.9e-17	1.09e-14	0.23	0.26	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
BRCA	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-8.6	2.9e-17	1.09e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	8.6	2.91e-17	1.09e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.766	rs9368561	ENSG00000220721.1	OR1F12	8.6	2.92e-17	1.09e-14	0.48	0.26	Depression;	chr6:28200565	chr6:28073316~28074233:+
BRCA	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-8.6	2.92e-17	1.09e-14	-0.24	-0.26	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-8.6	2.92e-17	1.09e-14	-0.34	-0.26	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
BRCA	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-8.6	2.92e-17	1.09e-14	-0.25	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
BRCA	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-8.6	2.94e-17	1.1e-14	-0.28	-0.26	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
BRCA	cis	rs853679	1	rs1419183	ENSG00000220721.1	OR1F12	8.6	2.94e-17	1.1e-14	0.4	0.26	Depression;	chr6:28275017	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	8.6	2.96e-17	1.11e-14	0.33	0.26	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
BRCA	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-8.6	2.98e-17	1.12e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
BRCA	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
BRCA	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-8.6	3e-17	1.12e-14	-0.27	-0.26	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
BRCA	cis	rs67981189	0.529	rs2810097	ENSG00000269927.1	RP6-91H8.3	-8.6	3e-17	1.12e-14	-0.34	-0.26	Schizophrenia;	chr14:70967397	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	8.6	3.01e-17	1.12e-14	0.26	0.26	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000222364.1	RNU6-96P	-8.59	3.02e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66318029	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-8.59	3.02e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000222364.1	RNU6-96P	-8.59	3.03e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66325577	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000222364.1	RNU6-96P	-8.59	3.03e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66339619	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	8.59	3.03e-17	1.13e-14	0.27	0.26	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
BRCA	cis	rs2067615	0.579	rs4964492	ENSG00000260329.1	RP11-412D9.4	-8.59	3.04e-17	1.14e-14	-0.28	-0.26	Heart rate;	chr12:106828996	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-8.59	3.05e-17	1.14e-14	-0.33	-0.26	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-8.59	3.06e-17	1.14e-14	-0.32	-0.26	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
BRCA	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	8.59	3.07e-17	1.14e-14	0.33	0.26	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
BRCA	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-8.59	3.07e-17	1.15e-14	-0.33	-0.26	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.59	3.08e-17	1.15e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	8.59	3.09e-17	1.15e-14	0.37	0.26	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
BRCA	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	8.59	3.09e-17	1.15e-14	0.19	0.26	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	8.59	3.09e-17	1.15e-14	0.19	0.26	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-8.59	3.09e-17	1.15e-14	-0.26	-0.26	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
BRCA	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	8.59	3.1e-17	1.16e-14	0.52	0.26	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
BRCA	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-8.59	3.12e-17	1.16e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
BRCA	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	8.59	3.13e-17	1.17e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
BRCA	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	8.59	3.13e-17	1.17e-14	0.27	0.26	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	8.59	3.13e-17	1.17e-14	0.27	0.26	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	8.59	3.14e-17	1.17e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
BRCA	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	8.59	3.14e-17	1.17e-14	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
BRCA	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-8.59	3.14e-17	1.17e-14	-0.3	-0.26	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
BRCA	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	8.59	3.15e-17	1.18e-14	0.34	0.26	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-8.59	3.16e-17	1.18e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
BRCA	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	8.59	3.17e-17	1.18e-14	0.36	0.26	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
BRCA	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-8.59	3.18e-17	1.18e-14	-0.4	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
BRCA	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	8.59	3.18e-17	1.19e-14	0.24	0.26	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	8.59	3.19e-17	1.19e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
BRCA	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	8.59	3.22e-17	1.2e-14	0.35	0.26	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	8.59	3.23e-17	1.2e-14	0.24	0.26	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
BRCA	cis	rs58873874	0.737	rs10476050	ENSG00000248544.2	CTB-47B11.3	8.59	3.24e-17	1.21e-14	0.6	0.26	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157375741~157384950:-
BRCA	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	8.59	3.25e-17	1.21e-14	0.33	0.26	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-8.59	3.26e-17	1.21e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
BRCA	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-8.59	3.26e-17	1.21e-14	-0.34	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
BRCA	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-8.58	3.26e-17	1.22e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
BRCA	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	8.58	3.27e-17	1.22e-14	0.33	0.26	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
BRCA	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	8.58	3.28e-17	1.22e-14	0.44	0.26	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	8.58	3.3e-17	1.23e-14	0.3	0.26	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	8.58	3.3e-17	1.23e-14	0.36	0.26	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	8.58	3.31e-17	1.23e-14	0.35	0.26	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
BRCA	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	8.58	3.31e-17	1.23e-14	0.34	0.26	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	8.58	3.31e-17	1.23e-14	0.28	0.26	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
BRCA	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	8.58	3.32e-17	1.24e-14	0.44	0.26	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
BRCA	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-8.58	3.32e-17	1.24e-14	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-8.58	3.32e-17	1.24e-14	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
BRCA	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	8.58	3.32e-17	1.24e-14	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
BRCA	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	8.58	3.33e-17	1.24e-14	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
BRCA	cis	rs13256369	1	rs13266699	ENSG00000253893.2	FAM85B	8.58	3.33e-17	1.24e-14	0.36	0.26	Obesity-related traits;	chr8:8712803	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	8.58	3.33e-17	1.24e-14	0.34	0.26	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
BRCA	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	8.58	3.35e-17	1.24e-14	0.36	0.26	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	8.58	3.36e-17	1.25e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-8.58	3.36e-17	1.25e-14	-0.33	-0.26	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
BRCA	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	8.58	3.37e-17	1.25e-14	0.51	0.26	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	8.58	3.38e-17	1.26e-14	0.18	0.26	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	8.58	3.38e-17	1.26e-14	0.23	0.26	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	8.58	3.39e-17	1.26e-14	0.27	0.26	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	8.58	3.39e-17	1.26e-14	0.33	0.26	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-8.58	3.39e-17	1.26e-14	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
BRCA	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	8.58	3.39e-17	1.26e-14	0.24	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
BRCA	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-8.58	3.39e-17	1.26e-14	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-8.58	3.4e-17	1.26e-14	-0.26	-0.26	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
BRCA	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	8.58	3.4e-17	1.26e-14	0.31	0.26	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
BRCA	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	8.58	3.41e-17	1.27e-14	0.3	0.26	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-8.58	3.41e-17	1.27e-14	-0.33	-0.26	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-8.58	3.41e-17	1.27e-14	-0.33	-0.26	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	8.58	3.42e-17	1.27e-14	0.28	0.26	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
BRCA	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-8.58	3.43e-17	1.27e-14	-0.33	-0.26	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
BRCA	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-8.58	3.43e-17	1.27e-14	-0.31	-0.26	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	8.58	3.43e-17	1.28e-14	0.32	0.26	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	8.58	3.43e-17	1.28e-14	0.25	0.26	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	8.58	3.45e-17	1.28e-14	0.35	0.26	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	8.58	3.45e-17	1.28e-14	0.35	0.26	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-8.58	3.46e-17	1.28e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-8.58	3.48e-17	1.29e-14	-0.26	-0.26	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	8.58	3.48e-17	1.29e-14	0.3	0.26	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	8.58	3.48e-17	1.29e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	8.58	3.49e-17	1.3e-14	0.18	0.26	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	8.58	3.49e-17	1.3e-14	0.18	0.26	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
BRCA	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-8.58	3.5e-17	1.3e-14	-0.34	-0.26	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
BRCA	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	8.58	3.5e-17	1.3e-14	0.32	0.26	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
BRCA	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-8.58	3.51e-17	1.3e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
BRCA	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	8.58	3.52e-17	1.31e-14	0.46	0.26	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
BRCA	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	8.58	3.53e-17	1.31e-14	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-8.58	3.53e-17	1.31e-14	-0.27	-0.26	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-8.58	3.54e-17	1.31e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
BRCA	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-8.57	3.55e-17	1.32e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-8.57	3.56e-17	1.32e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-8.57	3.56e-17	1.32e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	8.57	3.56e-17	1.32e-14	0.33	0.26	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
BRCA	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-8.57	3.57e-17	1.32e-14	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
BRCA	cis	rs4727443	0.866	rs2897075	ENSG00000214313.7	AZGP1P1	-8.57	3.57e-17	1.33e-14	-0.26	-0.26	Interstitial lung disease;	chr7:100032719	chr7:99980762~99987535:+
BRCA	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-8.57	3.58e-17	1.33e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	8.57	3.58e-17	1.33e-14	0.23	0.26	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	8.57	3.6e-17	1.33e-14	0.28	0.26	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
BRCA	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-8.57	3.62e-17	1.34e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
BRCA	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	8.57	3.62e-17	1.34e-14	0.29	0.26	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
BRCA	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	8.57	3.62e-17	1.34e-14	0.31	0.26	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
BRCA	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	8.57	3.62e-17	1.34e-14	0.31	0.26	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	8.57	3.63e-17	1.35e-14	0.33	0.26	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
BRCA	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	8.57	3.63e-17	1.35e-14	0.51	0.26	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-8.57	3.63e-17	1.35e-14	-0.27	-0.26	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	8.57	3.65e-17	1.35e-14	0.21	0.26	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
BRCA	cis	rs2067615	0.524	rs7309351	ENSG00000260329.1	RP11-412D9.4	8.57	3.65e-17	1.35e-14	0.28	0.26	Heart rate;	chr12:106683654	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	8.57	3.66e-17	1.36e-14	0.35	0.26	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
BRCA	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
BRCA	cis	rs58873874	0.737	rs10476052	ENSG00000248544.2	CTB-47B11.3	8.57	3.67e-17	1.36e-14	0.61	0.26	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs11739062	ENSG00000248544.2	CTB-47B11.3	8.57	3.68e-17	1.36e-14	0.61	0.26	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157375741~157384950:-
BRCA	cis	rs2041895	0.509	rs10861674	ENSG00000260329.1	RP11-412D9.4	-8.57	3.68e-17	1.37e-14	-0.32	-0.26	Glaucoma (low intraocular pressure);	chr12:106910259	chr12:106954029~106955497:-
BRCA	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-8.57	3.7e-17	1.37e-14	-0.34	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
BRCA	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-8.57	3.7e-17	1.37e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-8.57	3.71e-17	1.37e-14	-0.28	-0.26	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
BRCA	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-8.57	3.71e-17	1.37e-14	-0.29	-0.26	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
BRCA	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-8.57	3.73e-17	1.38e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-8.57	3.73e-17	1.38e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
BRCA	cis	rs58873874	0.737	rs79339674	ENSG00000248544.2	CTB-47B11.3	8.57	3.74e-17	1.39e-14	0.63	0.26	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157375741~157384950:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	8.57	3.75e-17	1.39e-14	0.34	0.26	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
BRCA	cis	rs4308124	0.708	rs2137168	ENSG00000230499.1	AC108463.1	-8.57	3.75e-17	1.39e-14	-0.34	-0.26	Vitiligo;	chr2:111228932	chr2:111195963~111206494:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	8.57	3.75e-17	1.39e-14	0.27	0.26	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	8.57	3.75e-17	1.39e-14	0.27	0.26	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	8.57	3.76e-17	1.39e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.57	3.77e-17	1.4e-14	0.35	0.26	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
BRCA	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-8.57	3.78e-17	1.4e-14	-0.34	-0.26	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
BRCA	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	8.57	3.78e-17	1.4e-14	0.46	0.26	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
BRCA	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	8.57	3.79e-17	1.4e-14	0.31	0.26	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
BRCA	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	8.57	3.8e-17	1.41e-14	0.37	0.26	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	8.57	3.8e-17	1.41e-14	0.37	0.26	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
BRCA	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-8.57	3.81e-17	1.41e-14	-0.24	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-8.57	3.82e-17	1.41e-14	-0.27	-0.26	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
BRCA	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-8.57	3.83e-17	1.42e-14	-0.33	-0.26	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
BRCA	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	8.56	3.85e-17	1.42e-14	0.36	0.26	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	8.56	3.85e-17	1.42e-14	0.36	0.26	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
BRCA	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-8.56	3.88e-17	1.43e-14	-0.3	-0.26	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
BRCA	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-8.56	3.88e-17	1.44e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
BRCA	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-8.56	3.88e-17	1.44e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-8.56	3.89e-17	1.44e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-8.56	3.89e-17	1.44e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	8.56	3.89e-17	1.44e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	8.56	3.9e-17	1.44e-14	0.26	0.26	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	8.56	3.91e-17	1.44e-14	0.34	0.26	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-8.56	3.91e-17	1.45e-14	-0.27	-0.26	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
BRCA	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	8.56	3.91e-17	1.45e-14	0.36	0.26	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-8.56	3.93e-17	1.45e-14	-0.28	-0.26	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.56	3.93e-17	1.45e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
BRCA	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	8.56	3.94e-17	1.45e-14	0.27	0.26	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.46e-14	-0.34	-0.26	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	8.56	3.95e-17	1.46e-14	0.37	0.26	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	8.56	3.95e-17	1.46e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
BRCA	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
BRCA	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-8.56	3.96e-17	1.46e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
BRCA	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-8.56	3.97e-17	1.47e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
BRCA	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
BRCA	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
BRCA	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
BRCA	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
BRCA	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-8.56	4.02e-17	1.48e-14	-0.29	-0.26	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-8.56	4.03e-17	1.49e-14	-0.29	-0.26	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-8.56	4.03e-17	1.49e-14	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000222364.1	RNU6-96P	8.56	4.04e-17	1.49e-14	0.33	0.26	Aortic root size;	chr7:66087510	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-8.56	4.04e-17	1.49e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
BRCA	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	8.56	4.04e-17	1.49e-14	0.36	0.26	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	8.56	4.04e-17	1.49e-14	0.18	0.26	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
BRCA	cis	rs3758911	0.929	rs10749894	ENSG00000255353.1	RP11-382M14.1	-8.56	4.05e-17	1.49e-14	-0.34	-0.26	Coronary artery disease;	chr11:107309586	chr11:107176286~107177530:+
BRCA	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	8.56	4.06e-17	1.5e-14	0.29	0.26	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	8.56	4.07e-17	1.5e-14	0.18	0.26	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
BRCA	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	8.56	4.07e-17	1.5e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	8.56	4.07e-17	1.5e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	8.56	4.09e-17	1.51e-14	0.32	0.26	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
BRCA	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	8.56	4.1e-17	1.51e-14	0.31	0.26	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
BRCA	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	8.56	4.11e-17	1.52e-14	0.37	0.26	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-8.56	4.12e-17	1.52e-14	-0.26	-0.26	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
BRCA	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	8.56	4.13e-17	1.52e-14	0.3	0.26	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
BRCA	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-8.56	4.13e-17	1.52e-14	-0.24	-0.26	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	8.56	4.13e-17	1.52e-14	0.26	0.26	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	8.56	4.13e-17	1.52e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
BRCA	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-8.56	4.15e-17	1.53e-14	-0.3	-0.26	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	8.56	4.16e-17	1.53e-14	0.21	0.26	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
BRCA	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	8.56	4.16e-17	1.53e-14	0.32	0.26	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
BRCA	cis	rs13256369	0.826	rs7846050	ENSG00000253893.2	FAM85B	-8.56	4.16e-17	1.53e-14	-0.36	-0.26	Obesity-related traits;	chr8:8718159	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-8.55	4.18e-17	1.54e-14	-0.33	-0.26	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-8.55	4.21e-17	1.55e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-8.55	4.21e-17	1.55e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
BRCA	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	8.55	4.21e-17	1.55e-14	0.35	0.26	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-8.55	4.22e-17	1.55e-14	-0.17	-0.26	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	8.55	4.22e-17	1.56e-14	0.34	0.26	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	8.55	4.22e-17	1.56e-14	0.34	0.26	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
BRCA	cis	rs3758911	0.894	rs10890698	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107308080	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.929	rs10890700	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107308243	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10789599	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107309145	chr11:107176286~107177530:+
BRCA	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	8.55	4.25e-17	1.56e-14	0.33	0.26	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs9329166	ENSG00000253893.2	FAM85B	-8.55	4.26e-17	1.57e-14	-0.35	-0.26	Obesity-related traits;	chr8:8719145	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-8.55	4.26e-17	1.57e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	8.55	4.3e-17	1.58e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	8.55	4.32e-17	1.59e-14	0.27	0.26	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000222364.1	RNU6-96P	-8.55	4.32e-17	1.59e-14	-0.35	-0.26	Aortic root size;	chr7:66370011	chr7:66395191~66395286:+
BRCA	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	8.55	4.32e-17	1.59e-14	0.33	0.26	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
BRCA	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	8.55	4.35e-17	1.6e-14	0.29	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
BRCA	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	8.55	4.37e-17	1.61e-14	0.33	0.26	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
BRCA	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-8.55	4.37e-17	1.61e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	8.55	4.38e-17	1.61e-14	0.26	0.26	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-8.55	4.38e-17	1.61e-14	-0.34	-0.26	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-8.55	4.4e-17	1.62e-14	-0.3	-0.26	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
BRCA	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	8.55	4.4e-17	1.62e-14	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
BRCA	cis	rs3758911	0.929	rs1843	ENSG00000255353.1	RP11-382M14.1	-8.55	4.4e-17	1.62e-14	-0.34	-0.26	Coronary artery disease;	chr11:107312219	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	8.55	4.41e-17	1.62e-14	0.26	0.26	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
BRCA	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	8.55	4.43e-17	1.63e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
BRCA	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-8.55	4.43e-17	1.63e-14	-0.39	-0.26	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-8.55	4.44e-17	1.63e-14	-0.27	-0.26	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
BRCA	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	8.55	4.45e-17	1.64e-14	0.3	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
BRCA	cis	rs2810114	0.916	rs2810099	ENSG00000269927.1	RP6-91H8.3	-8.55	4.46e-17	1.64e-14	-0.34	-0.26	Alcohol dependence;	chr14:70965704	chr14:71141125~71143253:-
BRCA	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-8.55	4.46e-17	1.64e-14	-0.33	-0.26	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
BRCA	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-8.55	4.47e-17	1.64e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
BRCA	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
BRCA	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	8.55	4.49e-17	1.65e-14	0.27	0.26	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
BRCA	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-8.55	4.51e-17	1.66e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	8.55	4.51e-17	1.66e-14	0.21	0.26	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.861	rs10890688	ENSG00000255353.1	RP11-382M14.1	-8.55	4.51e-17	1.66e-14	-0.34	-0.26	Coronary artery disease;	chr11:107272020	chr11:107176286~107177530:+
BRCA	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-8.54	4.51e-17	1.66e-14	-0.38	-0.26	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-8.54	4.51e-17	1.66e-14	-0.38	-0.26	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
BRCA	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	8.54	4.53e-17	1.66e-14	0.35	0.26	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
BRCA	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-8.54	4.54e-17	1.67e-14	-0.28	-0.26	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
BRCA	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	8.54	4.54e-17	1.67e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-8.54	4.54e-17	1.67e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	8.54	4.57e-17	1.68e-14	0.33	0.26	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
BRCA	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	8.54	4.58e-17	1.68e-14	0.37	0.26	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	8.54	4.6e-17	1.69e-14	0.26	0.26	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
BRCA	cis	rs7568498	0.564	rs10490563	ENSG00000227403.1	AC009299.3	8.54	4.6e-17	1.69e-14	0.37	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161244739~161249050:+
BRCA	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	8.54	4.62e-17	1.7e-14	0.33	0.26	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	8.54	4.63e-17	1.7e-14	0.33	0.26	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
BRCA	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-8.54	4.64e-17	1.7e-14	-0.26	-0.26	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	8.54	4.64e-17	1.7e-14	0.42	0.26	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
BRCA	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	8.54	4.64e-17	1.7e-14	0.46	0.26	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-8.54	4.68e-17	1.72e-14	-0.27	-0.26	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	8.54	4.68e-17	1.72e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	8.54	4.69e-17	1.72e-14	0.27	0.26	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	8.54	4.7e-17	1.72e-14	0.29	0.26	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-8.54	4.72e-17	1.73e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-8.54	4.73e-17	1.73e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
BRCA	cis	rs7246657	0.722	rs2909102	ENSG00000267422.1	CTD-2554C21.1	8.54	4.73e-17	1.74e-14	0.38	0.26	Coronary artery calcification;	chr19:37676463	chr19:37779686~37792865:+
BRCA	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-8.54	4.74e-17	1.74e-14	-0.3	-0.26	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-8.54	4.77e-17	1.75e-14	-0.34	-0.26	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
BRCA	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-8.54	4.77e-17	1.75e-14	-0.38	-0.26	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
BRCA	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-8.54	4.78e-17	1.75e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	8.54	4.79e-17	1.75e-14	0.21	0.26	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
BRCA	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	8.54	4.79e-17	1.76e-14	0.22	0.26	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
BRCA	cis	rs67981189	0.529	rs2158996	ENSG00000269927.1	RP6-91H8.3	8.54	4.84e-17	1.77e-14	0.34	0.26	Schizophrenia;	chr14:71062882	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-8.54	4.85e-17	1.78e-14	-0.3	-0.26	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
BRCA	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	8.54	4.86e-17	1.78e-14	0.33	0.26	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs1564208	ENSG00000267422.1	CTD-2554C21.1	-8.54	4.87e-17	1.78e-14	-0.38	-0.26	Coronary artery calcification;	chr19:37550319	chr19:37779686~37792865:+
BRCA	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	8.54	4.87e-17	1.78e-14	0.32	0.26	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
BRCA	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	8.54	4.88e-17	1.79e-14	0.27	0.26	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
BRCA	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-8.54	4.88e-17	1.79e-14	-0.33	-0.26	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
BRCA	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	8.54	4.88e-17	1.79e-14	0.43	0.26	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-8.54	4.89e-17	1.79e-14	-0.25	-0.26	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
BRCA	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	8.53	4.9e-17	1.79e-14	0.24	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
BRCA	cis	rs6430549	0.518	rs41521049	ENSG00000224043.6	CCNT2-AS1	-8.53	4.91e-17	1.8e-14	-0.35	-0.26	Hematocrit;	chr2:134935499	chr2:134735464~134918710:-
BRCA	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	8.53	4.91e-17	1.8e-14	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
BRCA	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-8.53	4.92e-17	1.8e-14	-0.33	-0.26	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
BRCA	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
BRCA	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	8.53	4.94e-17	1.81e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	8.53	4.94e-17	1.81e-14	0.42	0.26	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
BRCA	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	8.53	4.96e-17	1.81e-14	0.46	0.26	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	8.53	4.96e-17	1.81e-14	0.46	0.26	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
BRCA	cis	rs748404	0.629	rs34657657	ENSG00000249839.1	AC011330.5	-8.53	4.97e-17	1.82e-14	-0.38	-0.26	Lung cancer;	chr15:43315763	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.626	rs62019432	ENSG00000249839.1	AC011330.5	-8.53	4.97e-17	1.82e-14	-0.38	-0.26	Lung cancer;	chr15:43316482	chr15:43663654~43684339:-
BRCA	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-8.53	4.98e-17	1.82e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	8.53	4.98e-17	1.82e-14	0.27	0.26	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	8.53	4.98e-17	1.82e-14	0.27	0.26	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.929	rs2593635	ENSG00000271889.1	RP11-493E12.1	-8.53	4.98e-17	1.82e-14	-0.34	-0.26	Tuberculosis;	chr2:61407571	chr2:61151433~61162105:-
BRCA	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-8.53	5e-17	1.83e-14	-0.24	-0.26	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-8.53	5.04e-17	1.84e-14	-0.3	-0.26	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
BRCA	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	8.53	5.06e-17	1.85e-14	0.3	0.26	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	8.53	5.11e-17	1.87e-14	0.21	0.26	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.645	rs2956053	ENSG00000253983.2	RP1-16A9.1	8.53	5.13e-17	1.88e-14	0.35	0.26	Uterine fibroids;	chr8:74200205	chr8:74199396~74208441:+
BRCA	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	8.53	5.15e-17	1.88e-14	0.46	0.26	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
BRCA	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-8.53	5.15e-17	1.88e-14	-0.34	-0.26	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
BRCA	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	8.53	5.16e-17	1.88e-14	0.31	0.26	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
BRCA	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.53	5.17e-17	1.89e-14	-0.28	-0.26	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
BRCA	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	8.53	5.19e-17	1.9e-14	0.36	0.26	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	8.53	5.19e-17	1.9e-14	0.36	0.26	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
BRCA	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-8.53	5.22e-17	1.9e-14	-0.38	-0.26	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-8.53	5.24e-17	1.91e-14	-0.27	-0.26	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
BRCA	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-8.53	5.25e-17	1.92e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
BRCA	cis	rs6545883	0.826	rs777591	ENSG00000271889.1	RP11-493E12.1	8.53	5.26e-17	1.92e-14	0.33	0.26	Tuberculosis;	chr2:61190482	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-8.53	5.28e-17	1.93e-14	-0.34	-0.26	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-8.53	5.28e-17	1.93e-14	-0.36	-0.26	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
BRCA	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	8.53	5.29e-17	1.93e-14	0.37	0.26	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	8.52	5.31e-17	1.94e-14	0.25	0.26	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
BRCA	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	8.52	5.31e-17	1.94e-14	0.46	0.26	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	8.52	5.31e-17	1.94e-14	0.46	0.26	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
BRCA	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-8.52	5.32e-17	1.94e-14	-0.29	-0.26	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
BRCA	cis	rs4266144	0.632	rs56268334	ENSG00000244515.1	KRT18P34	-8.52	5.32e-17	1.94e-14	-0.37	-0.26	Coronary artery disease;	chr3:157130235	chr3:157162663~157163932:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	8.52	5.35e-17	1.95e-14	0.33	0.26	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	8.52	5.35e-17	1.95e-14	0.33	0.26	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	8.52	5.37e-17	1.96e-14	0.25	0.26	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
BRCA	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-8.52	5.39e-17	1.97e-14	-0.32	-0.26	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-8.52	5.39e-17	1.97e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
BRCA	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-8.52	5.4e-17	1.97e-14	-0.33	-0.26	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
BRCA	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	8.52	5.4e-17	1.97e-14	0.32	0.26	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	8.52	5.42e-17	1.98e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	8.52	5.42e-17	1.98e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	8.52	5.44e-17	1.98e-14	0.3	0.26	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
BRCA	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-8.52	5.45e-17	1.99e-14	-0.26	-0.26	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
BRCA	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	8.52	5.48e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
BRCA	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	8.52	5.49e-17	2e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	8.52	5.49e-17	2e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
BRCA	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	8.52	5.49e-17	2e-14	0.32	0.26	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
BRCA	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-8.52	5.49e-17	2e-14	-0.38	-0.26	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
BRCA	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-8.52	5.49e-17	2e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
BRCA	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	8.52	5.5e-17	2e-14	0.25	0.26	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	8.52	5.5e-17	2.01e-14	0.28	0.26	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
BRCA	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	8.52	5.52e-17	2.01e-14	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-8.52	5.54e-17	2.02e-14	-0.26	-0.26	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
BRCA	cis	rs7568498	0.564	rs9287807	ENSG00000227403.1	AC009299.3	8.52	5.54e-17	2.02e-14	0.37	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	8.52	5.55e-17	2.02e-14	0.27	0.26	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
BRCA	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	8.52	5.56e-17	2.03e-14	0.28	0.26	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
BRCA	cis	rs853679	1	rs1778511	ENSG00000220721.1	OR1F12	-8.52	5.56e-17	2.03e-14	-0.4	-0.26	Depression;	chr6:28261633	chr6:28073316~28074233:+
BRCA	cis	rs3758911	0.964	rs10789603	ENSG00000255353.1	RP11-382M14.1	-8.52	5.58e-17	2.03e-14	-0.34	-0.26	Coronary artery disease;	chr11:107311050	chr11:107176286~107177530:+
BRCA	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-8.52	5.59e-17	2.03e-14	-0.31	-0.26	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-8.52	5.6e-17	2.04e-14	-0.33	-0.26	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	8.52	5.6e-17	2.04e-14	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
BRCA	cis	rs7246657	0.663	rs10408619	ENSG00000267422.1	CTD-2554C21.1	-8.52	5.61e-17	2.04e-14	-0.38	-0.26	Coronary artery calcification;	chr19:37579573	chr19:37779686~37792865:+
BRCA	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	8.52	5.64e-17	2.05e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
BRCA	cis	rs3758911	0.861	rs1388171	ENSG00000255353.1	RP11-382M14.1	-8.52	5.65e-17	2.06e-14	-0.34	-0.26	Coronary artery disease;	chr11:107272411	chr11:107176286~107177530:+
BRCA	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-8.52	5.68e-17	2.07e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	8.52	5.69e-17	2.07e-14	0.17	0.26	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	8.52	5.7e-17	2.08e-14	0.21	0.26	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
BRCA	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
BRCA	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-8.52	5.73e-17	2.09e-14	-0.33	-0.26	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
BRCA	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	8.51	5.76e-17	2.09e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-8.51	5.77e-17	2.1e-14	-0.29	-0.26	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	8.51	5.77e-17	2.1e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000271889.1	RP11-493E12.1	8.51	5.77e-17	2.1e-14	0.33	0.26	Tuberculosis;	chr2:61445178	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	8.51	5.78e-17	2.1e-14	0.28	0.26	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
BRCA	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	8.51	5.82e-17	2.12e-14	0.33	0.26	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
BRCA	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	8.51	5.84e-17	2.12e-14	0.22	0.26	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	8.51	5.85e-17	2.13e-14	0.25	0.26	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-8.51	5.85e-17	2.13e-14	-0.29	-0.26	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
BRCA	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	8.51	5.85e-17	2.13e-14	0.3	0.26	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
BRCA	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-8.51	5.86e-17	2.13e-14	-0.32	-0.25	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
BRCA	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-8.51	5.86e-17	2.13e-14	-0.32	-0.25	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
BRCA	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	8.51	5.86e-17	2.13e-14	0.33	0.25	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
BRCA	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-8.51	5.88e-17	2.14e-14	-0.44	-0.25	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
BRCA	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	8.51	5.88e-17	2.14e-14	0.25	0.25	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	8.51	5.89e-17	2.14e-14	0.24	0.25	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
BRCA	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	8.51	5.9e-17	2.14e-14	0.27	0.25	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-8.51	5.9e-17	2.14e-14	-0.33	-0.25	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000222364.1	RNU6-96P	-8.51	5.9e-17	2.15e-14	-0.34	-0.25	Aortic root size;	chr7:66518628	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-8.51	5.91e-17	2.15e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
BRCA	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	8.51	5.92e-17	2.15e-14	0.28	0.25	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	8.51	5.92e-17	2.15e-14	0.21	0.25	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	8.51	5.92e-17	2.15e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
BRCA	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	8.51	5.94e-17	2.16e-14	0.25	0.25	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
BRCA	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	8.51	5.96e-17	2.17e-14	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
BRCA	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	8.51	5.98e-17	2.17e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
BRCA	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	8.51	5.99e-17	2.18e-14	0.35	0.25	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
BRCA	cis	rs4727443	0.866	rs13238380	ENSG00000214313.7	AZGP1P1	-8.51	6.01e-17	2.18e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100031438	chr7:99980762~99987535:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	8.51	6.01e-17	2.18e-14	0.43	0.25	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	8.51	6.03e-17	2.19e-14	0.26	0.25	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
BRCA	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	8.51	6.03e-17	2.19e-14	0.31	0.25	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
BRCA	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-8.51	6.04e-17	2.19e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-8.51	6.04e-17	2.19e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
BRCA	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	8.51	6.05e-17	2.19e-14	0.32	0.25	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	8.51	6.05e-17	2.19e-14	0.28	0.25	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
BRCA	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	8.51	6.09e-17	2.21e-14	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
BRCA	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	8.51	6.11e-17	2.21e-14	0.37	0.25	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
BRCA	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	8.51	6.11e-17	2.21e-14	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
BRCA	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	8.51	6.11e-17	2.21e-14	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
BRCA	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	8.51	6.11e-17	2.22e-14	0.25	0.25	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
BRCA	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	8.51	6.13e-17	2.22e-14	0.3	0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
BRCA	cis	rs1900504	0.614	rs2915761	ENSG00000266200.5	PNLIPRP2	-8.51	6.14e-17	2.23e-14	-0.34	-0.25	Tonsillectomy;	chr10:116601682	chr10:116620953~116645143:+
BRCA	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	8.51	6.14e-17	2.23e-14	0.46	0.25	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	8.51	6.15e-17	2.23e-14	0.26	0.25	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
BRCA	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	8.51	6.18e-17	2.24e-14	0.19	0.25	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
BRCA	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	8.51	6.18e-17	2.24e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	8.51	6.21e-17	2.25e-14	0.31	0.25	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	8.51	6.21e-17	2.25e-14	0.31	0.25	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.73	rs1361829	ENSG00000226822.1	RP11-356N1.2	-8.5	6.24e-17	2.26e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108051273	chr1:108071482~108074519:+
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	8.5	6.24e-17	2.26e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	8.5	6.26e-17	2.27e-14	0.35	0.25	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
BRCA	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-8.5	6.29e-17	2.28e-14	-0.31	-0.25	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
BRCA	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-8.5	6.29e-17	2.28e-14	-0.29	-0.25	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
BRCA	cis	rs1113500	0.73	rs1781080	ENSG00000226822.1	RP11-356N1.2	-8.5	6.3e-17	2.28e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108050793	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-8.5	6.34e-17	2.29e-14	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
BRCA	cis	rs42648	0.869	rs3810891	ENSG00000225498.1	AC002064.5	8.5	6.34e-17	2.3e-14	0.24	0.25	Homocysteine levels;	chr7:90279537	chr7:90312496~90322592:+
BRCA	cis	rs4308124	0.708	rs6749633	ENSG00000230499.1	AC108463.1	8.5	6.34e-17	2.3e-14	0.32	0.25	Vitiligo;	chr2:111230439	chr2:111195963~111206494:+
BRCA	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	8.5	6.35e-17	2.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
BRCA	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-8.5	6.36e-17	2.3e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-8.5	6.37e-17	2.31e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	8.5	6.38e-17	2.31e-14	0.46	0.25	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	8.5	6.38e-17	2.31e-14	0.46	0.25	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
BRCA	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
BRCA	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	8.5	6.41e-17	2.32e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
BRCA	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	8.5	6.41e-17	2.32e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	8.5	6.41e-17	2.32e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
BRCA	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-8.5	6.44e-17	2.33e-14	-0.3	-0.25	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
BRCA	cis	rs12188164	0.515	rs2672744	ENSG00000225138.6	CTD-2228K2.7	-8.5	6.44e-17	2.33e-14	-0.29	-0.25	Cystic fibrosis severity;	chr5:410932	chr5:473236~480884:+
BRCA	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-8.5	6.5e-17	2.35e-14	-0.42	-0.25	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
BRCA	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	8.5	6.52e-17	2.36e-14	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	8.5	6.53e-17	2.36e-14	0.28	0.25	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-8.5	6.55e-17	2.37e-14	-0.28	-0.25	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
BRCA	cis	rs3758911	0.861	rs11212112	ENSG00000255353.1	RP11-382M14.1	-8.5	6.59e-17	2.38e-14	-0.34	-0.25	Coronary artery disease;	chr11:107272667	chr11:107176286~107177530:+
BRCA	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-8.5	6.6e-17	2.39e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	8.5	6.61e-17	2.39e-14	0.46	0.25	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	8.5	6.61e-17	2.39e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
BRCA	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	8.5	6.62e-17	2.39e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	8.5	6.64e-17	2.4e-14	0.21	0.25	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
BRCA	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-8.5	6.64e-17	2.4e-14	-0.29	-0.25	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
BRCA	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	8.5	6.67e-17	2.41e-14	0.45	0.25	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
BRCA	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	8.5	6.68e-17	2.42e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	8.5	6.69e-17	2.42e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	8.5	6.69e-17	2.42e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
BRCA	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	8.5	6.71e-17	2.42e-14	0.27	0.25	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
BRCA	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
BRCA	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	8.5	6.71e-17	2.43e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
BRCA	cis	rs6472827	0.645	rs2956055	ENSG00000253983.2	RP1-16A9.1	8.5	6.72e-17	2.43e-14	0.35	0.25	Uterine fibroids;	chr8:74199718	chr8:74199396~74208441:+
BRCA	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.5	6.72e-17	2.43e-14	-0.29	-0.25	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
BRCA	cis	rs67981189	0.546	rs2810075	ENSG00000269927.1	RP6-91H8.3	-8.5	6.72e-17	2.43e-14	-0.34	-0.25	Schizophrenia;	chr14:70908363	chr14:71141125~71143253:-
BRCA	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	8.5	6.73e-17	2.43e-14	0.35	0.25	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
BRCA	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-8.5	6.74e-17	2.44e-14	-0.27	-0.25	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
BRCA	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	8.5	6.75e-17	2.44e-14	0.19	0.25	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
BRCA	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	8.5	6.75e-17	2.44e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
BRCA	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-8.5	6.76e-17	2.44e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
BRCA	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-8.49	6.76e-17	2.44e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
BRCA	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	8.49	6.76e-17	2.44e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	8.49	6.77e-17	2.44e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	8.49	6.77e-17	2.44e-14	0.29	0.25	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
BRCA	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-8.49	6.8e-17	2.45e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
BRCA	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-8.49	6.8e-17	2.45e-14	-0.33	-0.25	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
BRCA	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-8.49	6.82e-17	2.46e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
BRCA	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-8.49	6.83e-17	2.46e-14	-0.2	-0.25	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
BRCA	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	8.49	6.84e-17	2.47e-14	0.29	0.25	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-8.49	6.85e-17	2.47e-14	-0.29	-0.25	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-8.49	6.85e-17	2.47e-14	-0.29	-0.25	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-8.49	6.91e-17	2.49e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	8.49	6.93e-17	2.5e-14	0.19	0.25	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
BRCA	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-8.49	6.98e-17	2.51e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	8.49	7e-17	2.52e-14	0.29	0.25	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-8.49	7.03e-17	2.53e-14	-0.33	-0.25	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
BRCA	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	8.49	7.06e-17	2.54e-14	0.3	0.25	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-8.49	7.07e-17	2.55e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-8.49	7.1e-17	2.56e-14	-0.29	-0.25	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
BRCA	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	8.49	7.1e-17	2.56e-14	0.57	0.25	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
BRCA	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-8.49	7.12e-17	2.56e-14	-0.29	-0.25	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
BRCA	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	8.49	7.13e-17	2.57e-14	0.32	0.25	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
BRCA	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-8.49	7.13e-17	2.57e-14	-0.35	-0.25	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-8.49	7.14e-17	2.57e-14	-0.29	-0.25	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
BRCA	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	8.49	7.15e-17	2.58e-14	0.25	0.25	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
BRCA	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	8.49	7.19e-17	2.59e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-8.49	7.19e-17	2.59e-14	-0.37	-0.25	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-8.49	7.21e-17	2.6e-14	-0.36	-0.25	Gout;	chr7:66679692	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	8.49	7.21e-17	2.6e-14	0.36	0.25	Gout;	chr7:66682070	chr7:66902857~66906297:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	8.49	7.21e-17	2.6e-14	0.36	0.25	Gout;	chr7:66682162	chr7:66902857~66906297:+
BRCA	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	8.49	7.22e-17	2.6e-14	0.32	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
BRCA	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	8.49	7.23e-17	2.6e-14	0.38	0.25	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
BRCA	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	8.49	7.24e-17	2.61e-14	0.32	0.25	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	8.49	7.24e-17	2.61e-14	0.32	0.25	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	8.49	7.24e-17	2.61e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
BRCA	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	8.49	7.25e-17	2.61e-14	0.46	0.25	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-8.49	7.25e-17	2.61e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
BRCA	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	8.49	7.28e-17	2.62e-14	0.32	0.25	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
BRCA	cis	rs3758911	0.861	rs11212113	ENSG00000255353.1	RP11-382M14.1	-8.49	7.3e-17	2.63e-14	-0.34	-0.25	Coronary artery disease;	chr11:107272776	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	8.49	7.3e-17	2.63e-14	0.26	0.25	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-8.49	7.31e-17	2.63e-14	-0.28	-0.25	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
BRCA	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	8.49	7.32e-17	2.63e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	8.48	7.33e-17	2.64e-14	0.33	0.25	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
BRCA	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-8.48	7.34e-17	2.64e-14	-0.29	-0.25	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
BRCA	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	8.48	7.35e-17	2.64e-14	0.29	0.25	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
BRCA	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-8.48	7.39e-17	2.66e-14	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	8.48	7.4e-17	2.66e-14	0.31	0.25	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
BRCA	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	8.48	7.45e-17	2.68e-14	0.26	0.25	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
BRCA	cis	rs6539288	0.674	rs989560	ENSG00000260329.1	RP11-412D9.4	-8.48	7.5e-17	2.7e-14	-0.28	-0.25	Total body bone mineral density;	chr12:106891973	chr12:106954029~106955497:-
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-8.48	7.5e-17	2.7e-14	-0.23	-0.25	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
BRCA	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-8.48	7.5e-17	2.7e-14	-0.36	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	8.48	7.55e-17	2.71e-14	0.28	0.25	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
BRCA	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	8.48	7.56e-17	2.71e-14	0.33	0.25	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
BRCA	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	8.48	7.58e-17	2.72e-14	0.32	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-8.48	7.58e-17	2.72e-14	-0.22	-0.25	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
BRCA	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-8.48	7.61e-17	2.73e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
BRCA	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	8.48	7.61e-17	2.73e-14	0.45	0.25	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
BRCA	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	8.48	7.7e-17	2.77e-14	0.37	0.25	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	8.48	7.71e-17	2.77e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
BRCA	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	8.48	7.71e-17	2.77e-14	0.37	0.25	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
BRCA	cis	rs4727443	0.866	rs13243708	ENSG00000214313.7	AZGP1P1	-8.48	7.73e-17	2.78e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100018668	chr7:99980762~99987535:+
BRCA	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	8.48	7.74e-17	2.78e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
BRCA	cis	rs1113500	0.73	rs1777456	ENSG00000226822.1	RP11-356N1.2	-8.48	7.8e-17	2.8e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108045850	chr1:108071482~108074519:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	8.48	7.8e-17	2.8e-14	0.22	0.25	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-8.48	7.84e-17	2.82e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.48	7.87e-17	2.82e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	8.48	7.91e-17	2.84e-14	0.26	0.25	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
BRCA	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	8.48	7.92e-17	2.84e-14	0.19	0.25	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
BRCA	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	8.47	7.94e-17	2.85e-14	0.26	0.25	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
BRCA	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	8.47	7.94e-17	2.85e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
BRCA	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	8.47	7.94e-17	2.85e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
BRCA	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
BRCA	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-8.47	7.97e-17	2.86e-14	-0.3	-0.25	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	8.47	7.98e-17	2.86e-14	0.32	0.25	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-8.47	8e-17	2.87e-14	-0.26	-0.25	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
BRCA	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	8.47	8.02e-17	2.88e-14	0.29	0.25	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
BRCA	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-8.47	8.02e-17	2.88e-14	-0.32	-0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-8.47	8.1e-17	2.9e-14	-0.26	-0.25	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	8.47	8.12e-17	2.91e-14	0.31	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	8.47	8.13e-17	2.91e-14	0.35	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	8.47	8.13e-17	2.91e-14	0.35	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-8.47	8.13e-17	2.91e-14	-0.34	-0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000222364.1	RNU6-96P	-8.47	8.14e-17	2.92e-14	-0.34	-0.25	Aortic root size;	chr7:66387213	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-8.47	8.14e-17	2.92e-14	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
BRCA	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-8.47	8.16e-17	2.93e-14	-0.3	-0.25	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
BRCA	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	8.47	8.21e-17	2.94e-14	0.27	0.25	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	8.47	8.21e-17	2.94e-14	0.18	0.25	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
BRCA	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	8.47	8.33e-17	2.98e-14	0.45	0.25	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
BRCA	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	8.47	8.36e-17	2.99e-14	0.32	0.25	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	8.47	8.37e-17	3e-14	0.33	0.25	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.529	rs17108862	ENSG00000269927.1	RP6-91H8.3	8.47	8.38e-17	3e-14	0.33	0.25	Schizophrenia;	chr14:70997949	chr14:71141125~71143253:-
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000220721.1	OR1F12	8.47	8.39e-17	3e-14	0.34	0.25	Parkinson's disease;	chr6:28053491	chr6:28073316~28074233:+
BRCA	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	8.47	8.39e-17	3e-14	0.31	0.25	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
BRCA	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-8.47	8.43e-17	3.02e-14	-0.35	-0.25	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
BRCA	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	8.47	8.44e-17	3.02e-14	0.45	0.25	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-8.47	8.44e-17	3.02e-14	-0.34	-0.25	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
BRCA	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-8.47	8.46e-17	3.03e-14	-0.33	-0.25	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
BRCA	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-8.47	8.48e-17	3.04e-14	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-8.47	8.49e-17	3.04e-14	-0.31	-0.25	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
BRCA	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-8.47	8.51e-17	3.04e-14	-0.31	-0.25	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
BRCA	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	8.47	8.51e-17	3.05e-14	0.26	0.25	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	8.47	8.52e-17	3.05e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	8.47	8.54e-17	3.06e-14	0.35	0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
BRCA	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
BRCA	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	8.47	8.56e-17	3.06e-14	0.3	0.25	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
BRCA	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	8.47	8.57e-17	3.06e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
BRCA	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	8.47	8.58e-17	3.07e-14	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
BRCA	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	8.47	8.6e-17	3.07e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	8.46	8.61e-17	3.08e-14	0.23	0.25	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
BRCA	cis	rs5751614	0.62	rs1811017	ENSG00000230701.2	FBXW4P1	8.46	8.64e-17	3.09e-14	0.31	0.25	Height;	chr22:23264771	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-8.46	8.64e-17	3.09e-14	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	8.46	8.66e-17	3.1e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	8.46	8.68e-17	3.1e-14	0.33	0.25	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	8.46	8.69e-17	3.11e-14	0.31	0.25	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-8.46	8.69e-17	3.11e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	8.46	8.7e-17	3.11e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
BRCA	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	8.46	8.71e-17	3.11e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
BRCA	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-8.46	8.73e-17	3.12e-14	-0.26	-0.25	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
BRCA	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-8.46	8.73e-17	3.12e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
BRCA	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-8.46	8.74e-17	3.12e-14	-0.32	-0.25	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-8.46	8.75e-17	3.13e-14	-0.33	-0.25	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
BRCA	cis	rs2810114	0.76	rs2810105	ENSG00000269927.1	RP6-91H8.3	-8.46	8.77e-17	3.14e-14	-0.33	-0.25	Alcohol dependence;	chr14:70957934	chr14:71141125~71143253:-
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-8.46	8.81e-17	3.15e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
BRCA	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	8.46	8.82e-17	3.15e-14	0.32	0.25	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	8.46	8.84e-17	3.16e-14	0.21	0.25	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-8.46	8.84e-17	3.16e-14	-0.31	-0.25	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-8.46	8.87e-17	3.17e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
BRCA	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-8.46	8.88e-17	3.17e-14	-0.29	-0.25	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-8.46	8.88e-17	3.17e-14	-0.29	-0.25	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
BRCA	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	8.46	8.88e-17	3.17e-14	0.36	0.25	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-8.46	8.92e-17	3.18e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-8.46	8.92e-17	3.19e-14	-0.28	-0.25	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
BRCA	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	8.46	8.92e-17	3.19e-14	0.32	0.25	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
BRCA	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-8.46	8.93e-17	3.19e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
BRCA	cis	rs4727443	0.866	rs12531809	ENSG00000214313.7	AZGP1P1	-8.46	8.93e-17	3.19e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100022850	chr7:99980762~99987535:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.46	8.94e-17	3.19e-14	0.23	0.25	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66363676	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66374173	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66376216	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-8.46	9e-17	3.21e-14	-0.26	-0.25	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.722	rs2909105	ENSG00000267422.1	CTD-2554C21.1	8.46	9.04e-17	3.23e-14	0.37	0.25	Coronary artery calcification;	chr19:37677005	chr19:37779686~37792865:+
BRCA	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	8.46	9.07e-17	3.24e-14	0.29	0.25	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	8.46	9.07e-17	3.24e-14	0.27	0.25	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	8.46	9.09e-17	3.24e-14	0.26	0.25	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	8.46	9.14e-17	3.26e-14	0.33	0.25	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.46	9.14e-17	3.26e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	8.46	9.16e-17	3.27e-14	0.18	0.25	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
BRCA	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.46	9.17e-17	3.27e-14	-0.37	-0.25	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
BRCA	cis	rs748404	1	rs66651343	ENSG00000249839.1	AC011330.5	-8.46	9.17e-17	3.27e-14	-0.36	-0.25	Lung cancer;	chr15:43265806	chr15:43663654~43684339:-
BRCA	cis	rs250518	0.926	rs6896898	ENSG00000272081.1	CTD-2376I4.2	8.46	9.24e-17	3.3e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795174	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-8.46	9.24e-17	3.3e-14	-0.26	-0.25	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-8.46	9.24e-17	3.3e-14	-0.26	-0.25	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	8.46	9.24e-17	3.3e-14	0.26	0.25	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
BRCA	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-8.46	9.25e-17	3.3e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-8.46	9.25e-17	3.3e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
BRCA	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	8.46	9.25e-17	3.3e-14	0.44	0.25	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	8.46	9.25e-17	3.3e-14	0.44	0.25	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
BRCA	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	8.46	9.25e-17	3.3e-14	0.18	0.25	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-8.46	9.26e-17	3.3e-14	-0.33	-0.25	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
BRCA	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.46	0.25	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
BRCA	cis	rs13256369	1	rs13256369	ENSG00000253893.2	FAM85B	-8.46	9.28e-17	3.31e-14	-0.35	-0.25	Obesity-related traits;	chr8:8719869	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-8.46	9.28e-17	3.31e-14	-0.33	-0.25	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
BRCA	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-8.46	9.3e-17	3.31e-14	-0.29	-0.25	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
BRCA	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	8.46	9.3e-17	3.32e-14	0.37	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	8.46	9.32e-17	3.32e-14	0.29	0.25	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	8.45	9.35e-17	3.33e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-8.45	9.36e-17	3.34e-14	-0.29	-0.25	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
BRCA	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-8.45	9.37e-17	3.34e-14	-0.34	-0.25	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-8.45	9.38e-17	3.34e-14	-0.31	-0.25	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
BRCA	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
BRCA	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-8.45	9.39e-17	3.35e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
BRCA	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	8.45	9.4e-17	3.35e-14	0.28	0.25	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
BRCA	cis	rs6545883	0.929	rs2121660	ENSG00000271889.1	RP11-493E12.1	-8.45	9.41e-17	3.35e-14	-0.34	-0.25	Tuberculosis;	chr2:61425923	chr2:61151433~61162105:-
BRCA	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-8.45	9.42e-17	3.36e-14	-0.39	-0.25	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	8.45	9.44e-17	3.36e-14	0.25	0.25	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
BRCA	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-8.45	9.44e-17	3.36e-14	-0.32	-0.25	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
BRCA	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	8.45	9.45e-17	3.37e-14	0.29	0.25	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.501	rs3829954	ENSG00000269927.1	RP6-91H8.3	8.45	9.46e-17	3.37e-14	0.33	0.25	Schizophrenia;	chr14:70988823	chr14:71141125~71143253:-
BRCA	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	8.45	9.47e-17	3.37e-14	0.31	0.25	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-8.45	9.47e-17	3.37e-14	-0.31	-0.25	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
BRCA	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	8.45	9.52e-17	3.39e-14	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
BRCA	cis	rs8012947	0.917	rs57044214	ENSG00000279636.2	LINC00216	8.45	9.55e-17	3.4e-14	0.29	0.25	Alcohol consumption in current drinkers;	chr14:58367191	chr14:58288033~58289158:+
BRCA	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	8.45	9.58e-17	3.41e-14	0.45	0.25	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	8.45	9.58e-17	3.41e-14	0.45	0.25	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
BRCA	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	8.45	9.6e-17	3.42e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	8.45	9.6e-17	3.42e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
BRCA	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	8.45	9.61e-17	3.42e-14	0.37	0.25	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	8.45	9.61e-17	3.42e-14	0.22	0.25	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-8.45	9.65e-17	3.43e-14	-0.26	-0.25	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	8.45	9.65e-17	3.43e-14	0.29	0.25	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000257551.1	HLX-AS1	-8.45	9.66e-17	3.44e-14	-0.35	-0.25	Cholesterol, total;	chr1:220866908	chr1:220832763~220880140:-
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-8.45	9.67e-17	3.44e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
BRCA	cis	rs42648	0.869	rs3810890	ENSG00000225498.1	AC002064.5	8.45	9.7e-17	3.45e-14	0.24	0.25	Homocysteine levels;	chr7:90279519	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs10262603	ENSG00000225498.1	AC002064.5	8.45	9.7e-17	3.45e-14	0.24	0.25	Homocysteine levels;	chr7:90280128	chr7:90312496~90322592:+
BRCA	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	8.45	9.75e-17	3.47e-14	0.32	0.25	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-8.45	9.81e-17	3.49e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
BRCA	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	8.45	9.82e-17	3.49e-14	0.18	0.25	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
BRCA	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	8.45	9.83e-17	3.49e-14	0.35	0.25	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
BRCA	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-8.45	9.88e-17	3.51e-14	-0.33	-0.25	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
BRCA	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	8.45	9.9e-17	3.52e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
BRCA	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	8.45	9.96e-17	3.54e-14	0.38	0.25	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
BRCA	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-8.45	9.97e-17	3.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-8.45	9.97e-17	3.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
BRCA	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	8.45	9.98e-17	3.54e-14	0.32	0.25	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-8.45	9.99e-17	3.55e-14	-0.29	-0.25	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
BRCA	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	8.45	1e-16	3.55e-14	0.3	0.25	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
BRCA	cis	rs1113500	0.633	rs1777451	ENSG00000226822.1	RP11-356N1.2	-8.45	1e-16	3.55e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108035560	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000164669.11	INTS4P1	8.45	1e-16	3.56e-14	0.36	0.25	Aortic root size;	chr7:66066855	chr7:65141225~65234216:+
BRCA	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	8.45	1.01e-16	3.58e-14	0.33	0.25	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
BRCA	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-8.45	1.01e-16	3.58e-14	-0.32	-0.25	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
BRCA	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-8.44	1.01e-16	3.59e-14	-0.33	-0.25	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
BRCA	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.44	1.01e-16	3.59e-14	-0.29	-0.25	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
BRCA	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	8.44	1.02e-16	3.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	8.44	1.02e-16	3.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	8.44	1.02e-16	3.61e-14	0.26	0.25	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
BRCA	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.44	1.02e-16	3.62e-14	-0.29	-0.25	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	8.44	1.02e-16	3.62e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
BRCA	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-8.44	1.02e-16	3.63e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
BRCA	cis	rs42648	0.869	rs10266179	ENSG00000225498.1	AC002064.5	8.44	1.03e-16	3.64e-14	0.24	0.25	Homocysteine levels;	chr7:90280668	chr7:90312496~90322592:+
BRCA	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-8.44	1.03e-16	3.65e-14	-0.32	-0.25	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
BRCA	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	8.44	1.03e-16	3.66e-14	0.32	0.25	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
BRCA	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	8.44	1.03e-16	3.66e-14	0.32	0.25	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
BRCA	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	8.44	1.03e-16	3.66e-14	0.28	0.25	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
BRCA	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	8.44	1.03e-16	3.66e-14	0.33	0.25	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	8.44	1.03e-16	3.67e-14	0.23	0.25	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-8.44	1.04e-16	3.68e-14	-0.47	-0.25	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
BRCA	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	8.44	1.04e-16	3.69e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-8.44	1.04e-16	3.7e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	8.44	1.04e-16	3.7e-14	0.26	0.25	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
BRCA	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-8.44	1.04e-16	3.7e-14	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
BRCA	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-8.44	1.05e-16	3.72e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	8.44	1.05e-16	3.73e-14	0.26	0.25	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000222364.1	RNU6-96P	-8.44	1.05e-16	3.74e-14	-0.34	-0.25	Aortic root size;	chr7:66536825	chr7:66395191~66395286:+
BRCA	cis	rs3864261	0.515	rs55769858	ENSG00000272081.1	CTD-2376I4.2	8.44	1.06e-16	3.75e-14	0.32	0.25	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72955206~72955699:-
BRCA	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	8.44	1.06e-16	3.75e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
BRCA	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	8.44	1.06e-16	3.76e-14	0.33	0.25	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	8.44	1.06e-16	3.76e-14	0.33	0.25	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
BRCA	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	8.44	1.06e-16	3.77e-14	0.31	0.25	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
BRCA	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.44	1.07e-16	3.79e-14	0.34	0.25	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
BRCA	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-8.44	1.07e-16	3.79e-14	-0.27	-0.25	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
BRCA	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-8.44	1.08e-16	3.83e-14	-0.39	-0.25	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
BRCA	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	8.44	1.08e-16	3.83e-14	0.3	0.25	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
BRCA	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	8.44	1.09e-16	3.85e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	8.44	1.09e-16	3.86e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
BRCA	cis	rs7085104	0.632	rs3781287	ENSG00000213061.2	PFN1P11	8.44	1.09e-16	3.86e-14	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102838011~102845473:-
BRCA	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-8.44	1.09e-16	3.86e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-8.44	1.09e-16	3.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	8.44	1.09e-16	3.86e-14	0.21	0.25	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
BRCA	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-8.44	1.09e-16	3.87e-14	-0.3	-0.25	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
BRCA	cis	rs13256369	1	rs13282915	ENSG00000253893.2	FAM85B	-8.43	1.1e-16	3.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8713381	chr8:8167819~8226614:-
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000278665.1	RP11-666O2.4	8.43	1.1e-16	3.88e-14	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	8.43	1.1e-16	3.88e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8.43	1.1e-16	3.9e-14	0.37	0.25	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-8.43	1.1e-16	3.9e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
BRCA	cis	rs67981189	0.529	rs8014273	ENSG00000269927.1	RP6-91H8.3	8.43	1.1e-16	3.91e-14	0.33	0.25	Schizophrenia;	chr14:71043113	chr14:71141125~71143253:-
BRCA	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-8.43	1.11e-16	3.92e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
BRCA	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	8.43	1.11e-16	3.93e-14	0.33	0.25	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs1564206	ENSG00000267422.1	CTD-2554C21.1	-8.43	1.11e-16	3.93e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37549174	chr19:37779686~37792865:+
BRCA	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.43	1.11e-16	3.93e-14	-0.29	-0.25	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
BRCA	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	8.43	1.11e-16	3.95e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
BRCA	cis	rs67981189	0.529	rs17108808	ENSG00000269927.1	RP6-91H8.3	8.43	1.12e-16	3.96e-14	0.33	0.25	Schizophrenia;	chr14:70974835	chr14:71141125~71143253:-
BRCA	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-8.43	1.13e-16	3.98e-14	-0.26	-0.25	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	8.43	1.13e-16	3.99e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-8.43	1.13e-16	4e-14	-0.29	-0.25	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs4840352	ENSG00000253893.2	FAM85B	-8.43	1.14e-16	4.03e-14	-0.36	-0.25	Obesity-related traits;	chr8:8715998	chr8:8167819~8226614:-
BRCA	cis	rs6545883	0.929	rs778155	ENSG00000271889.1	RP11-493E12.1	-8.43	1.14e-16	4.03e-14	-0.34	-0.25	Tuberculosis;	chr2:61420766	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-8.43	1.14e-16	4.03e-14	-0.28	-0.25	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	8.43	1.14e-16	4.04e-14	0.33	0.25	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	8.43	1.15e-16	4.07e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
BRCA	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	8.43	1.16e-16	4.09e-14	0.28	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
BRCA	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
BRCA	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-8.43	1.16e-16	4.11e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-8.43	1.16e-16	4.11e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
BRCA	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.12e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.13e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.13e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-8.43	1.17e-16	4.14e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
BRCA	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-8.43	1.17e-16	4.15e-14	-0.29	-0.25	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
BRCA	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	8.43	1.17e-16	4.15e-14	0.25	0.25	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	8.43	1.18e-16	4.15e-14	0.23	0.25	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
BRCA	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-8.43	1.18e-16	4.15e-14	-0.34	-0.25	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
BRCA	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-8.43	1.18e-16	4.17e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-8.43	1.18e-16	4.17e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-8.43	1.18e-16	4.17e-14	-0.22	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
BRCA	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	8.42	1.19e-16	4.19e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	8.42	1.2e-16	4.24e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-8.42	1.2e-16	4.24e-14	-0.26	-0.25	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
BRCA	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	8.42	1.2e-16	4.24e-14	0.3	0.25	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
BRCA	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	8.42	1.2e-16	4.25e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
BRCA	cis	rs13256369	1	rs873063	ENSG00000253893.2	FAM85B	-8.42	1.2e-16	4.25e-14	-0.36	-0.25	Obesity-related traits;	chr8:8714937	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	8.42	1.21e-16	4.26e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-8.42	1.21e-16	4.26e-14	-0.44	-0.25	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-8.42	1.21e-16	4.27e-14	-0.27	-0.25	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
BRCA	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	8.42	1.21e-16	4.28e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
BRCA	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	8.42	1.21e-16	4.28e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
BRCA	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-8.42	1.21e-16	4.28e-14	-0.3	-0.25	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
BRCA	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	8.42	1.22e-16	4.29e-14	0.33	0.25	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
BRCA	cis	rs6472827	0.595	rs2936684	ENSG00000253983.2	RP1-16A9.1	8.42	1.22e-16	4.3e-14	0.35	0.25	Uterine fibroids;	chr8:74201522	chr8:74199396~74208441:+
BRCA	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	8.42	1.22e-16	4.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	8.42	1.22e-16	4.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
BRCA	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	8.42	1.23e-16	4.32e-14	0.3	0.25	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
BRCA	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-8.42	1.23e-16	4.33e-14	-0.33	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
BRCA	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-8.42	1.23e-16	4.33e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-8.42	1.23e-16	4.33e-14	-0.34	-0.25	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-8.42	1.24e-16	4.37e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
BRCA	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	8.42	1.25e-16	4.41e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	8.42	1.25e-16	4.41e-14	0.33	0.25	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	8.42	1.25e-16	4.41e-14	0.35	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
BRCA	cis	rs1113500	0.73	rs1781077	ENSG00000226822.1	RP11-356N1.2	-8.42	1.25e-16	4.41e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108046967	chr1:108071482~108074519:+
BRCA	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-8.42	1.25e-16	4.42e-14	-0.32	-0.25	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
BRCA	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-8.42	1.26e-16	4.43e-14	-0.3	-0.25	Migraine;	chr4:56852029	chr4:56960927~56961373:-
BRCA	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	8.42	1.26e-16	4.43e-14	0.33	0.25	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
BRCA	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	8.42	1.26e-16	4.44e-14	0.26	0.25	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
BRCA	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-8.42	1.26e-16	4.45e-14	-0.29	-0.25	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
BRCA	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-8.42	1.27e-16	4.46e-14	-0.28	-0.25	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
BRCA	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	8.42	1.27e-16	4.46e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
BRCA	cis	rs67981189	0.519	rs2526879	ENSG00000269927.1	RP6-91H8.3	-8.42	1.27e-16	4.47e-14	-0.33	-0.25	Schizophrenia;	chr14:70910501	chr14:71141125~71143253:-
BRCA	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-8.42	1.27e-16	4.47e-14	-0.37	-0.25	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
BRCA	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	8.42	1.27e-16	4.48e-14	0.28	0.25	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
BRCA	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
BRCA	cis	rs7246657	0.55	rs9941475	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37573615	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.765	rs4803262	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37575858	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.712	rs4803263	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37575880	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10412510	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37585043	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs3829688	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37586199	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs13744	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37587011	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10403173	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37587779	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.679	rs12461113	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37592287	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.639	rs12459015	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37592288	chr19:37779686~37792865:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-8.42	1.28e-16	4.51e-14	-0.29	-0.25	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	8.42	1.28e-16	4.52e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	8.41	1.28e-16	4.52e-14	0.25	0.25	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	8.41	1.29e-16	4.54e-14	0.23	0.25	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
BRCA	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	8.41	1.29e-16	4.54e-14	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-8.41	1.29e-16	4.54e-14	-0.33	-0.25	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.529	rs2810096	ENSG00000269927.1	RP6-91H8.3	-8.41	1.29e-16	4.54e-14	-0.33	-0.25	Schizophrenia;	chr14:70968583	chr14:71141125~71143253:-
BRCA	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-8.41	1.29e-16	4.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
BRCA	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	8.41	1.29e-16	4.55e-14	0.43	0.25	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
BRCA	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	8.41	1.3e-16	4.56e-14	0.35	0.25	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	8.41	1.3e-16	4.57e-14	0.26	0.25	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
BRCA	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	8.41	1.3e-16	4.58e-14	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
BRCA	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-8.41	1.3e-16	4.59e-14	-0.29	-0.25	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
BRCA	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	8.41	1.3e-16	4.59e-14	0.28	0.25	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
BRCA	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	8.41	1.31e-16	4.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	8.41	1.31e-16	4.62e-14	0.3	0.25	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-8.41	1.31e-16	4.62e-14	-0.21	-0.25	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
BRCA	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	8.41	1.31e-16	4.62e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	8.41	1.32e-16	4.64e-14	0.29	0.25	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	8.41	1.32e-16	4.64e-14	0.27	0.25	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
BRCA	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	8.41	1.32e-16	4.65e-14	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
BRCA	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	8.41	1.33e-16	4.66e-14	0.19	0.25	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
BRCA	cis	rs2041895	0.509	rs2072559	ENSG00000260329.1	RP11-412D9.4	-8.41	1.33e-16	4.69e-14	-0.32	-0.25	Glaucoma (low intraocular pressure);	chr12:106913509	chr12:106954029~106955497:-
BRCA	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-8.41	1.33e-16	4.69e-14	-0.34	-0.25	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-8.41	1.33e-16	4.69e-14	-0.34	-0.25	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
BRCA	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	8.41	1.33e-16	4.69e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
BRCA	cis	rs58873874	0.737	rs11749762	ENSG00000248544.2	CTB-47B11.3	8.41	1.34e-16	4.69e-14	0.57	0.25	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157375741~157384950:-
BRCA	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
BRCA	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	8.41	1.34e-16	4.71e-14	0.31	0.25	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	8.41	1.34e-16	4.72e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-8.41	1.35e-16	4.73e-14	-0.29	-0.25	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-8.41	1.35e-16	4.74e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
BRCA	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	8.41	1.35e-16	4.75e-14	0.38	0.25	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	8.41	1.35e-16	4.75e-14	0.38	0.25	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	8.41	1.36e-16	4.77e-14	0.26	0.25	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	8.41	1.36e-16	4.77e-14	0.26	0.25	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
BRCA	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	8.41	1.36e-16	4.78e-14	0.31	0.25	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-8.41	1.36e-16	4.78e-14	-0.33	-0.25	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	8.41	1.36e-16	4.78e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
BRCA	cis	rs853679	1	rs1778508	ENSG00000220721.1	OR1F12	-8.41	1.36e-16	4.79e-14	-0.4	-0.25	Depression;	chr6:28262103	chr6:28073316~28074233:+
BRCA	cis	rs13256369	1	rs1109619	ENSG00000253893.2	FAM85B	-8.41	1.37e-16	4.8e-14	-0.36	-0.25	Obesity-related traits;	chr8:8714106	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-8.41	1.37e-16	4.82e-14	-0.29	-0.25	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
BRCA	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-8.41	1.37e-16	4.82e-14	-0.41	-0.25	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
BRCA	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	8.41	1.38e-16	4.84e-14	0.23	0.25	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
BRCA	cis	rs13256369	1	rs13267501	ENSG00000253893.2	FAM85B	-8.41	1.38e-16	4.84e-14	-0.36	-0.25	Obesity-related traits;	chr8:8716548	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.95	rs13270006	ENSG00000253893.2	FAM85B	-8.41	1.38e-16	4.84e-14	-0.36	-0.25	Obesity-related traits;	chr8:8716687	chr8:8167819~8226614:-
BRCA	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	8.41	1.38e-16	4.85e-14	0.43	0.25	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
BRCA	cis	rs6545883	0.826	rs777590	ENSG00000271889.1	RP11-493E12.1	8.41	1.39e-16	4.88e-14	0.32	0.25	Tuberculosis;	chr2:61190010	chr2:61151433~61162105:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-8.4	1.39e-16	4.88e-14	-0.36	-0.25	Gout;	chr7:66721259	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	8.4	1.39e-16	4.89e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
BRCA	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	8.4	1.4e-16	4.9e-14	0.35	0.25	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
BRCA	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-8.4	1.4e-16	4.92e-14	-0.32	-0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
BRCA	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.4e-16	4.92e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.4e-16	4.92e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.63	rs12998475	ENSG00000271889.1	RP11-493E12.1	-8.4	1.4e-16	4.92e-14	-0.32	-0.25	Tuberculosis;	chr2:61210352	chr2:61151433~61162105:-
BRCA	cis	rs853679	1	rs7740487	ENSG00000220721.1	OR1F12	8.4	1.41e-16	4.94e-14	0.41	0.25	Depression;	chr6:28248708	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-8.4	1.41e-16	4.94e-14	-0.24	-0.25	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	8.4	1.41e-16	4.94e-14	0.35	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	8.4	1.41e-16	4.94e-14	0.35	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-8.4	1.41e-16	4.95e-14	-0.26	-0.25	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-8.4	1.42e-16	4.99e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	8.4	1.42e-16	4.99e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
BRCA	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	8.4	1.43e-16	5.01e-14	0.24	0.25	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
BRCA	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-8.4	1.43e-16	5.01e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
BRCA	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	8.4	1.43e-16	5.01e-14	0.39	0.25	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.43e-16	5.03e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.43e-16	5.03e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-8.4	1.44e-16	5.03e-14	-0.34	-0.25	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.895	rs4430924	ENSG00000271889.1	RP11-493E12.1	8.4	1.45e-16	5.07e-14	0.34	0.25	Tuberculosis;	chr2:61476721	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-8.4	1.45e-16	5.07e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	8.4	1.45e-16	5.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
BRCA	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	8.4	1.45e-16	5.08e-14	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
BRCA	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	8.4	1.45e-16	5.09e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
BRCA	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	8.4	1.45e-16	5.1e-14	0.26	0.25	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
BRCA	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	8.4	1.46e-16	5.11e-14	0.18	0.25	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	8.4	1.46e-16	5.12e-14	0.26	0.25	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	8.4	1.46e-16	5.12e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
BRCA	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-8.4	1.46e-16	5.13e-14	-0.32	-0.25	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
BRCA	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	8.4	1.47e-16	5.14e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	8.4	1.48e-16	5.17e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs7602859	ENSG00000271889.1	RP11-493E12.1	-8.4	1.48e-16	5.18e-14	-0.33	-0.25	Tuberculosis;	chr2:61231071	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	8.4	1.49e-16	5.21e-14	0.3	0.25	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
BRCA	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	8.4	1.49e-16	5.22e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	8.4	1.49e-16	5.22e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
BRCA	cis	rs67981189	0.529	rs8181986	ENSG00000269927.1	RP6-91H8.3	8.4	1.49e-16	5.22e-14	0.33	0.25	Schizophrenia;	chr14:71115527	chr14:71141125~71143253:-
BRCA	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-8.4	1.5e-16	5.26e-14	-0.33	-0.25	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
BRCA	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-8.39	1.51e-16	5.27e-14	-0.32	-0.25	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	8.39	1.51e-16	5.29e-14	0.25	0.25	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
BRCA	cis	rs6472827	0.645	rs2977070	ENSG00000253983.2	RP1-16A9.1	-8.39	1.51e-16	5.29e-14	-0.35	-0.25	Uterine fibroids;	chr8:74200535	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-8.39	1.51e-16	5.29e-14	-0.3	-0.25	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
BRCA	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	8.39	1.52e-16	5.31e-14	0.43	0.25	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-8.39	1.52e-16	5.33e-14	-0.26	-0.25	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
BRCA	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-8.39	1.53e-16	5.34e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
BRCA	cis	rs1113500	0.73	rs1777457	ENSG00000226822.1	RP11-356N1.2	-8.39	1.54e-16	5.37e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108045573	chr1:108071482~108074519:+
BRCA	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-8.39	1.54e-16	5.38e-14	-0.29	-0.25	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
BRCA	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.39	1.55e-16	5.42e-14	0.34	0.25	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
BRCA	cis	rs67981189	0.529	rs8010063	ENSG00000269927.1	RP6-91H8.3	8.39	1.56e-16	5.44e-14	0.33	0.25	Schizophrenia;	chr14:71043408	chr14:71141125~71143253:-
BRCA	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	8.39	1.56e-16	5.44e-14	0.32	0.25	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
BRCA	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-8.39	1.56e-16	5.46e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-8.39	1.56e-16	5.46e-14	-0.33	-0.25	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-8.39	1.56e-16	5.46e-14	-0.3	-0.25	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	8.39	1.57e-16	5.47e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-8.39	1.57e-16	5.49e-14	-0.26	-0.25	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	8.39	1.58e-16	5.52e-14	0.64	0.25	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	8.39	1.58e-16	5.52e-14	0.26	0.25	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.929	rs10749895	ENSG00000255353.1	RP11-382M14.1	-8.39	1.58e-16	5.53e-14	-0.33	-0.25	Coronary artery disease;	chr11:107310855	chr11:107176286~107177530:+
BRCA	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	8.39	1.59e-16	5.54e-14	0.27	0.25	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-8.39	1.59e-16	5.54e-14	-0.29	-0.25	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs873064	ENSG00000253893.2	FAM85B	-8.39	1.59e-16	5.55e-14	-0.35	-0.25	Obesity-related traits;	chr8:8714870	chr8:8167819~8226614:-
BRCA	cis	rs3758911	0.929	rs10789600	ENSG00000255353.1	RP11-382M14.1	-8.39	1.59e-16	5.55e-14	-0.34	-0.25	Coronary artery disease;	chr11:107310335	chr11:107176286~107177530:+
BRCA	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-8.39	1.59e-16	5.55e-14	-0.34	-0.25	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
BRCA	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8.39	1.59e-16	5.55e-14	0.34	0.25	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
BRCA	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-8.39	1.59e-16	5.57e-14	-0.27	-0.25	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
BRCA	cis	rs748404	0.666	rs12911569	ENSG00000249839.1	AC011330.5	-8.39	1.6e-16	5.57e-14	-0.38	-0.25	Lung cancer;	chr15:43305099	chr15:43663654~43684339:-
BRCA	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	8.39	1.61e-16	5.62e-14	0.32	0.25	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs954504	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37554492	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs8110865	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37556485	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.678	rs4802024	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37561291	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs4802029	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37564710	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs28512414	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37565672	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs6508736	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37570855	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-8.39	1.61e-16	5.63e-14	-0.25	-0.25	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	8.39	1.61e-16	5.63e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
BRCA	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-8.39	1.62e-16	5.64e-14	-0.33	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
BRCA	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	8.39	1.62e-16	5.64e-14	0.29	0.25	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
BRCA	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	8.39	1.62e-16	5.64e-14	0.37	0.25	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	8.39	1.62e-16	5.65e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
BRCA	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	8.39	1.63e-16	5.68e-14	0.28	0.25	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	8.39	1.63e-16	5.69e-14	0.45	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
BRCA	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-8.39	1.63e-16	5.69e-14	-0.3	-0.25	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
BRCA	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	8.38	1.64e-16	5.72e-14	0.43	0.25	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
BRCA	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	8.38	1.64e-16	5.73e-14	0.34	0.25	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
BRCA	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-8.38	1.65e-16	5.75e-14	-0.34	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
BRCA	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	8.38	1.65e-16	5.75e-14	0.37	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	8.38	1.65e-16	5.75e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
BRCA	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	8.38	1.65e-16	5.77e-14	0.25	0.25	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
BRCA	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	8.38	1.65e-16	5.77e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000164669.11	INTS4P1	8.38	1.65e-16	5.77e-14	0.36	0.25	Aortic root size;	chr7:66086944	chr7:65141225~65234216:+
BRCA	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-8.38	1.66e-16	5.78e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-8.38	1.66e-16	5.79e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
BRCA	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-8.38	1.66e-16	5.79e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
BRCA	cis	rs12999373	0.501	rs2867134	ENSG00000223751.1	AC116609.2	-8.38	1.66e-16	5.79e-14	-0.31	-0.25	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:742488~747767:+
BRCA	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
BRCA	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	8.38	1.66e-16	5.8e-14	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	8.38	1.67e-16	5.83e-14	0.36	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-8.38	1.68e-16	5.84e-14	-0.24	-0.25	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	8.38	1.68e-16	5.85e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
BRCA	cis	rs250518	0.926	rs1509131	ENSG00000272081.1	CTD-2376I4.2	8.38	1.68e-16	5.86e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72797651	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-8.38	1.68e-16	5.87e-14	-0.29	-0.25	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
BRCA	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	8.38	1.69e-16	5.88e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
BRCA	cis	rs13256369	0.76	rs7816171	ENSG00000253893.2	FAM85B	-8.38	1.69e-16	5.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8718325	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.76	rs7839473	ENSG00000253893.2	FAM85B	-8.38	1.69e-16	5.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8718326	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	8.38	1.69e-16	5.89e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
BRCA	cis	rs250518	0.926	rs6875887	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795067	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6876549	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795463	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6897422	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795532	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6452687	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795688	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6452690	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795785	chr5:72955206~72955699:-
BRCA	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	8.38	1.69e-16	5.9e-14	0.31	0.25	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
BRCA	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-8.38	1.7e-16	5.91e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
BRCA	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	8.38	1.7e-16	5.91e-14	0.32	0.25	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	8.38	1.7e-16	5.92e-14	0.26	0.25	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
BRCA	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	8.38	1.7e-16	5.93e-14	0.45	0.25	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	8.38	1.7e-16	5.93e-14	0.45	0.25	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
BRCA	cis	rs7246657	0.722	rs2291002	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37543024	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10404031	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37545052	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10406379	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37545823	chr19:37779686~37792865:+
BRCA	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-8.38	1.71e-16	5.95e-14	-0.29	-0.25	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
BRCA	cis	rs3758911	0.964	rs10789602	ENSG00000255353.1	RP11-382M14.1	-8.38	1.71e-16	5.95e-14	-0.33	-0.25	Coronary artery disease;	chr11:107310729	chr11:107176286~107177530:+
BRCA	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	8.38	1.71e-16	5.96e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	8.38	1.72e-16	5.98e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
BRCA	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-8.38	1.72e-16	5.99e-14	-0.32	-0.25	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
BRCA	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-8.38	1.73e-16	6.01e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
BRCA	cis	rs13256369	1	rs10103769	ENSG00000253893.2	FAM85B	-8.38	1.73e-16	6.01e-14	-0.35	-0.25	Obesity-related traits;	chr8:8715526	chr8:8167819~8226614:-
BRCA	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.38	1.73e-16	6.02e-14	-0.23	-0.25	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
BRCA	cis	rs3814244	0.528	rs7306466	ENSG00000236946.2	HNRNPA1P70	-8.38	1.73e-16	6.03e-14	-0.21	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:68035767~68036853:+
BRCA	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	8.38	1.74e-16	6.05e-14	0.34	0.25	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-8.38	1.74e-16	6.06e-14	-0.29	-0.25	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
BRCA	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-8.38	1.74e-16	6.06e-14	-0.56	-0.25	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
BRCA	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	8.38	1.76e-16	6.11e-14	0.25	0.25	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	8.38	1.76e-16	6.11e-14	0.25	0.25	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-8.38	1.76e-16	6.12e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	8.37	1.77e-16	6.16e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-8.37	1.78e-16	6.19e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	8.37	1.79e-16	6.23e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	8.37	1.79e-16	6.23e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
BRCA	cis	rs13256369	1	rs4841016	ENSG00000253893.2	FAM85B	-8.37	1.79e-16	6.23e-14	-0.35	-0.25	Obesity-related traits;	chr8:8715051	chr8:8167819~8226614:-
BRCA	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	8.37	1.79e-16	6.24e-14	0.33	0.25	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-8.37	1.8e-16	6.26e-14	-0.29	-0.25	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	8.37	1.8e-16	6.27e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	8.37	1.8e-16	6.27e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	8.37	1.8e-16	6.27e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
BRCA	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-8.37	1.81e-16	6.29e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
BRCA	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-8.37	1.81e-16	6.3e-14	-0.26	-0.25	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
BRCA	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-8.37	1.82e-16	6.31e-14	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
BRCA	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	8.37	1.82e-16	6.31e-14	0.37	0.25	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
BRCA	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	8.37	1.82e-16	6.31e-14	0.29	0.25	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
BRCA	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.37	1.82e-16	6.34e-14	0.28	0.25	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
BRCA	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	8.37	1.83e-16	6.36e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
BRCA	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	8.37	1.84e-16	6.38e-14	0.32	0.25	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	8.37	1.84e-16	6.39e-14	0.33	0.25	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
BRCA	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-8.37	1.84e-16	6.4e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-8.37	1.84e-16	6.4e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
BRCA	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	8.37	1.84e-16	6.4e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	8.37	1.84e-16	6.4e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-8.37	1.85e-16	6.42e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	8.37	1.85e-16	6.43e-14	0.35	0.25	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
BRCA	cis	rs6545883	0.894	rs2694639	ENSG00000271889.1	RP11-493E12.1	-8.37	1.86e-16	6.44e-14	-0.33	-0.25	Tuberculosis;	chr2:61368156	chr2:61151433~61162105:-
BRCA	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-8.37	1.86e-16	6.46e-14	-0.34	-0.25	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-8.37	1.86e-16	6.47e-14	-0.26	-0.25	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	8.37	1.87e-16	6.47e-14	0.26	0.25	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	8.37	1.87e-16	6.47e-14	0.26	0.25	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
BRCA	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	8.37	1.87e-16	6.49e-14	0.34	0.25	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
BRCA	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	8.37	1.87e-16	6.5e-14	0.26	0.25	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	8.37	1.87e-16	6.5e-14	0.26	0.25	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
BRCA	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-8.37	1.88e-16	6.54e-14	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
BRCA	cis	rs6545883	0.894	rs10177303	ENSG00000271889.1	RP11-493E12.1	-8.37	1.88e-16	6.54e-14	-0.33	-0.25	Tuberculosis;	chr2:61367324	chr2:61151433~61162105:-
BRCA	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	8.37	1.89e-16	6.55e-14	0.32	0.25	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
BRCA	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-8.37	1.89e-16	6.55e-14	-0.29	-0.25	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.722	rs4802051	ENSG00000267422.1	CTD-2554C21.1	-8.37	1.89e-16	6.57e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37581427	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.663	rs4803276	ENSG00000267422.1	CTD-2554C21.1	-8.37	1.89e-16	6.57e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37581429	chr19:37779686~37792865:+
BRCA	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-8.37	1.89e-16	6.57e-14	-0.28	-0.25	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
BRCA	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	8.37	1.9e-16	6.57e-14	0.29	0.25	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
BRCA	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
BRCA	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	8.36	1.91e-16	6.63e-14	0.32	0.25	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
BRCA	cis	rs6545883	0.929	rs10193666	ENSG00000271889.1	RP11-493E12.1	-8.36	1.91e-16	6.63e-14	-0.33	-0.25	Tuberculosis;	chr2:61402273	chr2:61151433~61162105:-
BRCA	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	8.36	1.92e-16	6.65e-14	0.28	0.25	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
BRCA	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.36	1.92e-16	6.67e-14	0.34	0.25	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	8.36	1.93e-16	6.68e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	8.36	1.93e-16	6.68e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
BRCA	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-8.36	1.93e-16	6.68e-14	-0.32	-0.25	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-8.36	1.93e-16	6.69e-14	-0.33	-0.25	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
BRCA	cis	rs5751614	0.577	rs2330369	ENSG00000230701.2	FBXW4P1	8.36	1.93e-16	6.69e-14	0.3	0.25	Height;	chr22:23265255	chr22:23262767~23265005:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-8.36	1.93e-16	6.7e-14	-0.26	-0.25	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
BRCA	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	8.36	1.93e-16	6.7e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
BRCA	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	8.36	1.94e-16	6.71e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
BRCA	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-8.36	1.94e-16	6.71e-14	-0.3	-0.25	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
BRCA	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	8.36	1.94e-16	6.73e-14	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-8.36	1.94e-16	6.74e-14	-0.34	-0.25	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	8.36	1.95e-16	6.75e-14	0.34	0.25	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
BRCA	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	8.36	1.95e-16	6.75e-14	0.3	0.25	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
BRCA	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.36	1.95e-16	6.76e-14	-0.29	-0.25	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
BRCA	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-8.36	1.95e-16	6.76e-14	-0.26	-0.25	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-8.36	1.95e-16	6.76e-14	-0.26	-0.25	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
BRCA	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-8.36	1.96e-16	6.78e-14	-0.4	-0.25	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
BRCA	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.36	1.96e-16	6.8e-14	-0.29	-0.25	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
BRCA	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-8.36	1.97e-16	6.82e-14	-0.61	-0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
BRCA	cis	rs7246657	0.606	rs2972439	ENSG00000267422.1	CTD-2554C21.1	8.36	1.98e-16	6.86e-14	0.37	0.25	Coronary artery calcification;	chr19:37721680	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs2909100	ENSG00000267422.1	CTD-2554C21.1	8.36	1.98e-16	6.86e-14	0.37	0.25	Coronary artery calcification;	chr19:37721779	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-8.36	1.98e-16	6.86e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-8.36	1.98e-16	6.87e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
BRCA	cis	rs4727443	0.866	rs35228488	ENSG00000214313.7	AZGP1P1	-8.36	1.99e-16	6.89e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100020229	chr7:99980762~99987535:+
BRCA	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-8.36	2e-16	6.91e-14	-0.26	-0.25	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	8.36	2e-16	6.94e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
BRCA	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-8.36	2.01e-16	6.94e-14	-0.32	-0.25	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-8.36	2.01e-16	6.95e-14	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
BRCA	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	8.36	2.01e-16	6.95e-14	0.37	0.25	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	8.36	2.01e-16	6.95e-14	0.37	0.25	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
BRCA	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-8.36	2.02e-16	6.98e-14	-0.3	-0.25	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
BRCA	cis	rs812925	0.559	rs2600667	ENSG00000271889.1	RP11-493E12.1	8.36	2.02e-16	6.98e-14	0.33	0.25	Immature fraction of reticulocytes;	chr2:61177796	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.637	rs12219247	ENSG00000213061.2	PFN1P11	8.36	2.02e-16	6.99e-14	0.33	0.25	Arsenic metabolism;	chr10:102853604	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.826	rs777593	ENSG00000271889.1	RP11-493E12.1	8.36	2.02e-16	7e-14	0.33	0.25	Tuberculosis;	chr2:61191968	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-8.36	2.03e-16	7.01e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
BRCA	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-8.36	2.03e-16	7.02e-14	-0.27	-0.25	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
BRCA	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	8.36	2.03e-16	7.03e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
BRCA	cis	rs753274	0.562	rs888876	ENSG00000267147.2	CTC-548K16.1	8.36	2.03e-16	7.04e-14	0.28	0.25	Tumor necrosis factor beta levels;	chr19:14305981	chr19:14333743~14343916:+
BRCA	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-8.36	2.04e-16	7.07e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	8.36	2.05e-16	7.09e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
BRCA	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-8.36	2.05e-16	7.09e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	8.36	2.05e-16	7.1e-14	0.26	0.25	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	8.36	2.05e-16	7.1e-14	0.26	0.25	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
BRCA	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	8.36	2.05e-16	7.1e-14	0.29	0.25	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-8.36	2.06e-16	7.11e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-8.36	2.06e-16	7.11e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	8.36	2.06e-16	7.11e-14	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
BRCA	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-8.36	2.06e-16	7.12e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-8.36	2.06e-16	7.12e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
BRCA	cis	rs11191419	1	rs11191419	ENSG00000213061.2	PFN1P11	8.36	2.06e-16	7.13e-14	0.33	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102838011~102845473:-
BRCA	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	8.36	2.07e-16	7.15e-14	0.37	0.25	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
BRCA	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	8.35	2.07e-16	7.15e-14	0.32	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
BRCA	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-8.35	2.07e-16	7.16e-14	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-8.35	2.08e-16	7.18e-14	-0.26	-0.25	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-8.35	2.09e-16	7.21e-14	-0.26	-0.25	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
BRCA	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	8.35	2.09e-16	7.22e-14	0.29	0.25	QT interval;	chr12:29272168	chr12:29280418~29317848:-
BRCA	cis	rs1113500	0.73	rs1618693	ENSG00000226822.1	RP11-356N1.2	-8.35	2.09e-16	7.22e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108048961	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.698	rs1781078	ENSG00000226822.1	RP11-356N1.2	-8.35	2.09e-16	7.22e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108049020	chr1:108071482~108074519:+
BRCA	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	8.35	2.09e-16	7.23e-14	0.4	0.25	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
BRCA	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	8.35	2.09e-16	7.23e-14	0.4	0.25	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
BRCA	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-8.35	2.09e-16	7.23e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-8.35	2.1e-16	7.27e-14	-0.26	-0.25	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-8.35	2.1e-16	7.27e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
BRCA	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-8.35	2.11e-16	7.27e-14	-0.41	-0.25	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
BRCA	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-8.35	2.11e-16	7.28e-14	-0.31	-0.25	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
BRCA	cis	rs4727443	0.866	rs6963345	ENSG00000214313.7	AZGP1P1	-8.35	2.11e-16	7.29e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100020983	chr7:99980762~99987535:+
BRCA	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	8.35	2.11e-16	7.29e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
BRCA	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	8.35	2.11e-16	7.3e-14	0.37	0.25	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
BRCA	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-8.35	2.11e-16	7.3e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	8.35	2.12e-16	7.32e-14	0.26	0.25	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	8.35	2.12e-16	7.33e-14	0.25	0.25	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
BRCA	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	8.35	2.12e-16	7.33e-14	0.34	0.25	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
BRCA	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	8.35	2.13e-16	7.36e-14	0.34	0.25	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-8.35	2.13e-16	7.36e-14	-0.26	-0.25	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	8.35	2.13e-16	7.36e-14	0.26	0.25	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	8.35	2.14e-16	7.39e-14	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
BRCA	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-8.35	2.14e-16	7.39e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	8.35	2.14e-16	7.4e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
BRCA	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-8.35	2.14e-16	7.4e-14	-0.31	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
BRCA	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	8.35	2.15e-16	7.41e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
BRCA	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	8.35	2.15e-16	7.42e-14	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-8.35	2.16e-16	7.44e-14	-0.17	-0.25	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
BRCA	cis	rs6472827	0.645	rs2936683	ENSG00000253983.2	RP1-16A9.1	8.35	2.16e-16	7.45e-14	0.34	0.25	Uterine fibroids;	chr8:74201004	chr8:74199396~74208441:+
BRCA	cis	rs6472827	0.645	rs16836	ENSG00000253983.2	RP1-16A9.1	8.35	2.16e-16	7.45e-14	0.34	0.25	Uterine fibroids;	chr8:74201827	chr8:74199396~74208441:+
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	8.35	2.17e-16	7.47e-14	0.25	0.25	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	8.35	2.17e-16	7.47e-14	0.29	0.25	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
BRCA	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	8.35	2.17e-16	7.48e-14	0.27	0.25	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
BRCA	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-8.35	2.17e-16	7.5e-14	-0.32	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000164669.11	INTS4P1	8.35	2.18e-16	7.51e-14	0.35	0.25	Aortic root size;	chr7:66091320	chr7:65141225~65234216:+
BRCA	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-8.35	2.18e-16	7.52e-14	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	8.35	2.18e-16	7.53e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-8.35	2.2e-16	7.59e-14	-0.3	-0.25	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
BRCA	cis	rs6539288	0.933	rs10746070	ENSG00000260329.1	RP11-412D9.4	-8.35	2.2e-16	7.59e-14	-0.29	-0.25	Total body bone mineral density;	chr12:106910681	chr12:106954029~106955497:-
BRCA	cis	rs807029	0.577	rs11190786	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.577	rs7902510	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.577	rs7903239	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100911103~100912739:-
BRCA	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	8.35	2.2e-16	7.6e-14	0.34	0.25	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
BRCA	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	8.35	2.21e-16	7.63e-14	0.27	0.25	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
BRCA	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	8.35	2.21e-16	7.63e-14	0.27	0.25	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
BRCA	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-8.35	2.23e-16	7.67e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
BRCA	cis	rs58873874	0.579	rs80253028	ENSG00000251405.2	CTB-109A12.1	8.35	2.23e-16	7.68e-14	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157362615~157460078:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-8.35	2.23e-16	7.7e-14	-0.24	-0.25	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
BRCA	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-8.35	2.24e-16	7.71e-14	-0.29	-0.25	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
BRCA	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-8.35	2.24e-16	7.71e-14	-0.26	-0.25	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
BRCA	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	8.35	2.24e-16	7.72e-14	0.33	0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	8.34	2.24e-16	7.73e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-8.34	2.25e-16	7.75e-14	-0.26	-0.25	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
BRCA	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-8.34	2.25e-16	7.76e-14	-0.29	-0.25	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-8.34	2.25e-16	7.76e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
BRCA	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	8.34	2.25e-16	7.76e-14	0.37	0.25	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
BRCA	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	8.34	2.26e-16	7.8e-14	0.35	0.25	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
BRCA	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
BRCA	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	8.34	2.27e-16	7.8e-14	0.25	0.25	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
BRCA	cis	rs4862750	0.872	rs4862748	ENSG00000250971.1	RP11-696F12.1	-8.34	2.27e-16	7.81e-14	-0.26	-0.25	Lobe attachment (rater-scored or self-reported);	chr4:186956234	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	8.34	2.27e-16	7.82e-14	0.26	0.25	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	8.34	2.27e-16	7.83e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	8.34	2.27e-16	7.83e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000257551.1	HLX-AS1	8.34	2.28e-16	7.84e-14	0.36	0.25	Cholesterol, total;	chr1:220869661	chr1:220832763~220880140:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-8.34	2.28e-16	7.84e-14	-0.29	-0.25	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-8.34	2.28e-16	7.84e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-8.34	2.28e-16	7.84e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	8.34	2.28e-16	7.84e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	8.34	2.28e-16	7.84e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
BRCA	cis	rs6472827	0.645	rs7009750	ENSG00000253983.2	RP1-16A9.1	8.34	2.28e-16	7.85e-14	0.34	0.25	Uterine fibroids;	chr8:74199894	chr8:74199396~74208441:+
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	8.34	2.29e-16	7.87e-14	0.25	0.25	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-8.34	2.29e-16	7.9e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-8.34	2.3e-16	7.9e-14	-0.26	-0.25	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
BRCA	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-8.34	2.3e-16	7.93e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
BRCA	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	8.34	2.31e-16	7.95e-14	0.38	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
BRCA	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-8.34	2.31e-16	7.96e-14	-0.35	-0.25	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-8.34	2.31e-16	7.97e-14	-0.29	-0.25	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
BRCA	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	8.34	2.33e-16	8.01e-14	0.34	0.25	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
BRCA	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	8.34	2.34e-16	8.04e-14	0.27	0.25	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
BRCA	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-8.34	2.35e-16	8.07e-14	-0.3	-0.25	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	8.34	2.35e-16	8.09e-14	0.24	0.25	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-8.34	2.36e-16	8.11e-14	-0.29	-0.25	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	8.34	2.36e-16	8.12e-14	0.22	0.25	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
BRCA	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-8.34	2.37e-16	8.14e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
BRCA	cis	rs7246657	0.722	rs1531549	ENSG00000267422.1	CTD-2554C21.1	-8.34	2.37e-16	8.15e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37597108	chr19:37779686~37792865:+
BRCA	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-8.34	2.38e-16	8.17e-14	-0.34	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	8.34	2.38e-16	8.18e-14	0.21	0.25	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
BRCA	cis	rs202072	0.72	rs1550526	ENSG00000272379.1	RP1-257A7.5	8.34	2.38e-16	8.18e-14	0.44	0.25	HIV-1 viral setpoint;	chr6:13295283	chr6:13290018~13290490:-
BRCA	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	8.34	2.39e-16	8.21e-14	0.28	0.25	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-8.34	2.39e-16	8.21e-14	-0.29	-0.25	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-8.34	2.39e-16	8.23e-14	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
BRCA	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	8.34	2.4e-16	8.23e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
BRCA	cis	rs67981189	0.57	rs67188216	ENSG00000269927.1	RP6-91H8.3	8.34	2.4e-16	8.23e-14	0.33	0.25	Schizophrenia;	chr14:71042607	chr14:71141125~71143253:-
BRCA	cis	rs6545883	0.929	rs10200055	ENSG00000271889.1	RP11-493E12.1	-8.34	2.4e-16	8.24e-14	-0.32	-0.25	Tuberculosis;	chr2:61400882	chr2:61151433~61162105:-
BRCA	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	8.34	2.4e-16	8.26e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
BRCA	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-8.34	2.41e-16	8.27e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
BRCA	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	8.34	2.41e-16	8.27e-14	0.39	0.25	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
BRCA	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-8.34	2.41e-16	8.28e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000164669.11	INTS4P1	8.34	2.42e-16	8.3e-14	0.35	0.25	Aortic root size;	chr7:66087627	chr7:65141225~65234216:+
BRCA	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-8.34	2.42e-16	8.3e-14	-0.29	-0.25	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-8.34	2.42e-16	8.31e-14	-0.26	-0.25	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	8.34	2.42e-16	8.31e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	8.34	2.42e-16	8.31e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.33	2.43e-16	8.34e-14	-0.28	-0.25	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
BRCA	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-8.33	2.43e-16	8.36e-14	-0.29	-0.25	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
BRCA	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-8.33	2.44e-16	8.36e-14	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-8.33	2.44e-16	8.38e-14	-0.26	-0.25	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-8.33	2.45e-16	8.42e-14	-0.29	-0.25	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	8.33	2.46e-16	8.44e-14	0.32	0.25	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
BRCA	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.33	2.46e-16	8.45e-14	-0.28	-0.25	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.86	rs6545847	ENSG00000271889.1	RP11-493E12.1	-8.33	2.47e-16	8.48e-14	-0.32	-0.25	Tuberculosis;	chr2:61218198	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	8.33	2.48e-16	8.5e-14	0.26	0.25	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
BRCA	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-8.33	2.49e-16	8.53e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.33	2.5e-16	8.56e-14	-0.28	-0.25	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
BRCA	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-8.33	2.5e-16	8.56e-14	-0.28	-0.25	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	8.33	2.51e-16	8.6e-14	0.21	0.25	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	8.33	2.51e-16	8.6e-14	0.21	0.25	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
BRCA	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-8.33	2.51e-16	8.6e-14	-0.33	-0.25	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
BRCA	cis	rs7246657	0.639	rs3112434	ENSG00000267422.1	CTD-2554C21.1	8.33	2.52e-16	8.64e-14	0.37	0.25	Coronary artery calcification;	chr19:37707247	chr19:37779686~37792865:+
BRCA	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-8.33	2.52e-16	8.64e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
BRCA	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	8.33	2.52e-16	8.65e-14	0.36	0.25	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-8.33	2.53e-16	8.67e-14	-0.26	-0.25	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-8.33	2.53e-16	8.68e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-8.33	2.53e-16	8.68e-14	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
BRCA	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-8.33	2.54e-16	8.69e-14	-0.29	-0.25	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
BRCA	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-8.33	2.54e-16	8.7e-14	-0.31	-0.25	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
BRCA	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-8.33	2.54e-16	8.7e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-8.33	2.54e-16	8.72e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
BRCA	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-8.33	2.55e-16	8.72e-14	-0.27	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	8.33	2.55e-16	8.73e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-8.33	2.56e-16	8.76e-14	-0.24	-0.25	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
BRCA	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-8.33	2.56e-16	8.76e-14	-0.36	-0.25	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
BRCA	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-8.33	2.56e-16	8.76e-14	-0.29	-0.25	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
BRCA	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-8.33	2.57e-16	8.82e-14	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
BRCA	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-8.33	2.58e-16	8.83e-14	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
BRCA	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	8.33	2.58e-16	8.83e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
BRCA	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-8.33	2.58e-16	8.84e-14	-0.29	-0.25	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-8.33	2.58e-16	8.85e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	8.33	2.59e-16	8.88e-14	0.26	0.25	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
BRCA	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.33	2.6e-16	8.91e-14	0.27	0.25	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
BRCA	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	8.33	2.61e-16	8.94e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
BRCA	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	8.33	2.61e-16	8.94e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-8.33	2.61e-16	8.95e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000222364.1	RNU6-96P	8.33	2.62e-16	8.95e-14	0.33	0.25	Aortic root size;	chr7:66592167	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	8.33	2.62e-16	8.98e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
BRCA	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	8.32	2.63e-16	8.99e-14	0.21	0.25	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-8.32	2.63e-16	8.99e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	8.32	2.65e-16	9.07e-14	0.22	0.25	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
BRCA	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	8.32	2.66e-16	9.09e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-8.32	2.66e-16	9.11e-14	-0.29	-0.25	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	8.32	2.67e-16	9.12e-14	0.21	0.25	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-8.32	2.67e-16	9.13e-14	-0.33	-0.25	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.542	rs1012725	ENSG00000269927.1	RP6-91H8.3	-8.32	2.67e-16	9.13e-14	-0.35	-0.25	Schizophrenia;	chr14:71138994	chr14:71141125~71143253:-
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	8.32	2.69e-16	9.19e-14	0.56	0.25	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
BRCA	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-8.32	2.69e-16	9.2e-14	-0.31	-0.25	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	8.32	2.69e-16	9.21e-14	0.25	0.25	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
BRCA	cis	rs6472827	0.645	rs2977069	ENSG00000253983.2	RP1-16A9.1	8.32	2.7e-16	9.22e-14	0.34	0.25	Uterine fibroids;	chr8:74199550	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000164669.11	INTS4P1	8.32	2.7e-16	9.23e-14	0.35	0.25	Aortic root size;	chr7:66089365	chr7:65141225~65234216:+
BRCA	cis	rs6472827	0.645	rs2936685	ENSG00000253983.2	RP1-16A9.1	8.32	2.7e-16	9.24e-14	0.35	0.25	Uterine fibroids;	chr8:74202449	chr8:74199396~74208441:+
BRCA	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-8.32	2.72e-16	9.32e-14	-0.28	-0.25	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
BRCA	cis	rs3758911	0.964	rs10890703	ENSG00000255353.1	RP11-382M14.1	-8.32	2.73e-16	9.33e-14	-0.34	-0.25	Coronary artery disease;	chr11:107310403	chr11:107176286~107177530:+
BRCA	cis	rs250518	0.926	rs7709640	ENSG00000272081.1	CTD-2376I4.2	8.32	2.74e-16	9.38e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72791653	chr5:72955206~72955699:-
BRCA	cis	rs7246657	0.722	rs2972437	ENSG00000267422.1	CTD-2554C21.1	-8.32	2.75e-16	9.38e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37719610	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	8.32	2.75e-16	9.39e-14	0.26	0.25	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
BRCA	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	8.32	2.75e-16	9.4e-14	0.32	0.25	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-8.32	2.75e-16	9.4e-14	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
BRCA	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-8.32	2.75e-16	9.4e-14	-0.3	-0.25	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	8.32	2.75e-16	9.41e-14	0.37	0.25	Depression;	chr6:28428413	chr6:28943877~28944537:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-8.32	2.76e-16	9.44e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
BRCA	cis	rs58873874	0.737	rs75022277	ENSG00000248544.2	CTB-47B11.3	8.32	2.76e-16	9.44e-14	0.62	0.25	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157375741~157384950:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-8.32	2.76e-16	9.44e-14	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
BRCA	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-8.32	2.76e-16	9.44e-14	-0.32	-0.25	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
BRCA	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-8.32	2.77e-16	9.46e-14	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
BRCA	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.32	2.78e-16	9.48e-14	-0.28	-0.25	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	8.32	2.78e-16	9.51e-14	0.26	0.25	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	8.32	2.79e-16	9.53e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.663	rs4803287	ENSG00000267422.1	CTD-2554C21.1	-8.32	2.81e-16	9.61e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37588534	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	8.32	2.82e-16	9.62e-14	0.33	0.25	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
BRCA	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.32	2.82e-16	9.63e-14	-0.31	-0.25	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
BRCA	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	8.32	2.83e-16	9.66e-14	0.32	0.25	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
BRCA	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-8.32	2.83e-16	9.66e-14	-0.3	-0.25	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-8.32	2.84e-16	9.7e-14	-0.26	-0.25	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	8.32	2.84e-16	9.7e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-8.31	2.84e-16	9.7e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
BRCA	cis	rs6545883	0.929	rs778154	ENSG00000271889.1	RP11-493E12.1	-8.31	2.84e-16	9.7e-14	-0.33	-0.25	Tuberculosis;	chr2:61419496	chr2:61151433~61162105:-
BRCA	cis	rs7085104	0.7	rs3740397	ENSG00000213061.2	PFN1P11	8.31	2.84e-16	9.71e-14	0.33	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102838011~102845473:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-8.31	2.85e-16	9.71e-14	-0.47	-0.25	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	8.31	2.85e-16	9.72e-14	0.26	0.25	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
BRCA	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-8.31	2.85e-16	9.73e-14	-0.21	-0.25	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	8.31	2.86e-16	9.76e-14	0.26	0.25	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	8.31	2.87e-16	9.8e-14	0.3	0.25	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
BRCA	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-8.31	2.89e-16	9.84e-14	-0.3	-0.25	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
BRCA	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	8.31	2.89e-16	9.86e-14	0.29	0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
BRCA	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.87e-14	-0.28	-0.25	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.87e-14	-0.28	-0.25	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.89e-14	-0.28	-0.25	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
BRCA	cis	rs6539288	0.803	rs7307895	ENSG00000260329.1	RP11-412D9.4	-8.31	2.9e-16	9.89e-14	-0.28	-0.25	Total body bone mineral density;	chr12:106938348	chr12:106954029~106955497:-
BRCA	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	8.31	2.9e-16	9.9e-14	0.27	0.25	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
BRCA	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	8.31	2.91e-16	9.91e-14	0.42	0.25	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	8.31	2.91e-16	9.91e-14	0.42	0.25	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	8.31	2.91e-16	9.91e-14	0.26	0.25	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	8.31	2.91e-16	9.92e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	8.31	2.91e-16	9.93e-14	0.33	0.25	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-8.31	2.92e-16	9.95e-14	-0.35	-0.25	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-8.31	2.92e-16	9.96e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
BRCA	cis	rs13256369	1	rs7004438	ENSG00000253893.2	FAM85B	-8.31	2.94e-16	1e-13	-0.35	-0.25	Obesity-related traits;	chr8:8716869	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	8.31	2.94e-16	1e-13	0.3	0.25	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
BRCA	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8.31	2.94e-16	1e-13	-0.28	-0.25	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
BRCA	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-8.31	2.95e-16	1.01e-13	-0.31	-0.25	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
BRCA	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-8.31	2.95e-16	1.01e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-8.31	2.95e-16	1.01e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
BRCA	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	8.31	2.97e-16	1.01e-13	0.31	0.25	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
BRCA	cis	rs58873874	0.737	rs76634949	ENSG00000248544.2	CTB-47B11.3	8.31	2.97e-16	1.01e-13	0.62	0.25	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	8.31	2.98e-16	1.02e-13	0.22	0.25	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
BRCA	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8.31	3.03e-16	1.03e-13	-0.28	-0.25	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8.31	3.03e-16	1.03e-13	-0.28	-0.25	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
BRCA	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	8.31	3.04e-16	1.04e-13	0.38	0.25	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-8.31	3.04e-16	1.04e-13	-0.29	-0.25	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
BRCA	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	8.31	3.06e-16	1.04e-13	0.44	0.25	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
BRCA	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	8.31	3.06e-16	1.04e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
BRCA	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.04e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.04e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
BRCA	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-8.31	3.07e-16	1.05e-13	-0.31	-0.25	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
BRCA	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.05e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
BRCA	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-8.3	3.09e-16	1.05e-13	-0.3	-0.25	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
BRCA	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-8.3	3.09e-16	1.05e-13	-0.38	-0.25	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
BRCA	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	8.3	3.09e-16	1.05e-13	0.28	0.25	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
BRCA	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.3	3.09e-16	1.05e-13	0.34	0.25	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
BRCA	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.929	rs2252662	ENSG00000271889.1	RP11-493E12.1	8.3	3.09e-16	1.05e-13	0.32	0.25	Tuberculosis;	chr2:61443596	chr2:61151433~61162105:-
BRCA	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	8.3	3.09e-16	1.05e-13	0.3	0.25	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
BRCA	cis	rs250518	0.926	rs6873718	ENSG00000272081.1	CTD-2376I4.2	8.3	3.09e-16	1.05e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72747581	chr5:72955206~72955699:-
BRCA	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	8.3	3.1e-16	1.05e-13	0.25	0.25	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-8.3	3.1e-16	1.06e-13	-0.17	-0.25	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000164669.11	INTS4P1	8.3	3.1e-16	1.06e-13	0.35	0.25	Aortic root size;	chr7:66101095	chr7:65141225~65234216:+
BRCA	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-8.3	3.11e-16	1.06e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
BRCA	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	8.3	3.11e-16	1.06e-13	0.27	0.25	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
BRCA	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	8.3	3.14e-16	1.07e-13	0.3	0.25	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	8.3	3.14e-16	1.07e-13	0.43	0.25	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
BRCA	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-8.3	3.15e-16	1.07e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-8.3	3.15e-16	1.07e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
BRCA	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	8.3	3.16e-16	1.07e-13	0.34	0.25	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
BRCA	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	8.3	3.16e-16	1.07e-13	0.28	0.25	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
BRCA	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	8.3	3.16e-16	1.07e-13	0.32	0.25	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	8.3	3.16e-16	1.07e-13	0.24	0.25	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	8.3	3.16e-16	1.07e-13	0.24	0.25	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
BRCA	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-8.3	3.16e-16	1.08e-13	-0.24	-0.25	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
BRCA	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-8.3	3.17e-16	1.08e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
BRCA	cis	rs42648	0.869	rs1015403	ENSG00000225498.1	AC002064.5	8.3	3.18e-16	1.08e-13	0.24	0.25	Homocysteine levels;	chr7:90284388	chr7:90312496~90322592:+
BRCA	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	8.3	3.18e-16	1.08e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	8.3	3.19e-16	1.08e-13	0.29	0.25	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.894	rs4672431	ENSG00000271889.1	RP11-493E12.1	-8.3	3.2e-16	1.09e-13	-0.32	-0.25	Tuberculosis;	chr2:61292787	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-8.3	3.2e-16	1.09e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
BRCA	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-8.3	3.21e-16	1.09e-13	-0.26	-0.25	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	8.3	3.21e-16	1.09e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
BRCA	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-8.3	3.22e-16	1.09e-13	-0.32	-0.25	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
BRCA	cis	rs6472827	0.571	rs2936692	ENSG00000253983.2	RP1-16A9.1	8.3	3.22e-16	1.1e-13	0.34	0.25	Uterine fibroids;	chr8:74199039	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
BRCA	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	8.3	3.23e-16	1.1e-13	0.3	0.25	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	8.3	3.23e-16	1.1e-13	0.26	0.25	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	8.3	3.23e-16	1.1e-13	0.34	0.25	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
BRCA	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	8.3	3.25e-16	1.1e-13	0.34	0.25	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.859	rs7561672	ENSG00000271889.1	RP11-493E12.1	-8.3	3.26e-16	1.11e-13	-0.32	-0.25	Tuberculosis;	chr2:61291959	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-8.3	3.26e-16	1.11e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-8.3	3.26e-16	1.11e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-8.3	3.26e-16	1.11e-13	-0.17	-0.25	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
BRCA	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-8.3	3.27e-16	1.11e-13	-0.3	-0.25	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	8.3	3.27e-16	1.11e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
BRCA	cis	rs7246657	0.722	rs10410588	ENSG00000267422.1	CTD-2554C21.1	-8.3	3.27e-16	1.11e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37551508	chr19:37779686~37792865:+
BRCA	cis	rs748404	0.666	rs7176923	ENSG00000249839.1	AC011330.5	-8.3	3.28e-16	1.11e-13	-0.38	-0.25	Lung cancer;	chr15:43317679	chr15:43663654~43684339:-
BRCA	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	8.3	3.29e-16	1.12e-13	0.29	0.25	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
BRCA	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	8.3	3.31e-16	1.12e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	8.3	3.31e-16	1.12e-13	0.29	0.25	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
BRCA	cis	rs7246657	0.722	rs2927746	ENSG00000267422.1	CTD-2554C21.1	8.29	3.33e-16	1.13e-13	0.37	0.25	Coronary artery calcification;	chr19:37665669	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	8.29	3.34e-16	1.13e-13	0.24	0.25	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	8.29	3.36e-16	1.14e-13	0.26	0.25	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.894	rs2694643	ENSG00000271889.1	RP11-493E12.1	8.29	3.36e-16	1.14e-13	0.32	0.25	Tuberculosis;	chr2:61377248	chr2:61151433~61162105:-
BRCA	cis	rs250518	0.926	rs34919293	ENSG00000272081.1	CTD-2376I4.2	8.29	3.37e-16	1.14e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72756687	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	8.29	3.37e-16	1.14e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs778148	ENSG00000271889.1	RP11-493E12.1	-8.29	3.37e-16	1.14e-13	-0.32	-0.25	Tuberculosis;	chr2:61379731	chr2:61151433~61162105:-
BRCA	cis	rs42648	0.869	rs6948139	ENSG00000225498.1	AC002064.5	8.29	3.37e-16	1.14e-13	0.24	0.25	Homocysteine levels;	chr7:90308467	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs6970750	ENSG00000225498.1	AC002064.5	8.29	3.37e-16	1.14e-13	0.24	0.25	Homocysteine levels;	chr7:90308877	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000222364.1	RNU6-96P	8.29	3.4e-16	1.15e-13	0.33	0.25	Aortic root size;	chr7:66622032	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
BRCA	cis	rs7246657	0.654	rs10407568	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.4e-16	1.15e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37632108	chr19:37779686~37792865:+
BRCA	cis	rs807029	0.577	rs3740490	ENSG00000272572.1	RP11-179B2.2	-8.29	3.41e-16	1.15e-13	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100911103~100912739:-
BRCA	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	8.29	3.41e-16	1.16e-13	0.42	0.25	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
BRCA	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-8.29	3.43e-16	1.16e-13	-0.36	-0.25	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	8.29	3.44e-16	1.17e-13	0.29	0.25	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	8.29	3.44e-16	1.17e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
BRCA	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	8.29	3.45e-16	1.17e-13	0.27	0.25	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-8.29	3.46e-16	1.17e-13	-0.35	-0.25	Gout;	chr7:66693028	chr7:66902857~66906297:+
BRCA	cis	rs67981189	0.529	rs61990387	ENSG00000269927.1	RP6-91H8.3	8.29	3.46e-16	1.17e-13	0.33	0.25	Schizophrenia;	chr14:71024850	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.722	rs1975937	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.47e-16	1.17e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37601031	chr19:37779686~37792865:+
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-8.29	3.48e-16	1.18e-13	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
BRCA	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	8.29	3.49e-16	1.18e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	8.29	3.5e-16	1.19e-13	0.27	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
BRCA	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	8.29	3.51e-16	1.19e-13	0.29	0.25	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	8.29	3.51e-16	1.19e-13	0.25	0.25	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	8.29	3.52e-16	1.19e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
BRCA	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	8.29	3.52e-16	1.19e-13	0.28	0.25	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	8.29	3.52e-16	1.19e-13	0.32	0.25	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
BRCA	cis	rs250518	0.926	rs1912005	ENSG00000272081.1	CTD-2376I4.2	-8.29	3.53e-16	1.19e-13	-0.32	-0.25	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72955206~72955699:-
BRCA	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	8.29	3.54e-16	1.2e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
BRCA	cis	rs7246657	0.722	rs35863684	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.55e-16	1.2e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37618876	chr19:37779686~37792865:+
BRCA	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	8.29	3.57e-16	1.21e-13	0.28	0.25	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
BRCA	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	8.29	3.58e-16	1.21e-13	0.34	0.25	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
BRCA	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	8.29	3.6e-16	1.22e-13	0.33	0.25	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	8.29	3.6e-16	1.22e-13	0.35	0.25	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.929	rs10190332	ENSG00000271889.1	RP11-493E12.1	-8.28	3.61e-16	1.22e-13	-0.32	-0.25	Tuberculosis;	chr2:61392132	chr2:61151433~61162105:-
BRCA	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	8.28	3.62e-16	1.22e-13	0.21	0.25	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
BRCA	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.28	3.63e-16	1.23e-13	0.38	0.25	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
BRCA	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
BRCA	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.28	3.64e-16	1.23e-13	-0.28	-0.25	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.929	rs2694625	ENSG00000271889.1	RP11-493E12.1	-8.28	3.65e-16	1.23e-13	-0.33	-0.25	Tuberculosis;	chr2:61388920	chr2:61151433~61162105:-
BRCA	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-8.28	3.66e-16	1.24e-13	-0.29	-0.25	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000226816.2	AC005082.12	8.28	3.68e-16	1.24e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23206013~23208045:+
BRCA	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-8.28	3.69e-16	1.24e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
BRCA	cis	rs13256369	1	rs4841017	ENSG00000253893.2	FAM85B	-8.28	3.69e-16	1.25e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719583	chr8:8167819~8226614:-
BRCA	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	8.28	3.7e-16	1.25e-13	0.57	0.25	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	8.28	3.7e-16	1.25e-13	0.57	0.25	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	8.28	3.7e-16	1.25e-13	0.26	0.25	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	8.28	3.7e-16	1.25e-13	0.26	0.25	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
BRCA	cis	rs10515750	0.656	rs112839393	ENSG00000251405.2	CTB-109A12.1	8.28	3.71e-16	1.25e-13	0.55	0.25	Lung function (FEV1/FVC);	chr5:157282304	chr5:157362615~157460078:-
BRCA	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-8.28	3.72e-16	1.26e-13	-0.29	-0.25	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.722	rs8100646	ENSG00000267422.1	CTD-2554C21.1	-8.28	3.74e-16	1.26e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37617042	chr19:37779686~37792865:+
BRCA	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	8.28	3.74e-16	1.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
BRCA	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	8.28	3.75e-16	1.26e-13	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
BRCA	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-8.28	3.76e-16	1.27e-13	-0.33	-0.25	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
BRCA	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	8.28	3.76e-16	1.27e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	8.28	3.76e-16	1.27e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
BRCA	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-8.28	3.76e-16	1.27e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-8.28	3.77e-16	1.27e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-8.28	3.77e-16	1.27e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-8.28	3.77e-16	1.27e-13	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
BRCA	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-8.28	3.78e-16	1.27e-13	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	8.28	3.82e-16	1.29e-13	0.34	0.25	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	8.28	3.82e-16	1.29e-13	0.34	0.25	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	8.28	3.84e-16	1.3e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	8.28	3.85e-16	1.3e-13	0.44	0.25	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
BRCA	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	8.28	3.85e-16	1.3e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23206013~23208045:+
BRCA	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	8.28	3.86e-16	1.3e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
BRCA	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	8.28	3.86e-16	1.3e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-8.28	3.87e-16	1.3e-13	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	8.28	3.88e-16	1.31e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
BRCA	cis	rs853679	1	rs1679709	ENSG00000220721.1	OR1F12	-8.27	3.9e-16	1.31e-13	-0.39	-0.25	Depression;	chr6:28260564	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.803	rs2374651	ENSG00000260329.1	RP11-412D9.4	-8.27	3.9e-16	1.32e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106934346	chr12:106954029~106955497:-
BRCA	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	8.27	3.91e-16	1.32e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	8.27	3.91e-16	1.32e-13	0.35	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
BRCA	cis	rs42648	0.869	rs6970376	ENSG00000225498.1	AC002064.5	-8.27	3.92e-16	1.32e-13	-0.24	-0.25	Homocysteine levels;	chr7:90308772	chr7:90312496~90322592:+
BRCA	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-8.27	3.92e-16	1.32e-13	-0.29	-0.25	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	8.27	3.92e-16	1.32e-13	0.24	0.25	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
BRCA	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	8.27	3.93e-16	1.32e-13	0.27	0.25	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
BRCA	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-8.27	3.93e-16	1.32e-13	-0.32	-0.25	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
BRCA	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-8.27	3.93e-16	1.33e-13	-0.31	-0.25	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.35	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-8.27	3.95e-16	1.33e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
BRCA	cis	rs7246657	0.722	rs8103647	ENSG00000267422.1	CTD-2554C21.1	-8.27	3.96e-16	1.33e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37609551	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	8.27	3.96e-16	1.33e-13	0.26	0.25	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-8.27	3.96e-16	1.33e-13	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
BRCA	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	8.27	3.97e-16	1.34e-13	0.27	0.25	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-8.27	3.97e-16	1.34e-13	-0.29	-0.25	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
BRCA	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	8.27	3.98e-16	1.34e-13	0.33	0.25	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
BRCA	cis	rs42648	0.777	rs4728878	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90294918	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs13239439	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90295086	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs7786771	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90295453	chr7:90312496~90322592:+
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-8.27	4e-16	1.35e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-8.27	4e-16	1.35e-13	-0.3	-0.25	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-8.27	4.01e-16	1.35e-13	-0.27	-0.25	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	8.27	4.01e-16	1.35e-13	0.25	0.25	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
BRCA	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	8.27	4.01e-16	1.35e-13	0.3	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
BRCA	cis	rs853679	1	rs853694	ENSG00000220721.1	OR1F12	8.27	4.02e-16	1.35e-13	0.39	0.25	Depression;	chr6:28311323	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	8.27	4.02e-16	1.35e-13	0.26	0.25	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
BRCA	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	8.27	4.02e-16	1.35e-13	0.26	0.25	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
BRCA	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-8.27	4.03e-16	1.36e-13	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
BRCA	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-8.27	4.03e-16	1.36e-13	-0.3	-0.25	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-8.27	4.03e-16	1.36e-13	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	8.27	4.03e-16	1.36e-13	0.24	0.25	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.894	rs778143	ENSG00000271889.1	RP11-493E12.1	8.27	4.03e-16	1.36e-13	0.32	0.25	Tuberculosis;	chr2:61354755	chr2:61151433~61162105:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66692349	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66693433	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66694214	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66701371	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66702658	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66706390	chr7:66902857~66906297:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66710076	chr7:66902857~66906297:+
BRCA	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	8.27	4.07e-16	1.37e-13	0.23	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
BRCA	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.27	4.07e-16	1.37e-13	-0.28	-0.25	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.27	4.07e-16	1.37e-13	-0.29	-0.25	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
BRCA	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	8.27	4.07e-16	1.37e-13	0.26	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
BRCA	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-8.27	4.08e-16	1.37e-13	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
BRCA	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	8.27	4.08e-16	1.37e-13	0.33	0.25	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.929	rs2593627	ENSG00000271889.1	RP11-493E12.1	-8.27	4.1e-16	1.38e-13	-0.32	-0.25	Tuberculosis;	chr2:61391439	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	8.27	4.1e-16	1.38e-13	0.3	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
BRCA	cis	rs67981189	0.529	rs17093738	ENSG00000269927.1	RP6-91H8.3	8.27	4.11e-16	1.38e-13	0.33	0.25	Schizophrenia;	chr14:71119931	chr14:71141125~71143253:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
BRCA	cis	rs250518	0.926	rs3846650	ENSG00000272081.1	CTD-2376I4.2	8.27	4.13e-16	1.39e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72768560	chr5:72955206~72955699:-
BRCA	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	8.27	4.13e-16	1.39e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	8.27	4.13e-16	1.39e-13	0.29	0.25	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-8.27	4.13e-16	1.39e-13	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
BRCA	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	8.27	4.15e-16	1.39e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
BRCA	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	8.27	4.15e-16	1.39e-13	0.23	0.25	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-8.27	4.15e-16	1.4e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	8.27	4.16e-16	1.4e-13	0.26	0.25	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	8.27	4.16e-16	1.4e-13	0.26	0.25	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-8.27	4.17e-16	1.4e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.722	rs2927747	ENSG00000267422.1	CTD-2554C21.1	8.27	4.18e-16	1.4e-13	0.37	0.25	Coronary artery calcification;	chr19:37668629	chr19:37779686~37792865:+
BRCA	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-8.27	4.18e-16	1.41e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
BRCA	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	8.27	4.19e-16	1.41e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
BRCA	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-8.27	4.21e-16	1.41e-13	-0.27	-0.25	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
BRCA	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-8.27	4.21e-16	1.41e-13	-0.31	-0.25	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000226816.2	AC005082.12	8.26	4.22e-16	1.42e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23206013~23208045:+
BRCA	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	8.26	4.22e-16	1.42e-13	0.25	0.25	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
BRCA	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	8.26	4.22e-16	1.42e-13	0.36	0.25	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs13271966	ENSG00000253893.2	FAM85B	-8.26	4.22e-16	1.42e-13	-0.35	-0.25	Obesity-related traits;	chr8:8717962	chr8:8167819~8226614:-
BRCA	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-8.26	4.23e-16	1.42e-13	-0.32	-0.25	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
BRCA	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.23e-16	1.42e-13	-0.3	-0.25	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
BRCA	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	8.26	4.23e-16	1.42e-13	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
BRCA	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-8.26	4.23e-16	1.42e-13	-0.27	-0.25	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
BRCA	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-8.26	4.23e-16	1.42e-13	-0.25	-0.25	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-8.26	4.25e-16	1.43e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
BRCA	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	8.26	4.26e-16	1.43e-13	0.28	0.25	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
BRCA	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-8.26	4.26e-16	1.43e-13	-0.34	-0.25	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.26	4.27e-16	1.43e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
BRCA	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-8.26	4.28e-16	1.44e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-8.26	4.28e-16	1.44e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-8.26	4.29e-16	1.44e-13	-0.34	-0.25	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
BRCA	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-8.26	4.3e-16	1.44e-13	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
BRCA	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	8.26	4.3e-16	1.44e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	8.26	4.3e-16	1.44e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
BRCA	cis	rs58873874	0.737	rs78832945	ENSG00000248544.2	CTB-47B11.3	8.26	4.3e-16	1.44e-13	0.57	0.25	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157375741~157384950:-
BRCA	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-8.26	4.31e-16	1.45e-13	-0.29	-0.25	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	8.26	4.32e-16	1.45e-13	0.26	0.25	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
BRCA	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-8.26	4.33e-16	1.45e-13	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	8.26	4.34e-16	1.46e-13	0.26	0.25	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
BRCA	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-8.26	4.34e-16	1.46e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
BRCA	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	8.26	4.35e-16	1.46e-13	0.3	0.25	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-8.26	4.35e-16	1.46e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	8.26	4.35e-16	1.46e-13	0.29	0.25	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	8.26	4.37e-16	1.47e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	8.26	4.37e-16	1.47e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-8.26	4.37e-16	1.47e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-8.26	4.38e-16	1.47e-13	-0.2	-0.25	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
BRCA	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.26	4.39e-16	1.47e-13	0.27	0.25	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
BRCA	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-8.26	4.4e-16	1.47e-13	-0.32	-0.25	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
BRCA	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	8.26	4.4e-16	1.47e-13	0.23	0.25	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
BRCA	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
BRCA	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.42e-16	1.48e-13	-0.31	-0.25	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
BRCA	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	8.26	4.44e-16	1.49e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
BRCA	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	8.26	4.46e-16	1.49e-13	0.24	0.25	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-8.26	4.46e-16	1.49e-13	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
BRCA	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-8.26	4.49e-16	1.5e-13	-0.32	-0.25	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
BRCA	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	8.26	4.49e-16	1.5e-13	0.27	0.25	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
BRCA	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	8.26	4.49e-16	1.5e-13	0.27	0.25	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
BRCA	cis	rs6545883	0.894	rs2600660	ENSG00000271889.1	RP11-493E12.1	-8.26	4.49e-16	1.5e-13	-0.32	-0.25	Tuberculosis;	chr2:61322465	chr2:61151433~61162105:-
BRCA	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-8.26	4.5e-16	1.51e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	8.26	4.51e-16	1.51e-13	0.3	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.51e-16	1.51e-13	-0.31	-0.25	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
BRCA	cis	rs58873874	0.737	rs11745566	ENSG00000248544.2	CTB-47B11.3	8.26	4.52e-16	1.51e-13	0.59	0.25	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157375741~157384950:-
BRCA	cis	rs250518	0.926	rs34749191	ENSG00000272081.1	CTD-2376I4.2	8.26	4.53e-16	1.52e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72749431	chr5:72955206~72955699:-
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	8.26	4.54e-16	1.52e-13	0.24	0.25	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	8.26	4.54e-16	1.52e-13	0.24	0.25	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
BRCA	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	8.25	4.57e-16	1.53e-13	0.31	0.25	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
BRCA	cis	rs858239	0.676	rs3807459	ENSG00000226816.2	AC005082.12	8.25	4.59e-16	1.54e-13	0.28	0.25	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-8.25	4.6e-16	1.54e-13	-0.23	-0.25	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
BRCA	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-8.25	4.62e-16	1.54e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-8.25	4.62e-16	1.54e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	8.25	4.63e-16	1.55e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	8.25	4.63e-16	1.55e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.25	4.63e-16	1.55e-13	0.33	0.25	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
BRCA	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	8.25	4.64e-16	1.55e-13	0.31	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-8.25	4.64e-16	1.55e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	8.25	4.65e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	8.25	4.65e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-8.25	4.66e-16	1.56e-13	-0.3	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
BRCA	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-8.25	4.67e-16	1.56e-13	-0.24	-0.25	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-8.25	4.71e-16	1.57e-13	-0.34	-0.25	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-8.25	4.71e-16	1.57e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
BRCA	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.25	4.71e-16	1.57e-13	0.33	0.25	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
BRCA	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-8.25	4.71e-16	1.57e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
BRCA	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	8.25	4.72e-16	1.58e-13	0.31	0.25	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
BRCA	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	8.25	4.72e-16	1.58e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
BRCA	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-8.25	4.73e-16	1.58e-13	-0.33	-0.25	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
BRCA	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	8.25	4.73e-16	1.58e-13	0.27	0.25	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-8.25	4.74e-16	1.58e-13	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
BRCA	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-8.25	4.74e-16	1.58e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-8.25	4.74e-16	1.58e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-8.25	4.74e-16	1.58e-13	-0.32	-0.25	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	8.25	4.74e-16	1.58e-13	0.21	0.25	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
BRCA	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	8.25	4.75e-16	1.59e-13	0.23	0.25	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
BRCA	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-8.25	4.75e-16	1.59e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	8.25	4.75e-16	1.59e-13	0.24	0.25	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	8.25	4.77e-16	1.59e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-8.25	4.78e-16	1.6e-13	-0.28	-0.25	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-8.25	4.79e-16	1.6e-13	-0.24	-0.25	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	8.25	4.79e-16	1.6e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-8.25	4.8e-16	1.6e-13	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
BRCA	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-8.25	4.81e-16	1.6e-13	-0.33	-0.25	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	8.25	4.81e-16	1.61e-13	0.24	0.25	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	8.25	4.81e-16	1.61e-13	0.24	0.25	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	8.25	4.82e-16	1.61e-13	0.26	0.25	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-8.25	4.83e-16	1.61e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	8.25	4.84e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	8.25	4.84e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	8.25	4.85e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.894	rs6545867	ENSG00000271889.1	RP11-493E12.1	-8.25	4.85e-16	1.62e-13	-0.32	-0.25	Tuberculosis;	chr2:61423892	chr2:61151433~61162105:-
BRCA	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-8.25	4.86e-16	1.62e-13	-0.21	-0.25	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-8.25	4.87e-16	1.62e-13	-0.26	-0.25	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-8.25	4.87e-16	1.63e-13	-0.3	-0.25	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	8.25	4.88e-16	1.63e-13	0.26	0.25	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
BRCA	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	8.25	4.88e-16	1.63e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
BRCA	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-8.25	4.88e-16	1.63e-13	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
BRCA	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	8.25	4.89e-16	1.63e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
BRCA	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	8.25	4.9e-16	1.63e-13	0.26	0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
BRCA	cis	rs6545883	0.894	rs4672436	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376222	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.859	rs35760550	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376730	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.859	rs62149714	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376734	chr2:61151433~61162105:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-8.25	4.9e-16	1.63e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
BRCA	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-8.25	4.9e-16	1.63e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
BRCA	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	8.25	4.92e-16	1.64e-13	0.3	0.25	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	8.24	4.95e-16	1.65e-13	0.32	0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
BRCA	cis	rs7246657	0.722	rs2972458	ENSG00000267422.1	CTD-2554C21.1	8.24	4.95e-16	1.65e-13	0.37	0.25	Coronary artery calcification;	chr19:37644502	chr19:37779686~37792865:+
BRCA	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-8.24	4.96e-16	1.65e-13	-0.36	-0.25	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
BRCA	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	8.24	4.98e-16	1.66e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
BRCA	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	8.24	4.99e-16	1.66e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-8.24	5e-16	1.67e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
BRCA	cis	rs11023332	0.706	rs10766197	ENSG00000251991.1	RNU7-49P	8.24	5.01e-16	1.67e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	8.24	5.02e-16	1.67e-13	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
BRCA	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	8.24	5.02e-16	1.67e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	8.24	5.02e-16	1.67e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
BRCA	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-8.24	5.03e-16	1.68e-13	-0.31	-0.25	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
BRCA	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	8.24	5.05e-16	1.68e-13	0.32	0.25	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
BRCA	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	8.24	5.06e-16	1.68e-13	0.42	0.25	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
BRCA	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	8.24	5.07e-16	1.69e-13	0.31	0.25	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
BRCA	cis	rs853679	1	rs68141011	ENSG00000220721.1	OR1F12	8.24	5.07e-16	1.69e-13	0.4	0.25	Depression;	chr6:28250019	chr6:28073316~28074233:+
BRCA	cis	rs853679	1	rs13200462	ENSG00000220721.1	OR1F12	8.24	5.07e-16	1.69e-13	0.4	0.25	Depression;	chr6:28250421	chr6:28073316~28074233:+
BRCA	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	8.24	5.08e-16	1.69e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	8.24	5.08e-16	1.69e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	8.24	5.08e-16	1.69e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
BRCA	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	8.24	5.09e-16	1.69e-13	0.31	0.25	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
BRCA	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-8.24	5.09e-16	1.69e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000226816.2	AC005082.12	8.24	5.1e-16	1.7e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-8.24	5.12e-16	1.71e-13	-0.16	-0.25	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	8.24	5.13e-16	1.71e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.859	rs2694644	ENSG00000271889.1	RP11-493E12.1	-8.24	5.13e-16	1.71e-13	-0.32	-0.25	Tuberculosis;	chr2:61377721	chr2:61151433~61162105:-
BRCA	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	8.24	5.15e-16	1.71e-13	0.32	0.25	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
BRCA	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	8.24	5.15e-16	1.72e-13	0.25	0.25	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
BRCA	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	8.24	5.17e-16	1.72e-13	0.35	0.25	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
BRCA	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	8.24	5.17e-16	1.72e-13	0.35	0.25	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-8.24	5.18e-16	1.72e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
BRCA	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	8.24	5.19e-16	1.73e-13	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
BRCA	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-8.24	5.19e-16	1.73e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
BRCA	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-8.24	5.22e-16	1.74e-13	-0.34	-0.25	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
BRCA	cis	rs7085104	0.7	rs7096183	ENSG00000236937.2	PTGES3P4	8.24	5.24e-16	1.74e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102845595~102845950:+
BRCA	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	8.24	5.26e-16	1.75e-13	0.37	0.25	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
BRCA	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-8.24	5.27e-16	1.75e-13	-0.29	-0.25	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
BRCA	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	8.24	5.28e-16	1.75e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
BRCA	cis	rs13256369	1	rs10098234	ENSG00000253893.2	FAM85B	-8.24	5.28e-16	1.76e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719182	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	8.24	5.29e-16	1.76e-13	0.26	0.25	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-8.24	5.3e-16	1.76e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
BRCA	cis	rs6545883	0.929	rs1186711	ENSG00000271889.1	RP11-493E12.1	8.24	5.3e-16	1.76e-13	0.33	0.25	Tuberculosis;	chr2:61461370	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	8.24	5.32e-16	1.77e-13	0.27	0.25	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-8.23	5.34e-16	1.78e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	8.23	5.37e-16	1.78e-13	0.26	0.25	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	8.23	5.37e-16	1.79e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-8.23	5.38e-16	1.79e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-8.23	5.38e-16	1.79e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
BRCA	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-8.23	5.38e-16	1.79e-13	-0.35	-0.25	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
BRCA	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	8.23	5.38e-16	1.79e-13	0.33	0.25	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs10088439	ENSG00000253893.2	FAM85B	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719189	chr8:8167819~8226614:-
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
BRCA	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-8.23	5.4e-16	1.79e-13	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
BRCA	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	8.23	5.4e-16	1.79e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-8.23	5.4e-16	1.8e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-8.23	5.4e-16	1.8e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
BRCA	cis	rs7085104	0.684	rs7092690	ENSG00000236937.2	PTGES3P4	8.23	5.41e-16	1.8e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102845595~102845950:+
BRCA	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	8.23	5.41e-16	1.8e-13	0.33	0.25	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
BRCA	cis	rs58873874	0.737	rs12654973	ENSG00000251405.2	CTB-109A12.1	8.23	5.42e-16	1.8e-13	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.579	rs74804793	ENSG00000251405.2	CTB-109A12.1	8.23	5.42e-16	1.8e-13	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157362615~157460078:-
BRCA	cis	rs3758911	0.861	rs10749890	ENSG00000255353.1	RP11-382M14.1	-8.23	5.44e-16	1.81e-13	-0.34	-0.25	Coronary artery disease;	chr11:107278357	chr11:107176286~107177530:+
BRCA	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	8.23	5.48e-16	1.82e-13	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
BRCA	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-8.23	5.48e-16	1.82e-13	-0.38	-0.25	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
BRCA	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-8.23	5.5e-16	1.83e-13	-0.32	-0.25	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
BRCA	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-8.23	5.51e-16	1.83e-13	-0.3	-0.25	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
BRCA	cis	rs7085104	0.632	rs6162	ENSG00000213061.2	PFN1P11	8.23	5.51e-16	1.83e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102838011~102845473:-
BRCA	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-8.23	5.54e-16	1.84e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-8.23	5.54e-16	1.84e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
BRCA	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	8.23	5.58e-16	1.85e-13	0.31	0.25	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	8.23	5.6e-16	1.86e-13	0.22	0.25	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
BRCA	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	8.23	5.6e-16	1.86e-13	0.3	0.25	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
BRCA	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	8.23	5.63e-16	1.87e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
BRCA	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	8.23	5.64e-16	1.87e-13	0.33	0.25	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
BRCA	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-8.23	5.65e-16	1.87e-13	-0.3	-0.25	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
BRCA	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-8.23	5.65e-16	1.87e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-8.23	5.65e-16	1.87e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
BRCA	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-8.23	5.66e-16	1.88e-13	-0.31	-0.25	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
BRCA	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.23	5.67e-16	1.88e-13	-0.28	-0.25	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.23	5.67e-16	1.88e-13	-0.28	-0.25	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
BRCA	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	8.23	5.68e-16	1.88e-13	0.27	0.25	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
BRCA	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	8.23	5.69e-16	1.89e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
BRCA	cis	rs250518	0.926	rs34426717	ENSG00000272081.1	CTD-2376I4.2	8.23	5.69e-16	1.89e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72752640	chr5:72955206~72955699:-
BRCA	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	8.23	5.71e-16	1.89e-13	0.31	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
BRCA	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	8.23	5.72e-16	1.9e-13	0.37	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
BRCA	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	8.23	5.73e-16	1.9e-13	0.36	0.25	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
BRCA	cis	rs42648	0.869	rs12374728	ENSG00000225498.1	AC002064.5	8.23	5.74e-16	1.9e-13	0.24	0.25	Homocysteine levels;	chr7:90312570	chr7:90312496~90322592:+
BRCA	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
BRCA	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	8.23	5.75e-16	1.91e-13	0.35	0.25	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
BRCA	cis	rs202072	0.72	rs4602719	ENSG00000272379.1	RP1-257A7.5	8.23	5.76e-16	1.91e-13	0.44	0.25	HIV-1 viral setpoint;	chr6:13295270	chr6:13290018~13290490:-
BRCA	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	8.23	5.76e-16	1.91e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	8.23	5.76e-16	1.91e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
BRCA	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-8.22	5.77e-16	1.91e-13	-0.55	-0.25	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	8.22	5.78e-16	1.91e-13	0.34	0.25	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-8.22	5.79e-16	1.92e-13	-0.35	-0.25	Gout;	chr7:66715944	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.929	rs1209434	ENSG00000271889.1	RP11-493E12.1	8.22	5.8e-16	1.92e-13	0.32	0.25	Tuberculosis;	chr2:61445823	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-8.22	5.81e-16	1.92e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
BRCA	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	8.22	5.81e-16	1.92e-13	0.31	0.25	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
BRCA	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-8.22	5.83e-16	1.93e-13	-0.3	-0.25	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	8.22	5.85e-16	1.94e-13	0.25	0.25	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-8.22	5.87e-16	1.94e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	8.22	5.88e-16	1.95e-13	0.32	0.25	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	8.22	5.88e-16	1.95e-13	0.27	0.25	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
BRCA	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-8.22	5.89e-16	1.95e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000164669.11	INTS4P1	8.22	5.89e-16	1.95e-13	0.35	0.25	Aortic root size;	chr7:66100789	chr7:65141225~65234216:+
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000226816.2	AC005082.12	8.22	5.92e-16	1.96e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23206013~23208045:+
BRCA	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	8.22	5.95e-16	1.97e-13	0.32	0.25	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
BRCA	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-8.22	5.97e-16	1.97e-13	-0.34	-0.25	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
BRCA	cis	rs6545883	0.929	rs1186707	ENSG00000271889.1	RP11-493E12.1	8.22	5.97e-16	1.97e-13	0.32	0.25	Tuberculosis;	chr2:61446385	chr2:61151433~61162105:-
BRCA	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	8.22	5.98e-16	1.98e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-8.22	5.98e-16	1.98e-13	-0.16	-0.25	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
BRCA	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-8.22	5.99e-16	1.98e-13	-0.3	-0.25	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
BRCA	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-8.22	5.99e-16	1.98e-13	-0.26	-0.25	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
BRCA	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-8.22	6e-16	1.98e-13	-0.3	-0.25	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
BRCA	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-8.22	6.01e-16	1.99e-13	-0.26	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
BRCA	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	8.22	6.02e-16	1.99e-13	0.31	0.25	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
BRCA	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	8.22	6.02e-16	1.99e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
BRCA	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-8.22	6.04e-16	2e-13	-0.31	-0.25	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
BRCA	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	8.22	6.05e-16	2e-13	0.29	0.25	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	8.22	6.06e-16	2e-13	0.37	0.25	Depression;	chr6:28431469	chr6:28943877~28944537:+
BRCA	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	8.22	6.1e-16	2.01e-13	0.42	0.25	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
BRCA	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-8.22	6.11e-16	2.02e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
BRCA	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	8.22	6.13e-16	2.02e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
BRCA	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	8.22	6.13e-16	2.03e-13	0.25	0.25	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	8.22	6.13e-16	2.03e-13	0.25	0.25	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
BRCA	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-8.22	6.16e-16	2.03e-13	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
BRCA	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.22	6.16e-16	2.03e-13	0.43	0.25	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.22	6.16e-16	2.03e-13	0.43	0.25	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
BRCA	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-8.22	6.17e-16	2.04e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	8.22	6.18e-16	2.04e-13	0.26	0.25	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	8.22	6.18e-16	2.04e-13	0.26	0.25	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
BRCA	cis	rs2028299	1	rs2351706	ENSG00000259677.1	RP11-493E3.1	8.22	6.18e-16	2.04e-13	0.33	0.25	Type 2 diabetes;	chr15:89840883	chr15:89876540~89877285:+
BRCA	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
BRCA	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	8.22	6.19e-16	2.04e-13	0.29	0.25	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
BRCA	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-8.22	6.19e-16	2.05e-13	-0.31	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
BRCA	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	8.22	6.21e-16	2.05e-13	0.27	0.25	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
BRCA	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	8.22	6.22e-16	2.06e-13	0.18	0.25	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	8.22	6.24e-16	2.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	8.21	6.24e-16	2.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
BRCA	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-8.21	6.26e-16	2.06e-13	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
BRCA	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	8.21	6.26e-16	2.06e-13	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-8.21	6.28e-16	2.07e-13	-0.33	-0.25	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	8.21	6.31e-16	2.08e-13	0.33	0.25	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	8.21	6.33e-16	2.09e-13	0.26	0.25	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.33e-16	2.09e-13	-0.3	-0.25	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.33e-16	2.09e-13	-0.3	-0.25	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	8.21	6.34e-16	2.09e-13	0.32	0.25	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	8.21	6.35e-16	2.1e-13	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	8.21	6.36e-16	2.1e-13	0.24	0.25	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	8.21	6.36e-16	2.1e-13	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
BRCA	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	8.21	6.37e-16	2.1e-13	0.37	0.25	Depression;	chr6:28430971	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	8.21	6.37e-16	2.1e-13	0.37	0.25	Depression;	chr6:28432562	chr6:28943877~28944537:+
BRCA	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	8.21	6.38e-16	2.1e-13	0.43	0.25	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	8.21	6.39e-16	2.11e-13	0.27	0.25	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	8.21	6.4e-16	2.11e-13	0.26	0.25	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
BRCA	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-8.21	6.41e-16	2.11e-13	-0.31	-0.25	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	8.21	6.42e-16	2.12e-13	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	8.21	6.43e-16	2.12e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
BRCA	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-8.21	6.45e-16	2.13e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
BRCA	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-8.21	6.46e-16	2.13e-13	-0.34	-0.25	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
BRCA	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-8.21	6.46e-16	2.13e-13	-0.24	-0.25	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	8.21	6.47e-16	2.13e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-8.21	6.48e-16	2.14e-13	-0.16	-0.25	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
BRCA	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	8.21	6.48e-16	2.14e-13	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
BRCA	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-8.21	6.48e-16	2.14e-13	-0.3	-0.25	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
BRCA	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-8.21	6.48e-16	2.14e-13	-0.31	-0.25	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
BRCA	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.48e-16	2.14e-13	-0.3	-0.25	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
BRCA	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-8.21	6.5e-16	2.14e-13	-0.34	-0.25	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
BRCA	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
BRCA	cis	rs4308124	0.708	rs6716091	ENSG00000230499.1	AC108463.1	-8.21	6.53e-16	2.15e-13	-0.31	-0.25	Vitiligo;	chr2:111233556	chr2:111195963~111206494:+
BRCA	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-8.21	6.53e-16	2.15e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
BRCA	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-8.21	6.54e-16	2.15e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
BRCA	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	8.21	6.56e-16	2.16e-13	0.46	0.25	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
BRCA	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-8.21	6.56e-16	2.16e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
BRCA	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-8.21	6.57e-16	2.16e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	8.21	6.57e-16	2.17e-13	0.26	0.25	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
BRCA	cis	rs250518	0.926	rs11953054	ENSG00000272081.1	CTD-2376I4.2	8.21	6.58e-16	2.17e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72746876	chr5:72955206~72955699:-
BRCA	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	8.21	6.59e-16	2.17e-13	0.33	0.25	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000222364.1	RNU6-96P	8.21	6.59e-16	2.17e-13	0.33	0.25	Aortic root size;	chr7:66646886	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.62e-16	2.18e-13	-0.31	-0.25	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-8.21	6.62e-16	2.18e-13	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	8.21	6.64e-16	2.19e-13	0.27	0.25	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	8.21	6.65e-16	2.19e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	8.21	6.65e-16	2.19e-13	0.24	0.25	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.722	rs2927739	ENSG00000267422.1	CTD-2554C21.1	8.21	6.68e-16	2.2e-13	0.36	0.25	Coronary artery calcification;	chr19:37658429	chr19:37779686~37792865:+
BRCA	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-8.21	6.7e-16	2.2e-13	-0.22	-0.25	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
BRCA	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	8.21	6.72e-16	2.21e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
BRCA	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	8.2	6.76e-16	2.22e-13	0.28	0.25	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
BRCA	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-8.2	6.77e-16	2.23e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-8.2	6.77e-16	2.23e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
BRCA	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-8.2	6.78e-16	2.23e-13	-0.28	-0.25	Longevity;	chr3:48360459	chr3:48256350~48256938:-
BRCA	cis	rs7246657	0.722	rs10402671	ENSG00000267422.1	CTD-2554C21.1	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37626185	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10417576	ENSG00000267422.1	CTD-2554C21.1	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37628311	chr19:37779686~37792865:+
BRCA	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
BRCA	cis	rs250518	0.926	rs4267846	ENSG00000272081.1	CTD-2376I4.2	8.2	6.84e-16	2.25e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72735617	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs2338788	ENSG00000272081.1	CTD-2376I4.2	8.2	6.84e-16	2.25e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72737690	chr5:72955206~72955699:-
BRCA	cis	rs7085104	0.552	rs11191414	ENSG00000213061.2	PFN1P11	8.2	6.85e-16	2.25e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102838011~102845473:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	8.2	6.86e-16	2.26e-13	0.25	0.25	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	8.2	6.87e-16	2.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	8.2	6.87e-16	2.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-8.2	6.87e-16	2.26e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
BRCA	cis	rs7085104	0.7	rs10786712	ENSG00000236937.2	PTGES3P4	-8.2	6.88e-16	2.26e-13	-0.31	-0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102845595~102845950:+
BRCA	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-8.2	6.88e-16	2.26e-13	-0.25	-0.25	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
BRCA	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-8.2	6.91e-16	2.27e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
BRCA	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	8.2	6.91e-16	2.27e-13	0.25	0.25	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	8.2	6.92e-16	2.27e-13	0.24	0.25	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	8.2	6.92e-16	2.27e-13	0.24	0.25	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
BRCA	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-8.2	6.92e-16	2.27e-13	-0.35	-0.25	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
BRCA	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-8.2	6.93e-16	2.28e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
BRCA	cis	rs6539288	0.803	rs7305715	ENSG00000260329.1	RP11-412D9.4	-8.2	6.94e-16	2.28e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106932774	chr12:106954029~106955497:-
BRCA	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-8.2	6.95e-16	2.28e-13	-0.3	-0.25	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-8.2	6.95e-16	2.28e-13	-0.3	-0.25	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.826	rs2694651	ENSG00000271889.1	RP11-493E12.1	-8.2	6.95e-16	2.28e-13	-0.32	-0.25	Tuberculosis;	chr2:61361507	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	8.2	6.96e-16	2.29e-13	0.31	0.25	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	8.2	6.96e-16	2.29e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
BRCA	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-8.2	6.97e-16	2.29e-13	-0.27	-0.25	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
BRCA	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-8.2	6.97e-16	2.29e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
BRCA	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-8.2	6.99e-16	2.3e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
BRCA	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	8.2	7e-16	2.3e-13	0.32	0.25	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-8.2	7.03e-16	2.31e-13	-0.31	-0.25	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
BRCA	cis	rs748404	1	rs17779494	ENSG00000249839.1	AC011330.5	8.2	7.05e-16	2.32e-13	0.35	0.25	Lung cancer;	chr15:43287025	chr15:43663654~43684339:-
BRCA	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-8.2	7.08e-16	2.32e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
BRCA	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-8.2	7.09e-16	2.33e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
BRCA	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-8.2	7.12e-16	2.34e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	8.2	7.13e-16	2.34e-13	0.31	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
BRCA	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	8.2	7.14e-16	2.34e-13	0.26	0.25	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
BRCA	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-8.2	7.15e-16	2.35e-13	-0.29	-0.25	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	8.2	7.17e-16	2.35e-13	0.34	0.25	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
BRCA	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	8.2	7.17e-16	2.36e-13	0.36	0.25	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-8.2	7.18e-16	2.36e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
BRCA	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-8.2	7.19e-16	2.36e-13	-0.21	-0.25	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
BRCA	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	8.2	7.21e-16	2.37e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
BRCA	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-8.2	7.21e-16	2.37e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-8.2	7.22e-16	2.37e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-8.2	7.22e-16	2.37e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
BRCA	cis	rs3758911	0.861	rs10890689	ENSG00000255353.1	RP11-382M14.1	-8.2	7.26e-16	2.38e-13	-0.34	-0.25	Coronary artery disease;	chr11:107275626	chr11:107176286~107177530:+
BRCA	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	8.2	7.27e-16	2.38e-13	0.28	0.25	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
BRCA	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-8.2	7.28e-16	2.39e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-8.2	7.28e-16	2.39e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
BRCA	cis	rs2028299	1	rs3960018	ENSG00000259677.1	RP11-493E3.1	8.19	7.3e-16	2.39e-13	0.33	0.25	Type 2 diabetes;	chr15:89840075	chr15:89876540~89877285:+
BRCA	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-8.19	7.34e-16	2.41e-13	-0.31	-0.25	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
BRCA	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	8.19	7.34e-16	2.41e-13	0.21	0.25	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
BRCA	cis	rs6545883	0.894	rs12615783	ENSG00000271889.1	RP11-493E12.1	-8.19	7.35e-16	2.41e-13	-0.32	-0.25	Tuberculosis;	chr2:61213812	chr2:61151433~61162105:-
BRCA	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.19	7.35e-16	2.41e-13	0.42	0.25	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
BRCA	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	8.19	7.4e-16	2.43e-13	0.24	0.25	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	8.19	7.42e-16	2.43e-13	0.25	0.25	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
BRCA	cis	rs3758911	0.861	rs11212116	ENSG00000255353.1	RP11-382M14.1	-8.19	7.43e-16	2.44e-13	-0.34	-0.25	Coronary artery disease;	chr11:107276621	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	8.19	7.43e-16	2.44e-13	0.24	0.25	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-8.19	7.45e-16	2.44e-13	-0.3	-0.25	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
BRCA	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	8.19	7.45e-16	2.44e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
BRCA	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	8.19	7.46e-16	2.45e-13	0.3	0.25	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
BRCA	cis	rs2993535	1	rs1586660	ENSG00000233626.2	RP11-565J7.1	8.19	7.48e-16	2.45e-13	0.52	0.25	Hip circumference adjusted for BMI;	chr1:212093189	chr1:211936249~211936634:+
BRCA	cis	rs3758911	0.861	rs11212114	ENSG00000255353.1	RP11-382M14.1	8.19	7.51e-16	2.46e-13	0.33	0.25	Coronary artery disease;	chr11:107274940	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-8.19	7.52e-16	2.47e-13	-0.29	-0.25	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	8.19	7.55e-16	2.47e-13	0.25	0.25	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	8.19	7.56e-16	2.48e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	8.19	7.57e-16	2.48e-13	0.34	0.25	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	8.19	7.59e-16	2.49e-13	0.23	0.25	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	8.19	7.59e-16	2.49e-13	0.35	0.25	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
BRCA	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	8.19	7.59e-16	2.49e-13	0.3	0.25	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	8.19	7.64e-16	2.5e-13	0.25	0.25	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
BRCA	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-8.19	7.65e-16	2.5e-13	-0.27	-0.25	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
BRCA	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-8.19	7.65e-16	2.51e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
BRCA	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	8.19	7.66e-16	2.51e-13	0.31	0.25	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
BRCA	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-8.19	7.7e-16	2.52e-13	-0.25	-0.25	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	8.19	7.71e-16	2.52e-13	0.25	0.25	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
BRCA	cis	rs42648	0.869	rs12704518	ENSG00000225498.1	AC002064.5	8.19	7.71e-16	2.53e-13	0.24	0.25	Homocysteine levels;	chr7:90285074	chr7:90312496~90322592:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	8.19	7.73e-16	2.53e-13	0.25	0.25	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.948	rs9820621	ENSG00000239213.4	NCK1-AS1	8.19	7.73e-16	2.53e-13	0.33	0.25	Height;Body mass index;	chr3:136391671	chr3:136841726~136862054:-
BRCA	cis	rs7246657	0.722	rs10409605	ENSG00000267422.1	CTD-2554C21.1	-8.19	7.74e-16	2.53e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37632236	chr19:37779686~37792865:+
BRCA	cis	rs250518	0.926	rs3846644	ENSG00000272081.1	CTD-2376I4.2	8.19	7.74e-16	2.53e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72727276	chr5:72955206~72955699:-
BRCA	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	8.19	7.75e-16	2.54e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
BRCA	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-8.19	7.78e-16	2.55e-13	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
BRCA	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	8.19	7.78e-16	2.55e-13	0.25	0.25	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
BRCA	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
BRCA	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-8.19	7.83e-16	2.56e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
BRCA	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-8.18	7.89e-16	2.58e-13	-0.34	-0.25	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
BRCA	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	8.18	7.92e-16	2.59e-13	0.31	0.25	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
BRCA	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	8.18	7.92e-16	2.59e-13	0.27	0.25	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-8.18	7.92e-16	2.59e-13	-0.35	-0.25	Gout;	chr7:66732812	chr7:66902857~66906297:+
BRCA	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	8.18	7.96e-16	2.6e-13	0.23	0.25	Breast size;	chr12:9232939	chr12:9277235~9313241:+
BRCA	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-8.18	7.99e-16	2.61e-13	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
BRCA	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-8.18	8e-16	2.62e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	8.18	8e-16	2.62e-13	0.25	0.25	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
BRCA	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	8.18	8.02e-16	2.62e-13	0.32	0.25	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
BRCA	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-8.18	8.06e-16	2.63e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-8.18	8.06e-16	2.63e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
BRCA	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-8.18	8.07e-16	2.64e-13	-0.28	-0.25	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
BRCA	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	8.18	8.07e-16	2.64e-13	0.45	0.25	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
BRCA	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-8.18	8.07e-16	2.64e-13	-0.28	-0.25	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
BRCA	cis	rs42648	0.869	rs1015402	ENSG00000225498.1	AC002064.5	8.18	8.08e-16	2.64e-13	0.24	0.25	Homocysteine levels;	chr7:90283955	chr7:90312496~90322592:+
BRCA	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	8.18	8.09e-16	2.64e-13	0.21	0.25	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
BRCA	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-8.18	8.11e-16	2.65e-13	-0.22	-0.25	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
BRCA	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	8.18	8.11e-16	2.65e-13	0.44	0.25	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
BRCA	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-8.18	8.14e-16	2.66e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
BRCA	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	8.18	8.15e-16	2.66e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
BRCA	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	8.18	8.15e-16	2.66e-13	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
BRCA	cis	rs202072	0.72	rs454563	ENSG00000272379.1	RP1-257A7.5	8.18	8.2e-16	2.68e-13	0.43	0.25	HIV-1 viral setpoint;	chr6:13295304	chr6:13290018~13290490:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	8.18	8.2e-16	2.68e-13	0.26	0.25	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-8.18	8.21e-16	2.68e-13	-0.33	-0.25	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
BRCA	cis	rs58873874	0.737	rs78565801	ENSG00000248544.2	CTB-47B11.3	8.18	8.22e-16	2.69e-13	0.61	0.25	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs79951742	ENSG00000248544.2	CTB-47B11.3	8.18	8.22e-16	2.69e-13	0.61	0.25	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157375741~157384950:-
BRCA	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-8.18	8.22e-16	2.69e-13	-0.3	-0.25	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
BRCA	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-8.18	8.24e-16	2.69e-13	-0.32	-0.25	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
BRCA	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	8.18	8.25e-16	2.69e-13	0.39	0.25	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
BRCA	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	8.18	8.25e-16	2.69e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
BRCA	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	8.18	8.26e-16	2.7e-13	0.3	0.25	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
BRCA	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	8.18	8.28e-16	2.7e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	8.18	8.29e-16	2.71e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
BRCA	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	8.18	8.29e-16	2.71e-13	0.39	0.25	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
BRCA	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	8.18	8.3e-16	2.71e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
BRCA	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-8.18	8.3e-16	2.71e-13	-0.27	-0.25	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
BRCA	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	8.18	8.31e-16	2.71e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
BRCA	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	8.18	8.34e-16	2.72e-13	0.26	0.25	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-8.18	8.34e-16	2.72e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
BRCA	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	8.18	8.35e-16	2.73e-13	0.3	0.25	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
BRCA	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	8.18	8.4e-16	2.74e-13	0.35	0.25	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs66629206	ENSG00000249839.1	AC011330.5	-8.18	8.43e-16	2.75e-13	-0.37	-0.25	Lung cancer;	chr15:43458804	chr15:43663654~43684339:-
BRCA	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
BRCA	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-8.18	8.45e-16	2.76e-13	-0.3	-0.25	Migraine;	chr4:56852087	chr4:56960927~56961373:-
BRCA	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	8.18	8.47e-16	2.76e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-8.18	8.51e-16	2.78e-13	-0.24	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-8.18	8.52e-16	2.78e-13	-0.16	-0.25	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
BRCA	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	8.17	8.55e-16	2.79e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
BRCA	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-8.17	8.56e-16	2.79e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
BRCA	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	8.17	8.57e-16	2.8e-13	0.28	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.558	rs56043821	ENSG00000269927.1	RP6-91H8.3	8.17	8.6e-16	2.8e-13	0.33	0.25	Schizophrenia;	chr14:71103835	chr14:71141125~71143253:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	8.17	8.6e-16	2.8e-13	0.36	0.25	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	8.17	8.65e-16	2.82e-13	0.21	0.25	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.645	rs2956024	ENSG00000253983.2	RP1-16A9.1	8.17	8.65e-16	2.82e-13	0.34	0.25	Uterine fibroids;	chr8:74191465	chr8:74199396~74208441:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
BRCA	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-8.17	8.68e-16	2.83e-13	-0.32	-0.25	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
BRCA	cis	rs6545883	0.86	rs6749226	ENSG00000271889.1	RP11-493E12.1	-8.17	8.69e-16	2.83e-13	-0.32	-0.25	Tuberculosis;	chr2:61282648	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	8.17	8.7e-16	2.84e-13	0.38	0.25	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
BRCA	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-8.17	8.7e-16	2.84e-13	-0.29	-0.25	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
BRCA	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-8.17	8.72e-16	2.84e-13	-0.31	-0.25	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-8.17	8.74e-16	2.85e-13	-0.16	-0.25	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
BRCA	cis	rs4237845	1	rs4237845	ENSG00000257159.1	RP11-58A17.3	-8.17	8.74e-16	2.85e-13	-0.28	-0.25	Intelligence (multi-trait analysis);	chr12:57908653	chr12:57967058~57968399:+
BRCA	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-8.17	8.75e-16	2.85e-13	-0.3	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
BRCA	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	8.17	8.76e-16	2.86e-13	0.35	0.25	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	8.17	8.76e-16	2.86e-13	0.35	0.25	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	8.17	8.78e-16	2.86e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
BRCA	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	8.17	8.79e-16	2.86e-13	0.33	0.25	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	8.17	8.79e-16	2.86e-13	0.33	0.25	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-8.17	8.79e-16	2.87e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-8.17	8.79e-16	2.87e-13	-0.28	-0.25	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
BRCA	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-8.17	8.81e-16	2.87e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-8.17	8.81e-16	2.87e-13	-0.32	-0.25	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-8.17	8.81e-16	2.87e-13	-0.32	-0.25	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
BRCA	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-8.17	8.81e-16	2.87e-13	-0.34	-0.25	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
BRCA	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.17	8.84e-16	2.88e-13	-0.28	-0.25	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
BRCA	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	8.17	8.85e-16	2.88e-13	0.32	0.25	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	8.17	8.85e-16	2.88e-13	0.32	0.25	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
BRCA	cis	rs3758911	0.861	rs10890692	ENSG00000255353.1	RP11-382M14.1	-8.17	8.86e-16	2.89e-13	-0.33	-0.25	Coronary artery disease;	chr11:107277053	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-8.17	8.89e-16	2.9e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
BRCA	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-8.17	8.89e-16	2.9e-13	-0.31	-0.25	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
BRCA	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-8.17	8.91e-16	2.9e-13	-0.3	-0.25	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
BRCA	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-8.17	8.95e-16	2.91e-13	-0.33	-0.25	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	8.17	8.95e-16	2.92e-13	0.25	0.25	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000220721.1	OR1F12	8.17	8.96e-16	2.92e-13	0.46	0.25	Depression;	chr6:28223052	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000220721.1	OR1F12	8.17	8.96e-16	2.92e-13	0.46	0.25	Depression;	chr6:28223279	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.674	rs4964494	ENSG00000260329.1	RP11-412D9.4	-8.17	8.96e-16	2.92e-13	-0.26	-0.25	Total body bone mineral density;	chr12:106890682	chr12:106954029~106955497:-
BRCA	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	8.17	8.97e-16	2.92e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
BRCA	cis	rs6545883	0.894	rs778157	ENSG00000271889.1	RP11-493E12.1	8.17	8.98e-16	2.92e-13	0.31	0.25	Tuberculosis;	chr2:61327154	chr2:61151433~61162105:-
BRCA	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-8.17	8.98e-16	2.93e-13	-0.31	-0.25	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
BRCA	cis	rs7085104	0.632	rs7097872	ENSG00000213061.2	PFN1P11	8.17	9.01e-16	2.93e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102838011~102845473:-
BRCA	cis	rs13256369	1	rs12547721	ENSG00000253893.2	FAM85B	-8.17	9.03e-16	2.94e-13	-0.34	-0.25	Obesity-related traits;	chr8:8713161	chr8:8167819~8226614:-
BRCA	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	8.17	9.04e-16	2.94e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	8.17	9.07e-16	2.95e-13	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
BRCA	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	8.17	9.08e-16	2.95e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
BRCA	cis	rs42648	0.869	rs1015404	ENSG00000225498.1	AC002064.5	8.17	9.14e-16	2.97e-13	0.23	0.25	Homocysteine levels;	chr7:90284632	chr7:90312496~90322592:+
BRCA	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	8.17	9.14e-16	2.97e-13	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	8.17	9.16e-16	2.98e-13	0.41	0.25	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
BRCA	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-8.17	9.16e-16	2.98e-13	-0.24	-0.25	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	8.17	9.18e-16	2.99e-13	0.25	0.25	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.825	rs4672426	ENSG00000271889.1	RP11-493E12.1	-8.17	9.2e-16	2.99e-13	-0.31	-0.25	Tuberculosis;	chr2:61230013	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.86	rs4671399	ENSG00000271889.1	RP11-493E12.1	-8.17	9.2e-16	2.99e-13	-0.31	-0.25	Tuberculosis;	chr2:61231383	chr2:61151433~61162105:-
BRCA	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8.17	9.21e-16	3e-13	0.27	0.25	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
BRCA	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	8.16	9.22e-16	3e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
BRCA	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	8.16	9.24e-16	3.01e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
BRCA	cis	rs7085104	0.7	rs743572	ENSG00000236937.2	PTGES3P4	8.16	9.29e-16	3.02e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102845595~102845950:+
BRCA	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	8.16	9.29e-16	3.02e-13	0.25	0.25	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	8.16	9.29e-16	3.02e-13	0.25	0.25	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	8.16	9.29e-16	3.02e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
BRCA	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	8.16	9.32e-16	3.03e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	8.16	9.34e-16	3.04e-13	0.25	0.25	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
BRCA	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-8.16	9.35e-16	3.04e-13	-0.28	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
BRCA	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-8.16	9.36e-16	3.04e-13	-0.27	-0.25	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	8.16	9.4e-16	3.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
BRCA	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	8.16	9.44e-16	3.07e-13	0.3	0.25	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	8.16	9.44e-16	3.07e-13	0.3	0.25	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
BRCA	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	8.16	9.45e-16	3.07e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
BRCA	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	8.16	9.46e-16	3.08e-13	0.26	0.25	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
BRCA	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	8.16	9.48e-16	3.08e-13	0.26	0.25	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
BRCA	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	8.16	9.5e-16	3.09e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
BRCA	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-8.16	9.5e-16	3.09e-13	-0.29	-0.25	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
BRCA	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	8.16	9.52e-16	3.09e-13	0.25	0.25	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
BRCA	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-8.16	9.53e-16	3.09e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
BRCA	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	8.16	9.58e-16	3.11e-13	0.34	0.25	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
BRCA	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	8.16	9.63e-16	3.13e-13	0.25	0.25	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
BRCA	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-8.16	9.64e-16	3.13e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
BRCA	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-8.16	9.66e-16	3.14e-13	-0.34	-0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
BRCA	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-8.16	9.69e-16	3.15e-13	-0.29	-0.25	Migraine;	chr4:56850720	chr4:56960927~56961373:-
BRCA	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-8.16	9.69e-16	3.15e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	8.16	9.73e-16	3.16e-13	0.3	0.25	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
BRCA	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	8.16	9.73e-16	3.16e-13	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
BRCA	cis	rs6545883	0.86	rs6545848	ENSG00000271889.1	RP11-493E12.1	-8.16	9.8e-16	3.18e-13	-0.31	-0.24	Tuberculosis;	chr2:61234048	chr2:61151433~61162105:-
BRCA	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-8.16	9.81e-16	3.19e-13	-0.29	-0.24	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
BRCA	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	8.16	9.85e-16	3.2e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
BRCA	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-8.16	9.86e-16	3.2e-13	-0.27	-0.24	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
BRCA	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-8.16	9.86e-16	3.2e-13	-0.27	-0.24	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.16	9.89e-16	3.21e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.16	9.89e-16	3.21e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
BRCA	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
BRCA	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	8.16	9.89e-16	3.21e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
BRCA	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-8.16	9.93e-16	3.22e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-8.16	9.94e-16	3.22e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
BRCA	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	8.15	9.97e-16	3.24e-13	0.36	0.24	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
BRCA	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-8.15	9.99e-16	3.24e-13	-0.34	-0.24	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
BRCA	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.15	1e-15	3.25e-13	0.39	0.24	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
BRCA	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	8.15	1e-15	3.25e-13	0.53	0.24	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
BRCA	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-8.15	1e-15	3.25e-13	-0.3	-0.24	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
BRCA	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-8.15	1e-15	3.25e-13	-0.34	-0.24	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
BRCA	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	8.15	1.01e-15	3.26e-13	0.32	0.24	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
BRCA	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	8.15	1.01e-15	3.26e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-8.15	1.01e-15	3.26e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
BRCA	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	8.15	1.01e-15	3.27e-13	0.32	0.24	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
BRCA	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	8.15	1.01e-15	3.27e-13	0.29	0.24	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
BRCA	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-8.15	1.01e-15	3.28e-13	-0.33	-0.24	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
BRCA	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	8.15	1.02e-15	3.29e-13	0.31	0.24	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
BRCA	cis	rs3758911	0.828	rs10890701	ENSG00000255353.1	RP11-382M14.1	-8.15	1.02e-15	3.3e-13	-0.33	-0.24	Coronary artery disease;	chr11:107309216	chr11:107176286~107177530:+
BRCA	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-8.15	1.02e-15	3.31e-13	-0.3	-0.24	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-8.15	1.02e-15	3.31e-13	-0.3	-0.24	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
BRCA	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	8.15	1.02e-15	3.31e-13	0.36	0.24	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
BRCA	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	8.15	1.02e-15	3.31e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-8.15	1.03e-15	3.33e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-8.15	1.03e-15	3.33e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
BRCA	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-8.15	1.03e-15	3.35e-13	-0.3	-0.24	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
BRCA	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-8.15	1.03e-15	3.35e-13	-0.32	-0.24	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
BRCA	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	8.15	1.03e-15	3.35e-13	0.3	0.24	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	8.15	1.04e-15	3.37e-13	0.24	0.24	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
BRCA	cis	rs250518	0.926	rs7723498	ENSG00000272081.1	CTD-2376I4.2	8.15	1.04e-15	3.38e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72791470	chr5:72955206~72955699:-
BRCA	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	8.15	1.04e-15	3.38e-13	0.27	0.24	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
BRCA	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-8.15	1.04e-15	3.38e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-8.15	1.04e-15	3.38e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
BRCA	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-8.15	1.05e-15	3.39e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
BRCA	cis	rs6539288	0.901	rs4964505	ENSG00000260329.1	RP11-412D9.4	-8.15	1.05e-15	3.4e-13	-0.28	-0.24	Total body bone mineral density;	chr12:106948062	chr12:106954029~106955497:-
BRCA	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-8.15	1.05e-15	3.41e-13	-0.3	-0.24	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.894	rs2694632	ENSG00000271889.1	RP11-493E12.1	-8.15	1.06e-15	3.42e-13	-0.31	-0.24	Tuberculosis;	chr2:61331547	chr2:61151433~61162105:-
BRCA	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	8.15	1.06e-15	3.42e-13	0.27	0.24	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
BRCA	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	8.15	1.06e-15	3.42e-13	0.32	0.24	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	8.15	1.06e-15	3.43e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.15	1.06e-15	3.43e-13	-0.33	-0.24	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-8.15	1.06e-15	3.44e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
BRCA	cis	rs6472827	0.645	rs2956052	ENSG00000253983.2	RP1-16A9.1	8.15	1.06e-15	3.44e-13	0.34	0.24	Uterine fibroids;	chr8:74200423	chr8:74199396~74208441:+
BRCA	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-8.15	1.07e-15	3.45e-13	-0.36	-0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
BRCA	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	8.15	1.07e-15	3.45e-13	0.33	0.24	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
BRCA	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-8.15	1.07e-15	3.45e-13	-0.3	-0.24	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-8.15	1.07e-15	3.45e-13	-0.3	-0.24	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-8.15	1.07e-15	3.46e-13	-0.16	-0.24	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	8.15	1.07e-15	3.46e-13	0.25	0.24	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	8.15	1.07e-15	3.46e-13	0.25	0.24	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
BRCA	cis	rs853679	1	rs853679	ENSG00000220721.1	OR1F12	8.15	1.07e-15	3.46e-13	0.38	0.24	Depression;	chr6:28329086	chr6:28073316~28074233:+
BRCA	cis	rs853679	1	rs853678	ENSG00000220721.1	OR1F12	8.15	1.07e-15	3.46e-13	0.38	0.24	Depression;	chr6:28329536	chr6:28073316~28074233:+
BRCA	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	8.14	1.08e-15	3.5e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	8.14	1.08e-15	3.5e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.894	rs6709441	ENSG00000271889.1	RP11-493E12.1	-8.14	1.08e-15	3.5e-13	-0.32	-0.24	Tuberculosis;	chr2:61209795	chr2:61151433~61162105:-
BRCA	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-8.14	1.08e-15	3.51e-13	-0.29	-0.24	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
BRCA	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	8.14	1.08e-15	3.51e-13	0.3	0.24	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-8.14	1.08e-15	3.51e-13	-0.3	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
BRCA	cis	rs58873874	0.579	rs35536103	ENSG00000251405.2	CTB-109A12.1	8.14	1.09e-15	3.51e-13	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157362615~157460078:-
BRCA	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-8.14	1.09e-15	3.52e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	8.14	1.09e-15	3.53e-13	0.26	0.24	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
BRCA	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	8.14	1.1e-15	3.54e-13	0.34	0.24	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
BRCA	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-8.14	1.1e-15	3.54e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
BRCA	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-8.14	1.1e-15	3.55e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
BRCA	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-8.14	1.1e-15	3.57e-13	-0.28	-0.24	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
BRCA	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	8.14	1.11e-15	3.57e-13	0.34	0.24	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-8.14	1.11e-15	3.58e-13	-0.3	-0.24	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-8.14	1.11e-15	3.58e-13	-0.3	-0.24	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
BRCA	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	8.14	1.11e-15	3.58e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	8.14	1.11e-15	3.58e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
BRCA	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-8.14	1.11e-15	3.59e-13	-0.3	-0.24	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	8.14	1.12e-15	3.61e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
BRCA	cis	rs6472827	0.645	rs1532577	ENSG00000253983.2	RP1-16A9.1	8.14	1.12e-15	3.61e-13	0.34	0.24	Uterine fibroids;	chr8:74193907	chr8:74199396~74208441:+
BRCA	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	8.14	1.12e-15	3.62e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	8.14	1.12e-15	3.62e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	8.14	1.12e-15	3.62e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	8.14	1.12e-15	3.62e-13	0.25	0.24	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
BRCA	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-8.14	1.12e-15	3.63e-13	-0.28	-0.24	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
BRCA	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-8.14	1.13e-15	3.64e-13	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
BRCA	cis	rs6545883	0.929	rs2264100	ENSG00000271889.1	RP11-493E12.1	8.14	1.13e-15	3.64e-13	0.32	0.24	Tuberculosis;	chr2:61443694	chr2:61151433~61162105:-
BRCA	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	8.14	1.13e-15	3.64e-13	0.32	0.24	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-8.14	1.14e-15	3.67e-13	-0.3	-0.24	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
BRCA	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	8.14	1.14e-15	3.67e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	8.14	1.14e-15	3.67e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-8.14	1.14e-15	3.68e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
BRCA	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-8.14	1.14e-15	3.68e-13	-0.3	-0.24	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	8.14	1.14e-15	3.69e-13	0.17	0.24	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
BRCA	cis	rs6545883	0.895	rs2256617	ENSG00000271889.1	RP11-493E12.1	8.14	1.14e-15	3.69e-13	0.32	0.24	Tuberculosis;	chr2:61452789	chr2:61151433~61162105:-
BRCA	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	8.14	1.15e-15	3.7e-13	0.31	0.24	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
BRCA	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	8.14	1.15e-15	3.7e-13	0.33	0.24	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs4840351	ENSG00000253893.2	FAM85B	-8.14	1.15e-15	3.7e-13	-0.34	-0.24	Obesity-related traits;	chr8:8715638	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	8.14	1.15e-15	3.72e-13	0.25	0.24	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-8.14	1.15e-15	3.72e-13	-0.3	-0.24	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	8.14	1.15e-15	3.72e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	8.13	1.17e-15	3.76e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
BRCA	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-8.13	1.17e-15	3.77e-13	-0.29	-0.24	Migraine;	chr4:56851192	chr4:56960927~56961373:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-8.13	1.17e-15	3.78e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	8.13	1.17e-15	3.78e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-8.13	1.18e-15	3.79e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.602	rs11125871	ENSG00000271889.1	RP11-493E12.1	-8.13	1.18e-15	3.8e-13	-0.31	-0.24	Tuberculosis;	chr2:61242991	chr2:61151433~61162105:-
BRCA	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-8.13	1.18e-15	3.8e-13	-0.31	-0.24	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	8.13	1.18e-15	3.81e-13	0.29	0.24	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	8.13	1.18e-15	3.82e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-8.13	1.18e-15	3.82e-13	-0.39	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.894	rs6739427	ENSG00000271889.1	RP11-493E12.1	-8.13	1.19e-15	3.83e-13	-0.31	-0.24	Tuberculosis;	chr2:61225744	chr2:61151433~61162105:-
BRCA	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-8.13	1.19e-15	3.83e-13	-0.29	-0.24	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	8.13	1.19e-15	3.84e-13	0.33	0.24	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
BRCA	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-8.13	1.2e-15	3.85e-13	-0.28	-0.24	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-8.13	1.2e-15	3.86e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
BRCA	cis	rs42648	0.869	rs42611	ENSG00000225498.1	AC002064.5	8.13	1.2e-15	3.87e-13	0.23	0.24	Homocysteine levels;	chr7:90320746	chr7:90312496~90322592:+
BRCA	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-8.13	1.2e-15	3.87e-13	-0.35	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
BRCA	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	8.13	1.2e-15	3.88e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	8.13	1.21e-15	3.88e-13	0.34	0.24	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
BRCA	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.13	1.21e-15	3.89e-13	-0.36	-0.24	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	8.13	1.21e-15	3.89e-13	0.33	0.24	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-8.13	1.21e-15	3.91e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
BRCA	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-8.13	1.22e-15	3.92e-13	-0.34	-0.24	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-8.13	1.22e-15	3.92e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
BRCA	cis	rs6545883	0.86	rs777589	ENSG00000271889.1	RP11-493E12.1	8.13	1.22e-15	3.92e-13	0.31	0.24	Tuberculosis;	chr2:61198486	chr2:61151433~61162105:-
BRCA	cis	rs7246657	0.722	rs16958861	ENSG00000267422.1	CTD-2554C21.1	-8.13	1.22e-15	3.93e-13	-0.36	-0.24	Coronary artery calcification;	chr19:37633278	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000222364.1	RNU6-96P	-8.13	1.22e-15	3.94e-13	-0.29	-0.24	Aortic root size;	chr7:65960907	chr7:66395191~66395286:+
BRCA	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-8.13	1.23e-15	3.96e-13	-0.31	-0.24	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
BRCA	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-8.13	1.23e-15	3.97e-13	-0.29	-0.24	Height;	chr2:46627225	chr2:46668870~46670778:+
BRCA	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-8.13	1.24e-15	3.98e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000222364.1	RNU6-96P	8.13	1.24e-15	3.99e-13	0.33	0.24	Aortic root size;	chr7:66645977	chr7:66395191~66395286:+
BRCA	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	8.13	1.25e-15	4.01e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
BRCA	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-8.13	1.25e-15	4.04e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-8.13	1.25e-15	4.04e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
BRCA	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
BRCA	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	8.13	1.26e-15	4.05e-13	0.38	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
BRCA	cis	rs13256369	1	rs10095733	ENSG00000253893.2	FAM85B	-8.12	1.26e-15	4.05e-13	-0.34	-0.24	Obesity-related traits;	chr8:8717136	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	8.12	1.26e-15	4.06e-13	0.35	0.24	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
BRCA	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	8.12	1.26e-15	4.06e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	8.12	1.26e-15	4.06e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
BRCA	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	8.12	1.27e-15	4.08e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
BRCA	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	8.12	1.27e-15	4.09e-13	0.32	0.24	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-8.12	1.27e-15	4.1e-13	-0.49	-0.24	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
BRCA	cis	rs9880211	0.528	rs75685279	ENSG00000273486.1	RP11-731C17.2	8.12	1.27e-15	4.1e-13	0.3	0.24	Height;Body mass index;	chr3:136715991	chr3:136837338~136839021:-
BRCA	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	8.12	1.28e-15	4.1e-13	0.29	0.24	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
BRCA	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-8.12	1.28e-15	4.1e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-8.12	1.28e-15	4.13e-13	-0.32	-0.24	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
BRCA	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	8.12	1.28e-15	4.13e-13	0.27	0.24	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
BRCA	cis	rs8012947	0.565	rs7151036	ENSG00000279636.2	LINC00216	8.12	1.29e-15	4.13e-13	0.25	0.24	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58288033~58289158:+
BRCA	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	8.12	1.29e-15	4.14e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
BRCA	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	8.12	1.29e-15	4.14e-13	0.3	0.24	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
BRCA	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-8.12	1.29e-15	4.14e-13	-0.55	-0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
BRCA	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	8.12	1.29e-15	4.14e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
BRCA	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	8.12	1.29e-15	4.14e-13	0.29	0.24	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
BRCA	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	8.12	1.29e-15	4.14e-13	0.33	0.24	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
BRCA	cis	rs853679	1	rs853685	ENSG00000220721.1	OR1F12	8.12	1.29e-15	4.14e-13	0.38	0.24	Depression;	chr6:28321008	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-8.12	1.29e-15	4.14e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	8.12	1.3e-15	4.17e-13	0.25	0.24	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-8.12	1.3e-15	4.17e-13	-0.29	-0.24	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
BRCA	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	8.12	1.3e-15	4.17e-13	0.32	0.24	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
BRCA	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-8.12	1.3e-15	4.18e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
BRCA	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	8.12	1.31e-15	4.2e-13	0.49	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
BRCA	cis	rs8062405	1	rs7187776	ENSG00000278665.1	RP11-666O2.4	8.12	1.31e-15	4.2e-13	0.25	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28599241~28601881:-
BRCA	cis	rs58873874	0.737	rs78738433	ENSG00000248544.2	CTB-47B11.3	8.12	1.31e-15	4.21e-13	0.59	0.24	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-8.12	1.31e-15	4.22e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
BRCA	cis	rs7580658	0.521	rs7605733	ENSG00000236682.1	AC068282.3	-8.12	1.31e-15	4.22e-13	-0.32	-0.24	Protein C levels;	chr2:127174211	chr2:127389130~127400580:+
BRCA	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	8.12	1.31e-15	4.22e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
BRCA	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-8.12	1.31e-15	4.22e-13	-0.37	-0.24	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
BRCA	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	8.12	1.31e-15	4.22e-13	0.31	0.24	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
BRCA	cis	rs853679	1	rs1679732	ENSG00000220721.1	OR1F12	-8.12	1.32e-15	4.23e-13	-0.38	-0.24	Depression;	chr6:28253486	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	8.12	1.32e-15	4.23e-13	0.25	0.24	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
BRCA	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-8.12	1.32e-15	4.23e-13	-0.33	-0.24	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
BRCA	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
BRCA	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-8.12	1.32e-15	4.24e-13	-0.3	-0.24	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	8.12	1.32e-15	4.25e-13	0.33	0.24	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
BRCA	cis	rs250518	0.926	rs3916445	ENSG00000272081.1	CTD-2376I4.2	8.12	1.33e-15	4.26e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72773821	chr5:72955206~72955699:-
BRCA	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	8.12	1.34e-15	4.3e-13	0.18	0.24	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
BRCA	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
BRCA	cis	rs3758911	0.861	rs10454489	ENSG00000255353.1	RP11-382M14.1	-8.12	1.35e-15	4.32e-13	-0.33	-0.24	Coronary artery disease;	chr11:107279206	chr11:107176286~107177530:+
BRCA	cis	rs6545883	0.825	rs7578139	ENSG00000271889.1	RP11-493E12.1	-8.12	1.35e-15	4.33e-13	-0.31	-0.24	Tuberculosis;	chr2:61336986	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-8.12	1.35e-15	4.34e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
BRCA	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-8.12	1.35e-15	4.34e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
BRCA	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	8.12	1.36e-15	4.35e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
BRCA	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-8.12	1.36e-15	4.36e-13	-0.34	-0.24	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	8.12	1.36e-15	4.36e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	8.12	1.36e-15	4.36e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	8.11	1.36e-15	4.36e-13	0.31	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
BRCA	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	8.11	1.37e-15	4.38e-13	0.31	0.24	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
BRCA	cis	rs6545883	0.929	rs3821222	ENSG00000271889.1	RP11-493E12.1	8.11	1.37e-15	4.39e-13	0.31	0.24	Tuberculosis;	chr2:61486391	chr2:61151433~61162105:-
BRCA	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-8.11	1.38e-15	4.42e-13	-0.32	-0.24	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
BRCA	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-8.11	1.38e-15	4.43e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-8.11	1.38e-15	4.43e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
BRCA	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	8.11	1.38e-15	4.44e-13	0.27	0.24	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
BRCA	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	8.11	1.39e-15	4.46e-13	0.3	0.24	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-8.11	1.4e-15	4.47e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.11	1.4e-15	4.49e-13	0.28	0.24	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	8.11	1.41e-15	4.51e-13	0.2	0.24	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.622	rs2956023	ENSG00000253983.2	RP1-16A9.1	8.11	1.41e-15	4.51e-13	0.33	0.24	Uterine fibroids;	chr8:74193978	chr8:74199396~74208441:+
BRCA	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-8.11	1.41e-15	4.53e-13	-0.27	-0.24	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-8.11	1.42e-15	4.53e-13	-0.3	-0.24	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
BRCA	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-8.11	1.42e-15	4.54e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
BRCA	cis	rs4308124	0.708	rs6747657	ENSG00000230499.1	AC108463.1	-8.11	1.42e-15	4.54e-13	-0.3	-0.24	Vitiligo;	chr2:111245586	chr2:111195963~111206494:+
BRCA	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	8.11	1.42e-15	4.54e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
BRCA	cis	rs6472827	0.645	rs2956058	ENSG00000253983.2	RP1-16A9.1	8.11	1.42e-15	4.55e-13	0.33	0.24	Uterine fibroids;	chr8:74197824	chr8:74199396~74208441:+
BRCA	cis	rs3758911	0.861	rs10890690	ENSG00000255353.1	RP11-382M14.1	-8.11	1.42e-15	4.55e-13	-0.33	-0.24	Coronary artery disease;	chr11:107276174	chr11:107176286~107177530:+
BRCA	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-8.11	1.42e-15	4.56e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-8.11	1.42e-15	4.56e-13	-0.29	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	8.11	1.43e-15	4.57e-13	0.33	0.24	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	8.11	1.43e-15	4.57e-13	0.34	0.24	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
BRCA	cis	rs2041895	0.509	rs12368448	ENSG00000260329.1	RP11-412D9.4	8.11	1.43e-15	4.59e-13	0.3	0.24	Glaucoma (low intraocular pressure);	chr12:106923018	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	8.11	1.43e-15	4.59e-13	0.25	0.24	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
BRCA	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-8.11	1.44e-15	4.6e-13	-0.25	-0.24	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
BRCA	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	8.11	1.44e-15	4.6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
BRCA	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	8.11	1.44e-15	4.62e-13	0.32	0.24	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	8.11	1.44e-15	4.62e-13	0.26	0.24	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
BRCA	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-8.11	1.45e-15	4.66e-13	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
BRCA	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	8.11	1.46e-15	4.66e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	8.11	1.46e-15	4.68e-13	0.24	0.24	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	8.11	1.46e-15	4.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	8.11	1.46e-15	4.68e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.894	rs2694649	ENSG00000271889.1	RP11-493E12.1	-8.11	1.47e-15	4.69e-13	-0.31	-0.24	Tuberculosis;	chr2:61346691	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	8.1	1.48e-15	4.72e-13	0.32	0.24	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	8.1	1.48e-15	4.73e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-8.1	1.48e-15	4.73e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-8.1	1.48e-15	4.73e-13	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.722	rs3101746	ENSG00000267422.1	CTD-2554C21.1	8.1	1.48e-15	4.74e-13	0.36	0.24	Coronary artery calcification;	chr19:37655499	chr19:37779686~37792865:+
BRCA	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	8.1	1.49e-15	4.76e-13	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	8.1	1.49e-15	4.76e-13	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
BRCA	cis	rs250518	0.926	rs6452683	ENSG00000272081.1	CTD-2376I4.2	8.1	1.49e-15	4.77e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72787076	chr5:72955206~72955699:-
BRCA	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-8.1	1.51e-15	4.81e-13	-0.3	-0.24	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
BRCA	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	8.1	1.51e-15	4.82e-13	0.3	0.24	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
BRCA	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	8.1	1.51e-15	4.83e-13	0.21	0.24	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
BRCA	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-8.1	1.51e-15	4.83e-13	-0.35	-0.24	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-8.1	1.51e-15	4.84e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
BRCA	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-8.1	1.51e-15	4.84e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
BRCA	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	8.1	1.52e-15	4.85e-13	0.34	0.24	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
BRCA	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	8.1	1.52e-15	4.85e-13	0.3	0.24	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
BRCA	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-8.1	1.52e-15	4.85e-13	-0.31	-0.24	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
BRCA	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.1	1.52e-15	4.85e-13	0.43	0.24	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
BRCA	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	8.1	1.52e-15	4.86e-13	0.32	0.24	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	8.1	1.52e-15	4.87e-13	0.26	0.24	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
BRCA	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	8.1	1.53e-15	4.88e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	8.1	1.53e-15	4.88e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	8.1	1.54e-15	4.91e-13	0.25	0.24	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
BRCA	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-8.1	1.54e-15	4.91e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000222364.1	RNU6-96P	8.1	1.54e-15	4.92e-13	0.32	0.24	Aortic root size;	chr7:66100789	chr7:66395191~66395286:+
BRCA	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-8.1	1.54e-15	4.92e-13	-0.34	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.894	rs2694642	ENSG00000271889.1	RP11-493E12.1	-8.1	1.54e-15	4.93e-13	-0.32	-0.24	Tuberculosis;	chr2:61369045	chr2:61151433~61162105:-
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	8.1	1.55e-15	4.94e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
BRCA	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	8.1	1.55e-15	4.94e-13	0.32	0.24	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
BRCA	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	8.1	1.55e-15	4.96e-13	0.3	0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-8.1	1.55e-15	4.97e-13	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.97e-13	0.24	0.24	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	8.1	1.56e-15	4.97e-13	0.35	0.24	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.98e-13	0.25	0.24	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
BRCA	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
BRCA	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.99e-13	0.23	0.24	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
BRCA	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-8.1	1.57e-15	5.01e-13	-0.3	-0.24	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
BRCA	cis	rs2028299	1	rs2351707	ENSG00000259677.1	RP11-493E3.1	8.1	1.57e-15	5.02e-13	0.33	0.24	Type 2 diabetes;	chr15:89840813	chr15:89876540~89877285:+
BRCA	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-8.1	1.57e-15	5.02e-13	-0.26	-0.24	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
BRCA	cis	rs6545883	0.894	rs9677047	ENSG00000271889.1	RP11-493E12.1	-8.1	1.58e-15	5.03e-13	-0.32	-0.24	Tuberculosis;	chr2:61358160	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	8.1	1.58e-15	5.03e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
BRCA	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	8.1	1.58e-15	5.03e-13	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
BRCA	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	8.1	1.58e-15	5.03e-13	0.38	0.24	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
BRCA	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-8.1	1.58e-15	5.04e-13	-0.32	-0.24	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
BRCA	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	8.09	1.59e-15	5.06e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-8.09	1.59e-15	5.07e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
BRCA	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	8.09	1.59e-15	5.08e-13	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-8.09	1.59e-15	5.08e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-8.09	1.59e-15	5.08e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	8.09	1.59e-15	5.09e-13	0.24	0.24	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
BRCA	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	8.09	1.6e-15	5.09e-13	0.41	0.24	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
BRCA	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.09	1.6e-15	5.09e-13	0.31	0.24	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
BRCA	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	8.09	1.6e-15	5.09e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
BRCA	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-8.09	1.6e-15	5.1e-13	-0.35	-0.24	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
BRCA	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.13e-13	-0.3	-0.24	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
BRCA	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	8.09	1.61e-15	5.13e-13	0.22	0.24	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
BRCA	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.13e-13	-0.29	-0.24	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
BRCA	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
BRCA	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.14e-13	-0.3	-0.24	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
BRCA	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	8.09	1.61e-15	5.14e-13	0.29	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
BRCA	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-8.09	1.62e-15	5.17e-13	-0.21	-0.24	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
BRCA	cis	rs9880211	0.898	rs9870825	ENSG00000239213.4	NCK1-AS1	8.09	1.63e-15	5.18e-13	0.32	0.24	Height;Body mass index;	chr3:136346878	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	8.09	1.64e-15	5.22e-13	0.32	0.24	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-8.09	1.65e-15	5.26e-13	-0.16	-0.24	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
BRCA	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-8.09	1.65e-15	5.26e-13	-0.29	-0.24	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
BRCA	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-8.09	1.65e-15	5.26e-13	-0.3	-0.24	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
BRCA	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-8.09	1.65e-15	5.27e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
BRCA	cis	rs13256369	1	rs7820159	ENSG00000253893.2	FAM85B	-8.09	1.66e-15	5.29e-13	-0.35	-0.24	Obesity-related traits;	chr8:8718705	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-8.09	1.66e-15	5.29e-13	-0.26	-0.24	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	8.09	1.66e-15	5.29e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	8.09	1.66e-15	5.29e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-8.09	1.67e-15	5.31e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-8.09	1.67e-15	5.31e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
BRCA	cis	rs7586673	0.893	rs889925	ENSG00000235724.7	AC009299.2	-8.09	1.68e-15	5.34e-13	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161222785~161308303:-
BRCA	cis	rs7586673	0.93	rs2884364	ENSG00000235724.7	AC009299.2	-8.09	1.68e-15	5.34e-13	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161222785~161308303:-
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	8.09	1.68e-15	5.34e-13	0.23	0.24	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	8.09	1.68e-15	5.35e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	8.09	1.69e-15	5.37e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
BRCA	cis	rs755249	1	rs61779359	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.959	rs61781363	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39565160~39573203:+
BRCA	cis	rs755249	1	rs4660808	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39565160~39573203:+
BRCA	cis	rs755249	1	rs61781364	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39565160~39573203:+
BRCA	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	8.09	1.69e-15	5.38e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
BRCA	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-8.09	1.69e-15	5.38e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
BRCA	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	8.09	1.69e-15	5.39e-13	0.33	0.24	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
BRCA	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-8.09	1.69e-15	5.39e-13	-0.28	-0.24	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
BRCA	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	8.09	1.7e-15	5.42e-13	0.31	0.24	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
BRCA	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-8.09	1.71e-15	5.45e-13	-0.32	-0.24	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
BRCA	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.73e-15	5.49e-13	-0.3	-0.24	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	8.08	1.73e-15	5.49e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs6545845	ENSG00000271889.1	RP11-493E12.1	-8.08	1.73e-15	5.51e-13	-0.31	-0.24	Tuberculosis;	chr2:61209909	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000222364.1	RNU6-96P	8.08	1.74e-15	5.53e-13	0.32	0.24	Aortic root size;	chr7:66105323	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	8.08	1.74e-15	5.53e-13	0.23	0.24	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	8.08	1.74e-15	5.54e-13	0.35	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
BRCA	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-8.08	1.76e-15	5.58e-13	-0.27	-0.24	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-8.08	1.77e-15	5.63e-13	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	8.08	1.78e-15	5.67e-13	0.34	0.24	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	8.08	1.78e-15	5.67e-13	0.34	0.24	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	8.08	1.79e-15	5.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	8.08	1.79e-15	5.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
BRCA	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	8.08	1.79e-15	5.69e-13	0.24	0.24	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
BRCA	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.79e-15	5.7e-13	-0.3	-0.24	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
BRCA	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-8.08	1.8e-15	5.7e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
BRCA	cis	rs853679	1	rs9986596	ENSG00000220721.1	OR1F12	8.08	1.8e-15	5.71e-13	0.39	0.24	Depression;	chr6:28251883	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	8.08	1.8e-15	5.72e-13	0.34	0.24	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
BRCA	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	8.08	1.81e-15	5.75e-13	0.39	0.24	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
BRCA	cis	rs42648	0.869	rs42613	ENSG00000225498.1	AC002064.5	8.08	1.82e-15	5.77e-13	0.23	0.24	Homocysteine levels;	chr7:90320989	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs42615	ENSG00000225498.1	AC002064.5	8.08	1.82e-15	5.77e-13	0.23	0.24	Homocysteine levels;	chr7:90321187	chr7:90312496~90322592:+
BRCA	cis	rs7274963	0.685	rs56039768	ENSG00000236474.1	GCNT1P1	8.08	1.82e-15	5.77e-13	0.33	0.24	Body mass index;	chr20:18360253	chr20:18420160~18421454:-
BRCA	cis	rs748404	1	rs12911132	ENSG00000249839.1	AC011330.5	-8.08	1.82e-15	5.77e-13	-0.34	-0.24	Lung cancer;	chr15:43268238	chr15:43663654~43684339:-
BRCA	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-8.08	1.82e-15	5.78e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
BRCA	cis	rs7246657	0.722	rs2927742	ENSG00000267422.1	CTD-2554C21.1	8.08	1.83e-15	5.81e-13	0.36	0.24	Coronary artery calcification;	chr19:37642717	chr19:37779686~37792865:+
BRCA	cis	rs2028299	1	rs6496609	ENSG00000259677.1	RP11-493E3.1	8.08	1.83e-15	5.81e-13	0.33	0.24	Type 2 diabetes;	chr15:89836400	chr15:89876540~89877285:+
BRCA	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.83e-15	5.82e-13	-0.3	-0.24	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
BRCA	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-8.08	1.85e-15	5.86e-13	-0.5	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
BRCA	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	8.07	1.85e-15	5.87e-13	0.37	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
BRCA	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	8.07	1.85e-15	5.88e-13	0.29	0.24	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
BRCA	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-8.07	1.85e-15	5.88e-13	-0.29	-0.24	Height;	chr2:46631182	chr2:46668870~46670778:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	8.07	1.86e-15	5.89e-13	0.34	0.24	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	8.07	1.86e-15	5.89e-13	0.34	0.24	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000222364.1	RNU6-96P	8.07	1.86e-15	5.9e-13	0.32	0.24	Aortic root size;	chr7:66101095	chr7:66395191~66395286:+
BRCA	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-8.07	1.86e-15	5.9e-13	-0.32	-0.24	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
BRCA	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-8.07	1.86e-15	5.9e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
BRCA	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	8.07	1.87e-15	5.91e-13	0.35	0.24	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	8.07	1.87e-15	5.92e-13	0.32	0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
BRCA	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-8.07	1.87e-15	5.92e-13	-0.33	-0.24	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
BRCA	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	8.07	1.87e-15	5.93e-13	0.35	0.24	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
BRCA	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.87e-15	5.94e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
BRCA	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-8.07	1.87e-15	5.94e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
BRCA	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-8.07	1.87e-15	5.94e-13	-0.3	-0.24	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
BRCA	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.87e-15	5.94e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-8.07	1.88e-15	5.96e-13	-0.3	-0.24	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-8.07	1.88e-15	5.97e-13	-0.29	-0.24	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
BRCA	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	8.07	1.89e-15	6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
BRCA	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	8.07	1.89e-15	6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
BRCA	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-8.07	1.9e-15	6.01e-13	-0.29	-0.24	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
BRCA	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	8.07	1.9e-15	6.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	8.07	1.9e-15	6.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	8.07	1.9e-15	6.02e-13	0.16	0.24	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
BRCA	cis	rs6539288	0.745	rs2041895	ENSG00000260329.1	RP11-412D9.4	-8.07	1.9e-15	6.03e-13	-0.27	-0.24	Total body bone mineral density;	chr12:106956310	chr12:106954029~106955497:-
BRCA	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	8.07	1.91e-15	6.04e-13	0.31	0.24	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
BRCA	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.91e-15	6.04e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
BRCA	cis	rs853679	0.666	rs200956	ENSG00000220721.1	OR1F12	8.07	1.91e-15	6.04e-13	0.36	0.24	Depression;	chr6:27871968	chr6:28073316~28074233:+
BRCA	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-8.07	1.92e-15	6.07e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-8.07	1.92e-15	6.07e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
BRCA	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	8.07	1.92e-15	6.08e-13	0.36	0.24	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
BRCA	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.92e-15	6.08e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
BRCA	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	8.07	1.92e-15	6.09e-13	0.4	0.24	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
BRCA	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	8.07	1.93e-15	6.1e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
BRCA	cis	rs67981189	0.529	rs61990380	ENSG00000269927.1	RP6-91H8.3	8.07	1.93e-15	6.11e-13	0.32	0.24	Schizophrenia;	chr14:71005229	chr14:71141125~71143253:-
BRCA	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	8.07	1.93e-15	6.12e-13	0.36	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	8.07	1.94e-15	6.13e-13	0.25	0.24	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	8.07	1.94e-15	6.13e-13	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
BRCA	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-8.07	1.94e-15	6.14e-13	-0.29	-0.24	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
BRCA	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	8.07	1.94e-15	6.14e-13	0.42	0.24	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	8.07	1.94e-15	6.14e-13	0.42	0.24	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
BRCA	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	8.07	1.94e-15	6.15e-13	0.34	0.24	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
BRCA	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	8.07	1.95e-15	6.17e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.95e-15	6.18e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
BRCA	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	8.07	1.96e-15	6.19e-13	0.32	0.24	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-8.07	1.97e-15	6.22e-13	-0.3	-0.24	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
BRCA	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-8.07	1.97e-15	6.23e-13	-0.32	-0.24	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
BRCA	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-8.07	1.98e-15	6.25e-13	-0.29	-0.24	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-8.07	1.98e-15	6.25e-13	-0.29	-0.24	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	8.07	1.98e-15	6.27e-13	0.25	0.24	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
BRCA	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	8.07	1.98e-15	6.28e-13	0.28	0.24	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
BRCA	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	8.07	1.99e-15	6.28e-13	0.39	0.24	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
BRCA	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-8.07	1.99e-15	6.3e-13	-0.29	-0.24	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
BRCA	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	8.07	2e-15	6.31e-13	0.3	0.24	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-8.06	2e-15	6.33e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-8.06	2.02e-15	6.38e-13	-0.28	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
BRCA	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-8.06	2.04e-15	6.43e-13	-0.26	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
BRCA	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-8.06	2.05e-15	6.48e-13	-0.26	-0.24	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-8.06	2.06e-15	6.51e-13	-0.29	-0.24	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
BRCA	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	8.06	2.07e-15	6.55e-13	0.24	0.24	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
BRCA	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	8.06	2.07e-15	6.55e-13	0.32	0.24	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-8.06	2.08e-15	6.56e-13	-0.32	-0.24	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-8.06	2.08e-15	6.56e-13	-0.32	-0.24	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
BRCA	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	8.06	2.08e-15	6.56e-13	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
BRCA	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	8.06	2.08e-15	6.57e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
BRCA	cis	rs58873874	0.579	rs77042939	ENSG00000251405.2	CTB-109A12.1	8.06	2.08e-15	6.59e-13	0.56	0.24	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157362615~157460078:-
BRCA	cis	rs4934494	0.813	rs34928397	ENSG00000240996.1	RP11-80H5.7	-8.06	2.09e-15	6.61e-13	-0.32	-0.24	Red blood cell count;	chr10:89766842	chr10:89694295~89697928:-
BRCA	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-8.06	2.1e-15	6.63e-13	-0.34	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
BRCA	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	8.06	2.1e-15	6.64e-13	0.36	0.24	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
BRCA	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	8.06	2.11e-15	6.65e-13	0.31	0.24	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
BRCA	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-8.06	2.11e-15	6.65e-13	-0.29	-0.24	Height;	chr2:46615271	chr2:46668870~46670778:+
BRCA	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	8.06	2.11e-15	6.65e-13	0.31	0.24	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
BRCA	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	8.06	2.11e-15	6.66e-13	0.26	0.24	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
BRCA	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	8.06	2.11e-15	6.67e-13	0.31	0.24	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
BRCA	cis	rs2742234	0.91	rs2505505	ENSG00000273008.1	RP11-351D16.3	-8.06	2.12e-15	6.68e-13	-0.28	-0.24	Hirschsprung disease;	chr10:43152773	chr10:43136824~43138334:-
BRCA	cis	rs6545883	0.826	rs2694617	ENSG00000271889.1	RP11-493E12.1	-8.06	2.13e-15	6.71e-13	-0.31	-0.24	Tuberculosis;	chr2:61310079	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.637	rs7096169	ENSG00000213061.2	PFN1P11	8.06	2.13e-15	6.72e-13	0.32	0.24	Arsenic metabolism;	chr10:102858938	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	8.06	2.15e-15	6.79e-13	0.24	0.24	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	8.06	2.16e-15	6.81e-13	0.23	0.24	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	8.05	2.16e-15	6.82e-13	0.29	0.24	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
BRCA	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	8.05	2.17e-15	6.86e-13	0.38	0.24	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
BRCA	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-8.05	2.18e-15	6.88e-13	-0.31	-0.24	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
BRCA	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	8.05	2.18e-15	6.88e-13	0.32	0.24	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	8.05	2.18e-15	6.88e-13	0.31	0.24	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
BRCA	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-8.05	2.19e-15	6.89e-13	-0.29	-0.24	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
BRCA	cis	rs10971721	0.822	rs307673	ENSG00000260947.1	RP11-384P7.7	8.05	2.19e-15	6.91e-13	0.43	0.24	Body mass index;	chr9:33968821	chr9:33697459~33700986:+
BRCA	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	8.05	2.19e-15	6.92e-13	0.29	0.24	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
BRCA	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.05	2.19e-15	6.92e-13	-0.27	-0.24	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	8.05	2.2e-15	6.93e-13	0.26	0.24	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	8.05	2.2e-15	6.93e-13	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
BRCA	cis	rs7246657	0.678	rs2972446	ENSG00000267422.1	CTD-2554C21.1	8.05	2.22e-15	6.99e-13	0.36	0.24	Coronary artery calcification;	chr19:37638992	chr19:37779686~37792865:+
BRCA	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-8.05	2.22e-15	6.99e-13	-0.32	-0.24	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
BRCA	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	8.05	2.22e-15	7.01e-13	0.24	0.24	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	8.05	2.22e-15	7.01e-13	0.24	0.24	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
BRCA	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	8.05	2.22e-15	7.01e-13	0.33	0.24	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	8.05	2.22e-15	7.01e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
BRCA	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	8.05	2.22e-15	7.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
BRCA	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-8.05	2.22e-15	7.01e-13	-0.26	-0.24	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
BRCA	cis	rs755249	1	rs4660293	ENSG00000228060.1	RP11-69E11.8	8.05	2.22e-15	7.01e-13	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39565160~39573203:+
BRCA	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-8.05	2.24e-15	7.05e-13	-0.29	-0.24	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
BRCA	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	8.05	2.24e-15	7.07e-13	0.26	0.24	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
BRCA	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	8.05	2.24e-15	7.07e-13	0.31	0.24	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	8.05	2.24e-15	7.07e-13	0.31	0.24	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	8.05	2.25e-15	7.08e-13	0.32	0.24	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
BRCA	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	8.05	2.26e-15	7.11e-13	0.36	0.24	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
BRCA	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-8.05	2.26e-15	7.11e-13	-0.28	-0.24	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
BRCA	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	8.05	2.27e-15	7.14e-13	0.27	0.24	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
BRCA	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	8.05	2.27e-15	7.16e-13	0.33	0.24	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
BRCA	cis	rs7085104	0.7	rs6163	ENSG00000236937.2	PTGES3P4	8.05	2.28e-15	7.17e-13	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102845595~102845950:+
BRCA	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-8.05	2.28e-15	7.18e-13	-0.32	-0.24	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	8.05	2.28e-15	7.19e-13	0.22	0.24	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.964	rs10789601	ENSG00000255353.1	RP11-382M14.1	-8.05	2.29e-15	7.2e-13	-0.33	-0.24	Coronary artery disease;	chr11:107310693	chr11:107176286~107177530:+
BRCA	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	8.05	2.3e-15	7.25e-13	0.3	0.24	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
BRCA	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	8.05	2.31e-15	7.27e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
BRCA	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-8.05	2.31e-15	7.28e-13	-0.27	-0.24	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
BRCA	cis	rs3758911	1	rs10789618	ENSG00000255353.1	RP11-382M14.1	-8.05	2.32e-15	7.3e-13	-0.31	-0.24	Coronary artery disease;	chr11:107319003	chr11:107176286~107177530:+
BRCA	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-8.05	2.32e-15	7.3e-13	-0.33	-0.24	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
BRCA	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-8.05	2.32e-15	7.3e-13	-0.3	-0.24	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs2972447	ENSG00000267422.1	CTD-2554C21.1	8.05	2.33e-15	7.32e-13	0.36	0.24	Coronary artery calcification;	chr19:37638835	chr19:37779686~37792865:+
BRCA	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	8.04	2.34e-15	7.36e-13	0.32	0.24	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.894	rs2600672	ENSG00000271889.1	RP11-493E12.1	8.04	2.34e-15	7.37e-13	0.31	0.24	Tuberculosis;	chr2:61309605	chr2:61151433~61162105:-
BRCA	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-8.04	2.34e-15	7.37e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-8.04	2.35e-15	7.39e-13	-0.35	-0.24	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
BRCA	cis	rs73173548	0.502	rs12187348	ENSG00000247828.6	TMEM161B-AS1	8.04	2.36e-15	7.41e-13	0.32	0.24	Macular telangiectasia type 2;	chr5:88424724	chr5:88268895~88436685:+
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-8.04	2.36e-15	7.43e-13	-0.28	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
BRCA	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	8.04	2.37e-15	7.44e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.894	rs778158	ENSG00000271889.1	RP11-493E12.1	-8.04	2.37e-15	7.45e-13	-0.31	-0.24	Tuberculosis;	chr2:61328286	chr2:61151433~61162105:-
BRCA	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-8.04	2.37e-15	7.46e-13	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.859	rs13004855	ENSG00000271889.1	RP11-493E12.1	-8.04	2.38e-15	7.47e-13	-0.32	-0.24	Tuberculosis;	chr2:61277937	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-8.04	2.38e-15	7.47e-13	-0.33	-0.24	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-8.04	2.38e-15	7.47e-13	-0.33	-0.24	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-8.04	2.38e-15	7.48e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
BRCA	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	8.04	2.39e-15	7.5e-13	0.35	0.24	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000222364.1	RNU6-96P	8.04	2.39e-15	7.52e-13	0.32	0.24	Aortic root size;	chr7:66066855	chr7:66395191~66395286:+
BRCA	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-8.04	2.39e-15	7.52e-13	-0.3	-0.24	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
BRCA	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	8.04	2.4e-15	7.53e-13	0.29	0.24	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
BRCA	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	8.04	2.4e-15	7.54e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
BRCA	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-8.04	2.4e-15	7.54e-13	-0.26	-0.24	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
BRCA	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	8.04	2.41e-15	7.57e-13	0.32	0.24	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
BRCA	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	8.04	2.41e-15	7.58e-13	0.35	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
BRCA	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	8.04	2.41e-15	7.58e-13	0.37	0.24	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
BRCA	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-8.04	2.42e-15	7.61e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-8.04	2.43e-15	7.63e-13	-0.25	-0.24	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
BRCA	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	8.04	2.43e-15	7.64e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-8.04	2.43e-15	7.64e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
BRCA	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-8.04	2.44e-15	7.66e-13	-0.26	-0.24	Monocyte count;	chr11:307036	chr11:318640~325631:+
BRCA	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	8.04	2.44e-15	7.66e-13	0.32	0.24	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.894	rs7566035	ENSG00000271889.1	RP11-493E12.1	-8.04	2.44e-15	7.67e-13	-0.31	-0.24	Tuberculosis;	chr2:61293680	chr2:61151433~61162105:-
BRCA	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-8.04	2.45e-15	7.7e-13	-0.29	-0.24	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
BRCA	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-8.04	2.46e-15	7.71e-13	-0.25	-0.24	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
BRCA	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
BRCA	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	8.04	2.48e-15	7.77e-13	0.22	0.24	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
BRCA	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-8.04	2.48e-15	7.78e-13	-0.29	-0.24	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
BRCA	cis	rs853679	0.76	rs9393909	ENSG00000220721.1	OR1F12	-8.04	2.48e-15	7.78e-13	-0.35	-0.24	Depression;	chr6:28239422	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.722	rs12979640	ENSG00000267422.1	CTD-2554C21.1	8.04	2.49e-15	7.8e-13	0.36	0.24	Coronary artery calcification;	chr19:37688255	chr19:37779686~37792865:+
BRCA	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	8.04	2.49e-15	7.8e-13	0.3	0.24	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
BRCA	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-8.04	2.49e-15	7.81e-13	-0.29	-0.24	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-8.04	2.49e-15	7.81e-13	-0.29	-0.24	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
BRCA	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-8.04	2.5e-15	7.83e-13	-0.29	-0.24	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	8.04	2.51e-15	7.89e-13	0.25	0.24	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-8.04	2.52e-15	7.9e-13	-0.3	-0.24	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
BRCA	cis	rs858239	0.539	rs870476	ENSG00000226816.2	AC005082.12	8.03	2.53e-15	7.92e-13	0.28	0.24	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23206013~23208045:+
BRCA	cis	rs6545883	0.86	rs13023037	ENSG00000271889.1	RP11-493E12.1	-8.03	2.53e-15	7.92e-13	-0.31	-0.24	Tuberculosis;	chr2:61393854	chr2:61151433~61162105:-
BRCA	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-8.03	2.53e-15	7.94e-13	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
BRCA	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-8.03	2.53e-15	7.94e-13	-0.35	-0.24	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
BRCA	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-8.03	2.54e-15	7.96e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
BRCA	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.03	2.54e-15	7.97e-13	-0.27	-0.24	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.03	2.54e-15	7.97e-13	0.27	0.24	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
BRCA	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-8.03	2.54e-15	7.97e-13	-0.31	-0.24	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.03	2.55e-15	7.98e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.03	2.55e-15	7.98e-13	-0.22	-0.24	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-8.03	2.55e-15	8e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
BRCA	cis	rs73173548	0.502	rs10452479	ENSG00000247828.6	TMEM161B-AS1	8.03	2.55e-15	8e-13	0.31	0.24	Macular telangiectasia type 2;	chr5:88445131	chr5:88268895~88436685:+
BRCA	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	8.03	2.56e-15	8.03e-13	0.22	0.24	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
BRCA	cis	rs250518	0.926	rs6875670	ENSG00000272081.1	CTD-2376I4.2	8.03	2.58e-15	8.09e-13	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72785943	chr5:72955206~72955699:-
BRCA	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	8.03	2.59e-15	8.12e-13	0.26	0.24	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
BRCA	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	8.03	2.59e-15	8.13e-13	0.31	0.24	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
BRCA	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.03	2.6e-15	8.14e-13	-0.28	-0.24	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
BRCA	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-8.03	2.6e-15	8.14e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.894	rs778144	ENSG00000271889.1	RP11-493E12.1	-8.03	2.62e-15	8.22e-13	-0.31	-0.24	Tuberculosis;	chr2:61355993	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.738	rs73171756	ENSG00000247828.6	TMEM161B-AS1	8.03	2.63e-15	8.23e-13	0.31	0.24	Depressive symptoms;	chr5:88446454	chr5:88268895~88436685:+
BRCA	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	8.03	2.63e-15	8.24e-13	0.38	0.24	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
BRCA	cis	rs6472827	0.595	rs2977068	ENSG00000253983.2	RP1-16A9.1	8.03	2.63e-15	8.25e-13	0.33	0.24	Uterine fibroids;	chr8:74192817	chr8:74199396~74208441:+
BRCA	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	8.03	2.63e-15	8.25e-13	0.31	0.24	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
BRCA	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	8.03	2.64e-15	8.27e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
BRCA	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	8.03	2.64e-15	8.28e-13	0.37	0.24	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
BRCA	cis	rs58873874	0.579	rs56666304	ENSG00000251405.2	CTB-109A12.1	8.03	2.65e-15	8.29e-13	0.52	0.24	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-8.03	2.66e-15	8.31e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
BRCA	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-8.03	2.67e-15	8.35e-13	-0.31	-0.24	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
BRCA	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	8.03	2.67e-15	8.36e-13	0.29	0.24	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-8.03	2.67e-15	8.36e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
BRCA	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	8.03	2.68e-15	8.39e-13	0.31	0.24	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-8.03	2.69e-15	8.41e-13	-0.43	-0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-8.03	2.69e-15	8.42e-13	-0.16	-0.24	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
BRCA	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	8.03	2.69e-15	8.42e-13	0.31	0.24	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
BRCA	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	8.03	2.69e-15	8.42e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
BRCA	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	8.03	2.69e-15	8.42e-13	0.29	0.24	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
BRCA	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	8.03	2.69e-15	8.42e-13	0.29	0.24	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
BRCA	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	8.03	2.7e-15	8.45e-13	0.41	0.24	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
BRCA	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	8.03	2.71e-15	8.47e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
BRCA	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-8.03	2.71e-15	8.47e-13	-0.29	-0.24	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
BRCA	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	8.03	2.71e-15	8.48e-13	0.32	0.24	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	8.02	2.73e-15	8.52e-13	0.24	0.24	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
BRCA	cis	rs62246343	0.605	rs34665459	ENSG00000206573.7	THUMPD3-AS1	-8.02	2.73e-15	8.52e-13	-0.25	-0.24	Fibrinogen levels;	chr3:9423041	chr3:9349689~9398579:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-8.02	2.73e-15	8.53e-13	-0.34	-0.24	Gout;	chr7:66645053	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	8.02	2.73e-15	8.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
BRCA	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-8.02	2.73e-15	8.55e-13	-0.34	-0.24	Gout;	chr7:66661502	chr7:66902857~66906297:+
BRCA	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-8.02	2.74e-15	8.55e-13	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
BRCA	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	8.02	2.74e-15	8.57e-13	0.61	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.929	rs2593625	ENSG00000271889.1	RP11-493E12.1	8.02	2.74e-15	8.57e-13	0.32	0.24	Tuberculosis;	chr2:61441634	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-8.02	2.76e-15	8.61e-13	-0.33	-0.24	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
BRCA	cis	rs58873874	0.579	rs56666304	ENSG00000248544.2	CTB-47B11.3	8.02	2.77e-15	8.65e-13	0.48	0.24	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157375741~157384950:-
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-8.02	2.78e-15	8.69e-13	-0.29	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
BRCA	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	8.02	2.79e-15	8.71e-13	0.31	0.24	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
BRCA	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	8.02	2.79e-15	8.72e-13	0.3	0.24	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-8.02	2.8e-15	8.75e-13	-0.16	-0.24	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
BRCA	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	8.02	2.81e-15	8.77e-13	0.29	0.24	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
BRCA	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-8.02	2.82e-15	8.8e-13	-0.27	-0.24	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
BRCA	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	8.02	2.82e-15	8.81e-13	0.28	0.24	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
BRCA	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-8.02	2.83e-15	8.85e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
BRCA	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	8.02	2.84e-15	8.88e-13	0.51	0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
BRCA	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	8.02	2.85e-15	8.88e-13	0.27	0.24	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-8.02	2.85e-15	8.89e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-8.02	2.85e-15	8.89e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
BRCA	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-8.02	2.87e-15	8.94e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
BRCA	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-8.02	2.87e-15	8.96e-13	-0.29	-0.24	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
BRCA	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-8.02	2.87e-15	8.96e-13	-0.28	-0.24	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
BRCA	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	8.02	2.87e-15	8.96e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
BRCA	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	8.02	2.88e-15	8.98e-13	0.34	0.24	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
BRCA	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-8.02	2.88e-15	9e-13	-0.29	-0.24	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
BRCA	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-8.02	2.89e-15	9e-13	-0.31	-0.24	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
BRCA	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	8.02	2.89e-15	9e-13	0.34	0.24	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
BRCA	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-8.02	2.89e-15	9.02e-13	-0.29	-0.24	Migraine;	chr4:56853383	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	8.02	2.89e-15	9.02e-13	0.24	0.24	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-8.02	2.9e-15	9.04e-13	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
BRCA	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-8.02	2.9e-15	9.05e-13	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
BRCA	cis	rs7085104	0.7	rs10883785	ENSG00000236937.2	PTGES3P4	8.02	2.91e-15	9.07e-13	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102845595~102845950:+
BRCA	cis	rs10971721	0.822	rs10971739	ENSG00000260947.1	RP11-384P7.7	8.02	2.91e-15	9.08e-13	0.4	0.24	Body mass index;	chr9:33855467	chr9:33697459~33700986:+
BRCA	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	8.02	2.92e-15	9.1e-13	0.29	0.24	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
BRCA	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-8.02	2.92e-15	9.1e-13	-0.3	-0.24	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.895	rs2421192	ENSG00000271889.1	RP11-493E12.1	-8.02	2.93e-15	9.13e-13	-0.31	-0.24	Tuberculosis;	chr2:61416496	chr2:61151433~61162105:-
BRCA	cis	rs13256369	0.95	rs13248096	ENSG00000253893.2	FAM85B	-8.01	2.94e-15	9.17e-13	-0.34	-0.24	Obesity-related traits;	chr8:8719966	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	8.01	2.94e-15	9.17e-13	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.765	rs10843119	ENSG00000247934.4	RP11-967K21.1	-8.01	2.95e-15	9.18e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28163298~28190738:-
BRCA	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-8.01	2.96e-15	9.21e-13	-0.35	-0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
BRCA	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-8.01	2.97e-15	9.24e-13	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-8.01	2.97e-15	9.25e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
BRCA	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-8.01	2.97e-15	9.26e-13	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.929	rs2593626	ENSG00000271889.1	RP11-493E12.1	8.01	2.97e-15	9.26e-13	0.31	0.24	Tuberculosis;	chr2:61438049	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.929	rs2592352	ENSG00000271889.1	RP11-493E12.1	8.01	2.97e-15	9.26e-13	0.31	0.24	Tuberculosis;	chr2:61438201	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	8.01	2.98e-15	9.28e-13	0.31	0.24	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
BRCA	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	8.01	2.99e-15	9.31e-13	0.37	0.24	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
BRCA	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	8.01	2.99e-15	9.32e-13	0.31	0.24	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-8.01	3.02e-15	9.39e-13	-0.56	-0.24	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-8.01	3.02e-15	9.4e-13	-0.33	-0.24	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
BRCA	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	8.01	3.03e-15	9.43e-13	0.31	0.24	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
BRCA	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-8.01	3.04e-15	9.45e-13	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
BRCA	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-8.01	3.04e-15	9.47e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
BRCA	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	8.01	3.04e-15	9.47e-13	0.32	0.24	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-8.01	3.04e-15	9.47e-13	-0.34	-0.24	Gout;	chr7:66654674	chr7:66902857~66906297:+
BRCA	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-8.01	3.05e-15	9.48e-13	-0.27	-0.24	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
BRCA	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	8.01	3.05e-15	9.5e-13	0.3	0.24	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
BRCA	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	8.01	3.06e-15	9.51e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
BRCA	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-8.01	3.07e-15	9.57e-13	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-8.01	3.07e-15	9.57e-13	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
BRCA	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-8.01	3.08e-15	9.57e-13	-0.31	-0.24	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
BRCA	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.01	3.09e-15	9.6e-13	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
BRCA	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	8.01	3.09e-15	9.62e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
BRCA	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	8.01	3.09e-15	9.62e-13	0.31	0.24	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-8.01	3.1e-15	9.63e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
BRCA	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-8.01	3.1e-15	9.64e-13	-0.29	-0.24	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	8.01	3.11e-15	9.68e-13	0.25	0.24	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
BRCA	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-8.01	3.11e-15	9.69e-13	-0.32	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
BRCA	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-8.01	3.12e-15	9.7e-13	-0.3	-0.24	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
BRCA	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-8.01	3.13e-15	9.73e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.894	rs10496092	ENSG00000271889.1	RP11-493E12.1	-8.01	3.14e-15	9.76e-13	-0.31	-0.24	Tuberculosis;	chr2:61297544	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-8.01	3.14e-15	9.77e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000222364.1	RNU6-96P	8.01	3.15e-15	9.78e-13	0.32	0.24	Aortic root size;	chr7:66091320	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	8.01	3.16e-15	9.81e-13	0.25	0.24	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	8.01	3.16e-15	9.81e-13	0.25	0.24	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
BRCA	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-8	3.19e-15	9.89e-13	-0.34	-0.24	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
BRCA	cis	rs9880211	0.528	rs75685279	ENSG00000239213.4	NCK1-AS1	8	3.2e-15	9.94e-13	0.3	0.24	Height;Body mass index;	chr3:136715991	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	8	3.21e-15	9.95e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-8	3.21e-15	9.96e-13	-0.27	-0.24	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
BRCA	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	8	3.22e-15	1e-12	0.32	0.24	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.894	rs6734628	ENSG00000271889.1	RP11-493E12.1	-8	3.22e-15	1e-12	-0.32	-0.24	Tuberculosis;	chr2:61224125	chr2:61151433~61162105:-
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	8	3.23e-15	1e-12	0.49	0.24	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
BRCA	cis	rs73173548	0.502	rs10505856	ENSG00000247828.6	TMEM161B-AS1	8	3.23e-15	1e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88440636	chr5:88268895~88436685:+
BRCA	cis	rs42648	0.869	rs2027965	ENSG00000225498.1	AC002064.5	8	3.23e-15	1e-12	0.23	0.24	Homocysteine levels;	chr7:90283199	chr7:90312496~90322592:+
BRCA	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	8	3.24e-15	1.01e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
BRCA	cis	rs2028299	0.959	rs893617	ENSG00000259677.1	RP11-493E3.1	8	3.24e-15	1.01e-12	0.32	0.24	Type 2 diabetes;	chr15:89838046	chr15:89876540~89877285:+
BRCA	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	8	3.25e-15	1.01e-12	0.36	0.24	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
BRCA	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	8	3.25e-15	1.01e-12	0.37	0.24	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
BRCA	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-8	3.25e-15	1.01e-12	-0.27	-0.24	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
BRCA	cis	rs6545883	0.831	rs1186704	ENSG00000271889.1	RP11-493E12.1	8	3.26e-15	1.01e-12	0.31	0.24	Tuberculosis;	chr2:61445856	chr2:61151433~61162105:-
BRCA	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-8	3.28e-15	1.02e-12	-0.32	-0.24	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
BRCA	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-8	3.28e-15	1.02e-12	-0.3	-0.24	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
BRCA	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	8	3.29e-15	1.02e-12	0.39	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
BRCA	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8	3.32e-15	1.03e-12	0.27	0.24	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
BRCA	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-8	3.32e-15	1.03e-12	-0.29	-0.24	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	8	3.33e-15	1.03e-12	0.24	0.24	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-8	3.33e-15	1.03e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
BRCA	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-8	3.34e-15	1.03e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	8	3.34e-15	1.04e-12	0.4	0.24	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	8	3.35e-15	1.04e-12	0.33	0.24	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
BRCA	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8	3.35e-15	1.04e-12	-0.35	-0.24	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
BRCA	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-8	3.36e-15	1.04e-12	-0.31	-0.24	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
BRCA	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-8	3.36e-15	1.04e-12	-0.32	-0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
BRCA	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-8	3.37e-15	1.04e-12	-0.29	-0.24	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
BRCA	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	8	3.37e-15	1.04e-12	0.38	0.24	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
BRCA	cis	rs67981189	0.647	rs36555	ENSG00000269927.1	RP6-91H8.3	-8	3.38e-15	1.05e-12	-0.32	-0.24	Schizophrenia;	chr14:70897844	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	8	3.38e-15	1.05e-12	0.34	0.24	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
BRCA	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-8	3.38e-15	1.05e-12	-0.29	-0.24	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
BRCA	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	8	3.39e-15	1.05e-12	0.29	0.24	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
BRCA	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	8	3.4e-15	1.05e-12	0.34	0.24	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
BRCA	cis	rs250518	0.926	rs7734796	ENSG00000272081.1	CTD-2376I4.2	8	3.41e-15	1.06e-12	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72781261	chr5:72955206~72955699:-
BRCA	cis	rs12188164	0.58	rs2672755	ENSG00000225138.6	CTD-2228K2.7	-8	3.41e-15	1.06e-12	-0.26	-0.24	Cystic fibrosis severity;	chr5:457134	chr5:473236~480884:+
BRCA	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	8	3.42e-15	1.06e-12	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
BRCA	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	8	3.42e-15	1.06e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
BRCA	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-8	3.42e-15	1.06e-12	-0.41	-0.24	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
BRCA	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-7.99	3.42e-15	1.06e-12	-0.3	-0.24	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.959	rs748508	ENSG00000259677.1	RP11-493E3.1	7.99	3.42e-15	1.06e-12	0.32	0.24	Type 2 diabetes;	chr15:89838026	chr15:89876540~89877285:+
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.99	3.46e-15	1.07e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-7.99	3.46e-15	1.07e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
BRCA	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	7.99	3.47e-15	1.07e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-7.99	3.48e-15	1.08e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
BRCA	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-7.99	3.48e-15	1.08e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	7.99	3.49e-15	1.08e-12	0.24	0.24	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	7.99	3.5e-15	1.08e-12	0.32	0.24	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	7.99	3.5e-15	1.08e-12	0.29	0.24	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
BRCA	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-7.99	3.52e-15	1.09e-12	-0.32	-0.24	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
BRCA	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-7.99	3.52e-15	1.09e-12	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	7.99	3.52e-15	1.09e-12	0.33	0.24	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-7.99	3.52e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
BRCA	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	7.99	3.52e-15	1.09e-12	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
BRCA	cis	rs6545883	0.894	rs2694634	ENSG00000271889.1	RP11-493E12.1	-7.99	3.53e-15	1.09e-12	-0.31	-0.24	Tuberculosis;	chr2:61324300	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-7.99	3.53e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-7.99	3.53e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
BRCA	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-7.99	3.54e-15	1.09e-12	-0.31	-0.24	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
BRCA	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-7.99	3.54e-15	1.1e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
BRCA	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	7.99	3.55e-15	1.1e-12	0.31	0.24	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
BRCA	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-7.99	3.56e-15	1.1e-12	-0.27	-0.24	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
BRCA	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-7.99	3.56e-15	1.1e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-7.99	3.56e-15	1.1e-12	-0.16	-0.24	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
BRCA	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	7.99	3.56e-15	1.1e-12	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	7.99	3.58e-15	1.11e-12	0.24	0.24	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
BRCA	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	7.99	3.58e-15	1.11e-12	0.32	0.24	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
BRCA	cis	rs7586673	0.93	rs7591506	ENSG00000235724.7	AC009299.2	-7.99	3.59e-15	1.11e-12	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161222785~161308303:-
BRCA	cis	rs7085104	0.632	rs4290163	ENSG00000236937.2	PTGES3P4	7.99	3.59e-15	1.11e-12	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102845595~102845950:+
BRCA	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	7.99	3.59e-15	1.11e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-7.99	3.6e-15	1.11e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
BRCA	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-7.99	3.6e-15	1.11e-12	-0.35	-0.24	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
BRCA	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-7.99	3.61e-15	1.12e-12	-0.32	-0.24	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-7.99	3.61e-15	1.12e-12	-0.32	-0.24	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
BRCA	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	7.99	3.61e-15	1.12e-12	0.28	0.24	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
BRCA	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	7.99	3.62e-15	1.12e-12	0.31	0.24	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-7.99	3.62e-15	1.12e-12	-0.32	-0.24	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
BRCA	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-7.99	3.63e-15	1.12e-12	-0.35	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
BRCA	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-7.99	3.64e-15	1.12e-12	-0.31	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
BRCA	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	7.99	3.64e-15	1.12e-12	0.46	0.24	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
BRCA	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	7.99	3.64e-15	1.13e-12	0.3	0.24	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
BRCA	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-7.99	3.66e-15	1.13e-12	-0.29	-0.24	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-7.99	3.66e-15	1.13e-12	-0.29	-0.24	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
BRCA	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-7.99	3.66e-15	1.13e-12	-0.26	-0.24	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
BRCA	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	7.99	3.67e-15	1.13e-12	0.28	0.24	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
BRCA	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-7.99	3.67e-15	1.13e-12	-0.3	-0.24	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
BRCA	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-7.99	3.68e-15	1.14e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-7.99	3.69e-15	1.14e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
BRCA	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-7.98	3.71e-15	1.15e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-7.98	3.72e-15	1.15e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-7.98	3.72e-15	1.15e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	7.98	3.73e-15	1.15e-12	0.26	0.24	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
BRCA	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-7.98	3.73e-15	1.15e-12	-0.29	-0.24	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
BRCA	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	7.98	3.73e-15	1.15e-12	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	7.98	3.73e-15	1.15e-12	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
BRCA	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	7.98	3.73e-15	1.15e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
BRCA	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-7.98	3.77e-15	1.16e-12	-0.32	-0.24	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
BRCA	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.98	3.78e-15	1.17e-12	-0.33	-0.24	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
BRCA	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	7.98	3.79e-15	1.17e-12	0.29	0.24	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
BRCA	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-7.98	3.79e-15	1.17e-12	-0.34	-0.24	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
BRCA	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-7.98	3.8e-15	1.17e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
BRCA	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	7.98	3.83e-15	1.18e-12	0.31	0.24	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
BRCA	cis	rs6545883	0.894	rs12620105	ENSG00000271889.1	RP11-493E12.1	-7.98	3.84e-15	1.18e-12	-0.31	-0.24	Tuberculosis;	chr2:61285186	chr2:61151433~61162105:-
BRCA	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-7.98	3.84e-15	1.18e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
BRCA	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	7.98	3.85e-15	1.19e-12	0.28	0.24	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
BRCA	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	7.98	3.85e-15	1.19e-12	0.3	0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
BRCA	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-7.98	3.86e-15	1.19e-12	-0.31	-0.24	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-7.98	3.86e-15	1.19e-12	-0.31	-0.24	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
BRCA	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-7.98	3.86e-15	1.19e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	7.98	3.87e-15	1.19e-12	0.17	0.24	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-7.98	3.88e-15	1.2e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
BRCA	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-7.98	3.92e-15	1.21e-12	-0.22	-0.24	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
BRCA	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-7.98	3.92e-15	1.21e-12	-0.33	-0.24	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
BRCA	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-7.98	3.92e-15	1.21e-12	-0.21	-0.24	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
BRCA	cis	rs2028299	1	rs7111	ENSG00000259677.1	RP11-493E3.1	7.98	3.94e-15	1.21e-12	0.32	0.24	Type 2 diabetes;	chr15:89830641	chr15:89876540~89877285:+
BRCA	cis	rs2028299	1	rs2028299	ENSG00000259677.1	RP11-493E3.1	7.98	3.94e-15	1.21e-12	0.32	0.24	Type 2 diabetes;	chr15:89831025	chr15:89876540~89877285:+
BRCA	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	7.97	3.99e-15	1.23e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
BRCA	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	7.97	3.99e-15	1.23e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
BRCA	cis	rs3758911	0.828	rs10890697	ENSG00000255353.1	RP11-382M14.1	-7.97	3.99e-15	1.23e-12	-0.32	-0.24	Coronary artery disease;	chr11:107307915	chr11:107176286~107177530:+
BRCA	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-7.97	4e-15	1.23e-12	-0.35	-0.24	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
BRCA	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	7.97	4.02e-15	1.24e-12	0.27	0.24	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	7.97	4.03e-15	1.24e-12	0.24	0.24	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
BRCA	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	7.97	4.03e-15	1.24e-12	0.38	0.24	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-7.97	4.03e-15	1.24e-12	-0.32	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
BRCA	cis	rs3758911	0.861	rs11212117	ENSG00000255353.1	RP11-382M14.1	-7.97	4.03e-15	1.24e-12	-0.33	-0.24	Coronary artery disease;	chr11:107276757	chr11:107176286~107177530:+
BRCA	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	7.97	4.03e-15	1.24e-12	0.28	0.24	QT interval;	chr12:29300269	chr12:29280418~29317848:-
BRCA	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	7.97	4.03e-15	1.24e-12	0.27	0.24	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
BRCA	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	7.97	4.04e-15	1.24e-12	0.22	0.24	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	7.97	4.05e-15	1.25e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-7.97	4.05e-15	1.25e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
BRCA	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-7.97	4.07e-15	1.25e-12	-0.33	-0.24	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
BRCA	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	7.97	4.08e-15	1.26e-12	0.3	0.24	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
BRCA	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	7.97	4.09e-15	1.26e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
BRCA	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	7.97	4.11e-15	1.27e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-7.97	4.12e-15	1.27e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
BRCA	cis	rs11723261	0.582	rs6830247	ENSG00000211553.1	AC253576.2	-7.97	4.12e-15	1.27e-12	-0.34	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:136461~136568:+
BRCA	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-7.97	4.12e-15	1.27e-12	-0.27	-0.24	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
BRCA	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	7.97	4.13e-15	1.27e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
BRCA	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-7.97	4.14e-15	1.27e-12	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
BRCA	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	7.97	4.15e-15	1.28e-12	0.36	0.24	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
BRCA	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	7.97	4.15e-15	1.28e-12	0.46	0.24	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
BRCA	cis	rs6545883	0.894	rs12622458	ENSG00000271889.1	RP11-493E12.1	-7.97	4.16e-15	1.28e-12	-0.31	-0.24	Tuberculosis;	chr2:61296419	chr2:61151433~61162105:-
BRCA	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-7.97	4.16e-15	1.28e-12	-0.29	-0.24	Height;	chr2:46616492	chr2:46668870~46670778:+
BRCA	cis	rs6539288	0.803	rs4479083	ENSG00000260329.1	RP11-412D9.4	-7.97	4.17e-15	1.28e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106927467	chr12:106954029~106955497:-
BRCA	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	7.97	4.18e-15	1.29e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-7.97	4.18e-15	1.29e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-7.97	4.2e-15	1.29e-12	-0.29	-0.24	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	7.97	4.2e-15	1.29e-12	0.32	0.24	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
BRCA	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	7.97	4.22e-15	1.3e-12	0.33	0.24	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
BRCA	cis	rs12664251	0.638	rs2782573	ENSG00000253194.1	RP11-351A11.1	-7.97	4.22e-15	1.3e-12	-0.29	-0.24	Schizophrenia;	chr6:119031549	chr6:118934785~119031541:+
BRCA	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	7.97	4.24e-15	1.3e-12	0.32	0.24	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
BRCA	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-7.97	4.24e-15	1.3e-12	-0.26	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
BRCA	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-7.97	4.25e-15	1.31e-12	-0.27	-0.24	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	7.97	4.25e-15	1.31e-12	0.25	0.24	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	7.97	4.25e-15	1.31e-12	0.33	0.24	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-7.97	4.26e-15	1.31e-12	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-7.97	4.27e-15	1.31e-12	-0.25	-0.24	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-7.97	4.29e-15	1.32e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	7.97	4.29e-15	1.32e-12	0.2	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-7.97	4.29e-15	1.32e-12	-0.29	-0.24	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-7.97	4.3e-15	1.32e-12	-0.32	-0.24	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
BRCA	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	7.97	4.3e-15	1.32e-12	0.31	0.24	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	7.97	4.3e-15	1.32e-12	0.25	0.24	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	7.97	4.3e-15	1.32e-12	0.25	0.24	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-7.97	4.3e-15	1.32e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
BRCA	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-7.96	4.31e-15	1.32e-12	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
BRCA	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	7.96	4.31e-15	1.32e-12	0.3	0.24	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
BRCA	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-7.96	4.32e-15	1.33e-12	-0.28	-0.24	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
BRCA	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-7.96	4.32e-15	1.33e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
BRCA	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-7.96	4.36e-15	1.34e-12	-0.28	-0.24	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	7.96	4.36e-15	1.34e-12	0.16	0.24	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
BRCA	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-7.96	4.36e-15	1.34e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
BRCA	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
BRCA	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-7.96	4.39e-15	1.35e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
BRCA	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	7.96	4.4e-15	1.35e-12	0.3	0.24	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-7.96	4.41e-15	1.35e-12	-0.19	-0.24	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
BRCA	cis	rs6545883	0.894	rs35292974	ENSG00000271889.1	RP11-493E12.1	-7.96	4.42e-15	1.36e-12	-0.3	-0.24	Tuberculosis;	chr2:61294912	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	7.96	4.43e-15	1.36e-12	0.26	0.24	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	7.96	4.43e-15	1.36e-12	0.26	0.24	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
BRCA	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	7.96	4.45e-15	1.36e-12	0.38	0.24	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
BRCA	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	7.96	4.45e-15	1.36e-12	0.38	0.24	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
BRCA	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	7.96	4.45e-15	1.37e-12	0.31	0.24	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
BRCA	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-7.96	4.46e-15	1.37e-12	-0.27	-0.24	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
BRCA	cis	rs74233809	1	rs12217501	ENSG00000213277.3	MARCKSL1P1	7.96	4.47e-15	1.37e-12	0.46	0.24	Birth weight;	chr10:103092132	chr10:103175554~103176094:+
BRCA	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	7.96	4.47e-15	1.37e-12	0.3	0.24	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
BRCA	cis	rs6545883	0.894	rs2177962	ENSG00000271889.1	RP11-493E12.1	-7.96	4.47e-15	1.37e-12	-0.31	-0.24	Tuberculosis;	chr2:61360935	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-7.96	4.47e-15	1.37e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
BRCA	cis	rs8012947	0.527	rs1190981	ENSG00000279636.2	LINC00216	-7.96	4.5e-15	1.38e-12	-0.25	-0.24	Alcohol consumption in current drinkers;	chr14:58348357	chr14:58288033~58289158:+
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	7.96	4.54e-15	1.39e-12	0.37	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	7.96	4.54e-15	1.39e-12	0.26	0.24	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.96	4.54e-15	1.39e-12	0.33	0.24	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-7.96	4.56e-15	1.4e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
BRCA	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-7.96	4.56e-15	1.4e-12	-0.29	-0.24	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
BRCA	cis	rs2348418	0.765	rs10843120	ENSG00000247934.4	RP11-967K21.1	-7.96	4.57e-15	1.4e-12	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28163298~28190738:-
BRCA	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	7.96	4.57e-15	1.4e-12	0.31	0.24	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
BRCA	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	7.96	4.57e-15	1.4e-12	0.24	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-7.96	4.57e-15	1.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
BRCA	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	7.96	4.58e-15	1.4e-12	0.31	0.24	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
BRCA	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-7.96	4.58e-15	1.4e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
BRCA	cis	rs812925	0.714	rs1900573	ENSG00000271889.1	RP11-493E12.1	-7.96	4.59e-15	1.41e-12	-0.32	-0.24	Immature fraction of reticulocytes;	chr2:61369777	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.571	rs160647	ENSG00000222364.1	RNU6-96P	7.96	4.59e-15	1.41e-12	0.32	0.24	Aortic root size;	chr7:66089365	chr7:66395191~66395286:+
BRCA	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-7.96	4.61e-15	1.41e-12	-0.28	-0.24	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
BRCA	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	7.96	4.64e-15	1.42e-12	0.46	0.24	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	7.96	4.64e-15	1.42e-12	0.46	0.24	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-7.96	4.64e-15	1.42e-12	-0.25	-0.24	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	7.95	4.65e-15	1.42e-12	0.24	0.24	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-7.95	4.66e-15	1.43e-12	-0.29	-0.24	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
BRCA	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-7.95	4.67e-15	1.43e-12	-0.29	-0.24	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
BRCA	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	7.95	4.69e-15	1.44e-12	0.3	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	7.95	4.69e-15	1.44e-12	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
BRCA	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-7.95	4.7e-15	1.44e-12	-0.29	-0.24	Height;	chr2:46630262	chr2:46668870~46670778:+
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	7.95	4.7e-15	1.44e-12	0.22	0.24	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-7.95	4.7e-15	1.44e-12	-0.35	-0.24	Depression;	chr6:28422360	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.948	rs9813691	ENSG00000273486.1	RP11-731C17.2	7.95	4.71e-15	1.44e-12	0.32	0.24	Height;Body mass index;	chr3:136541880	chr3:136837338~136839021:-
BRCA	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
BRCA	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	7.95	4.73e-15	1.45e-12	0.32	0.24	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-7.95	4.73e-15	1.45e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	7.95	4.73e-15	1.45e-12	0.25	0.24	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
BRCA	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-7.95	4.75e-15	1.45e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
BRCA	cis	rs42648	0.837	rs3761804	ENSG00000225498.1	AC002064.5	7.95	4.77e-15	1.46e-12	0.23	0.24	Homocysteine levels;	chr7:90286024	chr7:90312496~90322592:+
BRCA	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	7.95	4.77e-15	1.46e-12	0.31	0.24	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.929	rs9679557	ENSG00000271889.1	RP11-493E12.1	7.95	4.79e-15	1.47e-12	0.31	0.24	Tuberculosis;	chr2:61482214	chr2:61151433~61162105:-
BRCA	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-7.95	4.79e-15	1.47e-12	-0.33	-0.24	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
BRCA	cis	rs7246657	0.663	rs9304568	ENSG00000267422.1	CTD-2554C21.1	-7.95	4.82e-15	1.48e-12	-0.35	-0.24	Coronary artery calcification;	chr19:37563606	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	7.95	4.82e-15	1.48e-12	0.32	0.24	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-7.95	4.84e-15	1.48e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
BRCA	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-7.95	4.84e-15	1.48e-12	-0.29	-0.24	Height;	chr2:46629946	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-7.95	4.85e-15	1.48e-12	-0.27	-0.24	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
BRCA	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	7.95	4.87e-15	1.49e-12	0.27	0.24	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
BRCA	cis	rs12664251	0.66	rs794257	ENSG00000253194.1	RP11-351A11.1	-7.95	4.87e-15	1.49e-12	-0.29	-0.24	Schizophrenia;	chr6:119032047	chr6:118934785~119031541:+
BRCA	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.95	4.87e-15	1.49e-12	-0.28	-0.24	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-7.95	4.88e-15	1.49e-12	-0.28	-0.24	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
BRCA	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-7.95	4.88e-15	1.49e-12	-0.32	-0.24	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
BRCA	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	7.95	4.89e-15	1.49e-12	0.38	0.24	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
BRCA	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.95	4.92e-15	1.5e-12	0.33	0.24	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-7.95	4.92e-15	1.5e-12	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
BRCA	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-7.95	4.93e-15	1.51e-12	-0.27	-0.24	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
BRCA	cis	rs58873874	0.579	rs11551374	ENSG00000251405.2	CTB-109A12.1	7.95	4.95e-15	1.51e-12	0.51	0.24	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157362615~157460078:-
BRCA	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-7.95	4.95e-15	1.51e-12	-0.3	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-7.95	4.96e-15	1.51e-12	-0.29	-0.24	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
BRCA	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	7.95	4.96e-15	1.51e-12	0.26	0.24	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
BRCA	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	7.95	4.99e-15	1.52e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	7.95	5e-15	1.53e-12	0.26	0.24	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
BRCA	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	7.94	5.01e-15	1.53e-12	0.31	0.24	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
BRCA	cis	rs250518	0.888	rs6870112	ENSG00000272081.1	CTD-2376I4.2	7.94	5.03e-15	1.53e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72725093	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000222364.1	RNU6-96P	7.94	5.04e-15	1.54e-12	0.32	0.24	Aortic root size;	chr7:66087627	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.894	rs2121661	ENSG00000271889.1	RP11-493E12.1	-7.94	5.06e-15	1.54e-12	-0.31	-0.24	Tuberculosis;	chr2:61334523	chr2:61151433~61162105:-
BRCA	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-7.94	5.06e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
BRCA	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	7.94	5.07e-15	1.55e-12	0.27	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
BRCA	cis	rs6472827	0.794	rs4439117	ENSG00000253983.2	RP1-16A9.1	7.94	5.08e-15	1.55e-12	0.37	0.24	Uterine fibroids;	chr8:74207475	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
BRCA	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	7.94	5.08e-15	1.55e-12	0.38	0.24	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
BRCA	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.94	5.09e-15	1.55e-12	0.25	0.24	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
BRCA	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	7.94	5.09e-15	1.55e-12	0.32	0.24	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000225151.9	GOLGA2P7	7.94	5.09e-15	1.55e-12	0.26	0.24	P wave terminal force;	chr15:84695892	chr15:84199311~84230136:-
BRCA	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-7.94	5.13e-15	1.56e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
BRCA	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-7.94	5.15e-15	1.57e-12	-0.26	-0.24	Longevity;	chr3:48358338	chr3:48256350~48256938:-
BRCA	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.94	5.15e-15	1.57e-12	0.26	0.24	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	7.94	5.15e-15	1.57e-12	0.24	0.24	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
BRCA	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-7.94	5.16e-15	1.57e-12	-0.31	-0.24	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-7.94	5.16e-15	1.57e-12	-0.31	-0.24	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
BRCA	cis	rs7246657	0.678	rs2927740	ENSG00000267422.1	CTD-2554C21.1	7.94	5.16e-15	1.57e-12	0.35	0.24	Coronary artery calcification;	chr19:37650065	chr19:37779686~37792865:+
BRCA	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-7.94	5.17e-15	1.58e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
BRCA	cis	rs3758911	0.828	rs10890695	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107294923	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212142	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107302994	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs10789597	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107304314	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs12285607	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107304608	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs10890696	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107306487	chr11:107176286~107177530:+
BRCA	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	7.94	5.19e-15	1.58e-12	0.35	0.24	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
BRCA	cis	rs58873874	0.579	rs75099611	ENSG00000251405.2	CTB-109A12.1	7.94	5.19e-15	1.58e-12	0.53	0.24	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157362615~157460078:-
BRCA	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-7.94	5.2e-15	1.58e-12	-0.31	-0.24	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-7.94	5.21e-15	1.59e-12	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
BRCA	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-7.94	5.24e-15	1.6e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
BRCA	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-7.94	5.25e-15	1.6e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-7.94	5.25e-15	1.6e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-7.94	5.26e-15	1.6e-12	-0.43	-0.24	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-7.94	5.27e-15	1.6e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
BRCA	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	7.94	5.27e-15	1.6e-12	0.36	0.24	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	7.94	5.27e-15	1.61e-12	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	7.94	5.29e-15	1.61e-12	0.27	0.24	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
BRCA	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-7.94	5.29e-15	1.61e-12	-0.4	-0.24	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
BRCA	cis	rs3758911	0.796	rs112617433	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107282855	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs7929343	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107285183	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs7929345	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107285185	chr11:107176286~107177530:+
BRCA	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	7.94	5.3e-15	1.61e-12	0.6	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
BRCA	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-7.94	5.3e-15	1.61e-12	-0.29	-0.24	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
BRCA	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-7.94	5.31e-15	1.62e-12	-0.38	-0.24	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
BRCA	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	7.94	5.32e-15	1.62e-12	0.3	0.24	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
BRCA	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	7.94	5.32e-15	1.62e-12	0.29	0.24	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
BRCA	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	7.94	5.36e-15	1.63e-12	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
BRCA	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-7.94	5.36e-15	1.63e-12	-0.3	-0.24	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-7.94	5.37e-15	1.63e-12	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
BRCA	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	7.94	5.37e-15	1.63e-12	0.3	0.24	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-7.94	5.37e-15	1.63e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
BRCA	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	7.94	5.4e-15	1.64e-12	0.32	0.24	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
BRCA	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	7.94	5.4e-15	1.64e-12	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
BRCA	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	7.94	5.4e-15	1.64e-12	0.29	0.24	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
BRCA	cis	rs17213965	0.925	rs62030569	ENSG00000207425.1	Y_RNA	-7.94	5.4e-15	1.64e-12	-0.38	-0.24	Waist-hip ratio;	chr16:15786892	chr16:14915457~14915556:-
BRCA	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	7.93	5.41e-15	1.65e-12	0.31	0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
BRCA	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	7.93	5.42e-15	1.65e-12	0.23	0.24	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	7.93	5.42e-15	1.65e-12	0.23	0.24	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
BRCA	cis	rs2803122	0.501	rs10811140	ENSG00000273226.1	RP11-513M16.8	-7.93	5.42e-15	1.65e-12	-0.3	-0.24	Pulse pressure;	chr9:19230401	chr9:19375451~19375996:+
BRCA	cis	rs7246657	0.722	rs16958863	ENSG00000267422.1	CTD-2554C21.1	-7.93	5.43e-15	1.65e-12	-0.35	-0.24	Coronary artery calcification;	chr19:37633334	chr19:37779686~37792865:+
BRCA	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	7.93	5.44e-15	1.65e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	7.93	5.49e-15	1.67e-12	0.33	0.24	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-7.93	5.5e-15	1.67e-12	-0.29	-0.24	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	7.93	5.5e-15	1.67e-12	0.15	0.24	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
BRCA	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	7.93	5.54e-15	1.68e-12	0.43	0.24	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
BRCA	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-7.93	5.55e-15	1.69e-12	-0.27	-0.24	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
BRCA	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
BRCA	cis	rs2742234	1	rs1864395	ENSG00000273008.1	RP11-351D16.3	-7.93	5.55e-15	1.69e-12	-0.27	-0.24	Hirschsprung disease;	chr10:43160249	chr10:43136824~43138334:-
BRCA	cis	rs3758911	0.765	rs10789592	ENSG00000255353.1	RP11-382M14.1	-7.93	5.55e-15	1.69e-12	-0.33	-0.24	Coronary artery disease;	chr11:107283589	chr11:107176286~107177530:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.93	5.56e-15	1.69e-12	-0.34	-0.24	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
BRCA	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-7.93	5.57e-15	1.69e-12	-0.27	-0.24	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
BRCA	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	7.93	5.59e-15	1.7e-12	0.4	0.24	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
BRCA	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	7.93	5.61e-15	1.7e-12	0.31	0.24	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
BRCA	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	7.93	5.64e-15	1.71e-12	0.31	0.24	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-7.93	5.64e-15	1.71e-12	-0.29	-0.24	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	7.93	5.65e-15	1.71e-12	0.32	0.24	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-7.93	5.66e-15	1.72e-12	-0.16	-0.24	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
BRCA	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-7.93	5.67e-15	1.72e-12	-0.3	-0.24	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
BRCA	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	7.93	5.67e-15	1.72e-12	0.31	0.24	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
BRCA	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-7.93	5.68e-15	1.72e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
BRCA	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	7.93	5.69e-15	1.73e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
BRCA	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-7.93	5.69e-15	1.73e-12	-0.32	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
BRCA	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	7.93	5.69e-15	1.73e-12	0.31	0.24	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
BRCA	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	7.93	5.7e-15	1.73e-12	0.32	0.24	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
BRCA	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	7.93	5.71e-15	1.73e-12	0.29	0.24	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	7.93	5.72e-15	1.74e-12	0.31	0.24	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
BRCA	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	7.93	5.73e-15	1.74e-12	0.3	0.24	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
BRCA	cis	rs3758911	1	rs10789616	ENSG00000255353.1	RP11-382M14.1	-7.93	5.73e-15	1.74e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318365	chr11:107176286~107177530:+
BRCA	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	7.93	5.73e-15	1.74e-12	0.32	0.24	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
BRCA	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-7.93	5.75e-15	1.75e-12	-0.31	-0.24	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-7.93	5.75e-15	1.75e-12	-0.31	-0.24	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
BRCA	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-7.93	5.76e-15	1.75e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-7.93	5.76e-15	1.75e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
BRCA	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	7.93	5.76e-15	1.75e-12	0.26	0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	7.93	5.76e-15	1.75e-12	0.29	0.24	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	7.93	5.76e-15	1.75e-12	0.29	0.24	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
BRCA	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-7.93	5.76e-15	1.75e-12	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
BRCA	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	7.93	5.78e-15	1.75e-12	0.36	0.24	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	7.93	5.79e-15	1.76e-12	0.21	0.24	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-7.93	5.79e-15	1.76e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
BRCA	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-7.93	5.8e-15	1.76e-12	-0.27	-0.24	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
BRCA	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	7.93	5.82e-15	1.76e-12	0.53	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
BRCA	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-7.93	5.82e-15	1.77e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
BRCA	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	7.93	5.83e-15	1.77e-12	0.23	0.24	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
BRCA	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-7.92	5.86e-15	1.78e-12	-0.32	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
BRCA	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-7.92	5.87e-15	1.78e-12	-0.32	-0.24	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
BRCA	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-7.92	5.88e-15	1.78e-12	-0.3	-0.24	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
BRCA	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-7.92	5.91e-15	1.79e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
BRCA	cis	rs74233809	1	rs11191505	ENSG00000213277.3	MARCKSL1P1	7.92	5.93e-15	1.8e-12	0.46	0.24	Birth weight;	chr10:103007134	chr10:103175554~103176094:+
BRCA	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-7.92	5.93e-15	1.8e-12	-0.18	-0.24	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
BRCA	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-7.92	5.94e-15	1.8e-12	-0.27	-0.24	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-7.92	5.95e-15	1.8e-12	-0.16	-0.24	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	7.92	5.96e-15	1.81e-12	0.16	0.24	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
BRCA	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-7.92	5.96e-15	1.81e-12	-0.27	-0.24	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
BRCA	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-7.92	5.96e-15	1.81e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
BRCA	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	7.92	5.97e-15	1.81e-12	0.33	0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
BRCA	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-7.92	5.99e-15	1.82e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
BRCA	cis	rs250518	0.852	rs3846640	ENSG00000272081.1	CTD-2376I4.2	7.92	5.99e-15	1.82e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72724139	chr5:72955206~72955699:-
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-7.92	6.04e-15	1.83e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	7.92	6.08e-15	1.84e-12	0.29	0.24	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
BRCA	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	7.92	6.1e-15	1.85e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
BRCA	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	7.92	6.14e-15	1.86e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	7.92	6.14e-15	1.86e-12	0.24	0.24	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-7.92	6.15e-15	1.86e-12	-0.29	-0.24	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
BRCA	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	7.92	6.18e-15	1.87e-12	0.34	0.24	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
BRCA	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	7.92	6.2e-15	1.88e-12	0.31	0.24	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
BRCA	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	7.92	6.2e-15	1.88e-12	0.5	0.24	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000222364.1	RNU6-96P	7.92	6.22e-15	1.88e-12	0.32	0.24	Aortic root size;	chr7:66086944	chr7:66395191~66395286:+
BRCA	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
BRCA	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
BRCA	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
BRCA	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	7.92	6.24e-15	1.89e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
BRCA	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-7.92	6.25e-15	1.89e-12	-0.33	-0.24	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
BRCA	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	7.92	6.28e-15	1.9e-12	0.31	0.24	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
BRCA	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-7.91	6.32e-15	1.91e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-7.91	6.33e-15	1.91e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
BRCA	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	7.91	6.36e-15	1.92e-12	0.31	0.24	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-7.91	6.36e-15	1.93e-12	-0.32	-0.24	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
BRCA	cis	rs7131987	0.565	rs7137141	ENSG00000275476.1	RP11-996F15.4	7.91	6.38e-15	1.93e-12	0.27	0.24	QT interval;	chr12:29272168	chr12:29277397~29277882:-
BRCA	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	7.91	6.38e-15	1.93e-12	0.32	0.24	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-7.91	6.39e-15	1.93e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
BRCA	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	7.91	6.39e-15	1.93e-12	0.37	0.24	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
BRCA	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	7.91	6.42e-15	1.94e-12	0.31	0.24	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
BRCA	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-7.91	6.42e-15	1.94e-12	-0.23	-0.24	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
BRCA	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	7.91	6.42e-15	1.94e-12	0.25	0.24	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
BRCA	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-7.91	6.43e-15	1.94e-12	-0.32	-0.24	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
BRCA	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	7.91	6.44e-15	1.95e-12	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-7.91	6.45e-15	1.95e-12	-0.24	-0.24	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-7.91	6.45e-15	1.95e-12	-0.24	-0.24	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
BRCA	cis	rs3758911	1	rs11212153	ENSG00000255353.1	RP11-382M14.1	-7.91	6.45e-15	1.95e-12	-0.31	-0.24	Coronary artery disease;	chr11:107319234	chr11:107176286~107177530:+
BRCA	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-7.91	6.46e-15	1.95e-12	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
BRCA	cis	rs1113500	0.805	rs11185244	ENSG00000226822.1	RP11-356N1.2	7.91	6.48e-15	1.96e-12	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108058525	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.814	rs1592282	ENSG00000226822.1	RP11-356N1.2	7.91	6.48e-15	1.96e-12	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108058743	chr1:108071482~108074519:+
BRCA	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	7.91	6.49e-15	1.96e-12	0.32	0.24	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-7.91	6.49e-15	1.96e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-7.91	6.5e-15	1.96e-12	-0.29	-0.24	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
BRCA	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-7.91	6.5e-15	1.96e-12	-0.39	-0.24	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
BRCA	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-7.91	6.51e-15	1.97e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
BRCA	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	7.91	6.52e-15	1.97e-12	0.31	0.24	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
BRCA	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	7.91	6.55e-15	1.98e-12	0.29	0.24	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
BRCA	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	7.91	6.58e-15	1.99e-12	0.31	0.24	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
BRCA	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	7.91	6.59e-15	1.99e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
BRCA	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-7.91	6.59e-15	1.99e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
BRCA	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	7.91	6.61e-15	2e-12	0.31	0.24	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
BRCA	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-7.91	6.64e-15	2e-12	-0.32	-0.24	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
BRCA	cis	rs9880211	1	rs9883189	ENSG00000273486.1	RP11-731C17.2	7.91	6.64e-15	2e-12	0.32	0.24	Height;Body mass index;	chr3:136570624	chr3:136837338~136839021:-
BRCA	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
BRCA	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	7.91	6.66e-15	2.01e-12	0.29	0.24	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-7.91	6.67e-15	2.01e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
BRCA	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-7.91	6.67e-15	2.01e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
BRCA	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-7.91	6.71e-15	2.02e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
BRCA	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-7.91	6.74e-15	2.03e-12	-0.32	-0.24	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
BRCA	cis	rs6545883	0.929	rs6705235	ENSG00000271889.1	RP11-493E12.1	7.91	6.76e-15	2.04e-12	0.3	0.24	Tuberculosis;	chr2:61486445	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-7.91	6.77e-15	2.04e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	7.91	6.77e-15	2.04e-12	0.25	0.24	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
BRCA	cis	rs6539288	0.933	rs10861673	ENSG00000260329.1	RP11-412D9.4	-7.91	6.78e-15	2.04e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106906293	chr12:106954029~106955497:-
BRCA	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-7.9	6.81e-15	2.05e-12	-0.31	-0.24	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
BRCA	cis	rs1113500	0.787	rs4571989	ENSG00000226822.1	RP11-356N1.2	7.9	6.81e-15	2.05e-12	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108088722	chr1:108071482~108074519:+
BRCA	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	7.9	6.86e-15	2.07e-12	0.32	0.24	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.828	rs11212141	ENSG00000255353.1	RP11-382M14.1	-7.9	6.86e-15	2.07e-12	-0.33	-0.24	Coronary artery disease;	chr11:107298200	chr11:107176286~107177530:+
BRCA	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	7.9	6.86e-15	2.07e-12	0.3	0.24	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	7.9	6.86e-15	2.07e-12	0.3	0.24	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
BRCA	cis	rs7085104	0.66	rs3781286	ENSG00000236937.2	PTGES3P4	7.9	6.88e-15	2.07e-12	0.3	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102845595~102845950:+
BRCA	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.9	6.88e-15	2.07e-12	0.24	0.24	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
BRCA	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-7.9	6.9e-15	2.08e-12	-0.32	-0.24	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs9866840	ENSG00000273486.1	RP11-731C17.2	7.9	6.91e-15	2.08e-12	0.31	0.24	Height;Body mass index;	chr3:136310416	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	7.9	6.92e-15	2.09e-12	0.25	0.24	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	7.9	6.93e-15	2.09e-12	0.33	0.24	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
BRCA	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	7.9	6.94e-15	2.09e-12	0.32	0.24	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	7.9	6.94e-15	2.09e-12	0.26	0.24	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
BRCA	cis	rs4403732	1	rs4237333	ENSG00000230526.1	RP11-472G21.2	7.9	6.97e-15	2.1e-12	0.35	0.24	Coronary artery disease;	chr10:71877468	chr10:71878356~71879107:+
BRCA	cis	rs3758911	1	rs1046094	ENSG00000255353.1	RP11-382M14.1	-7.9	6.98e-15	2.1e-12	-0.31	-0.24	Coronary artery disease;	chr11:107326530	chr11:107176286~107177530:+
BRCA	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	7.9	6.98e-15	2.1e-12	0.31	0.24	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-7.9	7e-15	2.11e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
BRCA	cis	rs6545883	0.791	rs4672445	ENSG00000271889.1	RP11-493E12.1	-7.9	7e-15	2.11e-12	-0.31	-0.24	Tuberculosis;	chr2:61427873	chr2:61151433~61162105:-
BRCA	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-7.9	7.01e-15	2.11e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-7.9	7.01e-15	2.11e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
BRCA	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	7.9	7.03e-15	2.12e-12	0.29	0.24	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
BRCA	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	7.9	7.03e-15	2.12e-12	0.29	0.24	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
BRCA	cis	rs3758911	1	rs10789617	ENSG00000255353.1	RP11-382M14.1	-7.9	7.04e-15	2.12e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318968	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	7.9	7.04e-15	2.12e-12	0.18	0.24	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
BRCA	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-7.9	7.05e-15	2.12e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
BRCA	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-7.9	7.06e-15	2.12e-12	-0.31	-0.24	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.06e-15	2.12e-12	-0.28	-0.24	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
BRCA	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	7.9	7.07e-15	2.13e-12	0.31	0.24	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
BRCA	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	7.9	7.07e-15	2.13e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	7.9	7.11e-15	2.14e-12	0.28	0.24	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
BRCA	cis	rs812925	0.859	rs2593624	ENSG00000271889.1	RP11-493E12.1	-7.9	7.11e-15	2.14e-12	-0.31	-0.24	Immature fraction of reticulocytes;	chr2:61325349	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-7.9	7.12e-15	2.14e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-7.9	7.12e-15	2.14e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
BRCA	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.862	rs11691734	ENSG00000271889.1	RP11-493E12.1	7.9	7.12e-15	2.14e-12	0.31	0.24	Tuberculosis;	chr2:61475331	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.13e-15	2.14e-12	-0.28	-0.24	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
BRCA	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	7.9	7.15e-15	2.15e-12	0.37	0.24	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
BRCA	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
BRCA	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-7.9	7.17e-15	2.16e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
BRCA	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-7.9	7.21e-15	2.17e-12	-0.3	-0.24	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
BRCA	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-7.9	7.21e-15	2.17e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
BRCA	cis	rs3758911	0.861	rs10789621	ENSG00000255353.1	RP11-382M14.1	7.9	7.22e-15	2.17e-12	0.31	0.24	Coronary artery disease;	chr11:107388345	chr11:107176286~107177530:+
BRCA	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	7.9	7.22e-15	2.17e-12	0.29	0.24	Myopia;	chr2:171827496	chr2:171773482~171775844:+
BRCA	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	7.9	7.22e-15	2.17e-12	0.32	0.24	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	7.9	7.25e-15	2.18e-12	0.32	0.24	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
BRCA	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-7.9	7.25e-15	2.18e-12	-0.32	-0.24	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
BRCA	cis	rs6545883	0.894	rs6760075	ENSG00000271889.1	RP11-493E12.1	-7.9	7.27e-15	2.18e-12	-0.31	-0.24	Tuberculosis;	chr2:61385746	chr2:61151433~61162105:-
BRCA	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.89	7.33e-15	2.2e-12	-0.33	-0.24	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
BRCA	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	7.89	7.33e-15	2.2e-12	0.31	0.24	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-7.89	7.35e-15	2.21e-12	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
BRCA	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-7.89	7.37e-15	2.21e-12	-0.29	-0.24	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
BRCA	cis	rs3758911	1	rs10789615	ENSG00000255353.1	RP11-382M14.1	-7.89	7.38e-15	2.22e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318088	chr11:107176286~107177530:+
BRCA	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	7.89	7.38e-15	2.22e-12	0.36	0.24	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-7.89	7.41e-15	2.23e-12	-0.29	-0.24	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	7.89	7.43e-15	2.23e-12	0.23	0.24	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
BRCA	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	7.89	7.45e-15	2.24e-12	0.36	0.24	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
BRCA	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.89	7.45e-15	2.24e-12	0.33	0.24	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
BRCA	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-7.89	7.49e-15	2.25e-12	-0.3	-0.24	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	7.89	7.49e-15	2.25e-12	0.23	0.24	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
BRCA	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	7.89	7.51e-15	2.25e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	7.89	7.51e-15	2.25e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	7.89	7.52e-15	2.26e-12	0.27	0.24	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.894	rs7572603	ENSG00000271889.1	RP11-493E12.1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Tuberculosis;	chr2:61325010	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
BRCA	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-7.89	7.53e-15	2.26e-12	-0.3	-0.24	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-7.89	7.54e-15	2.26e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
BRCA	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	7.89	7.54e-15	2.26e-12	0.26	0.24	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
BRCA	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	7.89	7.55e-15	2.27e-12	0.25	0.24	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	7.89	7.56e-15	2.27e-12	0.26	0.24	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
BRCA	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-7.89	7.57e-15	2.27e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	7.89	7.58e-15	2.27e-12	0.19	0.24	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
BRCA	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-7.89	7.58e-15	2.27e-12	-0.31	-0.24	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-7.89	7.58e-15	2.27e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	7.89	7.63e-15	2.29e-12	0.33	0.24	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000224316.1	RP11-479O9.2	7.89	7.64e-15	2.29e-12	0.27	0.24	Aortic root size;	chr7:66168318	chr7:65773620~65802067:+
BRCA	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-7.89	7.66e-15	2.3e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-7.89	7.66e-15	2.3e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
BRCA	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-7.89	7.66e-15	2.3e-12	-0.3	-0.24	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
BRCA	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-7.89	7.71e-15	2.31e-12	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
BRCA	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.74e-15	2.32e-12	-0.3	-0.24	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.74e-15	2.32e-12	-0.3	-0.24	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-7.89	7.78e-15	2.33e-12	-0.34	-0.24	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
BRCA	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	7.89	7.79e-15	2.33e-12	0.29	0.24	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	7.89	7.79e-15	2.33e-12	0.29	0.24	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
BRCA	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	7.89	7.79e-15	2.33e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	7.89	7.81e-15	2.34e-12	0.23	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
BRCA	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-7.89	7.84e-15	2.35e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	7.89	7.84e-15	2.35e-12	0.16	0.24	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
BRCA	cis	rs58873874	0.522	rs111370613	ENSG00000251405.2	CTB-109A12.1	7.89	7.84e-15	2.35e-12	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157362615~157460078:-
BRCA	cis	rs62246343	0.564	rs17050383	ENSG00000206573.7	THUMPD3-AS1	-7.89	7.85e-15	2.35e-12	-0.27	-0.24	Fibrinogen levels;	chr3:9472896	chr3:9349689~9398579:-
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	7.89	7.86e-15	2.35e-12	0.37	0.24	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.787	rs12047429	ENSG00000226822.1	RP11-356N1.2	7.89	7.86e-15	2.36e-12	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108090617	chr1:108071482~108074519:+
BRCA	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	7.89	7.88e-15	2.36e-12	0.29	0.24	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
BRCA	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	7.88	7.91e-15	2.37e-12	0.34	0.24	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	7.88	7.92e-15	2.37e-12	0.29	0.24	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
BRCA	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-7.88	7.95e-15	2.38e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-7.88	8.01e-15	2.4e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
BRCA	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-7.88	8.01e-15	2.4e-12	-0.33	-0.24	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
BRCA	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	7.88	8.02e-15	2.4e-12	0.32	0.24	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
BRCA	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-7.88	8.02e-15	2.4e-12	-0.37	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	7.88	8.02e-15	2.4e-12	0.29	0.24	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
BRCA	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-7.88	8.03e-15	2.4e-12	-0.31	-0.24	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
BRCA	cis	rs9880211	1	rs6774964	ENSG00000239213.4	NCK1-AS1	7.88	8.03e-15	2.4e-12	0.31	0.24	Height;Body mass index;	chr3:136556740	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs6775314	ENSG00000239213.4	NCK1-AS1	7.88	8.03e-15	2.4e-12	0.31	0.24	Height;Body mass index;	chr3:136557106	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	7.88	8.06e-15	2.41e-12	0.16	0.24	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-7.88	8.12e-15	2.43e-12	-0.16	-0.24	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
BRCA	cis	rs7162943	0.708	rs293365	ENSG00000260123.1	RP11-326A19.4	-7.88	8.13e-15	2.43e-12	-0.27	-0.24	Mean platelet volume;	chr15:89070777	chr15:89041223~89082819:+
BRCA	cis	rs896854	0.738	rs1713669	ENSG00000253528.2	RP11-347C18.4	7.88	8.13e-15	2.43e-12	0.26	0.24	Type 2 diabetes;	chr8:94946409	chr8:94974573~94974853:-
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-7.88	8.14e-15	2.44e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
BRCA	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	7.88	8.15e-15	2.44e-12	0.26	0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
BRCA	cis	rs58873874	0.579	rs11738062	ENSG00000251405.2	CTB-109A12.1	7.88	8.15e-15	2.44e-12	0.48	0.24	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157362615~157460078:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	7.88	8.19e-15	2.45e-12	0.16	0.24	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
BRCA	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-7.88	8.2e-15	2.45e-12	-0.26	-0.24	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
BRCA	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	7.88	8.2e-15	2.45e-12	0.31	0.24	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	7.88	8.2e-15	2.45e-12	0.31	0.24	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
BRCA	cis	rs58873874	1	rs75720504	ENSG00000248544.2	CTB-47B11.3	7.88	8.21e-15	2.46e-12	0.56	0.24	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157375741~157384950:-
BRCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-7.88	8.22e-15	2.46e-12	-0.38	-0.24	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	7.88	8.25e-15	2.47e-12	0.16	0.24	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
BRCA	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-7.88	8.26e-15	2.47e-12	-0.27	-0.24	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
BRCA	cis	rs42648	0.869	rs1134956	ENSG00000225498.1	AC002064.5	7.88	8.27e-15	2.47e-12	0.23	0.24	Homocysteine levels;	chr7:90309366	chr7:90312496~90322592:+
BRCA	cis	rs3781264	0.595	rs6583937	ENSG00000273450.1	RP11-76P2.4	7.88	8.27e-15	2.47e-12	0.31	0.24	Esophageal cancer and gastric cancer;	chr10:94323695	chr10:94314907~94315327:-
BRCA	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-7.88	8.28e-15	2.47e-12	-0.33	-0.24	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
BRCA	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-7.88	8.31e-15	2.48e-12	-0.32	-0.24	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-7.88	8.36e-15	2.5e-12	-0.31	-0.24	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
BRCA	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	7.88	8.37e-15	2.5e-12	0.26	0.24	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-7.88	8.38e-15	2.5e-12	-0.16	-0.24	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	7.88	8.39e-15	2.51e-12	0.29	0.24	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
BRCA	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	7.88	8.4e-15	2.51e-12	0.27	0.24	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
BRCA	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	7.88	8.46e-15	2.53e-12	0.29	0.24	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
BRCA	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-7.88	8.47e-15	2.53e-12	-0.32	-0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
BRCA	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	7.88	8.48e-15	2.53e-12	0.28	0.24	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
BRCA	cis	rs1113500	0.814	rs893983	ENSG00000226822.1	RP11-356N1.2	-7.88	8.5e-15	2.54e-12	-0.3	-0.24	Growth-regulated protein alpha levels;	chr1:108087716	chr1:108071482~108074519:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	7.88	8.51e-15	2.54e-12	0.33	0.24	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
BRCA	cis	rs42648	0.869	rs42609	ENSG00000225498.1	AC002064.5	7.87	8.53e-15	2.55e-12	0.23	0.24	Homocysteine levels;	chr7:90320541	chr7:90312496~90322592:+
BRCA	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-7.87	8.56e-15	2.56e-12	-0.3	-0.24	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
BRCA	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	7.87	8.57e-15	2.56e-12	0.27	0.24	Longevity;	chr3:48442021	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	7.87	8.57e-15	2.56e-12	0.27	0.24	Longevity;	chr3:48442035	chr3:48440352~48446656:-
BRCA	cis	rs7580658	0.68	rs6710535	ENSG00000236682.1	AC068282.3	7.87	8.58e-15	2.56e-12	0.33	0.24	Protein C levels;	chr2:127433384	chr2:127389130~127400580:+
BRCA	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-7.87	8.58e-15	2.56e-12	-0.3	-0.24	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	7.87	8.58e-15	2.56e-12	0.3	0.24	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.87	8.59e-15	2.57e-12	0.33	0.24	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
BRCA	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
BRCA	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-7.87	8.6e-15	2.57e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
BRCA	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	7.87	8.62e-15	2.57e-12	0.24	0.24	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
BRCA	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	7.87	8.65e-15	2.58e-12	0.31	0.24	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
BRCA	cis	rs62246343	0.605	rs17050395	ENSG00000206573.7	THUMPD3-AS1	-7.87	8.65e-15	2.58e-12	-0.24	-0.24	Fibrinogen levels;	chr3:9492290	chr3:9349689~9398579:-
BRCA	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-7.87	8.65e-15	2.58e-12	-0.33	-0.24	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
BRCA	cis	rs853679	1	rs853676	ENSG00000220721.1	OR1F12	7.87	8.65e-15	2.58e-12	0.37	0.24	Depression;	chr6:28331910	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	7.87	8.65e-15	2.58e-12	0.21	0.24	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
BRCA	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-7.87	8.65e-15	2.58e-12	-0.31	-0.24	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	7.87	8.68e-15	2.59e-12	0.29	0.24	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	7.87	8.68e-15	2.59e-12	0.29	0.24	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	7.87	8.69e-15	2.59e-12	0.31	0.24	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
BRCA	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	7.87	8.71e-15	2.6e-12	0.28	0.24	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
BRCA	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	7.87	8.72e-15	2.6e-12	0.23	0.24	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
BRCA	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	7.87	8.75e-15	2.61e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
BRCA	cis	rs9880211	0.948	rs9844666	ENSG00000273486.1	RP11-731C17.2	7.87	8.76e-15	2.61e-12	0.32	0.24	Height;Body mass index;	chr3:136255374	chr3:136837338~136839021:-
BRCA	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	7.87	8.76e-15	2.61e-12	0.28	0.24	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
BRCA	cis	rs11009175	0.556	rs2093345	ENSG00000273038.2	RP11-479G22.8	-7.87	8.8e-15	2.63e-12	-0.35	-0.24	Depression (quantitative trait);	chr10:33037255	chr10:32887255~32889311:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-7.87	8.81e-15	2.63e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-7.87	8.81e-15	2.63e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
BRCA	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-7.87	8.82e-15	2.63e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-7.87	8.82e-15	2.63e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
BRCA	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-7.87	8.83e-15	2.63e-12	-0.28	-0.24	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
BRCA	cis	rs3814244	0.832	rs11177006	ENSG00000236946.2	HNRNPA1P70	-7.87	8.86e-15	2.64e-12	-0.2	-0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:68035767~68036853:+
BRCA	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-7.87	8.88e-15	2.65e-12	-0.39	-0.24	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
BRCA	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-7.87	8.89e-15	2.65e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
BRCA	cis	rs3758911	1	rs10789619	ENSG00000255353.1	RP11-382M14.1	-7.87	8.9e-15	2.65e-12	-0.31	-0.24	Coronary artery disease;	chr11:107324570	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs11212157	ENSG00000255353.1	RP11-382M14.1	-7.87	8.9e-15	2.65e-12	-0.31	-0.24	Coronary artery disease;	chr11:107324572	chr11:107176286~107177530:+
BRCA	cis	rs13256369	1	rs7843488	ENSG00000253893.2	FAM85B	-7.87	8.9e-15	2.65e-12	-0.34	-0.24	Obesity-related traits;	chr8:8718707	chr8:8167819~8226614:-
BRCA	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-7.87	8.92e-15	2.66e-12	-0.25	-0.24	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
BRCA	cis	rs853679	1	rs6905391	ENSG00000220721.1	OR1F12	7.87	8.93e-15	2.66e-12	0.37	0.24	Depression;	chr6:28294909	chr6:28073316~28074233:+
BRCA	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	7.87	8.95e-15	2.67e-12	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.862	rs1880866	ENSG00000271889.1	RP11-493E12.1	7.87	8.96e-15	2.67e-12	0.31	0.24	Tuberculosis;	chr2:61471837	chr2:61151433~61162105:-
BRCA	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-7.87	8.97e-15	2.67e-12	-0.29	-0.24	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
BRCA	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-7.87	8.99e-15	2.68e-12	-0.32	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
BRCA	cis	rs1476670	0.565	rs2108201	ENSG00000230615.5	RP5-1198O20.4	-7.87	9.01e-15	2.69e-12	-0.32	-0.24	Eotaxin levels;	chr1:44049211	chr1:44030443~44115913:+
BRCA	cis	rs3758911	0.861	rs10789594	ENSG00000255353.1	RP11-382M14.1	-7.87	9.02e-15	2.69e-12	-0.32	-0.24	Coronary artery disease;	chr11:107290391	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs12146472	ENSG00000255353.1	RP11-382M14.1	-7.87	9.03e-15	2.69e-12	-0.31	-0.24	Coronary artery disease;	chr11:107323450	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs12146473	ENSG00000255353.1	RP11-382M14.1	-7.87	9.03e-15	2.69e-12	-0.31	-0.24	Coronary artery disease;	chr11:107323540	chr11:107176286~107177530:+
BRCA	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-7.87	9.03e-15	2.69e-12	-0.29	-0.24	Height;	chr2:231556448	chr2:231508426~231514339:-
BRCA	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	7.87	9.04e-15	2.69e-12	0.31	0.24	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
BRCA	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-7.87	9.05e-15	2.7e-12	-0.3	-0.24	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
BRCA	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-7.87	9.07e-15	2.7e-12	-0.34	-0.24	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
BRCA	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-7.87	9.08e-15	2.7e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
BRCA	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	7.87	9.08e-15	2.7e-12	0.3	0.24	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
BRCA	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-7.87	9.1e-15	2.71e-12	-0.28	-0.24	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
BRCA	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	7.87	9.1e-15	2.71e-12	0.33	0.24	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	7.87	9.11e-15	2.71e-12	0.29	0.24	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
BRCA	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	7.87	9.13e-15	2.72e-12	0.28	0.24	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
BRCA	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-7.87	9.14e-15	2.72e-12	-0.3	-0.24	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
BRCA	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-7.87	9.15e-15	2.73e-12	-0.34	-0.24	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
BRCA	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
BRCA	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-7.87	9.17e-15	2.73e-12	-0.31	-0.24	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
BRCA	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	7.87	9.19e-15	2.74e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
BRCA	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	7.86	9.22e-15	2.75e-12	0.29	0.24	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
BRCA	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-7.86	9.23e-15	2.75e-12	-0.26	-0.24	Height;	chr5:36865567	chr5:36666214~36725195:-
BRCA	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-7.86	9.26e-15	2.76e-12	-0.32	-0.24	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
BRCA	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-7.86	9.27e-15	2.76e-12	-0.23	-0.24	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
BRCA	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-7.86	9.35e-15	2.78e-12	-0.29	-0.24	Height;	chr2:231559006	chr2:231508426~231514339:-
BRCA	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-7.86	9.36e-15	2.79e-12	-0.25	-0.24	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-7.86	9.39e-15	2.8e-12	-0.33	-0.24	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	7.86	9.4e-15	2.8e-12	0.3	0.24	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-7.86	9.42e-15	2.8e-12	-0.16	-0.24	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
BRCA	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	7.86	9.43e-15	2.81e-12	0.23	0.24	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
BRCA	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	7.86	9.45e-15	2.81e-12	0.3	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	7.86	9.47e-15	2.82e-12	0.29	0.24	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-7.86	9.47e-15	2.82e-12	-0.28	-0.24	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
BRCA	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	7.86	9.53e-15	2.84e-12	0.25	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
BRCA	cis	rs58873874	0.579	rs10037386	ENSG00000251405.2	CTB-109A12.1	7.86	9.53e-15	2.84e-12	0.49	0.24	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157362615~157460078:-
BRCA	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-7.86	9.56e-15	2.84e-12	-0.29	-0.24	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
BRCA	cis	rs3758911	0.964	rs10890715	ENSG00000255353.1	RP11-382M14.1	-7.86	9.6e-15	2.86e-12	-0.31	-0.24	Coronary artery disease;	chr11:107322457	chr11:107176286~107177530:+
BRCA	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-7.86	9.61e-15	2.86e-12	-0.27	-0.24	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
BRCA	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	7.86	9.64e-15	2.87e-12	0.31	0.24	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
BRCA	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	7.86	9.66e-15	2.87e-12	0.32	0.24	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.86	9.67e-15	2.88e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
BRCA	cis	rs812925	0.784	rs6735081	ENSG00000271889.1	RP11-493E12.1	-7.86	9.71e-15	2.89e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr2:61233582	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.86	9.73e-15	2.89e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	7.86	9.75e-15	2.9e-12	0.33	0.24	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	7.86	9.76e-15	2.9e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	7.86	9.76e-15	2.9e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-7.86	9.76e-15	2.9e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	7.86	9.78e-15	2.91e-12	0.24	0.24	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
BRCA	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-7.86	9.79e-15	2.91e-12	-0.29	-0.24	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-7.86	9.79e-15	2.91e-12	-0.29	-0.24	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
BRCA	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	7.86	9.79e-15	2.91e-12	0.31	0.24	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
BRCA	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	7.86	9.79e-15	2.91e-12	0.31	0.24	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
BRCA	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	7.86	9.8e-15	2.91e-12	0.33	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.86	9.83e-15	2.92e-12	-0.32	-0.24	Gout;	chr7:66671562	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.894	rs4672423	ENSG00000271889.1	RP11-493E12.1	-7.86	9.84e-15	2.92e-12	-0.31	-0.24	Tuberculosis;	chr2:61208140	chr2:61151433~61162105:-
BRCA	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-7.86	9.86e-15	2.93e-12	-0.29	-0.24	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
BRCA	cis	rs3814244	0.54	rs2159064	ENSG00000236946.2	HNRNPA1P70	7.86	9.89e-15	2.94e-12	0.19	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:68035767~68036853:+
BRCA	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-7.86	9.9e-15	2.94e-12	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
BRCA	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	7.85	9.92e-15	2.94e-12	0.26	0.24	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
BRCA	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	7.85	9.93e-15	2.95e-12	0.28	0.24	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
BRCA	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	7.85	9.93e-15	2.95e-12	0.29	0.24	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	7.85	9.93e-15	2.95e-12	0.29	0.24	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	7.85	9.93e-15	2.95e-12	0.3	0.24	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
BRCA	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-7.85	9.94e-15	2.95e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	7.85	9.95e-15	2.95e-12	0.25	0.24	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
BRCA	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
BRCA	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	7.85	9.96e-15	2.96e-12	0.32	0.24	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
BRCA	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	7.85	9.98e-15	2.96e-12	0.21	0.24	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
BRCA	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	7.85	9.98e-15	2.96e-12	0.32	0.24	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
BRCA	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-7.85	9.99e-15	2.96e-12	-0.38	-0.24	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
BRCA	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-7.85	9.99e-15	2.96e-12	-0.29	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-7.85	9.99e-15	2.96e-12	-0.29	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
BRCA	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-7.85	1e-14	2.97e-12	-0.28	-0.24	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
BRCA	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-7.85	1.01e-14	2.99e-12	-0.29	-0.24	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
BRCA	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	7.85	1.01e-14	2.99e-12	0.28	0.24	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	7.85	1.01e-14	2.99e-12	0.28	0.24	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
BRCA	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.85	1.01e-14	3e-12	0.32	0.24	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-7.85	1.01e-14	3e-12	-0.3	-0.24	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs67949818	ENSG00000273486.1	RP11-731C17.2	7.85	1.01e-14	3e-12	0.31	0.24	Height;Body mass index;	chr3:136494136	chr3:136837338~136839021:-
BRCA	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	7.85	1.01e-14	3e-12	0.31	0.24	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
BRCA	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	7.85	1.01e-14	3e-12	0.36	0.24	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
BRCA	cis	rs919433	1	rs1346649	ENSG00000231621.1	AC013264.2	7.85	1.01e-14	3e-12	0.22	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301393	chr2:197197991~197199273:+
BRCA	cis	rs6545883	0.895	rs7588814	ENSG00000271889.1	RP11-493E12.1	7.85	1.01e-14	3e-12	0.31	0.24	Tuberculosis;	chr2:61468454	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	7.85	1.02e-14	3.01e-12	0.29	0.24	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-7.85	1.02e-14	3.02e-12	-0.3	-0.24	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
BRCA	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-7.85	1.02e-14	3.03e-12	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
BRCA	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-7.85	1.02e-14	3.03e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000224316.1	RP11-479O9.2	7.85	1.03e-14	3.04e-12	0.27	0.24	Aortic root size;	chr7:66169164	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.898	rs9870825	ENSG00000273486.1	RP11-731C17.2	7.85	1.03e-14	3.04e-12	0.32	0.24	Height;Body mass index;	chr3:136346878	chr3:136837338~136839021:-
BRCA	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-7.85	1.03e-14	3.04e-12	-0.25	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
BRCA	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-7.85	1.03e-14	3.05e-12	-0.37	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
BRCA	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-7.85	1.03e-14	3.06e-12	-0.29	-0.24	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	7.85	1.04e-14	3.06e-12	0.31	0.24	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
BRCA	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-7.85	1.04e-14	3.07e-12	-0.43	-0.24	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
BRCA	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	7.85	1.04e-14	3.07e-12	0.35	0.24	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
BRCA	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	7.85	1.04e-14	3.07e-12	0.25	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-7.85	1.04e-14	3.08e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.794	rs778152	ENSG00000271889.1	RP11-493E12.1	-7.85	1.04e-14	3.08e-12	-0.3	-0.24	Tuberculosis;	chr2:61381405	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-7.85	1.04e-14	3.09e-12	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-7.85	1.05e-14	3.1e-12	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
BRCA	cis	rs7580658	0.68	rs12468304	ENSG00000236682.1	AC068282.3	7.85	1.05e-14	3.11e-12	0.31	0.24	Protein C levels;	chr2:127436236	chr2:127389130~127400580:+
BRCA	cis	rs6472827	0.904	rs2956031	ENSG00000253983.2	RP1-16A9.1	7.85	1.06e-14	3.12e-12	0.37	0.24	Uterine fibroids;	chr8:74203074	chr8:74199396~74208441:+
BRCA	cis	rs74233809	1	rs12412038	ENSG00000213277.3	MARCKSL1P1	7.85	1.06e-14	3.13e-12	0.45	0.24	Birth weight;	chr10:103096405	chr10:103175554~103176094:+
BRCA	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	7.85	1.06e-14	3.13e-12	0.36	0.24	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
BRCA	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	7.85	1.06e-14	3.13e-12	0.33	0.24	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
BRCA	cis	rs9527	0.571	rs10786715	ENSG00000213061.2	PFN1P11	7.84	1.07e-14	3.16e-12	0.31	0.24	Arsenic metabolism;	chr10:102860978	chr10:102838011~102845473:-
BRCA	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.84	1.07e-14	3.17e-12	-0.35	-0.24	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-7.84	1.07e-14	3.17e-12	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-7.84	1.07e-14	3.18e-12	-0.55	-0.24	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
BRCA	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	7.84	1.08e-14	3.18e-12	0.28	0.24	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
BRCA	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-7.84	1.08e-14	3.19e-12	-0.32	-0.24	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
BRCA	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.84	1.09e-14	3.22e-12	0.32	0.24	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
BRCA	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.84	1.09e-14	3.22e-12	0.32	0.24	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
BRCA	cis	rs812925	0.855	rs777592	ENSG00000271889.1	RP11-493E12.1	7.84	1.09e-14	3.23e-12	0.3	0.24	Immature fraction of reticulocytes;	chr2:61191208	chr2:61151433~61162105:-
BRCA	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-7.84	1.09e-14	3.23e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
BRCA	cis	rs250518	0.926	rs13157511	ENSG00000272081.1	CTD-2376I4.2	-7.84	1.09e-14	3.23e-12	-0.3	-0.24	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72955206~72955699:-
BRCA	cis	rs58873874	0.522	rs77458926	ENSG00000251405.2	CTB-109A12.1	7.84	1.09e-14	3.23e-12	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157362615~157460078:-
BRCA	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	7.84	1.1e-14	3.24e-12	0.32	0.24	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
BRCA	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	7.84	1.1e-14	3.24e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	7.84	1.1e-14	3.25e-12	0.27	0.24	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
BRCA	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	7.84	1.1e-14	3.25e-12	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
BRCA	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	7.84	1.1e-14	3.26e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	7.84	1.11e-14	3.27e-12	0.26	0.24	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.964	rs10789614	ENSG00000255353.1	RP11-382M14.1	-7.84	1.11e-14	3.27e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318047	chr11:107176286~107177530:+
BRCA	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-7.84	1.11e-14	3.28e-12	-0.24	-0.24	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	7.84	1.11e-14	3.28e-12	0.29	0.24	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
BRCA	cis	rs58873874	0.579	rs10040318	ENSG00000248544.2	CTB-47B11.3	7.84	1.11e-14	3.28e-12	0.45	0.24	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157375741~157384950:-
BRCA	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
BRCA	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-7.84	1.11e-14	3.29e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
BRCA	cis	rs17213965	0.852	rs4781691	ENSG00000207425.1	Y_RNA	-7.84	1.11e-14	3.29e-12	-0.39	-0.24	Waist-hip ratio;	chr16:15783798	chr16:14915457~14915556:-
BRCA	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-7.84	1.12e-14	3.3e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	7.84	1.12e-14	3.3e-12	0.25	0.24	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-7.84	1.12e-14	3.3e-12	-0.33	-0.24	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
BRCA	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-7.84	1.12e-14	3.31e-12	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
BRCA	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.84	1.12e-14	3.31e-12	-0.29	-0.24	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
BRCA	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-7.84	1.12e-14	3.31e-12	-0.5	-0.24	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-7.84	1.12e-14	3.32e-12	-0.27	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
BRCA	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-7.84	1.13e-14	3.32e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
BRCA	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	7.84	1.13e-14	3.32e-12	0.28	0.24	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
BRCA	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	7.84	1.13e-14	3.33e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
BRCA	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	7.84	1.13e-14	3.34e-12	0.23	0.24	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
BRCA	cis	rs11723261	0.582	rs11735742	ENSG00000211553.1	AC253576.2	7.84	1.13e-14	3.34e-12	0.33	0.24	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:136461~136568:+
BRCA	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	7.84	1.13e-14	3.34e-12	0.26	0.24	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
BRCA	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-7.84	1.13e-14	3.35e-12	-0.28	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
BRCA	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	7.84	1.14e-14	3.36e-12	0.27	0.24	Longevity;	chr3:48443151	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	7.84	1.14e-14	3.36e-12	0.27	0.24	Longevity;	chr3:48443275	chr3:48440352~48446656:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-7.84	1.14e-14	3.36e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-7.84	1.14e-14	3.36e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
BRCA	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	7.84	1.14e-14	3.36e-12	0.34	0.24	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.929	rs1186710	ENSG00000271889.1	RP11-493E12.1	7.84	1.14e-14	3.36e-12	0.31	0.24	Tuberculosis;	chr2:61461592	chr2:61151433~61162105:-
BRCA	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	7.84	1.14e-14	3.36e-12	0.25	0.24	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
BRCA	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	7.84	1.14e-14	3.36e-12	0.29	0.24	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-7.84	1.14e-14	3.37e-12	-0.25	-0.24	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
BRCA	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	7.84	1.15e-14	3.38e-12	0.32	0.24	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
BRCA	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	7.84	1.15e-14	3.38e-12	0.29	0.24	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	7.84	1.15e-14	3.39e-12	0.33	0.24	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
BRCA	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-7.83	1.15e-14	3.4e-12	-0.24	-0.24	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
BRCA	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	7.83	1.15e-14	3.4e-12	0.23	0.24	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-7.83	1.15e-14	3.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-7.83	1.15e-14	3.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000224316.1	RP11-479O9.2	7.83	1.15e-14	3.4e-12	0.27	0.24	Aortic root size;	chr7:66164012	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000224316.1	RP11-479O9.2	7.83	1.15e-14	3.4e-12	0.27	0.24	Aortic root size;	chr7:66166374	chr7:65773620~65802067:+
BRCA	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	7.83	1.16e-14	3.41e-12	0.28	0.24	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
BRCA	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	7.83	1.16e-14	3.41e-12	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
BRCA	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-7.83	1.16e-14	3.41e-12	-0.31	-0.24	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-7.83	1.16e-14	3.42e-12	-0.15	-0.24	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
BRCA	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-7.83	1.16e-14	3.42e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
BRCA	cis	rs812925	0.893	rs778160	ENSG00000271889.1	RP11-493E12.1	7.83	1.16e-14	3.42e-12	0.32	0.24	Immature fraction of reticulocytes;	chr2:61330029	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-7.83	1.16e-14	3.42e-12	-0.28	-0.24	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-7.83	1.16e-14	3.43e-12	-0.24	-0.24	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
BRCA	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-7.83	1.17e-14	3.43e-12	-0.31	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
BRCA	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	7.83	1.17e-14	3.44e-12	0.3	0.24	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
BRCA	cis	rs2993535	1	rs3010029	ENSG00000233626.2	RP11-565J7.1	-7.83	1.17e-14	3.44e-12	-0.48	-0.24	Hip circumference adjusted for BMI;	chr1:212024502	chr1:211936249~211936634:+
BRCA	cis	rs9880211	0.948	rs17298525	ENSG00000273486.1	RP11-731C17.2	7.83	1.17e-14	3.45e-12	0.32	0.24	Height;Body mass index;	chr3:136474183	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-7.83	1.17e-14	3.45e-12	-0.27	-0.24	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
BRCA	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-7.83	1.17e-14	3.45e-12	-0.23	-0.24	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-7.83	1.17e-14	3.46e-12	-0.16	-0.24	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-7.83	1.18e-14	3.47e-12	-0.16	-0.24	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
BRCA	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	7.83	1.18e-14	3.47e-12	0.32	0.24	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
BRCA	cis	rs3758911	0.861	rs7131522	ENSG00000255353.1	RP11-382M14.1	-7.83	1.18e-14	3.48e-12	-0.32	-0.24	Coronary artery disease;	chr11:107293773	chr11:107176286~107177530:+
BRCA	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-7.83	1.19e-14	3.49e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-7.83	1.19e-14	3.5e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-7.83	1.19e-14	3.5e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
BRCA	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	7.83	1.19e-14	3.51e-12	0.31	0.24	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66158946	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66160135	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66161064	chr7:65773620~65802067:+
BRCA	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	7.83	1.2e-14	3.53e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
BRCA	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-7.83	1.21e-14	3.56e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
BRCA	cis	rs7246657	0.722	rs11083432	ENSG00000267422.1	CTD-2554C21.1	7.83	1.21e-14	3.56e-12	0.34	0.24	Coronary artery calcification;	chr19:37691732	chr19:37779686~37792865:+
BRCA	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
BRCA	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	7.83	1.21e-14	3.57e-12	0.28	0.24	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
BRCA	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	7.83	1.22e-14	3.57e-12	0.26	0.24	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
BRCA	cis	rs3758911	1	rs10890716	ENSG00000255353.1	RP11-382M14.1	-7.83	1.22e-14	3.58e-12	-0.3	-0.24	Coronary artery disease;	chr11:107324310	chr11:107176286~107177530:+
BRCA	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-7.83	1.22e-14	3.58e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
BRCA	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	7.83	1.23e-14	3.6e-12	0.27	0.24	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-7.83	1.23e-14	3.61e-12	-0.29	-0.24	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-7.83	1.23e-14	3.61e-12	-0.29	-0.24	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-7.83	1.23e-14	3.61e-12	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
BRCA	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-7.83	1.23e-14	3.62e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
BRCA	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-7.83	1.24e-14	3.63e-12	-0.34	-0.24	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
BRCA	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	7.83	1.24e-14	3.64e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	7.83	1.24e-14	3.64e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
BRCA	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-7.82	1.25e-14	3.66e-12	-0.39	-0.24	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
BRCA	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	7.82	1.25e-14	3.67e-12	0.29	0.24	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
BRCA	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	7.82	1.25e-14	3.68e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
BRCA	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-7.82	1.26e-14	3.69e-12	-0.24	-0.24	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	7.82	1.26e-14	3.7e-12	0.31	0.24	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-7.82	1.26e-14	3.7e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
BRCA	cis	rs6539288	0.933	rs10778513	ENSG00000260329.1	RP11-412D9.4	-7.82	1.26e-14	3.7e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106908405	chr12:106954029~106955497:-
BRCA	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-7.82	1.27e-14	3.73e-12	-0.27	-0.24	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
BRCA	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-7.82	1.27e-14	3.74e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
BRCA	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-7.82	1.28e-14	3.74e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
BRCA	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-7.82	1.28e-14	3.75e-12	-0.32	-0.24	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
BRCA	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-7.82	1.29e-14	3.77e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-7.82	1.29e-14	3.77e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
BRCA	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	7.82	1.29e-14	3.79e-12	0.35	0.24	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
BRCA	cis	rs2060793	0.519	rs2597212	ENSG00000251991.1	RNU7-49P	-7.82	1.3e-14	3.8e-12	-0.25	-0.24	Vitamin D levels;	chr11:14560216	chr11:14478892~14478953:+
BRCA	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-7.82	1.3e-14	3.81e-12	-0.32	-0.24	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-7.82	1.3e-14	3.81e-12	-0.28	-0.24	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.905	rs42622	ENSG00000225498.1	AC002064.5	7.82	1.3e-14	3.81e-12	0.23	0.24	Homocysteine levels;	chr7:90327510	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.935	rs42624	ENSG00000225498.1	AC002064.5	7.82	1.3e-14	3.81e-12	0.23	0.24	Homocysteine levels;	chr7:90328227	chr7:90312496~90322592:+
BRCA	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-7.82	1.31e-14	3.82e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
BRCA	cis	rs3758911	1	rs10789611	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107316810	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10789612	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107316931	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10890707	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317153	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10890708	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317315	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890709	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317378	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890711	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317424	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs12290112	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317487	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs12270655	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317507	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890712	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317583	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-7.82	1.31e-14	3.83e-12	-0.15	-0.24	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
BRCA	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-7.82	1.31e-14	3.83e-12	-0.31	-0.24	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
BRCA	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	7.82	1.31e-14	3.83e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
BRCA	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	7.82	1.31e-14	3.85e-12	0.29	0.24	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
BRCA	cis	rs9880211	0.948	rs34135127	ENSG00000273486.1	RP11-731C17.2	7.82	1.32e-14	3.85e-12	0.32	0.24	Height;Body mass index;	chr3:136507656	chr3:136837338~136839021:-
BRCA	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	7.82	1.32e-14	3.85e-12	0.29	0.24	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	7.82	1.32e-14	3.86e-12	0.21	0.24	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	7.82	1.32e-14	3.86e-12	0.21	0.24	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.929	rs55837508	ENSG00000255353.1	RP11-382M14.1	-7.82	1.32e-14	3.87e-12	-0.3	-0.24	Coronary artery disease;	chr11:107323756	chr11:107176286~107177530:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-7.82	1.32e-14	3.87e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-7.82	1.33e-14	3.89e-12	-0.29	-0.24	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs12516483	ENSG00000247828.6	TMEM161B-AS1	7.82	1.33e-14	3.9e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88454718	chr5:88268895~88436685:+
BRCA	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-7.82	1.34e-14	3.91e-12	-0.29	-0.24	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
BRCA	cis	rs1113500	0.787	rs473704	ENSG00000226822.1	RP11-356N1.2	-7.81	1.34e-14	3.92e-12	-0.3	-0.24	Growth-regulated protein alpha levels;	chr1:108094688	chr1:108071482~108074519:+
BRCA	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-7.81	1.34e-14	3.93e-12	-0.23	-0.24	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
BRCA	cis	rs9527	0.571	rs7096249	ENSG00000213061.2	PFN1P11	7.81	1.34e-14	3.93e-12	0.31	0.24	Arsenic metabolism;	chr10:102858767	chr10:102838011~102845473:-
BRCA	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-7.81	1.35e-14	3.94e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-7.81	1.35e-14	3.94e-12	-0.34	-0.24	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.81	1.36e-14	3.96e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.81	1.36e-14	3.96e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
BRCA	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	7.81	1.36e-14	3.96e-12	0.23	0.24	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-7.81	1.36e-14	3.97e-12	-0.24	-0.24	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
BRCA	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-7.81	1.36e-14	3.97e-12	-0.3	-0.24	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
BRCA	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	7.81	1.36e-14	3.97e-12	0.27	0.24	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	7.81	1.36e-14	3.98e-12	0.35	0.24	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
BRCA	cis	rs6472827	0.953	rs35446151	ENSG00000253983.2	RP1-16A9.1	-7.81	1.36e-14	3.98e-12	-0.36	-0.24	Uterine fibroids;	chr8:74209236	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-7.81	1.37e-14	4e-12	-0.29	-0.24	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-7.81	1.37e-14	4e-12	-0.29	-0.24	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
BRCA	cis	rs250518	0.926	rs4321733	ENSG00000272081.1	CTD-2376I4.2	7.81	1.37e-14	4e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72759145	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs4618410	ENSG00000272081.1	CTD-2376I4.2	7.81	1.37e-14	4e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72759146	chr5:72955206~72955699:-
BRCA	cis	rs2028299	1	rs8031576	ENSG00000259677.1	RP11-493E3.1	7.81	1.37e-14	4e-12	0.31	0.24	Type 2 diabetes;	chr15:89836982	chr15:89876540~89877285:+
BRCA	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	7.81	1.37e-14	4e-12	0.38	0.24	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
BRCA	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	7.81	1.37e-14	4.01e-12	0.28	0.24	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
BRCA	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	7.81	1.37e-14	4.01e-12	0.31	0.24	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000207425.1	Y_RNA	7.81	1.38e-14	4.02e-12	0.39	0.24	Waist-hip ratio;	chr16:15784296	chr16:14915457~14915556:-
BRCA	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-7.81	1.38e-14	4.03e-12	-0.33	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
BRCA	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	7.81	1.39e-14	4.05e-12	0.38	0.24	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
BRCA	cis	rs3745672	1	rs73509026	ENSG00000219665.7	CTD-2006C1.2	-7.81	1.39e-14	4.06e-12	-0.61	-0.24	Multiple sclerosis;	chr19:11948652	chr19:11987617~12046275:+
BRCA	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	7.81	1.39e-14	4.06e-12	0.24	0.24	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
BRCA	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-7.81	1.39e-14	4.07e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-7.81	1.39e-14	4.07e-12	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	7.81	1.4e-14	4.08e-12	0.26	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
BRCA	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	7.81	1.4e-14	4.09e-12	0.32	0.24	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	7.81	1.4e-14	4.09e-12	0.27	0.24	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
BRCA	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-7.81	1.41e-14	4.11e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-7.81	1.41e-14	4.11e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	7.81	1.41e-14	4.11e-12	0.21	0.24	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
BRCA	cis	rs4753788	0.511	rs12224337	ENSG00000255353.1	RP11-382M14.1	-7.81	1.41e-14	4.12e-12	-0.28	-0.24	Coronary artery disease;	chr11:107269351	chr11:107176286~107177530:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-7.81	1.41e-14	4.12e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
BRCA	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	7.81	1.41e-14	4.12e-12	0.3	0.24	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
BRCA	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	7.81	1.41e-14	4.13e-12	0.27	0.24	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-7.81	1.41e-14	4.13e-12	-0.29	-0.24	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	7.81	1.41e-14	4.13e-12	0.28	0.24	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-7.81	1.42e-14	4.15e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-7.81	1.43e-14	4.17e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	7.81	1.43e-14	4.17e-12	0.29	0.24	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-7.81	1.43e-14	4.17e-12	-0.33	-0.24	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
BRCA	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	7.81	1.43e-14	4.18e-12	0.31	0.24	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.81	1.44e-14	4.19e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-7.81	1.44e-14	4.19e-12	-0.27	-0.24	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
BRCA	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	7.81	1.44e-14	4.19e-12	0.3	0.24	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
BRCA	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-7.81	1.44e-14	4.19e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	7.81	1.44e-14	4.2e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
BRCA	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-7.8	1.45e-14	4.21e-12	-0.29	-0.24	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
BRCA	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-7.8	1.45e-14	4.22e-12	-0.32	-0.24	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
BRCA	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	7.8	1.45e-14	4.22e-12	0.33	0.24	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
BRCA	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	7.8	1.45e-14	4.24e-12	0.28	0.23	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-7.8	1.45e-14	4.24e-12	-0.31	-0.23	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
BRCA	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	7.8	1.46e-14	4.24e-12	0.56	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
BRCA	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-7.8	1.46e-14	4.25e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	7.8	1.46e-14	4.25e-12	0.25	0.23	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	7.8	1.46e-14	4.26e-12	0.25	0.23	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
BRCA	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-7.8	1.47e-14	4.28e-12	-0.33	-0.23	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
BRCA	cis	rs812925	0.659	rs2167565	ENSG00000271889.1	RP11-493E12.1	-7.8	1.47e-14	4.28e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr2:61249323	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	7.8	1.47e-14	4.29e-12	0.3	0.23	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-7.8	1.47e-14	4.29e-12	-0.3	-0.23	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-7.8	1.47e-14	4.29e-12	-0.24	-0.23	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
BRCA	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-7.8	1.47e-14	4.29e-12	-0.33	-0.23	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
BRCA	cis	rs250518	0.926	rs11747669	ENSG00000272081.1	CTD-2376I4.2	7.8	1.47e-14	4.3e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72760354	chr5:72955206~72955699:-
BRCA	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-7.8	1.48e-14	4.3e-12	-0.24	-0.23	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-7.8	1.48e-14	4.32e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-7.8	1.49e-14	4.33e-12	-0.28	-0.23	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
BRCA	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-7.8	1.49e-14	4.34e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-7.8	1.49e-14	4.34e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-7.8	1.49e-14	4.34e-12	-0.23	-0.23	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	7.8	1.49e-14	4.35e-12	0.2	0.23	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
BRCA	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	7.8	1.5e-14	4.35e-12	0.24	0.23	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
BRCA	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-7.8	1.5e-14	4.36e-12	-0.31	-0.23	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-7.8	1.5e-14	4.36e-12	-0.31	-0.23	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
BRCA	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-7.8	1.5e-14	4.36e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
BRCA	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	7.8	1.5e-14	4.36e-12	0.55	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
BRCA	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	7.8	1.5e-14	4.37e-12	0.24	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
BRCA	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	7.8	1.5e-14	4.37e-12	0.34	0.23	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	7.8	1.5e-14	4.38e-12	0.31	0.23	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
BRCA	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	7.8	1.5e-14	4.38e-12	0.21	0.23	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
BRCA	cis	rs4934494	0.727	rs2418929	ENSG00000240996.1	RP11-80H5.7	-7.8	1.5e-14	4.38e-12	-0.29	-0.23	Red blood cell count;	chr10:89741720	chr10:89694295~89697928:-
BRCA	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-7.8	1.51e-14	4.39e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
BRCA	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	7.8	1.51e-14	4.4e-12	0.27	0.23	Longevity;	chr3:48437629	chr3:48440352~48446656:-
BRCA	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.8	1.52e-14	4.41e-12	0.26	0.23	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
BRCA	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-7.8	1.52e-14	4.41e-12	-0.5	-0.23	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
BRCA	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
BRCA	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
BRCA	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	7.8	1.54e-14	4.47e-12	0.38	0.23	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
BRCA	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-7.8	1.54e-14	4.47e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	7.8	1.54e-14	4.47e-12	0.36	0.23	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
BRCA	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.8	1.54e-14	4.49e-12	-0.29	-0.23	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
BRCA	cis	rs12188164	0.543	rs7728027	ENSG00000225138.6	CTD-2228K2.7	-7.8	1.55e-14	4.5e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:459828	chr5:473236~480884:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-7.8	1.55e-14	4.51e-12	-0.15	-0.23	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
BRCA	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	7.8	1.55e-14	4.51e-12	0.34	0.23	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
BRCA	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	7.79	1.56e-14	4.54e-12	0.31	0.23	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
BRCA	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-7.79	1.57e-14	4.55e-12	-0.31	-0.23	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-7.79	1.57e-14	4.55e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-7.79	1.57e-14	4.55e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
BRCA	cis	rs755249	1	rs2293476	ENSG00000228060.1	RP11-69E11.8	7.79	1.57e-14	4.56e-12	0.28	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39565160~39573203:+
BRCA	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-7.79	1.57e-14	4.57e-12	-0.3	-0.23	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
BRCA	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	7.79	1.58e-14	4.59e-12	0.31	0.23	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-7.79	1.58e-14	4.61e-12	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-7.79	1.58e-14	4.61e-12	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-7.79	1.59e-14	4.62e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
BRCA	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-7.79	1.59e-14	4.62e-12	-0.28	-0.23	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
BRCA	cis	rs9880211	1	rs35899944	ENSG00000273486.1	RP11-731C17.2	7.79	1.59e-14	4.62e-12	0.31	0.23	Height;Body mass index;	chr3:136510215	chr3:136837338~136839021:-
BRCA	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	7.79	1.59e-14	4.62e-12	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
BRCA	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	7.79	1.59e-14	4.62e-12	0.29	0.23	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	7.79	1.59e-14	4.62e-12	0.29	0.23	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
BRCA	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	7.79	1.59e-14	4.62e-12	0.33	0.23	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000224316.1	RP11-479O9.2	-7.79	1.59e-14	4.63e-12	-0.26	-0.23	Aortic root size;	chr7:66153687	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-7.79	1.59e-14	4.63e-12	-0.29	-0.23	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-7.79	1.6e-14	4.64e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	7.79	1.6e-14	4.64e-12	0.25	0.23	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
BRCA	cis	rs3758911	0.964	rs11212158	ENSG00000255353.1	RP11-382M14.1	-7.79	1.6e-14	4.66e-12	-0.31	-0.23	Coronary artery disease;	chr11:107325745	chr11:107176286~107177530:+
BRCA	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	7.79	1.61e-14	4.66e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
BRCA	cis	rs853679	1	rs1936365	ENSG00000220721.1	OR1F12	-7.79	1.61e-14	4.67e-12	-0.36	-0.23	Depression;	chr6:28300675	chr6:28073316~28074233:+
BRCA	cis	rs4934494	0.834	rs1359624	ENSG00000240996.1	RP11-80H5.7	-7.79	1.61e-14	4.67e-12	-0.26	-0.23	Red blood cell count;	chr10:89635671	chr10:89694295~89697928:-
BRCA	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
BRCA	cis	rs1113500	0.636	rs3853493	ENSG00000226822.1	RP11-356N1.2	7.79	1.61e-14	4.68e-12	0.3	0.23	Growth-regulated protein alpha levels;	chr1:108094571	chr1:108071482~108074519:+
BRCA	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	7.79	1.61e-14	4.68e-12	0.32	0.23	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.69e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
BRCA	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-7.79	1.62e-14	4.7e-12	-0.31	-0.23	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
BRCA	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-7.79	1.62e-14	4.7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-7.79	1.62e-14	4.7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
BRCA	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.79	1.63e-14	4.73e-12	-0.3	-0.23	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
BRCA	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	7.79	1.63e-14	4.74e-12	0.3	0.23	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
BRCA	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	7.79	1.63e-14	4.74e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	-7.79	1.63e-14	4.74e-12	-0.28	-0.23	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
BRCA	cis	rs1113500	0.73	rs1343203	ENSG00000226822.1	RP11-356N1.2	7.79	1.64e-14	4.75e-12	0.31	0.23	Growth-regulated protein alpha levels;	chr1:108048560	chr1:108071482~108074519:+
BRCA	cis	rs6545883	0.929	rs2421203	ENSG00000271889.1	RP11-493E12.1	7.79	1.64e-14	4.75e-12	0.3	0.23	Tuberculosis;	chr2:61442113	chr2:61151433~61162105:-
BRCA	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-7.79	1.64e-14	4.76e-12	-0.31	-0.23	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
BRCA	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	7.79	1.64e-14	4.76e-12	0.37	0.23	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
BRCA	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-7.79	1.64e-14	4.77e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	7.79	1.65e-14	4.78e-12	0.26	0.23	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
BRCA	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	7.79	1.65e-14	4.78e-12	0.36	0.23	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
BRCA	cis	rs7927771	0.8	rs11039200	ENSG00000280615.1	Y_RNA	-7.79	1.65e-14	4.79e-12	-0.3	-0.23	Subjective well-being;	chr11:47358095	chr11:47614898~47614994:-
BRCA	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	7.79	1.65e-14	4.79e-12	0.29	0.23	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	7.79	1.66e-14	4.81e-12	0.36	0.23	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
BRCA	cis	rs34779708	0.766	rs7897088	ENSG00000271335.4	RP11-324I22.4	7.79	1.66e-14	4.81e-12	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35314552~35336401:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	7.79	1.66e-14	4.81e-12	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
BRCA	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	7.79	1.66e-14	4.82e-12	0.29	0.23	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
BRCA	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	7.79	1.67e-14	4.83e-12	0.33	0.23	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.894	rs12997538	ENSG00000271889.1	RP11-493E12.1	-7.79	1.67e-14	4.84e-12	-0.31	-0.23	Tuberculosis;	chr2:61337114	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-7.79	1.67e-14	4.84e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.869	rs10251227	ENSG00000225498.1	AC002064.5	7.79	1.67e-14	4.84e-12	0.23	0.23	Homocysteine levels;	chr7:90262972	chr7:90312496~90322592:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	7.79	1.67e-14	4.84e-12	0.37	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
BRCA	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-7.79	1.67e-14	4.84e-12	-0.31	-0.23	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	7.78	1.68e-14	4.86e-12	0.15	0.23	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000273024.4	INTS4P2	7.78	1.68e-14	4.86e-12	0.27	0.23	Calcium levels;	chr7:65733651	chr7:65647864~65715661:+
BRCA	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-7.78	1.68e-14	4.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
BRCA	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	7.78	1.68e-14	4.87e-12	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.894	rs2593633	ENSG00000271889.1	RP11-493E12.1	-7.78	1.69e-14	4.89e-12	-0.3	-0.23	Tuberculosis;	chr2:61344378	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-7.78	1.69e-14	4.89e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
BRCA	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	7.78	1.69e-14	4.91e-12	0.31	0.23	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	7.78	1.69e-14	4.91e-12	0.31	0.23	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-7.78	1.7e-14	4.93e-12	-0.28	-0.23	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	7.78	1.7e-14	4.93e-12	0.3	0.23	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
BRCA	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	7.78	1.7e-14	4.93e-12	0.33	0.23	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9878078	ENSG00000273486.1	RP11-731C17.2	7.78	1.7e-14	4.93e-12	0.31	0.23	Height;Body mass index;	chr3:136518731	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-7.78	1.71e-14	4.94e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
BRCA	cis	rs12188164	0.543	rs890972	ENSG00000225138.6	CTD-2228K2.7	-7.78	1.71e-14	4.95e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:462350	chr5:473236~480884:+
BRCA	cis	rs12188164	0.543	rs2434694	ENSG00000225138.6	CTD-2228K2.7	-7.78	1.71e-14	4.95e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:462619	chr5:473236~480884:+
BRCA	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	7.78	1.71e-14	4.95e-12	0.27	0.23	Longevity;	chr3:48431794	chr3:48440352~48446656:-
BRCA	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	7.78	1.71e-14	4.97e-12	0.33	0.23	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-7.78	1.72e-14	4.98e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-7.78	1.73e-14	5.01e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
BRCA	cis	rs8012947	0.651	rs8008129	ENSG00000279636.2	LINC00216	7.78	1.73e-14	5.01e-12	0.25	0.23	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	7.78	1.73e-14	5.02e-12	0.25	0.23	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	7.78	1.74e-14	5.03e-12	0.24	0.23	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
BRCA	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-7.78	1.74e-14	5.04e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
BRCA	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-7.78	1.74e-14	5.04e-12	-0.29	-0.23	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
BRCA	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-7.78	1.75e-14	5.07e-12	-0.3	-0.23	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-7.78	1.75e-14	5.07e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	7.78	1.75e-14	5.08e-12	0.34	0.23	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
BRCA	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-7.78	1.76e-14	5.09e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
BRCA	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.78	1.76e-14	5.1e-12	0.25	0.23	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-7.78	1.77e-14	5.12e-12	-0.28	-0.23	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-7.78	1.77e-14	5.12e-12	-0.28	-0.23	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.894	rs1186703	ENSG00000271889.1	RP11-493E12.1	7.78	1.77e-14	5.12e-12	0.3	0.23	Tuberculosis;	chr2:61445830	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-7.78	1.77e-14	5.13e-12	-0.26	-0.23	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
BRCA	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	7.78	1.78e-14	5.15e-12	0.27	0.23	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
BRCA	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-7.78	1.78e-14	5.16e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
BRCA	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	7.78	1.78e-14	5.16e-12	0.33	0.23	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
BRCA	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-14	5.2e-12	0.36	0.23	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
BRCA	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-7.78	1.8e-14	5.21e-12	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-7.77	1.81e-14	5.23e-12	-0.29	-0.23	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
BRCA	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-7.77	1.81e-14	5.24e-12	-0.33	-0.23	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	7.77	1.81e-14	5.24e-12	0.3	0.23	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
BRCA	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	7.77	1.81e-14	5.25e-12	0.25	0.23	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
BRCA	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-7.77	1.82e-14	5.25e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
BRCA	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-7.77	1.82e-14	5.25e-12	-0.27	-0.23	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
BRCA	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	7.77	1.82e-14	5.25e-12	0.35	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
BRCA	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-7.77	1.82e-14	5.25e-12	-0.33	-0.23	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-7.77	1.82e-14	5.25e-12	-0.33	-0.23	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
BRCA	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-7.77	1.82e-14	5.26e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-7.77	1.82e-14	5.26e-12	-0.31	-0.23	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
BRCA	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-7.77	1.82e-14	5.27e-12	-0.31	-0.23	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
BRCA	cis	rs3758911	0.828	rs10789598	ENSG00000255353.1	RP11-382M14.1	-7.77	1.83e-14	5.28e-12	-0.32	-0.23	Coronary artery disease;	chr11:107307878	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212143	ENSG00000255353.1	RP11-382M14.1	-7.77	1.83e-14	5.28e-12	-0.32	-0.23	Coronary artery disease;	chr11:107308554	chr11:107176286~107177530:+
BRCA	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	7.77	1.83e-14	5.29e-12	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
BRCA	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-7.77	1.83e-14	5.29e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
BRCA	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-7.77	1.83e-14	5.3e-12	-0.3	-0.23	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
BRCA	cis	rs6539288	0.933	rs1037012	ENSG00000260329.1	RP11-412D9.4	-7.77	1.83e-14	5.3e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106908899	chr12:106954029~106955497:-
BRCA	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	7.77	1.83e-14	5.3e-12	0.37	0.23	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
BRCA	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-7.77	1.85e-14	5.33e-12	-0.27	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
BRCA	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-7.77	1.85e-14	5.33e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	7.77	1.86e-14	5.37e-12	0.25	0.23	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
BRCA	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-7.77	1.86e-14	5.37e-12	-0.27	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
BRCA	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-7.77	1.86e-14	5.38e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.868	rs28749199	ENSG00000271889.1	RP11-493E12.1	7.77	1.87e-14	5.39e-12	0.31	0.23	Tuberculosis;	chr2:61599917	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-7.77	1.87e-14	5.4e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-7.77	1.88e-14	5.42e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	7.77	1.88e-14	5.42e-12	0.24	0.23	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
BRCA	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-7.77	1.88e-14	5.43e-12	-0.32	-0.23	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
BRCA	cis	rs9527	0.571	rs12219246	ENSG00000213061.2	PFN1P11	7.77	1.89e-14	5.46e-12	0.31	0.23	Arsenic metabolism;	chr10:102853598	chr10:102838011~102845473:-
BRCA	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	7.77	1.89e-14	5.46e-12	0.32	0.23	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
BRCA	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	7.77	1.9e-14	5.47e-12	0.22	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
BRCA	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-7.77	1.9e-14	5.49e-12	-0.29	-0.23	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-7.77	1.91e-14	5.5e-12	-0.24	-0.23	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
BRCA	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-7.77	1.91e-14	5.51e-12	-0.32	-0.23	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
BRCA	cis	rs6539288	0.899	rs7298423	ENSG00000260329.1	RP11-412D9.4	-7.77	1.92e-14	5.53e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106908202	chr12:106954029~106955497:-
BRCA	cis	rs250518	0.926	rs2338791	ENSG00000272081.1	CTD-2376I4.2	7.77	1.92e-14	5.55e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72770970	chr5:72955206~72955699:-
BRCA	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	7.77	1.92e-14	5.55e-12	0.22	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	7.77	1.93e-14	5.56e-12	0.28	0.23	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
BRCA	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-7.77	1.93e-14	5.56e-12	-0.28	-0.23	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	7.77	1.94e-14	5.59e-12	0.28	0.23	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.567	rs12669304	ENSG00000225498.1	AC002064.5	7.77	1.94e-14	5.6e-12	0.22	0.23	Homocysteine levels;	chr7:90261726	chr7:90312496~90322592:+
BRCA	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-7.77	1.94e-14	5.6e-12	-0.33	-0.23	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
BRCA	cis	rs2115630	0.754	rs12595321	ENSG00000225151.9	GOLGA2P7	7.77	1.94e-14	5.6e-12	0.26	0.23	P wave terminal force;	chr15:84788038	chr15:84199311~84230136:-
BRCA	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
BRCA	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
BRCA	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-7.76	1.95e-14	5.62e-12	-0.28	-0.23	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
BRCA	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-7.76	1.95e-14	5.63e-12	-0.37	-0.23	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
BRCA	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-7.76	1.96e-14	5.65e-12	-0.31	-0.23	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs9857966	ENSG00000273486.1	RP11-731C17.2	7.76	1.96e-14	5.65e-12	0.31	0.23	Height;Body mass index;	chr3:136560548	chr3:136837338~136839021:-
BRCA	cis	rs58873874	0.579	rs3815829	ENSG00000251405.2	CTB-109A12.1	7.76	1.96e-14	5.66e-12	0.52	0.23	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157362615~157460078:-
BRCA	cis	rs516805	0.961	rs510283	ENSG00000279114.1	RP3-425C14.5	-7.76	1.96e-14	5.66e-12	-0.24	-0.23	Lymphocyte counts;	chr6:122451547	chr6:122471923~122484161:+
BRCA	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	7.76	1.96e-14	5.66e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
BRCA	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	7.76	1.97e-14	5.68e-12	0.25	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
BRCA	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	7.76	1.97e-14	5.69e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	7.76	1.97e-14	5.69e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
BRCA	cis	rs9880211	1	rs17200216	ENSG00000273486.1	RP11-731C17.2	7.76	1.97e-14	5.69e-12	0.31	0.23	Height;Body mass index;	chr3:136348390	chr3:136837338~136839021:-
BRCA	cis	rs12188164	0.525	rs2561665	ENSG00000225138.6	CTD-2228K2.7	-7.76	1.97e-14	5.69e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:460020	chr5:473236~480884:+
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	7.76	1.97e-14	5.69e-12	0.3	0.23	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
BRCA	cis	rs4934494	0.681	rs12572928	ENSG00000240996.1	RP11-80H5.7	-7.76	1.97e-14	5.69e-12	-0.3	-0.23	Red blood cell count;	chr10:89793792	chr10:89694295~89697928:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-7.76	1.98e-14	5.71e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	7.76	1.98e-14	5.71e-12	0.34	0.23	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
BRCA	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-7.76	1.99e-14	5.72e-12	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
BRCA	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	7.76	2e-14	5.75e-12	0.28	0.23	QT interval;	chr12:29255074	chr12:29280418~29317848:-
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-7.76	2.01e-14	5.79e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
BRCA	cis	rs42648	0.935	rs42635	ENSG00000225498.1	AC002064.5	7.76	2.01e-14	5.8e-12	0.23	0.23	Homocysteine levels;	chr7:90336884	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	7.76	2.02e-14	5.8e-12	0.32	0.23	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
BRCA	cis	rs6472827	0.645	rs2977067	ENSG00000253983.2	RP1-16A9.1	7.76	2.02e-14	5.81e-12	0.32	0.23	Uterine fibroids;	chr8:74190596	chr8:74199396~74208441:+
BRCA	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	7.76	2.02e-14	5.82e-12	0.26	0.23	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-7.76	2.05e-14	5.9e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
BRCA	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	7.76	2.06e-14	5.94e-12	0.24	0.23	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
BRCA	cis	rs2060793	0.519	rs10766187	ENSG00000251991.1	RNU7-49P	7.76	2.06e-14	5.94e-12	0.25	0.23	Vitamin D levels;	chr11:14603836	chr11:14478892~14478953:+
BRCA	cis	rs42648	0.905	rs42641	ENSG00000225498.1	AC002064.5	7.76	2.07e-14	5.94e-12	0.23	0.23	Homocysteine levels;	chr7:90343450	chr7:90312496~90322592:+
BRCA	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	7.76	2.07e-14	5.95e-12	0.25	0.23	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
BRCA	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-7.76	2.07e-14	5.96e-12	-0.31	-0.23	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-7.76	2.07e-14	5.96e-12	-0.31	-0.23	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
BRCA	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	7.76	2.07e-14	5.96e-12	0.31	0.23	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
BRCA	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	7.76	2.08e-14	5.97e-12	0.28	0.23	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
BRCA	cis	rs7131987	0.527	rs7308534	ENSG00000275476.1	RP11-996F15.4	7.76	2.08e-14	5.98e-12	0.27	0.23	QT interval;	chr12:29300269	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-7.76	2.08e-14	5.98e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-7.76	2.09e-14	6.01e-12	-0.31	-0.23	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
BRCA	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-7.76	2.09e-14	6.01e-12	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	7.75	2.1e-14	6.04e-12	0.24	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
BRCA	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-7.75	2.1e-14	6.04e-12	-0.25	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	7.75	2.1e-14	6.05e-12	0.28	0.23	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
BRCA	cis	rs250518	0.926	rs266428	ENSG00000272081.1	CTD-2376I4.2	-7.75	2.11e-14	6.06e-12	-0.3	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72832940	chr5:72955206~72955699:-
BRCA	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-7.75	2.11e-14	6.06e-12	-0.23	-0.23	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
BRCA	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	7.75	2.11e-14	6.06e-12	0.26	0.23	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
BRCA	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	7.75	2.11e-14	6.07e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
BRCA	cis	rs42648	0.748	rs6972119	ENSG00000225498.1	AC002064.5	7.75	2.11e-14	6.07e-12	0.22	0.23	Homocysteine levels;	chr7:90264694	chr7:90312496~90322592:+
BRCA	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	7.75	2.12e-14	6.08e-12	0.23	0.23	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	7.75	2.12e-14	6.09e-12	0.28	0.23	Shingles;	chr7:38346957	chr7:38353715~38354517:-
BRCA	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	7.75	2.12e-14	6.1e-12	0.25	0.23	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
BRCA	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-7.75	2.12e-14	6.1e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
BRCA	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-7.75	2.12e-14	6.1e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
BRCA	cis	rs6539288	0.899	rs7956807	ENSG00000260329.1	RP11-412D9.4	-7.75	2.13e-14	6.12e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106906748	chr12:106954029~106955497:-
BRCA	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-7.75	2.13e-14	6.12e-12	-0.29	-0.23	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-7.75	2.14e-14	6.14e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
BRCA	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-7.75	2.14e-14	6.15e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.75	2.14e-14	6.15e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	7.75	2.14e-14	6.15e-12	0.32	0.23	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
BRCA	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-7.75	2.15e-14	6.17e-12	-0.34	-0.23	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
BRCA	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-7.75	2.15e-14	6.17e-12	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
BRCA	cis	rs42648	0.935	rs42621	ENSG00000225498.1	AC002064.5	7.75	2.15e-14	6.17e-12	0.23	0.23	Homocysteine levels;	chr7:90327170	chr7:90312496~90322592:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-7.75	2.15e-14	6.17e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
BRCA	cis	rs712022	0.534	rs7927085	ENSG00000246225.5	RP11-17A1.3	-7.75	2.15e-14	6.17e-12	-0.28	-0.23	Dialysis-related mortality;	chr11:22852337	chr11:22829380~22945393:+
BRCA	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	7.75	2.16e-14	6.2e-12	0.26	0.23	Longevity;	chr3:48421052	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	7.75	2.16e-14	6.2e-12	0.26	0.23	Longevity;	chr3:48422302	chr3:48440352~48446656:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	7.75	2.16e-14	6.2e-12	0.18	0.23	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	7.75	2.16e-14	6.2e-12	0.18	0.23	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
BRCA	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	7.75	2.16e-14	6.21e-12	0.35	0.23	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
BRCA	cis	rs6545883	0.894	rs2463102	ENSG00000271889.1	RP11-493E12.1	-7.75	2.16e-14	6.21e-12	-0.3	-0.23	Tuberculosis;	chr2:61344160	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-7.75	2.17e-14	6.22e-12	-0.28	-0.23	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
BRCA	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-7.75	2.17e-14	6.22e-12	-0.26	-0.23	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
BRCA	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	7.75	2.17e-14	6.22e-12	0.24	0.23	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
BRCA	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	7.75	2.18e-14	6.26e-12	0.22	0.23	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
BRCA	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-7.75	2.19e-14	6.27e-12	-0.29	-0.23	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	7.75	2.19e-14	6.28e-12	0.19	0.23	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
BRCA	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-7.75	2.19e-14	6.29e-12	-0.31	-0.23	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.75	2.19e-14	6.29e-12	-0.29	-0.23	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
BRCA	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	7.75	2.19e-14	6.29e-12	0.26	0.23	Longevity;	chr3:48429347	chr3:48440352~48446656:-
BRCA	cis	rs919433	1	rs6741380	ENSG00000231621.1	AC013264.2	-7.75	2.19e-14	6.29e-12	-0.22	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197300397	chr2:197197991~197199273:+
BRCA	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	7.75	2.19e-14	6.29e-12	0.29	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
BRCA	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.75	2.2e-14	6.31e-12	-0.29	-0.23	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
BRCA	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-7.75	2.2e-14	6.31e-12	-0.51	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
BRCA	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-7.75	2.2e-14	6.33e-12	-0.27	-0.23	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
BRCA	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-7.75	2.21e-14	6.33e-12	-0.31	-0.23	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
BRCA	cis	rs6539288	0.933	rs4964498	ENSG00000260329.1	RP11-412D9.4	-7.75	2.21e-14	6.34e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106912945	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
BRCA	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	7.75	2.22e-14	6.36e-12	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
BRCA	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	7.75	2.22e-14	6.37e-12	0.31	0.23	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-7.75	2.23e-14	6.39e-12	-0.28	-0.23	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
BRCA	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	7.75	2.23e-14	6.4e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
BRCA	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	7.75	2.23e-14	6.41e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
BRCA	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	7.75	2.24e-14	6.41e-12	0.28	0.23	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
BRCA	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	7.75	2.24e-14	6.42e-12	0.3	0.23	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	7.74	2.27e-14	6.49e-12	0.26	0.23	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	7.74	2.27e-14	6.5e-12	0.24	0.23	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
BRCA	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	7.74	2.27e-14	6.5e-12	0.29	0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
BRCA	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-7.74	2.28e-14	6.52e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-7.74	2.28e-14	6.53e-12	-0.24	-0.23	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
BRCA	cis	rs16978956	0.592	rs16990336	ENSG00000236474.1	GCNT1P1	7.74	2.28e-14	6.53e-12	0.33	0.23	Body mass index;	chr20:18348968	chr20:18420160~18421454:-
BRCA	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-7.74	2.29e-14	6.55e-12	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
BRCA	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-7.74	2.29e-14	6.55e-12	-0.28	-0.23	Height;	chr2:46640019	chr2:46668870~46670778:+
BRCA	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	7.74	2.29e-14	6.55e-12	0.3	0.23	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
BRCA	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	7.74	2.29e-14	6.57e-12	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-7.74	2.29e-14	6.57e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
BRCA	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	7.74	2.29e-14	6.57e-12	0.43	0.23	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
BRCA	cis	rs10200159	1	rs6739788	ENSG00000272606.1	RP11-554J4.1	7.74	2.3e-14	6.58e-12	0.44	0.23	Vitiligo;	chr2:55635220	chr2:55617909~55618373:+
BRCA	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	7.74	2.3e-14	6.58e-12	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-7.74	2.3e-14	6.58e-12	-0.41	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
BRCA	cis	rs6539288	0.933	rs2053205	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106912489	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs759605	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913401	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs759604	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913518	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.899	rs759603	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913613	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs2075289	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913860	chr12:106954029~106955497:-
BRCA	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	7.74	2.3e-14	6.59e-12	0.3	0.23	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-7.74	2.3e-14	6.59e-12	-0.42	-0.23	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
BRCA	cis	rs8012947	0.565	rs12891852	ENSG00000279636.2	LINC00216	-7.74	2.31e-14	6.61e-12	-0.24	-0.23	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	7.74	2.31e-14	6.61e-12	0.24	0.23	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
BRCA	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-7.74	2.31e-14	6.62e-12	-0.31	-0.23	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
BRCA	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	7.74	2.32e-14	6.64e-12	0.28	0.23	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
BRCA	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	7.74	2.32e-14	6.64e-12	0.34	0.23	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
BRCA	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-7.74	2.33e-14	6.66e-12	-0.26	-0.23	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
BRCA	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	7.74	2.33e-14	6.67e-12	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
BRCA	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	7.74	2.33e-14	6.67e-12	0.28	0.23	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
BRCA	cis	rs3758911	1	rs11212164	ENSG00000255353.1	RP11-382M14.1	-7.74	2.33e-14	6.68e-12	-0.3	-0.23	Coronary artery disease;	chr11:107328113	chr11:107176286~107177530:+
BRCA	cis	rs9880211	1	rs28811905	ENSG00000273486.1	RP11-731C17.2	7.74	2.34e-14	6.69e-12	0.31	0.23	Height;Body mass index;	chr3:136533210	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-7.74	2.34e-14	6.7e-12	-0.35	-0.23	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
BRCA	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	7.74	2.34e-14	6.71e-12	0.27	0.23	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
BRCA	cis	rs6539288	0.705	rs1053051	ENSG00000260329.1	RP11-412D9.4	-7.74	2.34e-14	6.71e-12	-0.26	-0.23	Total body bone mineral density;	chr12:106973447	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.71e-12	-0.28	-0.23	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
BRCA	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	7.74	2.35e-14	6.72e-12	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
BRCA	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-7.74	2.35e-14	6.72e-12	-0.2	-0.23	Breast cancer;	chr11:743813	chr11:781645~782105:+
BRCA	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-7.74	2.36e-14	6.74e-12	-0.31	-0.23	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs28877020	ENSG00000273486.1	RP11-731C17.2	7.74	2.36e-14	6.75e-12	0.31	0.23	Height;Body mass index;	chr3:136676874	chr3:136837338~136839021:-
BRCA	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-7.74	2.36e-14	6.76e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
BRCA	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-7.74	2.36e-14	6.76e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
BRCA	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	7.74	2.36e-14	6.76e-12	0.34	0.23	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
BRCA	cis	rs3758911	0.894	rs10749902	ENSG00000255353.1	RP11-382M14.1	-7.74	2.37e-14	6.77e-12	-0.31	-0.23	Coronary artery disease;	chr11:107324855	chr11:107176286~107177530:+
BRCA	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
BRCA	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-7.74	2.37e-14	6.77e-12	-0.27	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
BRCA	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	7.74	2.37e-14	6.78e-12	0.27	0.23	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-7.74	2.38e-14	6.8e-12	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
BRCA	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-7.74	2.39e-14	6.83e-12	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
BRCA	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	7.74	2.39e-14	6.83e-12	0.46	0.23	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
BRCA	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-7.74	2.39e-14	6.83e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
BRCA	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	7.74	2.39e-14	6.84e-12	0.3	0.23	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
BRCA	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	7.74	2.4e-14	6.86e-12	0.43	0.23	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
BRCA	cis	rs9402682	0.668	rs2026938	ENSG00000232876.1	CTA-212D2.2	-7.74	2.41e-14	6.88e-12	-0.33	-0.23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135122871	chr6:135055033~135060550:+
BRCA	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-7.74	2.41e-14	6.88e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-7.74	2.41e-14	6.88e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.74	2.41e-14	6.89e-12	0.32	0.23	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
BRCA	cis	rs7520050	0.807	rs5021934	ENSG00000280836.1	AL355480.1	7.74	2.42e-14	6.9e-12	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-7.74	2.42e-14	6.9e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-7.74	2.42e-14	6.91e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-7.74	2.42e-14	6.91e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
BRCA	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	7.74	2.42e-14	6.91e-12	0.31	0.23	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
BRCA	cis	rs9527	0.637	rs7085104	ENSG00000213061.2	PFN1P11	7.74	2.42e-14	6.92e-12	0.31	0.23	Arsenic metabolism;	chr10:102869116	chr10:102838011~102845473:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
BRCA	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	7.74	2.43e-14	6.95e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	7.74	2.43e-14	6.95e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
BRCA	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	7.73	2.44e-14	6.98e-12	0.23	0.23	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-7.73	2.45e-14	6.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-7.73	2.45e-14	6.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
BRCA	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-7.73	2.45e-14	7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-7.73	2.45e-14	7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.73	2.45e-14	7e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.73	2.45e-14	7e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
BRCA	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	7.73	2.46e-14	7.01e-12	0.26	0.23	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
BRCA	cis	rs763512	0.532	rs3110626	ENSG00000276054.1	RP11-378E13.3	-7.73	2.46e-14	7.01e-12	-0.34	-0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37386886~37387926:+
BRCA	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-7.73	2.46e-14	7.01e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	7.73	2.46e-14	7.02e-12	0.28	0.23	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	7.73	2.46e-14	7.04e-12	0.32	0.23	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	7.73	2.47e-14	7.04e-12	0.28	0.23	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	7.73	2.47e-14	7.04e-12	0.24	0.23	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.828	rs11212138	ENSG00000255353.1	RP11-382M14.1	-7.73	2.47e-14	7.04e-12	-0.32	-0.23	Coronary artery disease;	chr11:107294553	chr11:107176286~107177530:+
BRCA	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-7.73	2.47e-14	7.05e-12	-0.35	-0.23	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-7.73	2.47e-14	7.05e-12	-0.56	-0.23	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
BRCA	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-7.73	2.48e-14	7.06e-12	-0.32	-0.23	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
BRCA	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	7.73	2.48e-14	7.08e-12	0.28	0.23	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
BRCA	cis	rs250518	0.926	rs6897924	ENSG00000272081.1	CTD-2376I4.2	7.73	2.48e-14	7.09e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72765713	chr5:72955206~72955699:-
BRCA	cis	rs10022462	0.933	rs10516806	ENSG00000246375.2	RP11-10L7.1	7.73	2.49e-14	7.12e-12	0.3	0.23	Breast cancer;Blood metabolite levels;	chr4:88325062	chr4:88284942~88331421:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000224316.1	RP11-479O9.2	7.73	2.5e-14	7.14e-12	0.26	0.23	Aortic root size;	chr7:66175760	chr7:65773620~65802067:+
BRCA	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-7.73	2.51e-14	7.17e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	7.73	2.52e-14	7.18e-12	0.25	0.23	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	7.73	2.52e-14	7.19e-12	0.3	0.23	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
BRCA	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-7.73	2.52e-14	7.2e-12	-0.34	-0.23	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
BRCA	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-7.73	2.53e-14	7.21e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-7.73	2.54e-14	7.23e-12	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
BRCA	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-7.73	2.54e-14	7.24e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
BRCA	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-7.73	2.54e-14	7.26e-12	-0.3	-0.23	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
BRCA	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	7.73	2.55e-14	7.27e-12	0.29	0.23	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
BRCA	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	7.73	2.55e-14	7.27e-12	0.29	0.23	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
BRCA	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-7.73	2.55e-14	7.28e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
BRCA	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	7.73	2.56e-14	7.29e-12	0.35	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
BRCA	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	7.73	2.56e-14	7.3e-12	0.31	0.23	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
BRCA	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	7.73	2.57e-14	7.32e-12	0.23	0.23	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
BRCA	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	7.73	2.57e-14	7.32e-12	0.25	0.23	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
BRCA	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	7.73	2.57e-14	7.32e-12	0.27	0.23	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	7.73	2.57e-14	7.32e-12	0.27	0.23	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-7.73	2.58e-14	7.34e-12	-0.34	-0.23	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-7.73	2.59e-14	7.39e-12	-0.31	-0.23	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
BRCA	cis	rs7432375	0.566	rs835636	ENSG00000239213.4	NCK1-AS1	7.73	2.6e-14	7.4e-12	0.24	0.23	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136841726~136862054:-
BRCA	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-7.73	2.61e-14	7.42e-12	-0.33	-0.23	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000224316.1	RP11-479O9.2	-7.73	2.61e-14	7.45e-12	-0.26	-0.23	Aortic root size;	chr7:66154218	chr7:65773620~65802067:+
BRCA	cis	rs6565180	0.632	rs8050812	ENSG00000273724.1	RP11-347C12.12	-7.73	2.62e-14	7.45e-12	-0.3	-0.23	Tonsillectomy;	chr16:30374516	chr16:30336400~30343336:+
BRCA	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	7.72	2.62e-14	7.47e-12	0.27	0.23	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
BRCA	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-7.72	2.62e-14	7.47e-12	-0.3	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
BRCA	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	7.72	2.62e-14	7.47e-12	0.23	0.23	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-7.72	2.63e-14	7.49e-12	-0.41	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
BRCA	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-7.72	2.65e-14	7.53e-12	-0.18	-0.23	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
BRCA	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-7.72	2.65e-14	7.54e-12	-0.29	-0.23	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-7.72	2.65e-14	7.54e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
BRCA	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-7.72	2.65e-14	7.54e-12	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
BRCA	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	7.72	2.65e-14	7.54e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
BRCA	cis	rs3758911	0.861	rs2355840	ENSG00000255353.1	RP11-382M14.1	-7.72	2.65e-14	7.55e-12	-0.32	-0.23	Coronary artery disease;	chr11:107287251	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212132	ENSG00000255353.1	RP11-382M14.1	-7.72	2.65e-14	7.55e-12	-0.32	-0.23	Coronary artery disease;	chr11:107288576	chr11:107176286~107177530:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7.72	2.66e-14	7.58e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
BRCA	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	7.72	2.67e-14	7.61e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
BRCA	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	7.72	2.68e-14	7.63e-12	0.28	0.23	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
BRCA	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	7.72	2.69e-14	7.65e-12	0.23	0.23	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
BRCA	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-7.72	2.69e-14	7.67e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
BRCA	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	7.72	2.69e-14	7.67e-12	0.23	0.23	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	7.72	2.7e-14	7.69e-12	0.28	0.23	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
BRCA	cis	rs2279440	0.85	rs3872707	ENSG00000206573.7	THUMPD3-AS1	-7.72	2.71e-14	7.71e-12	-0.26	-0.23	Glucose homeostasis traits;	chr3:9472332	chr3:9349689~9398579:-
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.71e-12	0.34	0.23	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
BRCA	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	7.72	2.73e-14	7.75e-12	0.33	0.23	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
BRCA	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	7.72	2.73e-14	7.75e-12	0.35	0.23	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
BRCA	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.72	2.73e-14	7.75e-12	-0.31	-0.23	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
BRCA	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-7.72	2.73e-14	7.76e-12	-0.35	-0.23	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
BRCA	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	7.72	2.73e-14	7.77e-12	0.3	0.23	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-7.72	2.74e-14	7.79e-12	-0.28	-0.23	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
BRCA	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	7.72	2.74e-14	7.8e-12	0.31	0.23	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
BRCA	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	7.72	2.74e-14	7.8e-12	0.25	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	7.72	2.74e-14	7.8e-12	0.24	0.23	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	7.72	2.74e-14	7.8e-12	0.24	0.23	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
BRCA	cis	rs293748	0.771	rs35899185	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.75e-14	7.81e-12	-0.33	-0.23	Obesity-related traits;	chr5:36795884	chr5:36666214~36725195:-
BRCA	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	7.72	2.75e-14	7.81e-12	0.28	0.23	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
BRCA	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-7.72	2.75e-14	7.81e-12	-0.29	-0.23	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
BRCA	cis	rs250518	0.692	rs10074296	ENSG00000272081.1	CTD-2376I4.2	7.72	2.75e-14	7.83e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72791089	chr5:72955206~72955699:-
BRCA	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	7.72	2.76e-14	7.83e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
BRCA	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-7.72	2.76e-14	7.84e-12	-0.27	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
BRCA	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.657	rs16903342	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.77e-14	7.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:36792480	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.657	rs72732585	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.77e-14	7.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:36792493	chr5:36666214~36725195:-
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-7.72	2.77e-14	7.87e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
BRCA	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	7.72	2.77e-14	7.88e-12	0.27	0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
BRCA	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-7.72	2.78e-14	7.89e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	7.72	2.78e-14	7.89e-12	0.28	0.23	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs13184774	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36803578	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.713	rs292162	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36803778	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292166	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36805367	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	7.72	2.78e-14	7.91e-12	0.34	0.23	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
BRCA	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-7.72	2.79e-14	7.93e-12	-0.29	-0.23	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
BRCA	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-7.72	2.8e-14	7.94e-12	-0.29	-0.23	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-7.72	2.81e-14	7.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-7.72	2.81e-14	7.99e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-7.72	2.81e-14	7.99e-12	-0.31	-0.23	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
BRCA	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	7.72	2.81e-14	7.99e-12	0.28	0.23	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000225151.9	GOLGA2P7	7.72	2.82e-14	8e-12	0.25	0.23	P wave terminal force;	chr15:84791721	chr15:84199311~84230136:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-7.72	2.82e-14	8e-12	-0.34	-0.23	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
BRCA	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	7.72	2.82e-14	8.01e-12	0.29	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
BRCA	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-7.71	2.82e-14	8.02e-12	-0.26	-0.23	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
BRCA	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	7.71	2.83e-14	8.03e-12	0.44	0.23	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
BRCA	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-7.71	2.84e-14	8.05e-12	-0.29	-0.23	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
BRCA	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-7.71	2.84e-14	8.05e-12	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
BRCA	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	7.71	2.84e-14	8.06e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	7.71	2.84e-14	8.06e-12	0.26	0.23	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
BRCA	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	7.71	2.84e-14	8.07e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	7.71	2.84e-14	8.07e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	7.71	2.85e-14	8.08e-12	0.34	0.23	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
BRCA	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-7.71	2.85e-14	8.09e-12	-0.31	-0.23	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
BRCA	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	7.71	2.86e-14	8.12e-12	0.34	0.23	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
BRCA	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	7.71	2.87e-14	8.15e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	7.71	2.87e-14	8.15e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
BRCA	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	7.71	2.87e-14	8.15e-12	0.28	0.23	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
BRCA	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-7.71	2.87e-14	8.16e-12	-0.23	-0.23	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
BRCA	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	7.71	2.88e-14	8.18e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-7.71	2.88e-14	8.18e-12	-0.28	-0.23	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
BRCA	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-7.71	2.88e-14	8.18e-12	-0.36	-0.23	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
BRCA	cis	rs9527	0.637	rs7096169	ENSG00000236937.2	PTGES3P4	7.71	2.89e-14	8.19e-12	0.3	0.23	Arsenic metabolism;	chr10:102858938	chr10:102845595~102845950:+
BRCA	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	7.71	2.89e-14	8.19e-12	0.27	0.23	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
BRCA	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-7.71	2.89e-14	8.2e-12	-0.29	-0.23	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-7.71	2.89e-14	8.2e-12	-0.29	-0.23	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
BRCA	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-7.71	2.89e-14	8.2e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
BRCA	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-7.71	2.9e-14	8.21e-12	-0.31	-0.23	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
BRCA	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-7.71	2.9e-14	8.22e-12	-0.3	-0.23	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-7.71	2.9e-14	8.22e-12	-0.24	-0.23	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
BRCA	cis	rs58873874	0.737	rs10061544	ENSG00000248544.2	CTB-47B11.3	7.71	2.9e-14	8.22e-12	0.51	0.23	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs10078836	ENSG00000248544.2	CTB-47B11.3	7.71	2.9e-14	8.22e-12	0.51	0.23	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157375741~157384950:-
BRCA	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	7.71	2.91e-14	8.24e-12	0.2	0.23	Breast cancer;	chr11:750849	chr11:781645~782105:+
BRCA	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	7.71	2.91e-14	8.24e-12	0.36	0.23	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
BRCA	cis	rs6472827	0.953	rs4449781	ENSG00000253983.2	RP1-16A9.1	-7.71	2.91e-14	8.24e-12	-0.35	-0.23	Uterine fibroids;	chr8:74209309	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.71	2.91e-14	8.25e-12	-0.29	-0.23	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-7.71	2.91e-14	8.25e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
BRCA	cis	rs42648	0.837	rs10262472	ENSG00000225498.1	AC002064.5	7.71	2.91e-14	8.25e-12	0.22	0.23	Homocysteine levels;	chr7:90271069	chr7:90312496~90322592:+
BRCA	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-7.71	2.91e-14	8.26e-12	-0.3	-0.23	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
BRCA	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-7.71	2.92e-14	8.27e-12	-0.26	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
BRCA	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	7.71	2.93e-14	8.31e-12	0.22	0.23	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
BRCA	cis	rs516805	0.961	rs471620	ENSG00000279114.1	RP3-425C14.5	-7.71	2.94e-14	8.33e-12	-0.24	-0.23	Lymphocyte counts;	chr6:122473532	chr6:122471923~122484161:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-7.71	2.94e-14	8.34e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-7.71	2.94e-14	8.34e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
BRCA	cis	rs3758911	1	rs10749901	ENSG00000255353.1	RP11-382M14.1	-7.71	2.96e-14	8.4e-12	-0.3	-0.23	Coronary artery disease;	chr11:107324776	chr11:107176286~107177530:+
BRCA	cis	rs6539288	0.899	rs4964192	ENSG00000260329.1	RP11-412D9.4	-7.71	2.97e-14	8.41e-12	-0.26	-0.23	Total body bone mineral density;	chr12:106915014	chr12:106954029~106955497:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-7.71	2.97e-14	8.41e-12	-0.16	-0.23	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	7.71	2.97e-14	8.41e-12	0.28	0.23	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	7.71	2.97e-14	8.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
BRCA	cis	rs6539288	0.933	rs4964497	ENSG00000260329.1	RP11-412D9.4	-7.71	2.97e-14	8.42e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106910711	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-7.71	2.99e-14	8.46e-12	-0.28	-0.23	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-7.71	2.99e-14	8.46e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-7.71	3e-14	8.49e-12	-0.28	-0.23	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
BRCA	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	7.71	3.01e-14	8.51e-12	0.35	0.23	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
BRCA	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	7.71	3.01e-14	8.52e-12	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-7.71	3.01e-14	8.52e-12	-0.28	-0.23	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-7.71	3.03e-14	8.57e-12	-0.35	-0.23	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-7.71	3.03e-14	8.58e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-7.7	3.04e-14	8.6e-12	-0.31	-0.23	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-7.7	3.04e-14	8.6e-12	-0.28	-0.23	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	7.7	3.04e-14	8.61e-12	0.34	0.23	Depression;	chr6:28364057	chr6:28943877~28944537:+
BRCA	cis	rs11671005	0.611	rs56026876	ENSG00000252334.1	RNU6-1337P	7.7	3.04e-14	8.62e-12	0.37	0.23	Mean platelet volume;	chr19:58494790	chr19:58483749~58483843:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-7.7	3.05e-14	8.62e-12	-0.28	-0.23	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-7.7	3.05e-14	8.62e-12	-0.28	-0.23	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
BRCA	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	7.7	3.06e-14	8.65e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	7.7	3.06e-14	8.67e-12	0.26	0.23	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-7.7	3.07e-14	8.69e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
BRCA	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	7.7	3.07e-14	8.7e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
BRCA	cis	rs42648	0.935	rs2188232	ENSG00000225498.1	AC002064.5	7.7	3.08e-14	8.72e-12	0.22	0.23	Homocysteine levels;	chr7:90329000	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.935	rs2188233	ENSG00000225498.1	AC002064.5	7.7	3.08e-14	8.72e-12	0.22	0.23	Homocysteine levels;	chr7:90329001	chr7:90312496~90322592:+
BRCA	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	7.7	3.09e-14	8.74e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
BRCA	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	7.7	3.09e-14	8.74e-12	0.3	0.23	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
BRCA	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-7.7	3.09e-14	8.75e-12	-0.31	-0.23	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
BRCA	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	7.7	3.09e-14	8.75e-12	0.29	0.23	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	7.7	3.1e-14	8.77e-12	0.24	0.23	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
BRCA	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	7.7	3.1e-14	8.77e-12	0.21	0.23	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
BRCA	cis	rs9880211	1	rs9828088	ENSG00000273486.1	RP11-731C17.2	7.7	3.11e-14	8.79e-12	0.3	0.23	Height;Body mass index;	chr3:136528948	chr3:136837338~136839021:-
BRCA	cis	rs919433	1	rs6761919	ENSG00000231621.1	AC013264.2	7.7	3.11e-14	8.79e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298604	chr2:197197991~197199273:+
BRCA	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-7.7	3.11e-14	8.79e-12	-0.29	-0.23	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.771	rs34920909	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.11e-14	8.79e-12	-0.32	-0.23	Obesity-related traits;	chr5:36792614	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs59889951	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.11e-14	8.79e-12	-0.32	-0.23	Obesity-related traits;	chr5:36793150	chr5:36666214~36725195:-
BRCA	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-7.7	3.11e-14	8.8e-12	-0.29	-0.23	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-7.7	3.11e-14	8.8e-12	-0.3	-0.23	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
BRCA	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-7.7	3.12e-14	8.81e-12	-0.31	-0.23	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
BRCA	cis	rs12999373	0.501	rs11127496	ENSG00000223751.1	AC116609.2	7.7	3.12e-14	8.81e-12	0.29	0.23	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:742488~747767:+
BRCA	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-7.7	3.12e-14	8.82e-12	-0.29	-0.23	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
BRCA	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	7.7	3.12e-14	8.82e-12	0.39	0.23	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
BRCA	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-7.7	3.13e-14	8.84e-12	-0.28	-0.23	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-7.7	3.13e-14	8.86e-12	-0.22	-0.23	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
BRCA	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	7.7	3.14e-14	8.87e-12	0.29	0.23	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	7.7	3.14e-14	8.87e-12	0.29	0.23	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
BRCA	cis	rs293748	0.771	rs151947	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.14e-14	8.88e-12	-0.32	-0.23	Obesity-related traits;	chr5:36865491	chr5:36666214~36725195:-
BRCA	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	7.7	3.14e-14	8.88e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
BRCA	cis	rs1861628	1	rs2712172	ENSG00000237930.1	AC007563.4	-7.7	3.15e-14	8.91e-12	-0.3	-0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216756010	chr2:216785774~216786144:-
BRCA	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-7.7	3.16e-14	8.92e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
BRCA	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-7.7	3.16e-14	8.93e-12	-0.24	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
BRCA	cis	rs3814244	0.528	rs12582272	ENSG00000236946.2	HNRNPA1P70	-7.7	3.16e-14	8.93e-12	-0.2	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:68035767~68036853:+
BRCA	cis	rs7246657	0.722	rs2972438	ENSG00000267422.1	CTD-2554C21.1	-7.7	3.16e-14	8.94e-12	-0.34	-0.23	Coronary artery calcification;	chr19:37719946	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	7.7	3.17e-14	8.94e-12	0.32	0.23	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-7.7	3.17e-14	8.96e-12	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-7.7	3.18e-14	8.98e-12	-0.28	-0.23	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.18e-14	8.99e-12	-0.32	-0.23	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
BRCA	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	7.7	3.19e-14	9.01e-12	0.23	0.23	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000274973.1	RP13-401N8.7	-7.7	3.19e-14	9.02e-12	-0.27	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25845497~25845862:+
BRCA	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	7.7	3.19e-14	9.02e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000244479.5	OR2A1-AS1	7.7	3.19e-14	9.02e-12	0.41	0.23	Obesity-related traits;	chr7:144076758	chr7:144251264~144356181:-
BRCA	cis	rs9880211	0.948	rs13326151	ENSG00000273486.1	RP11-731C17.2	7.7	3.2e-14	9.03e-12	0.31	0.23	Height;Body mass index;	chr3:136542902	chr3:136837338~136839021:-
BRCA	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-7.7	3.21e-14	9.05e-12	-0.44	-0.23	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
BRCA	cis	rs6545883	0.895	rs2177961	ENSG00000271889.1	RP11-493E12.1	-7.7	3.21e-14	9.07e-12	-0.3	-0.23	Tuberculosis;	chr2:61333129	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.948	rs9820621	ENSG00000273486.1	RP11-731C17.2	7.7	3.21e-14	9.07e-12	0.32	0.23	Height;Body mass index;	chr3:136391671	chr3:136837338~136839021:-
BRCA	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	7.7	3.21e-14	9.07e-12	0.32	0.23	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.828	rs1490946	ENSG00000255353.1	RP11-382M14.1	-7.7	3.21e-14	9.08e-12	-0.31	-0.23	Coronary artery disease;	chr11:107325374	chr11:107176286~107177530:+
BRCA	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-7.7	3.22e-14	9.1e-12	-0.3	-0.23	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
BRCA	cis	rs3814244	0.528	rs11177002	ENSG00000236946.2	HNRNPA1P70	-7.7	3.23e-14	9.11e-12	-0.2	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:68035767~68036853:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-7.7	3.23e-14	9.11e-12	-0.28	-0.23	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
BRCA	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	7.7	3.23e-14	9.12e-12	0.31	0.23	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	7.7	3.23e-14	9.12e-12	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	7.7	3.23e-14	9.12e-12	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
BRCA	cis	rs250518	0.926	rs10069567	ENSG00000272081.1	CTD-2376I4.2	7.7	3.23e-14	9.12e-12	0.29	0.23	Mean corpuscular hemoglobin concentration;	chr5:72771877	chr5:72955206~72955699:-
BRCA	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	7.7	3.23e-14	9.12e-12	0.28	0.23	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	7.7	3.23e-14	9.12e-12	0.3	0.23	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-7.7	3.23e-14	9.13e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-7.7	3.24e-14	9.13e-12	-0.24	-0.23	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
BRCA	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-7.7	3.24e-14	9.14e-12	-0.26	-0.23	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
BRCA	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	7.7	3.24e-14	9.14e-12	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
BRCA	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-7.7	3.24e-14	9.15e-12	-0.36	-0.23	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	7.7	3.24e-14	9.16e-12	0.29	0.23	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
BRCA	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	7.7	3.25e-14	9.16e-12	0.26	0.23	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-7.7	3.25e-14	9.17e-12	-0.23	-0.23	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
BRCA	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-7.7	3.25e-14	9.17e-12	-0.23	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	7.7	3.26e-14	9.2e-12	0.26	0.23	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
BRCA	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-7.7	3.27e-14	9.22e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
BRCA	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	7.69	3.27e-14	9.24e-12	0.53	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
BRCA	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	7.69	3.28e-14	9.25e-12	0.28	0.23	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
BRCA	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	7.69	3.29e-14	9.28e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	7.69	3.29e-14	9.28e-12	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-7.69	3.3e-14	9.3e-12	-0.28	-0.23	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-7.69	3.3e-14	9.3e-12	-0.23	-0.23	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
BRCA	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-7.69	3.3e-14	9.31e-12	-0.28	-0.23	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	7.69	3.32e-14	9.35e-12	0.34	0.23	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
BRCA	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	7.69	3.32e-14	9.37e-12	0.32	0.23	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
BRCA	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-7.69	3.33e-14	9.39e-12	-0.18	-0.23	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
BRCA	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-7.69	3.33e-14	9.39e-12	-0.3	-0.23	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
BRCA	cis	rs2060793	0.552	rs939968	ENSG00000251991.1	RNU7-49P	7.69	3.33e-14	9.4e-12	0.24	0.23	Vitamin D levels;	chr11:14608134	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	7.69	3.34e-14	9.42e-12	0.24	0.23	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
BRCA	cis	rs896854	0.738	rs527234	ENSG00000253528.2	RP11-347C18.4	-7.69	3.35e-14	9.45e-12	-0.25	-0.23	Type 2 diabetes;	chr8:94951570	chr8:94974573~94974853:-
BRCA	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-7.69	3.35e-14	9.46e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-7.69	3.36e-14	9.46e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
BRCA	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	7.69	3.36e-14	9.46e-12	0.23	0.23	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
BRCA	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	7.69	3.37e-14	9.5e-12	0.25	0.23	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-7.69	3.37e-14	9.51e-12	-0.15	-0.23	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
BRCA	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-7.69	3.38e-14	9.52e-12	-0.31	-0.23	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-7.69	3.38e-14	9.54e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	7.69	3.39e-14	9.57e-12	0.26	0.23	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
BRCA	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-7.69	3.4e-14	9.57e-12	-0.26	-0.23	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-7.69	3.4e-14	9.57e-12	-0.23	-0.23	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
BRCA	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-7.69	3.4e-14	9.58e-12	-0.35	-0.23	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
BRCA	cis	rs712022	0.537	rs4420266	ENSG00000246225.5	RP11-17A1.3	-7.69	3.4e-14	9.58e-12	-0.28	-0.23	Dialysis-related mortality;	chr11:22852637	chr11:22829380~22945393:+
BRCA	cis	rs3758911	0.894	rs10789620	ENSG00000255353.1	RP11-382M14.1	-7.69	3.4e-14	9.59e-12	-0.31	-0.23	Coronary artery disease;	chr11:107334700	chr11:107176286~107177530:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-7.69	3.41e-14	9.61e-12	-0.28	-0.23	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-7.69	3.42e-14	9.64e-12	-0.31	-0.23	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
BRCA	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	7.69	3.43e-14	9.65e-12	0.25	0.23	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
BRCA	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	7.69	3.43e-14	9.65e-12	0.23	0.23	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	7.69	3.43e-14	9.65e-12	0.23	0.23	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-7.69	3.43e-14	9.66e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-7.69	3.43e-14	9.66e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.69	3.43e-14	9.66e-12	0.32	0.23	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-7.69	3.43e-14	9.66e-12	-0.32	-0.23	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
BRCA	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	7.69	3.43e-14	9.66e-12	0.28	0.23	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
BRCA	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-7.69	3.43e-14	9.67e-12	-0.34	-0.23	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
BRCA	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	7.69	3.44e-14	9.68e-12	0.23	0.23	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
BRCA	cis	rs250518	0.926	rs7720803	ENSG00000272081.1	CTD-2376I4.2	7.69	3.45e-14	9.72e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72762870	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	7.69	3.46e-14	9.74e-12	0.33	0.23	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	7.69	3.46e-14	9.74e-12	0.33	0.23	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
BRCA	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-7.69	3.46e-14	9.75e-12	-0.29	-0.23	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	7.69	3.47e-14	9.75e-12	0.21	0.23	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	7.69	3.47e-14	9.77e-12	0.28	0.23	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-7.69	3.47e-14	9.77e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
BRCA	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-7.69	3.5e-14	9.84e-12	-0.28	-0.23	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
BRCA	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-7.69	3.51e-14	9.87e-12	-0.29	-0.23	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	7.69	3.51e-14	9.88e-12	0.28	0.23	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	7.68	3.54e-14	9.96e-12	0.28	0.23	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
BRCA	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-7.68	3.54e-14	9.97e-12	-0.3	-0.23	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
BRCA	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-7.68	3.55e-14	9.98e-12	-0.31	-0.23	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
BRCA	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-7.68	3.55e-14	9.98e-12	-0.35	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
BRCA	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	7.68	3.56e-14	1e-11	0.26	0.23	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
BRCA	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	7.68	3.56e-14	1e-11	0.2	0.23	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
BRCA	cis	rs9876781	0.933	rs6442124	ENSG00000244380.1	RP11-24C3.2	7.68	3.57e-14	1e-11	0.27	0.23	Longevity;	chr3:48463903	chr3:48440352~48446656:-
BRCA	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-7.68	3.57e-14	1e-11	-0.31	-0.23	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
BRCA	cis	rs6539288	0.899	rs2053206	ENSG00000260329.1	RP11-412D9.4	-7.68	3.57e-14	1e-11	-0.27	-0.23	Total body bone mineral density;	chr12:106912401	chr12:106954029~106955497:-
BRCA	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-7.68	3.58e-14	1.01e-11	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
BRCA	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-7.68	3.59e-14	1.01e-11	-0.25	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	7.68	3.59e-14	1.01e-11	0.31	0.23	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
BRCA	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-7.68	3.6e-14	1.01e-11	-0.27	-0.23	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
BRCA	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000224316.1	RP11-479O9.2	-7.68	3.61e-14	1.02e-11	-0.25	-0.23	Aortic root size;	chr7:66087510	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-7.68	3.62e-14	1.02e-11	-0.24	-0.23	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-7.68	3.62e-14	1.02e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
BRCA	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	7.68	3.63e-14	1.02e-11	0.28	0.23	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
BRCA	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-7.68	3.64e-14	1.02e-11	-0.29	-0.23	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
BRCA	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-7.68	3.65e-14	1.02e-11	-0.27	-0.23	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
BRCA	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-7.68	3.65e-14	1.03e-11	-0.26	-0.23	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
BRCA	cis	rs2060793	0.519	rs1403247	ENSG00000251991.1	RNU7-49P	-7.68	3.65e-14	1.03e-11	-0.25	-0.23	Vitamin D levels;	chr11:14611024	chr11:14478892~14478953:+
BRCA	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-7.68	3.66e-14	1.03e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	7.68	3.67e-14	1.03e-11	0.24	0.23	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
BRCA	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	7.68	3.67e-14	1.03e-11	0.28	0.23	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
BRCA	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	7.68	3.68e-14	1.03e-11	0.23	0.23	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	7.68	3.68e-14	1.03e-11	0.23	0.23	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
BRCA	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-7.68	3.68e-14	1.03e-11	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	7.68	3.69e-14	1.04e-11	0.24	0.23	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
BRCA	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-7.68	3.7e-14	1.04e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	7.68	3.7e-14	1.04e-11	0.28	0.23	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-7.68	3.7e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-7.68	3.7e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.894	rs2167566	ENSG00000271889.1	RP11-493E12.1	7.68	3.71e-14	1.04e-11	0.29	0.23	Tuberculosis;	chr2:61292273	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-7.68	3.71e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
BRCA	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-7.68	3.72e-14	1.04e-11	-0.29	-0.23	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-7.68	3.72e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	7.68	3.73e-14	1.05e-11	0.26	0.23	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
BRCA	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-7.68	3.73e-14	1.05e-11	-0.27	-0.23	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
BRCA	cis	rs3814244	0.868	rs10878726	ENSG00000236946.2	HNRNPA1P70	-7.68	3.73e-14	1.05e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:68035767~68036853:+
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-7.68	3.74e-14	1.05e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-7.68	3.74e-14	1.05e-11	-0.26	-0.23	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.772	rs1186709	ENSG00000271889.1	RP11-493E12.1	7.68	3.74e-14	1.05e-11	0.31	0.23	Tuberculosis;	chr2:61462245	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-7.68	3.74e-14	1.05e-11	-0.24	-0.23	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
BRCA	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	7.68	3.74e-14	1.05e-11	0.4	0.23	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
BRCA	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	7.68	3.74e-14	1.05e-11	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
BRCA	cis	rs6545883	0.895	rs6545871	ENSG00000271889.1	RP11-493E12.1	7.68	3.75e-14	1.05e-11	0.31	0.23	Tuberculosis;	chr2:61465068	chr2:61151433~61162105:-
BRCA	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-7.68	3.75e-14	1.05e-11	-0.3	-0.23	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-7.68	3.75e-14	1.05e-11	-0.26	-0.23	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	7.68	3.76e-14	1.05e-11	0.22	0.23	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	7.68	3.76e-14	1.05e-11	0.22	0.23	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
BRCA	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-7.68	3.76e-14	1.05e-11	-0.29	-0.23	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-7.68	3.76e-14	1.05e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	7.68	3.76e-14	1.06e-11	0.38	0.23	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
BRCA	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	7.68	3.77e-14	1.06e-11	0.23	0.23	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	7.68	3.79e-14	1.06e-11	0.24	0.23	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	7.68	3.79e-14	1.06e-11	0.24	0.23	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
BRCA	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-7.68	3.79e-14	1.06e-11	-0.24	-0.23	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
BRCA	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	7.68	3.79e-14	1.06e-11	0.27	0.23	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
BRCA	cis	rs4753788	0.534	rs10789590	ENSG00000255353.1	RP11-382M14.1	-7.68	3.79e-14	1.06e-11	-0.28	-0.23	Coronary artery disease;	chr11:107266877	chr11:107176286~107177530:+
BRCA	cis	rs4753788	0.511	rs1388168	ENSG00000255353.1	RP11-382M14.1	-7.68	3.79e-14	1.06e-11	-0.28	-0.23	Coronary artery disease;	chr11:107267191	chr11:107176286~107177530:+
BRCA	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	7.68	3.79e-14	1.06e-11	0.32	0.23	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.67	3.79e-14	1.06e-11	-0.3	-0.23	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	7.67	3.8e-14	1.06e-11	0.18	0.23	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-7.67	3.8e-14	1.06e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
BRCA	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-7.67	3.8e-14	1.07e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
BRCA	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	7.67	3.8e-14	1.07e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	7.67	3.8e-14	1.07e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	7.67	3.81e-14	1.07e-11	0.29	0.23	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
BRCA	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	7.67	3.83e-14	1.07e-11	0.25	0.23	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
BRCA	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-7.67	3.84e-14	1.08e-11	-0.27	-0.23	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-7.67	3.84e-14	1.08e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.67	3.85e-14	1.08e-11	-0.28	-0.23	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
BRCA	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-7.67	3.85e-14	1.08e-11	-0.25	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-7.67	3.86e-14	1.08e-11	-0.28	-0.23	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
BRCA	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-7.67	3.86e-14	1.08e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
BRCA	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	7.67	3.86e-14	1.08e-11	0.34	0.23	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	7.67	3.87e-14	1.08e-11	0.52	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
BRCA	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-7.67	3.87e-14	1.08e-11	-0.26	-0.23	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
BRCA	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-7.67	3.88e-14	1.09e-11	-0.31	-0.23	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
BRCA	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
BRCA	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	7.67	3.88e-14	1.09e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
BRCA	cis	rs516805	0.961	rs573709	ENSG00000279114.1	RP3-425C14.5	7.67	3.88e-14	1.09e-11	0.24	0.23	Lymphocyte counts;	chr6:122457673	chr6:122471923~122484161:+
BRCA	cis	rs3758911	0.796	rs10890720	ENSG00000255353.1	RP11-382M14.1	7.67	3.89e-14	1.09e-11	0.31	0.23	Coronary artery disease;	chr11:107335292	chr11:107176286~107177530:+
BRCA	cis	rs11143230	1	rs11143230	ENSG00000225434.2	LINC01504	7.67	3.89e-14	1.09e-11	0.26	0.23	Suicidal ideation;	chr9:72272787	chr9:72305430~72343210:+
BRCA	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	7.67	3.89e-14	1.09e-11	0.29	0.23	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
BRCA	cis	rs712022	0.534	rs4494299	ENSG00000246225.5	RP11-17A1.3	-7.67	3.9e-14	1.09e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22850686	chr11:22829380~22945393:+
BRCA	cis	rs919433	1	rs2889363	ENSG00000231621.1	AC013264.2	7.67	3.9e-14	1.09e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298975	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-7.67	3.9e-14	1.09e-11	-0.28	-0.23	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
BRCA	cis	rs712022	0.534	rs4550218	ENSG00000246225.5	RP11-17A1.3	-7.67	3.91e-14	1.09e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22842112	chr11:22829380~22945393:+
BRCA	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	7.67	3.92e-14	1.1e-11	0.32	0.23	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	7.67	3.92e-14	1.1e-11	0.32	0.23	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
BRCA	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	7.67	3.92e-14	1.1e-11	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	7.67	3.92e-14	1.1e-11	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
BRCA	cis	rs250518	0.926	rs35132569	ENSG00000272081.1	CTD-2376I4.2	7.67	3.93e-14	1.1e-11	0.29	0.23	Mean corpuscular hemoglobin concentration;	chr5:72763914	chr5:72955206~72955699:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-7.67	3.93e-14	1.1e-11	-0.32	-0.23	Gout;	chr7:66642037	chr7:66902857~66906297:+
BRCA	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	7.67	3.94e-14	1.1e-11	0.38	0.23	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	7.67	3.94e-14	1.1e-11	0.18	0.23	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	7.67	3.95e-14	1.11e-11	0.24	0.23	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-7.67	3.96e-14	1.11e-11	-0.28	-0.23	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	7.67	3.96e-14	1.11e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-7.67	3.97e-14	1.11e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	7.67	3.97e-14	1.11e-11	0.28	0.23	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
BRCA	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-7.67	3.97e-14	1.11e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	7.67	3.97e-14	1.11e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	7.67	3.97e-14	1.11e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
BRCA	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	7.67	3.98e-14	1.11e-11	0.26	0.23	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
BRCA	cis	rs812925	0.826	rs2694633	ENSG00000271889.1	RP11-493E12.1	-7.67	3.98e-14	1.11e-11	-0.31	-0.23	Immature fraction of reticulocytes;	chr2:61313507	chr2:61151433~61162105:-
BRCA	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	7.67	4.01e-14	1.12e-11	0.28	0.23	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
BRCA	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-7.67	4.01e-14	1.12e-11	-0.25	-0.23	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
BRCA	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	7.67	4.04e-14	1.13e-11	0.36	0.23	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	7.67	4.04e-14	1.13e-11	0.15	0.23	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-7.67	4.05e-14	1.13e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
BRCA	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-7.67	4.07e-14	1.14e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
BRCA	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	7.67	4.07e-14	1.14e-11	0.4	0.23	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
BRCA	cis	rs7085104	0.632	rs3781287	ENSG00000236937.2	PTGES3P4	7.67	4.07e-14	1.14e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102845595~102845950:+
BRCA	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	7.66	4.09e-14	1.14e-11	0.27	0.23	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
BRCA	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	7.66	4.1e-14	1.15e-11	0.3	0.23	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
BRCA	cis	rs3758911	0.861	rs11212163	ENSG00000255353.1	RP11-382M14.1	-7.66	4.1e-14	1.15e-11	-0.31	-0.23	Coronary artery disease;	chr11:107328005	chr11:107176286~107177530:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-7.66	4.11e-14	1.15e-11	-0.23	-0.23	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	7.66	4.11e-14	1.15e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.898	rs34031772	ENSG00000273486.1	RP11-731C17.2	7.66	4.11e-14	1.15e-11	0.3	0.23	Height;Body mass index;	chr3:136299299	chr3:136837338~136839021:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	7.66	4.12e-14	1.15e-11	0.27	0.23	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-7.66	4.12e-14	1.15e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
BRCA	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	7.66	4.12e-14	1.15e-11	0.3	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
BRCA	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-7.66	4.13e-14	1.15e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
BRCA	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	7.66	4.14e-14	1.16e-11	0.3	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
BRCA	cis	rs10200159	1	rs3748955	ENSG00000272606.1	RP11-554J4.1	7.66	4.15e-14	1.16e-11	0.44	0.23	Vitiligo;	chr2:55626335	chr2:55617909~55618373:+
BRCA	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	7.66	4.17e-14	1.17e-11	0.23	0.23	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
BRCA	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	7.66	4.17e-14	1.17e-11	0.32	0.23	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000224316.1	RP11-479O9.2	-7.66	4.19e-14	1.17e-11	-0.25	-0.23	Aortic root size;	chr7:66143851	chr7:65773620~65802067:+
BRCA	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-7.66	4.19e-14	1.17e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	7.66	4.2e-14	1.17e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
BRCA	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	7.66	4.2e-14	1.17e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	7.66	4.2e-14	1.17e-11	0.22	0.23	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
BRCA	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-7.66	4.21e-14	1.17e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-7.66	4.21e-14	1.17e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
BRCA	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	7.66	4.21e-14	1.17e-11	0.44	0.23	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
BRCA	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	7.66	4.21e-14	1.17e-11	0.44	0.23	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
BRCA	cis	rs9880211	1	rs28641809	ENSG00000273486.1	RP11-731C17.2	7.66	4.21e-14	1.17e-11	0.3	0.23	Height;Body mass index;	chr3:136571647	chr3:136837338~136839021:-
BRCA	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	7.66	4.21e-14	1.18e-11	0.34	0.23	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
BRCA	cis	rs6569038	0.557	rs9374777	ENSG00000253194.1	RP11-351A11.1	-7.66	4.22e-14	1.18e-11	-0.29	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119056334	chr6:118934785~119031541:+
BRCA	cis	rs3814244	0.528	rs7952790	ENSG00000236946.2	HNRNPA1P70	-7.66	4.22e-14	1.18e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:68035767~68036853:+
BRCA	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-7.66	4.22e-14	1.18e-11	-0.3	-0.23	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
BRCA	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	7.66	4.23e-14	1.18e-11	0.28	0.23	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
BRCA	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-7.66	4.23e-14	1.18e-11	-0.29	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
BRCA	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	7.66	4.24e-14	1.18e-11	0.26	0.23	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
BRCA	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	7.66	4.28e-14	1.19e-11	0.4	0.23	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	7.66	4.29e-14	1.2e-11	0.23	0.23	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	7.66	4.29e-14	1.2e-11	0.19	0.23	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
BRCA	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-7.66	4.3e-14	1.2e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
BRCA	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	7.66	4.3e-14	1.2e-11	0.17	0.23	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
BRCA	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	7.66	4.3e-14	1.2e-11	0.26	0.23	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
BRCA	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	7.66	4.3e-14	1.2e-11	0.32	0.23	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
BRCA	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	7.66	4.31e-14	1.2e-11	0.28	0.23	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
BRCA	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	7.66	4.32e-14	1.2e-11	0.22	0.23	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
BRCA	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-7.66	4.32e-14	1.2e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
BRCA	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	7.66	4.33e-14	1.21e-11	0.33	0.23	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	7.66	4.35e-14	1.21e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
BRCA	cis	rs919433	0.929	rs10931779	ENSG00000231621.1	AC013264.2	7.66	4.36e-14	1.21e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197302101	chr2:197197991~197199273:+
BRCA	cis	rs12237653	1	rs12237653	ENSG00000236404.7	VLDLR-AS1	7.66	4.36e-14	1.22e-11	0.35	0.23	Gambling;	chr9:2551654	chr9:2422702~2643359:-
BRCA	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-7.66	4.37e-14	1.22e-11	-0.24	-0.23	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
BRCA	cis	rs34779708	0.766	rs7913451	ENSG00000271335.4	RP11-324I22.4	7.66	4.37e-14	1.22e-11	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35314552~35336401:-
BRCA	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-7.66	4.37e-14	1.22e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
BRCA	cis	rs12188164	0.543	rs2672722	ENSG00000225138.6	CTD-2228K2.7	-7.66	4.37e-14	1.22e-11	-0.25	-0.23	Cystic fibrosis severity;	chr5:453452	chr5:473236~480884:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	7.66	4.39e-14	1.22e-11	0.28	0.23	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-7.66	4.39e-14	1.22e-11	-0.35	-0.23	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
BRCA	cis	rs7085104	0.7	rs3740397	ENSG00000236937.2	PTGES3P4	7.65	4.4e-14	1.22e-11	0.3	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102845595~102845950:+
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	7.65	4.41e-14	1.23e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	7.65	4.41e-14	1.23e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
BRCA	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	7.65	4.41e-14	1.23e-11	0.35	0.23	Height;	chr4:57019797	chr4:56960927~56961373:-
BRCA	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	7.65	4.42e-14	1.23e-11	0.32	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
BRCA	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	7.65	4.42e-14	1.23e-11	0.26	0.23	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-7.65	4.43e-14	1.23e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
BRCA	cis	rs853679	1	rs2799079	ENSG00000220721.1	OR1F12	7.65	4.44e-14	1.24e-11	0.35	0.23	Depression;	chr6:28267398	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	7.65	4.48e-14	1.25e-11	0.28	0.23	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-7.65	4.48e-14	1.25e-11	-0.28	-0.23	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-7.65	4.49e-14	1.25e-11	-0.3	-0.23	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
BRCA	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	7.65	4.5e-14	1.25e-11	0.35	0.23	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
BRCA	cis	rs250518	0.926	rs34669	ENSG00000272081.1	CTD-2376I4.2	-7.65	4.5e-14	1.25e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72866437	chr5:72955206~72955699:-
BRCA	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-7.65	4.5e-14	1.25e-11	-0.22	-0.23	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
BRCA	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	7.65	4.51e-14	1.25e-11	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
BRCA	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-7.65	4.51e-14	1.25e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
BRCA	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	7.65	4.52e-14	1.26e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
BRCA	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-7.65	4.52e-14	1.26e-11	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
BRCA	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	7.65	4.53e-14	1.26e-11	0.26	0.23	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
BRCA	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	7.65	4.54e-14	1.26e-11	0.28	0.23	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
BRCA	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	7.65	4.55e-14	1.27e-11	0.25	0.23	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
BRCA	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	7.65	4.56e-14	1.27e-11	0.27	0.23	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	7.65	4.57e-14	1.27e-11	0.28	0.23	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.65	4.58e-14	1.27e-11	0.31	0.23	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
BRCA	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-7.65	4.59e-14	1.28e-11	-0.25	-0.23	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
BRCA	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-7.65	4.59e-14	1.28e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
BRCA	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-7.65	4.6e-14	1.28e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000274973.1	RP13-401N8.7	7.65	4.6e-14	1.28e-11	0.27	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25845497~25845862:+
BRCA	cis	rs6545883	0.794	rs12053388	ENSG00000271889.1	RP11-493E12.1	-7.65	4.61e-14	1.28e-11	-0.3	-0.23	Tuberculosis;	chr2:61305185	chr2:61151433~61162105:-
BRCA	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	7.65	4.62e-14	1.29e-11	0.28	0.23	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
BRCA	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-7.65	4.63e-14	1.29e-11	-0.27	-0.23	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
BRCA	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	7.65	4.63e-14	1.29e-11	0.4	0.23	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
BRCA	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-7.65	4.65e-14	1.29e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-7.65	4.67e-14	1.3e-11	-0.55	-0.23	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-7.65	4.69e-14	1.3e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
BRCA	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	7.65	4.7e-14	1.3e-11	0.17	0.23	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	7.65	4.7e-14	1.3e-11	0.32	0.23	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-7.65	4.7e-14	1.31e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-7.65	4.7e-14	1.31e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
BRCA	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	7.65	4.7e-14	1.31e-11	0.4	0.23	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-7.65	4.7e-14	1.31e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
BRCA	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-7.65	4.7e-14	1.31e-11	-0.33	-0.23	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
BRCA	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.65	4.72e-14	1.31e-11	0.25	0.23	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
BRCA	cis	rs2014572	0.904	rs10412465	ENSG00000268379.1	CTC-360J11.4	7.65	4.72e-14	1.31e-11	0.28	0.23	Hyperactive-impulsive symptoms;	chr19:57242563	chr19:57175233~57177921:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-7.65	4.73e-14	1.31e-11	-0.28	-0.23	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-7.65	4.73e-14	1.31e-11	-0.28	-0.23	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-7.65	4.73e-14	1.31e-11	-0.24	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
BRCA	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-7.65	4.73e-14	1.31e-11	-0.31	-0.23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
BRCA	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
BRCA	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	7.64	4.74e-14	1.32e-11	0.27	0.23	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
BRCA	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-7.64	4.75e-14	1.32e-11	-0.3	-0.23	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	7.64	4.75e-14	1.32e-11	0.34	0.23	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	7.64	4.76e-14	1.32e-11	0.33	0.23	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
BRCA	cis	rs516805	0.847	rs520867	ENSG00000279114.1	RP3-425C14.5	-7.64	4.76e-14	1.32e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122465501	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.961	rs693669	ENSG00000279114.1	RP3-425C14.5	-7.64	4.76e-14	1.32e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122465690	chr6:122471923~122484161:+
BRCA	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	7.64	4.78e-14	1.33e-11	0.32	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
BRCA	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	7.64	4.78e-14	1.33e-11	0.23	0.23	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
BRCA	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-7.64	4.79e-14	1.33e-11	-0.36	-0.23	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
BRCA	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	7.64	4.79e-14	1.33e-11	0.3	0.23	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
BRCA	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-7.64	4.82e-14	1.34e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
BRCA	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	7.64	4.82e-14	1.34e-11	0.28	0.23	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
BRCA	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-7.64	4.84e-14	1.34e-11	-0.27	-0.23	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
BRCA	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-7.64	4.85e-14	1.35e-11	-0.21	-0.23	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-7.64	4.87e-14	1.35e-11	-0.28	-0.23	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-7.64	4.87e-14	1.35e-11	-0.28	-0.23	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
BRCA	cis	rs42648	0.935	rs42629	ENSG00000225498.1	AC002064.5	7.64	4.87e-14	1.35e-11	0.22	0.23	Homocysteine levels;	chr7:90334010	chr7:90312496~90322592:+
BRCA	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	7.64	4.87e-14	1.35e-11	0.29	0.23	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
BRCA	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-7.64	4.9e-14	1.36e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
BRCA	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	7.64	4.9e-14	1.36e-11	0.3	0.23	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
BRCA	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	7.64	4.9e-14	1.36e-11	0.3	0.23	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
BRCA	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-7.64	4.9e-14	1.36e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
BRCA	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	7.64	4.92e-14	1.36e-11	0.4	0.23	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
BRCA	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-7.64	4.93e-14	1.37e-11	-0.22	-0.23	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-7.64	4.94e-14	1.37e-11	-0.28	-0.23	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
BRCA	cis	rs253959	0.672	rs4920903	ENSG00000271918.1	CTD-2287O16.5	7.64	4.94e-14	1.37e-11	0.19	0.23	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116083807~116085416:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-7.64	4.96e-14	1.37e-11	-0.28	-0.23	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	7.64	4.96e-14	1.37e-11	0.18	0.23	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-7.64	4.97e-14	1.38e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
BRCA	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	7.64	4.97e-14	1.38e-11	0.4	0.23	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	7.64	4.99e-14	1.38e-11	0.28	0.23	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-7.64	4.99e-14	1.38e-11	-0.28	-0.23	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
BRCA	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	7.64	5e-14	1.39e-11	0.31	0.23	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
BRCA	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-7.64	5.01e-14	1.39e-11	-0.28	-0.23	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
BRCA	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	7.64	5.04e-14	1.39e-11	0.31	0.23	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
BRCA	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	7.64	5.05e-14	1.4e-11	0.26	0.23	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
BRCA	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-7.64	5.05e-14	1.4e-11	-0.19	-0.23	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
BRCA	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-7.64	5.05e-14	1.4e-11	-0.28	-0.23	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
BRCA	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-7.64	5.06e-14	1.4e-11	-0.3	-0.23	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
BRCA	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	7.64	5.06e-14	1.4e-11	0.29	0.23	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
BRCA	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	7.64	5.06e-14	1.4e-11	0.29	0.23	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
BRCA	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	7.64	5.07e-14	1.4e-11	0.26	0.23	Longevity;	chr3:48445934	chr3:48440352~48446656:-
BRCA	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	7.64	5.08e-14	1.41e-11	0.33	0.23	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
BRCA	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	7.64	5.09e-14	1.41e-11	0.25	0.23	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
BRCA	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	7.64	5.09e-14	1.41e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	7.64	5.09e-14	1.41e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	7.63	5.1e-14	1.41e-11	0.32	0.23	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	7.63	5.11e-14	1.42e-11	0.28	0.23	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	7.63	5.11e-14	1.42e-11	0.28	0.23	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
BRCA	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-7.63	5.11e-14	1.42e-11	-0.35	-0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
BRCA	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	7.63	5.12e-14	1.42e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	7.63	5.13e-14	1.42e-11	0.26	0.23	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-7.63	5.13e-14	1.42e-11	-0.28	-0.23	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
BRCA	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	7.63	5.14e-14	1.42e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.929	rs1838978	ENSG00000271889.1	RP11-493E12.1	-7.63	5.15e-14	1.42e-11	-0.3	-0.23	Tuberculosis;	chr2:61313788	chr2:61151433~61162105:-
BRCA	cis	rs1552244	0.882	rs13084194	ENSG00000180385.7	EMC3-AS1	7.63	5.17e-14	1.43e-11	0.31	0.23	Alzheimer's disease;	chr3:9989808	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs13099507	ENSG00000180385.7	EMC3-AS1	7.63	5.17e-14	1.43e-11	0.31	0.23	Alzheimer's disease;	chr3:9989919	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-7.63	5.17e-14	1.43e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
BRCA	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-7.63	5.17e-14	1.43e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-7.63	5.17e-14	1.43e-11	-0.27	-0.23	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.63	5.19e-14	1.44e-11	-0.28	-0.23	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs1604793	ENSG00000273486.1	RP11-731C17.2	7.63	5.2e-14	1.44e-11	0.31	0.23	Height;Body mass index;	chr3:136462228	chr3:136837338~136839021:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000273024.4	INTS4P2	-7.63	5.21e-14	1.44e-11	-0.26	-0.23	Calcium levels;	chr7:65751755	chr7:65647864~65715661:+
BRCA	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	7.63	5.22e-14	1.44e-11	0.28	0.23	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	7.63	5.23e-14	1.44e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
BRCA	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-7.63	5.24e-14	1.45e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	7.63	5.25e-14	1.45e-11	0.28	0.23	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
BRCA	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	7.63	5.26e-14	1.45e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
BRCA	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	7.63	5.26e-14	1.45e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
BRCA	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	7.63	5.26e-14	1.45e-11	0.32	0.23	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
BRCA	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	7.63	5.28e-14	1.46e-11	0.19	0.23	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	7.63	5.28e-14	1.46e-11	0.19	0.23	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.63	5.28e-14	1.46e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
BRCA	cis	rs6539288	0.77	rs1468908	ENSG00000260329.1	RP11-412D9.4	-7.63	5.28e-14	1.46e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106904539	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs1470380	ENSG00000260329.1	RP11-412D9.4	-7.63	5.28e-14	1.46e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106904961	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-7.63	5.29e-14	1.46e-11	-0.24	-0.23	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
BRCA	cis	rs12188164	0.525	rs1114665	ENSG00000225138.6	CTD-2228K2.7	-7.63	5.29e-14	1.46e-11	-0.25	-0.23	Cystic fibrosis severity;	chr5:452132	chr5:473236~480884:+
BRCA	cis	rs516805	0.961	rs483933	ENSG00000279114.1	RP3-425C14.5	-7.63	5.29e-14	1.46e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122460377	chr6:122471923~122484161:+
BRCA	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	7.63	5.29e-14	1.46e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
BRCA	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	7.63	5.3e-14	1.46e-11	0.34	0.23	Depression;	chr6:28386473	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	7.63	5.3e-14	1.46e-11	0.34	0.23	Depression;	chr6:28391932	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	7.63	5.31e-14	1.47e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-7.63	5.31e-14	1.47e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	7.63	5.33e-14	1.47e-11	0.22	0.23	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
BRCA	cis	rs516805	0.961	rs1267942	ENSG00000279114.1	RP3-425C14.5	-7.63	5.33e-14	1.47e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122472375	chr6:122471923~122484161:+
BRCA	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	7.63	5.34e-14	1.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
BRCA	cis	rs2279440	0.759	rs7642020	ENSG00000206573.7	THUMPD3-AS1	7.63	5.34e-14	1.48e-11	0.26	0.23	Glucose homeostasis traits;	chr3:9480796	chr3:9349689~9398579:-
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-7.63	5.35e-14	1.48e-11	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
BRCA	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	7.63	5.35e-14	1.48e-11	0.28	0.23	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	7.63	5.36e-14	1.48e-11	0.23	0.23	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
BRCA	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.36e-14	1.48e-11	-0.33	-0.23	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	7.63	5.37e-14	1.48e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-7.63	5.37e-14	1.48e-11	-0.28	-0.23	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.935	rs42644	ENSG00000225498.1	AC002064.5	7.63	5.37e-14	1.48e-11	0.22	0.23	Homocysteine levels;	chr7:90345550	chr7:90312496~90322592:+
BRCA	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-7.63	5.37e-14	1.48e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
BRCA	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
BRCA	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-7.63	5.38e-14	1.48e-11	-0.26	-0.23	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.63	5.39e-14	1.49e-11	-0.28	-0.23	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.41e-14	1.49e-11	-0.31	-0.23	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
BRCA	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	7.63	5.41e-14	1.49e-11	0.28	0.23	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
BRCA	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-7.63	5.43e-14	1.5e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
BRCA	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-7.63	5.45e-14	1.5e-11	-0.3	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
BRCA	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-7.63	5.46e-14	1.51e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
BRCA	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	7.63	5.47e-14	1.51e-11	0.27	0.23	QT interval;	chr12:29243072	chr12:29280418~29317848:-
BRCA	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.48e-14	1.51e-11	-0.25	-0.23	Height;	chr5:36817237	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-7.62	5.49e-14	1.52e-11	-0.15	-0.23	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
BRCA	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	7.62	5.5e-14	1.52e-11	0.3	0.23	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	7.62	5.5e-14	1.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
BRCA	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-7.62	5.5e-14	1.52e-11	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-7.62	5.5e-14	1.52e-11	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
BRCA	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	7.62	5.51e-14	1.52e-11	0.3	0.23	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	7.62	5.51e-14	1.52e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
BRCA	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	7.62	5.52e-14	1.52e-11	0.26	0.23	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
BRCA	cis	rs7474896	0.583	rs10827818	ENSG00000226578.1	RP11-258F22.1	-7.62	5.55e-14	1.53e-11	-0.3	-0.23	Obesity (extreme);	chr10:37711928	chr10:37775371~37784131:-
BRCA	cis	rs250518	0.926	rs10942402	ENSG00000272081.1	CTD-2376I4.2	-7.62	5.55e-14	1.53e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72760272	chr5:72955206~72955699:-
BRCA	cis	rs3758911	1	rs3758911	ENSG00000255353.1	RP11-382M14.1	-7.62	5.56e-14	1.53e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326914	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs11212159	ENSG00000255353.1	RP11-382M14.1	-7.62	5.57e-14	1.54e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326003	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs11212160	ENSG00000255353.1	RP11-382M14.1	-7.62	5.57e-14	1.54e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326192	chr11:107176286~107177530:+
BRCA	cis	rs6539288	0.933	rs1037011	ENSG00000260329.1	RP11-412D9.4	-7.62	5.6e-14	1.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106909000	chr12:106954029~106955497:-
BRCA	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-7.62	5.6e-14	1.54e-11	-0.26	-0.23	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
BRCA	cis	rs30380	1	rs27529	ENSG00000272109.1	CTD-2260A17.3	-7.62	5.61e-14	1.55e-11	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96804353~96806105:+
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-7.62	5.63e-14	1.55e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	7.62	5.64e-14	1.55e-11	0.22	0.23	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
BRCA	cis	rs1113500	0.787	rs10881502	ENSG00000226822.1	RP11-356N1.2	-7.62	5.64e-14	1.55e-11	-0.29	-0.23	Growth-regulated protein alpha levels;	chr1:108099197	chr1:108071482~108074519:+
BRCA	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-7.62	5.65e-14	1.56e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
BRCA	cis	rs3781264	0.595	rs11187881	ENSG00000273450.1	RP11-76P2.4	7.62	5.66e-14	1.56e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94335697	chr10:94314907~94315327:-
BRCA	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	7.62	5.66e-14	1.56e-11	0.25	0.23	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
BRCA	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-7.62	5.67e-14	1.56e-11	-0.26	-0.23	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-7.62	5.68e-14	1.56e-11	-0.23	-0.23	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
BRCA	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	7.62	5.71e-14	1.57e-11	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
BRCA	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	7.62	5.72e-14	1.58e-11	0.26	0.23	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
BRCA	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-7.62	5.72e-14	1.58e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
BRCA	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	7.62	5.72e-14	1.58e-11	0.23	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
BRCA	cis	rs516805	0.847	rs520046	ENSG00000279114.1	RP3-425C14.5	-7.62	5.73e-14	1.58e-11	-0.23	-0.23	Lymphocyte counts;	chr6:122446048	chr6:122471923~122484161:+
BRCA	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-7.62	5.73e-14	1.58e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
BRCA	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	7.62	5.74e-14	1.58e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
BRCA	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	7.62	5.74e-14	1.58e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-7.62	5.74e-14	1.58e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
BRCA	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
BRCA	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	7.62	5.76e-14	1.58e-11	0.34	0.23	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-7.62	5.78e-14	1.59e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
BRCA	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-7.62	5.78e-14	1.59e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
BRCA	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	7.62	5.79e-14	1.59e-11	0.19	0.23	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-7.62	5.8e-14	1.59e-11	-0.24	-0.23	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
BRCA	cis	rs62103177	0.608	rs59300126	ENSG00000261126.6	RP11-795F19.1	7.62	5.83e-14	1.6e-11	0.33	0.23	Opioid sensitivity;	chr18:79934439	chr18:80046900~80095482:+
BRCA	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-7.62	5.83e-14	1.6e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	7.62	5.84e-14	1.61e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
BRCA	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-7.62	5.84e-14	1.61e-11	-0.27	-0.23	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.574	rs34817002	ENSG00000272950.1	RP11-307C18.1	7.62	5.85e-14	1.61e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98322853~98323430:+
BRCA	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-7.62	5.85e-14	1.61e-11	-0.28	-0.23	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
BRCA	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	7.62	5.85e-14	1.61e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	7.62	5.85e-14	1.61e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
BRCA	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
BRCA	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-7.62	5.86e-14	1.61e-11	-0.26	-0.23	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-7.62	5.86e-14	1.61e-11	-0.26	-0.23	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
BRCA	cis	rs9880211	1	rs9812579	ENSG00000273486.1	RP11-731C17.2	7.62	5.86e-14	1.61e-11	0.31	0.23	Height;Body mass index;	chr3:136432408	chr3:136837338~136839021:-
BRCA	cis	rs1552244	0.882	rs55962400	ENSG00000180385.7	EMC3-AS1	7.62	5.86e-14	1.61e-11	0.31	0.23	Alzheimer's disease;	chr3:10002773	chr3:9986893~10006990:+
BRCA	cis	rs3758911	0.894	rs10890717	ENSG00000255353.1	RP11-382M14.1	-7.62	5.86e-14	1.61e-11	-0.31	-0.23	Coronary artery disease;	chr11:107324666	chr11:107176286~107177530:+
BRCA	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	7.62	5.86e-14	1.61e-11	0.27	0.23	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
BRCA	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	7.62	5.86e-14	1.61e-11	0.27	0.23	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	7.62	5.87e-14	1.61e-11	0.28	0.23	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs9813376	ENSG00000273486.1	RP11-731C17.2	7.62	5.87e-14	1.62e-11	0.31	0.23	Height;Body mass index;	chr3:136756584	chr3:136837338~136839021:-
BRCA	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.62	5.88e-14	1.62e-11	0.34	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-7.62	5.88e-14	1.62e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-7.61	5.94e-14	1.63e-11	-0.24	-0.23	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
BRCA	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-7.61	5.95e-14	1.63e-11	-0.25	-0.23	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
BRCA	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	7.61	5.95e-14	1.64e-11	0.28	0.23	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-7.61	5.96e-14	1.64e-11	-0.23	-0.23	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
BRCA	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	7.61	5.97e-14	1.64e-11	0.33	0.23	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	7.61	5.97e-14	1.64e-11	0.33	0.23	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-7.61	5.97e-14	1.64e-11	-0.28	-0.23	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-7.61	5.98e-14	1.64e-11	-0.31	-0.23	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
BRCA	cis	rs712022	0.534	rs4567455	ENSG00000246225.5	RP11-17A1.3	-7.61	5.99e-14	1.64e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22841980	chr11:22829380~22945393:+
BRCA	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-7.61	5.99e-14	1.65e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-7.61	6e-14	1.65e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
BRCA	cis	rs9527	0.571	rs4917985	ENSG00000213061.2	PFN1P11	7.61	6.01e-14	1.65e-11	0.3	0.23	Arsenic metabolism;	chr10:102864315	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.929	rs2600663	ENSG00000271889.1	RP11-493E12.1	-7.61	6.02e-14	1.65e-11	-0.29	-0.23	Tuberculosis;	chr2:61313552	chr2:61151433~61162105:-
BRCA	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-7.61	6.03e-14	1.66e-11	-0.33	-0.23	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
BRCA	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	7.61	6.04e-14	1.66e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-7.61	6.06e-14	1.66e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
BRCA	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-7.61	6.06e-14	1.66e-11	-0.27	-0.23	Height;	chr2:46636733	chr2:46668870~46670778:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-7.61	6.09e-14	1.67e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
BRCA	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-7.61	6.09e-14	1.67e-11	-0.24	-0.23	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
BRCA	cis	rs3781264	0.6	rs10882416	ENSG00000273450.1	RP11-76P2.4	-7.61	6.11e-14	1.68e-11	-0.3	-0.23	Esophageal cancer and gastric cancer;	chr10:94285297	chr10:94314907~94315327:-
BRCA	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-7.61	6.12e-14	1.68e-11	-0.27	-0.23	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	7.61	6.15e-14	1.69e-11	0.24	0.23	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
BRCA	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-7.61	6.17e-14	1.69e-11	-0.35	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
BRCA	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	7.61	6.18e-14	1.69e-11	0.41	0.23	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	7.61	6.2e-14	1.7e-11	0.23	0.23	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
BRCA	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	7.61	6.2e-14	1.7e-11	0.29	0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
BRCA	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	7.61	6.21e-14	1.7e-11	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.61	6.22e-14	1.71e-11	0.3	0.23	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
BRCA	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	7.61	6.24e-14	1.71e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	7.61	6.24e-14	1.71e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
BRCA	cis	rs925255	0.901	rs906805	ENSG00000270210.1	RP11-373D23.3	7.61	6.25e-14	1.71e-11	0.29	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28382012	chr2:28425945~28426719:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-7.61	6.25e-14	1.71e-11	-0.33	-0.23	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
BRCA	cis	rs9527	0.637	rs11191424	ENSG00000213061.2	PFN1P11	7.61	6.26e-14	1.72e-11	0.3	0.23	Arsenic metabolism;	chr10:102866129	chr10:102838011~102845473:-
BRCA	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	7.61	6.28e-14	1.72e-11	0.29	0.23	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
BRCA	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.61	6.29e-14	1.72e-11	0.32	0.23	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	7.61	6.29e-14	1.73e-11	0.24	0.23	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	7.61	6.3e-14	1.73e-11	0.25	0.23	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
BRCA	cis	rs1113500	0.787	rs10881501	ENSG00000226822.1	RP11-356N1.2	7.61	6.3e-14	1.73e-11	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108099123	chr1:108071482~108074519:+
BRCA	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	7.61	6.3e-14	1.73e-11	0.32	0.23	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
BRCA	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	7.61	6.31e-14	1.73e-11	0.34	0.23	Depression;	chr6:28399846	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-7.61	6.31e-14	1.73e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
BRCA	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-7.6	6.36e-14	1.74e-11	-0.25	-0.23	Height;	chr5:36878678	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-7.6	6.36e-14	1.74e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	7.6	6.36e-14	1.74e-11	0.26	0.23	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
BRCA	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	7.6	6.37e-14	1.74e-11	0.32	0.23	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
BRCA	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-7.6	6.37e-14	1.75e-11	-0.27	-0.23	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
BRCA	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-7.6	6.39e-14	1.75e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	7.6	6.41e-14	1.76e-11	0.29	0.23	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
BRCA	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	7.6	6.42e-14	1.76e-11	0.26	0.23	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
BRCA	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	7.6	6.43e-14	1.76e-11	0.28	0.23	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-7.6	6.43e-14	1.76e-11	-0.26	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
BRCA	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-7.6	6.43e-14	1.76e-11	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
BRCA	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	7.6	6.45e-14	1.77e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
BRCA	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-7.6	6.46e-14	1.77e-11	-0.37	-0.23	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
BRCA	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-7.6	6.46e-14	1.77e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs725310	ENSG00000244380.1	RP11-24C3.2	-7.6	6.46e-14	1.77e-11	-0.26	-0.23	Longevity;	chr3:48377081	chr3:48440352~48446656:-
BRCA	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	7.6	6.47e-14	1.77e-11	0.35	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
BRCA	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	7.6	6.47e-14	1.77e-11	0.23	0.23	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-7.6	6.47e-14	1.77e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-7.6	6.47e-14	1.77e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
BRCA	cis	rs10206020	0.885	rs6720797	ENSG00000231482.2	AC141930.2	-7.6	6.47e-14	1.77e-11	-0.29	-0.23	IgG glycosylation;	chr2:1570568	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
BRCA	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-7.6	6.49e-14	1.78e-11	-0.35	-0.23	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
BRCA	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	7.6	6.5e-14	1.78e-11	0.43	0.23	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
BRCA	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-7.6	6.51e-14	1.78e-11	-0.28	-0.23	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
BRCA	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-7.6	6.51e-14	1.78e-11	-0.29	-0.23	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	7.6	6.52e-14	1.78e-11	0.18	0.23	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-7.6	6.53e-14	1.79e-11	-0.24	-0.23	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
BRCA	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	7.6	6.53e-14	1.79e-11	0.27	0.23	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
BRCA	cis	rs10206020	0.885	rs6720923	ENSG00000231482.2	AC141930.2	-7.6	6.54e-14	1.79e-11	-0.29	-0.23	IgG glycosylation;	chr2:1570425	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-7.6	6.54e-14	1.79e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
BRCA	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-7.6	6.55e-14	1.79e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
BRCA	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	7.6	6.56e-14	1.8e-11	0.21	0.23	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	7.6	6.6e-14	1.8e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	7.6	6.6e-14	1.8e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
BRCA	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-7.6	6.6e-14	1.81e-11	-0.32	-0.23	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
BRCA	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	7.6	6.6e-14	1.81e-11	0.28	0.23	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
BRCA	cis	rs7927771	0.864	rs10838724	ENSG00000280615.1	Y_RNA	-7.6	6.6e-14	1.81e-11	-0.28	-0.23	Subjective well-being;	chr11:47505500	chr11:47614898~47614994:-
BRCA	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-7.6	6.61e-14	1.81e-11	-0.28	-0.23	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-7.6	6.61e-14	1.81e-11	-0.28	-0.23	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	7.6	6.62e-14	1.81e-11	0.24	0.23	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
BRCA	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	7.6	6.63e-14	1.81e-11	0.42	0.23	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	7.6	6.63e-14	1.81e-11	0.18	0.23	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
BRCA	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-7.6	6.63e-14	1.81e-11	-0.27	-0.23	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
BRCA	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	7.6	6.63e-14	1.81e-11	0.27	0.23	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
BRCA	cis	rs3758911	0.894	rs11212166	ENSG00000255353.1	RP11-382M14.1	-7.6	6.63e-14	1.81e-11	-0.31	-0.23	Coronary artery disease;	chr11:107331878	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs7358308	ENSG00000255353.1	RP11-382M14.1	-7.6	6.63e-14	1.81e-11	-0.31	-0.23	Coronary artery disease;	chr11:107333178	chr11:107176286~107177530:+
BRCA	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	7.6	6.66e-14	1.82e-11	0.26	0.23	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
BRCA	cis	rs6539288	0.933	rs6539291	ENSG00000260329.1	RP11-412D9.4	-7.6	6.67e-14	1.82e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106916033	chr12:106954029~106955497:-
BRCA	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	7.6	6.67e-14	1.82e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
BRCA	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.6	6.69e-14	1.83e-11	0.3	0.23	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
BRCA	cis	rs3814244	0.528	rs10878723	ENSG00000236946.2	HNRNPA1P70	-7.6	6.71e-14	1.83e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:68035767~68036853:+
BRCA	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	7.6	6.72e-14	1.84e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
BRCA	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-7.6	6.75e-14	1.85e-11	-0.31	-0.23	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
BRCA	cis	rs7085104	0.591	rs4919683	ENSG00000213061.2	PFN1P11	7.6	6.78e-14	1.85e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102838011~102845473:-
BRCA	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-7.6	6.8e-14	1.86e-11	-0.31	-0.23	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
BRCA	cis	rs12999373	0.523	rs9678953	ENSG00000272342.1	RP13-539J13.1	-7.6	6.8e-14	1.86e-11	-0.3	-0.23	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694759	chr2:739588~740164:-
BRCA	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	7.6	6.81e-14	1.86e-11	0.33	0.23	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
BRCA	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	7.6	6.82e-14	1.86e-11	0.27	0.23	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
BRCA	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	7.6	6.82e-14	1.86e-11	0.31	0.23	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
BRCA	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	7.6	6.82e-14	1.86e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	7.6	6.82e-14	1.86e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
BRCA	cis	rs7772486	0.875	rs2777482	ENSG00000235652.6	RP11-545I5.3	7.6	6.83e-14	1.86e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145999205	chr6:145799409~145886585:+
BRCA	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	7.6	6.83e-14	1.86e-11	0.25	0.23	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
BRCA	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	7.59	6.85e-14	1.87e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-7.59	6.85e-14	1.87e-11	-0.15	-0.23	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
BRCA	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-7.59	6.85e-14	1.87e-11	-0.25	-0.23	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	7.59	6.85e-14	1.87e-11	0.24	0.23	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
BRCA	cis	rs67981189	0.579	rs2240533	ENSG00000269927.1	RP6-91H8.3	7.59	6.86e-14	1.87e-11	0.29	0.23	Schizophrenia;	chr14:71074309	chr14:71141125~71143253:-
BRCA	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-7.59	6.89e-14	1.88e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
BRCA	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-7.59	6.89e-14	1.88e-11	-0.26	-0.23	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	7.59	6.91e-14	1.89e-11	0.32	0.23	Height;	chr4:55415153	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	7.59	6.92e-14	1.89e-11	0.23	0.23	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
BRCA	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-7.59	6.93e-14	1.89e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	7.59	6.94e-14	1.89e-11	0.24	0.23	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
BRCA	cis	rs919433	0.963	rs1366837	ENSG00000231621.1	AC013264.2	7.59	6.94e-14	1.9e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197295777	chr2:197197991~197199273:+
BRCA	cis	rs3758911	0.894	rs1490947	ENSG00000255353.1	RP11-382M14.1	-7.59	6.94e-14	1.9e-11	-0.31	-0.23	Coronary artery disease;	chr11:107325294	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	7.59	6.97e-14	1.9e-11	0.18	0.23	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
BRCA	cis	rs7474896	0.583	rs7071147	ENSG00000226578.1	RP11-258F22.1	-7.59	7e-14	1.91e-11	-0.3	-0.23	Obesity (extreme);	chr10:37714448	chr10:37775371~37784131:-
BRCA	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-7.59	7e-14	1.91e-11	-0.27	-0.23	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.01e-14	1.91e-11	-0.3	-0.23	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
BRCA	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	7.59	7.03e-14	1.92e-11	0.21	0.23	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
BRCA	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	7.59	7.03e-14	1.92e-11	0.28	0.23	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
BRCA	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-7.59	7.03e-14	1.92e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
BRCA	cis	rs9816784	0.901	rs12490036	ENSG00000231464.1	AC024937.4	-7.59	7.07e-14	1.93e-11	-0.28	-0.23	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-7.59	7.07e-14	1.93e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
BRCA	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	7.59	7.07e-14	1.93e-11	0.52	0.23	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
BRCA	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	7.59	7.07e-14	1.93e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	7.59	7.07e-14	1.93e-11	0.38	0.23	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
BRCA	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-7.59	7.09e-14	1.93e-11	-0.28	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	7.59	7.09e-14	1.93e-11	0.32	0.23	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	7.59	7.11e-14	1.94e-11	0.26	0.23	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
BRCA	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	7.59	7.11e-14	1.94e-11	0.34	0.23	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
BRCA	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-7.59	7.11e-14	1.94e-11	-0.28	-0.23	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
BRCA	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	7.59	7.12e-14	1.94e-11	0.21	0.23	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000273024.4	INTS4P2	7.59	7.12e-14	1.94e-11	0.26	0.23	Calcium levels;	chr7:66045710	chr7:65647864~65715661:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-7.59	7.13e-14	1.94e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
BRCA	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	7.59	7.13e-14	1.94e-11	0.33	0.23	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	7.59	7.14e-14	1.95e-11	0.31	0.23	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-7.59	7.14e-14	1.95e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
BRCA	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	7.59	7.14e-14	1.95e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	7.59	7.14e-14	1.95e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	7.59	7.15e-14	1.95e-11	0.24	0.23	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
BRCA	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-7.59	7.15e-14	1.95e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	7.59	7.16e-14	1.95e-11	0.26	0.23	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
BRCA	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-7.59	7.17e-14	1.96e-11	-0.26	-0.23	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
BRCA	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-7.59	7.17e-14	1.96e-11	-0.24	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
BRCA	cis	rs6472827	0.762	rs2936687	ENSG00000253983.2	RP1-16A9.1	7.59	7.17e-14	1.96e-11	0.37	0.23	Uterine fibroids;	chr8:74205136	chr8:74199396~74208441:+
BRCA	cis	rs6472827	0.762	rs77058572	ENSG00000253983.2	RP1-16A9.1	7.59	7.17e-14	1.96e-11	0.37	0.23	Uterine fibroids;	chr8:74205137	chr8:74199396~74208441:+
BRCA	cis	rs712022	0.534	rs10833839	ENSG00000246225.5	RP11-17A1.3	-7.59	7.18e-14	1.96e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22846282	chr11:22829380~22945393:+
BRCA	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-7.59	7.18e-14	1.96e-11	-0.26	-0.23	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-7.59	7.19e-14	1.96e-11	-0.25	-0.23	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
BRCA	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	7.59	7.19e-14	1.96e-11	0.4	0.23	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000273024.4	INTS4P2	-7.59	7.19e-14	1.96e-11	-0.26	-0.23	Calcium levels;	chr7:65977808	chr7:65647864~65715661:+
BRCA	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.2e-14	1.96e-11	-0.31	-0.23	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
BRCA	cis	rs250518	1	rs250518	ENSG00000272081.1	CTD-2376I4.2	-7.59	7.2e-14	1.96e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72905231	chr5:72955206~72955699:-
BRCA	cis	rs9880211	0.948	rs34282798	ENSG00000273486.1	RP11-731C17.2	7.59	7.23e-14	1.97e-11	0.3	0.23	Height;Body mass index;	chr3:136424515	chr3:136837338~136839021:-
BRCA	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.23e-14	1.97e-11	-0.32	-0.23	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
BRCA	cis	rs516805	0.961	rs527978	ENSG00000279114.1	RP3-425C14.5	-7.59	7.24e-14	1.97e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122475225	chr6:122471923~122484161:+
BRCA	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	7.59	7.24e-14	1.97e-11	0.27	0.23	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.25e-14	1.97e-11	-0.31	-0.23	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	7.59	7.29e-14	1.98e-11	0.28	0.23	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
BRCA	cis	rs74233809	1	rs10509759	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102929908	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883806	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102953319	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs78260931	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102962205	chr10:103175554~103176094:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	7.59	7.33e-14	2e-11	0.3	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
BRCA	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	7.58	7.36e-14	2e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-7.58	7.36e-14	2e-11	-0.33	-0.23	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	7.58	7.36e-14	2.01e-11	0.31	0.23	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
BRCA	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	7.58	7.37e-14	2.01e-11	0.21	0.23	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	7.58	7.37e-14	2.01e-11	0.24	0.23	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	7.58	7.37e-14	2.01e-11	0.32	0.23	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
BRCA	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	7.58	7.37e-14	2.01e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
BRCA	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-7.58	7.38e-14	2.01e-11	-0.35	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-7.58	7.39e-14	2.01e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
BRCA	cis	rs7474896	0.583	rs4934898	ENSG00000226578.1	RP11-258F22.1	-7.58	7.43e-14	2.02e-11	-0.3	-0.23	Obesity (extreme);	chr10:37701467	chr10:37775371~37784131:-
BRCA	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	7.58	7.43e-14	2.02e-11	0.17	0.23	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
BRCA	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-7.58	7.43e-14	2.02e-11	-0.26	-0.23	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
BRCA	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-7.58	7.44e-14	2.02e-11	-0.29	-0.23	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
BRCA	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-7.58	7.44e-14	2.02e-11	-0.32	-0.23	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
BRCA	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	7.58	7.44e-14	2.03e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
BRCA	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-7.58	7.49e-14	2.04e-11	-0.26	-0.23	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
BRCA	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	7.58	7.51e-14	2.04e-11	0.23	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
BRCA	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	7.58	7.51e-14	2.04e-11	0.33	0.23	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-7.58	7.52e-14	2.05e-11	-0.15	-0.23	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	7.58	7.54e-14	2.05e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
BRCA	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-7.58	7.54e-14	2.05e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
BRCA	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-7.58	7.56e-14	2.06e-11	-0.3	-0.23	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
BRCA	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	7.58	7.56e-14	2.06e-11	0.27	0.23	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-7.58	7.57e-14	2.06e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
BRCA	cis	rs9527	0.501	rs12244388	ENSG00000213061.2	PFN1P11	7.58	7.6e-14	2.07e-11	0.3	0.23	Arsenic metabolism;	chr10:102880295	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs11191514	ENSG00000213277.3	MARCKSL1P1	7.58	7.6e-14	2.07e-11	0.42	0.23	Birth weight;	chr10:103013607	chr10:103175554~103176094:+
BRCA	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-7.58	7.63e-14	2.08e-11	-0.39	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
BRCA	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	7.58	7.64e-14	2.08e-11	0.26	0.23	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
BRCA	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.58	7.64e-14	2.08e-11	0.3	0.23	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	7.58	7.64e-14	2.08e-11	0.27	0.23	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-7.58	7.68e-14	2.09e-11	-0.24	-0.23	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
BRCA	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	7.58	7.68e-14	2.09e-11	0.33	0.23	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	7.58	7.68e-14	2.09e-11	0.33	0.23	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
BRCA	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	7.58	7.68e-14	2.09e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
BRCA	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	7.58	7.7e-14	2.09e-11	0.27	0.23	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
BRCA	cis	rs919433	1	rs2195510	ENSG00000231621.1	AC013264.2	7.58	7.73e-14	2.1e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197296471	chr2:197197991~197199273:+
BRCA	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	7.58	7.74e-14	2.1e-11	0.25	0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	7.58	7.75e-14	2.11e-11	0.24	0.23	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
BRCA	cis	rs6740322	0.748	rs6544636	ENSG00000234936.1	AC010883.5	7.58	7.76e-14	2.11e-11	0.26	0.23	Coronary artery disease;	chr2:43260347	chr2:43229573~43233394:+
BRCA	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	7.58	7.76e-14	2.11e-11	0.26	0.23	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
BRCA	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-7.58	7.77e-14	2.11e-11	-0.28	-0.23	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
BRCA	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-7.58	7.77e-14	2.11e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
BRCA	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-7.58	7.77e-14	2.11e-11	-0.26	-0.23	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	7.58	7.78e-14	2.11e-11	0.24	0.23	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
BRCA	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-7.58	7.8e-14	2.12e-11	-0.22	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
BRCA	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	7.58	7.8e-14	2.12e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
BRCA	cis	rs9513627	0.915	rs7327204	ENSG00000280710.1	RP11-214F16.8	-7.58	7.81e-14	2.12e-11	-0.37	-0.23	Obesity-related traits;	chr13:99474698	chr13:99498524~99501315:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-7.58	7.82e-14	2.12e-11	-0.25	-0.23	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
BRCA	cis	rs9880211	1	rs12695649	ENSG00000273486.1	RP11-731C17.2	7.58	7.85e-14	2.13e-11	0.3	0.23	Height;Body mass index;	chr3:136553074	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.948	rs34913797	ENSG00000273486.1	RP11-731C17.2	7.58	7.85e-14	2.13e-11	0.31	0.23	Height;Body mass index;	chr3:136408728	chr3:136837338~136839021:-
BRCA	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-7.58	7.86e-14	2.13e-11	-0.28	-0.23	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
BRCA	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-7.58	7.88e-14	2.14e-11	-0.31	-0.23	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
BRCA	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-7.58	7.88e-14	2.14e-11	-0.31	-0.23	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-7.57	7.91e-14	2.15e-11	-0.24	-0.23	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
BRCA	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-7.57	7.91e-14	2.15e-11	-0.32	-0.23	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
BRCA	cis	rs4934494	0.689	rs17127596	ENSG00000240996.1	RP11-80H5.7	7.57	7.92e-14	2.15e-11	0.27	0.23	Red blood cell count;	chr10:89816128	chr10:89694295~89697928:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	7.57	7.95e-14	2.16e-11	0.18	0.23	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
BRCA	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	7.57	7.95e-14	2.16e-11	0.26	0.23	Longevity;	chr3:48458887	chr3:48440352~48446656:-
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-7.57	7.96e-14	2.16e-11	-0.24	-0.23	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
BRCA	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-7.57	7.96e-14	2.16e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
BRCA	cis	rs10861661	0.963	rs10444533	ENSG00000260329.1	RP11-412D9.4	7.57	7.97e-14	2.16e-11	0.3	0.23	Triglyceride levels;	chr12:106835927	chr12:106954029~106955497:-
BRCA	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-7.57	7.99e-14	2.17e-11	-0.26	-0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
BRCA	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	7.57	7.99e-14	2.17e-11	0.39	0.23	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
BRCA	cis	rs1113500	0.805	rs11185248	ENSG00000226822.1	RP11-356N1.2	-7.57	8e-14	2.17e-11	-0.29	-0.23	Growth-regulated protein alpha levels;	chr1:108068379	chr1:108071482~108074519:+
BRCA	cis	rs6472827	0.904	rs11996617	ENSG00000253983.2	RP1-16A9.1	-7.57	8.01e-14	2.17e-11	-0.36	-0.23	Uterine fibroids;	chr8:74208452	chr8:74199396~74208441:+
BRCA	cis	rs3758911	1	rs1046095	ENSG00000255353.1	RP11-382M14.1	-7.57	8.03e-14	2.18e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326509	chr11:107176286~107177530:+
BRCA	cis	rs812925	0.892	rs4672440	ENSG00000271889.1	RP11-493E12.1	-7.57	8.03e-14	2.18e-11	-0.3	-0.23	Immature fraction of reticulocytes;	chr2:61389518	chr2:61151433~61162105:-
BRCA	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	7.57	8.05e-14	2.18e-11	0.24	0.23	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	7.57	8.06e-14	2.19e-11	0.4	0.23	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
BRCA	cis	rs3733829	1	rs3733829	ENSG00000268529.1	CYP2T3P	-7.57	8.06e-14	2.19e-11	-0.29	-0.23	Smoking behavior;	chr19:40804666	chr19:41134722~41137308:+
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	7.57	8.07e-14	2.19e-11	0.34	0.23	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	7.57	8.07e-14	2.19e-11	0.33	0.23	Height;	chr4:55413708	chr4:55387949~55388271:+
BRCA	cis	rs12188164	0.561	rs2721010	ENSG00000225138.6	CTD-2228K2.7	-7.57	8.08e-14	2.19e-11	-0.24	-0.23	Cystic fibrosis severity;	chr5:456800	chr5:473236~480884:+
BRCA	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-7.57	8.09e-14	2.19e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	7.57	8.1e-14	2.2e-11	0.26	0.23	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
BRCA	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	7.57	8.1e-14	2.2e-11	0.31	0.23	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-7.57	8.13e-14	2.21e-11	-0.26	-0.23	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	7.57	8.15e-14	2.21e-11	0.32	0.23	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	7.57	8.16e-14	2.21e-11	0.32	0.23	Height;	chr4:55413708	chr4:55363971~55395847:-
BRCA	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-7.57	8.19e-14	2.22e-11	-0.28	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-7.57	8.2e-14	2.22e-11	-0.23	-0.23	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-7.57	8.21e-14	2.23e-11	-0.24	-0.23	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
BRCA	cis	rs1861628	1	rs1861628	ENSG00000237930.1	AC007563.4	7.57	8.21e-14	2.23e-11	0.27	0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763707	chr2:216785774~216786144:-
BRCA	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	7.57	8.24e-14	2.23e-11	0.34	0.23	Depression;	chr6:28379133	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	7.57	8.24e-14	2.23e-11	0.34	0.23	Depression;	chr6:28379168	chr6:28943877~28944537:+
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-7.57	8.27e-14	2.24e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-7.57	8.27e-14	2.24e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-7.57	8.28e-14	2.24e-11	-0.23	-0.23	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-7.57	8.28e-14	2.24e-11	-0.23	-0.23	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
BRCA	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-7.57	8.28e-14	2.24e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
BRCA	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	7.57	8.28e-14	2.25e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
BRCA	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	7.57	8.29e-14	2.25e-11	0.3	0.23	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
BRCA	cis	rs1113500	0.814	rs12039712	ENSG00000226822.1	RP11-356N1.2	7.57	8.29e-14	2.25e-11	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108098577	chr1:108071482~108074519:+
BRCA	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-7.57	8.31e-14	2.25e-11	-0.32	-0.23	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
BRCA	cis	rs4237845	0.844	rs7306124	ENSG00000257159.1	RP11-58A17.3	7.57	8.31e-14	2.25e-11	0.26	0.23	Intelligence (multi-trait analysis);	chr12:57909566	chr12:57967058~57968399:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	7.57	8.32e-14	2.25e-11	0.24	0.23	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-7.57	8.32e-14	2.25e-11	-0.31	-0.23	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
BRCA	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-7.57	8.32e-14	2.25e-11	-0.26	-0.23	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
BRCA	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-7.57	8.33e-14	2.26e-11	-0.31	-0.23	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	7.57	8.34e-14	2.26e-11	0.24	0.23	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-7.57	8.35e-14	2.26e-11	-0.28	-0.23	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
BRCA	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-7.57	8.38e-14	2.27e-11	-0.33	-0.23	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	7.57	8.4e-14	2.28e-11	0.25	0.23	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
BRCA	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-7.57	8.42e-14	2.28e-11	-0.26	-0.23	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
BRCA	cis	rs8012947	0.916	rs11627199	ENSG00000279636.2	LINC00216	7.57	8.42e-14	2.28e-11	0.27	0.23	Alcohol consumption in current drinkers;	chr14:58386288	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	7.57	8.42e-14	2.28e-11	0.28	0.23	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
BRCA	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-7.57	8.43e-14	2.28e-11	-0.27	-0.23	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-7.57	8.44e-14	2.29e-11	-0.23	-0.23	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-7.57	8.48e-14	2.3e-11	-0.23	-0.23	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
BRCA	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	7.57	8.49e-14	2.3e-11	0.43	0.23	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.637	rs1825040	ENSG00000251600.4	RP11-673E1.1	-7.57	8.5e-14	2.3e-11	-0.25	-0.23	Immature fraction of reticulocytes;	chr4:143794417	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	7.56	8.52e-14	2.31e-11	0.39	0.23	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
BRCA	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-7.56	8.53e-14	2.31e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
BRCA	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	7.56	8.53e-14	2.31e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-7.56	8.54e-14	2.31e-11	-0.28	-0.23	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-7.56	8.54e-14	2.31e-11	-0.28	-0.23	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	7.56	8.54e-14	2.31e-11	0.24	0.23	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	7.56	8.54e-14	2.31e-11	0.24	0.23	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-7.56	8.55e-14	2.31e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	7.56	8.58e-14	2.32e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
BRCA	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	7.56	8.59e-14	2.32e-11	0.28	0.23	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
BRCA	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	7.56	8.59e-14	2.32e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
BRCA	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	7.56	8.62e-14	2.33e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
BRCA	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-7.56	8.62e-14	2.33e-11	-0.3	-0.23	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-7.56	8.62e-14	2.33e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
BRCA	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	7.56	8.63e-14	2.33e-11	0.33	0.23	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
BRCA	cis	rs11723261	0.582	rs6599293	ENSG00000211553.1	AC253576.2	-7.56	8.64e-14	2.34e-11	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:136461~136568:+
BRCA	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	7.56	8.66e-14	2.34e-11	0.3	0.23	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
BRCA	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-7.56	8.66e-14	2.34e-11	-0.27	-0.23	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
BRCA	cis	rs7615952	0.576	rs2276727	ENSG00000250012.1	RP11-124N2.1	-7.56	8.66e-14	2.34e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126107400	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-7.56	8.68e-14	2.35e-11	-0.26	-0.23	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
BRCA	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-7.56	8.68e-14	2.35e-11	-0.31	-0.23	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-7.56	8.69e-14	2.35e-11	-0.15	-0.23	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-7.56	8.69e-14	2.35e-11	-0.15	-0.23	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
BRCA	cis	rs42648	0.617	rs11563435	ENSG00000225498.1	AC002064.5	7.56	8.7e-14	2.35e-11	0.22	0.23	Homocysteine levels;	chr7:90270893	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	7.56	8.71e-14	2.36e-11	0.23	0.23	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
BRCA	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-7.56	8.72e-14	2.36e-11	-0.27	-0.23	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
BRCA	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-7.56	8.75e-14	2.36e-11	-0.25	-0.23	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
BRCA	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-7.56	8.76e-14	2.37e-11	-0.23	-0.23	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
BRCA	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	7.56	8.77e-14	2.37e-11	0.28	0.23	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-7.56	8.78e-14	2.37e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-7.56	8.78e-14	2.37e-11	-0.23	-0.23	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
BRCA	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-7.56	8.78e-14	2.37e-11	-0.27	-0.23	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
BRCA	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-7.56	8.79e-14	2.38e-11	-0.25	-0.23	Height;	chr5:36882917	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	7.56	8.8e-14	2.38e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
BRCA	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	7.56	8.8e-14	2.38e-11	0.31	0.23	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-7.56	8.81e-14	2.38e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-7.56	8.81e-14	2.38e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-7.56	8.83e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-7.56	8.83e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
BRCA	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-7.56	8.83e-14	2.39e-11	-0.29	-0.23	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
BRCA	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-7.56	8.83e-14	2.39e-11	-0.27	-0.23	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-7.56	8.84e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
BRCA	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	7.56	8.84e-14	2.39e-11	0.39	0.23	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	7.56	8.84e-14	2.39e-11	0.23	0.23	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
BRCA	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	7.56	8.84e-14	2.39e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	7.56	8.85e-14	2.39e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-7.56	8.85e-14	2.39e-11	-0.26	-0.23	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	7.56	8.86e-14	2.39e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
BRCA	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	7.56	8.88e-14	2.4e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	7.56	8.89e-14	2.4e-11	0.24	0.23	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
BRCA	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	7.56	8.91e-14	2.41e-11	0.29	0.23	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	7.56	8.92e-14	2.41e-11	0.23	0.23	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
BRCA	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	7.56	8.94e-14	2.41e-11	0.43	0.23	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	7.56	8.94e-14	2.41e-11	0.43	0.23	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
BRCA	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	7.56	8.94e-14	2.42e-11	0.27	0.23	Longevity;	chr3:48440024	chr3:48440352~48446656:-
BRCA	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-7.56	8.95e-14	2.42e-11	-0.29	-0.23	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
BRCA	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	7.56	8.95e-14	2.42e-11	0.25	0.23	Height;	chr5:37025769	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-7.56	8.96e-14	2.42e-11	-0.23	-0.23	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-7.56	8.96e-14	2.42e-11	-0.23	-0.23	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	7.56	8.96e-14	2.42e-11	0.23	0.23	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-7.56	8.96e-14	2.42e-11	-0.32	-0.23	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
BRCA	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-7.56	8.97e-14	2.42e-11	-0.27	-0.23	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
BRCA	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-7.56	8.97e-14	2.42e-11	-0.25	-0.23	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
BRCA	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	7.56	8.98e-14	2.42e-11	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
BRCA	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	7.56	8.98e-14	2.42e-11	0.26	0.23	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
BRCA	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	7.56	9.02e-14	2.43e-11	0.24	0.23	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
BRCA	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-7.56	9.07e-14	2.45e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-7.56	9.07e-14	2.45e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
BRCA	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
BRCA	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-7.56	9.1e-14	2.46e-11	-0.29	-0.23	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
BRCA	cis	rs9880211	1	rs34757183	ENSG00000273486.1	RP11-731C17.2	7.56	9.11e-14	2.46e-11	0.3	0.23	Height;Body mass index;	chr3:136424826	chr3:136837338~136839021:-
BRCA	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	7.55	9.15e-14	2.47e-11	0.28	0.23	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-7.55	9.15e-14	2.47e-11	-0.28	-0.23	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
BRCA	cis	rs9527	0.637	rs12219247	ENSG00000236937.2	PTGES3P4	7.55	9.17e-14	2.47e-11	0.3	0.23	Arsenic metabolism;	chr10:102853604	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	7.55	9.18e-14	2.48e-11	0.23	0.23	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-7.55	9.2e-14	2.48e-11	-0.24	-0.23	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-7.55	9.2e-14	2.48e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
BRCA	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	7.55	9.22e-14	2.49e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-7.55	9.22e-14	2.49e-11	-0.32	-0.23	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
BRCA	cis	rs10492201	0.529	rs10878724	ENSG00000255733.4	IFNG-AS1	-7.55	9.25e-14	2.49e-11	-0.21	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006091	chr12:67989445~68234686:+
BRCA	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	7.55	9.25e-14	2.49e-11	0.42	0.23	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
BRCA	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	7.55	9.25e-14	2.49e-11	0.42	0.23	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
BRCA	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-7.55	9.26e-14	2.5e-11	-0.28	-0.23	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
BRCA	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-7.55	9.33e-14	2.52e-11	-0.25	-0.23	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
BRCA	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	7.55	9.34e-14	2.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	7.55	9.34e-14	2.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
BRCA	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.36e-14	2.52e-11	-0.3	-0.23	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.36e-14	2.52e-11	-0.3	-0.23	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	7.55	9.36e-14	2.52e-11	0.44	0.23	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	7.55	9.37e-14	2.52e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	7.55	9.37e-14	2.52e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	7.55	9.4e-14	2.53e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
BRCA	cis	rs4934494	0.689	rs11185895	ENSG00000240996.1	RP11-80H5.7	7.55	9.41e-14	2.53e-11	0.27	0.23	Red blood cell count;	chr10:89817482	chr10:89694295~89697928:-
BRCA	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	7.55	9.41e-14	2.53e-11	0.42	0.23	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	7.55	9.42e-14	2.54e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-7.55	9.42e-14	2.54e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-7.55	9.43e-14	2.54e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
BRCA	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	7.55	9.46e-14	2.55e-11	0.32	0.23	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
BRCA	cis	rs12188164	0.561	rs2251843	ENSG00000225138.6	CTD-2228K2.7	7.55	9.47e-14	2.55e-11	0.24	0.23	Cystic fibrosis severity;	chr5:457840	chr5:473236~480884:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-7.55	9.49e-14	2.56e-11	-0.24	-0.23	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-7.55	9.49e-14	2.56e-11	-0.28	-0.23	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
BRCA	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	7.55	9.5e-14	2.56e-11	0.25	0.23	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.55	9.52e-14	2.56e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
BRCA	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.54e-14	2.57e-11	-0.3	-0.23	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
BRCA	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-7.55	9.56e-14	2.57e-11	-0.28	-0.23	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
BRCA	cis	rs4713118	0.669	rs200997	ENSG00000220721.1	OR1F12	7.55	9.57e-14	2.58e-11	0.27	0.23	Parkinson's disease;	chr6:27844037	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	7.55	9.57e-14	2.58e-11	0.27	0.23	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	7.55	9.57e-14	2.58e-11	0.31	0.23	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
BRCA	cis	rs11191419	1	rs11191419	ENSG00000236937.2	PTGES3P4	7.55	9.59e-14	2.58e-11	0.3	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102845595~102845950:+
BRCA	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	7.55	9.6e-14	2.59e-11	0.3	0.23	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
BRCA	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	7.55	9.6e-14	2.59e-11	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	7.55	9.61e-14	2.59e-11	0.23	0.23	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
BRCA	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	7.55	9.62e-14	2.59e-11	0.29	0.23	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	7.55	9.62e-14	2.59e-11	0.23	0.23	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
BRCA	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-7.55	9.62e-14	2.59e-11	-0.32	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
BRCA	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-7.55	9.63e-14	2.59e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000255046.1	RP11-297N6.4	7.55	9.63e-14	2.59e-11	0.27	0.23	Systolic blood pressure;	chr8:11972641	chr8:11797928~11802568:-
BRCA	cis	rs58873874	0.579	rs10040318	ENSG00000251405.2	CTB-109A12.1	7.55	9.65e-14	2.6e-11	0.46	0.23	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157362615~157460078:-
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	7.55	9.68e-14	2.61e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
BRCA	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	7.55	9.69e-14	2.61e-11	0.25	0.23	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
BRCA	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-7.55	9.7e-14	2.61e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
BRCA	cis	rs3781264	0.761	rs11187869	ENSG00000273450.1	RP11-76P2.4	7.55	9.7e-14	2.61e-11	0.32	0.23	Esophageal cancer and gastric cancer;	chr10:94327740	chr10:94314907~94315327:-
BRCA	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	7.55	9.7e-14	2.61e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
BRCA	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	7.55	9.73e-14	2.62e-11	0.38	0.23	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
BRCA	cis	rs712022	0.534	rs7395098	ENSG00000246225.5	RP11-17A1.3	-7.55	9.74e-14	2.62e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22856901	chr11:22829380~22945393:+
BRCA	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-7.55	9.74e-14	2.62e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
BRCA	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-7.55	9.79e-14	2.63e-11	-0.41	-0.23	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
BRCA	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	7.55	9.79e-14	2.64e-11	0.26	0.23	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
BRCA	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-7.55	9.81e-14	2.64e-11	-0.29	-0.23	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	7.55	9.82e-14	2.64e-11	0.23	0.23	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	7.55	9.83e-14	2.64e-11	0.26	0.23	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-7.54	9.85e-14	2.65e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-7.54	9.86e-14	2.65e-11	-0.3	-0.23	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
BRCA	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-7.54	9.86e-14	2.65e-11	-0.26	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000273024.4	INTS4P2	7.54	9.88e-14	2.66e-11	0.26	0.23	Calcium levels;	chr7:66040056	chr7:65647864~65715661:+
BRCA	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	7.54	9.9e-14	2.66e-11	0.47	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
BRCA	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-7.54	9.91e-14	2.66e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
BRCA	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	7.54	9.92e-14	2.67e-11	0.28	0.23	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
BRCA	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	7.54	9.93e-14	2.67e-11	0.3	0.23	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
BRCA	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-7.54	9.95e-14	2.67e-11	-0.32	-0.23	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-7.54	9.96e-14	2.68e-11	-0.31	-0.23	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
BRCA	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	7.54	1e-13	2.69e-11	0.32	0.23	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	7.54	1e-13	2.69e-11	0.27	0.23	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	7.54	1e-13	2.69e-11	0.27	0.23	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
BRCA	cis	rs3794924	0.925	rs35427815	ENSG00000266521.1	RP11-650P15.1	7.54	1e-13	2.69e-11	0.41	0.23	Survival in colon cancer;	chr18:31466438	chr18:31496645~31497195:-
BRCA	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-7.54	1e-13	2.7e-11	-0.3	-0.23	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	7.54	1e-13	2.7e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
BRCA	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	7.54	1e-13	2.7e-11	0.3	0.23	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
BRCA	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	7.54	1.01e-13	2.7e-11	0.26	0.23	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	7.54	1.01e-13	2.71e-11	0.23	0.23	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
BRCA	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-7.54	1.01e-13	2.71e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-7.54	1.01e-13	2.71e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
BRCA	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	7.54	1.01e-13	2.71e-11	0.17	0.23	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
BRCA	cis	rs853679	0.882	rs9380069	ENSG00000220721.1	OR1F12	7.54	1.01e-13	2.71e-11	0.38	0.23	Depression;	chr6:28235522	chr6:28073316~28074233:+
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	7.54	1.01e-13	2.71e-11	0.32	0.23	Height;	chr4:55415153	chr4:55387949~55388271:+
BRCA	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.01e-13	2.72e-11	-0.31	-0.23	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
BRCA	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	7.54	1.01e-13	2.72e-11	0.3	0.23	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	7.54	1.01e-13	2.72e-11	0.25	0.23	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-7.54	1.02e-13	2.73e-11	-0.28	-0.23	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
BRCA	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-7.54	1.02e-13	2.73e-11	-0.37	-0.23	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
BRCA	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	7.54	1.02e-13	2.74e-11	0.26	0.23	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	7.54	1.02e-13	2.74e-11	0.32	0.23	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	7.54	1.02e-13	2.75e-11	0.24	0.23	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.02e-13	2.75e-11	-0.24	-0.23	Height;	chr5:36904297	chr5:36666214~36725195:-
BRCA	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.02e-13	2.75e-11	-0.25	-0.23	Height;	chr5:37045739	chr5:36666214~36725195:-
BRCA	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-7.54	1.02e-13	2.75e-11	-0.22	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
BRCA	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	7.54	1.03e-13	2.75e-11	0.39	0.23	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
BRCA	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-7.54	1.03e-13	2.76e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
BRCA	cis	rs3758911	0.894	rs12286915	ENSG00000255353.1	RP11-382M14.1	-7.54	1.03e-13	2.77e-11	-0.31	-0.23	Coronary artery disease;	chr11:107340608	chr11:107176286~107177530:+
BRCA	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-7.54	1.03e-13	2.78e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
BRCA	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	7.54	1.03e-13	2.78e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	7.54	1.03e-13	2.78e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-7.54	1.04e-13	2.78e-11	-0.4	-0.23	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
BRCA	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	7.54	1.04e-13	2.79e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-7.54	1.04e-13	2.79e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	7.54	1.04e-13	2.79e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	7.54	1.04e-13	2.79e-11	0.26	0.23	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-7.54	1.04e-13	2.79e-11	-0.24	-0.23	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	7.54	1.05e-13	2.81e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
BRCA	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	7.54	1.05e-13	2.81e-11	0.44	0.23	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
BRCA	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	7.54	1.05e-13	2.81e-11	0.26	0.23	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
BRCA	cis	rs748404	1	rs12909095	ENSG00000249839.1	AC011330.5	-7.54	1.05e-13	2.81e-11	-0.32	-0.23	Lung cancer;	chr15:43265944	chr15:43663654~43684339:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	7.54	1.05e-13	2.81e-11	0.24	0.23	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
BRCA	cis	rs10200159	1	rs13428382	ENSG00000272606.1	RP11-554J4.1	7.54	1.05e-13	2.82e-11	0.43	0.23	Vitiligo;	chr2:55636929	chr2:55617909~55618373:+
BRCA	cis	rs2378497	1	rs12137305	ENSG00000232679.1	RP11-400N13.3	7.54	1.05e-13	2.83e-11	0.3	0.23	Serum thyroid-stimulating hormone levels;	chr1:222047359	chr1:222041705~222064763:-
BRCA	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-7.54	1.06e-13	2.83e-11	-0.25	-0.23	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-7.54	1.06e-13	2.83e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
BRCA	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	7.53	1.06e-13	2.84e-11	0.33	0.23	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-7.53	1.06e-13	2.84e-11	-0.28	-0.23	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
BRCA	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-7.53	1.06e-13	2.85e-11	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
BRCA	cis	rs11143230	1	rs62564005	ENSG00000225434.2	LINC01504	-7.53	1.06e-13	2.85e-11	-0.26	-0.23	Suicidal ideation;	chr9:72273467	chr9:72305430~72343210:+
BRCA	cis	rs78456975	0.574	rs13412980	ENSG00000231482.2	AC141930.2	-7.53	1.06e-13	2.85e-11	-0.33	-0.23	Placebo response in major depressive disorder (% change in symptom score);	chr2:1541459	chr2:1572554~1580311:-
BRCA	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-7.53	1.07e-13	2.85e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
BRCA	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
BRCA	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	7.53	1.07e-13	2.86e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
BRCA	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-7.53	1.07e-13	2.86e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	7.53	1.07e-13	2.86e-11	0.34	0.23	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
BRCA	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	7.53	1.07e-13	2.86e-11	0.43	0.23	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
BRCA	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
BRCA	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	7.53	1.07e-13	2.88e-11	0.26	0.23	Longevity;	chr3:48414217	chr3:48440352~48446656:-
BRCA	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-7.53	1.07e-13	2.88e-11	-0.3	-0.23	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
BRCA	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	7.53	1.08e-13	2.88e-11	0.29	0.23	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
BRCA	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.08e-13	2.88e-11	-0.33	-0.23	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-7.53	1.08e-13	2.89e-11	-0.3	-0.23	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
BRCA	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-7.53	1.09e-13	2.92e-11	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
BRCA	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	7.53	1.09e-13	2.93e-11	0.3	0.23	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
BRCA	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-7.53	1.09e-13	2.93e-11	-0.32	-0.23	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
BRCA	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	7.53	1.09e-13	2.93e-11	0.23	0.23	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
BRCA	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	7.53	1.09e-13	2.93e-11	0.42	0.23	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	7.53	1.09e-13	2.93e-11	0.32	0.23	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
BRCA	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	7.53	1.1e-13	2.93e-11	0.21	0.23	Breast size;	chr12:9219433	chr12:9277235~9313241:+
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	7.53	1.1e-13	2.94e-11	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
BRCA	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	7.53	1.1e-13	2.94e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	7.53	1.1e-13	2.94e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
BRCA	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-7.53	1.1e-13	2.94e-11	-0.28	-0.23	Height;	chr2:46627569	chr2:46668870~46670778:+
BRCA	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	7.53	1.1e-13	2.94e-11	0.28	0.23	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
BRCA	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	7.53	1.1e-13	2.94e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
BRCA	cis	rs812925	0.784	rs7588041	ENSG00000271889.1	RP11-493E12.1	-7.53	1.1e-13	2.95e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr2:61234277	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-7.53	1.1e-13	2.95e-11	-0.24	-0.23	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
BRCA	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	7.53	1.11e-13	2.96e-11	0.21	0.23	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
BRCA	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.11e-13	2.96e-11	-0.25	-0.23	Height;	chr5:36880769	chr5:36666214~36725195:-
BRCA	cis	rs42648	0.806	rs6951894	ENSG00000225498.1	AC002064.5	7.53	1.11e-13	2.96e-11	0.22	0.23	Homocysteine levels;	chr7:90264631	chr7:90312496~90322592:+
BRCA	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
BRCA	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
BRCA	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
BRCA	cis	rs11723261	0.582	rs7679573	ENSG00000211553.1	AC253576.2	-7.53	1.11e-13	2.97e-11	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:136461~136568:+
BRCA	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	7.53	1.11e-13	2.97e-11	0.27	0.23	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	7.53	1.11e-13	2.97e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
BRCA	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	7.53	1.11e-13	2.98e-11	0.31	0.23	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.11e-13	2.98e-11	-0.25	-0.23	Height;	chr5:37053874	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs13321721	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.98e-11	0.3	0.23	Height;Body mass index;	chr3:136490708	chr3:136837338~136839021:-
BRCA	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-7.53	1.12e-13	2.98e-11	-0.35	-0.23	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
BRCA	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-7.53	1.12e-13	2.99e-11	-0.24	-0.23	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
BRCA	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-7.53	1.12e-13	2.99e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
BRCA	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-7.53	1.12e-13	2.99e-11	-0.25	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
BRCA	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	7.53	1.12e-13	2.99e-11	0.41	0.23	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
BRCA	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	7.53	1.12e-13	2.99e-11	0.32	0.23	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.894	rs10890723	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342510	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs7350479	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342553	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs56393657	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342902	chr11:107176286~107177530:+
BRCA	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	7.53	1.12e-13	2.99e-11	0.22	0.23	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	7.53	1.12e-13	2.99e-11	0.22	0.23	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
BRCA	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-7.53	1.12e-13	3e-11	-0.33	-0.23	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
BRCA	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	7.53	1.12e-13	3e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
BRCA	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	7.53	1.12e-13	3e-11	0.27	0.23	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
BRCA	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-7.53	1.12e-13	3e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	7.53	1.13e-13	3.01e-11	0.23	0.23	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.13e-13	3.01e-11	-0.3	-0.23	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
BRCA	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	7.53	1.13e-13	3.01e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
BRCA	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	7.53	1.13e-13	3.01e-11	0.31	0.23	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	7.53	1.13e-13	3.01e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
BRCA	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-7.53	1.13e-13	3.02e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-7.53	1.13e-13	3.02e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
BRCA	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	7.53	1.13e-13	3.02e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
BRCA	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	7.53	1.13e-13	3.03e-11	0.22	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
BRCA	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-7.53	1.14e-13	3.03e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	7.53	1.14e-13	3.04e-11	0.24	0.23	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
BRCA	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	7.53	1.14e-13	3.04e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-7.53	1.14e-13	3.04e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
BRCA	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	7.53	1.14e-13	3.04e-11	0.19	0.23	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000224316.1	RP11-479O9.2	-7.52	1.14e-13	3.06e-11	-0.26	-0.23	Aortic root size;	chr7:66100789	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-7.52	1.14e-13	3.06e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	7.52	1.15e-13	3.06e-11	0.31	0.23	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000164669.11	INTS4P1	7.52	1.15e-13	3.07e-11	0.28	0.23	Calcium levels;	chr7:66026136	chr7:65141225~65234216:+
BRCA	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-7.52	1.15e-13	3.07e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
BRCA	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-7.52	1.15e-13	3.07e-11	-0.28	-0.23	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-7.52	1.15e-13	3.08e-11	-0.29	-0.23	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
BRCA	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-7.52	1.15e-13	3.08e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
BRCA	cis	rs3758911	0.861	rs10789593	ENSG00000255353.1	RP11-382M14.1	-7.52	1.15e-13	3.08e-11	-0.31	-0.23	Coronary artery disease;	chr11:107286154	chr11:107176286~107177530:+
BRCA	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	7.52	1.15e-13	3.08e-11	0.23	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
BRCA	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	7.52	1.15e-13	3.08e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	7.52	1.15e-13	3.08e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
BRCA	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.52	1.16e-13	3.09e-11	-0.33	-0.23	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-7.52	1.16e-13	3.09e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
BRCA	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-7.52	1.16e-13	3.09e-11	-0.24	-0.23	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
BRCA	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	7.52	1.16e-13	3.1e-11	0.33	0.23	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
BRCA	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	7.52	1.17e-13	3.11e-11	0.44	0.23	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
BRCA	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-7.52	1.17e-13	3.11e-11	-0.29	-0.23	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
BRCA	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-7.52	1.17e-13	3.11e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
BRCA	cis	rs4934494	0.768	rs12570813	ENSG00000240996.1	RP11-80H5.7	-7.52	1.17e-13	3.11e-11	-0.29	-0.23	Red blood cell count;	chr10:89630974	chr10:89694295~89697928:-
BRCA	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	7.52	1.18e-13	3.14e-11	0.29	0.23	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	7.52	1.18e-13	3.14e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
BRCA	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-7.52	1.18e-13	3.14e-11	-0.25	-0.23	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-7.52	1.18e-13	3.15e-11	-0.28	-0.23	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	7.52	1.18e-13	3.16e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
BRCA	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-7.52	1.18e-13	3.16e-11	-0.29	-0.23	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
BRCA	cis	rs293748	0.771	rs35263618	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.19e-13	3.17e-11	-0.32	-0.23	Obesity-related traits;	chr5:36795112	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-7.52	1.19e-13	3.17e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-7.52	1.19e-13	3.17e-11	-0.28	-0.23	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
BRCA	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-7.52	1.19e-13	3.17e-11	-0.3	-0.23	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	7.52	1.19e-13	3.18e-11	0.24	0.23	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	7.52	1.19e-13	3.18e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
BRCA	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	7.52	1.19e-13	3.19e-11	0.28	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
BRCA	cis	rs7474896	0.609	rs11011336	ENSG00000226578.1	RP11-258F22.1	-7.52	1.2e-13	3.19e-11	-0.29	-0.23	Obesity (extreme);	chr10:37696388	chr10:37775371~37784131:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-7.52	1.2e-13	3.2e-11	-0.23	-0.23	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	7.52	1.2e-13	3.2e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	7.52	1.2e-13	3.2e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	7.52	1.2e-13	3.2e-11	0.24	0.23	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	7.52	1.2e-13	3.2e-11	0.24	0.23	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
BRCA	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	7.52	1.2e-13	3.21e-11	0.31	0.23	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.771	rs34092841	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803462	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs35660956	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803648	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292163	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803847	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs172384	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36804123	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292164	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36804643	chr5:36666214~36725195:-
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
BRCA	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	7.52	1.21e-13	3.22e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
BRCA	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	7.52	1.22e-13	3.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-7.52	1.22e-13	3.24e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	7.52	1.22e-13	3.24e-11	0.18	0.23	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
BRCA	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	7.52	1.22e-13	3.25e-11	0.23	0.23	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-7.51	1.22e-13	3.26e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	7.51	1.22e-13	3.26e-11	0.24	0.23	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-7.51	1.22e-13	3.26e-11	-0.24	-0.23	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-7.51	1.22e-13	3.26e-11	-0.24	-0.23	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
BRCA	cis	rs896854	0.516	rs12679044	ENSG00000253528.2	RP11-347C18.4	7.51	1.23e-13	3.26e-11	0.24	0.23	Type 2 diabetes;	chr8:94879128	chr8:94974573~94974853:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000213640.3	EEF1DP4	-7.51	1.23e-13	3.26e-11	-0.3	-0.23	Calcium levels;	chr7:65829495	chr7:64862999~64864370:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	7.51	1.23e-13	3.28e-11	0.18	0.23	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
BRCA	cis	rs712022	0.505	rs11026816	ENSG00000246225.5	RP11-17A1.3	-7.51	1.23e-13	3.29e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22855277	chr11:22829380~22945393:+
BRCA	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
BRCA	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
BRCA	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
BRCA	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	7.51	1.24e-13	3.31e-11	0.22	0.23	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.8	rs35100027	ENSG00000273486.1	RP11-731C17.2	7.51	1.24e-13	3.31e-11	0.31	0.23	Height;Body mass index;	chr3:136748719	chr3:136837338~136839021:-
BRCA	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	7.51	1.24e-13	3.31e-11	0.29	0.23	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
BRCA	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-7.51	1.24e-13	3.31e-11	-0.32	-0.23	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
BRCA	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	7.51	1.25e-13	3.31e-11	0.3	0.23	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
BRCA	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-7.51	1.25e-13	3.32e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
BRCA	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-7.51	1.25e-13	3.32e-11	-0.3	-0.23	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
BRCA	cis	rs6472827	0.953	rs4604419	ENSG00000253983.2	RP1-16A9.1	7.51	1.25e-13	3.32e-11	0.35	0.23	Uterine fibroids;	chr8:74209330	chr8:74199396~74208441:+
BRCA	cis	rs6539288	0.899	rs6539290	ENSG00000260329.1	RP11-412D9.4	-7.51	1.25e-13	3.32e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106915871	chr12:106954029~106955497:-
BRCA	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	7.51	1.25e-13	3.33e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
BRCA	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-7.51	1.26e-13	3.36e-11	-0.31	-0.23	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
BRCA	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-7.51	1.26e-13	3.36e-11	-0.26	-0.23	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
BRCA	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-7.51	1.26e-13	3.36e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
BRCA	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	7.51	1.27e-13	3.37e-11	0.18	0.23	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
BRCA	cis	rs6545883	0.859	rs2600661	ENSG00000271889.1	RP11-493E12.1	-7.51	1.27e-13	3.37e-11	-0.29	-0.23	Tuberculosis;	chr2:61315946	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-7.51	1.27e-13	3.37e-11	-0.25	-0.23	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
BRCA	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-7.51	1.27e-13	3.38e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
BRCA	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	7.51	1.28e-13	3.39e-11	0.42	0.23	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	7.51	1.28e-13	3.4e-11	0.22	0.23	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	7.51	1.28e-13	3.4e-11	0.26	0.23	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
BRCA	cis	rs3745672	1	rs10413462	ENSG00000219665.7	CTD-2006C1.2	-7.51	1.28e-13	3.4e-11	-0.57	-0.23	Multiple sclerosis;	chr19:11943821	chr19:11987617~12046275:+
BRCA	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	7.51	1.28e-13	3.41e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
BRCA	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-7.51	1.28e-13	3.41e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	7.51	1.29e-13	3.42e-11	0.23	0.23	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
BRCA	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.51	1.29e-13	3.42e-11	-0.33	-0.23	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
BRCA	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	7.51	1.29e-13	3.43e-11	0.23	0.23	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
BRCA	cis	rs755249	0.958	rs2068663	ENSG00000228060.1	RP11-69E11.8	-7.51	1.3e-13	3.44e-11	-0.27	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39565160~39573203:+
BRCA	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-7.51	1.3e-13	3.44e-11	-0.18	-0.23	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
BRCA	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-7.51	1.3e-13	3.44e-11	-0.18	-0.23	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	7.51	1.3e-13	3.45e-11	0.23	0.23	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	7.51	1.3e-13	3.46e-11	0.23	0.23	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	7.51	1.3e-13	3.46e-11	0.23	0.23	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	7.51	1.3e-13	3.46e-11	0.23	0.23	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
BRCA	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	7.51	1.3e-13	3.47e-11	0.31	0.23	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
BRCA	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	7.51	1.31e-13	3.47e-11	0.21	0.23	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-7.51	1.31e-13	3.47e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
BRCA	cis	rs7474896	0.559	rs10740949	ENSG00000226578.1	RP11-258F22.1	-7.51	1.31e-13	3.47e-11	-0.29	-0.23	Obesity (extreme);	chr10:37689507	chr10:37775371~37784131:-
BRCA	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	7.51	1.31e-13	3.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	7.51	1.31e-13	3.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	7.51	1.31e-13	3.48e-11	0.26	0.23	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
BRCA	cis	rs7586673	1	rs16845584	ENSG00000235724.7	AC009299.2	7.5	1.32e-13	3.5e-11	0.27	0.23	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161222785~161308303:-
BRCA	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	7.5	1.32e-13	3.51e-11	0.32	0.23	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-7.5	1.32e-13	3.51e-11	-0.36	-0.23	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	7.5	1.33e-13	3.53e-11	0.22	0.23	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
BRCA	cis	rs6539288	0.834	rs1545097	ENSG00000260329.1	RP11-412D9.4	-7.5	1.33e-13	3.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106919918	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.899	rs6539292	ENSG00000260329.1	RP11-412D9.4	-7.5	1.33e-13	3.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106919935	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	7.5	1.33e-13	3.54e-11	0.26	0.23	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
BRCA	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	7.5	1.33e-13	3.54e-11	0.22	0.23	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
BRCA	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	7.5	1.34e-13	3.55e-11	0.27	0.23	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
BRCA	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	7.5	1.34e-13	3.55e-11	0.32	0.23	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
BRCA	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-7.5	1.34e-13	3.56e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
BRCA	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-7.5	1.34e-13	3.56e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
BRCA	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-7.5	1.34e-13	3.56e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
BRCA	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.5	1.35e-13	3.57e-11	0.3	0.23	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
BRCA	cis	rs293748	0.724	rs55668350	ENSG00000250155.1	CTD-2353F22.1	-7.5	1.35e-13	3.57e-11	-0.31	-0.23	Obesity-related traits;	chr5:36801181	chr5:36666214~36725195:-
BRCA	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	7.5	1.35e-13	3.57e-11	0.34	0.23	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-7.5	1.35e-13	3.59e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
BRCA	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	7.5	1.35e-13	3.59e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
BRCA	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-7.5	1.35e-13	3.59e-11	-0.3	-0.23	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
BRCA	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	7.5	1.35e-13	3.59e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
BRCA	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	7.5	1.36e-13	3.6e-11	0.3	0.23	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
BRCA	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-7.5	1.36e-13	3.6e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	7.5	1.36e-13	3.6e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
BRCA	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-7.5	1.36e-13	3.61e-11	-0.26	-0.23	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
BRCA	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	7.5	1.36e-13	3.61e-11	0.24	0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
BRCA	cis	rs5751614	0.537	rs7288846	ENSG00000230701.2	FBXW4P1	-7.5	1.37e-13	3.62e-11	-0.29	-0.23	Height;	chr22:23281097	chr22:23262767~23265005:+
BRCA	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	7.5	1.37e-13	3.63e-11	0.33	0.23	Depression;	chr6:28402301	chr6:28943877~28944537:+
BRCA	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-7.5	1.37e-13	3.63e-11	-0.28	-0.23	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	7.5	1.37e-13	3.63e-11	0.3	0.23	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	7.5	1.37e-13	3.64e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
BRCA	cis	rs4784934	1	rs4784934	ENSG00000260186.4	RP11-481J2.2	7.5	1.38e-13	3.65e-11	0.29	0.23	QT interval;	chr16:58426022	chr16:58421326~58462470:+
BRCA	cis	rs2348418	0.67	rs4035202	ENSG00000247934.4	RP11-967K21.1	-7.5	1.38e-13	3.65e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118015	chr12:28163298~28190738:-
BRCA	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-7.5	1.38e-13	3.66e-11	-0.28	-0.23	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-7.5	1.38e-13	3.66e-11	-0.14	-0.23	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-7.5	1.38e-13	3.67e-11	-0.27	-0.23	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
BRCA	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-7.5	1.38e-13	3.67e-11	-0.28	-0.23	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-7.5	1.39e-13	3.67e-11	-0.24	-0.23	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
BRCA	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-7.5	1.39e-13	3.68e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
BRCA	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-7.5	1.39e-13	3.68e-11	-0.32	-0.23	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
BRCA	cis	rs6545883	0.868	rs6748003	ENSG00000271889.1	RP11-493E12.1	7.5	1.39e-13	3.68e-11	0.29	0.23	Tuberculosis;	chr2:61579565	chr2:61151433~61162105:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	7.5	1.39e-13	3.69e-11	0.22	0.23	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	7.5	1.39e-13	3.69e-11	0.22	0.23	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-7.5	1.4e-13	3.7e-11	-0.23	-0.23	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
BRCA	cis	rs9880211	0.8	rs9873536	ENSG00000273486.1	RP11-731C17.2	7.5	1.4e-13	3.71e-11	0.31	0.23	Height;Body mass index;	chr3:136755425	chr3:136837338~136839021:-
BRCA	cis	rs2028299	0.92	rs2043880	ENSG00000259677.1	RP11-493E3.1	7.5	1.4e-13	3.71e-11	0.32	0.23	Type 2 diabetes;	chr15:89889294	chr15:89876540~89877285:+
BRCA	cis	rs2014572	0.51	rs8111661	ENSG00000268379.1	CTC-360J11.4	-7.5	1.4e-13	3.71e-11	-0.28	-0.23	Hyperactive-impulsive symptoms;	chr19:57240958	chr19:57175233~57177921:+
BRCA	cis	rs74233809	1	rs11191454	ENSG00000213277.3	MARCKSL1P1	7.5	1.4e-13	3.71e-11	0.43	0.23	Birth weight;	chr10:102900247	chr10:103175554~103176094:+
BRCA	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	7.5	1.4e-13	3.71e-11	0.31	0.23	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	7.5	1.4e-13	3.71e-11	0.31	0.23	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
BRCA	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	7.5	1.4e-13	3.72e-11	0.28	0.23	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
BRCA	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	7.5	1.4e-13	3.72e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-7.5	1.41e-13	3.72e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
BRCA	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	7.5	1.41e-13	3.73e-11	0.31	0.23	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
BRCA	cis	rs2906856	0.848	rs3015001	ENSG00000236946.2	HNRNPA1P70	7.5	1.41e-13	3.74e-11	0.18	0.23	Mosquito bite size;	chr12:68003593	chr12:68035767~68036853:+
BRCA	cis	rs9880211	1	rs9826454	ENSG00000273486.1	RP11-731C17.2	7.5	1.41e-13	3.74e-11	0.3	0.23	Height;Body mass index;	chr3:136234378	chr3:136837338~136839021:-
BRCA	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	7.49	1.41e-13	3.74e-11	0.3	0.23	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	7.49	1.41e-13	3.74e-11	0.32	0.23	Height;	chr4:55501955	chr4:55363971~55395847:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	7.49	1.41e-13	3.74e-11	0.27	0.23	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	7.49	1.41e-13	3.74e-11	0.27	0.23	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
BRCA	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	7.49	1.42e-13	3.75e-11	0.3	0.23	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
BRCA	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.42e-13	3.76e-11	-0.31	-0.23	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
BRCA	cis	rs3814244	0.528	rs61923060	ENSG00000236946.2	HNRNPA1P70	-7.49	1.42e-13	3.77e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:68035767~68036853:+
BRCA	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	7.49	1.43e-13	3.77e-11	0.26	0.23	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	7.49	1.43e-13	3.78e-11	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
BRCA	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-7.49	1.44e-13	3.8e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-7.49	1.44e-13	3.8e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
BRCA	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	7.49	1.44e-13	3.81e-11	0.26	0.23	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-7.49	1.44e-13	3.81e-11	-0.27	-0.23	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-7.49	1.44e-13	3.81e-11	-0.27	-0.23	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.948	rs9872178	ENSG00000273486.1	RP11-731C17.2	7.49	1.44e-13	3.81e-11	0.3	0.23	Height;Body mass index;	chr3:136267596	chr3:136837338~136839021:-
BRCA	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-7.49	1.44e-13	3.82e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
BRCA	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-7.49	1.45e-13	3.82e-11	-0.26	-0.23	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
BRCA	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	7.49	1.45e-13	3.83e-11	0.2	0.23	Breast size;	chr12:9220132	chr12:9277235~9313241:+
BRCA	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.45e-13	3.83e-11	-0.25	-0.23	Height;	chr5:37046524	chr5:36666214~36725195:-
BRCA	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	7.49	1.46e-13	3.85e-11	0.31	0.23	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-7.49	1.46e-13	3.86e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	7.49	1.46e-13	3.86e-11	0.23	0.23	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-7.49	1.46e-13	3.87e-11	-0.28	-0.23	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-7.49	1.46e-13	3.87e-11	-0.28	-0.23	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
BRCA	cis	rs2933343	0.553	rs35076317	ENSG00000231305.3	RP11-723O4.2	7.49	1.46e-13	3.87e-11	0.26	0.23	IgG glycosylation;	chr3:128996692	chr3:128861313~128871540:-
BRCA	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.88e-11	-0.24	-0.23	Height;	chr5:36925633	chr5:36666214~36725195:-
BRCA	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	7.49	1.47e-13	3.88e-11	0.3	0.23	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
BRCA	cis	rs9880211	0.752	rs9838884	ENSG00000273486.1	RP11-731C17.2	7.49	1.47e-13	3.88e-11	0.31	0.23	Height;Body mass index;	chr3:136736862	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.89e-11	-0.25	-0.23	Height;	chr5:37068442	chr5:36666214~36725195:-
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-7.49	1.47e-13	3.89e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
BRCA	cis	rs293748	0.771	rs158799	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.89e-11	-0.31	-0.23	Obesity-related traits;	chr5:36869149	chr5:36666214~36725195:-
BRCA	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	7.49	1.48e-13	3.9e-11	0.27	0.23	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
BRCA	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-7.49	1.48e-13	3.9e-11	-0.3	-0.23	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
BRCA	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	7.49	1.48e-13	3.9e-11	0.26	0.23	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-7.49	1.48e-13	3.9e-11	-0.15	-0.23	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
BRCA	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-7.49	1.48e-13	3.92e-11	-0.23	-0.23	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
BRCA	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-7.49	1.49e-13	3.93e-11	-0.33	-0.23	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	7.49	1.49e-13	3.93e-11	0.23	0.23	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
BRCA	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	7.49	1.49e-13	3.94e-11	0.2	0.23	Breast size;	chr12:9220266	chr12:9277235~9313241:+
BRCA	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-7.49	1.5e-13	3.95e-11	-0.37	-0.23	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
BRCA	cis	rs9880211	1	rs9837158	ENSG00000273486.1	RP11-731C17.2	7.49	1.5e-13	3.97e-11	0.3	0.23	Height;Body mass index;	chr3:136354321	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.51e-13	3.98e-11	-0.25	-0.23	Height;	chr5:37061159	chr5:36666214~36725195:-
BRCA	cis	rs2348418	0.67	rs1824919	ENSG00000247934.4	RP11-967K21.1	-7.49	1.51e-13	3.99e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118449	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-7.49	1.51e-13	3.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-7.49	1.51e-13	3.99e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-7.49	1.51e-13	3.99e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
BRCA	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-7.49	1.51e-13	4e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
BRCA	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	7.49	1.52e-13	4e-11	0.38	0.23	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	7.49	1.52e-13	4.01e-11	0.32	0.23	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
BRCA	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	7.48	1.52e-13	4.01e-11	0.32	0.23	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
BRCA	cis	rs12188164	0.543	rs2672757	ENSG00000225138.6	CTD-2228K2.7	-7.48	1.52e-13	4.01e-11	-0.24	-0.23	Cystic fibrosis severity;	chr5:454617	chr5:473236~480884:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-7.48	1.53e-13	4.03e-11	-0.23	-0.23	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000274973.1	RP13-401N8.7	7.48	1.53e-13	4.04e-11	0.27	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25845497~25845862:+
BRCA	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-7.48	1.53e-13	4.04e-11	-0.25	-0.23	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
BRCA	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	7.48	1.54e-13	4.06e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
BRCA	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-7.48	1.54e-13	4.06e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
BRCA	cis	rs42648	0.748	rs10226014	ENSG00000225498.1	AC002064.5	-7.48	1.55e-13	4.08e-11	-0.22	-0.23	Homocysteine levels;	chr7:90273219	chr7:90312496~90322592:+
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000278665.1	RP11-666O2.4	-7.48	1.55e-13	4.08e-11	-0.25	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-7.48	1.55e-13	4.09e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
BRCA	cis	rs3781264	0.595	rs7096037	ENSG00000273450.1	RP11-76P2.4	7.48	1.55e-13	4.09e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94329950	chr10:94314907~94315327:-
BRCA	cis	rs1861628	0.927	rs6724363	ENSG00000237930.1	AC007563.4	7.48	1.55e-13	4.1e-11	0.27	0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216761868	chr2:216785774~216786144:-
BRCA	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	7.48	1.56e-13	4.11e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-7.48	1.56e-13	4.11e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	7.48	1.56e-13	4.12e-11	0.21	0.23	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
BRCA	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-7.48	1.56e-13	4.12e-11	-0.27	-0.23	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	7.48	1.56e-13	4.12e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-7.48	1.56e-13	4.12e-11	-0.33	-0.23	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
BRCA	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	7.48	1.56e-13	4.12e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
BRCA	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	7.48	1.57e-13	4.13e-11	0.26	0.23	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
BRCA	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	7.48	1.57e-13	4.13e-11	0.31	0.23	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
BRCA	cis	rs4660214	0.671	rs16826012	ENSG00000237624.1	OXCT2P1	-7.48	1.57e-13	4.14e-11	-0.36	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39514956~39516490:+
BRCA	cis	rs812925	0.859	rs778138	ENSG00000271889.1	RP11-493E12.1	7.48	1.57e-13	4.14e-11	0.29	0.23	Immature fraction of reticulocytes;	chr2:61460079	chr2:61151433~61162105:-
BRCA	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	7.48	1.57e-13	4.14e-11	0.25	0.23	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
BRCA	cis	rs42648	0.667	rs2157793	ENSG00000225498.1	AC002064.5	7.48	1.57e-13	4.14e-11	0.22	0.23	Homocysteine levels;	chr7:90251040	chr7:90312496~90322592:+
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-7.48	1.57e-13	4.14e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	7.48	1.57e-13	4.14e-11	0.18	0.23	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
BRCA	cis	rs74233809	1	rs74444347	ENSG00000213277.3	MARCKSL1P1	7.48	1.57e-13	4.15e-11	0.42	0.23	Birth weight;	chr10:103009518	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs12221335	ENSG00000213277.3	MARCKSL1P1	7.48	1.57e-13	4.15e-11	0.42	0.23	Birth weight;	chr10:103009635	chr10:103175554~103176094:+
BRCA	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	7.48	1.57e-13	4.15e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
BRCA	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	7.48	1.57e-13	4.15e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-7.48	1.58e-13	4.15e-11	-0.27	-0.23	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-7.48	1.58e-13	4.15e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	7.48	1.58e-13	4.16e-11	0.31	0.23	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
BRCA	cis	rs3814244	0.868	rs11177007	ENSG00000236946.2	HNRNPA1P70	-7.48	1.58e-13	4.16e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:68035767~68036853:+
BRCA	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	7.48	1.58e-13	4.17e-11	0.18	0.23	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
BRCA	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.48	1.58e-13	4.17e-11	0.33	0.23	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
BRCA	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	7.48	1.58e-13	4.17e-11	0.26	0.23	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
BRCA	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-7.48	1.58e-13	4.17e-11	-0.34	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
BRCA	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-7.48	1.59e-13	4.18e-11	-0.24	-0.23	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	7.48	1.59e-13	4.19e-11	0.23	0.23	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000272823.1	RP11-295M18.6	7.48	1.59e-13	4.2e-11	0.33	0.23	Cholesterol, total;	chr1:220869661	chr1:220828676~220829211:-
BRCA	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-7.48	1.6e-13	4.2e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	7.48	1.6e-13	4.22e-11	0.29	0.23	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
BRCA	cis	rs3781264	0.6	rs12263737	ENSG00000273450.1	RP11-76P2.4	7.48	1.6e-13	4.22e-11	0.29	0.23	Esophageal cancer and gastric cancer;	chr10:94285156	chr10:94314907~94315327:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	7.48	1.61e-13	4.23e-11	0.26	0.23	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs12713436	ENSG00000271889.1	RP11-493E12.1	7.48	1.61e-13	4.24e-11	0.29	0.23	Tuberculosis;	chr2:61464125	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	7.48	1.61e-13	4.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	7.48	1.61e-13	4.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.67	rs899504	ENSG00000247934.4	RP11-967K21.1	-7.48	1.62e-13	4.25e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118723	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	7.48	1.62e-13	4.25e-11	0.27	0.23	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-7.48	1.62e-13	4.25e-11	-0.31	-0.23	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	7.48	1.62e-13	4.26e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-7.48	1.62e-13	4.26e-11	-0.29	-0.23	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
BRCA	cis	rs712022	0.507	rs11026815	ENSG00000246225.5	RP11-17A1.3	-7.48	1.62e-13	4.27e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22854432	chr11:22829380~22945393:+
BRCA	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-7.48	1.62e-13	4.27e-11	-0.32	-0.23	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
BRCA	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-7.48	1.63e-13	4.28e-11	-0.29	-0.23	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-7.48	1.63e-13	4.28e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
BRCA	cis	rs293377	0.961	rs293370	ENSG00000260123.1	RP11-326A19.4	-7.48	1.63e-13	4.29e-11	-0.26	-0.23	Gut microbiota (beta diversity);	chr15:89087245	chr15:89041223~89082819:+
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000274973.1	RP13-401N8.7	7.47	1.64e-13	4.32e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25845497~25845862:+
BRCA	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	7.47	1.64e-13	4.32e-11	0.37	0.23	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000272823.1	RP11-295M18.6	-7.47	1.64e-13	4.32e-11	-0.31	-0.23	Cholesterol, total;	chr1:220866908	chr1:220828676~220829211:-
BRCA	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-7.47	1.65e-13	4.34e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
BRCA	cis	rs3781264	0.595	rs11187876	ENSG00000273450.1	RP11-76P2.4	7.47	1.65e-13	4.34e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94330382	chr10:94314907~94315327:-
BRCA	cis	rs2378497	0.887	rs12122410	ENSG00000232679.1	RP11-400N13.3	7.47	1.65e-13	4.35e-11	0.32	0.23	Serum thyroid-stimulating hormone levels;	chr1:222038169	chr1:222041705~222064763:-
BRCA	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-7.47	1.65e-13	4.35e-11	-0.27	-0.23	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-7.47	1.66e-13	4.35e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
BRCA	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.66e-13	4.36e-11	-0.32	-0.23	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.66e-13	4.37e-11	-0.31	-0.23	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
BRCA	cis	rs6539288	0.901	rs1444580	ENSG00000260329.1	RP11-412D9.4	-7.47	1.66e-13	4.37e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106920780	chr12:106954029~106955497:-
BRCA	cis	rs42648	0.748	rs10227385	ENSG00000225498.1	AC002064.5	7.47	1.66e-13	4.37e-11	0.22	0.23	Homocysteine levels;	chr7:90261054	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-7.47	1.66e-13	4.37e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	7.47	1.67e-13	4.38e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
BRCA	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-7.47	1.67e-13	4.38e-11	-0.34	-0.23	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
BRCA	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-7.47	1.67e-13	4.39e-11	-0.32	-0.23	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
BRCA	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	7.47	1.67e-13	4.39e-11	0.29	0.23	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
BRCA	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-7.47	1.67e-13	4.4e-11	-0.23	-0.23	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
BRCA	cis	rs7085104	0.552	rs11191414	ENSG00000236937.2	PTGES3P4	7.47	1.68e-13	4.4e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102845595~102845950:+
BRCA	cis	rs3781264	0.595	rs10882430	ENSG00000273450.1	RP11-76P2.4	7.47	1.68e-13	4.41e-11	0.29	0.23	Esophageal cancer and gastric cancer;	chr10:94330915	chr10:94314907~94315327:-
BRCA	cis	rs6545883	0.868	rs2518933	ENSG00000271889.1	RP11-493E12.1	7.47	1.68e-13	4.42e-11	0.29	0.23	Tuberculosis;	chr2:61569895	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	7.47	1.69e-13	4.44e-11	0.26	0.23	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	7.47	1.69e-13	4.44e-11	0.24	0.23	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	7.47	1.69e-13	4.44e-11	0.24	0.23	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.783	rs7579651	ENSG00000271889.1	RP11-493E12.1	7.47	1.7e-13	4.46e-11	0.29	0.23	Tuberculosis;	chr2:61573144	chr2:61151433~61162105:-
BRCA	cis	rs6472827	0.953	rs7827128	ENSG00000253983.2	RP1-16A9.1	7.47	1.71e-13	4.48e-11	0.34	0.23	Uterine fibroids;	chr8:74209641	chr8:74199396~74208441:+
BRCA	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	7.47	1.71e-13	4.48e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-7.47	1.71e-13	4.48e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	7.47	1.71e-13	4.5e-11	0.31	0.23	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
BRCA	cis	rs3781264	0.724	rs11558740	ENSG00000273450.1	RP11-76P2.4	7.47	1.72e-13	4.51e-11	0.32	0.23	Esophageal cancer and gastric cancer;	chr10:94333618	chr10:94314907~94315327:-
BRCA	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.72e-13	4.51e-11	-0.33	-0.23	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	7.47	1.72e-13	4.51e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
BRCA	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	7.47	1.72e-13	4.52e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
BRCA	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	7.47	1.72e-13	4.52e-11	0.28	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
BRCA	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-7.47	1.72e-13	4.52e-11	-0.34	-0.23	Depression;	chr6:27847716	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-7.47	1.73e-13	4.54e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
BRCA	cis	rs9880211	0.8	rs66509730	ENSG00000239213.4	NCK1-AS1	7.47	1.73e-13	4.55e-11	0.29	0.23	Height;Body mass index;	chr3:136785416	chr3:136841726~136862054:-
BRCA	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-7.47	1.74e-13	4.56e-11	-0.24	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000274973.1	RP13-401N8.7	7.47	1.74e-13	4.56e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-7.47	1.74e-13	4.56e-11	-0.25	-0.23	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	7.47	1.74e-13	4.57e-11	0.23	0.23	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	7.47	1.74e-13	4.57e-11	0.23	0.23	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
BRCA	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-7.47	1.75e-13	4.58e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-7.47	1.75e-13	4.59e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
BRCA	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	7.47	1.75e-13	4.6e-11	0.33	0.23	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-7.47	1.75e-13	4.6e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
BRCA	cis	rs7085104	0.632	rs7097872	ENSG00000236937.2	PTGES3P4	7.46	1.76e-13	4.61e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102845595~102845950:+
BRCA	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	7.46	1.76e-13	4.61e-11	0.5	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
BRCA	cis	rs74233809	1	rs11191472	ENSG00000213277.3	MARCKSL1P1	7.46	1.76e-13	4.61e-11	0.44	0.23	Birth weight;	chr10:102947259	chr10:103175554~103176094:+
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	7.46	1.76e-13	4.63e-11	0.25	0.23	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
BRCA	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	7.46	1.77e-13	4.63e-11	0.34	0.23	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
BRCA	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	7.46	1.77e-13	4.63e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	7.46	1.77e-13	4.63e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
BRCA	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	7.46	1.77e-13	4.64e-11	0.28	0.23	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
BRCA	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-7.46	1.77e-13	4.64e-11	-0.25	-0.23	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
BRCA	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	7.46	1.77e-13	4.65e-11	0.29	0.23	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
BRCA	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	7.46	1.77e-13	4.65e-11	0.26	0.23	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
BRCA	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-7.46	1.78e-13	4.65e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
BRCA	cis	rs74233809	1	rs11191502	ENSG00000213277.3	MARCKSL1P1	7.46	1.78e-13	4.66e-11	0.42	0.23	Birth weight;	chr10:103005737	chr10:103175554~103176094:+
BRCA	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-7.46	1.78e-13	4.67e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-7.46	1.79e-13	4.69e-11	-0.26	-0.23	Longevity;	chr3:48373517	chr3:48440352~48446656:-
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-7.46	1.8e-13	4.7e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000224316.1	RP11-479O9.2	7.46	1.8e-13	4.72e-11	0.25	0.23	Aortic root size;	chr7:66172694	chr7:65773620~65802067:+
BRCA	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.8e-13	4.72e-11	-0.28	-0.23	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
BRCA	cis	rs34779708	0.733	rs16935948	ENSG00000271335.4	RP11-324I22.4	7.46	1.81e-13	4.74e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35314552~35336401:-
BRCA	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	7.46	1.81e-13	4.74e-11	0.28	0.23	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
BRCA	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	7.46	1.81e-13	4.75e-11	0.17	0.23	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.46	1.81e-13	4.75e-11	0.3	0.23	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.894	rs12285491	ENSG00000255353.1	RP11-382M14.1	-7.46	1.82e-13	4.76e-11	-0.3	-0.23	Coronary artery disease;	chr11:107340319	chr11:107176286~107177530:+
BRCA	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	7.46	1.82e-13	4.77e-11	0.25	0.23	Height;	chr5:37041491	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-7.46	1.82e-13	4.77e-11	-0.43	-0.23	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
BRCA	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	7.46	1.83e-13	4.8e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.81e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.82e-11	-0.14	-0.23	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.82e-11	-0.14	-0.23	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
BRCA	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-7.46	1.84e-13	4.82e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.83e-11	-0.14	-0.23	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
BRCA	cis	rs3781264	0.761	rs12781451	ENSG00000273450.1	RP11-76P2.4	7.46	1.85e-13	4.83e-11	0.31	0.23	Esophageal cancer and gastric cancer;	chr10:94324163	chr10:94314907~94315327:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-7.46	1.85e-13	4.84e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
BRCA	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-7.46	1.85e-13	4.84e-11	-0.32	-0.23	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000274973.1	RP13-401N8.7	7.46	1.85e-13	4.85e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25845497~25845862:+
BRCA	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.86e-13	4.86e-11	-0.28	-0.23	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
BRCA	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	7.46	1.86e-13	4.87e-11	0.26	0.23	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	7.46	1.86e-13	4.87e-11	0.26	0.23	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
BRCA	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
BRCA	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
BRCA	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
BRCA	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	7.46	1.87e-13	4.88e-11	0.25	0.23	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
BRCA	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	7.46	1.87e-13	4.88e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
BRCA	cis	rs7085104	0.632	rs6162	ENSG00000236937.2	PTGES3P4	7.46	1.87e-13	4.88e-11	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102845595~102845950:+
BRCA	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-7.46	1.87e-13	4.89e-11	-0.25	-0.23	Height;	chr5:36982949	chr5:36666214~36725195:-
BRCA	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-7.46	1.87e-13	4.9e-11	-0.27	-0.23	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
BRCA	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-7.46	1.87e-13	4.9e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
BRCA	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-7.46	1.88e-13	4.91e-11	-0.19	-0.23	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
BRCA	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	7.46	1.88e-13	4.91e-11	0.31	0.23	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
BRCA	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	7.46	1.88e-13	4.92e-11	0.28	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-7.46	1.88e-13	4.92e-11	-0.27	-0.23	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	7.45	1.89e-13	4.94e-11	0.39	0.23	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	7.45	1.89e-13	4.94e-11	0.31	0.23	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
BRCA	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	7.45	1.89e-13	4.95e-11	0.27	0.23	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
BRCA	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	7.45	1.9e-13	4.95e-11	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
BRCA	cis	rs6472827	0.645	rs2956060	ENSG00000253983.2	RP1-16A9.1	-7.45	1.9e-13	4.96e-11	-0.31	-0.23	Uterine fibroids;	chr8:74197550	chr8:74199396~74208441:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-7.45	1.9e-13	4.96e-11	-0.14	-0.22	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
BRCA	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-7.45	1.9e-13	4.97e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-7.45	1.9e-13	4.97e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
BRCA	cis	rs3781264	0.595	rs10882424	ENSG00000273450.1	RP11-76P2.4	7.45	1.9e-13	4.98e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94326321	chr10:94314907~94315327:-
BRCA	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-7.45	1.91e-13	4.99e-11	-0.25	-0.22	Height;	chr5:37022673	chr5:36666214~36725195:-
BRCA	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-7.45	1.92e-13	5e-11	-0.34	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
BRCA	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-7.45	1.92e-13	5.01e-11	-0.28	-0.22	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-7.45	1.92e-13	5.01e-11	-0.22	-0.22	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000273024.4	INTS4P2	-7.45	1.92e-13	5.02e-11	-0.25	-0.22	Calcium levels;	chr7:65806798	chr7:65647864~65715661:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	7.45	1.92e-13	5.03e-11	0.22	0.22	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	7.45	1.92e-13	5.03e-11	0.22	0.22	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
BRCA	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-7.45	1.93e-13	5.04e-11	-0.27	-0.22	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-7.45	1.93e-13	5.05e-11	-0.24	-0.22	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.45	1.94e-13	5.07e-11	-0.23	-0.22	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-7.45	1.94e-13	5.08e-11	-0.25	-0.22	Height;	chr5:36911514	chr5:36666214~36725195:-
BRCA	cis	rs16978956	0.592	rs16990329	ENSG00000236474.1	GCNT1P1	7.45	1.94e-13	5.08e-11	0.33	0.22	Body mass index;	chr20:18345414	chr20:18420160~18421454:-
BRCA	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	7.45	1.94e-13	5.08e-11	0.31	0.22	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
BRCA	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-7.45	1.94e-13	5.08e-11	-0.27	-0.22	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	7.45	1.95e-13	5.08e-11	0.22	0.22	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	7.45	1.95e-13	5.1e-11	0.23	0.22	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-7.45	1.96e-13	5.11e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
BRCA	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	7.45	1.96e-13	5.11e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-7.45	1.96e-13	5.12e-11	-0.27	-0.22	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
BRCA	cis	rs3758911	0.796	rs59525924	ENSG00000255353.1	RP11-382M14.1	-7.45	1.96e-13	5.12e-11	-0.31	-0.22	Coronary artery disease;	chr11:107339286	chr11:107176286~107177530:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-7.45	1.96e-13	5.12e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
BRCA	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	7.45	1.97e-13	5.14e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	7.45	1.97e-13	5.14e-11	0.31	0.22	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000273024.4	INTS4P2	-7.45	1.97e-13	5.14e-11	-0.25	-0.22	Calcium levels;	chr7:65800652	chr7:65647864~65715661:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-7.45	1.97e-13	5.15e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
BRCA	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	7.45	1.97e-13	5.15e-11	0.34	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	7.45	1.97e-13	5.15e-11	0.22	0.22	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
BRCA	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	7.45	1.98e-13	5.16e-11	0.17	0.22	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
BRCA	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
BRCA	cis	rs9880211	0.898	rs13434116	ENSG00000273486.1	RP11-731C17.2	7.45	1.98e-13	5.18e-11	0.3	0.22	Height;Body mass index;	chr3:136634232	chr3:136837338~136839021:-
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	7.45	1.99e-13	5.19e-11	0.3	0.22	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
BRCA	cis	rs9880211	1	rs6771002	ENSG00000273486.1	RP11-731C17.2	7.45	1.99e-13	5.2e-11	0.29	0.22	Height;Body mass index;	chr3:136522186	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	7.45	1.99e-13	5.2e-11	0.31	0.22	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
BRCA	cis	rs763512	0.504	rs6607279	ENSG00000276054.1	RP11-378E13.3	7.45	2e-13	5.21e-11	0.33	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37564796	chr17:37386886~37387926:+
BRCA	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-7.45	2e-13	5.21e-11	-0.23	-0.22	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
BRCA	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-7.45	2e-13	5.22e-11	-0.33	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
BRCA	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-7.45	2e-13	5.22e-11	-0.33	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
BRCA	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	7.45	2e-13	5.22e-11	0.33	0.22	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
BRCA	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	7.45	2e-13	5.23e-11	0.3	0.22	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
BRCA	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	7.45	2e-13	5.23e-11	0.26	0.22	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
BRCA	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.45	2.01e-13	5.24e-11	-0.24	-0.22	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
BRCA	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-7.45	2.01e-13	5.24e-11	-0.29	-0.22	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
BRCA	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-7.45	2.02e-13	5.27e-11	-0.3	-0.22	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
BRCA	cis	rs2060793	0.519	rs10832285	ENSG00000251991.1	RNU7-49P	7.45	2.02e-13	5.27e-11	0.24	0.22	Vitamin D levels;	chr11:14628031	chr11:14478892~14478953:+
BRCA	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	7.45	2.02e-13	5.28e-11	0.29	0.22	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
BRCA	cis	rs42648	0.693	rs3747800	ENSG00000225498.1	AC002064.5	7.45	2.03e-13	5.28e-11	0.21	0.22	Homocysteine levels;	chr7:90270174	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-7.44	2.03e-13	5.29e-11	-0.27	-0.22	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
BRCA	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-7.44	2.03e-13	5.3e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
BRCA	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-7.44	2.03e-13	5.3e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-7.44	2.03e-13	5.3e-11	-0.25	-0.22	Longevity;	chr3:48464565	chr3:48440352~48446656:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-7.44	2.04e-13	5.31e-11	-0.32	-0.22	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-7.44	2.04e-13	5.31e-11	-0.21	-0.22	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
BRCA	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-7.44	2.04e-13	5.31e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
BRCA	cis	rs3814244	0.528	rs2860609	ENSG00000236946.2	HNRNPA1P70	7.44	2.04e-13	5.32e-11	0.19	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:68035767~68036853:+
BRCA	cis	rs9880211	0.752	rs13062352	ENSG00000273486.1	RP11-731C17.2	7.44	2.04e-13	5.33e-11	0.31	0.22	Height;Body mass index;	chr3:136745920	chr3:136837338~136839021:-
BRCA	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-7.44	2.04e-13	5.33e-11	-0.3	-0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
BRCA	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	7.44	2.05e-13	5.33e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
BRCA	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	7.44	2.06e-13	5.37e-11	0.28	0.22	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
BRCA	cis	rs9880211	0.718	rs28631273	ENSG00000273486.1	RP11-731C17.2	7.44	2.06e-13	5.37e-11	0.28	0.22	Height;Body mass index;	chr3:136215869	chr3:136837338~136839021:-
BRCA	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
BRCA	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	7.44	2.07e-13	5.38e-11	0.25	0.22	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
BRCA	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
BRCA	cis	rs9880211	1	rs6768743	ENSG00000273486.1	RP11-731C17.2	-7.44	2.07e-13	5.4e-11	-0.29	-0.22	Height;Body mass index;	chr3:136486165	chr3:136837338~136839021:-
BRCA	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	7.44	2.07e-13	5.4e-11	0.28	0.22	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-7.44	2.07e-13	5.4e-11	-0.22	-0.22	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	7.44	2.08e-13	5.4e-11	0.21	0.22	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	7.44	2.08e-13	5.43e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
BRCA	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-7.44	2.09e-13	5.45e-11	-0.26	-0.22	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
BRCA	cis	rs2933343	0.553	rs35979399	ENSG00000261159.1	RP11-723O4.9	7.44	2.09e-13	5.45e-11	0.25	0.22	IgG glycosylation;	chr3:128978470	chr3:128859716~128860526:-
BRCA	cis	rs6545883	0.931	rs12713438	ENSG00000271889.1	RP11-493E12.1	7.44	2.09e-13	5.45e-11	0.29	0.22	Tuberculosis;	chr2:61498366	chr2:61151433~61162105:-
BRCA	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-7.44	2.1e-13	5.46e-11	-0.24	-0.22	Height;	chr5:36804263	chr5:36666214~36725195:-
BRCA	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	7.44	2.1e-13	5.47e-11	0.29	0.22	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
BRCA	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-7.44	2.1e-13	5.47e-11	-0.27	-0.22	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	7.44	2.1e-13	5.48e-11	0.23	0.22	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
BRCA	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	7.44	2.11e-13	5.49e-11	0.29	0.22	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-7.44	2.11e-13	5.49e-11	-0.26	-0.22	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
BRCA	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-7.44	2.11e-13	5.5e-11	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
BRCA	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	7.44	2.12e-13	5.5e-11	0.26	0.22	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
BRCA	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-7.44	2.12e-13	5.52e-11	-0.23	-0.22	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
BRCA	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-7.44	2.13e-13	5.54e-11	-0.3	-0.22	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
BRCA	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	7.44	2.13e-13	5.54e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	7.44	2.13e-13	5.54e-11	0.17	0.22	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
BRCA	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-7.44	2.13e-13	5.55e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
BRCA	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-7.44	2.14e-13	5.56e-11	-0.27	-0.22	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
BRCA	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	7.44	2.14e-13	5.57e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
BRCA	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-7.44	2.14e-13	5.58e-11	-0.28	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
BRCA	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	7.44	2.15e-13	5.58e-11	0.3	0.22	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	7.44	2.15e-13	5.6e-11	0.25	0.22	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
BRCA	cis	rs3781264	0.848	rs3781265	ENSG00000273450.1	RP11-76P2.4	7.44	2.15e-13	5.6e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94303522	chr10:94314907~94315327:-
BRCA	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	7.44	2.16e-13	5.62e-11	0.24	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
BRCA	cis	rs755249	0.756	rs72637908	ENSG00000228060.1	RP11-69E11.8	-7.44	2.16e-13	5.62e-11	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39565160~39573203:+
BRCA	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	7.44	2.16e-13	5.62e-11	0.3	0.22	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
BRCA	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	7.44	2.16e-13	5.62e-11	0.3	0.22	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-7.44	2.16e-13	5.63e-11	-0.28	-0.22	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	7.44	2.16e-13	5.63e-11	0.27	0.22	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
BRCA	cis	rs9876781	1	rs6770470	ENSG00000244380.1	RP11-24C3.2	7.44	2.17e-13	5.63e-11	0.26	0.22	Longevity;	chr3:48393659	chr3:48440352~48446656:-
BRCA	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	7.44	2.17e-13	5.63e-11	0.24	0.22	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	7.44	2.17e-13	5.63e-11	0.24	0.22	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	7.44	2.17e-13	5.64e-11	0.23	0.22	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
BRCA	cis	rs9876781	1	rs6810060	ENSG00000244380.1	RP11-24C3.2	7.44	2.17e-13	5.64e-11	0.26	0.22	Longevity;	chr3:48393284	chr3:48440352~48446656:-
BRCA	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	7.44	2.17e-13	5.64e-11	0.32	0.22	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
BRCA	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-7.44	2.18e-13	5.66e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-7.44	2.18e-13	5.66e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	7.43	2.18e-13	5.67e-11	0.33	0.22	Height;	chr4:55361200	chr4:55387949~55388271:+
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-7.43	2.19e-13	5.68e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	7.43	2.19e-13	5.69e-11	0.17	0.22	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
BRCA	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	7.43	2.19e-13	5.7e-11	0.3	0.22	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	7.43	2.19e-13	5.7e-11	0.22	0.22	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
BRCA	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	7.43	2.2e-13	5.71e-11	0.31	0.22	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
BRCA	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.43	2.2e-13	5.71e-11	-0.27	-0.22	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
BRCA	cis	rs3758911	0.894	rs11212156	ENSG00000255353.1	RP11-382M14.1	-7.43	2.2e-13	5.71e-11	-0.29	-0.22	Coronary artery disease;	chr11:107323381	chr11:107176286~107177530:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-7.43	2.21e-13	5.73e-11	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-7.43	2.21e-13	5.73e-11	-0.23	-0.22	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	7.43	2.21e-13	5.74e-11	0.38	0.22	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
BRCA	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	7.43	2.21e-13	5.75e-11	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
BRCA	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-7.43	2.22e-13	5.77e-11	-0.29	-0.22	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
BRCA	cis	rs9880211	0.8	rs13314357	ENSG00000239213.4	NCK1-AS1	7.43	2.23e-13	5.78e-11	0.3	0.22	Height;Body mass index;	chr3:136768717	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-7.43	2.23e-13	5.79e-11	-0.27	-0.22	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-7.43	2.23e-13	5.8e-11	-0.28	-0.22	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
BRCA	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	7.43	2.24e-13	5.81e-11	0.18	0.22	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
BRCA	cis	rs9880211	1	rs28634226	ENSG00000273486.1	RP11-731C17.2	7.43	2.24e-13	5.81e-11	0.3	0.22	Height;Body mass index;	chr3:136411040	chr3:136837338~136839021:-
BRCA	cis	rs2221433	0.889	rs1394564	ENSG00000260310.1	RP11-27M24.2	7.43	2.24e-13	5.82e-11	0.27	0.22	Eating disorders;	chr16:10583324	chr16:10576499~10578183:-
BRCA	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	7.43	2.24e-13	5.82e-11	0.26	0.22	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	7.43	2.24e-13	5.82e-11	0.26	0.22	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
BRCA	cis	rs13178541	0.748	rs4976306	ENSG00000250378.1	RP11-119J18.1	7.43	2.24e-13	5.82e-11	0.31	0.22	IgG glycosylation;	chr5:135728489	chr5:135812667~135826582:+
BRCA	cis	rs7927771	0.793	rs3740686	ENSG00000280615.1	Y_RNA	7.43	2.24e-13	5.82e-11	0.27	0.22	Subjective well-being;	chr11:47354812	chr11:47614898~47614994:-
BRCA	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-7.43	2.24e-13	5.83e-11	-0.29	-0.22	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-7.43	2.24e-13	5.83e-11	-0.29	-0.22	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
BRCA	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-7.43	2.25e-13	5.83e-11	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
BRCA	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-7.43	2.25e-13	5.83e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	7.43	2.25e-13	5.84e-11	0.27	0.22	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	7.43	2.25e-13	5.85e-11	0.22	0.22	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-7.43	2.25e-13	5.85e-11	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
BRCA	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	7.43	2.26e-13	5.85e-11	0.26	0.22	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
BRCA	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	7.43	2.26e-13	5.87e-11	0.23	0.22	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
BRCA	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	7.43	2.26e-13	5.88e-11	0.27	0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
BRCA	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-7.43	2.27e-13	5.9e-11	-0.27	-0.22	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
BRCA	cis	rs12664251	0.706	rs2797356	ENSG00000253194.1	RP11-351A11.1	-7.43	2.27e-13	5.9e-11	-0.27	-0.22	Schizophrenia;	chr6:119014786	chr6:118934785~119031541:+
BRCA	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	7.43	2.27e-13	5.9e-11	0.24	0.22	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.899	rs12473030	ENSG00000271889.1	RP11-493E12.1	7.43	2.28e-13	5.91e-11	0.29	0.22	Tuberculosis;	chr2:61493362	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-7.43	2.28e-13	5.92e-11	-0.32	-0.22	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-7.43	2.28e-13	5.93e-11	-0.29	-0.22	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
BRCA	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-7.43	2.29e-13	5.95e-11	-0.33	-0.22	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	7.43	2.3e-13	5.96e-11	0.27	0.22	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-7.43	2.3e-13	5.96e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
BRCA	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	7.43	2.3e-13	5.96e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
BRCA	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-7.43	2.3e-13	5.97e-11	-0.32	-0.22	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs77860422	ENSG00000213277.3	MARCKSL1P1	7.43	2.3e-13	5.97e-11	0.42	0.22	Birth weight;	chr10:102988252	chr10:103175554~103176094:+
BRCA	cis	rs3794924	1	rs34350106	ENSG00000266521.1	RP11-650P15.1	7.43	2.3e-13	5.97e-11	0.41	0.22	Survival in colon cancer;	chr18:31462496	chr18:31496645~31497195:-
BRCA	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.43	2.3e-13	5.98e-11	0.36	0.22	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	7.43	2.31e-13	5.99e-11	0.31	0.22	Height;	chr4:55457922	chr4:55363971~55395847:-
BRCA	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-7.43	2.31e-13	6e-11	-0.32	-0.22	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
BRCA	cis	rs10206020	0.842	rs7609325	ENSG00000231482.2	AC141930.2	-7.43	2.32e-13	6e-11	-0.29	-0.22	IgG glycosylation;	chr2:1570946	chr2:1572554~1580311:-
BRCA	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	7.43	2.32e-13	6.01e-11	0.27	0.22	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-7.43	2.32e-13	6.01e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
BRCA	cis	rs10206020	0.885	rs11886082	ENSG00000231482.2	AC141930.2	-7.43	2.32e-13	6.02e-11	-0.29	-0.22	IgG glycosylation;	chr2:1572911	chr2:1572554~1580311:-
BRCA	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-7.43	2.33e-13	6.05e-11	-0.3	-0.22	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
BRCA	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-7.43	2.34e-13	6.05e-11	-0.29	-0.22	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
BRCA	cis	rs7274963	1	rs7274963	ENSG00000236474.1	GCNT1P1	7.43	2.34e-13	6.06e-11	0.29	0.22	Body mass index;	chr20:18310335	chr20:18420160~18421454:-
BRCA	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	7.43	2.34e-13	6.06e-11	0.26	0.22	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
BRCA	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	7.42	2.35e-13	6.08e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-7.42	2.35e-13	6.08e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-7.42	2.35e-13	6.1e-11	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.787	rs11185266	ENSG00000226822.1	RP11-356N1.2	7.42	2.35e-13	6.1e-11	0.29	0.22	Growth-regulated protein alpha levels;	chr1:108100042	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-7.42	2.35e-13	6.1e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
BRCA	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	7.42	2.36e-13	6.1e-11	0.31	0.22	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
BRCA	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
BRCA	cis	rs7178375	1	rs7169064	ENSG00000215302.7	CTD-3092A11.1	-7.42	2.37e-13	6.14e-11	-0.35	-0.22	Hypertriglyceridemia;	chr15:30918659	chr15:30470779~30507623:+
BRCA	cis	rs7474896	0.583	rs1735621	ENSG00000226578.1	RP11-258F22.1	7.42	2.37e-13	6.15e-11	0.29	0.22	Obesity (extreme);	chr10:37878795	chr10:37775371~37784131:-
BRCA	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	7.42	2.38e-13	6.15e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
BRCA	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-7.42	2.38e-13	6.17e-11	-0.27	-0.22	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
BRCA	cis	rs6472827	0.953	rs2936686	ENSG00000253983.2	RP1-16A9.1	7.42	2.38e-13	6.18e-11	0.36	0.22	Uterine fibroids;	chr8:74203974	chr8:74199396~74208441:+
BRCA	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-7.42	2.39e-13	6.18e-11	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-7.42	2.39e-13	6.19e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
BRCA	cis	rs11723261	0.582	rs4634177	ENSG00000211553.1	AC253576.2	-7.42	2.39e-13	6.2e-11	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:136461~136568:+
BRCA	cis	rs1861628	1	rs13020935	ENSG00000237930.1	AC007563.4	7.42	2.4e-13	6.2e-11	0.27	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760956	chr2:216785774~216786144:-
BRCA	cis	rs9880211	0.752	rs67145204	ENSG00000239213.4	NCK1-AS1	7.42	2.4e-13	6.21e-11	0.29	0.22	Height;Body mass index;	chr3:136609823	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	7.42	2.4e-13	6.22e-11	0.3	0.22	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	7.42	2.4e-13	6.22e-11	0.21	0.22	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
BRCA	cis	rs1861628	1	rs13015993	ENSG00000237930.1	AC007563.4	-7.42	2.41e-13	6.23e-11	-0.27	-0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760800	chr2:216785774~216786144:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-7.42	2.41e-13	6.23e-11	-0.22	-0.22	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-7.42	2.41e-13	6.24e-11	-0.27	-0.22	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-7.42	2.41e-13	6.24e-11	-0.27	-0.22	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
BRCA	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	7.42	2.41e-13	6.24e-11	0.18	0.22	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
BRCA	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-7.42	2.41e-13	6.24e-11	-0.24	-0.22	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
BRCA	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-7.42	2.42e-13	6.27e-11	-0.3	-0.22	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
BRCA	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	7.42	2.43e-13	6.28e-11	0.26	0.22	Longevity;	chr3:48422209	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	7.42	2.43e-13	6.28e-11	0.26	0.22	Longevity;	chr3:48423094	chr3:48440352~48446656:-
BRCA	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	7.42	2.43e-13	6.28e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
BRCA	cis	rs919433	0.963	rs10199410	ENSG00000231621.1	AC013264.2	7.42	2.43e-13	6.29e-11	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197291052	chr2:197197991~197199273:+
BRCA	cis	rs253959	0.672	rs4921056	ENSG00000271918.1	CTD-2287O16.5	7.42	2.43e-13	6.29e-11	0.18	0.22	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116083807~116085416:-
BRCA	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	7.42	2.43e-13	6.29e-11	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
BRCA	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-7.42	2.44e-13	6.3e-11	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
BRCA	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-7.42	2.44e-13	6.3e-11	-0.3	-0.22	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
BRCA	cis	rs6545883	0.965	rs6718887	ENSG00000271889.1	RP11-493E12.1	7.42	2.45e-13	6.33e-11	0.29	0.22	Tuberculosis;	chr2:61500080	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	7.42	2.45e-13	6.33e-11	0.26	0.22	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
BRCA	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-7.42	2.45e-13	6.34e-11	-0.29	-0.22	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	7.42	2.45e-13	6.34e-11	0.18	0.22	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
BRCA	cis	rs2060793	0.526	rs10766194	ENSG00000251991.1	RNU7-49P	7.42	2.46e-13	6.37e-11	0.24	0.22	Vitamin D levels;	chr11:14842668	chr11:14478892~14478953:+
BRCA	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
BRCA	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.42	2.47e-13	6.38e-11	0.25	0.22	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
BRCA	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	7.42	2.47e-13	6.38e-11	0.34	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	7.42	2.47e-13	6.39e-11	0.27	0.22	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
BRCA	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	7.42	2.47e-13	6.39e-11	0.26	0.22	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
BRCA	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	7.42	2.49e-13	6.43e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-7.42	2.49e-13	6.44e-11	-0.14	-0.22	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
BRCA	cis	rs138087875	1	rs138087875	ENSG00000264247.1	LINC00909	-7.42	2.5e-13	6.45e-11	-0.45	-0.22	Brain volume in infants (grey matter);	chr18:74593493	chr18:74591774~74598508:-
BRCA	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-7.42	2.5e-13	6.47e-11	-0.25	-0.22	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
BRCA	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	7.42	2.51e-13	6.48e-11	0.32	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
BRCA	cis	rs6740322	0.748	rs6732337	ENSG00000234936.1	AC010883.5	-7.42	2.51e-13	6.48e-11	-0.25	-0.22	Coronary artery disease;	chr2:43235683	chr2:43229573~43233394:+
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-7.42	2.51e-13	6.49e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
BRCA	cis	rs74233809	1	rs17115213	ENSG00000213277.3	MARCKSL1P1	7.42	2.51e-13	6.49e-11	0.43	0.22	Birth weight;	chr10:102921386	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	7.42	2.51e-13	6.49e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
BRCA	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-7.42	2.51e-13	6.49e-11	-0.32	-0.22	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
BRCA	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-7.41	2.52e-13	6.5e-11	-0.32	-0.22	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-7.41	2.52e-13	6.5e-11	-0.32	-0.22	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-7.41	2.52e-13	6.5e-11	-0.3	-0.22	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
BRCA	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	7.41	2.52e-13	6.5e-11	0.26	0.22	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	7.41	2.52e-13	6.52e-11	0.33	0.22	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
BRCA	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-7.41	2.53e-13	6.53e-11	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
BRCA	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-7.41	2.53e-13	6.54e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-7.41	2.53e-13	6.54e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-7.41	2.55e-13	6.58e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-7.41	2.56e-13	6.6e-11	-0.22	-0.22	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.869	rs42617	ENSG00000225498.1	AC002064.5	7.41	2.56e-13	6.6e-11	0.22	0.22	Homocysteine levels;	chr7:90322732	chr7:90312496~90322592:+
BRCA	cis	rs74233809	1	rs11191582	ENSG00000213277.3	MARCKSL1P1	7.41	2.56e-13	6.62e-11	0.46	0.22	Birth weight;	chr10:103153896	chr10:103175554~103176094:+
BRCA	cis	rs919433	1	rs919433	ENSG00000231621.1	AC013264.2	7.41	2.56e-13	6.62e-11	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.41	2.57e-13	6.64e-11	-0.25	-0.22	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
BRCA	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-7.41	2.58e-13	6.65e-11	-0.3	-0.22	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
BRCA	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-7.41	2.58e-13	6.65e-11	-0.27	-0.22	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
BRCA	cis	rs10206020	0.921	rs72778009	ENSG00000231482.2	AC141930.2	-7.41	2.58e-13	6.66e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569550	chr2:1572554~1580311:-
BRCA	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	7.41	2.6e-13	6.72e-11	0.23	0.22	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	7.41	2.61e-13	6.73e-11	0.3	0.22	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	7.41	2.61e-13	6.73e-11	0.32	0.22	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	7.41	2.61e-13	6.73e-11	0.26	0.22	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	7.41	2.61e-13	6.74e-11	0.33	0.22	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
BRCA	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	7.41	2.61e-13	6.75e-11	0.31	0.22	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-7.41	2.62e-13	6.75e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
BRCA	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-7.41	2.62e-13	6.75e-11	-0.26	-0.22	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
BRCA	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	7.41	2.62e-13	6.76e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
BRCA	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	7.41	2.62e-13	6.76e-11	0.3	0.22	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
BRCA	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	7.41	2.62e-13	6.76e-11	0.18	0.22	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
BRCA	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-7.41	2.62e-13	6.76e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.965	rs12713439	ENSG00000271889.1	RP11-493E12.1	7.41	2.62e-13	6.77e-11	0.29	0.22	Tuberculosis;	chr2:61525019	chr2:61151433~61162105:-
BRCA	cis	rs10206020	0.885	rs13411553	ENSG00000231482.2	AC141930.2	-7.41	2.63e-13	6.77e-11	-0.28	-0.22	IgG glycosylation;	chr2:1570246	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	7.41	2.63e-13	6.78e-11	0.29	0.22	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	7.41	2.63e-13	6.79e-11	0.25	0.22	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	7.41	2.63e-13	6.79e-11	0.23	0.22	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
BRCA	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-7.41	2.64e-13	6.8e-11	-0.24	-0.22	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
BRCA	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-7.41	2.64e-13	6.8e-11	-0.27	-0.22	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
BRCA	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	7.41	2.64e-13	6.8e-11	0.26	0.22	Longevity;	chr3:48440237	chr3:48440352~48446656:-
BRCA	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	7.41	2.64e-13	6.8e-11	0.27	0.22	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
BRCA	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	7.41	2.64e-13	6.81e-11	0.27	0.22	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
BRCA	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-7.41	2.64e-13	6.81e-11	-0.31	-0.22	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
BRCA	cis	rs3758911	0.765	rs609821	ENSG00000255353.1	RP11-382M14.1	7.41	2.64e-13	6.81e-11	0.3	0.22	Coronary artery disease;	chr11:107468429	chr11:107176286~107177530:+
BRCA	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-7.41	2.65e-13	6.82e-11	-0.27	-0.22	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
BRCA	cis	rs6545883	0.965	rs6734830	ENSG00000271889.1	RP11-493E12.1	7.41	2.65e-13	6.83e-11	0.29	0.22	Tuberculosis;	chr2:61503977	chr2:61151433~61162105:-
BRCA	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	7.41	2.65e-13	6.84e-11	0.29	0.22	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
BRCA	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-7.41	2.66e-13	6.85e-11	-0.24	-0.22	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
BRCA	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-7.41	2.66e-13	6.85e-11	-0.24	-0.22	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
BRCA	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	7.41	2.66e-13	6.85e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
BRCA	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	7.41	2.66e-13	6.86e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
BRCA	cis	rs6545883	0.965	rs7421663	ENSG00000271889.1	RP11-493E12.1	7.41	2.66e-13	6.86e-11	0.29	0.22	Tuberculosis;	chr2:61526651	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000224316.1	RP11-479O9.2	-7.41	2.66e-13	6.86e-11	-0.26	-0.22	Aortic root size;	chr7:66105323	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-7.41	2.67e-13	6.88e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.41	2.68e-13	6.89e-11	-0.21	-0.22	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
BRCA	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-7.41	2.68e-13	6.91e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
BRCA	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	7.41	2.69e-13	6.92e-11	0.26	0.22	Longevity;	chr3:48426493	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	7.41	2.69e-13	6.92e-11	0.26	0.22	Longevity;	chr3:48432839	chr3:48440352~48446656:-
BRCA	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	7.41	2.69e-13	6.92e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
BRCA	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	7.41	2.69e-13	6.94e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	7.41	2.69e-13	6.94e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
BRCA	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	7.41	2.7e-13	6.94e-11	0.32	0.22	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs13092193	ENSG00000273486.1	RP11-731C17.2	7.4	2.71e-13	6.97e-11	0.29	0.22	Height;Body mass index;	chr3:136521524	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.929	rs2463100	ENSG00000271889.1	RP11-493E12.1	7.4	2.71e-13	6.97e-11	0.31	0.22	Tuberculosis;	chr2:61432064	chr2:61151433~61162105:-
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.4	2.72e-13	6.99e-11	0.32	0.22	Height;	chr4:55361200	chr4:55363971~55395847:-
BRCA	cis	rs10206020	0.879	rs72778007	ENSG00000231482.2	AC141930.2	-7.4	2.72e-13	7e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569406	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.797	rs72778008	ENSG00000231482.2	AC141930.2	-7.4	2.72e-13	7e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569410	chr2:1572554~1580311:-
BRCA	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	7.4	2.72e-13	7e-11	0.27	0.22	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
BRCA	cis	rs11143230	1	rs17628494	ENSG00000225434.2	LINC01504	-7.4	2.72e-13	7.01e-11	-0.26	-0.22	Suicidal ideation;	chr9:72274251	chr9:72305430~72343210:+
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	7.4	2.73e-13	7.03e-11	0.21	0.22	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	7.4	2.73e-13	7.04e-11	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-7.4	2.74e-13	7.05e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
BRCA	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
BRCA	cis	rs473651	0.935	rs1103770	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430640	chr2:238427077~238427729:-
BRCA	cis	rs473651	0.935	rs10170056	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430650	chr2:238427077~238427729:-
BRCA	cis	rs473651	0.935	rs559579	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430860	chr2:238427077~238427729:-
BRCA	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-7.4	2.75e-13	7.07e-11	-0.31	-0.22	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-7.4	2.75e-13	7.08e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-7.4	2.75e-13	7.08e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.76e-13	7.09e-11	-0.32	-0.22	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
BRCA	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	7.4	2.76e-13	7.1e-11	0.26	0.22	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
BRCA	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	7.4	2.77e-13	7.13e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
BRCA	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	7.4	2.78e-13	7.15e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
BRCA	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.4	2.78e-13	7.15e-11	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
BRCA	cis	rs42648	0.693	rs2106274	ENSG00000225498.1	AC002064.5	7.4	2.78e-13	7.16e-11	0.21	0.22	Homocysteine levels;	chr7:90251234	chr7:90312496~90322592:+
BRCA	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	7.4	2.78e-13	7.16e-11	0.26	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	7.4	2.79e-13	7.16e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
BRCA	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-7.4	2.8e-13	7.19e-11	-0.27	-0.22	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
BRCA	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	7.4	2.8e-13	7.2e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-7.4	2.8e-13	7.21e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
BRCA	cis	rs9880211	0.699	rs34804893	ENSG00000239213.4	NCK1-AS1	7.4	2.81e-13	7.22e-11	0.3	0.22	Height;Body mass index;	chr3:136621128	chr3:136841726~136862054:-
BRCA	cis	rs34779708	0.801	rs12255409	ENSG00000271335.4	RP11-324I22.4	7.4	2.81e-13	7.22e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35314552~35336401:-
BRCA	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	7.4	2.81e-13	7.22e-11	0.29	0.22	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000261582.1	RP4-614O4.11	-7.4	2.82e-13	7.25e-11	-0.24	-0.22	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35267885~35280043:-
BRCA	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	7.4	2.82e-13	7.25e-11	0.38	0.22	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
BRCA	cis	rs3781264	0.816	rs7084339	ENSG00000273450.1	RP11-76P2.4	-7.4	2.83e-13	7.26e-11	-0.28	-0.22	Esophageal cancer and gastric cancer;	chr10:94283975	chr10:94314907~94315327:-
BRCA	cis	rs12548874	0.607	rs12543492	ENSG00000253528.2	RP11-347C18.4	7.4	2.83e-13	7.26e-11	0.24	0.22	Hemoglobin concentration;	chr8:94879615	chr8:94974573~94974853:-
BRCA	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	7.4	2.83e-13	7.27e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-7.4	2.83e-13	7.27e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
BRCA	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	7.4	2.83e-13	7.27e-11	0.36	0.22	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
BRCA	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	7.4	2.83e-13	7.28e-11	0.18	0.22	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
BRCA	cis	rs12664251	0.706	rs1775620	ENSG00000253194.1	RP11-351A11.1	-7.4	2.84e-13	7.29e-11	-0.27	-0.22	Schizophrenia;	chr6:119012273	chr6:118934785~119031541:+
BRCA	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	7.4	2.84e-13	7.3e-11	0.29	0.22	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
BRCA	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	7.4	2.85e-13	7.32e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-7.4	2.86e-13	7.33e-11	-0.26	-0.22	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
BRCA	cis	rs301901	1	rs6899155	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.87e-13	7.36e-11	-0.24	-0.22	Height;	chr5:36786357	chr5:36666214~36725195:-
BRCA	cis	rs12444979	0.517	rs720173	ENSG00000261195.1	CTD-2380F24.1	-7.4	2.87e-13	7.37e-11	-0.35	-0.22	Body mass index;	chr16:19710484	chr16:19761172~19766099:-
BRCA	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-7.4	2.87e-13	7.38e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-7.4	2.87e-13	7.38e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
BRCA	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	7.4	2.88e-13	7.4e-11	0.26	0.22	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
BRCA	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	7.4	2.88e-13	7.4e-11	0.29	0.22	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
BRCA	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	7.4	2.88e-13	7.4e-11	0.21	0.22	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7.4	2.89e-13	7.4e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7.4	2.89e-13	7.4e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-7.4	2.89e-13	7.41e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
BRCA	cis	rs293748	0.771	rs13174506	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36801678	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs12654600	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36802066	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs34139494	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36802466	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.898	rs6770476	ENSG00000239213.4	NCK1-AS1	7.4	2.9e-13	7.43e-11	0.26	0.22	Height;Body mass index;	chr3:136355078	chr3:136841726~136862054:-
BRCA	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	7.39	2.9e-13	7.45e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	7.39	2.91e-13	7.47e-11	0.31	0.22	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-7.39	2.91e-13	7.47e-11	-0.26	-0.22	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-7.39	2.91e-13	7.47e-11	-0.26	-0.22	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
BRCA	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-7.39	2.91e-13	7.48e-11	-0.3	-0.22	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-7.39	2.92e-13	7.48e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
BRCA	cis	rs2933343	0.533	rs11915889	ENSG00000261159.1	RP11-723O4.9	7.39	2.94e-13	7.53e-11	0.25	0.22	IgG glycosylation;	chr3:128982023	chr3:128859716~128860526:-
BRCA	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-7.39	2.96e-13	7.58e-11	-0.24	-0.22	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	7.39	2.96e-13	7.58e-11	0.27	0.22	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	7.39	2.96e-13	7.58e-11	0.23	0.22	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
BRCA	cis	rs10206020	0.921	rs9678719	ENSG00000231482.2	AC141930.2	-7.39	2.96e-13	7.59e-11	-0.3	-0.22	IgG glycosylation;	chr2:1545856	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.506	rs6756310	ENSG00000231482.2	AC141930.2	-7.39	2.96e-13	7.59e-11	-0.3	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1546037	chr2:1572554~1580311:-
BRCA	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-7.39	2.96e-13	7.59e-11	-0.25	-0.22	Height;	chr5:37053881	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs34701667	ENSG00000250155.1	CTD-2353F22.1	-7.39	2.97e-13	7.61e-11	-0.31	-0.22	Obesity-related traits;	chr5:36799375	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs6806123	ENSG00000273486.1	RP11-731C17.2	7.39	2.98e-13	7.63e-11	0.3	0.22	Height;Body mass index;	chr3:136586634	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-7.39	2.98e-13	7.63e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	7.39	2.98e-13	7.64e-11	0.25	0.22	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
BRCA	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	7.39	2.99e-13	7.65e-11	0.36	0.22	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
BRCA	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	7.39	2.99e-13	7.66e-11	0.26	0.22	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
BRCA	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-7.39	3e-13	7.68e-11	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-7.39	3e-13	7.68e-11	-0.14	-0.22	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
BRCA	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	7.39	3e-13	7.69e-11	0.26	0.22	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	7.39	3e-13	7.69e-11	0.34	0.22	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
BRCA	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-7.39	3e-13	7.7e-11	-0.28	-0.22	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
BRCA	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-7.39	3.01e-13	7.7e-11	-0.32	-0.22	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
BRCA	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	7.39	3.01e-13	7.7e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
BRCA	cis	rs3781264	0.848	rs7099485	ENSG00000273450.1	RP11-76P2.4	7.39	3.02e-13	7.73e-11	0.28	0.22	Esophageal cancer and gastric cancer;	chr10:94305937	chr10:94314907~94315327:-
BRCA	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	7.39	3.02e-13	7.73e-11	0.29	0.22	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
BRCA	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.39	3.02e-13	7.74e-11	0.34	0.22	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
BRCA	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	7.39	3.02e-13	7.74e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
BRCA	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	7.39	3.02e-13	7.74e-11	0.33	0.22	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
BRCA	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	7.39	3.03e-13	7.77e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-7.39	3.04e-13	7.78e-11	-0.32	-0.22	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
BRCA	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-7.39	3.04e-13	7.79e-11	-0.26	-0.22	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
BRCA	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	7.39	3.04e-13	7.79e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
BRCA	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-7.39	3.05e-13	7.81e-11	-0.29	-0.22	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	7.39	3.05e-13	7.81e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
BRCA	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-7.39	3.05e-13	7.81e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-7.39	3.05e-13	7.81e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
BRCA	cis	rs42648	0.633	rs11563909	ENSG00000225498.1	AC002064.5	7.39	3.05e-13	7.81e-11	0.21	0.22	Homocysteine levels;	chr7:90306390	chr7:90312496~90322592:+
BRCA	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-7.39	3.05e-13	7.82e-11	-0.32	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	7.39	3.06e-13	7.84e-11	0.23	0.22	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	7.39	3.06e-13	7.84e-11	0.27	0.22	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
BRCA	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-7.39	3.07e-13	7.84e-11	-0.25	-0.22	Height;	chr5:36832039	chr5:36666214~36725195:-
BRCA	cis	rs812925	0.964	rs11125883	ENSG00000271889.1	RP11-493E12.1	7.39	3.07e-13	7.85e-11	0.29	0.22	Immature fraction of reticulocytes;	chr2:61483438	chr2:61151433~61162105:-
BRCA	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	7.39	3.07e-13	7.85e-11	0.33	0.22	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
BRCA	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-7.39	3.07e-13	7.86e-11	-0.23	-0.22	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	7.39	3.07e-13	7.87e-11	0.27	0.22	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.574	rs7789440	ENSG00000272950.1	RP11-307C18.1	7.39	3.07e-13	7.87e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	7.39	3.08e-13	7.88e-11	0.27	0.22	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
BRCA	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	7.39	3.08e-13	7.88e-11	0.31	0.22	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
BRCA	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	7.39	3.09e-13	7.9e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
BRCA	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-7.39	3.1e-13	7.93e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	7.39	3.11e-13	7.95e-11	0.27	0.22	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-7.39	3.11e-13	7.95e-11	-0.28	-0.22	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	7.39	3.11e-13	7.96e-11	0.23	0.22	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-7.38	3.12e-13	7.97e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
BRCA	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-7.38	3.12e-13	7.99e-11	-0.32	-0.22	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-7.38	3.12e-13	7.99e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
BRCA	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-7.38	3.13e-13	8e-11	-0.31	-0.22	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
BRCA	cis	rs9880211	0.706	rs9289513	ENSG00000273486.1	RP11-731C17.2	7.38	3.13e-13	8.01e-11	0.3	0.22	Height;Body mass index;	chr3:136732904	chr3:136837338~136839021:-
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-7.38	3.13e-13	8.01e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
BRCA	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	7.38	3.14e-13	8.02e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
BRCA	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-7.38	3.14e-13	8.02e-11	-0.26	-0.22	Longevity;	chr3:48407742	chr3:48440352~48446656:-
BRCA	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	7.38	3.15e-13	8.04e-11	0.25	0.22	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
BRCA	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	7.38	3.15e-13	8.05e-11	0.37	0.22	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
BRCA	cis	rs42648	0.693	rs194533	ENSG00000225498.1	AC002064.5	7.38	3.15e-13	8.05e-11	0.21	0.22	Homocysteine levels;	chr7:90241463	chr7:90312496~90322592:+
BRCA	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.38	3.17e-13	8.09e-11	0.25	0.22	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
BRCA	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-7.38	3.17e-13	8.09e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-7.38	3.17e-13	8.1e-11	-0.2	-0.22	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
BRCA	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-7.38	3.18e-13	8.11e-11	-0.21	-0.22	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	7.38	3.19e-13	8.15e-11	0.27	0.22	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
BRCA	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	7.38	3.19e-13	8.15e-11	0.26	0.22	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
BRCA	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	7.38	3.19e-13	8.15e-11	0.31	0.22	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	7.38	3.19e-13	8.16e-11	0.18	0.22	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
BRCA	cis	rs7474896	0.583	rs10764144	ENSG00000226578.1	RP11-258F22.1	-7.38	3.19e-13	8.16e-11	-0.29	-0.22	Obesity (extreme);	chr10:37686804	chr10:37775371~37784131:-
BRCA	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	7.38	3.2e-13	8.17e-11	0.26	0.22	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
BRCA	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-7.38	3.2e-13	8.17e-11	-0.3	-0.22	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	7.38	3.2e-13	8.18e-11	0.22	0.22	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
BRCA	cis	rs7976269	0.559	rs10843304	ENSG00000257176.2	RP11-996F15.2	-7.38	3.21e-13	8.19e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29071226	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-7.38	3.22e-13	8.22e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-7.38	3.22e-13	8.22e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	7.38	3.23e-13	8.24e-11	0.17	0.22	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
BRCA	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-7.38	3.23e-13	8.26e-11	-0.24	-0.22	Height;	chr5:36999896	chr5:36666214~36725195:-
BRCA	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-7.38	3.24e-13	8.28e-11	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
BRCA	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-7.38	3.25e-13	8.3e-11	-0.26	-0.22	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
BRCA	cis	rs9880211	1	rs28718456	ENSG00000273486.1	RP11-731C17.2	7.38	3.26e-13	8.31e-11	0.29	0.22	Height;Body mass index;	chr3:136485164	chr3:136837338~136839021:-
BRCA	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-7.38	3.26e-13	8.32e-11	-0.3	-0.22	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
BRCA	cis	rs72772090	0.71	rs17479052	ENSG00000248734.2	CTD-2260A17.1	-7.38	3.27e-13	8.34e-11	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96784777~96785999:+
BRCA	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-7.38	3.28e-13	8.35e-11	-0.23	-0.22	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
BRCA	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	7.38	3.28e-13	8.36e-11	0.36	0.22	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
BRCA	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-7.38	3.28e-13	8.37e-11	-0.23	-0.22	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
BRCA	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-7.38	3.28e-13	8.37e-11	-0.28	-0.22	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-7.38	3.28e-13	8.37e-11	-0.28	-0.22	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
BRCA	cis	rs7927771	0.756	rs2856661	ENSG00000280615.1	Y_RNA	7.38	3.29e-13	8.38e-11	0.28	0.22	Subjective well-being;	chr11:47353447	chr11:47614898~47614994:-
BRCA	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	7.38	3.29e-13	8.38e-11	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
BRCA	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	7.38	3.29e-13	8.38e-11	0.29	0.22	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
BRCA	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	7.38	3.29e-13	8.38e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-7.38	3.29e-13	8.39e-11	-0.24	-0.22	Height;	chr5:37072722	chr5:36666214~36725195:-
BRCA	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-7.38	3.3e-13	8.41e-11	-0.23	-0.22	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
BRCA	cis	rs9527	0.525	rs12770034	ENSG00000213061.2	PFN1P11	7.38	3.3e-13	8.42e-11	0.29	0.22	Arsenic metabolism;	chr10:102875838	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-7.38	3.3e-13	8.42e-11	-0.22	-0.22	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	7.38	3.3e-13	8.42e-11	0.26	0.22	Longevity;	chr3:48437797	chr3:48440352~48446656:-
BRCA	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.38	3.31e-13	8.43e-11	-0.24	-0.22	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000224316.1	RP11-479O9.2	-7.38	3.31e-13	8.44e-11	-0.26	-0.22	Aortic root size;	chr7:66101095	chr7:65773620~65802067:+
BRCA	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	7.38	3.32e-13	8.47e-11	0.24	0.22	Height;	chr5:36887793	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	7.38	3.33e-13	8.48e-11	0.15	0.22	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
BRCA	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	7.38	3.33e-13	8.48e-11	0.24	0.22	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	7.38	3.33e-13	8.5e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	7.38	3.35e-13	8.52e-11	0.21	0.22	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
BRCA	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-7.37	3.35e-13	8.53e-11	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-7.37	3.35e-13	8.54e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
BRCA	cis	rs2060793	0.519	rs7931291	ENSG00000251991.1	RNU7-49P	-7.37	3.35e-13	8.54e-11	-0.24	-0.22	Vitamin D levels;	chr11:14622880	chr11:14478892~14478953:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-7.37	3.36e-13	8.55e-11	-0.14	-0.22	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
BRCA	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	7.37	3.36e-13	8.55e-11	0.26	0.22	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
BRCA	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	7.37	3.36e-13	8.56e-11	0.3	0.22	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	7.37	3.36e-13	8.56e-11	0.3	0.22	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
BRCA	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	7.37	3.37e-13	8.57e-11	0.26	0.22	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
BRCA	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-7.37	3.37e-13	8.58e-11	-0.26	-0.22	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
BRCA	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-7.37	3.37e-13	8.59e-11	-0.28	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
BRCA	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-7.37	3.37e-13	8.59e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
BRCA	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-7.37	3.37e-13	8.59e-11	-0.29	-0.22	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
BRCA	cis	rs4845875	0.626	rs12734761	ENSG00000242349.4	NPPA-AS1	7.37	3.37e-13	8.59e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11774125	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.8	rs9845862	ENSG00000273486.1	RP11-731C17.2	7.37	3.39e-13	8.63e-11	0.3	0.22	Height;Body mass index;	chr3:136753731	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-7.37	3.4e-13	8.64e-11	-0.22	-0.22	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	7.37	3.4e-13	8.65e-11	0.26	0.22	Longevity;	chr3:48446507	chr3:48440352~48446656:-
BRCA	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	7.37	3.4e-13	8.66e-11	0.18	0.22	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
BRCA	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-7.37	3.41e-13	8.68e-11	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	7.37	3.41e-13	8.68e-11	0.38	0.22	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	7.37	3.41e-13	8.68e-11	0.22	0.22	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	7.37	3.41e-13	8.68e-11	0.22	0.22	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-7.37	3.41e-13	8.68e-11	-0.23	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-7.37	3.41e-13	8.69e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	7.37	3.42e-13	8.71e-11	0.27	0.22	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	7.37	3.42e-13	8.72e-11	0.27	0.22	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
BRCA	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	7.37	3.43e-13	8.73e-11	0.26	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-7.37	3.44e-13	8.76e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-7.37	3.44e-13	8.76e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
BRCA	cis	rs74233809	1	rs5011520	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102937759	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883808	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102961369	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191479	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102963863	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	7.37	3.47e-13	8.83e-11	0.27	0.22	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
BRCA	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-7.37	3.48e-13	8.86e-11	-0.23	-0.22	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
BRCA	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	7.37	3.48e-13	8.86e-11	0.31	0.22	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
BRCA	cis	rs79040073	0.637	rs61259878	ENSG00000259531.2	RP11-295H24.3	7.37	3.49e-13	8.87e-11	0.37	0.22	Lung cancer in ever smokers;	chr15:49432564	chr15:49365124~49366685:-
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000274973.1	RP13-401N8.7	7.37	3.49e-13	8.88e-11	0.26	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25845497~25845862:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-7.37	3.5e-13	8.91e-11	-0.22	-0.22	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	7.37	3.51e-13	8.93e-11	0.18	0.22	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-7.37	3.52e-13	8.95e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-7.37	3.52e-13	8.95e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-7.37	3.52e-13	8.96e-11	-0.32	-0.22	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-7.37	3.53e-13	8.97e-11	-0.23	-0.22	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
BRCA	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-7.37	3.53e-13	8.97e-11	-0.3	-0.22	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
BRCA	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	7.37	3.53e-13	8.98e-11	0.28	0.22	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-7.37	3.53e-13	8.99e-11	-0.14	-0.22	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	7.37	3.54e-13	9.01e-11	0.27	0.22	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
BRCA	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.37	3.55e-13	9.04e-11	-0.27	-0.22	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
BRCA	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-7.37	3.56e-13	9.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
BRCA	cis	rs3781264	0.56	rs3765524	ENSG00000273450.1	RP11-76P2.4	7.37	3.57e-13	9.07e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94298541	chr10:94314907~94315327:-
BRCA	cis	rs9527	0.571	rs12765337	ENSG00000213061.2	PFN1P11	7.37	3.57e-13	9.07e-11	0.29	0.22	Arsenic metabolism;	chr10:102875587	chr10:102838011~102845473:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-7.37	3.58e-13	9.09e-11	-0.14	-0.22	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
BRCA	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	7.37	3.58e-13	9.1e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
BRCA	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	7.37	3.58e-13	9.1e-11	0.29	0.22	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-7.37	3.58e-13	9.11e-11	-0.24	-0.22	Height;	chr5:37081780	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-7.37	3.58e-13	9.11e-11	-0.26	-0.22	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
BRCA	cis	rs9876781	1	rs4858817	ENSG00000244380.1	RP11-24C3.2	-7.37	3.59e-13	9.13e-11	-0.25	-0.22	Longevity;	chr3:48375266	chr3:48440352~48446656:-
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-7.37	3.59e-13	9.13e-11	-0.25	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
BRCA	cis	rs2277027	0.541	rs56168343	ENSG00000248544.2	CTB-47B11.3	7.36	3.6e-13	9.14e-11	0.38	0.22	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157501000	chr5:157375741~157384950:-
BRCA	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-7.36	3.6e-13	9.15e-11	-0.34	-0.22	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	7.36	3.61e-13	9.17e-11	0.26	0.22	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
BRCA	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	7.36	3.61e-13	9.18e-11	0.3	0.22	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
BRCA	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	7.36	3.62e-13	9.2e-11	0.27	0.22	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
BRCA	cis	rs7927771	0.832	rs1542321	ENSG00000280615.1	Y_RNA	7.36	3.62e-13	9.2e-11	0.27	0.22	Subjective well-being;	chr11:47358064	chr11:47614898~47614994:-
BRCA	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-7.36	3.64e-13	9.24e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
BRCA	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-7.36	3.64e-13	9.24e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
BRCA	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	7.36	3.65e-13	9.27e-11	0.27	0.22	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-7.36	3.65e-13	9.27e-11	-0.32	-0.22	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
BRCA	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-7.36	3.65e-13	9.28e-11	-0.3	-0.22	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
BRCA	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-7.36	3.66e-13	9.28e-11	-0.32	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
BRCA	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-7.36	3.66e-13	9.28e-11	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
BRCA	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-7.36	3.67e-13	9.31e-11	-0.3	-0.22	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	7.36	3.67e-13	9.32e-11	0.22	0.22	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
BRCA	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.36	3.67e-13	9.32e-11	0.25	0.22	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.67e-13	9.32e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
BRCA	cis	rs6545883	0.931	rs12713437	ENSG00000271889.1	RP11-493E12.1	7.36	3.67e-13	9.33e-11	0.29	0.22	Tuberculosis;	chr2:61495769	chr2:61151433~61162105:-
BRCA	cis	rs4845875	0.626	rs2004445	ENSG00000242349.4	NPPA-AS1	7.36	3.68e-13	9.33e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11781309	chr1:11841017~11848079:+
BRCA	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	7.36	3.69e-13	9.36e-11	0.25	0.22	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-7.36	3.7e-13	9.38e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
BRCA	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	7.36	3.7e-13	9.4e-11	0.27	0.22	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
BRCA	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-7.36	3.71e-13	9.43e-11	-0.26	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
BRCA	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	7.36	3.72e-13	9.44e-11	0.28	0.22	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
BRCA	cis	rs6539288	0.933	rs1822736	ENSG00000260329.1	RP11-412D9.4	7.36	3.72e-13	9.44e-11	0.25	0.22	Total body bone mineral density;	chr12:106915481	chr12:106954029~106955497:-
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.45e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	7.36	3.72e-13	9.45e-11	0.29	0.22	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
BRCA	cis	rs4934494	0.768	rs12771413	ENSG00000240996.1	RP11-80H5.7	7.36	3.73e-13	9.47e-11	0.27	0.22	Red blood cell count;	chr10:89633010	chr10:89694295~89697928:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-7.36	3.74e-13	9.49e-11	-0.55	-0.22	Gout;	chr7:66723871	chr7:66654538~66669855:+
BRCA	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	7.36	3.74e-13	9.49e-11	0.37	0.22	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
BRCA	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	7.36	3.75e-13	9.5e-11	0.26	0.22	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
BRCA	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-7.36	3.75e-13	9.5e-11	-0.28	-0.22	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
BRCA	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	7.36	3.75e-13	9.52e-11	0.27	0.22	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
BRCA	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	7.36	3.76e-13	9.53e-11	0.38	0.22	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	7.36	3.76e-13	9.54e-11	0.22	0.22	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
BRCA	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	7.36	3.77e-13	9.56e-11	0.28	0.22	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
BRCA	cis	rs42648	0.642	rs11771963	ENSG00000225498.1	AC002064.5	7.36	3.78e-13	9.59e-11	0.21	0.22	Homocysteine levels;	chr7:90258273	chr7:90312496~90322592:+
BRCA	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-7.36	3.79e-13	9.61e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	7.36	3.79e-13	9.61e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
BRCA	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-7.36	3.8e-13	9.63e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
BRCA	cis	rs10206020	0.842	rs7590900	ENSG00000231482.2	AC141930.2	-7.36	3.81e-13	9.65e-11	-0.28	-0.22	IgG glycosylation;	chr2:1571130	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-7.36	3.81e-13	9.67e-11	-0.25	-0.22	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
BRCA	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-7.36	3.82e-13	9.67e-11	-0.28	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
BRCA	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-7.36	3.82e-13	9.68e-11	-0.23	-0.22	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
BRCA	cis	rs11976180	1	rs1320893	ENSG00000204959.4	ARHGEF34P	7.36	3.83e-13	9.7e-11	0.27	0.22	Obesity-related traits;	chr7:144055019	chr7:144272445~144286966:-
BRCA	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	7.36	3.83e-13	9.71e-11	0.42	0.22	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
BRCA	cis	rs7085104	0.66	rs7902804	ENSG00000236937.2	PTGES3P4	7.36	3.83e-13	9.71e-11	0.29	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-7.36	3.85e-13	9.76e-11	-0.24	-0.22	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	7.36	3.85e-13	9.76e-11	0.27	0.22	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs1872239	ENSG00000239213.4	NCK1-AS1	7.36	3.85e-13	9.76e-11	0.29	0.22	Height;Body mass index;	chr3:136785069	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-7.36	3.86e-13	9.77e-11	-0.14	-0.22	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
BRCA	cis	rs17495987	0.871	rs73061231	ENSG00000219545.8	UMAD1	7.36	3.86e-13	9.77e-11	0.29	0.22	Tonsillectomy;	chr7:7864765	chr7:7640711~8004059:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.86e-13	9.77e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	7.35	3.86e-13	9.78e-11	0.3	0.22	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
BRCA	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	7.35	3.88e-13	9.82e-11	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	7.35	3.88e-13	9.82e-11	0.24	0.22	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.935	rs42627	ENSG00000225498.1	AC002064.5	7.35	3.88e-13	9.83e-11	0.22	0.22	Homocysteine levels;	chr7:90332562	chr7:90312496~90322592:+
BRCA	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	7.35	3.9e-13	9.87e-11	0.33	0.22	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
BRCA	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-7.35	3.9e-13	9.88e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
BRCA	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	7.35	3.9e-13	9.88e-11	0.25	0.22	Height;	chr5:37439326	chr5:36666214~36725195:-
BRCA	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	7.35	3.9e-13	9.88e-11	0.2	0.22	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
BRCA	cis	rs7976269	0.559	rs10771477	ENSG00000257176.2	RP11-996F15.2	-7.35	3.91e-13	9.91e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29074137	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.559	rs10843307	ENSG00000257176.2	RP11-996F15.2	-7.35	3.91e-13	9.91e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29074710	chr12:29280418~29317848:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	7.35	3.94e-13	9.96e-11	0.17	0.22	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
BRCA	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	7.35	3.94e-13	9.96e-11	0.3	0.22	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
BRCA	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-7.35	3.94e-13	9.97e-11	-0.29	-0.22	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
BRCA	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	7.35	3.95e-13	9.98e-11	0.24	0.22	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
BRCA	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	7.35	3.95e-13	9.99e-11	0.3	0.22	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	7.35	3.95e-13	1e-10	0.18	0.22	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
BRCA	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-7.35	3.96e-13	1e-10	-0.31	-0.22	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-7.35	3.96e-13	1e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
BRCA	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	7.35	3.96e-13	1e-10	0.43	0.22	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-7.35	3.97e-13	1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
BRCA	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	7.35	3.98e-13	1.01e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
BRCA	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	7.35	3.99e-13	1.01e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
BRCA	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-7.35	4e-13	1.01e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
BRCA	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	7.35	4e-13	1.01e-10	0.43	0.22	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
BRCA	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
BRCA	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	7.35	4.01e-13	1.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	7.35	4.02e-13	1.02e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.555	rs6955259	ENSG00000272950.1	RP11-307C18.1	7.35	4.03e-13	1.02e-10	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-7.35	4.05e-13	1.02e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.931	rs9807965	ENSG00000271889.1	RP11-493E12.1	7.35	4.07e-13	1.03e-10	0.28	0.22	Tuberculosis;	chr2:61505024	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-7.35	4.08e-13	1.03e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
BRCA	cis	rs473651	0.935	rs558924	ENSG00000229915.1	AC016999.2	-7.35	4.08e-13	1.03e-10	-0.31	-0.22	Multiple system atrophy;	chr2:238430870	chr2:238427077~238427729:-
BRCA	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	7.35	4.08e-13	1.03e-10	0.32	0.22	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
BRCA	cis	rs3758911	0.894	rs11212162	ENSG00000255353.1	RP11-382M14.1	-7.35	4.09e-13	1.03e-10	-0.29	-0.22	Coronary artery disease;	chr11:107327884	chr11:107176286~107177530:+
BRCA	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	7.35	4.09e-13	1.03e-10	0.25	0.22	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
BRCA	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	7.35	4.09e-13	1.03e-10	0.22	0.22	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
BRCA	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	7.35	4.09e-13	1.03e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
BRCA	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-7.35	4.1e-13	1.04e-10	-0.22	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
BRCA	cis	rs42648	0.902	rs17874789	ENSG00000225498.1	AC002064.5	-7.35	4.12e-13	1.04e-10	-0.21	-0.22	Homocysteine levels;	chr7:90371846	chr7:90312496~90322592:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-7.35	4.12e-13	1.04e-10	-0.23	-0.22	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs2961144	ENSG00000204959.4	ARHGEF34P	-7.35	4.13e-13	1.04e-10	-0.27	-0.22	Obesity-related traits;	chr7:144050777	chr7:144272445~144286966:-
BRCA	cis	rs7085104	0.632	rs7096475	ENSG00000236937.2	PTGES3P4	7.35	4.14e-13	1.04e-10	0.28	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102845595~102845950:+
BRCA	cis	rs3758911	0.796	rs56753250	ENSG00000255353.1	RP11-382M14.1	-7.34	4.15e-13	1.05e-10	-0.3	-0.22	Coronary artery disease;	chr11:107338499	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	7.34	4.16e-13	1.05e-10	0.23	0.22	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	7.34	4.17e-13	1.05e-10	0.22	0.22	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	7.34	4.17e-13	1.05e-10	0.23	0.22	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
BRCA	cis	rs4845875	0.602	rs2001584	ENSG00000242349.4	NPPA-AS1	7.34	4.18e-13	1.06e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11781294	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-7.34	4.19e-13	1.06e-10	-0.26	-0.22	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
BRCA	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	7.34	4.19e-13	1.06e-10	0.25	0.22	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
BRCA	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	7.34	4.19e-13	1.06e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	7.34	4.19e-13	1.06e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	7.34	4.19e-13	1.06e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
BRCA	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	7.34	4.2e-13	1.06e-10	0.41	0.22	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-7.34	4.2e-13	1.06e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
BRCA	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	7.34	4.2e-13	1.06e-10	0.37	0.22	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
BRCA	cis	rs72772090	0.71	rs11739280	ENSG00000248734.2	CTD-2260A17.1	7.34	4.21e-13	1.06e-10	0.35	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96784777~96785999:+
BRCA	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	7.34	4.21e-13	1.06e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-7.34	4.21e-13	1.06e-10	-0.24	-0.22	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	7.34	4.21e-13	1.06e-10	0.26	0.22	Longevity;	chr3:48452692	chr3:48440352~48446656:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	7.34	4.21e-13	1.06e-10	0.3	0.22	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000261582.1	RP4-614O4.11	-7.34	4.23e-13	1.07e-10	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35267885~35280043:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-7.34	4.23e-13	1.07e-10	-0.2	-0.22	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
BRCA	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	7.34	4.23e-13	1.07e-10	0.26	0.22	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
BRCA	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-7.34	4.24e-13	1.07e-10	-0.23	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
BRCA	cis	rs6543140	0.964	rs6736135	ENSG00000234389.1	AC007278.3	7.34	4.24e-13	1.07e-10	0.22	0.22	Blood protein levels;	chr2:102448464	chr2:102438713~102440475:+
BRCA	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	7.34	4.24e-13	1.07e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
BRCA	cis	rs9880211	1	rs12695645	ENSG00000273486.1	RP11-731C17.2	7.34	4.25e-13	1.07e-10	0.29	0.22	Height;Body mass index;	chr3:136272039	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.868	rs2441381	ENSG00000271889.1	RP11-493E12.1	7.34	4.25e-13	1.07e-10	0.29	0.22	Tuberculosis;	chr2:61571694	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	7.34	4.27e-13	1.08e-10	0.27	0.22	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
BRCA	cis	rs755249	0.958	rs61781370	ENSG00000228060.1	RP11-69E11.8	-7.34	4.27e-13	1.08e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39565160~39573203:+
BRCA	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	7.34	4.27e-13	1.08e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
BRCA	cis	rs812925	0.855	rs6545851	ENSG00000271889.1	RP11-493E12.1	-7.34	4.27e-13	1.08e-10	-0.29	-0.22	Immature fraction of reticulocytes;	chr2:61271222	chr2:61151433~61162105:-
BRCA	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-7.34	4.27e-13	1.08e-10	-0.24	-0.22	Height;	chr5:36968438	chr5:36666214~36725195:-
BRCA	cis	rs73173548	0.502	rs13165428	ENSG00000247828.6	TMEM161B-AS1	-7.34	4.28e-13	1.08e-10	-0.29	-0.22	Macular telangiectasia type 2;	chr5:88443945	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	7.34	4.28e-13	1.08e-10	0.27	0.22	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-7.34	4.28e-13	1.08e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	7.34	4.3e-13	1.08e-10	0.32	0.22	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-7.34	4.31e-13	1.09e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
BRCA	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-7.34	4.31e-13	1.09e-10	-0.22	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
BRCA	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	7.34	4.32e-13	1.09e-10	0.3	0.22	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
BRCA	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	7.34	4.34e-13	1.09e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.38e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
BRCA	cis	rs6472827	0.953	rs6472828	ENSG00000253983.2	RP1-16A9.1	-7.34	4.39e-13	1.1e-10	-0.34	-0.22	Uterine fibroids;	chr8:74210961	chr8:74199396~74208441:+
BRCA	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-7.34	4.39e-13	1.1e-10	-0.26	-0.22	Height;	chr2:46611108	chr2:46668870~46670778:+
BRCA	cis	rs9880211	0.948	rs13316214	ENSG00000273486.1	RP11-731C17.2	7.34	4.39e-13	1.11e-10	0.29	0.22	Height;Body mass index;	chr3:136439379	chr3:136837338~136839021:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	7.34	4.4e-13	1.11e-10	0.29	0.22	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
BRCA	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-7.34	4.41e-13	1.11e-10	-0.26	-0.22	Height;	chr2:231516587	chr2:231501990~231502201:-
BRCA	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	7.34	4.41e-13	1.11e-10	0.37	0.22	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
BRCA	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	7.34	4.42e-13	1.11e-10	0.26	0.22	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
BRCA	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	7.34	4.42e-13	1.11e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
BRCA	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-7.34	4.43e-13	1.11e-10	-0.32	-0.22	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
BRCA	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	7.34	4.43e-13	1.12e-10	0.23	0.22	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
BRCA	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	7.34	4.43e-13	1.12e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
BRCA	cis	rs3781264	0.595	rs12220125	ENSG00000273450.1	RP11-76P2.4	7.34	4.44e-13	1.12e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94315182	chr10:94314907~94315327:-
BRCA	cis	rs42648	0.837	rs4728879	ENSG00000225498.1	AC002064.5	7.34	4.45e-13	1.12e-10	0.21	0.22	Homocysteine levels;	chr7:90294923	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000224316.1	RP11-479O9.2	-7.33	4.45e-13	1.12e-10	-0.26	-0.22	Aortic root size;	chr7:66091320	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	7.33	4.47e-13	1.12e-10	0.23	0.22	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
BRCA	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	7.33	4.48e-13	1.13e-10	0.27	0.22	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	7.33	4.48e-13	1.13e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
BRCA	cis	rs858239	1	rs858239	ENSG00000230042.1	AK3P3	-7.33	4.48e-13	1.13e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23129178~23129841:+
BRCA	cis	rs72772090	0.71	rs17400741	ENSG00000248734.2	CTD-2260A17.1	-7.33	4.48e-13	1.13e-10	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-7.33	4.49e-13	1.13e-10	-0.29	-0.22	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
BRCA	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	7.33	4.49e-13	1.13e-10	0.26	0.22	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
BRCA	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-7.33	4.5e-13	1.13e-10	-0.26	-0.22	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
BRCA	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	7.33	4.51e-13	1.13e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
BRCA	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	7.33	4.52e-13	1.14e-10	0.28	0.22	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	7.33	4.52e-13	1.14e-10	0.26	0.22	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	7.33	4.52e-13	1.14e-10	0.26	0.22	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-7.33	4.52e-13	1.14e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
BRCA	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-7.33	4.54e-13	1.14e-10	-0.24	-0.22	Height;	chr5:37019252	chr5:36666214~36725195:-
BRCA	cis	rs516805	0.961	rs544099	ENSG00000279114.1	RP3-425C14.5	7.33	4.54e-13	1.14e-10	0.23	0.22	Lymphocyte counts;	chr6:122479837	chr6:122471923~122484161:+
BRCA	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	7.33	4.56e-13	1.15e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	7.33	4.56e-13	1.15e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-7.33	4.56e-13	1.15e-10	-0.27	-0.22	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-7.33	4.56e-13	1.15e-10	-0.27	-0.22	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000261582.1	RP4-614O4.11	7.33	4.57e-13	1.15e-10	0.24	0.22	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35267885~35280043:-
BRCA	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-7.33	4.58e-13	1.15e-10	-0.29	-0.22	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-7.33	4.59e-13	1.15e-10	-0.14	-0.22	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-7.33	4.59e-13	1.15e-10	-0.14	-0.22	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
BRCA	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-7.33	4.6e-13	1.15e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
BRCA	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	7.33	4.6e-13	1.15e-10	0.31	0.22	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-7.33	4.62e-13	1.16e-10	-0.24	-0.22	Height;	chr5:36990381	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	7.33	4.66e-13	1.17e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
BRCA	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	7.33	4.66e-13	1.17e-10	0.28	0.22	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
BRCA	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	7.33	4.67e-13	1.17e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
BRCA	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	7.33	4.68e-13	1.17e-10	0.27	0.22	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	7.33	4.68e-13	1.17e-10	0.27	0.22	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
BRCA	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	7.33	4.68e-13	1.18e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
BRCA	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	7.33	4.69e-13	1.18e-10	0.31	0.22	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
BRCA	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	7.33	4.69e-13	1.18e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	7.33	4.69e-13	1.18e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
BRCA	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-7.33	4.7e-13	1.18e-10	-0.26	-0.22	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-7.33	4.71e-13	1.18e-10	-0.14	-0.22	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
BRCA	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-7.33	4.71e-13	1.18e-10	-0.32	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
BRCA	cis	rs6723162	0.757	rs4852724	ENSG00000237751.2	LINC01143	-7.33	4.76e-13	1.19e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70889967	chr2:70887871~70889959:+
BRCA	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-7.32	4.78e-13	1.2e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-7.32	4.78e-13	1.2e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000224316.1	RP11-479O9.2	-7.32	4.8e-13	1.2e-10	-0.26	-0.22	Aortic root size;	chr7:66087627	chr7:65773620~65802067:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-7.32	4.81e-13	1.21e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
BRCA	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	7.32	4.81e-13	1.21e-10	0.27	0.22	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
BRCA	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-7.32	4.82e-13	1.21e-10	-0.28	-0.22	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
BRCA	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
BRCA	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	7.32	4.82e-13	1.21e-10	0.26	0.22	Longevity;	chr3:48445949	chr3:48440352~48446656:-
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-7.32	4.84e-13	1.21e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
BRCA	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-7.32	4.85e-13	1.22e-10	-0.29	-0.22	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
BRCA	cis	rs78456975	0.527	rs7590743	ENSG00000231482.2	AC141930.2	-7.32	4.86e-13	1.22e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571276	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs7590742	ENSG00000231482.2	AC141930.2	-7.32	4.86e-13	1.22e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571277	chr2:1572554~1580311:-
BRCA	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	7.32	4.86e-13	1.22e-10	0.22	0.22	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	7.32	4.86e-13	1.22e-10	0.22	0.22	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
BRCA	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	7.32	4.87e-13	1.22e-10	0.41	0.22	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
BRCA	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	7.32	4.88e-13	1.22e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000273024.4	INTS4P2	-7.32	4.9e-13	1.23e-10	-0.25	-0.22	Calcium levels;	chr7:65829754	chr7:65647864~65715661:+
BRCA	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	7.32	4.91e-13	1.23e-10	0.28	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
BRCA	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-7.32	4.91e-13	1.23e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
BRCA	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	7.32	4.92e-13	1.23e-10	0.28	0.22	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
BRCA	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-7.32	4.92e-13	1.23e-10	-0.27	-0.22	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
BRCA	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	7.32	4.96e-13	1.24e-10	0.33	0.22	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000224316.1	RP11-479O9.2	-7.32	4.96e-13	1.24e-10	-0.26	-0.22	Aortic root size;	chr7:66086944	chr7:65773620~65802067:+
BRCA	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	7.32	4.96e-13	1.24e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
BRCA	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	7.32	4.96e-13	1.24e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	7.32	4.97e-13	1.24e-10	0.14	0.22	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
BRCA	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	7.32	4.97e-13	1.24e-10	0.28	0.22	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
BRCA	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-7.32	4.97e-13	1.24e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
BRCA	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	7.32	4.98e-13	1.25e-10	0.28	0.22	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
BRCA	cis	rs6545883	0.929	rs3732170	ENSG00000271889.1	RP11-493E12.1	7.32	4.98e-13	1.25e-10	0.28	0.22	Tuberculosis;	chr2:61522581	chr2:61151433~61162105:-
BRCA	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	7.32	4.98e-13	1.25e-10	0.26	0.22	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
BRCA	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	7.32	4.99e-13	1.25e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
BRCA	cis	rs10206020	0.885	rs11887527	ENSG00000231482.2	AC141930.2	-7.32	5.01e-13	1.25e-10	-0.29	-0.22	IgG glycosylation;	chr2:1574308	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.885	rs11885392	ENSG00000231482.2	AC141930.2	-7.32	5.01e-13	1.25e-10	-0.29	-0.22	IgG glycosylation;	chr2:1574410	chr2:1572554~1580311:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-7.32	5.04e-13	1.26e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
BRCA	cis	rs72772090	0.71	rs17400685	ENSG00000248734.2	CTD-2260A17.1	7.32	5.04e-13	1.26e-10	0.35	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730662	chr5:96784777~96785999:+
BRCA	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
BRCA	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	7.32	5.06e-13	1.27e-10	0.27	0.22	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	7.32	5.06e-13	1.27e-10	0.27	0.22	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
BRCA	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-7.32	5.06e-13	1.27e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000224316.1	RP11-479O9.2	-7.32	5.08e-13	1.27e-10	-0.25	-0.22	Aortic root size;	chr7:66089365	chr7:65773620~65802067:+
BRCA	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	7.32	5.09e-13	1.27e-10	0.26	0.22	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	7.32	5.09e-13	1.27e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	7.32	5.09e-13	1.27e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	7.32	5.1e-13	1.27e-10	0.26	0.22	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs7606167	ENSG00000271889.1	RP11-493E12.1	7.32	5.11e-13	1.28e-10	0.28	0.22	Tuberculosis;	chr2:61515519	chr2:61151433~61162105:-
BRCA	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	7.32	5.11e-13	1.28e-10	0.27	0.22	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-7.32	5.12e-13	1.28e-10	-0.22	-0.22	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	7.31	5.14e-13	1.29e-10	0.51	0.22	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-7.31	5.16e-13	1.29e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
BRCA	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-7.31	5.17e-13	1.29e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
BRCA	cis	rs4845875	0.626	rs10864542	ENSG00000242349.4	NPPA-AS1	7.31	5.17e-13	1.29e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11782087	chr1:11841017~11848079:+
BRCA	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	7.31	5.18e-13	1.29e-10	0.29	0.22	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
BRCA	cis	rs9527	0.551	rs28606370	ENSG00000213061.2	PFN1P11	7.31	5.18e-13	1.29e-10	0.3	0.22	Arsenic metabolism;	chr10:102911075	chr10:102838011~102845473:-
BRCA	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	7.31	5.19e-13	1.3e-10	0.26	0.22	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-7.31	5.2e-13	1.3e-10	-0.27	-0.22	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
BRCA	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-7.31	5.21e-13	1.3e-10	-0.31	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	7.31	5.22e-13	1.3e-10	0.24	0.22	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-7.31	5.23e-13	1.31e-10	-0.22	-0.22	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-7.31	5.23e-13	1.31e-10	-0.24	-0.22	Height;	chr5:36941456	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-7.31	5.24e-13	1.31e-10	-0.32	-0.22	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.8	rs35880395	ENSG00000239213.4	NCK1-AS1	7.31	5.24e-13	1.31e-10	0.3	0.22	Height;Body mass index;	chr3:136788248	chr3:136841726~136862054:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000213640.3	EEF1DP4	-7.31	5.25e-13	1.31e-10	-0.29	-0.22	Calcium levels;	chr7:65825628	chr7:64862999~64864370:+
BRCA	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-7.31	5.25e-13	1.31e-10	-0.24	-0.22	Height;	chr5:36795628	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	7.31	5.26e-13	1.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	7.31	5.26e-13	1.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
BRCA	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	7.31	5.29e-13	1.32e-10	0.27	0.22	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	7.31	5.31e-13	1.32e-10	0.27	0.22	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-7.31	5.32e-13	1.33e-10	-0.29	-0.22	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
BRCA	cis	rs74233809	1	rs11191453	ENSG00000213277.3	MARCKSL1P1	7.31	5.32e-13	1.33e-10	0.41	0.22	Birth weight;	chr10:102900095	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-7.31	5.32e-13	1.33e-10	-0.22	-0.22	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-7.31	5.32e-13	1.33e-10	-0.22	-0.22	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
BRCA	cis	rs6723162	0.965	rs11126307	ENSG00000237751.2	LINC01143	-7.31	5.32e-13	1.33e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70884060	chr2:70887871~70889959:+
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000274973.1	RP13-401N8.7	7.31	5.32e-13	1.33e-10	0.26	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25845497~25845862:+
BRCA	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	7.31	5.33e-13	1.33e-10	0.23	0.22	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.935	rs42664	ENSG00000225498.1	AC002064.5	7.31	5.34e-13	1.33e-10	0.21	0.22	Homocysteine levels;	chr7:90355095	chr7:90312496~90322592:+
BRCA	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-7.31	5.35e-13	1.33e-10	-0.26	-0.22	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-7.31	5.35e-13	1.33e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
BRCA	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	7.31	5.35e-13	1.33e-10	0.3	0.22	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
BRCA	cis	rs42648	0.935	rs42660	ENSG00000225498.1	AC002064.5	7.31	5.35e-13	1.33e-10	0.21	0.22	Homocysteine levels;	chr7:90353208	chr7:90312496~90322592:+
BRCA	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	7.31	5.35e-13	1.33e-10	0.27	0.22	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
BRCA	cis	rs10515750	0.588	rs73815868	ENSG00000251405.2	CTB-109A12.1	7.31	5.36e-13	1.34e-10	0.34	0.22	Lung function (FEV1/FVC);	chr5:157363429	chr5:157362615~157460078:-
BRCA	cis	rs6545883	0.965	rs6545872	ENSG00000271889.1	RP11-493E12.1	7.31	5.36e-13	1.34e-10	0.29	0.22	Tuberculosis;	chr2:61497433	chr2:61151433~61162105:-
BRCA	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-7.31	5.36e-13	1.34e-10	-0.26	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
BRCA	cis	rs3814244	0.528	rs1468487	ENSG00000236946.2	HNRNPA1P70	7.31	5.37e-13	1.34e-10	0.18	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:68035767~68036853:+
BRCA	cis	rs7809950	1	rs10273733	ENSG00000238832.1	snoU109	7.31	5.38e-13	1.34e-10	0.3	0.22	Coronary artery disease;	chr7:107617676	chr7:107603363~107603507:+
BRCA	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	7.31	5.38e-13	1.34e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	7.31	5.38e-13	1.34e-10	0.23	0.22	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
BRCA	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-7.31	5.38e-13	1.34e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
BRCA	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	7.31	5.39e-13	1.34e-10	0.26	0.22	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
BRCA	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	7.31	5.4e-13	1.34e-10	0.24	0.22	Height;	chr5:36941665	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-7.31	5.4e-13	1.35e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
BRCA	cis	rs1861628	0.927	rs737308	ENSG00000237930.1	AC007563.4	7.31	5.4e-13	1.35e-10	0.26	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758526	chr2:216785774~216786144:-
BRCA	cis	rs6740322	0.748	rs6720087	ENSG00000234936.1	AC010883.5	-7.31	5.41e-13	1.35e-10	-0.25	-0.22	Coronary artery disease;	chr2:43241606	chr2:43229573~43233394:+
BRCA	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	7.31	5.41e-13	1.35e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
BRCA	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	7.31	5.42e-13	1.35e-10	0.18	0.22	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
BRCA	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	7.31	5.43e-13	1.35e-10	0.32	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
BRCA	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	7.31	5.44e-13	1.36e-10	0.24	0.22	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
BRCA	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-7.31	5.47e-13	1.36e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
BRCA	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-7.31	5.47e-13	1.36e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
BRCA	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	7.31	5.47e-13	1.36e-10	0.31	0.22	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-7.31	5.5e-13	1.37e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
BRCA	cis	rs755249	0.517	rs66880209	ENSG00000237624.1	OXCT2P1	7.3	5.5e-13	1.37e-10	0.36	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39514956~39516490:+
BRCA	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	7.3	5.52e-13	1.37e-10	0.25	0.22	Longevity;	chr3:48355556	chr3:48256350~48256938:-
BRCA	cis	rs1861628	1	rs737310	ENSG00000237930.1	AC007563.4	7.3	5.52e-13	1.38e-10	0.26	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758503	chr2:216785774~216786144:-
BRCA	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	7.3	5.54e-13	1.38e-10	0.23	0.22	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
BRCA	cis	rs8012947	0.917	rs2145600	ENSG00000279636.2	LINC00216	7.3	5.55e-13	1.38e-10	0.26	0.22	Alcohol consumption in current drinkers;	chr14:58284184	chr14:58288033~58289158:+
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-7.3	5.55e-13	1.38e-10	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
BRCA	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	7.3	5.55e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
BRCA	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	7.3	5.56e-13	1.38e-10	0.29	0.22	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
BRCA	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	7.3	5.56e-13	1.38e-10	0.29	0.22	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-7.3	5.58e-13	1.39e-10	-0.14	-0.22	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
BRCA	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	7.3	5.59e-13	1.39e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.59e-13	1.39e-10	-0.24	-0.22	Height;	chr5:36848456	chr5:36666214~36725195:-
BRCA	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-7.3	5.59e-13	1.39e-10	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
BRCA	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-7.3	5.6e-13	1.39e-10	-0.26	-0.22	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
BRCA	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	7.3	5.61e-13	1.4e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	7.3	5.61e-13	1.4e-10	0.31	0.22	Height;	chr4:55457922	chr4:55387949~55388271:+
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-7.3	5.61e-13	1.4e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
BRCA	cis	rs58873874	0.579	rs35536103	ENSG00000248544.2	CTB-47B11.3	7.3	5.61e-13	1.4e-10	0.46	0.22	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157375741~157384950:-
BRCA	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-7.3	5.62e-13	1.4e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-7.3	5.62e-13	1.4e-10	-0.24	-0.22	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
BRCA	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.64e-13	1.4e-10	-0.24	-0.22	Height;	chr5:37007527	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-7.3	5.64e-13	1.4e-10	-0.29	-0.22	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	7.3	5.65e-13	1.4e-10	0.22	0.22	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-7.3	5.69e-13	1.41e-10	-0.24	-0.22	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.3	5.69e-13	1.42e-10	-0.24	-0.22	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	7.3	5.69e-13	1.42e-10	0.29	0.22	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
BRCA	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	7.3	5.71e-13	1.42e-10	0.3	0.22	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000278665.1	RP11-666O2.4	-7.3	5.71e-13	1.42e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28599241~28601881:-
BRCA	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-7.3	5.73e-13	1.42e-10	-0.28	-0.22	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
BRCA	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-7.3	5.73e-13	1.42e-10	-0.27	-0.22	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.74e-13	1.43e-10	-0.28	-0.22	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
BRCA	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	7.3	5.74e-13	1.43e-10	0.26	0.22	Longevity;	chr3:48358570	chr3:48256350~48256938:-
BRCA	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.75e-13	1.43e-10	-0.24	-0.22	Height;	chr5:37005003	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs13243677	ENSG00000204959.4	ARHGEF34P	7.3	5.75e-13	1.43e-10	0.27	0.22	Obesity-related traits;	chr7:144049479	chr7:144272445~144286966:-
BRCA	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	7.3	5.75e-13	1.43e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	7.3	5.75e-13	1.43e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
BRCA	cis	rs10206020	0.921	rs72776302	ENSG00000231482.2	AC141930.2	-7.3	5.76e-13	1.43e-10	-0.29	-0.22	IgG glycosylation;	chr2:1567611	chr2:1572554~1580311:-
BRCA	cis	rs8012947	0.607	rs1051858	ENSG00000279636.2	LINC00216	7.3	5.77e-13	1.43e-10	0.23	0.22	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58288033~58289158:+
BRCA	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	7.3	5.77e-13	1.43e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
BRCA	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	7.3	5.78e-13	1.44e-10	0.28	0.22	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
BRCA	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	7.3	5.78e-13	1.44e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
BRCA	cis	rs30380	1	rs30378	ENSG00000272109.1	CTD-2260A17.3	-7.3	5.78e-13	1.44e-10	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96804353~96806105:+
BRCA	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-7.3	5.79e-13	1.44e-10	-0.23	-0.22	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
BRCA	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	7.3	5.8e-13	1.44e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
BRCA	cis	rs10206020	0.885	rs11899557	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1572351	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.759	rs11903889	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1572829	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.885	rs6746052	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1573039	chr2:1572554~1580311:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-7.3	5.83e-13	1.45e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
BRCA	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.3	5.83e-13	1.45e-10	-0.23	-0.22	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
BRCA	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	7.3	5.85e-13	1.45e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000236529.1	RP13-254B10.1	7.3	5.86e-13	1.46e-10	0.27	0.22	Aortic root size;	chr7:66169334	chr7:65840212~65840596:+
BRCA	cis	rs847577	0.609	rs11763970	ENSG00000272950.1	RP11-307C18.1	7.3	5.87e-13	1.46e-10	0.29	0.22	Breast cancer;	chr7:98188009	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000232559.3	GS1-124K5.12	-7.3	5.87e-13	1.46e-10	-0.26	-0.22	Aortic root size;	chr7:66333558	chr7:66554588~66576923:-
BRCA	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	7.3	5.87e-13	1.46e-10	0.26	0.22	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
BRCA	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-7.3	5.89e-13	1.46e-10	-0.23	-0.22	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-7.3	5.89e-13	1.46e-10	-0.5	-0.22	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
BRCA	cis	rs7976269	0.537	rs10843303	ENSG00000257176.2	RP11-996F15.2	-7.29	5.92e-13	1.47e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29069435	chr12:29280418~29317848:-
BRCA	cis	rs10206020	0.885	rs13388254	ENSG00000231482.2	AC141930.2	-7.29	5.92e-13	1.47e-10	-0.28	-0.22	IgG glycosylation;	chr2:1573437	chr2:1572554~1580311:-
BRCA	cis	rs13178541	0.748	rs9327727	ENSG00000250378.1	RP11-119J18.1	-7.29	5.93e-13	1.47e-10	-0.3	-0.22	IgG glycosylation;	chr5:135725997	chr5:135812667~135826582:+
BRCA	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-7.29	5.93e-13	1.47e-10	-0.29	-0.22	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000263603.1	CTD-2349P21.5	-7.29	5.98e-13	1.48e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30729469~30731202:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-7.29	6.01e-13	1.49e-10	-0.26	-0.22	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
BRCA	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-7.29	6.01e-13	1.49e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
BRCA	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	7.29	6.02e-13	1.49e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	7.29	6.03e-13	1.5e-10	0.32	0.22	Height;	chr4:55501955	chr4:55387949~55388271:+
BRCA	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	7.29	6.03e-13	1.5e-10	0.18	0.22	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
BRCA	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-7.29	6.06e-13	1.5e-10	-0.26	-0.22	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
BRCA	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	7.29	6.06e-13	1.5e-10	0.26	0.22	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
BRCA	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	7.29	6.06e-13	1.5e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
BRCA	cis	rs6545883	0.868	rs7608483	ENSG00000271889.1	RP11-493E12.1	7.29	6.06e-13	1.5e-10	0.29	0.22	Tuberculosis;	chr2:61609100	chr2:61151433~61162105:-
BRCA	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	7.29	6.07e-13	1.5e-10	0.28	0.22	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-7.29	6.07e-13	1.51e-10	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
BRCA	cis	rs7586673	0.964	rs34444368	ENSG00000235724.7	AC009299.2	-7.29	6.08e-13	1.51e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161222785~161308303:-
BRCA	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
BRCA	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	7.29	6.08e-13	1.51e-10	0.25	0.22	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
BRCA	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-7.29	6.09e-13	1.51e-10	-0.27	-0.22	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	7.29	6.09e-13	1.51e-10	0.21	0.22	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
BRCA	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-7.29	6.1e-13	1.51e-10	-0.24	-0.22	Height;	chr5:37023796	chr5:36666214~36725195:-
BRCA	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-7.29	6.1e-13	1.51e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
BRCA	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-7.29	6.11e-13	1.51e-10	-0.27	-0.22	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.733	rs7081597	ENSG00000271335.4	RP11-324I22.4	7.29	6.11e-13	1.52e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35314552~35336401:-
BRCA	cis	rs6545883	0.868	rs2427885	ENSG00000271889.1	RP11-493E12.1	7.29	6.13e-13	1.52e-10	0.28	0.22	Tuberculosis;	chr2:61589642	chr2:61151433~61162105:-
BRCA	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	7.29	6.13e-13	1.52e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	7.29	6.14e-13	1.52e-10	0.23	0.22	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
BRCA	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-7.29	6.14e-13	1.52e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
BRCA	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	7.29	6.14e-13	1.52e-10	0.31	0.22	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	7.29	6.14e-13	1.52e-10	0.31	0.22	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
BRCA	cis	rs9527	0.571	rs7904113	ENSG00000213061.2	PFN1P11	7.29	6.15e-13	1.52e-10	0.29	0.22	Arsenic metabolism;	chr10:102873357	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-7.29	6.18e-13	1.53e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
BRCA	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-7.29	6.2e-13	1.53e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
BRCA	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	7.29	6.2e-13	1.54e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
BRCA	cis	rs7976269	0.537	rs2117992	ENSG00000257176.2	RP11-996F15.2	-7.29	6.2e-13	1.54e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29070611	chr12:29280418~29317848:-
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-7.29	6.22e-13	1.54e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-7.29	6.23e-13	1.54e-10	-0.25	-0.22	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-7.29	6.23e-13	1.54e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
BRCA	cis	rs2348418	0.639	rs2881788	ENSG00000247934.4	RP11-967K21.1	-7.29	6.24e-13	1.54e-10	-0.26	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28119641	chr12:28163298~28190738:-
BRCA	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-7.29	6.24e-13	1.55e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
BRCA	cis	rs73173548	0.502	rs13165211	ENSG00000247828.6	TMEM161B-AS1	7.29	6.26e-13	1.55e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88443772	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.528	rs68019847	ENSG00000247828.6	TMEM161B-AS1	7.29	6.26e-13	1.55e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88446795	chr5:88268895~88436685:+
BRCA	cis	rs4727443	0.866	rs13238380	ENSG00000235713.1	RP4-604G5.3	-7.29	6.26e-13	1.55e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100031438	chr7:99992397~99993050:+
BRCA	cis	rs3794924	0.925	rs35293326	ENSG00000266521.1	RP11-650P15.1	7.29	6.26e-13	1.55e-10	0.4	0.22	Survival in colon cancer;	chr18:31466467	chr18:31496645~31497195:-
BRCA	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-7.29	6.26e-13	1.55e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
BRCA	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	7.29	6.26e-13	1.55e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
BRCA	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-7.29	6.26e-13	1.55e-10	-0.38	-0.22	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
BRCA	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	7.29	6.27e-13	1.55e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
BRCA	cis	rs6723162	0.868	rs2192403	ENSG00000237751.2	LINC01143	-7.29	6.28e-13	1.55e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70886008	chr2:70887871~70889959:+
BRCA	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-7.29	6.28e-13	1.55e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-7.29	6.29e-13	1.56e-10	-0.24	-0.22	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-7.29	6.29e-13	1.56e-10	-0.24	-0.22	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	7.29	6.29e-13	1.56e-10	0.26	0.22	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
BRCA	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-7.29	6.29e-13	1.56e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
BRCA	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-7.29	6.3e-13	1.56e-10	-0.29	-0.22	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
BRCA	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-7.29	6.31e-13	1.56e-10	-0.27	-0.22	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-7.29	6.31e-13	1.56e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
BRCA	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-7.29	6.32e-13	1.56e-10	-0.5	-0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
BRCA	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-7.28	6.36e-13	1.57e-10	-0.28	-0.22	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.28	6.38e-13	1.58e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
BRCA	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	7.28	6.38e-13	1.58e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
BRCA	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-7.28	6.39e-13	1.58e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	7.28	6.41e-13	1.58e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
BRCA	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	7.28	6.41e-13	1.58e-10	0.31	0.22	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.899	rs1562309	ENSG00000271889.1	RP11-493E12.1	7.28	6.41e-13	1.58e-10	0.29	0.22	Tuberculosis;	chr2:61542991	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.571	rs3740400	ENSG00000213061.2	PFN1P11	7.28	6.42e-13	1.59e-10	0.29	0.22	Arsenic metabolism;	chr10:102869708	chr10:102838011~102845473:-
BRCA	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	7.28	6.42e-13	1.59e-10	0.29	0.22	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
BRCA	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-7.28	6.43e-13	1.59e-10	-0.27	-0.22	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
BRCA	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	7.28	6.43e-13	1.59e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
BRCA	cis	rs1113500	0.547	rs12076264	ENSG00000226822.1	RP11-356N1.2	-7.28	6.43e-13	1.59e-10	-0.28	-0.22	Growth-regulated protein alpha levels;	chr1:108014486	chr1:108071482~108074519:+
BRCA	cis	rs6545883	0.868	rs2518932	ENSG00000271889.1	RP11-493E12.1	7.28	6.43e-13	1.59e-10	0.28	0.22	Tuberculosis;	chr2:61574142	chr2:61151433~61162105:-
BRCA	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	7.28	6.44e-13	1.59e-10	0.42	0.22	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
BRCA	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-7.28	6.46e-13	1.6e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
BRCA	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-7.28	6.46e-13	1.6e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	7.28	6.47e-13	1.6e-10	0.33	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
BRCA	cis	rs253959	0.672	rs1133186	ENSG00000271918.1	CTD-2287O16.5	7.28	6.48e-13	1.6e-10	0.18	0.22	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116083807~116085416:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000222364.1	RNU6-96P	7.28	6.5e-13	1.6e-10	0.25	0.22	Aortic root size;	chr7:66316659	chr7:66395191~66395286:+
BRCA	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-7.28	6.5e-13	1.6e-10	-0.35	-0.22	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
BRCA	cis	rs42648	0.869	rs6973816	ENSG00000225498.1	AC002064.5	7.28	6.5e-13	1.61e-10	0.21	0.22	Homocysteine levels;	chr7:90291758	chr7:90312496~90322592:+
BRCA	cis	rs7586673	0.725	rs6715870	ENSG00000227403.1	AC009299.3	-7.28	6.51e-13	1.61e-10	-0.3	-0.22	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161244739~161249050:+
BRCA	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	7.28	6.52e-13	1.61e-10	0.28	0.22	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
BRCA	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	7.28	6.52e-13	1.61e-10	0.28	0.22	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
BRCA	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	7.28	6.53e-13	1.61e-10	0.27	0.22	Myopia;	chr2:171827893	chr2:171773482~171775844:+
BRCA	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	7.28	6.55e-13	1.62e-10	0.26	0.22	Longevity;	chr3:48357096	chr3:48256350~48256938:-
BRCA	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	7.28	6.56e-13	1.62e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
BRCA	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	7.28	6.57e-13	1.62e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
BRCA	cis	rs42648	0.87	rs7783199	ENSG00000225498.1	AC002064.5	-7.28	6.57e-13	1.62e-10	-0.21	-0.22	Homocysteine levels;	chr7:90369991	chr7:90312496~90322592:+
BRCA	cis	rs12446554	0.509	rs56100071	ENSG00000261195.1	CTD-2380F24.1	-7.28	6.57e-13	1.62e-10	-0.34	-0.22	Obesity;	chr16:19698429	chr16:19761172~19766099:-
BRCA	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	7.28	6.58e-13	1.62e-10	0.26	0.22	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
BRCA	cis	rs9880211	0.8	rs35422852	ENSG00000239213.4	NCK1-AS1	7.28	6.59e-13	1.63e-10	0.29	0.22	Height;Body mass index;	chr3:136787073	chr3:136841726~136862054:-
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
BRCA	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-7.28	6.61e-13	1.63e-10	-0.27	-0.22	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
BRCA	cis	rs6545883	0.965	rs1992765	ENSG00000271889.1	RP11-493E12.1	7.28	6.62e-13	1.63e-10	0.28	0.22	Tuberculosis;	chr2:61524198	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	7.28	6.62e-13	1.63e-10	0.28	0.22	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
BRCA	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-7.28	6.65e-13	1.64e-10	-0.3	-0.22	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
BRCA	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-7.28	6.65e-13	1.64e-10	-0.26	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-7.28	6.65e-13	1.64e-10	-0.37	-0.22	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
BRCA	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-7.28	6.66e-13	1.64e-10	-0.23	-0.22	Height;	chr5:36796728	chr5:36666214~36725195:-
BRCA	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-7.28	6.66e-13	1.64e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-7.28	6.67e-13	1.65e-10	-0.23	-0.22	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.931	rs778768	ENSG00000271889.1	RP11-493E12.1	7.28	6.68e-13	1.65e-10	0.29	0.22	Tuberculosis;	chr2:61563154	chr2:61151433~61162105:-
BRCA	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	7.28	6.7e-13	1.65e-10	0.47	0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
BRCA	cis	rs4727443	0.866	rs2897075	ENSG00000235713.1	RP4-604G5.3	-7.28	6.71e-13	1.66e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100032719	chr7:99992397~99993050:+
BRCA	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	7.28	6.72e-13	1.66e-10	0.28	0.22	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
BRCA	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-7.28	6.72e-13	1.66e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
BRCA	cis	rs11976180	1	rs2961115	ENSG00000204959.4	ARHGEF34P	7.28	6.73e-13	1.66e-10	0.27	0.22	Obesity-related traits;	chr7:144056278	chr7:144272445~144286966:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-7.28	6.74e-13	1.66e-10	-0.26	-0.22	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
BRCA	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-7.28	6.74e-13	1.66e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
BRCA	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	7.28	6.75e-13	1.66e-10	0.31	0.22	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
BRCA	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-7.28	6.76e-13	1.67e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
BRCA	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-7.28	6.76e-13	1.67e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
BRCA	cis	rs4727443	0.866	rs12531809	ENSG00000235713.1	RP4-604G5.3	-7.28	6.76e-13	1.67e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100022850	chr7:99992397~99993050:+
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	7.28	6.77e-13	1.67e-10	0.23	0.22	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
BRCA	cis	rs6545883	1	rs778758	ENSG00000271889.1	RP11-493E12.1	7.28	6.78e-13	1.67e-10	0.29	0.22	Tuberculosis;	chr2:61555026	chr2:61151433~61162105:-
BRCA	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	7.28	6.79e-13	1.67e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-7.28	6.8e-13	1.67e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-7.28	6.8e-13	1.68e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
BRCA	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	7.28	6.8e-13	1.68e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	7.27	6.81e-13	1.68e-10	0.22	0.22	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-7.27	6.82e-13	1.68e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-7.27	6.82e-13	1.68e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-7.27	6.82e-13	1.68e-10	-0.3	-0.22	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
BRCA	cis	rs78456975	0.506	rs10167704	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567265	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs10184112	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567340	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.921	rs72776300	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	IgG glycosylation;	chr2:1567380	chr2:1572554~1580311:-
BRCA	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-7.27	6.83e-13	1.68e-10	-0.26	-0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
BRCA	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-7.27	6.84e-13	1.68e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	7.27	6.84e-13	1.69e-10	0.27	0.22	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	7.27	6.84e-13	1.69e-10	0.27	0.22	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-7.27	6.85e-13	1.69e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-7.27	6.85e-13	1.69e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
BRCA	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-7.27	6.88e-13	1.69e-10	-0.14	-0.22	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
BRCA	cis	rs11976180	1	rs13226728	ENSG00000204959.4	ARHGEF34P	7.27	6.88e-13	1.69e-10	0.27	0.22	Obesity-related traits;	chr7:144049485	chr7:144272445~144286966:-
BRCA	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	7.27	6.89e-13	1.7e-10	0.23	0.22	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	7.27	6.9e-13	1.7e-10	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
BRCA	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	7.27	6.95e-13	1.71e-10	0.39	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
BRCA	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-7.27	6.95e-13	1.71e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
BRCA	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	7.27	6.95e-13	1.71e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.723	rs9684973	ENSG00000211553.1	AC253576.2	-7.27	6.95e-13	1.71e-10	-0.31	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:136461~136568:+
BRCA	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	7.27	6.96e-13	1.71e-10	0.25	0.22	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
BRCA	cis	rs10861661	1	rs10861661	ENSG00000260329.1	RP11-412D9.4	-7.27	6.96e-13	1.71e-10	-0.28	-0.22	Triglyceride levels;	chr12:106780868	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	7.27	6.97e-13	1.71e-10	0.25	0.22	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.27	6.98e-13	1.72e-10	-0.24	-0.22	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs10077326	ENSG00000248544.2	CTB-47B11.3	7.27	6.99e-13	1.72e-10	0.32	0.22	Lung function (FEV1/FVC);	chr5:157343761	chr5:157375741~157384950:-
BRCA	cis	rs10515750	0.588	rs10077470	ENSG00000248544.2	CTB-47B11.3	7.27	6.99e-13	1.72e-10	0.32	0.22	Lung function (FEV1/FVC);	chr5:157343975	chr5:157375741~157384950:-
BRCA	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	7.27	7e-13	1.72e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
BRCA	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	7.27	7e-13	1.72e-10	0.26	0.22	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-7.27	7.01e-13	1.72e-10	-0.27	-0.22	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
BRCA	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-7.27	7.01e-13	1.72e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-7.27	7.01e-13	1.72e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000230042.1	AK3P3	-7.27	7.02e-13	1.73e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23129178~23129841:+
BRCA	cis	rs74233809	1	rs11191499	ENSG00000213277.3	MARCKSL1P1	7.27	7.02e-13	1.73e-10	0.39	0.22	Birth weight;	chr10:103004514	chr10:103175554~103176094:+
BRCA	cis	rs2060793	0.55	rs1037378	ENSG00000251991.1	RNU7-49P	7.27	7.05e-13	1.73e-10	0.24	0.22	Vitamin D levels;	chr11:14830944	chr11:14478892~14478953:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-7.27	7.06e-13	1.74e-10	-0.3	-0.22	Gout;	chr7:66721259	chr7:66848496~66858136:+
BRCA	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-7.27	7.06e-13	1.74e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
BRCA	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	7.27	7.06e-13	1.74e-10	0.27	0.22	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
BRCA	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	7.27	7.06e-13	1.74e-10	0.3	0.22	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.965	rs9989775	ENSG00000271889.1	RP11-493E12.1	7.27	7.07e-13	1.74e-10	0.28	0.22	Tuberculosis;	chr2:61534639	chr2:61151433~61162105:-
BRCA	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	7.27	7.07e-13	1.74e-10	0.25	0.22	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
BRCA	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
BRCA	cis	rs12237653	0.929	rs4741732	ENSG00000236404.7	VLDLR-AS1	7.27	7.07e-13	1.74e-10	0.34	0.22	Gambling;	chr9:2548026	chr9:2422702~2643359:-
BRCA	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-7.27	7.1e-13	1.74e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
BRCA	cis	rs293748	0.54	rs12655320	ENSG00000250155.1	CTD-2353F22.1	-7.27	7.1e-13	1.75e-10	-0.3	-0.22	Obesity-related traits;	chr5:37104756	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	7.27	7.13e-13	1.75e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.929	rs55806663	ENSG00000271889.1	RP11-493E12.1	7.27	7.13e-13	1.75e-10	0.28	0.22	Tuberculosis;	chr2:61513352	chr2:61151433~61162105:-
BRCA	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	7.27	7.14e-13	1.75e-10	0.27	0.22	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
BRCA	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-7.27	7.15e-13	1.76e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-7.27	7.15e-13	1.76e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-7.27	7.16e-13	1.76e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-7.27	7.17e-13	1.76e-10	-0.22	-0.22	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
BRCA	cis	rs9880211	0.898	rs6770476	ENSG00000273486.1	RP11-731C17.2	7.27	7.19e-13	1.77e-10	0.26	0.22	Height;Body mass index;	chr3:136355078	chr3:136837338~136839021:-
BRCA	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	7.27	7.2e-13	1.77e-10	0.21	0.22	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-7.27	7.21e-13	1.77e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-7.27	7.21e-13	1.77e-10	-0.26	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
BRCA	cis	rs9880211	0.8	rs9865995	ENSG00000239213.4	NCK1-AS1	7.27	7.23e-13	1.77e-10	0.29	0.22	Height;Body mass index;	chr3:136794508	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs9871184	ENSG00000239213.4	NCK1-AS1	7.27	7.23e-13	1.77e-10	0.29	0.22	Height;Body mass index;	chr3:136795468	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	7.27	7.24e-13	1.78e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	7.27	7.24e-13	1.78e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
BRCA	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-7.27	7.24e-13	1.78e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.931	rs11125885	ENSG00000271889.1	RP11-493E12.1	7.27	7.24e-13	1.78e-10	0.28	0.22	Tuberculosis;	chr2:61528593	chr2:61151433~61162105:-
BRCA	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-7.27	7.28e-13	1.79e-10	-0.27	-0.22	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs2951368	ENSG00000204959.4	ARHGEF34P	7.26	7.3e-13	1.79e-10	0.27	0.22	Obesity-related traits;	chr7:144055728	chr7:144272445~144286966:-
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	7.26	7.32e-13	1.8e-10	0.26	0.22	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	7.26	7.32e-13	1.8e-10	0.26	0.22	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
BRCA	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-7.26	7.32e-13	1.8e-10	-0.29	-0.22	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
BRCA	cis	rs6545883	1	rs778763	ENSG00000271889.1	RP11-493E12.1	7.26	7.33e-13	1.8e-10	0.28	0.22	Tuberculosis;	chr2:61558504	chr2:61151433~61162105:-
BRCA	cis	rs3814244	0.515	rs2906856	ENSG00000236946.2	HNRNPA1P70	7.26	7.33e-13	1.8e-10	0.18	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:68035767~68036853:+
BRCA	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	7.26	7.35e-13	1.8e-10	0.4	0.22	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	7.26	7.36e-13	1.81e-10	0.26	0.22	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.869	rs10234301	ENSG00000225498.1	AC002064.5	7.26	7.39e-13	1.81e-10	0.21	0.22	Homocysteine levels;	chr7:90288964	chr7:90312496~90322592:+
BRCA	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-7.26	7.39e-13	1.81e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
BRCA	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-7.26	7.39e-13	1.81e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
BRCA	cis	rs73173548	0.502	rs34969608	ENSG00000247828.6	TMEM161B-AS1	7.26	7.41e-13	1.82e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88448606	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs6885165	ENSG00000247828.6	TMEM161B-AS1	7.26	7.41e-13	1.82e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88449705	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	7.26	7.42e-13	1.82e-10	0.28	0.22	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-7.26	7.42e-13	1.82e-10	-0.22	-0.22	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
BRCA	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	7.26	7.43e-13	1.82e-10	0.2	0.22	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000224316.1	RP11-479O9.2	7.26	7.44e-13	1.82e-10	0.25	0.22	Aortic root size;	chr7:66358032	chr7:65773620~65802067:+
BRCA	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	7.26	7.44e-13	1.83e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
BRCA	cis	rs74233809	1	rs35125602	ENSG00000213277.3	MARCKSL1P1	7.26	7.44e-13	1.83e-10	0.41	0.22	Birth weight;	chr10:102896282	chr10:103175554~103176094:+
BRCA	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-7.26	7.46e-13	1.83e-10	-0.23	-0.22	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000224316.1	RP11-479O9.2	-7.26	7.47e-13	1.83e-10	-0.25	-0.22	Aortic root size;	chr7:66624178	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.837	rs12375075	ENSG00000225498.1	AC002064.5	7.26	7.5e-13	1.84e-10	0.21	0.22	Homocysteine levels;	chr7:90311017	chr7:90312496~90322592:+
BRCA	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	7.26	7.5e-13	1.84e-10	0.29	0.22	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
BRCA	cis	rs6545883	0.831	rs9309336	ENSG00000271889.1	RP11-493E12.1	7.26	7.51e-13	1.84e-10	0.28	0.22	Tuberculosis;	chr2:61536030	chr2:61151433~61162105:-
BRCA	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-7.26	7.53e-13	1.84e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
BRCA	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-7.26	7.54e-13	1.85e-10	-0.26	-0.22	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
BRCA	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-7.26	7.57e-13	1.85e-10	-0.26	-0.22	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
BRCA	cis	rs2933343	0.553	rs35076317	ENSG00000261159.1	RP11-723O4.9	7.26	7.57e-13	1.85e-10	0.24	0.22	IgG glycosylation;	chr3:128996692	chr3:128859716~128860526:-
BRCA	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	7.26	7.58e-13	1.86e-10	0.29	0.22	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
BRCA	cis	rs42648	0.72	rs9655741	ENSG00000225498.1	AC002064.5	7.26	7.63e-13	1.87e-10	0.21	0.22	Homocysteine levels;	chr7:90304560	chr7:90312496~90322592:+
BRCA	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	7.26	7.64e-13	1.87e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
BRCA	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.26	7.66e-13	1.87e-10	-0.23	-0.22	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
BRCA	cis	rs9880211	1	rs9880211	ENSG00000273486.1	RP11-731C17.2	7.26	7.66e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136388707	chr3:136837338~136839021:-
BRCA	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	7.26	7.67e-13	1.88e-10	0.27	0.22	QT interval;	chr12:29304617	chr12:29280418~29317848:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000232559.3	GS1-124K5.12	-7.26	7.67e-13	1.88e-10	-0.26	-0.22	Aortic root size;	chr7:66081075	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs115050567	ENSG00000239213.4	NCK1-AS1	7.26	7.67e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136796817	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs9858560	ENSG00000239213.4	NCK1-AS1	7.26	7.67e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136798312	chr3:136841726~136862054:-
BRCA	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-7.26	7.68e-13	1.88e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
BRCA	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	7.26	7.7e-13	1.88e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	7.26	7.73e-13	1.89e-10	0.29	0.22	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
BRCA	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-7.26	7.74e-13	1.89e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
BRCA	cis	rs6740322	0.748	rs6544634	ENSG00000234936.1	AC010883.5	7.26	7.74e-13	1.89e-10	0.24	0.22	Coronary artery disease;	chr2:43244389	chr2:43229573~43233394:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-7.26	7.76e-13	1.9e-10	-0.14	-0.22	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
BRCA	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	7.26	7.76e-13	1.9e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	7.26	7.76e-13	1.9e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
BRCA	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
BRCA	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	7.26	7.77e-13	1.9e-10	0.27	0.22	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
BRCA	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	7.26	7.77e-13	1.9e-10	0.26	0.22	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
BRCA	cis	rs4845875	0.626	rs1889292	ENSG00000242349.4	NPPA-AS1	7.26	7.78e-13	1.9e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11780886	chr1:11841017~11848079:+
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	7.26	7.79e-13	1.9e-10	0.29	0.22	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
BRCA	cis	rs73173548	0.502	rs4129236	ENSG00000247828.6	TMEM161B-AS1	7.26	7.8e-13	1.91e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88441542	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs36077166	ENSG00000247828.6	TMEM161B-AS1	7.26	7.8e-13	1.91e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88441770	chr5:88268895~88436685:+
BRCA	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-7.26	7.8e-13	1.91e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
BRCA	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	7.26	7.81e-13	1.91e-10	0.29	0.22	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
BRCA	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	7.26	7.81e-13	1.91e-10	0.27	0.22	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
BRCA	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-7.26	7.82e-13	1.91e-10	-0.27	-0.22	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000229212.6	RP11-561C5.4	7.26	7.82e-13	1.91e-10	0.25	0.22	P wave terminal force;	chr15:84818413	chr15:85205440~85234795:-
BRCA	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	7.26	7.83e-13	1.91e-10	0.3	0.22	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
BRCA	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	7.25	7.84e-13	1.92e-10	0.37	0.22	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
BRCA	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-7.25	7.84e-13	1.92e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
BRCA	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	7.25	7.86e-13	1.92e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
BRCA	cis	rs34779708	0.733	rs4007271	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.702	rs4007272	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4934740	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.702	rs4244995	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4244997	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4298846	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4391768	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs7914468	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs7914560	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4444023	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs12243593	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs3936502	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35314552~35336401:-
BRCA	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	7.25	7.87e-13	1.92e-10	0.22	0.22	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-7.25	7.88e-13	1.92e-10	-0.23	-0.22	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
BRCA	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-7.25	7.88e-13	1.93e-10	-0.25	-0.22	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
BRCA	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	-7.25	7.88e-13	1.93e-10	-0.28	-0.22	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
BRCA	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-7.25	7.89e-13	1.93e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
BRCA	cis	rs4845875	0.535	rs4846045	ENSG00000242349.4	NPPA-AS1	7.25	7.89e-13	1.93e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11780323	chr1:11841017~11848079:+
BRCA	cis	rs6545883	0.965	rs1562308	ENSG00000271889.1	RP11-493E12.1	7.25	7.89e-13	1.93e-10	0.28	0.22	Tuberculosis;	chr2:61541286	chr2:61151433~61162105:-
BRCA	cis	rs1900504	0.509	rs11197779	ENSG00000266200.5	PNLIPRP2	7.25	7.89e-13	1.93e-10	0.36	0.22	Tonsillectomy;	chr10:116644721	chr10:116620953~116645143:+
BRCA	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	7.25	7.9e-13	1.93e-10	0.38	0.22	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	7.25	7.91e-13	1.93e-10	0.37	0.22	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
BRCA	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-7.25	7.91e-13	1.93e-10	-0.29	-0.22	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-7.25	7.93e-13	1.94e-10	-0.26	-0.22	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
BRCA	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	7.25	7.93e-13	1.94e-10	0.18	0.22	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
BRCA	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-7.25	7.93e-13	1.94e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-7.25	7.95e-13	1.94e-10	-0.24	-0.22	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
BRCA	cis	rs3126085	0.935	rs11204934	ENSG00000237975.5	FLG-AS1	7.25	7.96e-13	1.94e-10	0.31	0.22	Atopic dermatitis;	chr1:152204372	chr1:152168125~152445456:+
BRCA	cis	rs3781264	0.595	rs7084988	ENSG00000273450.1	RP11-76P2.4	7.25	8e-13	1.95e-10	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94314907~94315327:-
BRCA	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	7.25	8.01e-13	1.96e-10	0.28	0.22	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
BRCA	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	7.25	8.03e-13	1.96e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
BRCA	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
BRCA	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	7.25	8.06e-13	1.97e-10	0.22	0.22	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
BRCA	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-7.25	8.08e-13	1.97e-10	-0.28	-0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	7.25	8.09e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000261582.1	RP4-614O4.11	-7.25	8.1e-13	1.98e-10	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35267885~35280043:-
BRCA	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-7.25	8.1e-13	1.98e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
BRCA	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	7.25	8.11e-13	1.98e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
BRCA	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	7.25	8.13e-13	1.98e-10	0.38	0.22	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
BRCA	cis	rs473651	0.901	rs563282	ENSG00000229915.1	AC016999.2	-7.25	8.13e-13	1.98e-10	-0.28	-0.22	Multiple system atrophy;	chr2:238421095	chr2:238427077~238427729:-
BRCA	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-7.25	8.14e-13	1.99e-10	-0.29	-0.22	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-7.25	8.14e-13	1.99e-10	-0.29	-0.22	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
BRCA	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	7.25	8.14e-13	1.99e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
BRCA	cis	rs72772090	0.71	rs11750400	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.71	rs10515244	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.71	rs1559085	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96784777~96785999:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-7.25	8.17e-13	1.99e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
BRCA	cis	rs1853665	1	rs9383993	ENSG00000231760.4	RP11-350J20.5	-7.25	8.17e-13	1.99e-10	-0.33	-0.22	Radiation response;	chr6:149978163	chr6:149796151~149826294:-
BRCA	cis	rs3794924	1	rs35242229	ENSG00000266521.1	RP11-650P15.1	7.25	8.18e-13	2e-10	0.4	0.22	Survival in colon cancer;	chr18:31472920	chr18:31496645~31497195:-
BRCA	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	7.25	8.18e-13	2e-10	0.4	0.22	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
BRCA	cis	rs9402682	0.596	rs9494149	ENSG00000232876.1	CTA-212D2.2	7.25	8.18e-13	2e-10	0.31	0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135128177	chr6:135055033~135060550:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	7.25	8.18e-13	2e-10	0.34	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
BRCA	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	7.25	8.2e-13	2e-10	0.26	0.22	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
BRCA	cis	rs6543140	0.964	rs6761350	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102414316	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.929	rs7602207	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102415906	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs2160200	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102417503	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	7.25	8.22e-13	2.01e-10	0.27	0.22	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
BRCA	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-7.25	8.22e-13	2.01e-10	-0.26	-0.22	Height;	chr2:46641180	chr2:46668870~46670778:+
BRCA	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	7.25	8.22e-13	2.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	7.25	8.23e-13	2.01e-10	0.2	0.22	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
BRCA	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	7.25	8.24e-13	2.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
BRCA	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	7.25	8.29e-13	2.02e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
BRCA	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.25	8.29e-13	2.02e-10	-0.33	-0.22	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-7.25	8.29e-13	2.02e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-7.25	8.29e-13	2.02e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
BRCA	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	7.25	8.32e-13	2.03e-10	0.21	0.22	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
BRCA	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-7.25	8.33e-13	2.03e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
BRCA	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	7.25	8.33e-13	2.03e-10	0.26	0.22	Longevity;	chr3:48363659	chr3:48256350~48256938:-
BRCA	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-7.25	8.33e-13	2.03e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
BRCA	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-7.25	8.33e-13	2.03e-10	-0.29	-0.22	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
BRCA	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	7.25	8.33e-13	2.03e-10	0.32	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-7.25	8.34e-13	2.03e-10	-0.22	-0.22	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-7.25	8.35e-13	2.03e-10	-0.23	-0.22	Height;	chr5:36789899	chr5:36666214~36725195:-
BRCA	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	7.25	8.37e-13	2.04e-10	0.31	0.22	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
BRCA	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	7.25	8.37e-13	2.04e-10	0.28	0.22	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
BRCA	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-7.25	8.38e-13	2.04e-10	-0.25	-0.22	Longevity;	chr3:48393626	chr3:48256350~48256938:-
BRCA	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	7.25	8.38e-13	2.04e-10	0.23	0.22	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-7.25	8.39e-13	2.04e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
BRCA	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-7.24	8.41e-13	2.05e-10	-0.28	-0.22	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
BRCA	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-7.24	8.41e-13	2.05e-10	-0.26	-0.22	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
BRCA	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-7.24	8.43e-13	2.05e-10	-0.25	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
BRCA	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	7.24	8.43e-13	2.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	7.24	8.43e-13	2.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	7.24	8.43e-13	2.05e-10	0.21	0.22	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
BRCA	cis	rs4727443	0.866	rs13243708	ENSG00000235713.1	RP4-604G5.3	-7.24	8.46e-13	2.06e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100018668	chr7:99992397~99993050:+
BRCA	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	7.24	8.46e-13	2.06e-10	0.24	0.22	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	7.24	8.47e-13	2.06e-10	0.23	0.22	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	7.24	8.5e-13	2.07e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
BRCA	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	7.24	8.5e-13	2.07e-10	0.26	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
BRCA	cis	rs6543140	0.964	rs4851578	ENSG00000234389.1	AC007278.3	7.24	8.5e-13	2.07e-10	0.22	0.22	Blood protein levels;	chr2:102412491	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-7.24	8.51e-13	2.07e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.929	rs13413337	ENSG00000271889.1	RP11-493E12.1	7.24	8.53e-13	2.07e-10	0.28	0.22	Tuberculosis;	chr2:61519988	chr2:61151433~61162105:-
BRCA	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	7.24	8.54e-13	2.08e-10	0.3	0.22	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
BRCA	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	7.24	8.57e-13	2.09e-10	0.37	0.22	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
BRCA	cis	rs9527	0.545	rs35756290	ENSG00000213061.2	PFN1P11	7.24	8.59e-13	2.09e-10	0.33	0.22	Arsenic metabolism;	chr10:102825815	chr10:102838011~102845473:-
BRCA	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-7.24	8.6e-13	2.09e-10	-0.33	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-7.24	8.62e-13	2.1e-10	-0.26	-0.22	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
BRCA	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-7.24	8.68e-13	2.11e-10	-0.24	-0.22	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
BRCA	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-7.24	8.68e-13	2.11e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
BRCA	cis	rs6740322	0.948	rs6722694	ENSG00000234936.1	AC010883.5	7.24	8.68e-13	2.11e-10	0.24	0.22	Coronary artery disease;	chr2:43342659	chr2:43229573~43233394:+
BRCA	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	7.24	8.69e-13	2.11e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
BRCA	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-7.24	8.7e-13	2.12e-10	-0.3	-0.22	Gout;	chr7:66679692	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	7.24	8.7e-13	2.12e-10	0.3	0.22	Gout;	chr7:66682070	chr7:66848496~66858136:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	7.24	8.7e-13	2.12e-10	0.3	0.22	Gout;	chr7:66682162	chr7:66848496~66858136:+
BRCA	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	7.24	8.72e-13	2.12e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
BRCA	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-7.24	8.72e-13	2.12e-10	-0.27	-0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
BRCA	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-7.24	8.73e-13	2.12e-10	-0.26	-0.22	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-7.24	8.75e-13	2.13e-10	-0.14	-0.22	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
BRCA	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-7.24	8.75e-13	2.13e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000224316.1	RP11-479O9.2	-7.24	8.76e-13	2.13e-10	-0.22	-0.22	Aortic root size;	chr7:66185134	chr7:65773620~65802067:+
BRCA	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-7.24	8.78e-13	2.13e-10	-0.37	-0.22	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
BRCA	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	7.24	8.78e-13	2.13e-10	0.29	0.22	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
BRCA	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-7.24	8.79e-13	2.14e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-7.24	8.79e-13	2.14e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
BRCA	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-7.24	8.79e-13	2.14e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
BRCA	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
BRCA	cis	rs6723162	0.965	rs7594319	ENSG00000237751.2	LINC01143	-7.24	8.81e-13	2.14e-10	-0.25	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70891627	chr2:70887871~70889959:+
BRCA	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-7.24	8.81e-13	2.14e-10	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
BRCA	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	7.24	8.82e-13	2.14e-10	0.18	0.22	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
BRCA	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	7.24	8.82e-13	2.14e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	7.24	8.82e-13	2.14e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
BRCA	cis	rs7927771	0.689	rs10734557	ENSG00000280615.1	Y_RNA	7.24	8.82e-13	2.14e-10	0.27	0.22	Subjective well-being;	chr11:47358510	chr11:47614898~47614994:-
BRCA	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-7.24	8.84e-13	2.15e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
BRCA	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	7.24	8.86e-13	2.15e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
BRCA	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-7.24	8.88e-13	2.16e-10	-0.21	-0.22	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.24	8.89e-13	2.16e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
BRCA	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	7.24	8.89e-13	2.16e-10	0.21	0.22	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	7.24	8.9e-13	2.16e-10	0.23	0.22	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	7.24	8.9e-13	2.16e-10	0.23	0.22	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
BRCA	cis	rs7474896	0.559	rs1735641	ENSG00000226578.1	RP11-258F22.1	7.24	8.9e-13	2.16e-10	0.29	0.22	Obesity (extreme);	chr10:37895924	chr10:37775371~37784131:-
BRCA	cis	rs9880211	1	rs9841529	ENSG00000273486.1	RP11-731C17.2	7.24	8.94e-13	2.17e-10	0.29	0.22	Height;Body mass index;	chr3:136418441	chr3:136837338~136839021:-
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	7.24	8.95e-13	2.17e-10	0.21	0.22	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-7.24	8.95e-13	2.17e-10	-0.25	-0.22	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-7.24	8.96e-13	2.18e-10	-0.3	-0.22	Gout;	chr7:66732812	chr7:66848496~66858136:+
BRCA	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-7.24	8.96e-13	2.18e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
BRCA	cis	rs74233809	1	rs10883815	ENSG00000213277.3	MARCKSL1P1	7.24	8.97e-13	2.18e-10	0.41	0.22	Birth weight;	chr10:102979422	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs112390216	ENSG00000213277.3	MARCKSL1P1	7.24	8.97e-13	2.18e-10	0.41	0.22	Birth weight;	chr10:102981274	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	7.24	8.99e-13	2.18e-10	0.31	0.22	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
BRCA	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	7.24	9e-13	2.18e-10	0.37	0.22	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
BRCA	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	7.23	9.01e-13	2.19e-10	0.26	0.22	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
BRCA	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	7.23	9.01e-13	2.19e-10	0.26	0.22	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000261582.1	RP4-614O4.11	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35267885~35280043:-
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-7.23	9.04e-13	2.19e-10	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
BRCA	cis	rs74233809	0.892	rs11191447	ENSG00000213277.3	MARCKSL1P1	7.23	9.05e-13	2.2e-10	0.41	0.22	Birth weight;	chr10:102892566	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs74233296	ENSG00000213277.3	MARCKSL1P1	7.23	9.05e-13	2.2e-10	0.41	0.22	Birth weight;	chr10:102895593	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-7.23	9.06e-13	2.2e-10	-0.3	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
BRCA	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-7.23	9.06e-13	2.2e-10	-0.26	-0.22	Height;	chr2:46609300	chr2:46668870~46670778:+
BRCA	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-7.23	9.07e-13	2.2e-10	-0.24	-0.22	Height;	chr5:37088525	chr5:36666214~36725195:-
BRCA	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	7.23	9.1e-13	2.21e-10	0.32	0.22	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
BRCA	cis	rs875971	1	rs6460292	ENSG00000232559.3	GS1-124K5.12	-7.23	9.1e-13	2.21e-10	-0.26	-0.22	Aortic root size;	chr7:66345088	chr7:66554588~66576923:-
BRCA	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	7.23	9.11e-13	2.21e-10	0.4	0.22	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
BRCA	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	7.23	9.11e-13	2.21e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
BRCA	cis	rs3814244	0.528	rs7962511	ENSG00000236946.2	HNRNPA1P70	-7.23	9.14e-13	2.22e-10	-0.19	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:68035767~68036853:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-7.23	9.14e-13	2.22e-10	-0.23	-0.22	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
BRCA	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	7.23	9.19e-13	2.23e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
BRCA	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	7.23	9.2e-13	2.23e-10	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
BRCA	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	7.23	9.22e-13	2.24e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
BRCA	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	7.23	9.23e-13	2.24e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
BRCA	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-7.23	9.23e-13	2.24e-10	-0.24	-0.22	Height;	chr5:36997725	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	7.23	9.23e-13	2.24e-10	0.25	0.22	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	7.23	9.28e-13	2.25e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	7.23	9.28e-13	2.25e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
BRCA	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-7.23	9.29e-13	2.25e-10	-0.22	-0.22	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
BRCA	cis	rs6545883	0.929	rs7563678	ENSG00000271889.1	RP11-493E12.1	-7.23	9.32e-13	2.26e-10	-0.28	-0.22	Tuberculosis;	chr2:61514676	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000230042.1	AK3P3	-7.23	9.33e-13	2.26e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
BRCA	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	7.23	9.35e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	7.23	9.35e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	7.23	9.36e-13	2.27e-10	0.2	0.22	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
BRCA	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-7.23	9.36e-13	2.27e-10	-0.24	-0.22	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
BRCA	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-7.23	9.37e-13	2.27e-10	-0.33	-0.22	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	7.23	9.38e-13	2.27e-10	0.28	0.22	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
BRCA	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	7.23	9.38e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
BRCA	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-7.23	9.38e-13	2.27e-10	-0.27	-0.22	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
BRCA	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-7.23	9.39e-13	2.27e-10	-0.21	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
BRCA	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-7.23	9.39e-13	2.27e-10	-0.21	-0.22	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
BRCA	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-7.23	9.4e-13	2.28e-10	-0.27	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
BRCA	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
BRCA	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-7.23	9.42e-13	2.28e-10	-0.32	-0.22	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
BRCA	cis	rs6545883	0.929	rs6545877	ENSG00000271889.1	RP11-493E12.1	7.23	9.44e-13	2.29e-10	0.28	0.22	Tuberculosis;	chr2:61514812	chr2:61151433~61162105:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-7.23	9.46e-13	2.29e-10	-0.23	-0.22	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
BRCA	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	7.23	9.48e-13	2.29e-10	0.27	0.22	Height;	chr14:74458694	chr14:74471930~74472360:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-7.23	9.48e-13	2.29e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
BRCA	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	7.23	9.49e-13	2.3e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
BRCA	cis	rs2933343	0.533	rs13086121	ENSG00000261159.1	RP11-723O4.9	7.23	9.5e-13	2.3e-10	0.24	0.22	IgG glycosylation;	chr3:128985447	chr3:128859716~128860526:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000232559.3	GS1-124K5.12	-7.23	9.5e-13	2.3e-10	-0.26	-0.22	Aortic root size;	chr7:66341672	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	7.23	9.53e-13	2.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
BRCA	cis	rs9880211	1	rs9809988	ENSG00000273486.1	RP11-731C17.2	7.23	9.54e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136803379	chr3:136837338~136839021:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-7.23	9.55e-13	2.31e-10	-0.14	-0.22	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
BRCA	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	7.23	9.56e-13	2.31e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
BRCA	cis	rs11976180	1	rs2951364	ENSG00000204959.4	ARHGEF34P	7.23	9.58e-13	2.32e-10	0.27	0.22	Obesity-related traits;	chr7:144057390	chr7:144272445~144286966:-
BRCA	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.23	9.58e-13	2.32e-10	-0.23	-0.22	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-7.23	9.58e-13	2.32e-10	-0.26	-0.22	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	7.23	9.6e-13	2.32e-10	0.27	0.22	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
BRCA	cis	rs74233809	1	rs11191551	ENSG00000213277.3	MARCKSL1P1	7.23	9.61e-13	2.32e-10	0.41	0.22	Birth weight;	chr10:103091078	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs17094683	ENSG00000213277.3	MARCKSL1P1	7.23	9.61e-13	2.32e-10	0.41	0.22	Birth weight;	chr10:103091544	chr10:103175554~103176094:+
BRCA	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-7.23	9.62e-13	2.33e-10	-0.25	-0.22	Height;	chr14:75119585	chr14:75011269~75012851:-
BRCA	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-7.23	9.62e-13	2.33e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000254174.1	IGHV1-12	7.23	9.62e-13	2.33e-10	0.24	0.22	Alzheimer's disease (late onset);	chr14:106680831	chr14:106122420~106122709:-
BRCA	cis	rs9527	0.662	rs743575	ENSG00000213061.2	PFN1P11	7.23	9.62e-13	2.33e-10	0.31	0.22	Arsenic metabolism;	chr10:102835149	chr10:102838011~102845473:-
BRCA	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	7.23	9.63e-13	2.33e-10	0.28	0.22	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
BRCA	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
BRCA	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	7.23	9.65e-13	2.33e-10	0.18	0.22	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
BRCA	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-7.23	9.65e-13	2.33e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
BRCA	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	7.23	9.66e-13	2.34e-10	0.3	0.22	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
BRCA	cis	rs13178541	0.81	rs4976465	ENSG00000250378.1	RP11-119J18.1	-7.22	9.69e-13	2.34e-10	-0.3	-0.22	IgG glycosylation;	chr5:135815226	chr5:135812667~135826582:+
BRCA	cis	rs79040073	0.637	rs73398276	ENSG00000259531.2	RP11-295H24.3	7.22	9.69e-13	2.34e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49418782	chr15:49365124~49366685:-
BRCA	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-7.22	9.7e-13	2.34e-10	-0.33	-0.22	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
BRCA	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	7.22	9.71e-13	2.35e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-7.22	9.72e-13	2.35e-10	-0.28	-0.22	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
BRCA	cis	rs58873874	0.579	rs80253028	ENSG00000248544.2	CTB-47B11.3	7.22	9.75e-13	2.36e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157375741~157384950:-
BRCA	cis	rs9880211	0.679	rs9818740	ENSG00000273486.1	RP11-731C17.2	7.22	9.76e-13	2.36e-10	0.29	0.22	Height;Body mass index;	chr3:136220744	chr3:136837338~136839021:-
BRCA	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-7.22	9.77e-13	2.36e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
BRCA	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	7.22	9.78e-13	2.36e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	7.22	9.8e-13	2.37e-10	0.31	0.22	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
BRCA	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	7.22	9.8e-13	2.37e-10	0.29	0.22	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-7.22	9.81e-13	2.37e-10	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.746	rs969734	ENSG00000251411.1	RP11-397E7.4	-7.22	9.81e-13	2.37e-10	-0.32	-0.22	Insulin-related traits;	chr4:86744231	chr4:86913266~86914817:-
BRCA	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	7.22	9.81e-13	2.37e-10	0.29	0.22	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
BRCA	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	7.22	9.86e-13	2.38e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
BRCA	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	7.22	9.86e-13	2.38e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	7.22	9.87e-13	2.38e-10	0.26	0.22	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
BRCA	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-7.22	9.88e-13	2.39e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	7.22	9.89e-13	2.39e-10	0.26	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
BRCA	cis	rs7474896	0.559	rs1208779	ENSG00000226578.1	RP11-258F22.1	-7.22	9.92e-13	2.4e-10	-0.29	-0.22	Obesity (extreme);	chr10:37788801	chr10:37775371~37784131:-
BRCA	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	7.22	9.94e-13	2.4e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
BRCA	cis	rs6543140	0.964	rs62154972	ENSG00000234389.1	AC007278.3	7.22	9.94e-13	2.4e-10	0.22	0.22	Blood protein levels;	chr2:102432278	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	7.22	9.94e-13	2.4e-10	0.29	0.22	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-7.22	9.94e-13	2.4e-10	-0.3	-0.22	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
BRCA	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	7.22	9.99e-13	2.41e-10	0.26	0.22	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
BRCA	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	7.22	1e-12	2.41e-10	0.29	0.22	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
BRCA	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	7.22	1e-12	2.41e-10	0.29	0.22	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000224316.1	RP11-479O9.2	-7.22	1e-12	2.42e-10	-0.25	-0.22	Aortic root size;	chr7:66156017	chr7:65773620~65802067:+
BRCA	cis	rs10515750	0.588	rs11743536	ENSG00000251405.2	CTB-109A12.1	-7.22	1e-12	2.42e-10	-0.33	-0.22	Lung function (FEV1/FVC);	chr5:157347044	chr5:157362615~157460078:-
BRCA	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	7.22	1e-12	2.42e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	7.22	1e-12	2.42e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000230042.1	AK3P3	-7.22	1.01e-12	2.43e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23129178~23129841:+
BRCA	cis	rs3781264	0.687	rs11187900	ENSG00000273450.1	RP11-76P2.4	7.22	1.01e-12	2.43e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94348607	chr10:94314907~94315327:-
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	7.22	1.01e-12	2.44e-10	0.23	0.22	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
BRCA	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	7.22	1.01e-12	2.44e-10	0.2	0.22	Breast size;	chr12:9228263	chr12:9277235~9313241:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-7.22	1.02e-12	2.45e-10	-0.14	-0.22	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
BRCA	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	7.22	1.02e-12	2.45e-10	0.25	0.22	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
BRCA	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	7.22	1.02e-12	2.46e-10	0.2	0.22	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-7.22	1.02e-12	2.46e-10	-0.27	-0.22	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-7.22	1.02e-12	2.46e-10	-0.14	-0.22	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
BRCA	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-7.22	1.02e-12	2.46e-10	-0.25	-0.22	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
BRCA	cis	rs9880211	1	rs13071220	ENSG00000273486.1	RP11-731C17.2	7.22	1.02e-12	2.47e-10	0.29	0.22	Height;Body mass index;	chr3:136595277	chr3:136837338~136839021:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-7.22	1.02e-12	2.47e-10	-0.24	-0.22	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
BRCA	cis	rs6545883	0.965	rs3771258	ENSG00000271889.1	RP11-493E12.1	7.22	1.02e-12	2.47e-10	0.28	0.22	Tuberculosis;	chr2:61537005	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	7.22	1.03e-12	2.47e-10	0.22	0.22	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	7.22	1.03e-12	2.49e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
BRCA	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-7.22	1.03e-12	2.49e-10	-0.31	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-7.22	1.03e-12	2.49e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
BRCA	cis	rs11976180	1	rs2951363	ENSG00000204959.4	ARHGEF34P	7.22	1.04e-12	2.5e-10	0.27	0.22	Obesity-related traits;	chr7:144057631	chr7:144272445~144286966:-
BRCA	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	7.22	1.04e-12	2.5e-10	0.28	0.22	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-7.21	1.04e-12	2.5e-10	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-7.21	1.04e-12	2.5e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
BRCA	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	7.21	1.04e-12	2.5e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
BRCA	cis	rs202072	0.652	rs453695	ENSG00000272379.1	RP1-257A7.5	-7.21	1.04e-12	2.51e-10	-0.35	-0.22	HIV-1 viral setpoint;	chr6:13262274	chr6:13290018~13290490:-
BRCA	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	7.21	1.04e-12	2.51e-10	0.25	0.22	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
BRCA	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-7.21	1.04e-12	2.51e-10	-0.2	-0.22	Height;	chr11:118703207	chr11:118791254~118793137:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	7.21	1.04e-12	2.52e-10	0.14	0.22	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-7.21	1.05e-12	2.52e-10	-0.26	-0.22	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	7.21	1.05e-12	2.52e-10	0.21	0.22	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
BRCA	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	7.21	1.05e-12	2.52e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
BRCA	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-7.21	1.05e-12	2.53e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-7.21	1.05e-12	2.53e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
BRCA	cis	rs9880211	0.8	rs13314357	ENSG00000273486.1	RP11-731C17.2	7.21	1.06e-12	2.54e-10	0.29	0.22	Height;Body mass index;	chr3:136768717	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
BRCA	cis	rs34779708	0.741	rs34397613	ENSG00000271335.4	RP11-324I22.4	7.21	1.06e-12	2.55e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	7.21	1.06e-12	2.55e-10	0.29	0.22	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
BRCA	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-7.21	1.06e-12	2.55e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
BRCA	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	7.21	1.06e-12	2.55e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
BRCA	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	7.21	1.06e-12	2.55e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
BRCA	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	7.21	1.06e-12	2.56e-10	0.25	0.22	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
BRCA	cis	rs7247513	1	rs2042947	ENSG00000230310.1	CTD-2192J16.11	-7.21	1.06e-12	2.56e-10	-0.27	-0.22	Bipolar disorder;	chr19:12582289	chr19:12552597~12553644:+
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-7.21	1.06e-12	2.56e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-7.21	1.07e-12	2.56e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000204959.4	ARHGEF34P	7.21	1.07e-12	2.57e-10	0.27	0.22	Obesity-related traits;	chr7:144054709	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2951369	ENSG00000204959.4	ARHGEF34P	7.21	1.07e-12	2.57e-10	0.27	0.22	Obesity-related traits;	chr7:144055545	chr7:144272445~144286966:-
BRCA	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	7.21	1.07e-12	2.57e-10	0.31	0.22	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	7.21	1.07e-12	2.58e-10	0.3	0.22	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	7.21	1.07e-12	2.59e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
BRCA	cis	rs2014572	0.933	rs8107516	ENSG00000268379.1	CTC-360J11.4	7.21	1.08e-12	2.59e-10	0.27	0.22	Hyperactive-impulsive symptoms;	chr19:57247077	chr19:57175233~57177921:+
BRCA	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	7.21	1.08e-12	2.59e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
BRCA	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-7.21	1.08e-12	2.6e-10	-0.27	-0.22	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-7.21	1.08e-12	2.6e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
BRCA	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-7.21	1.08e-12	2.6e-10	-0.26	-0.22	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
BRCA	cis	rs12237653	0.929	rs10966858	ENSG00000236404.7	VLDLR-AS1	7.21	1.08e-12	2.6e-10	0.35	0.22	Gambling;	chr9:2541910	chr9:2422702~2643359:-
BRCA	cis	rs3781264	1	rs11187851	ENSG00000273450.1	RP11-76P2.4	7.21	1.08e-12	2.6e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94310118	chr10:94314907~94315327:-
BRCA	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-7.21	1.08e-12	2.6e-10	-0.28	-0.22	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
BRCA	cis	rs6740322	0.901	rs2163228	ENSG00000234936.1	AC010883.5	7.21	1.08e-12	2.61e-10	0.26	0.22	Coronary artery disease;	chr2:43322107	chr2:43229573~43233394:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-7.21	1.08e-12	2.61e-10	-0.22	-0.22	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
BRCA	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-7.21	1.09e-12	2.63e-10	-0.54	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
BRCA	cis	rs4845875	0.557	rs6659541	ENSG00000242349.4	NPPA-AS1	7.21	1.09e-12	2.63e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776385	chr1:11841017~11848079:+
BRCA	cis	rs9527	0.662	rs4919687	ENSG00000213061.2	PFN1P11	7.21	1.09e-12	2.63e-10	0.31	0.22	Arsenic metabolism;	chr10:102835491	chr10:102838011~102845473:-
BRCA	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-7.21	1.1e-12	2.64e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
BRCA	cis	rs4934494	0.768	rs12572608	ENSG00000240996.1	RP11-80H5.7	7.21	1.1e-12	2.65e-10	0.28	0.22	Red blood cell count;	chr10:89647170	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	7.21	1.1e-12	2.65e-10	0.24	0.22	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs2885510	ENSG00000244380.1	RP11-24C3.2	-7.21	1.1e-12	2.65e-10	-0.25	-0.22	Longevity;	chr3:48376736	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs725309	ENSG00000244380.1	RP11-24C3.2	-7.21	1.1e-12	2.65e-10	-0.25	-0.22	Longevity;	chr3:48377218	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	7.21	1.1e-12	2.65e-10	0.31	0.22	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
BRCA	cis	rs7621025	0.664	rs6439657	ENSG00000239213.4	NCK1-AS1	-7.21	1.1e-12	2.66e-10	-0.27	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136841726~136862054:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-7.21	1.11e-12	2.66e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
BRCA	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-7.21	1.11e-12	2.66e-10	-0.32	-0.22	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
BRCA	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	7.21	1.11e-12	2.66e-10	0.25	0.22	Longevity;	chr3:48361812	chr3:48256350~48256938:-
BRCA	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-7.21	1.11e-12	2.66e-10	-0.25	-0.22	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
BRCA	cis	rs9527	0.637	rs7085104	ENSG00000236937.2	PTGES3P4	7.21	1.11e-12	2.66e-10	0.29	0.22	Arsenic metabolism;	chr10:102869116	chr10:102845595~102845950:+
BRCA	cis	rs9880211	1	rs9828976	ENSG00000273486.1	RP11-731C17.2	7.21	1.11e-12	2.67e-10	0.29	0.22	Height;Body mass index;	chr3:136817993	chr3:136837338~136839021:-
BRCA	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	7.21	1.11e-12	2.67e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
BRCA	cis	rs7474896	0.537	rs2505255	ENSG00000226578.1	RP11-258F22.1	-7.2	1.11e-12	2.68e-10	-0.28	-0.22	Obesity (extreme);	chr10:38070714	chr10:37775371~37784131:-
BRCA	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-7.2	1.11e-12	2.68e-10	-0.19	-0.22	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
BRCA	cis	rs3781264	0.595	rs7085378	ENSG00000273450.1	RP11-76P2.4	7.2	1.11e-12	2.68e-10	0.28	0.22	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94314907~94315327:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-7.2	1.11e-12	2.68e-10	-0.26	-0.22	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-7.2	1.12e-12	2.68e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
BRCA	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-7.2	1.12e-12	2.69e-10	-0.33	-0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
BRCA	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	7.2	1.12e-12	2.69e-10	0.23	0.22	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
BRCA	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	7.2	1.12e-12	2.7e-10	0.23	0.22	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
BRCA	cis	rs9880211	0.8	rs75901823	ENSG00000273486.1	RP11-731C17.2	7.2	1.12e-12	2.7e-10	0.29	0.22	Height;Body mass index;	chr3:136775309	chr3:136837338~136839021:-
BRCA	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
BRCA	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
BRCA	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-7.2	1.13e-12	2.71e-10	-0.27	-0.22	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	7.2	1.13e-12	2.71e-10	0.15	0.22	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
BRCA	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
BRCA	cis	rs2906856	0.921	rs1019076	ENSG00000236946.2	HNRNPA1P70	7.2	1.13e-12	2.72e-10	0.18	0.22	Mosquito bite size;	chr12:68004338	chr12:68035767~68036853:+
BRCA	cis	rs10861661	0.963	rs11113118	ENSG00000260329.1	RP11-412D9.4	-7.2	1.13e-12	2.72e-10	-0.27	-0.22	Triglyceride levels;	chr12:106805364	chr12:106954029~106955497:-
BRCA	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-7.2	1.13e-12	2.73e-10	-0.23	-0.22	Height;	chr5:36791710	chr5:36666214~36725195:-
BRCA	cis	rs67311347	1	rs11129876	ENSG00000280739.1	EIF1B-AS1	-7.2	1.13e-12	2.73e-10	-0.24	-0.22	Renal cell carcinoma;	chr3:40360145	chr3:40173145~40309698:-
BRCA	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	7.2	1.14e-12	2.73e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
BRCA	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	7.2	1.14e-12	2.73e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
BRCA	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-7.2	1.14e-12	2.74e-10	-0.33	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
BRCA	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	7.2	1.14e-12	2.75e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
BRCA	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	7.2	1.14e-12	2.75e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-7.2	1.15e-12	2.75e-10	-0.26	-0.22	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
BRCA	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	7.2	1.15e-12	2.75e-10	0.28	0.22	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
BRCA	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	7.2	1.15e-12	2.75e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	7.2	1.15e-12	2.75e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
BRCA	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	7.2	1.15e-12	2.75e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
BRCA	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	7.2	1.15e-12	2.75e-10	0.24	0.22	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
BRCA	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-7.2	1.15e-12	2.76e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
BRCA	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	7.2	1.15e-12	2.76e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
BRCA	cis	rs7520050	0.751	rs592214	ENSG00000280836.1	AL355480.1	7.2	1.15e-12	2.76e-10	0.26	0.22	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45581219~45581321:-
BRCA	cis	rs78456975	0.657	rs116217838	ENSG00000231482.2	AC141930.2	-7.2	1.15e-12	2.77e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1565401	chr2:1572554~1580311:-
BRCA	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	7.2	1.15e-12	2.77e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	7.2	1.15e-12	2.77e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
BRCA	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-7.2	1.15e-12	2.77e-10	-0.54	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
BRCA	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	7.2	1.15e-12	2.77e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
BRCA	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-7.2	1.16e-12	2.78e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-7.2	1.16e-12	2.78e-10	-0.22	-0.22	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000263603.1	CTD-2349P21.5	-7.2	1.16e-12	2.78e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30729469~30731202:+
BRCA	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	7.2	1.16e-12	2.78e-10	0.29	0.22	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
BRCA	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	7.2	1.16e-12	2.78e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
BRCA	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	7.2	1.16e-12	2.79e-10	0.24	0.22	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	7.2	1.16e-12	2.79e-10	0.25	0.22	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
BRCA	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	7.2	1.16e-12	2.79e-10	0.31	0.22	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
BRCA	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-7.2	1.16e-12	2.79e-10	-0.24	-0.22	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
BRCA	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-7.2	1.16e-12	2.79e-10	-0.2	-0.22	Height;	chr11:118703185	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-7.2	1.16e-12	2.79e-10	-0.2	-0.22	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
BRCA	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	7.2	1.17e-12	2.8e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
BRCA	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	7.2	1.17e-12	2.8e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
BRCA	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-7.2	1.17e-12	2.8e-10	-0.27	-0.22	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
BRCA	cis	rs2348418	0.798	rs7310297	ENSG00000247934.4	RP11-967K21.1	7.2	1.17e-12	2.81e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs4740696	ENSG00000236404.7	VLDLR-AS1	7.2	1.17e-12	2.81e-10	0.34	0.22	Gambling;	chr9:2548106	chr9:2422702~2643359:-
BRCA	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	7.2	1.17e-12	2.82e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
BRCA	cis	rs74233809	1	rs12221064	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102917369	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs77602510	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102922845	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs78821730	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102924787	chr10:103175554~103176094:+
BRCA	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	7.2	1.18e-12	2.82e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
BRCA	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	7.2	1.18e-12	2.82e-10	0.19	0.22	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-7.2	1.18e-12	2.82e-10	-0.24	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
BRCA	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-7.2	1.18e-12	2.82e-10	-0.21	-0.22	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
BRCA	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	7.2	1.18e-12	2.83e-10	0.21	0.22	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
BRCA	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-7.2	1.18e-12	2.83e-10	-0.24	-0.22	Height;	chr5:36963703	chr5:36666214~36725195:-
BRCA	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-7.2	1.18e-12	2.83e-10	-0.29	-0.22	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
BRCA	cis	rs12237653	0.799	rs12684409	ENSG00000236404.7	VLDLR-AS1	-7.2	1.18e-12	2.83e-10	-0.32	-0.22	Gambling;	chr9:2546716	chr9:2422702~2643359:-
BRCA	cis	rs79040073	0.607	rs17400706	ENSG00000259531.2	RP11-295H24.3	7.2	1.18e-12	2.84e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49455148	chr15:49365124~49366685:-
BRCA	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-7.2	1.19e-12	2.84e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
BRCA	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-7.2	1.19e-12	2.84e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
BRCA	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	7.2	1.19e-12	2.84e-10	0.2	0.22	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
BRCA	cis	rs911555	0.755	rs2756132	ENSG00000244691.1	RPL10AP1	7.2	1.19e-12	2.85e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103412119~103412761:-
BRCA	cis	rs3760982	0.967	rs3760984	ENSG00000267058.1	RP11-15A1.3	-7.2	1.19e-12	2.85e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43891804~43901805:-
BRCA	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-7.2	1.19e-12	2.85e-10	-0.25	-0.22	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	7.19	1.19e-12	2.86e-10	0.3	0.22	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
BRCA	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-7.19	1.19e-12	2.86e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
BRCA	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-7.19	1.19e-12	2.86e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
BRCA	cis	rs30380	1	rs30379	ENSG00000272109.1	CTD-2260A17.3	-7.19	1.2e-12	2.87e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96804353~96806105:+
BRCA	cis	rs30380	1	rs30380	ENSG00000272109.1	CTD-2260A17.3	-7.19	1.2e-12	2.87e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96804353~96806105:+
BRCA	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-7.19	1.2e-12	2.87e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
BRCA	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	7.19	1.2e-12	2.88e-10	0.18	0.22	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
BRCA	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	7.19	1.2e-12	2.88e-10	0.22	0.22	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
BRCA	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
BRCA	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	7.19	1.21e-12	2.9e-10	0.25	0.22	Longevity;	chr3:48398713	chr3:48440352~48446656:-
BRCA	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-7.19	1.21e-12	2.91e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	7.19	1.23e-12	2.93e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
BRCA	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	7.19	1.23e-12	2.93e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
BRCA	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	7.19	1.23e-12	2.93e-10	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	7.19	1.23e-12	2.93e-10	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
BRCA	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-7.19	1.23e-12	2.94e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-7.19	1.23e-12	2.94e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
BRCA	cis	rs8054556	0.692	rs7201384	ENSG00000273724.1	RP11-347C12.12	-7.19	1.23e-12	2.94e-10	-0.24	-0.22	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30336400~30343336:+
BRCA	cis	rs78456975	0.506	rs13402886	ENSG00000231482.2	AC141930.2	-7.19	1.23e-12	2.94e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571576	chr2:1572554~1580311:-
BRCA	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	7.19	1.23e-12	2.95e-10	0.36	0.22	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	7.19	1.23e-12	2.95e-10	0.36	0.22	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
BRCA	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	7.19	1.23e-12	2.95e-10	0.27	0.22	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-7.19	1.24e-12	2.96e-10	-0.23	-0.22	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
BRCA	cis	rs7520050	0.751	rs2991975	ENSG00000280836.1	AL355480.1	7.19	1.24e-12	2.96e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45581219~45581321:-
BRCA	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	7.19	1.24e-12	2.96e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	7.19	1.24e-12	2.96e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
BRCA	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	7.19	1.24e-12	2.97e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	7.19	1.24e-12	2.97e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
BRCA	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	7.19	1.24e-12	2.98e-10	0.4	0.22	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
BRCA	cis	rs6740322	0.895	rs11684601	ENSG00000234936.1	AC010883.5	7.19	1.25e-12	2.98e-10	0.24	0.22	Coronary artery disease;	chr2:43347103	chr2:43229573~43233394:+
BRCA	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-7.19	1.25e-12	2.98e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
BRCA	cis	rs17253792	0.822	rs17746106	ENSG00000186615.9	KTN1-AS1	-7.19	1.25e-12	2.99e-10	-0.37	-0.22	Putamen volume;	chr14:55602450	chr14:55499278~55580110:-
BRCA	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-7.19	1.26e-12	3e-10	-0.23	-0.22	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
BRCA	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-7.19	1.26e-12	3.01e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-7.19	1.26e-12	3.01e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-7.19	1.26e-12	3.02e-10	-0.23	-0.22	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
BRCA	cis	rs7474896	0.583	rs1208770	ENSG00000226578.1	RP11-258F22.1	-7.19	1.26e-12	3.02e-10	-0.29	-0.22	Obesity (extreme);	chr10:37755755	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.526	rs1742235	ENSG00000226578.1	RP11-258F22.1	-7.19	1.26e-12	3.02e-10	-0.29	-0.22	Obesity (extreme);	chr10:37763328	chr10:37775371~37784131:-
BRCA	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	7.19	1.26e-12	3.02e-10	0.25	0.22	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
BRCA	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-7.19	1.27e-12	3.03e-10	-0.21	-0.22	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
BRCA	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-7.19	1.27e-12	3.03e-10	-0.28	-0.22	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
BRCA	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	7.19	1.27e-12	3.03e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
BRCA	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	7.19	1.27e-12	3.03e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
BRCA	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-7.19	1.27e-12	3.03e-10	-0.24	-0.22	Height;	chr5:36995103	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	7.19	1.27e-12	3.03e-10	0.29	0.22	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
BRCA	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-7.19	1.27e-12	3.04e-10	-0.29	-0.22	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
BRCA	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	7.19	1.27e-12	3.04e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	7.19	1.27e-12	3.04e-10	0.25	0.22	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
BRCA	cis	rs2286503	1	rs17724311	ENSG00000228649.7	AC005682.5	7.19	1.28e-12	3.05e-10	0.19	0.22	Fibrinogen;	chr7:22837174	chr7:22854178~22861579:+
BRCA	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	7.19	1.28e-12	3.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
BRCA	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-7.18	1.28e-12	3.06e-10	-0.25	-0.22	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-7.18	1.28e-12	3.06e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
BRCA	cis	rs2074409	0.53	rs7224979	ENSG00000276054.1	RP11-378E13.3	-7.18	1.28e-12	3.06e-10	-0.3	-0.22	Response to angiotensin II receptor blocker therapy;	chr17:37593525	chr17:37386886~37387926:+
BRCA	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.18	1.28e-12	3.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
BRCA	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-7.18	1.28e-12	3.07e-10	-0.3	-0.22	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
BRCA	cis	rs9880211	0.8	rs34324561	ENSG00000273486.1	RP11-731C17.2	7.18	1.28e-12	3.07e-10	0.29	0.22	Height;Body mass index;	chr3:136382400	chr3:136837338~136839021:-
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	7.18	1.29e-12	3.07e-10	0.34	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
BRCA	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.18	1.29e-12	3.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs62390102	ENSG00000251405.2	CTB-109A12.1	7.18	1.29e-12	3.08e-10	0.33	0.22	Lung function (FEV1/FVC);	chr5:157354934	chr5:157362615~157460078:-
BRCA	cis	rs72772090	0.71	rs11750399	ENSG00000248734.2	CTD-2260A17.1	-7.18	1.29e-12	3.08e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96784777~96785999:+
BRCA	cis	rs7586673	1	rs7586673	ENSG00000235724.7	AC009299.2	-7.18	1.29e-12	3.08e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161222785~161308303:-
BRCA	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	7.18	1.29e-12	3.09e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
BRCA	cis	rs919433	0.963	rs1896857	ENSG00000231621.1	AC013264.2	7.18	1.29e-12	3.09e-10	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197299806	chr2:197197991~197199273:+
BRCA	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-7.18	1.3e-12	3.1e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-7.18	1.3e-12	3.1e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	7.18	1.3e-12	3.1e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
BRCA	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	7.18	1.3e-12	3.1e-10	0.23	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
BRCA	cis	rs7131987	0.565	rs10743652	ENSG00000275476.1	RP11-996F15.4	7.18	1.3e-12	3.11e-10	0.25	0.22	QT interval;	chr12:29255074	chr12:29277397~29277882:-
BRCA	cis	rs73173548	0.502	rs12189501	ENSG00000247828.6	TMEM161B-AS1	-7.18	1.3e-12	3.11e-10	-0.29	-0.22	Macular telangiectasia type 2;	chr5:88462208	chr5:88268895~88436685:+
BRCA	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	7.18	1.31e-12	3.11e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	7.18	1.31e-12	3.12e-10	0.26	0.22	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.18	1.31e-12	3.13e-10	-0.23	-0.22	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
BRCA	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-7.18	1.31e-12	3.13e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
BRCA	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-7.18	1.32e-12	3.14e-10	-0.27	-0.22	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
BRCA	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	7.18	1.32e-12	3.14e-10	0.25	0.22	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
BRCA	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	7.18	1.32e-12	3.15e-10	0.28	0.22	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
BRCA	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	7.18	1.32e-12	3.15e-10	0.29	0.22	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	7.18	1.32e-12	3.15e-10	0.29	0.22	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
BRCA	cis	rs812925	1	rs4672441	ENSG00000271889.1	RP11-493E12.1	-7.18	1.32e-12	3.15e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr2:61411817	chr2:61151433~61162105:-
BRCA	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-7.18	1.32e-12	3.15e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
BRCA	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	7.18	1.33e-12	3.16e-10	0.32	0.22	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
BRCA	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-7.18	1.33e-12	3.16e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
BRCA	cis	rs3794924	1	rs3810005	ENSG00000266521.1	RP11-650P15.1	7.18	1.33e-12	3.17e-10	0.4	0.22	Survival in colon cancer;	chr18:31473913	chr18:31496645~31497195:-
BRCA	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	7.18	1.33e-12	3.17e-10	0.2	0.22	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
BRCA	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-7.18	1.33e-12	3.18e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
BRCA	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	7.18	1.33e-12	3.18e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-7.18	1.33e-12	3.18e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-7.18	1.33e-12	3.18e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
BRCA	cis	rs4845875	0.626	rs12735869	ENSG00000242349.4	NPPA-AS1	7.18	1.34e-12	3.2e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11774106	chr1:11841017~11848079:+
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-7.18	1.35e-12	3.21e-10	-0.39	-0.22	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
BRCA	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-7.18	1.35e-12	3.21e-10	-0.19	-0.22	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
BRCA	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	7.18	1.35e-12	3.21e-10	0.3	0.22	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
BRCA	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-7.18	1.36e-12	3.24e-10	-0.28	-0.22	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
BRCA	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-7.18	1.36e-12	3.24e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
BRCA	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-7.18	1.36e-12	3.24e-10	-0.23	-0.22	Height;	chr5:37239138	chr5:36666214~36725195:-
BRCA	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	7.18	1.36e-12	3.25e-10	0.23	0.22	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
BRCA	cis	rs42648	0.935	rs42668	ENSG00000225498.1	AC002064.5	7.18	1.37e-12	3.25e-10	0.21	0.22	Homocysteine levels;	chr7:90357211	chr7:90312496~90322592:+
BRCA	cis	rs74233809	1	rs3740390	ENSG00000213277.3	MARCKSL1P1	7.18	1.37e-12	3.26e-10	0.39	0.22	Birth weight;	chr10:102878723	chr10:103175554~103176094:+
BRCA	cis	rs10515750	0.656	rs112839393	ENSG00000248544.2	CTB-47B11.3	7.18	1.37e-12	3.26e-10	0.45	0.22	Lung function (FEV1/FVC);	chr5:157282304	chr5:157375741~157384950:-
BRCA	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	7.17	1.37e-12	3.27e-10	0.28	0.22	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
BRCA	cis	rs9880211	0.8	rs9819856	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773307	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs36109616	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773561	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs35198484	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773795	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.66	rs9289514	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136774361	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs79876804	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136775308	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.706	rs35716521	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136775828	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs35210994	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136777294	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs17365792	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136778550	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	7.17	1.38e-12	3.28e-10	0.21	0.22	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
BRCA	cis	rs812925	1	rs812925	ENSG00000271889.1	RP11-493E12.1	-7.17	1.38e-12	3.28e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr2:61453858	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	7.17	1.38e-12	3.29e-10	0.24	0.22	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
BRCA	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-7.17	1.38e-12	3.29e-10	-0.21	-0.22	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
BRCA	cis	rs2348418	0.832	rs11611406	ENSG00000247934.4	RP11-967K21.1	7.17	1.39e-12	3.29e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.832	rs11611382	ENSG00000247934.4	RP11-967K21.1	7.17	1.39e-12	3.29e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28163298~28190738:-
BRCA	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-7.17	1.39e-12	3.3e-10	-0.26	-0.22	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
BRCA	cis	rs13178541	0.683	rs4036630	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135752980	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.748	rs7379672	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135754136	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs11950793	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135754394	chr5:135812667~135826582:+
BRCA	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-7.17	1.39e-12	3.31e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
BRCA	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
BRCA	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
BRCA	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
BRCA	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	7.17	1.39e-12	3.31e-10	0.28	0.22	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
BRCA	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	7.17	1.39e-12	3.31e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
BRCA	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-7.17	1.4e-12	3.32e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
BRCA	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	7.17	1.4e-12	3.32e-10	0.36	0.22	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
BRCA	cis	rs6545883	0.965	rs2305156	ENSG00000271889.1	RP11-493E12.1	7.17	1.4e-12	3.32e-10	0.28	0.22	Tuberculosis;	chr2:61502133	chr2:61151433~61162105:-
BRCA	cis	rs10181042	0.565	rs2564117	ENSG00000271889.1	RP11-493E12.1	7.17	1.4e-12	3.33e-10	0.27	0.22	Crohn's disease;	chr2:61005887	chr2:61151433~61162105:-
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	7.17	1.4e-12	3.33e-10	0.3	0.22	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
BRCA	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	7.17	1.41e-12	3.34e-10	0.25	0.22	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-7.17	1.41e-12	3.34e-10	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-7.17	1.41e-12	3.34e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-7.17	1.41e-12	3.34e-10	-0.26	-0.22	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-7.17	1.41e-12	3.34e-10	-0.26	-0.22	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
BRCA	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-7.17	1.41e-12	3.35e-10	-0.23	-0.22	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
BRCA	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	7.17	1.41e-12	3.36e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
BRCA	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	7.17	1.41e-12	3.36e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-7.17	1.42e-12	3.36e-10	-0.26	-0.22	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
BRCA	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-7.17	1.42e-12	3.37e-10	-0.26	-0.22	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
BRCA	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-7.17	1.42e-12	3.37e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
BRCA	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	7.17	1.42e-12	3.37e-10	0.23	0.22	Height;	chr5:36789552	chr5:36666214~36725195:-
BRCA	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-7.17	1.42e-12	3.37e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
BRCA	cis	rs11976180	1	rs2951372	ENSG00000204959.4	ARHGEF34P	7.17	1.43e-12	3.39e-10	0.27	0.22	Obesity-related traits;	chr7:144052410	chr7:144272445~144286966:-
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-7.17	1.43e-12	3.39e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
BRCA	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-7.17	1.43e-12	3.4e-10	-0.2	-0.22	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
BRCA	cis	rs3760982	1	rs3760982	ENSG00000267058.1	RP11-15A1.3	-7.17	1.44e-12	3.41e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-7.17	1.44e-12	3.41e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
BRCA	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-7.17	1.44e-12	3.41e-10	-0.28	-0.22	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
BRCA	cis	rs4787491	0.658	rs11647753	ENSG00000273724.1	RP11-347C12.12	7.17	1.44e-12	3.42e-10	0.24	0.22	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-7.17	1.44e-12	3.42e-10	-0.25	-0.22	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	7.17	1.45e-12	3.44e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
BRCA	cis	rs13178541	0.81	rs2304074	ENSG00000250378.1	RP11-119J18.1	7.17	1.45e-12	3.44e-10	0.29	0.22	IgG glycosylation;	chr5:135824368	chr5:135812667~135826582:+
BRCA	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	7.17	1.45e-12	3.45e-10	0.43	0.22	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
BRCA	cis	rs9876781	0.967	rs2885509	ENSG00000244380.1	RP11-24C3.2	-7.17	1.46e-12	3.46e-10	-0.25	-0.22	Longevity;	chr3:48376729	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
BRCA	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	7.17	1.46e-12	3.47e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	7.17	1.46e-12	3.47e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
BRCA	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	7.17	1.46e-12	3.47e-10	0.23	0.22	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
BRCA	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	7.17	1.47e-12	3.48e-10	0.28	0.22	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000236529.1	RP13-254B10.1	-7.17	1.47e-12	3.48e-10	-0.27	-0.22	Aortic root size;	chr7:66100789	chr7:65840212~65840596:+
BRCA	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	7.17	1.47e-12	3.48e-10	0.27	0.22	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	7.16	1.47e-12	3.49e-10	0.3	0.22	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
BRCA	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	7.16	1.47e-12	3.49e-10	0.25	0.22	Longevity;	chr3:48455358	chr3:48440352~48446656:-
BRCA	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	7.16	1.47e-12	3.49e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
BRCA	cis	rs42648	0.748	rs12673914	ENSG00000225498.1	AC002064.5	7.16	1.48e-12	3.5e-10	0.21	0.22	Homocysteine levels;	chr7:90314075	chr7:90312496~90322592:+
BRCA	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	7.16	1.48e-12	3.5e-10	0.2	0.22	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	7.16	1.48e-12	3.51e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
BRCA	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	7.16	1.48e-12	3.51e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
BRCA	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	7.16	1.48e-12	3.52e-10	0.27	0.22	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-7.16	1.49e-12	3.52e-10	-0.26	-0.22	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.965	rs11887205	ENSG00000271889.1	RP11-493E12.1	7.16	1.49e-12	3.53e-10	0.28	0.22	Tuberculosis;	chr2:61547338	chr2:61151433~61162105:-
BRCA	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	7.16	1.49e-12	3.54e-10	0.22	0.22	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
BRCA	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-7.16	1.5e-12	3.55e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-7.16	1.5e-12	3.55e-10	-0.23	-0.22	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-7.16	1.5e-12	3.55e-10	-0.26	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	7.16	1.5e-12	3.55e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-7.16	1.5e-12	3.56e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
BRCA	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-7.16	1.5e-12	3.56e-10	-0.29	-0.22	Gout;	chr7:66715944	chr7:66848496~66858136:+
BRCA	cis	rs8012947	0.651	rs74055634	ENSG00000279636.2	LINC00216	7.16	1.5e-12	3.56e-10	0.23	0.22	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58288033~58289158:+
BRCA	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	7.16	1.51e-12	3.57e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-7.16	1.51e-12	3.57e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	7.16	1.51e-12	3.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
BRCA	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	7.16	1.51e-12	3.58e-10	0.3	0.22	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
BRCA	cis	rs10446497	0.585	rs13074050	ENSG00000272359.1	U4	7.16	1.51e-12	3.59e-10	0.3	0.22	Schizophrenia;	chr3:196816270	chr3:196747192~196747324:-
BRCA	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	7.16	1.52e-12	3.59e-10	0.28	0.22	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
BRCA	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-7.16	1.52e-12	3.59e-10	-0.34	-0.22	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
BRCA	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-7.16	1.52e-12	3.61e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	7.16	1.52e-12	3.61e-10	0.26	0.22	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
BRCA	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	7.16	1.52e-12	3.61e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
BRCA	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-7.16	1.53e-12	3.61e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
BRCA	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	7.16	1.53e-12	3.62e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-7.16	1.53e-12	3.62e-10	-0.29	-0.22	Gout;	chr7:66693028	chr7:66848496~66858136:+
BRCA	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
BRCA	cis	rs7976269	0.559	rs4930848	ENSG00000257176.2	RP11-996F15.2	-7.16	1.53e-12	3.62e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29068441	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	7.16	1.53e-12	3.62e-10	0.25	0.22	QT interval;	chr12:29262863	chr12:29280418~29317848:-
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000230042.1	AK3P3	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23129178~23129841:+
BRCA	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	7.16	1.53e-12	3.62e-10	0.18	0.22	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	7.16	1.53e-12	3.63e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
BRCA	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-7.16	1.53e-12	3.63e-10	-0.32	-0.22	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
BRCA	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	7.16	1.54e-12	3.64e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
BRCA	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	7.16	1.54e-12	3.64e-10	0.25	0.22	QT interval;	chr12:29264843	chr12:29280418~29317848:-
BRCA	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	7.16	1.54e-12	3.65e-10	0.26	0.22	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
BRCA	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-7.16	1.54e-12	3.65e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
BRCA	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	7.16	1.55e-12	3.66e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
BRCA	cis	rs34779708	0.733	rs4102764	ENSG00000271335.4	RP11-324I22.4	7.16	1.55e-12	3.66e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35314552~35336401:-
BRCA	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	7.16	1.55e-12	3.66e-10	0.24	0.22	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-7.16	1.55e-12	3.67e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66692349	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66693433	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66694214	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66701371	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66702658	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66706390	chr7:66848496~66858136:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66710076	chr7:66848496~66858136:+
BRCA	cis	rs12237653	0.929	rs13284385	ENSG00000236404.7	VLDLR-AS1	7.16	1.55e-12	3.68e-10	0.34	0.22	Gambling;	chr9:2544001	chr9:2422702~2643359:-
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	7.16	1.56e-12	3.68e-10	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
BRCA	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	7.16	1.56e-12	3.68e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-7.16	1.56e-12	3.68e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
BRCA	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-7.16	1.56e-12	3.69e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-7.16	1.56e-12	3.7e-10	-0.22	-0.22	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
BRCA	cis	rs12237653	0.929	rs4741731	ENSG00000236404.7	VLDLR-AS1	7.16	1.57e-12	3.72e-10	0.35	0.22	Gambling;	chr9:2547959	chr9:2422702~2643359:-
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
BRCA	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-7.15	1.58e-12	3.74e-10	-0.28	-0.22	Height;	chr20:49254902	chr20:49280319~49280409:+
BRCA	cis	rs9527	0.662	rs10786714	ENSG00000213061.2	PFN1P11	7.15	1.59e-12	3.76e-10	0.31	0.22	Arsenic metabolism;	chr10:102838849	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.15	1.6e-12	3.77e-10	0.29	0.22	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
BRCA	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	7.15	1.6e-12	3.78e-10	0.29	0.22	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.79e-10	0.29	0.22	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
BRCA	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-7.15	1.61e-12	3.79e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000230042.1	AK3P3	-7.15	1.61e-12	3.8e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23129178~23129841:+
BRCA	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	7.15	1.61e-12	3.81e-10	0.3	0.22	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
BRCA	cis	rs9880211	0.613	rs28535121	ENSG00000273486.1	RP11-731C17.2	7.15	1.62e-12	3.82e-10	0.28	0.22	Height;Body mass index;	chr3:136173956	chr3:136837338~136839021:-
BRCA	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	7.15	1.62e-12	3.82e-10	0.36	0.22	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
BRCA	cis	rs9880211	0.718	rs35320690	ENSG00000273486.1	RP11-731C17.2	-7.15	1.62e-12	3.82e-10	-0.27	-0.22	Height;Body mass index;	chr3:136213652	chr3:136837338~136839021:-
BRCA	cis	rs858267	1	rs858267	ENSG00000226816.2	AC005082.12	7.15	1.62e-12	3.82e-10	0.54	0.22	Blood protein levels;	chr7:23170510	chr7:23206013~23208045:+
BRCA	cis	rs4845875	0.602	rs4846043	ENSG00000242349.4	NPPA-AS1	7.15	1.62e-12	3.83e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11779909	chr1:11841017~11848079:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-7.15	1.62e-12	3.83e-10	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
BRCA	cis	rs4072705	1	rs10760370	ENSG00000224020.1	MIR181A2HG	-7.15	1.62e-12	3.83e-10	-0.24	-0.22	Menarche (age at onset);	chr9:124655724	chr9:124658467~124698631:+
BRCA	cis	rs7474896	0.515	rs675628	ENSG00000226578.1	RP11-258F22.1	7.15	1.62e-12	3.83e-10	0.28	0.22	Obesity (extreme);	chr10:38016403	chr10:37775371~37784131:-
BRCA	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	7.15	1.63e-12	3.84e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
BRCA	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	7.15	1.63e-12	3.85e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-7.15	1.64e-12	3.87e-10	-0.19	-0.22	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
BRCA	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	7.15	1.64e-12	3.88e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	7.15	1.64e-12	3.88e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
BRCA	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-7.15	1.64e-12	3.88e-10	-0.21	-0.22	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
BRCA	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-7.15	1.64e-12	3.88e-10	-0.21	-0.22	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	7.15	1.65e-12	3.89e-10	0.25	0.22	Longevity;	chr3:48396724	chr3:48440352~48446656:-
BRCA	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.89e-10	0.4	0.22	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.89e-10	0.4	0.22	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs12221193	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.9e-10	0.41	0.22	Birth weight;	chr10:102905510	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs77180047	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.9e-10	0.41	0.22	Birth weight;	chr10:102907000	chr10:103175554~103176094:+
BRCA	cis	rs7474896	0.515	rs594594	ENSG00000226578.1	RP11-258F22.1	7.15	1.66e-12	3.92e-10	0.28	0.22	Obesity (extreme);	chr10:38018795	chr10:37775371~37784131:-
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-7.15	1.66e-12	3.92e-10	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
BRCA	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-7.15	1.67e-12	3.93e-10	-0.32	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
BRCA	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	7.15	1.67e-12	3.93e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
BRCA	cis	rs2638953	0.924	rs11049415	ENSG00000278733.1	RP11-425D17.1	-7.15	1.68e-12	3.96e-10	-0.27	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28185625~28186190:-
BRCA	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-7.15	1.68e-12	3.96e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-7.15	1.68e-12	3.96e-10	-0.26	-0.22	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
BRCA	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	7.15	1.68e-12	3.96e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	7.15	1.68e-12	3.96e-10	0.29	0.22	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	7.15	1.68e-12	3.96e-10	0.29	0.22	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-7.14	1.69e-12	3.98e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
BRCA	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	7.14	1.69e-12	3.99e-10	0.2	0.22	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
BRCA	cis	rs17495987	1	rs17495987	ENSG00000219545.8	UMAD1	7.14	1.7e-12	3.99e-10	0.28	0.22	Tonsillectomy;	chr7:7860334	chr7:7640711~8004059:+
BRCA	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-7.14	1.7e-12	4e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
BRCA	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	7.14	1.7e-12	4e-10	0.22	0.22	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-7.14	1.7e-12	4e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
BRCA	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	7.14	1.7e-12	4.01e-10	0.25	0.22	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
BRCA	cis	rs9876781	1	rs6442117	ENSG00000244380.1	RP11-24C3.2	-7.14	1.7e-12	4.01e-10	-0.24	-0.22	Longevity;	chr3:48378407	chr3:48440352~48446656:-
BRCA	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-7.14	1.71e-12	4.02e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
BRCA	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	7.14	1.71e-12	4.03e-10	0.26	0.22	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	7.14	1.71e-12	4.04e-10	0.26	0.22	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
BRCA	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-7.14	1.72e-12	4.04e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
BRCA	cis	rs9876781	0.967	rs1870444	ENSG00000244380.1	RP11-24C3.2	7.14	1.72e-12	4.05e-10	0.25	0.22	Longevity;	chr3:48445369	chr3:48440352~48446656:-
BRCA	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	7.14	1.72e-12	4.05e-10	0.2	0.22	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
BRCA	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	7.14	1.72e-12	4.05e-10	0.18	0.22	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
BRCA	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	7.14	1.72e-12	4.05e-10	0.18	0.22	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
BRCA	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-7.14	1.72e-12	4.05e-10	-0.31	-0.22	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
BRCA	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	7.14	1.72e-12	4.05e-10	0.33	0.22	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
BRCA	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-7.14	1.72e-12	4.06e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-7.14	1.72e-12	4.06e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
BRCA	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-7.14	1.72e-12	4.06e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	7.14	1.73e-12	4.06e-10	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
BRCA	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	7.14	1.74e-12	4.1e-10	0.16	0.22	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
BRCA	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-7.14	1.74e-12	4.1e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	7.14	1.74e-12	4.11e-10	0.28	0.22	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	7.14	1.74e-12	4.11e-10	0.29	0.22	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	7.14	1.75e-12	4.11e-10	0.18	0.22	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-7.14	1.75e-12	4.12e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
BRCA	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-7.14	1.75e-12	4.12e-10	-0.3	-0.22	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
BRCA	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	7.14	1.75e-12	4.12e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
BRCA	cis	rs3760982	1	rs60184524	ENSG00000267058.1	RP11-15A1.3	-7.14	1.75e-12	4.12e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790063	chr19:43891804~43901805:-
BRCA	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-7.14	1.75e-12	4.13e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
BRCA	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-7.14	1.76e-12	4.13e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-7.14	1.76e-12	4.13e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-7.14	1.76e-12	4.13e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
BRCA	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-7.14	1.77e-12	4.17e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000224316.1	RP11-479O9.2	-7.14	1.78e-12	4.18e-10	-0.22	-0.22	Aortic root size;	chr7:66182595	chr7:65773620~65802067:+
BRCA	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-7.14	1.78e-12	4.19e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
BRCA	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-7.14	1.78e-12	4.19e-10	-0.28	-0.22	Height;	chr20:49262572	chr20:49280319~49280409:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-7.14	1.79e-12	4.2e-10	-0.26	-0.22	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.929	rs12617911	ENSG00000271889.1	RP11-493E12.1	7.14	1.79e-12	4.22e-10	0.27	0.22	Tuberculosis;	chr2:61513690	chr2:61151433~61162105:-
BRCA	cis	rs6545883	1	rs778762	ENSG00000271889.1	RP11-493E12.1	7.14	1.8e-12	4.22e-10	0.28	0.22	Tuberculosis;	chr2:61555786	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.706	rs67382287	ENSG00000273486.1	RP11-731C17.2	7.14	1.8e-12	4.23e-10	0.29	0.22	Height;Body mass index;	chr3:136661617	chr3:136837338~136839021:-
BRCA	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-7.14	1.8e-12	4.23e-10	-0.21	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-7.14	1.8e-12	4.24e-10	-0.29	-0.22	Gout;	chr7:66721259	chr7:66880708~66882981:+
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	7.14	1.8e-12	4.24e-10	0.31	0.22	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
BRCA	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-7.14	1.81e-12	4.24e-10	-0.27	-0.22	QT interval;	chr12:29331030	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-7.14	1.81e-12	4.25e-10	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-7.14	1.81e-12	4.25e-10	-0.23	-0.22	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
BRCA	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	7.13	1.81e-12	4.25e-10	0.25	0.22	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
BRCA	cis	rs9880211	0.8	rs1872239	ENSG00000273486.1	RP11-731C17.2	7.13	1.81e-12	4.26e-10	0.29	0.22	Height;Body mass index;	chr3:136785069	chr3:136837338~136839021:-
BRCA	cis	rs7178375	1	rs12907055	ENSG00000215302.7	CTD-3092A11.1	-7.13	1.81e-12	4.26e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30912091	chr15:30470779~30507623:+
BRCA	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-7.13	1.81e-12	4.26e-10	-0.32	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
BRCA	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-7.13	1.82e-12	4.26e-10	-0.26	-0.22	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000224316.1	RP11-479O9.2	-7.13	1.82e-12	4.28e-10	-0.22	-0.22	Aortic root size;	chr7:66228355	chr7:65773620~65802067:+
BRCA	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	7.13	1.82e-12	4.28e-10	0.26	0.22	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
BRCA	cis	rs2014572	0.967	rs10411941	ENSG00000268379.1	CTC-360J11.4	7.13	1.83e-12	4.29e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57251518	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.967	rs11667407	ENSG00000268379.1	CTC-360J11.4	7.13	1.83e-12	4.29e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57251754	chr19:57175233~57177921:+
BRCA	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-7.13	1.83e-12	4.29e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
BRCA	cis	rs3760982	1	rs3760983	ENSG00000267058.1	RP11-15A1.3	7.13	1.83e-12	4.29e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782508	chr19:43891804~43901805:-
BRCA	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	7.13	1.83e-12	4.3e-10	0.35	0.22	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
BRCA	cis	rs6545883	0.929	rs7561229	ENSG00000271889.1	RP11-493E12.1	7.13	1.83e-12	4.3e-10	0.27	0.22	Tuberculosis;	chr2:61510855	chr2:61151433~61162105:-
BRCA	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-7.13	1.83e-12	4.3e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	7.13	1.83e-12	4.3e-10	0.24	0.22	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs6707830	ENSG00000271889.1	RP11-493E12.1	7.13	1.84e-12	4.31e-10	0.28	0.22	Tuberculosis;	chr2:61522337	chr2:61151433~61162105:-
BRCA	cis	rs13178541	0.683	rs7378856	ENSG00000250378.1	RP11-119J18.1	-7.13	1.84e-12	4.31e-10	-0.3	-0.22	IgG glycosylation;	chr5:135751404	chr5:135812667~135826582:+
BRCA	cis	rs6723162	0.965	rs7564690	ENSG00000237751.2	LINC01143	-7.13	1.84e-12	4.31e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70885113	chr2:70887871~70889959:+
BRCA	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-7.13	1.84e-12	4.32e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-7.13	1.84e-12	4.32e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
BRCA	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-7.13	1.84e-12	4.33e-10	-0.22	-0.22	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
BRCA	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	7.13	1.85e-12	4.33e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-7.13	1.85e-12	4.34e-10	-0.21	-0.22	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
BRCA	cis	rs9880211	1	rs17364492	ENSG00000273486.1	RP11-731C17.2	-7.13	1.85e-12	4.35e-10	-0.28	-0.22	Height;Body mass index;	chr3:136485595	chr3:136837338~136839021:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000224316.1	RP11-479O9.2	-7.13	1.85e-12	4.35e-10	-0.22	-0.22	Aortic root size;	chr7:66161027	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-7.13	1.85e-12	4.35e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	7.13	1.85e-12	4.35e-10	0.21	0.22	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
BRCA	cis	rs3760982	1	rs10421887	ENSG00000267058.1	RP11-15A1.3	7.13	1.86e-12	4.36e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43891804~43901805:-
BRCA	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-7.13	1.86e-12	4.36e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
BRCA	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-7.13	1.86e-12	4.36e-10	-0.29	-0.22	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
BRCA	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-7.13	1.86e-12	4.37e-10	-0.18	-0.22	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
BRCA	cis	rs2014572	0.967	rs8111977	ENSG00000268379.1	CTC-360J11.4	7.13	1.86e-12	4.37e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57247790	chr19:57175233~57177921:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000263603.1	CTD-2349P21.5	-7.13	1.87e-12	4.38e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30729469~30731202:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-7.13	1.87e-12	4.38e-10	-0.14	-0.22	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-7.13	1.87e-12	4.39e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-7.13	1.87e-12	4.39e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
BRCA	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	7.13	1.88e-12	4.4e-10	0.25	0.22	Longevity;	chr3:48402409	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	7.13	1.88e-12	4.41e-10	0.29	0.22	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
BRCA	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	7.13	1.89e-12	4.42e-10	0.27	0.22	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
BRCA	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-7.13	1.89e-12	4.42e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
BRCA	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-7.13	1.89e-12	4.43e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-7.13	1.89e-12	4.43e-10	-0.24	-0.22	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
BRCA	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	7.13	1.89e-12	4.44e-10	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
BRCA	cis	rs712022	0.534	rs3213706	ENSG00000246225.5	RP11-17A1.3	-7.13	1.9e-12	4.44e-10	-0.26	-0.22	Dialysis-related mortality;	chr11:22859456	chr11:22829380~22945393:+
BRCA	cis	rs9880211	0.8	rs66509730	ENSG00000273486.1	RP11-731C17.2	7.13	1.9e-12	4.45e-10	0.29	0.22	Height;Body mass index;	chr3:136785416	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-7.13	1.9e-12	4.45e-10	-0.25	-0.22	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
BRCA	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-7.13	1.9e-12	4.45e-10	-0.24	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
BRCA	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-7.13	1.9e-12	4.46e-10	-0.23	-0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
BRCA	cis	rs3794924	1	rs3794924	ENSG00000266521.1	RP11-650P15.1	-7.13	1.91e-12	4.47e-10	-0.38	-0.22	Survival in colon cancer;	chr18:31461771	chr18:31496645~31497195:-
BRCA	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-7.13	1.91e-12	4.47e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
BRCA	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-7.13	1.91e-12	4.48e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
BRCA	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-7.13	1.92e-12	4.49e-10	-0.25	-0.22	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
BRCA	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-7.13	1.92e-12	4.49e-10	-0.25	-0.22	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.5e-10	0.36	0.22	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.5e-10	0.36	0.22	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	7.13	1.92e-12	4.5e-10	0.26	0.22	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
BRCA	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-7.13	1.92e-12	4.5e-10	-0.25	-0.22	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
BRCA	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	7.13	1.92e-12	4.5e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
BRCA	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
BRCA	cis	rs6472827	0.645	rs2956059	ENSG00000253983.2	RP1-16A9.1	7.13	1.93e-12	4.51e-10	0.3	0.22	Uterine fibroids;	chr8:74197795	chr8:74199396~74208441:+
BRCA	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	7.13	1.93e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
BRCA	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-7.12	1.94e-12	4.54e-10	-0.3	-0.22	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
BRCA	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-7.12	1.95e-12	4.56e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
BRCA	cis	rs4845875	0.626	rs7538516	ENSG00000242349.4	NPPA-AS1	7.12	1.95e-12	4.56e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776625	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.626	rs6697244	ENSG00000242349.4	NPPA-AS1	7.12	1.95e-12	4.56e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11778791	chr1:11841017~11848079:+
BRCA	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	7.12	1.95e-12	4.56e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
BRCA	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	7.12	1.96e-12	4.58e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
BRCA	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-7.12	1.96e-12	4.59e-10	-0.27	-0.22	Height;	chr20:49306363	chr20:49280319~49280409:+
BRCA	cis	rs7178375	1	rs9806159	ENSG00000215302.7	CTD-3092A11.1	-7.12	1.96e-12	4.59e-10	-0.32	-0.22	Hypertriglyceridemia;	chr15:30917451	chr15:30470779~30507623:+
BRCA	cis	rs12237653	0.929	rs13298979	ENSG00000236404.7	VLDLR-AS1	7.12	1.96e-12	4.6e-10	0.34	0.22	Gambling;	chr9:2543199	chr9:2422702~2643359:-
BRCA	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	7.12	1.97e-12	4.6e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	7.12	1.97e-12	4.6e-10	0.24	0.22	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
BRCA	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	7.12	1.97e-12	4.61e-10	0.25	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
BRCA	cis	rs6545883	0.965	rs778752	ENSG00000271889.1	RP11-493E12.1	7.12	1.97e-12	4.62e-10	0.28	0.22	Tuberculosis;	chr2:61549767	chr2:61151433~61162105:-
BRCA	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	7.12	1.97e-12	4.62e-10	0.41	0.22	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
BRCA	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-7.12	1.98e-12	4.62e-10	-0.23	-0.22	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
BRCA	cis	rs7178375	1	rs35162264	ENSG00000215302.7	CTD-3092A11.1	-7.12	1.98e-12	4.62e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30908480	chr15:30470779~30507623:+
BRCA	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-7.12	1.98e-12	4.63e-10	-0.26	-0.22	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
BRCA	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	7.12	1.98e-12	4.64e-10	0.26	0.22	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
BRCA	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	7.12	1.98e-12	4.64e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-7.12	1.99e-12	4.66e-10	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000224316.1	RP11-479O9.2	7.12	2e-12	4.67e-10	0.25	0.22	Aortic root size;	chr7:66518628	chr7:65773620~65802067:+
BRCA	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	7.12	2e-12	4.68e-10	0.25	0.22	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-7.12	2e-12	4.68e-10	-0.33	-0.22	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
BRCA	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-7.12	2.01e-12	4.69e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-7.12	2.01e-12	4.69e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	7.12	2.01e-12	4.69e-10	0.18	0.22	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
BRCA	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	7.12	2.01e-12	4.69e-10	0.24	0.22	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
BRCA	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-7.12	2.01e-12	4.69e-10	-0.32	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
BRCA	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-7.12	2.01e-12	4.69e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
BRCA	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-7.12	2.01e-12	4.69e-10	-0.24	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	7.12	2.01e-12	4.7e-10	0.26	0.22	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
BRCA	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	7.12	2.02e-12	4.71e-10	0.26	0.22	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
BRCA	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-7.12	2.02e-12	4.71e-10	-0.25	-0.22	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
BRCA	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	7.12	2.02e-12	4.72e-10	0.32	0.22	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-7.12	2.02e-12	4.72e-10	-0.14	-0.22	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
BRCA	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
BRCA	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
BRCA	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
BRCA	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
BRCA	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	7.12	2.03e-12	4.73e-10	0.26	0.22	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
BRCA	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	7.12	2.03e-12	4.73e-10	0.31	0.22	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
BRCA	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-7.12	2.03e-12	4.74e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
BRCA	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	7.12	2.03e-12	4.74e-10	0.28	0.22	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
BRCA	cis	rs56804039	0.524	rs11783173	ENSG00000253893.2	FAM85B	7.12	2.03e-12	4.74e-10	0.33	0.22	Cervical cancer;	chr8:8505200	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-7.12	2.03e-12	4.75e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
BRCA	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	7.12	2.04e-12	4.76e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
BRCA	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-7.12	2.04e-12	4.76e-10	-0.32	-0.22	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
BRCA	cis	rs10483853	0.806	rs12586996	ENSG00000258408.1	NT5CP2	7.12	2.04e-12	4.76e-10	0.29	0.22	Coronary artery calcification;	chr14:73342516	chr14:73539221~73539781:-
BRCA	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-7.12	2.04e-12	4.77e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
BRCA	cis	rs78456975	0.527	rs11886696	ENSG00000231482.2	AC141930.2	-7.12	2.05e-12	4.78e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1564069	chr2:1572554~1580311:-
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-7.12	2.05e-12	4.78e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
BRCA	cis	rs2835345	0.563	rs12482140	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451735	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.528	rs73204243	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451776	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.595	rs78237434	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451826	chr21:36430360~36481070:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	7.12	2.05e-12	4.79e-10	0.29	0.22	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	7.12	2.05e-12	4.79e-10	0.22	0.22	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.643	rs4275563	ENSG00000271335.4	RP11-324I22.4	7.12	2.05e-12	4.79e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-7.12	2.05e-12	4.8e-10	-0.22	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
BRCA	cis	rs8030379	1	rs11633301	ENSG00000230373.7	GOLGA6L5P	7.12	2.06e-12	4.8e-10	0.23	0.22	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84507885~84516814:-
BRCA	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	7.12	2.06e-12	4.81e-10	0.25	0.22	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	7.12	2.06e-12	4.81e-10	0.25	0.22	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
BRCA	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-7.12	2.06e-12	4.81e-10	-0.22	-0.22	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
BRCA	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	7.12	2.06e-12	4.81e-10	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	7.12	2.06e-12	4.81e-10	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-7.12	2.06e-12	4.81e-10	-0.23	-0.22	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
BRCA	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	7.12	2.06e-12	4.82e-10	0.23	0.22	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
BRCA	cis	rs17253792	0.822	rs77197405	ENSG00000186615.9	KTN1-AS1	-7.12	2.06e-12	4.82e-10	-0.44	-0.22	Putamen volume;	chr14:55692944	chr14:55499278~55580110:-
BRCA	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-7.12	2.07e-12	4.83e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30729469~30731202:+
BRCA	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-7.12	2.07e-12	4.84e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	7.12	2.07e-12	4.84e-10	0.25	0.22	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
BRCA	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	7.12	2.07e-12	4.84e-10	0.36	0.22	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
BRCA	cis	rs2015599	0.549	rs7311081	ENSG00000275476.1	RP11-996F15.4	7.12	2.08e-12	4.85e-10	0.24	0.22	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29277397~29277882:-
BRCA	cis	rs58873874	0.737	rs12654973	ENSG00000248544.2	CTB-47B11.3	7.11	2.08e-12	4.85e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.579	rs74804793	ENSG00000248544.2	CTB-47B11.3	7.11	2.08e-12	4.85e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157375741~157384950:-
BRCA	cis	rs42648	0.869	rs42614	ENSG00000225498.1	AC002064.5	7.11	2.08e-12	4.86e-10	0.2	0.22	Homocysteine levels;	chr7:90321049	chr7:90312496~90322592:+
BRCA	cis	rs2835345	0.563	rs58602880	ENSG00000230479.1	AP000695.6	7.11	2.08e-12	4.86e-10	0.22	0.22	Pulmonary function;	chr21:36454610	chr21:36430360~36481070:+
BRCA	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-7.11	2.08e-12	4.86e-10	-0.3	-0.22	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
BRCA	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	7.11	2.08e-12	4.86e-10	0.26	0.22	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
BRCA	cis	rs2060793	0.684	rs1597689	ENSG00000251991.1	RNU7-49P	7.11	2.09e-12	4.86e-10	0.24	0.22	Vitamin D levels;	chr11:14824638	chr11:14478892~14478953:+
BRCA	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	7.11	2.09e-12	4.87e-10	0.16	0.22	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
BRCA	cis	rs9876781	0.967	rs1459249	ENSG00000244380.1	RP11-24C3.2	7.11	2.09e-12	4.87e-10	0.24	0.22	Longevity;	chr3:48438208	chr3:48440352~48446656:-
BRCA	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-7.11	2.09e-12	4.88e-10	-0.21	-0.22	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	7.11	2.09e-12	4.88e-10	0.26	0.22	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
BRCA	cis	rs7044106	0.664	rs7861679	ENSG00000238181.2	AHCYP2	7.11	2.1e-12	4.9e-10	0.28	0.22	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120720673~120721972:+
BRCA	cis	rs9880211	0.563	rs1393787	ENSG00000273486.1	RP11-731C17.2	7.11	2.11e-12	4.9e-10	0.28	0.22	Height;Body mass index;	chr3:136135359	chr3:136837338~136839021:-
BRCA	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-7.11	2.11e-12	4.91e-10	-0.3	-0.22	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	7.11	2.11e-12	4.92e-10	0.26	0.22	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-7.11	2.11e-12	4.92e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
BRCA	cis	rs7178375	0.941	rs4779796	ENSG00000215302.7	CTD-3092A11.1	-7.11	2.12e-12	4.93e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30915847	chr15:30470779~30507623:+
BRCA	cis	rs420259	0.51	rs12921516	ENSG00000260136.4	CTD-2270L9.4	-7.11	2.12e-12	4.93e-10	-0.22	-0.22	Bipolar disorder;	chr16:23510082	chr16:23452758~23457606:+
BRCA	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	7.11	2.12e-12	4.94e-10	0.29	0.22	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-7.11	2.13e-12	4.95e-10	-0.28	-0.22	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	7.11	2.13e-12	4.95e-10	0.29	0.22	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	7.11	2.13e-12	4.95e-10	0.29	0.22	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
BRCA	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	7.11	2.13e-12	4.95e-10	0.18	0.22	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
BRCA	cis	rs17253792	0.822	rs17685102	ENSG00000186615.9	KTN1-AS1	-7.11	2.13e-12	4.95e-10	-0.45	-0.22	Putamen volume;	chr14:55662496	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77033617	ENSG00000186615.9	KTN1-AS1	-7.11	2.13e-12	4.95e-10	-0.45	-0.22	Putamen volume;	chr14:55663028	chr14:55499278~55580110:-
BRCA	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	7.11	2.13e-12	4.95e-10	0.29	0.22	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	7.11	2.13e-12	4.95e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	7.11	2.13e-12	4.95e-10	0.26	0.22	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-7.11	2.13e-12	4.96e-10	-0.28	-0.22	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
BRCA	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-7.11	2.13e-12	4.97e-10	-0.25	-0.22	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
BRCA	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	7.11	2.14e-12	4.98e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
BRCA	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-7.11	2.14e-12	4.98e-10	-0.23	-0.22	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs11749220	ENSG00000251405.2	CTB-109A12.1	7.11	2.15e-12	4.99e-10	0.33	0.22	Lung function (FEV1/FVC);	chr5:157362486	chr5:157362615~157460078:-
BRCA	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	7.11	2.16e-12	5.02e-10	0.18	0.22	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
BRCA	cis	rs73173548	0.528	rs34182576	ENSG00000247828.6	TMEM161B-AS1	7.11	2.16e-12	5.02e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88438321	chr5:88268895~88436685:+
BRCA	cis	rs2014572	0.967	rs8112572	ENSG00000268379.1	CTC-360J11.4	7.11	2.16e-12	5.03e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57248244	chr19:57175233~57177921:+
BRCA	cis	rs3760982	0.845	rs62116962	ENSG00000267058.1	RP11-15A1.3	7.11	2.16e-12	5.03e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43783082	chr19:43891804~43901805:-
BRCA	cis	rs11671005	0.571	rs56243535	ENSG00000252334.1	RNU6-1337P	7.11	2.16e-12	5.03e-10	0.36	0.22	Mean platelet volume;	chr19:58494783	chr19:58483749~58483843:-
BRCA	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-7.11	2.17e-12	5.04e-10	-0.29	-0.22	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
BRCA	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-7.11	2.17e-12	5.05e-10	-0.24	-0.22	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
BRCA	cis	rs9527	0.662	rs4919686	ENSG00000213061.2	PFN1P11	7.11	2.17e-12	5.06e-10	0.32	0.22	Arsenic metabolism;	chr10:102832492	chr10:102838011~102845473:-
BRCA	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-7.11	2.18e-12	5.06e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	7.11	2.18e-12	5.06e-10	0.28	0.22	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
BRCA	cis	rs7809950	1	rs2237677	ENSG00000238832.1	snoU109	-7.11	2.18e-12	5.06e-10	-0.28	-0.22	Coronary artery disease;	chr7:107562057	chr7:107603363~107603507:+
BRCA	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
BRCA	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-7.11	2.19e-12	5.08e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
BRCA	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-7.11	2.19e-12	5.09e-10	-0.24	-0.22	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
BRCA	cis	rs17253792	0.822	rs17253730	ENSG00000186615.9	KTN1-AS1	-7.11	2.19e-12	5.1e-10	-0.44	-0.22	Putamen volume;	chr14:55691193	chr14:55499278~55580110:-
BRCA	cis	rs2015599	0.517	rs7295212	ENSG00000275476.1	RP11-996F15.4	7.11	2.19e-12	5.1e-10	0.24	0.22	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29277397~29277882:-
BRCA	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	7.11	2.2e-12	5.1e-10	0.26	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
BRCA	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	7.11	2.2e-12	5.11e-10	0.22	0.22	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-7.11	2.2e-12	5.11e-10	-0.21	-0.22	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-7.11	2.2e-12	5.11e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
BRCA	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	7.11	2.2e-12	5.12e-10	0.25	0.22	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
BRCA	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	7.11	2.21e-12	5.13e-10	0.23	0.21	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
BRCA	cis	rs79040073	0.637	rs11633981	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49360903	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs11633282	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49372472	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs11638606	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49372564	chr15:49365124~49366685:-
BRCA	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	7.11	2.21e-12	5.14e-10	0.29	0.21	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
BRCA	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	7.11	2.21e-12	5.14e-10	0.27	0.21	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000224316.1	RP11-479O9.2	-7.11	2.22e-12	5.15e-10	-0.25	-0.21	Aortic root size;	chr7:66066855	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-7.11	2.22e-12	5.16e-10	-0.29	-0.21	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
BRCA	cis	rs2060793	1	rs2060793	ENSG00000251991.1	RNU7-49P	7.11	2.22e-12	5.16e-10	0.24	0.21	Vitamin D levels;	chr11:14893764	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	7.11	2.22e-12	5.16e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
BRCA	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-7.11	2.23e-12	5.17e-10	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.931	rs7557230	ENSG00000271889.1	RP11-493E12.1	7.11	2.23e-12	5.17e-10	0.28	0.21	Tuberculosis;	chr2:61509517	chr2:61151433~61162105:-
BRCA	cis	rs2348418	0.832	rs11049512	ENSG00000247934.4	RP11-967K21.1	7.1	2.23e-12	5.18e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28295880	chr12:28163298~28190738:-
BRCA	cis	rs9880211	0.563	rs6792630	ENSG00000273486.1	RP11-731C17.2	7.1	2.23e-12	5.18e-10	0.28	0.21	Height;Body mass index;	chr3:136106059	chr3:136837338~136839021:-
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000261582.1	RP4-614O4.11	-7.1	2.23e-12	5.18e-10	-0.24	-0.21	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35267885~35280043:-
BRCA	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-7.1	2.23e-12	5.19e-10	-0.28	-0.21	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
BRCA	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	7.1	2.23e-12	5.19e-10	0.26	0.21	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	7.1	2.23e-12	5.19e-10	0.24	0.21	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	7.1	2.23e-12	5.19e-10	0.24	0.21	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-7.1	2.23e-12	5.19e-10	-0.24	-0.21	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
BRCA	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-7.1	2.23e-12	5.19e-10	-0.28	-0.21	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
BRCA	cis	rs4845875	0.626	rs11121828	ENSG00000242349.4	NPPA-AS1	7.1	2.24e-12	5.19e-10	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11774397	chr1:11841017~11848079:+
BRCA	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	7.1	2.24e-12	5.19e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
BRCA	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-7.1	2.24e-12	5.19e-10	-0.2	-0.21	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000236529.1	RP13-254B10.1	7.1	2.24e-12	5.2e-10	0.26	0.21	Aortic root size;	chr7:66301366	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	7.1	2.24e-12	5.2e-10	0.24	0.21	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
BRCA	cis	rs17253792	0.822	rs78988988	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55685686	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17253716	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55686943	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17253723	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55687297	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77415412	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55687428	chr14:55499278~55580110:-
BRCA	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	7.1	2.25e-12	5.22e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
BRCA	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-7.1	2.25e-12	5.23e-10	-0.29	-0.21	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
BRCA	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-7.1	2.26e-12	5.24e-10	-0.28	-0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-7.1	2.26e-12	5.24e-10	-0.28	-0.21	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	7.1	2.26e-12	5.24e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
BRCA	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-7.1	2.26e-12	5.25e-10	-0.27	-0.21	QT interval;	chr12:29319943	chr12:29280418~29317848:-
BRCA	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
BRCA	cis	rs7829975	0.564	rs2976855	ENSG00000254153.1	CTA-398F10.2	7.1	2.27e-12	5.26e-10	0.26	0.21	Mood instability;	chr8:8444284	chr8:8456909~8461337:-
BRCA	cis	rs7809950	0.954	rs11977187	ENSG00000238832.1	snoU109	7.1	2.27e-12	5.27e-10	0.29	0.21	Coronary artery disease;	chr7:107569938	chr7:107603363~107603507:+
BRCA	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-7.1	2.27e-12	5.27e-10	-0.23	-0.21	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.839	rs1362348	ENSG00000234389.1	AC007278.3	7.1	2.28e-12	5.28e-10	0.2	0.21	Asthma;	chr2:102368164	chr2:102438713~102440475:+
BRCA	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	7.1	2.28e-12	5.28e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
BRCA	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-7.1	2.28e-12	5.28e-10	-0.25	-0.21	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
BRCA	cis	rs10861661	0.963	rs7977765	ENSG00000260329.1	RP11-412D9.4	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Triglyceride levels;	chr12:106811612	chr12:106954029~106955497:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000244479.5	OR2A1-AS1	7.1	2.28e-12	5.29e-10	0.38	0.21	Obesity-related traits;	chr7:144057308	chr7:144251264~144356181:-
BRCA	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
BRCA	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-7.1	2.29e-12	5.3e-10	-0.26	-0.21	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	7.1	2.29e-12	5.31e-10	0.17	0.21	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	7.1	2.29e-12	5.31e-10	0.17	0.21	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
BRCA	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	7.1	2.29e-12	5.32e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
BRCA	cis	rs681343	1	rs679574	ENSG00000232871.7	SEC1P	7.1	2.29e-12	5.32e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702851	chr19:48638071~48682245:+
BRCA	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-7.1	2.3e-12	5.32e-10	-0.24	-0.21	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
BRCA	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-7.1	2.3e-12	5.33e-10	-0.27	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-7.1	2.3e-12	5.33e-10	-0.27	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	7.1	2.3e-12	5.33e-10	0.24	0.21	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-7.1	2.3e-12	5.34e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-7.1	2.3e-12	5.34e-10	-0.31	-0.21	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
BRCA	cis	rs10861661	0.963	rs3782707	ENSG00000260329.1	RP11-412D9.4	-7.1	2.31e-12	5.35e-10	-0.28	-0.21	Triglyceride levels;	chr12:106791409	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-7.1	2.31e-12	5.35e-10	-0.2	-0.21	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	7.1	2.31e-12	5.35e-10	0.3	0.21	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
BRCA	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	7.1	2.32e-12	5.36e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
BRCA	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	7.1	2.32e-12	5.37e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
BRCA	cis	rs79040073	0.563	rs17478618	ENSG00000259531.2	RP11-295H24.3	-7.1	2.32e-12	5.37e-10	-0.35	-0.21	Lung cancer in ever smokers;	chr15:49444621	chr15:49365124~49366685:-
BRCA	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-7.1	2.32e-12	5.38e-10	-0.26	-0.21	Height;	chr2:46635327	chr2:46668870~46670778:+
BRCA	cis	rs6545883	0.965	rs766447	ENSG00000271889.1	RP11-493E12.1	7.1	2.32e-12	5.38e-10	0.27	0.21	Tuberculosis;	chr2:61508434	chr2:61151433~61162105:-
BRCA	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-7.1	2.33e-12	5.39e-10	-0.27	-0.21	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.1	2.33e-12	5.39e-10	-0.33	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
BRCA	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	7.1	2.33e-12	5.39e-10	0.36	0.21	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
BRCA	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	7.1	2.33e-12	5.4e-10	0.5	0.21	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
BRCA	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-7.1	2.34e-12	5.41e-10	-0.28	-0.21	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
BRCA	cis	rs681343	1	rs516246	ENSG00000232871.7	SEC1P	7.1	2.34e-12	5.41e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702915	chr19:48638071~48682245:+
BRCA	cis	rs74233809	1	rs12411886	ENSG00000213277.3	MARCKSL1P1	7.1	2.34e-12	5.42e-10	0.43	0.21	Birth weight;	chr10:102925542	chr10:103175554~103176094:+
BRCA	cis	rs17253792	0.822	rs75936910	ENSG00000186615.9	KTN1-AS1	-7.1	2.34e-12	5.42e-10	-0.44	-0.21	Putamen volume;	chr14:55682633	chr14:55499278~55580110:-
BRCA	cis	rs7615952	0.599	rs2333408	ENSG00000250012.1	RP11-124N2.1	-7.1	2.34e-12	5.42e-10	-0.28	-0.21	Blood pressure (smoking interaction);	chr3:126013255	chr3:126084220~126095349:+
BRCA	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-7.1	2.34e-12	5.42e-10	-0.28	-0.21	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
BRCA	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-7.1	2.35e-12	5.43e-10	-0.23	-0.21	Height;	chr5:36954710	chr5:36666214~36725195:-
BRCA	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	7.1	2.36e-12	5.46e-10	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
BRCA	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	7.1	2.36e-12	5.47e-10	0.3	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
BRCA	cis	rs681343	1	rs681343	ENSG00000232871.7	SEC1P	7.1	2.36e-12	5.47e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703205	chr19:48638071~48682245:+
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-7.1	2.37e-12	5.48e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
BRCA	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	7.1	2.37e-12	5.49e-10	0.25	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-7.1	2.38e-12	5.5e-10	-0.25	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
BRCA	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	7.1	2.38e-12	5.51e-10	0.31	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	7.1	2.38e-12	5.51e-10	0.24	0.21	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
BRCA	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	7.1	2.38e-12	5.51e-10	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
BRCA	cis	rs853679	1	rs10456362	ENSG00000220721.1	OR1F12	-7.1	2.39e-12	5.52e-10	-0.32	-0.21	Depression;	chr6:28254038	chr6:28073316~28074233:+
BRCA	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	7.09	2.39e-12	5.53e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
BRCA	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-7.09	2.39e-12	5.53e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
BRCA	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-7.09	2.4e-12	5.55e-10	-0.27	-0.21	Height;	chr20:49283115	chr20:49280319~49280409:+
BRCA	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	7.09	2.41e-12	5.57e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
BRCA	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	7.09	2.41e-12	5.58e-10	0.32	0.21	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
BRCA	cis	rs7474896	0.526	rs1208633	ENSG00000226578.1	RP11-258F22.1	7.09	2.42e-12	5.58e-10	0.28	0.21	Obesity (extreme);	chr10:37867945	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.559	rs1779075	ENSG00000226578.1	RP11-258F22.1	7.09	2.42e-12	5.58e-10	0.28	0.21	Obesity (extreme);	chr10:37878602	chr10:37775371~37784131:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	7.09	2.42e-12	5.59e-10	0.22	0.21	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
BRCA	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	7.09	2.42e-12	5.6e-10	0.25	0.21	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
BRCA	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	7.09	2.43e-12	5.61e-10	0.41	0.21	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
BRCA	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-7.09	2.43e-12	5.61e-10	-0.33	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
BRCA	cis	rs7474896	0.559	rs2753880	ENSG00000226578.1	RP11-258F22.1	7.09	2.43e-12	5.62e-10	0.28	0.21	Obesity (extreme);	chr10:37884410	chr10:37775371~37784131:-
BRCA	cis	rs812925	0.893	rs1186705	ENSG00000271889.1	RP11-493E12.1	7.09	2.43e-12	5.62e-10	0.27	0.21	Immature fraction of reticulocytes;	chr2:61446143	chr2:61151433~61162105:-
BRCA	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-7.09	2.43e-12	5.62e-10	-0.28	-0.21	AIDS;	chr2:105321650	chr2:105324210~105330529:+
BRCA	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-7.09	2.44e-12	5.63e-10	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
BRCA	cis	rs17253792	0.822	rs78143160	ENSG00000186615.9	KTN1-AS1	-7.09	2.44e-12	5.64e-10	-0.44	-0.21	Putamen volume;	chr14:55683379	chr14:55499278~55580110:-
BRCA	cis	rs6545883	0.868	rs6545887	ENSG00000271889.1	RP11-493E12.1	7.09	2.44e-12	5.64e-10	0.27	0.21	Tuberculosis;	chr2:61601683	chr2:61151433~61162105:-
BRCA	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-7.09	2.44e-12	5.64e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	7.09	2.44e-12	5.64e-10	0.24	0.21	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.931	rs778765	ENSG00000271889.1	RP11-493E12.1	7.09	2.44e-12	5.64e-10	0.28	0.21	Tuberculosis;	chr2:61559250	chr2:61151433~61162105:-
BRCA	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-7.09	2.44e-12	5.65e-10	-0.21	-0.21	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-7.09	2.45e-12	5.65e-10	-0.28	-0.21	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-7.09	2.45e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
BRCA	cis	rs601338	1	rs601338	ENSG00000232871.7	SEC1P	7.09	2.45e-12	5.65e-10	0.24	0.21	Blood metabolite ratios;Number of common colds;Blood metabolite levels;	chr19:48703417	chr19:48638071~48682245:+
BRCA	cis	rs712022	0.534	rs4281481	ENSG00000246225.5	RP11-17A1.3	-7.09	2.45e-12	5.66e-10	-0.26	-0.21	Dialysis-related mortality;	chr11:22859013	chr11:22829380~22945393:+
BRCA	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	7.09	2.45e-12	5.66e-10	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
BRCA	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	7.09	2.45e-12	5.66e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	7.09	2.45e-12	5.66e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
BRCA	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	7.09	2.45e-12	5.67e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
BRCA	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	7.09	2.46e-12	5.67e-10	0.21	0.21	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
BRCA	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-7.09	2.46e-12	5.68e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
BRCA	cis	rs17264034	0.95	rs17328863	ENSG00000250786.1	SNHG18	-7.09	2.46e-12	5.69e-10	-0.34	-0.21	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9542919	chr5:9546200~9550609:+
BRCA	cis	rs957448	1	rs1992370	ENSG00000253175.1	RP11-267M23.6	7.09	2.46e-12	5.69e-10	0.28	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94565036~94565715:+
BRCA	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-7.09	2.46e-12	5.69e-10	-0.15	-0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
BRCA	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-7.09	2.47e-12	5.7e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
BRCA	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-7.09	2.47e-12	5.7e-10	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	7.09	2.47e-12	5.71e-10	0.26	0.21	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-7.09	2.47e-12	5.71e-10	-0.25	-0.21	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
BRCA	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-7.09	2.48e-12	5.72e-10	-0.29	-0.21	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
BRCA	cis	rs7474896	0.559	rs1208645	ENSG00000226578.1	RP11-258F22.1	7.09	2.48e-12	5.72e-10	0.28	0.21	Obesity (extreme);	chr10:37843159	chr10:37775371~37784131:-
BRCA	cis	rs4660261	0.526	rs2485997	ENSG00000237950.1	RP11-7O11.3	7.09	2.49e-12	5.74e-10	0.25	0.21	Intelligence (multi-trait analysis);	chr1:43880169	chr1:43944370~43946551:-
BRCA	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	7.09	2.49e-12	5.75e-10	0.28	0.21	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
BRCA	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-7.09	2.49e-12	5.75e-10	-0.29	-0.21	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000230042.1	AK3P3	-7.09	2.49e-12	5.75e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23129178~23129841:+
BRCA	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	7.09	2.5e-12	5.76e-10	0.25	0.21	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
BRCA	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-7.09	2.5e-12	5.77e-10	-0.21	-0.21	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
BRCA	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-7.09	2.5e-12	5.77e-10	-0.29	-0.21	AIDS;	chr2:105333211	chr2:105324210~105330529:+
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-7.09	2.5e-12	5.77e-10	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
BRCA	cis	rs17253792	0.822	rs77182097	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55669977	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs45501402	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55673397	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76164147	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55673651	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs74935793	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55676559	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.749	rs45458197	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55678300	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10483650	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55678594	chr14:55499278~55580110:-
BRCA	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	7.09	2.5e-12	5.78e-10	0.25	0.21	Longevity;	chr3:48395329	chr3:48440352~48446656:-
BRCA	cis	rs9307551	0.817	rs13127970	ENSG00000250334.4	LINC00989	-7.09	2.51e-12	5.78e-10	-0.3	-0.21	Refractive error;	chr4:79581236	chr4:79492416~79576460:+
BRCA	cis	rs9880211	0.563	rs6769762	ENSG00000273486.1	RP11-731C17.2	7.09	2.51e-12	5.78e-10	0.28	0.21	Height;Body mass index;	chr3:136189336	chr3:136837338~136839021:-
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000278665.1	RP11-666O2.4	-7.09	2.51e-12	5.79e-10	-0.25	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28599241~28601881:-
BRCA	cis	rs10029851	0.627	rs72893189	ENSG00000234492.4	RPL34-AS1	7.09	2.52e-12	5.81e-10	0.34	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108635577	chr4:108538190~108620460:-
BRCA	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	7.09	2.52e-12	5.81e-10	0.32	0.21	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
BRCA	cis	rs2014572	1	rs3746231	ENSG00000268379.1	CTC-360J11.4	7.09	2.53e-12	5.84e-10	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57248689	chr19:57175233~57177921:+
BRCA	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	7.09	2.53e-12	5.84e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
BRCA	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	7.09	2.53e-12	5.84e-10	0.25	0.21	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
BRCA	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	7.09	2.53e-12	5.85e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000230042.1	AK3P3	-7.09	2.54e-12	5.85e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23129178~23129841:+
BRCA	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-7.09	2.54e-12	5.86e-10	-0.28	-0.21	AIDS;	chr2:105311539	chr2:105324210~105330529:+
BRCA	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-7.09	2.55e-12	5.87e-10	-0.24	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
BRCA	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-7.09	2.55e-12	5.87e-10	-0.27	-0.21	Height;	chr20:49310319	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	7.09	2.55e-12	5.88e-10	0.23	0.21	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
BRCA	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-7.09	2.55e-12	5.88e-10	-0.26	-0.21	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
BRCA	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	7.09	2.55e-12	5.89e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
BRCA	cis	rs6740322	1	rs6756736	ENSG00000234936.1	AC010883.5	7.09	2.56e-12	5.89e-10	0.24	0.21	Coronary artery disease;	chr2:43331604	chr2:43229573~43233394:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-7.08	2.56e-12	5.91e-10	-0.26	-0.21	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
BRCA	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	7.08	2.57e-12	5.92e-10	0.26	0.21	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
BRCA	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	7.08	2.57e-12	5.92e-10	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-7.08	2.57e-12	5.93e-10	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
BRCA	cis	rs6723162	1	rs6723162	ENSG00000237751.2	LINC01143	-7.08	2.58e-12	5.95e-10	-0.24	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70875156	chr2:70887871~70889959:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	7.08	2.58e-12	5.95e-10	0.28	0.21	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	7.08	2.58e-12	5.95e-10	0.28	0.21	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000236529.1	RP13-254B10.1	-7.08	2.58e-12	5.95e-10	-0.27	-0.21	Aortic root size;	chr7:66086944	chr7:65840212~65840596:+
BRCA	cis	rs838147	0.537	rs632111	ENSG00000232871.7	SEC1P	7.08	2.58e-12	5.96e-10	0.23	0.21	Dietary macronutrient intake;	chr19:48705721	chr19:48638071~48682245:+
BRCA	cis	rs7586673	0.725	rs6757645	ENSG00000227403.1	AC009299.3	-7.08	2.59e-12	5.97e-10	-0.29	-0.21	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161244739~161249050:+
BRCA	cis	rs4072705	1	rs10760371	ENSG00000224020.1	MIR181A2HG	-7.08	2.59e-12	5.97e-10	-0.23	-0.21	Menarche (age at onset);	chr9:124690698	chr9:124658467~124698631:+
BRCA	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	7.08	2.59e-12	5.98e-10	0.25	0.21	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
BRCA	cis	rs9876781	1	rs11712561	ENSG00000244380.1	RP11-24C3.2	7.08	2.59e-12	5.98e-10	0.25	0.21	Longevity;	chr3:48393807	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	7.08	2.59e-12	5.98e-10	0.25	0.21	Longevity;	chr3:48408490	chr3:48440352~48446656:-
BRCA	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-7.08	2.6e-12	6e-10	-0.25	-0.21	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
BRCA	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-7.08	2.6e-12	6e-10	-0.28	-0.21	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
BRCA	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	7.08	2.61e-12	6e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
BRCA	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-7.08	2.61e-12	6.01e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	7.08	2.61e-12	6.01e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
BRCA	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	7.08	2.61e-12	6.02e-10	0.25	0.21	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
BRCA	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	7.08	2.61e-12	6.02e-10	0.25	0.21	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	7.08	2.61e-12	6.02e-10	0.25	0.21	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
BRCA	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	7.08	2.62e-12	6.03e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	7.08	2.62e-12	6.03e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	7.08	2.62e-12	6.03e-10	0.25	0.21	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
BRCA	cis	rs1440410	0.835	rs7684481	ENSG00000250326.1	RP11-284M14.1	-7.08	2.62e-12	6.04e-10	-0.24	-0.21	Ischemic stroke;	chr4:143133252	chr4:142933195~143184861:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-7.08	2.62e-12	6.04e-10	-0.29	-0.21	Gout;	chr7:66679692	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	7.08	2.62e-12	6.04e-10	0.29	0.21	Gout;	chr7:66682070	chr7:66880708~66882981:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	7.08	2.62e-12	6.04e-10	0.29	0.21	Gout;	chr7:66682162	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	7.08	2.63e-12	6.05e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	7.08	2.63e-12	6.05e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
BRCA	cis	rs6545883	0.831	rs2592356	ENSG00000271889.1	RP11-493E12.1	7.08	2.63e-12	6.06e-10	0.28	0.21	Tuberculosis;	chr2:61583293	chr2:61151433~61162105:-
BRCA	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-7.08	2.63e-12	6.07e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-7.08	2.63e-12	6.07e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
BRCA	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	7.08	2.64e-12	6.07e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
BRCA	cis	rs79040073	0.637	rs73398272	ENSG00000259531.2	RP11-295H24.3	7.08	2.64e-12	6.08e-10	0.35	0.21	Lung cancer in ever smokers;	chr15:49416426	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs73396235	ENSG00000259531.2	RP11-295H24.3	7.08	2.65e-12	6.1e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49346956	chr15:49365124~49366685:-
BRCA	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	7.08	2.65e-12	6.11e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.08	2.66e-12	6.11e-10	0.26	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
BRCA	cis	rs9880211	0.613	rs1393786	ENSG00000273486.1	RP11-731C17.2	7.08	2.66e-12	6.12e-10	0.27	0.21	Height;Body mass index;	chr3:136135193	chr3:136837338~136839021:-
BRCA	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-7.08	2.66e-12	6.12e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-7.08	2.66e-12	6.12e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
BRCA	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.08	2.67e-12	6.14e-10	-0.25	-0.21	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.08	2.67e-12	6.14e-10	-0.25	-0.21	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
BRCA	cis	rs74233809	0.901	rs11191425	ENSG00000213277.3	MARCKSL1P1	7.08	2.67e-12	6.14e-10	0.39	0.21	Birth weight;	chr10:102866213	chr10:103175554~103176094:+
BRCA	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	7.08	2.67e-12	6.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
BRCA	cis	rs7474896	0.583	rs10740950	ENSG00000226578.1	RP11-258F22.1	-7.08	2.67e-12	6.15e-10	-0.28	-0.21	Obesity (extreme);	chr10:37714568	chr10:37775371~37784131:-
BRCA	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-7.08	2.67e-12	6.15e-10	-0.27	-0.21	Height;	chr20:49278705	chr20:49280319~49280409:+
BRCA	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-7.08	2.67e-12	6.15e-10	-0.21	-0.21	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000255046.1	RP11-297N6.4	7.08	2.68e-12	6.16e-10	0.26	0.21	Neuroticism;	chr8:11999808	chr8:11797928~11802568:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	7.08	2.68e-12	6.16e-10	0.25	0.21	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-7.08	2.68e-12	6.17e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
BRCA	cis	rs7079041	1	rs7079041	ENSG00000273038.2	RP11-479G22.8	-7.08	2.68e-12	6.18e-10	-0.25	-0.21	Suicide in bipolar disorder;	chr10:32704340	chr10:32887255~32889311:-
BRCA	cis	rs3781264	0.595	rs11187853	ENSG00000273450.1	RP11-76P2.4	7.08	2.69e-12	6.2e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94312471	chr10:94314907~94315327:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-7.08	2.7e-12	6.2e-10	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	7.08	2.7e-12	6.21e-10	0.26	0.21	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	7.08	2.7e-12	6.22e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	7.08	2.7e-12	6.22e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
BRCA	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	7.08	2.7e-12	6.22e-10	0.42	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
BRCA	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-7.08	2.7e-12	6.22e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
BRCA	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-7.08	2.71e-12	6.22e-10	-0.27	-0.21	Height;	chr20:49287143	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-7.08	2.71e-12	6.22e-10	-0.27	-0.21	Height;	chr20:49291523	chr20:49280319~49280409:+
BRCA	cis	rs9527	0.662	rs10883783	ENSG00000213061.2	PFN1P11	7.08	2.71e-12	6.24e-10	0.31	0.21	Arsenic metabolism;	chr10:102831395	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	7.08	2.71e-12	6.24e-10	0.28	0.21	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
BRCA	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	7.08	2.71e-12	6.24e-10	0.25	0.21	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
BRCA	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-7.08	2.72e-12	6.25e-10	-0.27	-0.21	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
BRCA	cis	rs3781264	0.595	rs11187901	ENSG00000273450.1	RP11-76P2.4	7.08	2.72e-12	6.25e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94355251	chr10:94314907~94315327:-
BRCA	cis	rs9876781	1	rs2362450	ENSG00000244380.1	RP11-24C3.2	7.08	2.72e-12	6.26e-10	0.24	0.21	Longevity;	chr3:48419904	chr3:48440352~48446656:-
BRCA	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-7.08	2.73e-12	6.28e-10	-0.24	-0.21	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
BRCA	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	7.08	2.73e-12	6.29e-10	0.34	0.21	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
BRCA	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
BRCA	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-7.08	2.74e-12	6.29e-10	-0.39	-0.21	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
BRCA	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-7.07	2.75e-12	6.32e-10	-0.26	-0.21	QT interval;	chr12:29300845	chr12:29280418~29317848:-
BRCA	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	7.07	2.75e-12	6.32e-10	0.24	0.21	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	7.07	2.75e-12	6.32e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
BRCA	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	7.07	2.75e-12	6.33e-10	0.21	0.21	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
BRCA	cis	rs10181042	0.528	rs2564118	ENSG00000271889.1	RP11-493E12.1	7.07	2.75e-12	6.33e-10	0.27	0.21	Crohn's disease;	chr2:61006154	chr2:61151433~61162105:-
BRCA	cis	rs3760982	1	rs11665924	ENSG00000267058.1	RP11-15A1.3	-7.07	2.76e-12	6.34e-10	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782830	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	7.07	2.76e-12	6.34e-10	0.3	0.21	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
BRCA	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-7.07	2.76e-12	6.35e-10	-0.27	-0.21	Height;	chr20:49282523	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-7.07	2.77e-12	6.36e-10	-0.28	-0.21	Height;	chr20:49257468	chr20:49280319~49280409:+
BRCA	cis	rs3781264	0.761	rs11187894	ENSG00000273450.1	RP11-76P2.4	7.07	2.77e-12	6.37e-10	0.3	0.21	Esophageal cancer and gastric cancer;	chr10:94346268	chr10:94314907~94315327:-
BRCA	cis	rs9880211	0.898	rs1052620	ENSG00000273486.1	RP11-731C17.2	7.07	2.77e-12	6.37e-10	0.3	0.21	Height;Body mass index;	chr3:136855679	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000224316.1	RP11-479O9.2	7.07	2.77e-12	6.37e-10	0.24	0.21	Aortic root size;	chr7:66511428	chr7:65773620~65802067:+
BRCA	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-7.07	2.78e-12	6.38e-10	-0.25	-0.21	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
BRCA	cis	rs9880211	0.563	rs9881400	ENSG00000273486.1	RP11-731C17.2	7.07	2.78e-12	6.39e-10	0.28	0.21	Height;Body mass index;	chr3:136142824	chr3:136837338~136839021:-
BRCA	cis	rs34779708	0.931	rs7079498	ENSG00000271335.4	RP11-324I22.4	7.07	2.78e-12	6.39e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35314552~35336401:-
BRCA	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	7.07	2.78e-12	6.39e-10	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
BRCA	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	7.07	2.79e-12	6.4e-10	0.3	0.21	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-7.07	2.8e-12	6.42e-10	-0.25	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
BRCA	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	7.07	2.81e-12	6.45e-10	0.36	0.21	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	7.07	2.81e-12	6.45e-10	0.36	0.21	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
BRCA	cis	rs919433	0.963	rs4850428	ENSG00000231621.1	AC013264.2	7.07	2.81e-12	6.45e-10	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305048	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-7.07	2.81e-12	6.46e-10	-0.24	-0.21	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	7.07	2.81e-12	6.46e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
BRCA	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.07	2.81e-12	6.46e-10	-0.24	-0.21	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	7.07	2.82e-12	6.47e-10	0.3	0.21	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
BRCA	cis	rs3794924	1	rs35777565	ENSG00000266521.1	RP11-650P15.1	7.07	2.82e-12	6.48e-10	0.4	0.21	Survival in colon cancer;	chr18:31469409	chr18:31496645~31497195:-
BRCA	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	7.07	2.83e-12	6.49e-10	0.3	0.21	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
BRCA	cis	rs9880211	0.752	rs9881831	ENSG00000273486.1	RP11-731C17.2	7.07	2.83e-12	6.49e-10	0.29	0.21	Height;Body mass index;	chr3:136670876	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-7.07	2.83e-12	6.49e-10	-0.22	-0.21	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
BRCA	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	7.07	2.83e-12	6.5e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-7.07	2.84e-12	6.51e-10	-0.24	-0.21	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-7.07	2.84e-12	6.51e-10	-0.24	-0.21	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	7.07	2.84e-12	6.52e-10	0.27	0.21	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-7.07	2.84e-12	6.52e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
BRCA	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-7.07	2.86e-12	6.57e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
BRCA	cis	rs13126694	0.71	rs4574459	ENSG00000248429.4	RP11-597D13.9	7.07	2.87e-12	6.58e-10	0.19	0.21	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158170752~158202877:+
BRCA	cis	rs7474896	0.559	rs1735629	ENSG00000226578.1	RP11-258F22.1	7.07	2.87e-12	6.58e-10	0.29	0.21	Obesity (extreme);	chr10:37889381	chr10:37775371~37784131:-
BRCA	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-7.07	2.87e-12	6.58e-10	-0.28	-0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
BRCA	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	7.07	2.87e-12	6.59e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-7.07	2.88e-12	6.61e-10	-0.21	-0.21	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	7.07	2.89e-12	6.62e-10	0.26	0.21	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-7.07	2.89e-12	6.63e-10	-0.14	-0.21	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-7.07	2.89e-12	6.64e-10	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
BRCA	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	7.07	2.9e-12	6.65e-10	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
BRCA	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	7.07	2.9e-12	6.66e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
BRCA	cis	rs7746199	0.673	rs35501037	ENSG00000220721.1	OR1F12	7.07	2.91e-12	6.66e-10	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28073316~28074233:+
BRCA	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	7.07	2.91e-12	6.66e-10	0.25	0.21	QT interval;	chr12:29260560	chr12:29280418~29317848:-
BRCA	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-7.07	2.91e-12	6.67e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
BRCA	cis	rs919433	0.963	rs10153881	ENSG00000231621.1	AC013264.2	7.07	2.92e-12	6.68e-10	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306374	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.07	2.92e-12	6.7e-10	-0.25	-0.21	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
BRCA	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-7.07	2.92e-12	6.7e-10	-0.27	-0.21	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
BRCA	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	7.06	2.94e-12	6.73e-10	0.18	0.21	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
BRCA	cis	rs6569038	0.631	rs2357030	ENSG00000253194.1	RP11-351A11.1	7.06	2.94e-12	6.73e-10	0.27	0.21	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065138	chr6:118934785~119031541:+
BRCA	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	7.06	2.94e-12	6.74e-10	0.25	0.21	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
BRCA	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	7.06	2.95e-12	6.75e-10	0.29	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	7.06	2.95e-12	6.76e-10	0.3	0.21	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	7.06	2.95e-12	6.76e-10	0.32	0.21	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
BRCA	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	7.06	2.96e-12	6.77e-10	0.41	0.21	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
BRCA	cis	rs2236231	0.55	rs4902496	ENSG00000259502.1	RP11-643G16.3	-7.06	2.96e-12	6.78e-10	-0.3	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67610986~67613864:+
BRCA	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-7.06	2.96e-12	6.78e-10	-0.26	-0.21	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
BRCA	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	7.06	2.96e-12	6.78e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
BRCA	cis	rs7085104	0.513	rs192569	ENSG00000236937.2	PTGES3P4	-7.06	2.97e-12	6.79e-10	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102845595~102845950:+
BRCA	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-7.06	2.97e-12	6.79e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
BRCA	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-7.06	2.97e-12	6.81e-10	-0.28	-0.21	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
BRCA	cis	rs58873874	0.579	rs75099611	ENSG00000248544.2	CTB-47B11.3	7.06	2.97e-12	6.81e-10	0.44	0.21	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	7.06	2.98e-12	6.82e-10	0.17	0.21	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
BRCA	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-7.06	2.98e-12	6.83e-10	-0.24	-0.21	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
BRCA	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-7.06	2.98e-12	6.83e-10	-0.3	-0.21	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
BRCA	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-7.06	3e-12	6.86e-10	-0.2	-0.21	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
BRCA	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	7.06	3e-12	6.87e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
BRCA	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	7.06	3e-12	6.87e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
BRCA	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-7.06	3.01e-12	6.89e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
BRCA	cis	rs250585	0.736	rs727238	ENSG00000260136.4	CTD-2270L9.4	-7.06	3.01e-12	6.89e-10	-0.22	-0.21	Egg allergy;	chr16:23509745	chr16:23452758~23457606:+
BRCA	cis	rs9876781	1	rs2045554	ENSG00000244380.1	RP11-24C3.2	-7.06	3.01e-12	6.89e-10	-0.24	-0.21	Longevity;	chr3:48453142	chr3:48440352~48446656:-
BRCA	cis	rs10206020	0.921	rs11884956	ENSG00000231482.2	AC141930.2	-7.06	3.01e-12	6.9e-10	-0.28	-0.21	IgG glycosylation;	chr2:1562654	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.8	rs115050567	ENSG00000273486.1	RP11-731C17.2	7.06	3.01e-12	6.9e-10	0.29	0.21	Height;Body mass index;	chr3:136796817	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs9858560	ENSG00000273486.1	RP11-731C17.2	7.06	3.01e-12	6.9e-10	0.29	0.21	Height;Body mass index;	chr3:136798312	chr3:136837338~136839021:-
BRCA	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.06	3.02e-12	6.91e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
BRCA	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-7.06	3.02e-12	6.91e-10	-0.36	-0.21	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
BRCA	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-7.06	3.02e-12	6.92e-10	-0.29	-0.21	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000261582.1	RP4-614O4.11	7.06	3.03e-12	6.92e-10	0.24	0.21	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35267885~35280043:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	7.06	3.03e-12	6.93e-10	0.3	0.21	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	7.06	3.03e-12	6.93e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	7.06	3.03e-12	6.94e-10	0.26	0.21	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	7.06	3.03e-12	6.94e-10	0.26	0.21	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
BRCA	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-7.06	3.03e-12	6.94e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
BRCA	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	7.06	3.04e-12	6.96e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
BRCA	cis	rs12664251	0.666	rs1889561	ENSG00000253194.1	RP11-351A11.1	-7.06	3.04e-12	6.96e-10	-0.26	-0.21	Schizophrenia;	chr6:119014700	chr6:118934785~119031541:+
BRCA	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-7.06	3.05e-12	6.97e-10	-0.27	-0.21	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000236529.1	RP13-254B10.1	-7.06	3.05e-12	6.98e-10	-0.27	-0.21	Aortic root size;	chr7:66101095	chr7:65840212~65840596:+
BRCA	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	7.06	3.05e-12	6.98e-10	0.2	0.21	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
BRCA	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
BRCA	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-7.06	3.07e-12	7.03e-10	-0.28	-0.21	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	7.06	3.08e-12	7.04e-10	0.19	0.21	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.85	rs11049402	ENSG00000278733.1	RP11-425D17.1	-7.06	3.09e-12	7.06e-10	-0.27	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28185625~28186190:-
BRCA	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-7.06	3.09e-12	7.06e-10	-0.28	-0.21	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
BRCA	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-7.06	3.09e-12	7.06e-10	-0.31	-0.21	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
BRCA	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-7.06	3.1e-12	7.08e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
BRCA	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	7.06	3.1e-12	7.08e-10	0.25	0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	7.06	3.1e-12	7.08e-10	0.23	0.21	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
BRCA	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	7.06	3.1e-12	7.09e-10	0.27	0.21	Height;	chr20:49286482	chr20:49280319~49280409:+
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-7.06	3.1e-12	7.09e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
BRCA	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-7.06	3.1e-12	7.1e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
BRCA	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	7.06	3.11e-12	7.1e-10	0.28	0.21	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
BRCA	cis	rs3781264	0.848	rs11187850	ENSG00000273450.1	RP11-76P2.4	7.06	3.12e-12	7.12e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94308723	chr10:94314907~94315327:-
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	7.06	3.12e-12	7.13e-10	0.2	0.21	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
BRCA	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-7.06	3.12e-12	7.14e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
BRCA	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-7.06	3.13e-12	7.15e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-7.06	3.13e-12	7.15e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
BRCA	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.06	3.14e-12	7.17e-10	-0.24	-0.21	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
BRCA	cis	rs681343	1	rs492602	ENSG00000232871.7	SEC1P	7.05	3.14e-12	7.18e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703160	chr19:48638071~48682245:+
BRCA	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	7.05	3.15e-12	7.19e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000224316.1	RP11-479O9.2	-7.05	3.15e-12	7.19e-10	-0.24	-0.21	Aortic root size;	chr7:66620931	chr7:65773620~65802067:+
BRCA	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-7.05	3.17e-12	7.24e-10	-0.24	-0.21	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
BRCA	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
BRCA	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-7.05	3.18e-12	7.25e-10	-0.3	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
BRCA	cis	rs10206020	0.921	rs10177509	ENSG00000231482.2	AC141930.2	-7.05	3.18e-12	7.25e-10	-0.28	-0.21	IgG glycosylation;	chr2:1564764	chr2:1572554~1580311:-
BRCA	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-7.05	3.19e-12	7.27e-10	-0.26	-0.21	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
BRCA	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-7.05	3.19e-12	7.27e-10	-0.25	-0.21	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
BRCA	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	7.05	3.19e-12	7.28e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
BRCA	cis	rs9880211	0.8	rs9865995	ENSG00000273486.1	RP11-731C17.2	7.05	3.19e-12	7.28e-10	0.29	0.21	Height;Body mass index;	chr3:136794508	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs9871184	ENSG00000273486.1	RP11-731C17.2	7.05	3.19e-12	7.28e-10	0.29	0.21	Height;Body mass index;	chr3:136795468	chr3:136837338~136839021:-
BRCA	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-7.05	3.2e-12	7.3e-10	-0.23	-0.21	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
BRCA	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	7.05	3.2e-12	7.31e-10	0.22	0.21	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
BRCA	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	7.05	3.22e-12	7.34e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	7.05	3.22e-12	7.34e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
BRCA	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	7.05	3.23e-12	7.36e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
BRCA	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	7.05	3.23e-12	7.36e-10	0.23	0.21	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	7.05	3.25e-12	7.4e-10	0.25	0.21	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-7.05	3.25e-12	7.4e-10	-0.25	-0.21	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	7.05	3.25e-12	7.41e-10	0.25	0.21	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-7.05	3.26e-12	7.43e-10	-0.23	-0.21	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-7.05	3.26e-12	7.43e-10	-0.23	-0.21	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	7.05	3.27e-12	7.44e-10	0.26	0.21	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
BRCA	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	7.05	3.27e-12	7.44e-10	0.26	0.21	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
BRCA	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	7.05	3.27e-12	7.46e-10	0.32	0.21	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	7.05	3.29e-12	7.5e-10	0.25	0.21	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	7.05	3.29e-12	7.5e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	7.05	3.3e-12	7.52e-10	0.22	0.21	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000236529.1	RP13-254B10.1	-7.05	3.31e-12	7.54e-10	-0.27	-0.21	Aortic root size;	chr7:66089365	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	7.05	3.32e-12	7.55e-10	0.26	0.21	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	7.05	3.32e-12	7.55e-10	0.28	0.21	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
BRCA	cis	rs9907295	0.901	rs4796120	ENSG00000270977.1	AC015849.16	7.05	3.32e-12	7.56e-10	0.37	0.21	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35893707~35911023:-
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-7.05	3.32e-12	7.57e-10	-0.27	-0.21	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
BRCA	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-7.05	3.32e-12	7.57e-10	-0.26	-0.21	Height;	chr14:74458749	chr14:74471930~74472360:-
BRCA	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	7.05	3.33e-12	7.57e-10	0.21	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
BRCA	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	7.05	3.34e-12	7.6e-10	0.3	0.21	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
BRCA	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-7.05	3.34e-12	7.6e-10	-0.26	-0.21	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000224316.1	RP11-479O9.2	-7.05	3.34e-12	7.6e-10	-0.21	-0.21	Aortic root size;	chr7:66165644	chr7:65773620~65802067:+
BRCA	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-7.05	3.34e-12	7.61e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
BRCA	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-7.05	3.34e-12	7.61e-10	-0.19	-0.21	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-7.05	3.34e-12	7.61e-10	-0.19	-0.21	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
BRCA	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-7.05	3.35e-12	7.62e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	7.05	3.35e-12	7.62e-10	0.21	0.21	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	7.05	3.35e-12	7.63e-10	0.19	0.21	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
BRCA	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	7.05	3.36e-12	7.64e-10	0.33	0.21	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
BRCA	cis	rs58873874	0.579	rs11551374	ENSG00000248544.2	CTB-47B11.3	7.05	3.36e-12	7.64e-10	0.43	0.21	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157375741~157384950:-
BRCA	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-7.05	3.36e-12	7.65e-10	-0.28	-0.21	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-7.04	3.37e-12	7.67e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
BRCA	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	7.04	3.37e-12	7.67e-10	0.23	0.21	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
BRCA	cis	rs79040073	0.637	rs57252806	ENSG00000259531.2	RP11-295H24.3	7.04	3.37e-12	7.68e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49352188	chr15:49365124~49366685:-
BRCA	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-7.04	3.37e-12	7.68e-10	-0.25	-0.21	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
BRCA	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	7.04	3.39e-12	7.7e-10	0.23	0.21	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
BRCA	cis	rs42648	0.935	rs7793743	ENSG00000225498.1	AC002064.5	-7.04	3.39e-12	7.71e-10	-0.2	-0.21	Homocysteine levels;	chr7:90402305	chr7:90312496~90322592:+
BRCA	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-7.04	3.39e-12	7.72e-10	-0.28	-0.21	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
BRCA	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-7.04	3.41e-12	7.76e-10	-0.17	-0.21	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
BRCA	cis	rs77204473	0.744	rs12420200	ENSG00000280143.1	AP000892.6	7.04	3.41e-12	7.77e-10	0.32	0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117204967~117210292:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-7.04	3.41e-12	7.77e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
BRCA	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-7.04	3.42e-12	7.78e-10	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	7.04	3.42e-12	7.78e-10	0.21	0.21	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
BRCA	cis	rs6125961	0.629	rs6125971	ENSG00000224397.4	LINC01272	7.04	3.43e-12	7.8e-10	0.24	0.21	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50299229	chr20:50267486~50279795:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
BRCA	cis	rs3814244	0.515	rs2906862	ENSG00000236946.2	HNRNPA1P70	7.04	3.46e-12	7.86e-10	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:68035767~68036853:+
BRCA	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	7.04	3.46e-12	7.86e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	7.04	3.46e-12	7.87e-10	0.25	0.21	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	7.04	3.46e-12	7.87e-10	0.25	0.21	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
BRCA	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	7.04	3.46e-12	7.87e-10	0.3	0.21	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000224316.1	RP11-479O9.2	-7.04	3.47e-12	7.88e-10	-0.21	-0.21	Aortic root size;	chr7:66249983	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	7.04	3.47e-12	7.88e-10	0.24	0.21	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
BRCA	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	7.04	3.47e-12	7.88e-10	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
BRCA	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	7.04	3.48e-12	7.92e-10	0.28	0.21	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
BRCA	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-7.04	3.5e-12	7.94e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
BRCA	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	7.04	3.5e-12	7.96e-10	0.25	0.21	Longevity;	chr3:48457056	chr3:48440352~48446656:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	7.04	3.51e-12	7.97e-10	0.22	0.21	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
BRCA	cis	rs473651	0.503	rs515342	ENSG00000229915.1	AC016999.2	7.04	3.52e-12	7.99e-10	0.32	0.21	Multiple system atrophy;	chr2:238458655	chr2:238427077~238427729:-
BRCA	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-7.04	3.53e-12	8.02e-10	-0.28	-0.21	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
BRCA	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-7.04	3.53e-12	8.02e-10	-0.28	-0.21	Height;	chr20:49227804	chr20:49280319~49280409:+
BRCA	cis	rs2835345	0.563	rs12483690	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451265	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.596	rs12482097	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451592	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.596	rs12482138	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451608	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12482257	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451660	chr21:36430360~36481070:+
BRCA	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-7.04	3.54e-12	8.04e-10	-0.21	-0.21	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
BRCA	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-7.04	3.54e-12	8.04e-10	-0.27	-0.21	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-7.04	3.55e-12	8.07e-10	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	7.04	3.56e-12	8.07e-10	0.25	0.21	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
BRCA	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-7.04	3.56e-12	8.07e-10	-0.25	-0.21	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
BRCA	cis	rs2835345	0.563	rs12627167	ENSG00000230479.1	AP000695.6	7.04	3.56e-12	8.09e-10	0.21	0.21	Pulmonary function;	chr21:36449855	chr21:36430360~36481070:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000236529.1	RP13-254B10.1	-7.04	3.57e-12	8.11e-10	-0.27	-0.21	Aortic root size;	chr7:66105323	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-7.04	3.57e-12	8.11e-10	-0.25	-0.21	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
BRCA	cis	rs79040073	0.636	rs74339964	ENSG00000259531.2	RP11-295H24.3	7.04	3.58e-12	8.13e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49329916	chr15:49365124~49366685:-
BRCA	cis	rs9527	0.641	rs4919684	ENSG00000213061.2	PFN1P11	7.04	3.59e-12	8.14e-10	0.31	0.21	Arsenic metabolism;	chr10:102827267	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-7.04	3.59e-12	8.14e-10	-0.23	-0.21	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
BRCA	cis	rs4072705	0.967	rs4076333	ENSG00000224020.1	MIR181A2HG	-7.04	3.6e-12	8.16e-10	-0.25	-0.21	Menarche (age at onset);	chr9:124623330	chr9:124658467~124698631:+
BRCA	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	7.04	3.6e-12	8.16e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	7.04	3.6e-12	8.16e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
BRCA	cis	rs7845219	0.539	rs713113	ENSG00000253528.2	RP11-347C18.4	-7.04	3.6e-12	8.17e-10	-0.22	-0.21	Type 2 diabetes;	chr8:94865559	chr8:94974573~94974853:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	7.03	3.61e-12	8.18e-10	0.28	0.21	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
BRCA	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	7.03	3.61e-12	8.2e-10	0.24	0.21	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
BRCA	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-7.03	3.62e-12	8.2e-10	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	7.03	3.62e-12	8.2e-10	0.38	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
BRCA	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.62e-12	8.22e-10	-0.26	-0.21	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
BRCA	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-7.03	3.62e-12	8.22e-10	-0.23	-0.21	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
BRCA	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	7.03	3.62e-12	8.22e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
BRCA	cis	rs2014572	1	rs2014572	ENSG00000268379.1	CTC-360J11.4	7.03	3.63e-12	8.22e-10	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57248650	chr19:57175233~57177921:+
BRCA	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.03	3.64e-12	8.26e-10	0.2	0.21	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
BRCA	cis	rs9402682	0.629	rs2223385	ENSG00000232876.1	CTA-212D2.2	-7.03	3.64e-12	8.27e-10	-0.29	-0.21	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135114033	chr6:135055033~135060550:+
BRCA	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-7.03	3.64e-12	8.27e-10	-0.25	-0.21	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
BRCA	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	7.03	3.65e-12	8.27e-10	0.32	0.21	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
BRCA	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	7.03	3.65e-12	8.27e-10	0.32	0.21	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
BRCA	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	7.03	3.65e-12	8.28e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
BRCA	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-7.03	3.65e-12	8.28e-10	-0.31	-0.21	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	7.03	3.66e-12	8.3e-10	0.23	0.21	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
BRCA	cis	rs79040073	0.637	rs73396238	ENSG00000259531.2	RP11-295H24.3	7.03	3.66e-12	8.31e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49347146	chr15:49365124~49366685:-
BRCA	cis	rs4722166	0.598	rs7804146	ENSG00000179428.2	AC073072.5	-7.03	3.67e-12	8.33e-10	-0.22	-0.21	Lung cancer;	chr7:22761310	chr7:22725395~22727620:-
BRCA	cis	rs7927771	0.757	rs1057233	ENSG00000280615.1	Y_RNA	7.03	3.67e-12	8.33e-10	0.26	0.21	Subjective well-being;	chr11:47354897	chr11:47614898~47614994:-
BRCA	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	7.03	3.68e-12	8.35e-10	0.25	0.21	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
BRCA	cis	rs293748	0.771	rs35135658	ENSG00000250155.1	CTD-2353F22.1	-7.03	3.69e-12	8.35e-10	-0.29	-0.21	Obesity-related traits;	chr5:36786777	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.69e-12	8.36e-10	-0.24	-0.21	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
BRCA	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	7.03	3.69e-12	8.37e-10	0.36	0.21	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
BRCA	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	7.03	3.69e-12	8.37e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
BRCA	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-7.03	3.7e-12	8.39e-10	-0.26	-0.21	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
BRCA	cis	rs3781264	1	rs3781264	ENSG00000273450.1	RP11-76P2.4	7.03	3.7e-12	8.4e-10	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94310618	chr10:94314907~94315327:-
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	7.03	3.71e-12	8.4e-10	0.26	0.21	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
BRCA	cis	rs2060793	0.519	rs1357332	ENSG00000251991.1	RNU7-49P	7.03	3.71e-12	8.41e-10	0.23	0.21	Vitamin D levels;	chr11:14618570	chr11:14478892~14478953:+
BRCA	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-7.03	3.71e-12	8.41e-10	-0.21	-0.21	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
BRCA	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	7.03	3.71e-12	8.41e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
BRCA	cis	rs7085104	0.591	rs4919683	ENSG00000236937.2	PTGES3P4	7.03	3.71e-12	8.41e-10	0.27	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102845595~102845950:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-7.03	3.71e-12	8.41e-10	-0.23	-0.21	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000236529.1	RP13-254B10.1	-7.03	3.71e-12	8.41e-10	-0.26	-0.21	Aortic root size;	chr7:66112359	chr7:65840212~65840596:+
BRCA	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	7.03	3.72e-12	8.43e-10	0.29	0.21	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	7.03	3.72e-12	8.43e-10	0.26	0.21	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
BRCA	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-7.03	3.73e-12	8.44e-10	-0.24	-0.21	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
BRCA	cis	rs7474896	0.609	rs1830612	ENSG00000226578.1	RP11-258F22.1	-7.03	3.73e-12	8.45e-10	-0.28	-0.21	Obesity (extreme);	chr10:37710955	chr10:37775371~37784131:-
BRCA	cis	rs9516	0.966	rs2887135	ENSG00000254974.1	RP11-702H23.2	7.03	3.73e-12	8.46e-10	0.25	0.21	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74485580~74486051:-
BRCA	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	7.03	3.74e-12	8.47e-10	0.36	0.21	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	7.03	3.74e-12	8.47e-10	0.36	0.21	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
BRCA	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.03	3.74e-12	8.47e-10	-0.24	-0.21	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
BRCA	cis	rs375066	0.736	rs62114649	ENSG00000267058.1	RP11-15A1.3	7.03	3.74e-12	8.47e-10	0.25	0.21	Breast cancer;	chr19:43912415	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-7.03	3.74e-12	8.48e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
BRCA	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-7.03	3.75e-12	8.5e-10	-0.31	-0.21	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
BRCA	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	7.03	3.75e-12	8.5e-10	0.25	0.21	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
BRCA	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	7.03	3.75e-12	8.5e-10	0.26	0.21	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.613	rs12330335	ENSG00000273486.1	RP11-731C17.2	7.03	3.75e-12	8.5e-10	0.27	0.21	Height;Body mass index;	chr3:136134690	chr3:136837338~136839021:-
BRCA	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-7.03	3.75e-12	8.5e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
BRCA	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-7.03	3.76e-12	8.51e-10	-0.28	-0.21	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
BRCA	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	7.03	3.76e-12	8.52e-10	0.21	0.21	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
BRCA	cis	rs2835345	0.528	rs12483650	ENSG00000230479.1	AP000695.6	7.03	3.76e-12	8.52e-10	0.21	0.21	Pulmonary function;	chr21:36450778	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12483621	ENSG00000230479.1	AP000695.6	7.03	3.76e-12	8.52e-10	0.21	0.21	Pulmonary function;	chr21:36450798	chr21:36430360~36481070:+
BRCA	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	7.03	3.76e-12	8.53e-10	0.19	0.21	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
BRCA	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.77e-12	8.53e-10	-0.25	-0.21	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
BRCA	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	7.03	3.77e-12	8.53e-10	0.25	0.21	Longevity;	chr3:48385276	chr3:48440352~48446656:-
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	7.03	3.77e-12	8.54e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	7.03	3.77e-12	8.54e-10	0.3	0.21	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
BRCA	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-7.03	3.78e-12	8.55e-10	-0.21	-0.21	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
BRCA	cis	rs6723162	0.965	rs11126308	ENSG00000237751.2	LINC01143	-7.03	3.78e-12	8.56e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70887591	chr2:70887871~70889959:+
BRCA	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	7.03	3.79e-12	8.57e-10	0.24	0.21	Longevity;	chr3:48379768	chr3:48440352~48446656:-
BRCA	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-7.03	3.79e-12	8.58e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
BRCA	cis	rs6539288	0.933	rs1444581	ENSG00000260329.1	RP11-412D9.4	-7.03	3.79e-12	8.58e-10	-0.24	-0.21	Total body bone mineral density;	chr12:106920473	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	7.03	3.79e-12	8.59e-10	0.23	0.21	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000230042.1	AK3P3	-7.03	3.81e-12	8.62e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23129178~23129841:+
BRCA	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	7.03	3.81e-12	8.62e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
BRCA	cis	rs4722166	0.598	rs4722178	ENSG00000179428.2	AC073072.5	-7.03	3.81e-12	8.63e-10	-0.22	-0.21	Lung cancer;	chr7:22759031	chr7:22725395~22727620:-
BRCA	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-7.03	3.82e-12	8.65e-10	-0.28	-0.21	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
BRCA	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-7.03	3.82e-12	8.65e-10	-0.24	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	7.03	3.83e-12	8.66e-10	0.17	0.21	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	7.03	3.83e-12	8.66e-10	0.17	0.21	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-7.03	3.83e-12	8.67e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
BRCA	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	7.03	3.83e-12	8.67e-10	0.29	0.21	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
BRCA	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	7.03	3.84e-12	8.69e-10	0.17	0.21	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
BRCA	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	7.03	3.84e-12	8.7e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
BRCA	cis	rs9880211	0.562	rs13068210	ENSG00000273486.1	RP11-731C17.2	7.03	3.85e-12	8.71e-10	0.27	0.21	Height;Body mass index;	chr3:136186704	chr3:136837338~136839021:-
BRCA	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	7.03	3.86e-12	8.72e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
BRCA	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	7.03	3.86e-12	8.72e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
BRCA	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	7.03	3.86e-12	8.73e-10	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-7.02	3.86e-12	8.73e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
BRCA	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	7.02	3.87e-12	8.74e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
BRCA	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	7.02	3.87e-12	8.74e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
BRCA	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	7.02	3.87e-12	8.75e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
BRCA	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	7.02	3.88e-12	8.77e-10	0.26	0.21	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
BRCA	cis	rs6723162	0.965	rs7567290	ENSG00000237751.2	LINC01143	-7.02	3.89e-12	8.81e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70887870	chr2:70887871~70889959:+
BRCA	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	7.02	3.9e-12	8.82e-10	0.3	0.21	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
BRCA	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	7.02	3.91e-12	8.83e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
BRCA	cis	rs2492286	0.597	rs2712372	ENSG00000242551.2	POU5F1P6	-7.02	3.91e-12	8.83e-10	-0.32	-0.21	Eosinophil counts;	chr3:128604994	chr3:128674735~128677005:-
BRCA	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
BRCA	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	7.02	3.91e-12	8.84e-10	0.21	0.21	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	7.02	3.91e-12	8.84e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
BRCA	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	7.02	3.92e-12	8.86e-10	0.26	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
BRCA	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	7.02	3.92e-12	8.86e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	7.02	3.93e-12	8.88e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
BRCA	cis	rs2145598	0.874	rs58231973	ENSG00000279636.2	LINC00216	-7.02	3.93e-12	8.88e-10	-0.21	-0.21	Coronary artery disease;	chr14:58330929	chr14:58288033~58289158:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-7.02	3.93e-12	8.89e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
BRCA	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	7.02	3.94e-12	8.89e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
BRCA	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-7.02	3.94e-12	8.9e-10	-0.22	-0.21	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
BRCA	cis	rs4372836	0.93	rs7607844	ENSG00000226833.4	AC097724.3	7.02	3.94e-12	8.91e-10	0.26	0.21	Body mass index;	chr2:28748872	chr2:28708953~28736205:-
BRCA	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-7.02	3.95e-12	8.93e-10	-0.25	-0.21	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-7.02	3.95e-12	8.93e-10	-0.25	-0.21	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
BRCA	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-7.02	3.96e-12	8.96e-10	-0.23	-0.21	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
BRCA	cis	rs7474896	0.583	rs11011341	ENSG00000226578.1	RP11-258F22.1	-7.02	3.97e-12	8.97e-10	-0.28	-0.21	Obesity (extreme);	chr10:37709572	chr10:37775371~37784131:-
BRCA	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-7.02	3.97e-12	8.97e-10	-0.25	-0.21	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
BRCA	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-7.02	3.97e-12	8.97e-10	-0.27	-0.21	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-7.02	3.97e-12	8.97e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
BRCA	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	7.02	3.99e-12	9.01e-10	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	7.02	3.99e-12	9.02e-10	0.29	0.21	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
BRCA	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-7.02	4.01e-12	9.05e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
BRCA	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	7.02	4.02e-12	9.07e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
BRCA	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-7.02	4.02e-12	9.07e-10	-0.24	-0.21	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
BRCA	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-7.02	4.02e-12	9.07e-10	-0.28	-0.21	AIDS;	chr2:105319955	chr2:105324210~105330529:+
BRCA	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	7.02	4.02e-12	9.08e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
BRCA	cis	rs4722166	0.598	rs35658589	ENSG00000179428.2	AC073072.5	-7.02	4.02e-12	9.08e-10	-0.22	-0.21	Lung cancer;	chr7:22760816	chr7:22725395~22727620:-
BRCA	cis	rs858267	1	rs858267	ENSG00000230658.1	KLHL7-AS1	-7.02	4.02e-12	9.09e-10	-0.6	-0.21	Blood protein levels;	chr7:23170510	chr7:23101228~23105703:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	7.02	4.02e-12	9.09e-10	0.25	0.21	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	7.02	4.03e-12	9.09e-10	0.26	0.21	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	7.02	4.03e-12	9.1e-10	0.25	0.21	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
BRCA	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-7.02	4.05e-12	9.14e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
BRCA	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	7.02	4.05e-12	9.15e-10	0.25	0.21	QT interval;	chr12:29252691	chr12:29280418~29317848:-
BRCA	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	7.02	4.06e-12	9.16e-10	0.27	0.21	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
BRCA	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	7.02	4.06e-12	9.16e-10	0.28	0.21	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
BRCA	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	7.02	4.07e-12	9.17e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
BRCA	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-7.02	4.07e-12	9.2e-10	-0.24	-0.21	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
BRCA	cis	rs79040073	0.637	rs73398250	ENSG00000259531.2	RP11-295H24.3	7.02	4.08e-12	9.22e-10	0.35	0.21	Lung cancer in ever smokers;	chr15:49404829	chr15:49365124~49366685:-
BRCA	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-7.02	4.08e-12	9.22e-10	-0.25	-0.21	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
BRCA	cis	rs9527	0.571	rs7096249	ENSG00000236937.2	PTGES3P4	7.02	4.09e-12	9.24e-10	0.27	0.21	Arsenic metabolism;	chr10:102858767	chr10:102845595~102845950:+
BRCA	cis	rs10861661	0.963	rs10778511	ENSG00000260329.1	RP11-412D9.4	-7.02	4.1e-12	9.24e-10	-0.26	-0.21	Triglyceride levels;	chr12:106831553	chr12:106954029~106955497:-
BRCA	cis	rs11024102	0.83	rs11024110	ENSG00000184669.7	OR7E14P	-7.02	4.1e-12	9.25e-10	-0.32	-0.21	Glaucoma (primary angle closure);	chr11:17006843	chr11:17013998~17053024:+
BRCA	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.32	-0.21	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
BRCA	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-7.02	4.11e-12	9.27e-10	-0.27	-0.21	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-7.02	4.11e-12	9.28e-10	-0.29	-0.21	Gout;	chr7:66732812	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
BRCA	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	7.02	4.11e-12	9.28e-10	0.48	0.21	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
BRCA	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	7.02	4.11e-12	9.28e-10	0.23	0.21	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
BRCA	cis	rs2835345	0.563	rs78113480	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452022	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs4378885	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452613	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs4481073	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452657	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs2835361	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452699	chr21:36430360~36481070:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
BRCA	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-7.01	4.14e-12	9.33e-10	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-7.01	4.14e-12	9.33e-10	-0.26	-0.21	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	7.01	4.14e-12	9.34e-10	0.29	0.21	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-7.01	4.15e-12	9.35e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
BRCA	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-7.01	4.15e-12	9.36e-10	-0.26	-0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
BRCA	cis	rs838147	0.537	rs504963	ENSG00000232871.7	SEC1P	7.01	4.16e-12	9.37e-10	0.23	0.21	Dietary macronutrient intake;	chr19:48705608	chr19:48638071~48682245:+
BRCA	cis	rs2835345	0.563	rs73204246	ENSG00000230479.1	AP000695.6	7.01	4.19e-12	9.45e-10	0.21	0.21	Pulmonary function;	chr21:36452402	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs73204248	ENSG00000230479.1	AP000695.6	7.01	4.19e-12	9.45e-10	0.21	0.21	Pulmonary function;	chr21:36452411	chr21:36430360~36481070:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000236529.1	RP13-254B10.1	-7.01	4.19e-12	9.46e-10	-0.27	-0.21	Aortic root size;	chr7:66091320	chr7:65840212~65840596:+
BRCA	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-7.01	4.2e-12	9.46e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-7.01	4.2e-12	9.46e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
BRCA	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-7.01	4.2e-12	9.46e-10	-0.24	-0.21	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
BRCA	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-7.01	4.2e-12	9.48e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
BRCA	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	7.01	4.21e-12	9.49e-10	0.26	0.21	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-7.01	4.21e-12	9.49e-10	-0.23	-0.21	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
BRCA	cis	rs10029851	0.627	rs2880787	ENSG00000234492.4	RPL34-AS1	7.01	4.21e-12	9.5e-10	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108632175	chr4:108538190~108620460:-
BRCA	cis	rs8030379	1	rs2401173	ENSG00000230373.7	GOLGA6L5P	-7.01	4.21e-12	9.5e-10	-0.23	-0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84507885~84516814:-
BRCA	cis	rs8003054	0.572	rs11626277	ENSG00000258515.1	RP11-203M5.7	7.01	4.22e-12	9.5e-10	0.19	0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445990	chr14:20451305~20451918:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-7.01	4.22e-12	9.51e-10	-0.24	-0.21	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.01	4.23e-12	9.53e-10	-0.24	-0.21	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
BRCA	cis	rs2236231	0.55	rs12897715	ENSG00000259502.1	RP11-643G16.3	-7.01	4.24e-12	9.56e-10	-0.29	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67610986~67613864:+
BRCA	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
BRCA	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
BRCA	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
BRCA	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	7.01	4.26e-12	9.59e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
BRCA	cis	rs3781264	0.848	rs10882422	ENSG00000273450.1	RP11-76P2.4	-7.01	4.26e-12	9.59e-10	-0.27	-0.21	Esophageal cancer and gastric cancer;	chr10:94313806	chr10:94314907~94315327:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	7.01	4.26e-12	9.59e-10	0.33	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	7.01	4.26e-12	9.6e-10	0.26	0.21	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	7.01	4.27e-12	9.61e-10	0.25	0.21	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
BRCA	cis	rs8003054	0.537	rs11160711	ENSG00000258515.1	RP11-203M5.7	-7.01	4.27e-12	9.61e-10	-0.19	-0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445837	chr14:20451305~20451918:+
BRCA	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-7.01	4.28e-12	9.64e-10	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
BRCA	cis	rs293748	0.771	rs58952013	ENSG00000250155.1	CTD-2353F22.1	-7.01	4.28e-12	9.64e-10	-0.29	-0.21	Obesity-related traits;	chr5:36787362	chr5:36666214~36725195:-
BRCA	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-7.01	4.28e-12	9.65e-10	-0.26	-0.21	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
BRCA	cis	rs79040073	0.637	rs11634636	ENSG00000259531.2	RP11-295H24.3	7.01	4.29e-12	9.65e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49315407	chr15:49365124~49366685:-
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-7.01	4.29e-12	9.66e-10	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000232559.3	GS1-124K5.12	7.01	4.3e-12	9.68e-10	0.25	0.21	Aortic root size;	chr7:66049635	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	7.01	4.3e-12	9.68e-10	0.25	0.21	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
BRCA	cis	rs7976269	0.515	rs11049999	ENSG00000257176.2	RP11-996F15.2	-7.01	4.3e-12	9.69e-10	-0.25	-0.21	Male-pattern baldness;	chr12:29042854	chr12:29280418~29317848:-
BRCA	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-7.01	4.3e-12	9.69e-10	-0.27	-0.21	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
BRCA	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-7.01	4.31e-12	9.7e-10	-0.21	-0.21	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
BRCA	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	7.01	4.32e-12	9.73e-10	0.27	0.21	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
BRCA	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	7.01	4.33e-12	9.75e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs10966874	ENSG00000236404.7	VLDLR-AS1	7.01	4.34e-12	9.77e-10	0.33	0.21	Gambling;	chr9:2545581	chr9:2422702~2643359:-
BRCA	cis	rs9907295	0.818	rs9303692	ENSG00000270977.1	AC015849.16	7.01	4.34e-12	9.77e-10	0.3	0.21	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35893707~35911023:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	7.01	4.34e-12	9.78e-10	0.26	0.21	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
BRCA	cis	rs748404	0.666	rs514438	ENSG00000249839.1	AC011330.5	-7.01	4.35e-12	9.78e-10	-0.3	-0.21	Lung cancer;	chr15:43328245	chr15:43663654~43684339:-
BRCA	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
BRCA	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	7.01	4.35e-12	9.79e-10	0.28	0.21	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
BRCA	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-7.01	4.36e-12	9.82e-10	-0.24	-0.21	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
BRCA	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	7.01	4.37e-12	9.83e-10	0.31	0.21	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	7.01	4.37e-12	9.84e-10	0.27	0.21	Height;	chr4:55611014	chr4:55363971~55395847:-
BRCA	cis	rs58873874	0.579	rs77042939	ENSG00000248544.2	CTB-47B11.3	7.01	4.38e-12	9.86e-10	0.46	0.21	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157375741~157384950:-
BRCA	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	7.01	4.39e-12	9.87e-10	0.3	0.21	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
BRCA	cis	rs2492286	0.597	rs2712407	ENSG00000242551.2	POU5F1P6	-7.01	4.39e-12	9.88e-10	-0.32	-0.21	Eosinophil counts;	chr3:128607964	chr3:128674735~128677005:-
BRCA	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-7.01	4.4e-12	9.89e-10	-0.21	-0.21	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	7.01	4.41e-12	9.91e-10	0.25	0.21	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
BRCA	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	7.01	4.42e-12	9.93e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
BRCA	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	7.01	4.42e-12	9.93e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
BRCA	cis	rs6723162	0.868	rs2215826	ENSG00000237751.2	LINC01143	-7	4.43e-12	9.95e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70886266	chr2:70887871~70889959:+
BRCA	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	7	4.43e-12	9.97e-10	0.28	0.21	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
BRCA	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	7	4.44e-12	9.98e-10	0.29	0.21	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	7	4.44e-12	9.99e-10	0.31	0.21	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
BRCA	cis	rs9880211	0.8	rs35880395	ENSG00000273486.1	RP11-731C17.2	7	4.45e-12	9.99e-10	0.29	0.21	Height;Body mass index;	chr3:136788248	chr3:136837338~136839021:-
BRCA	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-7	4.45e-12	1e-09	-0.25	-0.21	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
BRCA	cis	rs4727443	0.866	rs35228488	ENSG00000235713.1	RP4-604G5.3	-7	4.45e-12	1e-09	-0.24	-0.21	Interstitial lung disease;	chr7:100020229	chr7:99992397~99993050:+
BRCA	cis	rs9880211	0.752	rs9847427	ENSG00000273486.1	RP11-731C17.2	7	4.45e-12	1e-09	0.29	0.21	Height;Body mass index;	chr3:136632708	chr3:136837338~136839021:-
BRCA	cis	rs919433	0.963	rs1896854	ENSG00000231621.1	AC013264.2	7	4.46e-12	1e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283052	chr2:197197991~197199273:+
BRCA	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	7	4.46e-12	1e-09	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
BRCA	cis	rs7586673	0.93	rs6432667	ENSG00000235724.7	AC009299.2	-7	4.46e-12	1e-09	-0.25	-0.21	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161222785~161308303:-
BRCA	cis	rs9527	0.615	rs4919685	ENSG00000213061.2	PFN1P11	7	4.46e-12	1e-09	0.31	0.21	Arsenic metabolism;	chr10:102827605	chr10:102838011~102845473:-
BRCA	cis	rs293748	0.771	rs12656269	ENSG00000250155.1	CTD-2353F22.1	7	4.46e-12	1e-09	0.29	0.21	Obesity-related traits;	chr5:36787776	chr5:36666214~36725195:-
BRCA	cis	rs9527	1	rs4919690	ENSG00000213061.2	PFN1P11	-7	4.47e-12	1e-09	-0.32	-0.21	Arsenic metabolism;	chr10:102856743	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	7	4.47e-12	1e-09	0.27	0.21	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
BRCA	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-7	4.49e-12	1.01e-09	-0.26	-0.21	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-7	4.49e-12	1.01e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
BRCA	cis	rs9876781	1	rs2362452	ENSG00000244380.1	RP11-24C3.2	-7	4.49e-12	1.01e-09	-0.24	-0.21	Longevity;	chr3:48376724	chr3:48440352~48446656:-
BRCA	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-7	4.49e-12	1.01e-09	-0.28	-0.21	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-7	4.49e-12	1.01e-09	-0.28	-0.21	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
BRCA	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	7	4.49e-12	1.01e-09	0.24	0.21	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
BRCA	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	7	4.5e-12	1.01e-09	0.25	0.21	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	7	4.5e-12	1.01e-09	0.29	0.21	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
BRCA	cis	rs8054556	0.692	rs4424923	ENSG00000273724.1	RP11-347C12.12	-7	4.5e-12	1.01e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30336400~30343336:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-7	4.5e-12	1.01e-09	-0.25	-0.21	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
BRCA	cis	rs9840812	0.623	rs4678433	ENSG00000239213.4	NCK1-AS1	7	4.51e-12	1.01e-09	0.25	0.21	Fibrinogen levels;	chr3:136546840	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	7	4.51e-12	1.01e-09	0.25	0.21	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
BRCA	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	7	4.52e-12	1.01e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
BRCA	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	7	4.52e-12	1.02e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
BRCA	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	7	4.52e-12	1.02e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	7	4.53e-12	1.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
BRCA	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-7	4.53e-12	1.02e-09	-0.21	-0.21	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	7	4.54e-12	1.02e-09	0.28	0.21	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	7	4.54e-12	1.02e-09	0.28	0.21	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs76819679	ENSG00000186615.9	KTN1-AS1	-7	4.54e-12	1.02e-09	-0.44	-0.21	Putamen volume;	chr14:55667954	chr14:55499278~55580110:-
BRCA	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	7	4.55e-12	1.02e-09	0.22	0.21	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
BRCA	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	7	4.56e-12	1.02e-09	0.3	0.21	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
BRCA	cis	rs957448	1	rs2381882	ENSG00000253175.1	RP11-267M23.6	7	4.56e-12	1.02e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94565036~94565715:+
BRCA	cis	rs3781264	0.724	rs10882435	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94348110	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.761	rs11187899	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94348345	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.687	rs10882436	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94349043	chr10:94314907~94315327:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000224316.1	RP11-479O9.2	-7	4.58e-12	1.03e-09	-0.21	-0.21	Aortic root size;	chr7:66198126	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-7	4.58e-12	1.03e-09	-0.25	-0.21	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	7	4.59e-12	1.03e-09	0.25	0.21	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
BRCA	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	7	4.59e-12	1.03e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	7	4.59e-12	1.03e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
BRCA	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-7	4.59e-12	1.03e-09	-0.2	-0.21	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
BRCA	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	7	4.6e-12	1.03e-09	0.25	0.21	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
BRCA	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	7	4.6e-12	1.03e-09	0.28	0.21	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000224316.1	RP11-479O9.2	7	4.6e-12	1.03e-09	0.24	0.21	Aortic root size;	chr7:66276638	chr7:65773620~65802067:+
BRCA	cis	rs2145598	1	rs2145598	ENSG00000279636.2	LINC00216	-7	4.61e-12	1.03e-09	-0.21	-0.21	Coronary artery disease;	chr14:58327283	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	7	4.61e-12	1.04e-09	0.25	0.21	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	7	4.61e-12	1.04e-09	0.25	0.21	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-7	4.62e-12	1.04e-09	-0.23	-0.21	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
BRCA	cis	rs2060793	0.741	rs4757268	ENSG00000251991.1	RNU7-49P	7	4.62e-12	1.04e-09	0.23	0.21	Vitamin D levels;	chr11:14789216	chr11:14478892~14478953:+
BRCA	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	7	4.63e-12	1.04e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	7	4.63e-12	1.04e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
BRCA	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-7	4.64e-12	1.04e-09	-0.27	-0.21	Height;	chr20:49235382	chr20:49280319~49280409:+
BRCA	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	7	4.64e-12	1.04e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
BRCA	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-7	4.64e-12	1.04e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-7	4.64e-12	1.04e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
BRCA	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-7	4.66e-12	1.05e-09	-0.32	-0.21	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
BRCA	cis	rs6539288	0.803	rs10778517	ENSG00000260329.1	RP11-412D9.4	7	4.67e-12	1.05e-09	0.24	0.21	Total body bone mineral density;	chr12:106947886	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	7	4.68e-12	1.05e-09	0.23	0.21	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
BRCA	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	7	4.69e-12	1.05e-09	0.23	0.21	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
BRCA	cis	rs17253792	0.822	rs74940664	ENSG00000186615.9	KTN1-AS1	-7	4.7e-12	1.05e-09	-0.44	-0.21	Putamen volume;	chr14:55668347	chr14:55499278~55580110:-
BRCA	cis	rs591584	0.73	rs11020847	ENSG00000255893.1	RP11-685N10.1	7	4.7e-12	1.05e-09	0.25	0.21	Macrophage Migration Inhibitory Factor levels;	chr11:94590746	chr11:94472908~94473570:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	7	4.7e-12	1.05e-09	0.23	0.21	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
BRCA	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	7	4.71e-12	1.05e-09	0.26	0.21	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
BRCA	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	7	4.71e-12	1.06e-09	0.25	0.21	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
BRCA	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	7	4.71e-12	1.06e-09	0.25	0.21	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
BRCA	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	7	4.72e-12	1.06e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
BRCA	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	7	4.72e-12	1.06e-09	0.36	0.21	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
BRCA	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	7	4.74e-12	1.06e-09	0.29	0.21	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-7	4.74e-12	1.06e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	6.99	4.75e-12	1.06e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
BRCA	cis	rs2835345	0.63	rs55681268	ENSG00000230479.1	AP000695.6	6.99	4.75e-12	1.06e-09	0.21	0.21	Pulmonary function;	chr21:36449419	chr21:36430360~36481070:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-6.99	4.76e-12	1.07e-09	-0.22	-0.21	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
BRCA	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	6.99	4.76e-12	1.07e-09	0.27	0.21	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
BRCA	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-6.99	4.77e-12	1.07e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Depression;	chr6:28399886	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
BRCA	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	6.99	4.77e-12	1.07e-09	0.25	0.21	Longevity;	chr3:48378233	chr3:48440352~48446656:-
BRCA	cis	rs459482	1	rs459498	ENSG00000228318.3	AP001610.5	-6.99	4.77e-12	1.07e-09	-0.25	-0.21	IgG glycosylation;	chr21:41423100	chr21:41441056~41445708:-
BRCA	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	6.99	4.77e-12	1.07e-09	0.26	0.21	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
BRCA	cis	rs58873874	0.579	rs10037386	ENSG00000248544.2	CTB-47B11.3	6.99	4.78e-12	1.07e-09	0.41	0.21	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157375741~157384950:-
BRCA	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-6.99	4.79e-12	1.07e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
BRCA	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-6.99	4.79e-12	1.07e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
BRCA	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	6.99	4.79e-12	1.07e-09	0.28	0.21	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	6.99	4.79e-12	1.07e-09	0.28	0.21	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
BRCA	cis	rs10029851	0.627	rs6821411	ENSG00000234492.4	RPL34-AS1	6.99	4.79e-12	1.07e-09	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108618352	chr4:108538190~108620460:-
BRCA	cis	rs67981189	0.858	rs2526862	ENSG00000269927.1	RP6-91H8.3	-6.99	4.79e-12	1.07e-09	-0.26	-0.21	Schizophrenia;	chr14:70942897	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.788	rs2526860	ENSG00000269927.1	RP6-91H8.3	-6.99	4.79e-12	1.07e-09	-0.26	-0.21	Schizophrenia;	chr14:70945161	chr14:71141125~71143253:-
BRCA	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	6.99	4.8e-12	1.07e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
BRCA	cis	rs838147	0.508	rs507766	ENSG00000232871.7	SEC1P	6.99	4.8e-12	1.08e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48705286	chr19:48638071~48682245:+
BRCA	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-6.99	4.81e-12	1.08e-09	-0.24	-0.21	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
BRCA	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-6.99	4.81e-12	1.08e-09	-0.29	-0.21	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
BRCA	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	6.99	4.81e-12	1.08e-09	0.23	0.21	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
BRCA	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	6.99	4.81e-12	1.08e-09	0.23	0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
BRCA	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	6.99	4.81e-12	1.08e-09	0.42	0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
BRCA	cis	rs4727443	0.866	rs6963345	ENSG00000235713.1	RP4-604G5.3	-6.99	4.82e-12	1.08e-09	-0.24	-0.21	Interstitial lung disease;	chr7:100020983	chr7:99992397~99993050:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	6.99	4.82e-12	1.08e-09	0.23	0.21	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
BRCA	cis	rs1113500	0.575	rs1781070	ENSG00000226822.1	RP11-356N1.2	-6.99	4.82e-12	1.08e-09	-0.27	-0.21	Growth-regulated protein alpha levels;	chr1:108027076	chr1:108071482~108074519:+
BRCA	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	6.99	4.82e-12	1.08e-09	0.26	0.21	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
BRCA	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	6.99	4.83e-12	1.08e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-6.99	4.83e-12	1.08e-09	-0.28	-0.21	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-6.99	4.83e-12	1.08e-09	-0.24	-0.21	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
BRCA	cis	rs10200159	0.793	rs6545512	ENSG00000272606.1	RP11-554J4.1	6.99	4.84e-12	1.08e-09	0.39	0.21	Vitiligo;	chr2:55656896	chr2:55617909~55618373:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	6.99	4.85e-12	1.09e-09	0.25	0.21	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
BRCA	cis	rs7809950	0.834	rs2712199	ENSG00000238832.1	snoU109	-6.99	4.85e-12	1.09e-09	-0.28	-0.21	Coronary artery disease;	chr7:107499794	chr7:107603363~107603507:+
BRCA	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-6.99	4.85e-12	1.09e-09	-0.25	-0.21	Height;	chr5:36882886	chr5:36666214~36725195:-
BRCA	cis	rs853679	0.769	rs17720293	ENSG00000220721.1	OR1F12	6.99	4.86e-12	1.09e-09	0.43	0.21	Depression;	chr6:28246920	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	6.99	4.86e-12	1.09e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs858302	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23204624	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858301	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23204704	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
BRCA	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-6.99	4.86e-12	1.09e-09	-0.25	-0.21	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
BRCA	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	6.99	4.87e-12	1.09e-09	0.25	0.21	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000224316.1	RP11-479O9.2	6.99	4.87e-12	1.09e-09	0.24	0.21	Aortic root size;	chr7:66505541	chr7:65773620~65802067:+
BRCA	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-6.99	4.88e-12	1.09e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-6.99	4.88e-12	1.09e-09	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
BRCA	cis	rs7267979	0.789	rs6050472	ENSG00000274973.1	RP13-401N8.7	-6.99	4.89e-12	1.09e-09	-0.25	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25845497~25845862:+
BRCA	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	6.99	4.89e-12	1.09e-09	0.23	0.21	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	6.99	4.89e-12	1.09e-09	0.25	0.21	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
BRCA	cis	rs10515750	0.5	rs10463005	ENSG00000251405.2	CTB-109A12.1	-6.99	4.9e-12	1.1e-09	-0.33	-0.21	Lung function (FEV1/FVC);	chr5:157278870	chr5:157362615~157460078:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-6.99	4.9e-12	1.1e-09	-0.25	-0.21	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	6.99	4.91e-12	1.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	6.99	4.91e-12	1.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
BRCA	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	6.99	4.91e-12	1.1e-09	0.3	0.21	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
BRCA	cis	rs6163	0.727	rs284854	ENSG00000236937.2	PTGES3P4	-6.99	4.92e-12	1.1e-09	-0.27	-0.21	Waist circumference;Hip circumference;	chr10:102814805	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-6.99	4.92e-12	1.1e-09	-0.22	-0.21	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
BRCA	cis	rs12446554	0.511	rs72769544	ENSG00000261195.1	CTD-2380F24.1	-6.99	4.94e-12	1.1e-09	-0.33	-0.21	Obesity;	chr16:19765915	chr16:19761172~19766099:-
BRCA	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	6.99	4.94e-12	1.1e-09	0.2	0.21	Asthma;	chr2:102369762	chr2:102438713~102440475:+
BRCA	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	6.99	4.95e-12	1.11e-09	0.25	0.21	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
BRCA	cis	rs11671005	0.696	rs73066211	ENSG00000252334.1	RNU6-1337P	6.99	4.96e-12	1.11e-09	0.34	0.21	Mean platelet volume;	chr19:58485712	chr19:58483749~58483843:-
BRCA	cis	rs12999373	1	rs12999373	ENSG00000272342.1	RP13-539J13.1	6.99	4.96e-12	1.11e-09	0.28	0.21	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:663483	chr2:739588~740164:-
BRCA	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	6.99	4.97e-12	1.11e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	6.99	4.97e-12	1.11e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	6.99	4.97e-12	1.11e-09	0.28	0.21	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
BRCA	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-6.99	4.98e-12	1.11e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-6.99	4.99e-12	1.11e-09	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
BRCA	cis	rs2835345	0.563	rs12627161	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449649	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12627241	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449689	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12627173	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449715	chr21:36430360~36481070:+
BRCA	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-6.99	5e-12	1.12e-09	-0.24	-0.21	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
BRCA	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.99	5.01e-12	1.12e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000224316.1	RP11-479O9.2	-6.99	5.02e-12	1.12e-09	-0.21	-0.21	Aortic root size;	chr7:66160764	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	6.99	5.03e-12	1.12e-09	0.21	0.21	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
BRCA	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-6.99	5.04e-12	1.13e-09	-0.27	-0.21	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
BRCA	cis	rs4237845	0.715	rs4760340	ENSG00000257159.1	RP11-58A17.3	6.99	5.05e-12	1.13e-09	0.24	0.21	Intelligence (multi-trait analysis);	chr12:57881393	chr12:57967058~57968399:+
BRCA	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-6.99	5.05e-12	1.13e-09	-0.26	-0.21	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
BRCA	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	6.99	5.06e-12	1.13e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	6.99	5.06e-12	1.13e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
BRCA	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	6.99	5.06e-12	1.13e-09	0.23	0.21	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
BRCA	cis	rs13178541	0.745	rs4976326	ENSG00000250378.1	RP11-119J18.1	6.98	5.07e-12	1.13e-09	0.29	0.21	IgG glycosylation;	chr5:135728800	chr5:135812667~135826582:+
BRCA	cis	rs224090	0.54	rs11592442	ENSG00000238280.1	RP11-436D10.3	-6.98	5.08e-12	1.13e-09	-0.3	-0.21	Crohn's disease;	chr10:62774144	chr10:62793562~62805887:-
BRCA	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	6.98	5.09e-12	1.14e-09	0.2	0.21	Asthma;	chr2:102369915	chr2:102438713~102440475:+
BRCA	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	6.98	5.09e-12	1.14e-09	0.23	0.21	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
BRCA	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	6.98	5.1e-12	1.14e-09	0.21	0.21	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	6.98	5.1e-12	1.14e-09	0.28	0.21	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
BRCA	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-6.98	5.1e-12	1.14e-09	-0.26	-0.21	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
BRCA	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	6.98	5.11e-12	1.14e-09	0.24	0.21	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	6.98	5.11e-12	1.14e-09	0.14	0.21	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
BRCA	cis	rs375066	0.762	rs10424336	ENSG00000267058.1	RP11-15A1.3	-6.98	5.12e-12	1.14e-09	-0.25	-0.21	Breast cancer;	chr19:43887948	chr19:43891804~43901805:-
BRCA	cis	rs7976269	0.609	rs4931137	ENSG00000257176.2	RP11-996F15.2	-6.98	5.12e-12	1.14e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29049701	chr12:29280418~29317848:-
BRCA	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	6.98	5.12e-12	1.14e-09	0.26	0.21	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
BRCA	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	6.98	5.15e-12	1.15e-09	0.25	0.21	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
BRCA	cis	rs73173548	0.502	rs34933255	ENSG00000247828.6	TMEM161B-AS1	6.98	5.15e-12	1.15e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88446492	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs12188494	ENSG00000247828.6	TMEM161B-AS1	6.98	5.15e-12	1.15e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88447747	chr5:88268895~88436685:+
BRCA	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	6.98	5.15e-12	1.15e-09	0.25	0.21	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
BRCA	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-6.98	5.15e-12	1.15e-09	-0.2	-0.21	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-6.98	5.16e-12	1.15e-09	-0.24	-0.21	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-6.98	5.16e-12	1.15e-09	-0.2	-0.21	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
BRCA	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	6.98	5.16e-12	1.15e-09	0.27	0.21	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
BRCA	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.98	5.18e-12	1.16e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.98	5.18e-12	1.16e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-6.98	5.2e-12	1.16e-09	-0.36	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
BRCA	cis	rs3760982	0.626	rs12463370	ENSG00000267058.1	RP11-15A1.3	-6.98	5.22e-12	1.16e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788014	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-6.98	5.22e-12	1.16e-09	-0.26	-0.21	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	6.98	5.22e-12	1.16e-09	0.25	0.21	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
BRCA	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	6.98	5.23e-12	1.17e-09	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
BRCA	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	6.98	5.23e-12	1.17e-09	0.2	0.21	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
BRCA	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.98	5.25e-12	1.17e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.98	5.25e-12	1.17e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
BRCA	cis	rs10483853	0.525	rs10138789	ENSG00000258408.1	NT5CP2	-6.98	5.25e-12	1.17e-09	-0.29	-0.21	Coronary artery calcification;	chr14:73497574	chr14:73539221~73539781:-
BRCA	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-6.98	5.25e-12	1.17e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
BRCA	cis	rs253959	0.629	rs10054121	ENSG00000271918.1	CTD-2287O16.5	6.98	5.26e-12	1.17e-09	0.17	0.21	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116083807~116085416:-
BRCA	cis	rs73173548	0.502	rs6867204	ENSG00000247828.6	TMEM161B-AS1	6.98	5.26e-12	1.17e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88446423	chr5:88268895~88436685:+
BRCA	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	6.98	5.26e-12	1.17e-09	0.32	0.21	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-6.98	5.28e-12	1.18e-09	-0.2	-0.21	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
BRCA	cis	rs10515750	0.588	rs11739823	ENSG00000248544.2	CTB-47B11.3	6.98	5.29e-12	1.18e-09	0.3	0.21	Lung function (FEV1/FVC);	chr5:157342000	chr5:157375741~157384950:-
BRCA	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	6.98	5.29e-12	1.18e-09	0.49	0.21	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
BRCA	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	6.98	5.29e-12	1.18e-09	0.49	0.21	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
BRCA	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-6.98	5.3e-12	1.18e-09	-0.28	-0.21	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	6.98	5.31e-12	1.18e-09	0.24	0.21	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
BRCA	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	6.98	5.31e-12	1.18e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
BRCA	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	6.98	5.31e-12	1.18e-09	0.27	0.21	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
BRCA	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.98	5.31e-12	1.18e-09	-0.25	-0.21	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
BRCA	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	6.98	5.32e-12	1.18e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
BRCA	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-6.98	5.32e-12	1.18e-09	-0.24	-0.21	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
BRCA	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	6.98	5.33e-12	1.19e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	6.98	5.33e-12	1.19e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
BRCA	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	6.98	5.33e-12	1.19e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	6.98	5.35e-12	1.19e-09	0.3	0.21	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
BRCA	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	6.98	5.37e-12	1.2e-09	0.21	0.21	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
BRCA	cis	rs6545883	0.929	rs6545873	ENSG00000271889.1	RP11-493E12.1	6.98	5.37e-12	1.2e-09	0.27	0.21	Tuberculosis;	chr2:61505877	chr2:61151433~61162105:-
BRCA	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.98	5.38e-12	1.2e-09	0.23	0.21	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-6.98	5.39e-12	1.2e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
BRCA	cis	rs3760982	1	rs4803658	ENSG00000267058.1	RP11-15A1.3	-6.98	5.39e-12	1.2e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785861	chr19:43891804~43901805:-
BRCA	cis	rs12237653	0.929	rs4740695	ENSG00000236404.7	VLDLR-AS1	6.98	5.4e-12	1.2e-09	0.34	0.21	Gambling;	chr9:2547987	chr9:2422702~2643359:-
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	6.98	5.4e-12	1.2e-09	0.25	0.21	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000278665.1	RP11-666O2.4	-6.98	5.4e-12	1.2e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28599241~28601881:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-6.98	5.41e-12	1.2e-09	-0.13	-0.21	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
BRCA	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-6.98	5.41e-12	1.2e-09	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	6.98	5.41e-12	1.2e-09	0.25	0.21	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
BRCA	cis	rs9876781	1	rs9812647	ENSG00000244380.1	RP11-24C3.2	-6.98	5.42e-12	1.21e-09	-0.25	-0.21	Longevity;	chr3:48407507	chr3:48440352~48446656:-
BRCA	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-6.98	5.42e-12	1.21e-09	-0.22	-0.21	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
BRCA	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.98	5.42e-12	1.21e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.98	5.42e-12	1.21e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
BRCA	cis	rs3760982	1	rs11669175	ENSG00000267058.1	RP11-15A1.3	-6.98	5.43e-12	1.21e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785672	chr19:43891804~43901805:-
BRCA	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	6.97	5.44e-12	1.21e-09	0.25	0.21	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
BRCA	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-6.97	5.44e-12	1.21e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	6.97	5.45e-12	1.21e-09	0.23	0.21	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
BRCA	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	6.97	5.45e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
BRCA	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	6.97	5.45e-12	1.21e-09	0.26	0.21	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
BRCA	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
BRCA	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	6.97	5.46e-12	1.21e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
BRCA	cis	rs10181042	0.565	rs1177234	ENSG00000271889.1	RP11-493E12.1	6.97	5.46e-12	1.21e-09	0.26	0.21	Crohn's disease;	chr2:61032928	chr2:61151433~61162105:-
BRCA	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-6.97	5.46e-12	1.22e-09	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
BRCA	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-6.97	5.49e-12	1.22e-09	-0.35	-0.21	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
BRCA	cis	rs2014572	0.967	rs4801452	ENSG00000268379.1	CTC-360J11.4	6.97	5.5e-12	1.22e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57256698	chr19:57175233~57177921:+
BRCA	cis	rs9527	0.571	rs10786715	ENSG00000236937.2	PTGES3P4	6.97	5.5e-12	1.22e-09	0.27	0.21	Arsenic metabolism;	chr10:102860978	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	6.97	5.51e-12	1.22e-09	0.24	0.21	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
BRCA	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	6.97	5.51e-12	1.23e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
BRCA	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	6.97	5.53e-12	1.23e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
BRCA	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-6.97	5.55e-12	1.23e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	6.97	5.55e-12	1.23e-09	0.23	0.21	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
BRCA	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-6.97	5.55e-12	1.23e-09	-0.3	-0.21	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
BRCA	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	6.97	5.57e-12	1.24e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
BRCA	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-6.97	5.58e-12	1.24e-09	-0.21	-0.21	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
BRCA	cis	rs67981189	0.789	rs2810073	ENSG00000269927.1	RP6-91H8.3	-6.97	5.58e-12	1.24e-09	-0.27	-0.21	Schizophrenia;	chr14:70917131	chr14:71141125~71143253:-
BRCA	cis	rs812925	0.762	rs3213951	ENSG00000271889.1	RP11-493E12.1	6.97	5.59e-12	1.24e-09	0.28	0.21	Immature fraction of reticulocytes;	chr2:61395116	chr2:61151433~61162105:-
BRCA	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48384185	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48384586	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48385757	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48386489	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48387420	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48388977	chr3:48440352~48446656:-
BRCA	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-6.97	5.6e-12	1.24e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
BRCA	cis	rs4845875	0.626	rs11121827	ENSG00000242349.4	NPPA-AS1	6.97	5.6e-12	1.24e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11772043	chr1:11841017~11848079:+
BRCA	cis	rs838147	0.508	rs507711	ENSG00000232871.7	SEC1P	6.97	5.62e-12	1.25e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48705307	chr19:48638071~48682245:+
BRCA	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-6.97	5.63e-12	1.25e-09	-0.21	-0.21	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	6.97	5.63e-12	1.25e-09	0.26	0.21	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-6.97	5.63e-12	1.25e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
BRCA	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-6.97	5.65e-12	1.26e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
BRCA	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	6.97	5.65e-12	1.26e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
BRCA	cis	rs6603134	0.502	rs6603131	ENSG00000267939.1	CTD-2325M2.1	-6.97	5.66e-12	1.26e-09	-0.25	-0.21	Blood protein levels;	chr19:8037873	chr19:8008729~8016025:+
BRCA	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-6.97	5.66e-12	1.26e-09	-0.21	-0.21	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	6.97	5.67e-12	1.26e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
BRCA	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392157	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392588	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392923	chr3:48440352~48446656:-
BRCA	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-6.97	5.68e-12	1.26e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
BRCA	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-6.97	5.69e-12	1.26e-09	-0.21	-0.21	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
BRCA	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-6.97	5.7e-12	1.27e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
BRCA	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	6.97	5.7e-12	1.27e-09	0.39	0.21	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
BRCA	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	6.97	5.71e-12	1.27e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
BRCA	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-6.97	5.71e-12	1.27e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
BRCA	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	6.97	5.72e-12	1.27e-09	0.26	0.21	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000254866.2	DEFB109P3	6.97	5.72e-12	1.27e-09	0.28	0.21	Neuroticism;	chr8:11999808	chr8:12150895~12151134:-
BRCA	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	6.97	5.74e-12	1.27e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
BRCA	cis	rs9840812	0.592	rs12489577	ENSG00000239213.4	NCK1-AS1	6.97	5.75e-12	1.28e-09	0.25	0.21	Fibrinogen levels;	chr3:136494303	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-6.97	5.76e-12	1.28e-09	-0.26	-0.21	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	6.97	5.78e-12	1.28e-09	0.17	0.21	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000236529.1	RP13-254B10.1	-6.97	5.79e-12	1.28e-09	-0.26	-0.21	Aortic root size;	chr7:66087627	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	6.97	5.8e-12	1.29e-09	0.23	0.21	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs922075	ENSG00000244380.1	RP11-24C3.2	-6.97	5.81e-12	1.29e-09	-0.24	-0.21	Longevity;	chr3:48447994	chr3:48440352~48446656:-
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-6.96	5.81e-12	1.29e-09	-0.36	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
BRCA	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	6.96	5.81e-12	1.29e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	6.96	5.81e-12	1.29e-09	0.24	0.21	Longevity;	chr3:48408549	chr3:48440352~48446656:-
BRCA	cis	rs7976269	0.559	rs10771471	ENSG00000257176.2	RP11-996F15.2	-6.96	5.81e-12	1.29e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050894	chr12:29280418~29317848:-
BRCA	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	6.96	5.82e-12	1.29e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
BRCA	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	6.96	5.83e-12	1.29e-09	0.25	0.21	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
BRCA	cis	rs6723226	0.961	rs13010404	ENSG00000276334.1	AL133243.1	-6.96	5.83e-12	1.29e-09	-0.27	-0.21	Intelligence (multi-trait analysis);	chr2:32623787	chr2:32521927~32523547:+
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-6.96	5.85e-12	1.3e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
BRCA	cis	rs8054556	0.74	rs4609871	ENSG00000273724.1	RP11-347C12.12	6.96	5.86e-12	1.3e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-6.96	5.87e-12	1.3e-09	-0.26	-0.21	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
BRCA	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	6.96	5.88e-12	1.3e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	6.96	5.88e-12	1.3e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
BRCA	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	6.96	5.88e-12	1.3e-09	0.23	0.21	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	6.96	5.89e-12	1.31e-09	0.25	0.21	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
BRCA	cis	rs4845875	0.626	rs10779764	ENSG00000242349.4	NPPA-AS1	6.96	5.9e-12	1.31e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11772254	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.752	rs67145204	ENSG00000273486.1	RP11-731C17.2	6.96	5.91e-12	1.31e-09	0.28	0.21	Height;Body mass index;	chr3:136609823	chr3:136837338~136839021:-
BRCA	cis	rs4072705	1	rs4836985	ENSG00000224020.1	MIR181A2HG	-6.96	5.92e-12	1.31e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124645615	chr9:124658467~124698631:+
BRCA	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	6.96	5.92e-12	1.31e-09	0.28	0.21	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
BRCA	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	6.96	5.92e-12	1.31e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	6.96	5.93e-12	1.31e-09	0.23	0.21	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	6.96	5.93e-12	1.31e-09	0.23	0.21	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.585	rs2059362	ENSG00000275476.1	RP11-996F15.4	6.96	5.93e-12	1.31e-09	0.24	0.21	QT interval;	chr12:29243072	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	6.96	5.94e-12	1.32e-09	0.25	0.21	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	6.96	5.95e-12	1.32e-09	0.22	0.21	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
BRCA	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-6.96	5.95e-12	1.32e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
BRCA	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	6.96	5.97e-12	1.32e-09	0.23	0.21	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
BRCA	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-6.96	5.97e-12	1.32e-09	-0.23	-0.21	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
BRCA	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.96	5.99e-12	1.33e-09	-0.2	-0.21	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
BRCA	cis	rs293748	0.771	rs12659981	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Obesity-related traits;	chr5:36787996	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs12659983	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Obesity-related traits;	chr5:36788002	chr5:36666214~36725195:-
BRCA	cis	rs42648	0.755	rs1557650	ENSG00000225498.1	AC002064.5	6.96	6.01e-12	1.33e-09	0.21	0.21	Homocysteine levels;	chr7:90342242	chr7:90312496~90322592:+
BRCA	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
BRCA	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-6.96	6.01e-12	1.33e-09	-0.25	-0.21	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
BRCA	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.96	6.01e-12	1.33e-09	-0.19	-0.21	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
BRCA	cis	rs2933343	0.553	rs789212	ENSG00000261159.1	RP11-723O4.9	6.96	6.02e-12	1.33e-09	0.23	0.21	IgG glycosylation;	chr3:128968069	chr3:128859716~128860526:-
BRCA	cis	rs7085104	0.572	rs284858	ENSG00000236937.2	PTGES3P4	-6.96	6.03e-12	1.33e-09	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102845595~102845950:+
BRCA	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-6.96	6.03e-12	1.34e-09	-0.21	-0.21	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.96	6.04e-12	1.34e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.96	6.04e-12	1.34e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
BRCA	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	6.96	6.04e-12	1.34e-09	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
BRCA	cis	rs2014572	0.967	rs8100154	ENSG00000268379.1	CTC-360J11.4	6.96	6.05e-12	1.34e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57254064	chr19:57175233~57177921:+
BRCA	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-6.96	6.05e-12	1.34e-09	-0.3	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
BRCA	cis	rs3781264	1	rs7096678	ENSG00000273450.1	RP11-76P2.4	6.96	6.05e-12	1.34e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94309451	chr10:94314907~94315327:-
BRCA	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-6.96	6.07e-12	1.34e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
BRCA	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-6.96	6.07e-12	1.34e-09	-0.26	-0.21	QT interval;	chr12:29298788	chr12:29280418~29317848:-
BRCA	cis	rs2145598	1	rs10137475	ENSG00000279636.2	LINC00216	-6.96	6.08e-12	1.35e-09	-0.21	-0.21	Coronary artery disease;	chr14:58331235	chr14:58288033~58289158:+
BRCA	cis	rs67311347	1	rs11914297	ENSG00000280739.1	EIF1B-AS1	6.96	6.08e-12	1.35e-09	0.24	0.21	Renal cell carcinoma;	chr3:40368579	chr3:40173145~40309698:-
BRCA	cis	rs3781264	0.761	rs11187893	ENSG00000273450.1	RP11-76P2.4	-6.96	6.09e-12	1.35e-09	-0.29	-0.21	Esophageal cancer and gastric cancer;	chr10:94346222	chr10:94314907~94315327:-
BRCA	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-6.96	6.1e-12	1.35e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
BRCA	cis	rs3781264	0.848	rs6583935	ENSG00000273450.1	RP11-76P2.4	6.96	6.1e-12	1.35e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94313568	chr10:94314907~94315327:-
BRCA	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-6.96	6.12e-12	1.35e-09	-0.29	-0.21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
BRCA	cis	rs73173548	0.502	rs6865869	ENSG00000247828.6	TMEM161B-AS1	6.96	6.13e-12	1.36e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88449645	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.738	rs12659772	ENSG00000247828.6	TMEM161B-AS1	6.96	6.13e-12	1.36e-09	0.29	0.21	Depressive symptoms;	chr5:88451917	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.963	rs12693815	ENSG00000231621.1	AC013264.2	6.96	6.14e-12	1.36e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197303679	chr2:197197991~197199273:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	6.96	6.16e-12	1.36e-09	0.23	0.21	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
BRCA	cis	rs293748	0.771	rs12659960	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.16e-12	1.36e-09	-0.29	-0.21	Obesity-related traits;	chr5:36787913	chr5:36666214~36725195:-
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	6.96	6.16e-12	1.36e-09	0.27	0.21	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
BRCA	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-6.96	6.18e-12	1.37e-09	-0.24	-0.21	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
BRCA	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.18e-12	1.37e-09	-0.23	-0.21	Height;	chr5:36832512	chr5:36666214~36725195:-
BRCA	cis	rs7976269	0.559	rs1344853	ENSG00000257176.2	RP11-996F15.2	-6.96	6.19e-12	1.37e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29058623	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	6.96	6.21e-12	1.37e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
BRCA	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-6.95	6.22e-12	1.38e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	6.95	6.23e-12	1.38e-09	0.23	0.21	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.528	rs34857793	ENSG00000247828.6	TMEM161B-AS1	6.95	6.24e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88467749	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	6.95	6.24e-12	1.38e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	6.95	6.24e-12	1.38e-09	0.26	0.21	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs10505855	ENSG00000247828.6	TMEM161B-AS1	6.95	6.25e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88440962	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs4129235	ENSG00000247828.6	TMEM161B-AS1	6.95	6.25e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88441465	chr5:88268895~88436685:+
BRCA	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	6.95	6.25e-12	1.38e-09	0.23	0.21	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
BRCA	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-6.95	6.26e-12	1.38e-09	-0.27	-0.21	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
BRCA	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	6.95	6.27e-12	1.39e-09	0.31	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
BRCA	cis	rs10276381	1	rs10276381	ENSG00000234336.5	JAZF1-AS1	6.95	6.27e-12	1.39e-09	0.35	0.21	Crohn's disease;	chr7:28150502	chr7:28180322~28243917:+
BRCA	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	6.95	6.27e-12	1.39e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
BRCA	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	6.95	6.27e-12	1.39e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
BRCA	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	6.95	6.28e-12	1.39e-09	0.25	0.21	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-6.95	6.29e-12	1.39e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000224316.1	RP11-479O9.2	6.95	6.3e-12	1.39e-09	0.21	0.21	Aortic root size;	chr7:66049635	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000224316.1	RP11-479O9.2	6.95	6.3e-12	1.39e-09	0.21	0.21	Aortic root size;	chr7:66049641	chr7:65773620~65802067:+
BRCA	cis	rs783540	0.609	rs803686	ENSG00000278603.1	RP13-608F4.5	-6.95	6.31e-12	1.39e-09	-0.31	-0.21	Schizophrenia;	chr15:82550590	chr15:82472203~82472426:+
BRCA	cis	rs12468579	0.77	rs13395505	ENSG00000235852.1	AC005540.3	-6.95	6.31e-12	1.39e-09	-0.22	-0.21	JT interval (sulfonylurea treatment interaction);	chr2:190973788	chr2:190880797~190882059:-
BRCA	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	6.95	6.32e-12	1.4e-09	0.32	0.21	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
BRCA	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-6.95	6.34e-12	1.4e-09	-0.28	-0.21	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
BRCA	cis	rs6442522	0.733	rs4143273	ENSG00000249786.6	EAF1-AS1	-6.95	6.35e-12	1.4e-09	-0.22	-0.21	Uric acid levels;	chr3:15460301	chr3:15436171~15455940:-
BRCA	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	6.95	6.35e-12	1.4e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
BRCA	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-6.95	6.36e-12	1.4e-09	-0.24	-0.21	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
BRCA	cis	rs755249	0.567	rs6668369	ENSG00000228060.1	RP11-69E11.8	-6.95	6.36e-12	1.4e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39565160~39573203:+
BRCA	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-6.95	6.37e-12	1.41e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
BRCA	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-6.95	6.37e-12	1.41e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000267422.1	CTD-2554C21.1	-6.95	6.39e-12	1.41e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37517333	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	6.95	6.4e-12	1.41e-09	0.21	0.21	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
BRCA	cis	rs10515750	0.53	rs13358909	ENSG00000251405.2	CTB-109A12.1	6.95	6.4e-12	1.41e-09	0.46	0.21	Lung function (FEV1/FVC);	chr5:157288824	chr5:157362615~157460078:-
BRCA	cis	rs11723261	0.621	rs7440274	ENSG00000211553.1	AC253576.2	6.95	6.41e-12	1.42e-09	0.31	0.21	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:136461~136568:+
BRCA	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	6.95	6.42e-12	1.42e-09	0.25	0.21	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
BRCA	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	6.95	6.43e-12	1.42e-09	0.19	0.21	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
BRCA	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	6.95	6.44e-12	1.42e-09	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
BRCA	cis	rs8177876	0.642	rs4454990	ENSG00000261838.4	RP11-303E16.6	-6.95	6.44e-12	1.42e-09	-0.4	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81069854~81076598:+
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	6.95	6.44e-12	1.42e-09	0.25	0.21	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000232559.3	GS1-124K5.12	-6.95	6.45e-12	1.42e-09	-0.25	-0.21	Aortic root size;	chr7:66261628	chr7:66554588~66576923:-
BRCA	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
BRCA	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-6.95	6.46e-12	1.43e-09	-0.28	-0.21	Gout;	chr7:66693028	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.567	rs72661961	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.532	rs61779277	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.532	rs61779278	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2296172	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779279	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39565160~39573203:+
BRCA	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	6.95	6.48e-12	1.43e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
BRCA	cis	rs42648	0.935	rs42659	ENSG00000225498.1	AC002064.5	6.95	6.49e-12	1.43e-09	0.2	0.21	Homocysteine levels;	chr7:90352644	chr7:90312496~90322592:+
BRCA	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	6.95	6.49e-12	1.43e-09	0.29	0.21	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	6.95	6.49e-12	1.43e-09	0.29	0.21	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
BRCA	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-6.95	6.49e-12	1.43e-09	-0.29	-0.21	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	6.95	6.5e-12	1.43e-09	0.23	0.21	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
BRCA	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	6.95	6.5e-12	1.43e-09	0.26	0.21	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
BRCA	cis	rs6723226	1	rs6723226	ENSG00000276334.1	AL133243.1	6.95	6.5e-12	1.43e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32521927~32523547:+
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	6.95	6.51e-12	1.44e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
BRCA	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-6.95	6.52e-12	1.44e-09	-0.27	-0.21	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
BRCA	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-6.95	6.56e-12	1.45e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
BRCA	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	6.95	6.56e-12	1.45e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
BRCA	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-6.95	6.56e-12	1.45e-09	-0.27	-0.21	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
BRCA	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	6.95	6.56e-12	1.45e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
BRCA	cis	rs2014572	0.967	rs10413671	ENSG00000268379.1	CTC-360J11.4	6.95	6.58e-12	1.45e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57252121	chr19:57175233~57177921:+
BRCA	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	6.95	6.59e-12	1.45e-09	0.26	0.21	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.8	rs35422852	ENSG00000273486.1	RP11-731C17.2	6.95	6.59e-12	1.45e-09	0.29	0.21	Height;Body mass index;	chr3:136787073	chr3:136837338~136839021:-
BRCA	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-6.95	6.6e-12	1.45e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
BRCA	cis	rs2638953	0.924	rs1551987	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1551986	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs2078017	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28185625~28186190:-
BRCA	cis	rs78456975	0.527	rs72778003	ENSG00000231482.2	AC141930.2	-6.95	6.61e-12	1.46e-09	-0.28	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567715	chr2:1572554~1580311:-
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	6.95	6.61e-12	1.46e-09	0.2	0.21	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	6.95	6.61e-12	1.46e-09	0.23	0.21	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-6.95	6.61e-12	1.46e-09	-0.25	-0.21	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-6.95	6.63e-12	1.46e-09	-0.26	-0.21	QT interval;	chr12:29309811	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	6.95	6.64e-12	1.46e-09	0.25	0.21	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.924	rs11049415	ENSG00000247934.4	RP11-967K21.1	-6.95	6.64e-12	1.46e-09	-0.27	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.965	rs7591345	ENSG00000271889.1	RP11-493E12.1	6.95	6.64e-12	1.46e-09	0.27	0.21	Tuberculosis;	chr2:61502506	chr2:61151433~61162105:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-6.95	6.65e-12	1.46e-09	-0.23	-0.21	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	6.94	6.66e-12	1.47e-09	0.21	0.21	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
BRCA	cis	rs2014572	0.967	rs10412975	ENSG00000268379.1	CTC-360J11.4	6.94	6.67e-12	1.47e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57259186	chr19:57175233~57177921:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	6.94	6.67e-12	1.47e-09	0.23	0.21	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
BRCA	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-6.94	6.67e-12	1.47e-09	-0.3	-0.21	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
BRCA	cis	rs6545883	0.868	rs7574631	ENSG00000271889.1	RP11-493E12.1	6.94	6.68e-12	1.47e-09	0.27	0.21	Tuberculosis;	chr2:61598007	chr2:61151433~61162105:-
BRCA	cis	rs67311347	1	rs9860162	ENSG00000280739.1	EIF1B-AS1	6.94	6.69e-12	1.47e-09	0.24	0.21	Renal cell carcinoma;	chr3:40362384	chr3:40173145~40309698:-
BRCA	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-6.94	6.69e-12	1.47e-09	-0.24	-0.21	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
BRCA	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	6.94	6.7e-12	1.48e-09	0.23	0.21	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000251417.2	RP11-1348G14.4	-6.94	6.71e-12	1.48e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28802743~28817828:+
BRCA	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.94	6.71e-12	1.48e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	6.94	6.72e-12	1.48e-09	0.27	0.21	Height;	chr4:55522229	chr4:55363971~55395847:-
BRCA	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	6.94	6.72e-12	1.48e-09	0.23	0.21	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-6.94	6.72e-12	1.48e-09	-0.21	-0.21	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	6.94	6.72e-12	1.48e-09	0.25	0.21	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	6.94	6.72e-12	1.48e-09	0.25	0.21	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-6.94	6.73e-12	1.48e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	6.94	6.73e-12	1.48e-09	0.25	0.21	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	6.94	6.74e-12	1.48e-09	0.26	0.21	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	6.94	6.74e-12	1.49e-09	0.25	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
BRCA	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	6.94	6.75e-12	1.49e-09	0.26	0.21	QT interval;	chr12:29284120	chr12:29280418~29317848:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000254174.1	IGHV1-12	6.94	6.76e-12	1.49e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106679574	chr14:106122420~106122709:-
BRCA	cis	rs9307551	0.857	rs2165387	ENSG00000250334.4	LINC00989	-6.94	6.76e-12	1.49e-09	-0.28	-0.21	Refractive error;	chr4:79570666	chr4:79492416~79576460:+
BRCA	cis	rs375066	0.762	rs239939	ENSG00000267058.1	RP11-15A1.3	-6.94	6.76e-12	1.49e-09	-0.24	-0.21	Breast cancer;	chr19:43883815	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs239938	ENSG00000267058.1	RP11-15A1.3	-6.94	6.76e-12	1.49e-09	-0.24	-0.21	Breast cancer;	chr19:43886153	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	6.94	6.76e-12	1.49e-09	0.28	0.21	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	6.94	6.76e-12	1.49e-09	0.28	0.21	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
BRCA	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-6.94	6.76e-12	1.49e-09	-0.26	-0.21	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
BRCA	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	6.94	6.78e-12	1.49e-09	0.25	0.21	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
BRCA	cis	rs2835345	0.563	rs60727080	ENSG00000230479.1	AP000695.6	6.94	6.79e-12	1.49e-09	0.21	0.21	Pulmonary function;	chr21:36454876	chr21:36430360~36481070:+
BRCA	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	6.94	6.79e-12	1.49e-09	0.25	0.21	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	6.94	6.79e-12	1.49e-09	0.25	0.21	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	6.94	6.8e-12	1.5e-09	0.29	0.21	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
BRCA	cis	rs10200159	0.744	rs6545513	ENSG00000272606.1	RP11-554J4.1	6.94	6.8e-12	1.5e-09	0.38	0.21	Vitiligo;	chr2:55657729	chr2:55617909~55618373:+
BRCA	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	6.94	6.8e-12	1.5e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	6.94	6.83e-12	1.5e-09	0.25	0.21	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.752	rs9820717	ENSG00000273486.1	RP11-731C17.2	6.94	6.83e-12	1.5e-09	0.28	0.21	Height;Body mass index;	chr3:136627771	chr3:136837338~136839021:-
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	6.94	6.83e-12	1.5e-09	0.27	0.21	Height;	chr4:55529786	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	6.94	6.83e-12	1.5e-09	0.27	0.21	Height;	chr4:55532542	chr4:55363971~55395847:-
BRCA	cis	rs9880211	0.699	rs34804893	ENSG00000273486.1	RP11-731C17.2	6.94	6.84e-12	1.51e-09	0.28	0.21	Height;Body mass index;	chr3:136621128	chr3:136837338~136839021:-
BRCA	cis	rs2638953	0.924	rs10492368	ENSG00000278733.1	RP11-425D17.1	-6.94	6.85e-12	1.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	6.94	6.86e-12	1.51e-09	0.25	0.21	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-6.94	6.86e-12	1.51e-09	-0.27	-0.21	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
BRCA	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	6.94	6.87e-12	1.51e-09	0.23	0.21	Height;	chr5:36948260	chr5:36666214~36725195:-
BRCA	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-6.94	6.87e-12	1.51e-09	-0.21	-0.21	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-6.94	6.91e-12	1.52e-09	-0.24	-0.21	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	6.94	6.93e-12	1.52e-09	0.24	0.21	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	6.94	6.95e-12	1.53e-09	0.21	0.21	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
BRCA	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	6.94	6.97e-12	1.53e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
BRCA	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-6.94	6.98e-12	1.53e-09	-0.27	-0.21	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
BRCA	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	6.94	6.98e-12	1.54e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
BRCA	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-6.94	7.02e-12	1.54e-09	-0.27	-0.21	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
BRCA	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	6.94	7.02e-12	1.54e-09	0.2	0.21	Asthma;	chr2:102370999	chr2:102438713~102440475:+
BRCA	cis	rs9368481	0.524	rs9393768	ENSG00000241549.7	GUSBP2	6.94	7.03e-12	1.55e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26871484~26956554:-
BRCA	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	6.94	7.03e-12	1.55e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
BRCA	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.94	7.05e-12	1.55e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-6.94	7.06e-12	1.55e-09	-0.21	-0.21	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000274576.2	IGHV2-70	-6.94	7.07e-12	1.55e-09	-0.17	-0.21	Kawasaki disease;	chr14:106786292	chr14:106770577~106771020:-
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	6.94	7.07e-12	1.55e-09	0.35	0.21	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
BRCA	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-6.94	7.07e-12	1.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-6.94	7.07e-12	1.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
BRCA	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.94	7.07e-12	1.55e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
BRCA	cis	rs2014572	0.875	rs10405008	ENSG00000268379.1	CTC-360J11.4	-6.94	7.09e-12	1.56e-09	-0.26	-0.21	Hyperactive-impulsive symptoms;	chr19:57242275	chr19:57175233~57177921:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	6.94	7.09e-12	1.56e-09	0.22	0.21	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
BRCA	cis	rs755249	0.567	rs76111861	ENSG00000228060.1	RP11-69E11.8	-6.94	7.1e-12	1.56e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661965	ENSG00000228060.1	RP11-69E11.8	-6.94	7.1e-12	1.56e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39565160~39573203:+
BRCA	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	6.94	7.1e-12	1.56e-09	0.26	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
BRCA	cis	rs5758659	0.652	rs4822084	ENSG00000273366.1	CTA-989H11.1	6.94	7.11e-12	1.56e-09	0.26	0.21	Cognitive function;	chr22:42039864	chr22:42278188~42278846:+
BRCA	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	6.94	7.11e-12	1.56e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	6.94	7.12e-12	1.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-6.94	7.12e-12	1.56e-09	-0.28	-0.21	Gout;	chr7:66715944	chr7:66880708~66882981:+
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	6.93	7.12e-12	1.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
BRCA	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.93	7.13e-12	1.57e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.93	7.13e-12	1.57e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
BRCA	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	6.93	7.13e-12	1.57e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
BRCA	cis	rs3794924	1	rs8091481	ENSG00000266521.1	RP11-650P15.1	6.93	7.13e-12	1.57e-09	0.37	0.21	Survival in colon cancer;	chr18:31471714	chr18:31496645~31497195:-
BRCA	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	6.93	7.13e-12	1.57e-09	0.24	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	6.93	7.15e-12	1.57e-09	0.27	0.21	Height;	chr4:55561218	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	6.93	7.15e-12	1.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
BRCA	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	6.93	7.17e-12	1.57e-09	0.28	0.21	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
BRCA	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	6.93	7.17e-12	1.58e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	6.93	7.18e-12	1.58e-09	0.25	0.21	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	6.93	7.18e-12	1.58e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-6.93	7.21e-12	1.58e-09	-0.23	-0.21	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
BRCA	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-6.93	7.22e-12	1.59e-09	-0.23	-0.21	Height;	chr5:37182208	chr5:36666214~36725195:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-6.93	7.22e-12	1.59e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
BRCA	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-6.93	7.22e-12	1.59e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
BRCA	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	6.93	7.24e-12	1.59e-09	0.27	0.21	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
BRCA	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.93	7.24e-12	1.59e-09	0.25	0.21	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
BRCA	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	6.93	7.25e-12	1.59e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
BRCA	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	6.93	7.25e-12	1.59e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
BRCA	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-6.93	7.26e-12	1.59e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
BRCA	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	6.93	7.29e-12	1.6e-09	0.23	0.21	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	6.93	7.29e-12	1.6e-09	0.23	0.21	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
BRCA	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6.93	7.3e-12	1.6e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
BRCA	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-6.93	7.31e-12	1.6e-09	-0.24	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
BRCA	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	6.93	7.31e-12	1.6e-09	0.25	0.21	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
BRCA	cis	rs16846053	0.551	rs12692640	ENSG00000227403.1	AC009299.3	-6.93	7.32e-12	1.61e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161669405	chr2:161244739~161249050:+
BRCA	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.93	7.32e-12	1.61e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
BRCA	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	6.93	7.33e-12	1.61e-09	0.27	0.21	Height;	chr20:49220589	chr20:49280319~49280409:+
BRCA	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	6.93	7.33e-12	1.61e-09	0.26	0.21	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
BRCA	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-6.93	7.33e-12	1.61e-09	-0.29	-0.21	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
BRCA	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	6.93	7.34e-12	1.61e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	6.93	7.34e-12	1.61e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
BRCA	cis	rs7086627	0.515	rs4933390	ENSG00000226659.1	RP11-137H2.4	-6.93	7.34e-12	1.61e-09	-0.27	-0.21	Post bronchodilator FEV1;	chr10:80453325	chr10:80529597~80535942:-
BRCA	cis	rs8114671	0.967	rs6088747	ENSG00000269202.1	RP4-614O4.12	-6.93	7.35e-12	1.61e-09	-0.22	-0.21	Height;	chr20:35166801	chr20:35201747~35203288:-
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30729469~30731202:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	6.93	7.35e-12	1.61e-09	0.23	0.21	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-6.93	7.35e-12	1.61e-09	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
BRCA	cis	rs12501370	0.921	rs7674811	ENSG00000201736.1	RNA5SP160	6.93	7.35e-12	1.61e-09	0.25	0.21	Iris color (L* coordinate);	chr4:41037718	chr4:40990154~40990273:+
BRCA	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.93	7.36e-12	1.61e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.93	7.37e-12	1.62e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.93	7.37e-12	1.62e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
BRCA	cis	rs9307551	0.779	rs12501981	ENSG00000250334.4	LINC00989	-6.93	7.38e-12	1.62e-09	-0.28	-0.21	Refractive error;	chr4:79591850	chr4:79492416~79576460:+
BRCA	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-6.93	7.38e-12	1.62e-09	-0.3	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
BRCA	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-6.93	7.38e-12	1.62e-09	-0.24	-0.21	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
BRCA	cis	rs9880211	0.613	rs28519617	ENSG00000273486.1	RP11-731C17.2	6.93	7.38e-12	1.62e-09	0.27	0.21	Height;Body mass index;	chr3:136156088	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.613	rs28669017	ENSG00000273486.1	RP11-731C17.2	6.93	7.38e-12	1.62e-09	0.27	0.21	Height;Body mass index;	chr3:136156090	chr3:136837338~136839021:-
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000251417.2	RP11-1348G14.4	-6.93	7.39e-12	1.62e-09	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28802743~28817828:+
BRCA	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-6.93	7.4e-12	1.62e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
BRCA	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	6.93	7.41e-12	1.62e-09	0.2	0.21	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
BRCA	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	6.93	7.42e-12	1.63e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66692349	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66693433	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66694214	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66701371	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66702658	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66706390	chr7:66880708~66882981:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66710076	chr7:66880708~66882981:+
BRCA	cis	rs7586673	0.857	rs16845580	ENSG00000235724.7	AC009299.2	-6.93	7.43e-12	1.63e-09	-0.25	-0.21	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161222785~161308303:-
BRCA	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-6.93	7.43e-12	1.63e-09	-0.26	-0.21	QT interval;	chr12:29302457	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-6.93	7.43e-12	1.63e-09	-0.26	-0.21	QT interval;	chr12:29302458	chr12:29280418~29317848:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	6.93	7.43e-12	1.63e-09	0.23	0.21	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
BRCA	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-6.93	7.44e-12	1.63e-09	-0.22	-0.21	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
BRCA	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	6.93	7.44e-12	1.63e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
BRCA	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	6.93	7.45e-12	1.63e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-6.93	7.45e-12	1.63e-09	-0.23	-0.21	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	6.93	7.46e-12	1.63e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
BRCA	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	6.93	7.46e-12	1.63e-09	0.29	0.21	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	6.93	7.47e-12	1.64e-09	0.23	0.21	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
BRCA	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-6.93	7.47e-12	1.64e-09	-0.29	-0.21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
BRCA	cis	rs473651	0.777	rs550890	ENSG00000229915.1	AC016999.2	-6.93	7.47e-12	1.64e-09	-0.28	-0.21	Multiple system atrophy;	chr2:238423914	chr2:238427077~238427729:-
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	6.93	7.48e-12	1.64e-09	0.27	0.21	Height;	chr4:55517185	chr4:55363971~55395847:-
BRCA	cis	rs74233809	0.901	rs17115100	ENSG00000213277.3	MARCKSL1P1	6.93	7.49e-12	1.64e-09	0.37	0.21	Birth weight;	chr10:102831636	chr10:103175554~103176094:+
BRCA	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-6.93	7.5e-12	1.64e-09	-0.24	-0.21	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	6.93	7.5e-12	1.64e-09	0.14	0.21	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
BRCA	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.93	7.51e-12	1.64e-09	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
BRCA	cis	rs11971779	0.7	rs11763942	ENSG00000273391.1	RP11-634H22.1	6.93	7.52e-12	1.65e-09	0.25	0.21	Diisocyanate-induced asthma;	chr7:139321049	chr7:139359032~139359566:-
BRCA	cis	rs875971	1	rs6963646	ENSG00000224316.1	RP11-479O9.2	-6.93	7.53e-12	1.65e-09	-0.21	-0.21	Aortic root size;	chr7:66220780	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-6.93	7.53e-12	1.65e-09	-0.32	-0.21	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
BRCA	cis	rs9307551	0.817	rs1348086	ENSG00000250334.4	LINC00989	-6.93	7.54e-12	1.65e-09	-0.28	-0.21	Refractive error;	chr4:79605078	chr4:79492416~79576460:+
BRCA	cis	rs42648	0.935	rs7803012	ENSG00000225498.1	AC002064.5	-6.93	7.55e-12	1.65e-09	-0.2	-0.21	Homocysteine levels;	chr7:90396852	chr7:90312496~90322592:+
BRCA	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	6.93	7.55e-12	1.65e-09	0.4	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	6.93	7.57e-12	1.66e-09	0.24	0.21	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	6.93	7.58e-12	1.66e-09	0.23	0.21	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	6.93	7.58e-12	1.66e-09	0.23	0.21	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs11976037	ENSG00000204959.4	ARHGEF34P	6.93	7.61e-12	1.67e-09	0.27	0.21	Obesity-related traits;	chr7:144043931	chr7:144272445~144286966:-
BRCA	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-6.92	7.62e-12	1.67e-09	-0.27	-0.21	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-6.92	7.63e-12	1.67e-09	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	6.92	7.63e-12	1.67e-09	0.25	0.21	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
BRCA	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	6.92	7.63e-12	1.67e-09	0.22	0.21	Height;	chr20:35203478	chr20:35201747~35203288:-
BRCA	cis	rs9527	0.571	rs12219246	ENSG00000236937.2	PTGES3P4	6.92	7.64e-12	1.67e-09	0.27	0.21	Arsenic metabolism;	chr10:102853598	chr10:102845595~102845950:+
BRCA	cis	rs9807989	0.839	rs7603730	ENSG00000234389.1	AC007278.3	6.92	7.65e-12	1.67e-09	0.2	0.21	Asthma;	chr2:102357911	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-6.92	7.66e-12	1.68e-09	-0.22	-0.21	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000224316.1	RP11-479O9.2	-6.92	7.66e-12	1.68e-09	-0.24	-0.21	Aortic root size;	chr7:66603142	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	6.92	7.66e-12	1.68e-09	0.25	0.21	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	6.92	7.66e-12	1.68e-09	0.25	0.21	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
BRCA	cis	rs10515750	0.588	rs1900157	ENSG00000248544.2	CTB-47B11.3	6.92	7.67e-12	1.68e-09	0.31	0.21	Lung function (FEV1/FVC);	chr5:157333834	chr5:157375741~157384950:-
BRCA	cis	rs9880211	0.613	rs34864445	ENSG00000273486.1	RP11-731C17.2	6.92	7.68e-12	1.68e-09	0.27	0.21	Height;Body mass index;	chr3:136104082	chr3:136837338~136839021:-
BRCA	cis	rs9876781	1	rs7653691	ENSG00000244380.1	RP11-24C3.2	-6.92	7.69e-12	1.68e-09	-0.24	-0.21	Longevity;	chr3:48378199	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-6.92	7.73e-12	1.69e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000254174.1	IGHV1-12	6.92	7.73e-12	1.69e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106680856	chr14:106122420~106122709:-
BRCA	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-6.92	7.74e-12	1.69e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
BRCA	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-6.92	7.75e-12	1.69e-09	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
BRCA	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-6.92	7.76e-12	1.7e-09	-0.24	-0.21	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-6.92	7.76e-12	1.7e-09	-0.24	-0.21	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
BRCA	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.92	7.76e-12	1.7e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
BRCA	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	6.92	7.78e-12	1.7e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	6.92	7.78e-12	1.7e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
BRCA	cis	rs6543140	0.964	rs1523206	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102453715	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs1523205	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102453716	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs10169192	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102455751	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs11886793	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102455760	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs2310301	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102456475	chr2:102438713~102440475:+
BRCA	cis	rs6543140	1	rs6543140	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102457814	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs13390895	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102459039	chr2:102438713~102440475:+
BRCA	cis	rs11742741	0.652	rs66527927	ENSG00000248874.4	C5orf17	-6.92	7.79e-12	1.7e-09	-0.27	-0.21	Educational attainment;	chr5:24226579	chr5:23951348~24178263:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	6.92	7.81e-12	1.71e-09	0.22	0.21	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
BRCA	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-6.92	7.81e-12	1.71e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
BRCA	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	6.92	7.82e-12	1.71e-09	0.26	0.21	QT interval;	chr12:29379056	chr12:29280418~29317848:-
BRCA	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-6.92	7.84e-12	1.71e-09	-0.23	-0.21	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
BRCA	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-6.92	7.84e-12	1.71e-09	-0.27	-0.21	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
BRCA	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	6.92	7.84e-12	1.71e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
BRCA	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	6.92	7.86e-12	1.72e-09	0.22	0.21	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
BRCA	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	6.92	7.86e-12	1.72e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-6.92	7.87e-12	1.72e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
BRCA	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	6.92	7.89e-12	1.72e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
BRCA	cis	rs3781264	0.687	rs12217597	ENSG00000273450.1	RP11-76P2.4	-6.92	7.91e-12	1.73e-09	-0.29	-0.21	Esophageal cancer and gastric cancer;	chr10:94351055	chr10:94314907~94315327:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	6.92	7.91e-12	1.73e-09	0.28	0.21	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
BRCA	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	6.92	7.92e-12	1.73e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
BRCA	cis	rs7085104	0.572	rs284856	ENSG00000236937.2	PTGES3P4	-6.92	7.92e-12	1.73e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102845595~102845950:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
BRCA	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-6.92	7.95e-12	1.74e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	6.92	7.97e-12	1.74e-09	0.25	0.21	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	6.92	7.97e-12	1.74e-09	0.25	0.21	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
BRCA	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-6.92	7.98e-12	1.74e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
BRCA	cis	rs7613051	1	rs7613051	ENSG00000223899.1	SEC13P1	6.92	7.98e-12	1.74e-09	0.27	0.21	Atopic dermatitis;	chr3:33023847	chr3:33033863~33034810:+
BRCA	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	6.92	7.98e-12	1.74e-09	0.23	0.21	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
BRCA	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	6.92	7.99e-12	1.75e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	6.92	8.01e-12	1.75e-09	0.27	0.21	Height;	chr4:55451489	chr4:55363971~55395847:-
BRCA	cis	rs919433	0.963	rs4850786	ENSG00000231621.1	AC013264.2	-6.92	8.02e-12	1.75e-09	-0.21	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313884	chr2:197197991~197199273:+
BRCA	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	6.92	8.03e-12	1.75e-09	0.26	0.21	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
BRCA	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.92	8.03e-12	1.75e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
BRCA	cis	rs17253792	0.822	rs79873916	ENSG00000186615.9	KTN1-AS1	-6.92	8.04e-12	1.75e-09	-0.43	-0.21	Putamen volume;	chr14:55705913	chr14:55499278~55580110:-
BRCA	cis	rs2348418	0.832	rs2126894	ENSG00000247934.4	RP11-967K21.1	6.92	8.04e-12	1.75e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28163298~28190738:-
BRCA	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	6.92	8.04e-12	1.76e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
BRCA	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	6.92	8.05e-12	1.76e-09	0.26	0.21	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	6.92	8.05e-12	1.76e-09	0.16	0.21	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
BRCA	cis	rs2014572	0.967	rs7248000	ENSG00000268379.1	CTC-360J11.4	6.92	8.06e-12	1.76e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57250771	chr19:57175233~57177921:+
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-6.92	8.07e-12	1.76e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
BRCA	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	6.92	8.09e-12	1.76e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	6.92	8.09e-12	1.76e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	6.92	8.09e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
BRCA	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-6.92	8.1e-12	1.77e-09	-0.23	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
BRCA	cis	rs919433	0.927	rs1429418	ENSG00000231621.1	AC013264.2	6.92	8.1e-12	1.77e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293427	chr2:197197991~197199273:+
BRCA	cis	rs9876781	1	rs6442123	ENSG00000229759.1	MRPS18AP1	6.92	8.11e-12	1.77e-09	0.23	0.21	Longevity;	chr3:48458887	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	6.92	8.11e-12	1.77e-09	0.24	0.21	Longevity;	chr3:48378818	chr3:48440352~48446656:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	6.92	8.12e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	6.92	8.12e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-6.92	8.13e-12	1.77e-09	-0.24	-0.21	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
BRCA	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	6.92	8.13e-12	1.77e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
BRCA	cis	rs681343	1	rs516316	ENSG00000232871.7	SEC1P	6.92	8.14e-12	1.78e-09	0.23	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702888	chr19:48638071~48682245:+
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.91	8.16e-12	1.78e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.832	rs4931080	ENSG00000247934.4	RP11-967K21.1	6.91	8.16e-12	1.78e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28433843	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	6.91	8.18e-12	1.78e-09	0.17	0.21	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
BRCA	cis	rs7615952	0.599	rs6438955	ENSG00000250012.1	RP11-124N2.1	-6.91	8.18e-12	1.78e-09	-0.27	-0.21	Blood pressure (smoking interaction);	chr3:126011490	chr3:126084220~126095349:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	6.91	8.18e-12	1.78e-09	0.25	0.21	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	6.91	8.18e-12	1.78e-09	0.25	0.21	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.929	rs3732171	ENSG00000271889.1	RP11-493E12.1	6.91	8.18e-12	1.78e-09	0.27	0.21	Tuberculosis;	chr2:61522555	chr2:61151433~61162105:-
BRCA	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-6.91	8.19e-12	1.79e-09	-0.26	-0.21	QT interval;	chr12:29349303	chr12:29280418~29317848:-
BRCA	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	6.91	8.19e-12	1.79e-09	0.25	0.21	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	6.91	8.2e-12	1.79e-09	0.22	0.21	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	6.91	8.2e-12	1.79e-09	0.25	0.21	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
BRCA	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-6.91	8.21e-12	1.79e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	6.91	8.21e-12	1.79e-09	0.17	0.21	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
BRCA	cis	rs7246657	0.722	rs958305	ENSG00000267422.1	CTD-2554C21.1	6.91	8.22e-12	1.79e-09	0.31	0.21	Coronary artery calcification;	chr19:37698539	chr19:37779686~37792865:+
BRCA	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.91	8.23e-12	1.79e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
BRCA	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	6.91	8.23e-12	1.79e-09	0.25	0.21	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	6.91	8.25e-12	1.8e-09	0.19	0.21	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
BRCA	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	6.91	8.27e-12	1.8e-09	0.26	0.21	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
BRCA	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-6.91	8.3e-12	1.81e-09	-0.23	-0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
BRCA	cis	rs9307551	0.817	rs13142610	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79602297	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs17003985	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79602561	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs35487709	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79603180	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs35631270	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79603194	chr4:79492416~79576460:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-6.91	8.31e-12	1.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
BRCA	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	6.91	8.31e-12	1.81e-09	0.3	0.21	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
BRCA	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	6.91	8.32e-12	1.81e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
BRCA	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-6.91	8.32e-12	1.81e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-6.91	8.32e-12	1.81e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
BRCA	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	6.91	8.33e-12	1.81e-09	0.17	0.21	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
BRCA	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-6.91	8.33e-12	1.82e-09	-0.26	-0.21	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-6.91	8.34e-12	1.82e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
BRCA	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-6.91	8.34e-12	1.82e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
BRCA	cis	rs4713118	0.869	rs4713121	ENSG00000220721.1	OR1F12	6.91	8.34e-12	1.82e-09	0.26	0.21	Parkinson's disease;	chr6:27754285	chr6:28073316~28074233:+
BRCA	cis	rs67311347	1	rs6801859	ENSG00000280739.1	EIF1B-AS1	-6.91	8.35e-12	1.82e-09	-0.23	-0.21	Renal cell carcinoma;	chr3:40451727	chr3:40173145~40309698:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	6.91	8.35e-12	1.82e-09	0.28	0.21	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	6.91	8.35e-12	1.82e-09	0.28	0.21	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-6.91	8.35e-12	1.82e-09	-0.23	-0.21	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
BRCA	cis	rs2014572	0.967	rs10418480	ENSG00000268379.1	CTC-360J11.4	6.91	8.36e-12	1.82e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:57175233~57177921:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	6.91	8.37e-12	1.82e-09	0.23	0.21	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-6.91	8.38e-12	1.82e-09	-0.26	-0.21	QT interval;	chr12:29344573	chr12:29280418~29317848:-
BRCA	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	6.91	8.4e-12	1.83e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
BRCA	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-6.91	8.4e-12	1.83e-09	-0.24	-0.21	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
BRCA	cis	rs202072	0.652	rs202064	ENSG00000272379.1	RP1-257A7.5	-6.91	8.45e-12	1.84e-09	-0.35	-0.21	HIV-1 viral setpoint;	chr6:13263794	chr6:13290018~13290490:-
BRCA	cis	rs6545883	0.929	rs12612982	ENSG00000271889.1	RP11-493E12.1	6.91	8.46e-12	1.84e-09	0.27	0.21	Tuberculosis;	chr2:61520220	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-6.91	8.46e-12	1.84e-09	-0.24	-0.21	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
BRCA	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	6.91	8.46e-12	1.84e-09	0.25	0.21	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000224316.1	RP11-479O9.2	6.91	8.46e-12	1.84e-09	0.21	0.21	Aortic root size;	chr7:66049646	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs1459242	ENSG00000244380.1	RP11-24C3.2	-6.91	8.48e-12	1.85e-09	-0.24	-0.21	Longevity;	chr3:48372047	chr3:48440352~48446656:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000224316.1	RP11-479O9.2	-6.91	8.5e-12	1.85e-09	-0.21	-0.21	Aortic root size;	chr7:66122550	chr7:65773620~65802067:+
BRCA	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	6.91	8.5e-12	1.85e-09	0.2	0.21	Asthma;	chr2:102358304	chr2:102438713~102440475:+
BRCA	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-6.91	8.51e-12	1.85e-09	-0.26	-0.21	QT interval;	chr12:29310155	chr12:29280418~29317848:-
BRCA	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	6.91	8.51e-12	1.85e-09	0.25	0.21	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
BRCA	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-6.91	8.51e-12	1.85e-09	-0.28	-0.21	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	6.91	8.52e-12	1.85e-09	0.23	0.21	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	6.91	8.52e-12	1.85e-09	0.23	0.21	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
BRCA	cis	rs6543140	0.964	rs7561351	ENSG00000234389.1	AC007278.3	6.91	8.55e-12	1.86e-09	0.21	0.21	Blood protein levels;	chr2:102461320	chr2:102438713~102440475:+
BRCA	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	6.91	8.57e-12	1.86e-09	0.23	0.21	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
BRCA	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	6.91	8.57e-12	1.86e-09	0.34	0.21	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	6.91	8.58e-12	1.86e-09	0.25	0.21	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	6.91	8.58e-12	1.86e-09	0.25	0.21	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-6.91	8.59e-12	1.87e-09	-0.37	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
BRCA	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	6.91	8.59e-12	1.87e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
BRCA	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-6.91	8.6e-12	1.87e-09	-0.23	-0.21	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000254174.1	IGHV1-12	6.91	8.61e-12	1.87e-09	0.23	0.21	Alzheimer's disease (late onset);	chr14:106676559	chr14:106122420~106122709:-
BRCA	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-6.91	8.63e-12	1.88e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
BRCA	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-6.91	8.63e-12	1.88e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
BRCA	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-6.91	8.64e-12	1.88e-09	-0.23	-0.21	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
BRCA	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-6.91	8.64e-12	1.88e-09	-0.29	-0.21	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
BRCA	cis	rs17253792	0.822	rs77315200	ENSG00000186615.9	KTN1-AS1	-6.91	8.64e-12	1.88e-09	-0.4	-0.21	Putamen volume;	chr14:55605925	chr14:55499278~55580110:-
BRCA	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
BRCA	cis	rs847577	0.677	rs4729403	ENSG00000272950.1	RP11-307C18.1	-6.91	8.68e-12	1.88e-09	-0.27	-0.21	Breast cancer;	chr7:98078529	chr7:98322853~98323430:+
BRCA	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	6.91	8.68e-12	1.89e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
BRCA	cis	rs375066	0.762	rs62114648	ENSG00000267058.1	RP11-15A1.3	6.91	8.69e-12	1.89e-09	0.24	0.21	Breast cancer;	chr19:43910664	chr19:43891804~43901805:-
BRCA	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-6.91	8.7e-12	1.89e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-6.91	8.7e-12	1.89e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
BRCA	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	6.91	8.7e-12	1.89e-09	0.39	0.21	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
BRCA	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	6.91	8.7e-12	1.89e-09	0.25	0.21	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
BRCA	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	6.91	8.71e-12	1.89e-09	0.24	0.21	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
BRCA	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	6.91	8.71e-12	1.89e-09	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
BRCA	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-6.9	8.76e-12	1.9e-09	-0.21	-0.21	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	6.9	8.77e-12	1.9e-09	0.25	0.21	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-6.9	8.77e-12	1.91e-09	-0.23	-0.21	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
BRCA	cis	rs3781264	0.557	rs10882437	ENSG00000273450.1	RP11-76P2.4	6.9	8.78e-12	1.91e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94362073	chr10:94314907~94315327:-
BRCA	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-6.9	8.79e-12	1.91e-09	-0.25	-0.21	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-6.9	8.79e-12	1.91e-09	-0.26	-0.21	QT interval;	chr12:29287150	chr12:29280418~29317848:-
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000261582.1	RP4-614O4.11	-6.9	8.8e-12	1.91e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35267885~35280043:-
BRCA	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	6.9	8.81e-12	1.91e-09	0.21	0.21	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
BRCA	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.9	8.81e-12	1.91e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-6.9	8.81e-12	1.91e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000224316.1	RP11-479O9.2	6.9	8.82e-12	1.91e-09	0.21	0.21	Aortic root size;	chr7:66054263	chr7:65773620~65802067:+
BRCA	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-6.9	8.82e-12	1.92e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	6.9	8.83e-12	1.92e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	6.9	8.84e-12	1.92e-09	0.25	0.21	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000224316.1	RP11-479O9.2	-6.9	8.85e-12	1.92e-09	-0.21	-0.21	Aortic root size;	chr7:66128201	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.613	rs6767060	ENSG00000273486.1	RP11-731C17.2	6.9	8.85e-12	1.92e-09	0.26	0.21	Height;Body mass index;	chr3:136148248	chr3:136837338~136839021:-
BRCA	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	6.9	8.87e-12	1.93e-09	0.27	0.21	Height;	chr4:55577294	chr4:55363971~55395847:-
BRCA	cis	rs8003054	0.589	rs4465523	ENSG00000258515.1	RP11-203M5.7	6.9	8.87e-12	1.93e-09	0.18	0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445364	chr14:20451305~20451918:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	6.9	8.87e-12	1.93e-09	0.25	0.21	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
BRCA	cis	rs375066	0.762	rs12610287	ENSG00000267058.1	RP11-15A1.3	6.9	8.88e-12	1.93e-09	0.24	0.21	Breast cancer;	chr19:43896511	chr19:43891804~43901805:-
BRCA	cis	rs7432375	0.641	rs835649	ENSG00000239213.4	NCK1-AS1	6.9	8.89e-12	1.93e-09	0.22	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136841726~136862054:-
BRCA	cis	rs780096	0.814	rs780093	ENSG00000234072.1	AC074117.10	-6.9	8.89e-12	1.93e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27519736	chr2:27356246~27367622:+
BRCA	cis	rs11512640	1	rs11220120	ENSG00000254671.2	STT3A-AS1	6.9	8.9e-12	1.93e-09	0.48	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr11:125570284~125592568:-
BRCA	cis	rs10515750	0.588	rs56656884	ENSG00000251405.2	CTB-109A12.1	6.9	8.92e-12	1.94e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157361963	chr5:157362615~157460078:-
BRCA	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	6.9	8.93e-12	1.94e-09	0.24	0.21	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
BRCA	cis	rs10515750	0.588	rs11134720	ENSG00000251405.2	CTB-109A12.1	6.9	8.94e-12	1.94e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157358662	chr5:157362615~157460078:-
BRCA	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	6.9	8.95e-12	1.94e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
BRCA	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-6.9	8.96e-12	1.94e-09	-0.26	-0.21	QT interval;	chr12:29297620	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-6.9	8.99e-12	1.95e-09	-0.27	-0.21	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-6.9	9e-12	1.95e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
BRCA	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	6.9	9.02e-12	1.96e-09	0.35	0.21	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
BRCA	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-6.9	9.03e-12	1.96e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
BRCA	cis	rs67981189	0.865	rs2810115	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70928070	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs917065	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70931129	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs1018977	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70933936	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.752	rs2332477	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70936594	chr14:71141125~71143253:-
BRCA	cis	rs7613051	0.945	rs7629880	ENSG00000223899.1	SEC13P1	-6.9	9.04e-12	1.96e-09	-0.27	-0.21	Atopic dermatitis;	chr3:33017319	chr3:33033863~33034810:+
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-6.9	9.05e-12	1.96e-09	-0.27	-0.21	Height;	chr4:55593918	chr4:55363971~55395847:-
BRCA	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-6.9	9.08e-12	1.97e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
BRCA	cis	rs375066	0.762	rs1073654	ENSG00000267058.1	RP11-15A1.3	6.9	9.09e-12	1.97e-09	0.24	0.21	Breast cancer;	chr19:43907268	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs1073653	ENSG00000267058.1	RP11-15A1.3	6.9	9.09e-12	1.97e-09	0.24	0.21	Breast cancer;	chr19:43907391	chr19:43891804~43901805:-
BRCA	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-6.9	9.1e-12	1.97e-09	-0.25	-0.21	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
BRCA	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	6.9	9.11e-12	1.97e-09	0.26	0.21	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
BRCA	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	6.9	9.12e-12	1.98e-09	0.24	0.21	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
BRCA	cis	rs7871764	0.881	rs35017035	ENSG00000260947.1	RP11-384P7.7	6.9	9.13e-12	1.98e-09	0.27	0.21	Height;	chr9:34072896	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	6.9	9.13e-12	1.98e-09	0.25	0.21	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
BRCA	cis	rs78456975	0.739	rs13405352	ENSG00000231482.2	AC141930.2	-6.9	9.14e-12	1.98e-09	-0.29	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514954	chr2:1572554~1580311:-
BRCA	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-6.9	9.15e-12	1.98e-09	-0.31	-0.21	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
BRCA	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	6.9	9.15e-12	1.98e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
BRCA	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-6.9	9.15e-12	1.98e-09	-0.23	-0.21	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
BRCA	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.9	9.15e-12	1.98e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
BRCA	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	6.9	9.17e-12	1.99e-09	0.26	0.21	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
BRCA	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	6.9	9.17e-12	1.99e-09	0.29	0.21	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	6.9	9.17e-12	1.99e-09	0.26	0.21	Height;	chr4:55409063	chr4:55363971~55395847:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	6.9	9.2e-12	1.99e-09	0.25	0.21	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-6.9	9.23e-12	2e-09	-0.23	-0.21	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000224316.1	RP11-479O9.2	6.9	9.23e-12	2e-09	0.23	0.21	Aortic root size;	chr7:66622723	chr7:65773620~65802067:+
BRCA	cis	rs79040073	0.593	rs11632038	ENSG00000259531.2	RP11-295H24.3	6.9	9.24e-12	2e-09	0.37	0.21	Lung cancer in ever smokers;	chr15:49314101	chr15:49365124~49366685:-
BRCA	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-6.9	9.26e-12	2e-09	-0.24	-0.21	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
BRCA	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-6.9	9.26e-12	2e-09	-0.24	-0.21	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
BRCA	cis	rs7976269	0.609	rs2082943	ENSG00000257176.2	RP11-996F15.2	-6.9	9.27e-12	2.01e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050251	chr12:29280418~29317848:-
BRCA	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	6.9	9.28e-12	2.01e-09	0.24	0.21	Longevity;	chr3:48372725	chr3:48440352~48446656:-
BRCA	cis	rs6740322	0.843	rs6727237	ENSG00000234936.1	AC010883.5	6.9	9.28e-12	2.01e-09	0.23	0.21	Coronary artery disease;	chr2:43334861	chr2:43229573~43233394:+
BRCA	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.9	9.28e-12	2.01e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000224316.1	RP11-479O9.2	-6.9	9.32e-12	2.02e-09	-0.21	-0.21	Aortic root size;	chr7:66134459	chr7:65773620~65802067:+
BRCA	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	6.89	9.34e-12	2.02e-09	0.48	0.21	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
BRCA	cis	rs11671005	0.779	rs55875034	ENSG00000252334.1	RNU6-1337P	6.89	9.35e-12	2.02e-09	0.33	0.21	Mean platelet volume;	chr19:58472191	chr19:58483749~58483843:-
BRCA	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	6.89	9.36e-12	2.02e-09	0.29	0.21	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
BRCA	cis	rs6545883	0.868	rs7594191	ENSG00000271889.1	RP11-493E12.1	-6.89	9.39e-12	2.03e-09	-0.26	-0.21	Tuberculosis;	chr2:61612883	chr2:61151433~61162105:-
BRCA	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-6.89	9.39e-12	2.03e-09	-0.23	-0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-6.89	9.41e-12	2.04e-09	-0.26	-0.21	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-6.89	9.41e-12	2.04e-09	-0.26	-0.21	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	6.89	9.42e-12	2.04e-09	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	6.89	9.42e-12	2.04e-09	0.22	0.21	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
BRCA	cis	rs9880211	0.699	rs13433688	ENSG00000273486.1	RP11-731C17.2	6.89	9.44e-12	2.04e-09	0.28	0.21	Height;Body mass index;	chr3:136690329	chr3:136837338~136839021:-
BRCA	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-6.89	9.46e-12	2.05e-09	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
BRCA	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.89	9.46e-12	2.05e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
BRCA	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-6.89	9.47e-12	2.05e-09	-0.24	-0.21	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
BRCA	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	6.89	9.5e-12	2.05e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
BRCA	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-6.89	9.5e-12	2.05e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-6.89	9.5e-12	2.05e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
BRCA	cis	rs4072705	0.967	rs2148787	ENSG00000224020.1	MIR181A2HG	-6.89	9.51e-12	2.06e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124705925	chr9:124658467~124698631:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-6.89	9.53e-12	2.06e-09	-0.23	-0.21	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	6.89	9.54e-12	2.06e-09	0.2	0.21	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
BRCA	cis	rs10861661	1	rs4964491	ENSG00000260329.1	RP11-412D9.4	-6.89	9.55e-12	2.06e-09	-0.26	-0.21	Triglyceride levels;	chr12:106828737	chr12:106954029~106955497:-
BRCA	cis	rs2348418	0.67	rs10843098	ENSG00000247934.4	RP11-967K21.1	-6.89	9.55e-12	2.07e-09	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28116709	chr12:28163298~28190738:-
BRCA	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	6.89	9.56e-12	2.07e-09	0.22	0.21	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-6.89	9.56e-12	2.07e-09	-0.25	-0.21	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-6.89	9.57e-12	2.07e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-6.89	9.57e-12	2.07e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.714	rs301869	ENSG00000250155.1	CTD-2353F22.1	-6.89	9.57e-12	2.07e-09	-0.23	-0.21	Height;	chr5:37140495	chr5:36666214~36725195:-
BRCA	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	6.89	9.58e-12	2.07e-09	0.26	0.21	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
BRCA	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	6.89	9.58e-12	2.07e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
BRCA	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-6.89	9.6e-12	2.08e-09	-0.21	-0.21	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
BRCA	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	6.89	9.63e-12	2.08e-09	0.17	0.21	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-6.89	9.64e-12	2.08e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
BRCA	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
BRCA	cis	rs6569038	0.508	rs4946388	ENSG00000253194.1	RP11-351A11.1	6.89	9.67e-12	2.09e-09	0.26	0.21	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119032352	chr6:118934785~119031541:+
BRCA	cis	rs3781264	0.595	rs10786161	ENSG00000273450.1	RP11-76P2.4	6.89	9.69e-12	2.09e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94347914	chr10:94314907~94315327:-
BRCA	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	6.89	9.71e-12	2.1e-09	0.24	0.21	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-6.89	9.71e-12	2.1e-09	-0.22	-0.21	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
BRCA	cis	rs7976269	0.609	rs10771470	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050620	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs10743641	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050819	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs4930846	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29051306	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	6.89	9.73e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	6.89	9.73e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
BRCA	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	6.89	9.73e-12	2.1e-09	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	6.89	9.75e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
BRCA	cis	rs17495987	0.913	rs73059192	ENSG00000219545.8	UMAD1	6.89	9.75e-12	2.11e-09	0.27	0.21	Tonsillectomy;	chr7:7860495	chr7:7640711~8004059:+
BRCA	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	6.89	9.76e-12	2.11e-09	0.25	0.21	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
BRCA	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	6.89	9.77e-12	2.11e-09	0.25	0.21	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
BRCA	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	6.89	9.78e-12	2.11e-09	0.23	0.21	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	6.89	9.79e-12	2.11e-09	0.25	0.21	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
BRCA	cis	rs7937	0.693	rs12973666	ENSG00000268529.1	CYP2T3P	-6.89	9.79e-12	2.11e-09	-0.25	-0.21	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40783492	chr19:41134722~41137308:+
BRCA	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-6.89	9.79e-12	2.11e-09	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
BRCA	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-6.89	9.81e-12	2.12e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-6.89	9.81e-12	2.12e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
BRCA	cis	rs67311347	1	rs9849992	ENSG00000280739.1	EIF1B-AS1	6.89	9.82e-12	2.12e-09	0.24	0.21	Renal cell carcinoma;	chr3:40360649	chr3:40173145~40309698:-
BRCA	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	6.89	9.83e-12	2.12e-09	0.26	0.21	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
BRCA	cis	rs755249	0.642	rs28788506	ENSG00000237624.1	OXCT2P1	6.89	9.85e-12	2.12e-09	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	6.89	9.85e-12	2.12e-09	0.25	0.21	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
BRCA	cis	rs7247513	1	rs7247513	ENSG00000230310.1	CTD-2192J16.11	-6.89	9.87e-12	2.13e-09	-0.26	-0.21	Bipolar disorder;	chr19:12580371	chr19:12552597~12553644:+
BRCA	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	6.89	9.88e-12	2.13e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
BRCA	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	6.89	9.89e-12	2.13e-09	0.24	0.21	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	6.89	9.91e-12	2.14e-09	0.25	0.21	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
BRCA	cis	rs16846053	0.515	rs4664047	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161649360	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs6432699	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161652729	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs6758760	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161654331	chr2:161244739~161249050:+
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000267422.1	CTD-2554C21.1	-6.89	9.93e-12	2.14e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37323822	chr19:37779686~37792865:+
BRCA	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	6.89	9.95e-12	2.14e-09	0.23	0.21	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
BRCA	cis	rs7688540	0.771	rs10027325	ENSG00000211553.1	AC253576.2	-6.89	9.95e-12	2.15e-09	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:136461~136568:+
BRCA	cis	rs7688540	0.771	rs1986557	ENSG00000211553.1	AC253576.2	-6.89	9.95e-12	2.15e-09	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:136461~136568:+
BRCA	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	6.89	9.97e-12	2.15e-09	0.27	0.21	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
BRCA	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	6.88	9.98e-12	2.15e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
BRCA	cis	rs838147	0.507	rs692854	ENSG00000232871.7	SEC1P	6.88	9.99e-12	2.15e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48706207	chr19:48638071~48682245:+
BRCA	cis	rs2810114	0.834	rs36559	ENSG00000269927.1	RP6-91H8.3	6.88	1e-11	2.16e-09	0.27	0.21	Alcohol dependence;	chr14:70888232	chr14:71141125~71143253:-
BRCA	cis	rs9880211	0.613	rs10222451	ENSG00000273486.1	RP11-731C17.2	6.88	1e-11	2.16e-09	0.27	0.21	Height;Body mass index;	chr3:136158571	chr3:136837338~136839021:-
BRCA	cis	rs2638953	0.924	rs11049409	ENSG00000278733.1	RP11-425D17.1	-6.88	1e-11	2.16e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28185625~28186190:-
BRCA	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	6.88	1e-11	2.16e-09	0.31	0.21	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
BRCA	cis	rs6740322	1	rs4128209	ENSG00000234936.1	AC010883.5	6.88	1e-11	2.16e-09	0.23	0.21	Coronary artery disease;	chr2:43327590	chr2:43229573~43233394:+
BRCA	cis	rs2337406	1	rs4774172	ENSG00000254174.1	IGHV1-12	6.88	1e-11	2.16e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106681320	chr14:106122420~106122709:-
BRCA	cis	rs58873874	0.579	rs3815829	ENSG00000248544.2	CTB-47B11.3	6.88	1.01e-11	2.17e-09	0.43	0.21	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157375741~157384950:-
BRCA	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-6.88	1.01e-11	2.17e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
BRCA	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	6.88	1.01e-11	2.17e-09	0.21	0.21	Height;	chr20:35198453	chr20:35201747~35203288:-
BRCA	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	6.88	1.01e-11	2.17e-09	0.21	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
BRCA	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-6.88	1.01e-11	2.17e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
BRCA	cis	rs7613051	0.947	rs13093698	ENSG00000223899.1	SEC13P1	6.88	1.01e-11	2.17e-09	0.29	0.21	Atopic dermatitis;	chr3:33021558	chr3:33033863~33034810:+
BRCA	cis	rs6543140	0.964	rs918000	ENSG00000234389.1	AC007278.3	6.88	1.01e-11	2.18e-09	0.21	0.21	Blood protein levels;	chr2:102451402	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.927	rs917999	ENSG00000234389.1	AC007278.3	6.88	1.01e-11	2.18e-09	0.21	0.21	Blood protein levels;	chr2:102451409	chr2:102438713~102440475:+
BRCA	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.88	1.01e-11	2.18e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
BRCA	cis	rs17213965	0.561	rs11866891	ENSG00000207425.1	Y_RNA	-6.88	1.01e-11	2.18e-09	-0.3	-0.21	Waist-hip ratio;	chr16:15781561	chr16:14915457~14915556:-
BRCA	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-6.88	1.01e-11	2.18e-09	-0.3	-0.21	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	6.88	1.01e-11	2.19e-09	0.22	0.21	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000224316.1	RP11-479O9.2	-6.88	1.01e-11	2.19e-09	-0.21	-0.21	Aortic root size;	chr7:66226259	chr7:65773620~65802067:+
BRCA	cis	rs2014572	0.967	rs8106734	ENSG00000268379.1	CTC-360J11.4	6.88	1.02e-11	2.19e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57252178	chr19:57175233~57177921:+
BRCA	cis	rs6740322	0.895	rs10166994	ENSG00000234936.1	AC010883.5	6.88	1.02e-11	2.19e-09	0.23	0.21	Coronary artery disease;	chr2:43330838	chr2:43229573~43233394:+
BRCA	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-6.88	1.02e-11	2.19e-09	-0.27	-0.21	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
BRCA	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-6.88	1.02e-11	2.19e-09	-0.27	-0.21	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
BRCA	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-6.88	1.02e-11	2.19e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
BRCA	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-6.88	1.02e-11	2.2e-09	-0.24	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
BRCA	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	6.88	1.02e-11	2.2e-09	0.22	0.21	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
BRCA	cis	rs9880211	0.821	rs9832813	ENSG00000239213.4	NCK1-AS1	6.88	1.02e-11	2.2e-09	0.25	0.21	Height;Body mass index;	chr3:136346723	chr3:136841726~136862054:-
BRCA	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	6.88	1.02e-11	2.2e-09	0.31	0.21	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	6.88	1.02e-11	2.2e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
BRCA	cis	rs957448	1	rs16916874	ENSG00000253175.1	RP11-267M23.6	6.88	1.02e-11	2.2e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94565036~94565715:+
BRCA	cis	rs7976269	0.609	rs2117993	ENSG00000257176.2	RP11-996F15.2	-6.88	1.02e-11	2.2e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29060041	chr12:29280418~29317848:-
BRCA	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-6.88	1.03e-11	2.21e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
BRCA	cis	rs16978956	0.901	rs2424179	ENSG00000236474.1	GCNT1P1	-6.88	1.03e-11	2.21e-09	-0.25	-0.21	Body mass index;	chr20:18362464	chr20:18420160~18421454:-
BRCA	cis	rs2348418	0.832	rs11049559	ENSG00000247934.4	RP11-967K21.1	6.88	1.03e-11	2.21e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28372264	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.21e-09	0.25	0.21	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-6.88	1.03e-11	2.21e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
BRCA	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-6.88	1.03e-11	2.22e-09	-0.28	-0.21	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
BRCA	cis	rs6545883	0.929	rs10173974	ENSG00000271889.1	RP11-493E12.1	6.88	1.03e-11	2.22e-09	0.27	0.21	Tuberculosis;	chr2:61521765	chr2:61151433~61162105:-
BRCA	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-6.88	1.03e-11	2.22e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
BRCA	cis	rs7568498	0.564	rs10490563	ENSG00000235724.7	AC009299.2	6.88	1.03e-11	2.22e-09	0.26	0.21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161222785~161308303:-
BRCA	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	6.88	1.03e-11	2.22e-09	0.24	0.21	Longevity;	chr3:48380745	chr3:48440352~48446656:-
BRCA	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
BRCA	cis	rs67981189	0.865	rs2810117	ENSG00000269927.1	RP6-91H8.3	-6.88	1.03e-11	2.23e-09	-0.26	-0.21	Schizophrenia;	chr14:70924308	chr14:71141125~71143253:-
BRCA	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-6.88	1.04e-11	2.23e-09	-0.27	-0.21	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-6.88	1.04e-11	2.24e-09	-0.24	-0.21	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-6.88	1.04e-11	2.24e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
BRCA	cis	rs2645424	1	rs7009302	ENSG00000255046.1	RP11-297N6.4	6.88	1.04e-11	2.24e-09	0.25	0.21	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr8:11797928~11802568:-
BRCA	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	6.88	1.04e-11	2.24e-09	0.27	0.21	Height;	chr4:55587104	chr4:55363971~55395847:-
BRCA	cis	rs67981189	0.835	rs2526855	ENSG00000269927.1	RP6-91H8.3	-6.88	1.05e-11	2.26e-09	-0.26	-0.21	Schizophrenia;	chr14:70946629	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.766	rs2526852	ENSG00000269927.1	RP6-91H8.3	-6.88	1.05e-11	2.26e-09	-0.26	-0.21	Schizophrenia;	chr14:70949450	chr14:71141125~71143253:-
BRCA	cis	rs9876781	1	rs898225	ENSG00000244380.1	RP11-24C3.2	-6.88	1.05e-11	2.26e-09	-0.24	-0.21	Longevity;	chr3:48371689	chr3:48440352~48446656:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000254174.1	IGHV1-12	6.88	1.05e-11	2.26e-09	0.21	0.21	Alzheimer's disease (late onset);	chr14:106682029	chr14:106122420~106122709:-
BRCA	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
BRCA	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
BRCA	cis	rs7976269	0.609	rs4931142	ENSG00000257176.2	RP11-996F15.2	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29057877	chr12:29280418~29317848:-
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.88	1.05e-11	2.26e-09	0.25	0.21	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
BRCA	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-6.88	1.05e-11	2.26e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
BRCA	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	6.88	1.05e-11	2.27e-09	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
BRCA	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	6.88	1.06e-11	2.27e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000263065.1	AF001548.6	-6.88	1.06e-11	2.27e-09	-0.25	-0.21	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15741151~15741791:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-6.88	1.06e-11	2.27e-09	-0.28	-0.21	Gout;	chr7:66645053	chr7:66848496~66858136:+
BRCA	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	6.88	1.06e-11	2.28e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
BRCA	cis	rs10181042	0.565	rs1177233	ENSG00000271889.1	RP11-493E12.1	-6.88	1.06e-11	2.28e-09	-0.26	-0.21	Crohn's disease;	chr2:61034999	chr2:61151433~61162105:-
BRCA	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-6.88	1.06e-11	2.28e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-6.88	1.06e-11	2.28e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
BRCA	cis	rs250585	1	rs6497670	ENSG00000260136.4	CTD-2270L9.4	-6.88	1.06e-11	2.28e-09	-0.23	-0.21	Egg allergy;	chr16:23525045	chr16:23452758~23457606:+
BRCA	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	6.88	1.06e-11	2.28e-09	0.24	0.21	Longevity;	chr3:48413059	chr3:48440352~48446656:-
BRCA	cis	rs7085104	0.572	rs284860	ENSG00000236937.2	PTGES3P4	-6.88	1.06e-11	2.29e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102845595~102845950:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	6.88	1.06e-11	2.29e-09	0.27	0.21	Height;	chr4:55548666	chr4:55363971~55395847:-
BRCA	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	6.88	1.06e-11	2.29e-09	0.21	0.21	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
BRCA	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	6.88	1.06e-11	2.29e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
BRCA	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	6.88	1.07e-11	2.29e-09	0.22	0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
BRCA	cis	rs2835345	0.563	rs12482423	ENSG00000230479.1	AP000695.6	6.87	1.07e-11	2.3e-09	0.2	0.21	Pulmonary function;	chr21:36448662	chr21:36430360~36481070:+
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-6.87	1.07e-11	2.3e-09	-0.28	-0.21	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
BRCA	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	6.87	1.08e-11	2.31e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
BRCA	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	6.87	1.08e-11	2.31e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	6.87	1.08e-11	2.31e-09	0.22	0.21	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-6.87	1.08e-11	2.31e-09	-0.22	-0.21	Height;	chr5:36787860	chr5:36666214~36725195:-
BRCA	cis	rs2835345	0.563	rs73204244	ENSG00000230479.1	AP000695.6	6.87	1.08e-11	2.32e-09	0.2	0.21	Pulmonary function;	chr21:36452373	chr21:36430360~36481070:+
BRCA	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-6.87	1.08e-11	2.32e-09	-0.22	-0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
BRCA	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	6.87	1.08e-11	2.32e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
BRCA	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
BRCA	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-6.87	1.08e-11	2.33e-09	-0.28	-0.21	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
BRCA	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	6.87	1.08e-11	2.33e-09	0.24	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
BRCA	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-6.87	1.08e-11	2.33e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
BRCA	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-6.87	1.08e-11	2.33e-09	-0.31	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000273024.4	INTS4P2	-6.87	1.09e-11	2.33e-09	-0.26	-0.21	Aortic root size;	chr7:66276638	chr7:65647864~65715661:+
BRCA	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-6.87	1.09e-11	2.33e-09	-0.2	-0.21	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
BRCA	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-6.87	1.09e-11	2.34e-09	-0.24	-0.21	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
BRCA	cis	rs9307551	0.817	rs2903640	ENSG00000250334.4	LINC00989	-6.87	1.09e-11	2.34e-09	-0.28	-0.21	Refractive error;	chr4:79610171	chr4:79492416~79576460:+
BRCA	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	6.87	1.09e-11	2.34e-09	0.25	0.21	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
BRCA	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-6.87	1.09e-11	2.34e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-6.87	1.09e-11	2.35e-09	-0.22	-0.21	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-6.87	1.1e-11	2.35e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
BRCA	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	6.87	1.1e-11	2.36e-09	0.23	0.21	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
BRCA	cis	rs6163	0.727	rs284862	ENSG00000236937.2	PTGES3P4	-6.87	1.1e-11	2.36e-09	-0.27	-0.21	Waist circumference;Hip circumference;	chr10:102812324	chr10:102845595~102845950:+
BRCA	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-6.87	1.1e-11	2.36e-09	-0.23	-0.21	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	6.87	1.1e-11	2.36e-09	0.22	0.21	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
BRCA	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	6.87	1.1e-11	2.37e-09	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
BRCA	cis	rs67981189	0.896	rs2526882	ENSG00000269927.1	RP6-91H8.3	-6.87	1.1e-11	2.37e-09	-0.26	-0.21	Schizophrenia;	chr14:70907985	chr14:71141125~71143253:-
BRCA	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-6.87	1.1e-11	2.37e-09	-0.24	-0.21	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
BRCA	cis	rs67981189	0.865	rs2189806	ENSG00000269927.1	RP6-91H8.3	-6.87	1.11e-11	2.37e-09	-0.26	-0.21	Schizophrenia;	chr14:70921681	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.37e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.37e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	6.87	1.11e-11	2.37e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
BRCA	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	6.87	1.11e-11	2.38e-09	0.27	0.21	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	6.87	1.11e-11	2.38e-09	0.27	0.21	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-6.87	1.11e-11	2.38e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
BRCA	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-6.87	1.11e-11	2.38e-09	-0.25	-0.21	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
BRCA	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
BRCA	cis	rs2998286	0.862	rs2807732	ENSG00000254635.4	WAC-AS1	-6.87	1.12e-11	2.39e-09	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28522652~28532743:-
BRCA	cis	rs755249	0.762	rs1775654	ENSG00000228060.1	RP11-69E11.8	-6.87	1.12e-11	2.4e-09	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39565160~39573203:+
BRCA	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	6.87	1.12e-11	2.41e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
BRCA	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-6.87	1.12e-11	2.41e-09	-0.27	-0.21	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
BRCA	cis	rs4072705	1	rs10986391	ENSG00000224020.1	MIR181A2HG	-6.87	1.12e-11	2.41e-09	-0.22	-0.21	Menarche (age at onset);	chr9:124665956	chr9:124658467~124698631:+
BRCA	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-6.87	1.13e-11	2.41e-09	-0.21	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
BRCA	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-6.87	1.13e-11	2.42e-09	-0.27	-0.21	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000230042.1	AK3P3	-6.87	1.13e-11	2.42e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23129178~23129841:+
BRCA	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-6.87	1.13e-11	2.42e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
BRCA	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-6.87	1.13e-11	2.42e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
BRCA	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-6.87	1.13e-11	2.43e-09	-0.28	-0.21	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
BRCA	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-6.87	1.13e-11	2.43e-09	-0.2	-0.21	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
BRCA	cis	rs9880211	0.718	rs56398805	ENSG00000273486.1	RP11-731C17.2	6.87	1.14e-11	2.44e-09	0.26	0.21	Height;Body mass index;	chr3:136213558	chr3:136837338~136839021:-
BRCA	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-6.87	1.14e-11	2.44e-09	-0.28	-0.21	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
BRCA	cis	rs10515750	0.588	rs10077326	ENSG00000251405.2	CTB-109A12.1	6.87	1.14e-11	2.44e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157343761	chr5:157362615~157460078:-
BRCA	cis	rs10515750	0.588	rs10077470	ENSG00000251405.2	CTB-109A12.1	6.87	1.14e-11	2.44e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157343975	chr5:157362615~157460078:-
BRCA	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	6.87	1.14e-11	2.44e-09	0.22	0.21	Height;	chr20:35200390	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	6.87	1.14e-11	2.44e-09	0.22	0.21	Height;	chr20:35200671	chr20:35201747~35203288:-
BRCA	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	6.86	1.14e-11	2.45e-09	0.31	0.21	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
BRCA	cis	rs3814244	0.528	rs2906854	ENSG00000236946.2	HNRNPA1P70	6.86	1.14e-11	2.45e-09	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:68035767~68036853:+
BRCA	cis	rs588177	0.613	rs3782101	ENSG00000236935.1	AP003774.1	-6.86	1.14e-11	2.45e-09	-0.2	-0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64363808	chr11:64325050~64329504:-
BRCA	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	6.86	1.15e-11	2.46e-09	0.23	0.21	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
BRCA	cis	rs2014572	0.967	rs10413037	ENSG00000268379.1	CTC-360J11.4	6.86	1.15e-11	2.46e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57260515	chr19:57175233~57177921:+
BRCA	cis	rs755249	0.669	rs4660311	ENSG00000237624.1	OXCT2P1	6.86	1.15e-11	2.47e-09	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	6.86	1.15e-11	2.47e-09	0.27	0.21	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
BRCA	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
BRCA	cis	rs67981189	0.892	rs221899	ENSG00000269927.1	RP6-91H8.3	6.86	1.15e-11	2.47e-09	0.26	0.21	Schizophrenia;	chr14:71138551	chr14:71141125~71143253:-
BRCA	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-6.86	1.16e-11	2.47e-09	-0.23	-0.21	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
BRCA	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	6.86	1.16e-11	2.48e-09	0.22	0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
BRCA	cis	rs9880211	0.8	rs28390205	ENSG00000273486.1	RP11-731C17.2	6.86	1.16e-11	2.48e-09	0.28	0.21	Height;Body mass index;	chr3:136646008	chr3:136837338~136839021:-
BRCA	cis	rs11157436	0.56	rs11623957	ENSG00000211812.1	TRAV26-2	-6.86	1.16e-11	2.48e-09	-0.17	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22202583~22203368:+
BRCA	cis	rs655720	1	rs655720	ENSG00000239213.4	NCK1-AS1	6.86	1.16e-11	2.48e-09	0.24	0.21	Coronary artery disease;	chr3:136384425	chr3:136841726~136862054:-
BRCA	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-6.86	1.16e-11	2.48e-09	-0.26	-0.21	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
BRCA	cis	rs7568498	0.564	rs9287807	ENSG00000235724.7	AC009299.2	6.86	1.16e-11	2.48e-09	0.26	0.21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161222785~161308303:-
BRCA	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	6.86	1.16e-11	2.48e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-6.86	1.16e-11	2.48e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
BRCA	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	6.86	1.16e-11	2.48e-09	0.26	0.21	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
BRCA	cis	rs74233809	0.901	rs11191416	ENSG00000213277.3	MARCKSL1P1	-6.86	1.16e-11	2.49e-09	-0.37	-0.21	Birth weight;	chr10:102845159	chr10:103175554~103176094:+
BRCA	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	6.86	1.16e-11	2.49e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
BRCA	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	6.86	1.16e-11	2.49e-09	0.26	0.21	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-6.86	1.16e-11	2.49e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
BRCA	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.86	1.16e-11	2.49e-09	0.27	0.21	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
BRCA	cis	rs73173548	0.502	rs12659818	ENSG00000247828.6	TMEM161B-AS1	6.86	1.16e-11	2.49e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88451964	chr5:88268895~88436685:+
BRCA	cis	rs2599510	0.934	rs2710634	ENSG00000276334.1	AL133243.1	6.86	1.17e-11	2.5e-09	0.26	0.21	Interleukin-18 levels;	chr2:32583737	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-6.86	1.17e-11	2.5e-09	-0.22	-0.21	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-6.86	1.17e-11	2.5e-09	-0.25	-0.21	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
BRCA	cis	rs9402682	0.629	rs6924609	ENSG00000232876.1	CTA-212D2.2	6.86	1.17e-11	2.5e-09	0.28	0.21	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135119519	chr6:135055033~135060550:+
BRCA	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	6.86	1.18e-11	2.51e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
BRCA	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	6.86	1.18e-11	2.52e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
BRCA	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	6.86	1.18e-11	2.52e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	6.86	1.18e-11	2.52e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
BRCA	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-6.86	1.18e-11	2.52e-09	-0.27	-0.21	AIDS;	chr2:105313444	chr2:105324210~105330529:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000224316.1	RP11-479O9.2	-6.86	1.18e-11	2.53e-09	-0.21	-0.21	Aortic root size;	chr7:66218330	chr7:65773620~65802067:+
BRCA	cis	rs10029851	0.627	rs17512211	ENSG00000234492.4	RPL34-AS1	6.86	1.19e-11	2.54e-09	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108607724	chr4:108538190~108620460:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000236529.1	RP13-254B10.1	6.86	1.19e-11	2.54e-09	0.25	0.21	Aortic root size;	chr7:66175760	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.502	rs10942532	ENSG00000247828.6	TMEM161B-AS1	6.86	1.19e-11	2.55e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88462015	chr5:88268895~88436685:+
BRCA	cis	rs7976269	0.609	rs7310276	ENSG00000257176.2	RP11-996F15.2	6.86	1.19e-11	2.55e-09	0.25	0.21	Male-pattern baldness;	chr12:29054128	chr12:29280418~29317848:-
BRCA	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-6.86	1.2e-11	2.55e-09	-0.27	-0.21	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
BRCA	cis	rs2014572	0.967	rs10421632	ENSG00000268379.1	CTC-360J11.4	6.86	1.2e-11	2.55e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57253402	chr19:57175233~57177921:+
BRCA	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-6.86	1.2e-11	2.56e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
BRCA	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	6.86	1.2e-11	2.56e-09	0.24	0.21	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
BRCA	cis	rs4845875	0.626	rs6540999	ENSG00000242349.4	NPPA-AS1	6.86	1.2e-11	2.56e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11773309	chr1:11841017~11848079:+
BRCA	cis	rs919433	0.854	rs13013049	ENSG00000231621.1	AC013264.2	6.86	1.2e-11	2.56e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343940	chr2:197197991~197199273:+
BRCA	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-6.86	1.2e-11	2.56e-09	-0.25	-0.21	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	6.86	1.2e-11	2.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	6.86	1.2e-11	2.56e-09	0.25	0.21	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
BRCA	cis	rs7911264	0.507	rs2901597	ENSG00000236493.2	EIF2S2P3	6.86	1.2e-11	2.56e-09	0.28	0.21	Inflammatory bowel disease;	chr10:92582906	chr10:92668745~92669743:-
BRCA	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-6.86	1.2e-11	2.57e-09	-0.34	-0.21	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
BRCA	cis	rs804292	0.695	rs804279	ENSG00000255046.1	RP11-297N6.4	6.86	1.2e-11	2.57e-09	0.26	0.21	Nicotine use;Alcohol dependence;	chr8:11766380	chr8:11797928~11802568:-
BRCA	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	6.86	1.2e-11	2.57e-09	0.25	0.21	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.86	1.2e-11	2.57e-09	-0.33	-0.21	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
BRCA	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-6.86	1.21e-11	2.58e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
BRCA	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	6.86	1.21e-11	2.59e-09	0.26	0.21	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
BRCA	cis	rs7976269	0.609	rs4402335	ENSG00000257176.2	RP11-996F15.2	-6.86	1.21e-11	2.59e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052836	chr12:29280418~29317848:-
BRCA	cis	rs7085104	0.572	rs284860	ENSG00000213061.2	PFN1P11	-6.86	1.22e-11	2.59e-09	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102838011~102845473:-
BRCA	cis	rs2060793	0.539	rs962025	ENSG00000251991.1	RNU7-49P	6.86	1.22e-11	2.59e-09	0.22	0.21	Vitamin D levels;	chr11:14618744	chr11:14478892~14478953:+
BRCA	cis	rs375066	0.762	rs171238	ENSG00000267058.1	RP11-15A1.3	-6.86	1.22e-11	2.6e-09	-0.24	-0.21	Breast cancer;	chr19:43875402	chr19:43891804~43901805:-
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55514802	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55516548	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55516744	chr4:55363971~55395847:-
BRCA	cis	rs2998286	0.666	rs2491251	ENSG00000254635.4	WAC-AS1	-6.86	1.22e-11	2.6e-09	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28522652~28532743:-
BRCA	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-6.86	1.22e-11	2.6e-09	-0.31	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
BRCA	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	6.85	1.22e-11	2.6e-09	0.26	0.21	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
BRCA	cis	rs7976269	0.609	rs4931141	ENSG00000257176.2	RP11-996F15.2	-6.85	1.22e-11	2.61e-09	-0.24	-0.21	Male-pattern baldness;	chr12:29057763	chr12:29280418~29317848:-
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.85	1.22e-11	2.61e-09	0.2	0.21	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
BRCA	cis	rs67311347	1	rs11715214	ENSG00000280739.1	EIF1B-AS1	6.85	1.22e-11	2.61e-09	0.23	0.21	Renal cell carcinoma;	chr3:40361513	chr3:40173145~40309698:-
BRCA	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.85	1.22e-11	2.61e-09	0.23	0.21	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-6.85	1.22e-11	2.61e-09	-0.22	-0.21	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	6.85	1.22e-11	2.61e-09	0.28	0.21	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
BRCA	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	6.85	1.23e-11	2.62e-09	0.26	0.21	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-6.85	1.23e-11	2.62e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
BRCA	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	6.85	1.23e-11	2.62e-09	0.3	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-6.85	1.23e-11	2.63e-09	-0.24	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
BRCA	cis	rs67981189	0.865	rs2810071	ENSG00000269927.1	RP6-91H8.3	-6.85	1.23e-11	2.63e-09	-0.26	-0.21	Schizophrenia;	chr14:70920931	chr14:71141125~71143253:-
BRCA	cis	rs16978956	1	rs2284897	ENSG00000236474.1	GCNT1P1	6.85	1.23e-11	2.63e-09	0.24	0.21	Body mass index;	chr20:18309354	chr20:18420160~18421454:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-6.85	1.23e-11	2.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
BRCA	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	6.85	1.24e-11	2.63e-09	0.41	0.21	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
BRCA	cis	rs6545883	0.965	rs2305155	ENSG00000271889.1	RP11-493E12.1	6.85	1.24e-11	2.64e-09	0.26	0.21	Tuberculosis;	chr2:61502123	chr2:61151433~61162105:-
BRCA	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29319476	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29320175	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29321177	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29321323	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29322770	chr12:29280418~29317848:-
BRCA	cis	rs804280	0.565	rs1466785	ENSG00000255046.1	RP11-297N6.4	-6.85	1.24e-11	2.65e-09	-0.24	-0.21	Myopia (pathological);	chr8:11765947	chr8:11797928~11802568:-
BRCA	cis	rs2014572	0.933	rs8109882	ENSG00000268379.1	CTC-360J11.4	6.85	1.25e-11	2.66e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.901	rs35658377	ENSG00000268379.1	CTC-360J11.4	6.85	1.25e-11	2.66e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57175233~57177921:+
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000261582.1	RP4-614O4.11	-6.85	1.26e-11	2.68e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35267885~35280043:-
BRCA	cis	rs9638182	0.72	rs13235543	ENSG00000274080.1	CTA-315H11.2	6.85	1.26e-11	2.68e-09	0.42	0.21	Triglycerides;	chr7:73599571	chr7:73609262~73611502:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	6.85	1.26e-11	2.68e-09	0.26	0.21	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-6.85	1.26e-11	2.68e-09	-0.29	-0.21	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
BRCA	cis	rs516805	0.52	rs197678	ENSG00000279114.1	RP3-425C14.5	-6.85	1.27e-11	2.69e-09	-0.2	-0.21	Lymphocyte counts;	chr6:122534039	chr6:122471923~122484161:+
BRCA	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	6.85	1.27e-11	2.7e-09	0.27	0.21	Height;	chr20:49215517	chr20:49280319~49280409:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	6.85	1.27e-11	2.7e-09	0.23	0.21	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
BRCA	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-6.85	1.27e-11	2.7e-09	-0.26	-0.21	Height;	chr2:46617930	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000224316.1	RP11-479O9.2	-6.85	1.27e-11	2.7e-09	-0.21	-0.21	Aortic root size;	chr7:66224822	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
BRCA	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-6.85	1.27e-11	2.71e-09	-0.23	-0.21	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-6.85	1.27e-11	2.71e-09	-0.23	-0.21	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	6.85	1.28e-11	2.72e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
BRCA	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
BRCA	cis	rs2060793	1	rs1993116	ENSG00000251991.1	RNU7-49P	6.85	1.28e-11	2.72e-09	0.23	0.21	Vitamin D levels;	chr11:14888688	chr11:14478892~14478953:+
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000237624.1	OXCT2P1	6.85	1.28e-11	2.72e-09	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39514956~39516490:+
BRCA	cis	rs16846053	0.515	rs6750756	ENSG00000227403.1	AC009299.3	-6.85	1.28e-11	2.72e-09	-0.34	-0.21	Blood osmolality (transformed sodium);	chr2:161659798	chr2:161244739~161249050:+
BRCA	cis	rs11976180	1	rs2961120	ENSG00000204959.4	ARHGEF34P	6.85	1.28e-11	2.73e-09	0.26	0.21	Obesity-related traits;	chr7:144059492	chr7:144272445~144286966:-
BRCA	cis	rs9880211	0.752	rs35428413	ENSG00000273486.1	RP11-731C17.2	6.85	1.28e-11	2.73e-09	0.28	0.21	Height;Body mass index;	chr3:136661856	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
BRCA	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-6.85	1.28e-11	2.73e-09	-0.3	-0.21	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
BRCA	cis	rs7474896	0.583	rs12776092	ENSG00000226578.1	RP11-258F22.1	-6.85	1.28e-11	2.73e-09	-0.27	-0.21	Obesity (extreme);	chr10:37726867	chr10:37775371~37784131:-
BRCA	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-6.85	1.29e-11	2.73e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	6.85	1.29e-11	2.74e-09	0.38	0.21	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
BRCA	cis	rs957448	1	rs72674861	ENSG00000253175.1	RP11-267M23.6	6.85	1.29e-11	2.74e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94565036~94565715:+
BRCA	cis	rs2638953	0.924	rs11049398	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.74e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28185625~28186190:-
BRCA	cis	rs897984	0.762	rs8062719	ENSG00000260911.2	RP11-196G11.2	-6.85	1.29e-11	2.75e-09	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30991343	chr16:31043150~31049868:+
BRCA	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
BRCA	cis	rs2638953	0.924	rs11049399	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920227	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049400	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049401	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28185625~28186190:-
BRCA	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-6.85	1.3e-11	2.76e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
BRCA	cis	rs7978895	0.669	rs1399374	ENSG00000258331.1	RP11-118A3.1	-6.85	1.3e-11	2.76e-09	-0.21	-0.21	Type 2 diabetes;	chr12:43150804	chr12:43155315~43163110:+
BRCA	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-6.85	1.3e-11	2.76e-09	-0.21	-0.21	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
BRCA	cis	rs34526934	0.566	rs34028621	ENSG00000226363.3	HAGLROS	6.85	1.3e-11	2.76e-09	0.31	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176178051	chr2:176177717~176179008:+
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000263603.1	CTD-2349P21.5	-6.85	1.3e-11	2.76e-09	-0.37	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30729469~30731202:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000224316.1	RP11-479O9.2	-6.85	1.3e-11	2.77e-09	-0.21	-0.21	Aortic root size;	chr7:66182423	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	6.85	1.3e-11	2.77e-09	0.25	0.21	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	6.85	1.3e-11	2.77e-09	0.25	0.21	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
BRCA	cis	rs6543140	0.964	rs6543138	ENSG00000234389.1	AC007278.3	6.85	1.3e-11	2.77e-09	0.21	0.21	Blood protein levels;	chr2:102449672	chr2:102438713~102440475:+
BRCA	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	6.85	1.3e-11	2.77e-09	0.24	0.21	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	6.85	1.3e-11	2.77e-09	0.24	0.21	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
BRCA	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	6.84	1.31e-11	2.78e-09	0.22	0.21	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	6.84	1.31e-11	2.78e-09	0.25	0.21	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	6.84	1.31e-11	2.78e-09	0.28	0.21	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
BRCA	cis	rs7976269	0.609	rs10843300	ENSG00000257176.2	RP11-996F15.2	-6.84	1.32e-11	2.8e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29060934	chr12:29280418~29317848:-
BRCA	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-6.84	1.32e-11	2.8e-09	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
BRCA	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-6.84	1.32e-11	2.8e-09	-0.23	-0.21	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000236529.1	RP13-254B10.1	-6.84	1.32e-11	2.81e-09	-0.25	-0.21	Aortic root size;	chr7:66123233	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	6.84	1.32e-11	2.81e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
BRCA	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	6.84	1.33e-11	2.82e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
BRCA	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	6.84	1.33e-11	2.82e-09	0.19	0.21	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
BRCA	cis	rs2638953	0.924	rs11049405	ENSG00000278733.1	RP11-425D17.1	-6.84	1.33e-11	2.82e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28185625~28186190:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-6.84	1.33e-11	2.82e-09	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-6.84	1.33e-11	2.82e-09	-0.23	-0.21	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
BRCA	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	6.84	1.33e-11	2.82e-09	0.22	0.21	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
BRCA	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	6.84	1.33e-11	2.82e-09	0.21	0.21	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
BRCA	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-6.84	1.33e-11	2.83e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
BRCA	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	6.84	1.33e-11	2.83e-09	0.27	0.21	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-6.84	1.33e-11	2.83e-09	-0.23	-0.21	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
BRCA	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-6.84	1.34e-11	2.84e-09	-0.29	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.84	1.34e-11	2.84e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
BRCA	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-6.84	1.34e-11	2.84e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-6.84	1.34e-11	2.84e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
BRCA	cis	rs860818	1	rs858304	ENSG00000226816.2	AC005082.12	-6.84	1.34e-11	2.84e-09	-0.49	-0.21	Initial pursuit acceleration;	chr7:23203534	chr7:23206013~23208045:+
BRCA	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.84	1.34e-11	2.85e-09	0.34	0.21	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.84	1.34e-11	2.85e-09	0.34	0.21	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
BRCA	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	6.84	1.34e-11	2.85e-09	0.19	0.21	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	6.84	1.34e-11	2.85e-09	0.26	0.21	Height;	chr4:55542243	chr4:55363971~55395847:-
BRCA	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	6.84	1.34e-11	2.85e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
BRCA	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-6.84	1.35e-11	2.85e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-6.84	1.35e-11	2.86e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-6.84	1.35e-11	2.86e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
BRCA	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	6.84	1.35e-11	2.86e-09	0.25	0.21	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
BRCA	cis	rs6545883	0.718	rs3771260	ENSG00000271889.1	RP11-493E12.1	6.84	1.35e-11	2.87e-09	0.27	0.21	Tuberculosis;	chr2:61535249	chr2:61151433~61162105:-
BRCA	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.84	1.35e-11	2.87e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	6.84	1.36e-11	2.89e-09	0.25	0.21	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	6.84	1.36e-11	2.89e-09	0.25	0.21	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
BRCA	cis	rs3758785	0.512	rs7950328	ENSG00000255893.1	RP11-685N10.1	-6.84	1.36e-11	2.89e-09	-0.25	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94366449	chr11:94472908~94473570:-
BRCA	cis	rs42648	0.596	rs194524	ENSG00000225498.1	AC002064.5	6.84	1.36e-11	2.89e-09	0.2	0.21	Homocysteine levels;	chr7:90232518	chr7:90312496~90322592:+
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-6.84	1.36e-11	2.89e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
BRCA	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	6.84	1.36e-11	2.89e-09	0.29	0.21	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
BRCA	cis	rs16846053	0.515	rs3849355	ENSG00000227403.1	AC009299.3	-6.84	1.37e-11	2.89e-09	-0.34	-0.21	Blood osmolality (transformed sodium);	chr2:161531204	chr2:161244739~161249050:+
BRCA	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-6.84	1.37e-11	2.9e-09	-0.23	-0.21	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
BRCA	cis	rs7474896	0.583	rs11011347	ENSG00000226578.1	RP11-258F22.1	-6.84	1.37e-11	2.9e-09	-0.27	-0.21	Obesity (extreme);	chr10:37730336	chr10:37775371~37784131:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-6.84	1.37e-11	2.91e-09	-0.14	-0.21	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	6.84	1.37e-11	2.91e-09	0.17	0.21	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
BRCA	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-6.84	1.37e-11	2.91e-09	-0.23	-0.21	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
BRCA	cis	rs6545883	0.965	rs3771261	ENSG00000271889.1	RP11-493E12.1	6.84	1.37e-11	2.91e-09	0.27	0.21	Tuberculosis;	chr2:61535026	chr2:61151433~61162105:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	6.84	1.38e-11	2.92e-09	0.28	0.21	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs10083431	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55601630	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10083303	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55601803	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78820104	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602136	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76055105	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602409	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78386830	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602506	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75115817	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602819	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77990307	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55603331	chr14:55499278~55580110:-
BRCA	cis	rs12188164	0.543	rs2434695	ENSG00000225138.6	CTD-2228K2.7	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Cystic fibrosis severity;	chr5:464062	chr5:473236~480884:+
BRCA	cis	rs4356203	0.543	rs214093	ENSG00000272034.1	SNORD14A	-6.84	1.38e-11	2.92e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17074654~17074744:-
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	6.84	1.38e-11	2.92e-09	0.25	0.21	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
BRCA	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
BRCA	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	6.84	1.38e-11	2.93e-09	0.25	0.21	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
BRCA	cis	rs7085104	0.513	rs619824	ENSG00000236937.2	PTGES3P4	6.84	1.38e-11	2.93e-09	0.26	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	6.84	1.38e-11	2.93e-09	0.39	0.21	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
BRCA	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.84	1.39e-11	2.94e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-6.84	1.39e-11	2.94e-09	-0.22	-0.21	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
BRCA	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	6.84	1.39e-11	2.94e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	6.84	1.39e-11	2.94e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
BRCA	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000236529.1	RP13-254B10.1	6.84	1.39e-11	2.95e-09	0.26	0.21	Aortic root size;	chr7:66302237	chr7:65840212~65840596:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000254174.1	IGHV1-12	6.84	1.39e-11	2.95e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106688967	chr14:106122420~106122709:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	6.84	1.39e-11	2.95e-09	0.28	0.21	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
BRCA	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	6.84	1.39e-11	2.95e-09	0.22	0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-6.83	1.39e-11	2.95e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
BRCA	cis	rs2834288	0.5	rs766425	ENSG00000273102.1	AP000569.9	6.83	1.4e-11	2.96e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33967101~33968573:-
BRCA	cis	rs1476670	0.545	rs11210947	ENSG00000230615.5	RP5-1198O20.4	-6.83	1.4e-11	2.96e-09	-0.28	-0.21	Eotaxin levels;	chr1:44054398	chr1:44030443~44115913:+
BRCA	cis	rs2638953	0.814	rs11049413	ENSG00000278733.1	RP11-425D17.1	-6.83	1.4e-11	2.97e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs11049414	ENSG00000278733.1	RP11-425D17.1	-6.83	1.4e-11	2.97e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000224316.1	RP11-479O9.2	6.83	1.4e-11	2.97e-09	0.24	0.21	Aortic root size;	chr7:66441589	chr7:65773620~65802067:+
BRCA	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	6.83	1.4e-11	2.97e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	6.83	1.41e-11	2.98e-09	0.25	0.21	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
BRCA	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-6.83	1.41e-11	2.98e-09	-0.25	-0.21	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	6.83	1.41e-11	2.98e-09	0.25	0.21	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	6.83	1.41e-11	2.98e-09	0.25	0.21	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	6.83	1.41e-11	2.99e-09	0.28	0.21	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	6.83	1.41e-11	2.99e-09	0.28	0.21	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	6.83	1.42e-11	3e-09	0.25	0.21	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
BRCA	cis	rs2638953	0.925	rs11049412	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12366932	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478336	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478335	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478334	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28185625~28186190:-
BRCA	cis	rs2348418	0.798	rs11049546	ENSG00000247934.4	RP11-967K21.1	6.83	1.42e-11	3e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28346942	chr12:28163298~28190738:-
BRCA	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	6.83	1.42e-11	3.01e-09	0.21	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
BRCA	cis	rs2638953	0.924	rs61920228	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7306838	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7138173	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28185625~28186190:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-6.83	1.42e-11	3.01e-09	-0.22	-0.21	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	6.83	1.42e-11	3.01e-09	0.27	0.21	Height;	chr4:55578154	chr4:55363971~55395847:-
BRCA	cis	rs62246343	0.564	rs2279440	ENSG00000206573.7	THUMPD3-AS1	-6.83	1.42e-11	3.01e-09	-0.25	-0.21	Fibrinogen levels;	chr3:9476827	chr3:9349689~9398579:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	6.83	1.42e-11	3.01e-09	0.37	0.21	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
BRCA	cis	rs6603134	0.502	rs6603132	ENSG00000267939.1	CTD-2325M2.1	-6.83	1.42e-11	3.01e-09	-0.25	-0.21	Blood protein levels;	chr19:8037908	chr19:8008729~8016025:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
BRCA	cis	rs42648	0.792	rs4236517	ENSG00000225498.1	AC002064.5	6.83	1.43e-11	3.02e-09	0.2	0.21	Homocysteine levels;	chr7:90334151	chr7:90312496~90322592:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
BRCA	cis	rs7976269	0.609	rs7135891	ENSG00000257176.2	RP11-996F15.2	-6.83	1.43e-11	3.03e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29053944	chr12:29280418~29317848:-
BRCA	cis	rs301901	0.772	rs6887958	ENSG00000250155.1	CTD-2353F22.1	-6.83	1.43e-11	3.03e-09	-0.23	-0.21	Height;	chr5:37189717	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	6.83	1.43e-11	3.03e-09	0.25	0.21	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	6.83	1.44e-11	3.03e-09	0.26	0.21	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.25	0.21	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000224316.1	RP11-479O9.2	-6.83	1.44e-11	3.04e-09	-0.21	-0.21	Aortic root size;	chr7:66221457	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000274576.2	IGHV2-70	-6.83	1.44e-11	3.04e-09	-0.17	-0.21	Kawasaki disease;	chr14:106807157	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000224316.1	RP11-479O9.2	6.83	1.44e-11	3.04e-09	0.21	0.21	Aortic root size;	chr7:66054232	chr7:65773620~65802067:+
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.83	1.44e-11	3.05e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
BRCA	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	6.83	1.44e-11	3.05e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	6.83	1.44e-11	3.05e-09	0.37	0.21	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	6.83	1.44e-11	3.05e-09	0.25	0.21	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
BRCA	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	6.83	1.45e-11	3.05e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	6.83	1.45e-11	3.06e-09	0.24	0.21	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	6.83	1.45e-11	3.06e-09	0.24	0.21	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	6.83	1.45e-11	3.06e-09	0.27	0.21	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
BRCA	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102364846	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102365634	chr2:102438713~102440475:+
BRCA	cis	rs3126085	0.877	rs4456098	ENSG00000237975.5	FLG-AS1	-6.83	1.45e-11	3.06e-09	-0.27	-0.21	Atopic dermatitis;	chr1:152203558	chr1:152168125~152445456:+
BRCA	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361051	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361270	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361999	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102363164	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102364083	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	6.83	1.45e-11	3.07e-09	0.26	0.21	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
BRCA	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-6.83	1.45e-11	3.07e-09	-0.25	-0.21	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	-6.83	1.45e-11	3.07e-09	-0.25	-0.21	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	6.83	1.46e-11	3.08e-09	0.25	0.21	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
BRCA	cis	rs17253792	0.822	rs78429067	ENSG00000186615.9	KTN1-AS1	-6.83	1.46e-11	3.09e-09	-0.43	-0.21	Putamen volume;	chr14:55625833	chr14:55499278~55580110:-
BRCA	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	6.83	1.46e-11	3.09e-09	0.26	0.21	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-6.83	1.46e-11	3.09e-09	-0.26	-0.21	Height;	chr4:55364952	chr4:55387949~55388271:+
BRCA	cis	rs17253792	0.822	rs10139905	ENSG00000186615.9	KTN1-AS1	-6.83	1.46e-11	3.09e-09	-0.37	-0.21	Putamen volume;	chr14:55703313	chr14:55499278~55580110:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	6.83	1.47e-11	3.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	6.83	1.47e-11	3.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-6.83	1.47e-11	3.11e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-6.83	1.47e-11	3.11e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
BRCA	cis	rs10515750	0.5	rs7728460	ENSG00000248544.2	CTB-47B11.3	6.83	1.48e-11	3.11e-09	0.3	0.21	Lung function (FEV1/FVC);	chr5:157286607	chr5:157375741~157384950:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-6.83	1.48e-11	3.12e-09	-0.23	-0.21	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
BRCA	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102358590	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102359712	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102360736	chr2:102438713~102440475:+
BRCA	cis	rs3781264	0.595	rs3818432	ENSG00000273450.1	RP11-76P2.4	6.83	1.48e-11	3.12e-09	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94304411	chr10:94314907~94315327:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	6.83	1.48e-11	3.12e-09	0.37	0.21	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
BRCA	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-6.83	1.48e-11	3.12e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	6.83	1.48e-11	3.12e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
BRCA	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	6.83	1.48e-11	3.13e-09	0.25	0.21	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
BRCA	cis	rs17767294	0.612	rs12332927	ENSG00000220721.1	OR1F12	6.83	1.49e-11	3.14e-09	0.34	0.21	Parkinson's disease;	chr6:27987337	chr6:28073316~28074233:+
BRCA	cis	rs9880211	0.563	rs67589653	ENSG00000273486.1	RP11-731C17.2	6.83	1.49e-11	3.14e-09	0.27	0.21	Height;Body mass index;	chr3:136092732	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.563	rs10512990	ENSG00000273486.1	RP11-731C17.2	6.83	1.49e-11	3.14e-09	0.27	0.21	Height;Body mass index;	chr3:136095785	chr3:136837338~136839021:-
BRCA	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-6.82	1.49e-11	3.15e-09	-0.25	-0.21	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	6.82	1.5e-11	3.15e-09	0.25	0.21	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
BRCA	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-6.82	1.5e-11	3.16e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-6.82	1.5e-11	3.16e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
BRCA	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	6.82	1.5e-11	3.16e-09	0.23	0.21	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
BRCA	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-6.82	1.5e-11	3.16e-09	-0.26	-0.21	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
BRCA	cis	rs4237845	0.837	rs7954957	ENSG00000257159.1	RP11-58A17.3	6.82	1.5e-11	3.16e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr12:57905467	chr12:57967058~57968399:+
BRCA	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	6.82	1.51e-11	3.17e-09	0.19	0.21	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	6.82	1.51e-11	3.17e-09	0.23	0.21	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
BRCA	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.82	1.51e-11	3.18e-09	0.24	0.21	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	6.82	1.51e-11	3.18e-09	0.24	0.21	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-6.82	1.51e-11	3.18e-09	-0.22	-0.21	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs2961118	ENSG00000204959.4	ARHGEF34P	6.82	1.51e-11	3.18e-09	0.26	0.21	Obesity-related traits;	chr7:144058350	chr7:144272445~144286966:-
BRCA	cis	rs1029738	0.659	rs1608553	ENSG00000226329.2	AC005682.6	6.82	1.51e-11	3.18e-09	0.2	0.21	Fibrinogen levels;	chr7:22856612	chr7:22863874~22881350:-
BRCA	cis	rs78456975	0.527	rs4073862	ENSG00000231482.2	AC141930.2	-6.82	1.51e-11	3.18e-09	-0.27	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1559661	chr2:1572554~1580311:-
BRCA	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	6.82	1.51e-11	3.19e-09	0.25	0.21	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
BRCA	cis	rs67981189	0.865	rs34488204	ENSG00000269927.1	RP6-91H8.3	6.82	1.51e-11	3.19e-09	0.26	0.21	Schizophrenia;	chr14:71028571	chr14:71141125~71143253:-
BRCA	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-6.82	1.52e-11	3.19e-09	-0.23	-0.21	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
BRCA	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	6.82	1.52e-11	3.2e-09	0.22	0.21	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
BRCA	cis	rs6543140	0.855	rs4851591	ENSG00000234389.1	AC007278.3	6.82	1.52e-11	3.2e-09	0.2	0.21	Blood protein levels;	chr2:102460963	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-6.82	1.52e-11	3.2e-09	-0.23	-0.21	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	6.82	1.52e-11	3.2e-09	0.21	0.21	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
BRCA	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-6.82	1.52e-11	3.21e-09	-0.19	-0.21	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
BRCA	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	6.82	1.52e-11	3.21e-09	0.21	0.21	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000204959.4	ARHGEF34P	6.82	1.52e-11	3.21e-09	0.26	0.21	Obesity-related traits;	chr7:144058759	chr7:144272445~144286966:-
BRCA	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-6.82	1.52e-11	3.21e-09	-0.27	-0.21	Height;	chr1:41078607	chr1:41242373~41284861:+
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000261582.1	RP4-614O4.11	-6.82	1.52e-11	3.21e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	6.82	1.52e-11	3.21e-09	0.21	0.21	Height;	chr20:35201180	chr20:35201747~35203288:-
BRCA	cis	rs10515750	0.588	rs2289851	ENSG00000251405.2	CTB-109A12.1	6.82	1.53e-11	3.21e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157359160	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	6.82	1.53e-11	3.21e-09	0.22	0.21	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
BRCA	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.22e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	6.82	1.53e-11	3.22e-09	0.21	0.21	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
BRCA	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-6.82	1.53e-11	3.22e-09	-0.27	-0.21	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
BRCA	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.22e-09	0.2	0.21	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
BRCA	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-6.82	1.53e-11	3.23e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
BRCA	cis	rs4237845	0.837	rs7954591	ENSG00000257159.1	RP11-58A17.3	6.82	1.53e-11	3.23e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr12:57905254	chr12:57967058~57968399:+
BRCA	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.23e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	6.82	1.53e-11	3.23e-09	0.25	0.21	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
BRCA	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-6.82	1.53e-11	3.23e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
BRCA	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	6.82	1.53e-11	3.23e-09	0.25	0.21	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
BRCA	cis	rs11976180	1	rs1540894	ENSG00000204959.4	ARHGEF34P	6.82	1.54e-11	3.24e-09	0.26	0.21	Obesity-related traits;	chr7:144070583	chr7:144272445~144286966:-
BRCA	cis	rs420259	0.516	rs2239951	ENSG00000260136.4	CTD-2270L9.4	-6.82	1.54e-11	3.24e-09	-0.21	-0.21	Bipolar disorder;	chr16:23493672	chr16:23452758~23457606:+
BRCA	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-6.82	1.54e-11	3.25e-09	-0.28	-0.21	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
BRCA	cis	rs7809950	0.723	rs62483634	ENSG00000238832.1	snoU109	-6.82	1.55e-11	3.26e-09	-0.29	-0.21	Coronary artery disease;	chr7:107238071	chr7:107603363~107603507:+
BRCA	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-6.82	1.55e-11	3.27e-09	-0.25	-0.21	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	6.82	1.55e-11	3.27e-09	0.24	0.21	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	6.82	1.55e-11	3.27e-09	0.24	0.21	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-6.82	1.56e-11	3.28e-09	-0.23	-0.21	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
BRCA	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-6.82	1.56e-11	3.28e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
BRCA	cis	rs10446497	0.61	rs12497046	ENSG00000272359.1	U4	6.82	1.56e-11	3.29e-09	0.27	0.21	Schizophrenia;	chr3:196816775	chr3:196747192~196747324:-
BRCA	cis	rs2638953	0.924	rs7307078	ENSG00000278733.1	RP11-425D17.1	-6.82	1.56e-11	3.29e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28185625~28186190:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-6.82	1.56e-11	3.29e-09	-0.13	-0.21	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
BRCA	cis	rs4072705	0.967	rs4838210	ENSG00000224020.1	MIR181A2HG	6.82	1.57e-11	3.29e-09	0.22	0.21	Menarche (age at onset);	chr9:124783904	chr9:124658467~124698631:+
BRCA	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-6.82	1.57e-11	3.29e-09	-0.4	-0.21	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
BRCA	cis	rs4072705	1	rs2416949	ENSG00000224020.1	MIR181A2HG	-6.82	1.57e-11	3.3e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124712832	chr9:124658467~124698631:+
BRCA	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-6.82	1.57e-11	3.3e-09	-0.27	-0.21	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000224316.1	RP11-479O9.2	-6.82	1.57e-11	3.3e-09	-0.24	-0.21	Aortic root size;	chr7:66645977	chr7:65773620~65802067:+
BRCA	cis	rs10181042	0.535	rs2441465	ENSG00000271889.1	RP11-493E12.1	6.82	1.57e-11	3.3e-09	0.25	0.21	Crohn's disease;	chr2:61084052	chr2:61151433~61162105:-
BRCA	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-6.82	1.57e-11	3.3e-09	-0.27	-0.21	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
BRCA	cis	rs375066	0.762	rs239943	ENSG00000267058.1	RP11-15A1.3	-6.82	1.57e-11	3.3e-09	-0.24	-0.21	Breast cancer;	chr19:43870564	chr19:43891804~43901805:-
BRCA	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-6.82	1.57e-11	3.3e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
BRCA	cis	rs67981189	0.896	rs1859468	ENSG00000269927.1	RP6-91H8.3	-6.82	1.57e-11	3.3e-09	-0.26	-0.21	Schizophrenia;	chr14:70935573	chr14:71141125~71143253:-
BRCA	cis	rs812925	0.892	rs1186699	ENSG00000271889.1	RP11-493E12.1	6.82	1.57e-11	3.3e-09	0.26	0.21	Immature fraction of reticulocytes;	chr2:61435420	chr2:61151433~61162105:-
BRCA	cis	rs7845219	0.597	rs7002058	ENSG00000253528.2	RP11-347C18.4	6.82	1.57e-11	3.31e-09	0.21	0.21	Type 2 diabetes;	chr8:94861765	chr8:94974573~94974853:-
BRCA	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-6.82	1.57e-11	3.31e-09	-0.27	-0.21	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
BRCA	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	6.82	1.58e-11	3.31e-09	0.26	0.21	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
BRCA	cis	rs7976269	0.609	rs2117994	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29054666	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.583	rs6487753	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056103	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.583	rs6487754	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056104	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs6487755	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056156	chr12:29280418~29317848:-
BRCA	cis	rs2834288	0.5	rs2834304	ENSG00000273102.1	AP000569.9	6.82	1.58e-11	3.32e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33967101~33968573:-
BRCA	cis	rs4683346	0.549	rs6442067	ENSG00000173811.9	CCDC13-AS1	6.82	1.58e-11	3.32e-09	0.26	0.21	Granulocyte percentage of myeloid white cells;	chr3:42783623	chr3:42732575~42746768:+
BRCA	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-6.82	1.58e-11	3.32e-09	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
BRCA	cis	rs4372836	0.928	rs55836936	ENSG00000226833.4	AC097724.3	-6.82	1.58e-11	3.32e-09	-0.26	-0.21	Body mass index;	chr2:28699967	chr2:28708953~28736205:-
BRCA	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-6.82	1.58e-11	3.33e-09	-0.23	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
BRCA	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-6.82	1.59e-11	3.33e-09	-0.27	-0.21	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-6.82	1.59e-11	3.33e-09	-0.27	-0.21	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	6.82	1.59e-11	3.33e-09	0.25	0.21	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	6.82	1.59e-11	3.33e-09	0.25	0.21	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
BRCA	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	6.82	1.59e-11	3.33e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	6.82	1.59e-11	3.33e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
BRCA	cis	rs17253792	0.822	rs10137340	ENSG00000186615.9	KTN1-AS1	-6.82	1.59e-11	3.34e-09	-0.37	-0.21	Putamen volume;	chr14:55584271	chr14:55499278~55580110:-
BRCA	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	6.82	1.59e-11	3.34e-09	0.21	0.21	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
BRCA	cis	rs7474896	0.515	rs2505233	ENSG00000226578.1	RP11-258F22.1	-6.82	1.59e-11	3.34e-09	-0.26	-0.21	Obesity (extreme);	chr10:38051337	chr10:37775371~37784131:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000267422.1	CTD-2554C21.1	6.82	1.59e-11	3.34e-09	0.31	0.21	Coronary artery calcification;	chr19:37524807	chr19:37779686~37792865:+
BRCA	cis	rs919433	0.68	rs787983	ENSG00000231621.1	AC013264.2	-6.82	1.59e-11	3.34e-09	-0.19	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197481073	chr2:197197991~197199273:+
BRCA	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-6.82	1.59e-11	3.34e-09	-0.23	-0.21	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
BRCA	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-6.81	1.59e-11	3.35e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000224316.1	RP11-479O9.2	-6.81	1.6e-11	3.35e-09	-0.21	-0.21	Aortic root size;	chr7:66205775	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-6.81	1.6e-11	3.36e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	6.81	1.6e-11	3.36e-09	0.28	0.21	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
BRCA	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-6.81	1.6e-11	3.37e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
BRCA	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-6.81	1.61e-11	3.38e-09	-0.24	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
BRCA	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-6.81	1.61e-11	3.38e-09	-0.26	-0.21	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
BRCA	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-6.81	1.61e-11	3.38e-09	-0.23	-0.21	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	6.81	1.61e-11	3.38e-09	0.25	0.21	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
BRCA	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	6.81	1.61e-11	3.38e-09	0.23	0.21	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	6.81	1.61e-11	3.39e-09	0.25	0.21	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	6.81	1.62e-11	3.39e-09	0.24	0.21	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	6.81	1.62e-11	3.39e-09	0.25	0.21	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	6.81	1.62e-11	3.39e-09	0.25	0.21	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	6.81	1.62e-11	3.39e-09	0.24	0.21	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
BRCA	cis	rs67981189	0.821	rs61990419	ENSG00000269927.1	RP6-91H8.3	6.81	1.62e-11	3.4e-09	0.26	0.21	Schizophrenia;	chr14:71069570	chr14:71141125~71143253:-
BRCA	cis	rs79040073	0.637	rs57749497	ENSG00000259531.2	RP11-295H24.3	6.81	1.62e-11	3.4e-09	0.33	0.21	Lung cancer in ever smokers;	chr15:49297661	chr15:49365124~49366685:-
BRCA	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	6.81	1.62e-11	3.4e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000224316.1	RP11-479O9.2	6.81	1.62e-11	3.4e-09	0.21	0.21	Aortic root size;	chr7:66057711	chr7:65773620~65802067:+
BRCA	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-6.81	1.62e-11	3.41e-09	-0.32	-0.21	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	6.81	1.63e-11	3.41e-09	0.26	0.21	Height;	chr4:55465165	chr4:55363971~55395847:-
BRCA	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-6.81	1.63e-11	3.41e-09	-0.22	-0.21	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
BRCA	cis	rs9876781	1	rs7635522	ENSG00000244380.1	RP11-24C3.2	6.81	1.63e-11	3.42e-09	0.24	0.21	Longevity;	chr3:48382166	chr3:48440352~48446656:-
BRCA	cis	rs710913	0.531	rs1180331	ENSG00000237624.1	OXCT2P1	-6.81	1.63e-11	3.42e-09	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39514956~39516490:+
BRCA	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-6.81	1.63e-11	3.42e-09	-0.23	-0.21	Longevity;	chr3:48464565	chr3:48256350~48256938:-
BRCA	cis	rs10515750	0.588	rs11739823	ENSG00000251405.2	CTB-109A12.1	6.81	1.63e-11	3.42e-09	0.31	0.21	Lung function (FEV1/FVC);	chr5:157342000	chr5:157362615~157460078:-
BRCA	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	6.81	1.63e-11	3.43e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
BRCA	cis	rs34779708	0.931	rs4934524	ENSG00000271335.4	RP11-324I22.4	6.81	1.64e-11	3.43e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934693	ENSG00000271335.4	RP11-324I22.4	6.81	1.64e-11	3.43e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35314552~35336401:-
BRCA	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-6.81	1.64e-11	3.44e-09	-0.23	-0.21	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-6.81	1.64e-11	3.44e-09	-0.23	-0.21	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
BRCA	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	6.81	1.65e-11	3.46e-09	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	6.81	1.65e-11	3.46e-09	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
BRCA	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	6.81	1.65e-11	3.46e-09	0.19	0.21	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
BRCA	cis	rs420259	0.516	rs7190131	ENSG00000260136.4	CTD-2270L9.4	-6.81	1.65e-11	3.46e-09	-0.21	-0.21	Bipolar disorder;	chr16:23490828	chr16:23452758~23457606:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000224316.1	RP11-479O9.2	-6.81	1.65e-11	3.47e-09	-0.2	-0.21	Aortic root size;	chr7:66146001	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000224316.1	RP11-479O9.2	-6.81	1.65e-11	3.47e-09	-0.2	-0.21	Aortic root size;	chr7:66148700	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	6.81	1.65e-11	3.47e-09	0.21	0.21	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
BRCA	cis	rs67311347	1	rs9865348	ENSG00000280739.1	EIF1B-AS1	6.81	1.65e-11	3.47e-09	0.23	0.21	Renal cell carcinoma;	chr3:40356167	chr3:40173145~40309698:-
BRCA	cis	rs2239547	0.603	rs6805298	ENSG00000242142.1	SERBP1P3	-6.81	1.66e-11	3.47e-09	-0.25	-0.21	Schizophrenia;	chr3:53062536	chr3:53064283~53065091:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	6.81	1.66e-11	3.48e-09	0.25	0.21	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
BRCA	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	6.81	1.66e-11	3.48e-09	0.23	0.21	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-6.81	1.66e-11	3.49e-09	-0.28	-0.21	Gout;	chr7:66645053	chr7:66880708~66882981:+
BRCA	cis	rs5015933	0.902	rs1969045	ENSG00000232630.1	PRPS1P2	-6.81	1.66e-11	3.49e-09	-0.19	-0.21	Body mass index;	chr9:125368261	chr9:125150653~125151589:+
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-6.81	1.67e-11	3.5e-09	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
BRCA	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.81	1.67e-11	3.5e-09	-0.29	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
BRCA	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-6.81	1.67e-11	3.51e-09	-0.24	-0.21	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
BRCA	cis	rs2638953	0.924	rs12368652	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049392	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049394	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049395	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049397	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28185625~28186190:-
BRCA	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-6.81	1.68e-11	3.52e-09	-0.25	-0.21	QT interval;	chr12:29306799	chr12:29280418~29317848:-
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-6.81	1.68e-11	3.53e-09	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
BRCA	cis	rs17253792	0.822	rs10136155	ENSG00000186615.9	KTN1-AS1	-6.81	1.68e-11	3.53e-09	-0.4	-0.21	Putamen volume;	chr14:55582411	chr14:55499278~55580110:-
BRCA	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	6.81	1.69e-11	3.54e-09	0.29	0.21	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
BRCA	cis	rs7085104	0.514	rs284855	ENSG00000236937.2	PTGES3P4	-6.81	1.69e-11	3.54e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102845595~102845950:+
BRCA	cis	rs4356203	0.519	rs214092	ENSG00000272034.1	SNORD14A	-6.81	1.69e-11	3.54e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17074654~17074744:-
BRCA	cis	rs9307551	0.817	rs1031004	ENSG00000250334.4	LINC00989	-6.81	1.69e-11	3.54e-09	-0.28	-0.21	Refractive error;	chr4:79595695	chr4:79492416~79576460:+
BRCA	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-6.81	1.69e-11	3.55e-09	-0.24	-0.21	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
BRCA	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-6.81	1.69e-11	3.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
BRCA	cis	rs2749097	0.825	rs11208265	ENSG00000244256.3	RN7SL130P	-6.81	1.7e-11	3.56e-09	-0.26	-0.21	Alcohol consumption (transferrin glycosylation);	chr1:63659563	chr1:63655743~63656047:+
BRCA	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-6.81	1.7e-11	3.56e-09	-0.27	-0.21	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-6.81	1.7e-11	3.56e-09	-0.27	-0.21	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
BRCA	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	6.81	1.7e-11	3.56e-09	0.3	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	6.8	1.7e-11	3.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	6.8	1.7e-11	3.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-6.8	1.7e-11	3.57e-09	-0.25	-0.21	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
BRCA	cis	rs17253792	0.822	rs11546	ENSG00000186615.9	KTN1-AS1	-6.8	1.71e-11	3.57e-09	-0.4	-0.21	Putamen volume;	chr14:55679639	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10148122	ENSG00000186615.9	KTN1-AS1	-6.8	1.71e-11	3.57e-09	-0.4	-0.21	Putamen volume;	chr14:55679976	chr14:55499278~55580110:-
BRCA	cis	rs6543140	0.964	rs13393175	ENSG00000234389.1	AC007278.3	6.8	1.71e-11	3.57e-09	0.2	0.21	Blood protein levels;	chr2:102462389	chr2:102438713~102440475:+
BRCA	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	6.8	1.71e-11	3.57e-09	0.24	0.21	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
BRCA	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
BRCA	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-6.8	1.71e-11	3.58e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
BRCA	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-6.8	1.72e-11	3.6e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
BRCA	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	6.8	1.72e-11	3.61e-09	0.25	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
BRCA	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.8	1.72e-11	3.61e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.8	1.72e-11	3.61e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
BRCA	cis	rs4803480	0.678	rs3745936	ENSG00000270164.1	LINC01480	-6.8	1.73e-11	3.62e-09	-0.24	-0.21	Schizophrenia;	chr19:41586462	chr19:41535183~41536904:+
BRCA	cis	rs4691139	1	rs13134489	ENSG00000248632.1	RP11-366M4.11	6.8	1.73e-11	3.62e-09	0.21	0.21	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164968587~164970002:-
BRCA	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.8	1.74e-11	3.63e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
BRCA	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	6.8	1.74e-11	3.63e-09	0.21	0.21	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
BRCA	cis	rs1440410	0.835	rs11722027	ENSG00000250326.1	RP11-284M14.1	-6.8	1.74e-11	3.64e-09	-0.23	-0.21	Ischemic stroke;	chr4:143128864	chr4:142933195~143184861:-
BRCA	cis	rs67311347	1	rs17078511	ENSG00000280739.1	EIF1B-AS1	6.8	1.74e-11	3.64e-09	0.23	0.21	Renal cell carcinoma;	chr3:40354763	chr3:40173145~40309698:-
BRCA	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-6.8	1.74e-11	3.64e-09	-0.22	-0.21	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
BRCA	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-6.8	1.74e-11	3.64e-09	-0.28	-0.21	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
BRCA	cis	rs7914558	0.752	rs7896519	ENSG00000213061.2	PFN1P11	6.8	1.74e-11	3.64e-09	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102838011~102845473:-
BRCA	cis	rs78456975	0.699	rs17091772	ENSG00000231482.2	AC141930.2	-6.8	1.74e-11	3.64e-09	-0.29	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515907	chr2:1572554~1580311:-
BRCA	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-6.8	1.74e-11	3.65e-09	-0.24	-0.21	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
BRCA	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-6.8	1.75e-11	3.65e-09	-0.3	-0.21	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
BRCA	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-6.8	1.75e-11	3.65e-09	-0.3	-0.21	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000228409.4	CCT6P1	6.8	1.75e-11	3.66e-09	0.29	0.21	Diabetic kidney disease;	chr7:65914813	chr7:65751142~65763354:+
BRCA	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-6.8	1.75e-11	3.66e-09	-0.22	-0.21	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	6.8	1.75e-11	3.66e-09	0.23	0.21	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.596	rs194518	ENSG00000225498.1	AC002064.5	6.8	1.75e-11	3.66e-09	0.2	0.21	Homocysteine levels;	chr7:90223835	chr7:90312496~90322592:+
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	6.8	1.75e-11	3.66e-09	0.26	0.21	Height;	chr4:55542243	chr4:55540502~55540835:-
BRCA	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	6.8	1.76e-11	3.68e-09	0.26	0.21	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	6.8	1.76e-11	3.68e-09	0.26	0.21	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-6.8	1.76e-11	3.68e-09	-0.26	-0.21	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
BRCA	cis	rs17253792	0.822	rs10083499	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55599872	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75437558	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600080	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76267907	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600251	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75232282	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600572	chr14:55499278~55580110:-
BRCA	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-6.8	1.76e-11	3.68e-09	-0.23	-0.21	Height;	chr5:37318193	chr5:36666214~36725195:-
BRCA	cis	rs2835345	0.596	rs62229441	ENSG00000230479.1	AP000695.6	6.8	1.76e-11	3.68e-09	0.21	0.21	Pulmonary function;	chr21:36447559	chr21:36430360~36481070:+
BRCA	cis	rs2060793	1	rs10741657	ENSG00000251991.1	RNU7-49P	6.8	1.77e-11	3.69e-09	0.23	0.21	Vitamin D levels;	chr11:14893332	chr11:14478892~14478953:+
BRCA	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	6.8	1.77e-11	3.69e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
BRCA	cis	rs34779708	0.931	rs67976880	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs72789687	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35997236	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934719	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934720	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35314552~35336401:-
BRCA	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.8	1.77e-11	3.7e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
BRCA	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-6.8	1.77e-11	3.7e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
BRCA	cis	rs6740322	0.948	rs6715072	ENSG00000234936.1	AC010883.5	6.8	1.78e-11	3.71e-09	0.23	0.21	Coronary artery disease;	chr2:43335091	chr2:43229573~43233394:+
BRCA	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-6.8	1.78e-11	3.71e-09	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	6.8	1.78e-11	3.72e-09	0.26	0.21	Height;	chr4:55460485	chr4:55363971~55395847:-
BRCA	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-6.8	1.78e-11	3.72e-09	-0.25	-0.21	QT interval;	chr12:29303562	chr12:29280418~29317848:-
BRCA	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	6.8	1.78e-11	3.72e-09	0.31	0.21	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	6.8	1.78e-11	3.72e-09	0.15	0.21	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
BRCA	cis	rs79040073	0.637	rs73394355	ENSG00000259531.2	RP11-295H24.3	6.8	1.79e-11	3.73e-09	0.33	0.21	Lung cancer in ever smokers;	chr15:49299893	chr15:49365124~49366685:-
BRCA	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-6.8	1.79e-11	3.74e-09	-0.27	-0.21	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-6.8	1.79e-11	3.74e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.8	1.79e-11	3.74e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-6.8	1.8e-11	3.75e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
BRCA	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-6.8	1.8e-11	3.75e-09	-0.2	-0.21	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
BRCA	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	6.8	1.8e-11	3.75e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
BRCA	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	6.8	1.8e-11	3.75e-09	0.26	0.21	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
BRCA	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	6.8	1.8e-11	3.75e-09	0.24	0.21	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66197749	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66197774	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66204077	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.772	rs301873	ENSG00000250155.1	CTD-2353F22.1	-6.8	1.8e-11	3.76e-09	-0.22	-0.21	Height;	chr5:37136896	chr5:36666214~36725195:-
BRCA	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	6.8	1.8e-11	3.76e-09	0.23	0.21	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
BRCA	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-6.8	1.8e-11	3.76e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
BRCA	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-6.8	1.81e-11	3.77e-09	-0.27	-0.21	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
BRCA	cis	rs516805	0.52	rs9375150	ENSG00000279453.1	RP3-425C14.4	6.8	1.81e-11	3.77e-09	0.22	0.21	Lymphocyte counts;	chr6:122566410	chr6:122436789~122439223:-
BRCA	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	6.8	1.81e-11	3.78e-09	0.47	0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
BRCA	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-6.8	1.81e-11	3.78e-09	-0.29	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
BRCA	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	6.8	1.81e-11	3.78e-09	0.21	0.21	Height;	chr20:35197247	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	6.8	1.81e-11	3.78e-09	0.21	0.21	Height;	chr20:35197418	chr20:35201747~35203288:-
BRCA	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	6.8	1.81e-11	3.78e-09	0.22	0.21	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	6.8	1.81e-11	3.78e-09	0.25	0.21	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
BRCA	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-6.8	1.82e-11	3.79e-09	-0.24	-0.21	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-6.8	1.82e-11	3.79e-09	-0.24	-0.21	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
BRCA	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	6.8	1.82e-11	3.79e-09	0.24	0.21	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
BRCA	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-6.79	1.82e-11	3.8e-09	-0.27	-0.21	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
BRCA	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	6.79	1.82e-11	3.8e-09	0.23	0.21	Height;	chr5:37428489	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	6.79	1.82e-11	3.8e-09	0.26	0.21	Height;	chr4:55544621	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	6.79	1.82e-11	3.8e-09	0.26	0.21	Height;	chr4:55544621	chr4:55540502~55540835:-
BRCA	cis	rs11671005	0.779	rs11670125	ENSG00000252334.1	RNU6-1337P	6.79	1.82e-11	3.8e-09	0.33	0.21	Mean platelet volume;	chr19:58476023	chr19:58483749~58483843:-
BRCA	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	6.79	1.82e-11	3.8e-09	0.29	0.21	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000213640.3	EEF1DP4	6.79	1.83e-11	3.81e-09	0.26	0.21	Calcium levels;	chr7:65733651	chr7:64862999~64864370:+
BRCA	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	6.79	1.83e-11	3.81e-09	0.22	0.21	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000224373.3	IGHV4-59	6.79	1.83e-11	3.82e-09	0.14	0.21	Kawasaki disease;	chr14:106805607	chr14:106627249~106627825:-
BRCA	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	6.79	1.83e-11	3.82e-09	0.25	0.21	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
BRCA	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	6.79	1.83e-11	3.82e-09	0.25	0.21	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
BRCA	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	6.79	1.83e-11	3.83e-09	0.24	0.21	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
BRCA	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	6.79	1.84e-11	3.83e-09	0.26	0.21	Height;	chr4:55573424	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	6.79	1.84e-11	3.83e-09	0.26	0.21	Height;	chr4:55575856	chr4:55363971~55395847:-
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.79	1.84e-11	3.83e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000236529.1	RP13-254B10.1	-6.79	1.84e-11	3.83e-09	-0.26	-0.21	Aortic root size;	chr7:66624178	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	6.79	1.84e-11	3.83e-09	0.37	0.21	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
BRCA	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-6.79	1.84e-11	3.84e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
BRCA	cis	rs3126085	0.935	rs4845736	ENSG00000237975.5	FLG-AS1	-6.79	1.84e-11	3.84e-09	-0.27	-0.21	Atopic dermatitis;	chr1:152203075	chr1:152168125~152445456:+
BRCA	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.79	1.84e-11	3.85e-09	-0.24	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
BRCA	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-6.79	1.85e-11	3.85e-09	-0.22	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
BRCA	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-6.79	1.85e-11	3.85e-09	-0.23	-0.21	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
BRCA	cis	rs7976269	0.609	rs2196482	ENSG00000257176.2	RP11-996F15.2	-6.79	1.85e-11	3.86e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052559	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs2217906	ENSG00000257176.2	RP11-996F15.2	-6.79	1.85e-11	3.86e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052626	chr12:29280418~29317848:-
BRCA	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	6.79	1.85e-11	3.86e-09	0.23	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
BRCA	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.79	1.85e-11	3.86e-09	0.27	0.21	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
BRCA	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-6.79	1.86e-11	3.87e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-6.79	1.86e-11	3.87e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
BRCA	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	6.79	1.86e-11	3.88e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
BRCA	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	6.79	1.86e-11	3.88e-09	0.23	0.21	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
BRCA	cis	rs6543140	0.865	rs6760275	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102463147	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6734203	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102463606	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6543142	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102465546	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.929	rs6742530	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102465820	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	6.79	1.87e-11	3.89e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
BRCA	cis	rs79040073	0.607	rs17479205	ENSG00000259531.2	RP11-295H24.3	6.79	1.87e-11	3.89e-09	0.32	0.21	Lung cancer in ever smokers;	chr15:49456065	chr15:49365124~49366685:-
BRCA	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	6.79	1.87e-11	3.9e-09	0.39	0.21	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
BRCA	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	6.79	1.87e-11	3.9e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	6.79	1.87e-11	3.9e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
BRCA	cis	rs459482	1	rs464783	ENSG00000228318.3	AP001610.5	6.79	1.88e-11	3.91e-09	0.24	0.21	IgG glycosylation;	chr21:41424553	chr21:41441056~41445708:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	6.79	1.88e-11	3.91e-09	0.24	0.21	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
BRCA	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	6.79	1.88e-11	3.92e-09	0.24	0.21	Longevity;	chr3:48398582	chr3:48440352~48446656:-
BRCA	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-6.79	1.88e-11	3.92e-09	-0.17	-0.21	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	6.79	1.89e-11	3.93e-09	0.25	0.21	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
BRCA	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-6.79	1.89e-11	3.93e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
BRCA	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	6.79	1.89e-11	3.93e-09	0.24	0.21	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
BRCA	cis	rs12691307	1	rs12691307	ENSG00000273724.1	RP11-347C12.12	-6.79	1.89e-11	3.94e-09	-0.23	-0.21	Schizophrenia;	chr16:29928556	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000224316.1	RP11-479O9.2	-6.79	1.89e-11	3.94e-09	-0.21	-0.21	Aortic root size;	chr7:66228350	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.924	rs2061758	ENSG00000278733.1	RP11-425D17.1	-6.79	1.89e-11	3.94e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000224316.1	RP11-479O9.2	-6.79	1.9e-11	3.95e-09	-0.21	-0.21	Aortic root size;	chr7:66250256	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-6.79	1.9e-11	3.96e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000236529.1	RP13-254B10.1	6.79	1.91e-11	3.97e-09	0.25	0.21	Aortic root size;	chr7:66276638	chr7:65840212~65840596:+
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.79	1.91e-11	3.97e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
BRCA	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-6.79	1.91e-11	3.98e-09	-0.27	-0.21	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
BRCA	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	6.79	1.92e-11	3.99e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
BRCA	cis	rs7085104	0.572	rs284856	ENSG00000213061.2	PFN1P11	-6.79	1.92e-11	3.99e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102838011~102845473:-
BRCA	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	6.79	1.92e-11	3.99e-09	0.26	0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
BRCA	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-6.79	1.92e-11	4e-09	-0.25	-0.21	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
BRCA	cis	rs2835345	0.561	rs5026478	ENSG00000230479.1	AP000695.6	6.79	1.92e-11	4e-09	0.2	0.21	Pulmonary function;	chr21:36453531	chr21:36430360~36481070:+
BRCA	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	6.79	1.92e-11	4e-09	0.23	0.21	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
BRCA	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-6.79	1.92e-11	4e-09	-0.23	-0.21	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
BRCA	cis	rs67981189	0.758	rs221921	ENSG00000269927.1	RP6-91H8.3	-6.79	1.93e-11	4.01e-09	-0.26	-0.21	Schizophrenia;	chr14:71119411	chr14:71141125~71143253:-
BRCA	cis	rs11976180	1	rs2951360	ENSG00000204959.4	ARHGEF34P	6.79	1.93e-11	4.01e-09	0.26	0.21	Obesity-related traits;	chr7:144060256	chr7:144272445~144286966:-
BRCA	cis	rs875971	1	rs875971	ENSG00000224316.1	RP11-479O9.2	-6.79	1.93e-11	4.01e-09	-0.2	-0.21	Aortic root size;	chr7:66152608	chr7:65773620~65802067:+
BRCA	cis	rs7976269	0.559	rs10771473	ENSG00000257176.2	RP11-996F15.2	-6.79	1.94e-11	4.03e-09	-0.24	-0.21	Male-pattern baldness;	chr12:29068729	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-6.79	1.94e-11	4.03e-09	-0.26	-0.21	Height;	chr4:55514317	chr4:55363971~55395847:-
BRCA	cis	rs11723261	0.582	rs11732336	ENSG00000211553.1	AC253576.2	-6.78	1.94e-11	4.04e-09	-0.29	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:136461~136568:+
BRCA	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-6.78	1.94e-11	4.05e-09	-0.24	-0.21	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
BRCA	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-6.78	1.95e-11	4.05e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
BRCA	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	6.78	1.95e-11	4.05e-09	0.39	0.21	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
BRCA	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	6.78	1.96e-11	4.07e-09	0.22	0.21	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
BRCA	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	6.78	1.96e-11	4.08e-09	0.2	0.21	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
BRCA	cis	rs7826238	0.72	rs12546760	ENSG00000254153.1	CTA-398F10.2	-6.78	1.96e-11	4.08e-09	-0.24	-0.21	Systolic blood pressure;	chr8:8517326	chr8:8456909~8461337:-
BRCA	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	6.78	1.96e-11	4.08e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
BRCA	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-6.78	1.96e-11	4.08e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
BRCA	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-6.78	1.96e-11	4.08e-09	-0.21	-0.21	Height;	chr20:35142661	chr20:35201747~35203288:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	6.78	1.96e-11	4.08e-09	0.17	0.21	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
BRCA	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	6.78	1.97e-11	4.09e-09	0.24	0.21	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
BRCA	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	6.78	1.97e-11	4.09e-09	0.27	0.21	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	6.78	1.97e-11	4.09e-09	0.24	0.21	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	6.78	1.97e-11	4.09e-09	0.24	0.21	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-6.78	1.97e-11	4.09e-09	-0.25	-0.21	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
BRCA	cis	rs11671005	0.779	rs3794971	ENSG00000252334.1	RNU6-1337P	6.78	1.97e-11	4.09e-09	0.32	0.21	Mean platelet volume;	chr19:58474499	chr19:58483749~58483843:-
BRCA	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	6.78	1.97e-11	4.1e-09	0.31	0.21	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
BRCA	cis	rs4072705	1	rs10760374	ENSG00000224020.1	MIR181A2HG	-6.78	1.97e-11	4.1e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124733229	chr9:124658467~124698631:+
BRCA	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	6.78	1.98e-11	4.11e-09	0.26	0.21	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
BRCA	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	6.78	1.98e-11	4.11e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
BRCA	cis	rs34929064	0.781	rs2905324	ENSG00000179428.2	AC073072.5	-6.78	1.98e-11	4.11e-09	-0.22	-0.21	Major depression and alcohol dependence;	chr7:22669384	chr7:22725395~22727620:-
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	6.78	1.99e-11	4.13e-09	0.25	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
BRCA	cis	rs34779708	0.931	rs11593858	ENSG00000271335.4	RP11-324I22.4	6.78	1.99e-11	4.13e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35314552~35336401:-
BRCA	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	6.78	1.99e-11	4.14e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	6.78	1.99e-11	4.14e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
BRCA	cis	rs7085104	0.514	rs284855	ENSG00000213061.2	PFN1P11	-6.78	1.99e-11	4.14e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102838011~102845473:-
BRCA	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-6.78	2e-11	4.15e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
BRCA	cis	rs6088813	0.961	rs6060373	ENSG00000126005.14	MMP24-AS1	6.78	2e-11	4.15e-09	0.24	0.21	Height;	chr20:35326405	chr20:35216462~35278131:-
BRCA	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	6.78	2e-11	4.15e-09	0.24	0.21	Longevity;	chr3:48389129	chr3:48440352~48446656:-
BRCA	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-6.78	2e-11	4.16e-09	-0.29	-0.21	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	6.78	2e-11	4.16e-09	0.25	0.21	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
BRCA	cis	rs7474896	0.559	rs1212108	ENSG00000226578.1	RP11-258F22.1	-6.78	2.01e-11	4.17e-09	-0.28	-0.21	Obesity (extreme);	chr10:37805394	chr10:37775371~37784131:-
BRCA	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	6.78	2.01e-11	4.17e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
BRCA	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-6.78	2.01e-11	4.17e-09	-0.18	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
BRCA	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	6.78	2.01e-11	4.18e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	6.78	2.02e-11	4.19e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
BRCA	cis	rs7487075	0.754	rs10880962	ENSG00000257261.4	RP11-96H19.1	6.78	2.02e-11	4.19e-09	0.22	0.21	Itch intensity from mosquito bite;	chr12:46379661	chr12:46383679~46876159:+
BRCA	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-6.78	2.02e-11	4.19e-09	-0.22	-0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
BRCA	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-6.78	2.02e-11	4.19e-09	-0.32	-0.21	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
BRCA	cis	rs8054556	0.73	rs4788190	ENSG00000273724.1	RP11-347C12.12	-6.78	2.03e-11	4.21e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30336400~30343336:+
BRCA	cis	rs957448	1	rs72674852	ENSG00000253175.1	RP11-267M23.6	6.78	2.03e-11	4.21e-09	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94565036~94565715:+
BRCA	cis	rs13178541	0.689	rs12521005	ENSG00000250378.1	RP11-119J18.1	-6.78	2.03e-11	4.21e-09	-0.28	-0.21	IgG glycosylation;	chr5:135823313	chr5:135812667~135826582:+
BRCA	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-6.78	2.03e-11	4.21e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
BRCA	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	6.78	2.03e-11	4.21e-09	0.32	0.21	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
BRCA	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	6.78	2.03e-11	4.22e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
BRCA	cis	rs3781264	0.724	rs12780491	ENSG00000273450.1	RP11-76P2.4	6.78	2.03e-11	4.22e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94361265	chr10:94314907~94315327:-
BRCA	cis	rs7428	0.502	rs3184781	ENSG00000246575.2	AC093162.5	6.78	2.04e-11	4.23e-09	0.21	0.21	Ear protrusion;	chr2:85322404	chr2:85315041~85316529:+
BRCA	cis	rs7428	0.527	rs3184780	ENSG00000246575.2	AC093162.5	6.78	2.04e-11	4.23e-09	0.21	0.21	Ear protrusion;	chr2:85322424	chr2:85315041~85316529:+
BRCA	cis	rs4072705	1	rs10760373	ENSG00000224020.1	MIR181A2HG	-6.78	2.04e-11	4.23e-09	-0.22	-0.21	Menarche (age at onset);	chr9:124723166	chr9:124658467~124698631:+
BRCA	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	6.78	2.04e-11	4.23e-09	0.24	0.21	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
BRCA	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-6.78	2.04e-11	4.23e-09	-0.24	-0.21	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-6.78	2.04e-11	4.23e-09	-0.25	-0.21	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
BRCA	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	6.78	2.04e-11	4.24e-09	0.32	0.21	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
BRCA	cis	rs11976180	1	rs2961132	ENSG00000204959.4	ARHGEF34P	6.78	2.04e-11	4.24e-09	0.26	0.21	Obesity-related traits;	chr7:144071035	chr7:144272445~144286966:-
BRCA	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	6.78	2.04e-11	4.24e-09	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	6.78	2.04e-11	4.24e-09	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
BRCA	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-6.78	2.04e-11	4.24e-09	-0.24	-0.21	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	6.78	2.05e-11	4.24e-09	0.26	0.21	Height;	chr4:55407965	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	6.78	2.05e-11	4.25e-09	0.25	0.21	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
BRCA	cis	rs2834288	0.5	rs2834305	ENSG00000273102.1	AP000569.9	6.78	2.05e-11	4.26e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33967101~33968573:-
BRCA	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	6.78	2.05e-11	4.26e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.78	2.05e-11	4.26e-09	0.24	0.21	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
BRCA	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	6.78	2.06e-11	4.27e-09	0.25	0.21	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000236529.1	RP13-254B10.1	6.78	2.06e-11	4.27e-09	0.25	0.21	Aortic root size;	chr7:66172694	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.24	0.21	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-6.78	2.07e-11	4.28e-09	-0.23	-0.21	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	6.78	2.07e-11	4.29e-09	0.24	0.21	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	6.78	2.07e-11	4.29e-09	0.24	0.21	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	6.78	2.07e-11	4.29e-09	0.25	0.21	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
BRCA	cis	rs228614	0.509	rs223482	ENSG00000251288.2	RP11-10L12.2	-6.78	2.07e-11	4.29e-09	-0.24	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102751401~102752641:+
BRCA	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-6.78	2.07e-11	4.29e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
BRCA	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-6.78	2.07e-11	4.29e-09	-0.26	-0.21	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
BRCA	cis	rs74233809	0.901	rs3824754	ENSG00000213277.3	MARCKSL1P1	6.78	2.07e-11	4.3e-09	0.38	0.21	Birth weight;	chr10:102854593	chr10:103175554~103176094:+
BRCA	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-6.77	2.08e-11	4.31e-09	-0.24	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
BRCA	cis	rs6543140	0.964	rs6543136	ENSG00000234389.1	AC007278.3	6.77	2.08e-11	4.32e-09	0.21	0.21	Blood protein levels;	chr2:102449087	chr2:102438713~102440475:+
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000263335.1	AF001548.5	-6.77	2.09e-11	4.33e-09	-0.29	-0.21	Triglycerides;	chr16:15056648	chr16:15726674~15732993:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-6.77	2.09e-11	4.33e-09	-0.21	-0.21	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-6.77	2.09e-11	4.33e-09	-0.22	-0.21	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
BRCA	cis	rs12501370	1	rs17588627	ENSG00000201736.1	RNA5SP160	-6.77	2.09e-11	4.33e-09	-0.25	-0.21	Iris color (L* coordinate);	chr4:41016277	chr4:40990154~40990273:+
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	6.77	2.09e-11	4.34e-09	0.29	0.21	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
BRCA	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	6.77	2.1e-11	4.34e-09	0.17	0.21	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	6.77	2.1e-11	4.35e-09	0.27	0.21	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
BRCA	cis	rs838147	0.537	rs503279	ENSG00000232871.7	SEC1P	-6.77	2.1e-11	4.35e-09	-0.22	-0.21	Dietary macronutrient intake;	chr19:48705753	chr19:48638071~48682245:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	6.77	2.1e-11	4.35e-09	0.33	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
BRCA	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.1e-11	4.36e-09	-0.24	-0.21	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
BRCA	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.36e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
BRCA	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.36e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
BRCA	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-6.77	2.11e-11	4.37e-09	-0.27	-0.21	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
BRCA	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.38e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-6.77	2.11e-11	4.38e-09	-0.22	-0.21	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
BRCA	cis	rs6543140	0.964	rs10193485	ENSG00000234389.1	AC007278.3	6.77	2.11e-11	4.38e-09	0.21	0.21	Blood protein levels;	chr2:102473114	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs10196334	ENSG00000234389.1	AC007278.3	6.77	2.11e-11	4.38e-09	0.21	0.21	Blood protein levels;	chr2:102473582	chr2:102438713~102440475:+
BRCA	cis	rs6740322	0.895	rs9309098	ENSG00000234936.1	AC010883.5	-6.77	2.11e-11	4.38e-09	-0.23	-0.21	Coronary artery disease;	chr2:43327833	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000236529.1	RP13-254B10.1	-6.77	2.12e-11	4.38e-09	-0.26	-0.21	Aortic root size;	chr7:66066855	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	6.77	2.12e-11	4.39e-09	0.27	0.21	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-6.77	2.12e-11	4.39e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
BRCA	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-6.77	2.12e-11	4.39e-09	-0.21	-0.21	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	6.77	2.12e-11	4.39e-09	0.24	0.21	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
BRCA	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	6.77	2.12e-11	4.39e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
BRCA	cis	rs9876781	1	rs6810060	ENSG00000229759.1	MRPS18AP1	6.77	2.12e-11	4.39e-09	0.23	0.21	Longevity;	chr3:48393284	chr3:48256350~48256938:-
BRCA	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-6.77	2.13e-11	4.41e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
BRCA	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-6.77	2.13e-11	4.41e-09	-0.27	-0.21	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
BRCA	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.77	2.13e-11	4.41e-09	0.21	0.21	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
BRCA	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	6.77	2.13e-11	4.41e-09	0.22	0.21	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000234585.5	CCT6P3	6.77	2.13e-11	4.42e-09	0.2	0.21	Aortic root size;	chr7:66014585	chr7:65038354~65074713:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000234585.5	CCT6P3	6.77	2.13e-11	4.42e-09	0.2	0.21	Calcium levels;	chr7:66014891	chr7:65038354~65074713:+
BRCA	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	6.77	2.13e-11	4.42e-09	0.28	0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
BRCA	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	6.77	2.14e-11	4.42e-09	0.2	0.21	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
BRCA	cis	rs17767294	0.612	rs9461425	ENSG00000220721.1	OR1F12	6.77	2.14e-11	4.43e-09	0.35	0.21	Parkinson's disease;	chr6:27951910	chr6:28073316~28074233:+
BRCA	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-6.77	2.14e-11	4.43e-09	-0.27	-0.21	Height;	chr20:49267648	chr20:49280319~49280409:+
BRCA	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	6.77	2.14e-11	4.43e-09	0.2	0.21	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
BRCA	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-6.77	2.15e-11	4.44e-09	-0.23	-0.21	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000224316.1	RP11-479O9.2	-6.77	2.15e-11	4.44e-09	-0.2	-0.21	Aortic root size;	chr7:66282799	chr7:65773620~65802067:+
BRCA	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	6.77	2.15e-11	4.44e-09	0.3	0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
BRCA	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	6.77	2.15e-11	4.44e-09	0.27	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
BRCA	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	6.77	2.15e-11	4.45e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
BRCA	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	6.77	2.15e-11	4.45e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
BRCA	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
BRCA	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-6.77	2.15e-11	4.45e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
BRCA	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-6.77	2.15e-11	4.46e-09	-0.28	-0.21	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
BRCA	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-6.77	2.15e-11	4.46e-09	-0.24	-0.21	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-6.77	2.16e-11	4.47e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30729469~30731202:+
BRCA	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-6.77	2.16e-11	4.47e-09	-0.34	-0.21	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	6.77	2.16e-11	4.48e-09	0.26	0.21	Height;	chr4:55508982	chr4:55363971~55395847:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	6.77	2.17e-11	4.48e-09	0.27	0.21	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
BRCA	cis	rs9876781	1	rs6770470	ENSG00000229759.1	MRPS18AP1	6.77	2.17e-11	4.49e-09	0.23	0.21	Longevity;	chr3:48393659	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
BRCA	cis	rs79040073	0.563	rs17479003	ENSG00000259531.2	RP11-295H24.3	6.77	2.17e-11	4.49e-09	0.32	0.21	Lung cancer in ever smokers;	chr15:49453223	chr15:49365124~49366685:-
BRCA	cis	rs17253792	0.822	rs76918910	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55592044	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77599953	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55592187	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10137364	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593269	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17683728	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593671	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76264681	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593729	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17746033	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55595119	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs8009608	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55595872	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76201070	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55596886	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10150498	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55597406	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10133962	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55599370	chr14:55499278~55580110:-
BRCA	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	6.77	2.17e-11	4.5e-09	0.28	0.21	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
BRCA	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-6.77	2.17e-11	4.5e-09	-0.21	-0.21	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
BRCA	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	6.77	2.18e-11	4.5e-09	0.23	0.21	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
BRCA	cis	rs11009175	0.725	rs11009195	ENSG00000273038.2	RP11-479G22.8	-6.77	2.18e-11	4.5e-09	-0.34	-0.21	Depression (quantitative trait);	chr10:33045345	chr10:32887255~32889311:-
BRCA	cis	rs6543140	0.964	rs10200081	ENSG00000234389.1	AC007278.3	6.77	2.18e-11	4.5e-09	0.21	0.21	Blood protein levels;	chr2:102475097	chr2:102438713~102440475:+
BRCA	cis	rs7085104	0.572	rs284858	ENSG00000213061.2	PFN1P11	-6.77	2.18e-11	4.51e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.868	rs6752938	ENSG00000271889.1	RP11-493E12.1	6.77	2.18e-11	4.51e-09	0.26	0.21	Tuberculosis;	chr2:61614453	chr2:61151433~61162105:-
BRCA	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-6.77	2.18e-11	4.52e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-6.77	2.18e-11	4.52e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	6.77	2.19e-11	4.52e-09	0.37	0.21	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
BRCA	cis	rs301901	0.734	rs10941321	ENSG00000250155.1	CTD-2353F22.1	-6.77	2.19e-11	4.53e-09	-0.23	-0.21	Height;	chr5:37213248	chr5:36666214~36725195:-
BRCA	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.19e-11	4.53e-09	-0.24	-0.21	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
BRCA	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-6.77	2.2e-11	4.54e-09	-0.17	-0.21	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
BRCA	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-6.77	2.2e-11	4.54e-09	-0.28	-0.21	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
BRCA	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-6.77	2.2e-11	4.54e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
BRCA	cis	rs11671005	0.61	rs8103813	ENSG00000252334.1	RNU6-1337P	6.77	2.2e-11	4.56e-09	0.32	0.21	Mean platelet volume;	chr19:58561317	chr19:58483749~58483843:-
BRCA	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	6.77	2.21e-11	4.56e-09	0.19	0.21	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
BRCA	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.21e-11	4.56e-09	-0.24	-0.21	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
BRCA	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-6.77	2.21e-11	4.56e-09	-0.3	-0.21	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
BRCA	cis	rs4356203	0.519	rs214097	ENSG00000272034.1	SNORD14A	-6.77	2.21e-11	4.57e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17074654~17074744:-
BRCA	cis	rs7069191	0.668	rs10994491	ENSG00000254271.1	RP11-131N11.4	6.77	2.21e-11	4.57e-09	0.35	0.21	Pediatric bone mineral density (spine);	chr10:60744463	chr10:60734342~60741828:+
BRCA	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-6.77	2.21e-11	4.57e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	6.77	2.21e-11	4.57e-09	0.25	0.21	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
BRCA	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.77	2.21e-11	4.58e-09	0.29	0.21	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
BRCA	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	6.77	2.22e-11	4.58e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
BRCA	cis	rs3126085	0.935	rs12408581	ENSG00000237975.5	FLG-AS1	6.77	2.22e-11	4.58e-09	0.32	0.21	Atopic dermatitis;	chr1:152202735	chr1:152168125~152445456:+
BRCA	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.76	2.22e-11	4.59e-09	0.21	0.21	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
BRCA	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	6.76	2.22e-11	4.59e-09	0.27	0.21	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
BRCA	cis	rs8054556	0.74	rs3924855	ENSG00000273724.1	RP11-347C12.12	-6.76	2.22e-11	4.59e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30336400~30343336:+
BRCA	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	6.76	2.23e-11	4.61e-09	0.28	0.21	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
BRCA	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-6.76	2.23e-11	4.61e-09	-0.3	-0.21	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
BRCA	cis	rs67981189	0.896	rs7153237	ENSG00000269927.1	RP6-91H8.3	6.76	2.23e-11	4.61e-09	0.25	0.21	Schizophrenia;	chr14:71021937	chr14:71141125~71143253:-
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	6.76	2.23e-11	4.61e-09	0.26	0.21	Height;	chr4:55490176	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	6.76	2.23e-11	4.61e-09	0.26	0.21	Height;	chr4:55495262	chr4:55363971~55395847:-
BRCA	cis	rs7428	0.545	rs1053561	ENSG00000246575.2	AC093162.5	6.76	2.24e-11	4.62e-09	0.21	0.21	Ear protrusion;	chr2:85318929	chr2:85315041~85316529:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000228409.4	CCT6P1	6.76	2.24e-11	4.62e-09	0.28	0.21	Diabetic kidney disease;	chr7:65940751	chr7:65751142~65763354:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	6.76	2.24e-11	4.63e-09	0.24	0.21	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	6.76	2.24e-11	4.63e-09	0.25	0.21	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.679	rs9818740	ENSG00000239213.4	NCK1-AS1	6.76	2.24e-11	4.63e-09	0.26	0.21	Height;Body mass index;	chr3:136220744	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	6.76	2.25e-11	4.64e-09	0.22	0.21	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-6.76	2.25e-11	4.64e-09	-0.19	-0.21	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
BRCA	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	6.76	2.25e-11	4.65e-09	0.24	0.21	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-6.76	2.26e-11	4.66e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-6.76	2.26e-11	4.66e-09	-0.22	-0.21	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	6.76	2.26e-11	4.66e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-6.76	2.26e-11	4.66e-09	-0.19	-0.21	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-6.76	2.26e-11	4.66e-09	-0.19	-0.21	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
BRCA	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-6.76	2.26e-11	4.67e-09	-0.28	-0.21	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
BRCA	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-6.76	2.26e-11	4.67e-09	-0.23	-0.21	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
BRCA	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144063469	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2951354	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144063908	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961125	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144064677	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961126	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065643	chr7:144272445~144286966:-
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065644	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs1919948	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065750	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961128	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144066390	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2371248	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144067096	chr7:144272445~144286966:-
BRCA	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-6.76	2.26e-11	4.67e-09	-0.27	-0.21	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
BRCA	cis	rs3126085	0.56	rs11204985	ENSG00000237975.5	FLG-AS1	-6.76	2.27e-11	4.68e-09	-0.28	-0.21	Atopic dermatitis;	chr1:152361121	chr1:152168125~152445456:+
BRCA	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	6.76	2.27e-11	4.68e-09	0.22	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-6.76	2.27e-11	4.69e-09	-0.22	-0.21	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
BRCA	cis	rs5015933	0.815	rs13294021	ENSG00000232630.1	PRPS1P2	-6.76	2.27e-11	4.69e-09	-0.19	-0.21	Body mass index;	chr9:125306109	chr9:125150653~125151589:+
BRCA	cis	rs7978895	0.669	rs1399377	ENSG00000258331.1	RP11-118A3.1	-6.76	2.27e-11	4.69e-09	-0.21	-0.21	Type 2 diabetes;	chr12:43154835	chr12:43155315~43163110:+
BRCA	cis	rs301901	0.772	rs6860727	ENSG00000250155.1	CTD-2353F22.1	-6.76	2.28e-11	4.71e-09	-0.22	-0.2	Height;	chr5:37179239	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-6.76	2.28e-11	4.71e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
BRCA	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-6.76	2.28e-11	4.71e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
BRCA	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	6.76	2.28e-11	4.71e-09	0.25	0.2	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
BRCA	cis	rs7976269	0.609	rs6487744	ENSG00000257176.2	RP11-996F15.2	-6.76	2.29e-11	4.72e-09	-0.25	-0.2	Male-pattern baldness;	chr12:29030756	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-6.76	2.29e-11	4.72e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000273024.4	INTS4P2	-6.76	2.29e-11	4.73e-09	-0.26	-0.2	Aortic root size;	chr7:66255529	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-6.76	2.29e-11	4.73e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
BRCA	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	6.76	2.29e-11	4.73e-09	0.24	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
BRCA	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-6.76	2.3e-11	4.75e-09	-0.28	-0.2	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
BRCA	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	6.76	2.3e-11	4.75e-09	0.24	0.2	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
BRCA	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.76	2.31e-11	4.76e-09	0.27	0.2	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
BRCA	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.31e-11	4.76e-09	-0.25	-0.2	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-6.76	2.31e-11	4.77e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
BRCA	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	6.76	2.31e-11	4.77e-09	0.27	0.2	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
BRCA	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.32e-11	4.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.32e-11	4.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
BRCA	cis	rs860818	1	rs858245	ENSG00000226816.2	AC005082.12	6.76	2.32e-11	4.78e-09	0.49	0.2	Initial pursuit acceleration;	chr7:23183108	chr7:23206013~23208045:+
BRCA	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	6.76	2.32e-11	4.78e-09	0.26	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	6.76	2.32e-11	4.78e-09	0.24	0.2	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
BRCA	cis	rs7474896	0.583	rs10827817	ENSG00000226578.1	RP11-258F22.1	-6.76	2.32e-11	4.78e-09	-0.27	-0.2	Obesity (extreme);	chr10:37709046	chr10:37775371~37784131:-
BRCA	cis	rs42648	0.596	rs194520	ENSG00000225498.1	AC002064.5	6.76	2.32e-11	4.79e-09	0.2	0.2	Homocysteine levels;	chr7:90225132	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	6.76	2.34e-11	4.82e-09	0.27	0.2	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
BRCA	cis	rs79040073	0.637	rs73394359	ENSG00000259531.2	RP11-295H24.3	6.76	2.34e-11	4.82e-09	0.33	0.2	Lung cancer in ever smokers;	chr15:49300941	chr15:49365124~49366685:-
BRCA	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-6.76	2.34e-11	4.82e-09	-0.27	-0.2	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
BRCA	cis	rs34929064	0.881	rs2961311	ENSG00000179428.2	AC073072.5	6.76	2.34e-11	4.83e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22687919	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	6.76	2.35e-11	4.83e-09	0.27	0.2	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000228409.4	CCT6P1	6.76	2.35e-11	4.83e-09	0.28	0.2	Diabetic kidney disease;	chr7:65946971	chr7:65751142~65763354:+
BRCA	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	6.76	2.35e-11	4.84e-09	0.22	0.2	Height;	chr5:37430113	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.35e-11	4.84e-09	-0.24	-0.2	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-6.76	2.35e-11	4.84e-09	-0.3	-0.2	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
BRCA	cis	rs7978895	0.669	rs1399373	ENSG00000258331.1	RP11-118A3.1	-6.76	2.35e-11	4.85e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43150938	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs1399372	ENSG00000258331.1	RP11-118A3.1	-6.76	2.35e-11	4.85e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43150972	chr12:43155315~43163110:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-6.76	2.36e-11	4.85e-09	-0.22	-0.2	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
BRCA	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-6.76	2.36e-11	4.86e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-6.76	2.36e-11	4.86e-09	-0.2	-0.2	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
BRCA	cis	rs2835345	0.563	rs12482435	ENSG00000230479.1	AP000695.6	6.76	2.36e-11	4.86e-09	0.2	0.2	Pulmonary function;	chr21:36448658	chr21:36430360~36481070:+
BRCA	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-6.76	2.36e-11	4.87e-09	-0.22	-0.2	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
BRCA	cis	rs2998286	0.862	rs2185293	ENSG00000254635.4	WAC-AS1	-6.76	2.36e-11	4.87e-09	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28522652~28532743:-
BRCA	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	6.76	2.37e-11	4.88e-09	0.2	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-6.75	2.37e-11	4.89e-09	-0.23	-0.2	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
BRCA	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	6.75	2.38e-11	4.9e-09	0.27	0.2	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
BRCA	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	6.75	2.38e-11	4.9e-09	0.25	0.2	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	6.75	2.38e-11	4.9e-09	0.25	0.2	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
BRCA	cis	rs17253792	0.731	rs74829671	ENSG00000186615.9	KTN1-AS1	-6.75	2.38e-11	4.91e-09	-0.4	-0.2	Putamen volume;	chr14:55646041	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
BRCA	cis	rs11976180	1	rs11975942	ENSG00000204959.4	ARHGEF34P	6.75	2.39e-11	4.92e-09	0.26	0.2	Obesity-related traits;	chr7:144043487	chr7:144272445~144286966:-
BRCA	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-6.75	2.39e-11	4.92e-09	-0.27	-0.2	Height;	chr20:49311346	chr20:49280319~49280409:+
BRCA	cis	rs67981189	0.858	rs17108877	ENSG00000269927.1	RP6-91H8.3	6.75	2.39e-11	4.92e-09	0.25	0.2	Schizophrenia;	chr14:71007092	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-6.75	2.39e-11	4.92e-09	-0.22	-0.2	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
BRCA	cis	rs301901	0.772	rs2098713	ENSG00000250155.1	CTD-2353F22.1	-6.75	2.39e-11	4.93e-09	-0.22	-0.2	Height;	chr5:37144472	chr5:36666214~36725195:-
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-6.75	2.4e-11	4.94e-09	-0.3	-0.2	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
BRCA	cis	rs957448	1	rs957447	ENSG00000253175.1	RP11-267M23.6	6.75	2.4e-11	4.94e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94565036~94565715:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-6.75	2.4e-11	4.94e-09	-0.26	-0.2	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
BRCA	cis	rs919433	0.684	rs55775495	ENSG00000231621.1	AC013264.2	-6.75	2.41e-11	4.95e-09	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197381241	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-6.75	2.41e-11	4.96e-09	-0.22	-0.2	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
BRCA	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	6.75	2.41e-11	4.96e-09	0.28	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
BRCA	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.75	2.41e-11	4.96e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
BRCA	cis	rs7976269	0.609	rs2349574	ENSG00000257176.2	RP11-996F15.2	-6.75	2.41e-11	4.96e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29053805	chr12:29280418~29317848:-
BRCA	cis	rs228614	0.536	rs223478	ENSG00000251288.2	RP11-10L12.2	-6.75	2.41e-11	4.97e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.536	rs150898	ENSG00000251288.2	RP11-10L12.2	-6.75	2.41e-11	4.97e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102751401~102752641:+
BRCA	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	6.75	2.42e-11	4.97e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	6.75	2.42e-11	4.97e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
BRCA	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-6.75	2.42e-11	4.98e-09	-0.3	-0.2	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000204959.4	ARHGEF34P	6.75	2.42e-11	4.98e-09	0.26	0.2	Obesity-related traits;	chr7:144070805	chr7:144272445~144286966:-
BRCA	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	6.75	2.42e-11	4.99e-09	0.21	0.2	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000228409.4	CCT6P1	6.75	2.43e-11	4.99e-09	0.28	0.2	Diabetic kidney disease;	chr7:65928123	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.786	rs200503	ENSG00000220721.1	OR1F12	6.75	2.43e-11	4.99e-09	0.26	0.2	Parkinson's disease;	chr6:27818104	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.786	rs200502	ENSG00000220721.1	OR1F12	6.75	2.43e-11	4.99e-09	0.26	0.2	Parkinson's disease;	chr6:27820284	chr6:28073316~28074233:+
BRCA	cis	rs13178541	0.683	rs9800300	ENSG00000250378.1	RP11-119J18.1	-6.75	2.43e-11	5e-09	-0.29	-0.2	IgG glycosylation;	chr5:135760622	chr5:135812667~135826582:+
BRCA	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	6.75	2.44e-11	5.01e-09	0.24	0.2	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
BRCA	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-6.75	2.44e-11	5.01e-09	-0.27	-0.2	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	6.75	2.44e-11	5.01e-09	0.25	0.2	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	6.75	2.44e-11	5.01e-09	0.25	0.2	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
BRCA	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	6.75	2.44e-11	5.01e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000213640.3	EEF1DP4	-6.75	2.44e-11	5.02e-09	-0.26	-0.2	Calcium levels;	chr7:65829754	chr7:64862999~64864370:+
BRCA	cis	rs79040073	0.637	rs73392249	ENSG00000259531.2	RP11-295H24.3	6.75	2.44e-11	5.02e-09	0.33	0.2	Lung cancer in ever smokers;	chr15:49224264	chr15:49365124~49366685:-
BRCA	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-6.75	2.45e-11	5.03e-09	-0.27	-0.2	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	6.75	2.45e-11	5.04e-09	0.13	0.2	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
BRCA	cis	rs2380205	0.546	rs626344	ENSG00000232807.2	RP11-536K7.3	-6.75	2.46e-11	5.05e-09	-0.21	-0.2	Breast cancer;	chr10:5908272	chr10:5934270~5945900:-
BRCA	cis	rs858239	0.932	rs199355	ENSG00000230042.1	AK3P3	-6.75	2.46e-11	5.05e-09	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23129178~23129841:+
BRCA	cis	rs34779708	0.931	rs11592404	ENSG00000271335.4	RP11-324I22.4	6.75	2.46e-11	5.06e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35314552~35336401:-
BRCA	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	6.75	2.46e-11	5.06e-09	0.21	0.2	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
BRCA	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-6.75	2.46e-11	5.07e-09	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs79749947	ENSG00000271335.4	RP11-324I22.4	6.75	2.47e-11	5.07e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35314552~35336401:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000232559.3	GS1-124K5.12	6.75	2.47e-11	5.07e-09	0.24	0.2	Aortic root size;	chr7:66486690	chr7:66554588~66576923:-
BRCA	cis	rs7978895	0.669	rs10880428	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43165435	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs7953134	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43165884	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs7309190	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43167000	chr12:43155315~43163110:+
BRCA	cis	rs9876781	1	rs7636782	ENSG00000244380.1	RP11-24C3.2	6.75	2.47e-11	5.07e-09	0.23	0.2	Longevity;	chr3:48379897	chr3:48440352~48446656:-
BRCA	cis	rs9880211	0.613	rs13079205	ENSG00000273486.1	RP11-731C17.2	6.75	2.47e-11	5.08e-09	0.27	0.2	Height;Body mass index;	chr3:136081851	chr3:136837338~136839021:-
BRCA	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-6.75	2.47e-11	5.08e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	6.75	2.47e-11	5.09e-09	0.13	0.2	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
BRCA	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-6.75	2.47e-11	5.09e-09	-0.25	-0.2	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
BRCA	cis	rs2834288	0.5	rs881231	ENSG00000273102.1	AP000569.9	6.75	2.48e-11	5.09e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33967101~33968573:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-6.75	2.49e-11	5.12e-09	-0.22	-0.2	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
BRCA	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-6.75	2.49e-11	5.12e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-6.75	2.49e-11	5.12e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	6.75	2.49e-11	5.12e-09	0.27	0.2	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
BRCA	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	6.75	2.49e-11	5.12e-09	0.23	0.2	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
BRCA	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	6.75	2.5e-11	5.14e-09	0.21	0.2	Height;	chr20:35201339	chr20:35201747~35203288:-
BRCA	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	6.75	2.5e-11	5.14e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
BRCA	cis	rs7978895	0.669	rs1514675	ENSG00000258331.1	RP11-118A3.1	6.75	2.51e-11	5.15e-09	0.21	0.2	Type 2 diabetes;	chr12:43169324	chr12:43155315~43163110:+
BRCA	cis	rs11976180	1	rs2951353	ENSG00000204959.4	ARHGEF34P	6.75	2.51e-11	5.15e-09	0.26	0.2	Obesity-related traits;	chr7:144064023	chr7:144272445~144286966:-
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-6.75	2.51e-11	5.15e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
BRCA	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	6.75	2.51e-11	5.15e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
BRCA	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	6.75	2.51e-11	5.16e-09	0.26	0.2	Height;	chr4:55570843	chr4:55363971~55395847:-
BRCA	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-6.75	2.51e-11	5.16e-09	-0.25	-0.2	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
BRCA	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	6.75	2.51e-11	5.16e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
BRCA	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-6.75	2.51e-11	5.16e-09	-0.23	-0.2	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
BRCA	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-6.75	2.52e-11	5.17e-09	-0.23	-0.2	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
BRCA	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-6.75	2.52e-11	5.17e-09	-0.26	-0.2	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
BRCA	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-6.75	2.52e-11	5.18e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-6.75	2.52e-11	5.18e-09	-0.22	-0.2	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
BRCA	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-6.75	2.52e-11	5.18e-09	-0.25	-0.2	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
BRCA	cis	rs42648	0.596	rs194511	ENSG00000225498.1	AC002064.5	6.75	2.53e-11	5.19e-09	0.2	0.2	Homocysteine levels;	chr7:90217413	chr7:90312496~90322592:+
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000273765.1	RP11-370I10.11	6.74	2.53e-11	5.2e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48360920~48361377:+
BRCA	cis	rs12501370	1	rs4398555	ENSG00000201736.1	RNA5SP160	6.74	2.54e-11	5.22e-09	0.26	0.2	Iris color (L* coordinate);	chr4:41026846	chr4:40990154~40990273:+
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000267422.1	CTD-2554C21.1	-6.74	2.55e-11	5.22e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37507050	chr19:37779686~37792865:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	6.74	2.55e-11	5.23e-09	0.21	0.2	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
BRCA	cis	rs34929064	0.846	rs2905342	ENSG00000179428.2	AC073072.5	6.74	2.55e-11	5.24e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22691425	chr7:22725395~22727620:-
BRCA	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.74	2.55e-11	5.24e-09	-0.27	-0.2	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	6.74	2.56e-11	5.24e-09	0.24	0.2	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
BRCA	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	6.74	2.56e-11	5.25e-09	0.23	0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
BRCA	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-6.74	2.57e-11	5.27e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
BRCA	cis	rs712039	0.958	rs1016679	ENSG00000276054.1	RP11-378E13.3	-6.74	2.57e-11	5.28e-09	-0.27	-0.2	Tuberculosis;	chr17:37514228	chr17:37386886~37387926:+
BRCA	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	6.74	2.57e-11	5.28e-09	0.24	0.2	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
BRCA	cis	rs4372836	1	rs7562170	ENSG00000226833.4	AC097724.3	-6.74	2.57e-11	5.28e-09	-0.25	-0.2	Body mass index;	chr2:28720650	chr2:28708953~28736205:-
BRCA	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000254174.1	IGHV1-12	6.74	2.58e-11	5.3e-09	0.22	0.2	Alzheimer's disease (late onset);	chr14:106686309	chr14:106122420~106122709:-
BRCA	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-6.74	2.58e-11	5.3e-09	-0.27	-0.2	Height;	chr20:49279608	chr20:49280319~49280409:+
BRCA	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-6.74	2.59e-11	5.3e-09	-0.31	-0.2	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
BRCA	cis	rs7978895	0.647	rs8181625	ENSG00000258331.1	RP11-118A3.1	-6.74	2.59e-11	5.3e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43162246	chr12:43155315~43163110:+
BRCA	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-6.74	2.59e-11	5.32e-09	-0.28	-0.2	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
BRCA	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	6.74	2.59e-11	5.32e-09	0.21	0.2	Height;	chr20:35194822	chr20:35201747~35203288:-
BRCA	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-6.74	2.6e-11	5.32e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000273765.1	RP11-370I10.11	-6.74	2.6e-11	5.32e-09	-0.24	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48360920~48361377:+
BRCA	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-6.74	2.6e-11	5.33e-09	-0.27	-0.2	Height;	chr20:49282748	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-6.74	2.6e-11	5.33e-09	-0.27	-0.2	Height;	chr20:49286304	chr20:49280319~49280409:+
BRCA	cis	rs10515750	0.588	rs1900157	ENSG00000251405.2	CTB-109A12.1	6.74	2.6e-11	5.33e-09	0.32	0.2	Lung function (FEV1/FVC);	chr5:157333834	chr5:157362615~157460078:-
BRCA	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-6.74	2.61e-11	5.35e-09	-0.21	-0.2	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
BRCA	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	6.74	2.61e-11	5.35e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000263603.1	CTD-2349P21.5	-6.74	2.61e-11	5.36e-09	-0.37	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000263603.1	CTD-2349P21.5	-6.74	2.61e-11	5.36e-09	-0.37	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30729469~30731202:+
BRCA	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	6.74	2.61e-11	5.36e-09	0.23	0.2	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
BRCA	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-6.74	2.62e-11	5.37e-09	-0.27	-0.2	Height;	chr20:49246745	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	6.74	2.62e-11	5.38e-09	0.24	0.2	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
BRCA	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-6.74	2.62e-11	5.38e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
BRCA	cis	rs2235642	0.533	rs9922661	ENSG00000280231.1	LA16c-380F5.3	-6.74	2.63e-11	5.38e-09	-0.29	-0.2	Coronary artery disease;	chr16:1555162	chr16:1553655~1554130:-
BRCA	cis	rs73173548	0.502	rs4423262	ENSG00000247828.6	TMEM161B-AS1	6.74	2.63e-11	5.39e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88438609	chr5:88268895~88436685:+
BRCA	cis	rs467650	0.963	rs154197	ENSG00000248489.1	CTD-2007H13.3	6.74	2.63e-11	5.39e-09	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98642639	chr5:98929171~98995013:+
BRCA	cis	rs4691139	0.873	rs12509081	ENSG00000248632.1	RP11-366M4.11	6.74	2.63e-11	5.39e-09	0.21	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164968587~164970002:-
BRCA	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	6.74	2.63e-11	5.39e-09	0.22	0.2	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
BRCA	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-6.74	2.64e-11	5.4e-09	-0.31	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
BRCA	cis	rs8054556	0.656	rs4420550	ENSG00000273724.1	RP11-347C12.12	-6.74	2.64e-11	5.4e-09	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30336400~30343336:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	6.74	2.64e-11	5.42e-09	0.25	0.2	Height;	chr4:55548666	chr4:55540502~55540835:-
BRCA	cis	rs7474896	0.526	rs1208716	ENSG00000226578.1	RP11-258F22.1	-6.74	2.64e-11	5.42e-09	-0.28	-0.2	Obesity (extreme);	chr10:37800345	chr10:37775371~37784131:-
BRCA	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-6.74	2.65e-11	5.42e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-6.74	2.65e-11	5.43e-09	-0.22	-0.2	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-6.74	2.65e-11	5.43e-09	-0.22	-0.2	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
BRCA	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	6.74	2.65e-11	5.43e-09	0.29	0.2	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
BRCA	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-6.74	2.66e-11	5.44e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-6.74	2.66e-11	5.44e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
BRCA	cis	rs74233809	0.748	rs10786736	ENSG00000213277.3	MARCKSL1P1	6.74	2.66e-11	5.44e-09	0.36	0.2	Birth weight;	chr10:103089359	chr10:103175554~103176094:+
BRCA	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	6.74	2.66e-11	5.45e-09	0.21	0.2	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
BRCA	cis	rs853679	0.546	rs200952	ENSG00000220721.1	OR1F12	6.74	2.66e-11	5.45e-09	0.37	0.2	Depression;	chr6:27869198	chr6:28073316~28074233:+
BRCA	cis	rs11976180	1	rs2371247	ENSG00000204959.4	ARHGEF34P	6.74	2.67e-11	5.46e-09	0.26	0.2	Obesity-related traits;	chr7:144067086	chr7:144272445~144286966:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	6.74	2.67e-11	5.47e-09	0.28	0.2	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
BRCA	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-6.74	2.68e-11	5.48e-09	-0.24	-0.2	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000224316.1	RP11-479O9.2	-6.74	2.68e-11	5.48e-09	-0.21	-0.2	Aortic root size;	chr7:66163889	chr7:65773620~65802067:+
BRCA	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	6.74	2.68e-11	5.48e-09	0.25	0.2	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000228409.4	CCT6P1	6.74	2.68e-11	5.49e-09	0.28	0.2	Diabetic kidney disease;	chr7:65959671	chr7:65751142~65763354:+
BRCA	cis	rs11671005	0.572	rs11669127	ENSG00000252334.1	RNU6-1337P	-6.74	2.68e-11	5.49e-09	-0.33	-0.2	Mean platelet volume;	chr19:58492463	chr19:58483749~58483843:-
BRCA	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	6.74	2.69e-11	5.5e-09	0.25	0.2	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	6.74	2.69e-11	5.51e-09	0.24	0.2	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
BRCA	cis	rs42648	0.623	rs194505	ENSG00000225498.1	AC002064.5	6.74	2.69e-11	5.51e-09	0.2	0.2	Homocysteine levels;	chr7:90211993	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000224316.1	RP11-479O9.2	6.74	2.69e-11	5.51e-09	0.24	0.2	Aortic root size;	chr7:66311140	chr7:65773620~65802067:+
BRCA	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-6.74	2.7e-11	5.52e-09	-0.22	-0.2	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	6.74	2.7e-11	5.52e-09	0.26	0.2	Height;	chr4:55502504	chr4:55363971~55395847:-
BRCA	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.74	2.7e-11	5.53e-09	0.3	0.2	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000273765.1	RP11-370I10.11	6.74	2.7e-11	5.53e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48360920~48361377:+
BRCA	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	6.74	2.7e-11	5.53e-09	0.23	0.2	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	6.74	2.7e-11	5.53e-09	0.23	0.2	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-6.74	2.7e-11	5.53e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-6.74	2.7e-11	5.53e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
BRCA	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-6.74	2.7e-11	5.53e-09	-0.23	-0.2	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
BRCA	cis	rs9880211	0.821	rs9832813	ENSG00000273486.1	RP11-731C17.2	6.73	2.71e-11	5.54e-09	0.24	0.2	Height;Body mass index;	chr3:136346723	chr3:136837338~136839021:-
BRCA	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-6.73	2.71e-11	5.54e-09	-0.23	-0.2	Longevity;	chr3:48373517	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	6.73	2.71e-11	5.54e-09	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-6.73	2.71e-11	5.55e-09	-0.3	-0.2	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
BRCA	cis	rs8002861	0.664	rs9525873	ENSG00000274001.1	RP11-5G9.5	6.73	2.71e-11	5.55e-09	0.24	0.2	Leprosy;	chr13:43908068	chr13:43877715~43878163:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-6.73	2.72e-11	5.56e-09	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
BRCA	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	6.73	2.72e-11	5.56e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000236529.1	RP13-254B10.1	6.73	2.72e-11	5.56e-09	0.26	0.2	Aortic root size;	chr7:66311140	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000229886.1	RP5-1132H15.3	6.73	2.72e-11	5.56e-09	0.35	0.2	Diabetic kidney disease;	chr7:66143429	chr7:66025126~66031544:-
BRCA	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	6.73	2.73e-11	5.58e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000273765.1	RP11-370I10.11	6.73	2.73e-11	5.58e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-6.73	2.73e-11	5.58e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000254153.1	CTA-398F10.2	6.73	2.73e-11	5.59e-09	0.25	0.2	Mood instability;	chr8:8460105	chr8:8456909~8461337:-
BRCA	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	6.73	2.73e-11	5.59e-09	0.25	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
BRCA	cis	rs853679	0.546	rs200954	ENSG00000220721.1	OR1F12	6.73	2.73e-11	5.59e-09	0.37	0.2	Depression;	chr6:27870986	chr6:28073316~28074233:+
BRCA	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	6.73	2.74e-11	5.6e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
BRCA	cis	rs7608910	0.578	rs2564114	ENSG00000271889.1	RP11-493E12.1	6.73	2.74e-11	5.6e-09	0.26	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003512	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	6.73	2.74e-11	5.6e-09	0.25	0.2	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	6.73	2.74e-11	5.6e-09	0.25	0.2	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
BRCA	cis	rs67981189	0.896	rs2810100	ENSG00000269927.1	RP6-91H8.3	-6.73	2.74e-11	5.61e-09	-0.25	-0.2	Schizophrenia;	chr14:70965455	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66187797	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66189328	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66192326	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66192910	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	6.73	2.75e-11	5.61e-09	0.26	0.2	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
BRCA	cis	rs4671400	0.571	rs68020555	ENSG00000271889.1	RP11-493E12.1	-6.73	2.75e-11	5.62e-09	-0.26	-0.2	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258647	chr2:61151433~61162105:-
BRCA	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	6.73	2.75e-11	5.63e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
BRCA	cis	rs13178541	0.745	rs7380109	ENSG00000250378.1	RP11-119J18.1	-6.73	2.76e-11	5.64e-09	-0.27	-0.2	IgG glycosylation;	chr5:135751385	chr5:135812667~135826582:+
BRCA	cis	rs3126085	0.935	rs7533529	ENSG00000237975.5	FLG-AS1	-6.73	2.76e-11	5.64e-09	-0.27	-0.2	Atopic dermatitis;	chr1:152204395	chr1:152168125~152445456:+
BRCA	cis	rs3781264	0.761	rs12219063	ENSG00000273450.1	RP11-76P2.4	6.73	2.76e-11	5.64e-09	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94366173	chr10:94314907~94315327:-
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.73	2.76e-11	5.64e-09	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
BRCA	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-6.73	2.76e-11	5.65e-09	-0.27	-0.2	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
BRCA	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.65e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.65e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.897	rs34481177	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934723	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs72789690	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35314552~35336401:-
BRCA	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	6.73	2.77e-11	5.67e-09	0.23	0.2	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
BRCA	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-6.73	2.77e-11	5.67e-09	-0.25	-0.2	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
BRCA	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-6.73	2.78e-11	5.67e-09	-0.26	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
BRCA	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-6.73	2.78e-11	5.67e-09	-0.27	-0.2	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
BRCA	cis	rs853679	0.607	rs13199906	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27866361	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs36116761	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27850704	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs34194357	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27850757	chr6:28073316~28074233:+
BRCA	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000273765.1	RP11-370I10.11	6.73	2.79e-11	5.69e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48360920~48361377:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-6.73	2.79e-11	5.7e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
BRCA	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	6.73	2.8e-11	5.71e-09	0.28	0.2	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
BRCA	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	6.73	2.8e-11	5.71e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
BRCA	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-6.73	2.81e-11	5.73e-09	-0.3	-0.2	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	6.73	2.81e-11	5.73e-09	0.25	0.2	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
BRCA	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	6.73	2.81e-11	5.73e-09	0.18	0.2	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
BRCA	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	6.73	2.81e-11	5.73e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-6.73	2.81e-11	5.74e-09	-0.28	-0.2	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-6.73	2.82e-11	5.75e-09	-0.19	-0.2	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000224316.1	RP11-479O9.2	-6.73	2.82e-11	5.76e-09	-0.2	-0.2	Aortic root size;	chr7:66239589	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	6.73	2.82e-11	5.76e-09	0.37	0.2	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
BRCA	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.73	2.82e-11	5.76e-09	-0.24	-0.2	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000224316.1	RP11-479O9.2	-6.73	2.83e-11	5.76e-09	-0.2	-0.2	Aortic root size;	chr7:66297976	chr7:65773620~65802067:+
BRCA	cis	rs3814244	0.515	rs3015002	ENSG00000236946.2	HNRNPA1P70	6.73	2.83e-11	5.77e-09	0.16	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:68035767~68036853:+
BRCA	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	6.73	2.83e-11	5.77e-09	0.21	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
BRCA	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	6.73	2.83e-11	5.77e-09	0.25	0.2	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
BRCA	cis	rs10925040	0.666	rs10737808	ENSG00000227135.1	GCSAML-AS1	-6.73	2.83e-11	5.77e-09	-0.24	-0.2	Tumor necrosis factor beta levels;	chr1:247459638	chr1:247524679~247526752:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	6.73	2.83e-11	5.78e-09	0.27	0.2	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-6.73	2.83e-11	5.78e-09	-0.25	-0.2	Height;	chr4:55364952	chr4:55363971~55395847:-
BRCA	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-6.73	2.84e-11	5.79e-09	-0.26	-0.2	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
BRCA	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-6.73	2.84e-11	5.79e-09	-0.29	-0.2	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
BRCA	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-6.73	2.84e-11	5.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
BRCA	cis	rs442309	0.553	rs10995278	ENSG00000238280.1	RP11-436D10.3	-6.73	2.84e-11	5.8e-09	-0.29	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62694737	chr10:62793562~62805887:-
BRCA	cis	rs17253792	0.822	rs75509578	ENSG00000186615.9	KTN1-AS1	-6.73	2.84e-11	5.8e-09	-0.4	-0.2	Putamen volume;	chr14:55666775	chr14:55499278~55580110:-
BRCA	cis	rs12594515	0.967	rs11857628	ENSG00000259200.1	RP11-718O11.1	-6.73	2.84e-11	5.8e-09	-0.23	-0.2	Weight;Waist circumference;	chr15:45706008	chr15:45705078~45931069:+
BRCA	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-6.73	2.84e-11	5.8e-09	-0.2	-0.2	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-6.73	2.85e-11	5.81e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	6.73	2.85e-11	5.82e-09	0.36	0.2	Gout;	chr7:66693028	chr7:66025126~66031544:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	6.73	2.86e-11	5.82e-09	0.23	0.2	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	6.73	2.86e-11	5.83e-09	0.37	0.2	Gout;	chr7:66715944	chr7:66025126~66031544:-
BRCA	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-6.73	2.86e-11	5.84e-09	-0.25	-0.2	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
BRCA	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	6.73	2.87e-11	5.84e-09	0.42	0.2	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	6.73	2.87e-11	5.85e-09	0.22	0.2	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	6.73	2.87e-11	5.85e-09	0.24	0.2	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	6.73	2.87e-11	5.86e-09	0.22	0.2	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
BRCA	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	6.73	2.88e-11	5.87e-09	0.3	0.2	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
BRCA	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-6.73	2.88e-11	5.87e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-6.73	2.88e-11	5.88e-09	-0.22	-0.2	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-6.73	2.88e-11	5.88e-09	-0.22	-0.2	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	6.73	2.88e-11	5.88e-09	0.22	0.2	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
BRCA	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-6.73	2.88e-11	5.88e-09	-0.27	-0.2	Height;	chr20:49283420	chr20:49280319~49280409:+
BRCA	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	6.72	2.89e-11	5.89e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	6.72	2.89e-11	5.89e-09	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
BRCA	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	6.72	2.89e-11	5.89e-09	0.24	0.2	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	6.72	2.89e-11	5.89e-09	0.24	0.2	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
BRCA	cis	rs420259	0.516	rs9927961	ENSG00000260136.4	CTD-2270L9.4	-6.72	2.89e-11	5.89e-09	-0.21	-0.2	Bipolar disorder;	chr16:23503204	chr16:23452758~23457606:+
BRCA	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-6.72	2.89e-11	5.9e-09	-0.25	-0.2	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
BRCA	cis	rs67981189	0.896	rs2526890	ENSG00000269927.1	RP6-91H8.3	-6.72	2.9e-11	5.9e-09	-0.25	-0.2	Schizophrenia;	chr14:70963410	chr14:71141125~71143253:-
BRCA	cis	rs957448	1	rs60655325	ENSG00000253175.1	RP11-267M23.6	6.72	2.9e-11	5.91e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94565036~94565715:+
BRCA	cis	rs34929064	0.836	rs2961301	ENSG00000179428.2	AC073072.5	6.72	2.9e-11	5.91e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22669410	chr7:22725395~22727620:-
BRCA	cis	rs853679	0.607	rs13199772	ENSG00000220721.1	OR1F12	6.72	2.9e-11	5.91e-09	0.49	0.2	Depression;	chr6:27866307	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	6.72	2.91e-11	5.92e-09	0.22	0.2	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	6.72	2.91e-11	5.92e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	6.72	2.91e-11	5.92e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
BRCA	cis	rs10861661	0.856	rs4964190	ENSG00000260329.1	RP11-412D9.4	-6.72	2.91e-11	5.93e-09	-0.24	-0.2	Triglyceride levels;	chr12:106822581	chr12:106954029~106955497:-
BRCA	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-6.72	2.91e-11	5.94e-09	-0.23	-0.2	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
BRCA	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	6.72	2.92e-11	5.95e-09	0.28	0.2	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
BRCA	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.72	2.92e-11	5.95e-09	-0.24	-0.2	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
BRCA	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	6.72	2.93e-11	5.96e-09	0.27	0.2	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	6.72	2.93e-11	5.96e-09	0.27	0.2	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
BRCA	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-6.72	2.93e-11	5.97e-09	-0.27	-0.2	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-6.72	2.93e-11	5.97e-09	-0.27	-0.2	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
BRCA	cis	rs12501370	1	rs13109452	ENSG00000201736.1	RNA5SP160	6.72	2.93e-11	5.97e-09	0.26	0.2	Iris color (L* coordinate);	chr4:41042751	chr4:40990154~40990273:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	6.72	2.94e-11	5.98e-09	0.36	0.2	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	6.72	2.94e-11	5.98e-09	0.36	0.2	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
BRCA	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	6.72	2.94e-11	5.98e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
BRCA	cis	rs754466	0.651	rs11813532	ENSG00000204049.1	RP11-126H7.4	6.72	2.94e-11	5.99e-09	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77878233	chr10:77866875~77869610:+
BRCA	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-6.72	2.94e-11	5.99e-09	-0.21	-0.2	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-6.72	2.94e-11	6e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.581	rs292170	ENSG00000250155.1	CTD-2353F22.1	-6.72	2.95e-11	6e-09	-0.24	-0.2	Height;	chr5:36816559	chr5:36666214~36725195:-
BRCA	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	6.72	2.95e-11	6.01e-09	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	6.72	2.95e-11	6.01e-09	0.28	0.2	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
BRCA	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	6.72	2.96e-11	6.02e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
BRCA	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.72	2.96e-11	6.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.72	2.96e-11	6.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
BRCA	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-6.72	2.96e-11	6.03e-09	-0.23	-0.2	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
BRCA	cis	rs2834288	0.5	rs881230	ENSG00000273102.1	AP000569.9	6.72	2.97e-11	6.04e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33967101~33968573:-
BRCA	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.72	2.97e-11	6.04e-09	0.27	0.2	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.72	2.97e-11	6.04e-09	0.27	0.2	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	6.72	2.97e-11	6.04e-09	0.26	0.2	Height;	chr4:55509442	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	6.72	2.97e-11	6.04e-09	0.26	0.2	Height;	chr4:55510177	chr4:55363971~55395847:-
BRCA	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-6.72	2.97e-11	6.05e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
BRCA	cis	rs853679	0.607	rs17763089	ENSG00000220721.1	OR1F12	6.72	2.97e-11	6.05e-09	0.49	0.2	Depression;	chr6:27867440	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs17695758	ENSG00000220721.1	OR1F12	6.72	2.97e-11	6.05e-09	0.49	0.2	Depression;	chr6:27869405	chr6:28073316~28074233:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000228409.4	CCT6P1	6.72	2.97e-11	6.05e-09	0.28	0.2	Diabetic kidney disease;	chr7:65966800	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000228409.4	CCT6P1	6.72	2.97e-11	6.05e-09	0.28	0.2	Diabetic kidney disease;	chr7:65979301	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-6.72	2.97e-11	6.05e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-6.72	2.97e-11	6.05e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
BRCA	cis	rs3781264	0.761	rs7081265	ENSG00000273450.1	RP11-76P2.4	-6.72	2.98e-11	6.06e-09	-0.28	-0.2	Esophageal cancer and gastric cancer;	chr10:94365892	chr10:94314907~94315327:-
BRCA	cis	rs2014572	0.967	rs10426174	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.06e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.87	rs10426580	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.06e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57175233~57177921:+
BRCA	cis	rs67981189	0.865	rs2526876	ENSG00000269927.1	RP6-91H8.3	-6.72	2.98e-11	6.07e-09	-0.25	-0.2	Schizophrenia;	chr14:70911471	chr14:71141125~71143253:-
BRCA	cis	rs6740322	0.895	rs6760797	ENSG00000234936.1	AC010883.5	6.72	2.98e-11	6.07e-09	0.23	0.2	Coronary artery disease;	chr2:43332473	chr2:43229573~43233394:+
BRCA	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-6.72	2.98e-11	6.07e-09	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
BRCA	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	6.72	2.98e-11	6.07e-09	0.19	0.2	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
BRCA	cis	rs2014572	0.967	rs10427146	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.07e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.967	rs11084492	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.07e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57175233~57177921:+
BRCA	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	6.72	2.99e-11	6.07e-09	0.17	0.2	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
BRCA	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-6.72	2.99e-11	6.07e-09	-0.27	-0.2	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
BRCA	cis	rs34779708	0.658	rs4934715	ENSG00000271335.4	RP11-324I22.4	6.72	2.99e-11	6.08e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35314552~35336401:-
BRCA	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-6.72	2.99e-11	6.09e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
BRCA	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-6.72	2.99e-11	6.09e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
BRCA	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	6.72	2.99e-11	6.09e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
BRCA	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-6.72	2.99e-11	6.09e-09	-0.19	-0.2	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-6.72	3e-11	6.09e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
BRCA	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-6.72	3e-11	6.1e-09	-0.2	-0.2	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	6.72	3e-11	6.1e-09	0.21	0.2	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
BRCA	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	6.72	3.01e-11	6.11e-09	0.23	0.2	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
BRCA	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-6.72	3.01e-11	6.11e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-6.72	3.01e-11	6.11e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
BRCA	cis	rs9307551	0.817	rs11098762	ENSG00000250334.4	LINC00989	-6.72	3.01e-11	6.11e-09	-0.27	-0.2	Refractive error;	chr4:79575097	chr4:79492416~79576460:+
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000253175.1	RP11-267M23.6	6.72	3.01e-11	6.12e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94565036~94565715:+
BRCA	cis	rs4845875	0.603	rs10864539	ENSG00000242349.4	NPPA-AS1	6.72	3.01e-11	6.12e-09	0.22	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11773853	chr1:11841017~11848079:+
BRCA	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	6.72	3.01e-11	6.12e-09	0.25	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
BRCA	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	6.72	3.01e-11	6.12e-09	0.25	0.2	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
BRCA	cis	rs6543140	0.693	rs7579737	ENSG00000234389.1	AC007278.3	6.72	3.01e-11	6.12e-09	0.2	0.2	Blood protein levels;	chr2:102370901	chr2:102438713~102440475:+
BRCA	cis	rs4072705	0.967	rs10217141	ENSG00000224020.1	MIR181A2HG	-6.72	3.01e-11	6.13e-09	-0.22	-0.2	Menarche (age at onset);	chr9:124641656	chr9:124658467~124698631:+
BRCA	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.72	3.03e-11	6.16e-09	0.2	0.2	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
BRCA	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	6.72	3.03e-11	6.16e-09	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
BRCA	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-6.72	3.03e-11	6.16e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
BRCA	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-6.72	3.03e-11	6.17e-09	-0.24	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
BRCA	cis	rs860818	1	rs1637224	ENSG00000226816.2	AC005082.12	6.72	3.03e-11	6.17e-09	0.49	0.2	Initial pursuit acceleration;	chr7:23188781	chr7:23206013~23208045:+
BRCA	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.72	3.04e-11	6.17e-09	0.3	0.2	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
BRCA	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-6.72	3.04e-11	6.18e-09	-0.2	-0.2	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
BRCA	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	6.72	3.05e-11	6.19e-09	0.3	0.2	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
BRCA	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	6.72	3.05e-11	6.19e-09	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
BRCA	cis	rs6545883	1	rs6742276	ENSG00000271889.1	RP11-493E12.1	6.72	3.05e-11	6.19e-09	0.26	0.2	Tuberculosis;	chr2:61541610	chr2:61151433~61162105:-
BRCA	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	6.72	3.06e-11	6.21e-09	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
BRCA	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	6.72	3.06e-11	6.21e-09	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
BRCA	cis	rs17253792	0.545	rs12893610	ENSG00000186615.9	KTN1-AS1	-6.72	3.06e-11	6.21e-09	-0.4	-0.2	Putamen volume;	chr14:55549629	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-6.72	3.06e-11	6.21e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-6.72	3.06e-11	6.21e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55490228	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55491150	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55493557	chr4:55363971~55395847:-
BRCA	cis	rs2348418	0.733	rs11049508	ENSG00000247934.4	RP11-967K21.1	6.72	3.07e-11	6.23e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28163298~28190738:-
BRCA	cis	rs4372836	1	rs55835850	ENSG00000226833.4	AC097724.3	-6.72	3.07e-11	6.23e-09	-0.25	-0.2	Body mass index;	chr2:28726430	chr2:28708953~28736205:-
BRCA	cis	rs6088580	0.524	rs6088575	ENSG00000269202.1	RP4-614O4.12	-6.72	3.07e-11	6.24e-09	-0.22	-0.2	Glomerular filtration rate (creatinine);	chr20:34685599	chr20:35201747~35203288:-
BRCA	cis	rs6740322	0.748	rs6727631	ENSG00000234936.1	AC010883.5	6.72	3.08e-11	6.25e-09	0.23	0.2	Coronary artery disease;	chr2:43243269	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	6.72	3.08e-11	6.26e-09	0.25	0.2	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
BRCA	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	6.72	3.08e-11	6.26e-09	0.26	0.2	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	6.71	3.09e-11	6.27e-09	0.37	0.2	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-6.71	3.09e-11	6.27e-09	-0.22	-0.2	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.897	rs4934529	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs12830	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs7920095	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35314552~35336401:-
BRCA	cis	rs11742741	0.714	rs11744373	ENSG00000248874.4	C5orf17	-6.71	3.1e-11	6.29e-09	-0.26	-0.2	Educational attainment;	chr5:24156562	chr5:23951348~24178263:+
BRCA	cis	rs67981189	0.896	rs2526878	ENSG00000269927.1	RP6-91H8.3	-6.71	3.1e-11	6.29e-09	-0.25	-0.2	Schizophrenia;	chr14:70910578	chr14:71141125~71143253:-
BRCA	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	6.71	3.1e-11	6.3e-09	0.22	0.2	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000236529.1	RP13-254B10.1	-6.71	3.11e-11	6.32e-09	-0.25	-0.2	Aortic root size;	chr7:66620931	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	6.71	3.11e-11	6.32e-09	0.21	0.2	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
BRCA	cis	rs6569038	0.522	rs1334922	ENSG00000253194.1	RP11-351A11.1	6.71	3.12e-11	6.33e-09	0.26	0.2	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052007	chr6:118934785~119031541:+
BRCA	cis	rs9307551	0.817	rs6852514	ENSG00000250334.4	LINC00989	-6.71	3.12e-11	6.33e-09	-0.27	-0.2	Refractive error;	chr4:79580759	chr4:79492416~79576460:+
BRCA	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	6.71	3.12e-11	6.33e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	6.71	3.12e-11	6.33e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
BRCA	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-6.71	3.12e-11	6.34e-09	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
BRCA	cis	rs367615	0.591	rs4530812	ENSG00000249476.1	CTD-2587M2.1	-6.71	3.12e-11	6.34e-09	-0.23	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109522886	chr5:109237120~109326369:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-6.71	3.13e-11	6.34e-09	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000263603.1	CTD-2349P21.5	6.71	3.13e-11	6.35e-09	0.37	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30729469~30731202:+
BRCA	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.71	3.14e-11	6.37e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
BRCA	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-6.71	3.15e-11	6.38e-09	-0.27	-0.2	AIDS;	chr2:105300178	chr2:105324210~105330529:+
BRCA	cis	rs375066	0.762	rs17656688	ENSG00000267058.1	RP11-15A1.3	6.71	3.15e-11	6.39e-09	0.24	0.2	Breast cancer;	chr19:43920925	chr19:43891804~43901805:-
BRCA	cis	rs228614	0.509	rs223476	ENSG00000251288.2	RP11-10L12.2	-6.71	3.15e-11	6.39e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.509	rs150896	ENSG00000251288.2	RP11-10L12.2	-6.71	3.15e-11	6.39e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102751401~102752641:+
BRCA	cis	rs17253792	0.822	rs10142757	ENSG00000186615.9	KTN1-AS1	-6.71	3.15e-11	6.39e-09	-0.39	-0.2	Putamen volume;	chr14:55607493	chr14:55499278~55580110:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	6.71	3.15e-11	6.39e-09	0.21	0.2	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
BRCA	cis	rs9307551	0.779	rs1440854	ENSG00000250334.4	LINC00989	-6.71	3.16e-11	6.4e-09	-0.28	-0.2	Refractive error;	chr4:79585580	chr4:79492416~79576460:+
BRCA	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	6.71	3.16e-11	6.41e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
BRCA	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	6.71	3.16e-11	6.41e-09	0.24	0.2	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
BRCA	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	6.71	3.16e-11	6.41e-09	0.25	0.2	QT interval;	chr12:29310426	chr12:29280418~29317848:-
BRCA	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-6.71	3.17e-11	6.42e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
BRCA	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-6.71	3.17e-11	6.42e-09	-0.3	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
BRCA	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	6.71	3.17e-11	6.42e-09	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-6.71	3.17e-11	6.43e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-6.71	3.17e-11	6.44e-09	-0.24	-0.2	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
BRCA	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-6.71	3.17e-11	6.44e-09	-0.2	-0.2	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66692349	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66693433	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66694214	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66701371	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66702658	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66706390	chr7:66025126~66031544:-
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66710076	chr7:66025126~66031544:-
BRCA	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-6.71	3.19e-11	6.47e-09	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-6.71	3.2e-11	6.48e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
BRCA	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	6.71	3.2e-11	6.48e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
BRCA	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
BRCA	cis	rs11976180	1	rs7777389	ENSG00000204959.4	ARHGEF34P	6.71	3.2e-11	6.49e-09	0.26	0.2	Obesity-related traits;	chr7:144047709	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs67239267	ENSG00000204959.4	ARHGEF34P	6.71	3.2e-11	6.49e-09	0.26	0.2	Obesity-related traits;	chr7:144048023	chr7:144272445~144286966:-
BRCA	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-6.71	3.21e-11	6.49e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
BRCA	cis	rs9307551	1	rs9307551	ENSG00000250334.4	LINC00989	-6.71	3.22e-11	6.51e-09	-0.3	-0.2	Refractive error;	chr4:79609517	chr4:79492416~79576460:+
BRCA	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	6.71	3.22e-11	6.52e-09	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
BRCA	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	6.71	3.22e-11	6.52e-09	0.25	0.2	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
BRCA	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	6.71	3.22e-11	6.52e-09	0.2	0.2	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
BRCA	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	6.71	3.22e-11	6.53e-09	0.25	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
BRCA	cis	rs6740322	0.895	rs6711966	ENSG00000234936.1	AC010883.5	6.71	3.23e-11	6.53e-09	0.22	0.2	Coronary artery disease;	chr2:43334850	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66266868	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66268272	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66271055	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.24e-11	6.55e-09	-0.24	-0.2	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
BRCA	cis	rs2946505	0.871	rs2466244	ENSG00000251468.2	RP11-369K16.1	6.71	3.24e-11	6.56e-09	0.28	0.2	Migraine;	chr8:12964370	chr8:12958387~12962200:+
BRCA	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.25e-11	6.57e-09	-0.25	-0.2	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
BRCA	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-6.71	3.25e-11	6.58e-09	-0.25	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
BRCA	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	6.71	3.25e-11	6.58e-09	0.25	0.2	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
BRCA	cis	rs8103033	0.824	rs35457488	ENSG00000226025.8	LGALS17A	-6.71	3.26e-11	6.59e-09	-0.22	-0.2	Obesity-related traits;	chr19:39646532	chr19:39679374~39686373:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000273024.4	INTS4P2	-6.71	3.26e-11	6.6e-09	-0.26	-0.2	Aortic root size;	chr7:66234510	chr7:65647864~65715661:+
BRCA	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.27e-11	6.62e-09	-0.24	-0.2	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
BRCA	cis	rs12468579	0.74	rs11894425	ENSG00000235852.1	AC005540.3	6.71	3.27e-11	6.62e-09	0.21	0.2	JT interval (sulfonylurea treatment interaction);	chr2:190973115	chr2:190880797~190882059:-
BRCA	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	6.71	3.27e-11	6.63e-09	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	6.71	3.29e-11	6.66e-09	0.25	0.2	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
BRCA	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-6.71	3.29e-11	6.66e-09	-0.23	-0.2	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
BRCA	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-6.7	3.3e-11	6.67e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
BRCA	cis	rs16846053	0.515	rs7588198	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161508691	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs10202267	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161509616	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs7595197	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161510325	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	6.7	3.3e-11	6.68e-09	0.24	0.2	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	6.7	3.31e-11	6.7e-09	0.24	0.2	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
BRCA	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	6.7	3.32e-11	6.71e-09	0.26	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
BRCA	cis	rs17253792	0.822	rs10143002	ENSG00000186615.9	KTN1-AS1	-6.7	3.32e-11	6.71e-09	-0.39	-0.2	Putamen volume;	chr14:55607560	chr14:55499278~55580110:-
BRCA	cis	rs3126085	0.935	rs12063165	ENSG00000237975.5	FLG-AS1	-6.7	3.32e-11	6.72e-09	-0.27	-0.2	Atopic dermatitis;	chr1:152203881	chr1:152168125~152445456:+
BRCA	cis	rs74233809	0.901	rs17878846	ENSG00000213277.3	MARCKSL1P1	6.7	3.32e-11	6.72e-09	0.39	0.2	Birth weight;	chr10:102870655	chr10:103175554~103176094:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	6.7	3.33e-11	6.73e-09	0.35	0.2	Gout;	chr7:66671562	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-6.7	3.34e-11	6.75e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
BRCA	cis	rs8054556	0.692	rs12716972	ENSG00000273724.1	RP11-347C12.12	-6.7	3.34e-11	6.75e-09	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30336400~30343336:+
BRCA	cis	rs4722166	0.598	rs4722179	ENSG00000179428.2	AC073072.5	-6.7	3.34e-11	6.75e-09	-0.21	-0.2	Lung cancer;	chr7:22764242	chr7:22725395~22727620:-
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	6.7	3.34e-11	6.76e-09	0.26	0.2	Height;	chr4:55452921	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	6.7	3.34e-11	6.76e-09	0.25	0.2	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
BRCA	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-6.7	3.34e-11	6.76e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
BRCA	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	6.7	3.35e-11	6.77e-09	0.17	0.2	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
BRCA	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-6.7	3.35e-11	6.78e-09	-0.25	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
BRCA	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	6.7	3.36e-11	6.79e-09	0.36	0.2	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-6.7	3.36e-11	6.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
BRCA	cis	rs9307551	0.817	rs12507160	ENSG00000250334.4	LINC00989	-6.7	3.37e-11	6.82e-09	-0.27	-0.2	Refractive error;	chr4:79573647	chr4:79492416~79576460:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000204709.4	LINC01556	6.7	3.37e-11	6.82e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28109596	chr6:28943877~28944537:+
BRCA	cis	rs1499614	1	rs1267818	ENSG00000229886.1	RP5-1132H15.3	6.7	3.38e-11	6.82e-09	0.36	0.2	Gout;	chr7:66642037	chr7:66025126~66031544:-
BRCA	cis	rs34779708	0.897	rs9787566	ENSG00000271335.4	RP11-324I22.4	6.7	3.38e-11	6.83e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35314552~35336401:-
BRCA	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-6.7	3.39e-11	6.85e-09	-0.26	-0.2	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
BRCA	cis	rs375066	0.762	rs17713001	ENSG00000267058.1	RP11-15A1.3	6.7	3.39e-11	6.86e-09	0.24	0.2	Breast cancer;	chr19:43917073	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs2284245	ENSG00000267058.1	RP11-15A1.3	6.7	3.39e-11	6.86e-09	0.24	0.2	Breast cancer;	chr19:43918437	chr19:43891804~43901805:-
BRCA	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	6.7	3.4e-11	6.87e-09	0.21	0.2	Height;	chr20:35196485	chr20:35201747~35203288:-
BRCA	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-6.7	3.4e-11	6.87e-09	-0.17	-0.2	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000273765.1	RP11-370I10.11	6.7	3.4e-11	6.87e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48360920~48361377:+
BRCA	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	6.7	3.4e-11	6.87e-09	0.19	0.2	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	6.7	3.41e-11	6.89e-09	0.36	0.2	Gout;	chr7:66661502	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	6.7	3.41e-11	6.9e-09	0.16	0.2	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-6.7	3.42e-11	6.9e-09	-0.22	-0.2	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
BRCA	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	6.7	3.42e-11	6.92e-09	0.18	0.2	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
BRCA	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	6.7	3.43e-11	6.92e-09	0.19	0.2	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000213640.3	EEF1DP4	-6.7	3.43e-11	6.93e-09	-0.26	-0.2	Calcium levels;	chr7:65751755	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	6.7	3.44e-11	6.95e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
BRCA	cis	rs957448	1	rs28817653	ENSG00000253175.1	RP11-267M23.6	6.7	3.45e-11	6.96e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94565036~94565715:+
BRCA	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-6.7	3.45e-11	6.96e-09	-0.23	-0.2	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-6.7	3.45e-11	6.96e-09	-0.23	-0.2	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
BRCA	cis	rs78456975	0.941	rs11886649	ENSG00000231482.2	AC141930.2	-6.7	3.45e-11	6.96e-09	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1563985	chr2:1572554~1580311:-
BRCA	cis	rs227275	0.554	rs223485	ENSG00000251288.2	RP11-10L12.2	-6.7	3.45e-11	6.97e-09	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-6.7	3.45e-11	6.97e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	6.7	3.45e-11	6.97e-09	0.24	0.2	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
BRCA	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-6.7	3.46e-11	6.98e-09	-0.19	-0.2	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
BRCA	cis	rs67981189	0.821	rs34257131	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71053723	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.821	rs12896370	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71054623	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.821	rs2286310	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71056888	chr14:71141125~71143253:-
BRCA	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	6.7	3.46e-11	6.99e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
BRCA	cis	rs13178541	0.81	rs62365677	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135752861	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs7380576	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135752903	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs7380618	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135753120	chr5:135812667~135826582:+
BRCA	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-6.7	3.46e-11	6.99e-09	-0.23	-0.2	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
BRCA	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-6.7	3.46e-11	6.99e-09	-0.26	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	6.7	3.46e-11	6.99e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
BRCA	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-6.7	3.47e-11	7e-09	-0.2	-0.2	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
BRCA	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	6.7	3.47e-11	7.01e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	6.7	3.47e-11	7.01e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-6.7	3.47e-11	7.01e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-6.7	3.47e-11	7.01e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
BRCA	cis	rs8054556	0.647	rs8048433	ENSG00000273724.1	RP11-347C12.12	-6.7	3.47e-11	7.01e-09	-0.23	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30336400~30343336:+
BRCA	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-6.7	3.48e-11	7.02e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
BRCA	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-6.7	3.48e-11	7.02e-09	-0.18	-0.2	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
BRCA	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	6.7	3.48e-11	7.03e-09	0.21	0.2	Height;	chr20:35200735	chr20:35201747~35203288:-
BRCA	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	6.7	3.49e-11	7.04e-09	0.23	0.2	QT interval;	chr12:29241487	chr12:29280418~29317848:-
BRCA	cis	rs3126085	1	rs72696952	ENSG00000237975.5	FLG-AS1	6.7	3.5e-11	7.05e-09	0.31	0.2	Atopic dermatitis;	chr1:152200218	chr1:152168125~152445456:+
BRCA	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-6.7	3.5e-11	7.05e-09	-0.23	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
BRCA	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	6.7	3.5e-11	7.06e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
BRCA	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
BRCA	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-6.7	3.51e-11	7.08e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
BRCA	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	6.7	3.51e-11	7.08e-09	0.24	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
BRCA	cis	rs6740322	0.643	rs13390381	ENSG00000234936.1	AC010883.5	6.7	3.51e-11	7.08e-09	0.24	0.2	Coronary artery disease;	chr2:43307275	chr2:43229573~43233394:+
BRCA	cis	rs34779708	0.931	rs9663401	ENSG00000271335.4	RP11-324I22.4	6.7	3.51e-11	7.08e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35314552~35336401:-
BRCA	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	6.7	3.51e-11	7.08e-09	0.21	0.2	Height;	chr20:35201240	chr20:35201747~35203288:-
BRCA	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	6.7	3.51e-11	7.08e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
BRCA	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	6.7	3.52e-11	7.09e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	6.7	3.52e-11	7.09e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
BRCA	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-6.7	3.52e-11	7.09e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000273765.1	RP11-370I10.11	6.7	3.52e-11	7.09e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000273765.1	RP11-370I10.11	6.7	3.52e-11	7.09e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48360920~48361377:+
BRCA	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	6.69	3.52e-11	7.1e-09	0.22	0.2	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
BRCA	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-6.69	3.52e-11	7.1e-09	-0.24	-0.2	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	6.69	3.52e-11	7.1e-09	0.37	0.2	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
BRCA	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-6.69	3.52e-11	7.1e-09	-0.2	-0.2	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
BRCA	cis	rs11336847	1	rs11336847	ENSG00000234072.1	AC074117.10	-6.69	3.52e-11	7.11e-09	-0.2	-0.2	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:27526126	chr2:27356246~27367622:+
BRCA	cis	rs6163	0.727	rs284862	ENSG00000213061.2	PFN1P11	-6.69	3.52e-11	7.11e-09	-0.27	-0.2	Waist circumference;Hip circumference;	chr10:102812324	chr10:102838011~102845473:-
BRCA	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	6.69	3.53e-11	7.12e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
BRCA	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	6.69	3.53e-11	7.12e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
BRCA	cis	rs957448	1	rs72674843	ENSG00000253175.1	RP11-267M23.6	6.69	3.54e-11	7.13e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94565036~94565715:+
BRCA	cis	rs6740322	0.895	rs6744746	ENSG00000234936.1	AC010883.5	-6.69	3.54e-11	7.13e-09	-0.23	-0.2	Coronary artery disease;	chr2:43328666	chr2:43229573~43233394:+
BRCA	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-6.69	3.54e-11	7.14e-09	-0.22	-0.2	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
BRCA	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-6.69	3.55e-11	7.16e-09	-0.31	-0.2	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
BRCA	cis	rs4835473	0.6	rs9997101	ENSG00000251600.4	RP11-673E1.1	6.69	3.55e-11	7.16e-09	0.23	0.2	Immature fraction of reticulocytes;	chr4:143777892	chr4:143912331~143982454:+
BRCA	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	6.69	3.56e-11	7.17e-09	0.25	0.2	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
BRCA	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	6.69	3.56e-11	7.18e-09	0.21	0.2	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
BRCA	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	6.69	3.57e-11	7.19e-09	0.3	0.2	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
BRCA	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	6.69	3.57e-11	7.19e-09	0.2	0.2	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
BRCA	cis	rs11671005	0.779	rs731259	ENSG00000252334.1	RNU6-1337P	6.69	3.57e-11	7.2e-09	0.33	0.2	Mean platelet volume;	chr19:58478057	chr19:58483749~58483843:-
BRCA	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-6.69	3.57e-11	7.2e-09	-0.26	-0.2	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-6.69	3.58e-11	7.21e-09	-0.23	-0.2	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
BRCA	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-6.69	3.58e-11	7.21e-09	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.895	rs13384080	ENSG00000234936.1	AC010883.5	6.69	3.59e-11	7.23e-09	0.23	0.2	Coronary artery disease;	chr2:43330224	chr2:43229573~43233394:+
BRCA	cis	rs13126694	0.778	rs10000610	ENSG00000251429.1	RP11-597D13.7	6.69	3.6e-11	7.24e-09	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158270378~158278676:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-6.69	3.6e-11	7.24e-09	-0.26	-0.2	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
BRCA	cis	rs34779708	0.966	rs4934737	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.25e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35314552~35336401:-
BRCA	cis	rs4372836	1	rs7598876	ENSG00000226833.4	AC097724.3	6.69	3.6e-11	7.25e-09	0.25	0.2	Body mass index;	chr2:28751600	chr2:28708953~28736205:-
BRCA	cis	rs12501370	1	rs4323143	ENSG00000201736.1	RNA5SP160	6.69	3.6e-11	7.25e-09	0.25	0.2	Iris color (L* coordinate);	chr4:41026876	chr4:40990154~40990273:+
BRCA	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	6.69	3.6e-11	7.25e-09	0.24	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000228409.4	CCT6P1	6.69	3.6e-11	7.26e-09	0.28	0.2	Diabetic kidney disease;	chr7:65939105	chr7:65751142~65763354:+
BRCA	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-6.69	3.6e-11	7.26e-09	-0.19	-0.2	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
BRCA	cis	rs34779708	0.931	rs4351760	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.26e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.898	rs4934695	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.26e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-6.69	3.61e-11	7.26e-09	-0.32	-0.2	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-6.69	3.61e-11	7.28e-09	-0.26	-0.2	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	6.69	3.61e-11	7.28e-09	0.22	0.2	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
BRCA	cis	rs853679	0.599	rs149949	ENSG00000220721.1	OR1F12	6.69	3.61e-11	7.28e-09	0.36	0.2	Depression;	chr6:28043738	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	6.69	3.61e-11	7.28e-09	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
BRCA	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.69	3.62e-11	7.28e-09	-0.27	-0.2	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
BRCA	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-6.69	3.62e-11	7.28e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
BRCA	cis	rs34779708	0.931	rs59418206	ENSG00000271335.4	RP11-324I22.4	6.69	3.62e-11	7.29e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs1533268	ENSG00000204959.4	ARHGEF34P	6.69	3.62e-11	7.3e-09	0.25	0.2	Obesity-related traits;	chr7:144069265	chr7:144272445~144286966:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	6.69	3.62e-11	7.3e-09	0.22	0.2	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
BRCA	cis	rs34779708	0.931	rs4934700	ENSG00000271335.4	RP11-324I22.4	6.69	3.62e-11	7.3e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35314552~35336401:-
BRCA	cis	rs74233809	1	rs11191607	ENSG00000213277.3	MARCKSL1P1	6.69	3.63e-11	7.3e-09	0.38	0.2	Birth weight;	chr10:103199431	chr10:103175554~103176094:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	6.69	3.63e-11	7.31e-09	0.36	0.2	Gout;	chr7:66654674	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.599	rs202906	ENSG00000220721.1	OR1F12	-6.69	3.63e-11	7.31e-09	-0.35	-0.2	Depression;	chr6:28043874	chr6:28073316~28074233:+
BRCA	cis	rs11671005	0.779	rs3794970	ENSG00000252334.1	RNU6-1337P	-6.69	3.63e-11	7.32e-09	-0.32	-0.2	Mean platelet volume;	chr19:58474893	chr19:58483749~58483843:-
BRCA	cis	rs4683346	0.616	rs6779561	ENSG00000173811.9	CCDC13-AS1	6.69	3.63e-11	7.32e-09	0.26	0.2	Granulocyte percentage of myeloid white cells;	chr3:42808326	chr3:42732575~42746768:+
BRCA	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-6.69	3.64e-11	7.32e-09	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
BRCA	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	6.69	3.64e-11	7.33e-09	0.18	0.2	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
BRCA	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-6.69	3.64e-11	7.33e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	6.69	3.65e-11	7.35e-09	0.11	0.2	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
BRCA	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-6.69	3.65e-11	7.36e-09	-0.31	-0.2	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
BRCA	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	6.69	3.65e-11	7.36e-09	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	6.69	3.65e-11	7.36e-09	0.27	0.2	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
BRCA	cis	rs7662987	0.793	rs12697	ENSG00000272777.1	RP11-571L19.8	-6.69	3.66e-11	7.37e-09	-0.28	-0.2	Smoking initiation;	chr4:99072225	chr4:99067256~99068125:-
BRCA	cis	rs9880211	0.613	rs6439629	ENSG00000273486.1	RP11-731C17.2	6.69	3.66e-11	7.37e-09	0.26	0.2	Height;Body mass index;	chr3:136182428	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	6.69	3.66e-11	7.37e-09	0.22	0.2	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
BRCA	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	6.69	3.67e-11	7.39e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
BRCA	cis	rs10029851	0.627	rs17584324	ENSG00000234492.4	RPL34-AS1	6.69	3.67e-11	7.39e-09	0.32	0.2	Amyotrophic lateral sclerosis (sporadic);	chr4:108608230	chr4:108538190~108620460:-
BRCA	cis	rs6740322	1	rs11693666	ENSG00000234936.1	AC010883.5	-6.69	3.68e-11	7.4e-09	-0.22	-0.2	Coronary artery disease;	chr2:43335340	chr2:43229573~43233394:+
BRCA	cis	rs7474896	0.537	rs2749589	ENSG00000226578.1	RP11-258F22.1	6.69	3.68e-11	7.41e-09	0.26	0.2	Obesity (extreme);	chr10:37977942	chr10:37775371~37784131:-
BRCA	cis	rs9527	0.59	rs1475642	ENSG00000213061.2	PFN1P11	-6.69	3.69e-11	7.42e-09	-0.3	-0.2	Arsenic metabolism;	chr10:102786426	chr10:102838011~102845473:-
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	6.69	3.69e-11	7.42e-09	0.26	0.2	Height;	chr4:55452295	chr4:55363971~55395847:-
BRCA	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.69	3.69e-11	7.43e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
BRCA	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	6.69	3.69e-11	7.43e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-6.69	3.69e-11	7.43e-09	-0.22	-0.2	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-6.69	3.7e-11	7.44e-09	-0.24	-0.2	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
BRCA	cis	rs9307551	0.779	rs13124357	ENSG00000250334.4	LINC00989	-6.69	3.7e-11	7.45e-09	-0.27	-0.2	Refractive error;	chr4:79591148	chr4:79492416~79576460:+
BRCA	cis	rs7746199	0.736	rs34064842	ENSG00000220721.1	OR1F12	6.69	3.71e-11	7.46e-09	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28073316~28074233:+
BRCA	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
BRCA	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
BRCA	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-6.69	3.71e-11	7.47e-09	-0.26	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
BRCA	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-6.69	3.72e-11	7.48e-09	-0.24	-0.2	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
BRCA	cis	rs10492201	0.554	rs2870962	ENSG00000255733.4	IFNG-AS1	-6.69	3.72e-11	7.48e-09	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:67989445~68234686:+
BRCA	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-6.69	3.72e-11	7.49e-09	-0.26	-0.2	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
BRCA	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
BRCA	cis	rs755249	0.529	rs3768299	ENSG00000237624.1	OXCT2P1	6.69	3.74e-11	7.51e-09	0.29	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39514956~39516490:+
BRCA	cis	rs4763879	0.634	rs12424826	ENSG00000214776.8	RP11-726G1.1	-6.69	3.74e-11	7.51e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9701981	chr12:9467552~9576275:+
BRCA	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.69	3.74e-11	7.51e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
BRCA	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	6.69	3.75e-11	7.53e-09	0.36	0.2	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000236529.1	RP13-254B10.1	6.69	3.75e-11	7.55e-09	0.26	0.2	Aortic root size;	chr7:66226662	chr7:65840212~65840596:+
BRCA	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	6.69	3.76e-11	7.55e-09	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
BRCA	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-6.68	3.76e-11	7.56e-09	-0.21	-0.2	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
BRCA	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	6.68	3.76e-11	7.56e-09	0.25	0.2	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
BRCA	cis	rs375066	0.71	rs11881193	ENSG00000267058.1	RP11-15A1.3	6.68	3.77e-11	7.57e-09	0.24	0.2	Breast cancer;	chr19:43917364	chr19:43891804~43901805:-
BRCA	cis	rs1014246	0.807	rs10886003	ENSG00000232767.1	RP11-498B4.5	-6.68	3.77e-11	7.57e-09	-0.24	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116701715	chr10:116670103~116672739:+
BRCA	cis	rs34779708	0.966	rs10827487	ENSG00000271335.4	RP11-324I22.4	6.68	3.78e-11	7.59e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	6.68	3.78e-11	7.6e-09	0.19	0.2	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
BRCA	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
BRCA	cis	rs10492201	0.529	rs740420	ENSG00000255733.4	IFNG-AS1	-6.68	3.78e-11	7.6e-09	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:67989445~68234686:+
BRCA	cis	rs34779708	0.931	rs11597483	ENSG00000271335.4	RP11-324I22.4	6.68	3.79e-11	7.61e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35317849	ENSG00000271335.4	RP11-324I22.4	6.68	3.79e-11	7.61e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35314552~35336401:-
BRCA	cis	rs853679	0.607	rs34950484	ENSG00000220721.1	OR1F12	6.68	3.8e-11	7.62e-09	0.47	0.2	Depression;	chr6:28310911	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	6.68	3.8e-11	7.62e-09	0.25	0.2	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	6.68	3.8e-11	7.62e-09	0.25	0.2	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
BRCA	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
BRCA	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.68	3.81e-11	7.65e-09	0.3	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
BRCA	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	6.68	3.81e-11	7.66e-09	0.25	0.2	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	6.68	3.81e-11	7.66e-09	0.36	0.2	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	6.68	3.81e-11	7.66e-09	0.36	0.2	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
BRCA	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.68	3.81e-11	7.66e-09	0.24	0.2	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
BRCA	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	6.68	3.82e-11	7.66e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000236529.1	RP13-254B10.1	6.68	3.82e-11	7.66e-09	0.26	0.2	Aortic root size;	chr7:66215323	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
BRCA	cis	rs67981189	0.896	rs3814869	ENSG00000269927.1	RP6-91H8.3	6.68	3.82e-11	7.68e-09	0.25	0.2	Schizophrenia;	chr14:71028982	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	6.68	3.83e-11	7.69e-09	0.32	0.2	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	6.68	3.83e-11	7.7e-09	0.26	0.2	Height;	chr4:55486718	chr4:55363971~55395847:-
BRCA	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	6.68	3.83e-11	7.7e-09	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
BRCA	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	6.68	3.84e-11	7.71e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
BRCA	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-6.68	3.84e-11	7.71e-09	-0.27	-0.2	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
BRCA	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-6.68	3.84e-11	7.71e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	6.68	3.85e-11	7.73e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	6.68	3.85e-11	7.73e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
BRCA	cis	rs73173548	0.528	rs6872276	ENSG00000247828.6	TMEM161B-AS1	6.68	3.85e-11	7.73e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88473903	chr5:88268895~88436685:+
BRCA	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-6.68	3.85e-11	7.73e-09	-0.21	-0.2	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
BRCA	cis	rs9307551	0.817	rs11098764	ENSG00000250334.4	LINC00989	-6.68	3.85e-11	7.73e-09	-0.27	-0.2	Refractive error;	chr4:79578860	chr4:79492416~79576460:+
BRCA	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-6.68	3.86e-11	7.75e-09	-0.28	-0.2	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
BRCA	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	6.68	3.87e-11	7.76e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
BRCA	cis	rs34779708	0.897	rs7897827	ENSG00000271335.4	RP11-324I22.4	6.68	3.87e-11	7.76e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.895	rs9309097	ENSG00000234936.1	AC010883.5	6.68	3.87e-11	7.76e-09	0.23	0.2	Coronary artery disease;	chr2:43327258	chr2:43229573~43233394:+
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000273765.1	RP11-370I10.11	6.68	3.87e-11	7.77e-09	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-6.68	3.87e-11	7.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.546	rs200948	ENSG00000220721.1	OR1F12	6.68	3.88e-11	7.78e-09	0.37	0.2	Depression;	chr6:27867494	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs200950	ENSG00000220721.1	OR1F12	6.68	3.88e-11	7.78e-09	0.37	0.2	Depression;	chr6:27867994	chr6:28073316~28074233:+
BRCA	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	6.68	3.88e-11	7.79e-09	0.27	0.2	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
BRCA	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-6.68	3.88e-11	7.79e-09	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
BRCA	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-6.68	3.89e-11	7.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
BRCA	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	6.68	3.89e-11	7.8e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000236529.1	RP13-254B10.1	6.68	3.89e-11	7.81e-09	0.25	0.2	Aortic root size;	chr7:66221293	chr7:65840212~65840596:+
BRCA	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-6.68	3.9e-11	7.81e-09	-0.26	-0.2	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
BRCA	cis	rs9307551	0.817	rs1440852	ENSG00000250334.4	LINC00989	-6.68	3.9e-11	7.82e-09	-0.27	-0.2	Refractive error;	chr4:79585435	chr4:79492416~79576460:+
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55454900	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55454938	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55455102	chr4:55363971~55395847:-
BRCA	cis	rs2014572	0.967	rs7259978	ENSG00000268379.1	CTC-360J11.4	6.68	3.91e-11	7.83e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244761	chr19:57175233~57177921:+
BRCA	cis	rs7976269	0.583	rs7955393	ENSG00000257176.2	RP11-996F15.2	-6.68	3.91e-11	7.83e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29065773	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-6.68	3.91e-11	7.84e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65925352	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65925571	chr7:65751142~65763354:+
BRCA	cis	rs11976180	1	rs11976180	ENSG00000204959.4	ARHGEF34P	6.68	3.92e-11	7.85e-09	0.26	0.2	Obesity-related traits;	chr7:144044487	chr7:144272445~144286966:-
BRCA	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-6.68	3.92e-11	7.86e-09	-0.23	-0.2	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
BRCA	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	6.68	3.95e-11	7.92e-09	0.22	0.2	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
BRCA	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-6.68	3.95e-11	7.93e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-6.68	3.96e-11	7.94e-09	-0.25	-0.2	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
BRCA	cis	rs4072705	1	rs4838206	ENSG00000224020.1	MIR181A2HG	-6.68	3.97e-11	7.95e-09	-0.22	-0.2	Menarche (age at onset);	chr9:124749645	chr9:124658467~124698631:+
BRCA	cis	rs3126085	0.935	rs56013982	ENSG00000237975.5	FLG-AS1	6.68	3.97e-11	7.95e-09	0.32	0.2	Atopic dermatitis;	chr1:152204027	chr1:152168125~152445456:+
BRCA	cis	rs11976180	1	rs1919949	ENSG00000204959.4	ARHGEF34P	6.68	3.97e-11	7.96e-09	0.25	0.2	Obesity-related traits;	chr7:144070630	chr7:144272445~144286966:-
BRCA	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	6.68	3.97e-11	7.96e-09	0.19	0.2	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
BRCA	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	6.68	3.98e-11	7.97e-09	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-6.68	3.99e-11	7.99e-09	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000236529.1	RP13-254B10.1	6.68	4e-11	8e-09	0.26	0.2	Aortic root size;	chr7:66249202	chr7:65840212~65840596:+
BRCA	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.68	4e-11	8.01e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
BRCA	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	6.67	4.01e-11	8.03e-09	0.27	0.2	Height;	chr4:55457922	chr4:55540502~55540835:-
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000273765.1	RP11-370I10.11	6.67	4.02e-11	8.04e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48360920~48361377:+
BRCA	cis	rs3781264	0.761	rs7077192	ENSG00000273450.1	RP11-76P2.4	6.67	4.02e-11	8.05e-09	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94365407	chr10:94314907~94315327:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	6.67	4.03e-11	8.07e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000273024.4	INTS4P2	6.67	4.04e-11	8.09e-09	0.22	0.2	Calcium levels;	chr7:66026136	chr7:65647864~65715661:+
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	6.67	4.04e-11	8.09e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
BRCA	cis	rs7976269	0.609	rs1344854	ENSG00000257176.2	RP11-996F15.2	6.67	4.05e-11	8.11e-09	0.24	0.2	Male-pattern baldness;	chr12:29065440	chr12:29280418~29317848:-
BRCA	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-6.67	4.06e-11	8.12e-09	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
BRCA	cis	rs7688540	0.771	rs7674560	ENSG00000211553.1	AC253576.2	-6.67	4.06e-11	8.12e-09	-0.3	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:136461~136568:+
BRCA	cis	rs9307551	0.817	rs12507375	ENSG00000250334.4	LINC00989	-6.67	4.06e-11	8.12e-09	-0.27	-0.2	Refractive error;	chr4:79575206	chr4:79492416~79576460:+
BRCA	cis	rs6840360	0.558	rs2709821	ENSG00000270265.1	RP11-731D1.4	-6.67	4.06e-11	8.13e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151333775~151353224:-
BRCA	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-6.67	4.06e-11	8.13e-09	-0.23	-0.2	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
BRCA	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-6.67	4.07e-11	8.15e-09	-0.25	-0.2	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
BRCA	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	6.67	4.08e-11	8.15e-09	0.25	0.2	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
BRCA	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-6.67	4.08e-11	8.16e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-6.67	4.08e-11	8.16e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
BRCA	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-6.67	4.08e-11	8.16e-09	-0.27	-0.2	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-6.67	4.08e-11	8.17e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000236529.1	RP13-254B10.1	6.67	4.09e-11	8.18e-09	0.25	0.2	Aortic root size;	chr7:66234510	chr7:65840212~65840596:+
BRCA	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	6.67	4.09e-11	8.19e-09	0.26	0.2	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
BRCA	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-6.67	4.09e-11	8.19e-09	-0.19	-0.2	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
BRCA	cis	rs2834288	0.5	rs7277248	ENSG00000273102.1	AP000569.9	6.67	4.09e-11	8.19e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33967101~33968573:-
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	6.67	4.1e-11	8.2e-09	0.22	0.2	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-6.67	4.1e-11	8.21e-09	-0.24	-0.2	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
BRCA	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-6.67	4.11e-11	8.21e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
BRCA	cis	rs17253792	0.822	rs17683656	ENSG00000186615.9	KTN1-AS1	6.67	4.12e-11	8.23e-09	0.39	0.2	Putamen volume;	chr14:55586643	chr14:55499278~55580110:-
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	6.67	4.12e-11	8.23e-09	0.28	0.2	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
BRCA	cis	rs58873874	0.579	rs11738062	ENSG00000248544.2	CTB-47B11.3	6.67	4.12e-11	8.24e-09	0.38	0.2	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157375741~157384950:-
BRCA	cis	rs34779708	0.931	rs2384283	ENSG00000271335.4	RP11-324I22.4	6.67	4.13e-11	8.27e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
BRCA	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-6.67	4.14e-11	8.28e-09	-0.27	-0.2	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
BRCA	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.67	4.14e-11	8.28e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
BRCA	cis	rs7923837	0.656	rs6583826	ENSG00000236493.2	EIF2S2P3	6.67	4.15e-11	8.29e-09	0.26	0.2	Multiple sclerosis;Body mass index;	chr10:92588073	chr10:92668745~92669743:-
BRCA	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-6.67	4.15e-11	8.29e-09	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	6.67	4.15e-11	8.3e-09	0.36	0.2	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
BRCA	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	6.67	4.16e-11	8.31e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000228409.4	CCT6P1	6.67	4.16e-11	8.31e-09	0.28	0.2	Diabetic kidney disease;	chr7:65977771	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.591	rs2056924	ENSG00000220721.1	OR1F12	6.67	4.16e-11	8.32e-09	0.24	0.2	Parkinson's disease;	chr6:27722395	chr6:28073316~28074233:+
BRCA	cis	rs11512640	1	rs12363935	ENSG00000254671.2	STT3A-AS1	6.67	4.16e-11	8.32e-09	0.47	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr11:125570284~125592568:-
BRCA	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.67	4.16e-11	8.32e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000224316.1	RP11-479O9.2	-6.67	4.16e-11	8.32e-09	-0.2	-0.2	Aortic root size;	chr7:66278221	chr7:65773620~65802067:+
BRCA	cis	rs4218	0.859	rs1486878	ENSG00000277144.1	RP11-59H7.4	-6.67	4.16e-11	8.32e-09	-0.25	-0.2	Social communication problems;	chr15:59123268	chr15:59115547~59116089:-
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000224316.1	RP11-479O9.2	-6.67	4.16e-11	8.32e-09	-0.2	-0.2	Aortic root size;	chr7:66298631	chr7:65773620~65802067:+
BRCA	cis	rs2998286	0.862	rs2993989	ENSG00000254635.4	WAC-AS1	-6.67	4.17e-11	8.33e-09	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28522652~28532743:-
BRCA	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
BRCA	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	6.67	4.18e-11	8.34e-09	0.24	0.2	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	6.67	4.19e-11	8.37e-09	0.21	0.2	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
BRCA	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-6.67	4.19e-11	8.38e-09	-0.25	-0.2	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
BRCA	cis	rs72772090	1	rs72772090	ENSG00000248734.2	CTD-2260A17.1	-6.67	4.2e-11	8.38e-09	-0.32	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96700607	chr5:96784777~96785999:+
BRCA	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	6.67	4.2e-11	8.39e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
BRCA	cis	rs4237845	0.773	rs6650217	ENSG00000257159.1	RP11-58A17.3	6.67	4.21e-11	8.4e-09	0.23	0.2	Intelligence (multi-trait analysis);	chr12:57895289	chr12:57967058~57968399:+
BRCA	cis	rs4237845	0.773	rs6650218	ENSG00000257159.1	RP11-58A17.3	6.67	4.21e-11	8.4e-09	0.23	0.2	Intelligence (multi-trait analysis);	chr12:57895295	chr12:57967058~57968399:+
BRCA	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	6.67	4.21e-11	8.41e-09	0.27	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
BRCA	cis	rs73173548	0.502	rs74429030	ENSG00000247828.6	TMEM161B-AS1	6.67	4.21e-11	8.41e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88474689	chr5:88268895~88436685:+
BRCA	cis	rs9638182	0.778	rs35332062	ENSG00000274080.1	CTA-315H11.2	6.67	4.21e-11	8.41e-09	0.41	0.2	Triglycerides;	chr7:73597712	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.614	rs79624003	ENSG00000274080.1	CTA-315H11.2	6.67	4.21e-11	8.41e-09	0.41	0.2	Triglycerides;	chr7:73598455	chr7:73609262~73611502:-
BRCA	cis	rs7487075	0.78	rs1873793	ENSG00000257261.4	RP11-96H19.1	-6.67	4.23e-11	8.44e-09	-0.21	-0.2	Itch intensity from mosquito bite;	chr12:46367541	chr12:46383679~46876159:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-6.67	4.23e-11	8.44e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
BRCA	cis	rs957448	1	rs12678305	ENSG00000253175.1	RP11-267M23.6	6.67	4.23e-11	8.44e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94565036~94565715:+
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000214776.8	RP11-726G1.1	-6.67	4.23e-11	8.44e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9707040	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000229886.1	RP5-1132H15.3	6.67	4.23e-11	8.45e-09	0.38	0.2	Diabetic kidney disease;	chr7:66073444	chr7:66025126~66031544:-
BRCA	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	6.67	4.24e-11	8.46e-09	0.46	0.2	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
BRCA	cis	rs7976269	0.609	rs11050010	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29061952	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs2196480	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29062850	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.537	rs10743642	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29063557	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs10771472	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29063930	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	6.67	4.25e-11	8.47e-09	0.25	0.2	Height;	chr4:55451489	chr4:55540502~55540835:-
BRCA	cis	rs4372836	1	rs11688129	ENSG00000226833.4	AC097724.3	-6.67	4.25e-11	8.49e-09	-0.25	-0.2	Body mass index;	chr2:28729715	chr2:28708953~28736205:-
BRCA	cis	rs516805	0.52	rs9375150	ENSG00000279114.1	RP3-425C14.5	6.67	4.27e-11	8.52e-09	0.19	0.2	Lymphocyte counts;	chr6:122566410	chr6:122471923~122484161:+
BRCA	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-6.67	4.28e-11	8.53e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
BRCA	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-6.67	4.28e-11	8.53e-09	-0.2	-0.2	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
BRCA	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	6.67	4.28e-11	8.53e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	6.66	4.29e-11	8.56e-09	0.21	0.2	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.66	4.29e-11	8.56e-09	-0.3	-0.2	Depression;	chr6:28079011	chr6:28115628~28116551:+
BRCA	cis	rs67981189	0.896	rs7146932	ENSG00000269927.1	RP6-91H8.3	6.66	4.29e-11	8.56e-09	0.25	0.2	Schizophrenia;	chr14:71010328	chr14:71141125~71143253:-
BRCA	cis	rs16846053	0.515	rs4001644	ENSG00000227403.1	AC009299.3	-6.66	4.3e-11	8.58e-09	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161542357	chr2:161244739~161249050:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-6.66	4.3e-11	8.58e-09	-0.3	-0.2	Depression;	chr6:28074687	chr6:28115628~28116551:+
BRCA	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	6.66	4.3e-11	8.59e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
BRCA	cis	rs6840360	0.681	rs9968292	ENSG00000270265.1	RP11-731D1.4	-6.66	4.3e-11	8.59e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151333775~151353224:-
BRCA	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-6.66	4.31e-11	8.6e-09	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
BRCA	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-6.66	4.32e-11	8.61e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
BRCA	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-6.66	4.33e-11	8.63e-09	-0.25	-0.2	QT interval;	chr12:29314736	chr12:29280418~29317848:-
BRCA	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	6.66	4.33e-11	8.63e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs67998226	ENSG00000220721.1	OR1F12	6.66	4.33e-11	8.64e-09	0.46	0.2	Depression;	chr6:28270281	chr6:28073316~28074233:+
BRCA	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	6.66	4.34e-11	8.65e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
BRCA	cis	rs17253792	0.822	rs10142497	ENSG00000186615.9	KTN1-AS1	6.66	4.34e-11	8.65e-09	0.38	0.2	Putamen volume;	chr14:55581230	chr14:55499278~55580110:-
BRCA	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	6.66	4.35e-11	8.67e-09	0.24	0.2	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
BRCA	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-6.66	4.35e-11	8.67e-09	-0.29	-0.2	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
BRCA	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-6.66	4.35e-11	8.67e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
BRCA	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	6.66	4.35e-11	8.68e-09	0.31	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
BRCA	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	6.66	4.37e-11	8.7e-09	0.21	0.2	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
BRCA	cis	rs1440410	0.835	rs10011709	ENSG00000250326.1	RP11-284M14.1	-6.66	4.38e-11	8.73e-09	-0.22	-0.2	Ischemic stroke;	chr4:143159347	chr4:142933195~143184861:-
BRCA	cis	rs17253792	0.822	rs80328469	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55600983	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77420254	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55602928	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78395034	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55603065	chr14:55499278~55580110:-
BRCA	cis	rs67981189	0.896	rs17108925	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71033010	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs28374308	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71035040	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs8016506	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71039600	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.858	rs35631530	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71041312	chr14:71141125~71143253:-
BRCA	cis	rs957448	1	rs16916881	ENSG00000253175.1	RP11-267M23.6	6.66	4.4e-11	8.76e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94565036~94565715:+
BRCA	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-6.66	4.4e-11	8.76e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	6.66	4.4e-11	8.76e-09	0.24	0.2	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
BRCA	cis	rs11671005	0.61	rs3794966	ENSG00000252334.1	RNU6-1337P	6.66	4.4e-11	8.77e-09	0.32	0.2	Mean platelet volume;	chr19:58557629	chr19:58483749~58483843:-
BRCA	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-6.66	4.4e-11	8.77e-09	-0.27	-0.2	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
BRCA	cis	rs67340775	0.748	rs13212651	ENSG00000220721.1	OR1F12	6.66	4.41e-11	8.79e-09	0.47	0.2	Lung cancer in ever smokers;	chr6:27839207	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.66	4.41e-11	8.8e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
BRCA	cis	rs9307551	0.817	rs12500146	ENSG00000250334.4	LINC00989	-6.66	4.42e-11	8.8e-09	-0.27	-0.2	Refractive error;	chr4:79580002	chr4:79492416~79576460:+
BRCA	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	6.66	4.43e-11	8.82e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
BRCA	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	6.66	4.44e-11	8.84e-09	0.25	0.2	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
BRCA	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	6.66	4.44e-11	8.84e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
BRCA	cis	rs11009175	0.725	rs11009183	ENSG00000273038.2	RP11-479G22.8	-6.66	4.44e-11	8.84e-09	-0.33	-0.2	Depression (quantitative trait);	chr10:33017381	chr10:32887255~32889311:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000273024.4	INTS4P2	-6.66	4.44e-11	8.85e-09	-0.26	-0.2	Aortic root size;	chr7:66226662	chr7:65647864~65715661:+
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000273765.1	RP11-370I10.11	6.66	4.45e-11	8.86e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48360920~48361377:+
BRCA	cis	rs227275	0.554	rs223334	ENSG00000251288.2	RP11-10L12.2	6.66	4.46e-11	8.88e-09	0.24	0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	6.66	4.46e-11	8.88e-09	0.29	0.2	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
BRCA	cis	rs34929064	0.881	rs7802442	ENSG00000179428.2	AC073072.5	-6.66	4.47e-11	8.9e-09	-0.22	-0.2	Major depression and alcohol dependence;	chr7:22696827	chr7:22725395~22727620:-
BRCA	cis	rs67981189	0.896	rs2526846	ENSG00000269927.1	RP6-91H8.3	-6.66	4.47e-11	8.91e-09	-0.25	-0.2	Schizophrenia;	chr14:70957538	chr14:71141125~71143253:-
BRCA	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	6.66	4.48e-11	8.91e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
BRCA	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	6.66	4.48e-11	8.91e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
BRCA	cis	rs7069191	0.73	rs10994493	ENSG00000254271.1	RP11-131N11.4	6.66	4.48e-11	8.91e-09	0.36	0.2	Pediatric bone mineral density (spine);	chr10:60749542	chr10:60734342~60741828:+
BRCA	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-6.66	4.48e-11	8.92e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
BRCA	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-6.66	4.48e-11	8.93e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
BRCA	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-6.66	4.49e-11	8.93e-09	-0.26	-0.2	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000224316.1	RP11-479O9.2	-6.66	4.49e-11	8.94e-09	-0.2	-0.2	Aortic root size;	chr7:66136231	chr7:65773620~65802067:+
BRCA	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	6.66	4.49e-11	8.95e-09	0.33	0.2	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
BRCA	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-6.66	4.5e-11	8.95e-09	-0.29	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
BRCA	cis	rs4372836	1	rs4549034	ENSG00000226833.4	AC097724.3	6.66	4.5e-11	8.96e-09	0.25	0.2	Body mass index;	chr2:28749713	chr2:28708953~28736205:-
BRCA	cis	rs67981189	0.896	rs7157250	ENSG00000269927.1	RP6-91H8.3	6.66	4.5e-11	8.97e-09	0.25	0.2	Schizophrenia;	chr14:70991112	chr14:71141125~71143253:-
BRCA	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	6.66	4.52e-11	8.99e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	6.66	4.52e-11	8.99e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
BRCA	cis	rs13315649	0.724	rs7624610	ENSG00000242551.2	POU5F1P6	-6.66	4.52e-11	8.99e-09	-0.29	-0.2	Sum eosinophil basophil counts;	chr3:128698450	chr3:128674735~128677005:-
BRCA	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-6.66	4.52e-11	9e-09	-0.23	-0.2	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	6.66	4.53e-11	9e-09	0.36	0.2	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
BRCA	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.66	4.53e-11	9.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
BRCA	cis	rs11024102	1	rs10766368	ENSG00000184669.7	OR7E14P	-6.66	4.53e-11	9.02e-09	-0.32	-0.2	Glaucoma (primary angle closure);	chr11:16993335	chr11:17013998~17053024:+
BRCA	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-6.66	4.54e-11	9.02e-09	-0.27	-0.2	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
BRCA	cis	rs1440410	0.798	rs7663553	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143127883	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7663762	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143128019	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7670624	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143129092	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7665674	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143129181	chr4:142933195~143184861:-
BRCA	cis	rs17253792	0.822	rs8013714	ENSG00000186615.9	KTN1-AS1	-6.66	4.54e-11	9.03e-09	-0.36	-0.2	Putamen volume;	chr14:55705568	chr14:55499278~55580110:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28071237	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28076559	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28078391	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28080757	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28080760	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	6.66	4.54e-11	9.04e-09	0.21	0.2	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	6.66	4.54e-11	9.04e-09	0.21	0.2	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	6.66	4.55e-11	9.04e-09	0.27	0.2	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
BRCA	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.66	4.55e-11	9.04e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
BRCA	cis	rs5015933	0.815	rs13291655	ENSG00000232630.1	PRPS1P2	-6.66	4.55e-11	9.05e-09	-0.19	-0.2	Body mass index;	chr9:125348274	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000224316.1	RP11-479O9.2	-6.66	4.55e-11	9.05e-09	-0.23	-0.2	Aortic root size;	chr7:66646886	chr7:65773620~65802067:+
BRCA	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-6.66	4.56e-11	9.06e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	6.66	4.56e-11	9.07e-09	0.25	0.2	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
BRCA	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	6.66	4.56e-11	9.07e-09	0.21	0.2	Height;	chr20:35192965	chr20:35201747~35203288:-
BRCA	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	6.66	4.56e-11	9.08e-09	0.24	0.2	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
BRCA	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-6.66	4.57e-11	9.08e-09	-0.27	-0.2	AIDS;	chr2:105356755	chr2:105324210~105330529:+
BRCA	cis	rs67981189	0.896	rs2526874	ENSG00000269927.1	RP6-91H8.3	-6.65	4.58e-11	9.1e-09	-0.25	-0.2	Schizophrenia;	chr14:70914502	chr14:71141125~71143253:-
BRCA	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	6.65	4.58e-11	9.1e-09	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-6.65	4.59e-11	9.12e-09	-0.22	-0.2	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
BRCA	cis	rs34779708	0.931	rs66887762	ENSG00000271335.4	RP11-324I22.4	6.65	4.59e-11	9.12e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35314552~35336401:-
BRCA	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	6.65	4.59e-11	9.12e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
BRCA	cis	rs79040073	0.607	rs10519227	ENSG00000259531.2	RP11-295H24.3	6.65	4.59e-11	9.12e-09	0.3	0.2	Lung cancer in ever smokers;	chr15:49454167	chr15:49365124~49366685:-
BRCA	cis	rs67981189	0.784	rs58984901	ENSG00000269927.1	RP6-91H8.3	6.65	4.6e-11	9.14e-09	0.25	0.2	Schizophrenia;	chr14:71085271	chr14:71141125~71143253:-
BRCA	cis	rs11976180	1	rs2951308	ENSG00000204959.4	ARHGEF34P	-6.65	4.6e-11	9.14e-09	-0.25	-0.2	Obesity-related traits;	chr7:144070056	chr7:144272445~144286966:-
BRCA	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-6.65	4.6e-11	9.15e-09	-0.21	-0.2	Height;	chr20:35160450	chr20:35201747~35203288:-
BRCA	cis	rs67340775	0.541	rs200979	ENSG00000220721.1	OR1F12	6.65	4.61e-11	9.15e-09	0.3	0.2	Lung cancer in ever smokers;	chr6:27884579	chr6:28073316~28074233:+
BRCA	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	6.65	4.61e-11	9.16e-09	0.19	0.2	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000229886.1	RP5-1132H15.3	6.65	4.61e-11	9.16e-09	0.36	0.2	Diabetic kidney disease;	chr7:66140385	chr7:66025126~66031544:-
BRCA	cis	rs11742741	0.676	rs62347896	ENSG00000248874.4	C5orf17	-6.65	4.62e-11	9.18e-09	-0.25	-0.2	Educational attainment;	chr5:24204990	chr5:23951348~24178263:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-6.65	4.63e-11	9.19e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
BRCA	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	6.65	4.63e-11	9.19e-09	0.39	0.2	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
BRCA	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-6.65	4.63e-11	9.2e-09	-0.21	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
BRCA	cis	rs8086028	1	rs8086028	ENSG00000264714.1	RP11-21G15.1	6.65	4.63e-11	9.21e-09	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr18:10737781	chr18:10724619~10728539:+
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	6.65	4.64e-11	9.21e-09	0.25	0.2	Height;	chr4:55561218	chr4:55540502~55540835:-
BRCA	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	6.65	4.65e-11	9.23e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
BRCA	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-6.65	4.65e-11	9.25e-09	-0.25	-0.2	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
BRCA	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-6.65	4.66e-11	9.26e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	6.65	4.68e-11	9.29e-09	0.29	0.2	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
BRCA	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	6.65	4.68e-11	9.29e-09	0.25	0.2	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
BRCA	cis	rs2638953	0.924	rs1551987	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1551986	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs2078017	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28163298~28190738:-
BRCA	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	6.65	4.7e-11	9.32e-09	0.22	0.2	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
BRCA	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	6.65	4.7e-11	9.32e-09	0.22	0.2	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
BRCA	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-6.65	4.7e-11	9.33e-09	-0.3	-0.2	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
BRCA	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-6.65	4.7e-11	9.33e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.65	4.7e-11	9.33e-09	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	6.65	4.71e-11	9.35e-09	0.24	0.2	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	6.65	4.71e-11	9.36e-09	0.12	0.2	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
BRCA	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-6.65	4.72e-11	9.36e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
BRCA	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	6.65	4.72e-11	9.36e-09	0.25	0.2	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
BRCA	cis	rs853679	0.607	rs67101035	ENSG00000220721.1	OR1F12	6.65	4.72e-11	9.37e-09	0.47	0.2	Depression;	chr6:27831109	chr6:28073316~28074233:+
BRCA	cis	rs4763879	0.634	rs7974396	ENSG00000214776.8	RP11-726G1.1	-6.65	4.72e-11	9.37e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9708101	chr12:9467552~9576275:+
BRCA	cis	rs228614	0.51	rs223438	ENSG00000251288.2	RP11-10L12.2	6.65	4.72e-11	9.37e-09	0.24	0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000224373.3	IGHV4-59	6.65	4.73e-11	9.38e-09	0.13	0.2	Kawasaki disease;	chr14:106813798	chr14:106627249~106627825:-
BRCA	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	6.65	4.74e-11	9.4e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
BRCA	cis	rs13178541	0.745	rs3963615	ENSG00000250378.1	RP11-119J18.1	-6.65	4.74e-11	9.41e-09	-0.27	-0.2	IgG glycosylation;	chr5:135750292	chr5:135812667~135826582:+
BRCA	cis	rs4722166	0.532	rs4719711	ENSG00000179428.2	AC073072.5	6.65	4.74e-11	9.41e-09	0.21	0.2	Lung cancer;	chr7:22716069	chr7:22725395~22727620:-
BRCA	cis	rs34779708	0.931	rs3740083	ENSG00000271335.4	RP11-324I22.4	6.65	4.75e-11	9.43e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs2371244	ENSG00000204959.4	ARHGEF34P	6.65	4.75e-11	9.43e-09	0.25	0.2	Obesity-related traits;	chr7:144060518	chr7:144272445~144286966:-
BRCA	cis	rs58873874	1	rs11740562	ENSG00000251405.2	CTB-109A12.1	-6.65	4.76e-11	9.44e-09	-0.45	-0.2	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157362615~157460078:-
BRCA	cis	rs7615952	0.599	rs66532274	ENSG00000250012.1	RP11-124N2.1	-6.65	4.76e-11	9.44e-09	-0.26	-0.2	Blood pressure (smoking interaction);	chr3:126013002	chr3:126084220~126095349:+
BRCA	cis	rs16846053	0.515	rs1567981	ENSG00000227403.1	AC009299.3	-6.65	4.77e-11	9.46e-09	-0.35	-0.2	Blood osmolality (transformed sodium);	chr2:161692589	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000224316.1	RP11-479O9.2	-6.65	4.77e-11	9.47e-09	-0.2	-0.2	Aortic root size;	chr7:66146364	chr7:65773620~65802067:+
BRCA	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	6.65	4.78e-11	9.48e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
BRCA	cis	rs17253792	0.822	rs13379343	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583487	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379340	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583628	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379342	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583734	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379353	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583760	chr14:55499278~55580110:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000228409.4	CCT6P1	6.65	4.78e-11	9.49e-09	0.28	0.2	Diabetic kidney disease;	chr7:65966506	chr7:65751142~65763354:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	6.65	4.79e-11	9.5e-09	0.22	0.2	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000224316.1	RP11-479O9.2	-6.65	4.79e-11	9.5e-09	-0.2	-0.2	Aortic root size;	chr7:66278036	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-6.65	4.79e-11	9.51e-09	-0.25	-0.2	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.931	rs7923172	ENSG00000271335.4	RP11-324I22.4	6.65	4.81e-11	9.54e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35314552~35336401:-
BRCA	cis	rs4835473	0.637	rs11932061	ENSG00000251600.4	RP11-673E1.1	6.65	4.81e-11	9.54e-09	0.23	0.2	Immature fraction of reticulocytes;	chr4:143768124	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	6.65	4.82e-11	9.56e-09	0.22	0.2	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
BRCA	cis	rs375066	0.623	rs10415344	ENSG00000267058.1	RP11-15A1.3	6.65	4.83e-11	9.57e-09	0.23	0.2	Breast cancer;	chr19:43846566	chr19:43891804~43901805:-
BRCA	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-6.65	4.83e-11	9.57e-09	-0.23	-0.2	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-6.65	4.83e-11	9.58e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-6.65	4.83e-11	9.58e-09	-0.23	-0.2	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-6.65	4.83e-11	9.58e-09	-0.3	-0.2	Depression;	chr6:28076704	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	6.65	4.83e-11	9.59e-09	0.21	0.2	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
BRCA	cis	rs891378	1	rs2802217	ENSG00000274245.1	RP11-357P18.2	-6.65	4.84e-11	9.59e-09	-0.29	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207309625	chr1:207372559~207373252:+
BRCA	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-6.65	4.84e-11	9.59e-09	-0.26	-0.2	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
BRCA	cis	rs7976269	0.609	rs7979788	ENSG00000257176.2	RP11-996F15.2	-6.65	4.84e-11	9.6e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29064827	chr12:29280418~29317848:-
BRCA	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	6.65	4.85e-11	9.61e-09	0.24	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
BRCA	cis	rs34779708	0.931	rs4934697	ENSG00000271335.4	RP11-324I22.4	6.65	4.85e-11	9.61e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35314552~35336401:-
BRCA	cis	rs7131987	0.565	rs7976227	ENSG00000275476.1	RP11-996F15.4	6.65	4.85e-11	9.62e-09	0.22	0.2	QT interval;	chr12:29264843	chr12:29277397~29277882:-
BRCA	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-6.65	4.86e-11	9.63e-09	-0.27	-0.2	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-6.65	4.86e-11	9.63e-09	-0.27	-0.2	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
BRCA	cis	rs78456975	0.739	rs28913003	ENSG00000231482.2	AC141930.2	-6.65	4.86e-11	9.63e-09	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515848	chr2:1572554~1580311:-
BRCA	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	6.65	4.86e-11	9.63e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-6.65	4.86e-11	9.64e-09	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
BRCA	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	6.65	4.86e-11	9.64e-09	0.25	0.2	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
BRCA	cis	rs3758911	0.788	rs10890680	ENSG00000255353.1	RP11-382M14.1	-6.65	4.86e-11	9.64e-09	-0.28	-0.2	Coronary artery disease;	chr11:107255139	chr11:107176286~107177530:+
BRCA	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	6.65	4.87e-11	9.64e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
BRCA	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	6.65	4.87e-11	9.65e-09	0.22	0.2	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
BRCA	cis	rs7131987	0.565	rs10843372	ENSG00000275476.1	RP11-996F15.4	6.65	4.87e-11	9.65e-09	0.22	0.2	QT interval;	chr12:29262863	chr12:29277397~29277882:-
BRCA	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-6.65	4.87e-11	9.66e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-6.65	4.87e-11	9.66e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
BRCA	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-6.65	4.87e-11	9.66e-09	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
BRCA	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	6.65	4.88e-11	9.66e-09	0.22	0.2	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
BRCA	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-6.64	4.88e-11	9.68e-09	-0.23	-0.2	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000229886.1	RP5-1132H15.3	6.64	4.89e-11	9.68e-09	0.36	0.2	Diabetic kidney disease;	chr7:66632552	chr7:66025126~66031544:-
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000261582.1	RP4-614O4.11	-6.64	4.9e-11	9.7e-09	-0.23	-0.2	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35267885~35280043:-
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000273765.1	RP11-370I10.11	6.64	4.9e-11	9.71e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48360920~48361377:+
BRCA	cis	rs8002861	0.664	rs2184882	ENSG00000274001.1	RP11-5G9.5	6.64	4.9e-11	9.71e-09	0.23	0.2	Leprosy;	chr13:43876210	chr13:43877715~43878163:-
BRCA	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	6.64	4.91e-11	9.72e-09	0.16	0.2	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
BRCA	cis	rs34779708	0.897	rs4934527	ENSG00000271335.4	RP11-324I22.4	6.64	4.91e-11	9.73e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35314552~35336401:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-6.64	4.92e-11	9.74e-09	-0.26	-0.2	Gout;	chr7:66671562	chr7:66848496~66858136:+
BRCA	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	6.64	4.92e-11	9.75e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	6.64	4.93e-11	9.76e-09	0.23	0.2	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
BRCA	cis	rs78456975	0.739	rs11891867	ENSG00000231482.2	AC141930.2	-6.64	4.93e-11	9.77e-09	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514122	chr2:1572554~1580311:-
BRCA	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.64	4.93e-11	9.77e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.64	4.93e-11	9.77e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	6.64	4.93e-11	9.77e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	6.64	4.93e-11	9.77e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
BRCA	cis	rs2835345	0.563	rs60511692	ENSG00000230479.1	AP000695.6	6.64	4.93e-11	9.77e-09	0.2	0.2	Pulmonary function;	chr21:36454091	chr21:36430360~36481070:+
BRCA	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	6.64	4.93e-11	9.77e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
BRCA	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	6.64	4.93e-11	9.77e-09	0.26	0.2	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
BRCA	cis	rs78456975	1	rs6730391	ENSG00000231482.2	AC141930.2	-6.64	4.94e-11	9.77e-09	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1563066	chr2:1572554~1580311:-
BRCA	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-6.64	4.94e-11	9.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	6.64	4.94e-11	9.79e-09	0.22	0.2	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	6.64	4.95e-11	9.8e-09	0.36	0.2	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-6.64	4.95e-11	9.8e-09	-0.2	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
BRCA	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.64	4.95e-11	9.81e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	6.64	4.96e-11	9.82e-09	0.3	0.2	Depression;	chr6:28109824	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000224316.1	RP11-479O9.2	6.64	4.96e-11	9.82e-09	0.23	0.2	Aortic root size;	chr7:66318029	chr7:65773620~65802067:+
BRCA	cis	rs6543140	0.964	rs4851592	ENSG00000234389.1	AC007278.3	6.64	4.96e-11	9.83e-09	0.2	0.2	Blood protein levels;	chr2:102471181	chr2:102438713~102440475:+
BRCA	cis	rs17253792	0.822	rs8013831	ENSG00000186615.9	KTN1-AS1	-6.64	4.97e-11	9.85e-09	-0.36	-0.2	Putamen volume;	chr14:55706180	chr14:55499278~55580110:-
BRCA	cis	rs7845219	0.539	rs10441538	ENSG00000253528.2	RP11-347C18.4	6.64	4.97e-11	9.85e-09	0.21	0.2	Type 2 diabetes;	chr8:94856380	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000234585.5	CCT6P3	-6.64	4.98e-11	9.86e-09	-0.19	-0.2	Aortic root size;	chr7:65800193	chr7:65038354~65074713:+
BRCA	cis	rs11976180	1	rs4726669	ENSG00000204959.4	ARHGEF34P	6.64	4.98e-11	9.87e-09	0.25	0.2	Obesity-related traits;	chr7:144061098	chr7:144272445~144286966:-
BRCA	cis	rs6723226	0.882	rs13035097	ENSG00000276334.1	AL133243.1	-6.64	4.99e-11	9.88e-09	-0.26	-0.2	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32521927~32523547:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-6.64	5.01e-11	9.91e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-6.64	5.01e-11	9.91e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
BRCA	cis	rs9307551	0.817	rs13146986	ENSG00000250334.4	LINC00989	-6.64	5.01e-11	9.92e-09	-0.27	-0.2	Refractive error;	chr4:79591074	chr4:79492416~79576460:+
BRCA	cis	rs12439619	1	rs12439619	ENSG00000259429.4	UBE2Q2P2	-6.64	5.02e-11	9.93e-09	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82355142~82420075:+
BRCA	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
BRCA	cis	rs74233809	0.901	rs7098825	ENSG00000213277.3	MARCKSL1P1	6.64	5.03e-11	9.96e-09	0.37	0.2	Birth weight;	chr10:102868477	chr10:103175554~103176094:+
BRCA	cis	rs12594515	0.967	rs11854477	ENSG00000259200.1	RP11-718O11.1	-6.64	5.03e-11	9.96e-09	-0.22	-0.2	Weight;Waist circumference;	chr15:45706147	chr15:45705078~45931069:+
BRCA	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	6.64	5.04e-11	9.96e-09	0.23	0.2	Height;	chr7:77671806	chr7:77657660~77696265:-
BRCA	cis	rs3781264	0.848	rs7897678	ENSG00000273450.1	RP11-76P2.4	6.64	5.04e-11	9.97e-09	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94300853	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.804	rs7914672	ENSG00000273450.1	RP11-76P2.4	6.64	5.04e-11	9.97e-09	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94301090	chr10:94314907~94315327:-
BRCA	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	6.64	5.04e-11	9.97e-09	0.19	0.2	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
BRCA	cis	rs2554380	0.55	rs4572348	ENSG00000230373.7	GOLGA6L5P	-6.64	5.04e-11	9.97e-09	-0.25	-0.2	Height;	chr15:83871411	chr15:84507885~84516814:-
BRCA	cis	rs9907295	0.901	rs4796120	ENSG00000271013.1	AC015849.15	6.64	5.04e-11	9.98e-09	0.31	0.2	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35912635~35918010:-
BRCA	cis	rs9840812	0.567	rs2655008	ENSG00000239213.4	NCK1-AS1	6.64	5.05e-11	9.98e-09	0.24	0.2	Fibrinogen levels;	chr3:136404933	chr3:136841726~136862054:-
BRCA	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-6.64	5.05e-11	9.98e-09	-0.18	-0.2	Breast cancer;	chr11:825777	chr11:777578~784297:+
BRCA	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-6.64	5.05e-11	9.98e-09	-0.26	-0.2	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-6.64	5.05e-11	9.98e-09	-0.26	-0.2	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
BRCA	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-6.64	5.05e-11	9.99e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
BRCA	cis	rs67981189	0.806	rs2810107	ENSG00000269927.1	RP6-91H8.3	-6.64	5.05e-11	9.99e-09	-0.25	-0.2	Schizophrenia;	chr14:70954340	chr14:71141125~71143253:-
BRCA	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	6.64	5.06e-11	1e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
BRCA	cis	rs9876781	0.874	rs56298324	ENSG00000244380.1	RP11-24C3.2	-6.64	5.06e-11	1e-08	-0.23	-0.2	Longevity;	chr3:48393626	chr3:48440352~48446656:-
BRCA	cis	rs7976269	0.559	rs10843313	ENSG00000257176.2	RP11-996F15.2	-6.64	5.06e-11	1e-08	-0.25	-0.2	Male-pattern baldness;	chr12:29078317	chr12:29280418~29317848:-
BRCA	cis	rs4356203	0.543	rs214088	ENSG00000272034.1	SNORD14A	-6.64	5.07e-11	1e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17074654~17074744:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000261582.1	RP4-614O4.11	-6.64	5.08e-11	1e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35267885~35280043:-
BRCA	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-6.64	5.08e-11	1e-08	-0.26	-0.2	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
BRCA	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	6.64	5.1e-11	1.01e-08	0.41	0.2	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
BRCA	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	6.64	5.1e-11	1.01e-08	0.32	0.2	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	6.64	5.11e-11	1.01e-08	0.27	0.2	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	6.64	5.11e-11	1.01e-08	0.27	0.2	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	6.64	5.13e-11	1.01e-08	0.27	0.2	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	6.64	5.13e-11	1.01e-08	0.27	0.2	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
BRCA	cis	rs78456975	0.943	rs7602369	ENSG00000231482.2	AC141930.2	-6.64	5.13e-11	1.01e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1570982	chr2:1572554~1580311:-
BRCA	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	6.64	5.13e-11	1.01e-08	0.21	0.2	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000224316.1	RP11-479O9.2	-6.64	5.14e-11	1.02e-08	-0.23	-0.2	Aortic root size;	chr7:66592167	chr7:65773620~65802067:+
BRCA	cis	rs78456975	1	rs10189336	ENSG00000231482.2	AC141930.2	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554243	chr2:1572554~1580311:-
BRCA	cis	rs6543140	0.964	rs4851593	ENSG00000234389.1	AC007278.3	-6.64	5.15e-11	1.02e-08	-0.2	-0.2	Blood protein levels;	chr2:102472767	chr2:102438713~102440475:+
BRCA	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	6.64	5.15e-11	1.02e-08	0.31	0.2	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
BRCA	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
BRCA	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	6.64	5.15e-11	1.02e-08	0.21	0.2	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000229886.1	RP5-1132H15.3	6.64	5.16e-11	1.02e-08	0.35	0.2	Diabetic kidney disease;	chr7:66139312	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	6.64	5.16e-11	1.02e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
BRCA	cis	rs11976180	1	rs1533267	ENSG00000204959.4	ARHGEF34P	6.64	5.16e-11	1.02e-08	0.25	0.2	Obesity-related traits;	chr7:144069347	chr7:144272445~144286966:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66271195	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66272999	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66274686	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66274896	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-6.64	5.17e-11	1.02e-08	-0.26	-0.2	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
BRCA	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-6.64	5.17e-11	1.02e-08	-0.21	-0.2	Height;	chr20:35157243	chr20:35201747~35203288:-
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	6.64	5.18e-11	1.02e-08	0.25	0.2	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
BRCA	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-6.64	5.18e-11	1.02e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
BRCA	cis	rs12594515	1	rs8039622	ENSG00000259200.1	RP11-718O11.1	-6.64	5.19e-11	1.02e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694233	chr15:45705078~45931069:+
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-6.64	5.19e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
BRCA	cis	rs896854	0.552	rs2515236	ENSG00000253528.2	RP11-347C18.4	-6.64	5.19e-11	1.03e-08	-0.23	-0.2	Type 2 diabetes;	chr8:94922679	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000224316.1	RP11-479O9.2	-6.64	5.2e-11	1.03e-08	-0.21	-0.2	Aortic root size;	chr7:66278783	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	6.64	5.2e-11	1.03e-08	0.22	0.2	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	6.64	5.2e-11	1.03e-08	0.22	0.2	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
BRCA	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	6.64	5.21e-11	1.03e-08	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
BRCA	cis	rs7178375	1	rs7178375	ENSG00000215302.7	CTD-3092A11.1	-6.63	5.21e-11	1.03e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30923732	chr15:30470779~30507623:+
BRCA	cis	rs10181042	0.565	rs62150982	ENSG00000271889.1	RP11-493E12.1	-6.63	5.21e-11	1.03e-08	-0.24	-0.2	Crohn's disease;	chr2:61053540	chr2:61151433~61162105:-
BRCA	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	6.63	5.21e-11	1.03e-08	0.28	0.2	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
BRCA	cis	rs78456975	0.527	rs11885279	ENSG00000231482.2	AC141930.2	-6.63	5.22e-11	1.03e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1556861	chr2:1572554~1580311:-
BRCA	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	6.63	5.22e-11	1.03e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
BRCA	cis	rs12501370	1	rs2341573	ENSG00000201736.1	RNA5SP160	6.63	5.23e-11	1.03e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40997603	chr4:40990154~40990273:+
BRCA	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	6.63	5.23e-11	1.03e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
BRCA	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	6.63	5.23e-11	1.03e-08	0.22	0.2	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
BRCA	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	6.63	5.25e-11	1.04e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
BRCA	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-6.63	5.27e-11	1.04e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
BRCA	cis	rs13126694	0.778	rs4691454	ENSG00000251429.1	RP11-597D13.7	6.63	5.27e-11	1.04e-08	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158270378~158278676:+
BRCA	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
BRCA	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	6.63	5.28e-11	1.04e-08	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
BRCA	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-6.63	5.29e-11	1.04e-08	-0.23	-0.2	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
BRCA	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	6.63	5.29e-11	1.04e-08	0.29	0.2	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
BRCA	cis	rs7976269	0.609	rs10771475	ENSG00000257176.2	RP11-996F15.2	-6.63	5.29e-11	1.04e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29071077	chr12:29280418~29317848:-
BRCA	cis	rs17253792	0.822	rs8006705	ENSG00000186615.9	KTN1-AS1	-6.63	5.29e-11	1.04e-08	-0.36	-0.2	Putamen volume;	chr14:55704565	chr14:55499278~55580110:-
BRCA	cis	rs11009175	0.725	rs10827173	ENSG00000273038.2	RP11-479G22.8	-6.63	5.29e-11	1.04e-08	-0.33	-0.2	Depression (quantitative trait);	chr10:33039851	chr10:32887255~32889311:-
BRCA	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	6.63	5.3e-11	1.04e-08	0.24	0.2	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
BRCA	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-6.63	5.3e-11	1.04e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.63	5.3e-11	1.04e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
BRCA	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-6.63	5.31e-11	1.05e-08	-0.2	-0.2	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
BRCA	cis	rs17253792	0.822	rs74051609	ENSG00000186615.9	KTN1-AS1	-6.63	5.32e-11	1.05e-08	-0.36	-0.2	Putamen volume;	chr14:55704414	chr14:55499278~55580110:-
BRCA	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-6.63	5.32e-11	1.05e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
BRCA	cis	rs9876781	0.933	rs6442124	ENSG00000229759.1	MRPS18AP1	6.63	5.33e-11	1.05e-08	0.23	0.2	Longevity;	chr3:48463903	chr3:48256350~48256938:-
BRCA	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	6.63	5.34e-11	1.05e-08	0.23	0.2	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
BRCA	cis	rs847577	0.609	rs6465658	ENSG00000272950.1	RP11-307C18.1	6.63	5.35e-11	1.05e-08	0.26	0.2	Breast cancer;	chr7:98187326	chr7:98322853~98323430:+
BRCA	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	6.63	5.36e-11	1.06e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.555	rs223403	ENSG00000251288.2	RP11-10L12.2	-6.63	5.36e-11	1.06e-08	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.555	rs223402	ENSG00000251288.2	RP11-10L12.2	-6.63	5.36e-11	1.06e-08	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.63	5.36e-11	1.06e-08	0.3	0.2	Depression;	chr6:28086929	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000273024.4	INTS4P2	-6.63	5.37e-11	1.06e-08	-0.26	-0.2	Aortic root size;	chr7:66275908	chr7:65647864~65715661:+
BRCA	cis	rs10515750	0.5	rs7728460	ENSG00000251405.2	CTB-109A12.1	6.63	5.37e-11	1.06e-08	0.31	0.2	Lung function (FEV1/FVC);	chr5:157286607	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000224316.1	RP11-479O9.2	-6.63	5.38e-11	1.06e-08	-0.23	-0.2	Aortic root size;	chr7:66622032	chr7:65773620~65802067:+
BRCA	cis	rs4722166	0.598	rs4722180	ENSG00000179428.2	AC073072.5	-6.63	5.38e-11	1.06e-08	-0.21	-0.2	Lung cancer;	chr7:22765453	chr7:22725395~22727620:-
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000261582.1	RP4-614O4.11	-6.63	5.38e-11	1.06e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35267885~35280043:-
BRCA	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	6.63	5.39e-11	1.06e-08	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
BRCA	cis	rs78456975	1	rs13416881	ENSG00000231482.2	AC141930.2	-6.63	5.39e-11	1.06e-08	-0.3	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1551036	chr2:1572554~1580311:-
BRCA	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-6.63	5.4e-11	1.06e-08	-0.26	-0.2	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-6.63	5.41e-11	1.07e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
BRCA	cis	rs3781264	0.677	rs7100870	ENSG00000273450.1	RP11-76P2.4	6.63	5.41e-11	1.07e-08	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94363069	chr10:94314907~94315327:-
BRCA	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	6.63	5.42e-11	1.07e-08	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.896	rs2526877	ENSG00000269927.1	RP6-91H8.3	-6.63	5.44e-11	1.07e-08	-0.25	-0.2	Schizophrenia;	chr14:70966605	chr14:71141125~71143253:-
BRCA	cis	rs7428	0.545	rs17026212	ENSG00000246575.2	AC093162.5	6.63	5.44e-11	1.07e-08	0.21	0.2	Ear protrusion;	chr2:85324573	chr2:85315041~85316529:+
BRCA	cis	rs8016982	0.674	rs6574631	ENSG00000258999.1	RP11-114N19.3	6.63	5.44e-11	1.07e-08	0.25	0.2	Schizophrenia;	chr14:81209428	chr14:81107033~81170414:-
BRCA	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-6.63	5.45e-11	1.07e-08	-0.22	-0.2	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	6.63	5.45e-11	1.07e-08	0.24	0.2	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
BRCA	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-6.63	5.45e-11	1.07e-08	-0.24	-0.2	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
BRCA	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	6.63	5.46e-11	1.08e-08	0.2	0.2	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
BRCA	cis	rs9876781	1	rs6794875	ENSG00000229759.1	MRPS18AP1	6.63	5.47e-11	1.08e-08	0.22	0.2	Longevity;	chr3:48414217	chr3:48256350~48256938:-
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.63	5.47e-11	1.08e-08	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
BRCA	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-6.63	5.48e-11	1.08e-08	-0.24	-0.2	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
BRCA	cis	rs17213965	0.925	rs62030569	ENSG00000260872.1	RP11-680G24.5	-6.63	5.48e-11	1.08e-08	-0.28	-0.2	Waist-hip ratio;	chr16:15786892	chr16:15018106~15020488:-
BRCA	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-6.63	5.49e-11	1.08e-08	-0.25	-0.2	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
BRCA	cis	rs9876781	1	rs2362452	ENSG00000229759.1	MRPS18AP1	-6.63	5.5e-11	1.08e-08	-0.22	-0.2	Longevity;	chr3:48376724	chr3:48256350~48256938:-
BRCA	cis	rs7911264	0.967	rs2497318	ENSG00000236493.2	EIF2S2P3	-6.63	5.5e-11	1.08e-08	-0.27	-0.2	Inflammatory bowel disease;	chr10:92672243	chr10:92668745~92669743:-
BRCA	cis	rs867371	0.929	rs1501371	ENSG00000259429.4	UBE2Q2P2	-6.63	5.51e-11	1.08e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82355142~82420075:+
BRCA	cis	rs17253792	0.822	rs78323463	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55578733	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs111467375	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55579441	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs79483151	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55582133	chr14:55499278~55580110:-
BRCA	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-6.63	5.51e-11	1.09e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
BRCA	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179263	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179488	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179887	chr20:35201747~35203288:-
BRCA	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	6.63	5.52e-11	1.09e-08	0.21	0.2	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
BRCA	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-6.63	5.52e-11	1.09e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs4007289	ENSG00000271335.4	RP11-324I22.4	6.63	5.53e-11	1.09e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35314552~35336401:-
BRCA	cis	rs467650	0.782	rs56264044	ENSG00000248489.1	CTD-2007H13.3	6.63	5.55e-11	1.09e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98929171~98995013:+
BRCA	cis	rs681343	0.746	rs633372	ENSG00000232871.7	SEC1P	6.63	5.55e-11	1.09e-08	0.22	0.2	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48705969	chr19:48638071~48682245:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000224316.1	RP11-479O9.2	-6.63	5.55e-11	1.09e-08	-0.2	-0.2	Aortic root size;	chr7:66180374	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000224316.1	RP11-479O9.2	-6.63	5.55e-11	1.09e-08	-0.2	-0.2	Aortic root size;	chr7:66180412	chr7:65773620~65802067:+
BRCA	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-6.63	5.56e-11	1.09e-08	-0.29	-0.2	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
BRCA	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-6.63	5.56e-11	1.09e-08	-0.29	-0.2	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
BRCA	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-6.62	5.56e-11	1.09e-08	-0.2	-0.2	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
BRCA	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-6.62	5.57e-11	1.1e-08	-0.27	-0.2	Height;	chr20:49299758	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-6.62	5.57e-11	1.1e-08	-0.27	-0.2	Height;	chr20:49295502	chr20:49280319~49280409:+
BRCA	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	6.62	5.58e-11	1.1e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	6.62	5.58e-11	1.1e-08	0.25	0.2	Height;	chr4:55409063	chr4:55540502~55540835:-
BRCA	cis	rs957448	1	rs12680965	ENSG00000253175.1	RP11-267M23.6	6.62	5.59e-11	1.1e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94565036~94565715:+
BRCA	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-6.62	5.59e-11	1.1e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
BRCA	cis	rs34779708	0.931	rs10466072	ENSG00000271335.4	RP11-324I22.4	6.62	5.6e-11	1.1e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35314552~35336401:-
BRCA	cis	rs7809950	0.678	rs62482499	ENSG00000238832.1	snoU109	-6.62	5.6e-11	1.1e-08	-0.28	-0.2	Coronary artery disease;	chr7:107334614	chr7:107603363~107603507:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000232559.3	GS1-124K5.12	6.62	5.61e-11	1.1e-08	0.38	0.2	Diabetic kidney disease;	chr7:66632552	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	6.62	5.62e-11	1.1e-08	0.22	0.2	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
BRCA	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-6.62	5.62e-11	1.1e-08	-0.17	-0.2	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-6.62	5.62e-11	1.1e-08	-0.17	-0.2	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
BRCA	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-6.62	5.62e-11	1.1e-08	-0.3	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
BRCA	cis	rs420259	0.516	rs11643602	ENSG00000260136.4	CTD-2270L9.4	-6.62	5.62e-11	1.1e-08	-0.2	-0.2	Bipolar disorder;	chr16:23545588	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs4968019	ENSG00000260136.4	CTD-2270L9.4	-6.62	5.62e-11	1.1e-08	-0.2	-0.2	Bipolar disorder;	chr16:23546469	chr16:23452758~23457606:+
BRCA	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	6.62	5.62e-11	1.11e-08	0.28	0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
BRCA	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-6.62	5.62e-11	1.11e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
BRCA	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-6.62	5.63e-11	1.11e-08	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
BRCA	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-6.62	5.63e-11	1.11e-08	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000232559.3	GS1-124K5.12	-6.62	5.64e-11	1.11e-08	-0.38	-0.2	Diabetic kidney disease;	chr7:66139635	chr7:66554588~66576923:-
BRCA	cis	rs228614	0.509	rs223486	ENSG00000251288.2	RP11-10L12.2	-6.62	5.65e-11	1.11e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.931	rs12268745	ENSG00000271335.4	RP11-324I22.4	6.62	5.66e-11	1.11e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35314552~35336401:-
BRCA	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-6.62	5.66e-11	1.11e-08	-0.23	-0.2	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
BRCA	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-6.62	5.66e-11	1.11e-08	-0.26	-0.2	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-6.62	5.66e-11	1.11e-08	-0.26	-0.2	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
BRCA	cis	rs17253792	0.822	rs79398217	ENSG00000186615.9	KTN1-AS1	-6.62	5.66e-11	1.11e-08	-0.41	-0.2	Putamen volume;	chr14:55600632	chr14:55499278~55580110:-
BRCA	cis	rs748404	0.736	rs542036	ENSG00000249839.1	AC011330.5	6.62	5.67e-11	1.11e-08	0.25	0.2	Lung cancer;	chr15:43248941	chr15:43663654~43684339:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	6.62	5.68e-11	1.12e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
BRCA	cis	rs27524	0.734	rs27037	ENSG00000272109.1	CTD-2260A17.3	-6.62	5.68e-11	1.12e-08	-0.26	-0.2	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96804353~96806105:+
BRCA	cis	rs9876781	0.563	rs4858821	ENSG00000244380.1	RP11-24C3.2	-6.62	5.69e-11	1.12e-08	-0.26	-0.2	Longevity;	chr3:48512515	chr3:48440352~48446656:-
BRCA	cis	rs2489715	0.723	rs2801942	ENSG00000185904.10	LINC00839	-6.62	5.69e-11	1.12e-08	-0.28	-0.2	Helix rolling;	chr10:42443920	chr10:42475543~42495336:+
BRCA	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	6.62	5.69e-11	1.12e-08	0.15	0.2	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	6.62	5.7e-11	1.12e-08	0.29	0.2	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
BRCA	cis	rs4372836	1	rs34409160	ENSG00000226833.4	AC097724.3	-6.62	5.7e-11	1.12e-08	-0.25	-0.2	Body mass index;	chr2:28720999	chr2:28708953~28736205:-
BRCA	cis	rs78456975	0.739	rs11896906	ENSG00000231482.2	AC141930.2	-6.62	5.71e-11	1.12e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515778	chr2:1572554~1580311:-
BRCA	cis	rs3126085	0.935	rs12409762	ENSG00000237975.5	FLG-AS1	6.62	5.71e-11	1.12e-08	0.28	0.2	Atopic dermatitis;	chr1:152202922	chr1:152168125~152445456:+
BRCA	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-6.62	5.72e-11	1.12e-08	-0.25	-0.2	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
BRCA	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	6.62	5.72e-11	1.12e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	6.62	5.72e-11	1.12e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-6.62	5.73e-11	1.13e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	6.62	5.73e-11	1.13e-08	0.26	0.2	Height;	chr4:55387515	chr4:55363971~55395847:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000273765.1	RP11-370I10.11	6.62	5.73e-11	1.13e-08	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48360920~48361377:+
BRCA	cis	rs1440410	0.835	rs7685075	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143133546	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10155324	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143135820	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6537150	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143146716	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4337690	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143148408	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7670439	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143159114	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10015190	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143160595	chr4:142933195~143184861:-
BRCA	cis	rs516805	0.52	rs9388099	ENSG00000279114.1	RP3-425C14.5	6.62	5.75e-11	1.13e-08	0.19	0.2	Lymphocyte counts;	chr6:122566904	chr6:122471923~122484161:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000224316.1	RP11-479O9.2	-6.62	5.75e-11	1.13e-08	-0.2	-0.2	Aortic root size;	chr7:66280771	chr7:65773620~65802067:+
BRCA	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-6.62	5.77e-11	1.13e-08	-0.22	-0.2	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	6.62	5.78e-11	1.13e-08	0.24	0.2	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
BRCA	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-6.62	5.78e-11	1.13e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
BRCA	cis	rs2638953	0.924	rs10492368	ENSG00000247934.4	RP11-967K21.1	-6.62	5.78e-11	1.13e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28163298~28190738:-
BRCA	cis	rs78456975	0.527	rs11884165	ENSG00000231482.2	AC141930.2	-6.62	5.78e-11	1.14e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1557280	chr2:1572554~1580311:-
BRCA	cis	rs12594515	1	rs7172161	ENSG00000259200.1	RP11-718O11.1	-6.62	5.79e-11	1.14e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698582	chr15:45705078~45931069:+
BRCA	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.62	5.79e-11	1.14e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000273765.1	RP11-370I10.11	6.62	5.79e-11	1.14e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48360920~48361377:+
BRCA	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	6.62	5.79e-11	1.14e-08	0.26	0.2	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
BRCA	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-6.62	5.79e-11	1.14e-08	-0.19	-0.2	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
BRCA	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	6.62	5.8e-11	1.14e-08	0.23	0.2	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
BRCA	cis	rs9500256	0.515	rs12207710	ENSG00000215190.7	LINC00680	-6.62	5.81e-11	1.14e-08	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57946074~57961501:-
BRCA	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-6.62	5.81e-11	1.14e-08	-0.21	-0.2	Height;	chr20:35177782	chr20:35201747~35203288:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	6.62	5.83e-11	1.14e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	6.62	5.83e-11	1.14e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
BRCA	cis	rs12594515	1	rs8027000	ENSG00000259200.1	RP11-718O11.1	-6.62	5.83e-11	1.14e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695597	chr15:45705078~45931069:+
BRCA	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	6.62	5.84e-11	1.15e-08	0.26	0.2	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
BRCA	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-6.62	5.85e-11	1.15e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
BRCA	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-6.62	5.85e-11	1.15e-08	-0.28	-0.2	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
BRCA	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	6.62	5.85e-11	1.15e-08	0.23	0.2	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
BRCA	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-6.62	5.85e-11	1.15e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	6.62	5.86e-11	1.15e-08	0.21	0.2	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
BRCA	cis	rs228614	0.51	rs223443	ENSG00000251288.2	RP11-10L12.2	-6.62	5.86e-11	1.15e-08	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.62	5.87e-11	1.15e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
BRCA	cis	rs34779708	0.966	rs11010129	ENSG00000271335.4	RP11-324I22.4	6.62	5.88e-11	1.15e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35314552~35336401:-
BRCA	cis	rs2348418	0.639	rs41505151	ENSG00000247934.4	RP11-967K21.1	6.62	5.88e-11	1.15e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28112651	chr12:28163298~28190738:-
BRCA	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.62	5.88e-11	1.15e-08	0.24	0.2	Height;	chr2:46624894	chr2:46668870~46670778:+
BRCA	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-6.62	5.89e-11	1.16e-08	-0.28	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66363676	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66374173	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66376216	chr7:65773620~65802067:+
BRCA	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-6.62	5.9e-11	1.16e-08	-0.25	-0.2	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
BRCA	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-6.62	5.9e-11	1.16e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
BRCA	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	6.62	5.9e-11	1.16e-08	0.2	0.2	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000254174.1	IGHV1-12	-6.62	5.91e-11	1.16e-08	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106683485	chr14:106122420~106122709:-
BRCA	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.62	5.92e-11	1.16e-08	0.29	0.2	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs937495	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66314811	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66334917	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66340274	chr7:65773620~65802067:+
BRCA	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.62	5.92e-11	1.16e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
BRCA	cis	rs11742741	0.676	rs34323137	ENSG00000248874.4	C5orf17	-6.61	5.93e-11	1.16e-08	-0.25	-0.2	Educational attainment;	chr5:24196120	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.676	rs34415514	ENSG00000248874.4	C5orf17	-6.61	5.93e-11	1.16e-08	-0.25	-0.2	Educational attainment;	chr5:24196173	chr5:23951348~24178263:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000165178.9	NCF1C	-6.61	5.93e-11	1.16e-08	-0.16	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75156639~75172044:-
BRCA	cis	rs4356203	0.519	rs214084	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.519	rs214083	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.519	rs214082	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17074654~17074744:-
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-6.61	5.94e-11	1.16e-08	-0.27	-0.2	Gout;	chr7:66654674	chr7:66880708~66882981:+
BRCA	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	6.61	5.95e-11	1.17e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
BRCA	cis	rs3781264	0.557	rs7100430	ENSG00000273450.1	RP11-76P2.4	6.61	5.95e-11	1.17e-08	0.27	0.2	Esophageal cancer and gastric cancer;	chr10:94362786	chr10:94314907~94315327:-
BRCA	cis	rs12594515	1	rs8038058	ENSG00000259200.1	RP11-718O11.1	-6.61	5.96e-11	1.17e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698074	chr15:45705078~45931069:+
BRCA	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	6.61	5.97e-11	1.17e-08	0.2	0.2	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	6.61	5.97e-11	1.17e-08	0.24	0.2	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
BRCA	cis	rs11024102	0.962	rs12575487	ENSG00000184669.7	OR7E14P	-6.61	5.99e-11	1.17e-08	-0.31	-0.2	Glaucoma (primary angle closure);	chr11:16997770	chr11:17013998~17053024:+
BRCA	cis	rs3794924	1	rs7236589	ENSG00000266521.1	RP11-650P15.1	6.61	6e-11	1.18e-08	0.36	0.2	Survival in colon cancer;	chr18:31475207	chr18:31496645~31497195:-
BRCA	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	6.61	6e-11	1.18e-08	0.31	0.2	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
BRCA	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.61	6.01e-11	1.18e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
BRCA	cis	rs12594515	1	rs7173144	ENSG00000259200.1	RP11-718O11.1	-6.61	6.02e-11	1.18e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698998	chr15:45705078~45931069:+
BRCA	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	6.61	6.02e-11	1.18e-08	0.2	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-6.61	6.02e-11	1.18e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
BRCA	cis	rs5015933	0.815	rs13291322	ENSG00000232630.1	PRPS1P2	-6.61	6.03e-11	1.18e-08	-0.18	-0.2	Body mass index;	chr9:125348076	chr9:125150653~125151589:+
BRCA	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	6.61	6.04e-11	1.18e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
BRCA	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	6.61	6.05e-11	1.18e-08	0.23	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
BRCA	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	6.61	6.05e-11	1.19e-08	0.21	0.2	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
BRCA	cis	rs754466	0.651	rs10762767	ENSG00000204049.1	RP11-126H7.4	6.61	6.07e-11	1.19e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77885312	chr10:77866875~77869610:+
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000273765.1	RP11-370I10.11	6.61	6.07e-11	1.19e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48360920~48361377:+
BRCA	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	6.61	6.07e-11	1.19e-08	0.17	0.2	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
BRCA	cis	rs9876781	1	rs13076076	ENSG00000229759.1	MRPS18AP1	6.61	6.07e-11	1.19e-08	0.22	0.2	Longevity;	chr3:48437629	chr3:48256350~48256938:-
BRCA	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-6.61	6.08e-11	1.19e-08	-0.21	-0.2	Height;	chr20:35176829	chr20:35201747~35203288:-
BRCA	cis	rs7178375	1	rs1474382	ENSG00000215302.7	CTD-3092A11.1	-6.61	6.08e-11	1.19e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30922446	chr15:30470779~30507623:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000224316.1	RP11-479O9.2	6.61	6.09e-11	1.19e-08	0.23	0.2	Aortic root size;	chr7:66387213	chr7:65773620~65802067:+
BRCA	cis	rs2060793	0.87	rs1868997	ENSG00000251991.1	RNU7-49P	6.61	6.1e-11	1.19e-08	0.22	0.2	Vitamin D levels;	chr11:14872674	chr11:14478892~14478953:+
BRCA	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	6.61	6.1e-11	1.19e-08	0.21	0.2	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
BRCA	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-6.61	6.1e-11	1.19e-08	-0.26	-0.2	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-6.61	6.1e-11	1.19e-08	-0.26	-0.2	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	6.61	6.11e-11	1.2e-08	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	6.61	6.12e-11	1.2e-08	0.22	0.2	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
BRCA	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	6.61	6.13e-11	1.2e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
BRCA	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
BRCA	cis	rs1014246	0.848	rs10787714	ENSG00000232767.1	RP11-498B4.5	-6.61	6.14e-11	1.2e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116699873	chr10:116670103~116672739:+
BRCA	cis	rs1014246	0.848	rs10787715	ENSG00000232767.1	RP11-498B4.5	-6.61	6.14e-11	1.2e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116700060	chr10:116670103~116672739:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000224316.1	RP11-479O9.2	-6.61	6.15e-11	1.2e-08	-0.2	-0.2	Aortic root size;	chr7:66316668	chr7:65773620~65802067:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-6.61	6.16e-11	1.21e-08	-0.27	-0.2	Gout;	chr7:66661502	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs10137885	ENSG00000186615.9	KTN1-AS1	-6.61	6.17e-11	1.21e-08	-0.36	-0.2	Putamen volume;	chr14:55706872	chr14:55499278~55580110:-
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000273765.1	RP11-370I10.11	6.61	6.17e-11	1.21e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48360920~48361377:+
BRCA	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-6.61	6.17e-11	1.21e-08	-0.21	-0.2	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	6.61	6.18e-11	1.21e-08	0.25	0.2	Height;	chr4:55407965	chr4:55540502~55540835:-
BRCA	cis	rs7746199	0.736	rs13193542	ENSG00000220721.1	OR1F12	6.61	6.18e-11	1.21e-08	0.48	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs13193480	ENSG00000220721.1	OR1F12	6.61	6.18e-11	1.21e-08	0.48	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28073316~28074233:+
BRCA	cis	rs3814244	0.528	rs2906859	ENSG00000236946.2	HNRNPA1P70	-6.61	6.18e-11	1.21e-08	-0.16	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:68035767~68036853:+
BRCA	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-6.61	6.18e-11	1.21e-08	-0.24	-0.2	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
BRCA	cis	rs2638953	0.924	rs11049409	ENSG00000247934.4	RP11-967K21.1	-6.61	6.18e-11	1.21e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28163298~28190738:-
BRCA	cis	rs78456975	1	rs10192959	ENSG00000231482.2	AC141930.2	-6.61	6.19e-11	1.21e-08	-0.3	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549621	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	6.61	6.19e-11	1.21e-08	0.21	0.2	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
BRCA	cis	rs4356203	0.543	rs214081	ENSG00000272034.1	SNORD14A	-6.61	6.2e-11	1.21e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17074654~17074744:-
BRCA	cis	rs3758911	0.788	rs10890676	ENSG00000255353.1	RP11-382M14.1	-6.61	6.2e-11	1.21e-08	-0.27	-0.2	Coronary artery disease;	chr11:107254631	chr11:107176286~107177530:+
BRCA	cis	rs34779708	0.931	rs11010130	ENSG00000271335.4	RP11-324I22.4	6.61	6.2e-11	1.21e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs11010131	ENSG00000271335.4	RP11-324I22.4	6.61	6.2e-11	1.21e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-6.61	6.21e-11	1.21e-08	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
BRCA	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.61	6.21e-11	1.22e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	6.61	6.22e-11	1.22e-08	0.25	0.2	Height;	chr4:55452921	chr4:55540502~55540835:-
BRCA	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	6.61	6.22e-11	1.22e-08	0.22	0.2	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	6.61	6.22e-11	1.22e-08	0.22	0.2	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
BRCA	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	6.61	6.22e-11	1.22e-08	0.23	0.2	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
BRCA	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-6.61	6.22e-11	1.22e-08	-0.24	-0.2	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000253175.1	RP11-267M23.6	6.61	6.22e-11	1.22e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94565036~94565715:+
BRCA	cis	rs2998286	0.862	rs1339704	ENSG00000254635.4	WAC-AS1	-6.61	6.22e-11	1.22e-08	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28522652~28532743:-
BRCA	cis	rs12594515	0.967	rs67854274	ENSG00000259200.1	RP11-718O11.1	-6.61	6.23e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698320	chr15:45705078~45931069:+
BRCA	cis	rs2492286	0.597	rs2712384	ENSG00000242551.2	POU5F1P6	-6.61	6.25e-11	1.22e-08	-0.29	-0.2	Eosinophil counts;	chr3:128615429	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	6.61	6.26e-11	1.22e-08	0.23	0.2	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000224316.1	RP11-479O9.2	6.61	6.26e-11	1.22e-08	0.23	0.2	Aortic root size;	chr7:66339619	chr7:65773620~65802067:+
BRCA	cis	rs12594515	1	rs6493176	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697828	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs8039088	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697980	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs8038320	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698069	chr15:45705078~45931069:+
BRCA	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-6.61	6.27e-11	1.22e-08	-0.24	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
BRCA	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-6.61	6.27e-11	1.23e-08	-0.23	-0.2	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
BRCA	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	6.61	6.28e-11	1.23e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
BRCA	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	6.61	6.29e-11	1.23e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
BRCA	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	6.61	6.29e-11	1.23e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
BRCA	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	6.61	6.29e-11	1.23e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
BRCA	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	6.61	6.31e-11	1.23e-08	0.2	0.2	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	6.61	6.31e-11	1.23e-08	0.2	0.2	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000273765.1	RP11-370I10.11	6.61	6.31e-11	1.23e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48360920~48361377:+
BRCA	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-6.61	6.31e-11	1.23e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
BRCA	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
BRCA	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-6.61	6.32e-11	1.24e-08	-0.24	-0.2	Height;	chr20:49316942	chr20:49280319~49280409:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-6.61	6.32e-11	1.24e-08	-0.27	-0.2	Gout;	chr7:66654674	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.815	rs10986716	ENSG00000232630.1	PRPS1P2	-6.6	6.33e-11	1.24e-08	-0.18	-0.2	Body mass index;	chr9:125345606	chr9:125150653~125151589:+
BRCA	cis	rs2060793	0.769	rs7125781	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14856401	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.87	rs6486205	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14859710	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.87	rs7116978	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14860225	chr11:14478892~14478953:+
BRCA	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-6.6	6.33e-11	1.24e-08	-0.28	-0.2	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
BRCA	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	6.6	6.34e-11	1.24e-08	0.21	0.2	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
BRCA	cis	rs1440410	0.835	rs13139558	ENSG00000250326.1	RP11-284M14.1	-6.6	6.34e-11	1.24e-08	-0.22	-0.2	Ischemic stroke;	chr4:143149410	chr4:142933195~143184861:-
BRCA	cis	rs1124769	0.748	rs1318765	ENSG00000259378.1	DCAF13P3	6.6	6.36e-11	1.24e-08	0.29	0.2	Cognitive performance;	chr15:51029750	chr15:50944663~50945996:+
BRCA	cis	rs4237845	0.742	rs3751330	ENSG00000257159.1	RP11-58A17.3	6.6	6.36e-11	1.24e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57896443	chr12:57967058~57968399:+
BRCA	cis	rs6583826	0.758	rs7076966	ENSG00000236493.2	EIF2S2P3	6.6	6.36e-11	1.24e-08	0.26	0.2	Type 2 diabetes;	chr10:92565754	chr10:92668745~92669743:-
BRCA	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-6.6	6.36e-11	1.24e-08	-0.3	-0.2	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
BRCA	cis	rs17508449	0.821	rs1419231	ENSG00000232450.1	RP4-730K3.3	-6.6	6.38e-11	1.25e-08	-0.37	-0.2	Leprosy;	chr1:113583596	chr1:113698884~113699631:-
BRCA	cis	rs10181042	0.565	rs3108630	ENSG00000271889.1	RP11-493E12.1	-6.6	6.38e-11	1.25e-08	-0.24	-0.2	Crohn's disease;	chr2:61041025	chr2:61151433~61162105:-
BRCA	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	6.6	6.4e-11	1.25e-08	0.19	0.2	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
BRCA	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	6.6	6.4e-11	1.25e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
BRCA	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-6.6	6.4e-11	1.25e-08	-0.18	-0.2	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-6.6	6.4e-11	1.25e-08	-0.21	-0.2	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
BRCA	cis	rs10022260	1	rs10022260	ENSG00000251022.5	THAP9-AS1	-6.6	6.4e-11	1.25e-08	-0.26	-0.2	Adult asthma;	chr4:82872768	chr4:82893009~82900960:-
BRCA	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	6.6	6.42e-11	1.25e-08	0.3	0.2	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
BRCA	cis	rs875971	1	rs709595	ENSG00000224316.1	RP11-479O9.2	6.6	6.42e-11	1.25e-08	0.2	0.2	Aortic root size;	chr7:66352346	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs811880	ENSG00000224316.1	RP11-479O9.2	6.6	6.42e-11	1.25e-08	0.2	0.2	Aortic root size;	chr7:66353659	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000229886.1	RP5-1132H15.3	6.6	6.42e-11	1.25e-08	0.37	0.2	Diabetic kidney disease;	chr7:66063241	chr7:66025126~66031544:-
BRCA	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	6.6	6.42e-11	1.25e-08	0.21	0.2	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000224316.1	RP11-479O9.2	-6.6	6.43e-11	1.25e-08	-0.2	-0.2	Aortic root size;	chr7:66150410	chr7:65773620~65802067:+
BRCA	cis	rs12594515	1	rs58368732	ENSG00000259200.1	RP11-718O11.1	-6.6	6.43e-11	1.26e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698333	chr15:45705078~45931069:+
BRCA	cis	rs34779708	0.931	rs11010077	ENSG00000271335.4	RP11-324I22.4	-6.6	6.44e-11	1.26e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-6.6	6.45e-11	1.26e-08	-0.28	-0.2	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
BRCA	cis	rs13129838	1	rs13129838	ENSG00000250334.4	LINC00989	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Myopia;	chr4:79587634	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs12643976	ENSG00000250334.4	LINC00989	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Refractive error;	chr4:79589616	chr4:79492416~79576460:+
BRCA	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
BRCA	cis	rs11742741	0.702	rs3924719	ENSG00000248874.4	C5orf17	-6.6	6.46e-11	1.26e-08	-0.25	-0.2	Educational attainment;	chr5:24206968	chr5:23951348~24178263:+
BRCA	cis	rs17253792	0.822	rs10083493	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55578693	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.732	rs10146604	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55579052	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10149408	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55579357	chr14:55499278~55580110:-
BRCA	cis	rs2337406	1	rs17113276	ENSG00000211972.2	IGHV3-66	-6.6	6.46e-11	1.26e-08	-0.18	-0.2	Alzheimer's disease (late onset);	chr14:106683485	chr14:106675017~106675544:-
BRCA	cis	rs34779708	0.966	rs998658	ENSG00000271335.4	RP11-324I22.4	6.6	6.46e-11	1.26e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35314552~35336401:-
BRCA	cis	rs12594515	1	rs6493175	ENSG00000259200.1	RP11-718O11.1	-6.6	6.47e-11	1.26e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697700	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000236529.1	RP13-254B10.1	6.6	6.47e-11	1.26e-08	0.25	0.2	Aortic root size;	chr7:66255529	chr7:65840212~65840596:+
BRCA	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
BRCA	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
BRCA	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-6.6	6.47e-11	1.26e-08	-0.27	-0.2	Height;	chr20:49272073	chr20:49280319~49280409:+
BRCA	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	6.6	6.48e-11	1.26e-08	0.22	0.2	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	6.6	6.48e-11	1.26e-08	0.22	0.2	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
BRCA	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	6.6	6.48e-11	1.26e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
BRCA	cis	rs9880211	0.644	rs6799320	ENSG00000273486.1	RP11-731C17.2	6.6	6.49e-11	1.27e-08	0.26	0.2	Height;Body mass index;	chr3:136083597	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.613	rs9653930	ENSG00000273486.1	RP11-731C17.2	6.6	6.49e-11	1.27e-08	0.26	0.2	Height;Body mass index;	chr3:136091472	chr3:136837338~136839021:-
BRCA	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-6.6	6.5e-11	1.27e-08	-0.27	-0.2	Gout;	chr7:66661502	chr7:66848496~66858136:+
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55454900	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55454938	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55455102	chr4:55540502~55540835:-
BRCA	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	6.6	6.5e-11	1.27e-08	0.19	0.2	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
BRCA	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	6.6	6.51e-11	1.27e-08	0.22	0.2	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
BRCA	cis	rs7809950	0.731	rs2712196	ENSG00000238832.1	snoU109	-6.6	6.51e-11	1.27e-08	-0.29	-0.2	Coronary artery disease;	chr7:107488352	chr7:107603363~107603507:+
BRCA	cis	rs4372836	1	rs4666118	ENSG00000226833.4	AC097724.3	6.6	6.52e-11	1.27e-08	0.24	0.2	Body mass index;	chr2:28728832	chr2:28708953~28736205:-
BRCA	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	6.6	6.54e-11	1.27e-08	0.25	0.2	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
BRCA	cis	rs5015933	0.815	rs10124754	ENSG00000232630.1	PRPS1P2	-6.6	6.54e-11	1.28e-08	-0.18	-0.2	Body mass index;	chr9:125327479	chr9:125150653~125151589:+
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000253175.1	RP11-267M23.6	6.6	6.54e-11	1.28e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94565036~94565715:+
BRCA	cis	rs957448	1	rs1048029	ENSG00000253175.1	RP11-267M23.6	6.6	6.54e-11	1.28e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94565036~94565715:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000273024.4	INTS4P2	-6.6	6.55e-11	1.28e-08	-0.25	-0.2	Aortic root size;	chr7:66215323	chr7:65647864~65715661:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	6.6	6.56e-11	1.28e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
BRCA	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-6.6	6.57e-11	1.28e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
BRCA	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-6.6	6.58e-11	1.28e-08	-0.3	-0.2	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
BRCA	cis	rs754466	0.724	rs11002318	ENSG00000204049.1	RP11-126H7.4	6.6	6.58e-11	1.28e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77874049	chr10:77866875~77869610:+
BRCA	cis	rs860818	1	rs858232	ENSG00000226816.2	AC005082.12	6.6	6.58e-11	1.28e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23202100	chr7:23206013~23208045:+
BRCA	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-6.6	6.58e-11	1.28e-08	-0.23	-0.2	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
BRCA	cis	rs420259	0.516	rs2097662	ENSG00000260136.4	CTD-2270L9.4	-6.6	6.58e-11	1.28e-08	-0.2	-0.2	Bipolar disorder;	chr16:23512024	chr16:23452758~23457606:+
BRCA	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	6.6	6.58e-11	1.28e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
BRCA	cis	rs420259	0.516	rs1135045	ENSG00000260136.4	CTD-2270L9.4	-6.6	6.58e-11	1.28e-08	-0.2	-0.2	Bipolar disorder;	chr16:23478390	chr16:23452758~23457606:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000273024.4	INTS4P2	-6.6	6.59e-11	1.28e-08	-0.25	-0.2	Aortic root size;	chr7:66221293	chr7:65647864~65715661:+
BRCA	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	6.6	6.6e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	6.6	6.6e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000213640.3	EEF1DP4	-6.6	6.61e-11	1.29e-08	-0.25	-0.2	Calcium levels;	chr7:65800652	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	6.6	6.62e-11	1.29e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	6.6	6.62e-11	1.29e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
BRCA	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-6.6	6.63e-11	1.29e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
BRCA	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	6.6	6.64e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
BRCA	cis	rs4218	0.543	rs11852461	ENSG00000277144.1	RP11-59H7.4	-6.6	6.64e-11	1.29e-08	-0.24	-0.2	Social communication problems;	chr15:59021728	chr15:59115547~59116089:-
BRCA	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	6.6	6.66e-11	1.3e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000224316.1	RP11-479O9.2	-6.6	6.67e-11	1.3e-08	-0.2	-0.2	Aortic root size;	chr7:66119713	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.554	rs223467	ENSG00000251288.2	RP11-10L12.2	-6.6	6.68e-11	1.3e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-6.6	6.69e-11	1.3e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
BRCA	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-6.6	6.71e-11	1.31e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000273024.4	INTS4P2	-6.6	6.71e-11	1.31e-08	-0.25	-0.2	Aortic root size;	chr7:66325577	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000273024.4	INTS4P2	-6.6	6.71e-11	1.31e-08	-0.25	-0.2	Aortic root size;	chr7:66339619	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	6.6	6.71e-11	1.31e-08	0.18	0.2	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
BRCA	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	6.6	6.71e-11	1.31e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-6.6	6.72e-11	1.31e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
BRCA	cis	rs7976269	0.609	rs10843306	ENSG00000257176.2	RP11-996F15.2	-6.6	6.73e-11	1.31e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29073417	chr12:29280418~29317848:-
BRCA	cis	rs16863064	0.866	rs9855318	ENSG00000279891.1	FLJ42393	6.6	6.74e-11	1.31e-08	0.28	0.2	Schizophrenia;	chr3:188169593	chr3:188178543~188180812:+
BRCA	cis	rs838147	0.505	rs1688264	ENSG00000232871.7	SEC1P	6.6	6.75e-11	1.31e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706303	chr19:48638071~48682245:+
BRCA	cis	rs838147	0.507	rs1704773	ENSG00000232871.7	SEC1P	6.6	6.75e-11	1.31e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706309	chr19:48638071~48682245:+
BRCA	cis	rs2998286	0.822	rs2095901	ENSG00000254635.4	WAC-AS1	-6.59	6.75e-11	1.31e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.862	rs2993990	ENSG00000254635.4	WAC-AS1	-6.59	6.75e-11	1.31e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28522652~28532743:-
BRCA	cis	rs2638953	0.85	rs11049402	ENSG00000247934.4	RP11-967K21.1	-6.59	6.76e-11	1.32e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049405	ENSG00000247934.4	RP11-967K21.1	-6.59	6.76e-11	1.32e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	6.59	6.77e-11	1.32e-08	0.25	0.2	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
BRCA	cis	rs2060793	0.87	rs10732460	ENSG00000251991.1	RNU7-49P	6.59	6.77e-11	1.32e-08	0.22	0.2	Vitamin D levels;	chr11:14854025	chr11:14478892~14478953:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000229886.1	RP5-1132H15.3	6.59	6.79e-11	1.32e-08	0.36	0.2	Gout;	chr7:66645053	chr7:66025126~66031544:-
BRCA	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	6.59	6.79e-11	1.32e-08	0.21	0.2	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
BRCA	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-6.59	6.79e-11	1.32e-08	-0.26	-0.2	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
BRCA	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	6.59	6.8e-11	1.32e-08	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-6.59	6.8e-11	1.32e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
BRCA	cis	rs9816784	0.901	rs56253832	ENSG00000231464.1	AC024937.4	6.59	6.8e-11	1.32e-08	0.25	0.2	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195996738~195998233:+
BRCA	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-6.59	6.8e-11	1.32e-08	-0.19	-0.2	Asthma;	chr2:102351615	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-6.59	6.81e-11	1.32e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.815	rs4991998	ENSG00000232630.1	PRPS1P2	-6.59	6.81e-11	1.32e-08	-0.18	-0.2	Body mass index;	chr9:125314702	chr9:125150653~125151589:+
BRCA	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	6.59	6.83e-11	1.33e-08	0.27	0.2	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000224316.1	RP11-479O9.2	-6.59	6.83e-11	1.33e-08	-0.2	-0.2	Aortic root size;	chr7:66143495	chr7:65773620~65802067:+
BRCA	cis	rs11742741	0.64	rs62347897	ENSG00000248874.4	C5orf17	-6.59	6.83e-11	1.33e-08	-0.25	-0.2	Educational attainment;	chr5:24214756	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	6.59	6.83e-11	1.33e-08	0.36	0.2	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
BRCA	cis	rs5015933	0.815	rs937482	ENSG00000232630.1	PRPS1P2	-6.59	6.83e-11	1.33e-08	-0.18	-0.2	Body mass index;	chr9:125354538	chr9:125150653~125151589:+
BRCA	cis	rs11742741	0.714	rs1428203	ENSG00000248874.4	C5orf17	-6.59	6.84e-11	1.33e-08	-0.25	-0.2	Educational attainment;	chr5:24164504	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	6.59	6.84e-11	1.33e-08	0.24	0.2	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.609	rs10771474	ENSG00000257176.2	RP11-996F15.2	6.59	6.84e-11	1.33e-08	0.24	0.2	Male-pattern baldness;	chr12:29068776	chr12:29280418~29317848:-
BRCA	cis	rs9876781	1	rs2290822	ENSG00000229759.1	MRPS18AP1	6.59	6.85e-11	1.33e-08	0.22	0.2	Longevity;	chr3:48431794	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	6.59	6.86e-11	1.33e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
BRCA	cis	rs754466	0.651	rs11818687	ENSG00000204049.1	RP11-126H7.4	6.59	6.87e-11	1.34e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77877951	chr10:77866875~77869610:+
BRCA	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-6.59	6.87e-11	1.34e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
BRCA	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	6.59	6.87e-11	1.34e-08	0.18	0.2	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-6.59	6.88e-11	1.34e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-6.59	6.88e-11	1.34e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-6.59	6.88e-11	1.34e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-6.59	6.88e-11	1.34e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
BRCA	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	6.59	6.89e-11	1.34e-08	0.24	0.2	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
BRCA	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-6.59	6.89e-11	1.34e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
BRCA	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-6.59	6.89e-11	1.34e-08	-0.2	-0.2	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	6.59	6.9e-11	1.34e-08	0.21	0.2	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-6.59	6.91e-11	1.34e-08	-0.23	-0.2	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
BRCA	cis	rs17253792	0.822	rs112238223	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55589426	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs80174205	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55591976	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78261053	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595066	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs8008528	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595334	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs8009239	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595772	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79291233	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55598584	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.818	rs78393484	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55599084	chr14:55499278~55580110:-
BRCA	cis	rs853679	0.556	rs34706883	ENSG00000220721.1	OR1F12	6.59	6.91e-11	1.34e-08	0.47	0.2	Depression;	chr6:27837477	chr6:28073316~28074233:+
BRCA	cis	rs847577	0.588	rs6946915	ENSG00000272950.1	RP11-307C18.1	6.59	6.91e-11	1.34e-08	0.26	0.2	Breast cancer;	chr7:98082028	chr7:98322853~98323430:+
BRCA	cis	rs12594515	1	rs11070464	ENSG00000259200.1	RP11-718O11.1	-6.59	6.91e-11	1.34e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692578	chr15:45705078~45931069:+
BRCA	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-6.59	6.92e-11	1.34e-08	-0.22	-0.2	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-6.59	6.92e-11	1.34e-08	-0.25	-0.2	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000228409.4	CCT6P1	6.59	6.93e-11	1.35e-08	0.28	0.2	Diabetic kidney disease;	chr7:65924813	chr7:65751142~65763354:+
BRCA	cis	rs9307551	0.744	rs968176	ENSG00000250334.4	LINC00989	-6.59	6.93e-11	1.35e-08	-0.27	-0.2	Refractive error;	chr4:79585080	chr4:79492416~79576460:+
BRCA	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	6.59	6.93e-11	1.35e-08	0.25	0.2	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
BRCA	cis	rs4366055	1	rs4366055	ENSG00000253175.1	RP11-267M23.6	6.59	6.94e-11	1.35e-08	0.24	0.2	Body mass index;	chr8:94495100	chr8:94565036~94565715:+
BRCA	cis	rs17253792	0.822	rs78826571	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55582188	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs74823888	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55583082	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75016910	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55583748	chr14:55499278~55580110:-
BRCA	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-6.59	6.94e-11	1.35e-08	-0.29	-0.2	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000224316.1	RP11-479O9.2	6.59	6.95e-11	1.35e-08	0.2	0.2	Aortic root size;	chr7:66349822	chr7:65773620~65802067:+
BRCA	cis	rs7432375	0.609	rs835637	ENSG00000239213.4	NCK1-AS1	6.59	6.96e-11	1.35e-08	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136954315	chr3:136841726~136862054:-
BRCA	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-6.59	6.96e-11	1.35e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
BRCA	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-6.59	6.97e-11	1.35e-08	-0.26	-0.2	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
BRCA	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	6.59	6.97e-11	1.35e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
BRCA	cis	rs2638953	0.814	rs11049413	ENSG00000247934.4	RP11-967K21.1	-6.59	6.97e-11	1.36e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs11049414	ENSG00000247934.4	RP11-967K21.1	-6.59	6.97e-11	1.36e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28163298~28190738:-
BRCA	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.59	6.98e-11	1.36e-08	0.18	0.2	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	6.59	6.98e-11	1.36e-08	0.26	0.2	Height;	chr4:55483718	chr4:55363971~55395847:-
BRCA	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-6.59	6.98e-11	1.36e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
BRCA	cis	rs9307551	0.857	rs2218213	ENSG00000250334.4	LINC00989	-6.59	6.99e-11	1.36e-08	-0.27	-0.2	Refractive error;	chr4:79614890	chr4:79492416~79576460:+
BRCA	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.59	7e-11	1.36e-08	0.3	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-6.59	7.01e-11	1.36e-08	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-6.59	7.02e-11	1.36e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-6.59	7.03e-11	1.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
BRCA	cis	rs9638182	0.725	rs17145738	ENSG00000274080.1	CTA-315H11.2	6.59	7.04e-11	1.37e-08	0.39	0.2	Triglycerides;	chr7:73568544	chr7:73609262~73611502:-
BRCA	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	6.59	7.04e-11	1.37e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	6.59	7.04e-11	1.37e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	6.59	7.05e-11	1.37e-08	0.26	0.2	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	6.59	7.05e-11	1.37e-08	0.26	0.2	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
BRCA	cis	rs858239	1	rs199357	ENSG00000230042.1	AK3P3	6.59	7.05e-11	1.37e-08	0.23	0.2	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23129178~23129841:+
BRCA	cis	rs250585	0.92	rs11074563	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23511972	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs9940058	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23515741	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.915	rs2369011	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23518485	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs2040572	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23518565	chr16:23452758~23457606:+
BRCA	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	6.59	7.06e-11	1.37e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
BRCA	cis	rs860818	1	rs858247	ENSG00000226816.2	AC005082.12	6.59	7.06e-11	1.37e-08	0.48	0.2	Initial pursuit acceleration;	chr7:23181664	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000236529.1	RP13-254B10.1	6.59	7.07e-11	1.37e-08	0.25	0.2	Aortic root size;	chr7:66275908	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-6.59	7.07e-11	1.37e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
BRCA	cis	rs16846053	0.515	rs1510084	ENSG00000227403.1	AC009299.3	-6.59	7.08e-11	1.37e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161647233	chr2:161244739~161249050:+
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-6.59	7.08e-11	1.37e-08	-0.18	-0.2	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
BRCA	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-6.59	7.09e-11	1.38e-08	-0.24	-0.2	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
BRCA	cis	rs7178375	1	rs10163148	ENSG00000215302.7	CTD-3092A11.1	-6.59	7.09e-11	1.38e-08	-0.3	-0.2	Hypertriglyceridemia;	chr15:30920481	chr15:30470779~30507623:+
BRCA	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-6.59	7.09e-11	1.38e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs2961117	ENSG00000204959.4	ARHGEF34P	6.59	7.1e-11	1.38e-08	0.25	0.2	Obesity-related traits;	chr7:144058160	chr7:144272445~144286966:-
BRCA	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-6.59	7.1e-11	1.38e-08	-0.35	-0.2	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
BRCA	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-6.59	7.11e-11	1.38e-08	-0.21	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
BRCA	cis	rs9307551	0.857	rs2218212	ENSG00000250334.4	LINC00989	-6.59	7.11e-11	1.38e-08	-0.27	-0.2	Refractive error;	chr4:79614887	chr4:79492416~79576460:+
BRCA	cis	rs4934494	0.768	rs3740034	ENSG00000240996.1	RP11-80H5.7	-6.59	7.12e-11	1.38e-08	-0.24	-0.2	Red blood cell count;	chr10:89634902	chr10:89694295~89697928:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.59	7.12e-11	1.38e-08	0.3	0.2	Depression;	chr6:28110525	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000224316.1	RP11-479O9.2	6.59	7.12e-11	1.38e-08	0.23	0.2	Aortic root size;	chr7:66370011	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-6.59	7.12e-11	1.38e-08	-0.3	-0.2	Depression;	chr6:28070115	chr6:28115628~28116551:+
BRCA	cis	rs3781264	0.816	rs2274223	ENSG00000273450.1	RP11-76P2.4	6.59	7.13e-11	1.38e-08	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94306584	chr10:94314907~94315327:-
BRCA	cis	rs669446	0.533	rs4660261	ENSG00000237950.1	RP11-7O11.3	6.59	7.14e-11	1.38e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43763926	chr1:43944370~43946551:-
BRCA	cis	rs67981189	0.789	rs12101246	ENSG00000269927.1	RP6-91H8.3	6.59	7.14e-11	1.38e-08	0.25	0.2	Schizophrenia;	chr14:71084618	chr14:71141125~71143253:-
BRCA	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-6.59	7.14e-11	1.39e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	6.59	7.14e-11	1.39e-08	0.24	0.2	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	6.59	7.14e-11	1.39e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
BRCA	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-6.59	7.15e-11	1.39e-08	-0.23	-0.2	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
BRCA	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	6.59	7.15e-11	1.39e-08	0.21	0.2	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
BRCA	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	6.59	7.16e-11	1.39e-08	0.23	0.2	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
BRCA	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	6.59	7.16e-11	1.39e-08	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
BRCA	cis	rs2153535	0.518	rs9392227	ENSG00000230939.1	RP11-314C16.1	-6.59	7.16e-11	1.39e-08	-0.24	-0.2	Motion sickness;	chr6:8581553	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	6.59	7.17e-11	1.39e-08	0.24	0.2	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-6.59	7.17e-11	1.39e-08	-0.3	-0.2	Depression;	chr6:28071808	chr6:28115628~28116551:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	6.59	7.18e-11	1.39e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
BRCA	cis	rs4372836	0.93	rs4233727	ENSG00000226833.4	AC097724.3	6.59	7.19e-11	1.39e-08	0.24	0.2	Body mass index;	chr2:28754378	chr2:28708953~28736205:-
BRCA	cis	rs4845875	0.542	rs7537955	ENSG00000242349.4	NPPA-AS1	6.59	7.19e-11	1.4e-08	0.24	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11797353	chr1:11841017~11848079:+
BRCA	cis	rs9307551	0.817	rs1975399	ENSG00000250334.4	LINC00989	-6.59	7.19e-11	1.4e-08	-0.27	-0.2	Refractive error;	chr4:79582612	chr4:79492416~79576460:+
BRCA	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-6.59	7.2e-11	1.4e-08	-0.24	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
BRCA	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.58	7.22e-11	1.4e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000236529.1	RP13-254B10.1	6.58	7.22e-11	1.4e-08	0.25	0.2	Aortic root size;	chr7:66353241	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	6.58	7.24e-11	1.4e-08	0.23	0.2	QT interval;	chr12:29256859	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	6.58	7.24e-11	1.4e-08	0.23	0.2	QT interval;	chr12:29257066	chr12:29280418~29317848:-
BRCA	cis	rs2638953	0.925	rs11049412	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12366932	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478336	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478335	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478334	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28163298~28190738:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-6.58	7.26e-11	1.41e-08	-0.26	-0.2	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
BRCA	cis	rs4886920	0.692	rs4625694	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826137	chr15:77914217~77926846:-
BRCA	cis	rs4886920	0.692	rs4625695	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826153	chr15:77914217~77926846:-
BRCA	cis	rs4886920	0.723	rs11633959	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826362	chr15:77914217~77926846:-
BRCA	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	6.58	7.29e-11	1.41e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	6.58	7.29e-11	1.41e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
BRCA	cis	rs669446	0.533	rs7543520	ENSG00000237950.1	RP11-7O11.3	6.58	7.3e-11	1.41e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43778195	chr1:43944370~43946551:-
BRCA	cis	rs34779708	0.931	rs12776390	ENSG00000271335.4	RP11-324I22.4	6.58	7.3e-11	1.42e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35314552~35336401:-
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	6.58	7.32e-11	1.42e-08	0.25	0.2	Height;	chr4:55465165	chr4:55540502~55540835:-
BRCA	cis	rs7809950	0.817	rs2712195	ENSG00000238832.1	snoU109	-6.58	7.33e-11	1.42e-08	-0.29	-0.2	Coronary artery disease;	chr7:107487051	chr7:107603363~107603507:+
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	6.58	7.33e-11	1.42e-08	0.25	0.2	Height;	chr4:55452295	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	6.58	7.34e-11	1.42e-08	0.36	0.2	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	6.58	7.34e-11	1.42e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000261582.1	RP4-614O4.11	-6.58	7.35e-11	1.42e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35267885~35280043:-
BRCA	cis	rs79040073	0.637	rs11630318	ENSG00000259531.2	RP11-295H24.3	-6.58	7.35e-11	1.42e-08	-0.31	-0.2	Lung cancer in ever smokers;	chr15:49312606	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-6.58	7.37e-11	1.43e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
BRCA	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-6.58	7.39e-11	1.43e-08	-0.2	-0.2	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-6.58	7.39e-11	1.43e-08	-0.31	-0.2	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs68039650	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35136660	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs12764820	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs67261877	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12768019	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.857	rs11690012	ENSG00000234936.1	AC010883.5	6.58	7.4e-11	1.43e-08	0.22	0.2	Coronary artery disease;	chr2:43315341	chr2:43229573~43233394:+
BRCA	cis	rs853679	0.599	rs188015	ENSG00000220721.1	OR1F12	6.58	7.41e-11	1.43e-08	0.37	0.2	Depression;	chr6:27909668	chr6:28073316~28074233:+
BRCA	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-6.58	7.42e-11	1.44e-08	-0.23	-0.2	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
BRCA	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	6.58	7.43e-11	1.44e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	6.58	7.44e-11	1.44e-08	0.22	0.2	Height;	chr5:37427041	chr5:36666214~36725195:-
BRCA	cis	rs6583826	0.758	rs10882083	ENSG00000236493.2	EIF2S2P3	6.58	7.44e-11	1.44e-08	0.26	0.2	Type 2 diabetes;	chr10:92562216	chr10:92668745~92669743:-
BRCA	cis	rs467650	0.817	rs17730306	ENSG00000248489.1	CTD-2007H13.3	6.58	7.44e-11	1.44e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98721327	chr5:98929171~98995013:+
BRCA	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	6.58	7.47e-11	1.45e-08	0.25	0.2	Height;	chr4:55460485	chr4:55540502~55540835:-
BRCA	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	6.58	7.47e-11	1.45e-08	0.19	0.2	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
BRCA	cis	rs67981189	0.821	rs56021283	ENSG00000269927.1	RP6-91H8.3	6.58	7.47e-11	1.45e-08	0.25	0.2	Schizophrenia;	chr14:70996042	chr14:71141125~71143253:-
BRCA	cis	rs5015933	0.815	rs16928051	ENSG00000232630.1	PRPS1P2	-6.58	7.47e-11	1.45e-08	-0.18	-0.2	Body mass index;	chr9:125308738	chr9:125150653~125151589:+
BRCA	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-6.58	7.48e-11	1.45e-08	-0.26	-0.2	Height;	chr20:49310154	chr20:49280319~49280409:+
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	6.58	7.49e-11	1.45e-08	0.24	0.2	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.546	rs200989	ENSG00000220721.1	OR1F12	6.58	7.49e-11	1.45e-08	0.36	0.2	Depression;	chr6:27848664	chr6:28073316~28074233:+
BRCA	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	6.58	7.5e-11	1.45e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	6.58	7.5e-11	1.45e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
BRCA	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-6.58	7.5e-11	1.45e-08	-0.16	-0.2	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.58	7.51e-11	1.45e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.613	rs9834966	ENSG00000273486.1	RP11-731C17.2	6.58	7.53e-11	1.46e-08	0.26	0.2	Height;Body mass index;	chr3:136089778	chr3:136837338~136839021:-
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Depression;	chr6:28082231	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Depression;	chr6:28082261	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
BRCA	cis	rs4372836	1	rs4372836	ENSG00000226833.4	AC097724.3	6.58	7.54e-11	1.46e-08	0.24	0.2	Body mass index;	chr2:28751017	chr2:28708953~28736205:-
BRCA	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-6.58	7.55e-11	1.46e-08	-0.21	-0.2	Height;	chr20:35175051	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-6.58	7.55e-11	1.46e-08	-0.21	-0.2	Height;	chr20:35176148	chr20:35201747~35203288:-
BRCA	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-6.58	7.55e-11	1.46e-08	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
BRCA	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	6.58	7.55e-11	1.46e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
BRCA	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-6.58	7.55e-11	1.46e-08	-0.16	-0.2	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
BRCA	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	6.58	7.56e-11	1.46e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
BRCA	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	6.58	7.57e-11	1.46e-08	0.27	0.2	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
BRCA	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.58	7.57e-11	1.46e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
BRCA	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	6.58	7.58e-11	1.47e-08	0.37	0.2	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	6.58	7.59e-11	1.47e-08	0.24	0.2	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
BRCA	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	6.58	7.59e-11	1.47e-08	0.19	0.2	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
BRCA	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.58	7.6e-11	1.47e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000228409.4	CCT6P1	6.58	7.61e-11	1.47e-08	0.28	0.2	Diabetic kidney disease;	chr7:66004843	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs1267818	ENSG00000232559.3	GS1-124K5.12	6.58	7.62e-11	1.47e-08	0.38	0.2	Gout;	chr7:66642037	chr7:66554588~66576923:-
BRCA	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	6.58	7.64e-11	1.48e-08	0.25	0.2	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
BRCA	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-6.58	7.65e-11	1.48e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
BRCA	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	6.58	7.67e-11	1.48e-08	0.27	0.2	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	6.58	7.67e-11	1.48e-08	0.27	0.2	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
BRCA	cis	rs34779708	0.966	rs12765038	ENSG00000271335.4	RP11-324I22.4	6.58	7.67e-11	1.48e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11010095	ENSG00000271335.4	RP11-324I22.4	6.58	7.68e-11	1.48e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35314552~35336401:-
BRCA	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-6.57	7.68e-11	1.49e-08	-0.23	-0.2	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
BRCA	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	6.57	7.68e-11	1.49e-08	0.2	0.2	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
BRCA	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	6.57	7.69e-11	1.49e-08	0.18	0.2	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
BRCA	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	6.57	7.69e-11	1.49e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000273765.1	RP11-370I10.11	6.57	7.69e-11	1.49e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000273765.1	RP11-370I10.11	6.57	7.69e-11	1.49e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-6.57	7.69e-11	1.49e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-6.57	7.69e-11	1.49e-08	-0.19	-0.2	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
BRCA	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-6.57	7.71e-11	1.49e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
BRCA	cis	rs17818399	0.51	rs1451153	ENSG00000279254.1	RP11-536C12.1	-6.57	7.72e-11	1.49e-08	-0.24	-0.2	Height;	chr2:46572713	chr2:46668870~46670778:+
BRCA	cis	rs12501370	0.959	rs12501316	ENSG00000201736.1	RNA5SP160	6.57	7.72e-11	1.49e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41036503	chr4:40990154~40990273:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.57	7.74e-11	1.49e-08	-0.3	-0.2	Depression;	chr6:28091242	chr6:28115628~28116551:+
BRCA	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	6.57	7.74e-11	1.5e-08	0.31	0.2	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000273024.4	INTS4P2	6.57	7.75e-11	1.5e-08	0.24	0.2	Aortic root size;	chr7:66123233	chr7:65647864~65715661:+
BRCA	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.57	7.76e-11	1.5e-08	0.18	0.2	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
BRCA	cis	rs1440410	0.798	rs34664017	ENSG00000250326.1	RP11-284M14.1	-6.57	7.76e-11	1.5e-08	-0.22	-0.2	Ischemic stroke;	chr4:143173191	chr4:142933195~143184861:-
BRCA	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-6.57	7.77e-11	1.5e-08	-0.2	-0.2	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
BRCA	cis	rs6088813	1	rs1570004	ENSG00000126005.14	MMP24-AS1	6.57	7.77e-11	1.5e-08	0.23	0.2	Height;	chr20:35370450	chr20:35216462~35278131:-
BRCA	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-6.57	7.79e-11	1.51e-08	-0.26	-0.2	Height;	chr20:49279650	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-6.57	7.79e-11	1.51e-08	-0.26	-0.2	Height;	chr20:49282024	chr20:49280319~49280409:+
BRCA	cis	rs957448	1	rs10956915	ENSG00000253175.1	RP11-267M23.6	6.57	7.79e-11	1.51e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94565036~94565715:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000228409.4	CCT6P1	6.57	7.8e-11	1.51e-08	0.28	0.2	Diabetic kidney disease;	chr7:66007799	chr7:65751142~65763354:+
BRCA	cis	rs853679	0.607	rs13194781	ENSG00000220721.1	OR1F12	6.57	7.8e-11	1.51e-08	0.48	0.2	Depression;	chr6:27847861	chr6:28073316~28074233:+
BRCA	cis	rs3764021	1	rs3764021	ENSG00000214776.8	RP11-726G1.1	6.57	7.82e-11	1.51e-08	0.22	0.2	Type 1 diabetes;	chr12:9681032	chr12:9467552~9576275:+
BRCA	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-6.57	7.82e-11	1.51e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
BRCA	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	6.57	7.82e-11	1.51e-08	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
BRCA	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-6.57	7.83e-11	1.51e-08	-0.24	-0.2	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
BRCA	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.57	7.84e-11	1.51e-08	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
BRCA	cis	rs7976269	0.609	rs10843305	ENSG00000257176.2	RP11-996F15.2	-6.57	7.85e-11	1.52e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29073147	chr12:29280418~29317848:-
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000273765.1	RP11-370I10.11	6.57	7.85e-11	1.52e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48360920~48361377:+
BRCA	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	6.57	7.85e-11	1.52e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
BRCA	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	6.57	7.86e-11	1.52e-08	0.2	0.2	Height;	chr20:35192624	chr20:35201747~35203288:-
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	6.57	7.86e-11	1.52e-08	0.16	0.2	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
BRCA	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	6.57	7.86e-11	1.52e-08	0.23	0.2	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
BRCA	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.57	7.86e-11	1.52e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
BRCA	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	6.57	7.87e-11	1.52e-08	0.39	0.2	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
BRCA	cis	rs10050311	0.698	rs67867077	ENSG00000251411.1	RP11-397E7.4	-6.57	7.87e-11	1.52e-08	-0.29	-0.2	Insulin-related traits;	chr4:86722593	chr4:86913266~86914817:-
BRCA	cis	rs193541	0.632	rs246279	ENSG00000263432.2	RN7SL689P	-6.57	7.87e-11	1.52e-08	-0.34	-0.2	Glucose homeostasis traits;	chr5:122905568	chr5:123022487~123022783:-
BRCA	cis	rs12468579	0.74	rs12693588	ENSG00000235852.1	AC005540.3	6.57	7.88e-11	1.52e-08	0.21	0.2	JT interval (sulfonylurea treatment interaction);	chr2:190967766	chr2:190880797~190882059:-
BRCA	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-6.57	7.89e-11	1.52e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
BRCA	cis	rs12594515	1	rs6493170	ENSG00000259200.1	RP11-718O11.1	-6.57	7.9e-11	1.52e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694821	chr15:45705078~45931069:+
BRCA	cis	rs13178541	0.748	rs4317317	ENSG00000250378.1	RP11-119J18.1	-6.57	7.9e-11	1.53e-08	-0.27	-0.2	IgG glycosylation;	chr5:135740765	chr5:135812667~135826582:+
BRCA	cis	rs6740322	0.841	rs10210507	ENSG00000234936.1	AC010883.5	6.57	7.9e-11	1.53e-08	0.23	0.2	Coronary artery disease;	chr2:43329497	chr2:43229573~43233394:+
BRCA	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	6.57	7.91e-11	1.53e-08	0.23	0.2	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-6.57	7.91e-11	1.53e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
BRCA	cis	rs420259	0.516	rs10153059	ENSG00000260136.4	CTD-2270L9.4	-6.57	7.92e-11	1.53e-08	-0.2	-0.2	Bipolar disorder;	chr16:23501062	chr16:23452758~23457606:+
BRCA	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-6.57	7.92e-11	1.53e-08	-0.25	-0.2	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-6.57	7.93e-11	1.53e-08	-0.33	-0.2	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
BRCA	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-6.57	7.93e-11	1.53e-08	-0.24	-0.2	Height;	chr2:46572204	chr2:46668870~46670778:+
BRCA	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	6.57	7.93e-11	1.53e-08	0.22	0.2	Height;	chr5:37454360	chr5:36666214~36725195:-
BRCA	cis	rs6142102	1	rs6059672	ENSG00000275784.1	RP5-1125A11.6	-6.57	7.94e-11	1.53e-08	-0.24	-0.2	Skin pigmentation;	chr20:34117662	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	6.57	7.95e-11	1.53e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
BRCA	cis	rs2239547	0.603	rs4687698	ENSG00000242142.1	SERBP1P3	6.57	7.96e-11	1.54e-08	0.25	0.2	Schizophrenia;	chr3:53063092	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000236529.1	RP13-254B10.1	6.57	7.96e-11	1.54e-08	0.25	0.2	Aortic root size;	chr7:66390342	chr7:65840212~65840596:+
BRCA	cis	rs13118159	0.55	rs11941200	ENSG00000254094.1	AC078852.1	-6.57	7.96e-11	1.54e-08	-0.25	-0.2	Longevity;	chr4:1375305	chr4:1356581~1358075:+
BRCA	cis	rs13118159	0.55	rs11946956	ENSG00000254094.1	AC078852.1	-6.57	7.96e-11	1.54e-08	-0.25	-0.2	Longevity;	chr4:1375306	chr4:1356581~1358075:+
BRCA	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	6.57	7.96e-11	1.54e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
BRCA	cis	rs13126694	0.744	rs4077776	ENSG00000248429.4	RP11-597D13.9	6.57	7.97e-11	1.54e-08	0.18	0.2	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158170752~158202877:+
BRCA	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	6.57	7.97e-11	1.54e-08	0.23	0.2	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
BRCA	cis	rs8114671	0.869	rs2038503	ENSG00000269202.1	RP4-614O4.12	6.57	7.98e-11	1.54e-08	0.2	0.2	Height;	chr20:35088097	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	6.57	8e-11	1.54e-08	0.21	0.2	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	6.57	8e-11	1.54e-08	0.21	0.2	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000234585.5	CCT6P3	6.57	8.01e-11	1.55e-08	0.19	0.2	Calcium levels;	chr7:65967580	chr7:65038354~65074713:+
BRCA	cis	rs638893	0.617	rs7933007	ENSG00000255239.1	AP002954.6	-6.57	8.01e-11	1.55e-08	-0.26	-0.2	Vitiligo;	chr11:118859960	chr11:118688039~118690600:-
BRCA	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	6.57	8.01e-11	1.55e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-6.57	8.02e-11	1.55e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
BRCA	cis	rs7773456	1	rs7773456	ENSG00000228412.5	RP4-625H18.2	6.57	8.02e-11	1.55e-08	0.25	0.2	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:19802164~19804752:-
BRCA	cis	rs2638953	0.924	rs61920228	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7306838	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7138173	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28163298~28190738:-
BRCA	cis	rs4372836	0.964	rs4665432	ENSG00000226833.4	AC097724.3	-6.57	8.02e-11	1.55e-08	-0.24	-0.2	Body mass index;	chr2:28729160	chr2:28708953~28736205:-
BRCA	cis	rs78456975	1	rs6708604	ENSG00000231482.2	AC141930.2	-6.57	8.02e-11	1.55e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1553115	chr2:1572554~1580311:-
BRCA	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-6.57	8.03e-11	1.55e-08	-0.22	-0.2	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
BRCA	cis	rs58873874	1	rs11740562	ENSG00000248544.2	CTB-47B11.3	-6.57	8.03e-11	1.55e-08	-0.42	-0.2	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157375741~157384950:-
BRCA	cis	rs34779708	0.931	rs7084196	ENSG00000271335.4	RP11-324I22.4	6.57	8.04e-11	1.55e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35314552~35336401:-
BRCA	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	6.57	8.05e-11	1.55e-08	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-6.57	8.05e-11	1.55e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
BRCA	cis	rs34779708	0.931	rs12773169	ENSG00000271335.4	RP11-324I22.4	6.57	8.06e-11	1.55e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35314552~35336401:-
BRCA	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.57	8.06e-11	1.55e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
BRCA	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-6.57	8.06e-11	1.55e-08	-0.34	-0.2	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
BRCA	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-6.57	8.06e-11	1.56e-08	-0.29	-0.2	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
BRCA	cis	rs2348418	0.639	rs61301264	ENSG00000247934.4	RP11-967K21.1	-6.57	8.07e-11	1.56e-08	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28112922	chr12:28163298~28190738:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	6.57	8.07e-11	1.56e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
BRCA	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	6.57	8.08e-11	1.56e-08	0.23	0.2	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	6.57	8.09e-11	1.56e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
BRCA	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	6.57	8.09e-11	1.56e-08	0.3	0.2	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
BRCA	cis	rs539096	0.692	rs6686238	ENSG00000237950.1	RP11-7O11.3	6.57	8.09e-11	1.56e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43744582	chr1:43944370~43946551:-
BRCA	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-6.57	8.11e-11	1.56e-08	-0.23	-0.2	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	6.57	8.12e-11	1.56e-08	0.31	0.2	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
BRCA	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	6.57	8.12e-11	1.57e-08	0.36	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
BRCA	cis	rs78456975	1	rs13429866	ENSG00000231482.2	AC141930.2	-6.57	8.13e-11	1.57e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1551439	chr2:1572554~1580311:-
BRCA	cis	rs1124769	0.778	rs12902649	ENSG00000259378.1	DCAF13P3	6.57	8.14e-11	1.57e-08	0.28	0.2	Cognitive performance;	chr15:51039413	chr15:50944663~50945996:+
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	6.57	8.15e-11	1.57e-08	0.29	0.2	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
BRCA	cis	rs7474896	0.583	rs34185758	ENSG00000226578.1	RP11-258F22.1	-6.57	8.16e-11	1.57e-08	-0.27	-0.2	Obesity (extreme);	chr10:37701926	chr10:37775371~37784131:-
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000263603.1	CTD-2349P21.5	-6.57	8.18e-11	1.58e-08	-0.34	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30729469~30731202:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28089816	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28090857	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28091439	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28091659	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28093966	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28094014	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000228409.4	CCT6P1	6.56	8.2e-11	1.58e-08	0.28	0.2	Diabetic kidney disease;	chr7:65989196	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	6.56	8.21e-11	1.58e-08	0.26	0.2	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	6.56	8.21e-11	1.58e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
BRCA	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-6.56	8.21e-11	1.58e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
BRCA	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-6.56	8.22e-11	1.58e-08	-0.27	-0.2	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
BRCA	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	6.56	8.23e-11	1.59e-08	0.2	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
BRCA	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-6.56	8.25e-11	1.59e-08	-0.21	-0.2	Height;	chr20:35182684	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-6.56	8.25e-11	1.59e-08	-0.21	-0.2	Height;	chr20:35183632	chr20:35201747~35203288:-
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	6.56	8.25e-11	1.59e-08	0.24	0.2	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
BRCA	cis	rs12594515	1	rs8039974	ENSG00000259200.1	RP11-718O11.1	-6.56	8.26e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694467	chr15:45705078~45931069:+
BRCA	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-6.56	8.26e-11	1.59e-08	-0.25	-0.2	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
BRCA	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	6.56	8.27e-11	1.59e-08	0.23	0.2	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
BRCA	cis	rs12594515	1	rs6493167	ENSG00000259200.1	RP11-718O11.1	-6.56	8.27e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694611	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs6493168	ENSG00000259200.1	RP11-718O11.1	-6.56	8.27e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694613	chr15:45705078~45931069:+
BRCA	cis	rs4763879	0.865	rs4763840	ENSG00000214776.8	RP11-726G1.1	-6.56	8.28e-11	1.59e-08	-0.22	-0.2	Type 1 diabetes;	chr12:9731814	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000228409.4	CCT6P1	6.56	8.28e-11	1.59e-08	0.28	0.2	Diabetic kidney disease;	chr7:65985932	chr7:65751142~65763354:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	6.56	8.28e-11	1.6e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
BRCA	cis	rs11009175	0.725	rs1832926	ENSG00000273038.2	RP11-479G22.8	-6.56	8.29e-11	1.6e-08	-0.32	-0.2	Depression (quantitative trait);	chr10:33014676	chr10:32887255~32889311:-
BRCA	cis	rs12594515	0.967	rs11070466	ENSG00000259200.1	RP11-718O11.1	-6.56	8.3e-11	1.6e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692757	chr15:45705078~45931069:+
BRCA	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	6.56	8.3e-11	1.6e-08	0.14	0.2	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
BRCA	cis	rs991427	0.643	rs67078592	ENSG00000258100.1	RP11-121E16.1	-6.56	8.3e-11	1.6e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91063754	chr12:91362196~91368606:+
BRCA	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	6.56	8.31e-11	1.6e-08	0.14	0.2	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
BRCA	cis	rs1476670	0.545	rs2158822	ENSG00000230615.5	RP5-1198O20.4	6.56	8.32e-11	1.6e-08	0.27	0.2	Eotaxin levels;	chr1:44053775	chr1:44030443~44115913:+
BRCA	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	6.56	8.34e-11	1.6e-08	0.28	0.2	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000267422.1	CTD-2554C21.1	-6.56	8.35e-11	1.61e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37403292	chr19:37779686~37792865:+
BRCA	cis	rs6088580	0.524	rs6088565	ENSG00000269202.1	RP4-614O4.12	6.56	8.35e-11	1.61e-08	0.22	0.2	Glomerular filtration rate (creatinine);	chr20:34667182	chr20:35201747~35203288:-
BRCA	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-6.56	8.36e-11	1.61e-08	-0.28	-0.2	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
BRCA	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-6.56	8.37e-11	1.61e-08	-0.23	-0.2	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
BRCA	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-6.56	8.38e-11	1.61e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
BRCA	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	6.56	8.4e-11	1.62e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-6.56	8.41e-11	1.62e-08	-0.21	-0.2	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
BRCA	cis	rs1124769	0.748	rs57324163	ENSG00000259378.1	DCAF13P3	6.56	8.41e-11	1.62e-08	0.28	0.2	Cognitive performance;	chr15:51069551	chr15:50944663~50945996:+
BRCA	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	6.56	8.41e-11	1.62e-08	0.28	0.2	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-6.56	8.42e-11	1.62e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
BRCA	cis	rs13126694	0.778	rs10013448	ENSG00000251429.1	RP11-597D13.7	6.56	8.43e-11	1.62e-08	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158270378~158278676:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000273024.4	INTS4P2	-6.56	8.43e-11	1.62e-08	-0.25	-0.2	Aortic root size;	chr7:66318029	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000213640.3	EEF1DP4	-6.56	8.44e-11	1.62e-08	-0.25	-0.2	Calcium levels;	chr7:65806798	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-6.56	8.45e-11	1.63e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
BRCA	cis	rs9876781	1	rs9817615	ENSG00000229759.1	MRPS18AP1	6.56	8.47e-11	1.63e-08	0.22	0.2	Longevity;	chr3:48429347	chr3:48256350~48256938:-
BRCA	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	6.56	8.49e-11	1.63e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
BRCA	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000230042.1	AK3P3	-6.56	8.5e-11	1.63e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23129178~23129841:+
BRCA	cis	rs4372836	0.93	rs7589860	ENSG00000226833.4	AC097724.3	6.56	8.5e-11	1.63e-08	0.24	0.2	Body mass index;	chr2:28744782	chr2:28708953~28736205:-
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	6.56	8.5e-11	1.64e-08	0.25	0.2	Height;	chr4:55529786	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	6.56	8.5e-11	1.64e-08	0.25	0.2	Height;	chr4:55532542	chr4:55540502~55540835:-
BRCA	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	6.56	8.5e-11	1.64e-08	0.19	0.2	Asthma;	chr2:102351751	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	6.56	8.5e-11	1.64e-08	0.19	0.2	Asthma;	chr2:102351752	chr2:102438713~102440475:+
BRCA	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-6.56	8.51e-11	1.64e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000224316.1	RP11-479O9.2	-6.56	8.51e-11	1.64e-08	-0.21	-0.2	Aortic root size;	chr7:66221942	chr7:65773620~65802067:+
BRCA	cis	rs2749097	0.825	rs6671606	ENSG00000244256.3	RN7SL130P	-6.56	8.52e-11	1.64e-08	-0.25	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63658197	chr1:63655743~63656047:+
BRCA	cis	rs34792	0.554	rs12933773	ENSG00000207425.1	Y_RNA	-6.56	8.54e-11	1.64e-08	-0.24	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:14915457~14915556:-
BRCA	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-6.56	8.55e-11	1.64e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
BRCA	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-6.56	8.57e-11	1.65e-08	-0.26	-0.2	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
BRCA	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-6.56	8.57e-11	1.65e-08	-0.27	-0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
BRCA	cis	rs12501370	1	rs1022018	ENSG00000201736.1	RNA5SP160	6.56	8.57e-11	1.65e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41008954	chr4:40990154~40990273:+
BRCA	cis	rs12501370	1	rs12642733	ENSG00000201736.1	RNA5SP160	6.56	8.57e-11	1.65e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41009117	chr4:40990154~40990273:+
BRCA	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	6.56	8.58e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
BRCA	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-6.56	8.59e-11	1.65e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs11010101	ENSG00000271335.4	RP11-324I22.4	6.56	8.6e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11010102	ENSG00000271335.4	RP11-324I22.4	6.56	8.6e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35314552~35336401:-
BRCA	cis	rs467650	0.817	rs61637015	ENSG00000248489.1	CTD-2007H13.3	6.56	8.62e-11	1.66e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98716535	chr5:98929171~98995013:+
BRCA	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	6.56	8.63e-11	1.66e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
BRCA	cis	rs78456975	0.943	rs6721243	ENSG00000231482.2	AC141930.2	-6.56	8.63e-11	1.66e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1576478	chr2:1572554~1580311:-
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	6.56	8.63e-11	1.66e-08	0.25	0.2	Height;	chr4:55437438	chr4:55363971~55395847:-
BRCA	cis	rs67311347	0.866	rs2371183	ENSG00000280739.1	EIF1B-AS1	-6.56	8.63e-11	1.66e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40292756	chr3:40173145~40309698:-
BRCA	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	6.56	8.63e-11	1.66e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	6.56	8.64e-11	1.66e-08	0.22	0.2	Height;	chr5:37468413	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs1533266	ENSG00000204959.4	ARHGEF34P	6.56	8.64e-11	1.66e-08	0.25	0.2	Obesity-related traits;	chr7:144069621	chr7:144272445~144286966:-
BRCA	cis	rs6740322	0.895	rs10196095	ENSG00000234936.1	AC010883.5	6.56	8.64e-11	1.66e-08	0.23	0.2	Coronary artery disease;	chr2:43344746	chr2:43229573~43233394:+
BRCA	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-6.56	8.65e-11	1.66e-08	-0.22	-0.2	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
BRCA	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	6.56	8.66e-11	1.66e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
BRCA	cis	rs9840812	0.592	rs1711161	ENSG00000273486.1	RP11-731C17.2	6.56	8.67e-11	1.67e-08	0.24	0.2	Fibrinogen levels;	chr3:136361695	chr3:136837338~136839021:-
BRCA	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	6.56	8.69e-11	1.67e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
BRCA	cis	rs6543140	0.964	rs6543144	ENSG00000234389.1	AC007278.3	6.56	8.7e-11	1.67e-08	0.2	0.2	Blood protein levels;	chr2:102476116	chr2:102438713~102440475:+
BRCA	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-6.56	8.71e-11	1.67e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
BRCA	cis	rs420259	0.516	rs7405145	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.67e-08	-0.2	-0.2	Bipolar disorder;	chr16:23526451	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs1468138	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.68e-08	-0.22	-0.2	Egg allergy;	chr16:23524359	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs6497671	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.68e-08	-0.22	-0.2	Egg allergy;	chr16:23525363	chr16:23452758~23457606:+
BRCA	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	6.55	8.74e-11	1.68e-08	0.25	0.2	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-6.55	8.74e-11	1.68e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
BRCA	cis	rs4218	0.543	rs8027536	ENSG00000277144.1	RP11-59H7.4	-6.55	8.76e-11	1.68e-08	-0.24	-0.2	Social communication problems;	chr15:59022364	chr15:59115547~59116089:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000229886.1	RP5-1132H15.3	6.55	8.76e-11	1.68e-08	0.37	0.2	Diabetic kidney disease;	chr7:66062119	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	6.55	8.77e-11	1.68e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
BRCA	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	6.55	8.77e-11	1.68e-08	0.15	0.2	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	6.55	8.77e-11	1.68e-08	0.15	0.2	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
BRCA	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-6.55	8.78e-11	1.69e-08	-0.23	-0.2	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
BRCA	cis	rs7085104	0.572	rs284857	ENSG00000213061.2	PFN1P11	-6.55	8.78e-11	1.69e-08	-0.25	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102838011~102845473:-
BRCA	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-6.55	8.78e-11	1.69e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
BRCA	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29263297	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29264237	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29266228	chr12:29280418~29317848:-
BRCA	cis	rs420259	0.516	rs2072062	ENSG00000260136.4	CTD-2270L9.4	-6.55	8.8e-11	1.69e-08	-0.2	-0.2	Bipolar disorder;	chr16:23529477	chr16:23452758~23457606:+
BRCA	cis	rs78456975	0.622	rs11896517	ENSG00000231482.2	AC141930.2	-6.55	8.8e-11	1.69e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514340	chr2:1572554~1580311:-
BRCA	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-6.55	8.81e-11	1.69e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
BRCA	cis	rs3126085	0.935	rs11588174	ENSG00000237975.5	FLG-AS1	6.55	8.81e-11	1.69e-08	0.27	0.2	Atopic dermatitis;	chr1:152203494	chr1:152168125~152445456:+
BRCA	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-6.55	8.82e-11	1.69e-08	-0.19	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
BRCA	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-6.55	8.82e-11	1.69e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
BRCA	cis	rs2749097	0.825	rs11208261	ENSG00000244256.3	RN7SL130P	-6.55	8.82e-11	1.69e-08	-0.25	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63658331	chr1:63655743~63656047:+
BRCA	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-6.55	8.83e-11	1.7e-08	-0.27	-0.2	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
BRCA	cis	rs67981189	0.778	rs989501	ENSG00000269927.1	RP6-91H8.3	-6.55	8.84e-11	1.7e-08	-0.25	-0.2	Schizophrenia;	chr14:70894697	chr14:71141125~71143253:-
BRCA	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	6.55	8.84e-11	1.7e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
BRCA	cis	rs16846053	0.515	rs7557876	ENSG00000227403.1	AC009299.3	-6.55	8.84e-11	1.7e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161633024	chr2:161244739~161249050:+
BRCA	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-6.55	8.84e-11	1.7e-08	-0.24	-0.2	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
BRCA	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	6.55	8.84e-11	1.7e-08	0.24	0.2	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
BRCA	cis	rs3781264	1	rs10509671	ENSG00000273450.1	RP11-76P2.4	6.55	8.85e-11	1.7e-08	0.27	0.2	Esophageal cancer and gastric cancer;	chr10:94309297	chr10:94314907~94315327:-
BRCA	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-6.55	8.85e-11	1.7e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
BRCA	cis	rs4842666	0.528	rs7302816	ENSG00000258302.2	RP11-981P6.1	-6.55	8.85e-11	1.7e-08	-0.22	-0.2	Blood pressure;	chr12:89556543	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-6.55	8.85e-11	1.7e-08	-0.23	-0.2	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
BRCA	cis	rs67981189	0.896	rs221922	ENSG00000269927.1	RP6-91H8.3	-6.55	8.9e-11	1.71e-08	-0.25	-0.2	Schizophrenia;	chr14:71118396	chr14:71141125~71143253:-
BRCA	cis	rs7914558	0.966	rs10748835	ENSG00000213061.2	PFN1P11	6.55	8.9e-11	1.71e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102838011~102845473:-
BRCA	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-6.55	8.9e-11	1.71e-08	-0.29	-0.2	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000228409.4	CCT6P1	6.55	8.9e-11	1.71e-08	0.27	0.2	Diabetic kidney disease;	chr7:66005945	chr7:65751142~65763354:+
BRCA	cis	rs12594515	1	rs8026221	ENSG00000259200.1	RP11-718O11.1	-6.55	8.91e-11	1.71e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695712	chr15:45705078~45931069:+
BRCA	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	6.55	8.91e-11	1.71e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	6.55	8.91e-11	1.71e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
BRCA	cis	rs838147	0.534	rs2638280	ENSG00000232871.7	SEC1P	6.55	8.91e-11	1.71e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706061	chr19:48638071~48682245:+
BRCA	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.55	8.92e-11	1.71e-08	0.23	0.2	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
BRCA	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-6.55	8.92e-11	1.71e-08	-0.21	-0.2	Height;	chr20:35187574	chr20:35201747~35203288:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	6.55	8.94e-11	1.72e-08	0.35	0.2	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
BRCA	cis	rs4372836	1	rs6710959	ENSG00000226833.4	AC097724.3	6.55	8.95e-11	1.72e-08	0.24	0.2	Body mass index;	chr2:28735737	chr2:28708953~28736205:-
BRCA	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-6.55	8.96e-11	1.72e-08	-0.22	-0.2	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
BRCA	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	6.55	8.97e-11	1.72e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
BRCA	cis	rs4072705	1	rs721862	ENSG00000224020.1	MIR181A2HG	-6.55	8.97e-11	1.72e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124773713	chr9:124658467~124698631:+
BRCA	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-6.55	8.97e-11	1.72e-08	-0.21	-0.2	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
BRCA	cis	rs853679	0.556	rs45509595	ENSG00000220721.1	OR1F12	6.55	8.99e-11	1.72e-08	0.49	0.2	Depression;	chr6:27873148	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-6.55	8.99e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
BRCA	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-6.55	9e-11	1.73e-08	-0.21	-0.2	Height;	chr20:35185886	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-6.55	9e-11	1.73e-08	-0.21	-0.2	Height;	chr20:35186641	chr20:35201747~35203288:-
BRCA	cis	rs9307551	0.817	rs1440864	ENSG00000250334.4	LINC00989	-6.55	9.03e-11	1.73e-08	-0.27	-0.2	Refractive error;	chr4:79571830	chr4:79492416~79576460:+
BRCA	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	6.55	9.03e-11	1.73e-08	0.34	0.2	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
BRCA	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-6.55	9.04e-11	1.73e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
BRCA	cis	rs10208649	0.908	rs11887593	ENSG00000233266.1	HMGB1P31	6.55	9.04e-11	1.73e-08	0.48	0.2	Body mass index;	chr2:54040638	chr2:54051334~54051760:+
BRCA	cis	rs12501370	1	rs2063173	ENSG00000201736.1	RNA5SP160	6.55	9.05e-11	1.74e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41015610	chr4:40990154~40990273:+
BRCA	cis	rs12501370	1	rs17627002	ENSG00000201736.1	RNA5SP160	6.55	9.05e-11	1.74e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41017871	chr4:40990154~40990273:+
BRCA	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-6.55	9.06e-11	1.74e-08	-0.26	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
BRCA	cis	rs4713118	0.869	rs10214440	ENSG00000220721.1	OR1F12	6.55	9.06e-11	1.74e-08	0.25	0.2	Parkinson's disease;	chr6:27734661	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
BRCA	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	6.55	9.07e-11	1.74e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
BRCA	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-6.55	9.07e-11	1.74e-08	-0.25	-0.2	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
BRCA	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29256797	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29258881	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29259743	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29260002	chr12:29280418~29317848:-
BRCA	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-6.55	9.08e-11	1.74e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
BRCA	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-6.55	9.08e-11	1.74e-08	-0.19	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	6.55	9.09e-11	1.74e-08	0.36	0.2	Gout;	chr7:66721259	chr7:66025126~66031544:-
BRCA	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.55	9.11e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.55	9.11e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	6.55	9.11e-11	1.75e-08	0.25	0.2	Height;	chr4:55436423	chr4:55363971~55395847:-
BRCA	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-6.55	9.12e-11	1.75e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
BRCA	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.55	9.12e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
BRCA	cis	rs4934494	0.834	rs3740033	ENSG00000240996.1	RP11-80H5.7	6.55	9.14e-11	1.75e-08	0.22	0.2	Red blood cell count;	chr10:89634639	chr10:89694295~89697928:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-6.55	9.14e-11	1.75e-08	-0.21	-0.2	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
BRCA	cis	rs757081	0.506	rs11529609	ENSG00000184669.7	OR7E14P	-6.55	9.14e-11	1.75e-08	-0.3	-0.2	Systolic blood pressure;	chr11:17042243	chr11:17013998~17053024:+
BRCA	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	6.55	9.14e-11	1.75e-08	0.22	0.2	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-6.55	9.15e-11	1.75e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
BRCA	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.55	9.15e-11	1.75e-08	0.23	0.2	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
BRCA	cis	rs2638953	0.924	rs11049475	ENSG00000278733.1	RP11-425D17.1	-6.55	9.16e-11	1.76e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28185625~28186190:-
BRCA	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.55	9.18e-11	1.76e-08	0.23	0.2	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
BRCA	cis	rs73173548	0.528	rs12189274	ENSG00000247828.6	TMEM161B-AS1	-6.55	9.18e-11	1.76e-08	-0.27	-0.2	Macular telangiectasia type 2;	chr5:88468669	chr5:88268895~88436685:+
BRCA	cis	rs4372836	0.828	rs6728459	ENSG00000226833.4	AC097724.3	6.55	9.19e-11	1.76e-08	0.25	0.2	Body mass index;	chr2:28776470	chr2:28708953~28736205:-
BRCA	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-6.55	9.19e-11	1.76e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
BRCA	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	6.55	9.19e-11	1.76e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
BRCA	cis	rs60843830	0.508	rs300750	ENSG00000272342.1	RP13-539J13.1	6.55	9.21e-11	1.76e-08	0.23	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr2:208794	chr2:739588~740164:-
BRCA	cis	rs34779708	0.966	rs2045917	ENSG00000271335.4	RP11-324I22.4	6.55	9.23e-11	1.77e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-6.55	9.23e-11	1.77e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
BRCA	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	6.55	9.23e-11	1.77e-08	0.26	0.2	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
BRCA	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
BRCA	cis	rs710913	0.717	rs2068473	ENSG00000237624.1	OXCT2P1	-6.55	9.25e-11	1.77e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	6.55	9.25e-11	1.77e-08	0.26	0.2	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37446974	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37454372	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37464083	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Depression;	chr6:28104824	chr6:28115628~28116551:+
BRCA	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-6.55	9.26e-11	1.77e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
BRCA	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	6.55	9.26e-11	1.77e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
BRCA	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	6.55	9.27e-11	1.77e-08	0.22	0.2	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
BRCA	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	6.55	9.27e-11	1.77e-08	0.21	0.2	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000224316.1	RP11-479O9.2	-6.55	9.27e-11	1.77e-08	-0.2	-0.2	Aortic root size;	chr7:66279745	chr7:65773620~65802067:+
BRCA	cis	rs5015933	0.815	rs12338077	ENSG00000232630.1	PRPS1P2	-6.55	9.27e-11	1.78e-08	-0.18	-0.2	Body mass index;	chr9:125345427	chr9:125150653~125151589:+
BRCA	cis	rs2638953	0.861	rs11049685	ENSG00000278733.1	RP11-425D17.1	-6.55	9.28e-11	1.78e-08	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28185625~28186190:-
BRCA	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-6.55	9.29e-11	1.78e-08	-0.21	-0.2	Height;	chr20:35190180	chr20:35201747~35203288:-
BRCA	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	6.55	9.3e-11	1.78e-08	0.2	0.2	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
BRCA	cis	rs2348418	0.864	rs6487688	ENSG00000247934.4	RP11-967K21.1	-6.55	9.31e-11	1.78e-08	-0.22	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28163298~28190738:-
BRCA	cis	rs2998286	0.723	rs332161	ENSG00000254635.4	WAC-AS1	6.54	9.32e-11	1.78e-08	0.29	0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28522652~28532743:-
BRCA	cis	rs7937890	1	rs2970334	ENSG00000251991.1	RNU7-49P	-6.54	9.32e-11	1.78e-08	-0.21	-0.2	Mitochondrial DNA levels;	chr11:14307809	chr11:14478892~14478953:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	6.54	9.33e-11	1.79e-08	0.15	0.2	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
BRCA	cis	rs8002861	0.664	rs4941474	ENSG00000274001.1	RP11-5G9.5	6.54	9.33e-11	1.79e-08	0.23	0.2	Leprosy;	chr13:43876153	chr13:43877715~43878163:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-6.54	9.33e-11	1.79e-08	-0.27	-0.2	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
BRCA	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	6.54	9.33e-11	1.79e-08	0.23	0.2	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
BRCA	cis	rs67981189	0.896	rs4132849	ENSG00000269927.1	RP6-91H8.3	6.54	9.34e-11	1.79e-08	0.25	0.2	Schizophrenia;	chr14:70992806	chr14:71141125~71143253:-
BRCA	cis	rs42648	0.819	rs10953006	ENSG00000225498.1	AC002064.5	6.54	9.34e-11	1.79e-08	0.19	0.2	Homocysteine levels;	chr7:90400839	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000224316.1	RP11-479O9.2	-6.54	9.34e-11	1.79e-08	-0.2	-0.2	Aortic root size;	chr7:66263424	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	6.54	9.35e-11	1.79e-08	0.35	0.2	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
BRCA	cis	rs4845875	0.504	rs198396	ENSG00000242349.4	NPPA-AS1	-6.54	9.35e-11	1.79e-08	-0.24	-0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11821263	chr1:11841017~11848079:+
BRCA	cis	rs74233809	0.901	rs4409766	ENSG00000213277.3	MARCKSL1P1	6.54	9.36e-11	1.79e-08	0.33	0.2	Birth weight;	chr10:102856906	chr10:103175554~103176094:+
BRCA	cis	rs529866	0.5	rs918739	ENSG00000262636.1	CTD-3088G3.4	-6.54	9.37e-11	1.79e-08	-0.27	-0.2	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11380859~11381118:-
BRCA	cis	rs957448	1	rs1023767	ENSG00000253175.1	RP11-267M23.6	6.54	9.4e-11	1.8e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94565036~94565715:+
BRCA	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.54	9.4e-11	1.8e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
BRCA	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	6.54	9.41e-11	1.8e-08	0.21	0.2	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000273765.1	RP11-370I10.11	-6.54	9.41e-11	1.8e-08	-0.25	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48360920~48361377:+
BRCA	cis	rs2348418	0.864	rs7295120	ENSG00000247934.4	RP11-967K21.1	6.54	9.41e-11	1.8e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28163298~28190738:-
BRCA	cis	rs9907295	0.688	rs2526327	ENSG00000271013.1	AC015849.15	6.54	9.41e-11	1.8e-08	0.24	0.2	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35912635~35918010:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000273024.4	INTS4P2	6.54	9.41e-11	1.8e-08	0.25	0.2	Aortic root size;	chr7:66086944	chr7:65647864~65715661:+
BRCA	cis	rs1124769	0.748	rs12912106	ENSG00000259378.1	DCAF13P3	6.54	9.41e-11	1.8e-08	0.28	0.2	Cognitive performance;	chr15:51067255	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
BRCA	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-6.54	9.43e-11	1.8e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
BRCA	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
BRCA	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-6.54	9.45e-11	1.81e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
BRCA	cis	rs957448	1	rs2381885	ENSG00000253175.1	RP11-267M23.6	6.54	9.45e-11	1.81e-08	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94565036~94565715:+
BRCA	cis	rs1124769	0.748	rs35372376	ENSG00000259378.1	DCAF13P3	6.54	9.45e-11	1.81e-08	0.28	0.2	Cognitive performance;	chr15:51016774	chr15:50944663~50945996:+
BRCA	cis	rs4691139	1	rs7692919	ENSG00000248632.1	RP11-366M4.11	6.54	9.46e-11	1.81e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164968587~164970002:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000229886.1	RP5-1132H15.3	6.54	9.47e-11	1.81e-08	0.36	0.2	Diabetic kidney disease;	chr7:66078212	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160648	ENSG00000229886.1	RP5-1132H15.3	6.54	9.47e-11	1.81e-08	0.36	0.2	Diabetic kidney disease;	chr7:66078397	chr7:66025126~66031544:-
BRCA	cis	rs6583826	0.758	rs12220493	ENSG00000236493.2	EIF2S2P3	6.54	9.47e-11	1.81e-08	0.26	0.2	Type 2 diabetes;	chr10:92551152	chr10:92668745~92669743:-
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000211972.2	IGHV3-66	6.54	9.47e-11	1.81e-08	0.19	0.2	Alzheimer's disease (late onset);	chr14:106688967	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	6.54	9.47e-11	1.81e-08	0.26	0.2	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
BRCA	cis	rs2492286	0.518	rs2811506	ENSG00000242551.2	POU5F1P6	-6.54	9.48e-11	1.81e-08	-0.29	-0.2	Eosinophil counts;	chr3:128610801	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	6.54	9.48e-11	1.81e-08	0.25	0.2	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-6.54	9.48e-11	1.81e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
BRCA	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	6.54	9.49e-11	1.81e-08	0.2	0.2	Height;	chr20:35205344	chr20:35201747~35203288:-
BRCA	cis	rs467650	0.782	rs719246	ENSG00000248489.1	CTD-2007H13.3	-6.54	9.5e-11	1.82e-08	-0.23	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98929171~98995013:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000228409.4	CCT6P1	6.54	9.5e-11	1.82e-08	0.27	0.2	Diabetic kidney disease;	chr7:66005214	chr7:65751142~65763354:+
BRCA	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.5e-11	1.82e-08	-0.24	-0.2	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
BRCA	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	6.54	9.51e-11	1.82e-08	0.21	0.2	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
BRCA	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-6.54	9.51e-11	1.82e-08	-0.27	-0.2	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
BRCA	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-6.54	9.51e-11	1.82e-08	-0.27	-0.2	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
BRCA	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-6.54	9.52e-11	1.82e-08	-0.24	-0.2	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
BRCA	cis	rs60843830	0.55	rs300751	ENSG00000272342.1	RP13-539J13.1	6.54	9.52e-11	1.82e-08	0.23	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr2:209063	chr2:739588~740164:-
BRCA	cis	rs12594515	1	rs8025258	ENSG00000259200.1	RP11-718O11.1	-6.54	9.53e-11	1.82e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695356	chr15:45705078~45931069:+
BRCA	cis	rs4691139	1	rs1914859	ENSG00000248632.1	RP11-366M4.11	6.54	9.54e-11	1.82e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164968587~164970002:-
BRCA	cis	rs3760982	0.813	rs8111664	ENSG00000267058.1	RP11-15A1.3	6.54	9.55e-11	1.82e-08	0.23	0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790940	chr19:43891804~43901805:-
BRCA	cis	rs67981189	0.896	rs4048474	ENSG00000269927.1	RP6-91H8.3	6.54	9.55e-11	1.82e-08	0.25	0.2	Schizophrenia;	chr14:71060982	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000224316.1	RP11-479O9.2	-6.54	9.56e-11	1.83e-08	-0.2	-0.2	Aortic root size;	chr7:66110906	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000224316.1	RP11-479O9.2	-6.54	9.56e-11	1.83e-08	-0.2	-0.2	Aortic root size;	chr7:66115179	chr7:65773620~65802067:+
BRCA	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-6.54	9.56e-11	1.83e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	6.54	9.56e-11	1.83e-08	0.25	0.2	Height;	chr4:55489895	chr4:55363971~55395847:-
BRCA	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	6.54	9.56e-11	1.83e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
BRCA	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	6.54	9.59e-11	1.83e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
BRCA	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	6.54	9.59e-11	1.83e-08	0.22	0.2	Height;	chr5:37454091	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.59e-11	1.83e-08	-0.24	-0.2	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
BRCA	cis	rs16846053	0.515	rs1510094	ENSG00000227403.1	AC009299.3	6.54	9.59e-11	1.83e-08	0.33	0.2	Blood osmolality (transformed sodium);	chr2:161632681	chr2:161244739~161249050:+
BRCA	cis	rs4713118	0.869	rs9468214	ENSG00000220721.1	OR1F12	6.54	9.6e-11	1.83e-08	0.25	0.2	Parkinson's disease;	chr6:27745520	chr6:28073316~28074233:+
BRCA	cis	rs9840812	0.592	rs900048	ENSG00000239213.4	NCK1-AS1	6.54	9.62e-11	1.84e-08	0.23	0.2	Fibrinogen levels;	chr3:136500088	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000224316.1	RP11-479O9.2	-6.54	9.62e-11	1.84e-08	-0.2	-0.2	Aortic root size;	chr7:66108909	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-6.54	9.63e-11	1.84e-08	-0.23	-0.2	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-6.54	9.65e-11	1.84e-08	-0.23	-0.2	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-6.54	9.65e-11	1.84e-08	-0.3	-0.2	Depression;	chr6:28092227	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-6.54	9.67e-11	1.85e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
BRCA	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.69e-11	1.85e-08	-0.24	-0.2	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
BRCA	cis	rs4835473	0.637	rs13110964	ENSG00000251600.4	RP11-673E1.1	6.54	9.69e-11	1.85e-08	0.23	0.2	Immature fraction of reticulocytes;	chr4:143765119	chr4:143912331~143982454:+
BRCA	cis	rs7635879	0.693	rs4687496	ENSG00000230102.6	RP11-407B7.1	6.54	9.7e-11	1.85e-08	0.24	0.2	Breastfeeding duration;	chr3:194011436	chr3:194005259~194070970:-
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000273765.1	RP11-370I10.11	6.54	9.7e-11	1.85e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000273765.1	RP11-370I10.11	6.54	9.71e-11	1.85e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48360920~48361377:+
BRCA	cis	rs4072705	1	rs13283284	ENSG00000224020.1	MIR181A2HG	-6.54	9.71e-11	1.85e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124753898	chr9:124658467~124698631:+
BRCA	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-6.54	9.72e-11	1.85e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-6.54	9.72e-11	1.85e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-6.54	9.73e-11	1.86e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
BRCA	cis	rs2239547	0.603	rs9870898	ENSG00000242142.1	SERBP1P3	6.54	9.73e-11	1.86e-08	0.25	0.2	Schizophrenia;	chr3:53058359	chr3:53064283~53065091:-
BRCA	cis	rs228614	0.51	rs223415	ENSG00000251288.2	RP11-10L12.2	-6.54	9.76e-11	1.86e-08	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102751401~102752641:+
BRCA	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-6.54	9.76e-11	1.86e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
BRCA	cis	rs6583826	0.758	rs7073833	ENSG00000236493.2	EIF2S2P3	6.54	9.77e-11	1.86e-08	0.26	0.2	Type 2 diabetes;	chr10:92526663	chr10:92668745~92669743:-
BRCA	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	6.54	9.77e-11	1.86e-08	0.34	0.2	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	6.54	9.77e-11	1.86e-08	0.34	0.2	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
BRCA	cis	rs250585	0.646	rs66569010	ENSG00000260136.4	CTD-2270L9.4	-6.54	9.77e-11	1.86e-08	-0.2	-0.2	Egg allergy;	chr16:23475631	chr16:23452758~23457606:+
BRCA	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-6.54	9.78e-11	1.87e-08	-0.2	-0.2	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
BRCA	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	6.54	9.78e-11	1.87e-08	0.24	0.2	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-6.54	9.79e-11	1.87e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
BRCA	cis	rs9402682	0.592	rs9385717	ENSG00000232876.1	CTA-212D2.2	-6.54	9.79e-11	1.87e-08	-0.28	-0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135137285	chr6:135055033~135060550:+
BRCA	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-6.54	9.82e-11	1.87e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
BRCA	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	6.54	9.82e-11	1.87e-08	0.17	0.2	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	6.54	9.82e-11	1.87e-08	0.36	0.2	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
BRCA	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	6.54	9.82e-11	1.87e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
BRCA	cis	rs17253792	0.822	rs28409547	ENSG00000186615.9	KTN1-AS1	-6.54	9.84e-11	1.88e-08	-0.37	-0.2	Putamen volume;	chr14:55581108	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28478195	ENSG00000186615.9	KTN1-AS1	-6.54	9.84e-11	1.88e-08	-0.37	-0.2	Putamen volume;	chr14:55581133	chr14:55499278~55580110:-
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.54	9.84e-11	1.88e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	6.54	9.84e-11	1.88e-08	0.24	0.2	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	6.54	9.85e-11	1.88e-08	0.26	0.2	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
BRCA	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	6.54	9.87e-11	1.88e-08	0.31	0.2	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
BRCA	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	6.54	9.87e-11	1.88e-08	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000229886.1	RP5-1132H15.3	6.54	9.88e-11	1.88e-08	0.35	0.2	Diabetic kidney disease;	chr7:66015986	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000229886.1	RP5-1132H15.3	6.54	9.88e-11	1.88e-08	0.35	0.2	Diabetic kidney disease;	chr7:66028044	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.515	rs662928	ENSG00000226578.1	RP11-258F22.1	6.54	9.92e-11	1.89e-08	0.25	0.2	Obesity (extreme);	chr10:38027288	chr10:37775371~37784131:-
BRCA	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	6.53	9.94e-11	1.9e-08	0.31	0.2	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	6.53	9.95e-11	1.9e-08	0.35	0.2	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000267422.1	CTD-2554C21.1	-6.53	9.95e-11	1.9e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37327927	chr19:37779686~37792865:+
BRCA	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-6.53	9.95e-11	1.9e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
BRCA	cis	rs1440410	0.835	rs7693583	ENSG00000250326.1	RP11-284M14.1	-6.53	9.96e-11	1.9e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130189	chr4:142933195~143184861:-
BRCA	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-6.53	9.97e-11	1.9e-08	-0.27	-0.2	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
BRCA	cis	rs16846053	0.515	rs3843853	ENSG00000227403.1	AC009299.3	-6.53	9.97e-11	1.9e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161645081	chr2:161244739~161249050:+
BRCA	cis	rs853679	0.607	rs34661125	ENSG00000220721.1	OR1F12	6.53	9.97e-11	1.9e-08	0.46	0.2	Depression;	chr6:28314117	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13190888	ENSG00000220721.1	OR1F12	6.53	9.97e-11	1.9e-08	0.46	0.2	Depression;	chr6:28318208	chr6:28073316~28074233:+
BRCA	cis	rs12594515	1	rs6493172	ENSG00000259200.1	RP11-718O11.1	-6.53	9.98e-11	1.9e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695015	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	6.53	9.99e-11	1.9e-08	0.21	0.2	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
BRCA	cis	rs9638182	0.725	rs80189144	ENSG00000274080.1	CTA-315H11.2	6.53	1e-10	1.91e-08	0.39	0.2	Triglycerides;	chr7:73525609	chr7:73609262~73611502:-
BRCA	cis	rs4072705	0.933	rs10760376	ENSG00000224020.1	MIR181A2HG	6.53	1e-10	1.91e-08	0.22	0.2	Menarche (age at onset);	chr9:124791791	chr9:124658467~124698631:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-6.53	1e-10	1.91e-08	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
BRCA	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-6.53	1e-10	1.91e-08	-0.3	-0.2	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
BRCA	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	6.53	1e-10	1.91e-08	0.23	0.2	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
BRCA	cis	rs669446	0.533	rs2158956	ENSG00000237950.1	RP11-7O11.3	6.53	1e-10	1.91e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43746026	chr1:43944370~43946551:-
BRCA	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-6.53	1e-10	1.91e-08	-0.26	-0.2	Height;	chr20:49280020	chr20:49280319~49280409:+
BRCA	cis	rs12594515	0.967	rs11856523	ENSG00000259200.1	RP11-718O11.1	-6.53	1e-10	1.91e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697297	chr15:45705078~45931069:+
BRCA	cis	rs2880765	0.706	rs7172006	ENSG00000259295.5	CSPG4P12	6.53	1e-10	1.91e-08	0.26	0.2	Coronary artery disease;	chr15:85510128	chr15:85191438~85213905:+
BRCA	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	6.53	1e-10	1.91e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
BRCA	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-6.53	1.01e-10	1.92e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-6.53	1.01e-10	1.92e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
BRCA	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	6.53	1.01e-10	1.92e-08	0.21	0.2	Height;	chr20:35206707	chr20:35201747~35203288:-
BRCA	cis	rs853679	0.607	rs34878803	ENSG00000220721.1	OR1F12	6.53	1.01e-10	1.92e-08	0.45	0.2	Depression;	chr6:28282402	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs34396849	ENSG00000220721.1	OR1F12	6.53	1.01e-10	1.92e-08	0.45	0.2	Depression;	chr6:28283178	chr6:28073316~28074233:+
BRCA	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-6.53	1.01e-10	1.92e-08	-0.25	-0.2	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
BRCA	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	6.53	1.01e-10	1.92e-08	0.31	0.2	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
BRCA	cis	rs67981189	1	rs67981189	ENSG00000269927.1	RP6-91H8.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Schizophrenia;	chr14:71005509	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs7145484	ENSG00000269927.1	RP6-91H8.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Schizophrenia;	chr14:71006820	chr14:71141125~71143253:-
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28082984	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28083994	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28084025	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28085319	chr6:28115628~28116551:+
BRCA	cis	rs4372836	1	rs2169751	ENSG00000226833.4	AC097724.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Body mass index;	chr2:28743892	chr2:28708953~28736205:-
BRCA	cis	rs9876781	1	rs13314659	ENSG00000229759.1	MRPS18AP1	-6.53	1.01e-10	1.92e-08	-0.22	-0.2	Longevity;	chr3:48407742	chr3:48256350~48256938:-
BRCA	cis	rs2836950	0.565	rs7278297	ENSG00000238141.2	BRWD1-AS1	-6.53	1.01e-10	1.93e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39253826	chr21:39315707~39323218:+
BRCA	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-6.53	1.01e-10	1.93e-08	-0.15	-0.2	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000273765.1	RP11-370I10.11	6.53	1.02e-10	1.93e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48360920~48361377:+
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-6.53	1.02e-10	1.93e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
BRCA	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	6.53	1.02e-10	1.94e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
BRCA	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	6.53	1.02e-10	1.94e-08	0.23	0.2	QT interval;	chr12:29255006	chr12:29280418~29317848:-
BRCA	cis	rs12594515	1	rs8031128	ENSG00000259200.1	RP11-718O11.1	-6.53	1.02e-10	1.94e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696330	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs71405295	ENSG00000259200.1	RP11-718O11.1	-6.53	1.02e-10	1.94e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696723	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000236529.1	RP13-254B10.1	-6.53	1.02e-10	1.94e-08	-0.25	-0.2	Aortic root size;	chr7:66579422	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.02e-10	1.95e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.02e-10	1.95e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000273024.4	INTS4P2	-6.53	1.02e-10	1.95e-08	-0.25	-0.2	Aortic root size;	chr7:66302477	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000273024.4	INTS4P2	-6.53	1.02e-10	1.95e-08	-0.25	-0.2	Aortic root size;	chr7:66305392	chr7:65647864~65715661:+
BRCA	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	6.53	1.02e-10	1.95e-08	0.38	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
BRCA	cis	rs4907240	0.731	rs11900310	ENSG00000237510.6	AC008268.2	6.53	1.02e-10	1.95e-08	0.26	0.2	Event-related brain oscillations;	chr2:96476093	chr2:95789654~95800166:+
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000204556.4	CTD-2514C3.1	6.53	1.02e-10	1.95e-08	0.27	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26018832~26020684:+
BRCA	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	6.53	1.02e-10	1.95e-08	0.23	0.2	Migraine;	chr4:56861145	chr4:56960927~56961373:-
BRCA	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	6.53	1.02e-10	1.95e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000229886.1	RP5-1132H15.3	6.53	1.02e-10	1.95e-08	0.35	0.2	Diabetic kidney disease;	chr7:66144466	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000229886.1	RP5-1132H15.3	6.53	1.02e-10	1.95e-08	0.35	0.2	Diabetic kidney disease;	chr7:66144531	chr7:66025126~66031544:-
BRCA	cis	rs6472827	1	rs6472827	ENSG00000253983.2	RP1-16A9.1	-6.53	1.02e-10	1.95e-08	-0.34	-0.2	Uterine fibroids;	chr8:74207107	chr8:74199396~74208441:+
BRCA	cis	rs467650	0.817	rs977028	ENSG00000248489.1	CTD-2007H13.3	6.53	1.03e-10	1.95e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98720804	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000236529.1	RP13-254B10.1	6.53	1.03e-10	1.96e-08	0.24	0.2	Aortic root size;	chr7:66622723	chr7:65840212~65840596:+
BRCA	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	6.53	1.03e-10	1.96e-08	0.21	0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
BRCA	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	6.53	1.03e-10	1.96e-08	0.24	0.2	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
BRCA	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.53	1.03e-10	1.96e-08	0.23	0.2	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
BRCA	cis	rs755249	0.501	rs2455648	ENSG00000228060.1	RP11-69E11.8	-6.53	1.03e-10	1.96e-08	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39565160~39573203:+
BRCA	cis	rs227275	0.524	rs223337	ENSG00000251288.2	RP11-10L12.2	-6.53	1.03e-10	1.96e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102751401~102752641:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	6.53	1.03e-10	1.97e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000229886.1	RP5-1132H15.3	6.53	1.03e-10	1.97e-08	0.35	0.2	Diabetic kidney disease;	chr7:66146246	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.583	rs11011346	ENSG00000226578.1	RP11-258F22.1	-6.53	1.03e-10	1.97e-08	-0.26	-0.2	Obesity (extreme);	chr10:37720555	chr10:37775371~37784131:-
BRCA	cis	rs9840812	0.623	rs1145106	ENSG00000239213.4	NCK1-AS1	6.53	1.03e-10	1.97e-08	0.23	0.2	Fibrinogen levels;	chr3:136393075	chr3:136841726~136862054:-
BRCA	cis	rs2348418	0.832	rs4244844	ENSG00000247934.4	RP11-967K21.1	6.53	1.03e-10	1.97e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28434062	chr12:28163298~28190738:-
BRCA	cis	rs8031584	0.958	rs11293	ENSG00000260382.1	RP11-540B6.2	6.53	1.04e-10	1.97e-08	0.24	0.2	Huntington's disease progression;	chr15:30942778	chr15:30882267~30883231:-
BRCA	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.04e-10	1.98e-08	-0.24	-0.2	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
BRCA	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.04e-10	1.98e-08	-0.23	-0.2	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
BRCA	cis	rs11742741	0.714	rs61442687	ENSG00000248874.4	C5orf17	-6.53	1.04e-10	1.98e-08	-0.25	-0.2	Educational attainment;	chr5:24189306	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.04e-10	1.98e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
BRCA	cis	rs1861628	0.512	rs10932677	ENSG00000237930.1	AC007563.4	-6.53	1.04e-10	1.98e-08	-0.3	-0.2	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216762427	chr2:216785774~216786144:-
BRCA	cis	rs3764021	0.527	rs2114870	ENSG00000214776.8	RP11-726G1.1	6.53	1.04e-10	1.98e-08	0.24	0.2	Type 1 diabetes;	chr12:9670544	chr12:9467552~9576275:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000214776.8	RP11-726G1.1	6.53	1.04e-10	1.98e-08	0.21	0.2	Type 1 diabetes;	chr12:9703362	chr12:9467552~9576275:+
BRCA	cis	rs73173548	0.557	rs71580759	ENSG00000247828.6	TMEM161B-AS1	6.53	1.04e-10	1.98e-08	0.27	0.2	Macular telangiectasia type 2;	chr5:88474306	chr5:88268895~88436685:+
BRCA	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	6.53	1.04e-10	1.98e-08	0.23	0.2	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
BRCA	cis	rs9527	0.551	rs28606370	ENSG00000236937.2	PTGES3P4	6.53	1.04e-10	1.98e-08	0.26	0.2	Arsenic metabolism;	chr10:102911075	chr10:102845595~102845950:+
BRCA	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000254174.1	IGHV1-12	6.53	1.04e-10	1.99e-08	0.2	0.2	Alzheimer's disease (late onset);	chr14:106688061	chr14:106122420~106122709:-
BRCA	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
BRCA	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-6.53	1.05e-10	1.99e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000228409.4	CCT6P1	-6.53	1.05e-10	1.99e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65750468	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000228409.4	CCT6P1	-6.53	1.05e-10	1.99e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65750593	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-6.53	1.05e-10	1.99e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
BRCA	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	6.53	1.05e-10	1.99e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	6.53	1.05e-10	1.99e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
BRCA	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-6.53	1.05e-10	2e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
BRCA	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	6.53	1.05e-10	2e-08	0.26	0.2	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
BRCA	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	6.53	1.05e-10	2e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
BRCA	cis	rs34779708	0.931	rs2244100	ENSG00000271335.4	RP11-324I22.4	-6.53	1.05e-10	2e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35314552~35336401:-
BRCA	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	6.53	1.05e-10	2e-08	0.18	0.2	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
BRCA	cis	rs9876781	1	rs9849509	ENSG00000229759.1	MRPS18AP1	6.53	1.05e-10	2e-08	0.22	0.2	Longevity;	chr3:48442021	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs60512868	ENSG00000229759.1	MRPS18AP1	6.53	1.05e-10	2e-08	0.22	0.2	Longevity;	chr3:48442035	chr3:48256350~48256938:-
BRCA	cis	rs957448	1	rs1055797	ENSG00000253175.1	RP11-267M23.6	6.53	1.05e-10	2e-08	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94565036~94565715:+
BRCA	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	6.53	1.05e-10	2.01e-08	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
BRCA	cis	rs853679	0.585	rs201004	ENSG00000220721.1	OR1F12	6.53	1.06e-10	2.01e-08	0.29	0.2	Depression;	chr6:27837156	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.896	rs34049963	ENSG00000269927.1	RP6-91H8.3	6.53	1.06e-10	2.01e-08	0.24	0.2	Schizophrenia;	chr14:70974029	chr14:71141125~71143253:-
BRCA	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	6.53	1.06e-10	2.01e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-6.53	1.06e-10	2.01e-08	-0.28	-0.2	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
BRCA	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	6.52	1.06e-10	2.02e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
BRCA	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
BRCA	cis	rs10029851	0.54	rs7682499	ENSG00000234492.4	RPL34-AS1	6.52	1.06e-10	2.02e-08	0.31	0.2	Amyotrophic lateral sclerosis (sporadic);	chr4:108596565	chr4:108538190~108620460:-
BRCA	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
BRCA	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	6.52	1.06e-10	2.02e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
BRCA	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	6.52	1.07e-10	2.02e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000229886.1	RP5-1132H15.3	-6.52	1.07e-10	2.03e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:65750468	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6460261	ENSG00000229886.1	RP5-1132H15.3	-6.52	1.07e-10	2.03e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:65750593	chr7:66025126~66031544:-
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000273765.1	RP11-370I10.11	6.52	1.07e-10	2.03e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48360920~48361377:+
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-6.52	1.07e-10	2.03e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	6.52	1.07e-10	2.03e-08	0.27	0.2	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-6.52	1.07e-10	2.03e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
BRCA	cis	rs6688613	1	rs12130629	ENSG00000225171.2	DUTP6	-6.52	1.07e-10	2.03e-08	-0.24	-0.2	Refractive astigmatism;	chr1:166984047	chr1:166868748~166869209:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000224316.1	RP11-479O9.2	6.52	1.07e-10	2.03e-08	0.23	0.2	Aortic root size;	chr7:66481592	chr7:65773620~65802067:+
BRCA	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	6.52	1.07e-10	2.03e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.896	rs58133478	ENSG00000269927.1	RP6-91H8.3	6.52	1.07e-10	2.03e-08	0.25	0.2	Schizophrenia;	chr14:71058370	chr14:71141125~71143253:-
BRCA	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	6.52	1.07e-10	2.04e-08	0.24	0.2	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
BRCA	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	6.52	1.07e-10	2.04e-08	0.22	0.2	Height;	chr5:37499677	chr5:36666214~36725195:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000229886.1	RP5-1132H15.3	6.52	1.07e-10	2.04e-08	0.35	0.2	Diabetic kidney disease;	chr7:65977771	chr7:66025126~66031544:-
BRCA	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.52	1.07e-10	2.04e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
BRCA	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-6.52	1.07e-10	2.04e-08	-0.21	-0.2	Height;	chr20:35174686	chr20:35201747~35203288:-
BRCA	cis	rs2060793	0.867	rs2122941	ENSG00000251991.1	RNU7-49P	6.52	1.07e-10	2.04e-08	0.22	0.2	Vitamin D levels;	chr11:14834821	chr11:14478892~14478953:+
BRCA	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	6.52	1.07e-10	2.04e-08	0.21	0.2	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
BRCA	cis	rs4372836	1	rs11690423	ENSG00000226833.4	AC097724.3	-6.52	1.07e-10	2.04e-08	-0.24	-0.2	Body mass index;	chr2:28728671	chr2:28708953~28736205:-
BRCA	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-6.52	1.07e-10	2.04e-08	-0.24	-0.2	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000224316.1	RP11-479O9.2	-6.52	1.08e-10	2.04e-08	-0.2	-0.2	Aortic root size;	chr7:66345088	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.869	rs6902689	ENSG00000220721.1	OR1F12	6.52	1.08e-10	2.05e-08	0.25	0.2	Parkinson's disease;	chr6:27741662	chr6:28073316~28074233:+
BRCA	cis	rs35146811	0.586	rs1076237	ENSG00000235713.1	RP4-604G5.3	6.52	1.08e-10	2.05e-08	0.24	0.2	Coronary artery disease;	chr7:99987818	chr7:99992397~99993050:+
BRCA	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	6.52	1.08e-10	2.05e-08	0.23	0.2	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-6.52	1.08e-10	2.05e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000164669.11	INTS4P1	6.52	1.08e-10	2.05e-08	0.25	0.2	Aortic root size;	chr7:66120784	chr7:65141225~65234216:+
BRCA	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	6.52	1.08e-10	2.05e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	6.52	1.08e-10	2.05e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
BRCA	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.08e-10	2.06e-08	-0.24	-0.2	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
BRCA	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-6.52	1.09e-10	2.06e-08	-0.19	-0.2	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000228409.4	CCT6P1	6.52	1.09e-10	2.06e-08	0.27	0.2	Diabetic kidney disease;	chr7:65996588	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000228409.4	CCT6P1	6.52	1.09e-10	2.06e-08	0.27	0.2	Diabetic kidney disease;	chr7:66002158	chr7:65751142~65763354:+
BRCA	cis	rs891378	1	rs971317	ENSG00000274245.1	RP11-357P18.2	-6.52	1.09e-10	2.06e-08	-0.28	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302695	chr1:207372559~207373252:+
BRCA	cis	rs16846053	0.515	rs2892770	ENSG00000227403.1	AC009299.3	-6.52	1.09e-10	2.06e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161638321	chr2:161244739~161249050:+
BRCA	cis	rs7617773	0.78	rs9846818	ENSG00000228638.1	FCF1P2	-6.52	1.09e-10	2.06e-08	-0.2	-0.2	Coronary artery disease;	chr3:48334195	chr3:48290793~48291375:-
BRCA	cis	rs7937890	1	rs2970335	ENSG00000251991.1	RNU7-49P	6.52	1.09e-10	2.06e-08	0.21	0.2	Mitochondrial DNA levels;	chr11:14303855	chr11:14478892~14478953:+
BRCA	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-6.52	1.09e-10	2.07e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-6.52	1.09e-10	2.07e-08	-0.23	-0.2	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
BRCA	cis	rs7746199	0.736	rs13202291	ENSG00000220721.1	OR1F12	6.52	1.09e-10	2.07e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs17750424	ENSG00000220721.1	OR1F12	6.52	1.09e-10	2.07e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	6.52	1.09e-10	2.07e-08	0.23	0.2	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000267422.1	CTD-2554C21.1	-6.52	1.09e-10	2.07e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37445123	chr19:37779686~37792865:+
BRCA	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-6.52	1.09e-10	2.07e-08	-0.19	-0.2	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-6.52	1.09e-10	2.07e-08	-0.26	-0.2	Gout;	chr7:66671562	chr7:66880708~66882981:+
BRCA	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	6.52	1.09e-10	2.08e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
BRCA	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	6.52	1.09e-10	2.08e-08	0.33	0.2	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	6.52	1.09e-10	2.08e-08	0.33	0.2	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
BRCA	cis	rs6088580	0.524	rs4911437	ENSG00000269202.1	RP4-614O4.12	6.52	1.09e-10	2.08e-08	0.22	0.2	Glomerular filtration rate (creatinine);	chr20:34678345	chr20:35201747~35203288:-
BRCA	cis	rs2638953	0.924	rs2061758	ENSG00000247934.4	RP11-967K21.1	-6.52	1.1e-10	2.08e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	6.52	1.1e-10	2.08e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
BRCA	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-6.52	1.1e-10	2.08e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	6.52	1.1e-10	2.08e-08	0.21	0.2	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
BRCA	cis	rs13108904	0.901	rs2293634	ENSG00000254094.1	AC078852.1	-6.52	1.1e-10	2.08e-08	-0.21	-0.2	Obesity-related traits;	chr4:1297923	chr4:1356581~1358075:+
BRCA	cis	rs3781264	0.848	rs6583934	ENSG00000273450.1	RP11-76P2.4	6.52	1.1e-10	2.09e-08	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94309648	chr10:94314907~94315327:-
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	6.52	1.1e-10	2.09e-08	0.27	0.2	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
BRCA	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-6.52	1.1e-10	2.09e-08	-0.25	-0.2	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	6.52	1.1e-10	2.09e-08	0.21	0.2	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000224316.1	RP11-479O9.2	6.52	1.1e-10	2.09e-08	0.23	0.2	Aortic root size;	chr7:66480545	chr7:65773620~65802067:+
BRCA	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-6.52	1.11e-10	2.1e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	6.52	1.11e-10	2.1e-08	0.35	0.2	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	6.52	1.11e-10	2.1e-08	0.35	0.2	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
BRCA	cis	rs17680741	0.802	rs7088704	ENSG00000226659.1	RP11-137H2.4	-6.52	1.11e-10	2.1e-08	-0.26	-0.2	Coronary artery disease;	chr10:80482174	chr10:80529597~80535942:-
BRCA	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-6.52	1.11e-10	2.1e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000273765.1	RP11-370I10.11	6.52	1.11e-10	2.11e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48360920~48361377:+
BRCA	cis	rs13178541	0.638	rs6861738	ENSG00000250378.1	RP11-119J18.1	-6.52	1.12e-10	2.11e-08	-0.25	-0.2	IgG glycosylation;	chr5:135714486	chr5:135812667~135826582:+
BRCA	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.52	1.12e-10	2.11e-08	0.23	0.2	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	6.52	1.12e-10	2.12e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
BRCA	cis	rs754466	0.651	rs11815015	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77865724	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs56138814	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866037	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs10824584	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866189	chr10:77866875~77869610:+
BRCA	cis	rs10483853	0.525	rs7158272	ENSG00000258408.1	NT5CP2	6.52	1.12e-10	2.12e-08	0.28	0.2	Coronary artery calcification;	chr14:73476486	chr14:73539221~73539781:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000224316.1	RP11-479O9.2	-6.52	1.12e-10	2.12e-08	-0.2	-0.2	Aortic root size;	chr7:66149664	chr7:65773620~65802067:+
BRCA	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	6.52	1.12e-10	2.12e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
BRCA	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.52	1.12e-10	2.12e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.52	1.12e-10	2.12e-08	0.28	0.2	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
BRCA	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.52	1.12e-10	2.13e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
BRCA	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	6.52	1.12e-10	2.13e-08	0.33	0.2	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
BRCA	cis	rs78456975	1	rs11891809	ENSG00000231482.2	AC141930.2	-6.52	1.12e-10	2.13e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1562229	chr2:1572554~1580311:-
BRCA	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-6.52	1.13e-10	2.13e-08	-0.24	-0.2	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
BRCA	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	6.52	1.13e-10	2.13e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
BRCA	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Height;	chr20:49241753	chr20:49280319~49280409:+
BRCA	cis	rs34779708	0.966	rs7077242	ENSG00000271335.4	RP11-324I22.4	-6.52	1.13e-10	2.13e-08	-0.21	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35314552~35336401:-
BRCA	cis	rs78456975	0.527	rs11901028	ENSG00000231482.2	AC141930.2	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554200	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs10203194	ENSG00000231482.2	AC141930.2	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554249	chr2:1572554~1580311:-
BRCA	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-6.52	1.13e-10	2.13e-08	-0.36	-0.2	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
BRCA	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-6.52	1.13e-10	2.13e-08	-0.24	-0.2	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000273024.4	INTS4P2	-6.52	1.13e-10	2.13e-08	-0.25	-0.2	Aortic root size;	chr7:66249202	chr7:65647864~65715661:+
BRCA	cis	rs755249	0.567	rs16825939	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs16825942	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs67020650	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs72661925	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs72661927	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39514956~39516490:+
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	6.52	1.13e-10	2.13e-08	0.3	0.2	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.966	rs34296409	ENSG00000271335.4	RP11-324I22.4	6.52	1.13e-10	2.14e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35314552~35336401:-
BRCA	cis	rs2302464	1	rs2302464	ENSG00000214846.4	RP11-115L11.1	-6.52	1.13e-10	2.14e-08	-0.53	-0.2	Cerebrospinal fluid biomarker levels;	chr4:15707629	chr4:15730962~15731627:-
BRCA	cis	rs4372836	1	rs72782294	ENSG00000226833.4	AC097724.3	-6.51	1.13e-10	2.14e-08	-0.24	-0.2	Body mass index;	chr2:28730524	chr2:28708953~28736205:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000228409.4	CCT6P1	6.51	1.13e-10	2.14e-08	0.27	0.2	Diabetic kidney disease;	chr7:65739282	chr7:65751142~65763354:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	6.51	1.13e-10	2.14e-08	0.26	0.2	Height;	chr4:55363436	chr4:55363971~55395847:-
BRCA	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	6.51	1.13e-10	2.15e-08	0.26	0.2	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
BRCA	cis	rs12501370	0.959	rs4472173	ENSG00000201736.1	RNA5SP160	6.51	1.14e-10	2.15e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40998807	chr4:40990154~40990273:+
BRCA	cis	rs17253792	0.822	rs78522049	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55604485	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79022053	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55605003	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76555508	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55605150	chr14:55499278~55580110:-
BRCA	cis	rs17027633	0.5	rs1764808	ENSG00000260948.1	RP11-552M11.8	-6.51	1.14e-10	2.15e-08	-0.3	-0.2	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111413696	chr1:111431046~111433068:-
BRCA	cis	rs9876781	1	rs11130171	ENSG00000229759.1	MRPS18AP1	6.51	1.14e-10	2.15e-08	0.22	0.2	Longevity;	chr3:48421052	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9883927	ENSG00000229759.1	MRPS18AP1	6.51	1.14e-10	2.15e-08	0.22	0.2	Longevity;	chr3:48422302	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	6.51	1.14e-10	2.16e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
BRCA	cis	rs6840360	0.901	rs1443094	ENSG00000270265.1	RP11-731D1.4	-6.51	1.14e-10	2.16e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151333775~151353224:-
BRCA	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-6.51	1.14e-10	2.16e-08	-0.28	-0.2	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
BRCA	cis	rs4664293	0.541	rs1863218	ENSG00000226266.5	AC009961.3	6.51	1.14e-10	2.16e-08	0.23	0.2	Monocyte percentage of white cells;	chr2:159512276	chr2:159670708~159712435:-
BRCA	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-6.51	1.14e-10	2.16e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
BRCA	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	6.51	1.14e-10	2.16e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	6.51	1.15e-10	2.17e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-6.51	1.15e-10	2.17e-08	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
BRCA	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-6.51	1.15e-10	2.17e-08	-0.27	-0.2	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
BRCA	cis	rs4072705	0.967	rs12339980	ENSG00000224020.1	MIR181A2HG	-6.51	1.15e-10	2.17e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124556424	chr9:124658467~124698631:+
BRCA	cis	rs669446	0.533	rs3791042	ENSG00000237950.1	RP11-7O11.3	6.51	1.15e-10	2.17e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43753604	chr1:43944370~43946551:-
BRCA	cis	rs17253792	0.822	rs12323476	ENSG00000186615.9	KTN1-AS1	6.51	1.15e-10	2.18e-08	0.33	0.2	Putamen volume;	chr14:55706004	chr14:55499278~55580110:-
BRCA	cis	rs9876781	1	rs7636044	ENSG00000229759.1	MRPS18AP1	6.51	1.15e-10	2.18e-08	0.22	0.2	Longevity;	chr3:48443151	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs4490383	ENSG00000229759.1	MRPS18AP1	6.51	1.15e-10	2.18e-08	0.22	0.2	Longevity;	chr3:48443275	chr3:48256350~48256938:-
BRCA	cis	rs67981189	0.788	rs34093157	ENSG00000269927.1	RP6-91H8.3	6.51	1.15e-10	2.18e-08	0.25	0.2	Schizophrenia;	chr14:71101966	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000273024.4	INTS4P2	-6.51	1.15e-10	2.18e-08	-0.25	-0.2	Aortic root size;	chr7:66480545	chr7:65647864~65715661:+
BRCA	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-6.51	1.16e-10	2.18e-08	-0.22	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
BRCA	cis	rs10050311	0.586	rs2054592	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86752292	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.746	rs17454662	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86752611	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.746	rs72665791	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86757634	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	6.51	1.16e-10	2.18e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
BRCA	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	6.51	1.16e-10	2.19e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000274576.2	IGHV2-70	-6.51	1.16e-10	2.19e-08	-0.16	-0.2	Kawasaki disease;	chr14:106804049	chr14:106770577~106771020:-
BRCA	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	6.51	1.16e-10	2.19e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	6.51	1.16e-10	2.19e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
BRCA	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	6.51	1.16e-10	2.19e-08	0.24	0.2	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
BRCA	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-6.51	1.16e-10	2.19e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
BRCA	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-6.51	1.16e-10	2.19e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000229886.1	RP5-1132H15.3	6.51	1.16e-10	2.19e-08	0.35	0.2	Diabetic kidney disease;	chr7:66034996	chr7:66025126~66031544:-
BRCA	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	6.51	1.16e-10	2.19e-08	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000273765.1	RP11-370I10.11	6.51	1.16e-10	2.2e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48360920~48361377:+
BRCA	cis	rs9876781	1	rs6784322	ENSG00000229759.1	MRPS18AP1	6.51	1.16e-10	2.2e-08	0.23	0.2	Longevity;	chr3:48380745	chr3:48256350~48256938:-
BRCA	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	6.51	1.16e-10	2.2e-08	0.22	0.2	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
BRCA	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-6.51	1.16e-10	2.2e-08	-0.22	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
BRCA	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	6.51	1.16e-10	2.2e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	6.51	1.17e-10	2.2e-08	0.26	0.2	Height;	chr4:55409063	chr4:55387949~55388271:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-6.51	1.17e-10	2.2e-08	-0.23	-0.2	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	6.51	1.17e-10	2.21e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	6.51	1.17e-10	2.21e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
BRCA	cis	rs11009175	0.725	rs4934646	ENSG00000273038.2	RP11-479G22.8	-6.51	1.17e-10	2.21e-08	-0.29	-0.2	Depression (quantitative trait);	chr10:33007681	chr10:32887255~32889311:-
BRCA	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	6.51	1.17e-10	2.21e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
BRCA	cis	rs4713118	0.869	rs7776351	ENSG00000220721.1	OR1F12	-6.51	1.17e-10	2.21e-08	-0.25	-0.2	Parkinson's disease;	chr6:27758952	chr6:28073316~28074233:+
BRCA	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	6.51	1.17e-10	2.21e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	6.51	1.17e-10	2.21e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	6.51	1.17e-10	2.21e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	6.51	1.17e-10	2.21e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
BRCA	cis	rs7746199	0.736	rs13212318	ENSG00000220721.1	OR1F12	6.51	1.17e-10	2.21e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000224316.1	RP11-479O9.2	-6.51	1.17e-10	2.21e-08	-0.2	-0.2	Aortic root size;	chr7:66081075	chr7:65773620~65802067:+
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000273765.1	RP11-370I10.11	6.51	1.17e-10	2.21e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48360920~48361377:+
BRCA	cis	rs6163	0.727	rs284854	ENSG00000213061.2	PFN1P11	-6.51	1.17e-10	2.21e-08	-0.26	-0.2	Waist circumference;Hip circumference;	chr10:102814805	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000232559.3	GS1-124K5.12	6.51	1.17e-10	2.21e-08	0.36	0.2	Diabetic kidney disease;	chr7:66143429	chr7:66554588~66576923:-
BRCA	cis	rs7246657	0.943	rs7408563	ENSG00000267422.1	CTD-2554C21.1	-6.51	1.17e-10	2.21e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37317683	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	6.51	1.17e-10	2.21e-08	0.28	0.2	Depression;	chr6:28229408	chr6:28943877~28944537:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000229886.1	RP5-1132H15.3	6.51	1.17e-10	2.21e-08	0.34	0.2	Diabetic kidney disease;	chr7:65739282	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.756	rs7575389	ENSG00000231621.1	AC013264.2	6.51	1.17e-10	2.22e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197333765	chr2:197197991~197199273:+
BRCA	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	6.51	1.17e-10	2.22e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.509	rs223481	ENSG00000251288.2	RP11-10L12.2	-6.51	1.17e-10	2.22e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000229886.1	RP5-1132H15.3	6.51	1.17e-10	2.22e-08	0.35	0.2	Diabetic kidney disease;	chr7:66007799	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-6.51	1.18e-10	2.22e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
BRCA	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	6.51	1.18e-10	2.22e-08	0.29	0.2	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000273024.4	INTS4P2	-6.51	1.18e-10	2.22e-08	-0.25	-0.2	Aortic root size;	chr7:66258859	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000267422.1	CTD-2554C21.1	-6.51	1.18e-10	2.22e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37359235	chr19:37779686~37792865:+
BRCA	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	6.51	1.18e-10	2.23e-08	0.37	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
BRCA	cis	rs9307551	0.744	rs10004226	ENSG00000250334.4	LINC00989	-6.51	1.18e-10	2.23e-08	-0.27	-0.2	Refractive error;	chr4:79569654	chr4:79492416~79576460:+
BRCA	cis	rs4763879	0.634	rs2012643	ENSG00000214776.8	RP11-726G1.1	-6.51	1.18e-10	2.23e-08	-0.21	-0.2	Type 1 diabetes;	chr12:9707128	chr12:9467552~9576275:+
BRCA	cis	rs2638953	0.924	rs11049416	ENSG00000278733.1	RP11-425D17.1	6.51	1.18e-10	2.23e-08	0.27	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-6.51	1.18e-10	2.23e-08	-0.3	-0.2	Depression;	chr6:28140307	chr6:28170845~28172521:+
BRCA	cis	rs35146811	0.622	rs6946204	ENSG00000235713.1	RP4-604G5.3	6.51	1.18e-10	2.23e-08	0.24	0.2	Coronary artery disease;	chr7:99991502	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.586	rs6964754	ENSG00000235713.1	RP4-604G5.3	6.51	1.18e-10	2.23e-08	0.24	0.2	Coronary artery disease;	chr7:99991781	chr7:99992397~99993050:+
BRCA	cis	rs2638953	0.888	rs11049407	ENSG00000278733.1	RP11-425D17.1	-6.51	1.18e-10	2.23e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181431	chr12:28185625~28186190:-
BRCA	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-6.51	1.18e-10	2.23e-08	-0.23	-0.2	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
BRCA	cis	rs991427	0.643	rs2701155	ENSG00000258100.1	RP11-121E16.1	-6.51	1.18e-10	2.24e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91061769	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.643	rs73197018	ENSG00000258100.1	RP11-121E16.1	-6.51	1.18e-10	2.24e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91063690	chr12:91362196~91368606:+
BRCA	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	6.51	1.18e-10	2.24e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
BRCA	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	6.51	1.19e-10	2.24e-08	0.31	0.2	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-6.51	1.19e-10	2.24e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000236529.1	RP13-254B10.1	-6.51	1.19e-10	2.24e-08	-0.23	-0.2	Aortic root size;	chr7:66143851	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.966	rs17591163	ENSG00000271335.4	RP11-324I22.4	6.51	1.19e-10	2.24e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35314552~35336401:-
BRCA	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-6.51	1.19e-10	2.24e-08	-0.2	-0.2	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
BRCA	cis	rs77972916	0.505	rs6736400	ENSG00000234936.1	AC010883.5	6.51	1.19e-10	2.25e-08	0.24	0.2	Granulocyte percentage of myeloid white cells;	chr2:43273665	chr2:43229573~43233394:+
BRCA	cis	rs7274963	0.704	rs3918466	ENSG00000236474.1	GCNT1P1	6.51	1.19e-10	2.25e-08	0.22	0.2	Body mass index;	chr20:18312174	chr20:18420160~18421454:-
BRCA	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-6.51	1.19e-10	2.25e-08	-0.18	-0.2	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
BRCA	cis	rs2836950	0.501	rs2056844	ENSG00000238141.2	BRWD1-AS1	-6.51	1.2e-10	2.26e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39298534	chr21:39315707~39323218:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-6.51	1.2e-10	2.26e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
BRCA	cis	rs3736858	0.825	rs2120061	ENSG00000261105.4	LMO7-AS1	-6.51	1.2e-10	2.26e-08	-0.32	-0.2	Interleukin-9 levels;	chr13:75813370	chr13:75604700~75635994:-
BRCA	cis	rs58873874	0.579	rs79615135	ENSG00000248544.2	CTB-47B11.3	6.51	1.2e-10	2.26e-08	0.42	0.2	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157375741~157384950:-
BRCA	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	6.51	1.2e-10	2.26e-08	0.34	0.2	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	6.51	1.2e-10	2.26e-08	0.34	0.2	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-6.51	1.2e-10	2.26e-08	-0.23	-0.2	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
BRCA	cis	rs919433	0.783	rs788011	ENSG00000231621.1	AC013264.2	-6.51	1.2e-10	2.26e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366047	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000273024.4	INTS4P2	-6.51	1.2e-10	2.26e-08	-0.25	-0.2	Aortic root size;	chr7:66216128	chr7:65647864~65715661:+
BRCA	cis	rs228614	0.51	rs223472	ENSG00000251288.2	RP11-10L12.2	-6.51	1.2e-10	2.26e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102751401~102752641:+
BRCA	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-6.51	1.2e-10	2.26e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	6.51	1.2e-10	2.26e-08	0.21	0.2	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
BRCA	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	6.51	1.2e-10	2.27e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	6.51	1.2e-10	2.27e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
BRCA	cis	rs8002861	0.619	rs1337203	ENSG00000274001.1	RP11-5G9.5	6.51	1.2e-10	2.27e-08	0.23	0.2	Leprosy;	chr13:43849485	chr13:43877715~43878163:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000229886.1	RP5-1132H15.3	6.51	1.2e-10	2.27e-08	0.36	0.2	Diabetic kidney disease;	chr7:66068227	chr7:66025126~66031544:-
BRCA	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	6.5	1.21e-10	2.27e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
BRCA	cis	rs67981189	0.896	rs3814871	ENSG00000269927.1	RP6-91H8.3	6.5	1.21e-10	2.27e-08	0.24	0.2	Schizophrenia;	chr14:70978071	chr14:71141125~71143253:-
BRCA	cis	rs7178375	1	rs7178533	ENSG00000215302.7	CTD-3092A11.1	-6.5	1.21e-10	2.27e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30923773	chr15:30470779~30507623:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000228409.4	CCT6P1	6.5	1.21e-10	2.28e-08	0.28	0.2	Diabetic kidney disease;	chr7:65910845	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000273024.4	INTS4P2	-6.5	1.21e-10	2.28e-08	-0.25	-0.2	Aortic root size;	chr7:66370011	chr7:65647864~65715661:+
BRCA	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-6.5	1.21e-10	2.28e-08	-0.23	-0.2	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
BRCA	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	6.5	1.21e-10	2.28e-08	0.31	0.2	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
BRCA	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-6.5	1.21e-10	2.28e-08	-0.21	-0.2	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
BRCA	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	6.5	1.21e-10	2.28e-08	0.22	0.2	Height;	chr5:37504063	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000236529.1	RP13-254B10.1	-6.5	1.21e-10	2.28e-08	-0.25	-0.2	Aortic root size;	chr7:66156017	chr7:65840212~65840596:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	6.5	1.21e-10	2.28e-08	0.15	0.2	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
BRCA	cis	rs78456975	0.943	rs13421238	ENSG00000231482.2	AC141930.2	-6.5	1.21e-10	2.28e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1573107	chr2:1572554~1580311:-
BRCA	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	6.5	1.21e-10	2.29e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
BRCA	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-6.5	1.22e-10	2.29e-08	-0.22	-0.2	Height;	chr5:37344444	chr5:36666214~36725195:-
BRCA	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	6.5	1.22e-10	2.29e-08	0.24	0.2	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
BRCA	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-6.5	1.22e-10	2.29e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-6.5	1.22e-10	2.29e-08	-0.28	-0.2	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
BRCA	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	6.5	1.22e-10	2.29e-08	0.28	0.2	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
BRCA	cis	rs754466	0.58	rs1866437	ENSG00000204049.1	RP11-126H7.4	6.5	1.22e-10	2.29e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77767008	chr10:77866875~77869610:+
BRCA	cis	rs7586673	0.866	rs747003	ENSG00000235724.7	AC009299.2	6.5	1.22e-10	2.29e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161222785~161308303:-
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000273765.1	RP11-370I10.11	6.5	1.22e-10	2.3e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48360920~48361377:+
BRCA	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	6.5	1.22e-10	2.3e-08	0.22	0.2	Height;	chr5:37505544	chr5:36666214~36725195:-
BRCA	cis	rs10833905	0.697	rs10766983	ENSG00000246225.5	RP11-17A1.3	-6.5	1.22e-10	2.3e-08	-0.29	-0.2	Sudden cardiac arrest;	chr11:22924603	chr11:22829380~22945393:+
BRCA	cis	rs669446	0.533	rs28833034	ENSG00000237950.1	RP11-7O11.3	6.5	1.22e-10	2.3e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43747271	chr1:43944370~43946551:-
BRCA	cis	rs4691139	1	rs7693977	ENSG00000248632.1	RP11-366M4.11	6.5	1.22e-10	2.3e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164968587~164970002:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000224316.1	RP11-479O9.2	6.5	1.22e-10	2.3e-08	0.23	0.2	Aortic root size;	chr7:66474464	chr7:65773620~65802067:+
BRCA	cis	rs539096	0.692	rs7549094	ENSG00000237950.1	RP11-7O11.3	6.5	1.22e-10	2.3e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43747507	chr1:43944370~43946551:-
BRCA	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-6.5	1.22e-10	2.31e-08	-0.33	-0.2	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000267422.1	CTD-2554C21.1	-6.5	1.23e-10	2.31e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37334731	chr19:37779686~37792865:+
BRCA	cis	rs858239	1	rs199348	ENSG00000230042.1	AK3P3	-6.5	1.23e-10	2.31e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23129178~23129841:+
BRCA	cis	rs1440410	0.835	rs11100770	ENSG00000250326.1	RP11-284M14.1	-6.5	1.23e-10	2.31e-08	-0.22	-0.2	Ischemic stroke;	chr4:143132629	chr4:142933195~143184861:-
BRCA	cis	rs755249	0.567	rs4660546	ENSG00000237624.1	OXCT2P1	6.5	1.23e-10	2.31e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39514956~39516490:+
BRCA	cis	rs3126085	0.515	rs6668764	ENSG00000237975.5	FLG-AS1	-6.5	1.23e-10	2.31e-08	-0.25	-0.2	Atopic dermatitis;	chr1:152376602	chr1:152168125~152445456:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000236529.1	RP13-254B10.1	6.5	1.23e-10	2.32e-08	0.25	0.2	Aortic root size;	chr7:66358032	chr7:65840212~65840596:+
BRCA	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.5	1.23e-10	2.32e-08	0.2	0.2	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
BRCA	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-6.5	1.23e-10	2.32e-08	-0.27	-0.2	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
BRCA	cis	rs4372836	1	rs4640348	ENSG00000226833.4	AC097724.3	6.5	1.23e-10	2.32e-08	0.24	0.2	Body mass index;	chr2:28742613	chr2:28708953~28736205:-
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	6.5	1.24e-10	2.33e-08	0.24	0.2	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000224316.1	RP11-479O9.2	6.5	1.24e-10	2.33e-08	0.2	0.2	Aortic root size;	chr7:66114735	chr7:65773620~65802067:+
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-6.5	1.24e-10	2.33e-08	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
BRCA	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-6.5	1.24e-10	2.33e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
BRCA	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-6.5	1.24e-10	2.34e-08	-0.24	-0.2	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
BRCA	cis	rs2998286	0.862	rs2790448	ENSG00000254635.4	WAC-AS1	-6.5	1.24e-10	2.34e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.822	rs2807734	ENSG00000254635.4	WAC-AS1	-6.5	1.24e-10	2.34e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.35	0.2	Diabetic kidney disease;	chr7:65928123	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.34	0.2	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.34	0.2	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-6.5	1.25e-10	2.35e-08	-0.26	-0.2	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
BRCA	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	6.5	1.25e-10	2.35e-08	0.25	0.2	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
BRCA	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	6.5	1.25e-10	2.35e-08	0.18	0.2	Asthma;	chr2:102350776	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.35	0.2	Diabetic kidney disease;	chr7:66360703	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.537	rs1208683	ENSG00000226578.1	RP11-258F22.1	6.5	1.25e-10	2.35e-08	0.26	0.2	Obesity (extreme);	chr10:37804795	chr10:37775371~37784131:-
BRCA	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	6.5	1.25e-10	2.35e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
BRCA	cis	rs9876781	0.53	rs11708617	ENSG00000229759.1	MRPS18AP1	6.5	1.25e-10	2.36e-08	0.23	0.2	Longevity;	chr3:48354819	chr3:48256350~48256938:-
BRCA	cis	rs8002861	0.664	rs1808097	ENSG00000274001.1	RP11-5G9.5	6.5	1.25e-10	2.36e-08	0.23	0.2	Leprosy;	chr13:43850630	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.664	rs2218497	ENSG00000274001.1	RP11-5G9.5	6.5	1.25e-10	2.36e-08	0.23	0.2	Leprosy;	chr13:43854657	chr13:43877715~43878163:-
BRCA	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	6.5	1.25e-10	2.36e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	6.5	1.25e-10	2.36e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
BRCA	cis	rs17253792	0.822	rs75763956	ENSG00000186615.9	KTN1-AS1	-6.5	1.26e-10	2.36e-08	-0.37	-0.2	Putamen volume;	chr14:55604458	chr14:55499278~55580110:-
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000265443.1	CTD-2349P21.6	-6.5	1.26e-10	2.36e-08	-0.34	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30726305~30727564:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-6.5	1.26e-10	2.36e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
BRCA	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-6.5	1.26e-10	2.36e-08	-0.25	-0.2	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	6.5	1.26e-10	2.36e-08	0.36	0.2	Gout;	chr7:66732812	chr7:66025126~66031544:-
BRCA	cis	rs45509595	0.556	rs34409918	ENSG00000220721.1	OR1F12	6.5	1.26e-10	2.37e-08	0.47	0.2	Breast cancer;	chr6:27717569	chr6:28073316~28074233:+
BRCA	cis	rs9876781	0.967	rs1459249	ENSG00000229759.1	MRPS18AP1	6.5	1.26e-10	2.37e-08	0.22	0.2	Longevity;	chr3:48438208	chr3:48256350~48256938:-
BRCA	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-6.5	1.26e-10	2.37e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-6.5	1.26e-10	2.37e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000224316.1	RP11-479O9.2	-6.5	1.26e-10	2.37e-08	-0.2	-0.2	Aortic root size;	chr7:66102989	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.962	rs7303747	ENSG00000278733.1	RP11-425D17.1	-6.5	1.26e-10	2.37e-08	-0.27	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28185625~28186190:-
BRCA	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-6.5	1.26e-10	2.37e-08	-0.21	-0.2	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
BRCA	cis	rs7085104	0.513	rs192569	ENSG00000213061.2	PFN1P11	-6.5	1.26e-10	2.37e-08	-0.26	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102838011~102845473:-
BRCA	cis	rs16978956	0.901	rs2424168	ENSG00000236474.1	GCNT1P1	-6.5	1.26e-10	2.37e-08	-0.24	-0.2	Body mass index;	chr20:18345356	chr20:18420160~18421454:-
BRCA	cis	rs4691139	0.967	rs4588418	ENSG00000248632.1	RP11-366M4.11	6.5	1.26e-10	2.37e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164968587~164970002:-
BRCA	cis	rs420259	0.516	rs9933261	ENSG00000260136.4	CTD-2270L9.4	-6.5	1.27e-10	2.38e-08	-0.2	-0.2	Bipolar disorder;	chr16:23504631	chr16:23452758~23457606:+
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.5	1.27e-10	2.38e-08	0.28	0.2	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	6.5	1.27e-10	2.38e-08	0.24	0.2	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	6.5	1.27e-10	2.38e-08	0.24	0.2	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
BRCA	cis	rs6669008	1	rs1891969	ENSG00000232450.1	RP4-730K3.3	-6.5	1.27e-10	2.38e-08	-0.24	-0.2	Bacteremia;	chr1:113643233	chr1:113698884~113699631:-
BRCA	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	6.5	1.27e-10	2.38e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs34087268	ENSG00000271335.4	RP11-324I22.4	6.5	1.27e-10	2.39e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs58159560	ENSG00000271335.4	RP11-324I22.4	6.5	1.27e-10	2.39e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35314552~35336401:-
BRCA	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	6.5	1.27e-10	2.39e-08	0.25	0.2	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
BRCA	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	6.5	1.27e-10	2.39e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	6.5	1.27e-10	2.39e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000224316.1	RP11-479O9.2	6.5	1.27e-10	2.39e-08	0.2	0.2	Aortic root size;	chr7:66364510	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-6.5	1.27e-10	2.39e-08	-0.25	-0.2	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
BRCA	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.4e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.524	rs7118747	ENSG00000280615.1	Y_RNA	-6.5	1.28e-10	2.4e-08	-0.22	-0.2	Subjective well-being;	chr11:47867993	chr11:47614898~47614994:-
BRCA	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.4e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
BRCA	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-6.5	1.28e-10	2.4e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-6.5	1.28e-10	2.4e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	6.5	1.28e-10	2.4e-08	0.27	0.2	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
BRCA	cis	rs9527	0.571	rs3740400	ENSG00000236937.2	PTGES3P4	6.5	1.28e-10	2.4e-08	0.25	0.2	Arsenic metabolism;	chr10:102869708	chr10:102845595~102845950:+
BRCA	cis	rs34779708	0.897	rs16935880	ENSG00000271335.4	RP11-324I22.4	6.5	1.28e-10	2.4e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4934730	ENSG00000271335.4	RP11-324I22.4	6.5	1.28e-10	2.4e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35314552~35336401:-
BRCA	cis	rs7124681	0.584	rs11039448	ENSG00000280615.1	Y_RNA	-6.5	1.28e-10	2.41e-08	-0.23	-0.2	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47896864	chr11:47614898~47614994:-
BRCA	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.41e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
BRCA	cis	rs4072705	1	rs6478671	ENSG00000224020.1	MIR181A2HG	-6.5	1.28e-10	2.41e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124611716	chr9:124658467~124698631:+
BRCA	cis	rs228614	0.536	rs223484	ENSG00000251288.2	RP11-10L12.2	-6.5	1.28e-10	2.41e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-6.5	1.28e-10	2.41e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
BRCA	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-6.5	1.28e-10	2.41e-08	-0.25	-0.2	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
BRCA	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	6.5	1.28e-10	2.41e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
BRCA	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-6.49	1.28e-10	2.41e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
BRCA	cis	rs73193808	0.901	rs73354869	ENSG00000215533.7	LINC00189	-6.49	1.29e-10	2.41e-08	-0.28	-0.2	Coronary artery disease;	chr21:29194964	chr21:29193480~29288205:+
BRCA	cis	rs6840258	0.941	rs7665282	ENSG00000251411.1	RP11-397E7.4	-6.49	1.29e-10	2.41e-08	-0.27	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86979698	chr4:86913266~86914817:-
BRCA	cis	rs10506328	0.509	rs1920046	ENSG00000257534.1	RP11-834C11.10	6.49	1.29e-10	2.42e-08	0.21	0.2	Mean platelet volume;	chr12:54276271	chr12:54162065~54164452:-
BRCA	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-6.49	1.29e-10	2.42e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
BRCA	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	6.49	1.29e-10	2.42e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
BRCA	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-6.49	1.29e-10	2.42e-08	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
BRCA	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	6.49	1.29e-10	2.42e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
BRCA	cis	rs797680	0.576	rs55838267	ENSG00000229635.1	RP4-713B5.2	6.49	1.29e-10	2.42e-08	0.35	0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93384487~93384998:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	6.49	1.29e-10	2.42e-08	0.15	0.2	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	6.49	1.29e-10	2.42e-08	0.17	0.2	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
BRCA	cis	rs67981189	0.896	rs17108822	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70979189	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs8012728	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70981231	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs34731365	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70982877	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	6.49	1.3e-10	2.43e-08	0.21	0.2	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
BRCA	cis	rs2998286	0.768	rs332137	ENSG00000254635.4	WAC-AS1	-6.49	1.3e-10	2.43e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28522652~28532743:-
BRCA	cis	rs9638182	0.623	rs13246490	ENSG00000274080.1	CTA-315H11.2	6.49	1.3e-10	2.43e-08	0.39	0.2	Triglycerides;	chr7:73578020	chr7:73609262~73611502:-
BRCA	cis	rs4218	0.531	rs10431791	ENSG00000277144.1	RP11-59H7.4	-6.49	1.3e-10	2.44e-08	-0.24	-0.2	Social communication problems;	chr15:59055159	chr15:59115547~59116089:-
BRCA	cis	rs957448	1	rs957448	ENSG00000253175.1	RP11-267M23.6	6.49	1.3e-10	2.44e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94565036~94565715:+
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
BRCA	cis	rs42648	0.748	rs10225744	ENSG00000225498.1	AC002064.5	6.49	1.3e-10	2.44e-08	0.19	0.2	Homocysteine levels;	chr7:90316689	chr7:90312496~90322592:+
BRCA	cis	rs12594515	1	rs11070467	ENSG00000259200.1	RP11-718O11.1	6.49	1.3e-10	2.44e-08	0.22	0.2	Weight;Waist circumference;	chr15:45692803	chr15:45705078~45931069:+
BRCA	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-6.49	1.3e-10	2.44e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-6.49	1.3e-10	2.44e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
BRCA	cis	rs1124769	0.748	rs10851493	ENSG00000259378.1	DCAF13P3	6.49	1.3e-10	2.45e-08	0.28	0.2	Cognitive performance;	chr15:51056489	chr15:50944663~50945996:+
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.3e-10	2.45e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37471390	chr19:37779686~37792865:+
BRCA	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	6.49	1.3e-10	2.45e-08	0.4	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
BRCA	cis	rs9876781	1	rs4858817	ENSG00000229759.1	MRPS18AP1	-6.49	1.3e-10	2.45e-08	-0.22	-0.2	Longevity;	chr3:48375266	chr3:48256350~48256938:-
BRCA	cis	rs6142102	1	rs6059673	ENSG00000275784.1	RP5-1125A11.6	-6.49	1.31e-10	2.45e-08	-0.24	-0.2	Skin pigmentation;	chr20:34117755	chr20:33989480~33991818:-
BRCA	cis	rs8002861	0.664	rs9533662	ENSG00000274001.1	RP11-5G9.5	6.49	1.31e-10	2.45e-08	0.23	0.2	Leprosy;	chr13:43861852	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.619	rs9567289	ENSG00000274001.1	RP11-5G9.5	6.49	1.31e-10	2.45e-08	0.23	0.2	Leprosy;	chr13:43862968	chr13:43877715~43878163:-
BRCA	cis	rs7746199	0.736	rs34105070	ENSG00000220721.1	OR1F12	6.49	1.31e-10	2.45e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28073316~28074233:+
BRCA	cis	rs12501370	1	rs35089980	ENSG00000201736.1	RNA5SP160	6.49	1.31e-10	2.46e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40999201	chr4:40990154~40990273:+
BRCA	cis	rs6740322	0.748	rs13432574	ENSG00000234936.1	AC010883.5	6.49	1.31e-10	2.46e-08	0.22	0.2	Coronary artery disease;	chr2:43317189	chr2:43229573~43233394:+
BRCA	cis	rs7927771	0.524	rs4752798	ENSG00000280615.1	Y_RNA	-6.49	1.31e-10	2.47e-08	-0.22	-0.2	Subjective well-being;	chr11:47864812	chr11:47614898~47614994:-
BRCA	cis	rs67981189	0.896	rs12883437	ENSG00000269927.1	RP6-91H8.3	6.49	1.32e-10	2.47e-08	0.24	0.2	Schizophrenia;	chr14:70998064	chr14:71141125~71143253:-
BRCA	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-6.49	1.32e-10	2.47e-08	-0.24	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
BRCA	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-6.49	1.32e-10	2.47e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
BRCA	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
BRCA	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	6.49	1.32e-10	2.48e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
BRCA	cis	rs7131987	0.565	rs766445	ENSG00000275476.1	RP11-996F15.4	6.49	1.32e-10	2.48e-08	0.22	0.2	QT interval;	chr12:29260560	chr12:29277397~29277882:-
BRCA	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-6.49	1.32e-10	2.48e-08	-0.22	-0.2	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
BRCA	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	6.49	1.32e-10	2.48e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
BRCA	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-6.49	1.32e-10	2.48e-08	-0.26	-0.2	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.49	1.32e-10	2.48e-08	0.28	0.2	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
BRCA	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.33e-10	2.49e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37455278	chr19:37779686~37792865:+
BRCA	cis	rs8031584	0.958	rs7176569	ENSG00000260382.1	RP11-540B6.2	-6.49	1.33e-10	2.49e-08	-0.24	-0.2	Huntington's disease progression;	chr15:30952292	chr15:30882267~30883231:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	6.49	1.33e-10	2.49e-08	0.2	0.2	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.33e-10	2.49e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37491031	chr19:37779686~37792865:+
BRCA	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	6.49	1.33e-10	2.49e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
BRCA	cis	rs7746199	0.736	rs34965299	ENSG00000220721.1	OR1F12	6.49	1.33e-10	2.5e-08	0.45	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
BRCA	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	6.49	1.33e-10	2.5e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
BRCA	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-6.49	1.33e-10	2.5e-08	-0.26	-0.2	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
BRCA	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351825	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351896	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351902	chr2:102438713~102440475:+
BRCA	cis	rs873549	0.959	rs10779467	ENSG00000232679.1	RP11-400N13.3	-6.49	1.33e-10	2.5e-08	-0.23	-0.2	Keloid;	chr1:222092288	chr1:222041705~222064763:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-6.49	1.34e-10	2.5e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
BRCA	cis	rs228614	0.51	rs223405	ENSG00000251288.2	RP11-10L12.2	-6.49	1.34e-10	2.5e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.502	rs12627205	ENSG00000238141.2	BRWD1-AS1	-6.49	1.34e-10	2.5e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39258101	chr21:39315707~39323218:+
BRCA	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	6.49	1.34e-10	2.5e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
BRCA	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-6.49	1.34e-10	2.51e-08	-0.23	-0.2	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
BRCA	cis	rs11024102	1	rs4141194	ENSG00000184669.7	OR7E14P	6.49	1.34e-10	2.51e-08	0.31	0.2	Glaucoma (primary angle closure);	chr11:16989629	chr11:17013998~17053024:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000229886.1	RP5-1132H15.3	6.49	1.34e-10	2.51e-08	0.36	0.2	Diabetic kidney disease;	chr7:66085904	chr7:66025126~66031544:-
BRCA	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	6.49	1.34e-10	2.51e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	6.49	1.34e-10	2.51e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66363676	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66374173	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66376216	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-6.49	1.34e-10	2.52e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	6.49	1.34e-10	2.52e-08	0.28	0.2	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
BRCA	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-6.49	1.34e-10	2.52e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48355792~48356614:-
BRCA	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-6.49	1.35e-10	2.52e-08	-0.28	-0.2	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
BRCA	cis	rs228614	0.536	rs223437	ENSG00000251288.2	RP11-10L12.2	-6.49	1.35e-10	2.52e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223435	ENSG00000251288.2	RP11-10L12.2	-6.49	1.35e-10	2.52e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102751401~102752641:+
BRCA	cis	rs250585	1	rs2073951	ENSG00000260136.4	CTD-2270L9.4	-6.49	1.35e-10	2.52e-08	-0.22	-0.2	Egg allergy;	chr16:23535240	chr16:23452758~23457606:+
BRCA	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	6.49	1.35e-10	2.53e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
BRCA	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-6.49	1.35e-10	2.53e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000229886.1	RP5-1132H15.3	6.49	1.35e-10	2.53e-08	0.34	0.2	Diabetic kidney disease;	chr7:65940751	chr7:66025126~66031544:-
BRCA	cis	rs9527	0.571	rs7904113	ENSG00000236937.2	PTGES3P4	6.49	1.35e-10	2.53e-08	0.25	0.2	Arsenic metabolism;	chr10:102873357	chr10:102845595~102845950:+
BRCA	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	6.49	1.36e-10	2.54e-08	0.23	0.2	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
BRCA	cis	rs7621025	0.63	rs1681816	ENSG00000239213.4	NCK1-AS1	-6.49	1.36e-10	2.54e-08	-0.24	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136841726~136862054:-
BRCA	cis	rs1440410	0.835	rs4626148	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131307	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10034769	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131740	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6829621	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131818	chr4:142933195~143184861:-
BRCA	cis	rs1020064	0.636	rs12476328	ENSG00000235319.1	AC012360.4	-6.49	1.36e-10	2.54e-08	-0.27	-0.2	AIDS;	chr2:105359887	chr2:105324210~105330529:+
BRCA	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-6.49	1.36e-10	2.54e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
BRCA	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	6.49	1.36e-10	2.54e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
BRCA	cis	rs67766926	0.587	rs72809443	ENSG00000271889.1	RP11-493E12.1	6.49	1.36e-10	2.55e-08	0.3	0.2	Inflammatory skin disease;	chr2:61028918	chr2:61151433~61162105:-
BRCA	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	6.49	1.36e-10	2.55e-08	0.25	0.2	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
BRCA	cis	rs2726040	0.902	rs33957528	ENSG00000278665.1	RP11-666O2.4	-6.49	1.36e-10	2.55e-08	-0.21	-0.2	Hip circumference;	chr16:28296619	chr16:28599241~28601881:-
BRCA	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-6.49	1.36e-10	2.55e-08	-0.36	-0.2	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
BRCA	cis	rs3760982	1	rs12460161	ENSG00000267058.1	RP11-15A1.3	-6.49	1.36e-10	2.55e-08	-0.22	-0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789834	chr19:43891804~43901805:-
BRCA	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	6.49	1.36e-10	2.55e-08	0.25	0.2	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
BRCA	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	6.49	1.36e-10	2.55e-08	0.24	0.2	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-6.49	1.36e-10	2.55e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
BRCA	cis	rs2998286	0.723	rs332154	ENSG00000254635.4	WAC-AS1	-6.48	1.37e-10	2.56e-08	-0.29	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs332156	ENSG00000254635.4	WAC-AS1	-6.48	1.37e-10	2.56e-08	-0.29	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-6.48	1.37e-10	2.56e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
BRCA	cis	rs228614	0.51	rs223445	ENSG00000251288.2	RP11-10L12.2	-6.48	1.37e-10	2.57e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102751401~102752641:+
BRCA	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	6.48	1.37e-10	2.57e-08	0.21	0.2	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
BRCA	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	6.48	1.37e-10	2.57e-08	0.33	0.2	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-6.48	1.37e-10	2.57e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
BRCA	cis	rs875971	1	rs778726	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66363744	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66366357	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778685	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66371189	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66372947	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66377234	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000229886.1	RP5-1132H15.3	6.48	1.37e-10	2.57e-08	0.34	0.2	Diabetic kidney disease;	chr7:65946971	chr7:66025126~66031544:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000265443.1	CTD-2349P21.6	-6.48	1.38e-10	2.57e-08	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30726305~30727564:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
BRCA	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-6.48	1.38e-10	2.58e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-6.48	1.38e-10	2.58e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
BRCA	cis	rs991427	0.643	rs17018636	ENSG00000258100.1	RP11-121E16.1	-6.48	1.38e-10	2.58e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91061469	chr12:91362196~91368606:+
BRCA	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	6.48	1.38e-10	2.58e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
BRCA	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-6.48	1.38e-10	2.58e-08	-0.26	-0.2	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
BRCA	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	6.48	1.38e-10	2.58e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	6.48	1.38e-10	2.58e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
BRCA	cis	rs539096	0.692	rs6669157	ENSG00000237950.1	RP11-7O11.3	6.48	1.38e-10	2.58e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43751205	chr1:43944370~43946551:-
BRCA	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	6.48	1.38e-10	2.58e-08	0.25	0.2	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	6.48	1.38e-10	2.58e-08	0.24	0.2	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000236529.1	RP13-254B10.1	6.48	1.38e-10	2.59e-08	0.25	0.2	Aortic root size;	chr7:66441589	chr7:65840212~65840596:+
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-6.48	1.38e-10	2.59e-08	-0.18	-0.2	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.585	rs536208	ENSG00000272379.1	RP1-257A7.5	6.48	1.39e-10	2.59e-08	0.31	0.2	HIV-1 viral setpoint;	chr6:13256715	chr6:13290018~13290490:-
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000260872.1	RP11-680G24.5	6.48	1.39e-10	2.59e-08	0.29	0.2	Waist-hip ratio;	chr16:15784296	chr16:15018106~15020488:-
BRCA	cis	rs8114671	0.805	rs6060168	ENSG00000269202.1	RP4-614O4.12	-6.48	1.39e-10	2.59e-08	-0.2	-0.2	Height;	chr20:35033214	chr20:35201747~35203288:-
BRCA	cis	rs860818	1	rs858282	ENSG00000226816.2	AC005082.12	6.48	1.39e-10	2.59e-08	0.46	0.2	Initial pursuit acceleration;	chr7:23210416	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-6.48	1.39e-10	2.59e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
BRCA	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	6.48	1.39e-10	2.6e-08	0.25	0.2	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
BRCA	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-6.48	1.39e-10	2.6e-08	-0.24	-0.2	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
BRCA	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	6.48	1.39e-10	2.6e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
BRCA	cis	rs12439619	1	rs35152457	ENSG00000259429.4	UBE2Q2P2	-6.48	1.4e-10	2.61e-08	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82355142~82420075:+
BRCA	cis	rs73193808	1	rs8127464	ENSG00000215533.7	LINC00189	-6.48	1.4e-10	2.61e-08	-0.28	-0.2	Coronary artery disease;	chr21:29187381	chr21:29193480~29288205:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-6.48	1.4e-10	2.61e-08	-0.27	-0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
BRCA	cis	rs420259	0.516	rs7199108	ENSG00000260136.4	CTD-2270L9.4	-6.48	1.4e-10	2.61e-08	-0.2	-0.2	Bipolar disorder;	chr16:23537480	chr16:23452758~23457606:+
BRCA	cis	rs12594515	1	rs8032361	ENSG00000259200.1	RP11-718O11.1	-6.48	1.4e-10	2.61e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696355	chr15:45705078~45931069:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	6.48	1.4e-10	2.61e-08	0.27	0.2	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	6.48	1.4e-10	2.61e-08	0.27	0.2	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	6.48	1.4e-10	2.61e-08	0.26	0.2	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
BRCA	cis	rs420259	0.516	rs2106456	ENSG00000260136.4	CTD-2270L9.4	-6.48	1.4e-10	2.61e-08	-0.2	-0.2	Bipolar disorder;	chr16:23539610	chr16:23452758~23457606:+
BRCA	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	6.48	1.4e-10	2.62e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
BRCA	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-6.48	1.4e-10	2.62e-08	-0.27	-0.2	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	6.48	1.4e-10	2.62e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
BRCA	cis	rs1124769	0.748	rs17703518	ENSG00000259378.1	DCAF13P3	6.48	1.4e-10	2.62e-08	0.28	0.2	Cognitive performance;	chr15:51063746	chr15:50944663~50945996:+
BRCA	cis	rs6583826	0.758	rs11187072	ENSG00000236493.2	EIF2S2P3	6.48	1.4e-10	2.62e-08	0.26	0.2	Type 2 diabetes;	chr10:92564652	chr10:92668745~92669743:-
BRCA	cis	rs9527	0.614	rs4919691	ENSG00000213061.2	PFN1P11	6.48	1.4e-10	2.62e-08	0.26	0.2	Arsenic metabolism;	chr10:102864718	chr10:102838011~102845473:-
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-6.48	1.41e-10	2.63e-08	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
BRCA	cis	rs42648	0.596	rs194513	ENSG00000225498.1	AC002064.5	6.48	1.41e-10	2.63e-08	0.18	0.2	Homocysteine levels;	chr7:90220856	chr7:90312496~90322592:+
BRCA	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	6.48	1.41e-10	2.63e-08	0.25	0.2	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	6.48	1.41e-10	2.63e-08	0.25	0.2	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
BRCA	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.48	1.41e-10	2.63e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
BRCA	cis	rs12594515	1	rs12906442	ENSG00000259200.1	RP11-718O11.1	-6.48	1.41e-10	2.63e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45693056	chr15:45705078~45931069:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000228409.4	CCT6P1	6.48	1.41e-10	2.64e-08	0.27	0.2	Diabetic kidney disease;	chr7:66015986	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000228409.4	CCT6P1	6.48	1.41e-10	2.64e-08	0.27	0.2	Diabetic kidney disease;	chr7:66028044	chr7:65751142~65763354:+
BRCA	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	6.48	1.41e-10	2.64e-08	0.24	0.2	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
BRCA	cis	rs6740322	0.895	rs6710656	ENSG00000234936.1	AC010883.5	6.48	1.41e-10	2.64e-08	0.22	0.2	Coronary artery disease;	chr2:43339802	chr2:43229573~43233394:+
BRCA	cis	rs228614	0.51	rs223451	ENSG00000251288.2	RP11-10L12.2	-6.48	1.41e-10	2.64e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223450	ENSG00000251288.2	RP11-10L12.2	-6.48	1.41e-10	2.64e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102751401~102752641:+
BRCA	cis	rs16846053	0.515	rs1399650	ENSG00000227403.1	AC009299.3	-6.48	1.41e-10	2.64e-08	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161695208	chr2:161244739~161249050:+
BRCA	cis	rs73173548	0.528	rs80083342	ENSG00000247828.6	TMEM161B-AS1	6.48	1.42e-10	2.64e-08	0.27	0.2	Macular telangiectasia type 2;	chr5:88476921	chr5:88268895~88436685:+
BRCA	cis	rs10515750	0.5	rs2288069	ENSG00000251405.2	CTB-109A12.1	6.48	1.42e-10	2.65e-08	0.3	0.2	Lung function (FEV1/FVC);	chr5:157285187	chr5:157362615~157460078:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	6.48	1.42e-10	2.65e-08	0.15	0.2	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
BRCA	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	6.48	1.42e-10	2.65e-08	0.21	0.2	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
BRCA	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	6.48	1.42e-10	2.65e-08	0.18	0.2	Asthma;	chr2:102351547	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-6.48	1.42e-10	2.65e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
BRCA	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-6.48	1.42e-10	2.65e-08	-0.25	-0.2	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	6.48	1.42e-10	2.66e-08	0.3	0.2	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
BRCA	cis	rs2836950	0.527	rs2836958	ENSG00000238141.2	BRWD1-AS1	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39251600	chr21:39315707~39323218:+
BRCA	cis	rs12594515	1	rs7162201	ENSG00000259200.1	RP11-718O11.1	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45700460	chr15:45705078~45931069:+
BRCA	cis	rs858239	0.932	rs858275	ENSG00000230042.1	AK3P3	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23129178~23129841:+
BRCA	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-6.48	1.43e-10	2.66e-08	-0.26	-0.2	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
BRCA	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	6.48	1.43e-10	2.66e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	6.48	1.43e-10	2.66e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
BRCA	cis	rs7520050	0.966	rs785471	ENSG00000280836.1	AL355480.1	6.48	1.43e-10	2.66e-08	0.23	0.2	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45581219~45581321:-
BRCA	cis	rs7746199	0.673	rs72845046	ENSG00000220721.1	OR1F12	6.48	1.43e-10	2.67e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28073316~28074233:+
BRCA	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-6.48	1.43e-10	2.67e-08	-0.25	-0.2	QT interval;	chr12:29343291	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-6.48	1.43e-10	2.67e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
BRCA	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-6.48	1.43e-10	2.67e-08	-0.16	-0.2	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000228409.4	CCT6P1	6.48	1.43e-10	2.67e-08	0.27	0.2	Diabetic kidney disease;	chr7:66008327	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-6.48	1.43e-10	2.68e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
BRCA	cis	rs11671005	0.737	rs11673101	ENSG00000252334.1	RNU6-1337P	6.48	1.43e-10	2.68e-08	0.33	0.2	Mean platelet volume;	chr19:58483686	chr19:58483749~58483843:-
BRCA	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	6.48	1.44e-10	2.68e-08	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
BRCA	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	6.48	1.44e-10	2.68e-08	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
BRCA	cis	rs1440410	0.835	rs9790822	ENSG00000250326.1	RP11-284M14.1	-6.48	1.44e-10	2.68e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130748	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4323054	ENSG00000250326.1	RP11-284M14.1	-6.48	1.44e-10	2.68e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130970	chr4:142933195~143184861:-
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000267422.1	CTD-2554C21.1	-6.48	1.44e-10	2.68e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37403334	chr19:37779686~37792865:+
BRCA	cis	rs11722228	0.522	rs62286604	ENSG00000261490.1	RP11-448G15.3	6.48	1.44e-10	2.68e-08	0.22	0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10129537	chr4:10068089~10073019:-
BRCA	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-6.48	1.44e-10	2.68e-08	-0.24	-0.2	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
BRCA	cis	rs227275	0.556	rs223426	ENSG00000251288.2	RP11-10L12.2	-6.48	1.44e-10	2.69e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223425	ENSG00000251288.2	RP11-10L12.2	-6.48	1.44e-10	2.69e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102751401~102752641:+
BRCA	cis	rs2834288	0.535	rs13049489	ENSG00000273102.1	AP000569.9	6.48	1.44e-10	2.69e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33967101~33968573:-
BRCA	cis	rs7914558	0.966	rs4532960	ENSG00000213061.2	PFN1P11	6.48	1.44e-10	2.69e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs10786724	ENSG00000213061.2	PFN1P11	6.48	1.44e-10	2.69e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102838011~102845473:-
BRCA	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	6.48	1.44e-10	2.69e-08	0.2	0.2	Height;	chr20:35190631	chr20:35201747~35203288:-
BRCA	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	6.48	1.44e-10	2.7e-08	0.22	0.2	Height;	chr5:37533964	chr5:36666214~36725195:-
BRCA	cis	rs2015599	0.549	rs7134187	ENSG00000257176.2	RP11-996F15.2	-6.48	1.45e-10	2.7e-08	-0.23	-0.2	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs11599606	ENSG00000271335.4	RP11-324I22.4	6.48	1.45e-10	2.7e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35314552~35336401:-
BRCA	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.48	1.45e-10	2.7e-08	0.2	0.2	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
BRCA	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	6.48	1.45e-10	2.7e-08	0.25	0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
BRCA	cis	rs67981189	0.896	rs34763296	ENSG00000269927.1	RP6-91H8.3	6.48	1.45e-10	2.7e-08	0.24	0.2	Schizophrenia;	chr14:71083458	chr14:71141125~71143253:-
BRCA	cis	rs67340775	0.541	rs200965	ENSG00000220721.1	OR1F12	6.48	1.45e-10	2.7e-08	0.3	0.2	Lung cancer in ever smokers;	chr6:27898606	chr6:28073316~28074233:+
BRCA	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	6.48	1.45e-10	2.71e-08	0.22	0.2	Height;	chr5:37475788	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	6.48	1.45e-10	2.71e-08	0.15	0.2	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	6.48	1.45e-10	2.71e-08	0.15	0.2	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
BRCA	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-6.48	1.45e-10	2.71e-08	-0.22	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
BRCA	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	6.48	1.45e-10	2.71e-08	0.26	0.2	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
BRCA	cis	rs13178541	0.81	rs11951836	ENSG00000250378.1	RP11-119J18.1	-6.48	1.45e-10	2.71e-08	-0.27	-0.2	IgG glycosylation;	chr5:135816068	chr5:135812667~135826582:+
BRCA	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-6.48	1.46e-10	2.72e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-6.48	1.46e-10	2.72e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
BRCA	cis	rs4639966	0.836	rs10892282	ENSG00000255239.1	AP002954.6	6.47	1.46e-10	2.72e-08	0.26	0.2	Systemic lupus erythematosus;	chr11:118757069	chr11:118688039~118690600:-
BRCA	cis	rs67340775	0.541	rs200968	ENSG00000220721.1	OR1F12	6.47	1.46e-10	2.73e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27891790	chr6:28073316~28074233:+
BRCA	cis	rs12908161	0.515	rs12907646	ENSG00000225151.9	GOLGA2P7	-6.47	1.46e-10	2.73e-08	-0.28	-0.2	Schizophrenia;	chr15:84860265	chr15:84199311~84230136:-
BRCA	cis	rs4237845	0.742	rs6650219	ENSG00000257159.1	RP11-58A17.3	6.47	1.47e-10	2.73e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57895317	chr12:57967058~57968399:+
BRCA	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
BRCA	cis	rs2834288	0.5	rs2051189	ENSG00000273102.1	AP000569.9	6.47	1.47e-10	2.74e-08	0.21	0.2	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33967101~33968573:-
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	6.47	1.47e-10	2.74e-08	0.3	0.2	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
BRCA	cis	rs7937890	0.967	rs963212	ENSG00000251991.1	RNU7-49P	-6.47	1.47e-10	2.74e-08	-0.21	-0.2	Mitochondrial DNA levels;	chr11:14303186	chr11:14478892~14478953:+
BRCA	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	6.47	1.47e-10	2.74e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	6.47	1.47e-10	2.74e-08	0.15	0.2	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
BRCA	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	6.47	1.47e-10	2.74e-08	0.21	0.2	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000273024.4	INTS4P2	-6.47	1.47e-10	2.74e-08	-0.25	-0.2	Aortic root size;	chr7:66387213	chr7:65647864~65715661:+
BRCA	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	6.47	1.47e-10	2.74e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
BRCA	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-6.47	1.47e-10	2.74e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
BRCA	cis	rs7746199	0.736	rs67652222	ENSG00000220721.1	OR1F12	6.47	1.47e-10	2.75e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28073316~28074233:+
BRCA	cis	rs12594515	1	rs8029209	ENSG00000259200.1	RP11-718O11.1	-6.47	1.47e-10	2.75e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45701291	chr15:45705078~45931069:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
BRCA	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-6.47	1.48e-10	2.75e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000273024.4	INTS4P2	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Aortic root size;	chr7:66474464	chr7:65647864~65715661:+
BRCA	cis	rs228614	0.536	rs223475	ENSG00000251288.2	RP11-10L12.2	-6.47	1.48e-10	2.75e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.536	rs223474	ENSG00000251288.2	RP11-10L12.2	-6.47	1.48e-10	2.75e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102751401~102752641:+
BRCA	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-6.47	1.48e-10	2.75e-08	-0.26	-0.2	Height;	chr20:49249247	chr20:49280319~49280409:+
BRCA	cis	rs11742741	0.676	rs13155915	ENSG00000248874.4	C5orf17	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Educational attainment;	chr5:24191881	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.702	rs13154927	ENSG00000248874.4	C5orf17	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Educational attainment;	chr5:24191972	chr5:23951348~24178263:+
BRCA	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-6.47	1.48e-10	2.76e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-6.47	1.48e-10	2.76e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000224316.1	RP11-479O9.2	6.47	1.48e-10	2.76e-08	0.2	0.2	Aortic root size;	chr7:66421388	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000224316.1	RP11-479O9.2	6.47	1.48e-10	2.76e-08	0.2	0.2	Aortic root size;	chr7:66423583	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-6.47	1.48e-10	2.76e-08	-0.2	-0.2	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
BRCA	cis	rs9880211	0.718	rs35320690	ENSG00000239213.4	NCK1-AS1	-6.47	1.48e-10	2.76e-08	-0.24	-0.2	Height;Body mass index;	chr3:136213652	chr3:136841726~136862054:-
BRCA	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-6.47	1.48e-10	2.76e-08	-0.22	-0.2	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
BRCA	cis	rs17253792	0.822	rs80085988	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629455	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77676035	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629511	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75555677	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629711	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs2274075	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55630013	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs28587929	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55630774	chr14:55499278~55580110:-
BRCA	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-6.47	1.48e-10	2.76e-08	-0.25	-0.2	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
BRCA	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	6.47	1.49e-10	2.77e-08	0.35	0.2	Gout;	chr7:66679692	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.49e-10	2.77e-08	-0.35	-0.2	Gout;	chr7:66682070	chr7:66025126~66031544:-
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.49e-10	2.77e-08	-0.35	-0.2	Gout;	chr7:66682162	chr7:66025126~66031544:-
BRCA	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-6.47	1.49e-10	2.77e-08	-0.26	-0.2	Height;	chr20:49220669	chr20:49280319~49280409:+
BRCA	cis	rs710913	0.745	rs1180334	ENSG00000237624.1	OXCT2P1	-6.47	1.49e-10	2.77e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39514956~39516490:+
BRCA	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	6.47	1.49e-10	2.77e-08	0.33	0.2	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
BRCA	cis	rs42648	0.596	rs6465251	ENSG00000225498.1	AC002064.5	6.47	1.49e-10	2.77e-08	0.18	0.2	Homocysteine levels;	chr7:90218567	chr7:90312496~90322592:+
BRCA	cis	rs919433	0.783	rs55725278	ENSG00000231621.1	AC013264.2	-6.47	1.49e-10	2.78e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373499	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs787980	ENSG00000231621.1	AC013264.2	-6.47	1.49e-10	2.78e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197374501	chr2:197197991~197199273:+
BRCA	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	6.47	1.49e-10	2.78e-08	0.22	0.2	Height;	chr5:37407777	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	6.47	1.49e-10	2.78e-08	0.24	0.2	Height;	chr4:55490176	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	6.47	1.49e-10	2.78e-08	0.24	0.2	Height;	chr4:55495262	chr4:55540502~55540835:-
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	6.47	1.49e-10	2.78e-08	0.27	0.2	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
BRCA	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-6.47	1.49e-10	2.78e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
BRCA	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	6.47	1.5e-10	2.78e-08	0.2	0.2	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	6.47	1.5e-10	2.78e-08	0.2	0.2	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
BRCA	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-6.47	1.5e-10	2.79e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000273024.4	INTS4P2	-6.47	1.5e-10	2.79e-08	-0.25	-0.2	Aortic root size;	chr7:66280619	chr7:65647864~65715661:+
BRCA	cis	rs7937890	1	rs7937890	ENSG00000251991.1	RNU7-49P	6.47	1.5e-10	2.79e-08	0.21	0.2	Mitochondrial DNA levels;	chr11:14374939	chr11:14478892~14478953:+
BRCA	cis	rs467650	1	rs467650	ENSG00000248489.1	CTD-2007H13.3	6.47	1.5e-10	2.79e-08	0.22	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633749	chr5:98929171~98995013:+
BRCA	cis	rs17253792	0.822	rs76472022	ENSG00000186615.9	KTN1-AS1	-6.47	1.51e-10	2.8e-08	-0.4	-0.2	Putamen volume;	chr14:55586942	chr14:55499278~55580110:-
BRCA	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-6.47	1.51e-10	2.8e-08	-0.25	-0.2	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
BRCA	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	6.47	1.51e-10	2.8e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
BRCA	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	6.47	1.51e-10	2.8e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
BRCA	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	6.47	1.51e-10	2.81e-08	0.24	0.2	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
BRCA	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-6.47	1.51e-10	2.81e-08	-0.29	-0.2	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs697970	ENSG00000224316.1	RP11-479O9.2	-6.47	1.51e-10	2.81e-08	-0.2	-0.2	Aortic root size;	chr7:66095065	chr7:65773620~65802067:+
BRCA	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-6.47	1.51e-10	2.82e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
BRCA	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-6.47	1.51e-10	2.82e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.931	rs4934704	ENSG00000271335.4	RP11-324I22.4	6.47	1.51e-10	2.82e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35314552~35336401:-
BRCA	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-6.47	1.51e-10	2.82e-08	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
BRCA	cis	rs78456975	0.527	rs10206020	ENSG00000231482.2	AC141930.2	-6.47	1.52e-10	2.82e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554155	chr2:1572554~1580311:-
BRCA	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	6.47	1.52e-10	2.82e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
BRCA	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	6.47	1.52e-10	2.82e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
BRCA	cis	rs11722779	0.815	rs223347	ENSG00000251288.2	RP11-10L12.2	-6.47	1.52e-10	2.83e-08	-0.23	-0.2	Schizophrenia;	chr4:102858815	chr4:102751401~102752641:+
BRCA	cis	rs7746199	0.673	rs72847313	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.611	rs17750747	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28073316~28074233:+
BRCA	cis	rs5015933	0.801	rs4837016	ENSG00000232630.1	PRPS1P2	6.47	1.52e-10	2.83e-08	0.19	0.2	Body mass index;	chr9:125379530	chr9:125150653~125151589:+
BRCA	cis	rs45509595	0.841	rs17751184	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.46	0.2	Breast cancer;	chr6:27807250	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.52e-10	2.83e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
BRCA	cis	rs669446	0.533	rs3791041	ENSG00000237950.1	RP11-7O11.3	6.47	1.52e-10	2.83e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43737320	chr1:43944370~43946551:-
BRCA	cis	rs9876781	1	rs7636782	ENSG00000229759.1	MRPS18AP1	6.47	1.52e-10	2.83e-08	0.22	0.2	Longevity;	chr3:48379897	chr3:48256350~48256938:-
BRCA	cis	rs2348418	0.932	rs11049623	ENSG00000247934.4	RP11-967K21.1	6.47	1.52e-10	2.83e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28458374	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000229886.1	RP5-1132H15.3	6.47	1.52e-10	2.84e-08	0.34	0.2	Diabetic kidney disease;	chr7:65959671	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000232559.3	GS1-124K5.12	6.47	1.52e-10	2.84e-08	0.37	0.2	Gout;	chr7:66671562	chr7:66554588~66576923:-
BRCA	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-6.47	1.52e-10	2.84e-08	-0.19	-0.2	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
BRCA	cis	rs11742741	0.572	rs4701425	ENSG00000248874.4	C5orf17	-6.47	1.53e-10	2.84e-08	-0.25	-0.2	Educational attainment;	chr5:24172342	chr5:23951348~24178263:+
BRCA	cis	rs34779708	0.966	rs2045918	ENSG00000271335.4	RP11-324I22.4	6.47	1.53e-10	2.84e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4294520	ENSG00000271335.4	RP11-324I22.4	6.47	1.53e-10	2.84e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.698	rs217837	ENSG00000250155.1	CTD-2353F22.1	6.47	1.53e-10	2.84e-08	0.22	0.2	Height;	chr5:37376570	chr5:36666214~36725195:-
BRCA	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	6.47	1.53e-10	2.84e-08	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.515	rs624359	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38010204	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.537	rs598857	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38013998	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.515	rs2738208	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38017200	chr10:37775371~37784131:-
BRCA	cis	rs228614	0.51	rs223459	ENSG00000251288.2	RP11-10L12.2	-6.47	1.53e-10	2.84e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102751401~102752641:+
BRCA	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	6.47	1.53e-10	2.84e-08	0.23	0.2	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
BRCA	cis	rs4722166	0.532	rs6963591	ENSG00000179428.2	AC073072.5	6.47	1.53e-10	2.85e-08	0.2	0.2	Lung cancer;	chr7:22717651	chr7:22725395~22727620:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000234585.5	CCT6P3	-6.47	1.53e-10	2.85e-08	-0.19	-0.2	Aortic root size;	chr7:65950660	chr7:65038354~65074713:+
BRCA	cis	rs2836950	0.52	rs2836966	ENSG00000238141.2	BRWD1-AS1	-6.47	1.53e-10	2.85e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39265595	chr21:39315707~39323218:+
BRCA	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-6.47	1.53e-10	2.85e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
BRCA	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	6.47	1.53e-10	2.85e-08	0.25	0.2	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
BRCA	cis	rs7124681	0.584	rs1471712	ENSG00000280615.1	Y_RNA	-6.47	1.53e-10	2.85e-08	-0.22	-0.2	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47890598	chr11:47614898~47614994:-
BRCA	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	6.47	1.53e-10	2.85e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs12685652	ENSG00000236404.7	VLDLR-AS1	6.47	1.54e-10	2.86e-08	0.3	0.2	Gambling;	chr9:2546525	chr9:2422702~2643359:-
BRCA	cis	rs228614	0.536	rs223418	ENSG00000251288.2	RP11-10L12.2	-6.47	1.54e-10	2.86e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102751401~102752641:+
BRCA	cis	rs8114671	0.904	rs6060197	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066512	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.839	rs6142290	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066869	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.869	rs6060199	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066970	chr20:35201747~35203288:-
BRCA	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	6.47	1.54e-10	2.86e-08	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-6.47	1.54e-10	2.86e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	6.47	1.54e-10	2.87e-08	0.15	0.2	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
BRCA	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
BRCA	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	6.47	1.55e-10	2.87e-08	0.26	0.2	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.868	rs10484401	ENSG00000220721.1	OR1F12	-6.47	1.55e-10	2.87e-08	-0.26	-0.2	Parkinson's disease;	chr6:27778811	chr6:28073316~28074233:+
BRCA	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-6.47	1.55e-10	2.87e-08	-0.23	-0.2	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	6.47	1.55e-10	2.88e-08	0.2	0.2	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.47	1.55e-10	2.88e-08	0.28	0.2	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
BRCA	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	6.47	1.55e-10	2.88e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
BRCA	cis	rs7746199	0.736	rs13202295	ENSG00000220721.1	OR1F12	6.47	1.55e-10	2.88e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28073316~28074233:+
BRCA	cis	rs2835345	0.511	rs57583267	ENSG00000230479.1	AP000695.6	6.47	1.55e-10	2.88e-08	0.2	0.2	Pulmonary function;	chr21:36445230	chr21:36430360~36481070:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000224316.1	RP11-479O9.2	-6.46	1.55e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66301466	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000224316.1	RP11-479O9.2	-6.46	1.55e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66301574	chr7:65773620~65802067:+
BRCA	cis	rs1113500	0.575	rs1781067	ENSG00000226822.1	RP11-356N1.2	6.46	1.55e-10	2.89e-08	0.25	0.2	Growth-regulated protein alpha levels;	chr1:108025389	chr1:108071482~108074519:+
BRCA	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-6.46	1.56e-10	2.89e-08	-0.16	-0.2	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	6.46	1.56e-10	2.89e-08	0.34	0.2	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-6.46	1.56e-10	2.89e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.966	rs4934725	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12774834	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12775759	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs35777088	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11592567	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000224316.1	RP11-479O9.2	-6.46	1.56e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66313559	chr7:65773620~65802067:+
BRCA	cis	rs5015933	0.966	rs1965342	ENSG00000232630.1	PRPS1P2	-6.46	1.56e-10	2.9e-08	-0.19	-0.2	Body mass index;	chr9:125371382	chr9:125150653~125151589:+
BRCA	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-6.46	1.56e-10	2.9e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
BRCA	cis	rs7176527	0.579	rs366717	ENSG00000230373.7	GOLGA6L5P	6.46	1.56e-10	2.9e-08	0.26	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84507885~84516814:-
BRCA	cis	rs10515750	0.5	rs6890694	ENSG00000248544.2	CTB-47B11.3	6.46	1.56e-10	2.9e-08	0.29	0.2	Lung function (FEV1/FVC);	chr5:157283735	chr5:157375741~157384950:-
BRCA	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-6.46	1.56e-10	2.9e-08	-0.23	-0.2	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
BRCA	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-6.46	1.56e-10	2.91e-08	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
BRCA	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-6.46	1.56e-10	2.91e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37416890	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37442878	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37442939	chr19:37779686~37792865:+
BRCA	cis	rs2492286	0.597	rs6802078	ENSG00000242551.2	POU5F1P6	-6.46	1.57e-10	2.91e-08	-0.29	-0.2	Eosinophil counts;	chr3:128639910	chr3:128674735~128677005:-
BRCA	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-6.46	1.57e-10	2.91e-08	-0.24	-0.2	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
BRCA	cis	rs2348418	0.932	rs16932850	ENSG00000247934.4	RP11-967K21.1	6.46	1.57e-10	2.91e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28457941	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-6.46	1.57e-10	2.91e-08	-0.29	-0.2	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000236529.1	RP13-254B10.1	-6.46	1.57e-10	2.91e-08	-0.24	-0.2	Aortic root size;	chr7:66603142	chr7:65840212~65840596:+
BRCA	cis	rs10515750	0.588	rs11743536	ENSG00000248544.2	CTB-47B11.3	-6.46	1.57e-10	2.92e-08	-0.28	-0.2	Lung function (FEV1/FVC);	chr5:157347044	chr5:157375741~157384950:-
BRCA	cis	rs4763879	0.778	rs1056151	ENSG00000214776.8	RP11-726G1.1	-6.46	1.57e-10	2.92e-08	-0.22	-0.2	Type 1 diabetes;	chr12:9698427	chr12:9467552~9576275:+
BRCA	cis	rs13178541	0.81	rs4457070	ENSG00000250378.1	RP11-119J18.1	6.46	1.57e-10	2.92e-08	0.27	0.2	IgG glycosylation;	chr5:135814396	chr5:135812667~135826582:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-6.46	1.57e-10	2.92e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
BRCA	cis	rs4780355	0.619	rs918737	ENSG00000262636.1	CTD-3088G3.4	-6.46	1.57e-10	2.92e-08	-0.27	-0.2	Crohn's disease and psoriasis;	chr16:11345782	chr16:11380859~11381118:-
BRCA	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	6.46	1.58e-10	2.92e-08	0.22	0.2	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
BRCA	cis	rs2836950	0.545	rs2836956	ENSG00000238141.2	BRWD1-AS1	6.46	1.58e-10	2.93e-08	0.22	0.2	Menarche (age at onset);	chr21:39251092	chr21:39315707~39323218:+
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000229212.6	RP11-561C5.4	6.46	1.58e-10	2.93e-08	0.22	0.2	P wave terminal force;	chr15:84811882	chr15:85205440~85234795:-
BRCA	cis	rs34779708	0.966	rs34605125	ENSG00000271335.4	RP11-324I22.4	6.46	1.58e-10	2.93e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35314552~35336401:-
BRCA	cis	rs73193808	0.901	rs67137684	ENSG00000215533.7	LINC00189	-6.46	1.58e-10	2.93e-08	-0.28	-0.2	Coronary artery disease;	chr21:29195373	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000273024.4	INTS4P2	6.46	1.58e-10	2.93e-08	0.25	0.2	Aortic root size;	chr7:66156017	chr7:65647864~65715661:+
BRCA	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-6.46	1.58e-10	2.94e-08	-0.25	-0.2	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
BRCA	cis	rs67340775	0.541	rs200975	ENSG00000220721.1	OR1F12	6.46	1.58e-10	2.94e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27887847	chr6:28073316~28074233:+
BRCA	cis	rs67340775	0.541	rs200974	ENSG00000220721.1	OR1F12	6.46	1.58e-10	2.94e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27888067	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	6.46	1.59e-10	2.94e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
BRCA	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-6.46	1.59e-10	2.94e-08	-0.16	-0.2	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
BRCA	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	6.46	1.59e-10	2.95e-08	0.22	0.2	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
BRCA	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-6.46	1.59e-10	2.96e-08	-0.21	-0.2	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	6.46	1.59e-10	2.96e-08	0.26	0.2	Height;	chr4:55387515	chr4:55387949~55388271:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	6.46	1.59e-10	2.96e-08	0.34	0.2	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	6.46	1.59e-10	2.96e-08	0.34	0.2	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
BRCA	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	6.46	1.59e-10	2.96e-08	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000229886.1	RP5-1132H15.3	-6.46	1.6e-10	2.96e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66170354	chr7:66025126~66031544:-
BRCA	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	6.46	1.6e-10	2.96e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
BRCA	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	6.46	1.6e-10	2.97e-08	0.2	0.2	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	6.46	1.6e-10	2.97e-08	0.2	0.2	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
BRCA	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.46	1.6e-10	2.97e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
BRCA	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-6.46	1.6e-10	2.97e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
BRCA	cis	rs8002861	0.664	rs9567292	ENSG00000274001.1	RP11-5G9.5	6.46	1.6e-10	2.98e-08	0.23	0.2	Leprosy;	chr13:43870680	chr13:43877715~43878163:-
BRCA	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-6.46	1.61e-10	2.98e-08	-0.24	-0.2	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
BRCA	cis	rs6740322	0.841	rs10211126	ENSG00000234936.1	AC010883.5	6.46	1.61e-10	2.98e-08	0.22	0.2	Coronary artery disease;	chr2:43324277	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000224316.1	RP11-479O9.2	-6.46	1.61e-10	2.98e-08	-0.2	-0.2	Aortic root size;	chr7:66256452	chr7:65773620~65802067:+
BRCA	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-6.46	1.61e-10	2.98e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
BRCA	cis	rs11722779	0.873	rs223346	ENSG00000251288.2	RP11-10L12.2	-6.46	1.61e-10	2.99e-08	-0.23	-0.2	Schizophrenia;	chr4:102859339	chr4:102751401~102752641:+
BRCA	cis	rs4780355	0.776	rs9936459	ENSG00000262636.1	CTD-3088G3.4	-6.46	1.61e-10	2.99e-08	-0.27	-0.2	Crohn's disease and psoriasis;	chr16:11343922	chr16:11380859~11381118:-
BRCA	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	6.46	1.62e-10	3e-08	0.33	0.2	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	6.46	1.62e-10	3e-08	0.33	0.2	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
BRCA	cis	rs6740322	0.895	rs6738717	ENSG00000234936.1	AC010883.5	6.46	1.62e-10	3e-08	0.22	0.2	Coronary artery disease;	chr2:43346531	chr2:43229573~43233394:+
BRCA	cis	rs7914558	0.966	rs1591915	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs56946876	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.933	rs12763665	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs10786721	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102838011~102845473:-
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000261582.1	RP4-614O4.11	6.46	1.62e-10	3e-08	0.21	0.2	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35267885~35280043:-
BRCA	cis	rs11018904	0.575	rs12797899	ENSG00000280385.1	AP000648.5	-6.46	1.62e-10	3.01e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr11:90242309	chr11:90193614~90198120:+
BRCA	cis	rs12594515	0.967	rs11070465	ENSG00000259200.1	RP11-718O11.1	-6.46	1.62e-10	3.01e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692701	chr15:45705078~45931069:+
BRCA	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-6.46	1.62e-10	3.01e-08	-0.26	-0.2	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
BRCA	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-6.46	1.63e-10	3.01e-08	-0.24	-0.2	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
BRCA	cis	rs8002861	0.713	rs7339417	ENSG00000274001.1	RP11-5G9.5	6.46	1.63e-10	3.02e-08	0.23	0.2	Leprosy;	chr13:43839360	chr13:43877715~43878163:-
BRCA	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	6.46	1.63e-10	3.02e-08	0.2	0.2	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
BRCA	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	6.46	1.63e-10	3.02e-08	0.26	0.2	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
BRCA	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-6.46	1.63e-10	3.02e-08	-0.25	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.63e-10	3.02e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37347491	chr19:37779686~37792865:+
BRCA	cis	rs516805	0.52	rs197678	ENSG00000279453.1	RP3-425C14.4	-6.46	1.63e-10	3.02e-08	-0.21	-0.2	Lymphocyte counts;	chr6:122534039	chr6:122436789~122439223:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000228409.4	CCT6P1	6.46	1.63e-10	3.03e-08	0.27	0.2	Diabetic kidney disease;	chr7:66034996	chr7:65751142~65763354:+
BRCA	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.46	1.63e-10	3.03e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
BRCA	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-6.46	1.63e-10	3.03e-08	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
BRCA	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-6.46	1.63e-10	3.03e-08	-0.25	-0.2	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
BRCA	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	6.46	1.64e-10	3.03e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000273765.1	RP11-370I10.11	6.46	1.64e-10	3.03e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48360920~48361377:+
BRCA	cis	rs17253792	0.822	rs74412558	ENSG00000186615.9	KTN1-AS1	-6.46	1.64e-10	3.03e-08	-0.4	-0.2	Putamen volume;	chr14:55587593	chr14:55499278~55580110:-
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000204556.4	CTD-2514C3.1	6.46	1.64e-10	3.03e-08	0.27	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26018832~26020684:+
BRCA	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	6.46	1.64e-10	3.04e-08	0.24	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
BRCA	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	6.46	1.64e-10	3.04e-08	0.19	0.2	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
BRCA	cis	rs4908768	0.52	rs7520025	ENSG00000270282.1	RP5-1115A15.2	6.46	1.64e-10	3.04e-08	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8512653~8513021:+
BRCA	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	6.46	1.64e-10	3.04e-08	0.24	0.2	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000273024.4	INTS4P2	-6.46	1.64e-10	3.04e-08	-0.25	-0.2	Aortic root size;	chr7:66481592	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.607	rs67340775	ENSG00000220721.1	OR1F12	6.46	1.64e-10	3.04e-08	0.45	0.2	Depression;	chr6:28336607	chr6:28073316~28074233:+
BRCA	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-6.46	1.64e-10	3.04e-08	-0.22	-0.2	Height;	chr5:37275173	chr5:36666214~36725195:-
BRCA	cis	rs847577	0.63	rs6967926	ENSG00000272950.1	RP11-307C18.1	6.46	1.64e-10	3.04e-08	0.25	0.2	Breast cancer;	chr7:98085776	chr7:98322853~98323430:+
BRCA	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-6.46	1.64e-10	3.04e-08	-0.36	-0.2	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
BRCA	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-6.46	1.65e-10	3.05e-08	-0.27	-0.2	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-6.46	1.65e-10	3.05e-08	-0.27	-0.2	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
BRCA	cis	rs301901	0.531	rs292171	ENSG00000250155.1	CTD-2353F22.1	-6.46	1.65e-10	3.05e-08	-0.21	-0.2	Height;	chr5:36816591	chr5:36666214~36725195:-
BRCA	cis	rs7746199	0.736	rs13212093	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs34038546	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28073316~28074233:+
BRCA	cis	rs141342723	1	rs141342723	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs34543938	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs56405707	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28073316~28074233:+
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-6.46	1.65e-10	3.07e-08	-0.18	-0.2	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
BRCA	cis	rs5015933	0.705	rs13288223	ENSG00000232630.1	PRPS1P2	-6.45	1.66e-10	3.07e-08	-0.18	-0.2	Body mass index;	chr9:125335388	chr9:125150653~125151589:+
BRCA	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	6.45	1.66e-10	3.07e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
BRCA	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-6.45	1.66e-10	3.07e-08	-0.36	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-6.45	1.66e-10	3.07e-08	-0.29	-0.2	Depression;	chr6:28079011	chr6:28170845~28172521:+
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	6.45	1.66e-10	3.07e-08	0.24	0.2	Height;	chr4:55437438	chr4:55540502~55540835:-
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000244733.5	RP11-506M13.3	-6.45	1.66e-10	3.08e-08	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79660891~79677996:+
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-6.45	1.66e-10	3.08e-08	-0.28	-0.2	Pain;	chr19:21475141	chr19:21554640~21569237:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.45	1.66e-10	3.08e-08	-0.28	-0.2	Depression;	chr6:28199145	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000229886.1	RP5-1132H15.3	6.45	1.66e-10	3.08e-08	0.35	0.2	Diabetic kidney disease;	chr7:66133553	chr7:66025126~66031544:-
BRCA	cis	rs2834288	0.535	rs7278341	ENSG00000273102.1	AP000569.9	6.45	1.66e-10	3.08e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.535	rs7279183	ENSG00000273102.1	AP000569.9	6.45	1.66e-10	3.08e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33967101~33968573:-
BRCA	cis	rs10506328	0.509	rs4759075	ENSG00000257534.1	RP11-834C11.10	6.45	1.66e-10	3.08e-08	0.21	0.2	Mean platelet volume;	chr12:54273501	chr12:54162065~54164452:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	6.45	1.66e-10	3.08e-08	0.2	0.2	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000224316.1	RP11-479O9.2	6.45	1.66e-10	3.08e-08	0.23	0.2	Aortic root size;	chr7:66536825	chr7:65773620~65802067:+
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000244733.5	RP11-506M13.3	6.45	1.67e-10	3.09e-08	0.24	0.2	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79660891~79677996:+
BRCA	cis	rs2243480	1	rs4718270	ENSG00000228409.4	CCT6P1	6.45	1.67e-10	3.09e-08	0.27	0.2	Diabetic kidney disease;	chr7:65737415	chr7:65751142~65763354:+
BRCA	cis	rs7086627	0.515	rs4934189	ENSG00000226659.1	RP11-137H2.4	-6.45	1.67e-10	3.09e-08	-0.25	-0.2	Post bronchodilator FEV1;	chr10:80455036	chr10:80529597~80535942:-
BRCA	cis	rs228614	0.51	rs223447	ENSG00000251288.2	RP11-10L12.2	-6.45	1.67e-10	3.09e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102751401~102752641:+
BRCA	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	6.45	1.67e-10	3.09e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
BRCA	cis	rs34779708	0.931	rs34876468	ENSG00000271335.4	RP11-324I22.4	6.45	1.67e-10	3.1e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35314552~35336401:-
BRCA	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-6.45	1.67e-10	3.1e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
BRCA	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-6.45	1.68e-10	3.1e-08	-0.27	-0.2	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
BRCA	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	6.45	1.68e-10	3.1e-08	0.24	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
BRCA	cis	rs6583826	0.681	rs2421943	ENSG00000236493.2	EIF2S2P3	6.45	1.68e-10	3.1e-08	0.26	0.2	Type 2 diabetes;	chr10:92552058	chr10:92668745~92669743:-
BRCA	cis	rs9638182	0.725	rs13232120	ENSG00000274080.1	CTA-315H11.2	6.45	1.68e-10	3.1e-08	0.39	0.2	Triglycerides;	chr7:73568980	chr7:73609262~73611502:-
BRCA	cis	rs1124769	0.748	rs12593778	ENSG00000259378.1	DCAF13P3	6.45	1.68e-10	3.1e-08	0.28	0.2	Cognitive performance;	chr15:51005929	chr15:50944663~50945996:+
BRCA	cis	rs11722228	0.539	rs62287552	ENSG00000261490.1	RP11-448G15.3	6.45	1.68e-10	3.11e-08	0.23	0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10151573	chr4:10068089~10073019:-
BRCA	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	6.45	1.68e-10	3.11e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
BRCA	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	6.45	1.68e-10	3.11e-08	0.26	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000224316.1	RP11-479O9.2	-6.45	1.68e-10	3.11e-08	-0.2	-0.2	Aortic root size;	chr7:66285177	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000224316.1	RP11-479O9.2	-6.45	1.68e-10	3.11e-08	-0.2	-0.2	Aortic root size;	chr7:66294786	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000229886.1	RP5-1132H15.3	6.45	1.68e-10	3.11e-08	0.34	0.2	Diabetic kidney disease;	chr7:65966800	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000229886.1	RP5-1132H15.3	6.45	1.68e-10	3.11e-08	0.34	0.2	Diabetic kidney disease;	chr7:65979301	chr7:66025126~66031544:-
BRCA	cis	rs2998286	0.862	rs2153300	ENSG00000254635.4	WAC-AS1	-6.45	1.69e-10	3.12e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28522652~28532743:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000232559.3	GS1-124K5.12	6.45	1.69e-10	3.12e-08	0.38	0.2	Gout;	chr7:66661502	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.85	rs11049428	ENSG00000278733.1	RP11-425D17.1	-6.45	1.69e-10	3.12e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28185625~28186190:-
BRCA	cis	rs6740322	0.895	rs10210125	ENSG00000234936.1	AC010883.5	6.45	1.69e-10	3.13e-08	0.22	0.2	Coronary artery disease;	chr2:43329294	chr2:43229573~43233394:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	6.45	1.69e-10	3.13e-08	0.25	0.2	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
BRCA	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	6.45	1.69e-10	3.13e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	6.45	1.69e-10	3.13e-08	0.21	0.2	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.832	rs12301674	ENSG00000247934.4	RP11-967K21.1	6.45	1.69e-10	3.13e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28357543	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs778710	ENSG00000224316.1	RP11-479O9.2	6.45	1.69e-10	3.13e-08	0.19	0.2	Aortic root size;	chr7:66389847	chr7:65773620~65802067:+
BRCA	cis	rs11672691	0.756	rs8107333	ENSG00000270164.1	LINC01480	-6.45	1.7e-10	3.14e-08	-0.23	-0.2	Prostate cancer;	chr19:41481965	chr19:41535183~41536904:+
BRCA	cis	rs2337406	1	rs17113257	ENSG00000211972.2	IGHV3-66	6.45	1.7e-10	3.14e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106679574	chr14:106675017~106675544:-
BRCA	cis	rs1440410	0.798	rs1039763	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.14e-08	-0.22	-0.2	Ischemic stroke;	chr4:143246860	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.763	rs1039762	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.14e-08	-0.22	-0.2	Ischemic stroke;	chr4:143246893	chr4:142933195~143184861:-
BRCA	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	6.45	1.7e-10	3.14e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37398378	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37399252	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37400590	chr19:37779686~37792865:+
BRCA	cis	rs16846053	0.515	rs6432688	ENSG00000227403.1	AC009299.3	-6.45	1.7e-10	3.14e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161522146	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	6.45	1.7e-10	3.14e-08	0.14	0.2	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000224316.1	RP11-479O9.2	-6.45	1.7e-10	3.14e-08	-0.2	-0.2	Aortic root size;	chr7:66284091	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000273024.4	INTS4P2	6.45	1.7e-10	3.15e-08	0.25	0.2	Aortic root size;	chr7:66066855	chr7:65647864~65715661:+
BRCA	cis	rs1440410	0.798	rs1605581	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.15e-08	-0.22	-0.2	Ischemic stroke;	chr4:143245634	chr4:142933195~143184861:-
BRCA	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	6.45	1.7e-10	3.15e-08	0.25	0.2	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000234585.5	CCT6P3	6.45	1.71e-10	3.15e-08	0.19	0.2	Aortic root size;	chr7:65964026	chr7:65038354~65074713:+
BRCA	cis	rs228614	0.51	rs223434	ENSG00000251288.2	RP11-10L12.2	-6.45	1.71e-10	3.16e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.546	rs34295134	ENSG00000220721.1	OR1F12	6.45	1.71e-10	3.16e-08	0.36	0.2	Depression;	chr6:27860373	chr6:28073316~28074233:+
BRCA	cis	rs12594515	0.506	rs74199860	ENSG00000259200.1	RP11-718O11.1	-6.45	1.71e-10	3.16e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696992	chr15:45705078~45931069:+
BRCA	cis	rs9527	0.545	rs35756290	ENSG00000236937.2	PTGES3P4	6.45	1.71e-10	3.16e-08	0.29	0.2	Arsenic metabolism;	chr10:102825815	chr10:102845595~102845950:+
BRCA	cis	rs755249	0.567	rs2036463	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs2036464	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs905381	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39514956~39516490:+
BRCA	cis	rs42648	0.738	rs13247172	ENSG00000225498.1	AC002064.5	6.45	1.71e-10	3.16e-08	0.21	0.2	Homocysteine levels;	chr7:90259890	chr7:90312496~90322592:+
BRCA	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-6.45	1.71e-10	3.16e-08	-0.23	-0.2	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
BRCA	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-6.45	1.71e-10	3.16e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
BRCA	cis	rs301901	0.663	rs217847	ENSG00000250155.1	CTD-2353F22.1	6.45	1.71e-10	3.17e-08	0.22	0.2	Height;	chr5:37367135	chr5:36666214~36725195:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-6.45	1.71e-10	3.17e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
BRCA	cis	rs7927771	0.524	rs1563820	ENSG00000280615.1	Y_RNA	-6.45	1.71e-10	3.17e-08	-0.22	-0.2	Subjective well-being;	chr11:47811846	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs4752796	ENSG00000280615.1	Y_RNA	-6.45	1.71e-10	3.17e-08	-0.22	-0.2	Subjective well-being;	chr11:47820310	chr11:47614898~47614994:-
BRCA	cis	rs7432375	0.58	rs4678441	ENSG00000239213.4	NCK1-AS1	6.45	1.71e-10	3.17e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136813986	chr3:136841726~136862054:-
BRCA	cis	rs7432375	0.58	rs4678442	ENSG00000239213.4	NCK1-AS1	6.45	1.71e-10	3.17e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136814129	chr3:136841726~136862054:-
BRCA	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	6.45	1.72e-10	3.17e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
BRCA	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	6.45	1.72e-10	3.17e-08	0.2	0.2	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
BRCA	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-6.45	1.72e-10	3.17e-08	-0.26	-0.2	Height;	chr20:49254660	chr20:49280319~49280409:+
BRCA	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
BRCA	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-6.45	1.72e-10	3.18e-08	-0.29	-0.2	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
BRCA	cis	rs10515750	0.5	rs2288069	ENSG00000248544.2	CTB-47B11.3	6.45	1.72e-10	3.18e-08	0.28	0.2	Lung function (FEV1/FVC);	chr5:157285187	chr5:157375741~157384950:-
BRCA	cis	rs1476670	0.545	rs11210948	ENSG00000230615.5	RP5-1198O20.4	-6.45	1.73e-10	3.19e-08	-0.26	-0.2	Eotaxin levels;	chr1:44054441	chr1:44030443~44115913:+
BRCA	cis	rs78456975	1	rs13422995	ENSG00000231482.2	AC141930.2	-6.45	1.73e-10	3.19e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549782	chr2:1572554~1580311:-
BRCA	cis	rs78456975	1	rs13413096	ENSG00000231482.2	AC141930.2	-6.45	1.73e-10	3.19e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549816	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000229886.1	RP5-1132H15.3	6.45	1.73e-10	3.2e-08	0.35	0.2	Diabetic kidney disease;	chr7:66091293	chr7:66025126~66031544:-
BRCA	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-6.45	1.73e-10	3.2e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-6.45	1.73e-10	3.2e-08	-0.2	-0.2	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000232559.3	GS1-124K5.12	6.45	1.73e-10	3.2e-08	0.38	0.2	Gout;	chr7:66645053	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000229886.1	RP5-1132H15.3	-6.45	1.73e-10	3.2e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66184912	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6959002	ENSG00000229886.1	RP5-1132H15.3	-6.45	1.73e-10	3.2e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66185509	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66128561	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66131504	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66132354	chr7:66025126~66031544:-
BRCA	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-6.45	1.74e-10	3.21e-08	-0.22	-0.2	Height;	chr5:37276657	chr5:36666214~36725195:-
BRCA	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	6.45	1.74e-10	3.21e-08	0.25	0.2	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
BRCA	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	6.45	1.74e-10	3.21e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000228409.4	CCT6P1	-6.45	1.74e-10	3.21e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65751112	chr7:65751142~65763354:+
BRCA	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	6.45	1.74e-10	3.21e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.778	rs2189807	ENSG00000269927.1	RP6-91H8.3	6.45	1.74e-10	3.21e-08	0.24	0.2	Schizophrenia;	chr14:70896314	chr14:71141125~71143253:-
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211972.2	IGHV3-66	6.45	1.74e-10	3.22e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106688061	chr14:106675017~106675544:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-6.45	1.74e-10	3.22e-08	-0.3	-0.2	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.826	rs2893929	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27770953	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.666	rs4140646	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27771022	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.666	rs2893930	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27771027	chr6:28073316~28074233:+
BRCA	cis	rs3760982	0.935	rs10422990	ENSG00000267058.1	RP11-15A1.3	-6.45	1.75e-10	3.23e-08	-0.22	-0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43791121	chr19:43891804~43901805:-
BRCA	cis	rs7809950	0.817	rs2253833	ENSG00000238832.1	snoU109	6.45	1.75e-10	3.23e-08	0.29	0.2	Coronary artery disease;	chr7:107565224	chr7:107603363~107603507:+
BRCA	cis	rs17253792	0.822	rs75897560	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55624247	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28549152	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55624521	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147431	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625123	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75663029	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625667	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75991559	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625701	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79262019	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625986	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79024594	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55626279	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28392709	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55626967	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79618862	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55627253	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28513551	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55628275	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs74824071	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55628424	chr14:55499278~55580110:-
BRCA	cis	rs919433	0.783	rs787979	ENSG00000231621.1	AC013264.2	-6.45	1.76e-10	3.24e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197378144	chr2:197197991~197199273:+
BRCA	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.45	1.76e-10	3.24e-08	0.23	0.2	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
BRCA	cis	rs2348418	0.83	rs7977418	ENSG00000247934.4	RP11-967K21.1	6.45	1.76e-10	3.24e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28435309	chr12:28163298~28190738:-
BRCA	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	6.45	1.76e-10	3.24e-08	0.2	0.2	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
BRCA	cis	rs9307551	0.817	rs11098766	ENSG00000250334.4	LINC00989	-6.45	1.76e-10	3.24e-08	-0.26	-0.2	Refractive error;	chr4:79579266	chr4:79492416~79576460:+
BRCA	cis	rs710913	0.691	rs1180351	ENSG00000237624.1	OXCT2P1	-6.45	1.76e-10	3.24e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39514956~39516490:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	6.45	1.76e-10	3.24e-08	0.24	0.2	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.537	rs10843308	ENSG00000257176.2	RP11-996F15.2	-6.45	1.76e-10	3.24e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29075172	chr12:29280418~29317848:-
BRCA	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-6.45	1.76e-10	3.25e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
BRCA	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	6.45	1.76e-10	3.25e-08	0.21	0.2	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
BRCA	cis	rs1440410	0.798	rs10002867	ENSG00000250326.1	RP11-284M14.1	-6.44	1.76e-10	3.26e-08	-0.22	-0.2	Ischemic stroke;	chr4:143248497	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.585	rs201001	ENSG00000220721.1	OR1F12	6.44	1.77e-10	3.26e-08	0.28	0.2	Depression;	chr6:27841121	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.585	rs201000	ENSG00000220721.1	OR1F12	6.44	1.77e-10	3.26e-08	0.28	0.2	Depression;	chr6:27841381	chr6:28073316~28074233:+
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000244733.5	RP11-506M13.3	-6.44	1.77e-10	3.26e-08	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79660891~79677996:+
BRCA	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-6.44	1.77e-10	3.26e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
BRCA	cis	rs9638182	0.725	rs35173225	ENSG00000274080.1	CTA-315H11.2	6.44	1.77e-10	3.26e-08	0.4	0.2	Triglycerides;	chr7:73586691	chr7:73609262~73611502:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	6.44	1.77e-10	3.26e-08	0.34	0.2	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.924	rs11049398	ENSG00000247934.4	RP11-967K21.1	-6.44	1.77e-10	3.26e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-6.44	1.77e-10	3.26e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.524	rs10838769	ENSG00000280615.1	Y_RNA	-6.44	1.77e-10	3.27e-08	-0.22	-0.2	Subjective well-being;	chr11:47803781	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000229886.1	RP5-1132H15.3	6.44	1.77e-10	3.27e-08	0.35	0.2	Diabetic kidney disease;	chr7:66133233	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000230295.1	RP11-458F8.2	-6.44	1.77e-10	3.27e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66474549	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000228409.4	CCT6P1	6.44	1.77e-10	3.27e-08	0.27	0.2	Diabetic kidney disease;	chr7:65909309	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000228409.4	CCT6P1	6.44	1.77e-10	3.27e-08	0.27	0.2	Diabetic kidney disease;	chr7:65970805	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.77e-10	3.27e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
BRCA	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-6.44	1.78e-10	3.27e-08	-0.22	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
BRCA	cis	rs919433	0.75	rs788012	ENSG00000231621.1	AC013264.2	-6.44	1.78e-10	3.28e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197365132	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.78e-10	3.28e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
BRCA	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-6.44	1.78e-10	3.28e-08	-0.26	-0.2	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
BRCA	cis	rs67981189	0.896	rs4391999	ENSG00000269927.1	RP6-91H8.3	6.44	1.78e-10	3.28e-08	0.24	0.2	Schizophrenia;	chr14:70978696	chr14:71141125~71143253:-
BRCA	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-6.44	1.78e-10	3.28e-08	-0.19	-0.2	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
BRCA	cis	rs7474896	0.583	rs12783272	ENSG00000226578.1	RP11-258F22.1	-6.44	1.78e-10	3.28e-08	-0.27	-0.2	Obesity (extreme);	chr10:37735957	chr10:37775371~37784131:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000228409.4	CCT6P1	6.44	1.78e-10	3.29e-08	0.27	0.2	Diabetic kidney disease;	chr7:65973791	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-6.44	1.79e-10	3.29e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
BRCA	cis	rs67766926	0.587	rs12713431	ENSG00000271889.1	RP11-493E12.1	-6.44	1.79e-10	3.29e-08	-0.29	-0.2	Inflammatory skin disease;	chr2:61022541	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-6.44	1.79e-10	3.3e-08	-0.2	-0.2	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-6.44	1.79e-10	3.3e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-6.44	1.79e-10	3.3e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
BRCA	cis	rs3760982	0.813	rs8104447	ENSG00000267058.1	RP11-15A1.3	6.44	1.79e-10	3.3e-08	0.23	0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789126	chr19:43891804~43901805:-
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000204556.4	CTD-2514C3.1	-6.44	1.79e-10	3.31e-08	-0.27	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-6.44	1.8e-10	3.31e-08	-0.15	-0.2	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
BRCA	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	6.44	1.8e-10	3.32e-08	0.24	0.2	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
BRCA	cis	rs3126085	0.867	rs12748016	ENSG00000237975.5	FLG-AS1	6.44	1.81e-10	3.33e-08	0.26	0.2	Atopic dermatitis;	chr1:152224759	chr1:152168125~152445456:+
BRCA	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-6.44	1.81e-10	3.33e-08	-0.16	-0.2	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-6.44	1.81e-10	3.33e-08	-0.16	-0.2	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
BRCA	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.44	1.81e-10	3.33e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000232559.3	GS1-124K5.12	6.44	1.81e-10	3.33e-08	0.37	0.2	Gout;	chr7:66654674	chr7:66554588~66576923:-
BRCA	cis	rs2836950	0.52	rs11911087	ENSG00000238141.2	BRWD1-AS1	-6.44	1.81e-10	3.33e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39293266	chr21:39315707~39323218:+
BRCA	cis	rs1124769	0.748	rs11070832	ENSG00000259378.1	DCAF13P3	6.44	1.81e-10	3.33e-08	0.28	0.2	Cognitive performance;	chr15:51070642	chr15:50944663~50945996:+
BRCA	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-6.44	1.81e-10	3.33e-08	-0.36	-0.2	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	6.44	1.81e-10	3.33e-08	0.24	0.2	Height;	chr4:55508982	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-6.44	1.81e-10	3.33e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-6.44	1.81e-10	3.33e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000253175.1	RP11-267M23.6	6.44	1.81e-10	3.33e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94565036~94565715:+
BRCA	cis	rs1124769	0.748	rs2289304	ENSG00000259378.1	DCAF13P3	6.44	1.81e-10	3.34e-08	0.27	0.2	Cognitive performance;	chr15:50997198	chr15:50944663~50945996:+
BRCA	cis	rs793571	0.505	rs16940587	ENSG00000259250.1	RP11-50C13.1	-6.44	1.82e-10	3.35e-08	-0.33	-0.2	Schizophrenia;	chr15:58606464	chr15:58587507~58591676:+
BRCA	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.44	1.82e-10	3.35e-08	0.2	0.2	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
BRCA	cis	rs42648	0.738	rs10248104	ENSG00000225498.1	AC002064.5	6.44	1.82e-10	3.35e-08	0.21	0.2	Homocysteine levels;	chr7:90265948	chr7:90312496~90322592:+
BRCA	cis	rs2638953	0.924	rs7961407	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974904	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974979	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.44	1.82e-10	3.35e-08	0.29	0.2	Depression;	chr6:28167882	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
BRCA	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-6.44	1.82e-10	3.36e-08	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000267422.1	CTD-2554C21.1	6.44	1.83e-10	3.36e-08	0.29	0.2	Coronary artery calcification;	chr19:37476021	chr19:37779686~37792865:+
BRCA	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	6.44	1.83e-10	3.36e-08	0.26	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
BRCA	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	6.44	1.83e-10	3.37e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
BRCA	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-6.44	1.83e-10	3.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000273024.4	INTS4P2	-6.44	1.83e-10	3.37e-08	-0.24	-0.2	Aortic root size;	chr7:66249708	chr7:65647864~65715661:+
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	6.44	1.83e-10	3.37e-08	0.24	0.2	Height;	chr4:55486718	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-6.44	1.83e-10	3.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
BRCA	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	6.44	1.83e-10	3.38e-08	0.23	0.2	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
BRCA	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	6.44	1.83e-10	3.38e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
BRCA	cis	rs12444979	0.517	rs720176	ENSG00000261195.1	CTD-2380F24.1	-6.44	1.84e-10	3.38e-08	-0.29	-0.2	Body mass index;	chr16:19710193	chr16:19761172~19766099:-
BRCA	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	6.44	1.84e-10	3.38e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
BRCA	cis	rs17253792	0.822	rs76557162	ENSG00000186615.9	KTN1-AS1	-6.44	1.84e-10	3.38e-08	-0.37	-0.2	Putamen volume;	chr14:55597983	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.908	rs74354306	ENSG00000186615.9	KTN1-AS1	-6.44	1.84e-10	3.38e-08	-0.37	-0.2	Putamen volume;	chr14:55599060	chr14:55499278~55580110:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000224316.1	RP11-479O9.2	-6.44	1.84e-10	3.38e-08	-0.19	-0.2	Aortic root size;	chr7:66269796	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs16826009	ENSG00000237624.1	OXCT2P1	6.44	1.84e-10	3.39e-08	0.29	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39514956~39516490:+
BRCA	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-6.44	1.84e-10	3.39e-08	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
BRCA	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-6.44	1.84e-10	3.39e-08	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
BRCA	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	6.44	1.84e-10	3.39e-08	0.28	0.2	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
BRCA	cis	rs1440410	0.835	rs4690771	ENSG00000250326.1	RP11-284M14.1	-6.44	1.84e-10	3.39e-08	-0.22	-0.2	Ischemic stroke;	chr4:143129944	chr4:142933195~143184861:-
BRCA	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	6.44	1.84e-10	3.39e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
BRCA	cis	rs67981189	0.896	rs8003227	ENSG00000269927.1	RP6-91H8.3	6.44	1.84e-10	3.39e-08	0.24	0.2	Schizophrenia;	chr14:71093635	chr14:71141125~71143253:-
BRCA	cis	rs7978895	0.647	rs7299983	ENSG00000258331.1	RP11-118A3.1	-6.44	1.85e-10	3.4e-08	-0.2	-0.2	Type 2 diabetes;	chr12:43172570	chr12:43155315~43163110:+
BRCA	cis	rs2998286	0.862	rs2993981	ENSG00000254635.4	WAC-AS1	-6.44	1.85e-10	3.4e-08	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.862	rs2993982	ENSG00000254635.4	WAC-AS1	-6.44	1.85e-10	3.4e-08	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28522652~28532743:-
BRCA	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-6.44	1.85e-10	3.4e-08	-0.24	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000232559.3	GS1-124K5.12	6.44	1.85e-10	3.4e-08	0.38	0.2	Diabetic kidney disease;	chr7:66134209	chr7:66554588~66576923:-
BRCA	cis	rs1440410	0.835	rs7682068	ENSG00000250326.1	RP11-284M14.1	-6.44	1.85e-10	3.4e-08	-0.21	-0.2	Ischemic stroke;	chr4:143129226	chr4:142933195~143184861:-
BRCA	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	6.44	1.85e-10	3.4e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	6.44	1.85e-10	3.4e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
BRCA	cis	rs3781264	0.848	rs10509670	ENSG00000273450.1	RP11-76P2.4	-6.44	1.85e-10	3.4e-08	-0.25	-0.2	Esophageal cancer and gastric cancer;	chr10:94308190	chr10:94314907~94315327:-
BRCA	cis	rs2834288	0.536	rs762357	ENSG00000273102.1	AP000569.9	6.44	1.85e-10	3.4e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33967101~33968573:-
BRCA	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-6.44	1.85e-10	3.4e-08	-0.24	-0.2	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
BRCA	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-6.44	1.85e-10	3.41e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-6.44	1.85e-10	3.41e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs4934724	ENSG00000271335.4	RP11-324I22.4	6.44	1.85e-10	3.41e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35314552~35336401:-
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000255046.1	RP11-297N6.4	6.44	1.85e-10	3.41e-08	0.23	0.2	Monocyte count;	chr8:11974754	chr8:11797928~11802568:-
BRCA	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	6.44	1.86e-10	3.41e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
BRCA	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	6.44	1.86e-10	3.41e-08	0.22	0.2	Height;	chr5:37474739	chr5:36666214~36725195:-
BRCA	cis	rs17767294	0.612	rs9461424	ENSG00000220721.1	OR1F12	6.44	1.86e-10	3.41e-08	0.34	0.2	Parkinson's disease;	chr6:27951623	chr6:28073316~28074233:+
BRCA	cis	rs9876781	1	rs1563736	ENSG00000229759.1	MRPS18AP1	6.44	1.86e-10	3.42e-08	0.22	0.2	Longevity;	chr3:48395329	chr3:48256350~48256938:-
BRCA	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-6.44	1.86e-10	3.42e-08	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
BRCA	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-6.44	1.86e-10	3.42e-08	-0.23	-0.2	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	6.44	1.86e-10	3.42e-08	0.34	0.2	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
BRCA	cis	rs2836950	0.545	rs11701805	ENSG00000238141.2	BRWD1-AS1	-6.44	1.86e-10	3.43e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39315707~39323218:+
BRCA	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-6.44	1.87e-10	3.43e-08	-0.19	-0.2	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
BRCA	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	6.44	1.87e-10	3.43e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	6.44	1.87e-10	3.43e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
BRCA	cis	rs227275	0.554	rs223390	ENSG00000251288.2	RP11-10L12.2	-6.44	1.87e-10	3.43e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102751401~102752641:+
BRCA	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	6.44	1.87e-10	3.43e-08	0.33	0.2	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
BRCA	cis	rs860818	1	rs858278	ENSG00000226816.2	AC005082.12	6.44	1.87e-10	3.43e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23212583	chr7:23206013~23208045:+
BRCA	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	6.44	1.87e-10	3.44e-08	0.21	0.2	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	6.44	1.87e-10	3.44e-08	0.21	0.2	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
BRCA	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-6.44	1.87e-10	3.44e-08	-0.22	-0.2	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37337612	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37343021	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37351833	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37354602	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37361570	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37370959	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66172952	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs9769882	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66177938	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6966322	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66181767	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs4145008	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66182524	chr7:66025126~66031544:-
BRCA	cis	rs1440410	0.798	rs11100773	ENSG00000250326.1	RP11-284M14.1	-6.44	1.88e-10	3.45e-08	-0.21	-0.2	Ischemic stroke;	chr4:143133075	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000273024.4	INTS4P2	6.43	1.88e-10	3.46e-08	0.25	0.2	Aortic root size;	chr7:66100789	chr7:65647864~65715661:+
BRCA	cis	rs78456975	1	rs78456975	ENSG00000231482.2	AC141930.2	-6.43	1.88e-10	3.46e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550418	chr2:1572554~1580311:-
BRCA	cis	rs78456975	1	rs111935361	ENSG00000231482.2	AC141930.2	-6.43	1.88e-10	3.46e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550420	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000229886.1	RP5-1132H15.3	6.43	1.88e-10	3.46e-08	0.36	0.2	Diabetic kidney disease;	chr7:66086239	chr7:66025126~66031544:-
BRCA	cis	rs67766926	0.543	rs68180594	ENSG00000271889.1	RP11-493E12.1	6.43	1.88e-10	3.46e-08	0.3	0.2	Inflammatory skin disease;	chr2:61042787	chr2:61151433~61162105:-
BRCA	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	6.43	1.88e-10	3.46e-08	0.24	0.2	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
BRCA	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	6.43	1.89e-10	3.46e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	6.43	1.89e-10	3.47e-08	0.26	0.2	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	6.43	1.89e-10	3.47e-08	0.26	0.2	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
BRCA	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	6.43	1.89e-10	3.47e-08	0.22	0.2	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
BRCA	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
BRCA	cis	rs6728642	1	rs116171118	ENSG00000230606.9	AC159540.1	6.43	1.89e-10	3.48e-08	0.42	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97416165~97433527:-
BRCA	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-6.43	1.89e-10	3.48e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
BRCA	cis	rs6545883	0.965	rs10186325	ENSG00000271889.1	RP11-493E12.1	6.43	1.89e-10	3.48e-08	0.25	0.2	Tuberculosis;	chr2:61530586	chr2:61151433~61162105:-
BRCA	cis	rs9307551	0.948	rs13109727	ENSG00000250334.4	LINC00989	-6.43	1.9e-10	3.48e-08	-0.29	-0.2	Refractive error;	chr4:79609563	chr4:79492416~79576460:+
BRCA	cis	rs9876781	1	rs9876781	ENSG00000229759.1	MRPS18AP1	6.43	1.9e-10	3.48e-08	0.22	0.2	Longevity;	chr3:48445934	chr3:48256350~48256938:-
BRCA	cis	rs2239547	0.523	rs6803486	ENSG00000242142.1	SERBP1P3	6.43	1.9e-10	3.48e-08	0.24	0.2	Schizophrenia;	chr3:53064193	chr3:53064283~53065091:-
BRCA	cis	rs1440410	0.835	rs7684847	ENSG00000250326.1	RP11-284M14.1	-6.43	1.9e-10	3.48e-08	-0.22	-0.2	Ischemic stroke;	chr4:143133414	chr4:142933195~143184861:-
BRCA	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	6.43	1.9e-10	3.49e-08	0.24	0.2	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
BRCA	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-6.43	1.9e-10	3.49e-08	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
BRCA	cis	rs4237845	0.804	rs11172372	ENSG00000257159.1	RP11-58A17.3	6.43	1.9e-10	3.5e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57892490	chr12:57967058~57968399:+
BRCA	cis	rs2644899	0.593	rs3733828	ENSG00000268529.1	CYP2T3P	6.43	1.91e-10	3.5e-08	0.25	0.2	Post bronchodilator FEV1/FVC ratio;	chr19:40804704	chr19:41134722~41137308:+
BRCA	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	6.43	1.91e-10	3.5e-08	0.23	0.2	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000224316.1	RP11-479O9.2	-6.43	1.91e-10	3.5e-08	-0.2	-0.2	Aortic root size;	chr7:66253949	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778696	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66405826	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778694	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66406571	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66409394	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66415618	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66415707	chr7:65773620~65802067:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000214776.8	RP11-726G1.1	6.43	1.91e-10	3.51e-08	0.24	0.2	Type 1 diabetes;	chr12:9670678	chr12:9467552~9576275:+
BRCA	cis	rs67766926	0.587	rs6727926	ENSG00000271889.1	RP11-493E12.1	6.43	1.91e-10	3.51e-08	0.3	0.2	Inflammatory skin disease;	chr2:61013401	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-6.43	1.91e-10	3.51e-08	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
BRCA	cis	rs7586673	0.866	rs7579662	ENSG00000235724.7	AC009299.2	-6.43	1.91e-10	3.51e-08	-0.23	-0.2	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161222785~161308303:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-6.43	1.92e-10	3.52e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
BRCA	cis	rs8098244	0.597	rs1154246	ENSG00000264745.1	TTC39C-AS1	6.43	1.92e-10	3.52e-08	0.3	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984242	chr18:23994213~24015339:-
BRCA	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	6.43	1.92e-10	3.52e-08	0.24	0.2	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
BRCA	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	6.43	1.92e-10	3.52e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-6.43	1.92e-10	3.52e-08	-0.23	-0.2	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.52e-08	0.19	0.2	Aortic root size;	chr7:66379575	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778722	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.52e-08	0.19	0.2	Aortic root size;	chr7:66379841	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	6.43	1.92e-10	3.53e-08	0.21	0.2	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	6.43	1.92e-10	3.53e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000232546.1	RP11-458F8.1	-6.43	1.92e-10	3.53e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66038306	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.53e-08	0.19	0.2	Aortic root size;	chr7:66384991	chr7:65773620~65802067:+
BRCA	cis	rs8016982	0.674	rs1951614	ENSG00000258999.1	RP11-114N19.3	-6.43	1.92e-10	3.53e-08	-0.24	-0.2	Schizophrenia;	chr14:81205762	chr14:81107033~81170414:-
BRCA	cis	rs6840360	0.681	rs4519779	ENSG00000270265.1	RP11-731D1.4	-6.43	1.92e-10	3.53e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151333775~151353224:-
BRCA	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.43	1.93e-10	3.53e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000224316.1	RP11-479O9.2	6.43	1.93e-10	3.53e-08	0.19	0.2	Aortic root size;	chr7:66380410	chr7:65773620~65802067:+
BRCA	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	6.43	1.93e-10	3.54e-08	0.16	0.2	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000220721.1	OR1F12	6.43	1.93e-10	3.54e-08	0.22	0.2	Pubertal anthropometrics;	chr6:28420988	chr6:28073316~28074233:+
BRCA	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-6.43	1.93e-10	3.54e-08	-0.27	-0.2	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000234585.5	CCT6P3	6.43	1.93e-10	3.54e-08	0.19	0.2	Calcium levels;	chr7:65941231	chr7:65038354~65074713:+
BRCA	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	6.43	1.93e-10	3.55e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
BRCA	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	6.43	1.93e-10	3.55e-08	0.23	0.2	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
BRCA	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	6.43	1.94e-10	3.55e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48355792~48356614:-
BRCA	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	6.43	1.94e-10	3.55e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48355792~48356614:-
BRCA	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	6.43	1.94e-10	3.56e-08	0.24	0.2	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	6.43	1.94e-10	3.56e-08	0.27	0.2	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	6.43	1.94e-10	3.56e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
BRCA	cis	rs780096	0.967	rs1260334	ENSG00000234072.1	AC074117.10	-6.43	1.94e-10	3.56e-08	-0.18	-0.2	Total body bone mineral density;	chr2:27525730	chr2:27356246~27367622:+
BRCA	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.94e-10	3.56e-08	-0.24	-0.2	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.565	rs10843365	ENSG00000275476.1	RP11-996F15.4	6.43	1.94e-10	3.57e-08	0.22	0.2	QT interval;	chr12:29252691	chr12:29277397~29277882:-
BRCA	cis	rs78456975	1	rs10205916	ENSG00000231482.2	AC141930.2	6.43	1.95e-10	3.57e-08	0.29	0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554679	chr2:1572554~1580311:-
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	6.43	1.95e-10	3.57e-08	0.24	0.2	Height;	chr4:55489895	chr4:55540502~55540835:-
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	6.43	1.95e-10	3.57e-08	0.31	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
BRCA	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	6.43	1.95e-10	3.57e-08	0.27	0.2	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
BRCA	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	6.43	1.95e-10	3.58e-08	0.25	0.2	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
BRCA	cis	rs4908760	0.792	rs6577515	ENSG00000270282.1	RP5-1115A15.2	6.43	1.95e-10	3.58e-08	0.21	0.2	Vitiligo;	chr1:8654143	chr1:8512653~8513021:+
BRCA	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-6.43	1.95e-10	3.58e-08	-0.29	-0.2	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
BRCA	cis	rs710913	0.618	rs6587	ENSG00000237624.1	OXCT2P1	6.43	1.95e-10	3.58e-08	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39514956~39516490:+
BRCA	cis	rs12594515	1	rs12592190	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45701830	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11854554	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45702348	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs35182335	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45702986	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11855509	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45703276	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11855562	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45703461	chr15:45705078~45931069:+
BRCA	cis	rs34779708	0.931	rs35848945	ENSG00000271335.4	RP11-324I22.4	6.43	1.95e-10	3.58e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35314552~35336401:-
BRCA	cis	rs6688613	1	rs6688613	ENSG00000225171.2	DUTP6	6.43	1.96e-10	3.59e-08	0.23	0.2	Refractive astigmatism;	chr1:166982632	chr1:166868748~166869209:+
BRCA	cis	rs9876781	1	rs13071337	ENSG00000229759.1	MRPS18AP1	6.43	1.96e-10	3.59e-08	0.22	0.2	Longevity;	chr3:48396724	chr3:48256350~48256938:-
BRCA	cis	rs9907295	1	rs11655533	ENSG00000270977.1	AC015849.16	-6.43	1.96e-10	3.6e-08	-0.33	-0.2	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35893707~35911023:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	6.43	1.96e-10	3.6e-08	0.34	0.2	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-6.43	1.96e-10	3.6e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
BRCA	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	6.43	1.96e-10	3.6e-08	0.36	0.2	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
BRCA	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-6.43	1.97e-10	3.6e-08	-0.22	-0.2	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-6.43	1.97e-10	3.6e-08	-0.22	-0.2	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
BRCA	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	6.43	1.97e-10	3.6e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
BRCA	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	6.43	1.97e-10	3.61e-08	0.18	0.2	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000229886.1	RP5-1132H15.3	-6.43	1.97e-10	3.61e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66183554	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs4718316	ENSG00000229886.1	RP5-1132H15.3	-6.43	1.97e-10	3.61e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66183744	chr7:66025126~66031544:-
BRCA	cis	rs2638953	0.924	rs11049399	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs61920227	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049400	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049401	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28163298~28190738:-
BRCA	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-6.43	1.97e-10	3.61e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
BRCA	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	6.43	1.97e-10	3.61e-08	0.22	0.2	QT interval;	chr12:29253828	chr12:29280418~29317848:-
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000267422.1	CTD-2554C21.1	-6.43	1.97e-10	3.61e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37353404	chr19:37779686~37792865:+
BRCA	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-6.43	1.98e-10	3.62e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
BRCA	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	6.43	1.98e-10	3.63e-08	0.2	0.2	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000254866.2	DEFB109P3	6.43	1.98e-10	3.63e-08	0.26	0.2	Systolic blood pressure;	chr8:11972641	chr8:12150895~12151134:-
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000267422.1	CTD-2554C21.1	-6.43	1.98e-10	3.63e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37317961	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000236529.1	RP13-254B10.1	6.43	1.98e-10	3.63e-08	0.24	0.2	Aortic root size;	chr7:66479399	chr7:65840212~65840596:+
BRCA	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-6.43	1.99e-10	3.64e-08	-0.22	-0.2	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
BRCA	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-6.43	1.99e-10	3.64e-08	-0.2	-0.2	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
BRCA	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-6.43	1.99e-10	3.64e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-6.43	1.99e-10	3.64e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
BRCA	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.43	1.99e-10	3.65e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
BRCA	cis	rs5015933	1	rs10760395	ENSG00000232630.1	PRPS1P2	-6.43	1.99e-10	3.65e-08	-0.18	-0.2	Body mass index;	chr9:125369582	chr9:125150653~125151589:+
BRCA	cis	rs67981189	0.752	rs221902	ENSG00000269927.1	RP6-91H8.3	-6.43	1.99e-10	3.65e-08	-0.24	-0.2	Schizophrenia;	chr14:71134362	chr14:71141125~71143253:-
BRCA	cis	rs34779708	1	rs12769189	ENSG00000271335.4	RP11-324I22.4	6.43	1.99e-10	3.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35314552~35336401:-
BRCA	cis	rs13108904	0.71	rs11937232	ENSG00000254094.1	AC078852.1	-6.43	1.99e-10	3.65e-08	-0.21	-0.2	Obesity-related traits;	chr4:1213809	chr4:1356581~1358075:+
BRCA	cis	rs7914558	0.966	rs10786725	ENSG00000213061.2	PFN1P11	6.43	2e-10	3.66e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102838011~102845473:-
BRCA	cis	rs7809950	0.817	rs34325395	ENSG00000238832.1	snoU109	-6.43	2e-10	3.66e-08	-0.29	-0.2	Coronary artery disease;	chr7:107473363	chr7:107603363~107603507:+
BRCA	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-6.43	2e-10	3.67e-08	-0.27	-0.2	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
BRCA	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-6.43	2e-10	3.67e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
BRCA	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	6.42	2e-10	3.67e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
BRCA	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-6.42	2.01e-10	3.67e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
BRCA	cis	rs17253792	0.908	rs9972177	ENSG00000186615.9	KTN1-AS1	-6.42	2.01e-10	3.67e-08	-0.37	-0.2	Putamen volume;	chr14:55606488	chr14:55499278~55580110:-
BRCA	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	6.42	2.01e-10	3.68e-08	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
BRCA	cis	rs72772090	1	rs72772092	ENSG00000248734.2	CTD-2260A17.1	-6.42	2.01e-10	3.68e-08	-0.3	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96711208	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000273024.4	INTS4P2	6.42	2.01e-10	3.69e-08	0.25	0.2	Aortic root size;	chr7:66105323	chr7:65647864~65715661:+
BRCA	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-6.42	2.01e-10	3.69e-08	-0.22	-0.2	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
BRCA	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-6.42	2.01e-10	3.69e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
BRCA	cis	rs16978956	0.901	rs2424167	ENSG00000236474.1	GCNT1P1	-6.42	2.01e-10	3.69e-08	-0.23	-0.2	Body mass index;	chr20:18344711	chr20:18420160~18421454:-
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	6.42	2.01e-10	3.69e-08	0.23	0.2	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
BRCA	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	6.42	2.02e-10	3.69e-08	0.24	0.2	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
BRCA	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	6.42	2.02e-10	3.69e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
BRCA	cis	rs42648	0.569	rs110360	ENSG00000225498.1	AC002064.5	6.42	2.02e-10	3.69e-08	0.18	0.2	Homocysteine levels;	chr7:90227294	chr7:90312496~90322592:+
BRCA	cis	rs5015933	1	rs11998746	ENSG00000232630.1	PRPS1P2	-6.42	2.02e-10	3.7e-08	-0.18	-0.2	Body mass index;	chr9:125373083	chr9:125150653~125151589:+
BRCA	cis	rs42648	0.935	rs42651	ENSG00000225498.1	AC002064.5	6.42	2.03e-10	3.71e-08	0.19	0.2	Homocysteine levels;	chr7:90349276	chr7:90312496~90322592:+
BRCA	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.42	2.03e-10	3.71e-08	0.22	0.2	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
BRCA	cis	rs5015933	1	rs4289914	ENSG00000232630.1	PRPS1P2	-6.42	2.03e-10	3.71e-08	-0.18	-0.2	Body mass index;	chr9:125373526	chr9:125150653~125151589:+
BRCA	cis	rs1124769	0.748	rs3825798	ENSG00000259378.1	DCAF13P3	6.42	2.03e-10	3.71e-08	0.28	0.2	Cognitive performance;	chr15:51002635	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	6.42	2.03e-10	3.71e-08	0.24	0.2	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	6.42	2.03e-10	3.71e-08	0.24	0.2	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.563	rs9848926	ENSG00000239213.4	NCK1-AS1	6.42	2.03e-10	3.71e-08	0.25	0.2	Height;Body mass index;	chr3:136097460	chr3:136841726~136862054:-
BRCA	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	6.42	2.03e-10	3.71e-08	0.24	0.2	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
BRCA	cis	rs42648	0.596	rs194523	ENSG00000225498.1	AC002064.5	6.42	2.03e-10	3.72e-08	0.18	0.2	Homocysteine levels;	chr7:90231260	chr7:90312496~90322592:+
BRCA	cis	rs2638953	0.924	rs7307078	ENSG00000247934.4	RP11-967K21.1	-6.42	2.03e-10	3.72e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000228409.4	CCT6P1	6.42	2.03e-10	3.72e-08	0.27	0.2	Diabetic kidney disease;	chr7:65924743	chr7:65751142~65763354:+
BRCA	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	6.42	2.03e-10	3.72e-08	0.22	0.2	Height;	chr5:37475789	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000224316.1	RP11-479O9.2	-6.42	2.03e-10	3.72e-08	-0.19	-0.2	Aortic root size;	chr7:66333558	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.588	rs223458	ENSG00000251288.2	RP11-10L12.2	-6.42	2.03e-10	3.72e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102751401~102752641:+
BRCA	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	6.42	2.03e-10	3.72e-08	0.23	0.2	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000257763.1	OR5BK1P	-6.42	2.03e-10	3.72e-08	-0.21	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48355792~48356614:-
BRCA	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	6.42	2.03e-10	3.72e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
BRCA	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	6.42	2.04e-10	3.73e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
BRCA	cis	rs2919009	0.882	rs2919008	ENSG00000271670.1	RP11-95I16.4	6.42	2.04e-10	3.73e-08	0.25	0.2	Obesity-related traits;	chr10:120838163	chr10:120879256~120880667:-
BRCA	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	6.42	2.04e-10	3.73e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
BRCA	cis	rs7432375	0.61	rs28458819	ENSG00000239213.4	NCK1-AS1	6.42	2.04e-10	3.73e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136803472	chr3:136841726~136862054:-
BRCA	cis	rs2492286	0.597	rs2811487	ENSG00000242551.2	POU5F1P6	-6.42	2.04e-10	3.73e-08	-0.28	-0.2	Eosinophil counts;	chr3:128613036	chr3:128674735~128677005:-
BRCA	cis	rs9527	1	rs9527	ENSG00000213061.2	PFN1P11	6.42	2.04e-10	3.74e-08	0.3	0.2	Arsenic metabolism;	chr10:102863821	chr10:102838011~102845473:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	6.42	2.04e-10	3.74e-08	0.11	0.2	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
BRCA	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	6.42	2.04e-10	3.74e-08	0.23	0.2	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
BRCA	cis	rs12594515	1	rs12594515	ENSG00000259200.1	RP11-718O11.1	6.42	2.04e-10	3.74e-08	0.22	0.2	Weight;Waist circumference;	chr15:45692873	chr15:45705078~45931069:+
BRCA	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	6.42	2.04e-10	3.74e-08	0.25	0.2	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	6.42	2.05e-10	3.74e-08	0.34	0.2	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
BRCA	cis	rs72681920	0.881	rs12512053	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99281999	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs12508502	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99282019	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs2276332	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99282290	chr4:99088857~99301356:+
BRCA	cis	rs7927771	0.524	rs7116346	ENSG00000280615.1	Y_RNA	-6.42	2.05e-10	3.75e-08	-0.22	-0.2	Subjective well-being;	chr11:47862328	chr11:47614898~47614994:-
BRCA	cis	rs7914558	0.966	rs2297786	ENSG00000213061.2	PFN1P11	6.42	2.05e-10	3.75e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28197321	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28197412	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28198669	chr6:28943877~28944537:+
BRCA	cis	rs5758511	0.773	rs10154700	ENSG00000205702.9	CYP2D7	6.42	2.05e-10	3.75e-08	0.2	0.2	Birth weight;	chr22:41969069	chr22:42140203~42144577:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.05e-10	3.76e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37303626	chr19:37779686~37792865:+
BRCA	cis	rs6840360	0.87	rs1372978	ENSG00000270265.1	RP11-731D1.4	-6.42	2.05e-10	3.76e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151333775~151353224:-
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55490228	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55491150	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55493557	chr4:55540502~55540835:-
BRCA	cis	rs9527	0.501	rs12244388	ENSG00000236937.2	PTGES3P4	6.42	2.06e-10	3.76e-08	0.25	0.2	Arsenic metabolism;	chr10:102880295	chr10:102845595~102845950:+
BRCA	cis	rs4372836	0.964	rs4408686	ENSG00000226833.4	AC097724.3	-6.42	2.06e-10	3.76e-08	-0.24	-0.2	Body mass index;	chr2:28717660	chr2:28708953~28736205:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66407462	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66409301	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66409786	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66417741	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66418217	chr7:65773620~65802067:+
BRCA	cis	rs72772090	0.908	rs76539796	ENSG00000248734.2	CTD-2260A17.1	-6.42	2.06e-10	3.76e-08	-0.31	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96702971	chr5:96784777~96785999:+
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48360920~48361377:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	6.42	2.06e-10	3.76e-08	0.15	0.2	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
BRCA	cis	rs4664293	0.541	rs1425047	ENSG00000226266.5	AC009961.3	6.42	2.06e-10	3.77e-08	0.23	0.2	Monocyte percentage of white cells;	chr2:159517946	chr2:159670708~159712435:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.06e-10	3.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37428344	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-6.42	2.06e-10	3.77e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
BRCA	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	6.42	2.06e-10	3.77e-08	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
BRCA	cis	rs1014246	0.813	rs11197797	ENSG00000232767.1	RP11-498B4.5	-6.42	2.06e-10	3.77e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116694988	chr10:116670103~116672739:+
BRCA	cis	rs9876781	0.967	rs7618883	ENSG00000229759.1	MRPS18AP1	6.42	2.06e-10	3.77e-08	0.22	0.2	Longevity;	chr3:48457056	chr3:48256350~48256938:-
BRCA	cis	rs1440410	0.798	rs11100772	ENSG00000250326.1	RP11-284M14.1	-6.42	2.06e-10	3.77e-08	-0.21	-0.2	Ischemic stroke;	chr4:143132935	chr4:142933195~143184861:-
BRCA	cis	rs5015933	0.815	rs10114168	ENSG00000232630.1	PRPS1P2	-6.42	2.06e-10	3.77e-08	-0.18	-0.2	Body mass index;	chr9:125273170	chr9:125150653~125151589:+
BRCA	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-6.42	2.06e-10	3.77e-08	-0.22	-0.2	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-6.42	2.06e-10	3.77e-08	-0.22	-0.2	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.35	0.2	Diabetic kidney disease;	chr7:66136229	chr7:66025126~66031544:-
BRCA	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	6.42	2.07e-10	3.78e-08	0.25	0.2	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.34	0.2	Diabetic kidney disease;	chr7:65910845	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.34	0.2	Diabetic kidney disease;	chr7:66004843	chr7:66025126~66031544:-
BRCA	cis	rs17253792	0.822	rs9972178	ENSG00000186615.9	KTN1-AS1	-6.42	2.07e-10	3.78e-08	-0.37	-0.2	Putamen volume;	chr14:55606762	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs9972180	ENSG00000186615.9	KTN1-AS1	-6.42	2.07e-10	3.78e-08	-0.37	-0.2	Putamen volume;	chr14:55607014	chr14:55499278~55580110:-
BRCA	cis	rs2348418	0.864	rs6487690	ENSG00000247934.4	RP11-967K21.1	6.42	2.07e-10	3.79e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28560407	chr12:28163298~28190738:-
BRCA	cis	rs9527	0.525	rs12770034	ENSG00000236937.2	PTGES3P4	6.42	2.07e-10	3.79e-08	0.25	0.2	Arsenic metabolism;	chr10:102875838	chr10:102845595~102845950:+
BRCA	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-6.42	2.08e-10	3.79e-08	-0.18	-0.2	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
BRCA	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	6.42	2.08e-10	3.79e-08	0.23	0.2	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
BRCA	cis	rs860818	1	rs858303	ENSG00000226816.2	AC005082.12	6.42	2.08e-10	3.79e-08	0.44	0.2	Initial pursuit acceleration;	chr7:23203879	chr7:23206013~23208045:+
BRCA	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-6.42	2.08e-10	3.8e-08	-0.26	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
BRCA	cis	rs228614	0.51	rs3774987	ENSG00000251288.2	RP11-10L12.2	-6.42	2.08e-10	3.8e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102751401~102752641:+
BRCA	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	6.42	2.08e-10	3.8e-08	0.18	0.2	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
BRCA	cis	rs155076	1	rs155076	ENSG00000235438.6	ESRRAP2	6.42	2.08e-10	3.8e-08	0.28	0.2	White matter hyperintensity burden;	chr13:21295975	chr13:21260015~21295003:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000211972.2	IGHV3-66	6.42	2.08e-10	3.8e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106680856	chr14:106675017~106675544:-
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	6.42	2.08e-10	3.8e-08	0.31	0.2	Pain;	chr19:21516423	chr19:21554640~21569237:-
BRCA	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.42	2.08e-10	3.81e-08	0.2	0.2	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
BRCA	cis	rs891378	1	rs2802238	ENSG00000274245.1	RP11-357P18.2	-6.42	2.08e-10	3.81e-08	-0.28	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302796	chr1:207372559~207373252:+
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	6.42	2.08e-10	3.81e-08	0.28	0.2	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
BRCA	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-6.42	2.09e-10	3.81e-08	-0.25	-0.2	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
BRCA	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-6.42	2.09e-10	3.81e-08	-0.23	-0.2	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66014154	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66019087	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66023407	chr7:65751142~65763354:+
BRCA	cis	rs755249	0.567	rs16826000	ENSG00000237624.1	OXCT2P1	6.42	2.09e-10	3.81e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-6.42	2.09e-10	3.82e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
BRCA	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	6.42	2.09e-10	3.82e-08	0.25	0.2	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
BRCA	cis	rs2239547	0.562	rs6794389	ENSG00000242142.1	SERBP1P3	6.42	2.09e-10	3.82e-08	0.24	0.2	Schizophrenia;	chr3:53062378	chr3:53064283~53065091:-
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.1e-10	3.83e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37340137	chr19:37779686~37792865:+
BRCA	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	6.42	2.1e-10	3.83e-08	0.22	0.19	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000229886.1	RP5-1132H15.3	6.42	2.1e-10	3.83e-08	0.34	0.19	Diabetic kidney disease;	chr7:66302856	chr7:66025126~66031544:-
BRCA	cis	rs9527	0.571	rs12765337	ENSG00000236937.2	PTGES3P4	6.42	2.1e-10	3.83e-08	0.25	0.19	Arsenic metabolism;	chr10:102875587	chr10:102845595~102845950:+
BRCA	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	6.42	2.11e-10	3.85e-08	0.26	0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
BRCA	cis	rs853679	0.546	rs35819751	ENSG00000220721.1	OR1F12	6.42	2.11e-10	3.85e-08	0.47	0.19	Depression;	chr6:27842791	chr6:28073316~28074233:+
BRCA	cis	rs1552244	1	rs9849434	ENSG00000180385.7	EMC3-AS1	-6.42	2.11e-10	3.85e-08	-0.24	-0.19	Alzheimer's disease;	chr3:10092026	chr3:9986893~10006990:+
BRCA	cis	rs67981189	0.858	rs2526862	ENSG00000258571.1	PTTG4P	6.42	2.11e-10	3.85e-08	0.22	0.19	Schizophrenia;	chr14:70942897	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.788	rs2526860	ENSG00000258571.1	PTTG4P	6.42	2.11e-10	3.85e-08	0.22	0.19	Schizophrenia;	chr14:70945161	chr14:71085482~71085833:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000274576.2	IGHV2-70	-6.42	2.11e-10	3.85e-08	-0.16	-0.19	Kawasaki disease;	chr14:106792798	chr14:106770577~106771020:-
BRCA	cis	rs34779708	0.966	rs57081218	ENSG00000271335.4	RP11-324I22.4	6.42	2.11e-10	3.85e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-6.42	2.11e-10	3.85e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
BRCA	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-6.42	2.11e-10	3.86e-08	-0.2	-0.19	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	6.42	2.12e-10	3.86e-08	0.2	0.19	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
BRCA	cis	rs12594515	1	rs56220882	ENSG00000259200.1	RP11-718O11.1	-6.42	2.12e-10	3.86e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704877	chr15:45705078~45931069:+
BRCA	cis	rs1124769	0.748	rs17703435	ENSG00000259378.1	DCAF13P3	6.42	2.12e-10	3.86e-08	0.28	0.19	Cognitive performance;	chr15:51011007	chr15:50944663~50945996:+
BRCA	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	6.42	2.12e-10	3.86e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-6.42	2.12e-10	3.87e-08	-0.23	-0.19	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
BRCA	cis	rs7474896	0.515	rs688608	ENSG00000226578.1	RP11-258F22.1	6.42	2.12e-10	3.88e-08	0.27	0.19	Obesity (extreme);	chr10:38042696	chr10:37775371~37784131:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	6.42	2.13e-10	3.88e-08	0.23	0.19	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	6.42	2.13e-10	3.88e-08	0.23	0.19	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
BRCA	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-6.42	2.13e-10	3.89e-08	-0.27	-0.19	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000232559.3	GS1-124K5.12	6.41	2.13e-10	3.89e-08	0.37	0.19	Diabetic kidney disease;	chr7:66140385	chr7:66554588~66576923:-
BRCA	cis	rs459482	0.576	rs461448	ENSG00000228318.3	AP001610.5	-6.41	2.14e-10	3.9e-08	-0.23	-0.19	IgG glycosylation;	chr21:41428996	chr21:41441056~41445708:-
BRCA	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	6.41	2.14e-10	3.9e-08	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	6.41	2.14e-10	3.9e-08	0.24	0.19	Height;	chr4:55517185	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000274576.2	IGHV2-70	-6.41	2.14e-10	3.91e-08	-0.16	-0.19	Kawasaki disease;	chr14:106800208	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	6.41	2.14e-10	3.91e-08	0.34	0.19	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
BRCA	cis	rs6740322	0.895	rs28456986	ENSG00000234936.1	AC010883.5	6.41	2.14e-10	3.91e-08	0.22	0.19	Coronary artery disease;	chr2:43326182	chr2:43229573~43233394:+
BRCA	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	6.41	2.15e-10	3.92e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000273024.4	INTS4P2	6.41	2.15e-10	3.92e-08	0.25	0.19	Aortic root size;	chr7:66101095	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000267422.1	CTD-2554C21.1	-6.41	2.15e-10	3.92e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37392575	chr19:37779686~37792865:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000224316.1	RP11-479O9.2	6.41	2.15e-10	3.93e-08	0.2	0.19	Aortic root size;	chr7:66539151	chr7:65773620~65802067:+
BRCA	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	6.41	2.15e-10	3.93e-08	0.33	0.19	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
BRCA	cis	rs1124769	0.719	rs1009882	ENSG00000259378.1	DCAF13P3	6.41	2.15e-10	3.93e-08	0.28	0.19	Cognitive performance;	chr15:51099519	chr15:50944663~50945996:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	6.41	2.15e-10	3.93e-08	0.21	0.19	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
BRCA	cis	rs3760982	1	rs4802200	ENSG00000267058.1	RP11-15A1.3	-6.41	2.15e-10	3.93e-08	-0.22	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785366	chr19:43891804~43901805:-
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-6.41	2.16e-10	3.94e-08	-0.17	-0.19	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	6.41	2.16e-10	3.94e-08	0.24	0.19	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-6.41	2.16e-10	3.95e-08	-0.22	-0.19	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	6.41	2.17e-10	3.95e-08	0.11	0.19	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
BRCA	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-6.41	2.17e-10	3.95e-08	-0.23	-0.19	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
BRCA	cis	rs34779708	0.931	rs11010125	ENSG00000271335.4	RP11-324I22.4	6.41	2.17e-10	3.96e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000229886.1	RP5-1132H15.3	6.41	2.17e-10	3.96e-08	0.34	0.19	Diabetic kidney disease;	chr7:66121618	chr7:66025126~66031544:-
BRCA	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-6.41	2.18e-10	3.97e-08	-0.3	-0.19	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
BRCA	cis	rs58873874	0.522	rs111370613	ENSG00000248544.2	CTB-47B11.3	6.41	2.18e-10	3.97e-08	0.41	0.19	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157375741~157384950:-
BRCA	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-6.41	2.18e-10	3.97e-08	-0.23	-0.19	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
BRCA	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-6.41	2.18e-10	3.97e-08	-0.22	-0.19	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	6.41	2.18e-10	3.97e-08	0.17	0.19	Breast size;	chr12:9205627	chr12:9277235~9313241:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-6.41	2.18e-10	3.97e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
BRCA	cis	rs11742741	0.69	rs35311965	ENSG00000248874.4	C5orf17	-6.41	2.18e-10	3.98e-08	-0.24	-0.19	Educational attainment;	chr5:24176027	chr5:23951348~24178263:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	6.41	2.18e-10	3.98e-08	0.34	0.19	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	6.41	2.18e-10	3.98e-08	0.3	0.19	Depression;	chr6:28142370	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	6.41	2.19e-10	3.98e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
BRCA	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	6.41	2.19e-10	3.99e-08	0.18	0.19	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	6.41	2.19e-10	3.99e-08	0.23	0.19	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	6.41	2.19e-10	3.99e-08	0.24	0.19	Height;	chr4:55522229	chr4:55540502~55540835:-
BRCA	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-6.41	2.19e-10	3.99e-08	-0.22	-0.19	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
BRCA	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	6.41	2.19e-10	3.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000214776.8	RP11-726G1.1	-6.41	2.19e-10	3.99e-08	-0.24	-0.19	Type 1 diabetes;	chr12:9687442	chr12:9467552~9576275:+
BRCA	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	6.41	2.19e-10	4e-08	0.25	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
BRCA	cis	rs9876781	1	rs9826195	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392157	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.967	rs9864815	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392588	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9809843	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392923	chr3:48256350~48256938:-
BRCA	cis	rs9307551	1	rs1031005	ENSG00000250334.4	LINC00989	-6.41	2.19e-10	4e-08	-0.28	-0.19	Refractive error;	chr4:79595750	chr4:79492416~79576460:+
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	6.41	2.19e-10	4e-08	0.21	0.19	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
BRCA	cis	rs1440410	0.835	rs11100780	ENSG00000250326.1	RP11-284M14.1	-6.41	2.2e-10	4e-08	-0.21	-0.19	Ischemic stroke;	chr4:143183753	chr4:142933195~143184861:-
BRCA	cis	rs710913	0.717	rs1180349	ENSG00000237624.1	OXCT2P1	-6.41	2.2e-10	4e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39514956~39516490:+
BRCA	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	6.41	2.2e-10	4e-08	0.27	0.19	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-6.41	2.2e-10	4.01e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.567	rs72637906	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs67886352	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs60323161	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs66727439	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39514956~39516490:+
BRCA	cis	rs227932	0.541	rs78177212	ENSG00000234286.1	AC006026.13	-6.41	2.2e-10	4.01e-08	-0.33	-0.19	Schizophrenia;	chr7:23770500	chr7:23680195~23680786:-
BRCA	cis	rs1124769	0.654	rs12914185	ENSG00000259378.1	DCAF13P3	6.41	2.21e-10	4.02e-08	0.28	0.19	Cognitive performance;	chr15:51071687	chr15:50944663~50945996:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000234585.5	CCT6P3	6.41	2.21e-10	4.02e-08	0.19	0.19	Aortic root size;	chr7:65951183	chr7:65038354~65074713:+
BRCA	cis	rs2281558	0.837	rs56238023	ENSG00000125804.12	FAM182A	-6.41	2.21e-10	4.02e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:26054655~26086917:+
BRCA	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	6.41	2.21e-10	4.02e-08	0.22	0.19	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
BRCA	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-6.41	2.21e-10	4.02e-08	-0.36	-0.19	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-6.41	2.21e-10	4.02e-08	-0.36	-0.19	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
BRCA	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	6.41	2.21e-10	4.02e-08	0.22	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
BRCA	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	6.41	2.21e-10	4.03e-08	0.33	0.19	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65918494	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs56291018	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65925352	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs36033484	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65925571	chr7:66025126~66031544:-
BRCA	cis	rs2638953	0.893	rs1464011	ENSG00000278733.1	RP11-425D17.1	-6.41	2.21e-10	4.03e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28185625~28186190:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-6.41	2.21e-10	4.03e-08	-0.26	-0.19	Gout;	chr7:66642037	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000228409.4	CCT6P1	6.41	2.22e-10	4.04e-08	0.27	0.19	Diabetic kidney disease;	chr7:66030474	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-6.41	2.22e-10	4.04e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
BRCA	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-6.41	2.22e-10	4.04e-08	-0.22	-0.19	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
BRCA	cis	rs409045	0.525	rs452688	ENSG00000271874.1	CTD-2024P10.2	-6.41	2.22e-10	4.04e-08	-0.24	-0.19	Left ventricular mass;	chr5:34628325	chr5:34651457~34651888:-
BRCA	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	6.41	2.22e-10	4.04e-08	0.19	0.19	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
BRCA	cis	rs67981189	0.821	rs8007026	ENSG00000269927.1	RP6-91H8.3	6.41	2.22e-10	4.04e-08	0.24	0.19	Schizophrenia;	chr14:70997667	chr14:71141125~71143253:-
BRCA	cis	rs78456975	1	rs13413356	ENSG00000231482.2	AC141930.2	-6.41	2.22e-10	4.04e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550077	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.613	rs1393786	ENSG00000239213.4	NCK1-AS1	6.41	2.22e-10	4.05e-08	0.25	0.19	Height;Body mass index;	chr3:136135193	chr3:136841726~136862054:-
BRCA	cis	rs7520050	0.966	rs1707340	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45581219~45581321:-
BRCA	cis	rs7520050	1	rs785473	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs785472	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45581219~45581321:-
BRCA	cis	rs12594515	1	rs6493169	ENSG00000259200.1	RP11-718O11.1	6.41	2.22e-10	4.05e-08	0.22	0.19	Weight;Waist circumference;	chr15:45694796	chr15:45705078~45931069:+
BRCA	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
BRCA	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	6.41	2.22e-10	4.05e-08	0.22	0.19	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
BRCA	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-6.41	2.22e-10	4.05e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000244733.5	RP11-506M13.3	-6.41	2.23e-10	4.05e-08	-0.24	-0.19	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79660891~79677996:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.41	2.23e-10	4.06e-08	0.29	0.19	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
BRCA	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-6.41	2.23e-10	4.06e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
BRCA	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-6.41	2.24e-10	4.07e-08	-0.2	-0.19	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
BRCA	cis	rs2281558	0.837	rs67676850	ENSG00000125804.12	FAM182A	-6.41	2.24e-10	4.07e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:26054655~26086917:+
BRCA	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-6.41	2.24e-10	4.07e-08	-0.27	-0.19	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-6.41	2.24e-10	4.07e-08	-0.3	-0.19	Depression;	chr6:28140307	chr6:28115628~28116551:+
BRCA	cis	rs9876781	1	rs2362450	ENSG00000229759.1	MRPS18AP1	6.41	2.24e-10	4.07e-08	0.22	0.19	Longevity;	chr3:48419904	chr3:48256350~48256938:-
BRCA	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-6.41	2.24e-10	4.08e-08	-0.29	-0.19	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
BRCA	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	6.41	2.24e-10	4.08e-08	0.2	0.19	Height;	chr20:35002555	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000234585.5	CCT6P3	6.41	2.25e-10	4.09e-08	0.19	0.19	Aortic root size;	chr7:65832759	chr7:65038354~65074713:+
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-6.41	2.25e-10	4.09e-08	-0.26	-0.19	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
BRCA	cis	rs7976269	0.583	rs4931131	ENSG00000257176.2	RP11-996F15.2	-6.41	2.25e-10	4.09e-08	-0.24	-0.19	Male-pattern baldness;	chr12:29015898	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-6.41	2.25e-10	4.1e-08	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
BRCA	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	6.41	2.25e-10	4.1e-08	0.23	0.19	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
BRCA	cis	rs4372836	0.964	rs11683296	ENSG00000226833.4	AC097724.3	-6.41	2.25e-10	4.1e-08	-0.24	-0.19	Body mass index;	chr2:28702538	chr2:28708953~28736205:-
BRCA	cis	rs67311347	1	rs9874499	ENSG00000280739.1	EIF1B-AS1	6.41	2.26e-10	4.1e-08	0.22	0.19	Renal cell carcinoma;	chr3:40400417	chr3:40173145~40309698:-
BRCA	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-6.41	2.26e-10	4.11e-08	-0.24	-0.19	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
BRCA	cis	rs3764021	0.506	rs11052372	ENSG00000214776.8	RP11-726G1.1	6.41	2.26e-10	4.12e-08	0.24	0.19	Type 1 diabetes;	chr12:9679363	chr12:9467552~9576275:+
BRCA	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	6.41	2.27e-10	4.12e-08	0.2	0.19	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
BRCA	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.41	2.27e-10	4.12e-08	0.2	0.19	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
BRCA	cis	rs35146811	0.586	rs10267231	ENSG00000235713.1	RP4-604G5.3	6.41	2.27e-10	4.12e-08	0.24	0.19	Coronary artery disease;	chr7:99997857	chr7:99992397~99993050:+
BRCA	cis	rs7914558	0.899	rs7913682	ENSG00000213061.2	PFN1P11	6.41	2.27e-10	4.12e-08	0.26	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102838011~102845473:-
BRCA	cis	rs755249	0.565	rs7539261	ENSG00000228060.1	RP11-69E11.8	6.41	2.27e-10	4.13e-08	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39565160~39573203:+
BRCA	cis	rs224090	0.601	rs10761661	ENSG00000238280.1	RP11-436D10.3	-6.41	2.27e-10	4.13e-08	-0.26	-0.19	Crohn's disease;	chr10:62765375	chr10:62793562~62805887:-
BRCA	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-6.4	2.27e-10	4.13e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	6.4	2.27e-10	4.13e-08	0.28	0.19	Depression;	chr6:28199145	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.886	rs10492369	ENSG00000278733.1	RP11-425D17.1	6.4	2.27e-10	4.13e-08	0.26	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28185625~28186190:-
BRCA	cis	rs5015933	0.902	rs2270746	ENSG00000232630.1	PRPS1P2	6.4	2.28e-10	4.14e-08	0.18	0.19	Body mass index;	chr9:125359313	chr9:125150653~125151589:+
BRCA	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	6.4	2.28e-10	4.14e-08	0.21	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
BRCA	cis	rs12594515	1	rs12911309	ENSG00000259200.1	RP11-718O11.1	-6.4	2.28e-10	4.14e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693521	chr15:45705078~45931069:+
BRCA	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	6.4	2.28e-10	4.14e-08	0.24	0.19	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
BRCA	cis	rs10050311	0.8	rs17420966	ENSG00000251411.1	RP11-397E7.4	-6.4	2.28e-10	4.14e-08	-0.31	-0.19	Insulin-related traits;	chr4:86770976	chr4:86913266~86914817:-
BRCA	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	6.4	2.28e-10	4.15e-08	0.22	0.19	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
BRCA	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-6.4	2.28e-10	4.15e-08	-0.21	-0.19	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
BRCA	cis	rs2115630	1	rs2115630	ENSG00000229212.6	RP11-561C5.4	6.4	2.28e-10	4.15e-08	0.21	0.19	P wave terminal force;	chr15:84821285	chr15:85205440~85234795:-
BRCA	cis	rs2998286	0.723	rs332172	ENSG00000254635.4	WAC-AS1	-6.4	2.28e-10	4.15e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28522652~28532743:-
BRCA	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	6.4	2.28e-10	4.15e-08	0.3	0.19	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
BRCA	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	6.4	2.29e-10	4.15e-08	0.26	0.19	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
BRCA	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	6.4	2.29e-10	4.16e-08	0.33	0.19	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	6.4	2.29e-10	4.16e-08	0.21	0.19	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
BRCA	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-6.4	2.29e-10	4.16e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	6.4	2.29e-10	4.16e-08	0.27	0.19	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	6.4	2.29e-10	4.16e-08	0.27	0.19	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	6.4	2.29e-10	4.16e-08	0.27	0.19	Depression;	chr6:28193021	chr6:28943877~28944537:+
BRCA	cis	rs7474896	0.515	rs2749582	ENSG00000226578.1	RP11-258F22.1	6.4	2.29e-10	4.17e-08	0.25	0.19	Obesity (extreme);	chr10:37986356	chr10:37775371~37784131:-
BRCA	cis	rs78773383	0.505	rs10033019	ENSG00000249207.1	RP11-360F5.1	6.4	2.3e-10	4.17e-08	0.21	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39112677~39126818:-
BRCA	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	6.4	2.3e-10	4.18e-08	0.24	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
BRCA	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	6.4	2.31e-10	4.19e-08	0.22	0.19	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000211972.2	IGHV3-66	6.4	2.31e-10	4.19e-08	0.18	0.19	Alzheimer's disease (late onset);	chr14:106681320	chr14:106675017~106675544:-
BRCA	cis	rs17253792	0.822	rs28831725	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55620851	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.732	rs28380739	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55621684	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28681420	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55621685	chr14:55499278~55580110:-
BRCA	cis	rs2832191	0.716	rs1888439	ENSG00000176054.6	RPL23P2	6.4	2.31e-10	4.2e-08	0.21	0.19	Dental caries;	chr21:29082136	chr21:28997613~28998033:-
BRCA	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	6.4	2.32e-10	4.21e-08	0.29	0.19	Depression;	chr6:28086929	chr6:28170845~28172521:+
BRCA	cis	rs34779708	0.931	rs2148482	ENSG00000271335.4	RP11-324I22.4	6.4	2.32e-10	4.21e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	6.4	2.32e-10	4.21e-08	0.22	0.19	Height;	chr5:37488095	chr5:36666214~36725195:-
BRCA	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-6.4	2.32e-10	4.21e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
BRCA	cis	rs919433	0.783	rs788007	ENSG00000231621.1	AC013264.2	-6.4	2.32e-10	4.22e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368952	chr2:197197991~197199273:+
BRCA	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-6.4	2.32e-10	4.22e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	6.4	2.32e-10	4.22e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	6.4	2.32e-10	4.22e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
BRCA	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-6.4	2.32e-10	4.22e-08	-0.25	-0.19	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
BRCA	cis	rs875971	1	rs709597	ENSG00000224316.1	RP11-479O9.2	-6.4	2.32e-10	4.22e-08	-0.2	-0.19	Aortic root size;	chr7:66360996	chr7:65773620~65802067:+
BRCA	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-6.4	2.32e-10	4.22e-08	-0.28	-0.19	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
BRCA	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-6.4	2.32e-10	4.22e-08	-0.27	-0.19	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000244733.5	RP11-506M13.3	-6.4	2.33e-10	4.22e-08	-0.24	-0.19	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79660891~79677996:+
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	6.4	2.33e-10	4.22e-08	0.23	0.19	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
BRCA	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-6.4	2.33e-10	4.22e-08	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
BRCA	cis	rs2998286	0.541	rs332180	ENSG00000254635.4	WAC-AS1	-6.4	2.33e-10	4.23e-08	-0.32	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28522652~28532743:-
BRCA	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-6.4	2.33e-10	4.23e-08	-0.29	-0.19	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000228409.4	CCT6P1	6.4	2.33e-10	4.23e-08	0.28	0.19	Diabetic kidney disease;	chr7:66078212	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000228409.4	CCT6P1	6.4	2.33e-10	4.23e-08	0.28	0.19	Diabetic kidney disease;	chr7:66078397	chr7:65751142~65763354:+
BRCA	cis	rs73193808	0.901	rs67463471	ENSG00000215533.7	LINC00189	-6.4	2.33e-10	4.24e-08	-0.28	-0.19	Coronary artery disease;	chr21:29195488	chr21:29193480~29288205:+
BRCA	cis	rs2638953	0.924	rs10843124	ENSG00000278733.1	RP11-425D17.1	-6.4	2.33e-10	4.24e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28185625~28186190:-
BRCA	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-6.4	2.33e-10	4.24e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
BRCA	cis	rs11024102	1	rs11024102	ENSG00000184669.7	OR7E14P	-6.4	2.33e-10	4.24e-08	-0.3	-0.19	Glaucoma (primary angle closure);	chr11:16987058	chr11:17013998~17053024:+
BRCA	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	6.4	2.33e-10	4.24e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
BRCA	cis	rs35491132	1	rs35491132	ENSG00000220721.1	OR1F12	6.4	2.34e-10	4.24e-08	0.45	0.19	Urinary tract infection frequency;	chr6:27559449	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.896	rs12100737	ENSG00000269927.1	RP6-91H8.3	-6.4	2.34e-10	4.25e-08	-0.24	-0.19	Schizophrenia;	chr14:71004383	chr14:71141125~71143253:-
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000255046.1	RP11-297N6.4	6.4	2.34e-10	4.25e-08	0.22	0.19	Monocyte count;	chr8:11950067	chr8:11797928~11802568:-
BRCA	cis	rs34779708	0.966	rs35814343	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.26e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000224316.1	RP11-479O9.2	-6.4	2.35e-10	4.26e-08	-0.2	-0.19	Aortic root size;	chr7:66300017	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.26e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
BRCA	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	6.4	2.35e-10	4.26e-08	0.33	0.19	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	6.4	2.35e-10	4.26e-08	0.33	0.19	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000273765.1	RP11-370I10.11	6.4	2.35e-10	4.27e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000273765.1	RP11-370I10.11	6.4	2.35e-10	4.27e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	6.4	2.35e-10	4.27e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
BRCA	cis	rs35146811	0.66	rs6465760	ENSG00000235713.1	RP4-604G5.3	-6.4	2.35e-10	4.27e-08	-0.23	-0.19	Coronary artery disease;	chr7:99993795	chr7:99992397~99993050:+
BRCA	cis	rs34779708	0.966	rs17591781	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.27e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000224316.1	RP11-479O9.2	6.4	2.36e-10	4.28e-08	0.19	0.19	Aortic root size;	chr7:66391332	chr7:65773620~65802067:+
BRCA	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-6.4	2.36e-10	4.28e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
BRCA	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-6.4	2.36e-10	4.28e-08	-0.2	-0.19	Height;	chr20:35180449	chr20:35201747~35203288:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000228409.4	CCT6P1	6.4	2.36e-10	4.28e-08	0.27	0.19	Diabetic kidney disease;	chr7:65999249	chr7:65751142~65763354:+
BRCA	cis	rs11742741	0.579	rs17444609	ENSG00000248874.4	C5orf17	6.4	2.36e-10	4.29e-08	0.25	0.19	Educational attainment;	chr5:24110244	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	6.4	2.36e-10	4.29e-08	0.24	0.19	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
BRCA	cis	rs67981189	0.896	rs17108804	ENSG00000269927.1	RP6-91H8.3	-6.4	2.37e-10	4.3e-08	-0.24	-0.19	Schizophrenia;	chr14:70974807	chr14:71141125~71143253:-
BRCA	cis	rs2030746	1	rs2030746	ENSG00000237614.1	AC073257.2	6.4	2.37e-10	4.3e-08	0.24	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551912	chr2:120542909~120544326:-
BRCA	cis	rs919433	0.783	rs2565158	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371379	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs2565155	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371701	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs3097383	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372163	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.662	rs2043018	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372234	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.744	rs11049426	ENSG00000278733.1	RP11-425D17.1	-6.4	2.37e-10	4.3e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28185625~28186190:-
BRCA	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-6.4	2.37e-10	4.31e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	6.4	2.37e-10	4.31e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
BRCA	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.4	2.37e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
BRCA	cis	rs12594515	1	rs12595137	ENSG00000259200.1	RP11-718O11.1	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693907	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs12595138	ENSG00000259200.1	RP11-718O11.1	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693910	chr15:45705078~45931069:+
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000230042.1	AK3P3	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23129178~23129841:+
BRCA	cis	rs919433	1	rs1560277	ENSG00000231621.1	AC013264.2	-6.4	2.38e-10	4.31e-08	-0.19	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197197991~197199273:+
BRCA	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	6.4	2.38e-10	4.31e-08	0.3	0.19	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
BRCA	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	6.4	2.38e-10	4.31e-08	0.22	0.19	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
BRCA	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-6.4	2.38e-10	4.31e-08	-0.29	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
BRCA	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.4	2.38e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
BRCA	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.4	2.38e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
BRCA	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	6.4	2.38e-10	4.31e-08	0.24	0.19	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-6.4	2.38e-10	4.31e-08	-0.29	-0.19	Depression;	chr6:28140454	chr6:28170845~28172521:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-6.4	2.38e-10	4.31e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	6.4	2.38e-10	4.31e-08	0.24	0.19	Height;	chr4:55502504	chr4:55540502~55540835:-
BRCA	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.4	2.38e-10	4.32e-08	-0.18	-0.19	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000224316.1	RP11-479O9.2	-6.4	2.38e-10	4.32e-08	-0.2	-0.19	Aortic root size;	chr7:66653261	chr7:65773620~65802067:+
BRCA	cis	rs55702914	0.837	rs2195507	ENSG00000231621.1	AC013264.2	6.4	2.38e-10	4.32e-08	0.19	0.19	Major depression and alcohol dependence;	chr2:197307612	chr2:197197991~197199273:+
BRCA	cis	rs10208649	1	rs72906711	ENSG00000233266.1	HMGB1P31	6.4	2.39e-10	4.33e-08	0.47	0.19	Body mass index;	chr2:54036465	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs13387890	ENSG00000233266.1	HMGB1P31	6.4	2.39e-10	4.33e-08	0.47	0.19	Body mass index;	chr2:54039249	chr2:54051334~54051760:+
BRCA	cis	rs2348418	0.932	rs7136429	ENSG00000247934.4	RP11-967K21.1	6.4	2.39e-10	4.33e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28460306	chr12:28163298~28190738:-
BRCA	cis	rs2749097	0.609	rs2360159	ENSG00000244256.3	RN7SL130P	-6.4	2.39e-10	4.33e-08	-0.26	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653130	chr1:63655743~63656047:+
BRCA	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	6.4	2.39e-10	4.33e-08	0.22	0.19	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000229886.1	RP5-1132H15.3	6.4	2.39e-10	4.34e-08	0.34	0.19	Diabetic kidney disease;	chr7:65939105	chr7:66025126~66031544:-
BRCA	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	6.4	2.39e-10	4.34e-08	0.2	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
BRCA	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.4	2.39e-10	4.34e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000165178.9	NCF1C	6.4	2.39e-10	4.34e-08	0.16	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75156639~75172044:-
BRCA	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
BRCA	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
BRCA	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-6.4	2.4e-10	4.34e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000228409.4	CCT6P1	6.4	2.4e-10	4.35e-08	0.26	0.19	Diabetic kidney disease;	chr7:65963465	chr7:65751142~65763354:+
BRCA	cis	rs6928977	0.5	rs6925161	ENSG00000231028.7	LINC00271	-6.4	2.4e-10	4.35e-08	-0.2	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135497801~135716055:+
BRCA	cis	rs7931462	0.655	rs6483208	ENSG00000279696.1	RP11-178H8.7	-6.4	2.4e-10	4.35e-08	-0.3	-0.19	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93726654~93729805:-
BRCA	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	6.4	2.4e-10	4.36e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
BRCA	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-6.4	2.4e-10	4.36e-08	-0.24	-0.19	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000273765.1	RP11-370I10.11	6.4	2.4e-10	4.36e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000273765.1	RP11-370I10.11	6.4	2.4e-10	4.36e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48360920~48361377:+
BRCA	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-6.4	2.41e-10	4.36e-08	-0.31	-0.19	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
BRCA	cis	rs17253792	0.822	rs28481586	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587145	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147380	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587636	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147688	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587924	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10135426	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587926	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-6.4	2.41e-10	4.37e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
BRCA	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-6.4	2.42e-10	4.38e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	6.4	2.42e-10	4.38e-08	0.24	0.19	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.966	rs4934536	ENSG00000271335.4	RP11-324I22.4	6.4	2.42e-10	4.38e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs4660208	ENSG00000237624.1	OXCT2P1	6.4	2.42e-10	4.38e-08	0.28	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39514956~39516490:+
BRCA	cis	rs67981189	0.865	rs2189806	ENSG00000258571.1	PTTG4P	6.4	2.42e-10	4.38e-08	0.21	0.19	Schizophrenia;	chr14:70921681	chr14:71085482~71085833:-
BRCA	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	6.4	2.42e-10	4.38e-08	0.22	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
BRCA	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-6.39	2.42e-10	4.39e-08	-0.22	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
BRCA	cis	rs12594515	1	rs12185095	ENSG00000259200.1	RP11-718O11.1	-6.39	2.42e-10	4.39e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45702437	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000224316.1	RP11-479O9.2	-6.39	2.42e-10	4.39e-08	-0.2	-0.19	Aortic root size;	chr7:66312922	chr7:65773620~65802067:+
BRCA	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	6.39	2.43e-10	4.39e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.536	rs223477	ENSG00000251288.2	RP11-10L12.2	-6.39	2.43e-10	4.41e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102751401~102752641:+
BRCA	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	6.39	2.43e-10	4.41e-08	0.18	0.19	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
BRCA	cis	rs2638953	0.886	rs11049429	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.779	rs11049432	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs4284426	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28185625~28186190:-
BRCA	cis	rs6543140	0.964	rs4851589	ENSG00000234389.1	AC007278.3	6.39	2.44e-10	4.42e-08	0.19	0.19	Blood protein levels;	chr2:102460685	chr2:102438713~102440475:+
BRCA	cis	rs919433	0.75	rs788010	ENSG00000231621.1	AC013264.2	-6.39	2.44e-10	4.43e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366225	chr2:197197991~197199273:+
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000267422.1	CTD-2554C21.1	-6.39	2.45e-10	4.43e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37482872	chr19:37779686~37792865:+
BRCA	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	6.39	2.45e-10	4.44e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
BRCA	cis	rs10050311	0.746	rs17420607	ENSG00000251411.1	RP11-397E7.4	-6.39	2.45e-10	4.44e-08	-0.29	-0.19	Insulin-related traits;	chr4:86749048	chr4:86913266~86914817:-
BRCA	cis	rs10515750	0.5	rs10463005	ENSG00000248544.2	CTB-47B11.3	-6.39	2.45e-10	4.44e-08	-0.28	-0.19	Lung function (FEV1/FVC);	chr5:157278870	chr5:157375741~157384950:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000232559.3	GS1-124K5.12	6.39	2.45e-10	4.44e-08	0.37	0.19	Diabetic kidney disease;	chr7:66100518	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	6.39	2.46e-10	4.45e-08	0.27	0.19	Depression;	chr6:28205175	chr6:28943877~28944537:+
BRCA	cis	rs1014246	0.848	rs58568639	ENSG00000232767.1	RP11-498B4.5	-6.39	2.46e-10	4.45e-08	-0.23	-0.19	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116697375	chr10:116670103~116672739:+
BRCA	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	6.39	2.46e-10	4.45e-08	0.22	0.19	Height;	chr7:77668098	chr7:77657660~77696265:-
BRCA	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-6.39	2.46e-10	4.45e-08	-0.21	-0.19	Height;	chr5:37276224	chr5:36666214~36725195:-
BRCA	cis	rs2554380	0.55	rs62025831	ENSG00000230373.7	GOLGA6L5P	6.39	2.46e-10	4.46e-08	0.25	0.19	Height;	chr15:83876933	chr15:84507885~84516814:-
BRCA	cis	rs11154801	0.696	rs4432992	ENSG00000231028.7	LINC00271	-6.39	2.46e-10	4.46e-08	-0.21	-0.19	Multiple sclerosis;	chr6:135612356	chr6:135497801~135716055:+
BRCA	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	6.39	2.46e-10	4.46e-08	0.23	0.19	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
BRCA	cis	rs1440410	0.835	rs9790396	ENSG00000250326.1	RP11-284M14.1	-6.39	2.47e-10	4.47e-08	-0.21	-0.19	Ischemic stroke;	chr4:143130366	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs7693817	ENSG00000250326.1	RP11-284M14.1	-6.39	2.47e-10	4.47e-08	-0.21	-0.19	Ischemic stroke;	chr4:143130372	chr4:142933195~143184861:-
BRCA	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	6.39	2.47e-10	4.47e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	6.39	2.47e-10	4.47e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
BRCA	cis	rs11105298	0.891	rs10858890	ENSG00000270344.2	RP11-734K2.4	6.39	2.47e-10	4.47e-08	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000224316.1	RP11-479O9.2	-6.39	2.47e-10	4.47e-08	-0.19	-0.19	Aortic root size;	chr7:66344119	chr7:65773620~65802067:+
BRCA	cis	rs4683346	0.616	rs7641046	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42789838	chr3:42732575~42746768:+
BRCA	cis	rs4683346	0.585	rs11129975	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42794493	chr3:42732575~42746768:+
BRCA	cis	rs4683346	0.616	rs13096498	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42795494	chr3:42732575~42746768:+
BRCA	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	6.39	2.47e-10	4.48e-08	0.2	0.19	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
BRCA	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	6.39	2.48e-10	4.49e-08	0.36	0.19	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000274576.2	IGHV2-70	-6.39	2.48e-10	4.49e-08	-0.16	-0.19	Kawasaki disease;	chr14:106802182	chr14:106770577~106771020:-
BRCA	cis	rs9907295	0.681	rs9912284	ENSG00000270977.1	AC015849.16	-6.39	2.48e-10	4.49e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35893707~35911023:-
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000204556.4	CTD-2514C3.1	6.39	2.48e-10	4.49e-08	0.27	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26018832~26020684:+
BRCA	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-6.39	2.48e-10	4.5e-08	-0.22	-0.19	Height;	chr5:37266341	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	6.39	2.49e-10	4.5e-08	0.24	0.19	Height;	chr4:55509442	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	6.39	2.49e-10	4.5e-08	0.24	0.19	Height;	chr4:55510177	chr4:55540502~55540835:-
BRCA	cis	rs7746199	0.736	rs35848276	ENSG00000220721.1	OR1F12	6.39	2.49e-10	4.5e-08	0.46	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28073316~28074233:+
BRCA	cis	rs35146811	0.586	rs6946168	ENSG00000235713.1	RP4-604G5.3	6.39	2.49e-10	4.5e-08	0.24	0.19	Coronary artery disease;	chr7:100000663	chr7:99992397~99993050:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-6.39	2.49e-10	4.51e-08	-0.29	-0.19	Depression;	chr6:28091242	chr6:28170845~28172521:+
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	6.39	2.49e-10	4.51e-08	0.28	0.19	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
BRCA	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	6.39	2.49e-10	4.51e-08	0.24	0.19	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
BRCA	cis	rs4908760	0.864	rs1463052	ENSG00000270282.1	RP5-1115A15.2	6.39	2.49e-10	4.51e-08	0.21	0.19	Vitiligo;	chr1:8641172	chr1:8512653~8513021:+
BRCA	cis	rs9880211	0.613	rs12695644	ENSG00000273486.1	RP11-731C17.2	6.39	2.49e-10	4.51e-08	0.24	0.19	Height;Body mass index;	chr3:136126096	chr3:136837338~136839021:-
BRCA	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.39	2.49e-10	4.51e-08	0.2	0.19	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
BRCA	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	6.39	2.49e-10	4.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	6.39	2.49e-10	4.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
BRCA	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-6.39	2.49e-10	4.51e-08	-0.18	-0.19	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.39	2.51e-10	4.53e-08	0.22	0.19	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.824	rs9468225	ENSG00000220721.1	OR1F12	6.39	2.51e-10	4.53e-08	0.24	0.19	Parkinson's disease;	chr6:27777940	chr6:28073316~28074233:+
BRCA	cis	rs754466	0.606	rs11002315	ENSG00000204049.1	RP11-126H7.4	6.39	2.51e-10	4.54e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857627	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs11002317	ENSG00000204049.1	RP11-126H7.4	6.39	2.51e-10	4.54e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857890	chr10:77866875~77869610:+
BRCA	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000236529.1	RP13-254B10.1	6.39	2.51e-10	4.54e-08	0.25	0.19	Aortic root size;	chr7:66302477	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000236529.1	RP13-254B10.1	6.39	2.51e-10	4.54e-08	0.25	0.19	Aortic root size;	chr7:66305392	chr7:65840212~65840596:+
BRCA	cis	rs5015933	0.801	rs4240490	ENSG00000232630.1	PRPS1P2	-6.39	2.51e-10	4.54e-08	-0.18	-0.19	Body mass index;	chr9:125377728	chr9:125150653~125151589:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-6.39	2.51e-10	4.54e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-6.39	2.51e-10	4.54e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	6.39	2.51e-10	4.54e-08	0.29	0.19	Depression;	chr6:28142370	chr6:28170845~28172521:+
BRCA	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-6.39	2.51e-10	4.55e-08	-0.38	-0.19	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
BRCA	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-6.39	2.51e-10	4.55e-08	-0.38	-0.19	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
BRCA	cis	rs755249	0.567	rs61779309	ENSG00000237624.1	OXCT2P1	6.39	2.51e-10	4.55e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39514956~39516490:+
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	6.39	2.51e-10	4.55e-08	0.28	0.19	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
BRCA	cis	rs10029851	0.58	rs6854331	ENSG00000234492.4	RPL34-AS1	6.39	2.51e-10	4.55e-08	0.29	0.19	Amyotrophic lateral sclerosis (sporadic);	chr4:108589529	chr4:108538190~108620460:-
BRCA	cis	rs7085104	0.513	rs619824	ENSG00000213061.2	PFN1P11	6.39	2.52e-10	4.55e-08	0.25	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102838011~102845473:-
BRCA	cis	rs67766926	0.587	rs17539290	ENSG00000271889.1	RP11-493E12.1	6.39	2.52e-10	4.55e-08	0.29	0.19	Inflammatory skin disease;	chr2:61020375	chr2:61151433~61162105:-
BRCA	cis	rs10515750	0.5	rs6890694	ENSG00000251405.2	CTB-109A12.1	6.39	2.52e-10	4.56e-08	0.3	0.19	Lung function (FEV1/FVC);	chr5:157283735	chr5:157362615~157460078:-
BRCA	cis	rs12501370	1	rs13105816	ENSG00000201736.1	RNA5SP160	6.39	2.52e-10	4.56e-08	0.25	0.19	Iris color (L* coordinate);	chr4:40986763	chr4:40990154~40990273:+
BRCA	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-6.39	2.53e-10	4.57e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
BRCA	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
BRCA	cis	rs17253792	0.822	rs75995456	ENSG00000186615.9	KTN1-AS1	-6.39	2.53e-10	4.58e-08	-0.4	-0.19	Putamen volume;	chr14:55606476	chr14:55499278~55580110:-
BRCA	cis	rs2998286	0.723	rs332139	ENSG00000254635.4	WAC-AS1	-6.39	2.53e-10	4.58e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28522652~28532743:-
BRCA	cis	rs853679	0.607	rs13211507	ENSG00000220721.1	OR1F12	6.39	2.54e-10	4.58e-08	0.44	0.19	Depression;	chr6:28289600	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs34691223	ENSG00000220721.1	OR1F12	6.39	2.54e-10	4.58e-08	0.44	0.19	Depression;	chr6:28290431	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.858	rs221927	ENSG00000269927.1	RP6-91H8.3	-6.39	2.54e-10	4.59e-08	-0.24	-0.19	Schizophrenia;	chr14:71112024	chr14:71141125~71143253:-
BRCA	cis	rs6728642	0.708	rs115507803	ENSG00000230606.9	AC159540.1	6.39	2.54e-10	4.59e-08	0.41	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97416165~97433527:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-6.39	2.55e-10	4.6e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
BRCA	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	6.39	2.55e-10	4.6e-08	0.23	0.19	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
BRCA	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	6.39	2.55e-10	4.61e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-6.39	2.55e-10	4.61e-08	-0.3	-0.19	Pain;	chr19:21509773	chr19:21554640~21569237:-
BRCA	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.39	2.55e-10	4.61e-08	-0.31	-0.19	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
BRCA	cis	rs35146811	0.586	rs10267212	ENSG00000235713.1	RP4-604G5.3	6.39	2.55e-10	4.61e-08	0.23	0.19	Coronary artery disease;	chr7:99997799	chr7:99992397~99993050:+
BRCA	cis	rs957448	1	rs7829886	ENSG00000253175.1	RP11-267M23.6	6.39	2.55e-10	4.61e-08	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94565036~94565715:+
BRCA	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-6.39	2.55e-10	4.61e-08	-0.25	-0.19	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs7099036	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.62e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35314552~35336401:-
BRCA	cis	rs4691139	1	rs6855591	ENSG00000248632.1	RP11-366M4.11	6.39	2.56e-10	4.62e-08	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164968587~164970002:-
BRCA	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	6.39	2.56e-10	4.62e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs13343471	ENSG00000267422.1	CTD-2554C21.1	-6.39	2.56e-10	4.63e-08	-0.31	-0.19	Coronary artery calcification;	chr19:37441228	chr19:37779686~37792865:+
BRCA	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-6.39	2.56e-10	4.63e-08	-0.24	-0.19	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
BRCA	cis	rs7615952	0.599	rs6438953	ENSG00000250012.1	RP11-124N2.1	-6.39	2.56e-10	4.63e-08	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:126006108	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.599	rs1044215	ENSG00000250012.1	RP11-124N2.1	-6.39	2.56e-10	4.63e-08	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:126006716	chr3:126084220~126095349:+
BRCA	cis	rs34779708	0.931	rs4934535	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4934734	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12769575	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35314552~35336401:-
BRCA	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
BRCA	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	6.39	2.57e-10	4.64e-08	0.25	0.19	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
BRCA	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-6.39	2.57e-10	4.64e-08	-0.22	-0.19	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
BRCA	cis	rs7914558	1	rs11191541	ENSG00000213061.2	PFN1P11	6.39	2.57e-10	4.64e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102838011~102845473:-
BRCA	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-6.39	2.57e-10	4.65e-08	-0.28	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
BRCA	cis	rs9907295	1	rs9913488	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912571	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912793	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35893707~35911023:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
BRCA	cis	rs2749097	0.609	rs2269233	ENSG00000244256.3	RN7SL130P	-6.38	2.58e-10	4.66e-08	-0.26	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653675	chr1:63655743~63656047:+
BRCA	cis	rs7247513	0.964	rs4804202	ENSG00000230310.1	CTD-2192J16.11	-6.38	2.59e-10	4.67e-08	-0.24	-0.19	Bipolar disorder;	chr19:12607805	chr19:12552597~12553644:+
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-6.38	2.59e-10	4.68e-08	-0.29	-0.19	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000216906.2	RP11-350J20.9	-6.38	2.59e-10	4.68e-08	-0.27	-0.19	Dupuytren's disease;	chr6:149345484	chr6:149904243~149906418:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000224316.1	RP11-479O9.2	6.38	2.6e-10	4.69e-08	0.19	0.19	Aortic root size;	chr7:66427543	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	6.38	2.6e-10	4.69e-08	0.24	0.19	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000232559.3	GS1-124K5.12	6.38	2.6e-10	4.69e-08	0.37	0.19	Diabetic kidney disease;	chr7:66133553	chr7:66554588~66576923:-
BRCA	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-6.38	2.61e-10	4.7e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
BRCA	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	6.38	2.61e-10	4.71e-08	0.23	0.19	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
BRCA	cis	rs1440410	0.798	rs7684430	ENSG00000250326.1	RP11-284M14.1	-6.38	2.61e-10	4.71e-08	-0.21	-0.19	Ischemic stroke;	chr4:143133191	chr4:142933195~143184861:-
BRCA	cis	rs6740322	0.748	rs6544635	ENSG00000234936.1	AC010883.5	6.38	2.61e-10	4.72e-08	0.22	0.19	Coronary artery disease;	chr2:43259565	chr2:43229573~43233394:+
BRCA	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
BRCA	cis	rs3820443	0.83	rs57294801	ENSG00000234020.1	CHIAP3	-6.38	2.62e-10	4.72e-08	-0.23	-0.19	Late-onset Alzheimer's disease;	chr1:111353909	chr1:111353275~111367409:-
BRCA	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-6.38	2.62e-10	4.73e-08	-0.24	-0.19	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
BRCA	cis	rs8114671	0.836	rs6060140	ENSG00000269202.1	RP4-614O4.12	-6.38	2.62e-10	4.73e-08	-0.2	-0.19	Height;	chr20:34978704	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000273024.4	INTS4P2	6.38	2.63e-10	4.75e-08	0.24	0.19	Aortic root size;	chr7:66145627	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000273024.4	INTS4P2	6.38	2.63e-10	4.75e-08	0.24	0.19	Aortic root size;	chr7:66146002	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-6.38	2.63e-10	4.75e-08	-0.29	-0.19	Depression;	chr6:28096077	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-6.38	2.63e-10	4.75e-08	-0.29	-0.19	Depression;	chr6:28096855	chr6:28115628~28116551:+
BRCA	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	6.38	2.63e-10	4.75e-08	0.2	0.19	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
BRCA	cis	rs2998286	0.723	rs332146	ENSG00000254635.4	WAC-AS1	-6.38	2.63e-10	4.75e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28522652~28532743:-
BRCA	cis	rs227275	0.556	rs223449	ENSG00000251288.2	RP11-10L12.2	-6.38	2.64e-10	4.76e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223446	ENSG00000251288.2	RP11-10L12.2	-6.38	2.64e-10	4.76e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102751401~102752641:+
BRCA	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-6.38	2.64e-10	4.76e-08	-0.18	-0.19	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-6.38	2.64e-10	4.76e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-6.38	2.64e-10	4.76e-08	-0.29	-0.19	Depression;	chr6:28108492	chr6:28115628~28116551:+
BRCA	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-6.38	2.65e-10	4.77e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
BRCA	cis	rs9876781	1	rs898225	ENSG00000229759.1	MRPS18AP1	-6.38	2.65e-10	4.78e-08	-0.22	-0.19	Longevity;	chr3:48371689	chr3:48256350~48256938:-
BRCA	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-6.38	2.65e-10	4.78e-08	-0.22	-0.19	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
BRCA	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	6.38	2.65e-10	4.78e-08	0.18	0.19	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28197321	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28197412	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28198669	chr6:28115628~28116551:+
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	6.38	2.65e-10	4.78e-08	0.24	0.19	Height;	chr4:55436423	chr4:55540502~55540835:-
BRCA	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	6.38	2.66e-10	4.79e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
BRCA	cis	rs7927771	0.524	rs7122182	ENSG00000280615.1	Y_RNA	-6.38	2.66e-10	4.79e-08	-0.22	-0.19	Subjective well-being;	chr11:47821581	chr11:47614898~47614994:-
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-6.38	2.66e-10	4.79e-08	-0.26	-0.19	Height;	chr4:55593918	chr4:55387949~55388271:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	6.38	2.66e-10	4.8e-08	0.26	0.19	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	6.38	2.66e-10	4.8e-08	0.26	0.19	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
BRCA	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	6.38	2.67e-10	4.81e-08	0.22	0.19	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
BRCA	cis	rs2492286	0.569	rs2712383	ENSG00000242551.2	POU5F1P6	-6.38	2.67e-10	4.81e-08	-0.28	-0.19	Eosinophil counts;	chr3:128629033	chr3:128674735~128677005:-
BRCA	cis	rs6840258	1	rs55787557	ENSG00000251411.1	RP11-397E7.4	-6.38	2.67e-10	4.82e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87029673	chr4:86913266~86914817:-
BRCA	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	6.38	2.67e-10	4.82e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
BRCA	cis	rs793571	0.505	rs12901989	ENSG00000259250.1	RP11-50C13.1	-6.38	2.68e-10	4.83e-08	-0.35	-0.19	Schizophrenia;	chr15:58603861	chr15:58587507~58591676:+
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
BRCA	cis	rs12594515	1	rs8043291	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704049	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs56412446	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704226	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs57299255	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704334	chr15:45705078~45931069:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-6.38	2.68e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28159666	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-6.38	2.68e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28162598	chr6:28170845~28172521:+
BRCA	cis	rs8002861	0.641	rs4942252	ENSG00000274001.1	RP11-5G9.5	6.38	2.68e-10	4.84e-08	0.23	0.19	Leprosy;	chr13:43868903	chr13:43877715~43878163:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000267422.1	CTD-2554C21.1	-6.38	2.69e-10	4.84e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37426790	chr19:37779686~37792865:+
BRCA	cis	rs5015933	0.815	rs10819044	ENSG00000232630.1	PRPS1P2	-6.38	2.69e-10	4.84e-08	-0.18	-0.19	Body mass index;	chr9:125278750	chr9:125150653~125151589:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-6.38	2.69e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28141189	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-6.38	2.69e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28141484	chr6:28170845~28172521:+
BRCA	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	6.38	2.69e-10	4.85e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	6.38	2.69e-10	4.85e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.51	rs223455	ENSG00000251288.2	RP11-10L12.2	-6.38	2.69e-10	4.85e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102751401~102752641:+
BRCA	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	6.38	2.69e-10	4.85e-08	0.25	0.19	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
BRCA	cis	rs6723226	0.75	rs1033751	ENSG00000276334.1	AL133243.1	6.38	2.69e-10	4.85e-08	0.23	0.19	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32521927~32523547:+
BRCA	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	6.38	2.69e-10	4.85e-08	0.2	0.19	Height;	chr20:35064164	chr20:35201747~35203288:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000229886.1	RP5-1132H15.3	6.38	2.69e-10	4.85e-08	0.34	0.19	Diabetic kidney disease;	chr7:66135463	chr7:66025126~66031544:-
BRCA	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.38	2.69e-10	4.86e-08	0.22	0.19	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
BRCA	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	6.38	2.7e-10	4.86e-08	0.23	0.19	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
BRCA	cis	rs5015933	1	rs10760397	ENSG00000232630.1	PRPS1P2	-6.38	2.7e-10	4.86e-08	-0.18	-0.19	Body mass index;	chr9:125370928	chr9:125150653~125151589:+
BRCA	cis	rs7474896	0.537	rs2749586	ENSG00000226578.1	RP11-258F22.1	6.38	2.7e-10	4.87e-08	0.25	0.19	Obesity (extreme);	chr10:37981286	chr10:37775371~37784131:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
BRCA	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	6.38	2.7e-10	4.87e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
BRCA	cis	rs58873874	0.522	rs77458926	ENSG00000248544.2	CTB-47B11.3	6.38	2.71e-10	4.87e-08	0.41	0.19	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157375741~157384950:-
BRCA	cis	rs9527	0.615	rs11191401	ENSG00000213061.2	PFN1P11	6.38	2.71e-10	4.88e-08	0.28	0.19	Arsenic metabolism;	chr10:102813646	chr10:102838011~102845473:-
BRCA	cis	rs2638953	0.924	rs12368652	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049392	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049394	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049395	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049397	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28163298~28190738:-
BRCA	cis	rs78487399	0.908	rs57066469	ENSG00000234936.1	AC010883.5	6.38	2.72e-10	4.89e-08	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616674	chr2:43229573~43233394:+
BRCA	cis	rs1707322	1	rs1613296	ENSG00000281133.1	AL355480.3	6.38	2.72e-10	4.9e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45580892~45580996:-
BRCA	cis	rs13178541	0.81	rs10070559	ENSG00000250378.1	RP11-119J18.1	-6.38	2.72e-10	4.9e-08	-0.27	-0.19	IgG glycosylation;	chr5:135822430	chr5:135812667~135826582:+
BRCA	cis	rs919433	0.783	rs2565165	ENSG00000231621.1	AC013264.2	-6.38	2.72e-10	4.91e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368851	chr2:197197991~197199273:+
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	6.38	2.73e-10	4.91e-08	0.28	0.19	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
BRCA	cis	rs9880211	0.583	rs9870122	ENSG00000273486.1	RP11-731C17.2	6.38	2.74e-10	4.93e-08	0.24	0.19	Height;Body mass index;	chr3:136101423	chr3:136837338~136839021:-
BRCA	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.38	2.74e-10	4.94e-08	0.2	0.19	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
BRCA	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-6.38	2.74e-10	4.94e-08	-0.22	-0.19	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-6.38	2.74e-10	4.94e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
BRCA	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	6.37	2.75e-10	4.96e-08	0.2	0.19	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000232559.3	GS1-124K5.12	6.37	2.75e-10	4.96e-08	0.37	0.19	Diabetic kidney disease;	chr7:66133233	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	6.37	2.76e-10	4.96e-08	0.36	0.19	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-6.37	2.76e-10	4.97e-08	-0.3	-0.19	Depression;	chr6:28140454	chr6:28115628~28116551:+
BRCA	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	6.37	2.76e-10	4.97e-08	0.22	0.19	Height;	chr5:37490184	chr5:36666214~36725195:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-6.37	2.76e-10	4.97e-08	-0.29	-0.19	Depression;	chr6:28110254	chr6:28115628~28116551:+
BRCA	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-6.37	2.76e-10	4.98e-08	-0.22	-0.19	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28099759	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28100648	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28107222	chr6:28115628~28116551:+
BRCA	cis	rs9880211	0.635	rs6775778	ENSG00000273486.1	RP11-731C17.2	-6.37	2.77e-10	4.98e-08	-0.26	-0.19	Height;Body mass index;	chr3:136007837	chr3:136837338~136839021:-
BRCA	cis	rs2998286	0.768	rs332140	ENSG00000254635.4	WAC-AS1	-6.37	2.77e-10	4.98e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28522652~28532743:-
BRCA	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	6.37	2.77e-10	4.99e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
BRCA	cis	rs7621025	0.664	rs6439657	ENSG00000273486.1	RP11-731C17.2	-6.37	2.77e-10	4.99e-08	-0.24	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136837338~136839021:-
BRCA	cis	rs2492286	0.569	rs9848287	ENSG00000242551.2	POU5F1P6	-6.37	2.78e-10	4.99e-08	-0.28	-0.19	Eosinophil counts;	chr3:128628799	chr3:128674735~128677005:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000224316.1	RP11-479O9.2	6.37	2.78e-10	4.99e-08	0.2	0.19	Aortic root size;	chr7:66651069	chr7:65773620~65802067:+
BRCA	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-6.37	2.78e-10	5e-08	-0.23	-0.19	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
BRCA	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	6.37	2.78e-10	5e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
BRCA	cis	rs3126085	0.56	rs2525	ENSG00000237975.5	FLG-AS1	6.37	2.78e-10	5e-08	0.26	0.19	Atopic dermatitis;	chr1:152366588	chr1:152168125~152445456:+
BRCA	cis	rs3126085	0.56	rs941935	ENSG00000237975.5	FLG-AS1	6.37	2.78e-10	5e-08	0.26	0.19	Atopic dermatitis;	chr1:152367012	chr1:152168125~152445456:+
BRCA	cis	rs2492286	0.597	rs1126828	ENSG00000242551.2	POU5F1P6	-6.37	2.78e-10	5e-08	-0.27	-0.19	Eosinophil counts;	chr3:128625943	chr3:128674735~128677005:-
BRCA	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	6.37	2.78e-10	5.01e-08	0.25	0.19	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000263603.1	CTD-2349P21.5	-6.37	2.79e-10	5.02e-08	-0.36	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30729469~30731202:+
BRCA	cis	rs11105298	0.891	rs11105314	ENSG00000270344.2	RP11-734K2.4	6.37	2.79e-10	5.02e-08	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000236529.1	RP13-254B10.1	6.37	2.79e-10	5.02e-08	0.24	0.19	Aortic root size;	chr7:66511428	chr7:65840212~65840596:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-6.37	2.8e-10	5.03e-08	-0.18	-0.19	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	6.37	2.8e-10	5.04e-08	0.29	0.19	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
BRCA	cis	rs78456975	1	rs6712176	ENSG00000231482.2	AC141930.2	-6.37	2.8e-10	5.04e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1552621	chr2:1572554~1580311:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	6.37	2.8e-10	5.04e-08	0.28	0.19	Depression;	chr6:28110525	chr6:28170845~28172521:+
BRCA	cis	rs73193808	1	rs66716206	ENSG00000215533.7	LINC00189	-6.37	2.81e-10	5.04e-08	-0.28	-0.19	Coronary artery disease;	chr21:29183333	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.81e-10	5.05e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000274576.2	IGHV2-70	-6.37	2.81e-10	5.05e-08	-0.16	-0.19	Kawasaki disease;	chr14:106678273	chr14:106770577~106771020:-
BRCA	cis	rs6088813	0.961	rs3795159	ENSG00000126005.14	MMP24-AS1	-6.37	2.81e-10	5.06e-08	-0.23	-0.19	Height;	chr20:35308459	chr20:35216462~35278131:-
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000267422.1	CTD-2554C21.1	-6.37	2.82e-10	5.06e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37497895	chr19:37779686~37792865:+
BRCA	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-6.37	2.82e-10	5.06e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
BRCA	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	6.37	2.82e-10	5.07e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
BRCA	cis	rs9435732	0.778	rs3738815	ENSG00000186715.9	MST1L	6.37	2.82e-10	5.07e-08	0.24	0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16754910~16770237:-
BRCA	cis	rs10208649	0.908	rs60776154	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54026676	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.831	rs72906704	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54028088	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs11884857	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54033185	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.901	rs6748686	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54037481	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs6719990	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54037515	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs72906714	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54038423	chr2:54051334~54051760:+
BRCA	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	6.37	2.82e-10	5.08e-08	0.17	0.19	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
BRCA	cis	rs697003	0.705	rs701926	ENSG00000231057.3	RP11-122M14.1	-6.37	2.83e-10	5.08e-08	-0.22	-0.19	Red cell distribution width;	chr1:211678277	chr1:211675762~211690103:+
BRCA	cis	rs1440410	0.798	rs11727441	ENSG00000250326.1	RP11-284M14.1	-6.37	2.83e-10	5.08e-08	-0.21	-0.19	Ischemic stroke;	chr4:143242602	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs10010367	ENSG00000250326.1	RP11-284M14.1	-6.37	2.83e-10	5.08e-08	-0.21	-0.19	Ischemic stroke;	chr4:143243669	chr4:142933195~143184861:-
BRCA	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-6.37	2.83e-10	5.08e-08	-0.25	-0.19	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	6.37	2.83e-10	5.09e-08	0.26	0.19	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
BRCA	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.37	2.83e-10	5.09e-08	0.2	0.19	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-6.37	2.83e-10	5.09e-08	-0.35	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
BRCA	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	6.37	2.84e-10	5.1e-08	0.22	0.19	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
BRCA	cis	rs250585	0.85	rs394908	ENSG00000260136.4	CTD-2270L9.4	-6.37	2.84e-10	5.1e-08	-0.21	-0.19	Egg allergy;	chr16:23451984	chr16:23452758~23457606:+
BRCA	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	6.37	2.84e-10	5.1e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
BRCA	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	6.37	2.84e-10	5.11e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
BRCA	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-6.37	2.85e-10	5.11e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-6.37	2.85e-10	5.11e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
BRCA	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-6.37	2.85e-10	5.11e-08	-0.22	-0.19	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	6.37	2.85e-10	5.11e-08	0.28	0.19	Depression;	chr6:28226851	chr6:28943877~28944537:+
BRCA	cis	rs7608910	0.556	rs10181042	ENSG00000271889.1	RP11-493E12.1	-6.37	2.85e-10	5.12e-08	-0.24	-0.19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60997124	chr2:61151433~61162105:-
BRCA	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-6.37	2.85e-10	5.12e-08	-0.18	-0.19	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
BRCA	cis	rs2836950	0.509	rs11088466	ENSG00000238141.2	BRWD1-AS1	-6.37	2.85e-10	5.12e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39208091	chr21:39315707~39323218:+
BRCA	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	6.37	2.85e-10	5.13e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
BRCA	cis	rs7809950	0.817	rs2237671	ENSG00000238832.1	snoU109	-6.37	2.86e-10	5.13e-08	-0.28	-0.19	Coronary artery disease;	chr7:107491083	chr7:107603363~107603507:+
BRCA	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-6.37	2.86e-10	5.13e-08	-0.22	-0.19	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
BRCA	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	6.37	2.86e-10	5.14e-08	0.23	0.19	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	6.37	2.86e-10	5.14e-08	0.23	0.19	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
BRCA	cis	rs793571	0.505	rs12591290	ENSG00000259250.1	RP11-50C13.1	-6.37	2.86e-10	5.14e-08	-0.35	-0.19	Schizophrenia;	chr15:58603305	chr15:58587507~58591676:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000228409.4	CCT6P1	6.37	2.86e-10	5.14e-08	0.26	0.19	Diabetic kidney disease;	chr7:65940221	chr7:65751142~65763354:+
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000254153.1	CTA-398F10.2	6.37	2.86e-10	5.14e-08	0.23	0.19	Mood instability;	chr8:8515975	chr8:8456909~8461337:-
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000257763.1	OR5BK1P	-6.37	2.87e-10	5.15e-08	-0.21	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48355792~48356614:-
BRCA	cis	rs34929064	0.881	rs2067074	ENSG00000179428.2	AC073072.5	6.37	2.87e-10	5.15e-08	0.22	0.19	Major depression and alcohol dependence;	chr7:22681324	chr7:22725395~22727620:-
BRCA	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-6.37	2.87e-10	5.15e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000224316.1	RP11-479O9.2	6.37	2.87e-10	5.15e-08	0.19	0.19	Aortic root size;	chr7:66401463	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778699	ENSG00000224316.1	RP11-479O9.2	6.37	2.87e-10	5.15e-08	0.19	0.19	Aortic root size;	chr7:66403303	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-6.37	2.87e-10	5.15e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-6.37	2.87e-10	5.15e-08	-0.27	-0.19	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
BRCA	cis	rs67981189	0.896	rs2158997	ENSG00000269927.1	RP6-91H8.3	-6.37	2.87e-10	5.16e-08	-0.24	-0.19	Schizophrenia;	chr14:71031077	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-6.37	2.88e-10	5.16e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	6.37	2.88e-10	5.17e-08	0.23	0.19	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	6.37	2.88e-10	5.17e-08	0.23	0.19	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
BRCA	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-6.37	2.88e-10	5.17e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.924	rs61920245	ENSG00000278733.1	RP11-425D17.1	-6.37	2.88e-10	5.17e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7957056	ENSG00000278733.1	RP11-425D17.1	-6.37	2.88e-10	5.17e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28185625~28186190:-
BRCA	cis	rs73193808	0.901	rs8128235	ENSG00000215533.7	LINC00189	-6.37	2.89e-10	5.18e-08	-0.28	-0.19	Coronary artery disease;	chr21:29193197	chr21:29193480~29288205:+
BRCA	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-6.37	2.89e-10	5.18e-08	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
BRCA	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	6.37	2.89e-10	5.18e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
BRCA	cis	rs150658949	1	rs150658949	ENSG00000259087.4	RP11-356O9.2	6.37	2.89e-10	5.18e-08	0.2	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:37218926	chr14:37556158~37567095:-
BRCA	cis	rs9876781	1	rs28824259	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48384185	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs12487542	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48384586	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs73074358	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48385757	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.967	rs34761139	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48386489	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.868	rs9875280	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48387420	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs6796491	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48388977	chr3:48256350~48256938:-
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.37	2.89e-10	5.19e-08	0.28	0.19	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
BRCA	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	6.37	2.89e-10	5.19e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
BRCA	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-6.37	2.89e-10	5.19e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
BRCA	cis	rs77972916	0.505	rs6756575	ENSG00000234936.1	AC010883.5	6.37	2.89e-10	5.19e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43301380	chr2:43229573~43233394:+
BRCA	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.37	2.89e-10	5.19e-08	0.23	0.19	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
BRCA	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	6.37	2.9e-10	5.2e-08	0.18	0.19	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-6.37	2.9e-10	5.2e-08	-0.29	-0.19	Depression;	chr6:28139876	chr6:28115628~28116551:+
BRCA	cis	rs34779708	0.966	rs17591857	ENSG00000271335.4	RP11-324I22.4	-6.37	2.9e-10	5.2e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35314552~35336401:-
BRCA	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-6.37	2.9e-10	5.2e-08	-0.22	-0.19	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.9e-10	5.21e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66158142	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66128561	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66131504	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66132354	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.91e-10	5.22e-08	-0.32	-0.19	Diabetic kidney disease;	chr7:66063677	chr7:66025126~66031544:-
BRCA	cis	rs11977670	0.785	rs13225058	ENSG00000260231.1	JHDM1D-AS1	6.37	2.91e-10	5.22e-08	0.22	0.19	Breast cancer;	chr7:140246253	chr7:140177261~140179640:+
BRCA	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-6.37	2.91e-10	5.22e-08	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
BRCA	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-6.37	2.91e-10	5.22e-08	-0.16	-0.19	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-6.37	2.92e-10	5.23e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
BRCA	cis	rs710913	0.816	rs1727098	ENSG00000237624.1	OXCT2P1	-6.37	2.92e-10	5.23e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000164669.11	INTS4P1	6.37	2.92e-10	5.23e-08	0.24	0.19	Aortic root size;	chr7:66113790	chr7:65141225~65234216:+
BRCA	cis	rs12594515	0.904	rs8032875	ENSG00000259200.1	RP11-718O11.1	-6.37	2.92e-10	5.24e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45705812	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.874	rs8032878	ENSG00000259200.1	RP11-718O11.1	-6.37	2.92e-10	5.24e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45705817	chr15:45705078~45931069:+
BRCA	cis	rs10208649	0.908	rs10199995	ENSG00000233266.1	HMGB1P31	6.36	2.93e-10	5.25e-08	0.47	0.19	Body mass index;	chr2:53981138	chr2:54051334~54051760:+
BRCA	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-6.36	2.93e-10	5.25e-08	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
BRCA	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
BRCA	cis	rs3126085	0.56	rs11204987	ENSG00000237975.5	FLG-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Atopic dermatitis;	chr1:152370393	chr1:152168125~152445456:+
BRCA	cis	rs3126085	0.56	rs12027445	ENSG00000237975.5	FLG-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Atopic dermatitis;	chr1:152372311	chr1:152168125~152445456:+
BRCA	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
BRCA	cis	rs847577	0.748	rs55784506	ENSG00000272950.1	RP11-307C18.1	6.36	2.93e-10	5.26e-08	0.25	0.19	Breast cancer;	chr7:98088889	chr7:98322853~98323430:+
BRCA	cis	rs7927771	0.542	rs7122217	ENSG00000280615.1	Y_RNA	-6.36	2.93e-10	5.26e-08	-0.22	-0.19	Subjective well-being;	chr11:47756368	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs12421563	ENSG00000280615.1	Y_RNA	-6.36	2.93e-10	5.26e-08	-0.22	-0.19	Subjective well-being;	chr11:47758670	chr11:47614898~47614994:-
BRCA	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-6.36	2.93e-10	5.26e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
BRCA	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	6.36	2.94e-10	5.26e-08	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
BRCA	cis	rs9880211	0.563	rs6793835	ENSG00000273486.1	RP11-731C17.2	-6.36	2.94e-10	5.27e-08	-0.25	-0.19	Height;Body mass index;	chr3:136101092	chr3:136837338~136839021:-
BRCA	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	6.36	2.94e-10	5.27e-08	0.22	0.19	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
BRCA	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	6.36	2.94e-10	5.27e-08	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
BRCA	cis	rs35146811	0.586	rs12705067	ENSG00000235713.1	RP4-604G5.3	6.36	2.94e-10	5.27e-08	0.23	0.19	Coronary artery disease;	chr7:99997103	chr7:99992397~99993050:+
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000267422.1	CTD-2554C21.1	-6.36	2.95e-10	5.28e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37377002	chr19:37779686~37792865:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	6.36	2.95e-10	5.29e-08	0.26	0.19	Height;	chr4:55363436	chr4:55387949~55388271:+
BRCA	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-6.36	2.95e-10	5.29e-08	-0.26	-0.19	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
BRCA	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-6.36	2.95e-10	5.29e-08	-0.25	-0.19	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
BRCA	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-6.36	2.95e-10	5.29e-08	-0.3	-0.19	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000224316.1	RP11-479O9.2	6.36	2.95e-10	5.29e-08	0.19	0.19	Aortic root size;	chr7:66765873	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs4660214	ENSG00000237624.1	OXCT2P1	6.36	2.95e-10	5.29e-08	0.28	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39514956~39516490:+
BRCA	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.36	2.95e-10	5.3e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.36	2.95e-10	5.3e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
BRCA	cis	rs78456975	1	rs11884854	ENSG00000231482.2	AC141930.2	-6.36	2.96e-10	5.3e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1562382	chr2:1572554~1580311:-
BRCA	cis	rs3764021	1	rs3764021	ENSG00000256673.1	RP11-599J14.2	-6.36	2.96e-10	5.3e-08	-0.21	-0.19	Type 1 diabetes;	chr12:9681032	chr12:9398355~9414851:-
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000257763.1	OR5BK1P	6.36	2.96e-10	5.31e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48355792~48356614:-
BRCA	cis	rs77972916	0.505	rs6719754	ENSG00000234936.1	AC010883.5	6.36	2.96e-10	5.31e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43299247	chr2:43229573~43233394:+
BRCA	cis	rs4713118	0.869	rs6922574	ENSG00000220721.1	OR1F12	6.36	2.96e-10	5.31e-08	0.24	0.19	Parkinson's disease;	chr6:27725224	chr6:28073316~28074233:+
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-6.36	2.97e-10	5.32e-08	-0.18	-0.19	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	6.36	2.97e-10	5.32e-08	0.25	0.19	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	6.36	2.97e-10	5.32e-08	0.27	0.19	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
BRCA	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-6.36	2.97e-10	5.32e-08	-0.28	-0.19	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.888	rs11610011	ENSG00000278733.1	RP11-425D17.1	-6.36	2.97e-10	5.32e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000229886.1	RP5-1132H15.3	6.36	2.97e-10	5.33e-08	0.34	0.19	Diabetic kidney disease;	chr7:65966506	chr7:66025126~66031544:-
BRCA	cis	rs4372836	1	rs4666119	ENSG00000226833.4	AC097724.3	6.36	2.97e-10	5.33e-08	0.24	0.19	Body mass index;	chr2:28752824	chr2:28708953~28736205:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65943626	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65944004	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65944182	chr7:65751142~65763354:+
BRCA	cis	rs228614	0.536	rs223419	ENSG00000251288.2	RP11-10L12.2	-6.36	2.97e-10	5.33e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102751401~102752641:+
BRCA	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	6.36	2.98e-10	5.33e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
BRCA	cis	rs4072705	0.9	rs4836993	ENSG00000224020.1	MIR181A2HG	-6.36	2.98e-10	5.34e-08	-0.22	-0.19	Menarche (age at onset);	chr9:124796091	chr9:124658467~124698631:+
BRCA	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	6.36	2.98e-10	5.34e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-6.36	2.98e-10	5.35e-08	-0.29	-0.19	Depression;	chr6:28074687	chr6:28170845~28172521:+
BRCA	cis	rs250585	0.85	rs152460	ENSG00000260136.4	CTD-2270L9.4	6.36	2.99e-10	5.35e-08	0.19	0.19	Egg allergy;	chr16:23562512	chr16:23452758~23457606:+
BRCA	cis	rs2492286	0.569	rs9289331	ENSG00000242551.2	POU5F1P6	-6.36	2.99e-10	5.36e-08	-0.28	-0.19	Eosinophil counts;	chr3:128635173	chr3:128674735~128677005:-
BRCA	cis	rs1124769	0.7	rs12900777	ENSG00000259378.1	DCAF13P3	6.36	2.99e-10	5.36e-08	0.27	0.19	Cognitive performance;	chr15:51072382	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.654	rs12593764	ENSG00000259378.1	DCAF13P3	6.36	2.99e-10	5.36e-08	0.27	0.19	Cognitive performance;	chr15:51072743	chr15:50944663~50945996:+
BRCA	cis	rs2645424	0.686	rs2294140	ENSG00000255046.1	RP11-297N6.4	-6.36	2.99e-10	5.36e-08	-0.22	-0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr8:11797928~11802568:-
BRCA	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	6.36	2.99e-10	5.36e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
BRCA	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-6.36	2.99e-10	5.36e-08	-0.24	-0.19	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
BRCA	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.36	3e-10	5.37e-08	0.23	0.19	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-6.36	3e-10	5.37e-08	-0.29	-0.19	Depression;	chr6:28137418	chr6:28115628~28116551:+
BRCA	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-6.36	3e-10	5.37e-08	-0.23	-0.19	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.36	3e-10	5.37e-08	0.28	0.19	Depression;	chr6:28200948	chr6:28115628~28116551:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-6.36	3e-10	5.37e-08	-0.29	-0.19	Pain;	chr19:21513185	chr19:21554640~21569237:-
BRCA	cis	rs9307551	0.817	rs4975057	ENSG00000250334.4	LINC00989	-6.36	3e-10	5.38e-08	-0.26	-0.19	Refractive error;	chr4:79567191	chr4:79492416~79576460:+
BRCA	cis	rs11024102	0.925	rs7127818	ENSG00000184669.7	OR7E14P	-6.36	3e-10	5.38e-08	-0.3	-0.19	Glaucoma (primary angle closure);	chr11:16982543	chr11:17013998~17053024:+
BRCA	cis	rs2281558	1	rs2281558	ENSG00000125804.12	FAM182A	-6.36	3e-10	5.38e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:26054655~26086917:+
BRCA	cis	rs7911264	0.791	rs9420589	ENSG00000236493.2	EIF2S2P3	-6.36	3e-10	5.38e-08	-0.26	-0.19	Inflammatory bowel disease;	chr10:92690476	chr10:92668745~92669743:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-6.36	3e-10	5.38e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
BRCA	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-6.36	3e-10	5.38e-08	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-6.36	3.01e-10	5.38e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
BRCA	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	6.36	3.01e-10	5.39e-08	0.29	0.19	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
BRCA	cis	rs78456975	0.941	rs6755875	ENSG00000231482.2	AC141930.2	-6.36	3.01e-10	5.4e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1553337	chr2:1572554~1580311:-
BRCA	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	6.36	3.01e-10	5.4e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
BRCA	cis	rs78456975	1	rs6720874	ENSG00000231482.2	AC141930.2	-6.36	3.02e-10	5.41e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1576732	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	6.36	3.02e-10	5.41e-08	0.24	0.19	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
BRCA	cis	rs2998286	0.723	rs332152	ENSG00000254635.4	WAC-AS1	-6.36	3.02e-10	5.41e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28522652~28532743:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000274576.2	IGHV2-70	-6.36	3.02e-10	5.41e-08	-0.15	-0.19	Kawasaki disease;	chr14:106785926	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000234585.5	CCT6P3	6.36	3.02e-10	5.41e-08	0.18	0.19	Aortic root size;	chr7:65943052	chr7:65038354~65074713:+
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000214776.8	RP11-726G1.1	-6.36	3.03e-10	5.42e-08	-0.21	-0.19	Type 1 diabetes;	chr12:9727518	chr12:9467552~9576275:+
BRCA	cis	rs67981189	0.865	rs2810115	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70928070	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs917065	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70931129	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs1018977	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70933936	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.752	rs2332477	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70936594	chr14:71085482~71085833:-
BRCA	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-6.36	3.04e-10	5.43e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
BRCA	cis	rs1476670	0.565	rs942756	ENSG00000230615.5	RP5-1198O20.4	-6.36	3.04e-10	5.44e-08	-0.26	-0.19	Eotaxin levels;	chr1:44056602	chr1:44030443~44115913:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000229886.1	RP5-1132H15.3	6.36	3.04e-10	5.44e-08	0.35	0.19	Diabetic kidney disease;	chr7:66134209	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-6.36	3.04e-10	5.45e-08	-0.25	-0.19	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-6.36	3.04e-10	5.45e-08	-0.24	-0.19	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000236529.1	RP13-254B10.1	6.36	3.04e-10	5.45e-08	0.24	0.19	Aortic root size;	chr7:66534641	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000236529.1	RP13-254B10.1	6.36	3.04e-10	5.45e-08	0.24	0.19	Aortic root size;	chr7:66536353	chr7:65840212~65840596:+
BRCA	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	6.36	3.04e-10	5.45e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	6.36	3.04e-10	5.45e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	6.36	3.05e-10	5.45e-08	0.26	0.19	Height;	chr4:55611014	chr4:55387949~55388271:+
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.36	3.05e-10	5.46e-08	-0.28	-0.19	Depression;	chr6:28201380	chr6:28115628~28116551:+
BRCA	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	6.36	3.05e-10	5.46e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
BRCA	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-6.36	3.06e-10	5.47e-08	-0.22	-0.19	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
BRCA	cis	rs6688613	1	rs7533688	ENSG00000225171.2	DUTP6	-6.36	3.06e-10	5.47e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166974886	chr1:166868748~166869209:+
BRCA	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	6.36	3.06e-10	5.47e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	6.36	3.06e-10	5.48e-08	0.24	0.19	Height;	chr4:55483718	chr4:55540502~55540835:-
BRCA	cis	rs17253792	0.822	rs112374071	ENSG00000186615.9	KTN1-AS1	-6.36	3.07e-10	5.48e-08	-0.39	-0.19	Putamen volume;	chr14:55595201	chr14:55499278~55580110:-
BRCA	cis	rs1124769	0.719	rs4304967	ENSG00000259378.1	DCAF13P3	6.36	3.07e-10	5.48e-08	0.27	0.19	Cognitive performance;	chr15:51096981	chr15:50944663~50945996:+
BRCA	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	6.36	3.07e-10	5.48e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	6.36	3.07e-10	5.49e-08	0.22	0.19	Height;	chr5:37535278	chr5:36666214~36725195:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000220721.1	OR1F12	6.36	3.07e-10	5.49e-08	0.22	0.19	Pubertal anthropometrics;	chr6:28411584	chr6:28073316~28074233:+
BRCA	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-6.36	3.07e-10	5.49e-08	-0.2	-0.19	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000224316.1	RP11-479O9.2	6.36	3.08e-10	5.5e-08	0.19	0.19	Aortic root size;	chr7:66749580	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000224316.1	RP11-479O9.2	6.36	3.08e-10	5.5e-08	0.19	0.19	Aortic root size;	chr7:66759510	chr7:65773620~65802067:+
BRCA	cis	rs897984	0.762	rs2054213	ENSG00000275263.1	RP11-1072A3.4	6.36	3.08e-10	5.51e-08	0.23	0.19	Dementia with Lewy bodies;	chr16:30960489	chr16:30956872~30957199:-
BRCA	cis	rs3764021	0.84	rs10743823	ENSG00000214776.8	RP11-726G1.1	6.36	3.08e-10	5.51e-08	0.21	0.19	Type 1 diabetes;	chr12:9728529	chr12:9467552~9576275:+
BRCA	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
BRCA	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-6.36	3.08e-10	5.51e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
BRCA	cis	rs3740713	0.669	rs2896526	ENSG00000256464.1	YWHABP2	6.36	3.08e-10	5.51e-08	0.31	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr11:18490243~18490955:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-6.36	3.08e-10	5.51e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000229886.1	RP5-1132H15.3	-6.36	3.08e-10	5.52e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66139635	chr7:66025126~66031544:-
BRCA	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	6.36	3.09e-10	5.52e-08	0.3	0.19	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000230042.1	AK3P3	-6.36	3.09e-10	5.53e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23129178~23129841:+
BRCA	cis	rs9907295	0.688	rs2376287	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs4796133	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs7213636	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35893707~35911023:-
BRCA	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	6.36	3.09e-10	5.53e-08	0.2	0.19	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
BRCA	cis	rs78487399	0.71	rs17031133	ENSG00000234936.1	AC010883.5	-6.36	3.09e-10	5.53e-08	-0.26	-0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617694	chr2:43229573~43233394:+
BRCA	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	6.36	3.1e-10	5.54e-08	0.29	0.19	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-6.36	3.1e-10	5.54e-08	-0.26	-0.19	Gout;	chr7:66642037	chr7:66880708~66882981:+
BRCA	cis	rs2638953	0.924	rs4573721	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs4554927	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920243	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.679	rs7974882	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.679	rs7961395	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974701	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs7961769	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs61920244	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs34378873	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049437	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049438	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049440	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049441	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049442	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049443	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049444	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049445	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs60193273	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049446	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049447	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs10843123	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12146881	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049448	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843126	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843127	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs10843128	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs10843129	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843130	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920253	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs11612143	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.813	rs11609999	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049453	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs7957059	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.54e-08	0.28	0.19	Diabetic kidney disease;	chr7:66068227	chr7:65751142~65763354:+
BRCA	cis	rs754466	0.651	rs10824583	ENSG00000204049.1	RP11-126H7.4	-6.36	3.1e-10	5.54e-08	-0.23	-0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77859644	chr10:77866875~77869610:+
BRCA	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000211972.2	IGHV3-66	6.36	3.1e-10	5.55e-08	0.18	0.19	Alzheimer's disease (late onset);	chr14:106682029	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65918212	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65922114	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65923503	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65925372	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000228409.4	CCT6P1	-6.36	3.1e-10	5.55e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65928187	chr7:65751142~65763354:+
BRCA	cis	rs2998286	0.862	rs2993980	ENSG00000254635.4	WAC-AS1	-6.36	3.11e-10	5.55e-08	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506286	chr10:28522652~28532743:-
BRCA	cis	rs12594515	0.935	rs8042519	ENSG00000259200.1	RP11-718O11.1	-6.36	3.11e-10	5.55e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704143	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.862	rs949930	ENSG00000224316.1	RP11-479O9.2	-6.36	3.11e-10	5.56e-08	-0.19	-0.19	Aortic root size;	chr7:66301835	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.924	rs11049410	ENSG00000278733.1	RP11-425D17.1	-6.36	3.11e-10	5.56e-08	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-6.35	3.12e-10	5.57e-08	-0.24	-0.19	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.505	rs3851318	ENSG00000234936.1	AC010883.5	6.35	3.12e-10	5.57e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43305669	chr2:43229573~43233394:+
BRCA	cis	rs9527	0.571	rs4917985	ENSG00000236937.2	PTGES3P4	6.35	3.12e-10	5.58e-08	0.25	0.19	Arsenic metabolism;	chr10:102864315	chr10:102845595~102845950:+
BRCA	cis	rs16978956	0.779	rs6045352	ENSG00000236474.1	GCNT1P1	-6.35	3.12e-10	5.58e-08	-0.23	-0.19	Body mass index;	chr20:18346462	chr20:18420160~18421454:-
BRCA	cis	rs6740322	0.895	rs6544643	ENSG00000234936.1	AC010883.5	6.35	3.13e-10	5.59e-08	0.22	0.19	Coronary artery disease;	chr2:43332933	chr2:43229573~43233394:+
BRCA	cis	rs9840812	0.592	rs12489577	ENSG00000273486.1	RP11-731C17.2	6.35	3.13e-10	5.59e-08	0.23	0.19	Fibrinogen levels;	chr3:136494303	chr3:136837338~136839021:-
BRCA	cis	rs5167	0.506	rs35193317	ENSG00000280087.1	CTB-129P6.7	-6.35	3.13e-10	5.59e-08	-0.23	-0.19	Blood protein levels;	chr19:44967087	chr19:44909375~44914968:+
BRCA	cis	rs34779708	0.966	rs878264	ENSG00000271335.4	RP11-324I22.4	6.35	3.13e-10	5.6e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12261654	ENSG00000271335.4	RP11-324I22.4	6.35	3.13e-10	5.6e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35314552~35336401:-
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000244733.5	RP11-506M13.3	-6.35	3.14e-10	5.6e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79660891~79677996:+
BRCA	cis	rs4691139	1	rs12498808	ENSG00000248632.1	RP11-366M4.11	6.35	3.14e-10	5.61e-08	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164968587~164970002:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-6.35	3.14e-10	5.61e-08	-0.29	-0.19	Depression;	chr6:28139998	chr6:28115628~28116551:+
BRCA	cis	rs754466	0.651	rs11002316	ENSG00000204049.1	RP11-126H7.4	6.35	3.14e-10	5.61e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857753	chr10:77866875~77869610:+
BRCA	cis	rs9876781	1	rs7635522	ENSG00000229759.1	MRPS18AP1	6.35	3.14e-10	5.61e-08	0.21	0.19	Longevity;	chr3:48382166	chr3:48256350~48256938:-
BRCA	cis	rs853679	0.599	rs156743	ENSG00000220721.1	OR1F12	6.35	3.15e-10	5.62e-08	0.35	0.19	Depression;	chr6:27999311	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-6.35	3.15e-10	5.62e-08	-0.29	-0.19	Depression;	chr6:28076704	chr6:28170845~28172521:+
BRCA	cis	rs67981189	0.896	rs7146591	ENSG00000269927.1	RP6-91H8.3	-6.35	3.15e-10	5.63e-08	-0.24	-0.19	Schizophrenia;	chr14:70971511	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	6.35	3.15e-10	5.63e-08	0.26	0.19	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
BRCA	cis	rs11971779	0.666	rs7786851	ENSG00000273391.1	RP11-634H22.1	-6.35	3.16e-10	5.64e-08	-0.22	-0.19	Diisocyanate-induced asthma;	chr7:139322274	chr7:139359032~139359566:-
BRCA	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-6.35	3.16e-10	5.64e-08	-0.22	-0.19	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
BRCA	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	6.35	3.16e-10	5.64e-08	0.22	0.19	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000274576.2	IGHV2-70	-6.35	3.16e-10	5.64e-08	-0.15	-0.19	Kawasaki disease;	chr14:106787090	chr14:106770577~106771020:-
BRCA	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	6.35	3.16e-10	5.65e-08	0.22	0.19	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
BRCA	cis	rs8114671	0.836	rs6142280	ENSG00000269202.1	RP4-614O4.12	6.35	3.16e-10	5.65e-08	0.2	0.19	Height;	chr20:35034439	chr20:35201747~35203288:-
BRCA	cis	rs77972916	0.505	rs6727824	ENSG00000234936.1	AC010883.5	6.35	3.16e-10	5.65e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43301238	chr2:43229573~43233394:+
BRCA	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	6.35	3.16e-10	5.65e-08	0.29	0.19	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
BRCA	cis	rs2115630	1	rs6496452	ENSG00000229212.6	RP11-561C5.4	6.35	3.17e-10	5.66e-08	0.21	0.19	P wave terminal force;	chr15:84829414	chr15:85205440~85234795:-
BRCA	cis	rs6840258	1	rs56395939	ENSG00000251411.1	RP11-397E7.4	-6.35	3.17e-10	5.67e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87042481	chr4:86913266~86914817:-
BRCA	cis	rs7976269	0.537	rs4471475	ENSG00000257176.2	RP11-996F15.2	-6.35	3.18e-10	5.67e-08	-0.23	-0.19	Male-pattern baldness;	chr12:29022461	chr12:29280418~29317848:-
BRCA	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-6.35	3.18e-10	5.68e-08	-0.23	-0.19	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
BRCA	cis	rs250585	0.736	rs2040574	ENSG00000260136.4	CTD-2270L9.4	-6.35	3.18e-10	5.68e-08	-0.23	-0.19	Egg allergy;	chr16:23499005	chr16:23452758~23457606:+
BRCA	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-6.35	3.18e-10	5.68e-08	-0.3	-0.19	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
BRCA	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-6.35	3.18e-10	5.68e-08	-0.2	-0.19	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
BRCA	cis	rs2836950	0.565	rs8131132	ENSG00000238141.2	BRWD1-AS1	-6.35	3.18e-10	5.68e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39166330	chr21:39315707~39323218:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	6.35	3.19e-10	5.69e-08	0.2	0.19	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
BRCA	cis	rs9291683	0.668	rs2241474	ENSG00000250413.1	RP11-448G15.1	-6.35	3.19e-10	5.69e-08	-0.26	-0.19	Bone mineral density;	chr4:10084391	chr4:10006482~10009725:+
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	6.35	3.19e-10	5.69e-08	0.27	0.19	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000230042.1	AK3P3	-6.35	3.19e-10	5.7e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23129178~23129841:+
BRCA	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-6.35	3.2e-10	5.71e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
BRCA	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-6.35	3.2e-10	5.71e-08	-0.27	-0.19	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
BRCA	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	6.35	3.2e-10	5.71e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-6.35	3.21e-10	5.72e-08	-0.14	-0.19	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	6.35	3.21e-10	5.73e-08	0.24	0.19	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
BRCA	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	6.35	3.21e-10	5.73e-08	0.21	0.19	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
BRCA	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-6.35	3.21e-10	5.73e-08	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
BRCA	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-6.35	3.21e-10	5.73e-08	-0.27	-0.19	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
BRCA	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	6.35	3.21e-10	5.73e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	6.35	3.21e-10	5.73e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
BRCA	cis	rs73193808	0.901	rs12626758	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29194430	chr21:29193480~29288205:+
BRCA	cis	rs73193808	0.901	rs67211015	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29194901	chr21:29193480~29288205:+
BRCA	cis	rs73193808	0.802	rs66691348	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29195220	chr21:29193480~29288205:+
BRCA	cis	rs17253792	0.822	rs10483643	ENSG00000186615.9	KTN1-AS1	-6.35	3.22e-10	5.74e-08	-0.38	-0.19	Putamen volume;	chr14:55623213	chr14:55499278~55580110:-
BRCA	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-6.35	3.22e-10	5.74e-08	-0.35	-0.19	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-6.35	3.22e-10	5.74e-08	-0.35	-0.19	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000273024.4	INTS4P2	-6.35	3.22e-10	5.75e-08	-0.24	-0.19	Aortic root size;	chr7:66376399	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-6.35	3.22e-10	5.75e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000232546.1	RP11-458F8.1	-6.35	3.23e-10	5.76e-08	-0.22	-0.19	Diabetic kidney disease;	chr7:65988305	chr7:66848496~66858136:+
BRCA	cis	rs10483853	0.806	rs12586996	ENSG00000258695.2	RP3-414A15.2	6.35	3.23e-10	5.76e-08	0.3	0.19	Coronary artery calcification;	chr14:73342516	chr14:73522878~73530610:+
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000244733.5	RP11-506M13.3	-6.35	3.23e-10	5.77e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79660891~79677996:+
BRCA	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	6.35	3.23e-10	5.77e-08	0.24	0.19	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
BRCA	cis	rs227275	0.525	rs223461	ENSG00000251288.2	RP11-10L12.2	-6.35	3.23e-10	5.77e-08	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102751401~102752641:+
BRCA	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-6.35	3.23e-10	5.77e-08	-0.25	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-6.35	3.23e-10	5.77e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
BRCA	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-6.35	3.24e-10	5.77e-08	-0.22	-0.19	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-6.35	3.24e-10	5.78e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
BRCA	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-6.35	3.24e-10	5.78e-08	-0.18	-0.19	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
BRCA	cis	rs1124769	0.748	rs72727114	ENSG00000259378.1	DCAF13P3	6.35	3.24e-10	5.78e-08	0.27	0.19	Cognitive performance;	chr15:51082720	chr15:50944663~50945996:+
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000273765.1	RP11-370I10.11	6.35	3.25e-10	5.79e-08	0.23	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48360920~48361377:+
BRCA	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	6.35	3.25e-10	5.79e-08	0.17	0.19	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
BRCA	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-6.35	3.25e-10	5.79e-08	-0.23	-0.19	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
BRCA	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	6.35	3.25e-10	5.8e-08	0.22	0.19	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
BRCA	cis	rs67981189	0.896	rs17108967	ENSG00000269927.1	RP6-91H8.3	6.35	3.26e-10	5.82e-08	0.24	0.19	Schizophrenia;	chr14:71075451	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-6.35	3.27e-10	5.82e-08	-0.24	-0.19	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-6.35	3.27e-10	5.83e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000267422.1	CTD-2554C21.1	-6.35	3.27e-10	5.84e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37312346	chr19:37779686~37792865:+
BRCA	cis	rs6688613	1	rs6699159	ENSG00000225171.2	DUTP6	-6.35	3.27e-10	5.84e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166976835	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs6665341	ENSG00000225171.2	DUTP6	-6.35	3.27e-10	5.84e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166977781	chr1:166868748~166869209:+
BRCA	cis	rs12446554	0.509	rs56108048	ENSG00000261195.1	CTD-2380F24.1	-6.35	3.27e-10	5.84e-08	-0.28	-0.19	Obesity;	chr16:19698457	chr16:19761172~19766099:-
BRCA	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	6.35	3.28e-10	5.84e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	6.35	3.28e-10	5.84e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
BRCA	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
BRCA	cis	rs8002861	0.641	rs6561148	ENSG00000274001.1	RP11-5G9.5	6.35	3.28e-10	5.85e-08	0.23	0.19	Leprosy;	chr13:43852133	chr13:43877715~43878163:-
BRCA	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-6.35	3.28e-10	5.85e-08	-0.21	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-6.35	3.28e-10	5.85e-08	-0.3	-0.19	Pain;	chr19:21510513	chr19:21554640~21569237:-
BRCA	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-6.35	3.29e-10	5.86e-08	-0.27	-0.19	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-6.35	3.29e-10	5.86e-08	-0.27	-0.19	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
BRCA	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	6.35	3.29e-10	5.86e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000232559.3	GS1-124K5.12	-6.35	3.29e-10	5.86e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66144214	chr7:66554588~66576923:-
BRCA	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	6.35	3.29e-10	5.86e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	6.35	3.29e-10	5.86e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
BRCA	cis	rs7520050	0.966	rs785479	ENSG00000280836.1	AL355480.1	6.35	3.29e-10	5.87e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45581219~45581321:-
BRCA	cis	rs3740713	0.669	rs34740438	ENSG00000256464.1	YWHABP2	6.35	3.29e-10	5.87e-08	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr11:18490243~18490955:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000273024.4	INTS4P2	6.35	3.3e-10	5.87e-08	0.24	0.19	Aortic root size;	chr7:66152984	chr7:65647864~65715661:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000274576.2	IGHV2-70	-6.35	3.3e-10	5.87e-08	-0.16	-0.19	Kawasaki disease;	chr14:106681814	chr14:106770577~106771020:-
BRCA	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-6.35	3.3e-10	5.88e-08	-0.25	-0.19	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
BRCA	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	6.35	3.3e-10	5.88e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
BRCA	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-6.35	3.3e-10	5.89e-08	-0.22	-0.19	Longevity;	chr3:48453142	chr3:48256350~48256938:-
BRCA	cis	rs4761702	1	rs4761702	ENSG00000257322.4	RP11-511B23.2	-6.35	3.31e-10	5.89e-08	-0.25	-0.19	Immature fraction of reticulocytes;	chr12:93316116	chr12:93003415~93215679:-
BRCA	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	6.35	3.31e-10	5.89e-08	0.25	0.19	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
BRCA	cis	rs2489715	0.951	rs2801949	ENSG00000185904.10	LINC00839	6.35	3.31e-10	5.89e-08	0.27	0.19	Helix rolling;	chr10:42431295	chr10:42475543~42495336:+
BRCA	cis	rs73193808	0.901	rs8131103	ENSG00000215533.7	LINC00189	-6.34	3.31e-10	5.9e-08	-0.28	-0.19	Coronary artery disease;	chr21:29193427	chr21:29193480~29288205:+
BRCA	cis	rs957448	1	rs56716157	ENSG00000253175.1	RP11-267M23.6	6.34	3.31e-10	5.9e-08	0.26	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94565036~94565715:+
BRCA	cis	rs72772090	0.908	rs72772091	ENSG00000248734.2	CTD-2260A17.1	-6.34	3.32e-10	5.91e-08	-0.29	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96704418	chr5:96784777~96785999:+
BRCA	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	6.34	3.32e-10	5.91e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
BRCA	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-6.34	3.32e-10	5.92e-08	-0.23	-0.19	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
BRCA	cis	rs1440410	0.835	rs13150694	ENSG00000250326.1	RP11-284M14.1	-6.34	3.32e-10	5.92e-08	-0.21	-0.19	Ischemic stroke;	chr4:143155900	chr4:142933195~143184861:-
BRCA	cis	rs3760982	0.967	rs12463346	ENSG00000267058.1	RP11-15A1.3	-6.34	3.32e-10	5.92e-08	-0.22	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788092	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000232559.3	GS1-124K5.12	6.34	3.33e-10	5.92e-08	0.38	0.19	Diabetic kidney disease;	chr7:66085904	chr7:66554588~66576923:-
BRCA	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-6.34	3.33e-10	5.92e-08	-0.18	-0.19	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.92e-08	0.24	0.19	Height;	chr4:55578154	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55514802	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55516548	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55516744	chr4:55540502~55540835:-
BRCA	cis	rs1440410	0.835	rs7685461	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143133730	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10857405	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143134361	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs7666785	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143139311	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10004598	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143141264	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.763	rs9631769	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143144588	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs13107465	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143147664	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs4511955	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143149081	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs13140643	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143149221	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6817849	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143154848	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs10012434	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143156365	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7687417	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143158848	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6537151	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.95e-08	-0.21	-0.19	Ischemic stroke;	chr4:143146753	chr4:142933195~143184861:-
BRCA	cis	rs710913	0.717	rs2243761	ENSG00000237624.1	OXCT2P1	-6.34	3.34e-10	5.95e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39514956~39516490:+
BRCA	cis	rs3764021	0.743	rs7973535	ENSG00000214776.8	RP11-726G1.1	6.34	3.34e-10	5.95e-08	0.21	0.19	Type 1 diabetes;	chr12:9727801	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.87	rs7973638	ENSG00000214776.8	RP11-726G1.1	6.34	3.34e-10	5.95e-08	0.21	0.19	Type 1 diabetes;	chr12:9727845	chr12:9467552~9576275:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-6.34	3.34e-10	5.95e-08	-0.18	-0.19	Height;	chr11:118781100	chr11:118791254~118793137:+
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.34	3.35e-10	5.96e-08	-0.27	-0.19	Depression;	chr6:28205232	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28071237	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28076559	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28078391	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28080757	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28080760	chr6:28170845~28172521:+
BRCA	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-6.34	3.35e-10	5.96e-08	-0.25	-0.19	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
BRCA	cis	rs9876781	1	rs1459242	ENSG00000229759.1	MRPS18AP1	-6.34	3.35e-10	5.96e-08	-0.21	-0.19	Longevity;	chr3:48372047	chr3:48256350~48256938:-
BRCA	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	6.34	3.35e-10	5.96e-08	0.2	0.19	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
BRCA	cis	rs2554380	0.55	rs62025822	ENSG00000230373.7	GOLGA6L5P	6.34	3.36e-10	5.98e-08	0.24	0.19	Height;	chr15:83870162	chr15:84507885~84516814:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	6.34	3.36e-10	5.98e-08	0.25	0.19	Height;	chr4:55407965	chr4:55387949~55388271:+
BRCA	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	6.34	3.37e-10	5.99e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000267422.1	CTD-2554C21.1	-6.34	3.37e-10	5.99e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37390654	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	6.34	3.37e-10	6e-08	0.25	0.19	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
BRCA	cis	rs9638182	0.673	rs13221253	ENSG00000274080.1	CTA-315H11.2	6.34	3.37e-10	6e-08	0.38	0.19	Triglycerides;	chr7:73507903	chr7:73609262~73611502:-
BRCA	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	6.34	3.38e-10	6.01e-08	0.27	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
BRCA	cis	rs2281558	0.876	rs12625157	ENSG00000125804.12	FAM182A	-6.34	3.38e-10	6.01e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:26054655~26086917:+
BRCA	cis	rs4372836	1	rs2276547	ENSG00000226833.4	AC097724.3	6.34	3.38e-10	6.01e-08	0.24	0.19	Body mass index;	chr2:28752241	chr2:28708953~28736205:-
BRCA	cis	rs34779708	0.966	rs7070427	ENSG00000271335.4	RP11-324I22.4	6.34	3.38e-10	6.02e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35314552~35336401:-
BRCA	cis	rs2998286	0.723	rs332142	ENSG00000254635.4	WAC-AS1	-6.34	3.38e-10	6.02e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs332143	ENSG00000254635.4	WAC-AS1	-6.34	3.38e-10	6.02e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28522652~28532743:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
BRCA	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-6.34	3.39e-10	6.02e-08	-0.26	-0.19	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
BRCA	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	6.34	3.39e-10	6.03e-08	0.33	0.19	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
BRCA	cis	rs9876781	0.967	rs1870444	ENSG00000229759.1	MRPS18AP1	6.34	3.39e-10	6.03e-08	0.21	0.19	Longevity;	chr3:48445369	chr3:48256350~48256938:-
BRCA	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-6.34	3.39e-10	6.03e-08	-0.25	-0.19	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000224316.1	RP11-479O9.2	6.34	3.4e-10	6.04e-08	0.19	0.19	Aortic root size;	chr7:66360926	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	6.34	3.4e-10	6.05e-08	0.26	0.19	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
BRCA	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-6.34	3.41e-10	6.07e-08	-0.18	-0.19	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
BRCA	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	6.34	3.41e-10	6.07e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	6.34	3.42e-10	6.08e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
BRCA	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
BRCA	cis	rs6928977	0.5	rs12211833	ENSG00000231028.7	LINC00271	-6.34	3.42e-10	6.08e-08	-0.21	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135497801~135716055:+
BRCA	cis	rs17597773	0.527	rs2484698	ENSG00000272823.1	RP11-295M18.6	6.34	3.42e-10	6.09e-08	0.21	0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220828676~220829211:-
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.34	3.42e-10	6.09e-08	0.22	0.19	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
BRCA	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.